This	O
invention	O
relates	O
to	O
bis	O
mono-	O
and	O
/	O
or	O
bicyclic	O
aryl	O
and	O
/	O
or	O
heteroaryl	O
compounds	O
exhibiting	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibition	O
activity	O
.	O
More	O
specifically,	O
it	O
relates	O
to	O
the	O
method	O
of	O
inhibiting	O
abnormal	O
cell	O
proliferation	O
in	O
a	O
patient	O
suffering	O
from	O
a	O
disorder	O
characterized	O
by	O
such	O
proliferation	O
comprising	O
the	O
administration	O
thereto	O
of	O
an	O
EGF	B-GENE
and	O
/	O
or	O
PDGF	B-GENE
receptor	I-GENE
inhibiting	O
effective	O
amount	O
of	O
said	O
bis	O
mono-	O
and	O
/	O
or	O
bicyclic	O
aryl	O
and	O
/	O
or	O
heteroaryl	O
compound	O
and	O
to	O
the	O
preparation	O
of	O
said	O
compounds	O
and	O
their	O
use	O
in	O
pharmaceutical	O
compositions	O
used	O
in	O
this	O
method	O
.	O


Disclosed	O
is	O
a	O
method	O
for	O
reducing	O
non-ischemic	O
NMDA	O
receptor-mediated	O
neuronal	O
damage	O
in	O
a	O
mammal	O
by	O
administering	O
to	O
the	O
mammal	O
a	O
compound	O
of	O
the	O
formula	O
shown	O
in	O
Fig	O
.	O
1	O
(	O
or	O
a	O
physiologically-acceptable	O
salt	O
thereof	O
)	O
,	O
wherein	O
R1	O
includes	O
an	O
amino	O
group,	O
R2-R17	O
are	O
independently	O
H	O
or	O
a	O
short	O
chain	O
aliphatic	O
group	O
comprising	O
1-5	O
carbons,	O
and	O
R4	O
and	O
R10	O
also	O
may	O
(	O
independently	O
)	O
be	O
a	O
halogen	O
or	O
an	O
acyl	O
group	O
.	O
Also	O
disclosed	O
is	O
a	O
screen	O
for	O
antagonists	O
of	O
NMDA	B-GENE
receptor	I-GENE
mediated	O
neurotoxicity	O
which	O
have	O
an	O
enhanced	O
prospect	O
for	O
being	O
clinically	O
tolerated	O
and	O
selective	O
against	O
such	O
neurotoxicity	O
.	O


The	O
present	O
invention	O
provides	O
a	O
nucleic	O
acid	O
having	O
a	O
nucleotide	O
sequence	O
coding	O
for	O
Sor	B-GENE
h	I-GENE
I,	O
a	O
major	O
allergen	O
of	O
Sorghum	O
halepense,	O
and	O
fragments	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
provides	O
purified	O
5or	B-GENE
h	I-GENE
I	I-GENE
or	O
at	O
least	O
one	O
fragment	O
thereof,	O
produced	O
in	O
a	O
host	O
cell	O
transformed	O
with	O
a	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
Sor	B-GENE
h	I-GENE
I,	O
or	O
at	O
least	O
one	O
fragment	O
thereof	O
and	O
fragments	O
of	O
Sor	B-GENE
h	I-GENE
prepared	O
synthetically	O
.	O
Sor	B-GENE
h	I-GENE
I	I-GENE
and	O
fragments	O
thereof	O
are	O
useful	O
for	O
diagnosing,	O
treating,	O
and	O
preventing	O
allergy	O
to	O
Johnson	O
grass	O
pollen	O
.	O


Compound	O
having	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
one	O
of	O
X	O
and	O
Y	O
is	O
CH2	O
and	O
the	O
other	O
one	O
is	O
CH2,	O
O	O
or	O
S	O
;	O
R1	O
is	O
an	O
aliphatic	O
hydrocarbon	O
group,	O
arylalkyl,	O
aryl,	O
a	O
sulphonyl	O
group,	O
a	O
carbonate	O
group	O
or	O
R11R12NCO-	O
where	O
R11	O
and	O
R12	O
are	O
selected	O
form	O
hydrogen	O
and	O
a	O
hydrocarbon	O
group	O
;	O
R2	O
is	O
hydrogen	O
or	O
a	O
hydrocarbon	O
group	O
;	O
R3-R5	O
an	O
independently	O
selected	O
from	O
hydrogen,	O
halogen,	O
alkyl,	O
alkoxy,	O
alkylthio,	O
hydroxy,	O
alkylsulphonyl,	O
cyano,	O
trifluoromethyl,	O
cycloalkyl,	O
cycloalkylalkyl	O
or	O
nitro	O
;	O
R6	O
and	O
R7	O
are	O
each	O
hydrogen	O
or	O
lower	O
alkyl	O
or	O
they	O
are	O
linked	O
together	O
to	O
constitute	O
a	O
carbocyclic	O
ring	O
;	O
R8	O
and	O
R9	O
are	O
independently	O
hydrogen,	O
a	O
hydrocarbon	O
group	O
or	O
a	O
group	O
1a	O
wherein	O
R13	O
is	O
hydrogen,	O
or	O
a	O
hydrocarbon	O
group,	O
W	O
is	O
O	O
or	O
S,	O
and	O
r	O
is	O
2-6	O
;	O
R8	O
and	O
R9	O
are	O
linked	O
together	O
thereby	O
forming	O
alkylene	O
group	O
;	O
have	O
effect	O
at	O
central	O
5-HT1A	B-GENE
receptors	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
psychosis,	O
anxiety	O
disorders,	O
depression,	O
impulse	O
control	O
disorders,	O
alcohol	O
abuse,	O
aggression,	O
ischaemic	O
diseases,	O
side	O
effects	O
induced	O
by	O
conventional	O
antipsychotic	O
agents	O
or	O
cardiovascular	O
disorders	O
.	O


There	O
are	O
described	O
compounds	O
of	O
the	O
formula	O
I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
pharmaceutically	O
tolerable	O
salts	O
.	O
These	O
are	O
effective	O
inhibitors	O
of	O
the	O
cellular	O
sodium	B-GENE
proton	I-GENE
antiporter	I-GENE
(	O
Na+	O
/	O
H+	O
exchanger	O
)	O
.	O
They	O
are	O
therefore	O
outstandingly	O
suitable	O
for	O
the	O
treatment	O
of	O
all	O
diseases	O
which	O
can	O
be	O
attributed	O
to	O
increased	O
Na+/H+	O
exchange	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
pteridine	O
derivatives	O
of	O
the	O
formula	O
I	O
	O
	O
	O
in	O
which	O
X	O
is	O
0	O
or	O
NH	O
and	O
R4,	O
for	O
example,	O
is	O
hydrogen,	O
phenyl	O
or	O
the	O
radical	O
R4a-CH2-	O
and	O
R4a,	O
for	O
example,	O
is	O
hydrogen,	O
(	O
C1-C4	O
)	O
-alkylmercapto,	O
the	O
radical	O
-NR11R12	O
or	O
the	O
radical	O
-OR13,	O
and	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R5,	O
R6,	O
R7,	O
R11,	O
R12	O
and	O
R13	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1,	O
which	O
are	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
inhibitors,	O
for	O
the	O
treatment	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
an	O
increased	O
nitric	B-GENE
oxide	I-GENE
level	O
.	O


The	O
invention	O
concerns	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1,	O
R2,	O
R3	O
and	O
R4	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O
These	O
compounds	O
are	O
novel,	O
effective	O
PDE--inhibitors	O
.	O


Novel	O
inhibitors	O
of	O
.	O
beta	O
.	O
-glucuronidase	O
Compounds	O
of	O
the	O
formulae	O
I	O
and	O
II	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
(	O
see	O
formula	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
the	O
adhesion	O
and	O
migration	O
of	O
leucocytes	O
and	O
/	O
or	O
antagonists	O
of	O
the	O
adhesion	O
receptor	O
VLA-4	B-GENE
which	O
belongs	O
to	O
the	O
group	O
of	O
integrins	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
their	O
preparation,	O
to	O
the	O
use	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
an	O
undesired	O
extent	O
of	O
leucocyte	O
adhesion	O
and	O
/	O
or	O
leucocyte	O
migration	O
or	O
which	O
are	O
associated	O
therewith	O
or	O
in	O
which	O
cell-cell	O
or	O
cell-matrix	O
interactions	O
which	O
are	O
based	O
on	O
interactions	O
of	O
VLA-4	B-GENE
receptors	O
with	O
their	O
ligands	O
play	O
a	O
part,	O
for	O
example	O
of	O
inflammatory	O
processes,	O
of	O
rheumatoid	O
arthritis	O
or	O
of	O
allergic	O
disorders,	O
and	O
also	O
to	O
the	O
use	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
for	O
the	O
production	O
of	O
pharmaceuticals	O
for	O
use	O
in	O
such	O
diseases,	O
and	O
to	O
pharmaceutical	O
preparations	O
which	O
contain	O
the	O
compounds	O
of	O
the	O
formula	O
I	O
.	O


Methods	O
and	O
composition	O
are	O
disclosed	O
for	O
producing	O
air-activated,	O
i	O
.	O
e	O
.	O
,	O
oxygen	O
activated,	O
disinfectant-sterilent	O
solutions	O
.	O
Solutions	O
containing	O
a	O
haloperoxidase	B-GENE
(	O
i	O
.	O
e	O
.	O
,	O
a	O
halide	O
:	O
hydrogen	B-GENE
peroxide	I-GENE
oxidoreductase,	O
such	O
as	O
myeloperoxidase,	O
eosinophil	B-GENE
peroxidase	I-GENE
or	O
lactoperoxidase	B-GENE
)	O
plus	O
a	O
halide	O
or	O
combination	O
of	O
halides	O
(	O
i	O
.	O
e	O
.	O
,	O
chloride,	O
bromide	O
and	O
/	O
or	O
iodide	O
)	O
,	O
an	O
oxidase	B-GENE
(	O
i	O
.	O
e	O
.	O
,	O
a	O
substrate	O
:	O
oxygen	B-GENE
oxidoreductase	I-GENE
)	O
capable	O
of	O
generating	O
hydrogen	O
peroxide,	O
and	O
a	O
substrate	O
specific	O
for	O
that	O
oxidase,	O
are	O
separately	O
prepared	O
under	O
aerobic	O
conditions,	O
but	O
all	O
of	O
the	O
component	O
solutions	O
are	O
made	O
anaerobic	O
prior	O
to	O
final	O
combination	O
and	O
mixing	O
.	O
The	O
anaerobic	O
formulations	O
are	O
dispensed	O
into	O
containers	O
capable	O
of	O
maintaining	O
the	O
anaerobic	O
condition	O
(	O
e	O
.	O
g	O
.	O
,	O
pressurized	O
canisters	O
)	O
.	O
Dispensing	O
the	O
solution	O
at	O
the	O
time	O
of	O
use	O
exposes	O
the	O
formulation	O
to	O
air	O
(	O
i	O
.	O
e	O
.	O
,	O
oxygen	O
)	O
which	O
activates	O
its	O
disinfectant-sterilent	O
properties	O
.	O


The	O
soporific	O
activity	O
of	O
cis-9,10-octadecenoamide	O
and	O
other	O
soporific	O
fatty	O
acid	O
primary	O
amides	O
is	O
neutralized	O
by	O
hydrolysis	O
in	O
the	O
presence	O
of	O
cis-9,10-octadecenoamidase	B-GENE
.	O
Hydrolysis	O
of	O
cis-9,10-octadecenoamide	O
leads	O
to	O
the	O
formation	O
of	O
oleic	O
acid,	O
a	O
compound	O
without	O
soporific	O
activity	O
.	O
Inhibitors	O
of	O
cis-9,10-octadecenoamidase	B-GENE
are	O
disclosed	O
to	O
block	O
this	O
activity	O
.	O


A	O
method	O
for	O
treating	O
urinary	O
incontinence	O
while	O
avoiding	O
concomitant	O
liability	O
of	O
adverse	O
effects	O
associated	O
with	O
racemic	O
oxybutynin	O
is	O
disclosed	O
.	O
The	O
method	O
comprises	O
administering	O
from	O
100	O
mg	O
to	O
1	O
000	O
mg	O
/	O
day	O
of	O
(	O
S	O
)	O
-oxybutynin,	O
(	O
S	O
)	O
-desethyloxybutynin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
substantially	O
free	O
of	O
the	O
corresponding	O
R	O
enantiomer	O
.	O
Pharmaceutical	O
compositions	O
in	O
the	O
form	O
of	O
tablets	O
soft	O
elastic	O
gelatin	B-GENE
capsules	O
and	O
transdermal	O
devices	O
comprising	O
an	O
acceptable	O
corner	O
and	O
up	O
to	O
500	O
mg	O
of	O
(	O
S	O
)	O
-oxybutynin	O
or	O
(	O
S	O
)	O
-desethyloxybutynin	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
G-coupled	B-GENE
receptor	I-GENE
which	O
has	O
an	O
amino	O
acid	O
sequence	O
having	O
more	O
than	O
50	O
%	O
homology	O
with	O
the	O
amino	O
acid	O
sequence	O
shown	O
in	O
Figure	O
1	O
.	O


Compounds	O
of	O
formula	O
(	O
1	O
)	O
where	O
the	O
symbols	O
have	O
the	O
meaning	O
defined	O
in	O
the	O
specification,	O
have	O
retinoid,	O
retinoid	B-GENE
antagonist	O
or	O
retinoid	B-GENE
inverse	O
agonist-like	O
biological	O
activity	O
.	O


Disclosed	O
are	O
compounds	O
that	O
are	O
highly	O
selective	O
partial	O
agonists	O
or	O
antagonists	O
at	O
human	B-GENE
CRF1	I-GENE
receptors	I-GENE
that	O
are	O
useful	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
treating	O
stress	O
related	O
disorders	O
such	O
as	O
post	O
traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
as	O
well	O
as	O
depression,	O
headache	O
and	O
anxiety	O
.	O
The	O
compounds	O
have	O
formula	O
(	O
I	O
)	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
wherein	O
Ar,	O
R1,	O
R2	O
.	O
R3,	O
R4	O
and	O
W	O
are	O
various	O
organic	O
and	O
inorganic	O
substituents	O
.	O


Hydroxyazepanes	O
display	O
inhibitory	O
activity	O
with	O
respect	O
to	O
glycosidase,	O
with	O
K	O
i	O
values	O
from	O
moderate	O
to	O
low	O
micromolar	O
range	O
.	O
Benzyl	O
and	O
3,6-dibenzyl	O
derivatives	O
of	O
hydroxyazepanes	O
display	O
inhibitory	O
activity	O
with	O
respect	O
to	O
HIV	B-GENE
protease	I-GENE
.	O
These	O
compounds	O
are	O
synthesized	O
either	O
by	O
chemoenzymatic	O
or	O
chemical	O
methodologies	O
.	O
Methods	O
are	O
provided	O
for	O
producing	O
a	O
tetrahydroxyazepane	O
with	O
the	O
formula	O
:	O
(	O
see	O
formula	O
I	O
)	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
the	O
use	O
of	O
5HT3	B-GENE
antagonists	O
for	O
promoting	O
intestinal	O
lavage,	O
especially	O
in	O
combination	O
with	O
an	O
osmotic	O
agent	O
.	O


Novel	O
compounds	O
of	O
Formula	O
(	O
1	O
.	O
0	O
)	O
are	O
disclosed	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
farnesyl	B-GENE
protein	I-GENE
transferase	I-GENE
function	O
and	O
therefore	O
inhibiting	O
the	O
abnormal	O
growth	O
of	O
cells	O
.	O
The	O
method	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
1	O
.	O
0	O
)	O
to	O
a	O
biological	O
system	O
.	O
In	O
particular,	O
the	O
method	O
inhibits	O
the	O
abnormal	O
growth	O
of	O
cells	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
being	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
and	O
R1	O
to	O
R5	O
are	O
as	O
defined	O
in	O
the	O
description,	O
are	O
useful	O
for	O
treating	O
disorders	O
mediated	O
full	O
or	O
in	O
part	O
by	O
mGluR5	B-GENE
.	O


A	O
therapeutic	O
process	O
is	O
provided	O
for	O
the	O
inhibition	O
of	O
NF-.kappa.B	B-GENE
in	O
mammals	O
in	O
whose	O
cells	O
NF-.kappa.B	B-GENE
has	O
been	O
activated	O
by	O
an	O
agency	O
external	O
to	O
said	O
cell	O
.	O


A	O
chewable	O
dosage	O
form	O
containing	O
a	O
histamine	B-GENE
H2-receptor	I-GENE
antagonist	O
in	O
an	O
amount	O
which	O
is	O
effective	O
to	O
treat	O
a	O
gastrointestinal	O
disorder	O
is	O
provided	O
in	O
a	O
palatably	O
acceptable	O
form	O
.	O
The	O
dosage	O
form	O
comprises	O
granules	O
containing	O
the	O
histamine	B-GENE
H2--receptor	I-GENE
antagonist,	O
which	O
are	O
provided	O
with	O
a	O
taste-masking	O
coating	O
comprising	O
a	O
water-insoluble,	O
water-permeable	O
methacrylate	O
ester	O
copolymer	O
in	O
which	O
the	O
coating	O
is	O
applied	O
to	O
the	O
granules	O
in	O
an	O
amount	O
which	O
provides	O
a	O
taste-masking	O
effect	O
for	O
a	O
relatively	O
short	O
period	O
during	O
which	O
the	O
composition	O
is	O
being	O
chewed	O
by	O
a	O
patient,	O
but	O
which	O
allows	O
substantially	O
immediate	O
release	O
of	O
the	O
histamine	B-GENE
H2-receptor	I-GENE
antagonist	O
after	O
the	O
composition	O
has	O
been	O
chewed	O
and	O
ingested	O
.	O


The	O
invention	O
concerns	O
a	O
method	O
for	O
accelerating	O
the	O
digestion	O
rate	O
of	O
a	O
protein	O
matter	O
which	O
consists	O
in	O
treating	O
the	O
protein	O
matter	O
with	O
transglutaminase,	O
and	O
in	O
mixing	O
it	O
with	O
anionic	O
polysaccharides	O
.	O
The	O
invention	O
also	O
concerns	O
the	O
use	O
of	O
a	O
protein	O
matter	O
with	O
rapid	O
digestion	O
for	O
preparing	O
a	O
food	O
or	O
pharmaceutical	O
composition	O
to	O
be	O
orally	O
administered	O
to	O
a	O
mammal	O
so	O
as	O
to	O
induce	O
a	O
postprandial	O
peak	O
of	O
plasma	O
increase	O
in	O
amino	O
acids	O
.	O
Said	O
composition	O
is	O
designed	O
for	O
modulating	O
postprandial	O
protein	O
gain,	O
and	O
or	O
limiting	O
problems	O
related	O
to	O
disorders	O
of	O
gastrointestinal	O
motility,	O
and	O
/	O
or	O
limiting	O
postprandial	O
feelings	O
of	O
nausea	O
in	O
pregnant	O
women,	O
and	O
/	O
or	O
limiting	O
postprandial	O
risks	O
of	O
regurgitation	O
and	O
/	O
or	O
gastroesophageal	O
reflux	O
.	O
Finally	O
the	O
invention	O
also	O
concerns	O
a	O
food	O
or	O
pharmaceutical	O
composition	O
comprising	O
anionic	O
polysaccharides	O
and	O
a	O
protein	O
matter	O
treated	O
with	O
transglutaminase	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
cyclopentenopyridine	O
derivative	O
represented	O
by	O
general	O
formula	O
[	O
I	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
Ar	O
is	O
a	O
phenyl	O
group	O
or	O
the	O
like,	O
R1	O
is	O
a	O
mono-or	O
di-C1-C6	O
alkylamino	O
group	O
or	O
the	O
like,	O
and	O
R2	O
is	O
a	O
hydroxyl	O
group	O
or	O
the	O
like,	O
a	O
process	O
for	O
its	O
production	O
and	O
its	O
use	O
as	O
endothelin	B-GENE
antagonist	O
.	O


The	O
present	O
invention	O
provides	O
a	O
single-stranded	O
oligodeoxyribonucleotide,	O
which	O
(	O
i	O
)	O
comprises	O
from	O
about	O
5	O
to	O
11	O
bases,	O
at	O
least	O
one	O
of	O
which	O
is	O
a	O
substituted	O
or	O
an	O
unsubstituted	O
O6-benzylguanine,	O
and	O
(	O
ii	O
)	O
inactivates	O
human	B-GENE
AGT	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
single-stranded	O
oligodeoxyribonucleotide,	O
which	O
can	O
inactivate	O
a	O
mutant	O
human	O
AGT,	O
which	O
either	O
is	O
not	O
inactivated	O
by	O
O6-benzylguanine	O
or	O
is	O
less	O
inactivated	O
by	O
O6-benzylguanine	O
than	O
by	O
said	O
single-stranded	O
oligodeoxyribonucleotide	O
.	O
A	O
phosphate	O
of	O
the	O
single-stranded	O
oligodeoxyribonucleotide	O
can	O
be	O
replaced	O
by	O
a	O
methylphosphonate	O
or	O
a	O
phosphorothioate	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
composition	O
comprising	O
such	O
an	O
oligodeoxyribonucleotide	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
enhancing	O
the	O
effect	O
of	O
an	O
antineoplastic	O
alkylating	O
agent,	O
which	O
alkylates	O
the	O
O6	O
position	O
of	O
guanine	O
residues	O
in	O
DNA,	O
in	O
the	O
chemotherapeutic	O
treatment	O
of	O
cancer	O
in	O
a	O
mammal,	O
which	O
method	O
comprises	O
the	O
co-administration	O
to	O
the	O
mammal	O
of	O
a	O
cancer-treatment	O
effective	O
amount	O
of	O
an	O
antineoplastic	O
alkylating	O
agent	O
and	O
a	O
chemotherapeutic	O
treatment-enhancing	O
amount	O
of	O
a	O
present	O
inventive	O
oligodeoxyribonucleotide	O
or	O
composition	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
processes	O
for	O
the	O
production	O
of	O
mistletoe	B-GENE
lectin	I-GENE
polypeptides	O
in	O
homologous	O
and	O
heterologous	O
host	O
systems	O
and	O
mistletoe	B-GENE
lectin	I-GENE
peptides	O
as	O
such	O
.	O
Further,	O
nucleic	O
acid	O
molecules	O
are	O
provided,	O
which	O
code	O
for	O
these	O
mistletoe	B-GENE
lectin	I-GENE
polypeptides,	O
and	O
also	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
mistletoe	B-GENE
lectin	I-GENE
polypeptides	O
or	O
mistletoe	B-GENE
lectin	I-GENE
nucleic	O
acids	O
.	O
	O
	O
In	O
order	O
to	O
produce	O
the	O
many	O
mistletoe	B-GENE
lectin	I-GENE
isoenzymes	O
contained	O
in	O
the	O
natural	O
mistletoe	O
extract,	O
which	O
can	O
trigger	O
anti-tumorigenic	O
and	O
mood-brightening	O
effects,	O
in	O
sufficient	O
quantities,	O
the	O
present	O
invention	O
provides	O
a	O
process	O
which	O
makes	O
it	O
possible	O
to	O
produce	O
mistletoe	B-GENE
lectins	I-GENE
in	O
required	O
quantities	O
biotechnologically	O
and	O
at	O
the	O
same	O
time	O
to	O
recreate	O
the	O
diversity	O
of	O
the	O
natural	O
mistletoe	O
extract	O
in	O
mistletoe	B-GENE
lectin	I-GENE
isoenzymes	O
.	O


This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cyclic	B-GENE
guanosine	I-GENE
3',	I-GENE
5'-monophosphate	I-GENE
phosphodiesterase	I-GENE
type	I-GENE
five	I-GENE
(	O
cGMP	B-GENE
PDE5	I-GENE
)	O
inhibitors,	O
including	O
in	O
particular	O
the	O
compound	O
sildenafil,	O
in	O
combination	O
with	O
gabapentin	O
or	O
pregabalin,	O
which	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neuropathy,	O
including	O
in	O
particular	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
IA	O
)	O
and	O
of	O
Formula	O
(	O
IB	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
A	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
which	O
are	O
useful	O
in	O
the	O
curative	O
and	O
prophylactic	O
treatment	O
of	O
medical	O
conditions	O
for	O
which	O
inhibition	O
of	O
a	O
cyclic	B-GENE
guanosine	I-GENE
3',5'-monophosphate	I-GENE
phosphodiesterase	I-GENE
(	O
e	O
.	O
g	O
.	O
cGMP	O
PDE5	B-GENE
)	O
is	O
desired	O
.	O


Process	O
for	O
the	O
manufacturing	O
of	O
slightly	O
soluble	O
or	O
less	O
soluble	O
alkaline	O
salts	O
of	O
substituted	O
sulphinyl	O
heterocycles	O
containing	O
an	O
imidazole	O
moiety	O
with	O
formula	O
(	O
I	O
)	O
,	O
preferably	O
alkaline	O
salts	O
of	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
compound,	O
wherein	O
the	O
process	O
comprises	O
the	O
step	O
of	O
reacting	O
the	O
substituted	O
sulphinyl	O
heterocycle	O
of	O
formula	O
(	O
I	O
)	O
with	O
a	O
source	O
of	O
the	O
cation	O
in	O
the	O
presence	O
of	O
a	O
base,	O
characterized	O
by	O
a	O
washing	O
step	O
in	O
which	O
the	O
prepared	O
alkaline	O
salt	O
of	O
the	O
substituted	O
sulphinyl	O
compound	O
is	O
washed	O
with	O
a	O
basic	O
aqueous	O
solvent	O
mixture	O
.	O
The	O
obtained	O
bulk	O
drug	O
substance	O
resulting	O
in	O
a	O
bulk	O
product	O
that	O
in	O
an	O
aqueous	O
suspension	O
of	O
the	O
substituted	O
sulphinyl	O
heterocycle	O
having	O
a	O
pH	O
not	O
significantly	O
lower	O
than	O
that	O
of	O
a	O
saturated	O
water	O
solution	O
of	O
the	O
pure	O
compound	O
prepared	O
.	O
Alternatively,	O
the	O
process	O
for	O
manufacturing	O
a	O
pharmaceutical	O
dosage	O
form	O
comprising	O
the	O
active	O
substance	O
could	O
be	O
adjusted	O
.	O
For	O
instance	O
the	O
pH	O
of	O
an	O
aqueous	O
suspension	O
of	O
the	O
active	O
substance	O
is	O
adjusted	O
to	O
a	O
pH	O
not	O
significantly	O
lower	O
than	O
that	O
of	O
a	O
saturated	O
water	O
solution	O
of	O
the	O
pure	O
compound	O
.	O
The	O
processes	O
are	O
preferably	O
useful	O
in	O
the	O
manufacturing	O
of	O
omeprazole	O
magnesium	O
salt	O
or	O
magnesium	O
salt	O
of	O
one	O
of	O
its	O
single	O
enantiomers	O
used	O
in	O
pharmaceutical	O
dosage	O
forms	O
.	O


A	O
composition	O
and	O
method	O
for	O
treating	O
periodontal	O
disease	O
is	O
provided	O
comprising	O
resveratrol	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
composition	O
is	O
particularly	O
useful	O
for	O
administration	O
to	O
individuals	O
at	O
high	O
risk	O
of	O
developing	O
periodontal	O
disease	O
such	O
as	O
those	O
who	O
smoke	O
tobacco	O
products	O
and	O
those	O
exposed	O
to	O
second-hand	O
tobacco	O
smoke	O
or	O
environmental	O
pollutant	O
AhR	B-GENE
ligands	O
.	O


The	O
present	O
invention	O
provides	O
end-blocked	O
nucleic	O
acids,	O
e	O
.	O
g	O
.	O
,	O
2	O
'	O
-O-R,	O
2	O
'	O
-O-R-O-R,	O
3	O
'	O
-O-R,	O
and	O
3	O
'	O
-O-R-O-R	O
oligonucleotides,	O
that	O
exhibit	O
significant	O
low	O
pH	O
stability,	O
nuclease	B-GENE
resistance	O
and	O
optionally	O
antibacterial	O
properties	O
.	O
These	O
low	O
toxicity,	O
highly	O
specific,	O
acid	O
stable,	O
end-blocked	O
nucleic	O
acids	O
represent	O
a	O
novel	O
and	O
improved	O
oligonucleotide	O
structure	O
for	O
therapeutic	O
treatments	O
of	O
diseases	O
.	O
The	O
3	O
'	O
and	O
5	O
'	O
acid	O
stable,	O
exonuclease	B-GENE
resistant	O
polymers	O
of	O
the	O
invention	O
are	O
shown	O
here	O
to	O
provide	O
antibacterial	O
effects	O
when	O
applied	O
in	O
vivo,	O
e	O
.	O
g	O
.	O
,	O
applied	O
topically	O
to	O
skin	O
with	O
actual	O
sites	O
of	O
infection	O
on	O
dogs	O
and	O
humans	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
retinoid	B-GENE
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
dotted	O
bond	O
is	O
optional	O
;	O
and,	O
when	O
the	O
dotted	O
bond	O
is	O
present,	O
R1	O
is	O
lower	O
alkyl	O
and	O
R2	O
is	O
hydrogen	O
;	O
and,	O
when	O
the	O
dotted	O
bond	O
is	O
absent,	O
R1	O
and	O
R2	O
taken	O
together	O
are	O
methylene	O
to	O
form	O
a	O
cis-substituted	O
cyclopropyl	O
ring	O
;	O
R3	O
is	O
hydroxy	O
or	O
lower	O
alkoxy	O
;	O
R4	O
is	O
alkyl	O
or	O
alkoxy	O
;	O
and	O
R5	O
and	O
R6	O
are,	O
independently,	O
a	O
C4-12	O
alkyl	O
group	O
or	O
a	O
mono-	O
or	O
polycyclic	O
C5-12-hydrocarbon	O
group	O
which	O
are	O
linked	O
to	O
the	O
phenyl	O
ring	O
through	O
a	O
quaternary	O
carbon	O
atom,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
carboxylic	O
acids	O
of	O
formula	O
(	O
I	O
)	O
;	O
the	O
use	O
of	O
retinoid	B-GENE
antagonists,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
or	O
pharmaceutically	O
acceptable	O
hydrolyzable	O
esters,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
T-helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
-mediated	O
immune	O
diseases,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
and	O
for	O
use	O
in	O
the	O
treatment	O
of	O
preneoplastic	O
and	O
neoplastic	O
diseases	O
.	O


Designed	O
iminocyclitols	O
have	O
potent	O
inhibition	O
activity	O
with	O
respect	O
to	O
hexoaminidases	B-GENE
and	O
glycosidases	B-GENE
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	O
or	O
halogen	O
;	O
R2	O
is	O
hydrogen,	O
halogen,	O
lower	O
alkyl	O
or	O
lower	O
alkoxy	O
;	O
R1	O
and	O
R2	O
may	O
be	O
together	O
with	O
the	O
two	O
carbon	O
atoms	O
-CH	O
=	O
CH-CH	O
=	O
CH-	O
;	O
R3	O
is	O
halogen,	O
trifluoromethyl,	O
lower	O
alkyl	O
or	O
lower	O
alkoxy	O
;	O
R4	O
/	O
R4	O
'	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
R5	O
is	O
lower	O
alkyl,	O
lower	O
alkoxy,	O
amino,	O
phenyl,	O
hydroxy-lower	O
alkyl,	O
cyano-lower	O
alkyl,	O
carbamoyl-lower	O
alkyl,	O
pyridyl,	O
pyrimidyl,	O
-	O
(	O
CH2	O
)	O
n-piperazinyl,	O
which	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
lower	O
alkyl	O
groups	O
or	O
by	O
hydroxy-lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-morpholinyl,	O
-	O
(	O
CH2	O
)	O
n--piperidinyl,	O
-	O
(	O
CH2	O
)	O
n+1-imidazolyl,	O
lower	O
alkyl-sulfanyl,	O
lower	O
alkyl-sulfonyl,	O
benzylamino,	O
-NH-	O
(	O
CH2	O
)	O
n+1N	O
(	O
R4"	O
)	O
2,	O
-	O
(	O
CH2	O
)	O
n+1N	O
(	O
R4"	O
)	O
2,	O
-O-	O
(	O
CH2	O
)	O
n+1-morpholinyl,	O
-O-	O
(	O
CH2	O
)	O
n+1-piperidinyl	O
or	O
-O-	O
(	O
CH2	O
)	O
n+1N	O
(	O
R4"	O
)	O
2,	O
wherein	O
R4"	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
and	O
n	O
is	O
0-	O
2	O
;	O
X	O
is	O
-C	O
(	O
O	O
)	O
N	O
(	O
R4"	O
)	O
-	O
or	O
-N	O
(	O
R4"	O
)	O
C	O
(	O
O	O
)	O
-	O
;	O
and	O
to	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O
It	O
has	O
been	O
shown	O
that	O
the	O
compounds	O
have	O
a	O
good	O
affinity	O
to	O
the	O
NK-1	B-GENE
receptor	I-GENE
and	O
may	O
therefore	O
be	O
used	O
for	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
this	O
receptor	O
.	O


Modulators	O
of	O
PPAR	O
.	O
gamma	O
.	O
activity	O
are	O
provided	O
having	O
the	O
following	O
formula,	O
which	O
modulators	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O
	O
	O
(	O
See	O
above	O
Formula	O
)	O


The	O
invention	O
relates	O
to	O
arylsulphonamide-substituted	O
benzimidazole	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
wherein	O
the	O
groups	O
R1,	O
R2,	O
R3	O
and	O
R4	O
may	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
specification,	O
processes	O
for	O
preparing	O
them	O
as	O
well	O
as	O
the	O
use	O
of	O
arylsulphonamide-substituted	O
benzimidazole	O
derivatives	O
as	O
pharmaceutical	O
compositions,	O
particularly	O
as	O
pharmaceutical	O
compositions	O
with	O
a	O
tryptase-inhibiting	O
activity	O
.	O


The	O
identification	O
of	O
the	O
HYAL1	B-GENE
hyaluronidase	I-GENE
enzyme	O
as	O
a	O
human	B-GENE
plasma-derived	I-GENE
myeloid	I-GENE
colony-stimulating	I-GENE
factor	I-GENE
(	O
CSF	B-GENE
)	O
,	O
herein	O
designated	O
CSF5-hyaluronidase,	O
its	O
recombinant	O
production	O
and	O
methods	O
of	O
use	O
are	O
described	O
.	O
This	O
protein	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
myelosuppression	O
as	O
may	O
occur	O
after	O
irradiation,	O
chemotherapy	O
or	O
other	O
diseases	O
where	O
an	O
increase	O
in	O
leukocyte	O
levels	O
may	O
be	O
beneficial	O
.	O
For	O
example,	O
CSF5	B-GENE
may	O
be	O
used	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
or	O
other	O
diseases	O
associated	O
with	O
immune	O
suppression	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
preparation	O
and	O
use	O
of	O
novel	O
enhanced	O
biological	O
tissue	O
adhesives	O
which	O
rely	O
on	O
combining	O
fibrinogen	B-GENE
and	O
thrombin	B-GENE
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
preparing	O
a	O
fibrin	B-GENE
sealant	O
whereby	O
said	O
sealant	O
is	O
formed	O
by	O
reconstituting	O
the	O
fibrinogen	B-GENE
component	O
in	O
the	O
presence	O
of	O
various	O
critical	O
biological	O
and	O
non-biological	O
agents	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
novel	O
method	O
of	O
using	O
said	O
enhanced	O
fibrin	B-GENE
sealant	O
whereby	O
the	O
sealant	O
and	O
accompanying	O
agent	O
are	O
delivered	O
directly	O
to	O
a	O
critical	O
site	O
within	O
the	O
body	O
and	O
sealed	O
in	O
place	O
due	O
to	O
the	O
biostatic	O
quality	O
of	O
the	O
sealant	O
resulting	O
in	O
enhanced	O
therapeutic	O
value	O
derived	O
by	O
the	O
prolonged	O
presence,	O
and	O
optionally	O
time-released	O
delivery,	O
of	O
said	O
accompanying	O
agent	O
at	O
the	O
critical	O
site	O
.	O


Inhibitors	O
of	O
serine	B-GENE
proteases	I-GENE
are	O
provided	O
having	O
formula	O
(	O
I	O
)	O
wherein	O
X,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
herein	O
.	O
In	O
particular,	O
the	O
compounds	O
bind	O
to	O
factor	O
VIIa,	O
tissue	B-GENE
factor	O
/	O
factor	B-GENE
Xa	I-GENE
complex,	O
thrombin,	O
trypsin,	O
plasmin	B-GENE
and	O
kallikrein	B-GENE
and	O
have	O
anticoagulant	O
activity	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
are	O
useful	O
for	O
inhibiting	O
the	O
formation	O
of	O
veinous	O
and	O
/	O
or	O
arterial	O
thrombi	O
in	O
vivo	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptor	I-GENE
(	O
PPAR	B-GENE
)	O
activator	O
and	O
a	O
benzoquinone	O
and	O
their	O
use	O
in	O
treating	O
and	O
/	O
or	O
preventing	O
disorders	O
characterized	O
by	O
endothelial	O
dysfunction,	O
such	O
as	O
cardiovascular	O
disease,	O
strokes	O
and	O
myocardial	O
infarction	O
.	O
According	O
to	O
a	O
preferred	O
embodiment	O
of	O
the	O
invention	O
the	O
benzoquinone	O
or	O
precursor	O
thereof	O
is	O
a	O
ubiquinone	O
or	O
precursor	O
thereof,	O
more	O
preferably,	O
coenzyme	O
Q10	O
or	O
a	O
precursor	O
thereof,	O
and	O
the	O
PPAR	B-GENE
activator	O
is	O
a	O
fibrate	O
or	O
a	O
thiazolidinedione,	O
more	O
preferably	O
fenofibrate	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
polypeptide	O
which	O
comprises	O
i	O
)	O
a	O
first	O
portion	O
comprising	O
the	O
part	O
of	O
human	B-GENE
Fc	I-GENE
which	O
binds	O
to	O
CD64,	O
and	O
ii	O
)	O
a	O
second	O
portion	O
comprising	O
one	O
or	O
more	O
heterologous	O
T	O
cell	O
epitopes	O
for	O
stimulating	O
a	O
cytotoxic	O
T	O
cell	O
response	O
.	O
The	O
polypeptide	O
may	O
be	O
an	O
antibody	O
which	O
may	O
be	O
used	O
to	O
stimulate	O
an	O
cytotoxic	O
T	O
cell	O
response	O
against	O
pathogens	O
and	O
tumour	O
cells	O
in	O
patients	O
in	O
need	O
of	O
such	O
treatment	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
and	O
potent	O
tumor	O
antigen	O
capable	O
of	O
causing	O
T	O
cells	O
to	O
elicit	O
an	O
immune	O
response	O
and	O
methods	O
of	O
its	O
use	O
in	O
the	O
detection,	O
prevention,	O
and	O
treatment	O
of	O
cancer,	O
preferably	O
melanoma,	O
in	O
mammals	O
.	O
More	O
specifically,	O
this	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
a	O
novel	O
tyrosinase-related	B-GENE
protein	I-GENE
2	I-GENE
(	O
TRP2	B-GENE
)	O
,	O
specifically	O
TRP2-6b	B-GENE
protein,	O
and	O
peptides	O
derived	O
from	O
said	O
protein	O
.	O
The	O
present	O
invention	O
therefore	O
also	O
relates	O
to	O
nucleic	O
acid	O
sequences	O
that	O
encode	O
the	O
TRP2-6b	B-GENE
protein	I-GENE
or	O
peptide	O
fragments	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
a	O
combination	O
therapy	O
for	O
the	O
treatment	O
of	O
tumors	O
metastases	O
comprising	O
administration	O
of	O
anti-angiogenic	O
agents	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TNF	O
.	O
alpha	O
.	O
)	O
optionally	O
together	O
with	O
other	O
cytotoxic	O
agents,	O
such	O
as	O
interferon	B-GENE
gamma	I-GENE
(	O
IFNy	B-GENE
)	O
orchemotherapeutic	O
agents	O
such	O
as	O
anti-EGFR	O
antibodies	O
.	O
The	O
method	O
and	O
the	O
pharmaceuticalcompositions	O
comprising	O
said	O
agents	O
can	O
result	O
in	O
a	O
synergistic	O
potentiation	O
of	O
the	O
tumor	O
cell	O
proliferation	O
inhibition	O
effect	O
of	O
each	O
individual	O
therapeutic	O
agent,	O
yielding	O
more	O
effective	O
treatment	O
than	O
found	O
by	O
administering	O
an	O
individual	O
component	O
alone	O
.	O


The	O
present	O
invention	O
relates	O
to	O
Bar-locus-homeobox-like	B-GENE
(	O
Barhl	B-GENE
)	O
derived	O
peptides,	O
and	O
more	O
particularly	O
to	O
polypeptides	O
derived	O
from	O
Barhl2	B-GENE
polypeptides,	O
the	O
polynucleotides	O
coding	O
for	O
the	O
polypeptides	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
the	O
polypeptides	O
or	O
polynucleotides	O
in	O
the	O
prognostic	O
or	O
diagnostic,	O
in	O
the	O
prevention	O
and	O
in	O
the	O
treatment	O
of	O
certain	O
types	O
of	O
diseases	O
associated	O
with	O
proliferation	O
of	O
unhealthy	O
cells	O
and	O
/	O
or	O
abnormal	O
elimination	O
of	O
normal	O
cells	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
effective	O
method	O
of	O
treating	O
PML	O
(	O
human	O
progressive	O
multifocal	O
leukoencephalopathy	O
)	O
.	O
A	O
method	O
of	O
inhibiting	O
the	O
proliferation	O
of	O
JC	O
virus	O
in	O
JC	O
virus-infected	O
cells	O
by	O
inhibiting	O
the	O
expression	O
of	O
JV	B-GENE
virus	I-GENE
agno	I-GENE
gene	I-GENE
;	O
and	O
a	O
method	O
of	O
inhibiting	O
the	O
canceration	O
of	O
JC	O
virus-infected	O
cells	O
.	O


Method	O
of	O
preventing	O
or	O
reducing	O
diarrhea	O
and	O
correcting	O
fat	O
malabsorption	O
(	O
steatorrhea	O
)	O
and	O
loss	O
of	O
body	O
mass	O
in	O
HIV-positive	O
patients	O
being	O
treated	O
with	O
High	O
Activity	O
Antiretroviral	O
drugs	O
(	O
HAART	O
)	O
containing	O
protease	O
inhibitors,	O
nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitors	O
or	O
non-nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitors	O
and	O
by	O
co-administering	O
with	O
the	O
HAART	O
a	O
buffered	O
pancrelipase	O
composition	O
.	O
The	O
method	O
includes	O
the	O
steps	O
of	O
:	O
administering	O
to	O
the	O
HIV-positive	O
patient	O
a	O
High	O
Activity	O
Antiretroviral	O
drug	O
containing	O
a	O
protease	O
inhibitor,	O
a	O
nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitor	O
or	O
a	O
non-nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitor	O
;	O
and	O
co-administering	O
with	O
the	O
HAART	O
drug	O
a	O
gastric	O
acid-resistant	O
polymer-coated	O
and	O
buffered	O
pancrelipase	O
enzyme	O
composition	O
containing	O
pancreatic	O
proteases,	O
lipases,	O
co-lipases,	O
nucleases,	O
amylases	B-GENE
and	O
other	O
bio-active	O
substances	O
produced	O
by	O
the	O
pancreatic	O
gland	O
.	O


A	O
method	O
of	O
modulating	O
motor	O
neuron	O
activity	O
in	O
a	O
patient	O
in	O
need	O
thereof,	O
the	O
method	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
Müllerian	B-GENE
inhibitory	I-GENE
substance	I-GENE
receptor	I-GENE
agonist	O
or	O
antagonist	O
.	O


It	O
is	O
intended	O
to	O
provide	O
medicinal	O
compositions	O
and	O
the	O
like	O
useful	O
in	O
treating	O
depression	O
which	O
contain	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
(	O
for	O
example,	O
(	O
E	O
)	O
-8-	O
(	O
3,4-dimethoxystyryl	O
)	O
-1,3-diethyl-7-methyl-3,7-dihydro-1H-purin-2,6-dione	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
together	O
with	O
an	O
antidepressant	O
(	O
for	O
example,	O
a	O
tricyclic	O
antidepressant,	O
a	O
tetracyclic	O
antidepressant,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor,	O
a	O
selective	O
noradrenaline	O
reuptake	O
inhibitor,	O
a	O
dopamine	O
reuptake	O
inhibitor,	O
a	O
serotonin	O
/	O
noradrenaline	O
reuptake	O
inhibitor,	O
a	O
monoamine	B-GENE
oxidase	I-GENE
inhibitor	O
or	O
a	O
serotonin	B-GENE
2	I-GENE
antagonist	O
)	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
prostate	O
cancer	O
.	O
The	O
composition	O
comprises	O
a	O
morpholino	O
antisense	O
compound	O
having	O
uncharged	O
phosphorus-containing	O
backbone	O
linkages	O
and	O
a	O
base	O
sequence	O
that	O
is	O
complementary	O
to	O
a	O
target	O
region	O
containing	O
at	O
least	O
12	O
contiguous	O
bases	O
in	O
a	O
preprocessed	O
or	O
processed	O
human	B-GENE
androgen	I-GENE
receptor	I-GENE
transcript	O
.	O
The	O
method	O
is	O
designed	O
for	O
treating	O
prostate	O
cancer	O
in	O
a	O
subject	O
having	O
a	O
hormone-refractory	O
(	O
androgen-independent	O
)	O
prostate	O
cancer	O
.	O


A	O
use	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
cathepsin	B-GENE
B	I-GENE
inhibitor	O
for	O
correcting	O
bone	O
mineralization	O
defect	O
.	O


This	O
application	O
describes	O
fluormated	O
(	O
+	O
)	O
PHNO	O
and	O
analogs	O
thereof,	O
including	O
radiolabeled	O
analogs,	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
C1-6	O
alkyl	O
in	O
which	O
one	O
hydrogen	O
atom	O
on	O
the	O
alkyl	O
chain	O
is	O
replaced	O
with	O
fluoro	O
or	O
radioactive	O
fluoro	O
.	O
The	O
application	O
further	O
describes	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
have	O
good	O
affinity	O
and	O
selectivity	O
for	O
the	O
dopamine	B-GENE
D2	I-GENE
receptors	I-GENE
and	O
are	O
therefore	O
useful	O
for	O
the	O
labelling	O
of	O
dopamine	B-GENE
D2	I-GENE
receptors	I-GENE
in	O
vivo	O
and	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
the	O
extent	O
of	O
dopamine	O
supersensitivity	O
in	O
the	O
bram	O
in	O
various	O
stages	O
of	O
a	O
dopamine-related	O
disease	O
.	O


A	O
nutritional	O
composition	O
for	O
improving	O
blood	O
cholesterol	O
by	O
jointly	O
and	O
simultaneously	O
inhibiting	O
cholesterol	O
absorption,	O
decreasing	O
blood	O
LDL	B-GENE
levels,	O
increasing	O
blood	O
HDL	B-GENE
levels	O
and	O
interfering	O
with	O
HMG-CoA	B-GENE
reductase	I-GENE
synthesis	O
or	O
degradation	O
in	O
an	O
individual	O
comprising,	O
therapeutically	O
effective	O
amounts	O
of	O
plant	O
sterols	O
or	O
plant	O
stanols	O
or	O
derivatives	O
thereof,	O
procyanidins,	O
policosanol	O
and	O
niacin	O
or	O
derivatives	O
of	O
niacin	O
is	O
provided	O
.	O
Both	O
a	O
composition	O
and	O
a	O
method	O
are	O
provided	O
by	O
the	O
present	O
disclosure	O
.	O


A	O
nutritional	O
composition	O
comprising	O
at	O
least	O
an	O
effective	O
amount	O
of	O
geranylgeranylacetone	O
or	O
derivative	O
of	O
geranygeranylacetone	O
and	O
/	O
or	O
paeoniflorin	O
or	O
derivative	O
of	O
paeoniflorin	O
and	O
an	O
effective	O
amount	O
of	O
Schisandrin	O
B,	O
wherein	O
the	O
ingredients	O
act	O
substantially	O
simultaneously,	O
via	O
differing	O
mechanism,	O
to	O
enhance	O
the	O
expression	O
of	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
in	O
cells,	O
particularly	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
72	I-GENE
in	O
skeletal	O
muscle	O
.	O
A	O
method	O
of	O
same	O
is	O
also	O
provided	O
.	O


The	O
invention	O
provides	O
a	O
process	O
for	O
preparation	O
of	O
tiotropium	O
salts	O
of	O
Formula	O
1	O
(	O
see	O
formula	O
1	O
)	O
wherein	O
a	O
compound	O
of	O
Formula	O
2	O
(	O
see	O
formula	O
2	O
)	O
is	O
reacted	O
in	O
one	O
step	O
with	O
a	O
compound	O
of	O
Formula	O
3	O
(	O
see	O
formula	O
3	O
)	O
in	O
the	O
presence	O
of	O
a	O
solvent	O
and	O
a	O
catalyst	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
zeolites,	O
alkoxides,	O
lipases	B-GENE
and	O
tertiary	O
amines	O
to	O
obtain	O
a	O
compound	O
of	O
Formula	O
4	O
(	O
see	O
formula	O
4	O
)	O
and	O
without	O
being	O
isolated,	O
the	O
compound	O
of	O
Formula	O
4	O
is	O
converted	O
to	O
the	O
compound	O
of	O
Formula	O
1	O
with	O
a	O
salt	O
of	O
Formula	O
cat+X-	O
.	O


The	O
invention	O
provides	O
cereal	O
plants	O
having	O
a	O
high	O
level	O
of	O
fructan	O
useful	O
for	O
the	O
production	O
of	O
a	O
range	O
of	O
food,	O
beverage,	O
nutraceutical	O
and	O
pharmaceutical	O
products	O
.	O
The	O
invention	O
provides	O
methods	O
of	O
producing	O
high-fructan	O
products	O
from	O
plants	O
modified	O
to	O
comprise	O
a	O
reduced	O
level	O
of	O
an	O
endogenous	O
polypeptide	O
with	O
starch	B-GENE
synthase	I-GENE
activity,	O
and	O
products	O
so	O
produced	O
.	O
In	O
some	O
embodiments,	O
plants	O
are	O
modified	O
by	O
introduction	O
of	O
an	O
agent	O
such	O
as	O
a	O
nucleic	O
acid	O
molecule	O
which	O
down	O
regulates	O
endogenous	B-GENE
starch	B-GENE
synthase	I-GENE
II	I-GENE
gene	O
expression	O
.	O


Class	B-GENE
A	I-GENE
beta-lactamase	I-GENE
may	O
be	O
used	O
for	O
reducing	O
side-	O
effects	O
in	O
the	O
intestine	O
associated	O
with	O
antibiotic	O
therapy	O
with	O
a	O
combination	O
of	O
beta-iactam	O
antibiotic	O
and	O
beta-	B-GENE
lactamase	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
4-	O
(	O
Heterocyclyl	O
)	O
alkyl-N-	O
(	O
arylsulfonyl	O
)	O
indole	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives,	O
their	O
stereoisomers,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
above	O
said	O
novel	O
compounds,	O
their	O
derivatives,	O
their	O
stereoisomers,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
that	O
are	O
related	O
to	O
5-HT6	B-GENE
receptor	O
functions	O
.	O
Specifically,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
CNS	O
disorders,	O
hematological	O
disorders,	O
eating	O
disorders,	O
diseases	O
associated	O
with	O
pain,	O
respiratory	O
diseases,	O
genito-urological	O
disorders,	O
cardiovascular	O
diseases	O
and	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
uses	O
thereof	O
for	O
treating	O
cancers	O
which	O
have	O
acquired	O
resistance	O
to	O
a	O
KIT	B-GENE
inhibitor	O
by	O
administering	O
effective	O
amounts	O
of	O
DAST	O
(	O
4	O
{	O
4-	O
[	O
3-	O
(	O
4-chloro-3-	O
trifluoromethylphenyf	O
)	O
-ureido	O
]	O
-3-fluorophenoxy	O
}	O
-pyridine	O
-2-carboxylic	O
acid	O
methylamide	O
.	O
)	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
TGF-beta	B-GENE
stimulating	O
agents,	O
and	O
in	O
particular	O
members	O
of	O
the	O
triphenylethylene	O
class	O
of	O
pharmaceutical	O
agents,	O
for	O
the	O
prevention,	O
prophylaxis,	O
treatment	O
or	O
amelioration	O
of	O
symptoms	O
of	O
cardiovascular	O
disease,	O
autoimmune	O
diseases	O
or	O
neurodegeneration	O
.	O
In	O
particular,	O
improved	O
compositions	O
consisting	O
of	O
triphenylethylene	O
agents	O
combined	O
with	O
one	O
or	O
more	O
additional	O
active	O
pharmaceutical	O
agents	O
in	O
order	O
to	O
mitigate	O
against	O
side-effects	O
of	O
the	O
triphenylethylene	O
are	O
described	O
and	O
claimed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
specific	O
types	O
of	O
compounds	O
acting	O
as	O
pharmacological	O
chaperones	O
having	O
a	O
stabilizing	O
activity	O
op	O
the	O
phenylalanine	B-GENE
hydroxylase	I-GENE
(	O
PAH	B-GENE
)	O
enzyme	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
hyperphenylalaninemia	O
(	O
HPA	O
)	O
and	O
phenylketonuria	O
(	O
PKU	O
)	O
and	O
diseases,	O
disorders	O
and	O
conditions	O
related	O
thereto	O
.	O
Further,	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
as	O
well	O
as	O
to	O
methods	O
of	O
treatment	O
of	O
HPA,	O
in	O
particular,	O
PKU	O
and	O
diseases,	O
disorders	O
and	O
conditions	O
related	O
thereto	O
.	O


A	O
method	O
and	O
compound	O
for	O
suppressing	O
an	O
immune	O
response	O
in	O
a	O
mammalian	O
subject,	O
for	O
the	O
treatment	O
or	O
pre-vention	O
of	O
an	O
autoimmune	O
condition	O
or	O
transplantation	O
rejection	O
are	O
disclosed	O
.	O
The	O
compound	O
is	O
an	O
antisense	O
oligonucleotide	O
ana-log	O
compound	O
having	O
a	O
targeting	O
sequence	O
complementary	O
to	O
a	O
preprocessed	O
CTLA	B-GENE
4	I-GENE
mRNA	O
region	O
identified	O
by	O
SEQ	O
ID	O
NO	O
:	O
22	O
in	O
SEQ	O
ID	O
NO	O
:	O
1,	O
spanning	O
the	O
splice	O
junction	O
between	O
intron	O
1	O
and	O
exon	O
2	O
of	O
the	O
preprocessed	O
mRNA	O
of	O
the	O
subject	O
.	O
The	O
com-pound	O
is	O
effective,	O
when	O
administered	O
to	O
a	O
subject,	O
to	O
form	O
within	O
host	O
cells,	O
a	O
heteroduplex	O
structure	O
(	O
i	O
)	O
composed	O
of	O
the	O
prepro-cessed	O
CTLA	B-GENE
4	I-GENE
mRNA	O
and	O
the	O
oligonucleotide	O
compound,	O
(	O
ii	O
)	O
characterized	O
by	O
a	O
Tm	O
of	O
dissociation	O
of	O
at	O
least	O
45°C,	O
and	O
(	O
iii	O
)	O
re-sulting	O
in	O
an	O
increased	O
ratio	O
of	O
processed	O
mRNA	O
encoding	O
ligand	O
independent	O
CTLA	B-GENE
4	I-GENE
to	O
processed	O
mRNA	O
encoding	O
full	O
length	O
CTLA	B-GENE
4	I-GENE
.	O


Disclosed	O
are	O
methods	O
and	O
compositions	O
for	O
modulating	O
the	O
function	O
of	O
transcription	O
factors,	O
especially	O
transcription	O
factors	O
that	O
recruit	O
epigenetic	O
regulators	O
(	O
histone	O
modifying	O
enzymes	O
)	O
to	O
specific	O
DNA	O
promoters	O
.	O
The	O
targeted	O
transcription	O
factors	O
include	O
but	O
are	O
not	O
limited	O
to	O
the	O
myocyte	B-GENE
enhancing	I-GENE
factor	I-GENE
(	O
MEF2	B-GENE
)	O
,	O
the	O
forkhead	O
/	O
winged	O
helix	O
transcription	I-GENE
factor	I-GENE
FOX-P3	B-GENE
and	O
the	O
transcription	O
factor	I-GENE
GATA3	B-GENE
.	O
Also	O
disclosed	O
are	O
small	O
molecule	O
modulators	O
of	O
MEF2	B-GENE
and	O
its	O
associated	O
factors	O
that	O
include	O
but	O
not	O
limited	O
to	O
histone	B-GENE
deacetylases	I-GENE
(	O
HDACs	B-GENE
)	O
,	O
p300	B-GENE
/	O
CBP	B-GENE
and	O
Cabin	B-GENE
1	I-GENE
and	O
the	O
therapeutic	O
applications	O
thereof	O
.	O


Disclosed	O
are	O
JAK	B-GENE
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
where	O
G1,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions,	O
kits	O
and	O
articles	O
of	O
manufacture	O
which	O
contain	O
the	O
compounds,	O
methods	O
and	O
materials	O
for	O
making	O
the	O
compounds,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
to	O
treat	O
diseases,	O
disorders,	O
and	O
conditions	O
involving	O
the	O
immune	O
system	O
and	O
inflammation,	O
including	O
rheumatoid	O
arthritis,	O
hematological	O
malignancies,	O
epithelial	O
cancers	O
(	O
i	O
.	O
e	O
.	O
,	O
carcinomas	O
)	O
,	O
and	O
other	O
diseases,	O
disorders	O
or	O
conditions	O
associated	O
with	O
JAK	B-GENE
.	O


A	O
method	O
of	O
inhibiting	O
glycolysis	O
in	O
a	O
subject	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
including	O
a	O
thiazolidinedione	O
derivative	O
to	O
the	O
subject	O
is	O
described	O
.	O
The	O
thiazolidinedione	O
derivatives	O
are	O
effective	O
energy	O
restriction	O
mimetic	O
agents,	O
and	O
can	O
therefore	O
be	O
used	O
to	O
treat	O
or	O
prevent	O
cancer	O
in	O
a	O
subject,	O
treat	O
metabolic	O
disorder,	O
or	O
increase	O
the	O
longevity	O
of	O
a	O
subject	O
.	O
Various	O
thiazolidinedione	O
derivatives	O
are	O
also	O
suitable	O
for	O
activating	O
adenosine	O
phosphate-activated	O
protein	O
kinase	B-GENE
or	O
inhibiting	O
IL-6	B-GENE
expression	O
.	O


A	O
composition	O
and	O
method	O
for	O
replacement	O
and	O
regeneration	O
of	O
hair	O
cells	O
of	O
the	O
inner	O
ear	O
is	O
provided	O
.	O
The	O
composition	O
comprises	O
an	O
active	O
agent	O
in	O
an	O
amount	O
effective	O
to	O
decrease	O
Hesl	B-GENE
gene	O
expression	O
in	O
a	O
tissue	O
of	O
the	O
inner	O
ear	O
.	O
The	O
active	O
agent	O
can	O
be	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
encapsulated	O
in	O
a	O
biodegradable	O
nanoparticle	O
.	O
The	O
method	O
involves	O
administering	O
a	O
solution	O
to	O
the	O
inner	O
ear	O
where	O
the	O
solution	O
contains	O
an	O
active	O
agent	O
in	O
an	O
amount	O
effective	O
to	O
decrease	O
Hesl	B-GENE
gene	O
expression	O
.	O


The	O
invention	O
provides	O
methods,	O
compositions,	O
and	O
dietary	O
formulations	O
useful	O
for	O
preventing	O
or	O
treating	O
dermatitis,	O
promoting	O
healthy	O
skin,	O
and	O
retarding	O
skin	O
aging	O
.	O
The	O
methods	O
comprise	O
administering	O
to	O
an	O
animal	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
combination	O
of	O
at	O
least	O
two	O
of	O
one	O
or	O
more	O
antioxidants	O
;	O
one	O
or	O
more	O
anti-glycation	O
agents	O
;	O
one	O
or	O
more	O
body	O
fat	O
reducing	O
agents	O
;	O
one	O
or	O
more	O
insulin	B-GENE
sensitivity	O
enhancing	O
agents	O
;	O
and	O
one	O
or	O
more	O
anti-inflammatory	O
agents	O
.	O


An	O
antibacterial	O
composition	O
is	O
provided	O
including	O
a	O
combination	O
of	O
a	O
ß-lactam	O
antibiotic	O
that	O
has	O
a	O
binding	O
affinity	O
for	O
bacterial	O
penicillin-binding	B-GENE
protein	I-GENE
2	I-GENE
;	O
and	O
a	O
non-antibiotic	O
compound	O
which	O
may	O
be	O
a	O
thienopyridine	O
or	O
a	O
non-thienopyridine	O
compound	O
.	O
A	O
method	O
of	O
treatment	O
using	O
the	O
composition	O
is	O
also	O
provided	O
.	O


Provided	O
herein	O
are	O
methods,	O
compounds,	O
and	O
compositions	O
for	O
reducing	O
expression	O
of	O
GCCR	B-GENE
mRNA	O
and	O
protein	O
in	O
an	O
animal	O
.	O
Such	O
methods,	O
compounds,	O
and	O
compositions	O
are	O
useful	O
to	O
treat,	O
prevent,	O
delay,	O
or	O
ameliorate	O
metabolic	O
disease,	O
for	O
example,	O
diabetes,	O
or	O
a	O
symptom	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
phytocannabinoid	O
tetrahydrocannabivarin	O
(	O
THCV	O
)	O
for	O
use	O
in	O
the	O
protection	O
of	O
pancreatic	O
islet	O
cells	O
.	O
Preferably	O
the	O
pancreatic	O
islet	O
cells	O
to	O
be	O
protected	O
are	O
beta	O
cells	O
.	O
More	O
preferably	O
the	O
protection	O
of	O
the	O
pancreatic	O
islet	O
cells	O
maintains	O
insulin	B-GENE
production	O
at	O
levels	O
which	O
are	O
able	O
to	O
substantially	O
control	O
or	O
improve	O
control	O
of	O
blood	O
glucose	O
levels	O
in	O
a	O
patient	O
.	O


Gram	O
Liewei	O
in	O
the	O
preparation	O
tyrosinase	B-GENE
inhibitor	O
'	O
s	O
application	O
relates	O
to	O
one	O
kind	O
of	O
gram	O
Liewei	O
to	O
be	O
mellow	O
mellowly,	O
which	O
provides	O
one	O
kind	O
to	O
originate	O
from	O
mangrove	O
forest	O
endogenous	O
fungus	O
secondary	O
metabolite	O
gram	O
Liewei	O
mellowly	O
in	O
the	O
preparation	O
tyrosinase	B-GENE
inhibitor	O
application	O
.	O
The	O
preparation	O
method	O
is	O
:	O
dwarf	O
rods	O
Aspergillus	O
BYY-1	O
seed	O
culture	O
;	O
submerged	O
fermentation	O
;	O
broth	O
filter	O
strains	O
;	O
concentrated	O
filtrate	O
decompression	O
after	O
repeatedly	O
using	O
organic	O
solvent	O
extraction,	O
collection	O
and	O
decompression	O
organic	O
phase	O
was	O
concentrated	O
extracts	O
;	O
Extracts	O
of	O
the	O
silica	O
gel	O
column	O
chromatography	O
and	O
recrystallization	O
obtained	O
after	O
refining	O
grams	O
Levy	O
alcohol	O
.	O
The	O
pharmacological	O
experiments	O
have	O
confirmed	O
that	O
the	O
compound	O
significantly	O
inhibited	O
the	O
activity	O
of	O
tyrosine,	O
can	O
be	O
used	O
for	O
preparation	O
of	O
tyrosinase	B-GENE
inhibitors	O
and	O
applied	O
to	O
pharmaceuticals,	O
cosmetics	O
and	O
food	O
.	O
It	O
may	O
obtain	O
through	O
the	O
fermentation	O
system,	O
raw	O
material	O
is	O
rich,	O
moreover	O
the	O
extraction	O
purification	O
method	O
is	O
simple,	O
suits	O
the	O
formalization	O
production	O
.	O


This	O
invention	O
relates	O
to	O
quinazoline	O
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
as	O
shown	O
in	O
general	O
formula	O
I	O
.	O
In	O
the	O
formula,	O
R1,	O
Q1,	O
Q2	O
and	O
m	O
are	O
defined	O
in	O
the	O
invention	O
.	O
This	O
invention	O
also	O
relates	O
to	O
their	O
preparation	O
method,	O
and	O
drug	O
composition	O
containing	O
them	O
with	O
effective	O
dosage	O
.	O
The	O
quinazoline	O
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
as	O
shown	O
in	O
general	O
formula	O
I	O
can	O
inhibit	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
protein	O
on	O
bacteria	O
surface	O
thus	O
can	O
be	O
used	O
to	O
treat	O
hyperplasia	O
diseases	O
such	O
as	O
cancer	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
molecule	O
with	O
relative	O
structure	O
of	O
HEPT	O
and	O
pyridinone,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
adopting	O
1-í	O
(	O
2-hydroxy	O
ethoxy	O
)	O
-methylí	O
-6-	O
(	O
benzene	O
thio	O
)	O
thymine	O
(	O
HEPT	O
)	O
as	O
reverse	O
transcriptase	I-GENE
inhibitor	O
of	O
non-nucleoside	O
HIV-1	O
and	O
4-benzene	O
thiopyridinone	O
as	O
primer	O
;	O
linking	O
each	O
structure	O
and	O
activity	O
to	O
fuse	O
into	O
one	O
molecule	O
;	O
designing	O
a	O
new	O
molecule	O
with	O
general	O
formula	O
as	O
formula	O
I	O
with	O
each	O
group	O
defined	O
as	O
instruction	O
;	O
making	O
new	O
compound	O
connect	O
HIV-1	B-GENE
reverse	I-GENE
transcriptase	I-GENE
conveniently	O
;	O
inhibiting	O
the	O
activity	O
of	O
reverse	O
transcriptase	I-GENE
.	O


The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
both	O
phosphoinositide-3-kinase	B-GENE
inhibitor	O
and	O
alkylating	O
agent	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microsphere	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose,	O
etc	O
.	O
and	O
has	O
viscosity	O
of	O
100-3000	O
cp	O
at	O
20-30	O
deg	O
.	O
c	O
.	O
The	O
effective	O
anticancer	O
component	O
is	O
the	O
combination	O
of	O
phosphoinositide-3-kinase	B-GENE
inhibitor	O
and	O
/	O
or	O
alkylating	O
agent	O
selected	O
from	O
melphalan,	O
cyclophosphamide,	O
etc	O
.	O
The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
p	O
(	O
LAEG-EOP	O
)	O
,	O
p	O
(	O
DAPG-EOP	O
)	O
,	O
etc	O
.	O
The	O
anticancer	O
composition	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implanting	O
agent	O
for	O
use	O
alone	O
or	O
together	O
with	O
chemotherapeutic	O
and	O
/	O
or	O
radiotherapeutic	O
medicine	O
.	O


The	O
invention	O
relates	O
to	O
trifluoromethyl	O
substituted	O
benzamide	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
pharmaceuticals	O
comprising	O
these	O
compounds,	O
their	O
use	O
as	O
or	O
for	O
the	O
manufacture	O
of	O
pharmaceuticals,	O
particularly	O
as	O
inhibitors	O
of	O
protein	O
kinases	B-GENE
and	O
/	O
or	O
the	O
treatment	O
of	O
a	O
condition,	O
disorder	O
or	O
disease	O
state	O
mediated	O
by	O
a	O
protein	O
kinase	B-GENE
activity	O
and	O
/	O
or	O
a	O
proliferative	O
disease,	O
methods	O
of	O
treatment	O
comprising	O
administering	O
the	O
compounds,	O
especially	O
of	O
therapeutic	O
and	O
prophylactic	O
treatment,	O
methods	O
for	O
the	O
manufacture	O
of	O
the	O
compounds	O
and	O
novel	O
intermediates	O
and	O
partial	O
steps	O
for	O
their	O
synthesis	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
therapeutic	O
management	O
of	O
extrauterine	O
proliferation	O
of	O
endometrial	O
tissue,	O
chronic	O
pelvic	O
pain	O
and	O
fallopian	O
tube	O
obstruction	O
by	O
short	O
term	O
induction	O
treatment	O
with	O
an	O
LH-RH	B-GENE
antagonist	O
for	O
4	O
to	O
12	O
weeks	O
.	O
According	O
to	O
another	O
aspect	O
of	O
the	O
present	O
invention,	O
the	O
short	O
term	O
LH-RH	B-GENE
treatment	O
is	O
followed	O
by	O
the	O
combined	O
or	O
separate	O
administration	O
of	O
one	O
or	O
more	O
active	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
contraceptive,	O
preferably	O
an	O
oral	O
contraceptive,	O
a	O
non-steroidal	O
anti-rheumatic	O
agent,	O
an	O
analgetic,	O
an	O
androgen	O
other	O
than	O
a	O
17-alpha-alkyl	O
substituted	O
testosterone	O
or	O
any	O
combinations	O
thereof	O
.	O
According	O
to	O
a	O
further	O
aspect	O
of	O
the	O
present	O
invention	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
LHRH	B-GENE
antagonist	O
and	O
one	O
or	O
more	O
active	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
contraceptive,	O
preferably	O
an	O
oral	O
contraceptive,	O
a	O
non-steroidal	O
anti-rheumatic	O
agent,	O
an	O
analgetic,	O
an	O
androgen	O
other	O
than	O
a	O
17-alpha-alkyl	O
substituted	O
testosterone	O
or	O
any	O
combinations	O
thereof	O
are	O
provided	O
.	O


This	O
inventio	O
relates	O
to	O
preparation	O
method	O
of	O
helicid	O
-huperzine	O
methylal	O
imine	O
.	O
Structural	O
formula	O
as	O
(	O
1	O
)	O
described	O
.	O
It	O
also	O
relates	O
to	O
it	O
'	O
s	O
as	O
drug	O
compound	O
of	O
effective	O
ingredient,	O
as	O
well	O
as	O
application	O
in	O
preparing	O
restraining	O
acetyl	B-GENE
lipase	I-GENE
activity	O
medicine	O
.	O


The	O
present	O
invention	O
relates	O
to	O
siRNA	O
of	O
one	O
kind	O
of	O
gene	O
inhibiting	O
specifically	O
human	B-GENE
core	I-GENE
binding	I-GENE
factor	I-GENE
1	I-GENE
(	O
Cbfa1	B-GENE
)	O
and	O
its	O
expression	O
vector	O
and	O
application	O
in	O
preparing	O
medicine	O
for	O
treating	O
Cbfa1	B-GENE
relevant	O
diseases	O
.	O
Based	O
on	O
RNA	O
interfering	O
technology,	O
the	O
present	O
invention	O
designs	O
one	O
group	O
of	O
siRNA	O
capable	O
of	O
inducing	O
RNA	O
interference,	O
and	O
synthesizes	O
siRNA	O
through	O
chemically	O
or	O
expresses	O
certain	O
amount	O
of	O
siRNA	O
by	O
means	O
of	O
plasmid	O
and	O
virus	O
vector,	O
so	O
as	O
to	O
inhibit	O
specifically	O
the	O
expression	O
of	O
human	B-GENE
Cbfa1	B-GENE
gene	I-GENE
and	O
to	O
reach	O
the	O
aim	O
of	O
inhibiting	O
the	O
differentiation	O
of	O
osteoblast	O
and	O
the	O
hypertrophy	O
and	O
differentiation	O
of	O
chondrocyte	O
.	O
The	O
siRNA	O
and	O
its	O
expression	O
vector	O
may	O
be	O
used	O
in	O
preparing	O
medicine	O
for	O
treating	O
osteoarthritis	O
and	O
diseases	O
relevant	O
to	O
the	O
differentiation	O
of	O
osteoblast	O
and	O
the	O
hypertrophy	O
and	O
differentiation	O
of	O
chondrocyte,	O
and	O
the	O
medicine	O
has	O
high	O
efficiency,	O
fast	O
acting,	O
high	O
specificity	O
and	O
less	O
side	O
effects	O
.	O


A	O
saponin	O
compound,	O
its	O
production	O
and	O
use	O
are	O
disclosed	O
.	O
The	O
process	O
is	O
carried	O
out	O
by	O
extracting	O
while	O
separating	O
from	O
gray	O
coactus	O
honeysuckle	O
bud	O
and	O
purifying	O
to	O
obtain	O
gray	O
coactus	O
lonicerin	O
.	O
It	O
is	O
made	O
in	O
vitro-inhibiting	O
experiment	O
and	O
experiment	O
for	O
mouse	O
dimethyl	O
benzene	O
inflammation	O
.	O
It	O
can	O
be	O
used	O
as	O
PlA2	B-GENE
inhibitor	O
and	O
anti-inflammatory	O
medicine	O
.	O


The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
and	O
/	O
or	O
platinum	O
compound	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microsphere	O
includes	O
effective	O
anticancer	O
components	O
of	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
and	O
/	O
or	O
platinum	O
compound	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
suspending	O
agent	O
is	O
carboxymethyl	O
cellulose,	O
etc	O
.	O
and	O
has	O
viscosity	O
of	O
100-3000	O
cp	O
at	O
20-30	O
deg	O
.	O
c	O
.	O
The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
selected	O
from	O
p	O
(	O
LAEG-EOP	O
)	O
,	O
p	O
(	O
DAPG-EOP	O
)	O
,	O
p	O
(	O
BHET-EOP	O
/	O
TC	O
)	O
,	O
etc	O
.	O
The	O
anticancer	O
composition	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implant,	O
and	O
the	O
released	O
injection	O
and	O
slow	O
released	O
implant	O
may	O
be	O
injected	O
or	O
set	O
in	O
tumor	O
for	O
slow	O
releasing	O
to	O
maintain	O
effective	O
medicine	O
concentration	O
for	O
over	O
50	O
days,	O
and	O
has	O
obviously	O
lowered	O
systemic	O
reaction	O
on	O
the	O
medicine	O
and	O
capacity	O
of	O
enhancing	O
the	O
chemotherapeutic	O
and	O
radiotherapeutic	O
effect	O
.	O


An	O
anti-cancer	O
composition	O
comprises	O
anti-cancer	O
effective	O
ingredient	O
selected	O
from	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
and	O
/	O
or	O
uramustine	O
and	O
sustained	O
release	O
adjuvant,	O
and	O
can	O
be	O
made	O
into	O
sustained	O
release	O
injection	O
and	O
sustained	O
release	O
implant	O
agent	O
.	O
Sustained	O
release	O
injection	O
also	O
comprises	O
special	O
dissolvant	O
containing	O
suspending	O
agent	O
.	O
The	O
Suspending	O
agent	O
has	O
a	O
viscocity	O
of	O
100cp-3000cp	O
(	O
at	O
20deg	O
.	O
C-30deg	O
.	O
C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose,	O
and	O
so	O
on	O
.	O
the	O
sustained	O
release	O
adjuvant	O
is	O
selected	O
from	O
p	O
(	O
LAEG-EOP	O
)	O
,	O
p	O
(	O
DAPG-EOP	O
)	O
,	O
p	O
(	O
BHET-EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHET-EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHDPT-EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHDPT-EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
CHDM-HOP	O
)	O
or	O
p	O
(	O
CHDM-EOP	O
)	O
.	O
Slow	O
releasing	O
injection	O
and	O
implantable	O
agent	O
can	O
keep	O
high	O
medicinal	O
concentration	O
in	O
tumour	O
part	O
through	O
slow	O
releasing	O
for	O
over	O
60	O
days	O
after	O
being	O
injected	O
or	O
implanted	O
in	O
or	O
around	O
tumour	O
.	O
The	O
anticancer	O
composition	O
may	O
also	O
be	O
prepared	O
into	O
sustained-release	O
implant	O
.	O
It	O
can	O
reduce	O
systemic	O
toxic	O
reaction	O
of	O
anticancer	O
drugs,	O
and	O
also	O
selectively	O
improve	O
the	O
therapeutic	O
effect	O
of	O
non-operative	O
therapy	O
such	O
as	O
chemotherapy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
enrofloxacin	O
gelatin	B-GENE
microsphere	O
and	O
its	O
preparation	O
method	O
.	O
It	O
is	O
characterized	O
by	O
that	O
it	O
uses	O
type	O
A	O
gelatin	B-GENE
as	O
carrier,	O
uses	O
enrofloxacin	O
as	O
medicine	O
to	O
be	O
carried	O
and	O
adopts	O
an	O
emulsification-condensation	O
process	O
to	O
prepare	O
the	O
invented	O
gelatin	B-GENE
microsphere	O
which	O
can	O
take	O
the	O
lung	O
as	O
target	O
organ	O
after	O
intravenous	O
injection	O
.	O
The	O
average	O
grain	O
size	O
of	O
said	O
microspheres	O
is	O
12	O
micrometers	O
.	O


The	O
method	O
is	O
used	O
for	O
preventing	O
or	O
treating	O
an	O
amyloid-beta	B-GENE
related	O
disease	O
in	O
a	O
subject	O
.	O
The	O
method	O
comprises	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
first	O
agent	O
that	O
prevents	O
or	O
treats	O
amyloid-beta	B-GENE
related	O
disease,	O
and	O
a	O
second	O
agent	O
that	O
is	O
(	O
i	O
)	O
a	O
peptide	O
or	O
peptidomimetic	O
that	O
modulates	O
amyloid-beta	B-GENE
fibril	O
formulation	O
or	O
induces	O
a	O
prophylactic	O
or	O
therapeutic	O
immune	O
response	O
against	O
amyloid-beta	B-GENE
fibril	O
formulation,	O
or	O
(	O
ii	O
)	O
an	O
immune	O
system	O
modulator	O
that	O
prevents	O
or	O
inhibits	O
amyloid-beta	B-GENE
fibril	O
formulation	O
.	O


The	O
present	O
invention	O
is	O
the	O
use	O
of	O
one	O
kind	O
of	O
salvianolate	O
B	O
salt	O
or	O
its	O
isomer,	O
precursor,	O
derivative,	O
pharmaceutically	O
acceptable	O
salt	O
and	O
composition	O
as	O
Na+/K+-ATP	B-GENE
enzyme	I-GENE
inhibitor	O
.	O
The	O
Na+/K+-ATP	B-GENE
enzyme	I-GENE
activity	O
test	O
on	O
magnesium	O
salvianolate	O
B	O
as	O
one	O
common	O
salvianolate	O
B	O
salt	O
proves	O
that	O
magnesium	O
salvianolate	O
B	O
has	O
suck	O
structure	O
as	O
to	O
be	O
capable	O
of	O
substituting	O
cyclopentahydrophenanathrene,	O
as	O
one	O
kind	O
of	O
cardio-glucoside	O
steroid	O
medicine	O
.	O
The	O
brain	O
ischemia	O
experiment	O
proves	O
the	O
effect	O
of	O
magnesium	O
salvianolate	O
B	O
in	O
reducing	O
injury	O
on	O
brain	O
cell	O
.	O
All	O
the	O
said	O
functions	O
come	O
from	O
that	O
salvianolate	O
B	O
salt	O
can	O
inhibit	O
the	O
hydrolysis	O
of	O
Na+/K+-ATP	B-GENE
enzyme	I-GENE
actively	O
transported	O
phosphate	O
radical	O
to	O
reduce	O
the	O
Na+	O
/	O
K+	O
exchange	O
of	O
cell	O
and	O
increase	O
calcium	O
ions	O
inside	O
cell	O
.	O
The	O
present	O
invention	O
has	O
the	O
uses	O
of	O
tonifying	O
heart,	O
promoting	O
urination,	O
protecting	O
nerve	O
cell,	O
treating	O
heart	O
failure,	O
etc	O
.	O


The	O
invention	O
relates	O
to	O
a	O
huperzine	O
B	O
derivative	O
with	O
16	O
substituted	O
dual	O
function	O
groups	O
and	O
the	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
derivative	O
adopts	O
the	O
huperzine	O
B	O
as	O
a	O
lead	O
compound	O
and	O
is	O
obtained	O
by	O
the	O
steps	O
that	O
16-methyl	O
is	O
first	O
oxidated	O
to	O
aldehyde	O
group	O
and	O
then	O
treated	O
with	O
reductive	O
amination	O
with	O
substitution	O
amine	O
compounds	O
.	O
The	O
derivative	O
provided	O
in	O
the	O
invention	O
also	O
expresses	O
higher	O
inhibitory	O
activity	O
of	O
acetylcholinesterase	B-GENE
than	O
that	O
of	O
the	O
lead	O
compound	O
of	O
the	O
huperzine	O
B	O
in	O
a	O
test	O
of	O
vitro	O
bioactivity	O
.	O
The	O
huperzine	O
B	O
derivative	O
with	O
16	O
substituted	O
dual	O
function	O
groups	O
has	O
relatively	O
strong	O
inhibiting	O
effect	O
on	O
butyrylcholine	B-GENE
esterase	I-GENE
and	O
is	O
expected	O
to	O
become	O
a	O
candidate	O
drug	O
with	O
high	O
therapeutic	O
index	O
and	O
little	O
side	O
effect	O
to	O
treat	O
degenerative	O
brain	O
disorder	O
after	O
further	O
optimization	O
and	O
screening	O
.	O


Processes	O
are	O
provided	O
for	O
selectively	O
preparing	O
novel	O
stable	O
crystalline	O
salt	O
forms,	O
selectively	O
and	O
consistently,	O
namely,	O
preparing	O
Form	O
N-1	O
of	O
the	O
methanesulfonic	O
acid	O
salt,	O
and	O
Form	O
N-1	O
and	O
Form	O
N-4	O
of	O
the	O
hydrochloric	O
acid	O
salt	O
of	O
the	O
p38	B-GENE
kinase	I-GENE
inhibitor	O
4-	O
[	O
[	O
5-	O
[	O
(	O
cyclopropylamino	O
)	O
carbonyl	O
]	O
-2-methylphenyl	O
]	O
amino	O
]	O
-5-methyl-N-propylpyrrolo	O
[	O
2,1-f	O
]	O
[	O
1,2,4	O
]	O
triazine-6-carboxamide	O
.	O
The	O
processes	O
preferably	O
employ	O
solvent	O
systems	O
including	O
formic	O
acid	O
/	O
acetone	O
and	O
formic	O
acid	O
/	O
methylethyl	O
ketone	O
which	O
produce	O
crystals	O
having	O
suitable	O
flow	O
properties	O
and	O
desired	O
particle	O
size,	O
and	O
solvents	O
such	O
as	O
N,N-dimethylformamide	O
and	O
N,N-dimethylacetamide	O
may	O
be	O
employed	O
as	O
well	O
.	O
Novel	O
Form	O
N-1	O
crystals	O
of	O
the	O
Form	O
N-1	O
and	O
Form	O
N-4	O
crystals	O
of	O
the	O
hydrochloride	O
salt	O
and	O
Form	O
N-1	O
crystals	O
of	O
the	O
methanesulfonic	O
acid	O
salt	O
of	O
the	O
above	O
free	O
base,	O
pharmaceutical	O
compositions	O
containing	O
such	O
novel	O
forms	O
and	O
a	O
method	O
of	O
treating	O
p38	B-GENE
kinase	I-GENE
associated	O
conditions,	O
including	O
rheumatoid	O
arthritis	O
are	O
also	O
provided	O
.	O


The	O
invention	O
relates	O
to	O
compound	O
sulfamonomethoxine	O
injection	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
sulfamonomethoxine	O
injection	O
.	O
The	O
injection	O
comprises	O
main	O
drug,	O
antioxidant,	O
solvent	O
for	O
injection	O
and	O
water	O
for	O
injection	O
.	O
The	O
preparation	O
method	O
is	O
that	O
the	O
sulfamonomethoxine	O
and	O
trimethoprim	O
(	O
TMP	O
)	O
are	O
used	O
together,	O
which	O
can	O
doubly	O
block	O
folate	O
metabolism	O
of	O
bacteria	O
;	O
under	O
the	O
bidirectional	O
cooperative	O
effect	O
between	O
cyclooxygenase	B-GENE
and	O
ethyl	O
inhibitor,	O
the	O
sulfamonomethoxine	O
and	O
doxycycline	O
cooperate,	O
so	O
the	O
drug	O
absorption	O
is	O
fast	O
and	O
the	O
toxicity	O
is	O
reduced	O
with	O
better	O
efficacy	O
and	O
more	O
safety	O
.	O
With	O
scientific	O
compatibility,	O
lower	O
cost	O
and	O
simple	O
and	O
easy	O
preparation	O
method,	O
the	O
invention	O
is	O
suitable	O
for	O
industrialized	O
mass	O
production	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry,	O
in	O
particular	O
to	O
a	O
thiazole	O
[	O
5,	O
4-b	O
]	O
pyrimidine	O
compounds	O
(	O
I	O
)	O
,	O
preparation	O
methods	O
thereof	O
and	O
also	O
to	O
pharmaceutical	O
composites	O
containing	O
the	O
compounds	O
and	O
medical	O
purposes	O
thereof,	O
in	O
particular	O
to	O
telomerase	B-GENE
inhibitors	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
application	O
in	O
a	O
preparation	O
using	O
asiaticoside	O
in	O
a	O
drug	O
against	O
delayed	O
lung	O
fibrosis	O
.	O
At	O
the	O
end	O
of	O
the	O
delayed	O
lung	O
fibrosis,	O
the	O
asiaticoside	O
has	O
an	O
effect	O
against	O
the	O
lung	O
fibrosis	O
under	O
an	O
action	O
of	O
a	O
promoting	O
fibrosis	O
cytokine	B-GENE
in	O
vivo	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
drug	O
composition	O
against	O
delayed	O
lung	O
fibrosis,	O
which	O
active	O
component	O
comprises	O
the	O
asiaticoside	O
and	O
the	O
exogenous	O
promoting	O
fibrosis	O
cytokine	B-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
non-steroidal	O
androgen	B-GENE
receptor	I-GENE
modulator	O
containing	O
N-aryl-beta-aromatic	O
amine-propionamide	O
compound	O
(	O
I	O
)	O
and	O
a	O
relative	O
preparation	O
method	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
drug	O
compound	O
containing	O
the	O
N-aryl-beta-aromatic	O
amine-propionamide	O
compound	O
(	O
I	O
)	O
.	O
The	O
N-aryl-beta-aromatic	O
amine-propionamide	O
compound	O
(	O
I	O
)	O
has	O
androgen	B-GENE
receptor	I-GENE
antagonistic	O
activity,	O
therefore,	O
thecompound	O
can	O
be	O
used	O
to	O
prepare	O
the	O
non-steroidal	O
drug	O
for	O
preventing	O
or	O
/	O
treating	O
prostatic	O
hyperplasia,	O
prostate	O
cancer,	O
hirsutism,	O
serious	O
androgen	O
dependence	O
alopecia	O
and	O
acne	O
or	O
the	O
like	O
.	O


The	O
invention	O
provides	O
a	O
Selegiline	O
hydrochloride	O
smell	O
covering	O
compound,	O
which	O
contains	O
sugar	O
alcohol,	O
corrective	O
agent,	O
gelatin,	O
and	O
xanthan	O
gum,	O
and	O
is	O
treated	O
by	O
special	O
process	O
and	O
is	O
evenly	O
dispersed	O
with	O
Selegiline	O
hydrochloride	O
.	O
The	O
compound	O
covers	O
the	O
stimulating	O
taste	O
of	O
Selegiline	O
hydrochloride,	O
is	O
used	O
for	O
preparing	O
the	O
orally	O
disintegrating	O
tablet,	O
and	O
is	O
used	O
for	O
treating	O
Parkinsons	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
a	O
single	O
chain	O
fragment	O
antibody-polypeptide	O
fusion	O
protein	O
and	O
applications	O
thereof,	O
the	O
protein	O
is	O
a	O
fusion	O
protein	O
which	O
can	O
be	O
combined	O
with	O
Her2	B-GENE
receptors	I-GENE
and	O
can	O
carry	O
anti-cancer	O
siRNA	O
drug,	O
and	O
the	O
fusion	O
protein	O
can	O
serve	O
as	O
the	O
vector	O
of	O
the	O
anti-cancer	O
siRNA	O
drug	O
.	O
The	O
single	O
chain	O
fragment	O
antibody	O
is	O
Her2-ScFv,	O
and	O
the	O
polypeptide	O
is	O
nucleoprotamine	O
fragment	O
polypeptide	O
.	O
The	O
sequence	O
of	O
the	O
single	O
chain	O
fragment	O
antibody-polypeptide	O
fusion	O
protein	O
is	O
shown	O
as	O
SEQ	O
ID	O
NO	O
.	O
1	O
.	O
The	O
Her2	O
single	O
chain	O
fragment	O
antibody	O
and	O
the	O
nucleoprotamine	O
polypeptide	O
fusion	O
protein,	O
which	O
are	O
constructed	O
by	O
the	O
present	O
invention,	O
can	O
be	O
combined	O
with	O
Her2	B-GENE
receptors	I-GENE
and	O
can	O
carry	O
the	O
anti-cancer	O
siRNA	O
drug	O
.	O
The	O
fusion	O
protein	O
of	O
the	O
present	O
invention	O
can	O
directionallyintroduce	O
the	O
anti-cancer	O
siRNA	O
drug	O
into	O
target	O
cancer	O
cells,	O
and	O
a	O
non-viral	O
vector	O
tool	O
is	O
developed	O
to	O
speed	O
up	O
the	O
application	O
of	O
the	O
RNAi	O
technology	O
in	O
clinic	O
.	O


The	O
invention	O
provides	O
a	O
sulfonamide	O
derivative	O
having	O
DP	B-GENE
receptor	I-GENE
antagonistic	O
activity	O
;	O
and	O
a	O
medicinal	O
composition	O
and	O
a	O
therapeutic	O
agent	O
for	O
allergic	O
diseases	O
which	O
each	O
contains	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
derivative	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
II	O
)	O
:	O
(	O
II	O
)	O
(	O
wherein	O
ring	O
A	O
is	O
an	O
aromatic	O
carbocycle,	O
etc	O
.	O
;	O
ring	O
B	O
is	O
a	O
nitrogenous	O
nonaromatic	O
heterocycle,	O
etc	O
.	O
;	O
ring	O
C	O
is	O
an	O
aromaticcarbocycle,	O
etc	O
.	O
;	O
R	O
<	O
1	O
>	O
is	O
carboxy,	O
etc	O
.	O
;	O
R	O
<	O
2	O
>	O
'	O
s	O
each	O
independently	O
is	O
halogeno,	O
etc	O
.	O
;	O
R	O
<	O
3	O
>	O
is	O
optionally	O
substituted	O
alkyloxy,	O
etc	O
.	O
;	O
R	O
<	O
4	O
>	O
'	O
s	O
each	O
independently	O
is	O
halogeno,	O
etc	O
.	O
;	O
R	O
<	O
5	O
>	O
'	O
s	O
each	O
independently	O
is	O
optionally	O
substituted	O
alkyl,	O
etc	O
.	O
;	O
M	O
is	O
sulfonyl,	O
etc	O
.	O
;	O
Y	O
is	O
a	O
single	O
bond,	O
etc	O
.	O
;	O
L	O
<	O
1	O
>	O
is	O
a	O
single	O
bond,	O
etc	O
.	O
;	O
L	O
<	O
2	O
>	O
is	O
a	O
single	O
bond,	O
etc	O
.	O
;	O
k	O
is	O
0,	O
1,	O
2,	O
3,	O
or	O
4	O
;	O
n	O
is	O
0,	O
1,	O
or	O
2	O
;	O
and	O
q	O
is	O
0,1,	O
2,	O
or	O
3,	O
provided	O
that,	O
for	O
example,	O
a	O
)	O
when	O
ring	O
B	O
is	O
a	O
6-membered	O
nitrogenous	O
heterocycle	O
containing	O
one	O
or	O
two	O
nitrogen	O
atoms	O
and	O
ring	O
C	O
is	O
a	O
benzene	O
ring,	O
then	O
k	O
is	O
not	O
0	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
hydrate	O
of	O
either	O
.	O


The	O
present	O
invention	O
provides	O
an	O
antisense	O
oligonucleotide	O
of	O
tissue-specific	O
regulation	O
POKEMON	B-GENE
gene	O
expression	O
and	O
its	O
application	O
.	O
The	O
antisense	O
oligonucleotide	O
is	O
one	O
of	O
the	O
following	O
formulas	O
:	O
CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx	O
;	O
CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx	O
;	O
GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx	O
;	O
TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx	O
;	O
TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx	O
.	O
X	O
is	O
bond	O
between	O
thiophosphate	O
nucleoside	O
.	O
The	O
antisense	O
oligonucleotide	O
of	O
the	O
invention	O
is	O
used	O
for	O
preparing	O
gene	O
therapeutic	O
drug	O
for	O
curing	O
disease	O
caused	O
by	O
POKEMON	B-GENE
high	O
expression	O
.	O


The	O
invention	O
provides	O
a	O
medicine	O
for	O
protecting	O
liver	O
and	O
reducing	O
aminotransferase	B-GENE
.	O
The	O
medicine	O
is	O
composed	O
of	O
danshen	O
root	O
and	O
picrorhiza	O
rhizome	O
by	O
extracting	O
with	O
water	O
or	O
alcohol,	O
purifying	O
with	O
macroporous	O
resin	O
column	O
to	O
obtain	O
composition	O
active	O
component,	O
adding	O
pharmaceutically	O
acceptable	O
medicinal	O
adjuvants	O
and	O
making	O
into	O
various	O
preparations	O
in	O
the	O
conventional	O
method	O
.	O
The	O
composition	O
has	O
the	O
effects	O
of	O
protecting	O
liver,	O
reducing	O
aminotransferase,	O
and	O
preventing	O
hepatic	O
fibrosis	O
.	O


The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
Isobavachalcone	O
in	O
preparation	O
of	O
the	O
drugs	O
for	O
treating	O
tumor,	O
osteoporosis	O
and	O
senile	O
dementia,	O
which	O
belongs	O
to	O
the	O
medicine	O
field	O
.	O
The	O
Isobavachalcone	O
constitutional	O
formula	O
refers	O
to	O
formula	O
(	O
I	O
)	O
;	O
the	O
chemical	O
name	O
is	O
(	O
E	O
)	O
-1-	O
(	O
2,	O
4-dihydroxy-3-	O
(	O
3-	O
methyl-	O
butyl-2-	O
alkenyl	O
)	O
phenyl	O
)	O
-3-	O
(	O
4-paracetamol	O
)	O
propylene-2-	O
ketone-1	O
.	O
The	O
compound	O
does	O
not	O
change	O
the	O
expression	O
of	O
ER	B-GENE
alpha	I-GENE
66,	O
ER	B-GENE
alpha	I-GENE
46	I-GENE
and	O
ER	B-GENE
alpha	I-GENE
36	I-GENE
under	O
low	O
concentration	O
condition	O
and	O
can	O
inhibit	O
the	O
expression	O
of	O
the	O
ER	B-GENE
alpha	I-GENE
66,	O
ER	B-GENE
alpha	I-GENE
46	I-GENE
and	O
ER	B-GENE
alpha	I-GENE
36	I-GENE
at	O
the	O
same	O
time	O
under	O
high	O
concentration	O
condition	O
;	O
meanwhile,	O
the	O
compound	O
(	O
I	O
)	O
can	O
kill	O
the	O
breast	O
cancer	O
cell	O
MCF7	O
cell	O
expressing	O
ER	B-GENE
alpha	I-GENE
66,	O
ER	B-GENE
alpha	I-GENE
46	I-GENE
and	O
ER	B-GENE
alpha	I-GENE
36	I-GENE
.	O
The	O
formula	O
(	O
I	O
)	O
compound	O
can	O
also	O
be	O
used	O
as	O
regulator	O
of	O
the	O
estrogen	B-GENE
receptor	I-GENE
ER	B-GENE
alpha	I-GENE
36	I-GENE
for	O
treating	O
the	O
diseases	O
resulted	O
from	O
ectopic	O
expression	O
of	O
the	O
estrogen	B-GENE
receptor	I-GENE
ER	B-GENE
alpha	I-GENE
36,	O
such	O
as	O
tumor,	O
osteoporosis,	O
asthma,	O
heart	O
disease	O
or	O
senile	O
dementia,	O
etc	O
.	O


Compounds	O
and	O
methods	O
for	O
treating	O
diseases	O
mediated	O
by	O
a	O
P2X3	B-GENE
and	O
/	O
or	O
a	O
P2X2/3	B-GENE
receptor	I-GENE
antagonist,	O
the	O
compounds	O
being	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
D,	O
X,	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
,	O
R	O
<	O
3	O
>	O
,	O
R	O
<	O
4	O
>	O
,	O
R	O
<	O
5	O
>	O
,	O
R	O
<	O
6	O
>	O
,	O
R	O
<	O
7	O
>	O
and	O
R	O
<	O
8	O
>	O
are	O
as	O
defined	O
herein	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
medicine	O
technical	O
field,	O
in	O
particular	O
to	O
an	O
application	O
of	O
rutin	O
and	O
quercetin-7-rhamnose	O
in	O
preparation	O
of	O
anti-hepatitis	O
virus	O
agents	O
.	O
According	O
to	O
the	O
results	O
of	O
experiments	O
of	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
(	O
HBsAg	B-GENE
)	O
and	O
hepatitis	B-GENE
B	I-GENE
e	I-GENE
antigen	I-GENE
(	O
HBeAg	B-GENE
)	O
detection	O
reagents,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
suppress	O
HBsAg	B-GENE
and	O
HBeAg	B-GENE
obviously	O
and	O
can	O
prevent	O
and	O
cure	O
hepatitis	B-GENE
B	I-GENE
virus	O
.	O
Therefore,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
be	O
used	O
for	O
preparing	O
anti-hepatitis	O
virus	O
agents	O
or	O
health	O
care	O
products	O
.	O


The	O
invention	O
adopts	O
a	O
virtual	O
medicine	O
screening	O
technology	O
and	O
a	O
high-throughput	O
screening	O
technology,	O
assesses	O
the	O
AChE	B-GENE
inhibitory	O
activity	O
of	O
more	O
than	O
ten	O
thousand	O
samples	O
in	O
a	O
compound	O
sample	O
library	O
and	O
finds	O
a	O
batch	O
of	O
compounds	O
with	O
higher	O
inhibitory	O
activity	O
by	O
establishing	O
a	O
virtual	O
acetylcholinesterase	B-GENE
inhibitor	O
screening	O
method	O
and	O
an	O
AChE	B-GENE
activity	O
detection	O
method	O
.	O
Then	O
according	O
to	O
the	O
pathological	O
features	O
of	O
senile	O
dementia,	O
the	O
compounds	O
with	O
higher	O
AChE	B-GENE
inhibitory	O
activity	O
are	O
subject	O
to	O
butyryl	O
choline	O
esterase	O
inhibitory	O
activity	O
detection	O
.	O
Research	O
results	O
show	O
that	O
bimolecular	O
3-piperidyl-ethyl	O
phenyl	O
ketone	O
not	O
only	O
has	O
comparatively	O
high	O
AChE	B-GENE
inhibitory	O
activity,	O
but	O
also	O
has	O
very	O
strong	O
BuChE	B-GENE
inhibitory	O
activity	O
;	O
the	O
results	O
of	O
animal	O
experiments	O
prove	O
that	O
the	O
bimolecular	O
3-piperidyl-ethyl	O
phenyl	O
ketone	O
can	O
remarkably	O
improve	O
aphronesia	O
caused	O
by	O
scopolamine	O
and	O
sodium	O
nitrite	O
and	O
can	O
enhance	O
the	O
ability	O
of	O
learning	O
and	O
memory	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
microbial	O
source	O
phaffia	O
rhodozyma	O
astaxanthin	O
in	O
preparation	O
of	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
.	O
Experiments	O
show	O
that	O
the	O
phaffia	O
rhodozyma	O
astaxanthin	O
has	O
good	O
functions	O
of	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
and	O
can	O
be	O
used	O
to	O
prepare	O
the	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
.	O
In	O
particular,	O
the	O
phaffia	O
rhodozyma	O
astaxanthin	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
reducing	O
individual	O
blood	O
sugar	O
of	O
type	O
II	O
diabetes	O
mellitus,	O
or	O
medicines	O
for	O
preventing	O
individual	O
insulin	B-GENE
resistance	O
to	O
type	O
II	O
diabetes	O
mellitus	O
.	O
The	O
application	O
has	O
the	O
advantages	O
that	O
:	O
the	O
invention	O
provides	O
an	O
application	O
of	O
microbial	O
source	O
astaxanthin,	O
namely	O
phaffia	O
rhodozyma	O
astaxanthin	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
and	O
provides	O
a	O
foundation	O
for	O
development	O
of	O
new	O
drugs	O
.	O


The	O
present	O
invention	O
concerns	O
combination	O
of	O
an	O
amount	O
of	O
a	O
GPRl	B-GENE
19	I-GENE
agonist	O
with	O
an	O
amount	O
of	O
a	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP-IV	B-GENE
)	O
inhibitor	O
such	O
that	O
the	O
combination	O
provides	O
an	O
effect	O
in	O
lowering	O
a	O
blood	O
glucose	O
level	O
or	O
in	O
increasing	O
a	O
blood	O
GLP-I	B-GENE
level	O
in	O
a	O
subject	O
over	O
that	O
provided	O
by	O
the	O
amount	O
of	O
the	O
GPRl	B-GENE
19	I-GENE
agonist	O
or	O
the	O
amount	O
of	O
the	O
DPP-FV	B-GENE
inhibitor	O
alone	O
and	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
treating	O
or	O
preventing	O
diabetes	O
and	O
conditions	O
related	O
thereto	O
or	O
conditions	O
ameliorated	O
by	O
increasing	O
a	O
blood	O
GLP-I	B-GENE
level	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
G	B-GENE
protein-coupledreceptor	I-GENE
to	O
screen	O
for	O
GLP-I	B-GENE
secretagogues	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
tea	O
polyphenols	O
or	O
a	O
solvate	O
thereof	O
in	O
preparing	O
medicaments	O
for	O
treating	O
human	O
colon	O
tumor	O
and	O
rectal	O
tumor,	O
particularly	O
MSH2	O
gene-deleted	O
human	O
colon	O
tumor	O
and	O
rectal	O
tumor	O
.	O
The	O
tea	O
polyphenols	O
can	O
be	O
mixed	O
with	O
an	O
excipient,	O
a	O
diluent	O
or	O
a	O
carrier	O
and	O
made	O
into	O
tablets	O
;	O
or	O
made	O
into	O
medicaments	O
or	O
solutions	O
with	O
oral,	O
intramuscular	O
or	O
intravenous	O
administration	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
stereoisomer,	O
tautomer,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof,	O
wherein	O
the	O
variables	O
A,	O
B,	O
R	O
<	O
3	O
>	O
and	O
R	O
<	O
11	O
>	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
selective	O
inhibitors	O
of	O
serine	B-GENE
protease	I-GENE
enzymes	O
of	O
the	O
coagulation	O
cascade	O
and	O
/	O
or	O
contact	O
activation	O
system	O
;	O
for	O
example	O
thrombin,	O
factor	O
Xa,	O
factor	O
XIa,	O
factor	O
IXa,	O
factor	B-GENE
VIIa	I-GENE
and	O
/	O
or	O
plasma	B-GENE
kallikrein	I-GENE
.	O
In	O
particular,	O
it	O
relates	O
to	O
compounds	O
that	O
are	O
selective	O
factor	B-GENE
XIa	I-GENE
inhibitors	O
or	O
dual	O
inhibitors	O
of	O
fXIa	B-GENE
and	O
plasma	B-GENE
kallikrein	I-GENE
.	O
This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
thromboembolic	O
and	O
/	O
or	O
inflammatory	O
disorders	O
using	O
the	O
same	O
.	O


The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
medicine,	O
in	O
particular	O
to	O
a	O
cefquinome	O
sulfate	O
injection	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O
The	O
cefquinome	O
sulfate	O
injection	O
consists	O
of	O
cefquinome	O
sulfate	O
micro-powder	O
which	O
contains	O
not	O
less	O
than	O
50-300g	O
of	O
cefquinome,	O
0	O
.	O
4-40g	O
of	O
antioxidant	O
and	O
a	O
fat	O
or	O
ester	O
organic	O
solvent	O
which	O
is	O
added	O
to	O
be	O
10,000ml	O
.	O
The	O
preparation	O
process	O
is	O
as	O
follows	O
:	O
the	O
antioxidant	O
is	O
dissolved	O
into	O
the	O
fat	O
or	O
ester	O
organic	O
solvent,	O
the	O
mixture	O
is	O
filtrated	O
into	O
a	O
mixing	O
tank,	O
added	O
with	O
the	O
cefquinome	O
sulfate	O
micro-powder,	O
stirred	O
evenly	O
and	O
milled	O
through	O
a	O
colloid	O
mill,	O
thus	O
even	O
suspension	O
is	O
made,	O
and	O
then	O
the	O
suspension	O
is	O
stirred,	O
separately	O
filled	O
and	O
sterilized	O
.	O
The	O
cefquinome	O
sulfate	O
injection	O
and	O
the	O
preparation	O
process	O
solve	O
the	O
problem	O
of	O
no	O
domestic	O
fourth	O
generation	O
cefamandole	O
antibiotic	O
which	O
is	O
special	O
for	O
animals	O
existing	O
in	O
the	O
prior	O
art	O
.	O
The	O
product	O
prepared	O
has	O
wider	O
antimicrobial	O
spectrum,	O
stronger	O
antibacterial	O
activity	O
and	O
more	O
stable	O
Beta-lactamase	B-GENE
for	O
bacteria	O
compared	O
with	O
the	O
third	O
generation	O
cephalosporin,	O
fills	O
up	O
the	O
gap	O
of	O
no	O
domestic	O
fourth	O
generation	O
cefamandole	O
antibiotic	O
preparation	O
which	O
is	O
special	O
for	O
animals,	O
and	O
the	O
whole	O
preparation	O
process	O
is	O
simple	O
and	O
practicable	O
.	O


The	O
invention	O
discloses	O
a	O
compound	O
of	O
2-aryl-6-aryl	O
'	O
-glucoside	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O
The	O
compound	O
having	O
the	O
following	O
structural	O
formula	O
is	O
used	O
for	O
preparation	O
of	O
a	O
small-molecular	O
inhibitor	O
/	O
anti-neoplasm	O
drug	O
belonging	O
to	O
the	O
bcl-2	B-GENE
protein	O
family	O
.	O
The	O
preparation	O
method	O
of	O
the	O
compound	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
1	O
)	O
an	O
epoxidation	O
of	O
2-	O
iodoglucose-1,6-inner	O
ether	O
is	O
carried	O
out	O
;	O
2	O
)	O
a	O
ring	O
opening	O
reaction	O
of	O
a	O
compound	O
obtained	O
from	O
the	O
epoxidation	O
and	O
a	O
phenol	O
is	O
carried	O
out	O
under	O
alkali	O
condition	O
;	O
3	O
)	O
the	O
product	O
of	O
the	O
ring	O
opening	O
reaction	O
undergoes	O
benzyl	O
protection,	O
and	O
then	O
a	O
ring	O
opening	O
reaction	O
of	O
1,6-inner	O
ether	O
is	O
carried	O
out	O
;	O
4	O
)	O
the	O
product	O
obtained	O
from	O
the	O
ring	O
opening	O
reaction	O
of	O
step	O
3	O
)	O
undergoes	O
benzyl	O
protection	O
and	O
then	O
undergoes	O
a	O
substitution	O
reaction	O
with	O
a	O
phenol	O
or	O
an	O
alcohol	O
under	O
alkali	O
condition	O
;	O
and	O
5	O
)	O
the	O
product	O
obtained	O
from	O
the	O
substitution	O
undergoes	O
Pd	O
/	O
C	O
deoxidization	O
to	O
eliminate	O
the	O
benzyl	O
protecting	O
group	O
to	O
obtain	O
the	O
compound	O
of	O
2-aryl-6-aryl	O
'	O
-glucoside	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
following	O
formula	O
useful	O
as	O
inhibitors	O
of	O
voltage-gate	B-GENE
sodium	I-GENE
channels	I-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O


The	O
invention	O
discloses	O
a	O
compound	O
medicine	O
for	O
inhibiting	O
tumor	O
;	O
the	O
medicine	O
consists	O
of	O
coenzyme	O
Q10,	O
polysaccharide	O
and	O
triterpene	O
.	O
The	O
medicine	O
has	O
the	O
functions	O
of	O
enhancing	O
immunity,	O
resisting	O
the	O
proliferation	O
of	O
tumor	O
cells,	O
inducing	O
the	O
apoptosis	O
of	O
cells	O
and	O
interfering	O
with	O
the	O
synthesis	O
of	O
tubulin	B-GENE
of	O
tumor	O
cells,	O
so	O
as	O
to	O
play	O
the	O
inhibition	O
role	O
.	O
Furthermore,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
medicine	O
for	O
inhibiting	O
tumor	O
by	O
processing	O
materials	O
through	O
semi-synthesis	O
method	O
or	O
supercritical	O
CQ2	O
method	O
.	O


The	O
invention	O
discloses	O
a	O
novel	O
nano	O
preparation	O
with	O
stable	O
protein,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
purpose	O
thereof	O
.	O
The	O
invention	O
is	O
characterized	O
in	O
that	O
:	O
a	O
protein	O
coating	O
is	O
formed	O
from	O
albumin	B-GENE
and	O
other	O
materials	O
containing	O
sulphydryl	O
or	O
disulfide	O
bond	O
through	O
the	O
cross	O
linking	O
of	O
the	O
disulfide	O
bond	O
;	O
the	O
protein	O
coating	O
contains	O
free	O
protein	O
or	O
protein	O
derivatives	O
which	O
associate	O
(	O
s	O
)	O
with	O
the	O
protein	O
coating,	O
wherein,	O
part	O
of	O
insoluble	O
drugs	O
are	O
contained	O
in	O
the	O
protein	O
coating	O
and	O
part	O
of	O
such	O
drugs	O
are	O
associated	O
with	O
the	O
free	O
protein	O
or	O
the	O
protein	O
derivatives,	O
and	O
the	O
average	O
diameter	O
of	O
protein	O
coating	O
particles	O
is	O
not	O
more	O
than	O
1	O
micron	O
.	O
The	O
purpose	O
of	O
the	O
preparation	O
is	O
to	O
send	O
water	O
insoluble	O
drugs	O
into	O
the	O
bodies	O
of	O
living	O
things	O
.	O


The	O
invention	O
relates	O
to	O
an	O
androstane	O
azotic	O
glucocorticoid	B-GENE
receptor	I-GENE
stimulant	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
pharmaceutical	O
preparations	O
comprising	O
the	O
compound	O
and	O
the	O
therapeutic	O
use	O
of	O
the	O
compound,	O
in	O
particular	O
to	O
inflammatory	O
disease,	O
allergic	O
disease	O
or	O
anaphylactic	O
disease	O
.	O


The	O
invention	O
provides	O
a	O
pyrimidine	O
substituted	O
phenylpropionic	O
acid	O
compound	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
and	O
application	O
of	O
enantiomer,	O
racemic	O
modification,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
mixture	O
of	O
the	O
enantiomer,	O
the	O
racemic	O
modification	O
and	O
the	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
to	O
preparation	O
of	O
medicine	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
diabetes	O
mellitus	O
.	O
The	O
compound	O
as	O
PPAR-gamma	B-GENE
excitant	O
can	O
participate	O
in	O
the	O
regulation	O
of	O
genetic	O
transcription	O
through	O
activating	O
PXR	B-GENE
/	O
PPAR	B-GENE
heterodimer,	O
thereby	O
effectively	O
treating	O
and	O
/	O
or	O
preventing	O
the	O
diabetes	O
mellitus	O
.	O
The	O
invention	O
also	O
provides	O
a	O
medicine	O
composition	O
which	O
contains	O
the	O
compound	O
and	O
has	O
the	O
effect	O
of	O
preventing	O
and	O
/	O
or	O
treating	O
the	O
diabetes	O
mellitus	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
DPP-IV	B-GENE
inhibitor	O
derivative	O
which	O
is	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
and	O
contains	O
benzofuran	O
sulfonylurea,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
an	O
isomer	O
thereof,	O
wherein	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
,	O
R	O
<	O
3	O
>	O
,	O
R	O
<	O
4	O
>	O
,	O
A,	O
X,	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
instruction	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compounds,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds,	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
diabetes,	O
non-insulin-dependent	O
diabetes,	O
high	O
blood	O
sugar,	O
and	O
insulin	B-GENE
resistance	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
diabetes	O
related	O
medicine,	O
in	O
particular	O
to	O
a	O
depressor	O
for	O
a	O
Na-glucose	B-GENE
transporter	I-GENE
II	I-GENE
containing	O
a	O
structure	O
of	O
sulpho-glucose	O
(	O
SGLT2	B-GENE
)	O
and	O
a	O
preparation	O
method	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
SGLT2	B-GENE
and	O
an	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
diabetes	O
drugs,	O
wherein,	O
a	O
radical	O
group	O
is	O
defined	O
in	O
the	O
specification	O
.	O


The	O
invention	O
relates	O
to	O
a	O
composite	O
medicine	O
for	O
treating	O
malignant	O
pleuroperitoneal	O
cavity	O
effusion,	O
which	O
is	O
fit	O
for	O
treating	O
the	O
malignant	O
pleuroperitoneal	O
cavity	O
effusion	O
and	O
aims	O
to	O
achieve	O
specific	O
healing	O
effect,	O
easy	O
implementation	O
and	O
no	O
adverse	O
reaction	O
;	O
the	O
medicine	O
of	O
the	O
invention	O
has	O
such	O
a	O
formula	O
:	O
4-8	O
mg	O
of	O
lentinan,	O
500,000-3,000,000	O
units	O
of	O
interleukin-2,	O
1,000,000-3,000,000	O
units	O
of	O
gamma	B-GENE
interferon	I-GENE
;	O
the	O
medicines	O
in	O
the	O
formula	O
are	O
all	O
approved	O
by	O
the	O
state	O
and	O
mixed	O
according	O
to	O
a	O
certain	O
ratio,	O
thus	O
obtaining	O
the	O
composite	O
medicine	O
of	O
the	O
invention	O
.	O


The	O
invention	O
discloses	O
an	O
alliin	O
/	O
alliinase	B-GENE
dualistic	O
drug-releasing	O
multilayer	O
tablet	O
that	O
can	O
resist	O
infection	O
caused	O
by	O
helicobacter	O
pylori	O
and	O
candida	O
albicans	O
and	O
the	O
like	O
.	O
The	O
tablet	O
is	O
composed	O
of	O
three	O
layers,	O
the	O
middle	O
layer	O
is	O
a	O
separation	O
layer,	O
one	O
side	O
of	O
the	O
separation	O
layer	O
is	O
the	O
mixed	O
layer	O
of	O
alliin	O
and	O
auxiliary	O
materials,	O
the	O
other	O
side	O
is	O
the	O
mixed	O
layer	O
of	O
alliinase	B-GENE
and	O
auxiliary	O
material,	O
the	O
outside	O
of	O
the	O
three-layer	O
structure	O
is	O
wrapped	O
by	O
an	O
intestine-dissolving	O
film	O
coat	O
(	O
for	O
oral	O
administration	O
)	O
or	O
a	O
common	O
film	O
coat	O
(	O
for	O
vagina	O
application	O
)	O
.	O
The	O
medicament	O
forms	O
include	O
:	O
intestine-dissolving	O
multilayer	O
tablet	O
and	O
vagina	O
multilayer	O
tablet	O
.	O
The	O
tablet	O
can	O
effectively	O
kill	O
various	O
diseases	O
caused	O
by	O
shallow	O
and	O
deep	O
mycete	O
infection	O
of	O
helicobacter	O
pylori,	O
candida	O
albicans,	O
MRSA,	O
Acinetobacter	O
and	O
the	O
like	O
.	O
The	O
drug	O
catalyzer	O
and	O
the	O
catalyzer-acceptor	O
do	O
not	O
react	O
with	O
each	O
other	O
due	O
to	O
the	O
blocking	O
of	O
an	O
insulating	O
medium,	O
and	O
after	O
the	O
drug	O
enters	O
the	O
body,	O
the	O
outer	O
intestine-dissolving	O
film	O
coat	O
or	O
the	O
common	O
film	O
coat	O
are	O
dissolved	O
by	O
body	O
fluid,	O
and	O
the	O
alliin	O
and	O
the	O
alliinase	B-GENE
meet	O
each	O
other	O
and	O
begin	O
the	O
enzymolysis	O
reaction	O
which	O
can	O
be	O
finished	O
in	O
4-15	O
minutes	O
and	O
fully	O
play	O
the	O
curative	O
effect	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
in	O
particular	O
relates	O
to	O
a	O
dipeptidase-IV	B-GENE
inhibitor	O
containing	O
v-triazolo	O
[	O
b	O
]	O
pyrazine	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
an	O
isomer	O
and	O
a	O
hydrate	O
of	O
the	O
dipeptidase-IV	B-GENE
inhibitor,	O
as	O
well	O
as	O
a	O
hydrate	O
of	O
the	O
salt,	O
wherein	O
Ar,	O
R1,	O
R3	O
and	O
n	O
are	O
defined	O
as	O
description	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
and	O
application	O
of	O
the	O
compounds	O
in	O
preparing	O
medicaments	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
diabetes,	O
noninsulin-dependent	O
diabetes,	O
hyperglycemia	O
and	O
insulin	B-GENE
resistance	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
antagonist	O
of	O
ATP	B-GENE
citric	I-GENE
acid	I-GENE
lyase	I-GENE
(	O
ACL	B-GENE
)	O
,	O
which	O
is	O
used	O
for	O
preparing	O
a	O
composition	O
preventing	O
or	O
treating	O
glycolipid	O
metabolic	O
disturbance	O
diseases	O
.	O
The	O
invention	O
also	O
discloses	O
very	O
effective	O
antagonist	O
of	O
ATP	B-GENE
citric	I-GENE
acid	I-GENE
lyase	I-GENE
.	O
The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
sieving	O
potential	O
materials	O
preventing	O
or	O
treating	O
the	O
glycolipid	O
metabolic	O
disturbance	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
drug	O
combination	O
containing	O
nicotinic	O
acid,	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
and	O
TZD	O
medicines	O
and	O
carrier	O
which	O
can	O
be	O
accepted	O
by	O
pharmaceutics	O
and	O
an	O
application	O
of	O
the	O
combination	O
for	O
preparing	O
medicines	O
for	O
preventing	O
or	O
treating	O
diabetes	O
and	O
diabetes-related	O
complications	O
.	O
The	O
effect	O
of	O
the	O
medicines	O
prepared	O
with	O
the	O
combination	O
provided	O
by	O
the	O
invention	O
is	O
better	O
than	O
single-agent	O
in	O
preventing	O
or	O
curing	O
diabetes	O
and	O
diabetes-related	O
complications	O
and	O
the	O
medicines	O
are	O
easier	O
for	O
patients	O
to	O
take	O
.	O


The	O
invention	O
relates	O
to	O
an	O
aporphine	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
stereoisomer	O
thereof,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
pharmaceutically	O
acceptable	O
solvate	O
and	O
medical	O
application	O
thereof	O
.	O
The	O
compound	O
can	O
be	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
related	O
with	O
serotonin	B-GENE
1A	I-GENE
receptors,	O
wherein	O
the	O
diseases	O
comprise	O
central	O
nervous	O
system	O
diseases,	O
in	O
particular	O
schizophrenia,	O
depression	O
and	O
movement	O
disorder	O
caused	O
by	O
Parkinson	O
'	O
s	O
resistant	O
medicament	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
medicinal	O
composition	O
comprising	O
the	O
compound	O
.	O


The	O
invention	O
relates	O
to	O
an	O
anti-cancer	O
drug	O
slow	O
release	O
injection	O
containing	O
gemcitabine,	O
which	O
comprises	O
slow	O
release	O
microspheres	O
and	O
a	O
menstruum,	O
wherein	O
the	O
microsphere	O
comprises	O
anti-cancer	O
active	O
ingredients	O
and	O
slow	O
release	O
auxiliary	O
materials,	O
and	O
the	O
menstruum	O
is	O
a	O
special	O
menstruum	O
containing	O
a	O
suspending	O
agent	O
;	O
the	O
anti-cancer	O
active	O
ingredients	O
are	O
gemcitabine,	O
or	O
antimetabolites	O
selected	O
from	O
zalcitabine,	O
emtricitabine,	O
galocitabine,	O
ibacitabine,	O
ancitabine,	O
decitabine,	O
flurocitabine,	O
enocitabine,	O
imidazole	O
gemcitabine,	O
capecitabine,	O
gemcitabine,	O
fludarabine	O
or	O
cladribine,	O
and	O
/	O
or	O
antimetabolite	O
potentiating	O
agents	O
selected	O
from	O
phosphoinositide	B-GENE
3-kinase	I-GENE
inhibitor,	O
pyrimidine	O
analogue	O
and	O
/	O
or	O
DNA	B-GENE
repair	I-GENE
enzyme	I-GENE
inhibitor	O
;	O
the	O
slow	O
release	O
auxiliary	O
materials	O
are	O
polifeprosan,	O
dienoic	O
fatty	O
acid,	O
decanedioic	O
acid	O
copolymer,	O
polylactic	O
acid	O
copolymer,	O
EVAc	O
and	O
the	O
like	O
;	O
the	O
suspending	O
agent	O
has	O
a	O
viscosity	O
of	O
100cp-3000cp	O
(	O
20-30	O
DEG	O
C	O
)	O
,	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
and	O
the	O
like	O
.	O
The	O
slow	O
release	O
microspheres	O
can	O
be	O
prepared	O
into	O
slow	O
release	O
implants	O
.	O
When	O
injected	O
or	O
placed	O
into	O
tumors	O
or	O
at	O
peripheries	O
of	O
tumors,	O
the	O
slow	O
release	O
microspheres	O
can	O
enhance	O
the	O
treatment	O
effect	O
of	O
non-operative	O
treatment	O
methods,	O
such	O
as	O
radiotherapy,	O
chemotherapy,	O
etc	O
.	O


The	O
invention	O
provides	O
a	O
5-lipoxygenase	B-GENE
inhibitor	O
and	O
a	O
preparation	O
method,	O
a	O
medical	O
composite	O
and	O
an	O
application	O
thereof	O
.	O
More	O
specifically,	O
the	O
invention	O
provides	O
a	O
compound	O
shown	O
in	O
general	O
formula	O
(	O
I	O
)	O
or	O
acceptable	O
salt,	O
solvate	O
or	O
hydrate	O
thereof	O
in	O
pharmacy	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method,	O
medical	O
composite	O
and	O
application	O
of	O
the	O
compound	O
.	O
The	O
biological	O
activity	O
experiment	O
shows	O
that	O
the	O
compound	O
of	O
the	O
invention	O
is	O
effective	O
5-LOX	B-GENE
small	O
molecule	O
inhibitor	O
with	O
novel	O
structure	O
.	O
Therefore	O
the	O
compound	O
is	O
expected	O
to	O
be	O
developed	O
to	O
be	O
new	O
powerful	O
chemical	O
entity	O
forcuring	O
diseases	O
related	O
to	O
leukotriene	O
.	O


Disclosed	O
is	O
a	O
substance	O
which	O
has	O
a	O
low	O
molecular	O
weight,	O
can	O
be	O
applied	O
in	O
a	O
simpler	O
manner,	O
and	O
has	O
an	O
immunopotentiating	O
activity	O
against	O
cancer	O
and	O
/	O
or	O
a	O
microorganism-mediated	O
infectious	O
disease	O
.	O
An	O
EP4	B-GENE
agonist	O
exhibits	O
an	O
immunopotentiating	O
activity	O
through	O
the	O
activation	O
of	O
a	O
cytotoxic	O
T	O
cell,	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
cancer	O
or	O
a	O
microorganism-mediatedinfectious	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
a	O
new	O
compound	O
of	O
mangiferin,	O
which	O
has	O
a	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
new	O
compound	O
is	O
mangiferin	O
A	O
when	O
R	O
is	O
H	O
;	O
and	O
the	O
new	O
compound	O
is	O
mangiferin	O
B	O
when	O
R	O
is	O
-OCH3	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound,	O
as	O
well	O
as	O
the	O
application	O
of	O
the	O
compound	O
and	O
a	O
medicine	O
composition	O
in	O
activity	O
inhibition	O
of	O
alaph-glucosaccharase,	O
wherein	O
the	O
medicine	O
composition	O
takes	O
the	O
compound	O
as	O
an	O
active	O
component,	O
which	O
can	O
further	O
show	O
the	O
application	O
value	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
treating	O
diabetes	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry,	O
and	O
discloses	O
2,3-dihydro	O
[	O
1,5	O
]	O
benzothiazepine	O
compounds	O
of	O
non-adenosine	O
triphosphate	O
(	O
ATP	O
)	O
competitive	O
inhibition	O
glycogen	B-GENE
synthase	I-GENE
kinase-3beta	I-GENE
(	O
GSK-3beta	B-GENE
)	O
with	O
a	O
structure	O
shown	O
in	O
formula	O
I	O
.	O
The	O
compounds	O
can	O
inhibit	O
the	O
activity	O
of	O
the	O
GSK-3beta	B-GENE
in	O
a	O
non	O
ATP	O
competitive	O
mode,	O
and	O
can	O
be	O
used	O
as	O
micromolecule	O
inhibitors	O
of	O
the	O
GSK-3beta	B-GENE
for	O
preparing	O
medicines	O
for	O
preventing	O
or	O
treating	O
GSK-3beta	B-GENE
related	O
diseases	O
.	O
The	O
invention	O
further	O
provides	O
applications	O
of	O
the	O
compounds,	O
pharmaceutical	O
acceptable	O
salts	O
thereof,	O
or	O
medicine	O
compositions	O
thereof	O
to	O
preventing	O
or	O
treating	O
the	O
GSK-3beta	B-GENE
related	O
diseases	O
.	O
The	O
GSK-3beta	B-GENE
related	O
diseases	O
can	O
be	O
diabetes	O
and	O
an	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
provides	O
a	O
composite	O
for	O
preventing	O
and	O
curing	O
senile	O
dementia,	O
particularly,	O
the	O
invention	O
provides	O
a	O
composite	O
for	O
improving	O
the	O
ability	O
of	O
memory	O
and	O
cognition,	O
which	O
comprises	O
:	O
(	O
a	O
)	O
PQQ	O
(	O
pyrro-quinoline	O
quinone	O
)	O
,	O
salt	O
and	O
/	O
or	O
ester	O
which	O
are	O
(	O
is	O
)	O
pharmaceutically	O
or	O
physiologically	O
acceptable	O
;	O
(	O
b	O
)	O
acetylcholinesterase	B-GENE
inhibitor	O
;	O
and	O
(	O
c	O
)	O
carrier	O
which	O
can	O
be	O
pharmaceutically	O
or	O
physiologically	O
acceptable,	O
wherein	O
the	O
molar	O
ratio	O
of	O
the	O
group	O
(	O
a	O
)	O
and	O
the	O
group	O
(	O
b	O
)	O
is	O
1	O
:	O
100-100	O
:	O
1	O
.	O
The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
composite	O
of	O
the	O
invention,	O
the	O
use	O
of	O
the	O
composite,	O
a	O
kit	O
containing	O
the	O
composite	O
or	O
a	O
medicine	O
box,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
composite	O
.	O
The	O
composite	O
of	O
the	O
invention	O
can	O
effectively	O
and	O
safely	O
improve	O
the	O
ability	O
of	O
memory	O
and	O
cognition,	O
can	O
be	O
optimally	O
used	O
to	O
prevent	O
and	O
cure	O
the	O
senile	O
degenerative	O
neurologic	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
Morphine	O
in	O
preparing	O
medicaments	O
for	O
treating	O
the	O
Parkinson	O
disease,	O
in	O
particular	O
to	O
a	O
new	O
medical	O
application	O
of	O
Morphine,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O
Through	O
a	O
thiazolyl	O
blue	O
(	O
MTT	O
)	O
method,	O
the	O
Morphine	O
is	O
found	O
to	O
be	O
capable	O
of	O
promoting	O
the	O
growth	O
of	O
adrenal	O
gland	O
chromaffin	O
tumor	O
cells	O
(	O
PC12	O
cells	O
)	O
of	O
rats	O
.	O
The	O
Morphine	O
has	O
the	O
activity	O
of	O
promoting	O
the	O
proliferation	O
of	O
nerve	O
cells	O
and	O
can	O
inhibit	O
nerve	O
cell	O
injuries	O
caused	O
by	O
a	O
Parkinson	O
toxic	O
substance	O
MPP+	O
(	O
1-Methyl-4-Phenylpyridiniumion	O
)	O
.	O
Proved	O
by	O
a	O
protein	O
immunoblotting	O
method,	O
the	O
Morphine	O
can	O
induce	O
the	O
expression	O
level	O
of	O
thioredoxin	B-GENE
in	O
the	O
PC12	O
cells,	O
thus	O
the	O
Morphine	O
for	O
protecting	O
the	O
nerve	O
cells	O
from	O
injuries	O
of	O
MPP+	O
toxicity	O
is	O
related	O
to	O
the	O
induction	O
of	O
the	O
expression	O
of	O
the	O
thioredoxin	B-GENE
.	O


The	O
invention	O
provides	O
the	O
application	O
of	O
a	O
polymer	O
system	O
based	O
on	O
beta-cyclodextrin	O
in	O
P-glycoprotein	B-GENE
of	O
suppressive	O
tumour	O
cells	O
.	O
The	O
polymer	O
consists	O
of	O
the	O
beta-cyclodextrin	O
and	O
grafted	O
amphipathy	O
polymer	O
.	O
The	O
star-shaped	O
amphipathy	O
polymer	O
based	O
on	O
beta-CD	O
and	O
provided	O
by	O
the	O
invention	O
has	O
remarkable	O
effect	O
of	O
restraining	O
P-gp	B-GENE
protein,	O
and	O
the	O
restraining	O
effect	O
thereof	O
is	O
obviously	O
superior	O
to	O
the	O
inhibitor	O
CsA	O
of	O
the	O
P-gp	B-GENE
protein	O
.	O
The	O
polymer	O
of	O
the	O
invention	O
has	O
the	O
characteristics	O
of	O
low	O
cytotoxicity,	O
good	O
biocompatibility,	O
biodegradability,	O
long	O
intracorporeal	O
circulation	O
time	O
and	O
the	O
like,	O
and	O
provides	O
an	O
ideal	O
dose	O
carrier	O
material	O
for	O
hydrophobic	O
antineoplastic	O
agents	O
.	O


The	O
invention	O
discloses	O
the	O
application	O
of	O
low-molecule	O
heparin	O
in	O
preparing	O
medicaments	O
for	O
treating	O
collagen-induced	O
arthritis	O
.	O
The	O
invention	O
provides	O
the	O
application	O
of	O
the	O
low-molecule	O
heparin	O
in	O
preparing	O
the	O
medicaments	O
for	O
treating	O
rheumatic	O
diseases,	O
wherein	O
the	O
rheumatic	O
disease	O
are	O
chronic	O
infectious	O
arthritis	O
.	O
The	O
invention	O
has	O
the	O
advantages	O
of	O
exploring	O
the	O
purpose	O
medical	O
treatment	O
of	O
the	O
low-molecule	O
heparin	O
and	O
developing	O
a	O
new	O
application	O
field	O
.	O
The	O
result	O
indicates	O
that	O
the	O
low-molecule	O
heparin	O
has	O
the	O
function	O
of	O
restraining	O
the	O
synovium	O
inflammation	O
of	O
the	O
chronic	O
infectious	O
arthritis	O
and	O
has	O
one	O
of	O
purposes	O
of	O
restraining	O
the	O
adhesion	O
of	O
synovial	O
fibroblast	O
cells	O
and	O
inflammatory	O
cells	O
.	O
The	O
result	O
provides	O
the	O
experimental	O
basis	O
for	O
seeking	O
biological	O
treating	O
target	O
spots	O
and	O
other	O
small-molecule	O
treating	O
target	O
sports,	O
and	O
the	O
low-molecule	O
heparin	O
has	O
clinical	O
application	O
values	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
which	O
is	O
a	O
pyrimidine	O
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PI3K	B-GENE
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B-GENE
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
with	O
a	O
combination	O
of	O
cannabinoid-CB1antagonism	O
and	O
serotonin	O
reuptake	O
inhibition	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
to	O
methods	O
for	O
preparing	O
the	O
compounds,	O
methods	O
for	O
preparing	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis,	O
and	O
methods	O
for	O
preparing	O
compositions	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compounds	O
and	O
compositions,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
psychosis,	O
anxiety,	O
depression,	O
attention	O
deficits,	O
cognitive	O
disorders,	O
obesity,	O
drug	O
dependence,	O
Parkinson	O
'	O
s	O
disease,	O
Alzheimer	O
'	O
s	O
disease,	O
pain	O
disorders,	O
neuropathic	O
pain	O
disorders	O
and	O
sexual	O
disorders	O
.	O
In	O
particular	O
the	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O


The	O
invention	O
provides	O
application	O
of	O
resveratrol	O
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
vessel	O
endothelial	O
injuries	O
caused	O
by	O
organophosphorus	O
pesticides	O
and	O
also	O
provides	O
an	O
application	O
of	O
the	O
resveratrol	O
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
diseases	O
induced	O
by	O
the	O
vessel	O
endothelial	O
injuries	O
caused	O
by	O
the	O
organophosphorus	O
pesticides	O
.	O
Proved	O
by	O
pharmacological	O
tests,	O
the	O
resveratrol	O
can	O
suppress	O
vessel	O
endothelial	O
dependency	O
diastole	O
reaction	O
reduction	O
caused	O
by	O
the	O
organophosphorus	O
pesticides	O
and	O
has	O
better	O
dose	O
dependency	O
.	O
The	O
resveratrol	O
also	O
has	O
the	O
effects	O
of	O
protecting	O
the	O
vessel	O
endothelial	O
cell	O
activity	O
and	O
preventing	O
vessel	O
endothelial	O
permeability	O
increase	O
caused	O
by	O
oxygen	O
and	O
phosphorus	O
and	O
morphologic	O
changes	O
and	O
can	O
also	O
protect	O
the	O
function	O
of	O
endothelial	O
cells	O
for	O
releasing	O
NO	O
and	O
the	O
activity	O
of	O
superoxide	B-GENE
dismutase	I-GENE
and	O
reduce	O
the	O
content	O
of	O
malondialdehyde	O
which	O
is	O
a	O
lipid	O
peroxided	O
metabolic	O
product	O
.	O


The	O
invention	O
discloses	O
a	O
mouth	O
spraying	O
agent	O
consisting	O
of	O
ginseng,	O
epimedium	O
herb,	O
medlar,	O
dogwood,	O
a	O
cell	O
growth	O
factor,	O
vitamin	O
E	O
and	O
other	O
components,	O
which	O
has	O
the	O
efficacies	O
of	O
immunoregulation,	O
fatigue	O
resistance	O
and	O
aging	O
resistance	O
and	O
is	O
particularly	O
applicable	O
for	O
middle-aged	O
and	O
old	O
people	O
.	O


The	O
invention	O
relates	O
to	O
a	O
hybrid	O
pyrimido	O
ketone	O
DPP-IV	B-GENE
inhibitor	O
shown	O
as	O
a	O
formula	O
I	O
as	O
well	O
as	O
salts,	O
a	O
preparation	O
method,	O
compounds	O
and	O
application	O
thereof	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
benefit	O
from	O
the	O
DPP-IV	B-GENE
inhibitor	O
.	O
A	O
preparation	O
process	O
of	O
the	O
DPP-IV	B-GENE
inhibitor	O
is	O
simple,	O
easily-obtained	O
in	O
raw	O
materials	O
and	O
suitable	O
for	O
industrial	O
large-scale	O
production	O
;	O
and	O
in-vitro	O
and	O
in-vivo	O
experiments	O
verify	O
that	O
the	O
DPP-IV	B-GENE
inhibitor	O
has	O
very	O
good	O
selective	O
inhibition	O
effect	O
to	O
DPP-IV,	O
nearly	O
has	O
no	O
influence	O
on	O
activities	O
of	O
DPP-VIII	B-GENE
and	O
DPP-IX	B-GENE
at	O
the	O
same	O
time	O
of	O
effectively	O
inhibiting	O
the	O
DPP-IV	B-GENE
activity,	O
lower	O
toxicity	O
after	O
prepared	O
medicine	O
development,	O
stronger	O
effect	O
and	O
longer	O
acting	O
time	O
compared	O
with	O
the	O
effect	O
of	O
a	O
medicine	O
Alogliptin	O
with	O
the	O
same	O
mechanism	O
and	O
shows	O
excellent	O
effects	O
of	O
reducing	O
the	O
blood	O
sugar	O
and	O
increasing	O
the	O
insulin	B-GENE
sensitivity	O
.	O
The	O
formula	O
I	O
is	O
shown	O
as	O
follows	O
.	O


The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
aminobenzoyl	O
silybin	O
for	O
preparing	O
a	O
virus	O
hepatitis	B-GENE
B	I-GENE
medicine,	O
in	O
particular	O
to	O
the	O
application	O
of	O
23-bit	O
p-aminobenzoyl	O
substituted	O
silybin	O
ester	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
preparing	O
a	O
medicine	O
for	O
eliminating	O
hepatitis	B-GENE
B	I-GENE
virus	I-GENE
surface	I-GENE
antigen	I-GENE
and	O
hepatitis	B-GENE
B	I-GENE
e-antigen	I-GENE
and	O
inhibiting	O
HBV	O
DNA	O
reproduction	O
.	O
The	O
aminobenzoyl	O
silybin	O
has	O
obvious	O
activity	O
for	O
inhibiting	O
HBsAg	B-GENE
and	O
HBeAg,	O
the	O
intensities	O
for	O
eliminating	O
the	O
HBsAg	B-GENE
and	O
the	O
HBeAg	B-GENE
are	O
respectively	O
of	O
73	O
.	O
9	O
percent	O
and	O
95	O
.	O
3	O
percent	O
when	O
the	O
concentration	O
is	O
100	O
milligram	O
/	O
milliliter	O
and	O
are	O
respectively	O
higher	O
than	O
that	O
of	O
a	O
positive	O
control	O
medicine	O
alpha-interferon	O
by	O
4	O
.	O
6	O
times	O
and	O
5	O
.	O
6	O
times,	O
and	O
meanwhile,	O
under	O
the	O
same	O
concentration,	O
the	O
inhabitation	O
ratio	O
of	O
the	O
aminobenzoyl	O
silybin	O
for	O
the	O
HBV	O
DNA	O
is	O
larger	O
than	O
96	O
percent	O
.	O
The	O
invention	O
indicates	O
the	O
application	O
of	O
flavanolignan	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
which	O
can	O
be	O
used	O
for	O
preparing	O
a	O
non-nucleoside	O
medicine	O
for	O
eliminating	O
the	O
HBsAg	B-GENE
and	O
the	O
HBeAg,	O
inhibiting	O
HBV	O
DNA	O
reproduction,	O
treating	O
hepatitis	B-GENE
B	I-GENE
virus	I-GENE
infection	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicaments,	O
discloses	O
the	O
function	O
of	O
ginsenoside	O
Rg1	O
of	O
inducing	O
thioredoxin	B-GENE
in	O
cells	O
to	O
increase	O
expression,	O
and	O
provides	O
application	O
of	O
the	O
ginsenoside	O
Rg1	O
in	O
preventing	O
and	O
treating	O
the	O
harm	O
of	O
formaldehyde	O
to	O
organisms	O
.	O
The	O
invention	O
provides	O
application	O
of	O
the	O
ginsenoside	O
Rg1	O
in	O
preparing	O
products	O
for	O
preventing	O
and	O
treating	O
the	O
harm	O
of	O
the	O
formaldehyde	O
to	O
the	O
organisms,	O
particularly	O
healthcare	O
products,	O
and	O
application	O
of	O
the	O
ginsenoside	O
Rg1	O
in	O
preparing	O
healthcare	O
products	O
related	O
to	O
oxidative	O
stress	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
dioscin	O
in	O
preparation	O
of	O
a	O
liver-protecting	O
pharmaceutical	O
preparation	O
.	O
The	O
pharmaceutical	O
preparation	O
can	O
obviously	O
inhibit	O
increase	O
of	O
activity	O
of	O
aminotransferase	B-GENE
and	O
lactate	B-GENE
dehydrogenase	I-GENE
due	O
to	O
medicines	O
(	O
carbon	O
tetrachloride	O
or	O
paracetamol	O
)	O
and	O
alcohol,	O
and	O
reduce	O
the	O
liver	O
indices,	O
thereby	O
performing	O
the	O
liver-protecting	O
function	O
;	O
the	O
pharmaceutical	O
preparation	O
can	O
enhance	O
the	O
activity	O
of	O
SOD,	O
reduce	O
the	O
content	O
of	O
MDA,	O
increase	O
the	O
content	O
of	O
GSH	O
and	O
inhibit	O
liver	O
lipide	O
overoxidation	O
induced	O
by	O
medicines	O
(	O
carbon	O
tetrachloride	O
or	O
paracetamol	O
)	O
;	O
and	O
the	O
pharmaceutical	O
preparation	O
can	O
also	O
reduce	O
the	O
content	O
of	O
TG	O
and	O
TC	O
and	O
inhibit	O
the	O
liver	O
steatosis	O
caused	O
by	O
alcohol	O
.	O
The	O
dioscin	O
can	O
be	O
used	O
as	O
the	O
raw	O
material	O
to	O
prepare	O
various	O
preparation	O
formulations	O
for	O
clinic	O
applications	O
according	O
to	O
pharmaceutic	O
related	O
requirements	O
and	O
clinic	O
requirements,	O
such	O
as	O
tablets,	O
capsules,	O
injections,	O
oral	O
liquids,	O
granules	O
and	O
the	O
like	O
.	O
The	O
invention	O
is	O
safe	O
(	O
no	O
toxicity	O
or	O
side	O
effect	O
)	O
,	O
convenient,	O
economical	O
and	O
the	O
like	O
.	O


The	O
invention	O
discloses	O
new	O
application	O
of	O
a	O
2-	O
(	O
4-fluorophenyl	O
)	O
-3-nitro-8-O-ethyl-2-hydro-benzopyran	O
compound,	O
in	O
particular	O
application	O
of	O
the	O
compound	O
serving	O
as	O
phosphatidylinositol-3-kinase	B-GENE
(	O
PI3K	B-GENE
)	O
inhibitor	O
.	O
The	O
PI3K	B-GENE
inhibitor	O
can	O
inhibit	O
PI3K	B-GENE
and	O
disturb	O
a	O
PI3K	B-GENE
/	O
AKT	B-GENE
signal	O
channel,	O
has	O
good	O
treatment	O
effect	O
on	O
multiple	O
tumors,	O
particularly	O
malignant	O
hematological	O
diseases,	O
can	O
effectively	O
control	O
the	O
propagation	O
of	O
tumor	O
cells	O
and	O
induce	O
the	O
apoptosis	O
thereof,	O
and	O
has	O
the	O
effect	O
of	O
inhibiting	O
and	O
treating	O
the	O
tumors	O
;	O
and	O
meanwhile,	O
the	O
PI3K	B-GENE
has	O
low	O
toxicity	O
.	O


The	O
invention	O
provides	O
a	O
8,8-disubstituted-13,13a-dihyrdroberberine	O
derivative	O
with	O
a	O
structure	O
shown	O
as	O
the	O
following	O
general	O
formula	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
and	O
application	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
.	O
The	O
8,8-disubstituted-13,13a-dihyrdroberberine	O
derivative	O
has	O
the	O
effect	O
of	O
promoting	O
the	O
glucose	O
absorption	O
on	O
muscle	O
cells	O
.	O
Proved	O
by	O
in-vivo	O
animal	O
experiments,	O
the	O
compound	O
has	O
the	O
effects	O
on	O
improving	O
the	O
carbohydrate	O
tolerance	O
and	O
the	O
insulin	B-GENE
resistance,	O
reducing	O
weight,	O
relieving	O
fatty	O
livers,	O
and	O
the	O
like,	O
has	O
high	O
bioavailability,	O
enhances	O
the	O
in-vivo	O
pesticide	O
effect,	O
and	O
has	O
stable	O
structure	O
under	O
an	O
acidic	O
condition	O
.	O
The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
type-2	O
diabetes,	O
obesity,	O
fatty	O
livers	O
or	O
complications	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
new	O
application	O
of	O
a	O
compound,	O
in	O
particular	O
to	O
application	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
preventing	O
and	O
controlling	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	O
liver	O
damage	O
.	O
A	O
protein	B-GENE
kinase	I-GENE
D	I-GENE
(	O
PKD	B-GENE
)	O
inhibitor	O
has	O
the	O
advantages	O
of	O
preventing	O
LPS-induced	O
mice	O
acute	O
liver	O
damage,	O
remarkably	O
reducing	O
the	O
phosphorylation	O
level	O
of	O
LPS-induced	O
PKD,	O
lowering	O
death	O
rate	O
and	O
levels	O
of	O
alanine	B-GENE
aminotransferase	I-GENE
(	O
ALT	B-GENE
)	O
and	O
aspartate	B-GENE
transaminase	I-GENE
(	O
AST	B-GENE
)	O
,	O
improving	O
inflammatory	O
reaction,	O
restraining	O
the	O
signal	O
channel	O
of	O
LPS	O
activated	O
p38	B-GENE
mitogen-activated	I-GENE
protein	B-GENE
kinase	I-GENE
(	O
p38MAPK	B-GENE
)	O
,	O
lowering	O
the	O
level	O
of	O
LPS-induced	O
tumor	B-GENE
necrosis	I-GENE
factor-alpha	I-GENE
(	O
TNK-alpha	B-GENE
)	O
,	O
reducing	O
the	O
apoptosis	O
number	O
of	O
hepatic	O
cells,	O
the	O
activation	O
of	O
caspases	O
and	O
the	O
expression	O
level	O
of	O
hepatic	O
tissue	O
adhesion	O
molecules	O
and	O
lowering	O
the	O
activation	O
level	O
of	O
myeloperoxidase	B-GENE
(	O
MPO	B-GENE
)	O
.	O


The	O
invention	O
relates	O
to	O
N-substituted	O
benzenesulfonyl-substituted	O
benzamides	O
small	O
molecular	O
inhibitor	O
of	O
Bcl-2	B-GENE
protein	O
family	O
anti-apoptosis	O
members	O
and	O
application	O
thereof	O
.	O
The	O
invention	O
relates	O
to	O
N-substituted	O
benzenesulfonyl-substituted	O
benzamides	O
compounds	O
of	O
a	O
formula	O
I	O
for	O
inhibiting	O
Bcl-2	B-GENE
protein	O
family	O
anti-apoptosis	O
members	O
(	O
such	O
as	O
Bcl-2,	O
Bcl-xL,	O
Mcl-1,	O
and	O
the	O
like	O
)	O
,	O
wherein	O
the	O
definition	O
of	O
each	O
group	O
is	O
disclosed	O
as	O
a	O
specification	O
for	O
details	O
.	O
The	O
compounds	O
(	O
and	O
stereoisomerides	O
thereof	O
if	O
exist	O
)	O
,	O
medicine	O
salts,	O
hydrates,	O
solvates	O
and	O
medicine	O
compositions	O
thereof	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
or	O
symptoms	O
which	O
are	O
related	O
to	O
the	O
high	O
expression	O
of	O
the	O
Bcl-2	B-GENE
protein	O
family	O
anti-apoptosis	O
members	O
or	O
can	O
be	O
used	O
for	O
treating	O
tumors	O
or	O
can	O
be	O
used	O
as	O
a	O
synergistic	O
agent	O
which	O
is	O
combined	O
with	O
other	O
antineoplastics	O
for	O
treating	O
tumors	O
.	O
The	O
invention	O
also	O
relates	O
to	O
preparation	O
methods	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I	O
and	O
the	O
medicine	O
salts	O
thereof	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein,	O
R1	O
is	O
optionally	O
substituted	O
pyrazolyl,	O
and	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
diseases	O
associated	O
with	O
P2X3	B-GENE
and	O
/	O
or	O
a	O
P2X2/3	B-GENE
receptor	O
antagonists	O
and	O
methods	O
of	O
making	O
the	O
compounds	O
.	O


Compounds	O
of	O
the	O
following	O
formula	O
are	O
provided	O
for	O
use	O
with	O
kinases	B-GENE
:	O
(	O
I	O
)	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
and	O
intermediates	O
useful	O
for	O
making	O
the	O
compounds	O
;	O
and	O
methods	O
of	O
using	O
said	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
useful	O
for	O
inhibiting	O
fascin	B-GENE
.	O
These	O
compositions	O
and	O
methods	O
can	O
be	O
used	O
to	O
inhibit	O
fascin-related	O
diseases	O
.	O
For	O
example,	O
according	O
to	O
the	O
invention	O
inhibition	O
of	O
fascin	B-GENE
inhibits	O
metastasis	O
of	O
tumor	O
cells	O
in	O
mammals	O
.	O


Compounds	O
of	O
general	O
structure	O
in	O
which	O
X	O
and	O
Y	O
are	O
each	O
N	O
or	O
C	O
with	O
at	O
least	O
one	O
of	O
X	O
and	O
Y	O
being	O
N	O
;	O
Z	O
is	O
a	O
single	O
bond	O
or	O
an	O
optionally	O
substituted	O
linking	O
group	O
R1	O
is	O
hydrogen	O
or	O
a	O
substituent	O
group	O
;	O
R2	O
is	O
amino	O
or	O
a	O
substituent	O
group	O
;	O
N	O
*	O
is	O
amino	O
when	O
RI	O
is	O
hydrogen	O
or	O
=	O
NH	O
when	O
R1	O
is	O
a	O
substituent	O
group	O
;	O
or	O
N	O
*	O
is	O
a	O
group	O
NRaRb	O
where	O
Ra	O
and	O
Rb	O
are	O
independently	O
H	O
or	O
an	O
alkyl	O
group	O
;	O
or	O
N	O
*	O
is	O
an	O
optionally	O
substituted	O
piperazinyl	O
ring	O
;	O
and	O
A	O
is	O
an	O
optionally	O
substituted	O
heterocyclic	O
or	O
carbocyclic	O
ring	O
system	O
which	O
may	O
be	O
linked	O
to	O
the	O
triazo	O
/	O
diazo	O
ring	O
through	O
R2	O
to	O
form	O
a	O
fused	O
multicyclic	O
ring	O
;	O
are	O
indicated	O
as	O
suitable	O
for	O
treatment	O
of	O
disorders	O
in	O
mammals	O
that	O
are	O
susceptible	O
to	O
sodium	B-GENE
channel	I-GENE
blockers	O
and	O
antifolates,	O
and	O
particularly	O
disorders	O
such	O
epilepsy,	O
multiple	O
sclerosis,	O
glaucoma	O
and	O
uevitis,	O
cerebral	O
traumas	O
and	O
cerebral	O
ischaemias,	O
stroke,	O
head	O
injury,	O
spinal	O
cord	O
injury,	O
surgical	O
trauma,	O
neurodegenerative	O
disorders,	O
motorneurone	O
disease,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
chronic	O
inflammatory	O
pain,	O
neuropathic	O
pain,	O
migraine,	O
bipolar	O
disorder,	O
mood,	O
anxiety	O
and	O
cognitive	O
disorders,	O
schizophrenia	O
and	O
trigeminal	O
autonomic	O
cephalalgias	O
;	O
for	O
treatment	O
of	O
mammalian	O
cancers	O
;	O
and	O
for	O
treatment	O
of	O
malaria	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
total	O
aglycone	O
of	O
gleditsia	O
sinensis	O
in	O
the	O
preparation	O
of	O
alpha-glucosidase	B-GENE
inhibitor	O
drugs	O
.	O
The	O
total	O
aglycone	O
of	O
the	O
gleditsia	O
sinensis	O
is	O
prepared	O
by	O
alkalization	O
extraction,	O
acid	O
hydrolysis	O
and	O
purification	O
by	O
addition	O
of	O
active	O
carbon	O
and	O
so	O
on	O
.	O
The	O
obtained	O
total	O
aglycone	O
of	O
the	O
gleditsia	O
sinensis	O
is	O
used	O
for	O
activity	O
research	O
of	O
the	O
alpha-glucosidase	B-GENE
inhibitor,	O
and	O
the	O
effect	O
is	O
good	O
.	O


The	O
invention	O
discloses	O
a	O
novel	O
antitumor	O
medicament,	O
in	O
particular	O
a	O
benzisoselenazolone	O
difluorocytidine	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof,	O
wherein	O
a	O
benzisoselenazolone	O
structure	O
can	O
identify	O
selenocysteine	O
residues	O
in	O
the	O
activity	O
center	O
of	O
thioredoxin	B-GENE
reductase	I-GENE
to	O
generate	O
the	O
action	O
of	O
reversibly	O
competitive	O
inhibition	O
and	O
reserves	O
the	O
activity	O
structure	O
of	O
2	O
'	O
-deoxidization-2	O
'	O
2	O
'	O
-difluorocytidine	O
.	O
Therefore,	O
the	O
benzisoselenazolone	O
difluorocytidine	O
compound	O
in	O
the	O
invention	O
can	O
selectively	O
kill	O
tumor	O
cells,	O
inhibit	O
the	O
growth	O
of	O
the	O
tumor	O
cells,	O
and	O
has	O
the	O
characteristics	O
of	O
high	O
efficiency	O
and	O
low	O
toxicity	O
.	O


The	O
invention	O
provides	O
an	O
RGD	O
peptide-epimedium	O
flavone	O
combination	O
synthesized	O
by	O
combining	O
two	O
structural	O
units	O
of	O
RGD	O
peptides	O
and	O
epimedium	O
flavone	O
which	O
have	O
pharmacological	O
activities	O
of	O
different	O
action	O
mechanisms	O
on	O
osseous	O
metabolic	O
diseases,	O
and	O
also	O
provides	O
a	O
synthesis	O
method	O
thereof	O
.	O
The	O
compound	O
of	O
the	O
invention	O
has	O
two	O
receptor	O
combining	O
sites	O
and	O
simultaneously	O
has	O
the	O
capability	O
of	O
combining	O
estrogen	O
receptors	O
of	O
icaritin	O
and	O
the	O
capability	O
of	O
combining	O
integrins	B-GENE
alphaVbeta3	I-GENE
of	O
RGD,	O
and	O
the	O
capabilities	O
of	O
combining	O
the	O
two	O
different	O
receptors	O
can	O
produce	O
a	O
synergistic	O
effect	O
to	O
greatly	O
improve	O
the	O
curative	O
activity	O
of	O
the	O
medicament	O
on	O
osteoporosis	O
and	O
osseous	O
metabolic	O
diseases	O
.	O
The	O
synthesis	O
method	O
has	O
the	O
advantages	O
of	O
high	O
yield,	O
high	O
synthesis	O
speed	O
and	O
easy	O
purification	O
of	O
products	O
.	O


Inhibitors	O
for	O
matrix	O
metalloproteinases,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
.	O
The	O
inhibitors	O
for	O
matrix	B-GENE
metalloproteinases	I-GENE
have	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
W,	O
X1,	O
X2,	O
R1,	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
They	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
regulated	O
by	O
matrix	O
metalloproteinases,	O
in	O
particular	O
corneal	O
ulceration,	O
pulmonary	O
emphysema	O
or	O
dermal	O
ulceration	O
resulted	O
from	O
chemical	O
injury,	O
or	O
pulmonary	O
emphysema	O
caused	O
by	O
smoking	O
or	O
drowning	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
of	O
gene	O
immunization	O
treating	O
tumor	O
used	O
for	O
veins,	O
which	O
is	O
composed	O
of	O
replication	O
deficient	O
adenovirus	O
loading	O
human	B-GENE
telomerase	I-GENE
reverse	I-GENE
transcriptase	I-GENE
C-terminal	I-GENE
polypeptide	I-GENE
hTERTC27	B-GENE
and	O
an	O
acceptable	O
pharmaceutic	O
adjuvant	O
.	O
The	O
anti-tumor	O
gene	O
preparation	O
rAdv-hTERTC27	O
of	O
the	O
invention	O
has	O
high	O
transfection	O
efficiency,	O
and	O
is	O
more	O
effective	O
on	O
the	O
increment	O
and	O
the	O
apoptosis	O
regulation	O
of	O
the	O
tumor	O
cell	O
.	O
The	O
anti-tumor	O
gene	O
preparation	O
of	O
the	O
invention	O
can	O
effectively	O
lead	O
the	O
peptides	O
transfection	O
to	O
enter	O
into	O
the	O
dendritic	O
cell	O
DCs,	O
so	O
as	O
to	O
activate	O
the	O
DCs,	O
secrete	O
IFN-gamma,	O
IL-2,	O
increase	O
and	O
further	O
stimulate	O
T	O
lymphopoiesis,	O
promote	O
the	O
T	O
lymphocyte	O
to	O
generate	O
the	O
special	O
killing	O
effect	O
CTL	O
corresponding	O
to	O
the	O
tumor	O
cell,	O
and	O
immunoregulation	O
is	O
carried	O
out	O
on	O
the	O
tumor	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
nicotinamide	B-GENE
mononucleotide	I-GENE
ribose	I-GENE
phosphate	I-GENE
transferase	I-GENE
inhibitor	O
.	O
The	O
nicotinamide	B-GENE
mononucleotide	I-GENE
ribose	I-GENE
phosphate	I-GENE
transferase	I-GENE
inhibitor	O
can	O
effectively	O
prevent	O
or	O
treat	O
thrombocyte	O
hyperfunction,	O
and	O
blood	O
hypercoagulative	O
state	O
or	O
thrombi,	O
has	O
the	O
advantages	O
of	O
favorable	O
curative	O
effect,	O
small	O
side	O
effect	O
and	O
high	O
safety,	O
and	O
has	O
an	O
important	O
meaning	O
for	O
treating	O
coagulation	O
hyperfunction	O
diseases	O
.	O


The	O
invention	O
discloses	O
3-peperazinyl	O
coumarin	O
derivatives	O
shown	O
in	O
a	O
formula	O
(	O
I	O
)	O
,	O
medicinal	O
salt	O
of	O
the	O
derivatives,	O
a	O
preparation	O
method	O
for	O
the	O
derivatives,	O
a	O
derivative-containing	O
medicinal	O
composition,	O
and	O
the	O
application	O
of	O
the	O
derivatives	O
to	O
medicaments	O
for	O
preventing	O
or	O
treating	O
chemokine-like	B-GENE
factor	I-GENE
1	I-GENE
(	O
CKLF1	B-GENE
)	O
activity-related	O
diseases	O
and	O
as	O
a	O
CKLF1	B-GENE
/	O
C	B-GENE
chemokine	I-GENE
receptor	I-GENE
4	I-GENE
(	O
CCR4	B-GENE
)	O
action	O
antagonist	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof,	O
wherein	O
R1-R4	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	B-GENE
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O


The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
a	O
4-substituted	O
phenylamino-7-substituted	O
alkoxy-quinazoline	O
derivant	O
(	O
chemical	O
formula	O
I	O
)	O
,	O
which	O
comprises	O
the	O
step	O
of	O
:	O
carrying	O
out	O
etherifying	O
reaction	O
on	O
compounds	O
shown	O
in	O
a	O
general	O
formula	O
II	O
and	O
a	O
general	O
formula	O
III,	O
wherein	O
R1,	O
R2,	O
R3,	O
m,	O
n,	O
p	O
and	O
q	O
respectively	O
have	O
meanings	O
defined	O
in	O
the	O
specification	O
.	O
The	O
compounds	O
have	O
valuable	O
pharmacological	O
properties,	O
and	O
in	O
particular,	O
have	O
inhibiting	O
effect	O
on	O
signal	O
transmission	O
caused	O
by	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
PTK	B-GENE
)	O
.	O
The	O
method	O
provided	O
in	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simpleness	O
in	O
operation,	O
high	O
yield	O
and	O
low	O
cost	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
dehydrocorydaline	O
and	O
scoulerine	O
to	O
medicament	O
production	O
.	O
In	O
the	O
invention,	O
a	O
diagnostic	O
kit	O
for	O
hepatitis	B-GENE
B	I-GENE
virus	O
surface	O
antigen	O
and	O
a	O
diagnostic	O
kit	O
for	O
hepatitis	B-GENE
B	I-GENE
virus	O
e	O
antigen	I-GENE
are	O
adopted	O
to	O
perform	O
tests	O
of	O
resisting	O
hepatitis	B-GENE
B	I-GENE
surface	O
antigen	O
and	O
hepatitis	B-GENE
B	I-GENE
e	I-GENE
antigen	I-GENE
on	O
protoberberine	O
alkaloids	O
scoulerine	O
and	O
dehydrocorydaline	O
respectively	O
.	O
Results	O
prove	O
that	O
the	O
dehydrocorydaline	O
and	O
the	O
scoulerine	O
have	O
remarkable	O
hepatitis	B-GENE
B	I-GENE
virus	O
resisting	O
activity,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
hepatitis	B-GENE
B	I-GENE
virus	O
resistant	O
medicament	O
.	O


The	O
invention	O
provides	O
a	O
rabeprazole	O
sodium	O
combined	O
medicament	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O
The	O
rabeprazole	O
sodium	O
combined	O
medicament	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
as	O
components	O
in	O
proportion	O
by	O
weight	O
:	O
5-10	O
of	O
ilaprazole	O
sodium,	O
20-30	O
of	O
composition	O
of	O
reduced	O
glutathione	O
and	O
hepatocyte	B-GENE
growth-promoting	I-GENE
factors	I-GENE
in	O
proportion	O
by	O
weight	O
of	O
1	O
:	O
10,	O
and	O
50-60	O
of	O
diammonium	O
glycyrrhizinate	O
.	O
According	O
to	O
a	O
pharmaceutically	O
allowable	O
dose	O
of	O
rabeprazole	O
sodium,	O
pharmaceutical	O
preparations	O
in	O
dosage	O
forms	O
of	O
injection,	O
lyophilized	O
powder	O
injection,	O
enteric	O
coated	O
tablets,	O
enteric	O
coated	O
capsules,	O
spray	O
and	O
the	O
like	O
of	O
the	O
rabeprazole	O
sodium	O
combined	O
medicament	O
are	O
respectively	O
prepared	O
for	O
treating	O
gastric	O
ulcer	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
organic	O
synthesis	O
and	O
pharmaceutical	O
chemistry	O
and	O
relates	O
to	O
synthetic	O
derivatives	O
of	O
a	O
natural	O
product,	O
namely	O
physostigmine,	O
as	O
shown	O
in	O
a	O
chemical	O
structural	O
formula	O
2,	O
which	O
have	O
the	O
activity	O
of	O
inhibiting	O
acetylcholinesterase	B-GENE
.	O
In	O
addition,	O
the	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
physostigmine	O
derivatives	O
2,	O
and	O
the	O
structure	O
of	O
the	O
derivatives	O
is	O
basically	O
characterized	O
by	O
enabling	O
indole	O
5-bit	O
to	O
have	O
1,2,3-triazole	O
substituent	O
.	O
The	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
being	O
short	O
in	O
synthetic	O
routes,	O
and	O
being	O
economic	O
and	O
efficient	O
.	O
The	O
in	O
vitro	O
activity	O
screening	O
study	O
shows	O
that	O
part	O
of	O
the	O
newly	O
synthesized	O
physostigmine	O
derivatives	O
have	O
strong	O
activity	O
of	O
inhibiting	O
the	O
acetylcholinesterase,	O
and	O
are	O
candidate	O
medicaments	O
with	O
potential	O
clinical	O
application	O
prospect	O
for	O
preventing	O
senile	O
dementia	O
disease	O
.	O


The	O
invention	O
discloses	O
geldanamycin	O
derivative,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
.	O
The	O
structural	O
formula	O
as	O
shown	O
in	O
the	O
following	O
formula	O
(	O
I	O
)	O
is	O
a	O
novel	O
structural	O
formula	O
formed	O
by	O
modifying	O
the	O
geldanamycin,	O
and	O
the	O
pair	O
of	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
is	O
good	O
in	O
activity	O
.	O
The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
medical	O
salt	O
of	O
the	O
compound	O
;	O
R1	O
group	O
is	O
phenyl	O
or	O
3-furyl	O
or	O
3-pyrryl	O
or	O
the	O
other	O
hexahydric	O
heteroaromatic	O
group,	O
or	O
the	O
other	O
quinary	O
heteroaromatic	O
group	O
;	O
and	O
R2	O
group	O
is	O
carboxylic	O
acid	O
amide	O
or	O
acetyl	O
or	O
ethyl	O
or	O
the	O
fatty	O
hydrocarbon	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
or	O
the	O
carbonyl	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
fatty	O
hydrocarbon	O
.	O
The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
has	O
the	O
characteristic	O
of	O
the	O
high-efficiency	O
combined	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90,	O
so	O
that	O
the	O
geldanamycin	O
derivative	O
can	O
be	O
used	O
for	O
curing	O
or	O
preventing	O
the	O
tumor	O
of	O
the	O
mammal,	O
in	O
particular	O
to	O
the	O
solid	O
tumor	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
and	O
enantiomers,	O
diastereomers	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	B-GENE
kinase	I-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines,	O
in	O
particular	O
to	O
application	O
of	O
resveratrol	O
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
and	O
treating	O
respiratory	O
syncytial	O
virus	O
infections,	O
wherein	O
the	O
resveratrol	O
can	O
obviously	O
reduce	O
the	O
infection	O
titer	O
of	O
a	O
respiratory	O
syncytial	O
virus	O
and	O
IL-6	B-GENE
secretion	O
induced	O
by	O
the	O
respiratory	O
syncytial	O
virus	O
in	O
vitro	O
;	O
and	O
the	O
resveratrol	O
can	O
obviously	O
reduce	O
the	O
titer	O
of	O
the	O
respiratory	O
syncytial	O
virus	O
in	O
lung	O
tissues	O
of	O
a	O
mouse	O
with	O
the	O
respiratory	O
syncytial	O
virus	O
infection	O
in	O
vivo	O
and	O
has	O
a	O
better	O
therapeutic	O
action	O
on	O
airway	O
inflammations	O
and	O
airway	O
high	O
reaction	O
induced	O
by	O
the	O
respiratory	O
syncytial	O
virus	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
arachidonic	O
acid	O
as	O
a	O
xanthine	B-GENE
oxidase	I-GENE
inhibitor	O
and	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
.	O
Xanthine	B-GENE
oxidase	I-GENE
is	O
a	O
key	O
enzyme	O
for	O
the	O
generation	O
and	O
the	O
development	O
of	O
the	O
hyperuricemia	O
or	O
the	O
gout,	O
most	O
substrates	O
of	O
the	O
xanthine	B-GENE
oxidase	I-GENE
are	O
cyclic	O
small	O
molecules,	O
and	O
the	O
arachidonic	O
acid	O
is	O
long	O
chain	O
polyunsaturated	O
fatty	O
acid	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
xanthine	B-GENE
oxidase	I-GENE
is	O
downloaded	O
from	O
a	O
protein	O
data	O
bank	O
(	O
PDB	O
)	O
of	O
a	O
website	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
arachidonic	O
acid	O
is	O
downloaded	O
from	O
a	O
pubchem	O
;	O
molecular	O
docking	O
between	O
the	O
arachidonic	O
acid	O
and	O
the	O
xanthine	B-GENE
oxidase	I-GENE
is	O
performed	O
by	O
iGEMDOCK	O
software	O
and	O
docking	O
energy	O
is	O
computed	O
;	O
and	O
in-vitro	O
enzyme	O
activity	O
tests	O
prove	O
that	O
the	O
arachidonic	O
acid	O
has	O
an	O
inhibition	O
effect	O
on	O
the	O
xanthine	B-GENE
oxidase	I-GENE
.	O
By	O
the	O
application,	O
another	O
important	O
physiological	O
function	O
of	O
the	O
arachidonic	O
acid	O
is	O
discovered,	O
and	O
a	O
wider	O
way	O
is	O
provided	O
for	O
screening	O
the	O
xanthine	B-GENE
oxidase	I-GENE
inhibitor	O
from	O
a	O
natural	O
product	O
to	O
treat	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
simultaneously	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparation,	O
and	O
relates	O
to	O
a	O
supersaturated	O
self-microemulsified	O
administration	O
system	O
for	O
insoluble	O
anticancer	O
drugs,	O
prepared	O
from	O
insoluble	O
anti-tumor	O
drugs,	O
an	O
emulsifier,	O
a	O
co-emulsifier,	O
an	O
oil	O
phase	O
and	O
a	O
crystallization	O
inhibitor	O
in	O
different	O
mass	O
percents	O
;	O
and	O
the	O
administration	O
system	O
can	O
be	O
filled	O
into	O
soft	O
capsules	O
or	O
hard	O
capsules	O
.	O
The	O
supersaturated	O
self-microemulsified	O
administration	O
system	O
is	O
dispersible	O
after	O
oral	O
administration	O
to	O
form	O
microemulsion	O
with	O
the	O
particle	O
size	O
of	O
10-100nm,	O
thus	O
inhibiting	O
crystallization	O
and	O
separation	O
of	O
drugs,	O
promoting	O
absorption	O
of	O
drugs	O
and	O
improving	O
the	O
bioavailability	O
of	O
drugs	O
.	O
The	O
administration	O
system	O
has	O
the	O
advantages	O
of	O
improving	O
the	O
solubility	O
of	O
the	O
insoluble	O
anticancer	O
drugs	O
in	O
water,	O
inhibiting	O
the	O
exocytosis	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
p-glycoprotein	B-GENE
on	O
drugs,	O
improving	O
the	O
bioavailability	O
of	O
drugs,	O
eliminating	O
the	O
influence	O
of	O
foods	O
on	O
the	O
absorption	O
and	O
bioavailability	O
of	O
drugs,	O
and	O
the	O
like	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
2,	O
2,	O
3,	O
3-tetramethyl	O
cyclopropyl	O
carbonyl	O
thiourea	O
(	O
TCCT	O
)	O
in	O
the	O
process	O
for	O
preparing	O
an	O
antitumor	O
medicine	O
.	O
The	O
tumor	O
is	O
human	O
astrocytoma	O
.	O
The	O
antitumor	O
medicine	O
comprises	O
an	O
up-regulating	O
tumor	O
suppressor	O
gene	O
p21	B-GENE
<	O
WAF1	O
/	O
CIP1	O
>	O
medicine,	O
a	O
down-regulating	O
cyclin	O
D1	O
medicine	O
or	O
a	O
down-regulating	O
HDAC3	B-GENE
and	O
HDAC4	B-GENE
expression	O
medicine	O
.	O
The	O
invention	O
confirms	O
that	O
2,	O
2,	O
3,	O
3-tetramethyl	O
cyclopropyl	O
carbonyl	O
thiourea	O
(	O
TCCT	O
for	O
short	O
)	O
possesses	O
inhibitory	O
effect	O
on	O
the	O
growth	O
of	O
U251	O
human	O
glioma	O
cells	O
by	O
using	O
a	O
molecular	O
biology	O
method,	O
the	O
2,	O
2,	O
3,	O
3-tetramethyl	O
cyclopropyl	O
carbonyl	O
thiourea	O
provided	O
in	O
the	O
invention	O
interferes	O
the	O
cell	O
cycle	O
through	O
the	O
effect	O
of	O
p21	B-GENE
<	O
WAF1	O
/	O
CIP1	O
>	O
and	O
CyclinD1	B-GENE
expression,	O
so	O
as	O
to	O
exert	O
the	O
effect	O
of	O
inhibition,	O
whichhas	O
the	O
obvious	O
effect	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
PARP	B-GENE
inhibitors	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
n,	O
s,	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
,	O
R	O
<	O
3	O
>	O
,	O
Q,	O
X	O
and	O
Y	O
have	O
defined	O
meanings	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
in	O
vitro	O
method	O
for	O
identifying	O
and	O
evaluating	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
different	O
types	O
of	O
cancer,	O
especially	O
lung,	O
breast,	O
colorectal	O
and	O
bladder	O
cancer	O
in	O
an	O
individual,	O
for	O
determining	O
the	O
stage	O
or	O
severity	O
of	O
said	O
cancer	O
in	O
the	O
individual,	O
or	O
for	O
monitoring	O
the	O
effect	O
of	O
the	O
therapy	O
administered	O
to	O
an	O
individual	O
having	O
said	O
cancer	O
;	O
to	O
finding,	O
identifying,	O
developing	O
and	O
evaluating	O
the	O
efficacy	O
of	O
compounds	O
for	O
the	O
therapy	O
of	O
said	O
cancer,	O
for	O
the	O
purpose	O
of	O
developing	O
new	O
medicinal	O
products	O
;	O
as	O
well	O
as	O
to	O
agents	O
inhibiting	O
the	O
expression	O
and	O
/	O
or	O
activity	O
of	O
the	O
choline	B-GENE
kinase	I-GENE
alpha	I-GENE
protein	O
and	O
/	O
or	O
the	O
effects	O
of	O
this	O
expression	O
.	O


Disclosed	O
is	O
a	O
cell	O
which	O
enables	O
the	O
reproduction	O
of	O
a	O
cartilage	O
tissue	O
and	O
has	O
a	O
proliferative	O
ability	O
.	O
Also	O
disclosed	O
is	O
a	O
technique	O
for	O
providing	O
a	O
cell	O
supply	O
source	O
which	O
can	O
be	O
used	O
in	O
a	O
definitive	O
treatment	O
of	O
osteochondrosis	O
deformans	O
.	O
A	O
chondrocyte-like	O
cell	O
which	O
has	O
the	O
same	O
properties	O
as	O
those	O
of	O
a	O
chondrocyte	O
and	O
can	O
proliferate	O
can	O
be	O
produced	O
by	O
selecting	O
a	O
combination	O
of	O
an	O
Myc	B-GENE
family	O
gene	O
and	O
/	O
or	O
a	O
Klf	B-GENE
family	O
gene	O
and	O
a	O
SOX9	B-GENE
gene	I-GENE
and	O
introducing	O
the	O
combination	O
into	O
a	O
somatic	O
cell	O
.	O
The	O
chondrocyte-like	O
cell	O
can	O
be	O
used	O
for	O
a	O
medical	O
purpose	O
of	O
cartilage	O
regeneration	O
.	O


The	O
invention	O
relates	O
to	O
morin-7-sodium	O
sulfate	O
for	O
inhibiting	O
enzymatic	O
activity	O
of	O
PRL-3	B-GENE
(	O
phosphatase	B-GENE
of	I-GENE
regenerating	I-GENE
liver-3	I-GENE
)	O
and	O
application	O
of	O
the	O
morin-7-	O
sodium	O
sulfate	O
in	O
medicines	O
for	O
resisting	O
tumor	O
metastasis	O
.	O
Human	O
PRL-3	B-GENE
protein	O
with	O
enzymatic	O
activity	O
is	O
obtained	O
through	O
a	O
gene	O
engineering	O
technology,	O
the	O
water-soluble	O
morin-7-sodium	O
sulfate	O
obtained	O
through	O
screening	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
for	O
the	O
enzymatic	O
activity	O
of	O
the	O
PRL-3,	O
the	O
inhibiting	O
effect	O
of	O
the	O
morin-7-sodium	O
sulfate	O
is	O
stronger	O
than	O
that	O
of	O
parent	O
morin	O
of	O
the	O
morin-7-sodium	O
sulfate	O
and	O
is	O
also	O
superior	O
to	O
the	O
inhibiting	O
effects	O
of	O
other	O
compounds	O
or	O
natural	O
products,	O
a	O
Transwell	O
measurement	O
result	O
shows	O
that	O
the	O
compound	O
can	O
obviously	O
inhibit	O
the	O
invitro	O
invasive	O
capability	O
and	O
the	O
motility	O
of	O
a	O
tumour	O
cell,	O
and	O
a	O
Western	O
blot	O
and	O
fluorescence	O
quantitative	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
result	O
shows	O
that	O
the	O
compound	O
can	O
specifically	O
inhibit	O
the	O
PRL-3	B-GENE
protein	O
and	O
mRNA	O
(	O
Messenger	O
RNA	O
)	O
expression	O
rather	O
than	O
PRL-1	B-GENE
protein	O
and	O
PRL-2	B-GENE
protein	O
(	O
same	O
species	O
as	O
the	O
PRL-3	B-GENE
protein	O
)	O
and	O
mRNA	O
expression	O
.	O
The	O
compound	O
provided	O
by	O
the	O
invention	O
has	O
higher	O
application	O
value	O
in	O
researching	O
the	O
effect	O
of	O
the	O
PRL-3	B-GENE
in	O
the	O
tumor	O
metastasis	O
and	O
designing,	O
researching	O
and	O
developing	O
the	O
medicines	O
for	O
resisting	O
the	O
tumor	O
metastasis,	O
can	O
be	O
applied	O
to	O
preparing	O
a	O
positive	O
control	O
reagent	O
or	O
compound	O
of	O
a	O
PRL-3	B-GENE
enzyme	O
inhibitor,	O
and	O
is	O
used	O
as	O
one	O
component	O
or	O
precursor	O
for	O
preparing	O
the	O
medicines	O
for	O
resisting	O
the	O
tumor	O
metastasis	O
in	O
medicine	O
development	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
cucoline	O
derivative	O
as	O
well	O
as	O
salts,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
According	O
to	O
the	O
invention,	O
1,	O
4,	O
6	O
and	O
17	O
positions	O
in	O
a	O
cucoline	O
structure	O
are	O
modified	O
so	O
as	O
to	O
obtain	O
the	O
cucoline	O
derivative	O
the	O
structural	O
general	O
formula	O
of	O
which	O
is	O
as	O
follows	O
(	O
shown	O
in	O
the	O
specification	O
)	O
;	O
the	O
salts	O
of	O
the	O
cucoline	O
derivative	O
comprise	O
hydrochloride,	O
sulfate,	O
bisulfate,	O
hydrobromide,	O
oxalate,	O
citrate	O
and	O
mesylate	O
;	O
and	O
the	O
inhibition	O
activity	O
of	O
partial	O
compounds	O
of	O
the	O
invention	O
on	O
NF-kappa	B-GENE
B	I-GENE
are	O
obviously	O
superior	O
to	O
that	O
of	O
cucoline,	O
and	O
the	O
cucoline	O
derivative	O
and	O
salts	O
thereof	O
are	O
used	O
for	O
preparing	O
anti-inflammatory	O
medicaments	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
and	O
salts	O
of	O
the	O
compounds	O
.	O
The	O
compounds	O
are	O
TRPV1	B-GENE
(	O
transient	O
receptor	O
potential	O
cation	O
channel,	O
subfamily	O
V,	O
member	O
1	O
)	O
antagonists,	O
and	O
have	O
better	O
analgesic	O
action	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
the	O
compounds,	O
medicinal	O
preparations	O
containing	O
the	O
compounds,	O
and	O
application	O
of	O
the	O
compounds	O
and	O
medicinal	O
compositions	O
thereof	O
in	O
treatment	O
of	O
pain	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
curcumin	O
in	O
the	O
preparation	O
of	O
a	O
thyroid	O
carcinoma	O
therapeutic	O
agent,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
curcumin	O
pharmaceutical	O
application	O
.	O
Curcumin	O
can	O
kill	O
thyroid	O
carcinoma	O
cells	O
specifically	O
and	O
has	O
little	O
influence	O
on	O
normal	O
thyroid	O
cells	O
.	O
Curcumin	O
can	O
promote	O
the	O
apoptosis	O
of	O
thyroid	O
carcinoma	O
cells,	O
initiate	O
the	O
digestion	O
of	O
poly	B-GENE
adenosine	I-GENE
diphosphate-ribose	I-GENE
polymerase	I-GENE
(	O
PARP	B-GENE
)	O
,	O
and	O
significantly	O
inhibit	O
the	O
expression	O
of	O
anti-apoptotic	O
protein	O
Bcl-2	B-GENE
;	O
meanwhile,	O
curcumin	O
can	O
also	O
inhibit	O
the	O
secretion	O
of	O
thyroid	O
carcinoma	O
cell	O
matrix	B-GENE
metalloproteinase-9	I-GENE
and	O
the	O
adhesion	O
to	O
extracellular	O
matrix	O
.	O
Above	O
results	O
show	O
that	O
curcumin	O
has	O
good	O
intervention	O
effect	O
on	O
various	O
links	O
of	O
proliferation,	O
migration,	O
and	O
adhesion	O
of	O
thyroid	O
carcinoma	O
cells,	O
and	O
is	O
applicable	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating	O
thyroid	O
carcinoma	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
of	O
preparing	O
indazolyl	O
ureas	O
that	O
are	O
useful	O
as	O
antagonists	O
of	O
the	O
vanilloid	B-GENE
receptor	I-GENE
subtype	I-GENE
1	I-GENE
(	O
VR1	B-GENE
)	O
.	O


The	O
invention	O
discloses	O
N	O
'	O
-arylmethylene-2-	O
(	O
4-oxothiophene	O
[	O
2,3-d	O
]	O
pyrimidin-3-yl	O
)	O
acetyl	O
hydrazone	O
compounds,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
structural	O
general	O
formula	O
of	O
the	O
compounds	O
is	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
.	O
Experimental	O
results	O
indicate	O
that	O
the	O
compounds	O
can	O
induce	O
cells	O
to	O
which	O
Caspase-3	B-GENE
in	O
human	O
cervical	O
carcinoma	O
cells,	O
human	O
lung	O
carcinoma	O
cells	O
and	O
human	O
breast	O
carcinoma	O
cells	O
is	O
dependent	O
to	O
die	O
so	O
as	O
to	O
inhibit	O
the	O
propagation	O
of	O
the	O
carcinoma	O
cells,	O
also	O
have	O
low	O
toxicity	O
on	O
normal	O
cells,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
antitumor	O
medicines	O
for	O
treating	O
cervical	O
carcinoma,	O
lung	O
cancer	O
or	O
breast	O
cancer	O
.	O


The	O
invention	O
provides	O
application	O
of	O
an	O
atractylodin	O
alcohol	O
(	O
CZSC	O
)	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
animal	O
virus	O
diseases,	O
in	O
particular	O
application	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
infection	O
and	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
,	O
or	O
in	O
preparation	O
of	O
a	O
virus	O
gene	O
expression	O
inhibitor	O
and	O
an	O
anti-virus	O
medicament	O
and	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
inhibiting	O
blue	O
ear	O
disease	O
viruses	O
.	O
The	O
CZSC	O
has	O
remarkable	O
effects	O
of	O
regulating	O
nucleoprotein	B-GENE
gene	O
expression	O
of	O
the	O
PRRSV	O
down	O
and	O
inhibiting	O
virus	O
proliferation	O
;	O
and	O
in	O
vitro	O
cellular	O
pharmacological	O
tests	O
shows	O
that	O
the	O
CZSC	O
has	O
definite	O
anti-virus	O
effect	O
.	O
The	O
CZSC	O
has	O
wide	O
application	O
prospect	O
in	O
treatment	O
and	O
control	O
of	O
PRRSV	O
infection	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
thaspine	O
derivative	O
HMQ1611	O
in	O
inhibition	O
of	O
mammary	O
cancer	O
.	O
In	O
an	O
integral	O
level,	O
a	O
mammary	O
cancer	O
ZR-75-30	O
tumor	O
transplantation	O
tumor	O
model	O
is	O
built	O
on	O
the	O
basis	O
of	O
a	O
nude	O
mouse	O
transplantation	O
tumor	O
model,	O
the	O
inhibition	O
effect	O
of	O
the	O
thaspine	O
derivative	O
HMQ1611	O
on	O
mammary	O
cancer	O
is	O
researched,	O
and	O
then	O
the	O
mammary	O
cancer	O
resistance	O
passageway	O
of	O
the	O
thaspine	O
derivative	O
HMQ1611	O
is	O
also	O
researched,	O
thus	O
the	O
inhibition	O
effect	O
of	O
the	O
thaspine	O
derivative	O
HMQ1611	O
on	O
ER	B-GENE
(	O
estrogen	B-GENE
receptor	I-GENE
)	O
-dependent	O
mammary	O
cancer	O
is	O
verified,	O
and	O
the	O
influence	O
of	O
the	O
thaspine	O
derivative	O
HMQ1611	O
on	O
ER	B-GENE
passageway	O
of	O
mammary	O
cancer	O
cells	O
is	O
also	O
verified,	O
thereby	O
showing	O
that	O
the	O
thaspine	O
derivative	O
HMQ1611	O
can	O
truly	O
inhibit	O
mammary	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
steroidal	O
alkaloid	O
compounds	O
(	O
shown	O
in	O
the	O
formula	O
I	O
)	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
cholinesterase,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds,	O
as	O
well	O
as	O
applications	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
compounds	O
in	O
preparation	O
of	O
the	O
drugs	O
for	O
inhibiting	O
the	O
cholinesterase	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
azabicyclo	O
hexane	O
derivative,	O
a	O
preparation	O
method,	O
and	O
an	O
application	O
of	O
the	O
azabicyclo	O
hexane	O
derivative	O
in	O
medicine,	O
specifically	O
to	O
a	O
new	O
azabicyclo	O
hexane	O
derivative	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method,	O
a	O
drug	O
composition	O
containing	O
the	O
derivative,	O
a	O
use	O
of	O
the	O
derivative	O
as	O
a	O
therapeutic	O
agent,	O
especially	O
a	O
GPR119	B-GENE
agonist,	O
and	O
a	O
use	O
of	O
the	O
derivative	O
in	O
preparing	O
drugs	O
for	O
treating	O
diabetes,	O
metabolic	O
disorders,	O
and	O
other	O
diseases	O
.	O
Various	O
substituents	O
in	O
the	O
formula	O
(	O
I	O
)	O
are	O
the	O
same	O
as	O
the	O
definitions	O
in	O
the	O
instruction	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drugs,	O
and	O
particularly	O
relates	O
to	O
aminopeptidase	B-GENE
N	I-GENE
inhibitor,	O
a	O
preparation	O
method	O
and	O
application	O
to	O
tumor	O
resistance	O
.	O
The	O
technical	O
scheme	O
includes	O
that	O
the	O
aminopeptidase	B-GENE
N	I-GENE
inhibitor	O
is	O
chemically	O
named	O
as	O
(	O
S	O
)	O
-4-methyl-2-	O
(	O
3-naphthyl-1-ylmethyl-ureido	O
)	O
-valeryl	O
group	O
hydroxylamine	O
.	O
The	O
constitutional	O
formula	O
(	O
I	O
)	O
of	O
the	O
aminopeptidase	B-GENE
N	I-GENE
inhibitor	O
is	O
shown	O
here	O
.	O
The	O
pharmacodynamic	O
effect	O
of	O
the	O
aminopeptidase	B-GENE
N	I-GENE
inhibitor	O
is	O
evaluated	O
by	O
in-vitro	O
APN	B-GENE
(	O
adiponectin	B-GENE
)	O
inhibitory	O
experiments,	O
in-vitro	O
resistance	O
to	O
tumor	O
cell	O
invasion,	O
antiangiogenesis	O
and	O
mouse	O
in-vivo	O
resistance	O
to	O
melanoma	O
manual	O
transfer	O
and	O
antiangiogenesis	O
experiments	O
.	O


The	O
invention	O
relates	O
to	O
a	O
deuteroacetyl-containing	O
kinase	B-GENE
inhibitor	O
capable	O
of	O
inhibiting	O
kinase,	O
particularly	O
inhibiting	O
activity	O
of	O
breakpoint	B-GENE
cluster	I-GENE
region-abelson	I-GENE
(	O
BCR-ABL	B-GENE
)	O
.	O
The	O
inhibitor	O
has	O
the	O
structure	O
of	O
a	O
formula	O
(	O
I	O
)	O
.	O
The	O
inhibitor	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicinal	O
composition,	O
namely	O
used	O
for	O
inhibiting	O
the	O
kinase	B-GENE
of	O
human	O
beings	O
or	O
animals,	O
for	O
example,	O
used	O
for	O
treating	O
tumors	O
and	O
/	O
or	O
other	O
diseases	O
.	O


An	O
aptamer	O
which	O
can	O
bind	O
to	O
chymase	B-GENE
to	O
inhibit	O
the	O
activity	O
of	O
chymase	B-GENE
and	O
comprises	O
the	O
nucleotide	O
sequence	O
represented	O
by	O
the	O
formula	O
:	O
X1GAUAGAN1N2UAAX2	O
(	O
wherein	O
X1	O
and	O
X2	O
independently	O
represent	O
A	O
or	O
G	O
;	O
and	O
N1	O
and	O
N2	O
independently	O
represent	O
A,	O
G,	O
C,	O
U	O
or	O
T	O
)	O
;	O
a	O
complex	O
comprising	O
the	O
aptamer	O
and	O
a	O
functional	O
substance	O
(	O
e	O
.	O
g	O
.	O
,	O
an	O
affinity	O
substance,	O
a	O
labeling	O
substance,	O
an	O
enzyme,	O
a	O
drug	O
delivery	O
medium,	O
or	O
a	O
medicinal	O
agent	O
)	O
;	O
a	O
medicinal	O
agent	O
or	O
a	O
reagent	O
comprising	O
the	O
aptamer	O
or	O
the	O
complex	O
;	O
a	O
chymase	B-GENE
detection	O
method	O
or	O
a	O
chymase	B-GENE
purification	O
method	O
characterized	O
by	O
utilizing	O
the	O
aptamer	O
or	O
the	O
complex	O
;	O
and	O
others	O
.	O


The	O
invention	O
provides	O
a	O
spirotricyclic	O
compound	O
as	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
and	O
simultaneously	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
thereof,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
spirotricyclic	O
compound	O
.	O
Being	O
an	O
inhibitor	O
of	O
protein	O
kinase,	O
the	O
compound	O
in	O
the	O
invention	O
can	O
be	O
used	O
to	O
treat	O
diseases	O
caused	O
by	O
abnormal	O
protein	B-GENE
kinase	I-GENE
activity,	O
such	O
as	O
tumors	O
and	O
the	O
like	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pyrimidine	O
compounds	O
and	O
preparation	O
methods	O
thereof	O
.	O
The	O
novel	O
pyrimidine	O
derivatives	O
and	O
salts	O
thereof	O
are	O
compounds	O
shown	O
in	O
the	O
formula	O
(	O
1	O
)	O
in	O
the	O
specification,	O
wherein	O
R1	O
represents	O
-CH2NHR4	O
or	O
cyano	O
group	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
aryl	O
and	O
substituted	O
aryl	O
;	O
X	O
represents	O
methylene,	O
carbonyl	O
or	O
hydroxymethylene	O
;	O
R4	O
represents	O
H,	O
acetyl	O
or	O
tosyl	O
;	O
and	O
n	O
is	O
an	O
integer	O
of	O
0-5	O
.	O
A	O
series	O
of	O
new	O
compounds	O
are	O
prepared	O
by	O
the	O
inventor	O
of	O
the	O
invention	O
;	O
pharmacological	O
results	O
show	O
that	O
the	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPPIV	B-GENE
)	O
inhibition	O
rate	O
is	O
close	O
to	O
or	O
superior	O
to	O
that	O
of	O
the	O
reference	O
substance	O
R-1579	O
;	O
and	O
some	O
pyrimidine	O
compounds	O
with	O
new	O
structures	O
have	O
excellent	O
DPP-IV	B-GENE
inhibitory	O
activity	O
and	O
wide	O
application	O
prospects	O
.	O


The	O
invention	O
discloses	O
medicinal	O
composition,	O
synthesis	O
process	O
and	O
medical	O
application	O
of	O
hydantoin	O
derivatives	O
.	O
The	O
compounds	O
have	O
an	O
effect	O
of	O
inhibiting	O
an	O
androgen	O
receptor,	O
and	O
can	O
be	O
used	O
for	O
treating	O
prostatic	O
cancer	O
and	O
other	O
diseases	O
and	O
physiologic	O
derangement	O
related	O
with	O
androgen	B-GENE
receptor	I-GENE
activity	O
.	O


Disclosed	O
are	O
a	O
kinase	B-GENE
inhibitor	O
and	O
N-oxide	O
form	O
and	O
pharmaceutically	O
acceptable	O
isomerous	O
form	O
thereof	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z	O
is	O
NH,	O
and	O
the	O
other	O
substituents	O
are	O
as	O
defined	O
herein	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
application	O
of	O
sodium	O
oxamate,	O
in	O
particular	O
to	O
the	O
application	O
of	O
sodium	O
oxamate	O
in	O
preparation	O
of	O
a	O
(	O
fat	O
mass	O
and	O
obesity	O
)	O
FTO	B-GENE
enzyme	O
inhibitor	O
and	O
a	O
weight-losing	O
medicine	O
.	O
An	O
inventor	O
finds	O
that	O
the	O
sodium	O
oxamate	O
can	O
remarkably	O
suppress	O
the	O
expression	O
of	O
FTO	B-GENE
gene	O
through	O
vitro	O
cell	O
experiments	O
for	O
the	O
first	O
time	O
.	O
After	O
the	O
expression	O
of	O
the	O
FTO	B-GENE
gene	O
is	O
suppressed,	O
weight	O
and	O
fat	O
tissue	O
of	O
an	O
animal	O
can	O
be	O
remarkably	O
reduced,	O
and	O
the	O
function	O
mechanism	O
of	O
the	O
sodium	O
oxamate	O
is	O
relevant	O
to	O
adjusting	O
organism	O
food	O
intake	O
and	O
controlling	O
energy	O
metabolism	O
balance	O
.	O
The	O
application	O
of	O
sodium	O
oxamate	O
in	O
the	O
preparation	O
of	O
the	O
FTO	B-GENE
enzyme	O
inhibitor	O
and	O
the	O
weight-losing	O
medicine	O
adopts	O
sodium	O
oxamate	O
to	O
serve	O
as	O
the	O
novel	O
weight-loosing	O
medicine,	O
can	O
effectively	O
reduce	O
the	O
weight	O
and	O
the	O
fat	O
tissue,	O
and	O
can	O
prevent	O
obesity	O
relevant	O
diseases	O
including	O
diabetes	O
mellitus,	O
cardiovascular	O
diseases	O
and	O
relevant	O
neoplasms	O
from	O
happening	O
.	O


The	O
invention	O
provides	O
an	O
extract	O
containing	O
prodelphinidin	O
and	O
procyanidin	O
of	O
ginkgo	O
.	O
In	O
the	O
extract,	O
the	O
content	O
of	O
prodelphinidin	O
and	O
procyanidin	O
is	O
88	O
.	O
7-98	O
.	O
5	O
%	O
,	O
the	O
content	O
of	O
total	O
flavonoids	O
is	O
not	O
higher	O
than	O
10	O
%	O
,	O
and	O
the	O
content	O
of	O
flavonol	O
glycoside	O
is	O
not	O
higher	O
than	O
5	O
%	O
.	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
above	O
extract,	O
comprising	O
extracting	O
with	O
an	O
ethanol	O
water	O
solution,	O
hydrolyzing	O
with	O
beta-glucosidase,	O
and	O
adsorbing	O
and	O
separating	O
by	O
using	O
macroporous	O
resin	O
and	O
polyamide	O
resin	O
in	O
sequence	O
.	O
The	O
inventive	O
extract	O
containing	O
prodelphinidin	O
and	O
procyanidin	O
of	O
ginkgo	O
can	O
be	O
used	O
as	O
health	O
food,	O
medicine	O
or	O
cosmetic	O
for	O
preventing	O
or	O
treating	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
and	O
ophthalmic	O
diseases,	O
resisting	O
oxidation,	O
caring	O
skin	O
and	O
delaying	O
aging	O
.	O


The	O
invention	O
discloses	O
a	O
hypericin	O
albumin	B-GENE
nanoparticle-immune	O
globulin	O
G	O
antibody	O
conjugate,	O
which	O
comprises	O
the	O
following	O
preparing	O
steps	O
:	O
step	O
(	O
1	O
)	O
,	O
dissolving	O
the	O
hypericin	O
albumin	B-GENE
nanoparticle	O
and	O
the	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
into	O
phosphate	O
buffer	O
solution	O
(	O
PBF	O
)	O
,	O
step	O
(	O
2	O
)	O
,	O
adding	O
glutaraldehyde	O
into	O
the	O
solution	O
obtained	O
by	O
the	O
step	O
(	O
1	O
)	O
,	O
and	O
obtaining	O
the	O
hypericin	O
albumin	B-GENE
nanoparticle-immune	O
globulin	O
G	O
antibody	O
conjugate	O
.	O
The	O
hypericin	O
albumin	B-GENE
nanoparticle-immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
high	O
effective	O
utilization	O
;	O
simultaneously,	O
the	O
preparation	O
method	O
of	O
the	O
hypericin	O
albumin	B-GENE
nanoparticle-immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
being	O
simple	O
in	O
process,	O
easy	O
to	O
operate	O
and	O
specially	O
suitable	O
for	O
industrial	O
production	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
canosic	O
acid	O
in	O
preparing	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
relating	O
to	O
liver	O
injury	O
.	O
Canosic	O
acid	O
can	O
substantially	O
reduce	O
increase	O
of	O
transaminase	B-GENE
caused	O
by	O
ischemia	O
reperfusion	O
liver	O
injury	O
or	O
chemical	O
liver	O
injury,	O
obviously	O
improve	O
pathological	O
lesion	O
of	O
liver,	O
inhibit	O
increase	O
of	O
immune	O
factors	O
and	O
the	O
like,	O
has	O
a	O
substantial	O
effect	O
on	O
protecting	O
liver,	O
is	O
applied	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
relating	O
to	O
liver	O
injury	O
and	O
has	O
the	O
advantages	O
of	O
cheapness	O
and	O
safety	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
pharmaceutical	O
composition	O
for	O
treating	O
osteoporosis	O
.	O
The	O
pharmaceutical	O
composition	O
can	O
greatly	O
improve	O
the	O
efficacy	O
of	O
osteoporosis	O
treatment,	O
and	O
reduce	O
the	O
health	O
risks	O
and	O
side	O
effects	O
associated	O
with	O
taking	O
of	O
commonly	O
used	O
drugs	O
(	O
parathyroid	O
hormone,	O
thyroid	O
hormone,	O
estrogen,	O
and	O
calcium	O
supplements	O
)	O
for	O
treating	O
osteoporosis	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
combined	O
treatment	O
method	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
.	O
The	O
method	O
includes	O
a	O
step	O
of	O
applying	O
an	O
effective	O
dose	O
of	O
to	O
the	O
new	O
pharmaceutical	O
composition	O
treating	O
osteoporosis	O
to	O
an	O
object	O
so	O
as	O
to	O
treat	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
of	O
the	O
object	O
.	O


The	O
invention	O
relates	O
to	O
an	O
amino	O
aromatic	O
hydrocarbon	O
compound	O
capable	O
of	O
serving	O
as	O
an	O
active-mitogen-activated	O
protein	O
kinase	I-GENE
/	O
extracellular	B-GENE
signal	I-GENE
regulated	I-GENE
kinase	I-GENE
(ERK)	B-GENE
1/2	I-GENE
inhibitor	O
and	O
application	O
of	O
the	O
amino	O
aromatic	O
hydrocarbon	O
compound	O
to	O
preparation	O
of	O
a	O
medicine	O
for	O
resisting	O
malignant	O
tumor	O
.	O
The	O
amino	O
aromatic	O
hydrocarbon	O
compound	O
is	O
a	O
selective	O
active-mitogen-activated	O
protein	O
kinase	I-GENE
/	O
ERK	B-GENE
1/2	I-GENE
inhibitor	O
and	O
can	O
be	O
used	O
for	O
preventing	O
or	O
treating	O
malignant	O
tumor,	O
in	O
particular	O
for	O
treating	O
melanoma,	O
colorectal	O
cancer,	O
breast	O
cancer,	O
pancreatic	O
cancer,	O
epidermoid	O
tumor,	O
brain	O
tumor	O
and	O
liver	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
omega-carboxy-substituted	O
diphenylthiourea	O
derivatives	O
disclosed	O
as	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
a	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts	O
.	O
The	O
omega-carboxy-substituted	O
diphenylthiourea	O
compounds	O
are	O
an	O
effective	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
omega-carboxy-substituted	O
diphenylthiourea	O
derivatives,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
omega-carboxy-substituted	O
diphenylthiourea	O
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
the	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts,	O
and	O
application	O
of	O
the	O
omega-carboxy-substituted	O
diphenylthiourea	O
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
the	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
adjuvantly	O
treating	O
tyrosine	B-GENE
kinase	I-GENE
mediated	O
tumors	O
in	O
mammals	O
(	O
including	O
human	O
)	O
or	O
proliferation	O
and	O
migration	O
of	O
tyrosine	B-GENE
kinase	I-GENE
driven	O
tumor	O
cells	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
urea	O
compound	O
(	O
shown	O
in	O
figure	O
1	O
)	O
in	O
preparation	O
of	O
a	O
nicotinamide	B-GENE
phosphoribosyltransferase	I-GENE
inhibitor	O
.	O
The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
I	O
in	O
preparation	O
of	O
medicines	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
cancer	O
.	O
The	O
invention	O
finds	O
a	O
fully	O
new	O
application	O
of	O
the	O
compound	O
I	O
.	O
The	O
compound	O
I	O
shows	O
good	O
inhibiting	O
activity	O
on	O
nicotinamide	O
phosphoribosyltransferase,	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
by	O
inhibiting	O
nicotinamide	O
phosphoribosyltransferase,	O
and	O
also	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O


The	O
invention	O
discloses	O
a	O
solid	O
form	O
containing	O
(	O
+	O
)	O
-2-	O
[	O
1-	O
(	O
3-oxethyl-4-methoxyphenyl	O
)	O
-2-methylsulfonylethyl	O
]	O
-4-acetylaminoisoindoline-1,3-dione,	O
a	O
composition	O
containing	O
the	O
solid	O
form,	O
a	O
method	O
for	O
preparing	O
the	O
solid	O
form	O
and	O
an	O
application	O
method	O
thereof	O
.	O
The	O
method	O
comprises	O
a	O
treatment	O
and	O
/	O
or	O
prevention	O
method	O
capable	O
of	O
improving	O
disease	O
symptoms	O
by	O
lowering	O
TNF-alpha	B-GENE
level	O
or	O
inhibiting	O
PDE4	B-GENE
.	O


This	O
invention	O
relates	O
to	O
modulation	O
of	O
the	O
alpha	B-GENE
7	I-GENE
nicotinic	I-GENE
acetylcholine	I-GENE
receptor	I-GENE
(	O
nAChR	B-GENE
)	O
by	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
:	O
wherein	O
R1	O
is	O
imidazolyl,	O
pyridinyl	O
or	O
pyrimidinyl,	O
any	O
of	O
which	O
is	O
optionally	O
substituted	O
by	O
one	O
group	O
independently	O
selected	O
from	O
C1-3alkyl	O
and	O
C1-3alkoxy	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
lupenone	O
to	O
products	O
for	O
preventing	O
or	O
treating	O
diabetes	O
mellitus	O
.	O
Inventors	O
deeply	O
develop	O
the	O
lupenone	O
by	O
adopting	O
the	O
modern	O
medicine	O
efficacy	O
and	O
acute	O
toxicity	O
study	O
technology	O
.	O
Pharmacodynamic	O
experimental	O
study	O
shows	O
that	O
proper	O
medicine	O
can	O
be	O
processed	O
and	O
prepared	O
from	O
the	O
lupenone	O
as	O
major	O
ingredients	O
and	O
is	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
diabetes	O
mellitus,	O
the	O
pharmacological	O
activity	O
is	O
obvious,	O
the	O
performance	O
is	O
stable,	O
safety	O
and	O
reliability	O
are	O
realized,	O
the	O
hyperglycemic	O
effect	O
is	O
obvious,	O
and	O
phenomenon	O
of	O
serum	O
insulin	B-GENE
and	O
C	O
peptide	O
rise	O
caused	O
by	O
insulin	B-GENE
resistance	O
is	O
also	O
reduced,	O
so	O
the	O
sugar	O
tolerance	O
is	O
improved	O
.	O
In	O
addition,	O
the	O
extraction	O
raw	O
material	O
sources	O
of	O
the	O
lupenone	O
are	O
easy	O
to	O
obtain,	O
the	O
preparation	O
process	O
easily	O
realizes	O
the	O
industrialization,	O
and	O
medicine	O
materials	O
can	O
be	O
driven	O
to	O
be	O
fully	O
developed	O
and	O
utilized,	O
so	O
the	O
lupenone	O
has	O
good	O
application	O
prospects	O
in	O
aspects	O
of	O
diabetes	O
mellitus	O
treatment	O
medicine	O
or	O
health-care	O
products	O
.	O


The	O
invention	O
discloses	O
an	O
extract	O
of	O
eclipta	O
alba,	O
a	O
method	O
for	O
extracting	O
and	O
separating	O
the	O
extract	O
from	O
the	O
eclipta	O
alba	O
and	O
an	O
application	O
of	O
the	O
extract	O
of	O
the	O
eclipta	O
alba	O
.	O
The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
soaking	O
the	O
dry	O
powder	O
of	O
the	O
eclipta	O
alba	O
in	O
methanol	O
for	O
5-10	O
days,	O
extracting	O
and	O
filtering	O
for	O
0-10	O
times	O
and	O
preferentially	O
1-3	O
times,	O
and	O
mixing	O
filtrate,	O
wherein	O
the	O
proportion	O
of	O
the	O
dry	O
powder	O
of	O
the	O
eclipta	O
alba	O
to	O
the	O
methanol	O
is	O
1	O
:	O
(	O
6-10	O
)	O
;	O
and	O
(	O
2	O
)	O
concentrating	O
the	O
filtrate	O
under	O
reduced	O
pressure	O
to	O
obtain	O
the	O
methanol	O
extract	O
of	O
the	O
eclipta	O
alba	O
.	O
The	O
extract	O
of	O
the	O
eclipta	O
alba	O
can	O
be	O
used	O
for	O
inhibiting	O
the	O
appearance	O
of	O
TGF-beta	B-GENE
(	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
beta	I-GENE
)	O
effectively	O
so	O
as	O
to	O
prevent	O
the	O
alopecia	O
and	O
promote	O
the	O
hair	O
growth	O
and	O
can	O
be	O
applied	O
to	O
the	O
pharmaceutical	O
compositions	O
and	O
the	O
cosmetics	O
.	O


The	O
invention	O
discloses	O
a	O
use	O
of	O
a	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
.	O
The	O
compound	O
is	O
N	O
'	O
-	O
{	O
5-	O
[	O
acetyl	O
(	O
hydroxyl	O
)	O
amido	O
]	O
pentyl	O
}	O
-N-	O
[	O
5-	O
(	O
{	O
4-	O
[	O
(	O
5-aminopentyl	O
)	O
(	O
hydroxyl	O
)	O
amido	O
]	O
-4-keto-butyryl	O
}	O
amido	O
)	O
pentyl	O
]	O
-N-hydroxysuccinic	O
acid	O
amide	O
.	O
The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
preventing	O
and	O
treating	O
senile	O
dementia	O
.	O
The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
penetrate	O
a	O
blood	O
brain	O
barrier	O
and	O
then	O
bind	O
with	O
a	O
heavy	O
metal	O
to	O
form	O
a	O
chelate	O
thereby	O
inhibiting	O
production	O
of	O
amyloid	B-GENE
in	O
the	O
brain,	O
preventing	O
polymerization	O
and	O
accumulation	O
of	O
amyloid,	O
dissolving	O
produced	O
amyloid	B-GENE
plaques	O
and	O
promoting	O
amyloid	B-GENE
degradation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
pyridine	O
alkaloid	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
as	O
described	O
in	O
the	O
specification,	O
the	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same,	O
and	O
the	O
composition	O
comprising	O
the	O
same	O
.	O
The	O
uses	O
of	O
a	O
pyridine	O
compound	O
for	O
increasing	O
the	O
activity	O
of	O
PPAR	O
[	O
gamma	O
]	O
,	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B-GENE
resistance,	O
and	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
metabolic	O
syndrome	O
or	O
its	O
complication	O
are	O
also	O
provided	O
.	O
The	O
invention	O
also	O
provides	O
extracts	O
of	O
red	O
yeast-fermented	O
products	O
and	O
their	O
uses	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B-GENE
resistance,	O
such	O
as	O
metabolic	O
syndrome	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
bio-medicines,	O
and	O
discloses	O
application	O
of	O
a	O
medicament	O
of	O
target	O
adenosine	O
receptor	O
A2BAR	B-GENE
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
treating	O
autoimmune	O
diseases	O
.	O
Studies	O
discover	O
that	O
:	O
compared	O
with	O
a	O
healthy	O
wild	O
mouse,	O
the	O
expression	O
of	O
adenosine	O
receptor	O
A2BAR	B-GENE
in	O
the	O
immune	O
tissue	O
in	O
an	O
EAE	O
(	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
)	O
mouse	O
is	O
up-regulated	O
.	O
After	O
two	O
antagonists	O
of	O
the	O
adenosine	O
receptor	O
A2BAR,	O
CVT-6883	O
and	O
MRS-1754	O
are	O
administrated	O
to	O
the	O
EAE	O
mouse,	O
the	O
onset	O
time	O
of	O
the	O
EAE	O
mouse	O
is	O
delayed,	O
the	O
attack	O
symptom	O
is	O
relieved,	O
the	O
attack	O
rate	O
is	O
reduced,	O
and	O
infiltration	O
of	O
CNS	O
(	O
central	O
nervous	O
system	O
)	O
inflammatory	O
cells	O
is	O
reduced	O
.	O
The	O
application	O
has	O
the	O
advantages	O
that	O
the	O
expression	O
of	O
the	O
adenosine	O
receptor	O
A2BAR	B-GENE
in	O
an	O
MS	O
(	O
metabolic	O
syndrome	O
)	O
patient	O
and	O
an	O
animal	O
model	O
EAE	O
thereof	O
is	O
up-regulated,	O
the	O
antagonist	O
CVT-6883	O
of	O
the	O
adenosine	O
receptor	O
A2BAR	B-GENE
can	O
be	O
used	O
for	O
effectively	O
relieving	O
the	O
EAE	O
attach	O
symptom	O
.	O
At	O
present,	O
the	O
antagonist	O
CVT-6883	O
of	O
the	O
adenosine	O
receptor	O
A2BAR	B-GENE
is	O
used	O
in	O
clinical	O
experimental	O
medicament	O
for	O
treating	O
asthma,	O
has	O
great	O
possibility	O
in	O
serving	O
as	O
a	O
medicament	O
for	O
treating	O
MS	O
diseases,	O
and	O
provides	O
a	O
new	O
action	O
target	O
and	O
medicinal	O
source	O
for	O
treating	O
MS	O
diseases	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemicals,	O
and	O
relates	O
to	O
a	O
substituted	O
phenyl-	O
(	O
diazaspiro-N	O
)	O
-ketone	O
derivative	O
.	O
The	O
compound	O
or	O
pharmaceutical	O
salt	O
thereof	O
are	O
shown	O
as	O
a	O
formula	O
I	O
in	O
the	O
specifications,	O
wherein	O
R1	O
is	O
C1	O
to	O
C6	O
straight-chain	O
or	O
branched-chain	O
alkyl	O
substituted	O
by	O
one	O
or	O
more	O
halogens	O
;	O
R2	O
is	O
selected	O
from	O
hydrogen,	O
C1	O
to	O
C6	O
straight-chain	O
or	O
branched-chain	O
alkyl,	O
halogen,	O
amino,	O
nitro,	O
hydroxyl	O
and	O
C1	O
to	O
C6	O
straight-chain	O
or	O
branched-chain	O
alkoxy	O
;	O
R3	O
is	O
selected	O
from	O
hydrogen,	O
C1	O
to	O
C6	O
straight-chain	O
or	O
branched-chain	O
alkyl	O
and	O
C1	O
to	O
C6	O
straight-chain	O
or	O
branched-chain	O
alkylacyl	O
;	O
m	O
is	O
1	O
or	O
2	O
;	O
and	O
n	O
is	O
1	O
or	O
2	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
medicinal	O
composition,	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
derivative	O
.	O
The	O
compound	O
or	O
the	O
pharmaceutical	O
salt	O
thereof	O
can	O
regulate	O
apolipoprotein	B-GENE
A-I	I-GENE
(	O
Apo	B-GENE
A-I	I-GENE
)	O
and	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
level,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
regulating	O
blood	O
fat	O
or	O
preventing	O
and	O
treating	O
atherosclerosis	O
.	O


The	O
invention	O
falls	O
into	O
the	O
field	O
of	O
biotechnology	O
and	O
relates	O
to	O
an	O
inhibitor	O
for	O
inhibiting	O
histidine	O
kinase	O
activity	O
of	O
PhoQ	B-GENE
in	O
bacterial	O
signal	O
transduction	O
system	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
a	O
histidine	O
kinase	O
inhibitor	O
of	O
bacterial	O
PhoQ,	O
especially	O
the	O
PhoQ	B-GENE
protein	O
inhibitor	O
of	O
the	O
signal	O
transduction	O
system	O
of	O
gram	O
negative	O
bacteria,	O
containing	O
a	O
small	O
molecular	O
compound	O
.	O
The	O
preparation	O
comprises	O
a	O
small	O
molecular	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
DMSO	O
.	O
The	O
inventive	O
preparation	O
for	O
inhibiting	O
histidine	O
kinase	O
activity	O
of	O
PhoQ	B-GENE
in	O
bacterial	O
signal	O
transduction	O
system	O
has	O
inhibitory	O
activity	O
against	O
PhoQ	B-GENE
protein	O
of	O
Shigella	O
signal	O
transduction	O
system	O
;	O
and	O
can	O
inhibit	O
the	O
virulence	O
of	O
Shigella,	O
be	O
used	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
inhibiting	O
the	O
virulence	O
of	O
Shigella	O
or	O
drugs	O
for	O
the	O
treatment	O
of	O
gram	O
negative	O
bacteria	O
induced	O
diseases,	O
and	O
be	O
prepared	O
into	O
disinfection	O
solution	O
for	O
use	O
in	O
medical	O
equipments	O
and	O
medical	O
appliances	O
.	O


The	O
invention	O
relates	O
to	O
a	O
Toll-like	O
receptor	O
regulatory	O
oligonucleotide	O
and	O
a	O
functional	O
analog	O
thereof,	O
and	O
application	O
of	O
the	O
oligonucleotide	O
and	O
the	O
functional	O
analog	O
thereof	O
in	O
prevention	O
and	O
treatment	O
of	O
immune-mediated	O
diseases	O
.	O
The	O
oligonucleotide	O
provided	O
by	O
the	O
invention	O
contains	O
a	O
CT	O
repeated	O
sequence	O
[	O
(	O
CT	O
)	O
n	O
]	O
or	O
a	O
CCT	O
repeated	O
sequence	O
[	O
(	O
CCT	O
)	O
n	O
]	O
or	O
a	O
TC	O
repeated	O
sequence	O
[	O
(	O
TC	O
)	O
n	O
]	O
,	O
or	O
is	O
an	O
oligonucleotide	O
which	O
is	O
rich	O
in	O
CT	O
or	O
CCT	O
or	O
TC	O
.	O
The	O
immune-mediated	O
diseases	O
include	O
autoimmune	O
diseases,	O
graft	O
rejection,	O
hypersensitivity,	O
diseases	O
caused	O
by	O
microbial	O
over-strong	O
stimulation	O
on	O
the	O
immune	O
system	O
of	O
a	O
host	O
and	O
TOLL-like	B-GENE
receptor	I-GENE
activation-related	O
diseases	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines,	O
discloses	O
an	O
application	O
of	O
naringin	O
in	O
preparing	O
drugs	O
for	O
improving	O
brain	O
tissue	O
glucose	O
hypometabolism	O
and	O
long-term	O
hypomnesis	O
.	O
What	O
firstly	O
found	O
is	O
that	O
the	O
naringin	O
can	O
increase	O
glucose	O
uptake	O
and	O
transport	O
of	O
the	O
brain	O
tissues,	O
improve	O
energy	O
metabolism	O
disturbance,	O
simultaneously	O
activate	O
calcium/calmodulin	B-GENE
dependence	I-GENE
protein	I-GENE
kinase	I-GENE
and	O
downstream	O
AMPA	B-GENE
glutamate	I-GENE
receptors,	O
promote	O
excitability	O
transmission	O
of	O
glutamatergic	O
neurons	O
and	O
improve	O
long-term	O
memory,	O
thereby	O
improving	O
symptoms	O
of	O
neurodegenerative	O
diseases	O
and	O
delaying	O
disease	O
'	O
s	O
progression	O
.	O
The	O
naringin	O
has	O
the	O
potentiality	O
for	O
developing	O
into	O
drugs	O
or	O
health	O
preparations	O
for	O
treating	O
brain	O
tissue	O
diseases	O
which	O
are	O
characterized	O
by	O
brain	O
glycometabolism	O
disturbance	O
and	O
/	O
or	O
long-term	O
memory	O
impairment	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
mollugin	O
.	O
The	O
preparation	O
method	O
includes	O
:	O
taking	O
India	O
madder	O
root,	O
and	O
using	O
5-15	O
times	O
of	O
petroleum	O
ether	O
to	O
perform	O
heating	O
reflux	O
extraction	O
for	O
20-40min	O
;	O
recycling	O
petroleum	O
ether,	O
and	O
vacuum	O
drying	O
to	O
remove	O
petroleum	O
ether	O
so	O
as	O
to	O
obtain	O
extract	O
;	O
and	O
subjecting	O
the	O
extract	O
to	O
200-300-mesh	O
silica	O
gel	O
column	O
chromatography,	O
eluting	O
with	O
petroleum	O
ether,	O
performing	O
TLC	O
(	O
thin	O
layer	O
chromatography	O
)	O
detection,	O
combining	O
components	O
rich	O
in	O
mollugin,	O
subjecting	O
to	O
Sephadex	O
LH-20	O
gel	O
column	O
chromatography,	O
eluting	O
with	O
mixture	O
of	O
chloroform,	O
petroleum	O
ether,	O
and	O
methanol	O
in	O
mass	O
ratio	O
of	O
5	O
:	O
5	O
:	O
1,	O
subjecting	O
to	O
silica	O
gel	O
H-column	O
decompression	O
column	O
chromatography,	O
eluting	O
with	O
petroleum	O
ether,	O
and	O
recrystalizing	O
with	O
hot	O
ethanol	O
to	O
obtain	O
the	O
mollugin	O
.	O
The	O
invention	O
further	O
discloses	O
application	O
of	O
the	O
mollugin	O
in	O
preparation	O
of	O
hypoglycemic	O
drugs	O
and	O
preparation	O
of	O
drugs	O
for	O
treating	O
diabetes	O
.	O
Experiments	O
show	O
that	O
the	O
mollugin	O
can	O
effectively	O
reduce	O
blood	O
sugar,	O
TC	O
(	O
total	O
cholesterol	O
)	O
,	O
TG	O
(	O
total	O
glycerin	O
)	O
and	O
MDA	O
(	O
methylene	O
dioxyamphetamine	O
)	O
content	O
of	O
mice	O
with	O
high	O
blood	O
sugar	O
caused	O
by	O
alloxan,	O
and	O
can	O
evidently	O
increase	O
SOD	B-GENE
(	O
superoxide	B-GENE
dismutase	I-GENE
)	O
activity	O
and	O
hepatic	O
glycogen	O
content	O
of	O
the	O
mice	O
.	O


The	O
invention	O
relates	O
to	O
a	O
strong	O
carboxylesterase	B-GENE
inhibitor	O
with	O
a	O
tanshinone	O
structure	O
and	O
application	O
thereof	O
for	O
improving	O
the	O
oral	O
bioavailability	O
of	O
predrug	O
with	O
carboxylic	O
ester	O
structures	O
and	O
weakening	O
diarrhea	O
caused	O
by	O
anti-tumor	O
medicament	O
such	O
as	O
irinotecan	O
.	O
The	O
compound	O
specifically	O
comprises	O
tanshinone	O
I,	O
tanshinone	O
IIA,	O
dihydrotanshinone	O
I,	O
cryptotanshinone	O
and	O
analogues	O
and	O
derivatives	O
thereof	O
.	O
In-vitro	O
activity	O
measurement	O
discovers	O
that	O
the	O
IC50	O
of	O
the	O
compound	O
for	O
inhibiting	O
carboxylesterase	B-GENE
can	O
reach	O
nano	O
mole	O
level	O
;	O
and	O
the	O
compound	O
is	O
high	O
in	O
safety	O
and	O
has	O
a	O
good	O
patent	O
medicament	O
prospect	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
pectin	O
enzymatic	O
hydrolysis	O
product	O
having	O
functions	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	O
and	O
resisting	O
drunk	O
.	O
Constant-temperature	O
enzymatic	O
hydrolysis	O
and	O
de-fatting	O
are	O
performed	O
to	O
polymer	O
high-fat	O
pectin	O
by	O
pectin	B-GENE
esterase	I-GENE
and	O
pectinase,	O
filtrate	O
is	O
subjected	O
to	O
alcohol	O
precipitation	O
and	O
alcohol	O
leaching	O
after	O
product	O
is	O
filtered	O
to	O
obtain	O
high-purity	O
product,	O
and	O
the	O
high-purity	O
product	O
is	O
subjected	O
to	O
vacuum	O
drying	O
and	O
crushing	O
and	O
screening	O
to	O
obtain	O
pectin	O
enzymatic	O
hydrolysis	O
product	O
having	O
excellent	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	O
and	O
resisting	O
drunk	O
.	O
Esterification	O
degree	O
and	O
molecular	O
weight	O
of	O
the	O
pectin	O
are	O
reduced	O
by	O
enzymatic	O
hydrolysis	O
and	O
de-fatting	O
of	O
the	O
pectin,	O
the	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	O
and	O
resisting	O
drunk	O
of	O
product	O
are	O
enhanced	O
by	O
the	O
pectin	O
compared	O
with	O
by	O
the	O
raw	O
materials	O
.	O
Pectin	O
is	O
deeply	O
developed	O
and	O
utilized,	O
additional	O
value	O
of	O
the	O
pectin	O
is	O
convenient	O
to	O
increase,	O
and	O
application	O
range	O
of	O
pectin	O
is	O
broadened	O
.	O
The	O
enzymatic	O
hydrolysis	O
product	O
has	O
high	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	O
and	O
resisting	O
drunk	O
and	O
can	O
be	O
used	O
as	O
alcohol-effect-dispelling	O
and	O
drunk-resisting	O
components	O
to	O
be	O
applied	O
to	O
the	O
field	O
of	O
medicine	O
and	O
food	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine,	O
in	O
particular	O
to	O
a	O
bromophenol	O
compound	O
applied	O
to	O
a	O
receptor	O
inhibitor	O
or	O
a	O
malignant	O
tumor	O
drug	O
of	O
a	O
receptor	B-GENE
tyrosine	I-GENE
kinasec-kit	I-GENE
which	O
is	O
also	O
called	O
KIT,	O
CD117,	O
stem	B-GENE
cell	I-GENE
factor	I-GENE
receptor	O
and	O
mast	B-GENE
cell	I-GENE
growth	I-GENE
factor	I-GENE
receptor	O
.	O
The	O
bromophenol	O
compound	O
is	O
a	O
new	O
compound	O
with	O
a	O
novel	O
structure	O
.	O
The	O
molecular	O
biology	O
experiment	O
and	O
pharmacological	O
experiment	O
verify	O
that	O
the	O
compound	O
has	O
a	O
good	O
inhibiting	O
effect	O
on	O
the	O
receptor	B-GENE
tyrosine	I-GENE
kinasec-kit	I-GENE
and	O
an	O
important	O
value	O
for	O
treatment	O
of	O
the	O
malignant	O
tumor	O
.	O


Isolated	O
compounds	O
from	O
adelostemma	O
gracillimum	O
refined	O
fractions	O
and	O
compositions	O
containing	O
the	O
compounds	O
are	O
provided	O
by	O
the	O
present	O
invention	O
.	O
Adelostemma	O
gracillimum	O
refined	O
fractions	O
and	O
the	O
extraction	O
process	O
thereof	O
are	O
also	O
provided	O
by	O
the	O
present	O
invention	O
.	O
The	O
uses	O
of	O
the	O
compounds	O
and	O
the	O
adelostemma	O
gracillimum	O
refined	O
fractions	O
for	O
inhibiting	O
the	O
activities	O
of	O
NMDA	O
receptor	O
or	O
amyloid-beta	O
peptide,	O
for	O
improving	O
memory,	O
and	O
for	O
treating	O
neurodegenerative	O
diseases,	O
neuropathological	O
conditions	O
or	O
epilepsy	O
are	O
further	O
provided	O
by	O
the	O
present	O
invention	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pyridine	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
ATR	B-GENE
protein	O
kinase	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
methods	O
of	O
treating	O
various	O
diseases,	O
disorders,	O
and	O
conditions	O
using	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
intermediates	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
in	O
vitro	O
applications,	O
such	O
as	O
the	O
study	O
of	O
kinases	B-GENE
in	O
biological	O
and	O
pathological	O
phenomena	O
;	O
the	O
study	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
mediated	O
by	O
such	O
kinases	B-GENE
;	O
and	O
the	O
comparative	O
evaluation	O
of	O
new	O
kinase	B-GENE
inhibitors	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
have	O
formula	O
(	O
III	O
)	O
:	O
(	O
Formula	O
(	O
III	O
)	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O


The	O
invention	O
discloses	O
a	O
moisturizing	O
composition,	O
containing	O
collagen,	O
soybean	O
extract,	O
grape	O
seed	O
extract	O
and	O
vitamin	O
E	O
.	O
Compared	O
with	O
the	O
prior	O
art,	O
the	O
composition	O
has	O
the	O
advantages	O
that	O
collagen,	O
soybean	O
extract,	O
grape	O
seed	O
extract	O
and	O
vitamin	O
E	O
are	O
selected	O
as	O
main	O
raw	O
materials,	O
nutrition	O
required	O
by	O
organism	O
can	O
be	O
supplemented,	O
free	O
radical	O
can	O
be	O
eliminated,	O
and	O
the	O
aims	O
of	O
moistening	O
skin	O
and	O
improving	O
skin	O
moisture	O
can	O
be	O
realized	O
.	O


The	O
invention	O
discloses	O
seven-element-ring	O
polyhydroxy	O
nitrone	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O
The	O
seven-element-ring	O
polyhydroxy	O
nitrone	O
is	O
shown	O
as	O
the	O
formula	O
I,	O
wherein	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
respectively	O
selected	O
from	O
the	O
following	O
groups	O
:	O
C1-C12	O
linear	O
or	O
branched	O
saturated	O
alkyl	O
groups,	O
allyl,	O
propylidene,	O
acetyl,	O
benzoyl,	O
benzyl,	O
or	O
benzyl	O
of	O
which	O
partial	O
or	O
all	O
the	O
positions	O
of	O
the	O
benzene	O
ring	O
are	O
replaced	O
by	O
alkoxy	O
or	O
halogen	O
;	O
and	O
the	O
spatial	O
configurations	O
of	O
the	O
Cs	O
at	O
the	O
positions	O
1,	O
2,	O
3	O
and	O
4	O
are	O
in	O
R	O
or	O
S	O
.	O
According	O
to	O
the	O
seven-element-ring	O
polyhydroxy	O
nitrone,	O
various	O
kinds	O
of	O
aldohexose	O
are	O
taken	O
as	O
raw	O
materials,	O
and	O
the	O
condensation	O
reaction	O
of	O
intramolecular	O
hydroxylamine	O
and	O
aldehyde	O
is	O
taken	O
as	O
a	O
key	O
step,	O
so	O
as	O
to	O
finish	O
the	O
preparation	O
of	O
seven-element-ring	O
polyhydroxy	O
nitrone,	O
so	O
that	O
a	O
method	O
for	O
simply	O
and	O
effectively	O
synthesizing	O
seven-element-ring	O
polyhydroxy	O
nitrone	O
is	O
provided	O
;	O
and	O
seven-element-ring	O
polyhydroxy	O
nitrone	O
prepared	O
by	O
using	O
the	O
method	O
can	O
be	O
used	O
for	O
preparing	O
imino	O
sugar	O
with	O
glycosidase	B-GENE
inhibitory	O
activity	O
.	O


A	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
the	O
following	O
structural	O
general	O
formula	O
.	O
The	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
good	O
inhibitional	O
effect	O
on	O
urease	B-GENE
and	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treating	O
gastritis,	O
gastric	O
ulcer,	O
lithangiuria	O
and	O
the	O
like	O
.	O
A	O
manufacturing	O
method	O
of	O
the	O
genistein	O
hydroxamic	O
acid	O
compound	O
is	O
disclosed	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
mannitol	O
in	O
preparation	O
of	O
an	O
anti-gastric	O
adenocarcinoma	O
drug,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
use	O
of	O
a	O
mannitol	O
injection	O
with	O
a	O
specific	O
concentration	O
of	O
10	O
%	O
-19	O
%	O
for	O
treating	O
gastric	O
adenocarcinoma	O
.	O
Traditionally,	O
mannitol	O
is	O
only	O
used	O
as	O
a	O
diuretic,	O
a	O
high-permeability	O
hypotensor	O
and	O
the	O
like,	O
while	O
the	O
inventor	O
discovers	O
through	O
scientific	O
experiments	O
that	O
mannitol	O
has	O
anti-tumor	O
activity,	O
and	O
through	O
several	O
cell	O
apoptosis	O
detection	O
technologies	O
and	O
by	O
detecting	O
apoptosis-related	O
genes	O
bcl-1,	O
and	O
bax,	O
proves	O
that	O
the	O
specific-concentration	O
mannitol	O
can	O
induce	O
various	O
human	O
cancer	O
cell	O
strains	O
to	O
generate	O
obvious	O
cancer	O
cell	O
apoptosis,	O
grasps	O
the	O
effect	O
relation	O
with	O
concentration	O
and	O
time,	O
and	O
first	O
illustrates	O
the	O
possible	O
mechanism	O
;	O
furthermore,	O
the	O
inventor	O
has	O
used	O
the	O
research	O
result	O
for	O
tumor	O
patient	O
treatment	O
and	O
has	O
achieved	O
obvious	O
curative	O
effect,	O
which	O
provides	O
theoretical	O
basis	O
and	O
practical	O
cases	O
for	O
the	O
application	O
of	O
mannitol	O
in	O
preparation	O
of	O
the	O
anti-tumor	O
drug	O
and	O
the	O
clinical	O
generalization	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
an	O
active	O
component	O
baicalin	O
of	O
a	O
Qingkailing	O
compound,	O
which	O
has	O
an	O
inhibiting	O
effect	O
on	O
acinetobacter	O
calcoaceticus,	O
acinetobacter	O
baumannii,	O
A	O
.	O
baumannii,	O
stenotrophomonas	O
maltophilia	O
and	O
escherichia	B-GENE
coli	I-GENE
containing	I-GENE
NDM-1	I-GENE
drug	O
resistance	O
gene,	O
so	O
that	O
the	O
active	O
component	O
baicalin	O
can	O
be	O
used	O
for	O
inhibiting	O
these	O
bacterial	O
diseases	O
and	O
treating	O
and	O
/	O
or	O
preventing	O
diseases	O
caused	O
by	O
these	O
bacteria	O
.	O


The	O
invention	O
relates	O
to	O
an	O
imidazoquinoline	O
derivative	O
and	O
a	O
medicinal	O
salt	O
thereof	O
and	O
a	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O
.	O
Specifically,	O
the	O
invention	O
relates	O
to	O
an	O
imidazoquinoline	O
derivative	O
shown	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
a	O
medicinal	O
salt	O
thereof	O
and	O
application	O
thereof	O
serving	O
as	O
a	O
cancer	O
treatment	O
agent	O
and	O
particularly	O
as	O
an	O
mTOR	B-GENE
and	O
/	O
or	O
PI3K-kinase	O
inhibitor,	O
wherein	O
the	O
definition	O
of	O
each	O
substituent	O
group	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
is	O
the	O
same	O
as	O
that	O
in	O
the	O
specification	O
.	O


The	O
invention	O
relates	O
to	O
an	O
anti-hepatoma	O
effect	O
of	O
an	O
antagonist	O
SR140333	O
of	O
a	O
neurokinin	B-GENE
receptor	I-GENE
1,	O
in	O
particular	O
to	O
a	O
method	O
for	O
treating	O
hepatoma	O
of	O
a	O
subject,	O
relieving	O
a	O
hepatoma	O
symptom	O
of	O
the	O
subject	O
or	O
inhibiting	O
hepatoma	O
cell	O
proliferation,	O
an	O
application	O
of	O
the	O
antagonist	O
of	O
the	O
neurokinin	B-GENE
receptor	I-GENE
1	I-GENE
in	O
preparing	O
medicine,	O
an	O
reagent	O
or	O
a	O
medicine	O
composition	O
for	O
treating	O
the	O
hepatoma,	O
relieving	O
the	O
hepatoma	O
symptom	O
or	O
inhibiting	O
the	O
hepatoma	O
cell	O
proliferation,	O
and	O
a	O
pharmaceutical	O
product	O
.	O
The	O
pharmaceutical	O
product	O
comprises	O
the	O
antagonist	O
SR140333	O
of	O
the	O
neurokinin	B-GENE
receptor	I-GENE
1	I-GENE
as	O
an	O
active	O
ingredient	O
and	O
a	O
specification	O
of	O
the	O
pharmaceutical	O
product	O
.	O


The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
flavone-C-glycoside	O
6	O
'	O
'	O
hydroxyl-ester	O
derivative	O
.	O
By	O
taking	O
a	O
flavone-C-glycoside	O
6	O
'	O
'	O
hydroxyl	O
extract	O
having	O
wide	O
source	O
and	O
low	O
activity	O
as	O
a	O
substrate,	O
the	O
method	O
enables	O
esterification	O
reaction	O
between	O
the	O
substrate	O
and	O
carboxylic	O
acid	O
in	O
the	O
presence	O
of	O
microorganism	O
lipase	B-GENE
and	O
organic	O
solvent	O
so	O
as	O
to	O
obtain	O
a	O
flavone-C-glycoside	O
6	O
'	O
'	O
hydroxyl-ester	O
derivative	O
rarely	O
seen	O
in	O
nature	O
and	O
having	O
high	O
activity	O
through	O
local	O
specific	O
synthesis	O
.	O
In	O
the	O
reaction	O
process,	O
monitoring	O
is	O
performed	O
by	O
a	O
detection	O
method	O
of	O
thin-layer	O
chromatography	O
or	O
efficient	O
liquid	O
chromatography	O
until	O
all	O
start	O
raw	O
materials	O
are	O
consumed	O
;	O
and	O
after	O
the	O
reaction,	O
lipase	B-GENE
is	O
filtered,	O
and	O
the	O
esterified	O
product	O
is	O
washed	O
and	O
purified	O
by	O
the	O
organic	O
solvent	O
.	O
The	O
method	O
has	O
the	O
advantages	O
of	O
easily	O
available	O
substrate,	O
simple	O
preparation	O
technology,	O
high	O
specificity	O
and	O
mild	O
reaction	O
conditions	O
;	O
the	O
obtained	O
product	O
is	O
easy	O
to	O
purify	O
;	O
and	O
sufficient	O
raw	O
material	O
guarantee	O
is	O
provided	O
to	O
the	O
application	O
of	O
flavone-C-glycoside	O
6	O
'	O
'	O
hydroxyl-ester	O
derivative	O
in	O
the	O
fields	O
of	O
functional	O
food,	O
beverage,	O
cosmetics,	O
medicine	O
and	O
the	O
like	O
.	O


The	O
invention	O
discloses	O
a	O
use	O
of	O
pinocembrin	O
(	O
PCB	O
)	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
neurodegenerative	O
diseases,	O
and	O
belongs	O
to	O
the	O
medicinal	O
field	O
.	O
Wide	O
researches	O
on	O
the	O
screening	O
of	O
oxidation	O
damage	O
resistant	O
medicines	O
prove	O
that	O
pinocembrin	O
has	O
a	O
nerve	O
protection	O
effect	O
.	O
Concrete	O
researches	O
prove	O
that	O
pinocembrin	O
has	O
the	O
nerve	O
protection	O
effect	O
on	O
Alzheimer	O
disease	O
beta-amyloid	B-GENE
protein	I-GENE
(	O
Abeta	B-GENE
)	O
and	O
1-methyl-4-phenylpyridine	O
(	O
MPP	O
<	O
+	O
>	O
)	O
induced	O
Parkinson	O
'	O
s	O
disease	O
models,	O
so	O
pinocembrin	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
preventing	O
and	O
treating	O
the	O
neurodegenerative	O
diseases	O
.	O
Medicines	O
treating	O
pinocembrin	O
as	O
an	O
active	O
component	O
will	O
have	O
substantial	O
curative	O
effects	O
clinically,	O
so	O
great	O
social	O
and	O
economic	O
benefits	O
are	O
generated	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
natural	O
drugs,	O
especially	O
to	O
application	O
of	O
tanshinone	O
IIA	O
as	O
an	O
inhibitor	O
for	O
the	O
redox	O
function	O
of	O
APE1	B-GENE
and	O
application	O
of	O
tanshinone	O
IIA	O
in	O
preparation	O
of	O
drugs	O
used	O
for	O
treating	O
cancers	O
.	O
Tanshinone	O
IIA	O
can	O
inhibit	O
the	O
redox	O
function	O
of	O
APE1	B-GENE
and	O
directly	O
kill	O
tumor	O
cells	O
through	O
inhibition	O
of	O
the	O
redox	O
function	O
of	O
APE1	B-GENE
;	O
tanshinone	O
IIA	O
can	O
also	O
reverse	O
overactivity	O
of	O
the	O
redox	O
function	O
caused	O
by	O
high	O
expression	O
of	O
APE1	B-GENE
in	O
the	O
tumor	O
cells,	O
inhibit	O
propagation	O
and	O
infiltration	O
of	O
tumor	O
cells,	O
reverse	O
anti-apoptosis	O
of	O
the	O
tumor	O
cells	O
and	O
prevent	O
metastasis	O
of	O
the	O
tumor	O
cells	O
;	O
tanshinone	O
IIA	O
can	O
further	O
reverse	O
drug	O
resistance	O
of	O
the	O
tumor	O
cells	O
to	O
chemotherapeutics	O
caused	O
by	O
high	O
expression	O
of	O
APE1	B-GENE
in	O
the	O
tumor	O
cells	O
;	O
moreover,	O
while	O
having	O
anticancer	O
and	O
chemosensitization	O
performances,	O
tanshinone	O
IIA	O
has	O
a	O
usage	O
and	O
development	O
potential	O
due	O
to	O
small	O
toxic	O
and	O
side	O
effects	O
.	O


The	O
invention	O
discloses	O
a	O
medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
.	O
The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
'	O
s	O
disease	O
comprises	O
procyanidine	O
and	O
cysteine,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
procyanidine	O
to	O
the	O
cysteine	O
is	O
(	O
0	O
.	O
1-10	O
)	O
:	O
1,	O
preferably	O
(	O
1-3	O
)	O
:	O
1	O
;	O
and	O
the	O
procyanidine	O
is	O
preferably	O
lotus	O
procyanidine	O
.	O
The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
'	O
s	O
disease	O
can	O
improve	O
the	O
oxidation	O
resistance	O
of	O
brain	O
tissue,	O
avoid	O
free	O
radical	O
injury	O
to	O
the	O
brain	O
tissue,	O
inhibit	O
MAO-B	B-GENE
and	O
AchE	B-GENE
activity	O
and	O
enhance	O
the	O
oxidation	O
resistance	O
of	O
brain	O
and	O
hippocampal	O
anti-oxidation	O
system	O
and	O
serum	O
so	O
as	O
to	O
improve	O
the	O
learning	O
and	O
memory	O
function	O
.	O
According	O
to	O
animal	O
tests,	O
the	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
'	O
s	O
disease	O
can	O
effectively	O
improve	O
mouse	O
learning	O
and	O
memory	O
injury	O
induced	O
by	O
ethanol	O
and	O
scopolamine,	O
and	O
the	O
curative	O
effect	O
is	O
more	O
excellent	O
than	O
that	O
of	O
piracetam	O
and	O
procyanidine	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
in	O
particular	O
relates	O
to	O
indoles	O
derivatives	O
shown	O
in	O
general	O
formula	O
(	O
I	O
)	O
and	O
functioning	O
as	O
a	O
CRTH2	B-GENE
receptor	I-GENE
antagonist,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
stereoisomerides	O
of	O
the	O
indoles	O
derivatives,	O
wherein	O
X1,	O
X2,	O
X3,	O
X4,	O
R1,	O
R2,	O
R3,	O
Z,	O
Y,	O
A,	O
and	O
B	O
are	O
defined	O
in	O
specifications,	O
and	O
the	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds,	O
medicine	O
preparations	O
and	O
medicine	O
compositions	O
containing	O
the	O
compounds,	O
and	O
an	O
application	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
CRTH2	O
activity	O
relevant	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
stilbene	O
glucoside	O
compound	O
2,3,5,4	O
'	O
-tetrahydroxy	O
stilbene-2-O-beta-D-glucoside	O
and	O
new	O
application	O
of	O
an	O
extract	O
or	O
preparation	O
containing	O
the	O
stilbene	O
glucoside	O
compound	O
as	O
a	O
tyrosinase	B-GENE
inhibitor	O
.	O
The	O
new	O
application	O
includes	O
application	O
of	O
the	O
compound	O
and	O
the	O
extract	O
containing	O
the	O
compound	O
in	O
skin	O
whitening	O
cosmetic,	O
stain	O
prevention	O
medicine,	O
food	O
browning	O
inhibitor	O
and	O
biological	O
insecticide	O
.	O


The	O
invention	O
relates	O
to	O
cyclocarya	O
paliurus	O
extract	O
and	O
the	O
application	O
of	O
the	O
cyclocarya	O
paliurus	O
extract	O
.	O
The	O
cyclocarya	O
paliurus	O
extract	O
at	O
least	O
comprises	O
the	O
following	O
effective	O
ingredients	O
:	O
10-methoxy-nb-alpha-methyl	O
corynantheol,	O
n-nonyl	O
nitrate,	O
iso-butoxyamine,	O
pentadecanoic	O
acid,	O
4,	O
6,	O
10,	O
14-tetramethyl-methyl-ester,	O
adipic	O
acid,	O
bis--	O
(	O
2-ethylhexyl	O
)	O
ester,	O
2-butyl,	O
1-octanol,	O
octadecyl	O
vinyl	O
ether	O
and	O
erythro	O
cis-4,	O
5-dimethyl-2-undecene	O
.	O
The	O
weight	O
percentage	O
of	O
the	O
effective	O
ingredients	O
in	O
the	O
cyclocarya	O
paliurus	O
extract	O
is	O
50	O
%	O
to	O
98	O
%	O
.	O
The	O
cyclocarya	O
paliurus	O
extract	O
can	O
significantly	O
promote	O
the	O
secretion	O
of	O
insulin	B-GENE
by	O
islet	O
beta	O
cells	O
so	O
as	O
to	O
enhance	O
glucose	O
tolerance	O
of	O
mice	O
and	O
regulate	O
blood	O
sugar,	O
and	O
therefore	O
the	O
cyclocarya	O
paliurus	O
extract	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
diabetes,	O
and	O
the	O
direction	O
is	O
pointed	O
out	O
for	O
further	O
developing	O
and	O
utilizing	O
the	O
medical	O
value	O
of	O
cyclocarya	O
paliurus	O
.	O


The	O
invention	O
relates	O
to	O
a	O
tree-like	O
polymer	O
nanometer	O
drug	O
delivery	O
carrier	O
targeting	O
doxorubicin	O
.	O
The	O
structural	O
general	O
formula	O
of	O
the	O
targeting	O
doxorubicin	O
is	O
PEG-b-PAMAM-hydrozone-	O
(	O
DOX	O
)	O
n	O
.	O
A	O
tree-like	O
polymer	O
nanometer	O
drug	O
delivery	O
carrier	O
targeting	O
doxorubicin	O
of	O
liquid	O
tumors	O
representative	O
to	O
myeloma	O
is	O
provided	O
in	O
the	O
invention	O
.	O
The	O
acidic	O
environment	O
(	O
pH	O
of	O
5	O
.	O
5	O
)	O
of	O
myeloma	O
makes	O
a	O
hydrogen	O
bond	O
connecting	O
a	O
carrier	O
with	O
doxorubicin	O
be	O
broken,	O
so	O
complete	O
doxorubicin	O
molecules	O
are	O
released	O
.	O
The	O
release	O
is	O
only	O
carried	O
out	O
under	O
the	O
acidic	O
condition	O
of	O
the	O
myeloma,	O
so	O
the	O
treatment	O
pertinence	O
of	O
the	O
drug	O
is	O
greatly	O
improved	O
.	O
P-glycoprotein	B-GENE
will	O
diffuse	O
to	O
doxorubicin	O
monomer	O
elimination	O
cells	O
in	O
cells,	O
so	O
tumor	O
cells	O
generate	O
multiple	O
drug	O
resistances	O
.	O
The	O
carrier	O
drug	O
can	O
avoid	O
the	O
medicine	O
efflux	O
phenomenon	O
caused	O
by	O
the	O
p-glycoprotein	B-GENE
and	O
can	O
also	O
avoid	O
the	O
multiple	O
drug	O
resistances	O
.	O


Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
kinases	B-GENE
including	O
Mixed	B-GENE
Lineage	I-GENE
Kinases	I-GENE
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
methods	O
of	O
preparing	O
the	O
compounds,	O
synthetic	O
intermediates,	O
and	O
methods	O
of	O
using	O
the	O
compounds,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents,	O
for	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
affected	O
by	O
Mixed	B-GENE
Lineage	I-GENE
Kinase	I-GENE
inhibition	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
that	O
comprise	O
the	O
inhibition	O
of	O
Mixed	B-GENE
Lineage	I-GENE
Kinases	I-GENE
.	O


According	O
to	O
a	O
technical	O
scheme	O
on	O
the	O
first	O
aspect,	O
the	O
invention	O
provides	O
a	O
drug	O
for	O
treatment	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
abnormal	O
glucose	O
metabolism	O
coexisting	O
diseases	O
.	O
The	O
drug	O
is	O
characterized	O
by	O
including	O
the	O
following	O
four	O
fatty	O
acid	O
components	O
by	O
mass	O
:	O
17-22	O
%	O
of	O
palmitic	O
acid,	O
11-23	O
%	O
of	O
hexadecenoic	O
acid,	O
22-28	O
%	O
of	O
9-octadecenoic	O
acid,	O
13-35	O
%	O
of	O
9,	O
12,	O
15-octatecatrienoic	O
acid,	O
and	O
the	O
balance	O
pharmaceutically	O
acceptable	O
additives	O
or	O
excipients	O
.	O
The	O
components	O
are	O
mixed	O
according	O
to	O
compatibility	O
to	O
be	O
prepared	O
into	O
soft	O
capsules	O
and	O
other	O
oral	O
preparations,	O
so	O
that	O
the	O
insulin	B-GENE
receptor	I-GENE
substrate	O
(	O
IRS	O
)	O
protein	O
level	O
can	O
be	O
effectively	O
reduced	O
so	O
as	O
to	O
inhibit	O
the	O
glucose	O
way,	O
the	O
insulin	B-GENE
receptor	I-GENE
active	O
time	O
can	O
be	O
increased	O
and	O
the	O
insulin	O
level	O
can	O
be	O
enhanced,	O
and	O
the	O
insulin	O
sensitivity	O
is	O
increased	O
so	O
as	O
to	O
facilitate	O
the	O
reduction	O
of	O
insulin	O
resistance	O
degree	O
.	O
Thus,	O
the	O
drug	O
can	O
have	O
the	O
functions	O
of	O
improving	O
and	O
recuperating	O
ovary	O
ovulatory	O
dysfunction,	O
i	O
.	O
e	O
.	O
PCOS	O
and	O
abnormal	O
glucose	O
metabolism	O
diseases	O
.	O
Compared	O
with	O
other	O
drugs,	O
the	O
drug	O
has	O
simple	O
components,	O
and	O
belongs	O
to	O
highly	O
effective,	O
safety,	O
and	O
simplified	O
drugs	O
.	O


The	O
invention	O
provides	O
an	O
isatin-5-amide	O
compound	O
represented	O
by	O
a	O
formula	O
(	O
1	O
)	O
.	O
The	O
compound	O
has	O
an	O
inhibition	O
activity	O
against	O
SARS	O
coronavirus	O
main	O
protease,	O
and	O
can	O
be	O
used	O
as	O
a	O
SARS	O
coronavirus	O
main	O
protease	B-GENE
inhibiting	O
agent,	O
and	O
can	O
be	O
applied	O
in	O
SARS	O
treatment	O
.	O
The	O
structural	O
formula	O
of	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
is	O
as	O
the	O
following	O
.	O


The	O
invention	O
relates	O
to	O
a	O
benzisothiazole-3-ketone-2-amide	O
compound	O
with	O
Caspase-3	B-GENE
inhibiting	O
activity	O
.	O
The	O
benzisothiazole-3-ketone-2-amide	O
compound	O
has	O
the	O
Caspase-3	B-GENE
inhibiting	O
activity,	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
mediated	O
by	O
Caspase-3,	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry,	O
and	O
has	O
a	O
structural	O
formula	O
(	O
I	O
)	O
as	O
shown	O
in	O
the	O
specification	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R1a,	O
R1b	O
have	O
the	O
meaning	O
as	O
cited	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O
Said	O
compounds	O
are	O
useful	O
as	O
JAK	B-GENE
inhibitors	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
immunological,	O
inflammatory,	O
autoimmune,	O
allergic	O
disorders,	O
and	O
immunologically-mediated	O
diseases	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
including	O
said	O
compounds,	O
the	O
preparation	O
of	O
such	O
compounds	O
as	O
well	O
as	O
the	O
use	O
as	O
medicaments	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
a	O
specific	O
piperidone-containing	O
single-carbonyl	O
curcumin	O
compound	O
in	O
preparation	O
of	O
an	O
anti-inflammatory	O
drug	O
and	O
medicines	O
used	O
for	O
treating	O
related	O
inflammation	O
diseases	O
.	O
The	O
curcumin	O
compound	O
can	O
inhibit	O
expression	O
and	O
release	O
of	O
an	O
inflammation-suppressing	O
factor	O
IL-6,	O
obviously	O
reverse	O
degradation	O
of	O
I	O
kappa	O
B	O
related	O
to	O
regulation	O
of	O
inflammation	O
and	O
inhibit	O
phosphorylation	O
of	O
inflammation	O
signal	O
channels	O
such	O
as	O
ERK	B-GENE
and	O
JNK	B-GENE
;	O
and	O
in	O
vivo	O
experiments	O
show	O
the	O
curcumin	O
compound	O
can	O
obviously	O
improve	O
survival	O
rate	O
of	O
mice	O
which	O
are	O
about	O
to	O
die	O
owning	O
to	O
induction	O
by	O
virtue	O
of	O
LPS	O
(	O
lean	O
process	O
solution	O
)	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
polymer	O
synthesis	O
and	O
in	O
particular	O
relates	O
to	O
a	O
specific	O
inhibition	O
compound	O
of	O
an	O
SAHN	B-GENE
enzyme	O
protein	O
and	O
a	O
synthetic	O
method	O
of	O
the	O
specific	O
inhibition	O
compound	O
.	O
The	O
specific	O
inhibition	O
compound	O
of	O
escherichia	B-GENE
coli	I-GENE
SAHN	B-GENE
enzyme	O
protein	O
is	O
obtained	O
in	O
a	O
targeted	O
manner	O
by	O
virtue	O
of	O
an	O
organic	O
synthetic	O
method,	O
so	O
that	O
a	O
novel	O
anti-infective	O
drug	O
pilot	O
compound	O
is	O
developed	O
.	O


The	O
invention	O
provides	O
tanshinone	O
compounds,	O
a	O
preparation	O
method	O
and	O
use	O
thereof,	O
and	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
chemistry	O
.	O
The	O
tanshinone	O
compounds	O
possess	O
a	O
structure	O
formula	O
I	O
or	O
II	O
as	O
shown	O
in	O
the	O
specification	O
.	O
The	O
use	O
of	O
the	O
tanshinone	O
compounds	O
includes	O
but	O
not	O
limited	O
to	O
anticancer	O
drugs,	O
particularly	O
the	O
treatment	O
of	O
prostate	O
cancer	O
and	O
bladder	O
cancer,	O
and	O
induction	O
of	O
androgen	B-GENE
receptor	I-GENE
antagonist	O
activity	O
when	O
patients	O
have	O
androgen-related	O
diseases,	O
wherein	O
the	O
androgen-related	O
diseases	O
include	O
but	O
not	O
limited	O
to	O
multi-disease,	O
acne,	O
and	O
spermatogenesis	O
without	O
inhibition	O
in	O
need	O
of	O
suppressing	O
spermatogenesis	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
Shen-Gui	O
pills	O
in	O
preparation	O
of	O
drugs	O
for	O
tumor	O
inhibition	O
and	O
combined	O
chemotherapy	O
drugs	O
.	O
The	O
application	O
has	O
the	O
advantages	O
that	O
effective	O
tumor	O
inhibition	O
rate	O
of	O
the	O
Shen-Gui	O
pills	O
is	O
30	O
%	O
,	O
effective	O
body	O
weight	O
of	O
cis-platinum	O
chemotherapy	O
tumor-bearing	O
mouse	O
is	O
increased,	O
living	O
states	O
of	O
the	O
tumor-bearing	O
mouse	O
are	O
improved,	O
reduction	O
of	O
neutrophile	O
granulocyte	O
and	O
monocytes	O
caused	O
by	O
cis-platinum	O
chemotherapy	O
is	O
reduced,	O
reduction	O
of	O
spleen	O
and	O
thymus	O
indexes	O
caused	O
by	O
cis-platinum	O
chemotherapy	O
can	O
be	O
resisted	O
by	O
the	O
Shen-Gui	O
pills,	O
the	O
spleen	O
and	O
thymus	O
indexes	O
can	O
be	O
increased,	O
important	O
immune	O
organs	O
of	O
the	O
mouse	O
are	O
protected	O
to	O
some	O
extent,	O
concentration	O
of	O
HIF-1alpha	B-GENE
(	O
hypoxia	B-GENE
inducible	I-GENE
factor-1	I-GENE
alpha	I-GENE
)	O
can	O
be	O
reduced,	O
hypoxia	O
resistance	O
of	O
tumor	O
cells	O
is	O
weakened,	O
death	O
of	O
the	O
tumor	O
cells	O
is	O
accelerated,	O
activity	O
of	O
LDH	B-GENE
(	O
lactate	B-GENE
dehydrogenase	I-GENE
)	O
is	O
lowered,	O
damages	O
of	O
LDH	B-GENE
on	O
normal	O
cells	O
are	O
reduced,	O
and	O
toxic	O
action	O
of	O
the	O
cis-platinum	O
chemotherapy	O
can	O
be	O
alleviated	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
a	O
terpenoid	O
to	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
.	O
The	O
terpenoid	O
has	O
a	O
structural	O
formula	O
I	O
which	O
is	O
as	O
shown	O
in	O
the	O
description,	O
wherein	O
R1	O
represents	O
H,	O
C1-C5	O
linear	O
alkyl,	O
glycosyl	O
or	O
a	O
formula	O
which	O
is	O
as	O
shown	O
in	O
the	O
description,	O
and	O
R2	O
is	O
selected	O
from	O
C1-C4	O
linear	O
alkyl	O
.	O
According	O
to	O
the	O
application	O
of	O
the	O
terpenoid,	O
an	O
ionane	O
type	O
sesquiterpene	O
compound	O
separated	O
and	O
obtained	O
from	O
leonurus	O
for	O
the	O
first	O
time	O
can	O
obviously	O
inhibit	O
the	O
platelet	O
aggregation	O
in	O
vitro	O
and	O
has	O
extension	O
tendencies	O
to	O
prothrombin	B-GENE
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
(	O
APTT	O
)	O
and	O
thrombin	B-GENE
time	O
(	O
TT	O
)	O
and	O
has	O
a	O
certain	O
anticoagulation	O
activity,	O
so	O
that	O
a	O
new	O
choice	O
is	O
provided	O
for	O
the	O
development	O
of	O
natural	O
anti-thrombus	O
drugs	O
.	O


The	O
invention	O
discloses	O
a	O
5-	O
[	O
[	O
4-	O
[	O
(	O
2,	O
3-dimethyl-2H-indazole-6-yl	O
)	O
methylamino	O
]	O
-2-pyrimidyl	O
]	O
amino	O
]	O
-2-methyl-benzsulfamide	O
derivative	O
and	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O
The	O
compound	O
disclosed	O
by	O
the	O
invention	O
is	O
shown	O
in	O
the	O
structural	O
formula	O
I,	O
wherein	O
R	O
is	O
selected	O
from	O
any	O
one	O
of	O
the	O
following	O
groups	O
:	O
an	O
alkyl	O
or	O
benzyl	O
substituted	O
six-membered	O
nitrogen-containing	O
heterocyclic	O
group,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	O
containing	O
5-8	O
carbon	O
atoms,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	O
containing	O
one	O
oxygen	O
atom	O
and	O
6-11	O
carbon	O
atoms,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	O
containing	O
one	O
carboxyl	O
and	O
at	O
least	O
4	O
carbon	O
atoms,	O
and	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	O
containing	O
one	O
carboxyl	O
and	O
at	O
least	O
5	O
carbon	O
atoms	O
.	O
According	O
to	O
the	O
invention,	O
a	O
new	O
compound	O
is	O
obtained	O
through	O
modifying	O
the	O
structure	O
of	O
an	O
amino-side	O
chain	O
part	O
on	O
the	O
basis	O
of	O
a	O
drug	O
Pazopanib	O
applied	O
to	O
the	O
clinic	O
.	O
Pharmacodynamic	O
tests	O
prove	O
that	O
the	O
compound	O
has	O
a	O
better	O
anti-blood-vessel-endothelium-growth	O
factor	O
receptor	I-GENE
inhibition	O
effect	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
relates	O
to	O
a	O
type	O
of	O
compounds	O
with	O
antitumor	O
activities,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O
The	O
compounds	O
have	O
a	O
structural	O
general	O
formula	O
represented	O
below	O
.	O
R1	O
is	O
alkyl	O
group,	O
heterocyclic	O
group,	O
substituted	O
phenyl	O
group,	O
substituted	O
alicyclic	O
group,	O
or	O
aliphatic	O
heterocyclic	O
group,	O
wherein	O
the	O
substituent	O
is	O
2,3-ethylenedioxy,	O
3,4-ethylenedioxy,	O
2,3-methylenedioxy,	O
or	O
3,4-methylenedioxy	O
;	O
or	O
all-site-substituted	O
hydrogen,	O
alkyl,	O
alkoxy,	O
halogen,	O
amino,	O
hydroxyl,	O
trifluoromethyl,	O
formate,	O
and	O
the	O
like	O
.	O
R2	O
is	O
heterocyclic	O
group	O
or	O
substituted	O
phenyl	O
group,	O
wherein	O
the	O
phenyl	O
substituent	O
is	O
2,3-ethylenedioxy,	O
3,4-ethylenedioxy,	O
2,3-methylenedioxy,	O
or	O
3,4-methylenedioxy	O
;	O
or	O
all-site-substituted	O
hydrogen,	O
alkyl,	O
alkoxy,	O
halogen,	O
amino,	O
hydroxyl,	O
trifluoromethyl,	O
formate,	O
and	O
the	O
like	O
.	O
The	O
compounds	O
provided	O
by	O
the	O
invention	O
have	O
substantial	O
tumor	O
cytotoxic	O
effect	O
and	O
broad-spectrum	O
kinase	B-GENE
inhibitory	O
activity,	O
and	O
can	O
be	O
used	O
in	O
preparing	O
antitumor	O
medicines	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines,	O
in	O
particular	O
relates	O
to	O
a	O
physalin	O
A	O
extracting	O
process	O
and	O
medical	O
application	O
thereof,	O
in	O
particular	O
relates	O
to	O
a	O
novel	O
application	O
of	O
physalin	O
A	O
in	O
preparation	O
of	O
an	O
anti-tumor	O
dug	O
and	O
in	O
particular	O
relates	O
to	O
the	O
use	O
of	O
physalin	O
A	O
in	O
treatment	O
of	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma	O
.	O
After	O
process	O
optimization,	O
the	O
extracting	O
rate	O
of	O
physalin	O
A	O
is	O
0	O
.	O
2133	O
%	O
.	O
Physalin	O
A	O
can	O
be	O
used	O
for	O
inhibiting	O
the	O
growth	O
of	O
various	O
tumor	O
cells,	O
particularly	O
has	O
obvious	O
inhibiting	O
action	O
on	O
the	O
growth	O
of	O
the	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma,	O
but	O
does	O
not	O
inhibit	O
the	O
activities	O
of	O
the	O
human	O
normal	O
cells	O
obviously	O
.	O
The	O
mechanism	O
is	O
that	O
the	O
downstream	O
caspase	B-GENE
family-associated	O
protein	O
is	O
activated	O
by	O
activating	O
Fas	B-GENE
death	I-GENE
receptors,	O
so	O
that	O
the	O
tumor	O
cells	O
are	O
induced	O
to	O
generate	O
apoptosis	O
.	O
Meanwhile,	O
the	O
physalin	O
A	O
can	O
be	O
used	O
for	O
inducing	O
the	O
tumor	O
cells	O
to	O
generate	O
autophagy	O
for	O
achieving	O
autophagy	O
antagonism	O
apoptosis	O
in	O
the	O
HT1080	O
and	O
the	O
A375-S2	O
cells	O
;	O
and	O
the	O
p53	B-GENE
protein	O
and	O
the	O
MAPK	B-GENE
(	O
Mitogen-Activated	B-GENE
Protein	I-GENE
Kinase	I-GENE
)	O
-familty	O
p38	B-GENE
protein	O
have	O
a	O
key	O
regulation	O
effect	O
.	O
The	O
physalin	O
A	O
can	O
be	O
used	O
for	O
preparing	O
a	O
digestive	O
tract	O
dosage	O
form	O
or	O
a	O
non-digestive	O
tract	O
dosage	O
form,	O
which	O
can	O
be	O
used	O
for	O
treating	O
tumors	O
including	O
the	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma	O
.	O


Provided	O
herein	O
are	O
methods,	O
compositions,	O
and	O
kits	O
for	O
preventing,	O
inhibiting,	O
reducing	O
the	O
severity	O
of,	O
or	O
treating	O
a	O
disease	O
or	O
condition	O
.	O
A	O
pharmaceutical	O
composition	O
provided	O
herein	O
can	O
comprise	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
an	O
antigen	O
fused	O
to	O
an	O
immune	O
cell	O
product,	O
e	O
.	O
g	O
.	O
,	O
MIP-3a,	O
and	O
an	O
adjuvant	O
.	O
The	O
antigen	O
can	O
be	O
from	O
a	O
bacteria,	O
virus,	O
fungus,	O
parasite,	O
or	O
cancer	O
.	O
The	O
antigen	O
can	O
be	O
an	O
Alzheimer	O
'	O
s	O
disease	O
antigen	O
.	O


The	O
invention	O
provides	O
an	O
aquatic	O
product	O
anesthetic	O
which	O
takes	O
alpha-glucose	O
eugenol	O
as	O
a	O
main	O
ingredient	O
and	O
has	O
the	O
synergistic	O
effect	O
with	O
alpha-glucosidase	B-GENE
.	O
Compared	O
with	O
the	O
traditional	O
anesthetic	O
eugenol,	O
the	O
alpha-glucose	O
eugenol	O
has	O
high	O
stability,	O
high	O
water	O
solubility,	O
low	O
toxic	O
or	O
side	O
effect	O
and	O
high	O
safety	O
.	O
The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
anesthetic	O
.	O


The	O
invention	O
discloses	O
an	O
indole	O
derivative,	O
which	O
is	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
derivative	O
is	O
a	O
selective	O
antagonist	O
of	O
a	O
muscarinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
linear	O
or	O
branched	O
alkyl	O
containing	O
1-3	O
carbon	O
atoms	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
hydrogen	O
atoms	O
or	O
linear	O
or	O
branched	O
alkyl	O
containing	O
1-3	O
carbon	O
atoms	O
;	O
and	O
R4	O
represents	O
hydrogen	O
atom	O
or	O
halogen	O
.	O
In	O
addition,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative,	O
and	O
use	O
as	O
a	O
muscarinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
antagonist	O
.	O


The	O
invention	O
relates	O
to	O
a	O
small	O
molecule	O
medicament	O
based	O
on	O
PI3K	B-GENE
(	O
Phosphatidyl	B-GENE
Inositol	I-GENE
3-kinase	I-GENE
)	O
/	O
mTOR	B-GENE
(	O
Mammalian	B-GENE
Target	I-GENE
of	I-GENE
Rapamycin	I-GENE
)	O
double	O
targets,	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
chemical	O
medicines,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
five-membered	O
urea	O
ring-coumarin	O
derivative	O
or	O
a	O
pharmaceutical	O
salt	O
and	O
an	O
application	O
thereof	O
.	O
A	O
compound	O
claimed	O
by	O
the	O
invention	O
has	O
a	O
structure	O
shown	O
as	O
formula	O
I	O
described	O
in	O
the	O
specification,	O
and	O
pharmacological	O
experiments	O
show	O
that	O
the	O
compound	O
has	O
excellent	O
inhibitory	O
activity	O
in	O
a	O
plurality	O
of	O
tumor	O
cell	O
strains	O
.	O


The	O
invention	O
provides	O
a	O
3-substituted	O
coumarin	O
derivative,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates	O
or	O
crystal	O
forms	O
thereof	O
.	O
The	O
above	O
compound	O
has	O
a	O
high	O
calcium	O
flow	O
activity	O
and	O
a	O
very	O
good	O
selectivity	O
on	O
a	O
human	O
derived	O
cannabinoid	B-GENE
receptor	I-GENE
CB2,	O
and	O
is	O
a	O
specific	O
agonist	O
or	O
inverse	O
agonist	O
of	O
the	O
cannabinoid	B-GENE
receptor	I-GENE
CB2	I-GENE
.	O
The	O
compound	O
is	O
an	O
active	O
ligand	O
of	O
a	O
novel	O
cannabinoid	B-GENE
II	I-GENE
receptor	I-GENE
CB2,	O
and	O
compounds	O
of	O
the	O
above	O
kind	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates	O
or	O
crystal	O
forms	O
thereof	O
have	O
high	O
calcium	O
flow	O
activities	O
and	O
a	O
very	O
good	O
selectivity	O
on	O
the	O
human	O
derived	O
cannabinoid	B-GENE
receptor	I-GENE
CB2	I-GENE
.	O
The	O
compound	O
is	O
the	O
specific	O
agonist	O
or	O
inverse	O
agonist	O
of	O
the	O
cannabinoid	B-GENE
receptor	I-GENE
CB2,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
medicines	O
for	O
treating,	O
preventing	O
and	O
inhibiting	O
CB2	O
receptor	I-GENE
mediated	O
diseases	O
.	O
The	O
structure	O
of	O
the	O
derivative	O
is	O
represented	O
by	O
a	O
general	O
formula	O
A	O
shown	O
in	O
the	O
specification	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
alkannin	O
and	O
/	O
or	O
derivatives	O
thereof	O
in	O
preparing	O
a	O
medicine	O
for	O
prohibiting	O
cancer	O
cell	O
metastasis	O
.	O
The	O
cancer	O
cell	O
refers	O
to	O
one	O
or	O
more	O
of	O
brain	O
tumor,	O
hematologic	O
tumer,	O
esophagus	O
cancer,	O
liver	O
cancer,	O
skin	O
cancer,	O
prostate	O
cancer,	O
bone	O
cancer,	O
breast	O
cancer	O
and	O
lung	O
carcinoma	O
cells	O
.	O
The	O
invention	O
provides	O
a	O
novel	O
application	O
of	O
the	O
alkannin	O
and	O
derivatives	O
thereof	O
;	O
the	O
alkannin	O
can	O
effectively	O
prohibit	O
adhesion,	O
migration	O
and	O
invasion	O
of	O
cells,	O
expression	O
of	O
alkannin	O
beta1	O
and	O
phosphorylation	O
of	O
ERK1	O
/	O
2,	O
so	O
that	O
cancer	O
cell	O
metastasis	O
is	O
effectively	O
prohibited	O
;	O
moreover	O
the	O
alkannin	O
and	O
derivatives	O
thereof	O
are	O
low	O
in	O
toxicity,	O
are	O
nonhazardous	O
for	O
ordinary	O
cells	O
of	O
human	O
bodies,	O
and	O
have	O
good	O
clinical	O
antineoplastic	O
application	O
prospects	O
.	O


The	O
invention	O
relates	O
to	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone,	O
which	O
has	O
a	O
chemical	O
structure	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
.	O
The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
reacting	O
phenylpiperazine	O
pyridazinone	O
and	O
1-	O
(	O
2-bromoethoxyl	O
)	O
-2-chlorobenzene	O
.	O
The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
is	O
remarkable	O
in	O
effect	O
of	O
suppressing	O
an	O
alpha	B-GENE
1-adrenergic	I-GENE
receptor	I-GENE
.	O


The	O
invention	O
discloses	O
a	O
spiro	O
compound	O
as	O
shown	O
in	O
a	O
formula	O
I,	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
a	O
hydrate,	O
a	O
solvate,	O
an	O
optical	O
isomer	O
or	O
a	O
prodrug	O
of	O
the	O
spiro	O
compound,	O
as	O
well	O
as	O
a	O
preparation	O
method,	O
an	O
intermediate,	O
a	O
pharmaceutical	O
composition	O
and	O
an	O
application	O
of	O
the	O
spiro	O
compound	O
.	O
The	O
spiro	O
compound	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
activity	O
of	O
serving	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors	O
and	O
tyrosine	B-GENE
kinase	I-GENE
inhibitors	O
such	O
as	O
c-Met,	O
and	O
the	O
spiro	O
compound	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
abnormal	O
activity	O
of	O
kinases,	O
such	O
as	O
cancer,	O
or	O
used	O
for	O
preparing	O
medicaments	O
for	O
treating	O
the	O
diseases	O
.	O


The	O
invention	O
discloses	O
applications	O
of	O
latanoprost	O
in	O
preparation	O
of	O
medications	O
for	O
treating	O
diabetes	O
and	O
/	O
or	O
hypertriglyceridemia	O
and	O
complications	O
thereof	O
;	O
and	O
to	O
be	O
specific,	O
the	O
diabetes	O
is	O
type	O
2	O
diabetes	O
induced	O
by	O
insulin	B-GENE
resistance	O
.	O
In	O
the	O
applications,	O
latanoprost	O
is	O
used	O
as	O
an	O
antagonist	O
to	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
alpha	I-GENE
(	O
RXR	B-GENE
alpha	I-GENE
)	O
which	O
is	O
a	O
type	O
of	O
nuclear	O
receptors,	O
and	O
/	O
or	O
an	O
agonist	O
of	O
AMP-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
AMPK	B-GENE
)	O
.	O
Latanoprost	O
has	O
an	O
antagonistic	O
effect	O
on	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
alpha	I-GENE
(	O
RXR	B-GENE
alpha	I-GENE
)	O
and	O
can	O
antagonize	O
the	O
transcriptional	O
activity	O
of	O
PPAR	B-GENE
gamma	I-GENE
:	O
RXR	B-GENE
alpha	I-GENE
heterodimers,	O
so	O
that	O
latanoprost	O
has	O
the	O
activity	O
to	O
inhibit	O
synthesis	O
and	O
storage	O
of	O
triglycerides	O
in	O
fat	O
cells	O
.	O
At	O
the	O
same	O
time,	O
latanoprost	O
has	O
the	O
activity	O
to	O
activate	O
AMP-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
AMPK	B-GENE
)	O
and	O
facilitates	O
the	O
translocation	O
of	O
glucose	B-GENE
transporter	I-GENE
4	I-GENE
(	O
GLUT4	B-GENE
)	O
to	O
plasma	O
membranes	O
and	O
further	O
glucose	O
absorption	O
.	O
Besides,	O
latanoprost	O
acid	O
also	O
has	O
significant	O
activity	O
to	O
activate	O
AMPK	B-GENE
.	O


The	O
present	O
invention	O
provides	O
application	O
of	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
to	O
medicine	O
for	O
autoimmunity	O
disease	O
and	O
transplant	O
rejection	O
disease	O
.	O
Through	O
experiments,	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
is	O
found	O
to	O
be	O
capable	O
of	O
restraining	O
multiplication	O
of	O
human	O
dendritic	O
cells	O
in	O
vitro,	O
restraining	O
human	O
denderitic	O
cells	O
to	O
promote	O
breeder	O
reaction	O
of	O
allogeneic	O
T	O
cells,	O
and	O
enhancing	O
the	O
ability	O
of	O
human	O
denderitic	O
cells	O
to	O
secrete	O
interleukin	B-GENE
10	I-GENE
.	O
In	O
a	O
model	O
of	O
experimental	O
autoimmunity	O
disease	O
cerebrospinal	O
meningitis,	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
is	O
capable	O
of	O
reducing	O
an	O
average	O
mouse	O
clinical	O
score	O
and	O
restraining	O
spinal	O
cord	O
invasion	O
degree	O
of	O
the	O
mononuclear	O
cells	O
.	O
In	O
an	O
experiment	O
of	O
heart	O
transplantation,	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
is	O
capable	O
of	O
prolonging	O
the	O
survival	O
time	O
of	O
the	O
transplanted	O
heart	O
.	O
In	O
a	O
model	O
of	O
delayed	O
type	O
hypersensitivity,	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
is	O
capable	O
of	O
reducing	O
mouse	O
ear	O
swelling	O
degree	O
.	O
According	O
to	O
the	O
results	O
both	O
in	O
vivo	O
and	O
in	O
vitro,	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
possesses	O
a	O
certain	O
effect	O
on	O
autoimmunity	O
disease	O
and	O
transplant	O
rejection	O
disease	O
.	O
The	O
medicine	O
provided	O
by	O
the	O
invention	O
comprises	O
p-hydroxyl	B-GENE
acetophenone	I-GENE
glycosidase	I-GENE
as	O
an	O
active	O
component	O
and	O
a	O
medicinal	O
carrier,	O
and	O
the	O
medicine	O
includes	O
oral	O
dosage	O
form,	O
injection,	O
suppository,	O
and	O
topical	O
dosage	O
form,	O
etc	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
biguanide	O
based	O
medicament	O
in	O
medicaments	O
for	O
delaying	O
or	O
reversing	O
acquired	O
drug-resistance	O
of	O
NSELC	O
treated	O
by	O
EGFR-TKI,	O
wherein	O
the	O
biguanide	O
based	O
medicament	O
and	O
EGFR-TKI	O
are	O
taken	O
simultaneously	O
or	O
intervally	O
.	O
A	O
new	O
application	O
of	O
the	O
biguanide	O
based	O
medicament	O
is	O
discovered	O
.	O
The	O
biguanide	O
based	O
medicament	O
is	O
used	O
to	O
delay	O
or	O
reverse	O
generation	O
of	O
EGFR-TKI	O
acquired	O
drug-resistance,	O
and	O
performs	O
varying-degree	O
inhibition	O
effects	O
on	O
main	O
mechanisms	O
of	O
EGFR-TKI	O
acquired	O
drug-resistance	O
of	O
NSCLC	O
patients,	O
and	O
thus	O
the	O
sensibility	O
of	O
the	O
lung-cancer	O
patients	O
to	O
EGFR-TKI	O
is	O
increased,	O
the	O
disadvantage	O
that	O
EGFR-TKI	O
is	O
easy	O
to	O
resist	O
drugs	O
is	O
overcome,	O
and	O
the	O
curative	O
effect	O
of	O
EGFR-TKI	O
is	O
improved	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
a	O
5-HT2A	B-GENE
receptor	O
stimulant,	O
and	O
provides	O
an	O
application	O
of	O
the	O
5-HT2A	B-GENE
receptor	O
stimulant	O
in	O
the	O
preparation	O
of	O
products	O
.	O
The	O
products	O
can	O
alleviate	O
the	O
inhibition	O
of	O
gestational	O
sootiness	O
to	O
the	O
filial	O
generation	O
medulla	O
respiratory	O
center	O
.	O
The	O
invention	O
also	O
provides	O
an	O
application	O
of	O
the	O
5-HT2A	B-GENE
receptor	O
stimulant	O
in	O
the	O
preparation	O
of	O
other	O
products	O
.	O
The	O
other	O
products	O
are	O
medicines	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
sootiness	O
damages	O
;	O
and	O
the	O
sootiness	O
damages	O
comprise	O
(	O
I	O
)	O
the	O
damages	O
of	O
gestational	O
sootiness	O
to	O
the	O
filial	O
generation	O
medulla	O
respiratory	O
center	O
and	O
/	O
or	O
(	O
II	O
)	O
the	O
reduction	O
of	O
the	O
oxygen	O
consumption	O
of	O
the	O
filial	O
generation	O
in	O
the	O
low-oxygen	O
environment,	O
caused	O
by	O
gestational	O
sootiness	O
.	O
The	O
use	O
provides	O
a	O
new	O
idea	O
and	O
experimental	O
basis	O
for	O
the	O
clinic	O
treatment	O
or	O
prevention	O
of	O
central	O
respiratory	O
diseases	O
caused	O
by	O
gestational	O
sootiness	O
in	O
the	O
invention,	O
and	O
has	O
great	O
practical	O
values	O
.	O


The	O
invention	O
discloses	O
a	O
coumarone	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
.	O
The	O
coumarone	O
derivative	O
is	O
prepared	O
by	O
reacting	O
4-amino-1-benzylpiperidine	O
with	O
a	O
carboxylic	O
acid	O
derivative	O
prepared	O
by	O
oxidation	O
of	O
oleanolic	O
alcohol	O
with	O
chromium	O
trioxide	O
.	O
The	O
coumarone	O
derivative	O
can	O
be	O
used	O
for	O
preparation	O
of	O
an	O
inhibitor	O
for	O
aggregation	O
of	O
acetylcholinesterase	B-GENE
and	O
amyloid	B-GENE
protein	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
purinylpyridinylamino-2,4-difluorophenyl	O
sulfonamide	O
derivative,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
a	O
preparation	O
method	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
with	O
an	O
inhibitory	O
activity	O
against	O
Raf	O
kinase,	O
containing	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
purinylpyridinylamino-2,4-difluorophenyl	O
sulfonamide	O
derivative	O
of	O
the	O
present	O
invention	O
effectively	O
regulates	O
the	O
activity	O
of	O
B-raf	O
kinase,	O
and	O
thus	O
may	O
be	O
useful	O
for	O
preventing	O
or	O
treating	O
cancer	O
induced	O
by	O
the	O
over-activation	O
of	O
Raf	O
kinase,	O
especially	O
various	O
melanoma,	O
colorectal	O
cancer,	O
prostate	O
cancer,	O
thyroid	O
cancer,	O
ovarian	O
cancer	O
and	O
the	O
like	O
.	O


The	O
invention	O
discloses	O
a	O
diethylstilbestrol	O
compound	O
and	O
application	O
thereof	O
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
osteoporosis	O
and	O
/	O
or	O
hyperlipemia	O
.	O
The	O
structural	O
formula	O
of	O
the	O
diethylstilbestrol	O
compound	O
is	O
shown	O
in	O
the	O
specification	O
.	O
The	O
data	O
of	O
a	O
cellular	O
level	O
pharmacodynamic	O
test	O
show	O
that	O
cajanstilbene	O
H	O
(	O
R	O
is	O
H,	O
and	O
X	O
is	O
Cl	O
)	O
can	O
promote	O
multiplication	O
and	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
of	O
an	O
SD	O
rat	O
.	O
After	O
an	O
ob	O
/	O
ob	O
obese	O
mice	O
orally	O
takes	O
the	O
cajanstilbene	O
H	O
(	O
20	O
mg	O
/	O
kg	O
/	O
d	O
)	O
continuously	O
for	O
21	O
days,	O
the	O
results	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
no	O
obvious	O
effect	O
on	O
weight	O
is	O
generated	O
;	O
(	O
2	O
)	O
the	O
bone	O
density	O
of	O
the	O
mice	O
is	O
obviously	O
increased	O
;	O
serum	O
alkaline	B-GENE
phosphatase	I-GENE
(	O
ALP	B-GENE
)	O
and	O
tartrate	B-GENE
resistant	I-GENE
acid	I-GENE
phosphatase	I-GENE
(	O
TRACP	B-GENE
)	O
level	O
are	O
obviously	O
reduced	O
;	O
and	O
the	O
serum	O
calcium	O
concentration	O
is	O
improved	O
;	O
and	O
(	O
3	O
)	O
levels	O
of	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
and	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
in	O
the	O
serum	O
of	O
the	O
mice	O
are	O
obviously	O
reduced	O
.	O
The	O
results	O
show	O
that	O
the	O
cajanstilbene	O
H	O
has	O
positive	O
significance	O
in	O
treatment	O
of	O
the	O
osteoporosis	O
caused	O
by	O
obesity	O
and	O
high	O
blood	O
sugar,	O
and	O
has	O
a	O
clear	O
curative	O
effect	O
on	O
the	O
aspect	O
of	O
improvement	O
of	O
lipid	O
metabolism	O
of	O
the	O
obese	O
mice	O
.	O
The	O
cajanstilbene	O
H	O
has	O
a	O
clear	O
treatment	O
effect	O
on	O
the	O
osteoporosis	O
caused	O
by	O
obesity	O
and	O
high	O
blood	O
sugar	O
and	O
simultaneously	O
can	O
improve	O
lipid	O
metabolism	O
;	O
and	O
metabasis	O
of	O
hyperlipemia	O
to	O
diabetes	O
mellitus	O
to	O
chronic	O
complication	O
of	O
diabetes	O
mellitus	O
to	O
osteoporosis	O
can	O
be	O
avoided	O
to	O
a	O
certain	O
extent	O
.	O


The	O
invention	O
provides	O
a	O
composition	O
for	O
regulation	O
of	O
blood	O
sugar	O
level	O
and	O
adjunctive	O
treatment	O
of	O
diabetes	O
mellitus	O
.	O
The	O
composition	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
percent	O
:	O
10-70	O
%	O
of	O
resveratrol,	O
10-50	O
%	O
of	O
piperine,	O
10-70	O
%	O
of	O
gamma-aminobutyric	O
acid,	O
and	O
0	O
.	O
01-5	O
%	O
of	O
organic	O
selenium	O
.	O
According	O
to	O
the	O
composition,	O
in	O
the	O
active	O
ingredients,	O
the	O
resveratrol	O
has	O
the	O
effects	O
of	O
regulating	O
the	O
blood	O
sugar	O
level	O
and	O
preventing	O
oxidative	O
stress	O
of	O
a	O
body	O
caused	O
by	O
the	O
diabetes	O
mellitus	O
;	O
the	O
bioavailability	O
of	O
the	O
resveratrol	O
can	O
be	O
improved	O
by	O
the	O
piperine	O
;	O
pancreas	O
cell	O
apoptosis	O
is	O
prevented	O
and	O
beta-cell	O
palingenesis	O
is	O
facilitated	O
by	O
the	O
gamma-aminobutyric	O
acid	O
;	O
and	O
the	O
antioxidant	O
ability	O
of	O
the	O
body	O
and	O
glucose	O
utilization	O
are	O
indirectly	O
improved	O
by	O
the	O
organic	O
selenium	O
participating	O
into	O
in	O
vivo	O
synthesis	O
of	O
glutathion	B-GENE
peroxidase	I-GENE
and	I-GENE
deiodinase	I-GENE
.	O
By	O
adopting	O
the	O
composition,	O
the	O
effects	O
of	O
the	O
four	O
raw	O
materials	O
are	O
combined	O
according	O
to	O
a	O
certain	O
dosage	O
;	O
and	O
the	O
functional	O
food	O
is	O
prepared	O
according	O
to	O
a	O
certain	O
component	O
proportion,	O
so	O
that	O
the	O
four	O
raw	O
materials	O
play	O
respective	O
effects	O
in	O
the	O
process	O
of	O
preventing	O
the	O
diabetes	O
mellitus	O
.	O


The	O
invention	O
discloses	O
a	O
new	O
application	O
of	O
Sarcaboside	O
B	O
.	O
The	O
Sarcaboside	O
B	O
has	O
inhibitory	O
activity	O
on	O
acetylcholin	B-GENE
esterase	I-GENE
and	O
a	O
nerve	O
cell	O
protection	O
effect	O
.	O
As	O
a	O
multi-target	O
directed	O
compound,	O
the	O
Sarcaboside	O
B	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
alzheimer	O
disease	O
.	O
The	O
application	O
of	O
the	O
Sarcaboside	O
B	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
alzheimer	O
disease	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O
As	O
the	O
skeleton	O
type	O
of	O
the	O
Sarcaboside	O
B	O
belongs	O
to	O
a	O
brand-new	O
skeleton	O
type,	O
the	O
Sarcaboside	O
B	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
the	O
acetylcholin	O
esterase,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O
The	O
Sarcaboside	O
B	O
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
alzheimer	O
disease	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	O
B	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
disease,	O
wherein	O
the	O
Chukrasone	O
B	O
has	O
an	O
acetylcholin	B-GENE
esterase	I-GENE
inhibiting	O
activity	O
and	O
a	O
nerve	O
cell	O
protective	O
effect	O
.	O
The	O
Chukrasone	O
B,	O
serving	O
as	O
a	O
multiple	O
effect	O
target	O
compound,	O
can	O
be	O
used	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
alzheimer	O
disease	O
.	O
The	O
application	O
of	O
the	O
Chukrasone	O
B	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
disease	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O
As	O
the	O
framework	O
type	O
is	O
a	O
brand	O
new	O
framework	O
type	O
and	O
the	O
acetylcholin	B-GENE
esterase	I-GENE
inhibiting	O
activity	O
of	O
the	O
Chukrasone	O
B	O
is	O
unimaginably	O
strong,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O
The	O
Chukrasone	O
B	O
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
in	O
treatment	O
of	O
Alzheimer	O
disease	O
.	O


The	O
invention	O
discloses	O
a	O
novel	O
application	O
of	O
a	O
ginseng	O
oligosaccharide	O
composition	O
in	O
preparation	O
of	O
an	O
anti-oxidation	O
medicine	O
and	O
a	O
health-care	O
food	O
.	O
The	O
ginseng	O
oligosaccharide	O
composition	O
is	O
extracted	O
from	O
ginseng	O
.	O
According	O
to	O
an	O
in-vitro	O
experiment,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
a	O
good	O
effect	O
of	O
clearing	O
away	O
hydroxyl	O
free	O
radicals	O
and	O
DPPH	O
(	O
1,1-Diphenyl-2-picrylhydrazyl	O
radical	O
2,2-Diphenyl-1-	O
(	O
2,4,6-trinitrophenyl	O
)	O
hydrazyl	O
)	O
,	O
and	O
also	O
has	O
the	O
good	O
effect	O
of	O
chelating	O
Fe	O
<	O
2+	O
>	O
.	O
According	O
to	O
an	O
animal	O
experiment,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
the	O
good	O
effect	O
of	O
enhancing	O
the	O
enzyme	O
activities	O
of	O
SOD	B-GENE
(	O
Superoxide	B-GENE
Dismutase	I-GENE
)	O
,	O
CAT	B-GENE
(	O
Catalase	B-GENE
)	O
,	O
GSH-Px	B-GENE
(	O
Glutathione	B-GENE
Peroxidase	I-GENE
)	O
and	O
T-AOC	O
(	O
Total	O
Antioxidative	O
Capacity	O
)	O
in	O
the	O
serum	O
and	O
the	O
liver	O
of	O
an	O
oxidative	O
stress-injured	O
mice	O
induced	O
by	O
D-Gal	O
(	O
Galactosamine	O
)	O
,	O
and	O
can	O
be	O
used	O
for	O
obviously	O
decreasing	O
the	O
MDA	O
(	O
Methane	O
Dicarboxylic	O
Aldehyde	O
)	O
level	O
of	O
the	O
oxidative	O
stress-injured	O
mice	O
.	O


The	O
invention	O
provides	O
a	O
novel	O
use	O
of	O
Aphanamgrandiol	O
A	O
in	O
medical	O
science,	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
Aphanamgrandiol	O
A	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
acute	O
gout	O
.	O
Experimental	O
research	O
results	O
show	O
that	O
the	O
Aphanamgrandiol	O
A	O
has	O
the	O
protective	O
effect	O
on	O
an	O
acute	O
gout	O
model	O
of	O
urate-caused	O
injury	O
of	O
human	O
vascular	O
endothelial	O
cells	O
and	O
inhibits	O
expression	O
of	O
ICAM-1	B-GENE
(	O
Intercellular	B-GENE
Adhesion	I-GENE
Molecule	I-GENE
1	I-GENE
)	O
,	O
so	O
that	O
the	O
Aphanamgrandiol	O
A	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
treating	O
acute	O
gouty	O
inflammation	O
.	O
The	O
application	O
of	O
the	O
Aphanamgrandiol	O
A	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
acute	O
gout	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O
As	O
the	O
framework	O
type	O
of	O
the	O
Aphanamgrandiol	O
A	O
is	O
a	O
novel	O
framework	O
type,	O
and	O
the	O
activity	O
of	O
the	O
Aphanamgrandiol	O
A	O
to	O
prevent	O
and	O
treat	O
acute	O
gout	O
is	O
unexpectedly	O
strong,	O
the	O
probability	O
of	O
giving	O
any	O
indication	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O
The	O
Aphanamgrandiol	O
A	O
has	O
remarkable	O
substantive	O
characteristics	O
and	O
meanwhile	O
has	O
a	O
remarkable	O
progress	O
for	O
preventing	O
and	O
treating	O
acute	O
gout	O
.	O


The	O
invention	O
discloses	O
substituted-pyrrolidinyl-contained	O
thiomorpholine	O
compounds,	O
a	O
preparation	O
method	O
thereof	O
and	O
applications	O
thereof	O
.	O
In	O
concrete,	O
the	O
invention	O
relates	O
to	O
compounds	O
having	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
stereoisomers	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
acceptable	O
salts	O
of	O
the	O
compounds,	O
wherein	O
R	O
is	O
shown	O
in	O
the	O
specification	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
the	O
applications	O
of	O
the	O
compounds	O
in	O
preparing	O
medicines	O
used	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
disease	O
or	O
a	O
symptom	O
which	O
are	O
related	O
to	O
over-high	O
activity	O
of	O
DPP-IV	B-GENE
or	O
over-expression	O
of	O
the	O
DPP-IV,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
related	O
diseases	O
.	O
The	O
compounds	O
have	O
activity	O
for	O
effectively	O
inhibiting	O
the	O
DPP-IV	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
as	O
further	O
described	O
herein,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
enantiomers,	O
rotamers,	O
tautomers,	O
or	O
racemates	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
PIM	B-GENE
kinase	I-GENE
using	O
the	O
compounds	O
of	O
Formula	O
I,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
a	O
preparation	O
process	O
for	O
glycyrrhizic	O
acid-mediated	O
hydroxycamptothecine	O
albumin	B-GENE
liver	O
cancer	O
targeting	O
nanoparticle	O
lyophilized	O
powder	O
.	O
The	O
glycyrrhizic	O
acid-mediated	O
hydroxycamptothecine	O
albumin	B-GENE
liver	O
cancer	O
targeting	O
nanoparticle	O
lyophilized	O
powder	O
is	O
obtained	O
by	O
the	O
steps	O
of	O
reacting	O
glycyrrhizic	O
acid	O
and	O
albumin	B-GENE
under	O
a	O
certain	O
conditions	O
to	O
successfully	O
couple	O
glycyrrhizic	O
acid	O
and	O
albumin	B-GENE
;	O
removing	O
glycyrrhizic	O
acid	O
uncoupled	O
with	O
albumin	B-GENE
by	O
a	O
dialysis	O
method	O
;	O
then	O
lyophilizing	O
albumin	B-GENE
coupled	O
with	O
glycyrrhizic	O
acid	O
to	O
obtain	O
lyophilized	O
powder	O
of	O
albumin	B-GENE
coupled	O
with	O
glycyrrhizic	O
acid	O
;	O
dissolving	O
albumin	B-GENE
coupled	O
with	O
glycyrrhizic	O
acid	O
in	O
water	O
at	O
a	O
certain	O
concentration	O
and	O
hydroxycamptothecine	O
in	O
a	O
mixed	O
solution	O
of	O
chloroform	O
and	O
ethanol	O
;	O
dropwise	O
adding	O
the	O
hydroxycamptothecine	O
solution	O
to	O
the	O
albumin	B-GENE
solution	O
slowly	O
;	O
homogenizing	O
at	O
a	O
certain	O
rotation	O
speed	O
and	O
time	O
;	O
homogenizing	O
the	O
homogenized	O
mixed	O
suspension	O
for	O
a	O
certain	O
times	O
under	O
a	O
certain	O
pressure	O
to	O
obtain	O
an	O
oil-in-water	O
emulsion	O
;	O
removing	O
organic	O
solvents-ethanol	O
and	O
chloroform	O
from	O
the	O
mixed	O
suspension	O
by	O
a	O
rotary	O
evaporation	O
method	O
;	O
and	O
then	O
removing	O
water	O
from	O
the	O
mixed	O
suspension	O
in	O
a	O
lyophilization	O
manner	O
.	O


The	O
invention	O
provides	O
an	O
effect	O
of	O
activating	O
serine,	O
threonine	O
and	O
tyrosine	O
phosphorylation	O
of	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
by	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
,	O
and	O
the	O
effect	O
is	O
similar	O
to	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
,	O
that	O
is,	O
the	O
EGCG	O
can	O
serve	O
as	O
the	O
EGF	B-GENE
of	O
a	O
plant	O
origin	O
to	O
be	O
applied	O
to	O
promotion	O
of	O
epidermal	O
repair	O
and	O
regeneration	O
.	O
The	O
invention	O
provides	O
application	O
of	O
the	O
EGCG	O
to	O
preparation	O
of	O
drugs	O
and	O
cosmetics	O
for	O
promoting	O
epidermal	O
repair	O
and	O
regeneration	O
.	O
The	O
invention	O
further	O
provides	O
the	O
EGCG	O
serving	O
as	O
the	O
epidermal	B-GENE
growth	I-GENE
factor,	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
activator	O
and	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
signal	O
channel	O
promoter	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
amphiphilic	O
poly-fullerene	O
tree-based	O
cross-linked	O
poly-cation	O
gel	O
as	O
a	O
chelating	O
agent	O
for	O
binding	O
phosphate,	O
fatty	O
acid	O
and	O
bile	O
acid	O
.	O
According	O
to	O
the	O
application,	O
the	O
gel	O
has	O
effects	O
of	O
resisting	O
obesity	O
and	O
reducing	O
low-density	B-GENE
lipoprotein	I-GENE
(	O
LDL	B-GENE
)	O
in	O
the	O
fields	O
of	O
prevention	O
and	O
healthcare	O
.	O
The	O
composition	O
in	O
the	O
application	O
is	O
provided	O
with	O
components	O
comprising	O
different	O
chemical	O
formulae	O
.	O
In	O
the	O
chemical	O
formulae,	O
F	O
represents	O
a	O
fullerene	O
core	O
;	O
P1	O
and	O
P2	O
represent	O
poly-cation	O
halides	O
of	O
low	O
polymers	O
or	O
high	O
polymers	O
containing	O
polyamine	O
;	O
E	O
represents	O
an	O
affine	O
substituent	O
group	O
;	O
n	O
is	O
2	O
to	O
50	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
poly-cation	O
polymer	O
gel	O
substance	O
by	O
taking	O
nitryl	O
poly-fullerene	O
or	O
cyclically	O
sulfated	O
poly-fullerene	O
as	O
an	O
intermediate	O
reactant	O
.	O


Provided	O
are	O
:	O
methods	O
for	O
treating	O
aging	O
or	O
an	O
age-related	O
condition,	O
symptom	O
or	O
disease	O
;	O
methods	O
for	O
stimulating	O
hair	O
growth,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
methods	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	O
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
methods	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof,	O
including	O
cosmetic	O
treatment	O
(	O
e	O
.	O
g	O
.	O
,	O
wrinkles,	O
hyperpigmentation,	O
redness,	O
rosacea,	O
dryness,	O
cracking,	O
loss	O
of	O
firmness,	O
loss	O
of	O
elasticity,	O
thinning,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O
The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
a	O
CBP	B-GENE
/	O
catenin	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CBP	B-GENE
/	O
ss-catenin	O
)	O
antagonist	O
as	O
disclosed,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O
In	O
particular	O
aspects,	O
the	O
CBP	B-GENE
/	O
catenin	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CBP	B-GENE
/	O
ss-catenin	O
)	O
antagonist	O
comprises	O
an	O
alkyl	O
and	O
/	O
or	O
fatty	O
acid	O
ester	O
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O


The	O
presently	O
disclosed	O
subject	O
matter	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
protecting	O
cells	O
and	O
or	O
tissues	O
from	O
damage	O
due	O
to	O
ischemia	O
.	O
In	O
particular,	O
the	O
presently	O
disclosed	O
subject	O
matter	O
relates	O
to	O
the	O
protective	O
action	O
of	O
cyclin	B-GENE
dependent	I-GENE
kinase	I-GENE
4/6	I-GENE
(	O
CDK4	O
/	O
6	O
)	O
inhibitors	O
administered	O
to	O
subjects	O
that	O
have	O
been	O
exposed	O
to,	O
or	O
that	O
are	O
at	O
risk	O
of,	O
ischemia	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
a	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
an	O
antiviral	O
drug	O
.	O
Experiments	O
prove	O
that	O
the	O
small-molecule	O
inhibitor	O
MLN4924	O
with	O
good	O
performance	O
in	O
human	O
anti-tumor	O
clinical	O
trials	O
is	O
strong	O
in	O
antiviral	O
activity	O
and	O
can	O
inhibit	O
virus	O
replication	O
by	O
more	O
than	O
80	O
%	O
due	O
to	O
the	O
virus	O
inhibition	O
accessory	O
protein	O
function	O
.	O
With	O
long	O
preliminary	O
experimental	O
clinical	O
experience	O
and	O
a	O
strong	O
drug	O
action	O
effect,	O
the	O
drug	O
can	O
be	O
produced	O
in	O
a	O
large	O
scale	O
and	O
has	O
great	O
potential	O
of	O
becoming	O
an	O
efficient	O
antiviral	O
drug	O
.	O
Through	O
an	O
ubiquitin	B-GENE
system	O
for	O
inhibiting	O
Neddylation	O
activation	O
dominated	O
by	O
virus	O
protein	O
by	O
small	O
molecule	O
drugs,	O
the	O
application	O
value	O
of	O
the	O
tumor	O
inhibitor	O
MLN4924	O
for	O
preparing	O
the	O
antiviral	O
drug	O
is	O
detected	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
anticoagulation,	O
anti-thrombosis	O
and	O
cardioprotective	O
effects	O
.	O
The	O
drug	O
can	O
reduce	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response,	O
and	O
has	O
the	O
anticoagulation,	O
anti-thrombosis	O
and	O
cardioprotective	O
effects	O
.	O
According	O
to	O
the	O
technical	O
scheme	O
provided	O
by	O
the	O
invention,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
for	O
generating	O
anticoagulation	O
effects	O
is	O
for	O
inhibiting	O
ADP-induced	O
platelet	O
aggregation,	O
inhibiting	O
thrombocyte	O
release,	O
and	O
reducing	O
serum	O
Fg	O
and	O
vWF	B-GENE
content	O
to	O
achieve	O
anticoagulation	O
function	O
;	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anti-thrombosis	O
drug	O
is	O
also	O
for	O
significantly	O
prolonging	O
CT,	O
PT,	O
TT	O
and	O
APTT	O
to	O
indirectly	O
achieve	O
an	O
anti-thrombosis	O
effect	O
;	O
moreover,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
the	O
cardioprotective	O
effects	O
on	O
ischemia	O
/	O
reperfusion	O
myocardial	O
cells	O
is	O
for	O
reducing	O
the	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response,	O
decreasing	O
the	O
infarct	O
area	O
of	O
injured	O
cardiac	O
muscle	O
and	O
achieving	O
a	O
protection	O
effect	O
on	O
the	O
ischemic	O
myocardial	O
cell	O
by	O
means	O
of	O
inhibiting	O
inflammatory	O
cells	O
invasion,	O
MMP-9	B-GENE
and	O
NF-kB	B-GENE
expression	O
and	O
NF-kB	B-GENE
nuclear	O
migration,	O
myocardial	O
apoptosis	O
and	O
the	O
like	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
cardiac	O
glycoside	O
compound	O
in	O
treatment	O
of	O
a	O
non-small	O
cell	O
lung	O
cancer,	O
and	O
particularly	O
relates	O
to	O
use	O
of	O
the	O
cardiac	O
glycoside	O
compound	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
the	O
non-small	O
cell	O
lung	O
cancer	O
.	O
The	O
non-small	O
cell	O
lung	O
cancer	O
is	O
the	O
non-small	O
cell	O
lung	O
cancer	O
which	O
has	O
tolerance	O
on	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
.	O


The	O
invention	O
discloses	O
tetravalent	O
platinum	O
complexes	O
containing	O
an	O
imidazole	O
group,	O
protein	O
complexes	O
formed	O
by	O
binding	O
the	O
tetravalent	O
platinum	O
complexes	O
and	O
azurin	B-GENE
mutant,	O
and	O
a	O
preparation	O
method	O
of	O
the	O
protein	O
complexes	O
.	O
Specifically,	O
the	O
invention	O
relates	O
to	O
azurin	B-GENE
and	O
tetravalent	O
platinum	O
complexes,	O
wherein	O
the	O
azurin	B-GENE
has	O
a	O
mutant	O
histidine	O
at	O
a	O
copper	O
binding	O
site,	O
and	O
each	O
platinum	O
complex	O
contains	O
an	O
imidazole	O
group,	O
and	O
a	O
protein	O
complex	O
is	O
constructed	O
by	O
coordination	O
of	O
the	O
azurin	B-GENE
and	O
the	O
platinum	O
complex	O
.	O
The	O
coordination	O
manner	O
of	O
each	O
tetravalent	O
platinum	O
complex	O
and	O
the	O
azurin	B-GENE
mutant	O
is	O
that	O
:	O
the	O
imidazole	O
group	O
of	O
the	O
tetravalent	O
platinum	O
complex	O
is	O
coordinated	O
with	O
the	O
copper	O
atom	O
by	O
replacing	O
the	O
imidazole	O
group	O
of	O
the	O
mutant	O
histidine	O
of	O
the	O
azurin	B-GENE
protein,	O
so	O
that	O
the	O
tetravalent	O
platinum	O
complex	O
is	O
coordinated	O
to	O
the	O
copper	O
atom	O
center	O
of	O
the	O
azurin	B-GENE
protein	O
mutant	O
.	O
Results	O
of	O
tumor	O
cell	O
growth	O
inhibition	O
experiments	O
show	O
that	O
:	O
the	O
azurin	B-GENE
protein	O
contains	O
the	O
tetravalent	O
platinum	O
complex	O
has	O
relatively	O
good	O
tumor-cell	O
growth	O
inhibition	O
effect,	O
and	O
has	O
antitumor	O
drug	O
application	O
prospect	O
.	O


The	O
present	O
invention	O
provides	O
pyrazolopyridine	O
compounds	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method,	O
uses	O
and	O
a	O
drug	O
composition	O
thereof	O
.	O
The	O
compounds	O
can	O
inhibit	O
PI3K	B-GENE
activity	O
so	O
as	O
to	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treatments	O
of	O
diseases	O
or	O
disorders	O
caused	O
by	O
PI3K-AKT-mTOR	O
signaling	O
pathway	O
dysfunction,	O
wherein	O
the	O
diseases	O
or	O
disorders	O
are	O
malignant	O
tumors,	O
immunologic	O
diseases,	O
cardiovascular	O
diseases,	O
inflammations,	O
metabolism	O
/	O
endocrine	O
dysfunction,	O
neurological	O
diseases	O
and	O
the	O
like	O
.	O
The	O
general	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicine,	O
and	O
particularly	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
protamine-deoxycholic	O
acid	O
conjugate	O
with	O
a	O
heparin	O
transfer	O
function	O
.	O
The	O
amidogen	O
of	O
protamine	O
and	O
the	O
carboxyl	O
of	O
deoxycholic	O
acid	O
form	O
an	O
amide	O
bond	O
through	O
teh	O
effect	O
of	O
a	O
cross-linking	O
agent	O
to	O
prepare	O
an	O
amphipathic	O
conjugate,	O
and	O
then	O
the	O
amphipathic	O
conjugate	O
and	O
heparin	O
form	O
a	O
self-assembled	O
aggregation	O
in	O
order	O
to	O
conveniently	O
release	O
the	O
heparin	O
in	O
cells	O
.	O
The	O
hydrophobic	O
modification	O
of	O
the	O
conjugate	O
can	O
enhance	O
the	O
self-aggregation	O
stability	O
of	O
nano-composites	O
;	O
the	O
cationic	O
performance	O
of	O
the	O
conjugate	O
entraps	O
the	O
heparin,	O
so	O
that	O
the	O
distribution	O
capability	O
of	O
the	O
heparin	O
in	O
the	O
cells	O
is	O
increased,	O
and	O
the	O
heparin	O
is	O
prevented	O
from,	O
degradation	O
caused	O
by	O
the	O
effect	O
of	O
heparinase	B-GENE
and	O
further	O
the	O
transfer	O
of	O
the	O
heparin	O
into	O
cancer	O
cells	O
and	O
the	O
release	O
and	O
biological	O
effect	O
of	O
the	O
heparin	O
in	O
the	O
cells	O
are	O
realized	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
fumarate	O
of	O
a	O
harmol	O
derivative,	O
and	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
thereof,	O
and	O
applications	O
of	O
the	O
fumarate	O
and	O
the	O
solvate	O
thereof	O
in	O
preparation	O
of	O
acetylcholine	B-GENE
esterase	I-GENE
inhibitor	O
drugs	O
.	O


The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
.	O
The	O
extraction	O
method	O
of	O
apigenin	O
comprises	O
the	O
steps	O
of	O
1	O
)	O
enzymatically	O
hydrolyzing	O
celery	O
which	O
is	O
taken	O
as	O
a	O
substrate	O
for	O
10	O
hours	O
at	O
30-35	O
DEG	O
C	O
through	O
a	O
mixing	O
solution	O
of	O
apigenin	O
which	O
is	O
33-37	O
%	O
and	O
glucosidase	B-GENE
which	O
is	O
43-47	O
%	O
in	O
mass	O
percentage	O
concentration	O
;	O
and	O
2	O
)	O
ultrasonically	O
extracting	O
enzymatic	O
hydrolysate	O
obtained	O
from	O
the	O
step	O
1	O
)	O
through	O
an	O
ethanol	O
solution	O
of	O
70	O
%	O
,	O
condensing	O
an	O
extracting	O
solution,	O
extracting	O
respectively	O
through	O
petroleum	O
ether	O
and	O
ethyl	O
acetate,	O
evaporating	O
the	O
extracting	O
solution,	O
dissolving	O
through	O
ethanol	O
of	O
70	O
%	O
,	O
and	O
separating	O
and	O
extracting	O
through	O
a	O
high	O
performance	O
liquid	O
chromatograph	O
.	O
The	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
consists	O
of	O
apigenin	O
and	O
glucobay	O
at	O
mass	O
ratio	O
of	O
1	O
:	O
(	O
2-5	O
)	O
.	O
The	O
extraction	O
method,	O
which	O
extracts	O
apigenin	O
through	O
a	O
multi-enzymatic	O
process,	O
greatly	O
improves	O
extraction	O
yield	O
.	O
The	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
not	O
only	O
can	O
effectively	O
control	O
blood	O
sugar	O
but	O
also	O
can	O
avoid	O
circumstances	O
of	O
low	O
blood	O
sugar	O
and	O
rapid	O
weight	O
loss	O
of	O
a	O
patient	O
due	O
to	O
simple	O
use	O
of	O
a	O
diabetes	O
medicine	O
.	O


The	O
invention	O
relates	O
to	O
JNK	B-GENE
inhibitors	O
and	O
corresponding	O
methods,	O
formulations,	O
and	O
compositions	O
for	O
inhibiting	O
JNK	B-GENE
and	O
treating	O
JNK-mediated	O
disorders	O
.	O
The	O
application	O
discloses	O
the	O
JNK	B-GENE
inhibitors,	O
as	O
described	O
below	O
in	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
the	O
JNK	B-GENE
and	O
treat	O
diseases	O
associated	O
with	O
the	O
JNK	B-GENE
activity	O
.	O
Disclosed	O
are	O
the	O
methods	O
and	O
the	O
formulations	O
for	O
inhibiting	O
the	O
JNK	B-GENE
and	O
treating	O
the	O
JNK-mediated	O
disorders,	O
and	O
the	O
like,	O
with	O
the	O
compounds,	O
and	O
processes	O
for	O
making	O
said	O
compounds,	O
and	O
corresponding	O
compositions,	O
disclosed	O
herein	O
.	O


Provided	O
are	O
a	O
novel	O
derivative	O
of	O
5-carbamoyl	O
adamantan-2-yl	O
amide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
a	O
pharmaceutical	O
use	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
11hydroxystreroid	B-GENE
dehydrogenase	I-GENE
type1	I-GENE
(	O
11b-HSD1	B-GENE
)	O
or	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
various	O
diseases	O
mediated	O
by	O
11hydroxystreroid	B-GENE
dehydrogenase	I-GENE
type1	I-GENE
.	O


The	O
invention	O
discloses	O
a	O
small	O
molecule	O
compound	O
for	O
promoting	O
bone	O
formation	O
.	O
The	O
compound	O
shown	O
as	O
a	O
formula	O
I	O
can	O
be	O
used	O
in	O
preparation	O
of	O
medicines	O
for	O
promoting	O
bone	O
formation	O
and	O
preparation	O
of	O
a	O
BMP	B-GENE
sensitizing	O
agent	O
.	O
The	O
invention	O
also	O
provides	O
one	O
of	O
the	O
applications	O
of	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
:	O
(	O
1	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
osteogenic	O
potential	O
of	O
cells,	O
wherein	O
the	O
cells	O
are	O
specifically	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
;	O
(	O
2	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
alkaline	O
phosphatase,	O
osteocalcin	B-GENE
and	O
/	O
or	O
type	O
I	O
collagen	O
mRNA	O
levels	O
in	O
cells,	O
wherein	O
the	O
cells	O
are	O
specifically	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
;	O
(	O
3	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
activity	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
in	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
or	O
osteoblasts	O
;	O
(	O
4	O
)	O
preparation	O
of	O
products	O
for	O
inhibiting	O
degradation	O
of	O
an	O
Smad1	B-GENE
/	I-GENE
5	I-GENE
protein	O
under	O
the	O
condition	O
of	O
BMP	B-GENE
pathway	O
activation	O
;	O
and	O
(	O
5	O
)	O
preparation	O
of	O
products	O
for	O
reducing	O
ubiquitination	O
level	O
of	O
the	O
Smad1	B-GENE
/	I-GENE
5	I-GENE
protein	O
under	O
the	O
condition	O
of	O
BMP	B-GENE
pathway	O
activation	O
.	O


Inhibitors	O
of	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase,	O
ways	O
to	O
make	O
them	O
and	O
methods	O
of	O
treating	O
patients	O
using	O
them	O
are	O
disclosed	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
polydatin	O
to	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
chronic	O
alcoholism	O
cerebral	O
injury	O
.	O
The	O
key	O
point	O
of	O
the	O
technical	O
scheme	O
of	O
the	O
invention	O
is	O
that	O
the	O
medicament	O
for	O
treating	O
or	O
preventing	O
hypomnesia	O
in	O
chronic	O
alcoholism	O
cerebral	O
injury	O
is	O
prepared	O
from	O
polydatin	O
or	O
an	O
addition	O
salt	O
formed	O
by	O
the	O
polydatin	O
and	O
pharmaceutically-acceptable	O
acid	O
or	O
alkali	O
or	O
a	O
medicinal	O
composition	O
containing	O
any	O
one	O
of	O
the	O
polydatin	O
or	O
the	O
addition	O
salt	O
and	O
medicinal	O
auxiliary	O
materials	O
.	O
The	O
polydatin	O
has	O
the	O
effect	O
of	O
protecting	O
nerves,	O
and	O
can	O
remarkably	O
improve	O
the	O
nerve	O
injury	O
of	O
a	O
chronic	O
alcoholism	O
model	O
rat	O
and	O
reduce	O
the	O
expression	O
of	O
the	O
hippocampus	O
Cdk5	B-GENE
of	O
the	O
chronic	O
alcoholism	O
model	O
rat	O
.	O


The	O
invention	O
discloses	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment,	O
and	O
is	O
applicable	O
to	O
diagnosis	O
and	O
treatment	O
in	O
dental	O
clinic	O
.	O
A	O
formula	O
of	O
the	O
mouth	O
wash	O
consists	O
of	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
3-6	O
%	O
of	O
carboxymethyl	O
chitosan,	O
2-6	O
%	O
of	O
marine	O
organism	O
lysozyme	B-GENE
and	O
reverse	O
osmosis	O
pure	O
water	O
to	O
100	O
%	O
.	O
The	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
containing	O
a	O
marine	O
organism	O
antibacterial	O
component	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
(	O
1	O
)	O
being	O
remarkable	O
in	O
antibacterial	O
effect	O
;	O
(	O
2	O
)	O
being	O
free	O
from	O
irritation	O
to	O
mucous	O
membrane	O
of	O
mouth	O
;	O
and	O
(	O
3	O
)	O
being	O
environmentally	O
friendly	O
and	O
non-toxic	O
due	O
to	O
the	O
marine	O
organism	O
component	O
.	O


The	O
invention	O
relates	O
to	O
1,3,5-tri-substituted-1H-imidazo	O
[	O
4,5-h	O
]	O
1,6-diazanaphthalene-2	O
(	O
3H	O
)	O
-one	O
compounds	O
shown	O
as	O
the	O
general	O
formula	O
I,	O
isomers	O
thereof	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
a	O
preparation	O
method	O
and	O
applications	O
thereof,	O
and	O
compositions	O
comprising	O
the	O
compounds	O
.	O
The	O
invention	O
also	O
relates	O
to	O
applications	O
of	O
the	O
compounds,	O
the	O
isomers	O
thereof,	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
the	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
protein	O
multi-target	O
kinase	B-GENE
inhibitors,	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
protein	B-GENE
kinase	B-GENE
related	O
disease,	O
especially	O
c-Met	B-GENE
related	O
disease,	O
such	O
as	O
neoplastic	O
disease	O
.	O


The	O
invention	O
discloses	O
a	O
dammarane	O
triterpene	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
;	O
a	O
pharmaceutical	O
salt	O
thereof	O
;	O
a	O
preparation	O
method	O
of	O
the	O
dammarane	O
triterpene	O
derivative	O
;	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
dammarane	O
triterpene	O
derivative	O
as	O
an	O
active	O
ingredient	O
;	O
applications	O
of	O
the	O
dammarane	O
triterpene	O
derivative,	O
the	O
pharmaceutical	O
salt,	O
and	O
the	O
pharmaceutical	O
composition	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
or	O
preventing	O
obesity,	O
diabetes,	O
hypertension,	O
cardiovascular	O
and	O
cerebrovascular	O
diseases,	O
and	O
related	O
metabolic	O
diseases	O
;	O
and	O
applications	O
of	O
the	O
dammarane	O
triterpene	O
derivative,	O
the	O
pharmaceutical	O
salt,	O
and	O
the	O
pharmaceutical	O
composition	O
in	O
preparation	O
of	O
11<beta>-HSD1	B-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
wherein	O
R1,	O
R2,	O
R3,	O
A,	O
Q,	O
W	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
These	O
compounds	O
selectively	O
modulate,	O
regulate,	O
and	O
/	O
or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and	O
/	O
or	O
mutant	O
proteine	O
kinases	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative,	O
metabolic,	O
allergic,	O
and	O
degenerative	O
disorders	O
.	O
More	O
particularly,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
native	O
and	O
/	O
or	O
mutant	O
c-kit	B-GENE
inhibitors	O
.	O


The	O
invention	O
discloses	O
use	O
of	O
a	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
(TGF)-beta1	I-GENE
inhibitor	O
in	O
lung	O
cancer	O
treatment	O
.	O
The	O
TGF-beta1	B-GENE
inhibitor	O
inhibits	O
a	O
TGF-beta1	B-GENE
channel	O
to	O
increase	O
the	O
radiosensitivity	O
of	O
lung	O
cancer	O
cells	O
.	O
Through	O
the	O
manner,	O
according	O
to	O
the	O
use	O
of	O
the	O
TGF-beta1	B-GENE
inhibitor	O
in	O
lung	O
cancer	O
treatment,	O
the	O
sensitivity	O
enhancement	O
effect	O
of	O
the	O
TGF-beta1	B-GENE
inhibitor	O
on	O
the	O
lung	O
cancer	O
cells	O
is	O
caused	O
by	O
inhibition	O
on	O
non-homologous	O
end	O
joining	O
repair	O
of	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
double-strand	O
break,	O
change	O
of	O
cycle	O
distribution	O
of	O
the	O
lung	O
cancer	O
cells	O
after	O
irradiation,	O
and	O
obvious	O
reduction	O
of	O
tumor	O
growth	O
by	O
the	O
TGF-beta1	B-GENE
inhibitor	O
combined	O
with	O
X-ray	O
treatment	O
of	O
5Gy	O
.	O
The	O
DNA	O
repair	O
capacity	O
can	O
be	O
reduced	O
by	O
inhibition	O
on	O
the	O
TGF-beta1	B-GENE
channel	O
of	O
tumor	O
cells	O
before	O
irradiation,	O
the	O
cell	O
cycle	O
distribution	O
is	O
changed,	O
the	O
cell	O
cloning	O
ability	O
is	O
reduced,	O
the	O
tumor	O
growth	O
is	O
delayed,	O
and	O
effective	O
auxiliary	O
means	O
are	O
provided	O
by	O
inhibiting	O
the	O
TGF-beta1	B-GENE
channel	O
as	O
radiotherapy	O
of	O
a	O
patient	O
with	O
a	O
lung	O
cancer	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
xanthohumol	O
in	O
preparation	O
of	O
a	O
drug	O
or	O
a	O
health-care	O
product	O
for	O
inhibiting	O
alpha-glucosaccharase	B-GENE
activity	O
.	O
An	O
experiment	O
proves	O
that	O
the	O
xanthohumol	O
has	O
strong	O
inhibitory	O
activity	O
on	O
the	O
alpha-glucosaccharase	B-GENE
under	O
a	O
low-concentration	O
condition,	O
IC50	O
for	O
in	O
vitro	O
inhibition	O
of	O
the	O
alpha-glucosaccharase	B-GENE
is	O
8	O
.	O
8mu	O
M,	O
the	O
inhibition	O
type	O
is	O
noncompetitive	O
inhibition,	O
the	O
alpha-glucosaccharase	B-GENE
activity	O
can	O
be	O
effectively	O
inhibited,	O
the	O
xanthohumol	O
has	O
reversibility	O
on	O
the	O
activity	O
of	O
the	O
alpha-glucosaccharase,	O
and	O
a	O
potential	O
side	O
effect	O
of	O
an	O
irreversible	O
inhibitor	O
can	O
be	O
effectively	O
avoided	O
.	O
Furthermore,	O
the	O
xanthohumol	O
is	O
from	O
a	O
main	O
raw	O
material	O
lupulus	O
for	O
brewing	O
beer,	O
belongs	O
to	O
a	O
natural	O
product	O
of	O
a	O
food	O
source,	O
is	O
abundant	O
in	O
source,	O
and	O
mature	O
in	O
preparation	O
technology,	O
and	O
can	O
be	O
greatly	O
extracted	O
and	O
prepared	O
.	O
Meanwhile,	O
the	O
xanthohumol	O
is	O
safe	O
and	O
nontoxic,	O
and	O
free	O
of	O
toxic	O
and	O
side	O
effects,	O
and	O
appearance	O
of	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
drug	O
is	O
avoided	O
.	O
The	O
xanthohumol	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
drugs	O
for	O
treating	O
diabetes	O
mellitus,	O
acquired	O
immune	O
deficiency	O
syndrome,	O
malignant	O
tumors,	O
and	O
a	O
lysosomal	O
storage	O
disease,	O
and	O
has	O
a	O
good	O
market	O
application	O
prospect	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
2-	O
[	O
3,	O
5-dihydroxy-2-	O
(	O
1-acyl	O
)	O
phenyl	O
]	O
acetate,	O
and	O
relates	O
to	O
a	O
small	O
organic	O
molecule	O
compound	O
.	O
The	O
2-	O
[	O
3,	O
5-dihydroxy-2-	O
(	O
1-acyl	O
)	O
phenyl	O
]	O
acetate	O
can	O
be	O
applied	O
in	O
the	O
preparation	O
of	O
a	O
sepsis	O
treating	O
and	O
anti-inflammatory	O
drug	O
.	O
Medicinal	O
excipients	O
or	O
carriers	O
can	O
be	O
added	O
in	O
the	O
sepsis	O
treating	O
and	O
anti-inflammatory	O
drug	O
to	O
form	O
a	O
sepsis	O
treating	O
and	O
anti-inflammatory	O
drug	O
composition	O
.	O
The	O
sepsis	O
treating	O
and	O
anti-inflammatory	O
drug	O
can	O
adopt	O
tableting	O
agents,	O
capsules,	O
injections	O
or	O
other	O
appropriate	O
dosage	O
forms	O
;	O
the	O
sepsis	O
treating	O
and	O
anti-inflammatory	O
drug	O
composition	O
can	O
further	O
adopt	O
tableting	O
agents,	O
capsules,	O
injections	O
or	O
other	O
appropriate	O
dosage	O
forms	O
.	O
According	O
to	O
the	O
invention,	O
by	O
the	O
inhibition	O
of	O
NF-kB	B-GENE
activity,	O
proinflammatory	O
cytokines	B-GENE
relieved	O
by	O
immune	O
cells	O
can	O
be	O
inhibited,	O
so	O
that	O
symptoms	O
of	O
mice	O
with	O
sepsis	O
can	O
be	O
relieved	O
and	O
the	O
survival	O
rate	O
is	O
increased	O
;	O
the	O
2-	O
[	O
3,	O
5-dihydroxy-2-	O
(	O
1-acyl	O
)	O
phenyl	O
]	O
acetate	O
has	O
good	O
application	O
prospects	O
in	O
drugs	O
for	O
preventing	O
and	O
treating	O
sepsis	O
and	O
anti-inflammatory	O
drugs,	O
and	O
is	O
simple	O
in	O
structure	O
and	O
easy	O
to	O
prepare	O
.	O


An	O
injection	O
of	O
fluarizine	O
hydrochloride	O
as	O
a	O
Ca	B-GENE
channel	I-GENE
blocker	O
for	O
preventing	O
cell	O
injury	O
caused	O
by	O
ischemia,	O
relaxing	O
vascular	O
spasm,	O
suppressing	O
vestibule,	O
preventing	O
and	O
treating	O
epilepsy,	O
protecting	O
heart	O
and	O
kidney,	O
etc	O
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O


The	O
invention	O
provides	O
a	O
base	O
sequence	O
of	O
new	O
neurotrophin-humanized	O
neurotrophin-6-	O
(	O
NT-6	B-GENE
)	O
and	O
proves	O
application	O
of	O
said	O
hummnized	O
NT-6	B-GENE
gene	O
.	O
the	O
humanized	O
NT-6	B-GENE
gene	O
described	O
by	O
said	O
invention	O
can	O
be	O
obtained	O
from	O
RNA	O
of	O
brain	O
tissue	O
of	O
abortus	O
by	O
adopting	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
method	O
.	O
the	O
experiments	O
show	O
that	O
the	O
prokaryotic	O
expression	O
product	O
of	O
coded	O
mature	O
peptide	O
fragment	O
in	O
the	O
above-mentioned	O
humanized	O
NT-6	B-GENE
cDNA	O
has	O
trophic	O
action	O
on	O
neuron,	O
and	O
can	O
resist	O
the	O
neuronal	O
degeneration	O
due	O
to	O
axonal	O
injury,	O
so	O
that	O
the	O
medicine	O
containing	O
the	O
above-mentioned	O
humanized	O
NT-6	B-GENE
gene	O
can	O
be	O
prepared,	O
and	O
used	O
for	O
curing	O
the	O
diseaxes	O
of	O
traumatic	O
pathologic	O
changes	O
of	O
nervous	O
system	O
.	O


The	O
azasaccharide	O
compounds,	O
their	O
three	O
formulas,	O
their	O
preparing	O
process	O
and	O
their	O
medical	O
application	O
are	O
disclosed	O
.	O
Said	O
compounds	O
have	O
high	O
immunosuppression	O
activity	O
and	O
glycosidase	B-GENE
(	O
galactosidase	B-GENE
or	O
alpha-glucosidase	B-GENE
A	I-GENE
)	O
suppressing	O
activity	O
.	O


A	O
method	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cardiac	O
insulin	B-GENE
resistance	O
or	O
conditions	O
associated	O
with	O
cardiac	O
insulin	B-GENE
resistance,	O
in	O
humans	O
or	O
non-human	O
mammals,	O
which	O
method	O
comprises	O
the	O
administration	O
of	O
an	O
effective,	O
non-toxic	O
and	O
pharmaceutically	O
acceptable	O
amount	O
of	O
PPARy	B-GENE
agonist,	O
such	O
as	O
Compound	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
.	O
Conditions	O
associated	O
with	O
cardiac	O
insulin	B-GENE
resistance	O
are	O
:	O
microvascular	O
angina,	O
atherosclerosis	O
and	O
congestive	O
heart	O
failure	O
.	O
Compounds	O
include	O
rosiglitazone,	O
troglitazone,	O
englitazone	O
and	O
pioglitazone	O
.	O


Application	O
of	O
a	O
composition	O
in	O
preparation	O
of	O
nutrient	O
production	O
which	O
can	O
enhance	O
immunity	O
and	O
wide-adaptable	O
cancer	O
prevention	O
and	O
prolong	O
the	O
life	O
of	O
the	O
cancer	O
patients	O
is	O
characterized	O
in	O
that	O
the	O
composition	O
is	O
formed	O
by	O
the	O
completely	O
essential	O
nucleotide,	O
compound	O
vitamin,	O
mineral	O
substance	O
and	O
trace	O
element	O
compound	O
.	O
As	O
for	O
production	O
pill,	O
main	O
medicinal	O
preparation	O
of	O
the	O
oral	O
liquid	O
and	O
the	O
inoculation	O
fluid	O
as	O
well	O
as	O
additive	O
of	O
the	O
drugs,	O
food,	O
drink,	O
flavouring,	O
and	O
cosmetic	O
product,	O
the	O
dosage	O
is	O
required	O
as	O
GMP	O
namely	O
the	O
normal	O
production	O
.	O
Generally	O
75	O
%	O
-90	O
%	O
of	O
tumor	O
is	O
caused	O
by	O
the	O
nutrition	O
factor,	O
and	O
the	O
mortality	O
rate	O
accounts	O
for	O
about	O
45	O
%	O
of	O
the	O
complete	O
malignant	O
tumor	O
.	O
Obviously,	O
the	O
cancer	O
prevention	O
and	O
prolonging	O
the	O
life	O
of	O
the	O
cancer	O
patients	O
in	O
nutrition	O
mode	O
saves	O
the	O
expense	O
and	O
has	O
huge	O
effect,	O
as	O
well	O
as	O
wide	O
service	O
and	O
is	O
actual	O
and	O
feasible	O
.	O
The	O
nucleotide	O
can	O
repair	O
the	O
damaged	O
and	O
easily	O
cancerate	O
gene,	O
induct	O
the	O
interferon	B-GENE
to	O
enhance	O
bacterium	O
and	O
virus	O
resistance	O
and	O
improve	O
the	O
patient	O
rehabilitation,	O
resist	O
cancer	O
recurrence,	O
and	O
prolong	O
the	O
life	O
.	O
The	O
composition	O
contains	O
the	O
vitamin,	O
the	O
trace	O
element	O
and	O
the	O
mineral	O
substance	O
and	O
cooperates	O
with	O
the	O
nucleotide	O
to	O
greatly	O
improve	O
the	O
carcinomatous	O
change	O
immunity,	O
resistibility	O
and	O
rehabilitation	O
force	O
.	O
The	O
composition	O
has	O
legal	O
edible	O
raw	O
materials	O
and	O
reliable	O
effect,	O
the	O
implementation	O
thereof	O
has	O
no	O
legal	O
barrier,	O
and	O
the	O
beneficiary	O
is	O
wide	O
.	O


The	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
composition	O
includes	O
antisense	O
fup1	B-GENE
gene	O
and	O
/	O
or	O
small	O
molecular	O
interfering	O
RNA	O
and	O
pharmaceutically	O
acceptable	O
supplementary	O
material	O
.	O
The	O
antisense	O
fup1	B-GENE
gene	O
has	O
the	O
DNA	O
sequence	O
of	O
SEQ	O
ID	O
No	O
.	O
2	O
in	O
the	O
sequence	O
list,	O
while	O
the	O
small	O
molecular	O
interfering	O
RNA	O
includes	O
the	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No	O
.	O
3	O
in	O
the	O
sequence	O
list	O
.	O
The	O
present	O
invention	O
also	O
provides	O
the	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
screening	O
method	O
to	O
design	O
small	O
molecular	O
interfering	O
RNA	O
based	O
on	O
fup1	B-GENE
encoding	O
area	O
via	O
adopting	O
ambion	O
web	O
site	O
provided	O
RNAi	O
design	O
software	O
.	O
The	O
present	O
invention	O
further	O
provides	O
liver	O
cancer	O
resisting	O
small	O
molecule	O
include	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No	O
.	O
3	O
in	O
the	O
sequence	O
list	O
.	O
The	O
present	O
invention	O
adopts	O
gene	O
fup1	B-GENE
high	O
expressed	O
in	O
liver	O
cancer	O
cell	O
as	O
medicine	O
target	O
to	O
design	O
the	O
antagonistic	O
molecule	O
to	O
provide	O
powerful	O
measure	O
for	O
the	O
gene	O
treatment	O
of	O
liver	O
cancer	O
and	O
excellent	O
platform	O
for	O
further	O
screening	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
.	O


The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
pentacyclic	O
triterpene	O
compounds	O
in	O
preparing	O
glycogenic	B-GENE
phosphorylase	I-GENE
inhibitor,	O
and	O
includes	O
the	O
application	O
of	O
medicine	O
composition	O
of	O
crataegolic	O
acid,	O
Corosolic	O
acid,	O
oleanolic	O
acid,	O
ursolic	O
acid,	O
betulin,	O
betulic	O
acid,	O
lupeol	O
or	O
their	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
in	O
preparing	O
medicine	O
for	O
treating	O
diabetes	O
.	O


The	O
dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
non-insulin	O
dependent	O
diabetes	O
consists	O
of	O
purine	O
nucleotide,	O
compound	O
vitamin,	O
compound	O
trace	O
elements,	O
compound	O
mineral	O
matter,	O
essential	O
fatty	O
acid	O
oil	O
and	O
proper	O
amount	O
of	O
edible	O
cellulose	O
as	O
stuffing	O
and	O
hypoglycemic	O
.	O
The	O
dietotherapeutic	O
nutrient	O
is	O
used	O
as	O
main	O
material	O
or	O
additive	O
for	O
food	O
products	O
and	O
medicines	O
for	O
preventing	O
and	O
treating	O
diabetes	O
through	O
balancing	O
insulin	B-GENE
and	O
hyperglycemic	O
hormone,	O
repairing	O
the	O
functions	O
of	O
pancreatic	O
island	O
and	O
kidney,	O
preventing	O
and	O
treating	O
complication	O
and	O
restoring	O
normal	O
synthesis	O
and	O
metabolism	O
.	O
The	O
present	O
invention	O
has	O
c-GMP,	O
trace	O
elements,	O
etc	O
.	O
to	O
regulate	O
second	O
messenger	O
c-AMP	O
amount,	O
lift,	O
activity	O
and	O
release	O
time	O
of	O
hyperglycemic	O
hormone,	O
calcium	O
carbonate	O
to	O
buffer	O
and	O
neutralize	O
flavone	O
and	O
other	O
acid	O
matter	O
and	O
acid	O
poisoning,	O
potassium	O
citrate	O
to	O
replenish	O
potassium	O
and	O
to	O
maintain	O
acid-alkali	O
and	O
electrolyte	O
balance	O
.	O
The	O
dietotherapeutic	O
nutrient	O
has	O
no	O
toxic	O
side	O
effect	O
and	O
dependence	O
.	O


The	O
present	O
invention	O
relates	O
to	O
immunology,	O
cytobiology	O
and	O
tumor	O
treatment,	O
and	O
is	O
especially	O
the	O
application	O
of	O
recombinant	O
allophycocyanin	O
produced	O
by	O
means	O
of	O
gene	O
engineering	O
technology	O
in	O
preparing	O
medicine	O
for	O
treating	O
liver	O
cancer	O
.	O
The	O
present	O
invention	O
is	O
genetically	O
engineered	O
recombinant	O
protein	O
prepared	O
through	O
fusing	O
maltose-binding	O
protein	O
of	O
colibacillus	O
and	O
allophycocyanin	O
of	O
blue-green	O
algae	O
.	O
The	O
recombinant	O
allophycocyanin	O
has	O
obvious	O
tumor	O
growth	O
inhibiting	O
effect,	O
and	O
the	O
immunopotentiation	O
characteristic	O
of	O
raising	O
the	O
immunological	O
function	O
of	O
T	O
cell,	O
promoting	O
the	O
proliferation	O
of	O
T	O
cell	O
and	O
increasing	O
cell	O
factor	O
IL-2	B-GENE
and	O
gamma-IFN	B-GENE
.	O


The	O
recipe	O
of	O
skin	O
repairing	O
composition	O
includes	O
:	O
EDTA-2Na,	O
glycerin,	O
1,	O
3-butanediol,	O
metallothionein	O
zinc,	O
heparin	O
sodium,	O
recombinant	O
human	B-GENE
epidermal	I-GENE
growth	I-GENE
factor,	O
liposoluble	O
preservative,	O
recombinant	O
human	O
stem	O
cell	O
factor,	O
and	O
buffering	O
solution	O
.	O
The	O
skin	O
repairing	O
composition	O
in	O
the	O
recipe	O
can	O
speed	O
proliferation	O
of	O
stem	O
cell	O
to	O
split	O
and	O
convert	O
into	O
great	O
amount	O
of	O
transient	O
proliferating	O
cells	O
.	O
The	O
addition	O
of	O
the	O
epidermal	O
growth	I-GENE
factor	I-GENE
can	O
induce	O
the	O
fast	O
proliferation	O
of	O
the	O
transient	O
proliferating	O
cells	O
and	O
improve	O
intercellular	O
substance	O
circumstance	O
to	O
regulate	O
the	O
growth	O
of	O
skin	O
cell	O
.	O
The	O
metallothionein	O
can	O
eliminate	O
free	O
radical	O
and	O
other	O
cell	O
metabolism	O
products	O
during	O
cell	O
growth	O
specifically,	O
so	O
as	O
to	O
create	O
clean	O
circumstance	O
for	O
sustained	O
effective	O
action	O
of	O
stem	O
cell	O
factor	O
and	O
epidermal	O
growth	I-GENE
factor	I-GENE
on	O
the	O
cells	O
.	O


A	O
blastocyst	O
nidation	O
associated	O
factor	O
EMO-2	B-GENE
able	O
to	O
promote	O
the	O
nidation	O
of	O
blastocyst	O
is	O
disclosed	O
.	O
Its	O
antisense	O
nucleic	O
acid	O
and	O
its	O
polypeptide	O
antibody	O
can	O
suppress	O
the	O
nidation	O
of	O
blastocyst	O
.	O
A	O
process	O
for	O
screening	O
the	O
compounds	O
to	O
suppress	O
or	O
promote	O
the	O
nidation	O
of	O
blastocyst	O
by	O
use	O
of	O
said	O
EMO-2	B-GENE
factor	O
is	O
also	O
disclosed	O
.	O


A	O
Xenopus	O
laevis	O
(	O
the	O
African	O
clawed	O
frog	O
)	O
embryo	O
model	O
is	O
provided	O
to	O
study	O
the	O
effects	O
of	O
alcohol	O
on	O
fetal	O
development	O
.	O
Exposure	O
of	O
Xenopus	O
embryos	O
in	O
specific	O
developmental	O
stages	O
to	O
alcohol	O
results	O
in	O
tadpoles	O
with	O
microencephaly	O
and	O
growth	O
retardation,	O
in	O
a	O
dose-	O
and	O
time-dependent	O
manner,	O
similar	O
to	O
those	O
observed	O
in	O
human	O
fetal	O
alcohol	O
syndrome	O
(	O
FAS	O
)	O
.	O
The	O
invention	O
further	O
provides	O
methodsfor	O
screening	O
an	O
agent	O
to	O
determine	O
its	O
usefulness	O
for	O
preventing	O
or	O
treating	O
FAS	O
.	O
Moreover,	O
the	O
invention	O
provides	O
methods	O
for	O
preventing	O
or	O
treating	O
FAS	O
in	O
an	O
animal	O
by	O
administering	O
an	O
agent,	O
suchan	O
agent	O
includes	O
vitamin	O
C	O
and	O
a	O
catalase,	O
which	O
causes	O
or	O
enhances	O
an	O
expression	O
of	O
Pax6	B-GENE
that	O
is	O
a	O
neural	O
and	O
eye	O
marker	O
.	O
In	O
addition,	O
the	O
invention	O
provides	O
methods	O
for	O
preventing	O
or	O
treating	O
FAS	O
by	O
administering	O
an	O
agent,	O
such	O
as	O
vitamin	O
C,	O
which	O
causes	O
suppression	O
of	O
NF-kappaB	B-GENE
activation	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
certain	O
neurologic	O
and	O
psychiatric	O
disorders	O
in	O
mammals,	O
including	O
humans,	O
comprising	O
administration	O
of	O
a	O
selective	O
PDE10	B-GENE
inhbitor	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
treatment	O
of	O
mood,	O
movement,	O
and	O
anxiety	O
disorders	O
;	O
psychosis	O
;	O
drug,	O
for	O
example	O
alcohol,	O
addiction	O
;	O
and	O
disorders	O
having	O
as	O
a	O
symptom	O
deficient	O
cognition	O
.	O
The	O
invention	O
furthermore	O
provides	O
the	O
use	O
of	O
papaverine	O
as	O
a	O
selective	O
inhibitor	O
of	O
PDE10	B-GENE
.	O


The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
fluoroplex	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
effective	O
anticancer	O
component	O
is	O
5-FU	O
and	O
/	O
or	O
5-FU	O
synergist	O
selected	O
from	O
platinum	O
compound,	O
topoisomerase	B-GENE
inhibitor,	O
guanine	O
analogue	O
and	O
tetrazine	O
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA,	O
PLGA,	O
EVAc,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose,	O
Tween-40	O
and	O
/	O
or	O
Tween-80	O
.	O
Injecting	O
the	O
slow	O
released	O
injection	O
to	O
tumor	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O


The	O
slow	O
released	O
anticancer	O
preparation	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
effective	O
anticancer	O
component	O
is	O
bendamustine	O
and	O
/	O
or	O
bendamustine	O
synergist	O
of	O
topoisomerase	B-GENE
inhibitor,	O
guanine	O
analogue,	O
tetrazine	O
compound	O
and	O
/	O
or	O
platinum	O
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA,	O
PLGA,	O
EVAc,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose,	O
etc	O
of	O
viscosity	O
of	O
100-3000	O
cp	O
(	O
at	O
20-30	O
deg	O
.	O
c	O
)	O
.	O
The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implantation	O
preparation	O
.	O
Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O


The	O
slow	O
released	O
injection	O
containing	O
taxane	O
and	O
its	O
synergist	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
effective	O
anticancer	O
component	O
is	O
taxane	O
and	O
/	O
or	O
taxane	O
synergist	O
of	O
topoisomerase	B-GENE
inhibitor,	O
guanine	O
analogue,	O
tetrazine	O
compound	O
and	O
/	O
or	O
platinum	O
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA,	O
PLGA,	O
EVAc,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose,	O
Tween-40,	O
Tween-80	O
or	O
their	O
composition	O
.	O
The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
implantation	O
preparation	O
.	O
Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
treating	O
effect	O
.	O


The	O
slow	O
released	O
injection	O
containing	O
taxane	O
and	O
its	O
synergist	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O
The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O
The	O
effective	O
anticancer	O
component	O
is	O
taxane	O
and	O
/	O
or	O
taxane	O
synergist	O
of	O
phosphorinositide	B-GENE
3-kinase	I-GENE
inhibitor,	O
pyrimidine	O
analogue	O
and	O
/	O
or	O
DNA	O
repair	O
enzyme	O
inhibitor	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA,	O
PLGA,	O
EVAc,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose,	O
etc	O
.	O
The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
implantation	O
preparation	O
.	O
Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
slow-released	O
injection	O
containing	O
aminoglycoside	O
antibiotics	O
.	O
It	O
composed	O
of	O
slow-released	O
microsphere	O
and	O
solvent	O
.	O
Said	O
slow-released	O
microsphere	O
contains	O
slow-released	O
auxiliary	O
material	O
and	O
aminoglycoside	O
antibiotics,	O
and	O
the	O
solvent	O
is	O
special	O
solvent	O
containing	O
suspension	O
adjuvant	O
of	O
carboxymethyl	O
cellulose	O
sodium,	O
its	O
viscosity	O
is	O
100	O
cp-3000	O
cp	O
(	O
20	O
deg	O
.	O
C-30	O
deg	O
.	O
C	O
)	O
,	O
the	O
slow-released	O
auxiliary	O
material	O
is	O
selected	O
from	O
EVAc,	O
PLA,	O
PLGA,	O
sebacic	O
acid	O
copolymer,	O
albumin	B-GENE
glue	O
and	O
gelatin,	O
etc	O
.	O
The	O
slow-released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
slow-released	O
implant	O
preparation	O
and	O
ointment	O
preparation	O
.	O
Said	O
invention	O
also	O
provides	O
its	O
application	O
range	O
and	O
can	O
obtain	O
obvious	O
therapeutic	O
effect	O
for	O
curing	O
various	O
infective	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
medicinal	O
compound	O
for	O
improving	O
blood	O
lipid	O
and	O
body	O
insulin	B-GENE
resistance	O
state	O
.	O
Said	O
medicinal	O
compound	O
contains	O
phenoxyaromatic	O
acid	O
medicine	O
(	O
including	O
fenofibrate,	O
bezafibrate	O
and	O
gemfibrozil,	O
etc	O
.	O
)	O
or	O
its	O
medicinal	O
salt,	O
taurine	O
and	O
medicinal	O
carrier	O
or	O
excipient	O
.	O
Said	O
medicinal	O
compound	O
also	O
can	O
be	O
used	O
for	O
reducing	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
low	B-GENE
density	I-GENE
lipoprotein	I-GENE
(	O
LDL	B-GENE
)	O
and	O
triglyceride	O
(	O
TG	O
)	O
and	O
raising	O
high	B-GENE
density	I-GENE
lipoprotein	I-GENE
(	O
HDL	B-GENE
)	O
,	O
and	O
can	O
be	O
used	O
for	O
curing	O
abnormal	O
blood-lipid	O
and	O
metabolic	O
syndrome,	O
etc	O
.	O


The	O
invention	O
relates	O
to	O
a	O
group	O
of	O
novel	O
benzimidazolone	O
and	O
quinazolinone	O
derivatives	O
which	O
are	O
agonists	O
on	O
human	B-GENE
ORL1	I-GENE
(	O
nociceptin	O
)	O
receptors	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
these	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
pharmacologically	O
active	O
amount	O
of	O
at	O
least	O
one	O
of	O
these	O
imidazolone	O
and	O
quinazolinone	O
derivatives	O
as	O
an	O
active	O
ingredient,	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
disorders	O
in	O
which	O
ORL1	O
receptors	O
are	O
involved	O
.	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
skin	O
examination	O
method	O
for	O
predicting	O
spot	O
formation	O
on	O
the	O
skin	O
.	O
This	O
method	O
is	O
characterized	O
by	O
comprising	O
judging	O
the	O
skin	O
as	O
having	O
a	O
high	O
risk	O
of	O
spot	O
formation	O
in	O
the	O
case	O
where	O
the	O
expression	O
of	O
MCP-2	B-GENE
gene,	O
a	O
polynucleotide	O
hybridizable	O
with	O
mouse	B-GENE
AK012157	I-GENE
gene,	O
human	B-GENE
FLJ21763	I-GENE
gene	O
or	O
rat	B-GENE
S74257	I-GENE
gene	O
under	O
highly	O
stringent	O
conditions,	O
or	O
Mcp9,	O
Mcp10,	O
Isg15,	O
Usp18,	O
Oas	O
12,	O
Gbp2,	O
Gtpi,	O
Ifi47,	O
Igtp,	O
Tgtp,	O
Sprr2A,	O
Krt2-6b,	O
Cdk5rap2,	O
Mef2C,	O
Gsta4,	O
Osf2,	O
Tnc,	O
Igfbp6,	O
Ppicap,	O
MCP-6	B-GENE
or	O
Mm.74656	B-GENE
gene	O
is	O
accelerated	O
in	O
the	O
epidermis	O
compared	O
with	O
the	O
expression	O
thereof	O
in	O
normal	O
epidermis	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R,	O
R,	O
R,	O
R,	O
R,	O
R,	O
R,	O
R,	O
R,	O
R,R,	O
X	O
and	O
X	O
'	O
which	O
have	O
the	O
meaning	O
cited	O
in	O
claim	O
1,	O
are	O
tyrosine	B-GENE
kinase	I-GENE
inhibitors,	O
in	O
particular	O
TIE-2,	O
and	O
Raf-kinases,	O
and	O
can	O
also	O
be	O
used	O
in	O
the	O
treatment	O
of	O
tumours	O
.	O


A	O
composite	O
collagen	B-GENE
liquid	O
for	O
treating	O
skin	O
anaphylactin	O
contains	O
proportionally	O
the	O
collagen	B-GENE
extracted	O
from	O
the	O
tendon	O
of	O
ox	O
or	O
pig,	O
the	O
vitamin	O
which	O
is	O
the	O
VC	O
including	O
VC	O
magnesium	O
phosphate,	O
levo-VC	O
and	O
VC	O
glycoside,	O
and	O
purified	O
water	O
.	O


A	O
medicinal	O
composition	O
used	O
for	O
preparing	O
the	O
medicines	O
to	O
prevent	O
and	O
treat	O
hyperglycemia,	O
diabetes,	O
and	O
their	O
complications	O
contains	O
insulin	B-GENE
sensitizer	O
and	O
B-family	O
vitamins	O
.	O


This	O
invention	O
provides	O
a	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
and	O
its	O
preparation	O
method	O
.	O
Weight	O
ratio	O
of	O
the	O
effective	O
ingredients	O
in	O
the	O
said	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
is	O
:	O
spiny	O
grape	O
seed	O
oiling	O
capsule	O
powder	O
(	O
60-70wt	O
%	O
)	O
,	O
extracts	O
of	O
spiny	O
grape	O
seed	O
(	O
10-20wt	O
%	O
)	O
,	O
lecithin	O
(	O
10-15wt	O
%	O
)	O
,E	O
vitamin	O
E	O
(	O
1-5wt	O
%	O
)	O
.	O
The	O
preparing	O
method	O
is	O
as	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
.	O
Extracting	O
spiny	O
grape	O
seed	O
oil	O
and	O
spiny	O
grape	O
seed	O
extracts	O
from	O
the	O
spiny	O
grape	O
seeds	O
by	O
using	O
the	O
super	O
critical	O
line	O
CO2	O
extracting	O
technology	O
.	O
(	O
2	O
)	O
.	O
Implement	O
capsule	O
processing	O
to	O
the	O
extracted	O
spiny	O
grape	O
seed	O
oil	O
.	O
(	O
3	O
)	O
.	O
Weighing	O
the	O
extracted	O
ingredients	O
according	O
to	O
the	O
given	O
ratio,	O
and	O
evenly	O
mix	O
the	O
extracted	O
ingredients,	O
the	O
mixed	O
ingredients	O
is	O
the	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
.	O
The	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
of	O
this	O
invention	O
of	O
this	O
invention	O
can	O
effectively	O
decrease	O
the	O
contents	O
of	O
tracyglycerol	O
of	O
the	O
total	O
cholesterol	O
in	O
blood	O
serum,	O
increase	O
the	O
contents	O
of	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
and	O
upgrade	O
the	O
energy	O
and	O
total	O
anti-oxidation	O
ability	O
of	O
blood	O
serum	O
superoxide	B-GENE
dismutase	I-GENE
(	O
SOD	B-GENE
)	O
,	O
glutathione	O
cholesterol	O
enzyme	O
.	O
The	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
is	O
easy	O
for	O
storage	O
.	O


Disclosed	O
are	O
4-arylamino-quinazolines	O
and	O
analogs	O
thereof	O
effective	O
as	O
activators	O
of	O
caspases	B-GENE
and	O
inducers	O
of	O
apoptosis	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
clinical	O
conditions	O
in	O
which	O
uncontrolled	O
growth	O
and	O
spread	O
of	O
abnormal	O
cells	O
occurs	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
pharmaceutical	O
formulations	O
containing	O
the	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
mGluR5	B-GENE
receptor-mediated	O
disorders	O
.	O


Method	O
and	O
composition	O
(	O
A	O
)	O
for	O
topical	O
treatment	O
to	O
improve	O
the	O
symptoms	O
of	O
hypersensitive	O
teeth	O
or	O
toothache	O
comprises	O
applying	O
(	O
A	O
)	O
(	O
comprising	O
a	O
dosage	O
of	O
sodium	B-GENE
channel	I-GENE
blockers	O
(	O
local	O
anesthetic	O
of	O
ester	O
or	O
amide	O
type	O
)	O
(	O
B	O
)	O
,	O
which	O
influences	O
the	O
hypersensitive	O
irritated	O
terminal	O
nerves	O
for	O
tooth	O
normalizing	O
)	O
on	O
one	O
or	O
more	O
tooth	O
surface	O
in	O
a	O
mechanical	O
order	O
.	O
-	O
ACTIVITY	O
:	O
Analgesic	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Sodium	B-GENE
channel	I-GENE
blocker	O
.	O


Use	O
of	O
phosphatidyl	O
choline	O
and	O
/	O
or	O
other	O
lipids	O
(	O
A	O
)	O
for	O
preparing	O
medicaments	O
with	O
inflammation	O
inhibiting	O
activity	O
in	O
small	O
intestine	O
and	O
/	O
or	O
large	O
intestine	O
for	O
rectal	O
or	O
oral	O
administration	O
with	O
extended	O
release	O
of	O
active	O
substance	O
in	O
lower	O
ileum	O
and	O
/	O
or	O
colon	O
for	O
treating	O
inflammatory	O
small	O
and	O
/	O
or	O
large	O
intestine	O
diseases	O
.	O
-	O
ACTIVITY	O
:	O
Antiinflammatory	O
;	O
Cytostatic	O
;	O
Gastrointestinal-Gen	O
.	O
;	O
Antiulcer	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Actin	O
polymerization	O
inhibitor	O
.	O
The	O
ability	O
of	O
(	O
A	O
)	O
to	O
inhibit	O
actin	B-GENE
polymerization	O
was	O
tested	O
in	O
membrane-organelle	O
(	O
isolated	O
membrane	O
)	O
using	O
biological	O
assays	O
.	O
The	O
results	O
showed	O
that	O
(	O
A	O
)	O
significantly	O
inhibited	O
the	O
actin	B-GENE
polymerization	O
in	O
phagosomal	O
membrane	O
.	O


Use	O
of	O
isocitrate,	O
isocitronic	O
acid	O
and	O
/	O
or	O
their	O
derivatives,	O
in	O
the	O
preparation	O
of	O
medicament	O
to	O
reduce	O
sequences	O
of	O
aging-conditions	O
mutations	O
in	O
cells	O
of	O
an	O
organism	O
.	O
Use	O
of	O
isocitrate,	O
isocitric	O
acid	O
(	O
I	O
)	O
of	O
formula	O
(	O
C	O
(	O
=	O
O	O
)	O
(	O
R1	O
)	O
-C	O
(	O
H	O
)	O
(	O
O	O
)	O
(	O
R2	O
)	O
-C	O
(	O
=	O
O	O
)	O
(	O
C	O
)	O
(	O
R3	O
)	O
(	O
H	O
)	O
-C	O
(	O
H	O
)	O
(	O
H	O
)	O
(	O
C	O
)	O
(	O
R4	O
)	O
(	O
=	O
O	O
)	O
)	O
or	O
their	O
derivatives,	O
in	O
the	O
preparation	O
of	O
medicament	O
to	O
reduce	O
sequences	O
of	O
aging-conditions	O
mutations	O
in	O
cells	O
in	O
an	O
organism	O
.	O
R1,	O
R3,	O
R4-OH,	O
-O-	O
>	O
or	O
-O-R5	O
;	O
R2hydrocarbon,	O
organic	O
compound,	O
fatty	O
acid	O
(	O
preferably	O
food	O
fatty	O
acid	O
)	O
,	O
alcohol,	O
alcohol	O
ester,	O
polyol,	O
polyol	O
ester	O
(	O
preferably	O
glycerin	O
ester	O
)	O
,	O
H	O
or	O
-C	O
(	O
R6	O
)	O
=	O
O	O
;	O
and	O
R5,	O
R6R2	O
excluding	O
-C	O
(	O
R6	O
)	O
=	O
O	O
.	O
-	O
ACTIVITY	O
:	O
Nootropic	O
;	O
Dermatological	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Aconitase	B-GENE
Inhibitor	O
.	O


Use	O
of	O
octahydro-indoloquinoline	O
derivatives	O
(	O
I	O
)	O
is	O
claimed	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
composition	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
gastrointestinal	O
and	O
endocardial	O
disease	O
and	O
carcinoid	O
syndrome	O
.	O
Use	O
of	O
octahydro-indoloquinoline	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts,	O
enantiomers,	O
diasteromers,	O
hydrates,	O
solvates,	O
or	O
racemates	O
is	O
claimed	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
composition	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
gastrointestinal	O
and	O
endocardial	O
disease	O
and	O
carcinoid	O
syndrome	O
.	O
R1	O
>	O
,	O
R4	O
>	O
=	O
e	O
.	O
g	O
.	O
H,	O
CHO,	O
alkanoyl,	O
cyclopropanoyl,	O
COOH	O
and	O
esters,	O
optionally	O
substituted	O
alkyl,	O
C	O
(	O
O	O
)	O
NH2	O
or	O
NH2,	O
alkylsulfinyl,	O
alkylsulfonyl,	O
SO3H,	O
alkoxysulfonyl,	O
cyclopropyl,	O
cyclobutyl,	O
cyclopentyl,	O
cyclohexyl,	O
Ph,	O
benzyl,	O
alkenyl,	O
alkynyl,	O
CPh3,	O
CR11	O
>	O
R12	O
>	O
CR13	O
>	O
R14	O
>	O
R15	O
>	O
,	O
CR16	O
>	O
R17	O
>	O
CR81	O
>	O
R19	O
>	O
CR20	O
>	O
R21	O
>	O
R22	O
>	O
,	O
(	O
CH2	O
)	O
nCR23	O
>	O
R24	O
>	O
R25	O
>	O
,	O
C	O
(	O
O	O
)	O
CR26	O
>	O
R27	O
>	O
R28	O
>	O
,	O
C	O
(	O
O	O
)	O
CR29	O
>	O
R30	O
>	O
CR31	O
>	O
R32	O
>	O
R33	O
>	O
,	O
CR8	O
>	O
R9	O
>	O
R10	O
>	O
,	O
C	O
(	O
O	O
)	O
CR34	O
>	O
R35	O
>	O
CR36	O
>	O
R37	O
>	O
CR38	O
>	O
R39	O
>	O
R40	O
>	O
or	O
C	O
(	O
O	O
)	O
(	O
CH2	O
)	O
nCR41	O
>	O
R42	O
>	O
R43	O
>	O
;	O
R2	O
>	O
,	O
R3	O
>	O
=	O
1-10C	O
alkyl,	O
CO	O
(	O
1-10C	O
alkyl	O
)	O
,	O
NHC	O
(	O
O	O
)	O
1-10C	O
alkyl,	O
1-10C	O
(	O
di	O
)	O
alkylureido,	O
(	O
hetero	O
)	O
aryl,	O
(	O
hetero	O
)	O
cycloalkyl,	O
bi-	O
or	O
tricyclic	O
carbocycle,	O
bi-	O
or	O
tricyclic	O
heterocycle	O
(	O
all	O
optionally	O
substituted	O
)	O
,	O
R6	O
>	O
or	O
R7	O
>	O
;	O
R5	O
>	O
=	O
H,	O
F,	O
Cl,	O
Br,	O
I,	O
CN	O
or	O
NO2	O
;	O
R6	O
>	O
-R45	O
>	O
=	O
e	O
.	O
g	O
.	O
H,	O
ON,	O
OCH3,	O
OC2H5,	O
OC	O
(	O
CH3	O
)	O
3,	O
OC4N9,	O
benzyloxy,	O
SH,	O
SCH3,	O
NO2,	O
F,	O
Cl,	O
Br,	O
I,	O
N3,	O
CN,	O
OCN,	O
NCO,	O
SCN,	O
NCS,	O
CHO,	O
C	O
(	O
O	O
)	O
CH3,	O
C	O
(	O
O	O
)	O
N	O
[	O
CH	O
(	O
CH3	O
)	O
2	O
]	O
2,	O
NH2,	O
S	O
(	O
O	O
)	O
CH3,	O
SO2-cyclopropyl,	O
OCF3,	O
ureido,	O
NHC	O
(	O
O	O
)	O
N	O
(	O
cyclopropyl	O
)	O
2,	O
NHC	O
(	O
S	O
)	O
NHCH3,	O
NHC	O
(	O
NH	O
)	O
NH-cyclopropyl,	O
OC	O
(	O
O	O
)	O
NH2,	O
OC	O
(	O
O	O
)	O
NHCH3,	O
OC	O
(	O
O	O
)	O
OCH3,	O
CH2CH2I,	O
(	O
m	O
)	O
ethyl,	O
C3H7,	O
CH	O
(	O
CH3	O
)	O
2,	O
C	O
(	O
CH3	O
)	O
3,	O
C4H9,	O
CH2CH	O
(	O
CH3	O
)	O
2,	O
CH	O
(	O
CH3	O
)	O
C2H5,	O
C5H11,	O
C6H13,	O
C7H15,	O
C8H17,	O
cyclopropyl,	O
benzyl,	O
CH	O
=	O
CH2,	O
CH	O
=	O
CH2,	O
CH	O
=	O
C	O
(	O
CH3	O
)	O
2	O
or	O
CCH	O
;	O
a	O
=	O
single	O
or	O
double	O
bond	O
;	O
and	O
n	O
=	O
1-10	O
.	O
Full	O
definitions	O
are	O
in	O
the	O
Definitions	O
:	O
Full	O
Definitions	O
section	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Cytostatic	O
;	O
Antidiarrheic	O
;	O
Cardiant	O
;	O
Immunosuppressive	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Serotonin	B-GENE
receptor	I-GENE
inhibitor	O
.	O


Aza-heterocycle	O
compounds	O
(	O
I	O
)	O
and	O
their	O
salts,	O
derivatives	O
and	O
/	O
or	O
stereoisomers,	O
are	O
new	O
.	O
Aza-heterocycle	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts,	O
derivatives	O
and	O
/	O
or	O
stereoisomers,	O
are	O
new	O
.	O
R1	O
>	O
H,	O
A,	O
Ar,	O
Ar-A	O
or	O
A-Ar	O
;	O
A	O
:	O
cyclic	O
1-14C	O
alkyl	O
(	O
where	O
one	O
or	O
two	O
CH2-group	O
is	O
replaced	O
by	O
O-	O
or	O
S-	O
atom	O
and	O
/	O
or	O
NH,	O
NA,	O
CONH,	O
NHCO	O
or	O
-CH	O
=	O
CH-,	O
1-7	O
H-atom	O
is	O
replaced	O
by	O
hal,	O
and	O
/	O
or	O
one	O
or	O
two	O
CH3	O
group	O
is	O
replaced	O
by	O
NH2,	O
NAH,	O
NA2,	O
NHCOOA,	O
NHCONHA,	O
NHCONHAr	O
or	O
CN	O
)	O
;	O
Ar	O
:	O
one	O
or	O
two	O
aromatic	O
homo-	O
or	O
heterocyclic	O
group	O
with	O
1-4	O
N-,	O
O-	O
and	O
/	O
or	O
S	O
atoms	O
and	O
5-10	O
scaffolding	O
atoms,	O
optionally	O
substituted	O
by	O
carbonyloxide,	O
hal,	O
A,	O
OH,	O
OA,	O
NH2,	O
NHA,	O
NA2,	O
NO2,	O
CN,	O
OCN,	O
SCN,	O
COOH,	O
COOA,	O
CONH2,	O
CONHA,	O
CONA2,	O
NHCOA,	O
NHCONH2,	O
NHSO2A,	O
CHO,	O
COA,	O
SO2NH2	O
and	O
/	O
or	O
S	O
(	O
O	O
)	O
gA	O
;	O
Ar-A	O
:	O
aryl-alkyl	O
;	O
A-Ar	O
:	O
alkyl-aryl	O
;	O
hal	O
:	O
F,	O
Cl,	O
Br	O
or	O
I	O
;	O
X,	O
Z	O
:	O
CH	O
or	O
N	O
;	O
Y1	O
>	O
CH2	O
or	O
saturated	O
bond	O
;	O
R-2a,	O
R-2b,	O
R-2c,	O
R-2d	O
:	O
H,	O
hal,	O
OH,	O
CN,	O
NH2,	O
1-6C	O
alkyl,	O
where	O
CH2	O
is	O
replaced	O
by	O
O	O
or	O
S	O
and	O
/	O
or	O
NH,	O
NA,	O
CONH,	O
NHCO	O
or	O
-CH	O
=	O
CH	O
and	O
/	O
or	O
1-4	O
H	O
atoms	O
is	O
replaced	O
by	O
hal,	O
and	O
CH3	O
is	O
replaced	O
by	O
NH2,	O
NAH,	O
NA2,	O
CN	O
or	O
Ar	O
;	O
R3	O
>	O
H,	O
A	O
or	O
Ar-A	O
;	O
dotted	O
line	O
with	O
solid	O
line	O
:	O
single	O
or	O
a	O
double	O
bond	O
;	O
and	O
g	O
:	O
0-2	O
.	O
Where	O
:	O
one	O
group	O
of	O
X	O
is	O
N	O
then	O
the	O
other	O
two	O
groups	O
of	O
X	O
is	O
CH	O
;	O
and	O
up	O
to	O
two	O
group	O
(	O
preferably	O
0	O
or	O
1	O
)	O
of	O
Z	O
is	O
NH	O
.	O
Independent	O
claims	O
are	O
included	O
for	O
:	O
(	O
1	O
)	O
the	O
preparation	O
of	O
(	O
I	O
)	O
;	O
(	O
2	O
)	O
a	O
medicament	O
comprising	O
(	O
I	O
)	O
and	O
at	O
least	O
a	O
further	O
medically	O
active	O
agent	O
;	O
and	O
(	O
3	O
)	O
a	O
kit	O
comprising	O
(	O
I	O
)	O
and	O
the	O
medicament	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Cytostatic	O
;	O
Antiangiogenic	O
;	O
Antiarteriosclerotic	O
;	O
Antidiabetic	O
;	O
Ophthalmological	O
;	O
Antiinflammatory	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
;	O
Insulin	B-GENE
like	I-GENE
growth	I-GENE
factor-1	I-GENE
receptor	O
inhibitor	O
.	O
The	O
ability	O
of	O
(	O
I	O
)	O
to	O
inhibit	O
insulin	B-GENE
like	I-GENE
growth	I-GENE
factor-1	I-GENE
receptor	O
was	O
tested	O
using	O
biological	O
assays	O
.	O
The	O
results	O
showed	O
that	O
N-pyridin-3-yl-	O
[	O
2-	O
(	O
3,4,5-trimethoxy-phenyl	O
)	O
-1H-pyrrolo	O
[	O
2,3-b	O
]	O
pyridin-	O
4-yl	O
]	O
-amine	O
(	O
Ia	O
)	O
exhibited	O
an	O
IC50	O
value	O
of	O
0	O
.	O
76	O
mu	O
M	O
.	O


Transdermal	O
system	O
comprises	O
:	O
at	O
least	O
an	O
immunomodulator,	O
as	O
active	O
agent,	O
comprising	O
quinoline,	O
isoxazoles,	O
fumaric	O
acid	O
derivatives	O
or	O
sphingosine-1-phosphatase	B-GENE
receptor	I-GENE
modulators	O
or	O
their	O
salts	O
and	O
metabolites	O
;	O
an	O
active	O
agent	O
impermeable	O
protective	O
layer	O
;	O
an	O
active	O
agent	O
reservoir	O
;	O
and	O
a	O
carrier	O
for	O
the	O
active	O
agent	O
reservoir	O
.	O
-	O
ACTIVITY	O
:	O
Neuroprotective	O
;	O
Antiinflammatory	O
;	O
Gastrointestinal-Gen	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O


Lisuride	O
(	O
I	O
)	O
,	O
terguride	O
(	O
II	O
)	O
or	O
a	O
1,1-diethyl-3-	O
(	O
R	O
)	O
-4,6,6a,7,8,9,10,1	O
0a-octahydro-indolo	O
[	O
4,3-fg	O
]	O
quinolin-9-yl-urea	O
derivative	O
(	O
III	O
)	O
is	O
new,	O
where	O
(	O
I	O
)	O
-	O
(	O
III	O
)	O
is	O
useful	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
of	O
fibrotic	O
changes	O
of	O
organ	O
and	O
other	O
vascular	O
structure	O
in	O
human	O
or	O
animal	O
for	O
arresting	O
and	O
/	O
or	O
for	O
remodeling	O
of	O
fibrotic	O
changes	O
of	O
organs	O
and	O
their	O
vascular	O
structure	O
.	O
Lisuride	O
(	O
I	O
)	O
,	O
terguride	O
(	O
II	O
)	O
or	O
a	O
1,1-diethyl-3-	O
(	O
R	O
)	O
-4,6,6a,7,8,9,10,1	O
0a-octahydro-indolo	O
[	O
4,3-fg	O
]	O
quinolin-9-yl-urea	O
derivative	O
of	O
formula	O
(	O
III	O
)	O
is	O
new,	O
where	O
(	O
I	O
)	O
-	O
(	O
III	O
)	O
is	O
useful	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
of	O
fibrotic	O
changes	O
of	O
organ	O
and	O
other	O
vascular	O
structure	O
in	O
human	O
or	O
animal	O
for	O
arresting	O
and	O
/	O
or	O
for	O
remodeling	O
of	O
fibrotic	O
changes	O
of	O
organs	O
and	O
their	O
vascular	O
structure	O
.	O
R	O
1	O
>	O
:	O
alkyl	O
or	O
alkynyl	O
;	O
R	O
2	O
>	O
:	O
C	O
2H	O
5,	O
n-propyl,	O
isopropyl	O
or	O
alkyl	O
;	O
R	O
3	O
>	O
:	O
H,	O
CH	O
3,	O
C	O
2H	O
5,	O
isopropyl	O
or	O
CH	O
2OH	O
;	O
and	O
dotted	O
line	O
:	O
single	O
or	O
double	O
bond	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Hypotensive	O
;	O
Respiratory-Gen	O
.	O
;	O
Cardiant	O
;	O
Anti-HIV	O
;	O
Fungicide	O
;	O
Antibacterial	O
;	O
Antiparasitic	O
;	O
Antiinflammatory	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
5-Hydroxytryptamine	B-GENE
2A	I-GENE
receptor	I-GENE
antagonist	O
;	O
5-Hydroxytryptamine	B-GENE
2B	I-GENE
receptor	I-GENE
antagonist	O
.	O
The	O
5-hydroxytryptamine	B-GENE
2A	I-GENE
receptor	I-GENE
antagonistic	O
activity	O
of	O
(	O
I	O
)	O
was	O
tested	O
.	O
The	O
results	O
showed	O
that	O
lisuride	O
exhibited	O
an	O
IC	O
5	O
0value	O
of	O
1	O
mmole	O
/	O
l	O
.	O


An	O
adenoviral	O
vector	O
including	O
at	O
least	O
one	O
DNA	O
sequence	O
encoding	O
a	O
clotting	O
factor,	O
such	O
as,	O
for	O
example,	O
Factor	O
VIII,	O
or	O
Factor	B-GENE
IX	I-GENE
.	O
Such	O
vectors	O
may	O
be	O
administered	O
to	O
a	O
host	O
in	O
an	O
amount	O
effective	O
to	O
treat	O
hemophilia	O
in	O
the	O
host	O
.	O
The	O
vectors	O
infect	O
hepatocytes	O
very	O
efficiently,	O
whereby	O
the	O
hepatocytes	O
express	O
the	O
DNA	O
sequence	O
encoding	O
the	O
clotting	B-GENE
factor	I-GENE
.	O


The	O
human	B-GENE
PKD1	B-GENE
gene,	O
responsible	O
for	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(	O
APKD	O
)	O
,	O
or	O
adult	O
onset	O
polycystic	O
kidney	O
disease,	O
has	O
been	O
identified	O
.	O
The	O
genomic	O
and	O
cDNA	O
sequences	O
of	O
the	O
5	O
'	O
end	O
of	O
PKD1	B-GENE
are	O
disclosed	O
.	O


Novel	O
compounds	O
of	O
Formula	O
(	O
1	O
.	O
0	O
)	O
are	O
disclosed	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Ras	B-GENE
function	O
and	O
therefore	O
inhibiting	O
the	O
abnormal	O
growth	O
of	O
cells	O
.	O
The	O
method	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
1	O
.	O
0	O
)	O
to	O
a	O
biological	O
system	O
.	O
In	O
particular,	O
the	O
method	O
inhibits	O
the	O
abnormal	O
growth	O
of	O
cells	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
being	O
.	O


The	O
invention	O
provides	O
a	O
novel	O
vehicle	O
for	O
vaccination,	O
in	O
particular	O
peptide	O
vaccination	O
.	O
The	O
new	O
vehicle	O
has	O
been	O
termed	O
an	O
exosome	O
.	O
Exosomes	O
are	O
vesicles	O
derived	O
from	O
MHC	B-GENE
class	I-GENE
II	I-GENE
enriched	O
compartments	O
in	O
antigen	O
presenting	O
cells	O
.	O
The	O
exosomes	O
possess	O
MHC	B-GENE
II	I-GENE
and	O
/	O
or	O
MHC	B-GENE
I	I-GENE
molecules	O
at	O
their	O
surface	O
and	O
possibly	O
peptides	O
derived	O
from	O
processed	O
antigens	O
in	O
said	O
MHC	O
'	O
s	O
.	O
Thus	O
the	O
exosome	O
is	O
a	O
perfect	O
vaccination	O
vehicle	O
in	O
that	O
it	O
presents	O
the	O
peptide	O
in	O
a	O
natural	O
setting	O
.	O
The	O
peptides	O
present	O
in	O
the	O
exosome	O
in	O
the	O
MHC	O
molecule	O
may	O
be	O
processed	O
by	O
the	O
antigen	O
presenting	O
cell	O
from	O
which	O
the	O
exosome	O
is	O
derived	O
.	O
Empty	O
MHC	O
molecules	O
on	O
exosomes	O
may	O
also	O
be	O
loaded	O
with	O
peptides	O
afterwards	O
.	O


Methods	O
for	O
evaluating	O
the	O
risk	O
of	O
an	O
individual	O
to	O
develop	O
Alzheimer	O
'	O
s	O
disease	O
using	O
cultured	O
neural	O
crest-derived	O
melanocytes	O
are	O
described	O
.	O
Also	O
described	O
are	O
methods	O
of	O
therapy	O
for	O
Alzheimer	O
'	O
s	O
disease	O
using	O
peptides	O
that	O
bind	O
to	O
the	O
neurotrophin	B-GENE
receptor	I-GENE
(	O
p75	B-GENE
<	O
NTR	O
>	O
)	O
and	O
competitively	O
inhibit	O
the	O
binding	O
of	O
	O
beta	B-GENE
-amyloid	I-GENE
to	O
the	O
p75	B-GENE
<	O
NTR	O
>	O
.	O


An	O
in	O
vivo	O
method	O
for	O
depleting	O
mammalian	O
cells	O
of	O
adenosine	O
5	O
'	O
-monophosphate	O
(	O
AMP	O
)	O
useful	O
in	O
the	O
treatment	O
of	O
certain	O
cancers	O
is	O
provided	O
.	O
According	O
to	O
the	O
method,	O
a	O
population	O
of	O
cells	O
is	O
obtained	O
from	O
a	O
host	O
and	O
assayed	O
for	O
loss	O
of	O
methylthioadenosine	B-GENE
phosphorylase	I-GENE
(	O
MTAse	B-GENE
)	O
activity	O
.	O
MTAse	B-GENE
catabolizes	O
methylthioadenosine	O
to	O
adenine	O
for	O
endogenous	O
salvage	O
incorporation	O
into	O
the	O
intracellular	O
AMP	O
pool	O
.	O
The	O
preferred	O
method	O
for	O
assaying	O
loss	O
of	O
MTAse	B-GENE
activity	O
is	O
a	O
hybridization	O
technique	O
for	O
detection	O
of	O
a	O
homozygous	O
loss	O
of	O
the	O
gene	O
which	O
encodes	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
which	O
inhibits	O
the	O
activity	O
of	O
adenylsuccinate	O
synthetase,	O
which	O
converts	O
inosine	O
5	O
'	O
-monophosphate	O
to	O
AMP,	O
thus	O
depleting	O
the	O
tumor	O
cells	O
of	O
substrates	O
for	O
de	O
novo	O
AMP	O
production	O
.	O
L-alanosine	O
is	O
the	O
preferred	O
ASS	B-GENE
inhibitory	O
agent	O
for	O
use	O
in	O
the	O
method	O
of	O
the	O
invention	O
.	O
The	O
figure	O
is	O
a	O
nucleotide	O
sequence	O
for	O
genomic	O
MTAse	B-GENE
(	O
SEQ	O
.	O
ID	O
.	O
No	O
.	O
1	O
)	O
wherein	O
the	O
exons	O
are	O
underlined	O
.	O


The	O
present	O
inventors	O
have	O
now	O
discovered	O
that	O
humans	O
have	O
a	O
gene	O
that	O
encodes	O
a	O
novel	O
protein	O
of	O
the	O
thymosin	B-GENE
	I-GENE
beta	I-GENE
	I-GENE
family	O
.	O
This	O
novel	O
protein,	O
herein	O
referred	O
to	O
as	O
thymosin	B-GENE
	I-GENE
beta	I-GENE
15,	O
has	O
the	O
ability	O
to	O
bind	O
and	O
sequester	O
G-actin,	O
like	O
other	O
members	O
of	O
the	O
thymosin	B-GENE
	I-GENE
beta	I-GENE
	I-GENE
family,	O
but	O
unlike	O
what	O
is	O
known	O
about	O
other	O
members	O
it	O
also	O
directly	O
regulates	O
cell	O
motility	O
in	O
prostatic	O
carcinoma	O
cells	O
.	O
The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
isolated	O
cDNA	O
encoding	O
the	O
human	B-GENE
thymosin	B-GENE
	I-GENE
beta	I-GENE
15	I-GENE
gene	O
(	O
SEQ	O
ID	O
NO	O
:	O
1	O
)	O
and	O
have	O
deduced	O
the	O
amino	O
acid	O
sequence	O
(	O
SEQ	O
ID	O
NO	O
:	O
2	O
)	O
.	O


The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
an	O
orally	O
active,	O
long	O
acting,	O
CNS-penetrant	O
NK-1	B-GENE
receptor	I-GENE
antagonist	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
adapted	O
for	O
oral	O
administration	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
major	O
depressive	O
disorder	O
with	O
anxiety	O
without	O
concomitant	O
therapy	O
with	O
other	O
anti-depressant	O
or	O
anti-anxiety	O
agents,	O
methods	O
of	O
treatment	O
using	O
such	O
a	O
NK-1	B-GENE
receptor	I-GENE
antagonist	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
.	O


Lipid	O
lowering	O
dosage	O
units,	O
to	O
be	O
used	O
once	O
a	O
day,	O
produce	O
minimal	O
side	O
effects	O
.	O
They	O
contain	O
a	O
combination	O
of	O
microspheres	O
formulated	O
to	O
co-deliver	O
a	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
component	O
and	O
a	O
niacin	O
component	O
.	O


The	O
APC	B-GENE
tumor	O
suppressor	O
protein	O
binds	O
to	O
	O
beta	O
-catenin,	O
a	O
protein	O
recently	O
shown	O
to	O
interact	O
with	O
Tcf	B-GENE
/	O
Lef	O
transcription	O
factors	O
.	O
Here,	O
the	O
gene	O
encoding	O
a	O
Tcf	B-GENE
family	O
member	O
that	O
is	O
expressed	O
in	O
colonic	O
epithelium	O
(	O
hTcf-4	B-GENE
)	O
was	O
cloned	O
and	O
characterized	O
.	O
hTcf-4	B-GENE
transactivates	O
transcription	O
only	O
when	O
associated	O
with	O
	O
beta	B-GENE
-catenin	I-GENE
.	O
Nuclei	O
of	O
APC	B-GENE
<	O
-	O
/	O
-	O
>	O
colon	O
carcinoma	O
cells	O
were	O
found	O
to	O
contain	O
a	O
stable	O
	O
beta	O
-catenin-hTCF-4	O
complex	O
that	O
was	O
constitutively	O
active,	O
as	O
measured	O
by	O
transcription	O
of	O
a	O
Tcf	B-GENE
reporter	O
gene	O
.	O
Reintroduction	O
of	O
APC	B-GENE
removed	O
	O
beta	B-GENE
-catenin	I-GENE
from	O
hTcf4	B-GENE
and	O
abrogated	O
the	O
transcriptional	O
transactivation	O
.	O
Constitutive	O
transcription	O
of	O
TCF	B-GENE
target	O
genes,	O
caused	O
by	O
loss	O
of	O
APC	B-GENE
function,	O
may	O
be	O
a	O
crucial	O
event	O
in	O
the	O
early	O
transformation	O
of	O
colonic	O
epithelium	O
.	O
It	O
is	O
also	O
shown	O
here	O
that	O
the	O
products	O
of	O
mutant	O
APC	B-GENE
genes	O
found	O
in	O
colorectal	O
tumors	O
are	O
defective	O
in	O
regulating	O
	O
beta	B-GENE
-catenin	I-GENE
/	O
Tcf-4	B-GENE
transcriptional	O
activation	O
.	O
Furthermore,	O
colorectal	O
tumors	O
with	O
intact	O
APC	B-GENE
genes	O
were	O
shown	O
to	O
contain	O
subtle	O
activating	O
mutations	O
of	O
	O
beta	B-GENE
-catenin	I-GENE
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O
These	O
results	O
indicate	O
that	O
regulation	O
of	O
	O
beta	B-GENE
-catenin	I-GENE
is	O
critical	O
to	O
APC	B-GENE
'	O
s	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	B-GENE
or	O
	O
beta	B-GENE
-catenin	I-GENE
.	O


This	O
invention	O
is	O
directed	O
to	O
quinoline	O
/	O
quinoxaline	O
compounds	O
which	O
inhibit	O
platelet-derived	B-GENE
growth	I-GENE
factor	I-GENE
or	O
p56<lck>	B-GENE
tyrosine	I-GENE
kinase	I-GENE
activity,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
treating	O
a	O
patient	O
suffering	O
from	O
or	O
subject	O
to	O
disorders	O
/	O
conditions	O
involving	O
cellular	O
differentiation,	O
proliferation,	O
extracellular	O
matrix	O
production	O
or	O
mediator	O
release	O
and	O
/	O
or	O
T	O
cell	O
activation	O
and	O
proliferation	O
.	O


The	O
invention	O
provides	O
isolated	O
nucleic	O
acids	O
molecules,	O
designated	O
PGC-1	B-GENE
nucleic	O
acid	O
molecules,	O
which	O
encode	O
proteins	O
which	O
can	O
modulate	O
various	O
adipocyte-associated	O
activities	O
including,	O
for	O
example,	O
thermogenesis	O
in	O
adipocytes,	O
e	O
.	O
g	O
.	O
,	O
brown	O
adipocytes,	O
and	O
adipogenesis	O
.	O
The	O
invention	O
also	O
provides	O
antisense	O
nucleic	O
acid	O
molecules,	O
recombinant	O
expression	O
vectors	O
containing	O
PGC-1	B-GENE
nucleic	O
acid	O
molecules,	O
host	O
cells	O
into	O
which	O
the	O
expression	O
vectors	O
have	O
been	O
introduced,	O
and	O
nonhuman	O
transgenic	O
animals	O
in	O
which	O
a	O
PGC-1	B-GENE
gene	O
has	O
been	O
introduced	O
or	O
disrupted	O
.	O
The	O
invention	O
still	O
further	O
provides	O
isolated	O
PGC-1	B-GENE
proteins,	O
fusion	O
proteins,	O
antigenic	O
peptides	O
and	O
anti-PGC-1	O
antibodies	O
.	O
Diagnostic,	O
screening,	O
and	O
therapeutic	O
methods	O
utilizing	O
compositions	O
of	O
the	O
invention	O
are	O
also	O
provided	O
.	O


Invented	O
are	O
zinc	O
chelated	O
G-CSF	B-GENE
receptor	I-GENE
ligands,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
as	O
agonist	O
of	O
the	O
G-CSF	B-GENE
receptor	I-GENE
.	O
Also	O
invented	O
are	O
novel	O
processes	O
used	O
in	O
preparing	O
these	O
compounds	O
.	O
Also	O
invented	O
are	O
novel	O
G-CSF	B-GENE
receptor	I-GENE
binding	O
moieties	O
of	O
the	O
invented	O
zinc	O
chelated	O
G-CSF	B-GENE
receptor	I-GENE
ligands	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
As	O
used	O
in	O
formula	O
(	O
I	O
)	O
,	O
and	O
throughout	O
the	O
specification,	O
the	O
symbols	O
have	O
the	O
following	O
meanings	O
:	O
R1	O
and	O
R2	O
are	O
independently	O
hydrogen,	O
fluorine	O
or	O
alkyl	O
;	O
R3	O
is	O
aryl	O
or	O
heteroaryl	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
protein	O
kinase	B-GENE
inhibitors	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
proliferative	O
diseases,	O
for	O
example	O
cancer,	O
inflammation	O
and	O
arthritis	O
.	O


The	O
present	O
invention	O
describes	O
novel	O
treatments	O
for	O
movement	O
disorders,	O
including	O
tardive	O
dyskinesia	O
and	O
tardive	O
dystonia,	O
tic	O
disorders,	O
Tourette	O
'	O
s	O
syndrome,	O
and	O
blepharospasm,	O
and	O
other	O
focal	O
dystonias	O
.	O
The	O
treatments	O
of	O
the	O
present	O
invention	O
utilize	O
agents	O
that	O
simultaneously	O
act	O
as	O
NMDA-type	B-GENE
glutamate	I-GENE
receptor	I-GENE
antagonists	O
.	O
Additionally,	O
the	O
treatments	O
of	O
the	O
present	O
invention	O
utilize	O
agents	O
that	O
simultaneously	O
act	O
as	O
NMDA-type	B-GENE
glutamate	I-GENE
receptor	I-GENE
antagonists	O
and	O
GABA-A	B-GENE
receptor	I-GENE
agonists	O
.	O
Preferably	O
these	O
two	O
activities	O
are	O
characteristic	O
of	O
a	O
single	O
agent,	O
for	O
example	O
acamprosate	O
.	O
Alternatively,	O
separate	O
agents	O
having	O
these	O
activities	O
can	O
be	O
combined	O
and	O
administered	O
together	O
.	O
The	O
invention	O
also	O
provides	O
a	O
third	O
agent	O
that	O
can	O
be	O
used	O
in	O
combination	O
with	O
a	O
treatment	O
for	O
movement	O
disorders,	O
that	O
acts	O
as	O
a	O
non-competitive	O
NMDA-receptor	B-GENE
blocking	O
agent	O
or	O
ion	O
channel	O
blocker	O
that	O
augments	O
the	O
effect	O
of	O
the	O
primary	O
treatment	O
.	O
A	O
particularly	O
preferred	O
ion	O
channel	O
blocking	O
agent	O
is	O
magnesium	O
.	O
Alternatively,	O
magnesium	O
can	O
be	O
administered	O
alone	O
for	O
prevention	O
and	O
treatment	O
of	O
movement	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
active	O
agent	O
from	O
the	O
following	O
group	O
:	O
17α-estradiol,	O
its	O
chemically	O
modified	O
derivatives	O
and	O
chemically	O
modified	O
derivatives	O
of	O
17β-estradiol	O
or	O
estriol	O
;	O
for	O
producing	O
pharmaceutical	O
preparations	O
for	O
treating	O
side	O
effects	O
such	O
as	O
hot	O
flushes	O
during	O
and	O
/	O
or	O
after	O
a	O
treatment	O
with	O
analogs	O
or	O
antagonists	O
of	O
the	O
gonadotropin-releasing	B-GENE
hormone	I-GENE
(	O
GnRHa-therapy	O
)	O
.	O
Said	O
pharmaceutical	O
preparations	O
can	O
be	O
produced	O
in	O
oral	O
and	O
parenteral,	O
including	O
topical,	O
rectal,	O
sub-cutaneous,	O
intravenous,	O
intramuscular,	O
intraperitoneal,	O
intranasal,	O
intravaginal,	O
intrabuccal	O
or	O
sub-lingual	O
forms	O
of	O
administration	O
.	O


The	O
present	O
invention	O
relates	O
to	O
thienyl	O
substituted	O
acylguanidine	O
derivatives,	O
such	O
as	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
which	O
R	O
?	O
1,	O
R2,	O
R4,	O
R6¿,	O
A,	O
B	O
and	O
D	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims,	O
their	O
physiologically	O
tolerable	O
salts	O
and	O
their	O
prodrugs	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
valuable	O
pharmaceutical	O
active	O
compounds	O
.	O
They	O
are	O
vitronectin	B-GENE
receptor	I-GENE
antagonists	O
and	O
inhibitors	O
of	O
bone	O
resorption	O
by	O
osteoclasts	O
.	O
They	O
are	O
suitable,	O
for	O
example,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
caused	O
at	O
least	O
partially	O
by	O
an	O
undesired	O
extent	O
of	O
bone	O
resorption,	O
for	O
example	O
of	O
osteoporosis	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
thienyl	O
substituted	O
acylguanidines,	O
their	O
use,	O
in	O
particular	O
as	O
active	O
ingredients	O
in	O
pharmaceuticals,	O
and	O
pharmaceutical	O
preparations	O
comprising	O
them	O
.	O


The	O
invention	O
relates	O
to	O
aryl	O
alkanoylpyridazine	O
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
their	O
physiologically	O
compatible	O
salts	O
and	O
solvates,	O
where	O
R1,	O
R2,	O
Q	O
and	O
B	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1	O
.	O
Said	O
compounds	O
have	O
a	O
phosphodiesterase-IV	B-GENE
inhibiting	O
action	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
allergic	O
disorders,	O
asthma,	O
chronic	O
bronchitis,	O
atopic	O
dermatitis,	O
psoriasis	O
and	O
other	O
skin	O
diseases,	O
inflammatory	O
diseases,	O
auto-immune	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis,	O
multiple	O
sclerosis,	O
Crohn	O
'	O
s	O
disease,	O
diabetes	O
mellitus	O
or	O
ulcerative	O
colitis,	O
osteoporosis,	O
transplant	O
rejection	O
reactions,	O
cachexia,	O
tumour	O
growth	O
or	O
tumour	O
metastases,	O
sepsis,	O
memory	O
disturbances,	O
atherosclerosis	O
and	O
AIDS	O
.	O


A	O
method	O
of	O
treating	O
a	O
hyperproliferative	O
disorder	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment,	O
comprising	O
administering	O
to	O
said	O
subject,	O
in	O
combination,	O
a	O
treatment	O
effective	O
amount	O
of	O
:	O
(	O
a	O
)	O
a	O
ceramide-generating	O
retinoid	O
such	O
as	O
fenretinide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
(	O
and	O
in	O
certain	O
embodiments	O
at	O
least	O
two	O
)	O
ceramide	O
degredation	O
inhibitor,	O
such	O
as	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
i	O
)	O
glucosylceramide	O
synthesis	O
inhibitors,	O
(	O
ii	O
)	O
sphingosine-1-phosphate	O
synthesis	O
inhibitors,	O
and	O
(	O
iii	O
)	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitors	O
.	O
A	O
preferred	O
glucosyl	O
ceramide	O
synthesis	O
inhibitor	O
is	O
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol	O
.	O
A	O
preferred	O
sphingosine-1-phosphate	O
synthesis	O
inhibitor	O
is	O
D-erytho-N,N-dimethylsphingosine	O
.	O
A	O
preferred	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitor	O
is	O
L-threo-dihydrosphingosine	O
.	O


A	O
biocompatible	O
and	O
biodegradable	O
material	O
is	O
applied	O
to	O
a	O
tissue	O
region,	O
e	O
.	O
g	O
.	O
,	O
to	O
seal	O
a	O
vascular	O
puncture	O
site,	O
or	O
to	O
arrest	O
the	O
flow	O
of	O
blood	O
or	O
fluid	O
from	O
body	O
tissue,	O
or	O
to	O
arrest	O
diffuse	O
bleeding	O
.	O
The	O
material	O
preferably	O
includes	O
a	O
protein	O
comprising	O
recombinant	O
or	O
natural	O
serum	O
albumin,	O
which	O
is	O
mixed	O
with	O
a	O
polymer	O
that	O
comprises	O
poly	O
(	O
ethylene	O
)	O
glycol	O
(	O
PEG	O
)	O
,	O
and,	O
most	O
preferably,	O
a	O
multi-armed	O
PEG	O
polymer	O
.	O


A	O
patient	O
with	O
an	O
inflammatory	O
disease	O
of	O
the	O
head	O
and	O
neck	O
is	O
treated	O
with	O
a	O
therapeutic	O
amount	O
of	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	B-GENE
or	O
a	O
cyclooxygenase-2	B-GENE
inhibitor	O
from	O
a	O
natural	O
source	O
.	O
In	O
one	O
embodiment,	O
a	O
patient	O
with	O
a	O
sore	O
throat	O
caused	O
by	O
tonsillitis	O
or	O
pharyngitis	O
is	O
treated	O
with	O
the	O
topical	O
application	O
of	O
a	O
cyclooxygenase-2	B-GENE
inhibitor	O
from	O
a	O
natural	O
source	O
.	O
In	O
other	O
embodiments,	O
patients	O
with	O
sore	O
throat	O
caused	O
by	O
tonsillitis	O
or	O
pharyngitis	O
or	O
a	O
patient	O
with	O
sinusitis	O
are	O
treated	O
by	O
systemic	O
administration	O
of	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	B-GENE
.	O
In	O
another	O
embodiment,	O
a	O
patient	O
with	O
periodontitis	O
is	O
treated	O
by	O
administration	O
of	O
a	O
cyclooxygenase-2	B-GENE
inhibitor	O
from	O
a	O
natural	O
source	O
.	O


Recombinant	O
nucleic	O
acid	O
molecules	O
are	O
described	O
.	O
The	O
molecules	O
have	O
a	O
first	O
sequence	O
encoding	O
a	O
Hepatitis	B-GENE
B	I-GENE
virus	I-GENE
core	I-GENE
antigen	I-GENE
and	O
a	O
second	O
sequence	O
encoding	O
at	O
least	O
one	O
T	O
cell	O
epitope	O
inserted	O
within	O
the	O
first	O
sequence	O
.	O
Vectors	O
and	O
compositions	O
containing	O
these	O
molecules	O
are	O
also	O
described	O
.	O
Methods	O
of	O
eliciting	O
an	O
immune	O
response	O
using	O
these	O
molecules	O
are	O
also	O
described	O
.	O


The	O
invention	O
relates	O
to	O
a	O
nucleotide	O
sequence	O
coding	O
for	O
the	O
PRV-1	B-GENE
gene	O
and	O
essentially	O
comprising	O
sequence	O
ID	O
No	O
.	O
1	O
and	O
to	O
a	O
method	O
for	O
detecting	O
said	O
gene	O
as	O
well	O
as	O
to	O
the	O
polypeptide	O
coded	O
by	O
said	O
gene	O
.	O


The	O
present	O
invention	O
is	O
the	O
novel	O
use	O
of	O
NK-3	B-GENE
receptor	O
antagonist	O
compounds	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
high	O
or	O
inappropriate	O
levels	O
of	O
gonadotropins	O
and	O
/	O
or	O
androgens,	O
particularly	O
testosterone	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
?	O
1	O
and	O
R2¿	O
independently	O
represent	O
H	O
or	O
C¿1-6	O
?	O
alkyl	O
;	O
R	O
?	O
3¿	O
represents	O
phenyl	O
substituted	O
by	O
at	O
least	O
one	O
group	O
selected	O
form	O
halo,	O
CF¿3	O
?	O
,	O
OCF3,	O
CN,	O
OH,	O
C1-6	O
alkyl	O
and	O
C1-6	O
alkoxy	O
;	O
and	O
R	O
?	O
4,	O
R5	O
and	O
R11¿	O
independently	O
represent	O
H	O
or	O
-	O
(	O
CH¿2	O
?	O
)	O
n-A,	O
wherein	O
n	O
represents	O
0,	O
1	O
or	O
2,	O
provided	O
that	O
at	O
least	O
one	O
of	O
R	O
?	O
4,	O
R5	O
and	O
R11¿	O
is	O
other	O
than	O
H	O
;	O
A	O
represents	O
CONR6R7	O
or	O
SO¿2NR	O
?	O
6R7,	O
wherein	O
R	O
?	O
6	O
and	O
R7¿	O
independently	O
represent	O
H,	O
C¿3-6	O
?	O
cycloalkyl	O
or	O
C1-6	O
alkyl,	O
the	O
C	O
?	O
1-6¿	O
alkyl	O
group	O
being	O
optionally	O
substituted,	O
in	O
addition,	O
R	O
?	O
6	O
and	O
R7¿	O
may,	O
together	O
with	O
the	O
N	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
represent	O
a	O
ring	O
which	O
is	O
optionally	O
substituted	O
;	O
CO¿2R	O
?	O
8,	O
wherein	O
R8	O
represents	O
H	O
or	O
C¿1-6	O
?	O
alkyl	O
;	O
NR	O
?	O
9R10¿,	O
wherein	O
R	O
?	O
9	O
and	O
R10¿	O
independently	O
represent	O
H,	O
C¿1-6	O
?	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
,	O
(	O
C1-6	O
alkyl	O
)	O
SO2-,	O
(	O
C1-6	O
alkyl	O
)	O
CO-,	O
H2NSO2-	O
or	O
H2NCO-	O
;	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
containing	O
1,	O
2	O
or	O
3	O
heteroatoms	O
selected	O
from	O
N,	O
S	O
and	O
O,	O
which	O
is	O
optionally	O
substituted	O
;	O
S	O
(	O
O	O
)	O
x	O
(	O
C1-6	O
alkyl	O
)	O
,	O
wherein	O
x	O
represents	O
0,	O
1	O
or	O
2	O
;	O
OH	O
;	O
CN,	O
NO2	O
;	O
or	O
C1-6	O
alkoxy	O
which	O
is	O
optionally	O
substituted	O
;	O
provided	O
that	O
when	O
NR	O
?	O
1R2¿	O
represents	O
N	O
(	O
H	O
)	O
methyl,	O
R4	O
represents	O
H	O
and	O
R3	O
represents	O
4-	O
chlorophenyl,	O
then	O
R5	O
does	O
not	O
represent	O
methoxy	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
variety	O
of	O
disorders,	O
including	O
those	O
in	O
which	O
the	O
regulation	O
of	O
monoamine	B-GENE
transporter	I-GENE
function	O
is	O
implicated	O
.	O


The	O
present	O
invention	O
provides	O
methods,	O
kits,	O
and	O
pharmaceutical	O
compositions	O
for	O
limiting	O
scar	O
or	O
adhesion	O
formation	O
by	O
administration	O
of	O
angiotensinogen,	O
AI,	O
AI	B-GENE
analogues,	O
and	O
/	O
or	O
AI	B-GENE
fragments	O
and	O
analogues	O
thereof,	O
AII	B-GENE
analogues,	O
AII	B-GENE
fragments	O
or	O
analogues	O
thereof,	O
ACE	O
inhibitors,	O
AII	B-GENE
AT2	I-GENE
type	I-GENE
2	I-GENE
receptor	I-GENE
agonists,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
compounds	O
.	O


The	O
use	O
of	O
a	O
3-substituted	O
indole	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
amide	O
or	O
ester	O
thereof	O
;	O
X	O
is	O
CH2	O
or	O
SO2	O
and	O
R	O
?	O
1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
R7¿	O
are	O
certain	O
specified	O
organic	O
moieties,	O
for	O
use	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
inhibition	O
of	O
monocyte	B-GENE
chemoattractant	I-GENE
protein-1	I-GENE
and	O
/	O
or	O
RANTES	B-GENE
induced	O
chemotaxis	O
.	O
Pharmaceutical	O
compositions	O
containing	O
certain	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
also	O
described	O
and	O
claimed	O
.	O


A	O
hydroxamic	O
acid	O
derivative	O
represented	O
by	O
formula	O
(	O
1	O
)	O
or	O
a	O
prodrug	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
which	O
has	O
a	O
matrix	B-GENE
metalo-proteinase	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
or	O
prodrug	O
thereof	O
;	O
wherein	O
Y	O
is	O
selected	O
from	O
-	O
(	O
CH2	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
NH-Q1	O
;	O
-	O
(	O
CO	O
)	O
-O-Q1	O
;	O
-	O
(	O
SO2	O
)	O
-Q1	O
or	O
-	O
(	O
SO2	O
)	O
NH-Q1	O
;	O
Q1	O
is	O
a	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkyl	O
or	O
alkenyl	O
group	O
;	O
a	O
5-7	O
membered	O
aromatic	O
or	O
non-aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
;	O
or	O
a	O
9-14	O
membered	O
bicyclic	O
or	O
tricyclic	O
aromatic	O
or	O
non-aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
system,	O
W	O
is	O
N	O
or	O
C	O
;	O
Z	O
is	O
CH	O
or	O
N,	O
which	O
are	O
inhibitors	O
of	O
JNK,	O
a	O
mammalian	O
protein	O
kinase	B-GENE
involved	O
cell	O
proliferation,	O
cell	O
death	O
and	O
response	O
to	O
extracellular	O
stimuli	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
producing	O
these	O
inhibitors	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
signify	O
hydrogen	O
or	O
hydroxy	O
;	O
R2	O
signify	O
hydrogen	O
or	O
methyl	O
;	O
and	O
X	O
signify	O
-O-	O
or	O
-CH¿2	O
?	O
-	O
;	O
and	O
their	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
.	O
It	O
has	O
been	O
shown	O
that	O
these	O
compounds	O
have	O
a	O
good	O
affinity	O
to	O
the	O
NMDA	B-GENE
receptor	I-GENE
and	O
they	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
diseases,	O
wherein	O
the	O
therapeutic	O
indications	O
include	O
acute	O
forms	O
of	O
neurodegeneration	O
caused,	O
e	O
.	O
g	O
.	O
,	O
by	O
stroke	O
or	O
brain	O
trauma	O
;	O
chronic	O
forms	O
of	O
neurodegeneration	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinsons	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
disease	O
or	O
ALS	O
(	O
amyotrophic	O
lateral	O
sclerosis	O
)	O
;	O
neurodegeneration	O
associated	O
with	O
bacterial	O
or	O
viral	O
infections,	O
and,	O
diseases	O
such	O
as	O
schizophrenia,	O
anxiety,	O
depression	O
and	O
chronic	O
/	O
acute	O
pain	O
.	O


Methods	O
of	O
screening	O
for	O
compounds	O
that	O
affect	O
melanogenesis	O
and	O
the	O
function	O
of	O
P	B-GENE
protein	I-GENE
in	O
organisms,	O
cells,	O
or	O
cell-free	O
systems	O
are	O
provided	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
pharmacologic	O
and	O
cosmetic	O
uses	O
of	O
such	O
compounds	O
to	O
reduce	O
or	O
increase	O
the	O
synthesis	O
of	O
melanin	O
in	O
animal	O
and	O
human	O
melanocytes	O
and	O
melanocyte-derived	O
cells	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
polypeptides	O
belonging	O
to	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
family	I-GENE
and	O
to	O
nucleic	O
acid	O
molecules	O
encoding	O
those	O
polypeptides	O
.	O
Also	O
provided	O
herein	O
are	O
vectors	O
and	O
host	O
cells	O
comprising	O
those	O
nucleic	O
acid	O
sequences,	O
chimeric	O
polypeptide	O
molecules	O
comprising	O
the	O
polypeptides	O
of	O
the	O
present	O
invention	O
fused	O
to	O
heterologous	O
polypeptide	O
sequences,	O
antibodies	O
which	O
bind	O
to	O
the	O
polypeptides	O
of	O
the	O
present	O
invention	O
and	O
to	O
methods	O
for	O
producing	O
the	O
polypeptides	O
of	O
the	O
present	O
invention	O
.	O
Furthermore,	O
methods	O
of	O
treating	O
obesity	O
are	O
provided	O
.	O


Compounds	O
of	O
the	O
formula	O
A	O
-	O
Q	O
-	O
D	O
-	O
E	O
-	O
G	O
-	O
J	O
-	O
X	O
in	O
which	O
D	O
is	O
a	O
direct	O
link,	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	O
or	O
naphthyl	O
group	O
or	O
a	O
heterocyclic	O
ring	O
system	O
;	O
X	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	O
or	O
naphthyl	O
group	O
or	O
a	O
heterocyclic	O
system	O
;	O
and	O
the	O
other	O
variables	O
are	O
as	O
defined	O
in	O
the	O
claims,	O
their	O
salts	O
and	O
compositions	O
related	O
thereto	O
having	O
activity	O
against	O
mammalian	B-GENE
factor	I-GENE
Xa	I-GENE
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
useful	O
in	O
vitro	O
or	O
in	O
vivo	O
for	O
preventing	O
or	O
treating	O
coagulation	O
disorders	O
.	O


Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
,	O
where	O
R	O
?	O
1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6¿,	O
and	O
X	O
are	O
defined	O
herein	O
.	O
These	O
compounds	O
are	O
selective	O
modulators	O
of	O
NPY1	B-GENE
receptors	I-GENE
.	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
CNS	O
disorders,	O
metabolic	O
disorders,	O
and	O
peripheral	O
disorders,	O
particularly	O
eating	O
disorders	O
and	O
hypertension	O
.	O
Methods	O
of	O
treatment	O
of	O
such	O
disorders	O
as	O
well	O
as	O
packaged	O
pharmaceutical	O
compositions	O
are	O
also	O
provided	O
.	O
Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
NPY1	B-GENE
receptors	I-GENE
and	O
as	O
standards	O
in	O
assays	O
for	O
NPY1	B-GENE
receptor	I-GENE
binding	O
.	O
Methods	O
of	O
using	O
the	O
compounds	O
in	O
receptor	O
localization	O
studies	O
are	O
given	O
.	O


A	O
pharmaceutical	O
composition	O
is	O
disclosed	O
which	O
comprises	O
a	O
soliddispersion	O
of	O
an	O
HIV	B-GENE
protease	I-GENE
inhibitor	O
in	O
a	O
water	O
soluble	O
carrier,	O
such	O
as	O
PEG,	O
having	O
enhanced	O
bioavailability	O
and	O
improved	O
dissolution	O
properties	O
.	O
The	O
solid	O
dispersion	O
may	O
optionally	O
be	O
encapsulated	O
in	O
hard	O
gelatin	B-GENE
capsules,	O
compressed	O
into	O
a	O
tablet,	O
or	O
may	O
be	O
granulated	O
with	O
a	O
pharmaceutically	O
acceptable	O
granulating	O
agent	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
said	O
solid	O
dispersion	O
and	O
methods	O
of	O
treating	O
an	O
HIV	O
infection	O
employing	O
said	O
solid	O
dispersion	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
diseases,	O
in	O
which	O
an	O
increased	O
activity	O
of	O
matrix-degrading	O
enzymes,	O
in	O
particular,	O
stromelysin,	O
are	O
implicated	O
.	O


The	O
present	O
invention	O
includes	O
the	O
cloning	O
of	O
a	O
novel	O
human	B-GENE
Cα	B-GENE
isoform,	O
identified	O
as	O
the	O
human	B-GENE
Cα-s	B-GENE
protein	I-GENE
on	O
the	O
basis	O
of	O
its	O
similarity	O
to	O
a	O
recently	O
characterized	O
Cα	B-GENE
isoform	O
which	O
was	O
identified	O
by	O
purification	O
and	O
peptide	O
sequencing	O
of	O
Cα	B-GENE
from	O
ovine	O
sperm	O
[	O
11	O
]	O
.	O
The	O
human	B-GENE
Cα-s	B-GENE
protein	I-GENE
was	O
present	O
in	O
testis	O
and	O
ejaculated	O
sperm	O
and	O
Cα-s	B-GENE
localized	O
to	O
the	O
midpiece	O
of	O
human	O
sperm	O
.	O
The	O
present	O
invention	O
includes	O
in	O
this	O
respect	O
a	O
cDNA	O
sequence	O
encoding	O
a	O
Cα-s	B-GENE
protein	I-GENE
and	O
comprises	O
the	O
specific	O
nucleotide	O
sequence	O
shown	O
in	O
SEQ	O
ID	O
NO	O
:	O
1,	O
(	O
underlined	O
)	O
wherein	O
the	O
said	O
protein	O
is	O
a	O
new	O
splice	O
variant	O
of	O
Cα	B-GENE
catalytic	O
subunit	O
of	O
cAMP	B-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
.	O
The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
vector	O
comprising	O
the	O
said	O
cDNA	O
sequence	O
.	O
The	O
invention	O
also	O
includes	O
a	O
protein	O
characterised	O
by	O
the	O
Cα-s	B-GENE
protein	I-GENE
specific	O
amino	O
acid	O
sequence	O
shown	O
in	O
SEQ	O
ID	O
NO	O
:	O
2	O
(	O
underlined	O
)	O
.	O
The	O
invention	O
includes	O
further	O
use	O
of	O
Cα-s	B-GENE
protein	I-GENE
and	O
cDNA	O
sequence	O
in	O
preparation	O
of	O
pharmaceuticals,	O
medicaments	O
to	O
manipulate	O
the	O
motility	O
in	O
sperm	O
or	O
for	O
use	O
as	O
contraceptive,	O
as	O
well	O
as	O
methods	O
and	O
testsystems	O
for	O
screening	O
molecules	O
interacting	O
with	O
Cα-s	B-GENE
.	O
The	O
present	O
invention	O
includes	O
also	O
a	O
kit	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
inhibit	O
farnesylation	O
of	O
gene	O
products	O
through	O
inhibition	O
of	O
the	O
enzyme	O
farnesyl-protein	B-GENE
transferase	I-GENE
(	O
FPTase	B-GENE
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
manufacturing	O
the	O
compounds,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treating	O
diseases,	O
especially	O
cancer,	O
which	O
are	O
mediated	O
through	O
farnesylation	O
.	O


New	O
RAR	O
selective	O
retinoid	O
agonists	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
active	O
salts	O
of	O
carboxylic	O
acids	O
of	O
formula	O
(	O
I	O
)	O
,	O
further	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
such	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
agonists,	O
particularly	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
η	I-GENE
(	O
RARη	B-GENE
)	O
selective	O
agonists	O
for	O
the	O
treatment	O
of	O
emphysema	O
and	O
associated	O
pulmonary	O
diseases,	O
as	O
well	O
as	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
dermatological	O
disorders,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
malignant	O
and	O
premalignant	O
epithelial	O
lesions,	O
tumours	O
and	O
precancerous	O
changes	O
of	O
the	O
mucous	O
membrane	O
in	O
the	O
mouth,	O
tongue,	O
larynx,	O
oesophagus,	O
bladder,	O
cervix	O
and	O
colon	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
N-	O
(	O
substituted	O
glycyl	O
)	O
-2-cyanopyrrolidines	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
Y	O
is	O
as	O
defined	O
herein,	O
in	O
free	O
form	O
or	O
in	O
acid	O
addition	O
salt	O
form	O
.	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
inhibit	O
DPP-IV	B-GENE
(	O
dipeptidyl-peptidase-IV	B-GENE
)	O
activity	O
.	O
They	O
are	O
therefore	O
indicated	O
for	O
use	O
as	O
pharmaceuticals	O
in	O
inhibiting	O
DPP-IV	B-GENE
and	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
DPP-IV,	O
such	O
as	O
non-insulin-dependent	O
diabetes	O
mellitus,	O
arthritis,	O
obesity,	O
osteoporosis	O
and	O
further	O
conditions	O
of	O
impaired	O
glucose	O
tolerance	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
2H-tetrazole-5-yl-amide	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
signifies	O
hydrogen,	O
lower	O
alkyl,	O
-	O
(	O
CH¿2	O
?	O
)	O
n-CF3,	O
-	O
(	O
CH2	O
)	O
n-CHF2,	O
-	O
(	O
CH2	O
)	O
n-CN,	O
-	O
(	O
CH2	O
)	O
n-cycloalkyl,	O
-	O
(	O
CH2	O
)	O
n-O-lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-O-cycloalkyl	O
or	O
-	O
(	O
CH2	O
)	O
n-C	O
(	O
O	O
)	O
O-lower	O
alkyl	O
;	O
R	O
?	O
2¿	O
signifies	O
hydrogen,	O
lower	O
alkyl,	O
lower	O
alkoxy,	O
halogen,	O
-C	O
(	O
O	O
)	O
-lower	O
alkyl,	O
-C	O
(	O
O	O
)	O
OH,	O
-C	O
(	O
O	O
)	O
O-lower	O
alkyl,	O
-NR3R4	O
or	O
-C	O
(	O
O	O
)	O
-NR3R4	O
and	O
wherein	O
R	O
?	O
3	O
and	O
R4¿	O
may	O
be	O
independently	O
from	O
each	O
other	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
signifies	O
-O-,	O
-S-,	O
-CH¿2	O
?	O
,	O
-OCH2-	O
or	O
two	O
hydrogen	O
atoms	O
not	O
forming	O
a	O
bridge	O
;	O
and	O
n	O
signifies	O
0,	O
1,	O
2,	O
3	O
or	O
4	O
;	O
as	O
well	O
as	O
with	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O
It	O
has	O
been	O
found	O
that	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
are	O
group	B-GENE
1	I-GENE
metabotropic	I-GENE
glutamate	I-GENE
receptor	I-GENE
agonists	O
(	O
mGluR	B-GENE
)	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
corresponding	O
CNS-disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substantially	O
pure	O
mannin-binding	B-GENE
lectin	I-GENE
associated	I-GENE
serine	I-GENE
protease-2	I-GENE
(	O
MASP-2	B-GENE
)	O
polypeptides	O
and	O
fragments	O
thereof	O
as	O
well	O
as	O
nucleic	O
acids	O
encoding	O
such	O
polpeptides	O
.	O
	O
Futhermone,	O
the	O
present	O
invention	O
realates	O
to	O
uses	O
of	O
a	O
substantially	O
pure	O
polypeptide	O
comprising	O
amino	O
acid	O
sequences	O
derived	O
from	O
mannan-binding	B-GENE
lectin	I-GENE
associated	I-GENE
serine	I-GENE
protease-2	I-GENE
(	O
MASP2	B-GENE
)	O
or	O
a	O
functional	O
homologue	O
thereof	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
composition	O
as	O
well	O
as	O
pharmaceutical	O
compositons	O
comprising	O
MASP-2	B-GENE
and	O
/	O
or	O
MASP-2	B-GENE
fragments	O
.	O
	O
In	O
addition	O
the	O
present	O
invetion	O
relates	O
to	O
inhibitors	O
of	O
MASP-2	B-GENE
and	O
pharmaceutical	O
compositiosn	O
compring	O
such	O
inhibitors	O
.	O
	O
Methods	O
for	O
detecting	O
MASP-2	B-GENE
nucleic	O
acid	O
expression	O
are	O
included	O
in	O
the	O
invention	O
.	O


A	O
method	O
employing	O
a	O
compositon	O
comprising	O
a	O
2	O
to	O
10	O
base	O
synthetic	O
oligonucleotide	O
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
GG	O
)	O
n,	O
(	O
GT	O
)	O
n,	O
at	O
(	O
GT	O
)	O
nb,	O
a	O
(	O
GA	O
)	O
nb,	O
and	O
a	O
(	O
GC	O
)	O
nb,	O
wherein	O
n	O
is	O
an	O
integer	O
between	O
1	O
and	O
3,	O
and	O
a	O
and	O
b	O
are	O
independently	O
either	O
none	O
or	O
one	O
or	O
more	O
As,	O
Cs,	O
Gs,	O
or	O
Ts,	O
or	O
combinations	O
thereof,	O
for	O
modulation	O
of	O
Fas	B-GENE
and	O
FasL	B-GENE
expression	O
or	O
for	O
modulation	O
of	O
the	O
efficacy	O
of	O
therapeutic	O
agents	O
.	O
The	O
composition	O
is	O
administered	O
to	O
an	O
animal	O
or	O
human	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
and	O
optionally	O
with	O
a	O
therapeutic	O
agent,	O
in	O
an	O
amount	O
effective	O
to	O
modulate	O
Fas	B-GENE
and	O
FasL	B-GENE
expression,	O
to	O
treat	O
the	O
disease,	O
or	O
to	O
modulate	O
efficacy	O
of	O
the	O
therapeutic	O
agent	O
.	O


The	O
present	O
invention	O
relates	O
to	O
trimesic	O
acid	O
amides,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds,	O
uses	O
of	O
said	O
compounds	O
and	O
compositions,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O
Specifically,	O
this	O
invention	O
relates	O
to	O
means	O
to	O
enhance	O
insulin-dependent	O
glucose	O
uptake	O
.	O
More	O
specifically,	O
the	O
invention	O
concerns	O
compounds	O
and	O
pharmaceutical	O
compositions	O
that	O
active	O
the	O
insulin	B-GENE
receptor	I-GENE
kinase,	O
which	O
leads	O
to	O
an	O
increased	O
sensitivity	O
to	O
insulin	B-GENE
and	O
an	O
increase	O
in	O
glucose	O
uptake,	O
as	O
well	O
as	O
processes	O
for	O
preparation	O
of	O
the	O
compounds	O
.	O
As	O
such,	O
the	O
invention	O
also	O
concerns	O
methods	O
or	O
uses	O
of	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
animals	O
with	O
hyperglycemia,	O
especially	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O


Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
wherein	O
:	O
(	O
i	O
)	O
represents	O
:	O
(	O
ii,	O
iii,	O
iv,	O
v	O
)	O
and	O
A,	O
B,	O
G,	O
D,	O
E,	O
Ra,	O
Rb,	O
W,	O
and	O
Z	O
are	O
defined	O
herein	O
.	O
These	O
compounds	O
are	O
agonists,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAA	B-GENE
brain	I-GENE
receptors	I-GENE
or	O
prodrugs	O
of	O
agonists,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAA	B-GENE
brain	I-GENE
receptors	I-GENE
and	O
are	O
therefore	O
useful	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
anxiety,	O
depression,	O
down	O
Syndrome,	O
sleep	O
and	O
seizure	O
disorders,	O
overdose	O
with	O
benzodiazepine	O
drugs	O
and	O
for	O
enhancement	O
of	O
memory	O
.	O
Pharmaceutical	O
compositions,	O
including	O
packaged	O
pharmaceutical	O
compositions,	O
are	O
further	O
provided	O
.	O
Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
GABAA	B-GENE
receptors	I-GENE
in	O
tissue	O
samples	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
compounds	O
represented	O
by	O
structural	O
Formulas	O
(	O
I	O
)	O
and	O
(	O
I-a	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
R1,	O
R4a,	O
R4b,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
n,	O
and	O
X	O
are	O
described	O
.	O
The	O
invention	O
is	O
also	O
concerned	O
with	O
pharmaceutical	O
formulations	O
comprising	O
these	O
novel	O
compounds	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
novel	O
compounds	O
and	O
their	O
formulations	O
in	O
the	O
treatment	O
of	O
certain	O
disorders	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
are	O
serotonin	B-GENE
agonists	O
and	O
antagonists	O
and	O
are	O
useful	O
in	O
the	O
control	O
or	O
prevention	O
of	O
central	O
nervous	O
system	O
disorders	O
including	O
obesity,	O
anxiety,	O
depression,	O
psychosis,	O
schizophrenia,	O
sleep	O
and	O
sexual	O
disorders,	O
migraine	O
and	O
other	O
conditions	O
associated	O
with	O
cephalic	O
pain,	O
social	O
phobias,	O
and	O
gastrointestinal	O
disorders	O
such	O
as	O
dysfunction	O
of	O
the	O
gastrointestinal	O
tract	O
motility	O
.	O


This	O
invention	O
relates	O
to	O
stable	O
pharmaceutical	O
compositions	O
of	O
the	O
NMDA	B-GENE
receptor	I-GENE
agonist,	O
(	O
1S,	O
2S	O
)	O
-1-	O
(	O
4-hydroxyphenyl	O
)	O
-2-	O
(	O
4-hydroxy-4-phenylpiperidin-1-yl	O
)	O
-1-propanol	O
]	O
,	O
methods	O
of	O
preparing	O
such	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treating	O
stroke,	O
spinal	O
cord	O
trauma,	O
traumatic	O
brain	O
injury,	O
multiinfarct	O
dementia,	O
CNS	O
degenerative	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
'	O
s	O
type,	O
Huntington	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
epilepsy,	O
amyotrophic	O
lateral	O
sclerosis,	O
pain,	O
AIDS	O
dementia,	O
psychotic	O
conditions,	O
drug	O
addictions,	O
migraine,	O
hypoglycemia,	O
anxiolytic	O
conditions,	O
urinary	O
incontinence	O
and	O
an	O
ischemic	O
event	O
arising	O
from	O
CNS	O
surgery,	O
open	O
heart	O
surgery	O
or	O
any	O
procedure	O
during	O
which	O
the	O
function	O
of	O
the	O
cardiovascular	O
system	O
is	O
compromised	O
using	O
the	O
pharmaceutical	O
compositions	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
a	O
linkage	O
independently	O
selected	O
from	O
(	O
CH2	O
)	O
12	O
or	O
(	O
CH2CH2	O
)	O
4O3	O
and	O
wherein	O
R3	O
is	O
independently	O
selected	O
from	O
H,	O
CH2CH3,	O
COCH3	O
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
acid	O
addition	O
salts,	O
solvates	O
and	O
hydrates	O
thereof	O
.	O
The	O
compounds	O
have	O
unusually	O
high	O
affinity	O
for	O
muscarinic	O
receptors,	O
and	O
exhibit	O
agonist	O
activity	O
useful	O
in	O
the	O
treatment	O
of	O
neurological	O
and	O
other	O
disorders,	O
in	O
which	O
stimulating	O
cholinergic	O
activity	O
is	O
desirable	O
.	O


Biocompatible	O
materials	O
that	O
have	O
the	O
ability	O
to	O
release	O
nitric	O
oxide	O
(	O
NO	O
)	O
	O
	O
	O
in	O
situ	O
	O
	O
	O
	O
at	O
the	O
surface-blood	O
interface	O
when	O
in	O
contact	O
with	O
blood	O
.	O
The	O
materials	O
which	O
may	O
be	O
polymers	O
(	O
e	O
.	O
g	O
.	O
,	O
polyurethane,	O
poly	O
(	O
vinyl	O
chloride	O
)	O
,	O
silicone	O
rubbers	O
)	O
,	O
metals,	O
such	O
as	O
stainless	O
steel,	O
carbon,	O
and	O
the	O
like	O
are	O
provided	O
with	O
biocatalysts	O
or	O
biomimetic	O
catalysts	O
on	O
their	O
surface	O
that	O
have	O
nitrite,	O
nitrate	O
and	O
/	O
or	O
nitrosothiol-reducing	O
capability	O
that	O
.	O
Illustratively,	O
the	O
catalysts	O
are	O
adsorbed	O
or	O
immobilized	O
at	O
the	O
surface	O
of	O
the	O
material	O
.	O
The	O
catalysts	O
can	O
act	O
on	O
endogenous	O
nitrite	O
/	O
nitrate	O
or	O
nitrosothiols	O
within	O
the	O
blood	O
creating	O
a	O
local	O
increase	O
in	O
the	O
NO	O
levels	O
at	O
the	O
surface	O
of	O
the	O
material	O
.	O
An	O
illustrative	O
enzymatic	O
biocatalyst	O
is	O
mammalian	B-GENE
xanthine	I-GENE
oxidase	I-GENE
.	O
In	O
another	O
illustrative	O
embodiment,	O
a	O
biomimetic	O
catalyst	O
is	O
a	O
copper	O
(	O
Cu	O
(	O
II	O
)	O
-ligands	O
complex,	O
e	O
.	O
g	O
.	O
,	O
dibenzo	O
[	O
e,k	O
]	O
-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene	O
.	O
In	O
some	O
cases,	O
lipophilic	O
salts	O
of	O
nitrite	O
/	O
nitrate	O
(	O
e	O
.	O
g	O
.	O
,	O
tridodecylmethylammonium	O
nitrite	O
(	O
TDMA	O
<	O
+	O
>	O
NO2	O
<	O
-	O
>	O
/	O
NO3	O
<	O
-	O
>	O
)	O
)	O
or	O
certain	O
salts	O
of	O
nitrosothiols	O
can	O
be	O
doped	O
within	O
a	O
polymer	O
material,	O
or	O
an	O
underlying	O
polymeric	O
film,	O
to	O
create	O
a	O
reservoir	O
of	O
nitrite	O
or	O
nitrosothiol	O
that	O
continuously	O
leaks	O
into	O
the	O
immobilized	O
catalytic	O
layer	O
.	O
Adequate	O
levels	O
of	O
endogenous	O
reducing	O
equivalents	O
are	O
present	O
within	O
blood	O
to	O
provide	O
catalytically-generated	O
surface	O
levels	O
of	O
NO	O
that	O
are	O
above	O
the	O
threshold	O
reportedly	O
required	O
to	O
prevent	O
platelet	O
adhesion	O
or	O
activation	O
.	O


Substituted	O
diarylureas,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
their	O
use	O
for	O
stimulating	O
Fas-mediated	O
apoptosis	O
.	O
The	O
compounds,	O
as	O
single	O
stereoisomers	O
or	O
mixtures	O
of	O
stereoisomers,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them,	O
are	O
useful	O
in	O
methods	O
of	O
treating	O
autoimmune	O
diseases,	O
infectious	O
diseases,	O
and	O
malignancies	O
.	O


Compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
or	O
veterinarily	O
acceptable	O
salts,	O
solvates,	O
polymorphs	O
or	O
pro-drugs	O
thereof	O
wherein	O
:	O
wherein	O
R	O
?	O
1,	O
R2,	O
R3,	O
R4¿,	O
X	O
and	O
A	O
have	O
the	O
meanings	O
given	O
herein	O
which	O
are	O
useful	O
in	O
the	O
curative	O
and	O
prophylactic	O
treatment	O
of	O
a	O
medical	O
condition	O
for	O
which	O
inhibition	O
of	O
a	O
cyclic	B-GENE
guanosine	I-GENE
3',5'-monophosphate	I-GENE
phosphodiesterase	I-GENE
(	O
e	O
.	O
g	O
.	O
cGMP	O
PDE5	B-GENE
)	O
is	O
desired	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
inhibitors	O
of	O
trypsin	B-GENE
like	I-GENE
serine	I-GENE
protease	I-GENE
enzymes	O
such	O
as	O
thrombin,	O
factor	O
VIIa,	O
factor	O
Xa,	O
TF	B-GENE
/	O
FVIIa,	O
and	O
trypsin	B-GENE
.	O
These	O
compounds	O
could	O
be	O
useful	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
clotting	O
disorders,	O
and	O
as	O
anticoagulating	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
heterocyclic	O
compound,	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
compound,	O
a	O
method	O
and	O
use	O
of	O
said	O
compound	O
for	O
clinical	O
treatment	O
of	O
medical	O
conditions	O
which	O
may	O
benefit	O
from	O
immunomodulation,	O
e	O
.	O
g	O
.	O
rheumatoid	O
arthritis,	O
multiple	O
sclerosis,	O
diabetes,	O
asthma,	O
transplantation,	O
systemic	O
lupus	O
erythematosis	O
and	O
psoriasis	O
.	O
More	O
particularly	O
the	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds,	O
which	O
are	O
CD80	B-GENE
antagonists	O
capable	O
of	O
inhibiting	O
the	O
interactions	O
between	O
CD80	B-GENE
and	O
CD28	B-GENE
.	O


GnRH	B-GENE
receptor	O
antagonists	O
of	O
formula	O
I	O
are	O
disclosed	O
which	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
sex-hormone	O
related	O
conditions	O
in	O
both	O
men	O
and	O
women	O
.	O
Also	O
disclosed	O
are	O
compositions	O
containing	O
a	O
compound	O
of	O
this	O
invention	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
as	O
well	O
as	O
methods	O
relating	O
to	O
the	O
use	O
thereof	O
for	O
antagonizing	O
gonadotropin-releasing	B-GENE
hormone	I-GENE
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


Oral	O
semi-solid	O
or	O
liquid	O
composition	O
for	O
treating	O
hyperlipidemia	O
or	O
hypercholesterolemia	O
in	O
humans,	O
which	O
comprises	O
at	O
least	O
an	O
effective	O
amount	O
of	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptor	I-GENE
alpha	I-GENE
agent	O
(	O
PPARa	B-GENE
)	O
,	O
one	O
polyglycolized	O
glyceride	O
and	O
one	O
hydrophilic	O
disintegrating	O
agent	O
.	O


There	O
are	O
provided	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O
wherein	O
R	O
?	O
1,	O
R2,	O
R3¿,	O
Q,	O
T,	O
U,	O
X,	O
Y,	O
V	O
and	O
W	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
enantiomers	O
and	O
racemates	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
disease	O
and	O
pain	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compound	O
which	O
are	O
capable	O
of	O
preventing	O
the	O
extracellular	O
release	O
of	O
inflammatory	O
cytokines,	O
said	O
compounds,	O
including	O
all	O
enantiomeric	O
and	O
diasteriomeric	O
forms	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
have	O
the	O
formula	O
:	O
wherein	O
R	O
comprises	O
ethers	O
or	O
amines	O
;	O
R	O
<	O
1	O
>	O
is	O
:	O
a	O
)	O
substituted	O
or	O
unsubstituted	O
aryl	O
;	O
orb	O
)	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
;	O
R	O
<	O
2a	O
>	O
and	O
R	O
<	O
2b	O
>	O
units	O
are	O
each	O
independently	O
hydrogen,	O
ethers,	O
amines,	O
amides,	O
carboxylates,	O
or	O
said	O
units	O
can	O
form	O
a	O
double	O
bond,	O
a	O
carbonyl,	O
or	O
R	O
<	O
2a	O
>	O
and	O
R	O
<	O
2b	O
>	O
can	O
be	O
taken	O
together	O
to	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
ring	O
comprising	O
from	O
4	O
to	O
8	O
atoms,	O
said	O
ring	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
i	O
)	O
carbocyclic	O
;	O
ii	O
)	O
heterocyclic	O
;	O
iii	O
)	O
aryl	O
;	O
iv	O
)	O
heteroaryl	O
;	O
v	O
)	O
bicyclic	O
;	O
andvi	O
)	O
heterobicyclic	O
.	O


This	O
invention	O
discloses	O
pyrimidine	O
compounds,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
prodrugs	O
thereof,	O
useful	O
in	O
therapeutically	O
and	O
/	O
or	O
prophylactically	O
treating	O
patients	O
with	O
cancer	O
by	O
inhibiting	O
receptor	B-GENE
tyrosine	I-GENE
kinases	I-GENE
and	O
/	O
or	O
dihydrofolate	B-GENE
reductase	I-GENE
and	O
/	O
or	O
thymidylate	B-GENE
synthase	I-GENE
.	O
The	O
compounds,	O
and	O
methods	O
of	O
using	O
these	O
compounds,	O
are	O
disclosed	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
(HCV)	I-GENE
RNA-dependent	I-GENE
RNA	I-GENE
polymerase	I-GENE
(	O
RdRp	B-GENE
)	O
inhibitors,	O
and	O
are	O
useful	O
in	O
therapeutic	O
and	O
prophylactic	O
treatment	O
of	O
persons	O
infected	O
with	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
.	O


Novel	O
carboximide	O
derivatives,	O
which	O
selectively	O
inhibit	O
binding	O
to	O
the	O
α-1A	B-GENE
adrenergic	I-GENE
receptor,	O
a	O
receptor	O
which	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O


Novel	O
α,ω-dicarboximide	O
derivatives	O
which	O
selectively	O
inhibit	O
binding	O
to	O
the	O
α-1A	B-GENE
adrenergic	I-GENE
receptor,	O
a	O
receptor	O
which	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
compositions	O
based	O
on	O
anticholinergics	O
and	O
p38	B-GENE
kinase	I-GENE
inhibitors,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O


Indole	O
compounds	O
of	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
wherein	O
L1	O
is	O
CO	O
;	O
L2	O
is	O
a	O
bond	O
;	O
R1	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
R2	O
is	O
H,	O
aryl,	O
heteroaryl,	O
halogen,	O
nitro,	O
nitroso,	O
cyano,	O
azide,	O
isothionitro,	O
OR,	O
OC	O
(	O
O	O
)	O
R,	O
OC	O
(	O
O	O
)	O
OR,	O
OC	O
(	O
O	O
)	O
NRR	O
'	O
,	O
SO2R,	O
SO3R,	O
SO2NRR	O
'	O
,	O
SR,	O
NRR	O
'	O
,	O
NRSO2NR	O
'	O
R	O
'	O
'	O
,	O
NRSO2R	O
'	O
,	O
NRSO3R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
NRC	O
(	O
C	O
)	O
OR	O
'	O
,	O
NRC	O
(	O
N	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
C	O
(	O
O	O
)	O
OR,	O
C	O
(	O
O	O
)	O
NRR	O
'	O
,	O
an	O
amino	O
acid	O
moiety,	O
a	O
polypeptide	O
moiety,	O
a	O
carbohydrate	O
moiety,	O
or	O
a	O
PEG	O
moiety	O
;	O
each	O
of	O
Ra,	O
Rb,	O
Rc,	O
and	O
Rd,	O
independently,	O
is	O
R,	O
halogen,	O
nitro,	O
nitroso,	O
cyano,	O
azide,	O
isothionitro,	O
OR,	O
OC	O
(	O
O	O
)	O
R,	O
OC	O
(	O
O	O
)	O
OR,	O
OC	O
(	O
O	O
)	O
NRR	O
'	O
,	O
SO2R,	O
SO3R,	O
SO2NRR	O
'	O
,	O
SR,	O
NRR	O
'	O
,	O
NRSO2NR	O
'	O
R	O
'	O
'	O
,	O
NRSO2R	O
'	O
,	O
NRSO3R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
NRC	O
(	O
O	O
)	O
OR	O
'	O
,	O
NRC	O
(	O
N	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
C	O
(	O
O	O
)	O
R,	O
C	O
(	O
O	O
)	O
OR,	O
C	O
(	O
O	O
)	O
NRR	O
'	O
,	O
OP	O
(	O
O	O
)	O
(	O
OR	O
)	O
(	O
OR	O
'	O
)	O
,	O
O	O
(	O
CH2	O
)	O
nOP	O
(	O
O	O
)	O
(	O
OR	O
)	O
(	O
OR	O
'	O
)	O
,	O
or	O
O	O
(	O
CH2	O
)	O
n-PEG,	O
or	O
Rb	O
and	O
Rc,	O
Ra	O
and	O
Rb,	O
or	O
Rc	O
and	O
Rd	O
taken	O
together	O
are	O
O	O
(	O
CH2	O
)	O
nO	O
;	O
and	O
Re	O
is	O
H,	O
alkyl,	O
alkenyl,	O
alkynyl,	O
cyclyl,	O
heterocyclyl,	O
halogen,	O
nitro,	O
nitroso,	O
cyano,	O
azide,	O
isothionitro,	O
OR,	O
OC	O
(	O
O	O
)	O
R,	O
OC	O
(	O
O	O
)	O
OR,	O
OC	O
(	O
O	O
)	O
NRR	O
'	O
,	O
SO2R,	O
SO3R,	O
SO2NRR	O
'	O
,	O
SR,	O
NRR	O
'	O
,	O
NRSO2NR	O
'	O
R	O
'	O
'	O
,	O
NRSO2R	O
'	O
,	O
NRSO3R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
R	O
'	O
,	O
NRC	O
(	O
O	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
NRC	O
(	O
O	O
)	O
OR	O
'	O
,	O
NRC	O
(	O
N	O
)	O
NR	O
'	O
R	O
'	O
'	O
,	O
C	O
(	O
O	O
)	O
R,	O
C	O
(	O
O	O
)	O
OR,	O
or	O
C	O
(	O
O	O
)	O
NRR	O
'	O
;	O
in	O
which	O
each	O
of	O
R,	O
R	O
'	O
,	O
and	O
R	O
'	O
'	O
,	O
independently,	O
is	O
H,	O
alkyl,	O
alkenyl,	O
alkynyl,	O
aryl,	O
heteroaryl,	O
cyclyl,	O
or	O
heterocyclyl	O
;	O
and	O
n	O
is	O
1,	O
2,	O
3,	O
4,	O
or	O
5,	O
as	O
inhibitors	O
of	O
tubulin	B-GENE
polymerisation	O
useful	O
in	O
the	O
treatment	O
of	O
angiogenesis-related	O
disorders	O
such	O
as	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
2-naphthamides,	O
which	O
are	O
useful	O
as	O
an	O
active	O
ingredient	O
of	O
pharmaceutical	O
preparations	O
.	O
The	O
2-naphthamides	O
of	O
the	O
present	O
invention	O
have	O
IP	B-GENE
receptor	I-GENE
antagonistic	O
activity,	O
and	O
can	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
associated	O
with	O
IP	B-GENE
receptor	I-GENE
activity	O
.	O
Such	O
diseases	O
include	O
urological	O
diseases	O
or	O
disorder	O
as	O
follows	O
:	O
bladder	O
outlet	O
obstruction,	O
overactive	O
bladder,	O
urinary	O
incontinence,	O
detrusor	O
hyper-reflexia,	O
detrusor	O
instability,	O
reduced	O
bladder	O
capacity,	O
frequency	O
of	O
micturition,	O
urge	O
incontinence,	O
stress	O
incontinence,	O
bladder	O
hyperreactivity,	O
benign	O
prostatic	O
hypertrophy	O
(	O
BPH	O
)	O
,	O
prostatitis,	O
urinary	O
frequency,	O
nocturia,	O
urinary	O
urgency,	O
pelvic	O
hypersensitivity,	O
urethritis,	O
pelvic	O
pain	O
syndrome,	O
prostatodynia,	O
cystitis,	O
or	O
idiophatic	O
bladder	O
hypersensitivity	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
useful	O
for	O
treatment	O
of	O
pain	O
including,	O
but	O
not	O
limited	O
to	O
inflammatory	O
pain,	O
neuropathic	O
pain,	O
acute	O
pain,	O
chronic	O
pain,	O
dental	O
pain,	O
premenstrual	O
pain,	O
visceral	O
pain,	O
headaches,	O
and	O
the	O
like	O
;	O
hypotension	O
;	O
hemophilia	O
and	O
hemorrhage	O
;	O
and	O
inflammation,	O
since	O
the	O
disease	O
is	O
also	O
alleviated	O
by	O
treatment	O
with	O
an	O
IP	B-GENE
receptor	I-GENE
antagonist	O
.	O


The	O
present	O
invention	O
provides	O
carbocyclic	O
nucleoside	O
compounds	O
and	O
certain	O
derivatives	O
thereof	O
which	O
are	O
inhibitors	O
of	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
polymerase	I-GENE
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
replication	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
infection	O
.	O
They	O
are	O
particularly	O
useful	O
as	O
inhibitors	O
of	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
(HCV)	I-GENE
NS5B	I-GENE
polymerase,	O
as	O
inhibitors	O
of	O
HCV	O
replication,	O
and	O
/	O
or	O
for	O
the	O
treatment	O
of	O
hepatitis	B-GENE
C	I-GENE
infection	O
.	O
The	O
invention	O
also	O
describes	O
pharmaceutical	O
compositions	O
containing	O
such	O
carbocyclic	O
nucleoside	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
other	O
agents	O
active	O
against	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
infection,	O
in	O
particular	O
HCV	O
infection	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
inhibiting	O
RNA-dependent	B-GENE
RNA	I-GENE
polymerase,	O
inhibiting	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
replication,	O
and	O
/	O
or	O
treating	O
RNA-dependent	B-GENE
RNA	I-GENE
viral	I-GENE
infection	O
with	O
the	O
carbocyclic	O
nucleoside	O
compounds	O
of	O
the	O
present	O
invention	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
comprising	O
a	O
polypeptide	O
selected	O
from	O
a	O
group	O
containing	O
insulin,	O
an	O
insulin	B-GENE
metabolite,	O
an	O
insulin	B-GENE
analogue,	O
an	O
insulin	B-GENE
derivative	O
or	O
combinations	O
thereof	O
and	O
also	O
comprising	O
a	O
surfactant	O
or	O
combinations	O
of	O
several	O
surfactants,	O
optionally	O
a	O
preservative	O
or	O
combinations	O
of	O
several	O
preservatives	O
and	O
optionally	O
an	O
isotonic	O
agent,	O
buffers	O
or	O
additional	O
auxiliary	O
agents	O
or	O
combinations	O
thereof	O
.	O
According	O
to	O
the	O
invention,	O
said	O
pharmaceutical	O
formulation	O
has	O
an	O
acidic	O
pH	O
value	O
.	O


This	O
invention	O
relates	O
to	O
the	O
pyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salt,	O
solvate	O
or	O
derivatives	O
thereof,	O
to	O
their	O
use	O
in	O
medicine,	O
to	O
compositions	O
containing	O
them,	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
to	O
intermediates	O
used	O
in	O
such	O
processes	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
bind	O
to	O
the	O
enzyme	O
reverse	B-GENE
transcriptase	I-GENE
and	O
are	O
modulators,	O
especially	O
inhibitors,	O
thereof	O
.	O
Reverse	B-GENE
transcriptase	I-GENE
is	O
implicated	O
in	O
the	O
infectious	O
lifecycle	O
of	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
.	O
Compounds	O
which	O
interfere	O
with	O
the	O
function	O
of	O
this	O
enzyme	O
have	O
shown	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
caused	O
by	O
HIV	O
and	O
genetically	O
related	O
retroviruses,	O
such	O
as	O
Acquired	O
Immune	O
Deficiency	O
Syndrome	O
(	O
AIDS	O
)	O
.	O


This	O
invention	O
generally	O
relates	O
to	O
the	O
derivatives	O
of	O
3,6	O
disubstituted	O
azabicyclo	O
[	O
3	O
.	O
1	O
.	O
0	O
]	O
hexanes	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
are	O
muscarinic	B-GENE
receptor	I-GENE
antagonists	O
which	O
are	O
useful,	O
inter-alia,	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
of	O
the	O
respiratory,	O
urinary	O
and	O
gastrointestinal	O
systems	O
mediated	O
through	O
muscarinic	B-GENE
receptors	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
and	O
the	O
methods	O
for	O
treating	O
the	O
diseases	O
mediated	O
through	O
muscarinic	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
composition	O
of	O
compounds	O
that	O
modulate	O
norepinephrine	O
levels	O
for	O
the	O
treatment	O
of	O
vasomotor	O
symptoms	O
such	O
as	O
thermoregulatory	O
disorders	O
.	O
Furthermore,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
compositions	O
of	O
compounds	O
having	O
norepinephrine	O
reuptake	O
inhibitor	O
(	O
NRI	O
)	O
activity	O
alone	O
or	O
norepinephrine	O
reuptake	O
inhibitor	O
and	O
serotonin	O
reuptake	O
inhibitor	O
(	O
NRI	O
/	O
SRI	O
)	O
dual	O
activity	O
in	O
combination	O
with	O
5-HT2a	B-GENE
receptor	O
antagonist	O
activity	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
R10,	O
R11,	O
R27,	O
R28,	O
R29,	O
R30,	O
R31,	O
X,	O
m,	O
n	O
and	O
the	O
dashed	O
line	O
are	O
defined	O
herein	O
)	O
which	O
are	O
useful	O
as	O
modulators	O
of	O
chemokine	B-GENE
receptor	I-GENE
activity	O
.	O
In	O
particular,	O
these	O
compounds	O
are	O
useful	O
as	O
modulators	O
of	O
the	O
chemokine	B-GENE
receptor	I-GENE
CCR-2	I-GENE
.	O


Growth	B-GENE
differentiation	I-GENE
factor-10	I-GENE
(	O
GDF-10	B-GENE
)	O
is	O
disclosed	O
along	O
with	O
its	O
polynucleotide	O
sequence	O
and	O
amino	O
acid	O
sequence	O
.	O
Also	O
disclosed	O
are	O
diagnostic	O
and	O
therapeutic	O
methods	O
of	O
using	O
the	O
GDF-10	B-GENE
polypeptide	O
and	O
polynucleotide	O
sequences	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
providing	O
alpha	B-GENE
-glucosidase	I-GENE
inhibition	O
to	O
a	O
subject	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
alpha	B-GENE
-glucosidase	I-GENE
inhibitory	O
agent	O
selected	O
from	O
pipataline	O
(	O
formula	O
1a	O
)	O
,	O
sesamin	O
(	O
formula	O
1b	O
)	O
,	O
pellitorine	O
(	O
Formula	O
1c	O
)	O
,	O
guineensine	O
(	O
Formula	O
1d	O
)	O
and	O
brachystamide-B	O
(	O
formula	O
1e	O
)	O
having	O
therapeutic	O
application	O
for	O
diabetes	O
mellitus,	O
cancer,	O
viral	O
diseases	O
such	O
as	O
hepatitis	O
B	O
and	O
C,	O
HIV,	O
AIDS	O
etc	O
;	O
also	O
the	O
invention	O
provides	O
a	O
process	O
for	O
the	O
isolation	O
of	O
said	O
alpha	B-GENE
-glucosidase	I-GENE
inhibitory	O
agent	O
from	O
the	O
plant	O
source	O
Piper	O
longum	O
in	O
significant	O
yields	O
.	O


The	O
present	O
invention	O
relates	O
to	O
spirocyclic	O
ureas,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
The	O
compounds	O
are	O
glucagon	B-GENE
receptor	I-GENE
antagonists	O
and	O
thus	O
are	O
useful	O
for	O
treating,	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O


Disclosed	O
are	O
methods	O
of	O
lowering	O
plasma	O
CRP	B-GENE
levels,	O
reducing	O
systemic	O
inflammation,	O
and	O
inhibiting	O
proinlammatory	O
cytokine	B-GENE
induced	O
CRP	B-GENE
production	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
substituted	O
dialkyl	O
ether,	O
substituted	O
alkyl,	O
substituted	O
aryl-alkyl,	O
substituted	O
dialkyl	O
thioether,	O
substituted	O
dialkyl	O
ketone,	O
substituted-alkyl,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
substituted	O
dialkyl	O
ether,	O
substituted	O
alkyl,	O
substituted	O
aryl-alkyl,	O
substituted	O
dialkyl	O
thioether,	O
substituted	O
dialkyl	O
ketone,	O
or	O
substituted-alkyl	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
substituted	O
dialkyl	O
ether,	O
substituted	O
alkyl,	O
substituted	O
aryl-alkyl,	O
substituted	O
dialkyl	O
thioether,	O
substituted	O
dialkyl	O
ketone,	O
substituted-alkyl	O
.	O


The	O
invention	O
concerns	O
methods	O
for	O
modulating	O
the	O
ß-adrenergic	B-GENE
pathway	O
.	O
In	O
particular,	O
the	O
invention	O
concerns	O
methods	O
for	O
counteracting	O
a	O
pathologic	O
change,	O
such	O
as,	O
for	O
example,	O
a	O
loss	O
in	O
ß-adrenergic	B-GENE
sensitivity,	O
in	O
the	O
ß-adrenergic	B-GENE
signal	O
transduction	O
pathway	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
TGF-ß	B-GENE
signaling	O
through	O
a	O
TGF-ß	B-GENE
receptor	I-GENE
.	O


This	O
invention	O
provides	O
novel	O
transcriptional	O
regulatory	O
elements	O
from	O
the	O
human	B-GENE
TRPM4	B-GENE
(	O
Transient	B-GENE
Receptor	I-GENE
Potential-Melastatin	I-GENE
4	I-GENE
)	O
gene	O
.	O
These	O
promoter	O
and	O
enhancer	O
elements	O
preferentially	O
activate	O
transcription	O
in	O
prostate	O
tumor	O
cells	O
and	O
tissues	O
as	O
compared	O
to	O
other	O
tissues	O
.	O
Methods	O
and	O
compositions	O
are	O
provided	O
to	O
employ	O
TRPM4	B-GENE
promoter	O
elements	O
for	O
prostate	O
tumor-specific	O
expression	O
of	O
therapeutic	O
molecules	O
.	O
Prostate	O
tumor-restricted	O
replicating	O
adenoviral	O
vectors	O
are	O
also	O
provided	O
.	O


An	O
antibody	O
that	O
specifically	O
reacts	O
with	O
a	O
protein	O
comprising	O
an	O
amino	O
acid	O
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
	O
(	O
a	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
;	O
(	O
b	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
from	O
amino	O
acids	O
11	O
to	O
163	O
;	O
(	O
c	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
from	O
amino	O
acids	O
29	O
to	O
163	O
;	O
(	O
d	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
from	O
amino	O
acids	O
31	O
to	O
163	O
;	O
and	O
(	O
e	O
)	O
a	O
fragment	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
having	O
a	O
CTLA-8	B-GENE
activity	O
chosen	O
from	O
one	O
or	O
more	O
of	O
induction	O
of	O
expression	O
or	O
secretion	O
of	O
γ-IFN,	O
IL-6,	O
or	O
IL-8,	O
or	O
inhibition	O
of	O
angiogenesis	O
.	O


Use	O
of	O
a	O
glycoalkaloid	O
composition	O
containing	O
at	O
least	O
one	O
Z	O
Glycoalkaloid	O
of	O
formula	O
I,	O
wherein	O
:	O
either	O
one	O
or	O
both	O
of	O
the	O
dotted	O
lines	O
represents	O
a	O
double	O
bond,	O
and	O
the	O
other	O
a	O
single	O
bond,	O
or	O
both	O
represent	O
single	O
bonds	O
;	O
A	O
:	O
represents	O
a	O
radical	O
selected	O
from	O
the	O
radicals	O
of	O
general	O
formulae	O
(	O
II	O
)	O
to	O
(	O
V	O
)	O
;	O
each	O
of	O
R	O
<	O
1	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
amino,	O
oxo	O
and	O
OR	O
<	O
4	O
>	O
;	O
each	O
of	O
R	O
<	O
2	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
amino	O
and	O
OR	O
<	O
4	O
>	O
;	O
each	O
of	O
R	O
<	O
3	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
carbohydrate	O
and	O
a	O
carbohydrate	O
;	O
"X"	O
is	O
a	O
radical	O
selected	O
from	O
the	O
group	O
comprising	O
-CH2-,	O
-O-	O
and	O
-NH2-	O
;	O
and	O
wherein	O
the	O
compound	O
includes	O
at	O
least	O
one	O
R	O
<	O
4	O
>	O
group	O
that	O
is	O
a	O
carbohydrate	O
or	O
a	O
derivative	O
such	O
as	O
one	O
selected	O
from	O
the	O
group	O
comprising	O
glyceric	O
aldehyde,	O
glycerose,	O
erythrose,	O
threose,	O
ribose,	O
arabinose,	O
xylose,	O
lyxose,	O
altrose,	O
allose,	O
gulose,	O
mannose,	O
glucose,	O
idose,	O
galactose,	O
talose,	O
rhamnose,	O
dihydroxyactone,	O
erythrulose,	O
ribulose,	O
xylulose,	O
psicose,	O
fructose,	O
sorbose,	O
tagatose,	O
and	O
other	O
hexoses,	O
heptoses,	O
octoses,	O
nanoses,	O
decoses,	O
deoxysugars	O
with	O
branched	O
chains,	O
(	O
e	O
.	O
g	O
.	O
apiose,	O
hamamelose,	O
streptose,	O
cordycepose,	O
mycarose	O
and	O
cladinose	O
)	O
,	O
compounds	O
wherein	O
the	O
aldehyde,	O
ketone	O
or	O
hydroxyl	O
groups	O
have	O
been	O
substituted	O
(	O
e	O
.	O
g	O
.	O
N-acetyl,	O
acetyl,	O
methyl,	O
replacement	O
of	O
CH2OH	O
)	O
,	O
sugar	O
alcohols,	O
sugar	O
acids,	O
benzimidazoles,	O
the	O
enol	O
salts	O
of	O
the	O
carbohydrates,	O
saccharinic	O
acids,	O
sugar	O
phosphates	O
;	O
as	O
an	O
IL-6	B-GENE
antagonist	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
of	O
inhibiting	O
HCV	O
viral	O
replication	O
activityy	O
comprising	O
contacting	O
an	O
HCV	B-GENE
polymerase	I-GENE
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
hydroxamate	O
MMP	B-GENE
inhibitor,	O
and	O
composition	O
comprising	O
the	O
same	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods,	O
kits,	O
combinations,	O
and	O
compositions	O
for	O
treating,	O
preventing	O
or	O
reducing	O
the	O
risk	O
of	O
developing	O
a	O
gastrointestinal	O
disorder	O
or	O
disease,	O
or	O
the	O
symptoms	O
associated	O
with,	O
or	O
related	O
to	O
a	O
gastrointestinal	O
disorder	O
or	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O
In	O
one	O
aspect,	O
the	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
proton	B-GENE
pump	I-GENE
inhibiting	O
agent	O
and	O
a	O
buffering	O
agent	O
for	O
oral	O
administration	O
and	O
ingestion	O
by	O
a	O
subject	O
.	O
Upon	O
administration,	O
the	O
composition	O
contacts	O
the	O
gastric	O
fluid	O
of	O
the	O
stomach	O
and	O
increases	O
the	O
gastric	O
fluid	O
pH	O
of	O
the	O
stomach	O
to	O
a	O
pH	O
that	O
substantially	O
prevents	O
or	O
inhibits	O
acid	O
degradation	O
of	O
the	O
proton	B-GENE
pump	I-GENE
inhibiting	O
agent	O
in	O
the	O
gastric	O
fluid	O
and	O
allows	O
a	O
measurable	O
serum	O
concentration	O
of	O
the	O
proton	B-GENE
pump	I-GENE
inhibiting	O
agent	O
to	O
be	O
absorbed	O
into	O
the	O
blood	O
serum	O
of	O
the	O
subject	O
.	O


A	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
neuropathic	O
pain	O
which	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
a	O
compound	O
having	O
histamine	B-GENE
H3-receptor	I-GENE
antagonism	O
such	O
as	O
a	O
compound	O
represented	O
by	O
Formula	O
(	O
II	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
W	O
represents	O
a	O
residue	O
which	O
imparts	O
antagonistic	O
and	O
/	O
or	O
agonistic	O
activity	O
at	O
histamine	B-GENE
H3-receptors	I-GENE
when	O
attached	O
to	O
an	O
imidazole	O
ring	O
in	O
4-	O
or	O
5-position,	O
and	O
R3	O
and	O
R4	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
or	O
the	O
like	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
provided	O
.	O


Provided	O
are	O
polypeptide	O
ligands	O
for	O
the	O
receptor	B-GENE
tyrosine	I-GENE
kinase,	O
Flt4	B-GENE
.	O
Also	O
provided	O
are	O
cDNAs	O
and	O
vectors	O
encoding	O
the	O
ligands,	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
reagents	O
comprising	O
the	O
ligands,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
ligands	O
.	O


This	O
invention	O
provides	O
the	O
use	O
of	O
a	O
combination	O
of	O
CCI-779	O
and	O
interferon	B-GENE
alfa	I-GENE
(α)	I-GENE
in	O
the	O
treatment	O
of	O
neoplasms	O
.	O


The	O
use	O
of	O
substituted	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyrimidines	O
for	O
modulating	O
the	O
activity	O
of	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11βHSD1	B-GENE
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
phar-maceutical	O
compositions	O
are	O
described	O
.	O
Also	O
a	O
novel	O
class	O
of	O
substituted	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyrimidines	O
their	O
use	O
in	O
therapy,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
The	O
present	O
com-pounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSD1	B-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
/	O
or	O
prophylaxis	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	O
is	O
desirable	O
.	O


Pharmaceutical	O
compositions	O
(	O
A	O
)	O
for	O
local	O
application	O
to	O
stop	O
bleeding,	O
close	O
wounds	O
and	O
/	O
or	O
stimulate	O
wound	O
healing,	O
contain	O
fibrinogen	B-GENE
(	O
I	B-GENE
)	O
or	O
fibrin	B-GENE
(	O
Ia	B-GENE
)	O
,	O
thrombin	B-GENE
(	O
II	B-GENE
)	O
and	O
one	O
or	O
more	O
transglutaminases	B-GENE
(	O
III	B-GENE
)	O
,	O
also	O
at	O
least	O
one	O
serpin-type	B-GENE
protease	I-GENE
inhibitor	O
(	O
IV	O
)	O
that	O
has	O
no	O
inhibitory	O
action	O
on	O
collagenases	B-GENE
or	O
elastases,	O
are	O
new	O
.	O
All	O
active	O
ingredients	O
are	O
of	O
allogenic	O
origin	O
(	O
isolated	O
from	O
plasma	O
or	O
tissue,	O
or	O
recombinant	O
)	O
and	O
have	O
been	O
subjected	O
to	O
a	O
virus	O
removal	O
and	O
/	O
or	O
inactivation	O
step,	O
provided	O
that	O
virus	O
inactivation	O
of	O
(	O
IV	O
)	O
is	O
not	O
done	O
in	O
presence	O
of	O
other	O
active	O
ingredients	O
.	O
Independent	O
claims	O
are	O
also	O
included	O
for	O
the	O
following	O
:	O
(	O
a	O
)	O
preparation	O
of	O
a	O
(	O
I	B-GENE
)	O
-containing	O
solution,	O
as	O
such	O
or	O
as	O
part	O
of	O
(	O
A	O
)	O
,	O
that	O
can	O
be	O
stored	O
at	O
refrigerator	O
or	O
room	O
temperature	O
;	O
(	O
b	O
)	O
pharmaceutical	O
compositions	O
(	O
B	O
)	O
containing	O
a	O
highly	O
purified	O
(	O
I	B-GENE
)	O
-	O
or	O
(	O
I	B-GENE
)	O
plus	O
fibronectin-containing	O
composition	O
that	O
has	O
activated	O
prothrombin	O
time	O
and	O
Taipan	O
viper	O
venom	O
prothrombin	O
time	O
at	O
37	O
[	O
deg	O
]	O
C	O
of	O
at	O
least	O
200	O
and	O
300	O
sec,	O
respectively	O
;	O
(	O
c	O
)	O
a	O
method	O
for	O
preparing	O
pathogen-free	O
(	O
A	O
)	O
;	O
(	O
d	O
)	O
a	O
method	O
for	O
covalent	O
binding	O
of	O
(	O
A	O
)	O
to	O
a	O
biological	O
matrix	O
;	O
(	O
e	O
)	O
a	O
method	O
for	O
preparing	O
a	O
(	O
Ia	B-GENE
)	O
-containing	O
gel	O
of	O
20-90	O
%	O
water	O
content	O
;	O
(	O
f	O
)	O
a	O
method	O
for	O
solidifying	O
a	O
(	O
Ia	B-GENE
)	O
-containing	O
gel	O
with	O
or	O
without	O
removal	O
of	O
water	O
;	O
(	O
g	O
)	O
a	O
freeze-dried	O
(	O
Ia	B-GENE
)	O
-containing	O
gel	O
to	O
which	O
a	O
plasticizer,	O
particularly	O
glycol,	O
has	O
been	O
added	O
before	O
solidification	O
and	O
freeze-drying	O
;	O
(	O
h	O
)	O
a	O
method	O
for	O
producing	O
a	O
high	O
viscosity	O
(	O
I	B-GENE
)	O
-containing	O
solution	O
;	O
and	O
(	O
i	O
)	O
a	O
method	O
for	O
determining	O
the	O
adhesive	O
capacity	O
of	O
a	O
fibrin	B-GENE
clot	O
to	O
a	O
wound	O
bed	O
.	O


An	O
antimicrobial	O
composition	O
comprising	O
silver	O
and	O
at	O
least	O
one	O
compound	O
which	O
interacts	O
with	O
a	O
microbial	O
cell	O
wall	O
to	O
inhibit	O
microbial	O
silver	O
resistance	O
.	O
The	O
resistance	O
inhibitors	O
include	O
molecules	O
that	O
can	O
promote	O
the	O
transport	O
of	O
silver	O
across	O
the	O
cell	O
wall,	O
and	O
/	O
or	O
disrupt	O
the	O
cell	O
wall	O
to	O
allow	O
silver	O
into	O
the	O
cell,	O
and	O
/	O
or	O
disrupt	O
ion	B-GENE
pump	I-GENE
mechanisms	O
in	O
the	O
cell	O
wall	O
for	O
removing	O
silver	O
from	O
the	O
cell	O
.	O
Inhibitor	O
compounds	O
include	O
fusaric	O
acid,	O
tocopherol,	O
resveratrol,	O
and	O
myristic	O
acid	O
.	O
Also	O
provided	O
are	O
wound	O
dressings	O
comprising	O
the	O
inventive	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
Formulae	O
(	O
I	O
)	O
-	O
(	O
IV	O
)	O
,	O
wherein	O
R1	O
-	O
R6,	O
R11	O
-	O
R13,	O
X	O
and	O
Y	O
are	O
defined	O
herein,	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O
These	O
compounds	O
modulate	O
the	O
activity	O
of	O
c-Met	B-GENE
and	O
are	O
therefore	O
expected	O
to	O
be	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
c-Met	B-GENE
related	O
disorders	O
such	O
as	O
cancer	O
.	O


A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I-A	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
is	O
hydroxy	O
and	O
the	O
like	O
;	O
R2	O
is	O
optionally	O
substituted	O
lower	O
alkyl	O
and	O
the	O
like	O
;	O
R3	O
is	O
hydrogen	O
atom	O
and	O
the	O
like	O
;	O
R4	O
is	O
optionally	O
substituted	O
arylene	O
and	O
the	O
like	O
;	O
R5	O
is	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
or	O
	O
	O
	O
	O
	O
	O
	O
R6	O
is	O
optionally	O
substituted	O
aryl	O
and	O
the	O
like,	O
its	O
optically	O
active	O
substance,	O
their	O
pharmaceutically	O
acceptable	O
salt,	O
or	O
a	O
solvate	O
thereof	O
;	O
and	O
a	O
metalloproteinase	B-GENE
inhibitor	O
containing	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
medical	O
use	O
of	O
4,5-dihydro-1H-pyrazole	O
compounds	O
which	O
are	O
potent	O
antagonists	O
of	O
the	O
cannabis	O
CB1-receptor	O
.	O
Said	O
compounds	O
are	O
particularly	O
suitable	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
CB1	B-GENE
receptor	O
related	O
diseases	O
in	O
juvenile	O
patients	O
and	O
/	O
or	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
drug	O
induced	O
obesity	O
in	O
juvenile	O
as	O
well	O
as	O
in	O
adolescent	O
patients	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
the	O
group	O
Bb	O
represents	O
sulfonyl	O
or	O
carbonyl,	O
and	O
the	O
substituents	O
R,	O
R1,	O
R2and	O
R3,	O
and	O
the	O
group	O
Aa	O
are	O
defined	O
as	O
shown	O
in	O
the	O
description	O
.	O


Benzimidazole	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
esters	O
thereof	O
are	O
peptide	B-GENE
deformylase	I-GENE
inhibitors	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
infections	O
and	O
other	O
diseases	O
in	O
which	O
peptide	B-GENE
deformylases	I-GENE
are	O
involved,	O
especially	O
in	O
the	O
treatment	O
of	O
bacterial	O
and	O
parasitic	O
infections,	O
for	O
example	O
infections	O
fully	O
or	O
partly	O
caused	O
by	O
microorganisms	O
belonging	O
to	O
Staphylococcus,	O
Enterococcus,	O
Streptococcus,	O
Haemophilus,	O
Moraxella,	O
Escherichia,	O
Mycobacterium,	O
Mycoplasma,	O
Pseudomonas,	O
Chlamydia,	O
Rickettsia,	O
Klebsiella,	O
Shigella,	O
Salmonella,	O
Bordetella,	O
Clostridium,	O
helicobacter,	O
Campylobacter,	O
Legionella,	O
or	O
Neisseria	O
.	O


A	O
series	O
of	O
thieno	O
[	O
2,3-b	O
]	O
pyridin-6	O
(	O
7H	O
)	O
-one	O
derivatives,	O
substituted	O
in	O
the	O
3-position	O
by	O
an	O
arylcarbonyl	O
or	O
heteroarylcarbonyl	O
moiety,	O
being	O
inhibitors	O
of	O
p38	B-GENE
MAP	I-GENE
kinase,	O
are	O
accordingly	O
of	O
use	O
in	O
medicine,	O
for	O
example	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
immune	O
or	O
inflammatory	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
a	O
new	O
combination	O
for	O
treating	O
dysfunction	O
of	O
the	O
bladder,	O
containing	O
alpha	O
agonists	O
and	O
a	O
beta-3	B-GENE
adrenoceptor	I-GENE
agonist	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
metastatic	O
disease	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
have	O
specificity	O
for	O
EphA2,	O
an	O
epithelial	O
cell	O
tyrosine	B-GENE
kinase	I-GENE
that	O
is	O
overexpressed	O
in	O
metastatic	O
tumor	O
cells	O
.	O
The	O
compounds	O
used	O
in	O
accordance	O
with	O
this	O
invention	O
may	O
be	O
provided	O
in	O
a	O
pharmaceutical	O
composition	O
for	O
treatment	O
of	O
metastatic	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
X	O
=	O
CH2	O
or	O
S	O
or	O
an	O
pharmaceutical	O
acceptable	O
salt	O
thereof	O
.	O
	O
	O
	O
	O
Such	O
compounds	O
and	O
their	O
corresponding	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
forms,	O
are	O
useful	O
in	O
treating	O
conditions	O
mediated	O
by	O
DPIV	B-GENE
or	O
DPIV-like	O
enzymes,	O
such	O
as	O
arthritis,	O
obesity,	O
immune	O
and	O
autoimmune	O
disorders,	O
allograft	O
transplantation,	O
cancer,	O
neuronal	O
disorders	O
and	O
dermal	O
diseases	O
.	O


This	O
invention	O
relates	O
to	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
antibiotic	O
associated	O
diarrhea,	O
including	O
Clostridium	O
difficile	O
associated	O
diarrhea	O
(	O
CDAD	O
)	O
,	O
pseudomembranous	O
colitis	O
(	O
PMC	O
)	O
and	O
other	O
conditions	O
associated	O
with	O
C.	B-GENE
difficile	I-GENE
infection,	O
using	O
oligosaccharide	O
compositions	O
which	O
bind	O
C.	B-GENE
difficile	I-GENE
toxin	I-GENE
B,	O
More	O
specifically,	O
the	O
invention	O
concerns	O
neutralization	O
of	O
C.	B-GENE
difficile	I-GENE
toxin	I-GENE
B	I-GENE
associated	O
with	O
such	O
conditions	O
.	O


Thieno	O
[	O
2,3-c	O
]	O
pyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
defined	O
in	O
the	O
specification,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comrising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
in	O
therapy,	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
a	O
disregulated	O
protein	O
kinase	B-GENE
activity,	O
like	O
cancer	O
.	O


Disclosed	O
are	O
methods	O
for	O
treating	O
a	O
patient	O
identified	O
as	O
having	O
a	O
hemoglobinopathy	O
that	O
is	O
characterized	O
by	O
a	O
reduced	O
affinity	O
of	O
hemoglobin	B-GENE
for	O
oxygen	O
.	O
The	O
methods	O
involve	O
providing	O
gaseous	O
nitric	O
oxide	O
and	O
/	O
or	O
carbon	O
monoxide	O
for	O
(	O
i	O
)	O
inhalation	O
by	O
the	O
patient	O
or	O
(	O
ii	O
)	O
ex	O
vivo	O
treatment	O
of	O
the	O
patient	O
'	O
s	O
erythrocytes	O
.	O
Alternatively,	O
a	O
nitric-oxide-releasing	O
compound	O
can	O
be	O
administered	O
to	O
the	O
patient	O
.	O


In	O
the	O
case	O
where	O
the	O
sensitivity	O
of	O
a	O
cancer	O
cell	O
to	O
a	O
compound	O
can	O
be	O
understood	O
by	O
examining	O
molecules	O
expressed	O
in	O
the	O
cancer	O
cell	O
collected	O
from	O
a	O
cancer	O
patient	O
by	O
biopsy	O
or	O
the	O
like,	O
it	O
is	O
possible	O
to	O
administer	O
the	O
compound	O
selectively	O
to	O
cancer	O
patients	O
on	O
whom	O
the	O
compound	O
can	O
exert	O
its	O
antitumor	O
effect	O
.	O
Thus,	O
it	O
is	O
expected	O
that	O
the	O
therapeutic	O
effect	O
can	O
be	O
enhanced	O
while	O
relieving	O
unnecessary	O
side	O
effects	O
thereby	O
.	O
More	O
specifically	O
speaking,	O
it	O
is	O
found	O
out	O
that	O
the	O
characteristics	O
“low	O
pRB-expression”,	O
“positive	O
to	O
p16	B-GENE
expression”	O
and	O
“high	O
cyclin	O
E-expression”	O
are	O
usable	O
as	O
a	O
marker	O
for	O
the	O
high	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
this	O
compound	O
.	O
Examination	O
of	O
these	O
characteristics	O
of	O
cancer	O
cells,	O
therefore,	O
the	O
sensitivity	O
of	O
the	O
cancer	O
cells	O
to	O
this	O
compound	O
can	O
be	O
preliminarily	O
understood	O
.	O


The	O
invention	O
relates	O
to	O
substituted	O
arylamide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
the	O
production	O
and	O
use	O
thereof	O
for	O
the	O
production	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases,	O
in	O
particular	O
tumours	O
and	O
/	O
or	O
diseases	O
which	O
are	O
provoked,	O
transmitted	O
and	O
/	O
or	O
propagated	O
by	O
angiogenesis	O
.	O
	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
active	O
inhibitors	O
of	O
tyrosine	O
kinases,	O
in	O
particular	O
TIE-2	B-GENE
and	O
VEGFR,	O
and	O
the	O
Raf-kinases	O
.	O


A	O
method	O
for	O
treating	O
demyelinating	O
diseases	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
by	O
treatment	O
with	O
an	O
effective	O
amount	O
of	O
a	O
PPAR	B-GENE
delta	I-GENE
agonist	O
is	O
disclosed	O
.	O
Demyelinating	O
diseases	O
that	O
may	O
be	O
effectively	O
treated	O
by	O
this	O
method	O
include	O
but	O
are	O
not	O
limited	O
to	O
multiple	O
sclerosis,	O
Charcot-Marie-Tooth	O
disease,	O
Pelizaeus-Merzbacher	O
disease,	O
encephalomyelitis,	O
neuromyelitis	O
optica,	O
adrenoleukodystrophy,	O
Guillian-Barre	O
syndrome	O
and	O
disorders	O
in	O
which	O
myelin	O
forming	O
glial	O
cells	O
are	O
damaged	O
including	O
spinal	O
cord	O
injuries,	O
neuropathies	O
and	O
nerve	O
injury	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof,	O
wherein	O
the	O
variables	O
A,	O
B,	O
L1,	O
L2,	O
X1,	O
X2,	O
X3,	O
X4,	O
X5,	O
R4,	O
and	O
W	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
selective	O
inhibitors	O
of	O
serine	O
protease	O
enzymes	O
of	O
the	O
coagulation	O
cascade	O
and	O
/	O
or	O
contact	O
activation	O
system	O
;	O
for	O
example	O
thrombin,	O
factor	O
Xa,	O
factor	O
XIa,	O
factor	O
IXa,	O
factor	B-GENE
VIIa	I-GENE
and	O
/	O
or	O
plasma	B-GENE
kallikrein	I-GENE
.	O
In	O
particular,	O
it	O
relates	O
to	O
compounds	O
that	O
are	O
selective	O
factor	B-GENE
XIa	I-GENE
inhibitors	O
.	O
This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
thromboembolic	O
and	O
/	O
or	O
inflammatory	O
disorders	O
using	O
the	O
same	O
.	O


Use	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
X1	O
and	O
X2	O
have	O
the	O
definitions	O
illustrated	O
in	O
detail	O
in	O
the	O
description,	O
as	O
beta-secretase,	O
cathepsin	O
D,	O
plasmepsin	B-GENE
II	I-GENE
and	O
/	O
or	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
.	O


Method	O
for	O
identifying	O
a	O
compound	O
useful	O
for	O
the	O
therapeutic	O
treatment	O
of	O
a	O
neurological	O
disease	O
or	O
disorder	O
such	O
as	O
stroke,	O
head	O
trauma,	O
spinal	O
cord	O
injury,	O
epilepsy,	O
anxiety,	O
or	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
Disease,	O
Huntington	O
'	O
s	O
Disease	O
or	O
Parkinson	O
'	O
s	O
Disease,	O
or	O
useful	O
as	O
a	O
muscle	O
relaxant,	O
analgesic,	O
or	O
adjuvant	O
to	O
general	O
anesthetics	O
.	O
The	O
compounds	O
is	O
active	O
on	O
a	O
receptor-operated	B-GENE
calcium	I-GENE
channel,	O
including,	O
but	O
not	O
limited	O
to,	O
that	O
present	O
as	O
part	O
of	O
an	O
NMDA	O
receptor-ionophore	O
complex,	O
a	O
calcium-permeable	O
AMPA	O
receptor,	O
or	O
a	O
nicotinic	O
cholinergic	O
receptor,	O
as	O
a	O
noncompetitive	O
antagonist	O
.	O
The	O
method	O
includes	O
identifying	O
a	O
compound	O
which	O
bonds	O
to	O
the	O
receptor-operated	B-GENE
calcium	I-GENE
channel	I-GENE
at	O
the	O
site	O
bound	O
by	O
the	O
arylalkylamines	O
Compound	O
1,	O
Compound	O
2	O
or	O
Compound	O
3	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
Multi-tumor	B-GENE
Aberrant	I-GENE
Growth	I-GENE
(MAG)	I-GENE
gene	I-GENE
having	O
the	O
nucleotide	O
sequence	O
of	O
any	O
one	O
of	O
the	O
strands	O
of	O
any	O
one	O
of	O
the	O
members	O
of	O
the	O
High	B-GENE
Mobility	I-GENE
Group	I-GENE
protein	I-GENE
genes,	O
including	O
modified	O
versions	O
thereof	O
.	O
Specifically,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
Multi-tumor	B-GENE
Aberrant	I-GENE
Growth	I-GENE
(MAG)	I-GENE
gene	I-GENE
having	O
essentially	O
the	O
nucleotide	O
sequence	O
of	O
the	O
HMGI-C	B-GENE
gene	I-GENE
as	O
depicted	O
in	O
Fig	O
.	O
7,	O
or	O
the	O
complementary	O
strand	O
thereof,	O
including	O
modified	O
or	O
elongated	O
versions	O
of	O
both	O
strands	O
.	O


Use	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
X	O
have	O
the	O
definitions	O
elucidated	O
in	O
more	O
detail	O
in	O
the	O
description,	O
as	O
beta-secretase,	O
cathepsin	O
D,	O
plasmepsin	B-GENE
II	I-GENE
and	O
/	O
or	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
.	O


A	O
method	O
of	O
contraception	O
is	O
provided	O
which	O
involves	O
delivery	O
of	O
21	O
to	O
27	O
consecutive	O
days	O
of	O
one	O
or	O
more	O
PR	B-GENE
antagonists	O
in	O
the	O
absence	O
of	O
a	O
progestin,	O
estrogen,	O
or	O
other	O
steroidal	O
compound,	O
followed	O
by	O
1	O
to	O
7	O
days	O
without	O
any	O
active	O
agent	O
.	O
Also	O
described	O
is	O
a	O
pharmaceutically	O
useful	O
kit	O
to	O
facilitate	O
delivery	O
of	O
this	O
regimen	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
-X-Y-,	O
Rl	O
to	O
R11	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
which	O
are	O
mediated	O
by	O
CETP	B-GENE
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R,	O
R	O
'	O
and	O
R	O
'	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
and	O
the	O
pharmaceutically	O
acceptable	O
esters	O
thereof	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
reduce	O
the	O
synthesis	O
of	O
kynurenic	O
acid	O
thus	O
inhibiting	O
the	O
enzyme	O
kynurenine	B-GENE
aminotransferase	I-GENE
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
those	O
psychiatric	O
and	O
neurological	O
diseases	O
which	O
benefit	O
from	O
an	O
increase	O
in	O
glutamatergic	O
and	O
/	O
or	O
cholinergic	O
neurotransmission,	O
such	O
as	O
depression,	O
bipolar	O
illness,	O
anxiety,	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Furthemore,	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
stimulating	O
attention,	O
memory	O
and	O
other	O
cognitive	O
processes	O
in	O
normal	O
individuals	O
of	O
any	O
age,	O
including	O
children,	O
adolescents	O
and	O
the	O
elderly	O
.	O


The	O
use	O
of	O
fused	O
1,2,4-triazoles	O
for	O
modulating	O
the	O
activity	O
of	O
11	B-GENE
β-hydroxysteroid	I-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11βHSD1	B-GENE
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutical	O
compositions	O
has	O
been	O
described	O
.	O
Also	O
a	O
novel	O
class	O
of	O
fused	O
1,2,4-triazoles,	O
their	O
use	O
in	O
therapy,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
has	O
been	O
described	O
.	O
The	O
present	O
compounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSD1	B-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
/	O
or	O
prophylaxis	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	O
is	O
desirable	O
.	O


The	O
present	O
invention	O
discloses	O
novel	O
aryl	O
oxazole	O
compounds	O
of	O
Formula	O
I	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
have	O
histamine-H3	B-GENE
receptor	I-GENE
antagonist	O
or	O
inverse	O
agonist	O
activity,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
and	O
using	O
such	O
compounds	O
.	O
In	O
another	O
embodiment,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
I	O
as	O
well	O
as	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
obesity,	O
cognitive	O
deficiencies,	O
narcolepsy,	O
and	O
other	O
histamine	B-GENE
H3	I-GENE
receptor-related	O
diseases	O
.	O
Formula	O
I	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
:	O
m	O
is	O
independenlly	O
at	O
each	O
occurrence	O
1,	O
2,	O
or	O
3,	O
Z	O
independently	O
represents	O
carbon	O
(	O
substituted	O
with	O
hydrogen	O
or	O
the	O
optional	O
substituents	O
indicated	O
herein	O
)	O
or	O
nitrogen,	O
provided	O
that	O
when	O
Z	O
is	O
nitrogen	O
then	O
R6	O
is	O
not	O
attached	O
to	O
Z	O
;	O
R1	O
and	O
R2	O
are	O
independently	O
-	O
(	O
C1-C7	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
with	O
one	O
to	O
three	O
halogens	O
)	O
,	O
or	O
R1	O
and	O
R2	O
and	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
azetidinyl	O
ring,	O
a	O
pyrrolidinyl	O
ring,	O
or	O
a	O
piperidinyl	O
ring,	O
wherein	O
further	O
the	O
azetidinyl,	O
pyrrolidinyl,	O
or	O
piperidinyl	O
ring	O
so	O
formed	O
may	O
be	O
optionally	O
substituted	O
one	O
to	O
three	O
times	O
with	O
R5	O
;	O
R6	O
is	O
independently	O
at	O
each	O
occurrence	O
-H,	O
-halogen,	O
or	O
-CH3	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
possess	O
unexpectedly	O
high	O
affinity	O
for	O
Alk	B-GENE
5	I-GENE
and	O
/	O
or	O
Alk	O
4,	O
and	O
can	O
be	O
useful	O
as	O
antagonists	O
thereof	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
numerous	O
diseases,	O
including	O
fibrotic	O
disorders	O
.	O
The	O
invention	O
features	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
uses	O
thereof	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
method	O
of	O
preventing	O
or	O
relieving	O
reperfusion-induced	O
cell	O
death	O
(	O
apoptotic	O
cell	O
death	O
)	O
of	O
myocardial	O
cells	O
due	O
to	O
postischemic	O
reperfusion	O
;	O
a	O
reperfusion-induced	O
cell	O
death	O
(	O
apoptotic	O
myocardial	O
cell	O
death	O
)	O
inhibitor	O
;	O
and	O
therapeutic	O
drug	O
or	O
a	O
preventive	O
drug	O
for	O
diseases	O
caused	O
by	O
reperfusion-induced	O
cell	O
death	O
(	O
apoptotic	O
cell	O
death	O
)	O
which	O
contains	O
the	O
reperfusion-induced	O
cell	O
death	O
inhibitor	O
.	O
Namely,	O
reperfusion-induced	O
cell	O
death	O
(	O
apoptotic	O
cell	O
death	O
)	O
can	O
be	O
significantly	O
inhibited	O
by	O
administering	O
a	O
VSOR	B-GENE
Cl	I-GENE
channel	I-GENE
blocker	O
or	O
an	O
ROS	O
scavenger	O
to	O
myocardial	O
cells,	O
which	O
have	O
been	O
subjected	O
to	O
an	O
ischemic	O
treatment,	O
.	O
during	O
reperfusion	O
.	O
As	O
the	O
VSOR	B-GENE
Cl	I-GENE
channel	I-GENE
blocker,	O
it	O
is	O
preferable	O
to	O
use,	O
for	O
example,	O
DIDS	O
or	O
NPPB	O
.	O
As	O
the	O
ROS	O
scavenger,	O
it	O
is	O
preferable	O
to	O
use,	O
for	O
example,	O
Tiron,	O
catalase	B-GENE
or	O
NAC	O
.	O
Thus,	O
various	O
diseases	O
caused	O
by	O
reperfusion-induced	O
cell	O
death	O
can	O
be	O
effectively	O
treated	O
or	O
prevented	O
.	O


The	O
invention	O
relates	O
generally	O
to	O
novel	O
compositions	O
and	O
methods	O
comprising	O
at	O
least	O
one	O
Vitamin	O
B12	O
compound,	O
at	O
least	O
one	O
IMPDH	B-GENE
inhibitor,	O
and	O
optionally	O
an	O
interferon	O
.	O
The	O
compositions	O
and	O
methods	O
provide	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
viral,	O
inflammatory,	O
immunodeficiency,	O
IMPDH-mediated,	O
and	O
proliferative	O
diseases	O
.	O


A	O
method	O
of	O
screening	O
a	O
novel	O
BAFF	B-GENE
suppressor	O
or	O
inhibitor	O
.	O
More	O
specifically	O
speaking,	O
a	O
method	O
which	O
comprises	O
adding	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	O
and	O
/	O
or	O
an	O
anti-CD3	O
antibody	O
to	O
a	O
cultured	O
human	O
cell	O
to	O
thereby	O
induce	O
the	O
production	O
of	O
BAFF	B-GENE
by	O
the	O
cell	O
;	O
a	O
method	O
of	O
screening	O
a	O
substance	O
capable	O
of	O
suppressing	O
the	O
expression	O
or	O
activity	O
of	O
BAFF	B-GENE
which	O
comprises	O
adding	O
a	O
test	O
substance	O
to	O
a	O
BAFF-production	O
system	O
prepared	O
by	O
adding	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	O
and	O
/	O
or	O
an	O
anti-CD3	O
antibody	O
to	O
a	O
cultured	O
human	O
cell	O
and	O
measuring	O
the	O
expression	O
amount	O
and	O
/	O
or	O
the	O
activity	O
of	O
BAFF	B-GENE
in	O
the	O
BAFF-production	O
system	O
;	O
and	O
a	O
BAFF	B-GENE
production	O
inducer	O
for	O
a	O
BAFF-producing	O
cell	O
which	O
contains	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	O
and	O
/	O
or	O
an	O
anti-CD3	O
antibody	O
.	O


The	O
invention	O
generally	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
Yersinia	O
spp	O
.	O
infection	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
inhibitors	O
and	O
derivatives	O
and	O
analogs	O
thereof,	O
pharmaceutical	O
compositions	O
containing	O
the	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
inhibitors	O
and	O
analogs,	O
methods	O
of	O
making	O
the	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
inhibitors	O
and	O
analogs	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


Substituted	O
dipiperidine	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt,	O
isomer,	O
prodrug,	O
metabolite	O
or	O
polymorph	O
thereof,	O
which	O
are	O
CCR2	B-GENE
antagonists	O
and	O
are	O
useful	O
in	O
preventing,	O
treating	O
or	O
ameliorating	O
CCR2	B-GENE
mediated	O
inflammatory	O
syndromes,	O
disorders	O
or	O
diseases	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


The	O
following	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compounds	O
and	O
compositions	O
of	O
the	O
Formula	O
(	O
I	O
)	O
.	O
useful	O
for	O
treating	O
conditions	O
mediated	O
by	O
αVβ3	B-GENE
and	O
/	O
or	O
αVβ5	O
integrin	O
.	O


A	O
present	O
invention	O
provides	O
aromatic	O
amide	O
derivatives	O
which	O
have	O
an	O
agonism	O
of	O
V2	O
receptor,	O
are	O
useful	O
as	O
agents	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
diabetes	O
insipidus,	O
nocturia,	O
nocturnal	O
enuresis,	O
overactive	O
bladder	O
or	O
the	O
like,	O
and	O
are	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-6	O
alkyl	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
R2	O
is	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-6	O
alkyl	O
group,	O
R3	O
is	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like,	O
R4,	O
R5	O
and	O
R6	O
are	O
independently	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
the	O
like,	O
R7	O
is	O
a	O
hydrogen	O
atom,	O
a	O
heteroaryl	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
a	O
C3-8	O
cycloalkyl	O
group	O
'	O
,	O
an	O
amino	O
group	O
which	O
may	O
have	O
a	O
substituent	O
or	O
a	O
C1-6	O
alkoxy	O
group	O
which	O
may	O
have	O
a	O
substituted	O
group	O
;	O
M1	O
is	O
a	O
single	O
bond,	O
a	O
C1-4	O
alkylene	O
group	O
or	O
the	O
like	O
Y	O
is	O
N	O
or	O
CRF	O
(	O
in	O
the	O
formula,	O
RF	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
prodrug	O
thereof,	O
or	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
pharmaceutical	O
uses	O
thereof	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
salt	O
or	O
zwitterionic	O
form,	O
wherein	O
J,	O
L,	O
M,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
as	O
indicated	O
in	O
the	O
specification,	O
are	O
useful	O
for	O
treating	O
conditions	O
that	O
are	O
mediated	O
by	O
the	O
muscarinic	B-GENE
M3	I-GENE
receptor	I-GENE
.	O
Pharmaceutical	O
compositions	O
that	O
contain	O
the	O
compounds	O
and	O
a	O
process	O
for	O
preparing	O
the	O
compounds	O
are	O
also	O
described	O
.	O


Monoclonal	O
antibodies	O
directed	O
against	O
coagulation	B-GENE
factors	I-GENE
and	O
their	O
use	O
in	O
inhibiting	O
thrombosis	O
is	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
cosmetic	O
mixture	O
comprising	O
phytosterols	O
in	O
quantities	O
ranging	O
from	O
1	O
to	O
20	O
%	O
by	O
weight,	O
isoflavones	O
from	O
0	O
.	O
1	O
to	O
4	O
%	O
by	O
weight	O
and	O
methylricinoleate	O
from	O
80	O
to	O
90	O
%	O
by	O
weight	O
.	O
Said	O
cosmetic	O
mixture	O
is	O
formulated	O
with	O
excipients	O
normally	O
used	O
in	O
the	O
cosmetic	O
sector,	O
to	O
give	O
a	O
cosmetic	O
formulation	O
.	O
The	O
cosmetic	O
mixture	O
and	O
formulation	O
are	O
capable	O
of	O
inhibiting	O
the	O
enzyme	O
5-alpha-reductase,	O
and	O
thus	O
have	O
inhibitory	O
or	O
retardatory	O
activity	O
towards	O
the	O
growth	O
of	O
body	O
hair	O
.	O


There	O
is	O
provided	O
inter	O
alia	O
use	O
of	O
2	O
'	O
,3	O
'	O
-dideoxy-3	O
'	O
-hydroxymethylcytosine	O
or	O
a	O
prodrug	O
or	O
salt	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O
wherein	O
the	O
reverse	B-GENE
transcriptase	I-GENE
of	O
the	O
HIV	O
bears	O
at	O
least	O
one	O
mutation	O
that	O
allows	O
an	O
obligate	O
chain	O
terminating	O
nucleoside-	O
or	O
nucleotide	O
phosphate	O
to	O
be	O
excised	O
from	O
the	O
nascent	O
DNA	O
strand	O
by	O
ATP-	O
or	O
pyrophosphate-mediated	O
excision	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
pyrrolodihydroisoquinoline	O
derivatives,	O
which	O
are	O
efficacious	O
inhibitors	O
of	O
PDE10	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
pyrazole	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
ring	O
A0	O
is	O
a	O
pyrazole	O
ring	O
optionally	O
further	O
having	O
1	O
or	O
2	O
substituents	O
;	O
Ra	O
is	O
a	O
substituted	O
carbamoyl	O
group	O
;	O
and	O
Rb	O
is	O
an	O
optionally	O
substituted	O
acylamino	O
group,	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof,	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
GSK-3β	B-GENE
related	O
pathology	O
or	O
disease,	O
and	O
a	O
GSK-3β	B-GENE
inhibitor	O
including	O
same	O
.	O


Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
neurodegenerative	O
disorders	O
or	O
blood	O
coagulation	O
disorders	O
.	O
Methods	O
may	O
comprise	O
modulating	O
the	O
activity	O
or	O
level	O
of	O
a	O
sirtuin,	O
such	O
as	O
SIRTl	B-GENE
or	O
Sir2	B-GENE
.	O
Exemplary	O
methods	O
comprise	O
contacting	O
a	O
cell	O
with	O
a	O
sirtuin	B-GENE
activating	O
compound,	O
such	O
as	O
a	O
flavone,	O
stilbene,	O
flavanone,	O
isoflavone,	O
catechin,	O
chalcone,	O
tannin	O
or	O
anthocyanidin	O
;	O
or	O
an	O
inhibitory	O
compound,	O
such	O
as	O
nicotinamide	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
selectively	O
activating	O
PPARα,	O
which	O
is	O
useful	O
as	O
a	O
medicament	O
.	O
The	O
present	O
invention	O
is	O
specifically	O
directed	O
to	O
a	O
benzoic	O
acid	O
derivative	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A	O
represents	O
an	O
oxygen	O
atom,	O
a	O
nitrogen	O
atom,	O
or	O
a	O
sulfur	O
atom	O
;	O
R	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
alkyl	O
group,	O
an	O
alkenyl	O
group,	O
an	O
alkynyl	O
group,	O
a	O
cycloalkyl	O
group,	O
a	O
cycloalkyl-alkyl	O
group,	O
an	O
aryl	O
group,	O
an	O
aryl-alkyl	O
group	O
an	O
aryl-oxy-alkyl	O
group,	O
a	O
pyridyl-alkyl	O
group,	O
an	O
alkoxycarbonyl-alkyl	O
group,	O
or	O
a	O
carboxy-alkyl	O
group	O
;	O
X	O
represents	O
an	O
oxygen	O
atom,	O
an	O
NH	O
group,	O
or	O
an	O
S	O
(	O
O	O
)	O
n	O
group	O
(	O
wherein	O
n	O
represents	O
an	O
integer	O
of	O
0,	O
1,	O
or	O
2	O
)	O
;	O
and	O
m	O
represents	O
an	O
integer	O
from	O
2	O
to	O
8	O
;	O
or	O
a	O
salt	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
medicament	O
comprising	O
the	O
benzoic	O
acid	O
derivative	O
or	O
the	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
novel	O
pyrazine	O
2-carboxyamide	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
useful	O
as	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
antagonists	O
:	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
compounds	O
of	O
structural	O
formula	O
IA	O
or	O
IB	O
where	O
R1-R8	O
are	O
as	O
disclosed	O
herein	O
Formula	O
(	O
IA	O
)	O
or	O
(	O
IB	O
)	O
as	O
inhibitors	O
of	O
the	O
CCR5	B-GENE
receptors,	O
methods	O
of	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
such	O
compounds,	O
methods	O
of	O
preparing	O
pharmaceutical	O
formulations	O
comprising	O
one	O
or	O
more	O
such	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
diseases	O
associated	O
with	O
CCR5	B-GENE
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
a	O
compound	O
of	O
this	O
invention	O
and	O
one	O
or	O
more	O
antiviral	O
or	O
other	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
this	O
invention,	O
alone	O
or	O
in	O
combination	O
with	O
another	O
agent,	O
in	O
the	O
treatment	O
of	O
solid	O
organ	O
transplant	O
rejection,	O
graft	O
v	O
.	O
host	O
disease,	O
arthritis,	O
rheumatoid	O
arthritis,	O
inflammatory	O
bowel	O
disease,	O
atopic	O
dermatitis,	O
psoriasis,	O
asthma,	O
allergies	O
or	O
multiple	O
sclerosis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
enantiomers	O
of	O
amino	O
pyrimidine	O
compounds	O
for	O
the	O
modulation	O
of	O
the	O
histamine	B-GENE
H4	I-GENE
receptor	I-GENE
and	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
mediated	O
by	O
the	O
histamine	B-GENE
H4	I-GENE
receptor	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
such	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
methyl	O
;	O
and	O
R1	O
is	O
4-methyl-4-oxy-piperazin-l-yl	O
;	O
or	O
R	O
is	O
CH2OH	O
and	O
R1	O
is	O
4-methyl-piperazin-l-yl	O
or	O
is	O
4-methyl-4-oxy-piperazin-l-yl	O
;	O
and	O
to	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
for	O
the	O
treatment	O
of	O
NK-I	B-GENE
receptor	O
related	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
which	O
is	O
protected	O
from	O
destabilization	O
in	O
acidic	O
environments	O
by	O
utilizing	O
cyclodextrin	O
as	O
an	O
inclusion	O
complexing	O
agent	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
the	O
preparation	O
of	O
inclusion	O
complexes	O
of	O
HMG-CoA	O
and	O
cyclodextrin	O
and	O
to	O
their	O
use	O
in	O
the	O
treatment	O
of	O
hypercholesterolemia	O
and	O
hyperlipidemia	O
.	O


The	O
invention	O
relates	O
to	O
substituted	O
sulphoximines	O
according	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
A,	O
E,	O
G,	O
X,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
m,	O
p,	O
q,	O
are	O
given	O
in	O
the	O
claims,	O
and	O
salts	O
thereof,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
substituted	O
sulphoximines,	O
to	O
methods	O
of	O
preparing	O
said	O
substituted	O
sulphoximines	O
as	O
well	O
as	O
the	O
use	O
thereof	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
dysregulated	O
vascular	O
growth	O
or	O
of	O
diseases	O
which	O
are	O
accompanied	O
with	O
dysregulated	O
vascular	O
growth,	O
wherein	O
the	O
compounds	O
effectively	O
interfere	O
with	O
Tie2	B-GENE
signalling	O
.	O


[	O
Solving	O
means	O
]	O
	O
	O
	O
	O
A	O
thienotriazolodiazepine	O
compound	O
of	O
the	O
following	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
a	O
pharmaceutical	O
agent	O
containing	O
the	O
compound	O
as	O
an	O
active	O
ingredient,	O
and	O
a	O
production	O
intermediate	O
and	O
a	O
production	O
method	O
of	O
the	O
thienotriazolodiazepine	O
compound	O
.	O
	O
	O
	O
	O
[	O
Effect	O
]	O
	O
	O
	O
	O
Since	O
this	O
compound	O
has	O
an	O
inhibitory	O
action	O
on	O
costimulatory	O
signal	O
from	O
CD28	B-GENE
on	O
T	O
cell,	O
it	O
is	O
useful	O
for	O
the	O
prophylaxis	O
or	O
suppression	O
of	O
rejection	O
reaction	O
in	O
transplantation	O
of	O
organ	O
or	O
bone	O
marrow	O
and	O
the	O
like,	O
and	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
autoimmune	O
diseases	O
or	O
allergic	O
diseases	O
.	O


The	O
methods	O
and	O
compositions	O
disclosed	O
herein	O
relate	O
to	O
using	O
carbazole,	O
and	O
derivatives	O
thereof	O
to	O
modify	O
a	O
signaling	O
activity	O
such	O
as	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
signalling,	O
and	O
angiogenesis	O
activity,	O
in	O
a	O
cell	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
ureas	O
containing	O
N	O
/	O
-aryl	O
or	O
N-heteroaryl	O
substituted	O
heterocycles	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer,	O
tautomer,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof,	O
wherein	O
the	O
variables	O
A,	O
B,	O
D	O
and	O
W	O
are	O
defined	O
herein	O
.	O
These	O
compounds	O
are	O
selective	O
inhibitors	O
of	O
the	O
human	B-GENE
P2Y,	I-GENE
receptor	I-GENE
which	O
can	O
be	O
used	O
as	O
medicaments	O
for	O
treating	O
thromboembolic	O
disorders	O
.	O


Novel	O
compounds	O
are	O
provided	O
which	O
are	O
11-beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I	I-GENE
inhibitors	O
.	O
11-beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I	I-GENE
inhibitors	O
are	O
useful	O
in	O
treating,	O
preventing,	O
or	O
slowing	O
the	O
progression	O
of	O
diseases	O
requiring	O
11-beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I	I-GENE
inhibitor	O
therapy	O
.	O
These	O
novel	O
compounds	O
have	O
the	O
structure	O
:	O
W-L-Z	O
(	O
I	O
)	O
or	O
stereoisomers	O
or	O
prodrugs	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
W,	O
L	O
and	O
Z	O
are	O
defined	O
herein	O
.	O


The	O
present	O
invention	O
provides	O
derivatives	O
of	O
pyrido	O
[	O
2,3-d	O
]	O
pyrimidin-7-one	O
of	O
formula	O
(	O
I	O
)	O
.	O
These	O
compounds	O
are	O
kinase	B-GENE
inhibitors,	O
including	O
compounds	O
that	O
show	O
anti-proliferative	O
activity,	O
including	O
against	O
tumor	O
cells,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
cancer	O
.	O


A	O
method	O
of	O
combating	O
toxicity	O
caused	O
by	O
an	O
antifolate	O
compound	O
of	O
Formula	O
I,	O
in	O
an	O
individual	O
who	O
has	O
been	O
administered	O
the	O
compound	O
.	O
The	O
method	O
comprises	O
administering	O
an	O
enzyme	O
that	O
has	O
carboxypeptidase	B-GENE
G	I-GENE
activity	O
to	O
the	O
individual	O
.	O
A	O
method	O
of	O
cleaving	O
a	O
compound	O
comprising	O
a	O
structural	O
fragment	O
of	O
Formula	O
IV,	O
the	O
method	O
comprising	O
contacting	O
the	O
compound	O
comprising	O
the	O
structural	O
fragment	O
of	O
Formula	O
IV	O
with	O
an	O
enzyme	O
that	O
has	O
carboxypeptidase	B-GENE
G	I-GENE
activity	O
.	O


Improved	O
pharmaceutical	O
compositions	O
are	O
provided	O
comprising	O
one	O
or	O
more	O
solubilized	O
HIV	B-GENE
protease	I-GENE
inhibiting	O
compounds	O
having	O
improved	O
solubility	O
properties	O
in	O
a	O
medium	O
and	O
/	O
or	O
long	O
chain	O
fatty	O
acid,	O
or	O
mixtures	O
thereof,	O
a	O
pharmaceutically	O
acceptable	O
alcohol,	O
and	O
water	O
.	O


The	O
present	O
invention	O
relates	O
to	O
genetically	O
engineered	O
recombinant	O
respiratory	O
syncytial	O
viruses	O
and	O
viral	O
vectors	O
which	O
contain	O
deletions	O
of	O
various	O
viral	O
accessory	O
gene	O
(	O
s	O
)	O
either	O
singly	O
or	O
in	O
combination	O
.	O
In	O
accordance	O
with	O
the	O
present	O
invention,	O
the	O
recombinant	O
respiratory	O
syncytial	O
viral	O
vectors	O
and	O
viruses	O
are	O
engineered	O
to	O
contain	O
complete	O
deletions	O
of	O
the	O
M2-2,	O
NS1,	O
NS2	B-GENE
or	O
SH	B-GENE
viral	O
accessory	O
genes	O
or	O
various	O
combinations	O
thereof	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
attenuation	O
of	O
respiratory	O
syncytial	O
virus	O
by	O
mutagenisis	O
of	O
the	O
M2-1	B-GENE
gene	O
.	O


Alkoxy	O
indolinone	O
based	O
acid	O
and	O
amide	O
derivatives	O
have	O
enhanced	O
and	O
unexpected	O
drug	O
properties	O
as	O
inhibitors	O
of	O
protein	O
kinases	B-GENE
and	O
are	O
useful	O
in	O
treating	O
disorders	O
related	O
to	O
abnormal	O
protein	O
kinase	B-GENE
activities	O
such	O
as	O
cancer	O
.	O


The	O
invention	O
concerns	O
the	O
association	O
of	O
at	O
least	O
one	O
ß3	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist	O
(	O
or	O
ß3	O
agonist	O
)	O
with	O
a	O
monoamine	O
reuptake	O
inhibitor	O
.	O
The	O
invention	O
also	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
inventive	O
association	O
and	O
its	O
therapeutic	O
use	O
.	O


The	O
present	O
invention	O
has	O
an	O
object	O
to	O
provide	O
a	O
means	O
for	O
durably	O
exerting	O
an	O
action	O
of	O
enhancing	O
collagen-production,	O
and	O
the	O
object	O
is	O
attained	O
by	O
providing	O
a	O
collagen-production	O
enhancer	O
which	O
contains,	O
as	O
an	O
effective	O
ingredient,	O
α,α-trehalose	O
and	O
/	O
or	O
a	O
saccharide	O
derivative	O
thereof,	O
and	O
by	O
a	O
composition	O
incorporated	O
with	O
the	O
collagen-production	O
enhancer	O
to	O
be	O
used	O
for	O
such	O
purpose	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
peptide,	O
such	O
as	O
an	O
antibody,	O
capable	O
of	O
binding	O
to	O
CD4	B-GENE
and	O
use	O
thereof	O
for	O
the	O
mediation	O
of	O
radiation	O
treatment	O
of	O
a	O
clinical	O
condition	O
.	O
The	O
radiation	O
treatment	O
may	O
for	O
instance	O
by	O
treatment	O
with	O
PUVA	O
.	O


A	O
composition	O
including	O
a	O
CXCR4	B-GENE
antagonist	O
and	O
a	O
CCR5	B-GENE
antagonist	O
represented	O
by	O
formula	O
I	O
or	O
II	O
:	O
or	O
an	O
acceptable	O
salt,	O
solvate	O
or	O
ester	O
thereof	O
.	O
The	O
GXCR4	B-GENE
antagonist	O
includes	O
at	O
least	O
one	O
of	O
AMD-070	O
.	O
CS-3955,	O
KRH-1	O
120,	O
KRH-2731,	O
and	O
KRH-1636	O
.	O
These	O
compositions	O
are	O
used	O
to	O
manufacture	O
medicaments	O
for	O
the	O
treatment	O
of	O
HIV	O
infections	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
mGluRl	B-GENE
and	O
mGluR5	B-GENE
receptor	O
subtype	O
preferring	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
represents	O
a	O
group	O
selected	O
from	O
SO,	O
SO2	O
;	O
Y	O
represents	O
a	O
group	O
selected	O
from	O
(	O
CH2	O
)	O
n,	O
NH,	O
NHCH2	O
;	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
1	O
;	O
Z	O
is	O
H	O
or	O
monosubstituted	O
by	O
alkyl,	O
nitro,	O
halogen,	O
alkoxy,	O
trifluoromethyl,	O
cyano,	O
amino,	O
alkylamino,	O
dialkylamino,	O
aminomethyl,	O
alkylaminomethyl,	O
dialkylaminomethyl,	O
hydroxyl,	O
alkylsulfonylamino	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
alkyl,	O
cycloalkyl,	O
phenyl,	O
biphenyl,	O
heterocyclyl	O
;	O
R2	O
is	O
an	O
optionally	O
substituted	O
phenyl,	O
heterocyclyl,	O
or	O
NR3R4	O
group	O
wherein	O
R3	O
and	O
R4	O
are	O
independently	O
selected	O
from	O
the	O
group	O
of	O
hydrogen	O
and	O
an	O
optionally	O
substituted	O
alkyl,	O
or	O
R3	O
and	O
R4	O
together	O
with	O
the	O
N	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
C5-7	O
heterocyclyl	O
group,	O
containing	O
one	O
or	O
more	O
heteroatom	O
(	O
s	O
)	O
,	O
or	O
NH-CO-NR5R6	O
group,	O
wherein	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
the	O
group	O
of	O
hydrogen	O
and	O
an	O
optionally	O
substituted	O
alkyl,	O
or	O
R5	O
and	O
R6	O
together	O
with	O
the	O
N	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
C5-7	O
heterocyclyl	O
group,	O
containing	O
one	O
or	O
more	O
heteroatom	O
(	O
s	O
)	O
;	O
and	O
/	O
or	O
hydrates	O
and	O
/	O
or	O
solvates	O
and	O
/	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
formed	O
with	O
acids	O
or	O
bases,	O
to	O
the	O
processes	O
for	O
producing	O
the	O
same,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
and	O
to	O
their	O
use	O
in	O
therapy	O
and	O
/	O
or	O
prevention	O
of	O
pathological	O
conditions	O
which	O
require	O
the	O
modulation	O
of	O
mGluRl	B-GENE
and	O
mGluR5	B-GENE
receptors	O
such	O
as	O
neurological	O
disorders,	O
psychiatric	O
disorders,	O
acute	O
and	O
chronic	O
pain,	O
neuromuscular	O
dysfunctions	O
of	O
the	O
lower	O
urinary	O
tract	O
and	O
gastrointestinal	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	B-GENE
receptors	I-GENE
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
have	O
antibacterial	O
activity	O
wherein	O
R	O
represents	O
hydrogen	O
or	O
1,	O
2	O
or	O
3	O
optional	O
substituents	O
;	O
W	O
is	O
=	O
C	O
(	O
R1	O
)	O
-	O
or	O
=	O
N-	O
;	O
R1	O
is	O
hydrogen	O
or	O
an	O
optional	O
substituent	O
and	O
R2	O
is	O
hydrogen,	O
methyl,	O
or	O
fluorine	O
;	O
or	O
R1	O
and	O
R2	O
taken	O
together	O
are	O
-CH2-,	O
-CH2CH2-,	O
-O-,	O
or,	O
in	O
either	O
orientation,	O
-O-	O
CH2-	O
Or	O
-OCH2CH2-	O
;	O
R3	O
is	O
a	O
radical	O
of	O
formula	O
-	O
(	O
Alk1	B-GENE
)	O
m-	O
(	O
Z	O
)	O
p-	O
(	O
Alk2	B-GENE
)	O
n-Q	O
wherein	O
m,	O
p	O
and	O
n	O
are	O
independently	O
0	O
or	O
1,	O
provided	O
that	O
at	O
least	O
one	O
of	O
m,	O
p	O
and	O
n	O
is	O
1,	O
Z	O
is	O
-O-,	O
-S-,	O
-S	O
(	O
O	O
)	O
-,	O
-S	O
(	O
O2	O
)	O
-,	O
-NH-,	O
-N	O
(	O
CH3	O
)	O
-,	O
-N	O
(	O
CH2CH3	O
)	O
-,	O
-C	O
(	O
=	O
O	O
)	O
-,	O
-O-	O
(	O
C	O
=	O
O	O
)	O
-,	O
-C	O
(	O
=	O
O	O
)	O
-O-,	O
or	O
an	O
optionally	O
substituted	O
divalent	O
monocyclic	O
carbocyclic	O
or	O
heterocyclic	O
radical	O
having	O
3	O
to	O
6	O
ring	O
atoms	O
;	O
or	O
an	O
optionally	O
substituted	O
divalent	O
bicyclic	O
heterocyclic	O
radical	O
having	O
5	O
to	O
10	O
ring	O
atoms	O
;	O
Alk1	B-GENE
and	O
Alk2	B-GENE
are	O
optionally	O
substituted	O
C1C6	O
alkylene,	O
C2-C6	O
alkenylene,	O
or	O
C2-C6	O
alkynylene	O
radicals,	O
which	O
may	O
optionally	O
terminate	O
with	O
or	O
be	O
interrupted	O
by	O
-O-,	O
-S-,	O
-S	O
(	O
O	O
)	O
-,	O
-S	O
(	O
O2	O
)	O
-,	O
-NH-,	O
-N	O
(	O
CH3	O
)	O
-,	O
or	O
-N	O
(	O
CH2CH3	O
)	O
-	O
;	O
and	O
Q	O
is	O
hydrogen,	O
halogen,	O
nitrile,	O
or	O
hydroxyl	O
or	O
an	O
optionally	O
substituted	O
monocyclic	O
carbocyclic	O
or	O
heterocyclic	O
radical	O
having	O
3	O
to	O
6	O
ring	O
atoms	O
;	O
or	O
an	O
optionally	O
substituted	O
bicyclic	O
heterocyclic	O
radical	O
having	O
5	O
to	O
10	O
ring	O
atoms	O
.	O


Disclosed	O
herein	O
is	O
an	O
immunologically	O
active,	O
chimeric	O
anti-CD20	O
antibody	O
for	O
use	O
as	O
a	O
medicament,	O
which	O
antibody	O
is	O
capable	O
of	O
substantial	O
B-cell	O
depletion	O
when	O
administered	O
to	O
a	O
subject	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
muscular	O
dystrophies	O
or	O
myopathies	O
resulting	O
from	O
mutations	O
in	O
genes	O
encoding	O
for	O
collagen	B-GENE
VI	I-GENE
.	O


Use	O
of	O
tenatoprazole	O
is	O
claimed	O
in	O
medicines	O
for	O
the	O
treatment	O
of	O
atypical	O
and	O
esophageal	O
symptoms	O
of	O
gastroesophageal	O
reflux,	O
digestive	O
hemorrhages	O
and	O
dyspepsias	O
.	O
-	O
ACTIVITY	O
:	O
Gastrointestinal-Gen	O
;	O
Antiasthmatic	O
;	O
Antitussive	O
;	O
Respiratory-Gen	O
.	O
;	O
Antianginal	O
;	O
Hemostatic	O
.	O
In	O
a	O
test,	O
fourteen	O
patients	O
suffering	O
from	O
gastroesophageal	O
reflux	O
were	O
given	O
a	O
daily	O
dose	O
of	O
tenatoprazole	O
(	O
20	O
mg	O
)	O
for	O
4-12	O
weeks	O
.	O
In	O
twelve	O
cases,	O
the	O
dosage	O
was	O
tolerated	O
perfectly	O
and	O
in	O
the	O
other	O
two	O
cases	O
it	O
was	O
well-tolerated	O
.	O
The	O
effect	O
on	O
the	O
symptoms	O
was	O
very	O
good	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	B-GENE
pump	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
discloses	O
novel	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
(	O
in	O
which	O
X1	O
-	O
X5,	O
R5	O
-	O
R8b,	O
Z1	O
-	O
Z2	O
and	O
Ar1	O
are	O
defined	O
herein	O
)	O
,	O
pharmaceutical	O
compositions	O
including	O
those	O
compounds	O
and	O
a	O
process	O
for	O
making	O
those	O
compounds	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
for	O
treating	O
pain,	O
bladder	O
overreactivity,	O
urinary	O
incontinence,	O
inflammatory	O
hyperalgesia	O
by	O
inhibiting	O
the	O
VR1	B-GENE
receptor	O
in	O
mammals	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description,	O
as	O
well	O
as	O
salts	O
and	O
enantiomers	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
in	O
therapy,	O
e	O
.	O
g	O
.	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O
The	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
.	O
The	O
compounds	O
are	O
neurokinin	B-GENE
(NK)	I-GENE
receptor	I-GENE
antagonists	O
.	O


The	O
present	O
invention	O
relates	O
to	O
2-	O
(	O
substituted-amino	O
)	O
-benzothiazole	O
sulfonamide	O
compounds	O
and	O
derivatives,	O
their	O
use	O
as	O
protease	O
inhibitors,	O
in	O
particular	O
as	O
broadspectrum	O
HIV	B-GENE
protease	I-GENE
inhibitors,	O
processes	O
for	O
their	O
preparation	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
kits	O
comprising	O
them	O
.	O
The	O
present	O
invention	O
also	O
concerns	O
combinations	O
of	O
the	O
present	O
2-	O
(	O
substituted-amino	O
)	O
-benzothiazole	O
sulfonamide	O
compounds	O
and	O
derivatives	O
with	O
another	O
anti-retroviral	O
agent	O
.	O
It	O
further	O
relates	O
to	O
their	O
use	O
in	O
assays	O
as	O
reference	O
compounds	O
or	O
as	O
reagents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
regulating	O
the	O
activity	O
of	O
the	O
purinergic	B-GENE
receptors	I-GENE
for	O
the	O
modulation	O
of	O
the	O
vascular	O
tone,	O
particularly	O
for	O
the	O
purpose	O
of	O
treatment	O
of	O
haemodynamic	O
conditions	O
by	O
overriding	O
of	O
vasoconstriction	O
activity,	O
such	O
as	O
increases	O
in	O
sympathic	O
vasoconstriction	O
.	O
Modulators,	O
such	O
as	O
UTP	O
analogues	O
as	O
described	O
herein	O
are	O
preferably	O
specific	O
for	O
P2Y2	O
.	O
Compounds	O
capable	O
of	O
stimulating	O
the	O
P2Y2	B-GENE
receptor	I-GENE
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasoconstriction	O
activity	O
is	O
desirable	O
such	O
as	O
hypertension	O
and	O
hypertension	O
relates	O
disorders	O
or	O
diseases,	O
whereas	O
compound	O
capable	O
of	O
counteracting	O
the	O
activity	O
of	O
the	O
P2Y2	B-GENE
receptor	I-GENE
are	O
suitable	O
for	O
the	O
treatment	O
of	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasodilatation	O
is	O
desirable	O
.	O


The	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	O
phosphodiesterase	B-GENE
4	I-GENE
(	O
PDE4	B-GENE
)	O
enzyme	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
derivatives	O
of	O
1-phenyl-2-pyridynyl	O
alkylene	O
alcohols,	O
methods	O
of	O
preparing	O
such	O
compounds,	O
compositions	O
containing	O
them	O
and	O
therapeutic	O
use	O
thereof	O
.	O


Described	O
is	O
the	O
treatment	O
of	O
immunologically	O
relevant	O
diseases	O
such	O
as	O
infections	O
or	O
a	O
proliferative	O
disease,	O
in	O
particular	O
cancer,	O
by	O
increasing	O
the	O
IL-12	B-GENE
/	O
IL-10	B-GENE
ratio	O
caused	O
by	O
the	O
sequential	O
administration	O
of	O
lipopeptides	O
(	O
e	O
.	O
g	O
.	O
,	O
FSL-1,	O
FSL-2	O
or	O
OspA-Lp	O
)	O
and	O
lipopolysaccharides	O
(	O
e	O
.	O
g	O
.	O
,	O
LPS	O
R60	O
)	O
alone	O
or	O
in	O
combination	O
with	O
IFN-γ	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
novel	O
compound	O
having	O
an	O
excellent	O
AMPA	B-GENE
receptor	I-GENE
inhibitory	O
action	O
and	O
/	O
or	O
kainate	O
inhibitory	O
action	O
.	O
A	O
compound	O
represented	O
by	O
the	O
following	O
formula,	O
a	O
salt	O
thereof	O
or	O
hydrates	O
thereof	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
In	O
the	O
formula,	O
Q	O
indicates	O
NH,	O
O	O
or	O
S	O
;	O
and	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
the	O
same	O
as	O
or	O
different	O
from	O
each	O
other	O
and	O
each	O
indicates	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
C1-6alkyl	O
group	O
or	O
a	O
group	O
represented	O
by	O
the	O
formula	O
-X-A	O
(	O
wherein	O
X	O
indicates	O
a	O
single	O
bond,	O
an	O
optionally	O
sbutituted	O
C1-6	O
alkylene	O
group	O
etc	O
.	O
;	O
and	O
A	O
indicates	O
an	O
optionally	O
substituted	O
C6-14	O
aromatic	O
hydrocarbocyclic	O
group	O
or	O
5-	O
to	O
14-membered	O
aromatic	O
heterocyclic	O
group	O
etc	O
.	O
)	O
.	O


Disclosed	O
is	O
a	O
novel	O
compound	O
having	O
an	O
NPY	B-GENE
Y5	I-GENE
receptor	O
antagonistic	O
activity	O
.	O
A	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
lower	O
alkyl	O
or	O
the	O
like,	O
R2	O
and	O
R8	O
are	O
each	O
independently	O
hydrogen	O
or	O
lower	O
alkyl,	O
X	O
is	O
optionally	O
substituted	O
lower	O
alkylene	O
or	O
the	O
like,	O
Y	O
is	O
-OCONR7-	O
or	O
the	O
like,	O
R7	O
is	O
hydrogen,	O
lower	O
alkyl	O
or	O
the	O
like,	O
Z	O
is	O
optionally	O
substituted	O
carbocyclyl	O
or	O
the	O
like,	O
W	O
is	O
optionally	O
substituted	O
alkylene	O
or	O
the	O
like	O
.	O


Provided	O
herein	O
are	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
phosphodiesterase	B-GENE
inhibitors	I-GENE
of	I-GENE
type	I-GENE
IV	I-GENE
(	O
"PDE-IV"	O
)	O
,	O
and	O
atleast	O
one	O
other	O
active	O
ingredients	O
selected	O
from	O
muscarinic	B-GENE
receptor	I-GENE
antagonists	O
(	O
MRA	O
)	O
,	O
β2-agonists,	O
p38	B-GENE
MAP	I-GENE
Kinase	I-GENE
inhibitors,	O
and	O
corticosteroids	O
and	O
optionally	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
and	O
/	O
or	O
other	O
therapeutic	O
agents	O
.	O
In	O
addition,	O
methods	O
of	O
treating	O
autoimmune,	O
inflammatory	O
or	O
allergic	O
diseases	O
or	O
disorders	O
are	O
provided	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
acute	O
lung	O
injuries,	O
such	O
as	O
acute	O
lung	O
injury	O
induced	O
by	O
peritonitis	O
during	O
sepsis,	O
acute	O
lung	O
injury	O
induced	O
by	O
intravenous	O
bacteremia	O
during	O
sepsis,	O
acute	O
lung	O
injury	O
caused	O
by	O
smoke	O
inhalation,	O
acute	O
lung	O
injury	O
occurring	O
in	O
a	O
premature	O
infant	O
with	O
deficiency	O
of	O
surfactant,	O
acute	O
lung	O
injury	O
caused	O
by	O
oxygen	O
toxicity	O
or	O
acute	O
lung	O
injury	O
caused	O
by	O
barotraumas	O
from	O
mechanical	O
ventilation,	O
using	O
an	O
ERβ	B-GENE
selective	O
ligand	O
such	O
as	O
2-	O
(	O
3-fluoro-4-hydroxyphenyl	O
)	O
-7-vinyl-1,3-benzoxazol-5-ol	O
or	O
3-	O
(	O
3-fluoro-4-hydroxy-phenyl	O
)	O
-7-hydroxy-naphthalene-1-carbonitrile	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
use	O
of	O
ERβ	B-GENE
selective	O
ligands	O
or	O
compositions	O
thereof	O
for	O
the	O
prevention	O
of	O
acute	O
lung	O
injuries	O
in	O
those	O
being	O
at	O
risk	O
thereof	O
.	O


Disclosed	O
is	O
a	O
disinfectant	O
which	O
is	O
safe,	O
has	O
few	O
adverse	O
side-effects,	O
can	O
be	O
ingested	O
together	O
with	O
a	O
food	O
or	O
beverage	O
by	O
adding	O
the	O
disinfectant	O
to	O
the	O
food	O
or	O
beverage,	O
shows	O
a	O
bactericidal	O
effect	O
in	O
the	O
oral	O
cavity,	O
and	O
has	O
no	O
problem	O
even	O
when	O
ingested	O
on	O
a	O
daily	O
basis	O
over	O
a	O
long	O
period	O
.	O
	O
Also	O
disclosed	O
is	O
a	O
food	O
additive	O
comprising	O
the	O
disinfectant	O
.	O
	O
Specifically,	O
disclosed	O
is	O
an	O
oral	O
disinfectant	O
for	O
the	O
disinfection	O
of	O
an	O
oral	O
bacterium,	O
which	O
comprises	O
lactoperoxidase,	O
glucose	O
oxidase,	O
glucose	O
and	O
a	O
pH-adjusting	O
component	O
.	O


An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
safe	O
and	O
effective	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
and	O
a	O
medicament	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
disease	O
comprising	O
amyloid	B-GENE
β	I-GENE
peptide	I-GENE
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
.	O
An	O
amyloid	B-GENE
β	I-GENE
peptide	I-GENE
or	O
a	O
portion	O
thereof	O
with	O
addition	O
or	O
insertion	O
of	O
cysteine	O
and	O
a	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
using	O
the	O
peptide	O
or	O
a	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
using	O
the	O
peptide	O
together	O
with	O
an	O
adjuvant	O
.	O
A	O
medicament	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
disease	O
comprising	O
an	O
amyloid	B-GENE
β	I-GENE
peptide	I-GENE
or	O
a	O
portion	O
thereof	O
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
.	O
A	O
DNA	O
vaccine,	O
that	O
may	O
have	O
the	O
same	O
effect,	O
comprising	O
the	O
gene	O
encoding	O
an	O
amyloid	B-GENE
β	I-GENE
peptide	I-GENE
or	O
a	O
portion	O
thereof	O
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
with	O
addition	O
or	O
insertion	O
of	O
cysteine	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
which	O
are	O
capable	O
of	O
modulating	O
Toll-like	O
receptor	O
(	O
TLR	B-GENE
)	O
activity	O
.	O
Compounds	O
are	O
of	O
the	O
following	O
Formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
evaluating	O
patients	O
to	O
help	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
in	O
a	O
human	O
patient	O
population	O
.	O
More	O
specifically,	O
the	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
a	O
)	O
determining	O
the	O
OCT-1	B-GENE
Activity	O
in	O
pre-therapy	O
blood	O
of	O
a	O
warm-blooded	O
animal	O
suffering	O
from	O
CML,	O
and	O
(	O
b	O
)	O
administering	O
a	O
daily	O
dose	O
between	O
about	O
500	O
and	O
1200	O
mg	O
of	O
Imatinib	O
mesylate	O
to	O
the	O
warm-blooded	O
animal	O
suffering	O
from	O
CML	O
showing	O
an	O
OCT-1	B-GENE
Activity	O
corresponding	O
to	O
Imatinib	O
intracellular	O
concentration	O
below	O
about	O
6	O
.	O
0	O
to	O
10	O
.	O
0	O
ng	O
/	O
200,000	O
cells,	O
especially	O
about	O
8	O
.	O
0	O
to	O
8	O
.	O
5	O
ng	O
/	O
200,000	O
cells	O
.	O


A	O
hybrid	O
type	B-GENE
I	I-GENE
polyketide	I-GENE
synthase	I-GENE
gene	O
typically	O
containing	O
a	O
starter	O
module	O
and	O
a	O
plurality	O
of	O
heterologous	O
extender	O
modules	O
is	O
used	O
to	O
synthesise	O
novel	O
polyketides	O
.	O
It	O
is	O
preferably	O
under	O
the	O
control	O
of	O
a	O
type	O
II	O
polypolyketide	O
synthase	O
promoter	O
e	O
.	O
g	O
.	O
act	O
I	O
of	O
S	O
.	O
coelicolor	O
.	O


The	O
invention	O
relates	O
to	O
the	O
derivatives	O
of	O
1-oxo-1,2-dihydro­isoquinoline-5-carboxamides	O
and	O
of	O
4-oxo-3,4-dihydroquinazoline-8-carboxamides,	O
of	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
:	O
R1	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
(	O
C1-C10	O
)	O
alkyl,	O
(	O
C3-C7	O
)	O
cycloalkyl,	O
(	O
CH2	O
)	O
n-	O
(	O
C1-C6	O
)	O
alkenyl,	O
(	O
CH2	O
)	O
n-	O
(	O
C1-C6	O
)	O
alkynyl	O
or	O
(	O
C1-C6	O
)	O
alkyl-Z-	O
(	O
C1-C6	O
)	O
alkyl	O
group	O
in	O
which	O
Z	O
represents	O
a	O
heteroatom	O
chosen	O
from	O
O,	O
N	O
and	O
S	O
(	O
O	O
)	O
m,	O
or	O
else	O
R1	O
represents	O
a	O
COOR	O
or	O
S	O
(	O
O	O
)	O
mR	O
group,	O
an	O
aryl	O
or	O
an	O
aralkyl,	O
the	O
(	O
C1-C10	O
)	O
alkyl,	O
(	O
C3-C7	O
)	O
cycloalkyl,	O
(	O
CH2	O
)	O
n-	O
(	O
C1-C6	O
)	O
alkenyl,	O
(	O
CH2	O
)	O
n-	O
(	O
C1-C6	O
)	O
alkynyl,	O
(	O
C1-C6	O
)	O
alkyl-Z-	O
(	O
C1-C6	O
)	O
alkyl,	O
aryl	O
or	O
aralkyl	O
groups	O
;	O
R2	O
represents	O
one	O
or	O
more	O
groups	O
chosen	O
from	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
(	O
C1-C6	O
)	O
alkyl,	O
(	O
C3-C7	O
)	O
cycloalkyl,	O
(	O
C1-C6	O
)	O
alkenyl,	O
(	O
C1-C6	O
)	O
alkynyl	O
or	O
(	O
C1-C6	O
)	O
alkyl-Z-	O
(	O
C1-C6	O
)	O
alkyl	O
group,	O
in	O
which	O
Z	O
represents	O
a	O
heteroatom	O
chosen	O
from	O
O,	O
N	O
and	O
S	O
(	O
O	O
)	O
m,	O
or	O
else	O
R2	O
represents	O
a	O
halo	O
(	O
C1-C6	O
)	O
alkyl,	O
halo	O
(	O
C1-C6	O
)	O
alkoxy,	O
hydroxy,	O
(	O
C1-C6	O
)	O
alkoxy,	O
nitro,	O
cyano	O
or	O
amino	O
group,	O
an	O
NR7R8,	O
COOR,	O
CONR7R8,	O
OCO	O
(	O
C1-C6	O
)	O
alkyl	O
or	O
S	O
(	O
O	O
)	O
m-NR7R8	O
group,	O
or	O
an	O
aryl	O
group	O
;	O
R4	O
and	O
R5	O
represent,	O
independently	O
of	O
one	O
another,	O
a	O
hydrogen	O
atom,	O
or	O
else	O
R4	O
and	O
R5	O
form,	O
with	O
the	O
carbon	O
atom	O
which	O
bears	O
them,	O
a	O
saturated	O
ring	O
containing	O
from	O
3	O
to	O
6	O
carbon	O
atoms	O
and	O
optionally	O
containing	O
from	O
0	O
to	O
1	O
heteroatoms	O
chosen	O
from	O
O,	O
N	O
or	O
S	O
;	O
R6	O
represents	O
a	O
group	O
chosen	O
from	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
(	O
C1-C6	O
)	O
alkyl,	O
(	O
C3-C7	O
)	O
cycloalkyl	O
or	O
(	O
C3-C7	O
)	O
cycloalkyl	O
(	O
C1-C6	O
)	O
alkyl	O
group,	O
a	O
halo	O
(	O
C1-C6	O
)	O
alkyl,	O
nitro	O
or	O
amino	O
group,	O
an	O
NR7R8	O
or	O
COOR	O
group,	O
an	O
NR7	O
(	O
SO2	O
)	O
R8	O
or	O
CONR7R8	O
group,	O
or	O
an	O
aryl	O
group	O
;	O
X	O
represents	O
a	O
carbon	O
atom	O
or	O
a	O
nitrogen	O
atom	O
;	O
m	O
represents	O
an	O
integer	O
between	O
0	O
and	O
2	O
and	O
n	O
represents	O
an	O
integer	O
between	O
1	O
and	O
6	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
producing	O
said	O
derivatives	O
and	O
the	O
application	O
thereof	O
in	O
therapeutics	O
as	O
β-secretase	B-GENE
for	O
treating	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinases,	O
particularly	O
inhibitors	O
of	O
GSK-3	B-GENE
mammalian	O
protein	O
kinases	B-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compounds	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
protein	O
kinase	B-GENE
mediated	O
disorders,	O
such	O
as	O
diabetes,	O
cancer,	O
stroke	O
and	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
first	O
amount	O
of	O
a	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	O
thereof,	O
in	O
a	O
first	O
treatment	O
procedure,	O
and	O
a	O
second	O
amount	O
of	O
an	O
anti-cancer	O
agent	O
in	O
a	O
second	O
treatment	O
procedure	O
.	O
The	O
first	O
and	O
second	O
amounts	O
together	O
comprise	O
a	O
therapeutically	O
effective	O
amount	O
.	O
The	O
effect	O
of	O
the	O
HDAC	B-GENE
inhibitor	O
and	O
the	O
anti-cancer	O
agent	O
may	O
be	O
additive	O
or	O
synergistic	O
.	O


Imidazo	O
[	O
1,2-a	O
]	O
pyridine	O
and	O
imidazo	O
[	O
1,2-b	O
]	O
pyridazine	O
derivatives	O
which	O
inhibit	O
Btk	B-GENE
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto-immune	O
and	O
inflammatory	O
diseases	O
caused	O
by	O
aberrant	O
B-cell	O
activation,	O
e	O
.	O
g	O
.	O
arthritis	O
.	O


Compounds,	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds,	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
triphenyl	O
methane	O
analogs	O
.	O
The	O
compounds	O
and	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
a	O
wide	O
variety	O
of	O
cancers,	O
including	O
drug	O
resistant	O
cancers,	O
inflammatory,	O
degenerative	O
and	O
vascular	O
diseases,	O
including	O
various	O
ocular	O
diseases,	O
and	O
parasitic	O
infections	O
.	O
Representative	O
triphenyl	O
methane	O
analogs	O
include	O
triphenyl	O
methane	O
analogues	O
of	O
various	O
dyes,	O
hormones,	O
sugars,	O
peptides,	O
oligonucleotides,	O
amino	O
acids,	O
nucleotides,	O
nucleosides,	O
and	O
polyols	O
.	O
The	O
compounds	O
are	O
believed	O
to	O
function	O
by	O
inhibiting	O
tNOX	B-GENE
expression,	O
the	O
effects	O
of	O
ROS,	O
and	O
/	O
or	O
the	O
production	O
of	O
HIF2	B-GENE
.	O
Thus,	O
the	O
compounds	O
are	O
novel	O
therapeutic	O
agents	O
for	O
a	O
variety	O
of	O
cancers	O
and	O
other	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
Philadelphia	O
positive	O
(	O
Ph+	O
)	O
leukemia,	O
such	O
as	O
Philadelphia	O
chromosome	O
positive	O
acute	O
lymphoblastic	O
leukemia	O
(	O
Ph+	O
ALL	O
)	O
or	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
in	O
a	O
human	O
patient	O
population	O
comprising	O
the	O
steps	O
of	O
(	O
a	O
)	O
administering	O
a	O
predetermined	O
fixed	O
amount	O
of	O
a	O
Bcr-Abl	O
tyrosine	O
kinase	O
inhibitor,	O
such	O
as	O
Imatinib,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
human	O
patients	O
suffering	O
from	O
a	O
Ph+	O
leukemia,	O
(	O
b	O
)	O
collecting	O
at	O
least	O
one	O
blood	O
sample	O
from	O
said	O
patients,	O
(	O
c	O
)	O
determining	O
the	O
plasma	O
trough	O
level	O
(	O
Cmin	O
)	O
of	O
the	O
Bcr-Abl	O
tyrosine	O
kinase	O
inhibitor	O
or	O
of	O
a	O
metabolite	O
thereof	O
as	O
well	O
as	O
the	O
MMR	O
rates,	O
(	O
d	O
)	O
assessing	O
a	O
discrimination	O
potential	O
of	O
trough	O
plasma	O
concentrations	O
for	O
MMR	O
and	O
identifying	O
a	O
Cmin	O
threshold	O
for	O
optimal	O
sensitivity	O
and	O
specificity	O
and	O
(	O
e	O
)	O
adjusting	O
the	O
dose	O
of	O
the	O
inhibitor	O
of	O
the	O
Bcr-Abl	O
tyrosine	O
kinase	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
applied	O
to	O
the	O
individual	O
patients	O
from	O
said	O
patient	O
population	O
and,	O
optionally,	O
future	O
patients	O
suffering	O
from	O
a	O
Ph+	O
leukemia	O
in	O
a	O
manner	O
that	O
a	O
Cmin	O
is	O
achieved	O
in	O
each	O
single	O
patient	O
equal	O
to	O
or	O
higher	O
than	O
the	O
Cmin	O
threshold	O
obtained	O
under	O
step	O
(	O
d	O
)	O
.	O


Polyaromatic	O
sodium	B-GENE
channel	I-GENE
blockers	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
are	O
provided	O
where	O
the	O
structural	O
variables	O
are	O
defined	O
herein	O
.	O
The	O
invention	O
also	O
includes	O
a	O
variety	O
of	O
compositions,	O
combinations	O
and	O
methods	O
of	O
treatment	O
using	O
these	O
inventive	O
sodium	B-GENE
channel	I-GENE
blockers	O
.	O


The	O
present	O
invention	O
provides	O
HTV	B-GENE
aspartyl	I-GENE
protease	I-GENE
inhibitors	O
of	O
the	O
formula	O
;	O
	O
	O
	O
	O
	O
	O
	O
and	O
when	O
the	O
compound	O
of	O
formula	O
I	O
comprises	O
an	O
amino	O
group,	O
pharmaceutically	O
acceptable	O
ammonium	O
salts	O
thereof,	O
wherein	O
n	O
is	O
3	O
or	O
4,	O
wherein	O
R1	O
may	O
be,	O
for	O
example,	O
iso-butyl,	O
wherein	O
X	O
and	O
Y,	O
same	O
or	O
different,	O
may	O
be,	O
for	O
example,	O
NH2	O
and	O
F,	O
and	O
wherein	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
herein	O
.	O


2-Aminopyridine	O
compounds	O
having	O
the	O
structure	O
of	O
Formula	O
I,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
these	O
compounds	O
.	O
Compounds	O
of	O
Formula	O
I	O
inhibit	O
the	O
activity	O
of	O
tyrosine	B-GENE
kinase	I-GENE
enzymes	O
in	O
animals,	O
including	O
humans,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
various	O
diseases	O
and	O
conditions	O
.	O
In	O
particular,	O
compounds	O
disclosed	O
herein	O
are	O
inhibitors	O
of	O
kinases,	O
in	O
particular,	O
but	O
not	O
limited	O
to,	O
KDR,	O
Tie-2,	O
F1t3,	O
FGFR3,	O
Ab1,	O
Aurora	O
A,	O
c-Src,	O
IGF-	O
IR,	O
ALK,	O
c-MET,	O
RON,	O
PAK1,	O
PAK2,	O
and	O
TAK1,	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases,	O
such	O
as,	O
but	O
not	O
limited	O
to,	O
cancer	O
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
patient	O
having	O
a	O
condition	O
which	O
is	O
mediated	O
by	O
protein	B-GENE
kinase	I-GENE
activity	O
by	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
above-mentioned	O
pharmaceutical	O
composition	O
.	O


Disclosed	O
herein	O
are	O
6-oxa-2-azabicyclo	O
[	O
3	O
.	O
2	O
.	O
0	O
]	O
heptane-3,7-dione	O
or	O
heterobicyclic	O
γ-lactam-β-lactone	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
that	O
include	O
a	O
sulfonate	O
ester,	O
ester	O
or	O
ether	O
group	O
in	O
the	O
substituent	O
at	O
the	O
4-position	O
as	O
proteasome	B-GENE
inhibitors	O
.	O
These	O
Salinosporamide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
included	O
in	O
pharmaceutical	O
compositions	O
and	O
can	O
be	O
used	O
for	O
treating	O
or	O
ameliorating	O
a	O
disease	O
or	O
condition	O
such	O
as	O
cancer,	O
a	O
microbial	O
disease	O
or	O
inflammation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
compound	O
4-	O
(	O
acetylamino	O
)	O
-3-	O
[	O
(	O
4-chlorophenyl	O
)	O
thio	O
]	O
-2-	O
methyl-1H-indole-acetic	O
acid	O
ethyl	O
ester	O
as	O
intermediate	O
for	O
the	O
preparation	O
of	O
4-	O
(	O
acetylamino	O
)	O
-3-	O
[	O
(	O
4-chlorophenyl	O
)	O
thio	O
]	O
-2-methyl-1H-indole-acetic	O
acid	O
which	O
is	O
a	O
modulator	O
of	O
the	O
CRTh2	B-GENE
receptor	O
activity	O
useful	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O


Modification	O
II	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro-N-	O
(	O
{	O
(	O
5S	O
)	O
-2-oxo-3-	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
)	O
phenyl	O
]	O
-1,3-oxazolidin-5-yl	O
}	O
methyl	O
)	O
-2-thiophen	O
ecarboxamide	O
(	O
rivaroxaban	O
)	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O
Modification	O
II	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro-N-	O
(	O
{	O
(	O
5S	O
)	O
-2-oxo-3-	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
)	O
phenyl	O
]	O
-1,3-oxazolidin-5-yl	O
}	O
methyl	O
)	O
-2-thiophen	O
ecarboxamide	O
(	O
rivaroxaban	O
)	O
of	O
formula	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O
Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
(	O
1	O
)	O
method	O
for	O
preparing	O
modification	O
II	O
by	O
either	O
:	O
(	O
a	O
)	O
dissolving	O
modification	O
I	O
in	O
inert	O
solvent,	O
then	O
precipitating	O
;	O
(	O
b	O
)	O
dissolving	O
modification	O
I	O
in	O
inert	O
solvent	O
and	O
storing	O
the	O
solution	O
at	O
elevated	O
temperature	O
until	O
all	O
solvent	O
has	O
evaporated	O
;	O
or	O
(	O
c	O
)	O
suspending	O
amorphous	O
(	O
I	O
)	O
in	O
anhydrous,	O
inert	O
solvent	O
and	O
stirring	O
or	O
shaking	O
the	O
suspension	O
until	O
quantitative	O
conversion	O
to	O
modification	O
II	O
has	O
occurred	O
;	O
and	O
(	O
2	O
)	O
method	O
for	O
preparing	O
amorphous	O
(	O
I	O
)	O
by	O
melting	O
crystalline	O
(	O
I	O
)	O
then	O
cooling	O
rapidly	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Thrombolytic	O
;	O
Anticoagulant	O
;	O
Cardiant	O
;	O
Antianginal	O
;	O
Vasotropic	O
;	O
Cerebroprotective	O
;	O
Antiarteriosclerotic	O
;	O
Antiinflammatory	O
;	O
Antirheumatic	O
;	O
Nootropic	O
;	O
Neuroprotective	O
;	O
Cytostatic	O
;	O
Ophthalmological	O
.	O
No	O
biological	O
data	O
given	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Inhibition	O
of	O
blood	B-GENE
coagulation	I-GENE
factor	I-GENE
Xa	I-GENE
.	O
No	O
biological	O
data	O
given	O
.	O


Compounds	O
of	O
Formula	O
I	O
that	O
inhibit	O
Btk	B-GENE
are	O
described	O
herein	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
compound	O
of	O
Formula	O
I,	O
together	O
with	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
vehicle	O
chosen	O
from	O
carriers,	O
adjuvants,	O
and	O
excipients	O
.	O
are	O
described	O
.	O
Methods	O
of	O
treating	O
patients	O
suffering	O
from	O
certain	O
diseases	O
responsive	O
to	O
inhibition	O
of	O
Btk	B-GENE
activity	O
and	O
/	O
or	O
B-cell	O
activity	O
are	O
described	O
.	O
Methods	O
for	O
determining	O
the	O
presence	O
of	O
Btk	B-GENE
in	O
a	O
sample	O
are	O
described	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
phentermine	O
and	O
a	O
selective	O
5HT-2C	B-GENE
receptor	O
agonist	O
.	O
In	O
addition,	O
the	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
phentermine	O
and	O
a	O
selective	O
5HT-2C	B-GENE
receptor	O
agonist	O
having	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate	O
or	O
hydrate	O
thereof	O
.	O
The	O
compositions	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
whose	O
use	O
includes	O
the	O
treatment	O
of	O
obesity	O
.	O


The	O
present	O
invention	O
relates	O
in	O
general	O
to	O
an	O
inhibitor	O
of	O
a	O
glutaminyl	B-GENE
peptide	I-GENE
cyclotransferase-like	I-GENE
protein	I-GENE
(	O
QPCTL	B-GENE
)	O
,	O
and	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
an	O
inflammatory	O
disease	O
or	O
disorderselected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
.	O
chronic	O
and	O
acute	O
inflammations,	O
e	O
.	O
g	O
.	O
rheumatoid	O
arthritis,	O
atherosclerosis,	O
restenosis,	O
pancreatitis,	O
b	O
.	O
other	O
inflammatory	O
diseases,	O
e	O
.	O
g	O
.	O
neuropathic	O
pain,	O
graft	O
rejection	O
/	O
graft	O
failure	O
/	O
graft	O
vasculopathy,	O
HIV	O
infections	O
/	O
AIDS,	O
gestosis,	O
tuberous	O
sclerosis,	O
Guillain-Barr	O
syndrome,	O
chronic	O
inflammatory	O
demyelinising	O
polyradiculoneuropathy	O
and	O
multiple	O
sclerosis,	O
c	O
.	O
neuroinflammation,	O
and	O
d	O
.	O
neurodegenerative	O
diseases,	O
e	O
.	O
g	O
.	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
,	O
Alzheimer	O
'	O
s	O
disease,	O
neurodegeneration	O
in	O
Down	O
Syndrome,	O
Familial	O
British	O
Dementia,	O
and	O
Familial	O
Danish	O
Dementia,	O
which	O
may	O
result	O
from	O
neuroinflammation	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
phosphoinositide	B-GENE
3-kinase	I-GENE
inhibitor	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
b	O
)	O
a	O
mTOR	B-GENE
inhibitor	O
for	O
the	O
treatment	O
of	O
a	O
target	B-GENE
of	I-GENE
raparnycin	I-GENE
(mTOR)	I-GENE
kinase	I-GENE
dependent	O
disease,	O
especially	O
a	O
cancer	O
disease	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
combination	O
;	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
;	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
such	O
a	O
combination	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous,	O
separate	O
or	O
sequential	O
use	O
;	O
and	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
warm¬	O
blooded	O
animal,	O
especially	O
a	O
human	O
.	O


The	O
subject	O
of	O
the	O
inventions	O
are	O
a	O
compound,	O
a	O
process	O
for	O
its	O
preparation,	O
a	O
pharmaceutical	O
composition,	O
use	O
of	O
a	O
compound,	O
a	O
method	O
for	O
modulating	O
or	O
regulating	O
serine/threonine	B-GENE
kinases	I-GENE
and	O
a	O
serine/threonine	B-GENE
kinases	I-GENE
modulating	O
agent	O
.	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
small-molecule	O
compounds	O
with	O
kinase	B-GENE
inhibitory	O
activity,	O
having	O
superior	O
properties	O
as	O
pharmaceutical	O
agents,	O
production	O
method	O
thereof	O
and	O
uses	O
thereof	O
.	O
In	O
particular,	O
this	O
invention	O
relates	O
to	O
new	O
derivatives	O
of	O
tetrabromobenzimidazole	O
with	O
serine/threonine	B-GENE
kinases	I-GENE
inhibitory	O
properties,	O
preferably	O
selected	O
from	O
the	O
group	O
of	O
Pim,	O
HIPK,	O
DYRK	B-GENE
and	O
CLK	O
kinases,	O
which	O
exhibits	O
superior	O
pharmacological	O
actions,	O
and	O
can	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
disease	O
conditions,	O
especially	O
cancers	O
depending	O
on	O
serine/threonine	O
kinases,	O
such	O
as	O
leukemias	O
and	O
prostate	O
cancer	O
.	O


Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
Mixed	B-GENE
Lineage	I-GENE
Kinases	I-GENE
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
methods	O
of	O
preparing	O
the	O
compounds,	O
synthetic	O
intermediates,	O
and	O
methods	O
of	O
using	O
the	O
compounds,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents,	O
for	O
treating	O
diseases	O
and	O
conditions	O
which	O
are	O
affected	O
by	O
Mixed	B-GENE
Lineage	I-GENE
Kinase	I-GENE
inhibition	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
which	O
comprise	O
the	O
inhibition	O
of	O
Mixed	B-GENE
Lineage	I-GENE
Kinases	I-GENE
.	O


New	O
pyridazin-3	O
(	O
2H	O
)	O
-one	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
the	O
phosphodiesterase	B-GENE
IV	I-GENE
(	O
PDE4	B-GENE
)	O
.	O


There	O
is	O
provided	O
an	O
inhibitor	O
that	O
inhibits	O
casein	B-GENE
kinase	I-GENE
1δ	I-GENE
and	O
casein	B-GENE
kinase	I-GENE
1ε,	O
and	O
thus,	O
there	O
is	O
also	O
provided	O
a	O
pharmaceutical	O
agent	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
disease,	O
with	O
the	O
pathological	O
condition	O
of	O
which	O
the	O
mechanism	O
of	O
activation	O
of	O
casein	B-GENE
kinase	I-GENE
1δ	I-GENE
or	O
casein	B-GENE
kinase	I-GENE
1ε	I-GENE
is	O
associated	O
.	O
Particularly,	O
the	O
above-described	O
inhibitor	O
is	O
used	O
to	O
provide	O
a	O
pharmaceutical	O
agent	O
useful	O
for	O
the	O
treatment	O
of	O
circadian	O
rhythm	O
disorder	O
(	O
including	O
sleep	O
disorder	O
)	O
,	O
central	O
neurodegenerative	O
disease,	O
and	O
cancer	O
.	O
	O
	O
	O
	O
An	O
inhibitor	O
of	O
casein	B-GENE
kinase	I-GENE
1δ	I-GENE
and	O
casein	B-GENE
kinase	I-GENE
1ε,	O
which	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
an	O
oxazolone	O
derivative	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
salt	O
thereof,	O
a	O
solvate	O
thereof,	O
or	O
a	O
hydrate	O
thereof	O
:	O
	O
	O
	O
	O
	O
	O
	O
[	O
wherein,	O
in	O
the	O
formula	O
(	O
1	O
)	O
,	O
each	O
of	O
R1	O
and	O
R2	O
independently	O
represents	O
any	O
one	O
of	O
a	O
substituted	O
or	O
unsubstituted	O
6-membered	O
or	O
5-membered	O
heterocyclic	O
group	O
optionally	O
having	O
a	O
condensed	O
ring,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
hydrocarbon	O
group	O
optionally	O
having	O
a	O
condensed	O
ring,	O
and	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
hydrocarbon	O
lower	O
alkyl	O
group	O
or	O
aromatic	O
hydrocarbon	O
lower	O
alkenyl	O
group	O
optionally	O
having	O
a	O
condensed	O
ring	O
.	O
]	O


Methods	O
and	O
compositions	O
containing	O
a	O
berberine	O
related	O
compound	O
are	O
provided	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
and	O
cardiovascular	O
disorders	O
including	O
metabolic	O
syndrome,	O
hyperlipidemia,	O
obesity,	O
diabetes,	O
insulin	B-GENE
resistance,	O
hyperglycemia,	O
hypertension	O
and	O
elevated	O
cholesterol	O
in	O
mammalian	O
subjects	O
.	O
The	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
are	O
effective	O
for	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
syndrome,	O
hyperlipidemia,	O
obesity,	O
diabetes,	O
insulin	B-GENE
resistance,	O
hyperglycemia,	O
hypertension	O
and	O
elevated	O
cholesterol	O
.	O
Additional	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
employ	O
a	O
berberine	O
related	O
or	O
derivative	O
compound	O
including	O
demethylated	O
derivatives	O
in	O
combination	O
with	O
a	O
second	O
anti-	O
therapeutic	O
agent	O
to	O
yield	O
more	O
effective	O
treatment	O
tools	O
against	O
metabolic	O
disorders,	O
and	O
/	O
or	O
dual	O
activity	O
therapeutic	O
methods	O
and	O
formulations	O
useful	O
to	O
prevent	O
or	O
reduce	O
hyperlipidemia	O
and	O
/	O
or	O
hyperglycemia	O
and	O
one	O
or	O
more	O
causal	O
or	O
related	O
symptoms	O
or	O
conditions	O
associated	O
with	O
hyperlipidemia	O
and	O
/	O
or	O
hyperglycemia	O
in	O
mammalian	O
subjects	O
.	O


The	O
invention	O
relates	O
to	O
a	O
CuII	O
complex	O
in	O
which	O
the	O
copper	O
ion	O
is	O
coordinated	O
to	O
an	O
aromatic,	O
non-aromatic	O
or	O
aliphatic	O
dicarboxylate	O
ligand	O
via	O
an	O
oxygen	O
atom	O
of	O
one	O
of	O
the	O
carboxylate	O
groups,	O
and	O
two	O
phenanthroline,	O
or	O
phenanthroline	O
derivative,	O
ligands,	O
and	O
the	O
use	O
of	O
the	O
metal	O
complexes	O
as	O
self-activating	O
nucleases	B-GENE
to	O
treat	O
cancer	O
and	O
other	O
proliferative	O
disorders	O
.	O
In	O
one	O
embodiment,	O
the	O
CuII	O
complex	O
is	O
a	O
dinuclear	O
complex	O
comprising	O
two	O
CuII	O
ions,	O
in	O
which	O
the	O
aromatic,	O
non-aromatic	O
or	O
aliphatic	O
dicarboxylate	O
ligand	O
is	O
a	O
bridging	O
ligand,	O
and	O
in	O
which	O
each	O
copper	O
is	O
coordinated	O
to	O
the	O
bridging	O
ligand	O
via	O
the	O
carboxylate	O
groups	O
.	O


This	O
invention	O
provides	O
an	O
isolated	O
nucleic	O
acid	O
molecule	O
which	O
encodes	O
immunoglobulin	O
receptor,	O
Immunoglobulin	B-GENE
superfamily	I-GENE
Receptor	I-GENE
Translocation	I-GENE
Associated,	O
IRTA,	O
protein	O
.	O
Provided	O
too,	O
are	O
the	O
IRTA	B-GENE
proteins	I-GENE
encoded	O
by	O
the	O
isolated	O
nucleic	O
acid	O
molecules,	O
IRTA1,	O
IRTA2,	O
IRTA3,	O
IRTA4	B-GENE
or	O
IRTA5	B-GENE
proteins,	O
having	O
the	O
amino	O
acid	O
sequences	O
set	O
forth	O
in	O
any	O
of	O
Figures	O
18A,	O
18B-1-18B-3,	O
18C-1-18C-2,	O
18D-1-18D-2	O
or	O
18E-1-18E-2	O
.	O
Oligonucleotides	O
of	O
the	O
isolated	O
nucleic	O
acid	O
molecules	O
are	O
provided	O
.	O
Antibodies	O
directed	O
to	O
an	O
epitope	O
of	O
a	O
purified	O
IRTA1,	O
IRTA2,	O
IRTA3,	O
IRTA4	B-GENE
or	O
IRTA5	B-GENE
proteins	I-GENE
are	O
also	O
provided,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
antibodies	O
or	O
oligonucleotides	O
.	O
Methods	O
for	O
detecting	O
a	O
B	O
cell	O
malignancy	O
in	O
a	O
sample	O
from	O
a	O
subject	O
;	O
diagnosing	O
B	O
cell	O
malignancy	O
in	O
a	O
sample	O
from	O
a	O
subject	O
;	O
detecting	O
human	O
IRTA	B-GENE
protein	I-GENE
in	O
a	O
sample	O
;	O
and	O
treating	O
a	O
subject	O
having	O
a	O
B	O
cell	O
cancer	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
provides	O
a	O
means	O
for	O
prevention	O
and	O
treatment	O
of	O
sarcopenia	O
by	O
administration	O
of	O
a	O
substance	O
that	O
both	O
reduces	O
the	O
sensibility	O
of	O
beta-adrenergic	O
receptors	O
and	O
of	O
5-HT1a	B-GENE
receptors	O
.	O
(	O
S	O
)	O
-pindolol,	O
(	O
S	O
)	O
-propanol,	O
tertatolol	O
or	O
bopindolol	O
are	O
preferred	O
for	O
this	O
purpose	O
.	O


The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
,	O
one	O
or	O
more	O
triglycerides	O
of	O
straight-chain	O
saturated	O
fatty	O
acids	O
having	O
from	O
6	O
to	O
12	O
carbon	O
atoms	O
and	O
vegetable	B-GENE
superoxide	I-GENE
dismutase	I-GENE
(	O
SOD	B-GENE
)	O
.	O
The	O
composition	O
according	O
to	O
the	O
invention	O
is	O
suitable	O
in	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
and	O
/	O
or	O
non-alcoholic	O
hepatic	O
steatosis,	O
in	O
particular	O
in	O
paediatrics	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
metabolic	O
disorder	O
or	O
key	O
elements	O
of	O
a	O
metabolic	O
disorder	O
such	O
method	O
comprising	O
the	O
use	O
of	O
an	O
agent	O
(	O
s	O
)	O
that	O
increases	O
central	O
dopaminergic	O
activity	O
plus	O
a	O
first-phase	O
insulin	B-GENE
secretagouge	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
:	O
wherein	O
A1,	O
A2,	O
A3,	O
A4,	O
X	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description	O
.	O
The	O
present	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
making	O
said	O
compounds,	O
and	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
aurora	B-GENE
and	O
KDR	B-GENE
.	O


A	O
method	O
for	O
the	O
treatment	O
of	O
inflammation	O
in	O
an	O
individual	O
is	O
described,	O
for	O
example	O
a	O
causal	O
therapy	O
of	O
a	O
disease	O
or	O
condition	O
for	O
which	O
an	O
inflammatory	O
state	O
is	O
an	O
underlying	O
cause	O
of	O
the	O
disease,	O
or	O
a	O
treatment	O
of	O
inflammation	O
as	O
a	O
symptom	O
of	O
a	O
disease	O
state,	O
for	O
example	O
inflammation	O
caused	O
by	O
cancer,	O
cardiovascular	O
disease,	O
an	O
infection	O
or	O
trauma,	O
by	O
treating	O
the	O
individual	O
with	O
an	O
agent	O
capable	O
of	O
attenuating	O
the	O
activity	O
of	O
Ubiquitin	B-GENE
Serine	I-GENE
Protease	I-GENE
7	I-GENE
(	O
USP7	B-GENE
)	O
protein,	O
in	O
particular	O
a	O
USP7	B-GENE
inhibitor	O
chemical	O
.	O


The	O
invention	O
relates	O
to	O
FGF	O
receptor-activating	O
N-sulfate	O
oligosaccharides	O
having	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R4,	O
R6,	O
and	O
R8	O
are	O
	O
OSO3-	O
or	O
hydroxyl	O
groups,	O
R2	O
is	O
an	O
	O
O-alkyl	O
group	O
or	O
a	O
monosaccharide	O
having	O
Formula	O
(	O
II	O
)	O
,	O
R3	O
is	O
a	O
disaccharide	O
having	O
Formula	O
(	O
III	O
)	O
,	O
R5	O
is	O
a	O
disaccharide	O
having	O
Formula	O
(	O
IV	O
)	O
,	O
R7	O
is	O
a	O
hydroxyl	O
group	O
or	O
a	O
disaccharide	O
having	O
Formula	O
(	O
VI	O
)	O
,	O
and	O
R9	O
is	O
a	O
hydroxyl	O
or	O
	O
O-alkyl	O
group	O
or	O
a	O
disaccharide	O
having	O
Formula	O
(	O
VII	O
)	O
,	O
where	O
R10	O
is	O
an	O
	O
O-alkyl	O
group	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
preparation	O
of	O
said	O
oligosaccharides	O
and	O
to	O
the	O
therapeutic	O
use	O
thereof	O
.	O


This	O
disclosure	O
relates	O
to	O
new	O
heterocyclic	O
compounds	O
that	O
may	O
be	O
used	O
to	O
modulate	O
a	O
histamine	B-GENE
receptor	I-GENE
in	O
an	O
individual	O
.	O
Pyrido	O
[	O
4,3-b	O
]	O
indoles	O
are	O
described,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications,	O
including	O
the	O
treatment	O
of	O
a	O
cognitive	O
disorder,	O
psychotic	O
disorder,	O
neurotransmitter-mediated	O
disorder	O
and	O
/	O
or	O
a	O
neuronal	O
disorder	O
.	O


Benzoxepin	O
compounds	O
of	O
Formula	O
I,	O
and	O
including	O
stereoisomers,	O
geometric	O
isomers,	O
tautomers,	O
solvates,	O
metabolites	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
:	O
Z1	O
is	O
CR1	O
or	O
N	O
;	O
Z2	O
is	O
CR2	O
or	O
N	O
;	O
Z3	O
is	O
CR3	O
or	O
N	O
;	O
Z4	O
is	O
CR4	O
or	O
N	O
;	O
and	O
where	O
(	O
i	O
)	O
X1	O
is	O
N	O
and	O
X2	O
is	O
S,	O
(	O
ii	O
)	O
X1	O
is	O
S	O
and	O
X2	O
is	O
N,	O
(	O
iii	O
)	O
X1	O
is	O
CR7	O
and	O
X2	O
is	O
S,	O
(	O
iv	O
)	O
X1	O
is	O
S	O
and	O
X2	O
is	O
CR7	O
;	O
(	O
v	O
)	O
X1	O
is	O
NR8	O
and	O
X2	O
is	O
N,	O
(	O
vi	O
)	O
X1	O
is	O
N	O
and	O
X2	O
is	O
NR8,	O
(	O
vii	O
)	O
X1	O
is	O
CR7	O
and	O
X2	O
is	O
O,	O
(	O
viii	O
)	O
X1	O
is	O
O	O
and	O
X2	O
is	O
CR7,	O
(	O
ix	O
)	O
X1	O
is	O
CR7	O
and	O
X2	O
is	O
C	O
(	O
R7	O
)	O
2,	O
(	O
x	O
)	O
X1	O
is	O
C	O
(	O
R7	O
)	O
2	O
and	O
X2	O
is	O
CR7	O
;	O
(	O
xi	O
)	O
X1	O
is	O
N	O
and	O
X2	O
is	O
O,	O
or	O
(	O
xii	O
)	O
X1	O
is	O
O	O
and	O
X2	O
is	O
N,	O
are	O
useful	O
for	O
inhibiting	O
lipid	B-GENE
kinases	I-GENE
including	O
p110	B-GENE
alpha	I-GENE
and	O
other	O
isoforms	O
of	O
P13K,	O
and	O
for	O
treating	O
disorders	O
such	O
as	O
cancer	O
mediated	O
by	O
lipid	B-GENE
kinases	I-GENE
.	O
Methods	O
of	O
using	O
compounds	O
of	O
Formula	O
I	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis,	O
prevention	O
or	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells,	O
or	O
associated	O
pathological	O
conditions,	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
arylated	O
camphenes,	O
processes	O
for	O
their	O
preparation	O
and	O
uses	O
thereof	O
for	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
diseases,	O
disorders	O
or	O
conditions	O
associated	O
with,	O
or	O
benefiting	O
from	O
stimulation	O
of	O
CB2	B-GENE
receptors	I-GENE
.	O


Oxadiazole	O
substituted	O
indazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
salts	O
thereof	O
having	O
pharmacological	O
activity,	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
mediated	O
by	O
S1P1	B-GENE
receptor	I-GENE
are	O
disclosed	O
.	O


Anhydrous	O
Polymorphic	O
Forms	O
A,	O
B,	O
D	O
and	O
E	O
and	O
polymorphic	O
form	O
C	O
of	O
1-	O
[	O
(	O
4-methyl-quinazolin-2-yl	O
)	O
methyl	O
]	O
-3-methyl-7-	O
(	O
2-butyn-1-yl	O
)	O
-8-	O
(	O
3-	O
(	O
R	O
)	O
-amino-piperidin-1-yl	O
)	O
-xanthine	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O
Form	O
A	O
has	O
a	O
melting	O
point	O
of	O
206+-	O
[	O
deg	O
]	O
C	O
;	O
Form	O
D	O
melts	O
at	O
150+-3	O
[	O
deg	O
]	O
C	O
;	O
and	O
Form	O
E	O
melts	O
at	O
175+-3	O
[	O
deg	O
]	O
C	O
.	O
Form	O
B	O
transforms	O
reversibly	O
into	O
the	O
polymorph	O
A	O
at	O
10-40	O
[	O
deg	O
]	O
C	O
.	O
Form	O
C	O
loses	O
water	O
at	O
30-100	O
[	O
deg	O
]	O
C	O
.	O
An	O
independent	O
claim	O
is	O
included	O
for	O
a	O
method	O
(	O
M1	O
)	O
of	O
preparing	O
polymorph	O
form	O
C	O
involving	O
refluxing	O
(	O
I	O
)	O
in	O
methanol	O
;	O
cooling	O
the	O
methanolic	O
solution	O
to	O
40-60	O
[	O
deg	O
]	O
C	O
;	O
adding	O
a	O
solvent	O
such	O
as	O
tert-butylmethylether	O
;	O
cooling	O
the	O
resulting	O
suspension	O
to	O
15-25	O
[	O
deg	O
]	O
C	O
and	O
then	O
to	O
0-5	O
[	O
deg	O
]	O
C	O
;	O
filtering	O
the	O
crystals	O
by	O
suction	O
and	O
drying	O
in	O
vacuo	O
at	O
70	O
[	O
deg	O
]	O
C	O
.	O
ACTIVITY	O
:	O
Antidiabetic	O
;	O
Anorectic	O
;	O
Antarthritic	O
;	O
Antirheumatoid	O
;	O
Osteopathic	O
;	O
Immunosuppressive	O
.	O
No	O
biological	O
data	O
is	O
given	O
.	O
MECHANISM	O
OF	O
ACTION	O
:	O
Dipeptidyl	B-GENE
peptidase	I-GENE
(DPP)-IV	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
of	O
recombinant	O
human	B-GENE
lysosomal	I-GENE
acid	I-GENE
lipase	I-GENE
having	O
particular	O
glycosylation	O
patterns	O
for	O
internalization	O
into	O
target	O
cells,	O
a	O
vector	O
containing	O
the	O
nucleic	O
acid	O
encoding	O
human	B-GENE
lysosomal	I-GENE
acid	I-GENE
lipase,	O
a	O
host	O
cell	O
transformed	O
with	O
the	O
vector,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
recombinant	O
human	B-GENE
lysosomal	I-GENE
acid	I-GENE
lipase	I-GENE
and	O
method	O
of	O
treating	O
conditions	O
associated	O
with	O
lysosomal	O
acid	I-GENE
lipase	I-GENE
deficiency	O
.	O


Provided	O
are	O
therapeutic	O
and	O
/	O
or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprise,	O
as	O
an	O
active	O
ingredient,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
antagonistic	O
activity	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
therapeutic	O
and	O
/	O
or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
antagonistic	O
activity,	O
which	O
has	O
an	O
affinity	O
for	O
the	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
10	O
times	O
or	O
higher	O
than	O
that	O
for	O
the	O
adenosine	B-GENE
A1	I-GENE
receptor,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
the	O
like	O
.	O


This	O
invention	O
discloses	O
a	O
method	O
of	O
inducing	O
expression	O
of	O
full-length	O
collagen	O
7	O
in	O
cells	O
that	O
contain	O
nonsense	O
mutations	O
in	O
the	O
COL7A1	B-GENE
gene	O
by	O
treating	O
the	O
cell	O
with	O
an	O
aminoglycoside	O
such	O
as	O
G418,	O
gentamicin,	O
and	O
paromomycin	O
.	O
Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
DEB	O
due	O
to	O
nonsense	O
mutation	O
in	O
the	O
COL7A1	B-GENE
gene	O
by	O
administering	O
a	O
composition	O
containing	O
an	O
effective	O
amount	O
of	O
an	O
aminoglycoside	O
.	O
Also	O
provided	O
is	O
a	O
novel	O
composition	O
useful	O
to	O
treating	O
conditions	O
due	O
to	O
nonsense	O
mutation	O
in	O
the	O
COL7A1	B-GENE
gene,	O
containing	O
an	O
aminoglycoside,	O
a	O
C7,	O
a	O
min-C7	O
or	O
both	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


GPR120	B-GENE
agonists	O
are	O
provided	O
.	O
These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
diseases,	O
including	O
Type	O
II	O
diabetes	O
and	O
diseases	O
associated	O
with	O
poor	O
glycemic	O
control	O
.	O


The	O
present	O
invention	O
comprises	O
methods	O
and	O
pharmaceutical	O
compositions	O
for	O
intranasal	O
delivery	O
of	O
effective	O
amounts	O
of	O
DFO	O
directly	O
to	O
the	O
CNS,	O
in	O
particular	O
the	O
brain	O
treatments	O
that	O
inhibit	O
GSK3b	B-GENE
in	O
patients	O
with	O
psychiatric	O
disorders	O
including,	O
but	O
not	O
limited	O
to,	O
bipolar	O
disorder,	O
depression,	O
ADHD	O
and	O
schizophrenia	O
.	O
In	O
addition	O
a	O
treatment	O
composition	O
is	O
disclosed	O
which	O
comprises	O
DFO	O
and	O
in	O
certain	O
embodiments	O
combines	O
DFO	O
with	O
one	O
or	O
more	O
of	O
the	O
psychotropic	O
drug	O
types,	O
i	O
.	O
e	O
.	O
,	O
antipsychotics,	O
mood	O
stabilizers	O
and	O
antidepressants	O
.	O
Moreover,	O
a	O
treatment	O
for	O
treating	O
impairment	O
of	O
neural	O
plasticity	O
through	O
inhibition	O
of	O
GSK3b	B-GENE
is	O
provided	O
as	O
well	O
as	O
prevention	O
of	O
apoptosis	O
of	O
cells	O
through	O
inhibition	O
of	O
GSK3b	B-GENE
.	O


Disclosed	O
is	O
a	O
medicament	O
characterized	O
by	O
the	O
combination	O
of	O
:	O
epigallocatechin	O
gallate,	O
methylated	O
epigallocatechin	O
gallate,	O
or	O
a	O
pharmacologically	O
permitted	O
salt	O
thereof	O
;	O
and	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
.	O


Methods	O
for	O
treating	O
a	O
disease	O
state	O
for	O
which	O
HGF	B-GENE
/	O
cMET	B-GENE
possesses	O
activity	O
that	O
contributes	O
to	O
the	O
pathology	O
and	O
/	O
or	O
symptomology	O
of	O
the	O
disease	O
state,	O
as	O
well	O
as	O
kits	O
and	O
articles	O
of	O
manufacture	O
for	O
use	O
in	O
practicing	O
these	O
methods	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
fused	O
heterocyclic	O
derivative	O
of	O
the	O
formula	O
(	O
I	O
)	O
The	O
variables	O
R1-R4,	O
z,	O
A,	O
Q,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
following	O
heterocycles	O
are	O
exemplified	O
substructures	O
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
modulators	O
of	O
the	O
S1P	B-GENE
receptor	I-GENE
(	O
Sphingosine-1-phosphate	B-GENE
receptor	I-GENE
)	O
,	O
More	O
specifically,	O
they	O
are	O
agonists	O
of	O
S1P5	B-GENE
.	O
The	O
compounds	O
have	O
therapeutic	O
use	O
in	O
treatment	O
of	O
cognitive	O
disorders,	O
age-relate	O
cognitive	O
decline	O
and	O
dementia	O
.	O


The	O
present	O
invention	O
discloses	O
novel	O
compounds	O
useful	O
for	O
the	O
inhibition	O
of	O
IL-6	B-GENE
/	O
STAT	B-GENE
signaling	O
and	O
/	O
or	O
PI3K	B-GENE
/	O
NF-ĸΒ	B-GENE
signaling	O
in	O
the	O
treatment	O
of	O
associated	O
diseases	O
or	O
conditions,	O
e	O
.	O
g	O
.	O
cancer	O
.	O
A	O
pharmaceutical	O
composition	O
comprising	O
such	O
novel	O
compounds,	O
its	O
use	O
and	O
a	O
method	O
thereof,	O
is	O
also	O
disclosed	O
.	O


A	O
stable	O
solid	O
dosage	O
form	O
comprising	O
a	O
non-toxic	O
base	O
and	O
an	O
amorphous	O
benzimidazole	O
compound	O
having	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
(	O
PPI	O
)	O
activity	O
.	O


[	O
Problem	O
]	O
	O
	O
	O
	O
A	O
novel	O
and	O
excellent	O
compound	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
rejection	O
reactions	O
in	O
various	O
organ	O
transplantations,	O
allergy	O
diseases,	O
autoimmune	O
diseases,	O
and	O
hematologic	O
tumor,	O
and	O
based	O
on	O
a	O
PI3Kδ	B-GENE
selective	O
inhibitory	O
action	O
and	O
/	O
or	O
an	O
IL-2	B-GENE
production	O
inhibitory	O
action	O
and	O
/	O
or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
.	O
	O
	O
	O
	O
[	O
Means	O
for	O
Solution	O
]	O
	O
	O
	O
	O
The	O
present	O
inventors	O
have	O
investigated	O
a	O
compound	O
having	O
a	O
PI3Kδ	B-GENE
selective	O
inhibitory	O
action	O
and	O
/	O
or	O
an	O
IL-2	B-GENE
production	O
inhibitory	O
action	O
and	O
/	O
or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
and	O
have	O
found	O
that	O
the	O
heterocyclic	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
PI3Kδ	B-GENE
selective	O
inhibitory	O
action	O
and	O
/	O
or	O
and	O
IL-2	B-GENE
production	O
inhibitory	O
action	O
and	O
/	O
or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
thereby	O
completing	O
the	O
present	O
invention	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
which	O
is	O
effective	O
in	O
inhibiting	O
the	O
function	O
of	O
the	O
TRPM4	B-GENE
ion	O
channel	O
and	O
the	O
use	O
of	O
such	O
compound	O
in	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease,	O
such	O
as	O
Multiple	O
Sclerosis,	O
Parkinson	O
'	O
s	O
disease,	O
Alzheimer	O
'	O
s	O
disease,	O
or	O
amyotrophic	O
lateral	O
sclerosis,	O
in	O
a	O
subject	O
.	O
The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
TRPM4	B-GENE
inhibitory	O
compound	O
.	O
The	O
invention	O
further	O
relates	O
to	O
in	O
vitro	O
methods	O
for	O
identifying	O
pharmaceutically	O
active	O
compounds	O
that	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
probiotic	O
(	O
s	O
)	O
which	O
can	O
activate	O
an	O
aromatic	B-GENE
hydrocarbon	I-GENE
receptor	I-GENE
(	O
AhR	B-GENE
)	O
and	O
can	O
consequently	O
prevent	O
inflammatory	O
damage	O
in	O
the	O
digestive	O
tract	O
.	O
The	O
present	O
invention	O
relates	O
to	O
;	O
a	O
probiotic	O
(	O
s	O
)	O
capable	O
of	O
activating	O
an	O
AhR	B-GENE
;	O
an	O
anti-inflammatory	O
agent	O
comprising	O
the	O
probiotic	O
(	O
s	O
)	O
;	O
an	O
orally	O
ingestible	O
composition	O
containing	O
the	O
anti-inflammatory	O
agent	O
;	O
and	O
a	O
method	O
for	O
screening	O
for	O
the	O
probiotic	O
(	O
s	O
)	O
.	O


The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
product	O
for	O
inhibiting	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA,	O
SCD-1	O
mRNA,	O
and	O
SREBP1c	O
mRNA,	O
the	O
present	O
invention	O
is	O
also	O
intended	O
to	O
provide	O
a	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
various	O
diseases	O
based	O
on	O
inhibition	O
of	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA,	O
SCD-1	O
mRNA,	O
and	O
SREBP1c	O
mRNA,	O
and	O
the	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
inhibiting	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA,	O
SCD-1	O
mRNA,	O
and	O
SREBP1c	O
mRNA,	O
and	O
relates	O
also	O
to	O
a	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
various	O
diseases	O
based	O
on	O
the	O
inhibition	O
of	O
the	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA,	O
SCD-1	O
mRNA,	O
and	O
SREBP1c	O
mRNA,	O
the	O
agent	O
comprising	O
a	O
compound	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
,	O
its	O
salt,	O
or	O
a	O
solvate	O
of	O
any	O
of	O
them	O
as	O
an	O
active	O
ingredient	O
:	O
	O
	O
wherein	O
the	O
symbols	O
are	O
the	O
same	O
as	O
those	O
given	O
in	O
the	O
description	O
.	O
.	O


Disclosed	O
are	O
methods	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
diseases,	O
disorders	O
or	O
conditions	O
responsive	O
to	O
the	O
inhibition	O
of	O
NAE	B-GENE
(	O
Nedd8-activating	B-GENE
enzyme	I-GENE
)	O
,	O
e	O
.	O
g	O
.	O
,	O
cancer	O
.	O
The	O
methods	O
comprise	O
administering	O
a	O
clinically	O
effective	O
amount	O
of	O
the	O
NAE-inhibitor	O
(	O
(	O
1S,2S,4R	O
)	O
-4-	O
(	O
4-	O
(	O
(	O
1S	O
)	O
-2,3-dihydro-1H-	O
inden-1-ylamino	O
)	O
-7H-pyrrolo	O
[	O
2,3-d	O
]	O
pyrimidin-7-yl	O
)	O
-2-hydroxycyclopentyl	O
)	O
methyl	O
sulfamate	O
(	O
MLN4924	O
)	O
according	O
to	O
an	O
intermittent	O
dosing	O
regimen	O
in	O
which	O
there	O
is	O
a	O
rest	O
period	O
of	O
at	O
least	O
two	O
days	O
between	O
each	O
administration	O
.	O


Disclosed	O
are	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
as	O
modulators	O
of	O
histone	O
methyltransferases,	O
and	O
for	O
treating	O
diseases	O
influenced	O
by	O
modulation	O
of	O
histone	B-GENE
methyltransferase	I-GENE
activity	O
.	O


This	O
invention	O
relates	O
to	O
bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalized	O
phenols	O
of	O
general	O
formula	O
1,	O
their	O
use	O
as	O
inhibitors	O
of	O
CXCR2	B-GENE
activity,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints	O
or	O
diseases,	O
inflammatory	O
diseases	O
of	O
the	O
joints,	O
skin,	O
or	O
eyes,	O
diseases	O
of	O
the	O
peripheral	O
or	O
central	O
nervous	O
system	O
or	O
cancers,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
I,	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
wherein	O
R	O
is	O
aryl	O
substituted	O
by	O
R3	O
;	O
or	O
R	O
is	O
(	O
C3-Ci3	O
)	O
-cycloalkyl,	O
(	O
C3-Ci3	O
)	O
-cycloalkenyl	O
or	O
(	O
C7-Ci3	O
)	O
-cycloalkynyl	O
optionally	O
substituted	O
by	O
R4	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates,	O
or	O
solvates	O
thereof,	O
for	O
use-alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds-in	O
therapy,	O
for	O
preventing,	O
treating	O
or	O
ameliorating	O
diseases	O
or	O
conditions	O
responsive	O
to	O
stimulation	O
of	O
neutrophil	O
oxidative	O
burst,	O
responsive	O
to	O
stimulation	O
of	O
keratinocyte	O
IL-8	B-GENE
release	O
or	O
responsive	O
to	O
induction	O
of	O
necrosis	O
.	O


Disclosed	O
herein	O
are	O
new	O
heterocyclic	O
compounds	O
and	O
compositions	O
and	O
their	O
application	O
as	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
disease	O
.	O
Methods	O
of	O
inhibiting	O
PAS	B-GENE
Kinase	I-GENE
(	O
PASK	B-GENE
)	O
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
also	O
provided	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
diabetes	O
mellitus	O
.	O


The	O
present	O
disclosure	O
provides	O
a	O
series	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
which	O
modulate	O
&	O
bgr	O
;	O
-amyloid	O
peptide	O
(	O
&	O
bgr	O
;	O
-AP	O
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
&	O
bgr	O
;	O
-amyloid	O
peptide	O
(	O
&	O
bgr	O
;	O
-AP	O
)	O
production	O
.	O


The	O
present	O
invention	O
describes	O
the	O
use	O
of	O
compounds	O
and	O
combinations	O
thereof	O
which	O
inhibit	O
the	O
phosphatidic	B-GENE
acid	I-GENE
phosphohydrolase	I-GENE
enyzme	O
(	O
PAP	B-GENE
)	O
for	O
producing	O
medicines	O
that	O
can	O
be	O
used	O
to	O
treat	O
cancer	O
;	O
PAP	B-GENE
inhibitors	O
are	O
used	O
to	O
block	O
the	O
progression	O
of	O
cancers	O
that	O
depend	O
on	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
,	O
oncogenic	O
variants	O
thereof	O
and	O
other	O
members	O
of	O
the	O
ErbB	O
family,	O
by	O
inducing	O
the	O
endocytosis	O
thereof	O
and	O
thus	O
making	O
them	O
inaccessible	O
to	O
stimuli	O
which	O
promote	O
cancer	O
survival	O
and	O
progression	O
;	O
the	O
PAP	B-GENE
inhibitors	O
which	O
are	O
part	O
of	O
the	O
invention	O
include	O
drugs	O
which	O
are	O
currently	O
used	O
for	O
other	O
clinical	O
purposes	O
and	O
which	O
are	O
not	O
connected	O
apart	O
from	O
the	O
fact	O
that	O
they	O
are	O
cationic	O
amphiphilic	O
molecules	O
;	O
these	O
include	O
propranolol,	O
desipramine	O
and	O
chlorpromazine,	O
drugs	O
which	O
are	O
used	O
for	O
other	O
clinical	O
purposes	O
;	O
the	O
present	O
invention	O
covers	O
all	O
PAP	B-GENE
inhibitors,	O
including	O
sphingosine	O
and	O
bromoenol	O
lactone	O
and	O
any	O
new	O
inhibitors	O
which	O
may	O
be	O
discovered	O
in	O
the	O
future	O
.	O


The	O
present	O
embodiments	O
provide	O
for	O
compositions	O
and	O
methods	O
that	O
regulate	O
microRNA-binding	O
protein-mediated	O
miRNA	O
biogenesis	O
;	O
for	O
example	O
Lin28-mediated	O
biogenesis	O
of	O
let-7	B-GENE
;	O
and	O
in	O
particular	O
Lin28A-recruited	O
3'	B-GENE
terminal	I-GENE
uridylyl	I-GENE
transferase	I-GENE
(	O
TUTase	B-GENE
)	O
uridylation	O
of	O
pre-let-7	O
.	O
A	O
particular	O
embodiment	O
provides	O
compositions	O
and	O
methods	O
for	O
screening	O
for	O
agents	O
that	O
inhibit	O
TUTase-dependent	O
Lin28A-mediated	O
repression	O
of	O
let-7	B-GENE
miRNA	O
.	O


The	O
invention	O
provides	O
modulators	O
for	O
the	O
orphan	O
nuclear	O
receptor	O
RORy	B-GENE
and	O
methods	O
for	O
treating	O
RORy	B-GENE
mediated	O
diseases	O
by	O
administrating	O
these	O
novel	O
RORy	B-GENE
modulators	O
to	O
a	O
human	O
or	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O
Specifically,	O
the	O
present	O
invention	O
provides	O
pyrrolo	O
sulfonamide	O
compounds	O
of	O
Formula	O
(	O
1	O
)	O
and	O
the	O
enantiomers,	O
diastereomers,	O
tautomers,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O


Methods	O
are	O
provided	O
for	O
treating	O
mesothelioma	O
patients	O
with	O
a	O
dual	O
PI3K	B-GENE
/	O
m	B-GENE
TOR	I-GENE
inhibitor,	O
GDC-0980	O
:	O
(	O
S	O
)	O
-1-	O
(	O
4-	O
(	O
(	O
2-	O
(	O
2-aminopyrimidin-5-yl	O
)	O
-7-methyl-4-morpholinothieno	O
[	O
3,2-	O
d	O
]	O
pyrimidin-6-yl	O
)	O
methyl	O
)	O
piperazin-1-yl	O
)	O
-2-hydroxypropan-1-one,	O
and	O
having	O
the	O
structure	O
:	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
4,6,4	O
'	O
-trimethylangelicin	O
(	O
TMA	O
)	O
and	O
structural	O
analogues	O
thereof	O
to	O
prepare	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
with	O
the	O
primary	O
objective	O
of	O
correcting	O
the	O
defective	O
CFTR	B-GENE
in	O
a	O
sub-group	O
of	O
cystic	O
fibrosis	O
patients	O
consisting	O
of	O
patients	O
carrying	O
the	O
F508del-CFTR	O
mutation	O
.	O


The	O
present	O
invention	O
provides	O
a	O
protein	O
comprising	O
a	O
truncated	O
form	O
of	O
an	O
extracellular	B-GENE
region	I-GENE
protein	I-GENE
of	I-GENE
Frizzled	I-GENE
2,	O
which	O
has	O
higher	O
secretion	O
activity	O
than	O
that	O
of	O
a	O
known	O
protein	O
comprising	O
an	O
extralellular	B-GENE
cysteine-rich	I-GENE
domain	I-GENE
of	I-GENE
Frizzled	I-GENE
2	I-GENE
in	O
a	O
production	O
cell	O
and	O
bone	O
mass-increasing	O
activity	O
higher	O
than	O
or	O
equal	O
to	O
that	O
of	O
the	O
known	O
protein,	O
or	O
DNA	O
encoding	O
said	O
protein	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
R1	O
is	O
hydrogen	O
or	O
fluorine,	O
one	O
of	O
A	O
and	O
B	O
is	O
R2,	O
the	O
other	O
is	O
a	O
group	O
-X-Y-R3	O
.	O
R3	O
represents	O
a	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
.	O
Further	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Also	O
claimed	O
are-	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia,	O
cognitive	O
disorders	O
and	O
pain	O
by	O
modulating	O
the	O
D-amino	B-GENE
acid	I-GENE
oxidase	I-GENE
enzyme	O
(	O
DAAO	B-GENE
)	O
.	O


This	O
invention	O
generally	O
provides	O
compounds,	O
pharmaceutical	O
compositions,	O
and	O
methods	O
for	O
their	O
use,	O
which	O
include	O
methods	O
that	O
result	O
in	O
increased	O
expression	O
in	O
an	O
Atoh1	B-GENE
gene	O
(	O
e	O
.	O
g	O
.	O
,	O
Hath1	B-GENE
)	O
in	O
a	O
biological	O
cell	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
diseases	O
and	O
/	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
Atoh1	B-GENE
expression,	O
e	O
.	O
g	O
.	O
a	O
hearing	O
impairment	O
or	O
imbalance	O
disorder	O
associated	O
with	O
a	O
loss	O
of	O
auditory	O
hair	O
cells,	O
or	O
a	O
disorder	O
associated	O
with	O
abnormal	O
cellular	O
proliferation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
which	O
are	O
inhibitors	O
of	O
CRAC	B-GENE
channel	I-GENE
activity	O
.	O
This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
them,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
.	O


Methods	O
for	O
treating	O
neurodegeneration	O
and	O
/	O
or	O
myelination	O
in	O
patients	O
are	O
disclosed	O
comprising	O
treating	O
the	O
patient	O
with	O
a	O
progestin	O
compound	O
which	O
exerts	O
binding	O
to	O
progesterone	B-GENE
receptors	I-GENE
and	O
elicits	O
progesterone-receptor-induced	O
biological	O
responses	O
without	O
interacting	O
with	O
the	O
androgen	B-GENE
receptor	I-GENE
and	O
without	O
inducing	O
androgen	O
or	O
glucocorticoid	O
biological	O
responses	O
at	O
a	O
dosage	O
sufficient	O
to	O
prevent	O
or	O
reduce	O
neurodegeneration	O
.	O
The	O
progestin	O
compound	O
preferably	O
comprises	O
16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione,	O
and	O
the	O
methods	O
include	O
combining	O
the	O
progestin	O
compound	O
with	O
an	O
estrogen	O
compound	O
to	O
provide	O
both	O
contraception	O
and	O
treatment	O
for	O
myelin	O
repair	O
and	O
neurodegeneration,	O
and	O
include	O
effects	O
on	O
stroke	O
and	O
TBI	O
.	O


The	O
present	O
invention	O
provides	O
a	O
novel	O
amino	O
compound	O
that	O
blocks	O
the	O
IKur	O
current	O
or	O
the	O
Kv1.5	B-GENE
channel	O
potently	O
and	O
more	O
selectively	O
than	O
other	O
K+	B-GENE
channels	I-GENE
.	O
The	O
present	O
invention	O
relates	O
to	O
an	O
amino	O
compound	O
represented	O
by	O
General	O
Formula	O
(	O
1	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
salt	O
thereof,	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
independently	O
hydrogen	O
or	O
organic	O
group	O
;	O
XA	O
and	O
XB	O
are	O
each	O
independently	O
a	O
bond,	O
alkylene,	O
alkenylene,	O
-CO-,	O
-SO2-,	O
or	O
-CONH-,	O
wherein	O
each	O
of	O
the	O
alkylene	O
and	O
alkenylene	O
chains	O
can	O
optionally	O
contain	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-S-,	O
-C	O
(	O
=	O
S	O
)	O
-,	O
-SO2-,	O
-CO-,	O
-O-,	O
-NH-,	O
-CONH-	O
and	O
-SO2NH-,	O
and	O
the	O
hydrogen	O
atom	O
(	O
H	O
)	O
bonded	O
to	O
the	O
nitrogen	O
atom	O
(	O
N	O
)	O
in	O
XA	O
and	O
XB	O
is	O
optionnally	O
substituted	O
with	O
a	O
subsituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lower	O
alkyl,	O
phenyl	O
lower	O
alkyl	O
and	O
phenyl	O
;	O
A1	O
is	O
lower	O
alkylene	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxyl	O
and	O
oxo	O
;	O
R3	O
is	O
(	O
i	O
)	O
a	O
heterocyclic	O
group	O
which	O
is	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
substituents,	O
or	O
(	O
ii	O
)	O
an	O
aryl	O
group	O
substituted	O
with	O
one	O
or	O
more	O
substituents	O
select	O
from	O
the	O
group	O
consisting	O
of	O
oxo,	O
lower	O
alkyl,	O
carboxyl,	O
halo-lower	O
alkyl,	O
lower	O
alkanoyl	O
lower	O
alkyl,	O
phenyl	O
lower	O
alkyl,	O
cyclo	O
lower	O
alkyl,	O
lower	O
alkoxy,	O
halo	O
lower	O
alkoxy,	O
phenyl	O
lower	O
alkoxy,	O
phenoxy,	O
cyano,	O
hydroxyl,	O
halogen,	O
nitro,	O
lower	O
alkylthio,	O
lower	O
alkanoyl,	O
lower	O
alkoxy	O
carbonyl,	O
lower	O
alkenyl,	O
phenyl,	O
triazolyl,	O
isoxazolyl,	O
imidazolyl,	O
pyrrolyl,	O
benzo	O
[	O
d	O
]	O
oxazolyl,	O
benzo	O
[	O
d	O
]	O
thiazolyl	O
and	O
the	O
group	O
represented	O
by	O
General	O
Formula	O
(	O
2	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Y	O
is	O
a	O
bond,	O
lower	O
alkylene,	O
or	O
-CO-	O
;	O
R4	O
and	O
R5	O
are	O
each	O
independently	O
hydrogen,	O
lower	O
alkyl,	O
cyclo	O
lower	O
alkyl,	O
phenyl,	O
or	O
lower	O
alkanoyl	O
;	O
or	O
R4	O
and	O
R5	O
may	O
be	O
linked	O
to	O
form	O
a	O
ring	O
together	O
with	O
the	O
neighboring	O
nitrogen,	O
and	O
the	O
ring	O
may	O
optionally	O
have	O
one	O
or	O
more	O
substituents	O
.	O


An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
cancer	O
stem	O
cell	O
isolated	O
using	O
a	O
cell	O
marker	O
;	O
a	O
substantively	O
homogeneous	O
cancer	O
stem	O
cell	O
population	O
including	O
said	O
cancer	O
stem	O
cell	O
;	O
and	O
a	O
method	O
of	O
preparing	O
said	O
cancer	O
stem	O
cell	O
population	O
.	O
Another	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
for	O
separating	O
cancer	O
stem	O
cells	O
with	O
a	O
high	O
proliferative	O
potential	O
and	O
those	O
with	O
a	O
low	O
proliferative	O
potential	O
;	O
a	O
method	O
for	O
inducing	O
cancer	O
stem	O
cells	O
to	O
have	O
a	O
different	O
proliferative	O
potential	O
;	O
and	O
cancer	O
stem	O
cells	O
separated	O
or	O
induced	O
by	O
these	O
separation	O
or	O
induction	O
methods	O
.	O
A	O
further	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
of	O
screening	O
for	O
pharmaceuticals	O
using	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
;	O
a	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
and	O
for	O
identifying	O
or	O
quantifying	O
the	O
same	O
.	O
The	O
present	O
inventors	O
discovered	O
that	O
highly	O
pure	O
colon	O
cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
can	O
be	O
obtained	O
in	O
a	O
large	O
quantity,	O
and	O
identified	O
two	O
types	O
of	O
states	O
of	O
colon	O
CSCs	O
distinguishable	O
through	O
Lgr5	B-GENE
expression	O
.	O


Provided	O
are	O
:	O
composition	O
and	O
methods	O
for	O
:	O
treating	O
aging	O
or	O
an	O
age-related	O
condition,	O
symptom	O
or	O
disease	O
;	O
stimulating	O
hair	O
growth,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	O
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof,	O
including	O
cosmetic	O
treatment	O
(	O
e	O
.	O
g	O
.	O
,	O
wrinkles,	O
hyperpigmentation,	O
redness,	O
rosacea,	O
dryness,	O
cracking,	O
loss	O
of	O
firmness,	O
loss	O
of	O
elasticity,	O
thinning,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O
The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
the	O
disclosed	O
CBP	B-GENE
/	O
catenin	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CBP	B-GENE
/	O
B-catenin	B-GENE
)	O
antagonist	O
compositions,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O
In	O
particular	O
aspects,	O
the	O
CBP	B-GENE
/	O
catenin	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CBP	B-GENE
/	O
B-catenin	B-GENE
)	O
antagonist	O
comprises	O
an	O
alkyl	O
and	O
/	O
or	O
fatty	O
acid	O
ester	O
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O


Disclosed	O
are	O
quinazolines	O
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
hydrates	O
thereof	O
.	O
The	O
compounds	O
have	O
protein	B-GENE
kinases	I-GENE
inhibitory	O
activities	O
and	O
are	O
expected	O
to	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
protein	B-GENE
kinases	I-GENE
mediated	O
diseases	O
and	O
conditions	O
.	O


Agents,	O
methods,	O
and	O
devices	O
for	O
affecting	O
nerve	O
function	O
are	O
described	O
.	O
One	O
embodiment	O
of	O
an	O
agent	O
includes	O
a	O
cardiac	O
glycoside,	O
an	O
ACE	B-GENE
inhibitor,	O
and	O
an	O
NSAID	O
.	O
The	O
agent	O
may	O
be	O
delivered	O
locally	O
in	O
a	O
site-specific	O
manner	O
to	O
a	O
targeted	O
nerve	O
or	O
portion	O
of	O
a	O
nerve	O
.	O
For	O
example,	O
the	O
agent	O
may	O
be	O
delivered	O
locally	O
to	O
the	O
renal	O
nerves	O
to	O
impair	O
their	O
function	O
and	O
treat	O
hypertension	O
.	O
One	O
embodiment	O
of	O
a	O
delivery	O
device	O
includes	O
one	O
or	O
more	O
needle	O
housings	O
supported	O
by	O
a	O
balloon	O
.	O
A	O
delivery	O
needle	O
is	O
slidably	O
disposed	O
within	O
a	O
needle	O
lumen	O
of	O
each	O
needle	O
housing	O
.	O


A	O
compound	O
of	O
the	O
general	O
structure	O
(	O
I	O
)	O
is	O
capable	O
of	O
abrogating	O
the	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
of	O
the	O
19S	B-GENE
RP	I-GENE
DUBs	I-GENE
.	O
The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
cancer,	O
in	O
particular	O
of	O
cancer	O
refractory	O
to	O
treatment	O
by	O
state-of-the-art	O
chemotherapy	O
.	O
Also	O
disclosed	O
are	O
corresponding	O
methods	O
of	O
treatment	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
inducing	O
or	O
enhancing	O
chondrogenesis	O
in	O
vivo	O
and	O
/	O
or	O
ex	O
vivo	O
.	O
More	O
specifically,	O
the	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
RAR	B-GENE
pan-antagonist	O
compositions	O
for	O
the	O
treatment,	O
repair	O
and	O
engineering	O
of	O
cartilage	O
.	O


This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
E2	O
polypeptide	O
to	O
induce	O
apoptosis	O
(	O
a	O
form	O
of	O
programmed	O
cell	O
death	O
)	O
in	O
cells	O
.	O
The	O
mutant	O
E2	O
derived	O
polypeptide	O
is	O
p53	B-GENE
binding	O
deficient	O
.	O
Preferably	O
it	O
is	O
unable	O
to	O
bind	O
p53	B-GENE
;	O
or	O
able	O
to	O
bind	O
p53	B-GENE
but	O
unable	O
to	O
induce	O
p53-dependent	O
apoptosis	O
.	O


Compounds	O
represented	O
by	O
the	O
general	O
formula	O
.	O
[	O
I	O
]	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
hydrogen,	O
halogen,	O
an	O
optionally	O
substituted	O
linear	O
hydrocarbon	O
group,	O
or	O
hydroxyl	O
which	O
may	O
be	O
substituted	O
with	O
an	O
optionally	O
substituted	O
liner	O
hydrocarbon	O
group,	O
or	O
R1	O
and	O
R2	O
together	O
with	O
the	O
carbon	O
atoms	O
adjacent	O
thereto	O
may	O
form	O
an	O
optionally	O
substituted	O
cyclic	O
hydrocarbon	O
or	O
a	O
dihydrofuran	O
ring	O
which	O
may	O
have	O
an	O
oxo	O
group	O
;	O
ring	O
A	O
is	O
a	O
benzene	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
an	O
aromatic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
whose	O
main	O
chain	O
has	O
1	O
to	O
6	O
atoms	O
;	O
Y	O
is	O
carboxyl	O
which	O
may	O
be	O
esterified,	O
carbamoyl	O
which	O
may	O
be	O
substituted,	O
cyano,	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
bearing	O
a	O
hydrogen	O
atom	O
capable	O
of	O
being	O
deprotonated,	O
or	O
salts	O
thereof,	O
which	O
are	O
useful	O
as	O
lipid-rich	O
plaque	O
regressing	O
agents	O
and	O
/	O
or	O
ACAT	B-GENE
inhibitors	O
.	O


A	O
method	O
of	O
treating	O
a	O
human	O
being	O
suffering	O
from	O
a	O
hormone-dependent	O
disorder	O
characterized	O
by	O
the	O
overexpression	O
of	O
EGFR,	O
comprising	O
administering	O
to	O
said	O
human	O
being	O
an	O
aromatase	O
inhibitor	O
and	O
an	O
EGFR	B-GENE
antagonist	O
or	O
EGFR	B-GENE
inhibitor,	O
in	O
amounts	O
effective	O
to	O
produce	O
a	O
superadditive	O
or	O
synergistic	O
therapeutic	O
effect	O
.	O


The	O
present	O
invention	O
is	O
a	O
method	O
of	O
treating	O
Alzheimer	O
'	O
s	O
disease,	O
and	O
other	O
diseases,	O
and	O
/	O
or	O
inhibiting	O
beta-secretase	B-GENE
enzyme,	O
and	O
/	O
or	O
inhibiting	O
deposition	O
of	O
A	B-GENE
beta	I-GENE
peptide	I-GENE
in	O
a	O
mammal,	O
by	O
use	O
of	O
known	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein,	O
A,	O
R,	O
J,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
product	O
for	O
administration	O
to	O
a	O
patient,	O
the	O
product	O
comprising	O
4′-cyano-α′,α′,α′-trifluoro-3-	O
(	O
4-fluorophenylsulphonyl	O
)	O
-2-hydroxy-2-methylpropiono-m-toluidide,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
in	O
solid	O
dispersion	O
with	O
an	O
enteric	O
polymer	O
having	O
a	O
pKa	O
from	O
3	O
to	O
6,	O
the	O
product	O
further	O
comprising	O
an	O
anti-oestrogen	O
(	O
eg,	O
tamoxifen	O
citrate	O
)	O
and	O
/	O
or	O
an	O
aromatase	B-GENE
inhibitor	O
(	O
eg,	O
anastrozole	O
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
dose	O
of	O
the	O
drug	O
and	O
anti-oestrogen	O
/	O
aromatase	B-GENE
inhibitor	O
provided	O
by	O
such	O
a	O
formulation	O
.	O
An	O
advantage	O
is	O
the	O
treating	O
and	O
/	O
or	O
preventing	O
of	O
at	O
least	O
one	O
side	O
effect	O
selected	O
from	O
gynaecomastia,	O
breast	O
tenderness,	O
hot	O
flushes,	O
impotence	O
and	O
reduction	O
in	O
libido,	O
while	O
increasing	O
the	O
bioavailability	O
of	O
the	O
drug	O
;	O
reducing	O
inter-patient	O
variability	O
in	O
plasma	O
concentrations	O
of	O
the	O
4′-cyano-α′,α′,α′-trifluoro-3-	O
(	O
4-fluorophenylsulphonyl	O
)	O
-2-hydroxy-2-methylpropiono-m-toluidide	O
;	O
enhancing	O
the	O
storage	O
stability	O
of	O
the	O
drug	O
;	O
and	O
/	O
or	O
treating	O
and	O
/	O
or	O
reducing	O
the	O
risk	O
of	O
prostate	O
cancer	O
in	O
a	O
patient	O
.	O


A	O
hydroxyeicosenoic	O
acid	O
analog	O
represented	O
by	O
the	O
following	O
Formula	O
(	O
I	O
)	O
,	O
the	O
bond	O
≡	O
represents	O
a	O
cis-vinylene	O
group	O
or	O
an	O
ethynylene	O
group	O
;	O
Y	O
represents	O
CH2,	O
O	O
or	O
S	O
(	O
O	O
)	O
p	O
wherein	O
p	O
is	O
0,	O
1	O
or	O
2	O
;	O
m	O
represents	O
an	O
integer	O
of	O
1	O
to	O
4	O
inclusive	O
;	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
3	O
inclusive	O
;	O
the	O
sum	O
of	O
m	O
and	O
n	O
is	O
an	O
integer	O
of	O
3	O
to	O
7	O
inclusive	O
;	O
R1	O
represents	O
a	O
C1-4	O
alkyl	O
group	O
or	O
a	O
C3-8	O
cycloalkyl	O
group	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
methyl	O
group	O
;	O
R3	O
represents	O
COR4,	O
a	O
nitrile	O
group,	O
a	O
halogen	O
atom,	O
a	O
tetrazole	O
group	O
or	O
a	O
thiazolidinedione	O
group	O
;	O
R4	O
represents	O
OR6,	O
NHR6,	O
N	O
(	O
OH	O
)	O
R6,	O
NHSO2R5,	O
glycerol	O
or	O
functionalized	O
glycerols	O
;	O
R5	O
represents	O
a	O
C1-15	O
alkyl	O
group,	O
a	O
C6-10	O
aryl	O
group	O
or	O
a	O
C7-14	O
aryl	O
group	O
substituted	O
with	O
alkyl	O
groups,	O
halogens	O
or	O
amino	O
groups	O
;	O
R6	O
represents	O
a	O
hydrogen,	O
a	O
C1-10	O
alkyl	O
group	O
or	O
a	O
C1-10	O
alkyl	O
group	O
substituted	O
with	O
a	O
hydroxyl	O
group,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	O
thereof	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
an	O
elastase	B-GENE
release	O
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof,	O
wherein	O
A-B	O
is	O
N—O	O
or	O
O—N	O
and	O
G,	O
R1,	O
R2,	O
R3,	O
and	O
R4	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinase,	O
particularly	O
inhibitors	O
of	O
Src	B-GENE
and	O
Lck	B-GENE
kinase	B-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O


The	O
invention	O
relates	O
generally	O
to	O
phosphoinositide	B-GENE
3-kinases	I-GENE
(	O
PI3Ks	B-GENE
)	O
,	O
and	O
more	O
particularly	O
to	O
methods	O
of	O
inhibiting	O
leukocyte	O
accumulation	O
comprising	O
selectively	O
inhibiting	O
phosphoinositide	B-GENE
3-kinase	I-GENE
delta	I-GENE
(	O
PI3Kδ	B-GENE
)	O
activity	O
in	O
endothelial	O
cells	O
.	O


Compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
their	O
acid	O
addition	O
salts	O
are	O
provided	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
:	O
	O
	O
	O
	O
	O
R1	O
signifies	O
a	O
piperazino,	O
p-phenylenediamino,	O
a	O
2,5-diazabicyclo-	O
[	O
2	O
.	O
2	O
.	O
1	O
]	O
-heptane,	O
a	O
2,5-diazabicyclo-	O
[	O
2	O
.	O
2	O
.	O
2	O
]	O
-octane	O
radical	O
or	O
a	O
3,8-diazabicyclo-	O
[	O
3	O
.	O
2	O
.	O
1	O
]	O
-octane	O
radical,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent,	O
	O
	O
	O
	O
	O
R2,	O
R4,	O
which	O
are	O
in	O
each	O
case	O
the	O
same,	O
signify	O
a	O
pyrrolidino,	O
thiazolidino,	O
oxazolidino	O
or	O
imidazolidino	O
radical,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent,	O
and	O
	O
	O
	O
	O
	O
R3	O
signifies	O
an	O
alkyl,	O
alkoxy,	O
alkylmercapto	O
or	O
an	O
alkylamino	O
radical,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent	O
.	O
These	O
pteridine	O
derivatives	O
are	O
suitable	O
for	O
the	O
inhibition	O
of	O
phosphodiesterases	B-GENE
and	O
therefore	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
thrombo-embolic,	O
neurodegenerative	O
diseases,	O
inflammatory	O
diseases,	O
asthmatic	O
diseases	O
as	O
well	O
as	O
hemato-oncological	O
diseases	O
.	O


The	O
present	O
invention	O
discloses	O
novel	O
peptide	O
compounds	O
which	O
have	O
HCV	B-GENE
protease	I-GENE
inhibitory	O
activity	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
such	O
compounds	O
.	O
In	O
another	O
embodiment,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
such	O
peptides	O
as	O
well	O
as	O
methods	O
of	O
using	O
them	O
to	O
treat	O
disorders	O
associated	O
with	O
the	O
HCV	B-GENE
protease	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
plasmids	O
suitable	O
for	O
IL-2	B-GENE
expression,	O
particularly,	O
human	B-GENE
IL-2	B-GENE
expression,	O
and	O
related	O
methods	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R3	O
is	O
the	O
group	O
;	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof,	O
and	O
their	O
use	O
as	O
pharmaceuticals,	O
particularly	O
as	O
p38	B-GENE
kinase	I-GENE
inhibitors	O
.	O


NK3	B-GENE
receptor	O
antagonists	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
are	O
useful	O
in	O
treating	O
inter	O
alia	O
pulmonary	O
disorders,	O
CNS	O
disorders	O
and	O
neurodegenerative	O
disorders	O
.	O


The	O
phosphoric	O
acid	O
salt	O
of	O
3-	O
(	O
2-methoxy-pyrimidin-5-yl	O
)	O
-5-oxo-9-	O
(	O
6,7,8,9-tetrahydro-5H-pyrido	O
[	O
2,3-b	O
]	O
azepin-2-yl	O
)	O
-nonanoic	O
acid	O
is	O
a	O
potent	O
antagonist	O
of	O
the	O
integrin	B-GENE
αvβ3	I-GENE
receptor	I-GENE
and	O
is	O
useful	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
osteoporosis	O
and	O
vascular	O
restenosis,	O
as	O
well	O
as	O
conditions	O
associated	O
with	O
excessive	O
angiogenesis,	O
such	O
as	O
macular	O
degeneration,	O
diabetic	O
retinopathy,	O
atherosclerosis,	O
inflammatory	O
arthritis,	O
cancer,	O
and	O
metastatic	O
tumor	O
growth	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
novel	O
salt	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
.	O


The	O
present	O
invention	O
provides	O
a	O
heterocyclic	O
compound	O
having	O
potent	O
tyrosine	O
kinase-inhibiting	O
activity	O
represented	O
by	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein,	O
R1b	O
is	O
a	O
C6-10	O
aryl	O
group	O
which	O
has	O
substituent	O
(	O
s	O
)	O
,	O
and	O
the	O
like	O
;	O
Ta	O
is	O
a	O
single	O
bond,	O
a	O
C1-6	O
alkyl	O
group,	O
—CH2O—,	O
and	O
the	O
like	O
;	O
X	O
and	O
Y	O
are	O
the	O
same	O
or	O
different,	O
and	O
each	O
is	O
a	O
nitrogen	O
atom	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
,	O
and	O
the	O
like	O
;	O
the	O
broken	O
line	O
is	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
;	O
Za	O
is	O
a	O
nitrogen	O
atom	O
or	O
CH	O
;	O
W	O
is	O
a	O
single	O
bond,	O
an	O
oxygen	O
atom,	O
and	O
the	O
like	O
;	O
Q	O
is	O
a	O
C6-10	O
aryl	O
group	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
or	O
an	O
aromatic	O
heterocyclic	O
group	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
)	O
;	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
the	O
combined	O
administration	O
of	O
PDE4	B-GENE
or	O
PDE3/4	B-GENE
inhibitors	O
and	O
histamine	B-GENE
receptor	I-GENE
antagonists	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O


It	O
has	O
been	O
unexpectedly	O
found	O
that	O
a	O
drug	O
resistant	O
strain	O
of	O
HIV	O
exhibits	O
the	O
behavior	O
of	O
drug-naïve	O
virus	O
when	O
given	O
the	O
combination	O
of	O
a	O
β-D-1,3-dioxolanyl	O
nucleoside	O
and	O
an	O
IMPDH	B-GENE
inhibitor	O
.	O
In	O
one	O
nonlimiting	O
embodiment,	O
the	O
HIV	O
strain	O
is	O
resistant	O
to	O
a	O
β-D-1,3-dioxolanyl	O
nucleoside	O
.	O


There	O
is	O
provided	O
the	O
use	O
of	O
a	O
phosphodiesterase	O
antagonist	O
to	O
reduce	O
insulin	B-GENE
resistance,	O
and	O
to	O
amplify	O
the	O
effect	O
of	O
nitric	O
oxide	O
on	O
skeletal	O
muscle	O
insulin-mediated	O
glucose	O
uptake	O
in	O
a	O
mammal	O
.	O
In	O
some	O
instances,	O
the	O
antagonist	O
is	O
targeted	O
to	O
the	O
liver	O
.	O
In	O
some	O
instances,	O
the	O
insulin	B-GENE
resistance	O
is	O
hepatic	O
insulin	B-GENE
sensitizing	O
substance	O
(	O
“HISS”	O
)	O
dependant	O
insulin	B-GENE
resistance	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
the	O
treatment	O
of	O
immunological	O
disorders	O
other	O
than	O
cancer,	O
comprising	O
administering	O
proteins	O
characterized	O
by	O
their	O
ability	O
to	O
bind	O
to	O
CD30	B-GENE
and	O
exert	O
a	O
cytostatic	O
or	O
cytotoxic	O
effect	O
on	O
an	O
activated	O
lymphocyte	O
.	O
Such	O
proteins	O
include	O
monoclonal	O
antibodies	O
AC10	O
and	O
IleFi1	O
.	O
AC10	O
and	O
HeFi-1	O
derivatives,	O
and	O
antibodies	O
that	O
compete	O
with	O
AC10	O
and	O
HeFi-1	O
for	O
binding	O
to	O
CD30	B-GENE
.	O
Other	O
such	O
proteins	O
include	O
multivalent	O
anti-CD30	O
antibodies	O
and	O
anti-CD30	O
antibodies	O
conjugated	O
to	O
cytotoxic	O
agents	O
.	O
Treatment	O
modalities	O
with	O
antibodies	O
of	O
the	O
invention	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
concerns	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
PTH	B-GENE
and	O
PTHrP	B-GENE
.	O
In	O
accordance	O
with	O
the	O
present	O
invention,	O
modulators	O
of	O
PTH	B-GENE
and	O
PTHrP	B-GENE
comprise	O
:	O
(	O
a	O
)	O
a	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domain	O
;	O
and	O
(	O
b	O
)	O
a	O
vehicle,	O
such	O
as	O
a	O
polymer	O
(	O
e	O
.	O
g	O
.	O
,	O
PEG	O
or	O
dextran	O
)	O
or	O
an	O
Fc	O
domain,	O
which	O
is	O
preferred	O
;	O
wherein	O
the	O
vehicle	O
is	O
covalently	O
attached	O
to	O
the	O
C-terminus	O
of	O
the	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domain	O
or	O
through	O
a	O
sidechain	O
at	O
any	O
residue	O
from	O
residue	O
14	O
through	O
the	O
C-terminal	O
residue	O
.	O
The	O
vehicle	O
and	O
the	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domain	O
may	O
be	O
linked	O
through	O
the	O
N-	O
or	O
C-terminus	O
of	O
the	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domain,	O
as	O
described	O
further	O
below	O
.	O
The	O
preferred	O
vehicle	O
is	O
PEG	O
.	O
Preferred	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domains	O
comprise	O
the	O
PTH	B-GENE
and	O
PTHrP-derived	O
amino	O
acid	O
sequences	O
described	O
hereinafter	O
.	O
Other	O
PTH	B-GENE
/	O
PTHrP	B-GENE
modulating	O
domains	O
can	O
be	O
generated	O
by	O
phage	O
display,	O
RNA-peptide	O
screening	O
and	O
the	O
other	O
techniques	O
mentioned	O
herein	O
.	O
Such	O
peptides	O
typically	O
will	O
be	O
modulators	O
of	O
both	O
PTH	B-GENE
activity	O
and	O
PTHrP	B-GENE
activity,	O
although	O
such	O
techniques	O
can	O
be	O
used	O
to	O
generate	O
peptide	O
sequences	O
that	O
serve	O
as	O
selective	O
modulators	O
(	O
e	O
.	O
g	O
.	O
,	O
agonists	O
of	O
PTH	B-GENE
activity	O
but	O
not	O
PTHrP	B-GENE
activity	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
α-substituted	O
heteroarylalkylphosphonate	O
derivatives	O
and	O
their	O
uses	O
for	O
lowering	O
plasma	O
levels	O
of	O
apo	O
(	O
a	O
)	O
,	O
Lp	O
(	O
a	O
)	O
,	O
apo	O
B,	O
apo	B-GENE
B	I-GENE
associated	O
lipoproteins	O
(	O
low	O
density	O
lipoproteins	O
and	O
very	O
low	O
density	O
lipoproteins	O
)	O
and	O
for	O
lowering	O
plasma	O
levels	O
of	O
total	O
cholesterol	O
.	O


A	O
composition	O
and	O
a	O
kit	O
for	O
treating	O
cancer	O
comprising	O
N,N-dimethylphytosphingosine	O
.	O
The	O
composition	O
represses	O
the	O
activity	O
of	O
sphingosine	O
kinase,	O
and	O
therefore,	O
intercepts	O
various	O
mechanisms	O
which	O
sphingosine	B-GENE
kinase	I-GENE
induces	O
.	O
For	O
example,	O
the	O
composition	O
blocks	O
the	O
phosphorylation	O
of	O
ceramide	O
and	O
sphingosine,	O
thereby	O
maintaining	O
high	O
concentration	O
of	O
ceramide	O
and	O
sphingosine	O
.	O
The	O
ceramide	O
and	O
sphingosine	O
induce	O
apoptosis	O
in	O
cancer	O
cells	O
.	O
Therefore,	O
the	O
composition	O
according	O
to	O
the	O
present	O
invention	O
induces	O
apoptosis	O
in	O
cancer	O
cells	O
and	O
accordingly	O
kills	O
the	O
cancer	O
cells	O
.	O


A	O
Her2	B-GENE
and	O
/	O
or	O
EGFR	B-GENE
inhibitor	O
to	O
be	O
administered	O
to	O
a	O
subject	O
determined	O
to	O
show	O
overexpression	O
or	O
activation	O
of	O
Her2	B-GENE
and	O
/	O
or	O
EGFR	B-GENE
as	O
a	O
result	O
of	O
a	O
diagnosis	O
of	O
the	O
subject	O
for	O
the	O
expression	O
or	O
activity	O
of	O
Her2	B-GENE
and	O
/	O
or	O
EGFR	B-GENE
based	O
on	O
a	O
test	O
for	O
detecting	O
the	O
expression	O
or	O
activity	O
of	O
Her2	B-GENE
and	O
/	O
or	O
EGFR,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
inhibitor	O
.	O


Calcium	B-GENE
channels	I-GENE
which	O
form	O
in	O
neuronal	O
membranes	O
in	O
response	O
to	O
injury	O
are	O
disclosed	O
.	O
Methods	O
and	O
compositions	O
for	O
blocking	O
this	O
injury	O
induced	O
calcium	B-GENE
channel	I-GENE
and	O
preventing	O
further	O
injury	O
to	O
neuronal	O
cells	O
and	O
/	O
or	O
neuronal	O
cell	O
death	O
are	O
disclosed	O
.	O
The	O
compositions	O
and	O
methods	O
disclosed	O
may	O
be	O
used	O
to	O
alleviate	O
acute	O
or	O
chronic	O
injury	O
to	O
neuronal	O
cells	O
.	O


Novel	O
compounds	O
of	O
structural	O
formula	O
(	O
I	O
)	O
are	O
antagonists	O
and	O
/	O
or	O
inverse	O
agonists	O
of	O
the	O
Cannabinoid-1	B-GENE
(CB1)	I-GENE
receptor	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
CB1	B-GENE
receptor	I-GENE
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
psychotropic	O
drugs	O
in	O
the	O
treatment	O
of	O
psychosis,	O
memory	O
deficits,	O
cognitive	O
disorders,	O
migraine,	O
neuropathy,	O
neuro-inflammatory	O
disorders	O
including	O
multiple	O
sclerosis	O
and	O
Guillain-Barre	O
syndrome	O
and	O
the	O
inflammatory	O
sequelae	O
of	O
viral	O
encephalitis,	O
cerebral	O
vascular	O
accidents,	O
and	O
head	O
trauma,	O
anxiety	O
disorders,	O
stress,	O
epilepsy,	O
Parkinson	O
'	O
s	O
disease,	O
movement	O
disorders,	O
and	O
schizophrenia	O
.	O
The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
substance	O
abuse	O
disorders,	O
the	O
treatment	O
of	O
obesity	O
or	O
eating	O
disorders,	O
as	O
well	O
as,	O
the	O
treatment	O
of	O
asthma,	O
constipation,	O
chronic	O
intestinal	O
pseudo-obstruction,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
3-substituted	O
quinuclidine	O
derivatives,	O
which	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
and	I-GENE
modulators	O
of	O
the	O
monoamine	B-GENE
receptors	I-GENE
and	I-GENE
transporters	I-GENE
.	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neurodegeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O


An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
method	O
of	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease,	O
a	O
method	O
of	O
screening	O
for	O
candidate	O
compounds	O
for	O
treating	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease,	O
and	O
a	O
pharmaceutical	O
agent	O
for	O
treating	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
The	O
present	O
invention	O
identified	O
genes	O
whose	O
expression	O
levels	O
varied	O
between	O
respiratory	O
epithelial	O
cells	O
that	O
had	O
been	O
stimulated	O
by	O
IL-13	B-GENE
to	O
induce	O
the	O
goblet	O
cell	O
differentiation,	O
and	O
unstimulated	O
respiratory	O
epithelial	O
cells	O
.	O
The	O
respiratory	O
epithelial	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
air	O
interface	O
method	O
.	O
The	O
genes	O
were	O
revealed	O
to	O
be	O
useful	O
as	O
markers	O
for	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
screening	O
for	O
therapeutic	O
agents	O
for	O
such	O
diseases	O
.	O
Specifically,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
methods	O
of	O
screening	O
for	O
compounds	O
to	O
treat	O
the	O
diseases	O
based	O
on	O
the	O
comparison	O
of	O
the	O
expression	O
levels	O
of	O
marker	O
genes	O
identified	O
as	O
described	O
above	O
.	O


The	O
invention	O
concerns	O
combination	O
products	O
comprising	O
(	O
i	O
)	O
at	O
least	O
a	O
substance	O
capable	O
of	O
inhibiting	O
CSF-1	B-GENE
activity	O
and	O
/	O
or	O
at	O
least	O
a	O
nucleic	O
acid,	O
comprising	O
at	O
least	O
a	O
sequence	O
coding	O
for	O
a	O
substance	O
capable	O
of	O
inhibiting	O
CSF-1	B-GENE
activity	O
and	O
(	O
ii	O
)	O
at	O
least	O
a	O
substance	O
having	O
a	O
cytotoxic	O
activity	O
and	O
/	O
or	O
at	O
least	O
a	O
nucleic	O
acid,	O
comprising	O
at	O
least	O
a	O
sequence	O
coding	O
for	O
a	O
substance	O
having	O
cytotoxic	O
activity	O
.	O
The	O
invention	O
also	O
concerns	O
oligonucleotides	O
capable	O
of	O
inhibiting	O
CSF-1	B-GENE
expression	O
.	O
The	O
invention	O
is	O
particular	O
useful	O
for	O
implementing	O
an	O
antitumoral	O
treatment	O
.	O


Methods	O
for	O
identifying	O
a	O
compound	O
that	O
activates	O
a	O
TLR-mediated	O
cellular	O
signaling	O
pathway	O
is	O
disclosed	O
.	O
The	O
method	O
includes	O
(	O
a	O
)	O
exposing	O
a	O
TLR-positive	O
cell	O
culture	O
to	O
a	O
test	O
compound	O
and	O
measuring	O
a	O
TLR-mediated	O
cellular	O
response	O
;	O
(	O
b	O
)	O
exposing	O
a	O
TLR-negative	O
cell	O
culture	O
to	O
a	O
test	O
compound	O
and	O
measuring	O
a	O
TLR-mediated	O
cellular	O
response	O
;	O
and	O
(	O
c	O
)	O
identifying	O
the	O
test	O
compound	O
as	O
an	O
IRM	O
if	O
the	O
cellular	O
response	O
in	O
the	O
TLR-positive	O
cell	O
culture	O
is	O
greater	O
than	O
the	O
cellular	O
response	O
of	O
the	O
TLR-negative	O
cell	O
culture	O
.	O
Methods	O
of	O
eliciting	O
a	O
TLR-mediated	O
cellular	O
response	O
are	O
also	O
disclosed	O
.	O
Such	O
methods	O
include	O
administration	O
of	O
an	O
IRM	O
compound	O
to	O
an	O
IRM-responsive	O
cell	O
so	O
that	O
the	O
IRM	O
compound	O
affects	O
at	O
least	O
one	O
TLR-mediate	O
cellular	O
signaling	O
pathway	O
.	O


This	O
invention	O
is	O
directed	O
to	O
compounds	O
which	O
are	O
selective	O
antagonists	O
for	O
melanin	B-GENE
concentrating	I-GENE
hormone-1	I-GENE
(MCH1)	I-GENE
receptors	I-GENE
.	O
The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
This	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
made	O
by	O
combining	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
this	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
This	O
invention	O
further	O
provides	O
a	O
process	O
for	O
making	O
a	O
pharmaceutical	O
composition	O
comprising	O
combining	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
This	O
invention	O
also	O
provides	O
a	O
method	O
of	O
reducing	O
the	O
body	O
mass	O
of	O
a	O
subject	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
effective	O
to	O
reduce	O
the	O
body	O
mass	O
of	O
the	O
subject	O
.	O
This	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
depression	O
and	O
/	O
or	O
anxiety	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
effective	O
to	O
treat	O
the	O
subject	O
=	O
s	O
depression	O
and	O
/	O
or	O
anxiety	O
.	O
This	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
urinary	O
disorder	O
.	O


A	O
combination	O
of	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
(	O
i	O
)	O
an	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
agonist	O
;	O
and	O
(	O
ii	O
)	O
an	O
anti-cholinergic	O
agent,	O
preferably	O
comprising	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tiotropium	O
and	O
derivatives	O
thereof	O
;	O
the	O
combination	O
being	O
therapeutically	O
effective	O
in	O
the	O
treatment	O
of	O
the	O
diseases	O
when	O
administered	O
by	O
inhalation	O
;	O
as	O
well	O
as	O
to	O
a	O
method	O
of	O
treating	O
the	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
administering	O
separately,	O
simultaneously	O
or	O
sequentially	O
to	O
the	O
mammal	O
by	O
inhalation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
together	O
with	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
product	O
containing	O
the	O
compounds	O
of	O
the	O
combination	O
for	O
separate,	O
simultaneous	O
or	O
sequential	O
administration	O
by	O
inhalation	O
to	O
a	O
mammal	O
for	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
.	O
It	O
is	O
preferred	O
that	O
the	O
anti-cholinergic	O
agent	O
component	O
be	O
tiotropium	O
bromide	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
uses	O
of	O
a	O
polynucleotide	O
sequence	O
of	O
a	O
novel	O
G-Protein	B-GENE
Coupled	I-GENE
Receptor	I-GENE
5HT6	B-GENE
.	O
The	O
invention	O
also	O
provides	O
the	O
human	B-GENE
5-HT6	I-GENE
receptor	I-GENE
as	O
being	O
associated	O
with	O
hematological	O
disorders,	O
pain	O
diseases,	O
respiratory	O
diseases,	O
genito-urological	O
disorders,	O
cardio	O
vascular	O
diseases	O
and	O
cancer	O
.	O
The	O
invention	O
also	O
provides	O
assays	O
for	O
the	O
identification	O
of	O
compounds	O
useful	O
for	O
the	O
modulation	O
of	O
hematological	O
disorders,	O
pain	O
diseases,	O
respiratory	O
diseases,	O
genito-uro-logical	O
disorders,	O
cardio	O
vascular	O
diseases	O
and	O
cancer	O
for	O
treating	O
or	O
preventing	O
hematological	O
disorders,	O
pain	O
diseases,	O
respiratory	O
diseases,	O
genito-urological	O
disorders,	O
cardio	O
vascular	O
diseases	O
and	O
cancer	O
associated	O
with	O
expression	O
of	O
the	O
5-HT6	O
receptor	I-GENE
.	O


Disclosed	O
are	O
substituted	O
pyridazinones	O
that	O
are	O
useful	O
for	O
treating	O
diseases	O
and	O
conditions	O
caused	O
or	O
exacerbated	O
by	O
unregulated	O
p38	B-GENE
MAP	I-GENE
Kinase	I-GENE
and	O
/	O
or	O
TNF	B-GENE
activity	O
.	O
Pharmaceutical	O
composition	O
containing	O
the	O
pyridazinone	O
compounds,	O
methods	O
of	O
preparing	O
the	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
are	O
also	O
disclosed	O
.	O


The	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R3,	O
R10,	O
m	O
and	O
Ar	O
are	O
as	O
defined	O
in	O
the	O
Specification	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
or	O
conditions	O
in	O
which	O
inhibition	O
of	O
kinase	O
Itk	B-GENE
activity	O
is	O
beneficial	O
is	O
disclosed	O
.	O
Certain	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
capable	O
of	O
inhibiting,	O
modulating	O
and	O
/	O
or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor-type	B-GENE
and	I-GENE
non-receptor	I-GENE
type	I-GENE
tyrosine	I-GENE
kinases	I-GENE
.	O
The	O
compounds	O
of	O
the	O
instant	O
invention	O
possess	O
a	O
core	O
structure	O
that	O
comprises	O
a	O
sulfonyl	O
indole	O
moiety	O
.	O
The	O
present	O
invention	O
is	O
also	O
related	O
to	O
the	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates	O
and	O
stereoisomers	O
of	O
these	O
compounds	O
.	O


Substituted	O
piperidine	O
compounds	O
represented	O
by	O
the	O
structure	O
I	O
are	O
provided,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
each	O
of	O
R1a,	O
R1b,	O
R1c,	O
R1d,	O
R1e,	O
R1f,	O
R1g,	O
R1h,	O
R2,	O
R2A,	O
R3,	O
R4,	O
A,	O
X,	O
a,	O
x	O
and	O
n	O
is	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Substituted	O
piperidine	O
compounds	O
of	O
structure	O
I	O
may	O
permeate	O
or	O
penetrate	O
across	O
a	O
nerve	O
cell	O
membrane	O
into	O
the	O
interior	O
of	O
a	O
nerve	O
cell,	O
may	O
inhibit	O
intracellular	O
Rho	B-GENE
kinase	I-GENE
enzyme	O
found	O
in	O
nerve	O
cells	O
in	O
mammals,	O
and	O
may	O
find	O
utility	O
in	O
repair	O
of	O
damaged	O
nerves	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
of	O
such	O
mammals	O
.	O
These	O
compounds	O
may	O
induce	O
the	O
regeneration	O
or	O
growth	O
of	O
neurites	O
in	O
mammalian	O
nerve	O
cells	O
and	O
may	O
thereby	O
induce	O
regeneration	O
of	O
damaged	O
or	O
diseased	O
nerve	O
tissue	O
.	O
These	O
compounds	O
also	O
find	O
additional	O
utility	O
as	O
antagonists	O
of	O
the	O
enzyme	O
Rho	B-GENE
kinase	I-GENE
in	O
treatment	O
of	O
disease	O
states	O
in	O
which	O
Rho	B-GENE
kinase	I-GENE
is	O
implicated	O
.	O
Pharmaceutical	O
compositions	O
containing	O
these	O
substituted	O
piperidine	O
compounds	O
may	O
be	O
useful	O
to	O
promote	O
neurite	O
growth	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
Rho	B-GENE
kinase	I-GENE
inhibition	O
is	O
indicated	O
.	O


The	O
present	O
invention	O
is	O
for	O
a	O
method	O
for	O
decreasing	O
C-reactive	B-GENE
protein	I-GENE
levels	O
(	O
CRP	B-GENE
)	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O
The	O
method	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
non-antibacterial	O
tetracycline	O
formulation,	O
to	O
the	O
mammal	O
.	O
In	O
one	O
embodiment,	O
the	O
non-antibacterial	O
tetracycline	O
formulation	O
is	O
a	O
non-antibacterial	O
amount	O
of	O
an	O
antibacterial	O
tetracycline	O
.	O
In	O
another	O
embodiment,	O
the	O
non-antibacterial	O
tetracycline	O
formulation	O
is	O
a	O
non-antibacterial	O
tetracycline	O
.	O


Compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
in	O
vivo	O
hydrolysable	O
esters	O
thereof,	O
have	O
activity	O
as	O
pharmaceuticals,	O
in	O
particular	O
as	O
modulators	O
of	O
chemokine	B-GENE
receptor	I-GENE
(	O
especially	O
CXCR2	B-GENE
)	O
activity,	O
and	O
may	O
be	O
in	O
the	O
treatment	O
(	O
therapeutic	O
or	O
prophylactic	O
)	O
of	O
conditions	O
/	O
diseases	O
in	O
human	O
and	O
non-human	O
animals	O
which	O
are	O
exacerbated	O
or	O
caused	O
by	O
excessive	O
or	O
unregulated	O
production	O
of	O
chemokines	B-GENE
.	O


Methods	O
are	O
disclosed	O
for	O
fast	O
and	O
accurate	O
readout	O
of	O
kidney	O
toxicity	O
before	O
it	O
occurs	O
and	O
before	O
it	O
is	O
demonstrated	O
by	O
histopathology	O
examination	O
.	O
Ultimately,	O
this	O
approach	O
shall	O
allow	O
earlier	O
compound	O
selection	O
.	O
The	O
twelve	O
genes	O
identified,	O
namely	O
Calbindin-D28k,	O
KIM-1,	O
OPN,	O
EGF,	O
Clusterin,	O
VEGF,	O
OAT-K1,	O
Aldolase	O
A,	O
Aldolase	O
B,	O
Podocin,	O
Alpha-2u	B-GENE
and	I-GENE
C4,	O
were	O
grouped	O
and	O
ultimately	O
can	O
be	O
assessed	O
in	O
the	O
form	O
of	O
a	O
kit	O
using	O
PCR,	O
a	O
high	O
throughput	O
technology,	O
in	O
order	O
to	O
characterize	O
and	O
rank	O
new	O
compounds	O
according	O
to	O
their	O
anticipated	O
general	O
kidney	O
toxicity	O
.	O
Also	O
disclosed	O
are	O
methods	O
for	O
identifying	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
kidney	O
disease,	O
methods	O
for	O
monitoring	O
the	O
efficacy	O
of	O
a	O
treatment	O
for	O
kidney	O
disease	O
and	O
kidney-specific	O
vectors	O
including	O
the	O
sequences	O
of	O
the	O
disclosed	O
genes,	O
and	O
a	O
method	O
for	O
identifying	O
a	O
candidate	O
gene	O
associated	O
with	O
a	O
biological	O
process	O
including	O
kidney	O
function	O
.	O


The	O
invention	O
concerns	O
a	O
combination	O
product	O
comprising	O
an	O
antisense	O
oligonucleotide	O
of	O
the	O
gene	O
encoding	O
MBD2-demethylase	O
and	O
at	O
least	O
an	O
agent	O
used	O
in	O
antitumour	O
chemotherapy,	O
in	O
particular	O
bleomycin,	O
for	O
simultaneous,	O
separate	O
or	O
prolonged	O
use	O
for	O
treating	O
proliferative	O
and	O
inflammatory	O
diseases,	O
in	O
particular	O
for	O
cancer	O
treatment	O
.	O


The	O
invention	O
provides	O
novel	O
(	O
2S	O
)	O
-2-ethylphenylpropanoic	O
acid	O
derivatives	O
that	O
bind	O
to	O
the	O
receptor	O
as	O
ligands	O
of	O
human	B-GENE
peroxisome	I-GENE
proliferator-activated	I-GENE
receptor	I-GENE
(PPAR)	I-GENE
α	I-GENE
to	O
activate	O
and	O
exhibit	O
lipid-lowering	O
effect,	O
inhibitory	O
effect	O
on	O
the	O
arteriosclerosis,	O
antiobesity	O
effect,	O
blood	O
glucose-lowering	O
effect,	O
etc	O
.	O
,	O
their	O
addition	O
salts,	O
and	O
their	O
medicinal	O
compositions	O
.	O
	O
	O
(	O
2S	O
)	O
-2-Ethylphenylpropanoic	O
acid	O
derivatives	O
represented	O
by	O
a	O
general	O
formula	O
(	O
1	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
[	O
wherein	O
R1	O
denotes	O
a	O
halogen	O
atom	O
or	O
trifluoromethyl	O
group,	O
R2	O
denotes	O
a	O
hydrogen	O
atom,	O
halogen	O
atom	O
or	O
trifluoromethyl	O
group,	O
and,	O
when	O
R2	O
denotes	O
a	O
hydrogen	O
atom,	O
R3	O
denotes	O
a	O
halogen	O
atom	O
or	O
trifluoromethyl	O
group	O
and,	O
when	O
R2	O
denotes	O
a	O
halogen	O
atom	O
or	O
trifluoromethyl	O
group,	O
R3	O
denotes	O
a	O
hydrogen	O
atom,	O
halogen	O
atom	O
or	O
trifluoromethyl	O
group	O
]	O
,	O
and	O
their	O
addition	O
salts	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
to	O
block	O
the	O
invasion	O
of	O
normal,	O
neoplastic	O
inflammatory	O
or	O
immune	O
cells,	O
tissue	O
infiltration,	O
and	O
/	O
or	O
oedema	O
formation	O
through	O
inhibition	O
or	O
modulation	O
of	O
molecules	O
and	O
proteolytic	O
enzymes	O
such	O
as—but	O
not	O
exclusively—MMPs,	O
for	O
the	O
therapy	O
of	O
all	O
diseases	O
whose	O
pathogenesis	O
is	O
related	O
to	O
the	O
above	O
processes,	O
including	O
tumours,	O
non-neoplastic	O
angioproliferative	O
diseases,	O
inflammatory	O
diseases,	O
or	O
autoimmune	O
diseases,	O
the	O
method	O
being	O
based	O
on	O
the	O
use	O
of	O
inhibitors	O
of	O
the	O
protease	B-GENE
of	O
the	O
HIV	O
virus	O
(	O
HIV-PI	O
)	O
.	O


An	O
improved	O
adjuvant	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
which	O
patients	O
are	O
administered	O
an	O
anthracycline	O
chemotherapeutic	O
agent	O
and	O
a	O
taxane	O
chemotherapeutic	O
agent	O
is	O
provided	O
in	O
which	O
a	O
diphenyl	O
compound	O
which	O
is	O
a	O
potent	O
antagonist	O
of	O
histamine	O
binding	O
at	O
the	O
intracellular	O
histamine	B-GENE
receptor	I-GENE
is	O
initially	O
administered	O
prior	O
to	O
administration	O
of	O
the	O
chemotherapeutic	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
pollakiuria	O
comprising	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
an	O
EP1	B-GENE
receptor	I-GENE
which	O
is	O
a	O
prostaglandin	B-GENE
E2	I-GENE
receptor	I-GENE
subtype	O
.	O
A	O
compound	O
having	O
an	O
antagonism	O
to	O
an	O
EP1	B-GENE
receptor	I-GENE
antagonistically	O
acts	O
on	O
an	O
EP1	B-GENE
receptor	I-GENE
which	O
is	O
a	O
prostaglandin	B-GENE
PGE2	I-GENE
receptor	I-GENE
subtype	O
and	O
significantly	O
shows	O
a	O
suppressive	O
activity	O
for	O
urination	O
frequency	O
in	O
models	O
where	O
pollakiuria	O
is	O
induced	O
.	O
Therefore,	O
it	O
is	O
effective	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
pollakiuria	O
(	O
that	O
which	O
is	O
due	O
to	O
nurogenic	O
bladder,	O
nervous	O
bladder,	O
stimulated	O
bladder,	O
unstable	O
bladder,	O
benign	O
prostatic	O
hypertrophy,	O
etc	O
.	O
)	O
.	O


A	O
compound	O
having	O
a	O
xanthine	B-GENE
oxidase	I-GENE
inhibitory	O
activity,	O
such	O
as	O
1-	O
(	O
3-cyano-4-neopentyloxyphenyl	O
)	O
pyrazole-4-carboxylic	O
acid	O
and	O
the	O
like,	O
can	O
be	O
a	O
drug	O
for	O
preventing	O
cancer	O
including	O
colon	O
cancer	O
and	O
the	O
like,	O
as	O
an	O
agent	O
for	O
suppressing	O
tumorigenesis	O
.	O


A	O
pharmaceutical	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
amyloidosis	O
such	O
as	O
familial	O
amyloid	O
polyneuropathy	O
is	O
provided	O
.	O
A	O
pharmaceutical	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
amyloidosis	O
that	O
contains	O
a	O
compound	O
containing	O
the	O
trivalent	O
chromium	O
ion,	O
such	O
as	O
a	O
fatty	O
acid	O
chromium	O
salt,	O
as	O
an	O
active	O
ingredient,	O
and	O
that	O
is	O
capable	O
of	O
suppressing	O
the	O
decomposition	O
of	O
mutant	O
transthyretin	B-GENE
in	O
amyloidosis	O
.	O


Compositions	O
and	O
methods	O
comprising	O
protein	B-GENE
activated	I-GENE
receptor	I-GENE
antagonists	O
are	O
provided	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
proteins,	O
peptides	O
and	O
biomolecules	O
that	O
bind	O
to	O
protein	B-GENE
activated	I-GENE
receptor	I-GENE
2,	O
and	O
inhibit	O
the	O
processes	O
associated	O
with	O
the	O
activation	O
of	O
that	O
receptor	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
provides	O
novel	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
those	O
associated	O
with	O
abnormal	O
cellular	O
proliferation,	O
angiogenesis,	O
inflammation	O
and	O
cancer	O
.	O


Compounds	O
of	O
formula	O
I	O
wherein	O
R	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
are	O
PDE	B-GENE
4	I-GENE
inhibitors	O
.	O


Medical	O
devices	O
comprising	O
an	O
interventional	O
component	O
for	O
delivering	O
multiple	O
beneficial	O
agents	O
in	O
which	O
a	O
hydration	O
inhibitor	O
controls	O
release	O
of	O
at	O
least	O
one	O
beneficial	O
agent	O
from	O
the	O
device	O
.	O
The	O
hydration	O
inhibitor	O
is	O
relatively	O
less	O
hydrophilic	O
than	O
the	O
beneficial	O
agent	O
and	O
preferably	O
is	O
a	O
drug	O
.	O
Suitable	O
beneficial	O
agents	O
include	O
(	O
I	O
)	O
dexamethasone,	O
estradiol,	O
anti-proliferative	O
agents,	O
anti-platelet	O
agents,	O
anti-inflammatory	O
agents,	O
anti-thrombotic	O
agents,	O
cytotoxic	O
drugs,	O
agents	O
that	O
inhibit	O
cytokine	B-GENE
or	O
chemokine	B-GENE
binding,	O
cell	O
de-differentiation	O
inhibitors,	O
anti-lipacdemic	O
agents,	O
matrix	B-GENE
metalloproteinase	I-GENE
inhibitors,	O
cytostatic	O
drugs,	O
or	O
combinations	O
of	O
these	O
drugs,	O
radiopaque	O
markers,	O
beta-carotene,	O
tocopherols,	O
tocotrienols,	O
and	O
antioxidants	O


The	O
present	O
invention	O
relates	O
to	O
new	O
compounds,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
new	O
intermediates	O
used	O
therein,	O
pharmaceutical	O
formulations	O
containing	O
said	O
therapeutically	O
active	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
active	O
compounds	O
in	O
therapy,	O
such	O
as	O
provide	O
compounds	O
having	O
a	O
selective	O
inhibiting	O
effect	O
at	O
GSK3	B-GENE
.	O


There	O
are	O
provided	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
L1,	O
L2,	O
L3	O
and	O
Q	O
are	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
disease	O
and	O
pain	O
.	O


A	O
combination	O
of	O
a	O
5HT1B/1D	B-GENE
agonist	O
and	O
a	O
COX-2	B-GENE
selective	O
inhibitor	O
is	O
useful	O
in	O
the	O
treatment	O
and	O
or	O
prevention	O
of	O
migraine	O
.	O


The	O
present	O
invention	O
provides	O
a	O
TGR5	B-GENE
receptor	I-GENE
agonist	O
comprising	O
a	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
ring	O
A	O
is	O
an	O
optionally	O
substituted	O
aromatic	O
ring	O
;	O
and	O
ring	O
B′	O
is	O
a	O
5-	O
to	O
8-membered	O
ring	O
having	O
one	O
or	O
more	O
substituents	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
dopamine	B-GENE
receptor	I-GENE
agonists	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
reduction	O
of	O
excessive	O
food	O
intake	O
.	O


The	O
present	O
application	O
relates	O
to	O
the	O
secondary	O
binding	O
site	O
of	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV,	O
its	O
relationship	O
amongst	O
substrates	O
and	O
to	O
the	O
modulation	O
of	O
substrate	O
specificity	O
of	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DP	O
IV,	O
synonym	O
:	O
DPP	O
IV,	O
CD26,	O
EC	O
3	O
.	O
4	O
.	O
14	O
.	O
5	O
)	O
.	O
The	O
application	O
relates	O
further	O
to	O
compounds	O
that	O
bind	O
to	O
the	O
secondary	O
binding	O
site	O
of	O
DP	B-GENE
IV	I-GENE
and	O
their	O
use	O
to	O
modulate	O
the	O
substrate	O
specificity	O
of	O
DP	B-GENE
IV	I-GENE
;	O
methods	O
of	O
treatment	O
of	O
various	O
DP	B-GENE
IV	I-GENE
mediated	O
disorders	O
;	O
and	O
screening	O
methods	O
for	O
the	O
identification	O
of	O
secondary	O
binding	O
sites	O
on	O
DP	B-GENE
IV	I-GENE
and	O
DP	O
IV-like	O
enzymes	O
.	O


A	O
method	O
of	O
inhibiting	O
cdc25	B-GENE
phosphatases	I-GENE
in	O
warm-blooded	O
animals	O
comprising	O
administering	O
to	O
warm-blooded	O
animals	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
substituents	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
useful	O
for	O
treatment	O
or	O
prevention	O
of	O
neoplasia	O
by	O
administering	O
a	O
combination	O
comprising	O
a	O
3-heteroaryl-2-indolinone	O
compound	O
and	O
a	O
COX-2	B-GENE
selective	O
inhibitor	O
.	O
Further	O
provided	O
are	O
compositions,	O
pharmaceutical	O
compositions,	O
and	O
kits	O
for	O
treatment	O
and	O
prevention	O
of	O
neoplasia	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
use	O
in	O
the	O
inhibition	O
of	O
c-Jun	B-GENE
N-terminal	I-GENE
kinases	I-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
the	O
use	O
of	O
these	O
compounds	O
in	O
medicine,	O
in	O
particular	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
neurodegenerative	O
disorders	O
related	O
to	O
apoptosis	O
and	O
/	O
or	O
inflammation	O
.	O


The	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
:	O
R1	O
is	O
aryl	O
;	O
R2	O
is	O
H,	O
alkyl	O
or	O
aryl	O
;	O
and	O
R3	O
is	O
hydrogen	O
or	O
alkyl	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof,	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
mediated	O
by	O
CB1	B-GENE
receptors	I-GENE
.	O


Specific	O
aryl	O
phosphate	O
nucleoside	O
derivatives	O
show	O
activity	O
against	O
HIV	O
without	O
undesirable	O
levels	O
of	O
cytotoxic	O
activity	O
.	O
In	O
particular,	O
these	O
derivatives	O
are	O
potent	O
inhibitors	O
of	O
HIV	B-GENE
reverse	I-GENE
transcriptase	I-GENE
.	O
Examples	O
of	O
aryl	O
phosphate	O
nucleoside	O
derivatives	O
include	O
aryl	O
phosphate	O
derivatives	O
of	O
d4T	O
having	O
one	O
or	O
more	O
substituents	O
on	O
the	O
aryl	O
group,	O
and	O
wherein	O
the	O
phosphorus	O
of	O
the	O
aryl	O
phosphate	O
group	O
is	O
attached	O
to	O
an	O
amino	O
acid	O
residue	O
that	O
may	O
be	O
esterified	O
or	O
substituted,	O
such	O
as	O
a	O
methoxyalaninyl	O
group	O
.	O


This	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
and	O
R2	O
independently	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
an	O
aryl	O
group	O
having	O
from	O
6	O
to	O
10	O
ring	O
carbon	O
or	O
the	O
like	O
;	O
said	O
aryl	O
groups	O
having	O
from	O
6	O
to	O
10	O
ring	O
carbon	O
atoms	O
and	O
said	O
heteroaryl	O
groups	O
having	O
from	O
5	O
to	O
10	O
atoms	O
are	O
unsubstituted	O
or	O
are	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
substituents	O
a	O
;	O
said	O
substituents	O
a	O
are	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
atoms	O
or	O
the	O
like	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester	O
of	O
such	O
compound,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
disease	O
conditions	O
caused	O
by	O
overactivation	O
of	O
NMDA	B-GENE
NR2B	I-GENE
receptor	I-GENE
such	O
of	O
pain,	O
or	O
the	O
like	O
in	O
mammalian	O
.	O
This	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
above	O
compound	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrazole	O
carboxylic	O
acid	O
and	O
ester	O
derivatives,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
exhibit	O
useful	O
pharmaceutical	O
properties,	O
for	O
example	O
as	O
agonists	O
for	O
the	O
RUP25	B-GENE
receptor	I-GENE
.	O
(	O
I	O
)	O
Also	O
provided	O
by	O
the	O
present	O
invention	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
the	O
invention,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
metabolic-related	O
disorders,	O
including	O
dyslipidemia,	O
atherosclerosis,	O
coronary	O
heart	O
disease,	O
insulin	B-GENE
resistance,	O
type	O
2	O
diabetes,	O
Syndrome-X	O
and	O
the	O
like	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
also	O
provides	O
for	O
the	O
use	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
in	O
combination	O
with	O
other	O
active	O
agents	O
such	O
as	O
those	O
belonging	O
to	O
the	O
class	O
of	O
α-glucosidase	B-GENE
inhibitors,	O
aldose	B-GENE
reductase	I-GENE
inhibitors,	O
biguanides,	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitors,	O
squalene	O
synthesis	O
inhibitors,	O
fibrates,	O
LDL	B-GENE
catabolism	O
enhancers,	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
(	O
ACE	B-GENE
)	O
inhibitors,	O
insulin	B-GENE
secretion	O
enhancers	O
and	O
the	O
like	O
the	O
substituents	O
are	O
defined	O
in	O
claim	O
1	O
.	O


The	O
hexuronic	O
acid	O
derivative	O
represented	O
by	O
the	O
following	O
formula	O
1	O
or	O
a	O
salt	O
thereof	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
heparin	O
/	O
heparan	O
sulfate	O
sulfotransferase	B-GENE
inhibitor	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
In	O
the	O
formula,	O
each	O
of	O
R1,	O
R2,	O
and	O
R3	O
independently	O
represent	O
(	O
s	O
)	O
SO3	O
−	O
or	O
H	O
which	O
may	O
have	O
a	O
substituent,	O
provided	O
that	O
at	O
least	O
one	O
thereof	O
represents	O
SO3	O
−	O
;	O
X	O
represents	O
OR4,	O
SR4,	O
N	O
(	O
R4	O
)	O
2,	O
or	O
C	O
(	O
R4	O
)	O
3,	O
R4	O
independently	O
represents	O
H,	O
alkyl,	O
alkenyl,	O
alkynyl,	O
acyl,	O
aryl,	O
or	O
aralkyl	O
group	O
;	O
one	O
of	O
R5	O
and	O
R6	O
represents	O
COOH	O
while	O
the	O
other	O
represents	O
H	O
;	O
and	O
the	O
wavy	O
line	O
represents	O
α-glycosidic	O
bond	O
or	O
β-glycosidic	O
bond	O
.	O


A	O
method	O
of	O
preventing	O
the	O
headache	O
phase	O
of	O
migraine	O
in	O
a	O
human	O
comprises	O
administration	O
of	O
a	O
5HT1	B-GENE
receptor	I-GENE
agonist	O
or	O
administration	O
of	O
an	O
over-the-counter	O
or	O
nonprescription	O
drug	O
to	O
said	O
human	O
exhibiting	O
prodrome	O
symptoms	O
of	O
migraine	O
.	O
Suitably,	O
the	O
method	O
comprises	O
administration	O
of	O
a	O
migraine	O
headache	O
phase-preventing	O
effective	O
amount	O
of	O
the	O
5HT1	O
or	O
over-the-counter	O
or	O
nonprescription	O
drug	O
.	O
There	O
is	O
disclosed	O
a	O
preemptive	O
prophylaxis	O
migraine	O
method	O
using	O
the	O
following	O
cognitive	O
tests	O
:	O
Simple	O
Reaction	O
Time	O
;	O
Running	O
Memory	O
Continuous	O
Performance	O
Task	O
;	O
Matching	O
to	O
Sample	O
;	O
Mathematical	O
Processing	O
Task	O
;	O
and	O
interpreting	O
the	O
results	O
as	O
a	O
percent	O
of	O
baseline	O
indicator	O
of	O
need	O
for	O
prophylaxis	O
.	O


The	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
at	O
least	O
two	O
therapeutic	O
combination	O
components	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
	O
	O
(	O
i	O
)	O
an	O
AT1-receptor	B-GENE
antagonist	O
or	O
an	O
AT1	B-GENE
receptor	O
antagonist	O
combined	O
with	O
a	O
diuretic	O
or,	O
in	O
each	O
case,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
(	O
ii	O
)	O
a	O
HMG-Co-A	B-GENE
reductase	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
iii	O
)	O
an	O
ACE	B-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
use	O
in	O
the	O
prevention	O
of,	O
delay	O
of	O
progression	O
of,	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hyperlipidaemia	O
and	O
dyslipidemia,	O
atherosclerosis,	O
insulin	B-GENE
resistance	O
and	O
syndrome	O
X,	O
diabetes	O
mellitus	O
type	O
2,	O
obesity,	O
nephropathy,	O
renal	O
failure,	O
e	O
.	O
g	O
.	O
chronic	O
renal	O
failure,	O
hypothyroidism,	O
survival	O
post	O
myocardial	O
infarction	O
(	O
MI	O
)	O
,	O
coronary	O
heart	O
diseases,	O
hypertension	O
in	O
the	O
elderly,	O
familial	O
dyslipidemic	O
hypertension,	O
and	O
remodeling	O
following	O
hypertension	O
(	O
antiproliferative	O
effect	O
of	O
the	O
combination	O
)	O
,	O
all	O
these	O
diseases	O
or	O
conditions	O
associated	O
with	O
or	O
without	O
hypertension,	O
and,	O
furthermore,	O
in	O
the	O
prevention	O
of,	O
delay	O
of	O
progression	O
of,	O
treatment	O
of	O
stroke,	O
erectile	O
dysfunction	O
and	O
vascular	O
disease	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R	O
represents	O
a	O
substituted	O
benzyl	O
group,	O
are	O
useful	O
as	O
inhibitors	O
of	O
glucosylceramide	B-GENE
synthase	I-GENE
.	O


The	O
invention	O
is	O
related	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt,	O
solvate	O
or	O
prodrug	O
thereof,	O
wherein	O
R1,	O
R2,	O
R3,	O
n	O
and	O
m	O
are	O
as	O
described	O
in	O
the	O
specification,	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
through	O
glucokinase	B-GENE
(	O
GLK	B-GENE
)	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
medicaments	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
glucokinase	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
prophylaxis	O
and	O
therapy	O
of	O
infectious	O
diseases	O
caused	O
by	O
microorganisms	O
present	O
in	O
biofilms	O
adherent	O
to	O
cell	O
surfaces	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
an	O
individual	O
in	O
need	O
thereof	O
a	O
composition	O
comprising	O
a	O
combination	O
of	O
at	O
least	O
one	O
compound	O
chosen	O
from	O
the	O
group	O
of	O
peroxidase,	O
lactoferrin,	O
lactoferrin	B-GENE
peptides,	O
lysozyme	B-GENE
and	O
immunoglobulins	B-GENE
and	O
at	O
least	O
one	O
growth	O
factor	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
pyrrolidine	O
esters	O
of	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
premature	O
labor,	O
premature	O
birth	O
and	O
dysmenorrhea	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
pyrrolidine	O
esters	O
of	O
formula	O
(	O
I	O
)	O
to	O
modulate,	O
notably	O
to	O
antagonise	O
the	O
oxytocin	B-GENE
receptor	I-GENE
.	O
The	O
present	O
invention	O
is	O
furthermore	O
related	O
to	O
novel	O
pyrrolidine	O
esters	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
X	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
CR6R7,	O
NOR6,	O
NNR6R7	O
;	O
	O
R	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
or	O
consisting	O
of	O
C1-C6	O
alkyl,	O
C2-C6	O
alkenyl,	O
C2-C6	O
alkynyl,	O
saturated	O
or	O
unsaturated	O
3-8-membered	O
cycloalkyl	O
which	O
may	O
contain	O
1	O
to	O
3	O
heteroatoms	O
selected	O
of	O
N,	O
O,	O
S,	O
aryl,	O
heteroaryl,	O
C1-C6-alkyl	O
aryl,	O
C1-C6-alkyl	O
heteroaryl	O
.	O
	O
R1	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
or	O
consisting	O
of	O
C1-C6-alkyl,	O
C2-C6-alkenyl,	O
C2-C6-alkynyl,	O
aryl,	O
heteroaryl,	O
3-8-membered	O
cycloalkyl,	O
acyl,	O
C1-C6-alkyl	O
aryl,	O
C1-C6-alkyl	O
heteroaryl,	O
said	O
cycloalkyl	O
or	O
aryl	O
or	O
heteroaryl	O
groups	O
may	O
be	O
fused	O
with	O
1-2	O
further	O
cycloalkyl	O
or	O
aryl	O
or	O
heteroaryl	O
group	O
.	O


The	O
invention	O
relates	O
to	O
a	O
combination	O
which	O
comprises	O
a	O
P-glycoprotein	B-GENE
(	O
P-gp	B-GENE
)	O
inhibitor	O
and	O
an	O
antiepileptic	O
drug	O
selected	O
from	O
phenytoin	O
(	O
5,5-diphenyl-2,4-imidazolidinedione	O
)	O
,	O
carbamazepine,	O
lamotrigine,	O
gabapentin,	O
oxcarbazepin,	O
valproic	O
acid,	O
and	O
topiramate,	O
and	O
its	O
use	O
for	O
the	O
prevention,	O
delay	O
of	O
progression	O
or	O
treatment	O
of	O
diseases,	O
in	O
particular	O
epilepsy,	O
especially	O
epilepsy	O
which	O
is	O
resistant	O
to	O
antiepileptic	O
drugs	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
enhancing	O
resistance	O
to	O
the	O
onset	O
of	O
skin	O
damage	O
caused	O
by	O
irradiation	O
of	O
the	O
skin	O
with	O
ultraviolet	O
light	O
by	O
inhibiting	O
ultraviolet	O
irradiation-induced	O
apoptosis	O
of	O
epidermal	O
cells	O
as	O
a	O
result	O
of	O
increasing	O
expression	O
of	O
SCCA-1	B-GENE
and	O
/	O
or	O
SCCA-2	B-GENE
in	O
epidermal	O
cells	O
.	O
Moreover,	O
the	O
present	O
invention	O
provides	O
a	O
skin	O
testing	O
method	O
for	O
evaluating	O
resistance	O
of	O
the	O
skin	O
to	O
skin	O
damage	O
caused	O
by	O
ultraviolet	O
irradiation	O
by	O
measuring	O
the	O
expression	O
of	O
SCCA-1	B-GENE
and	O
/	O
or	O
SCCA-2	B-GENE
in	O
epidermal	O
cells,	O
and	O
judging	O
UV	O
resistance	O
of	O
the	O
epidermis	O
to	O
be	O
weak	O
in	O
the	O
case	O
expression	O
is	O
decreased	O
as	O
compared	O
with	O
expression	O
in	O
epidermal	O
cells	O
.	O
Moreover,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
screening	O
drugs	O
which	O
enhance	O
resistance	O
of	O
the	O
skin	O
to	O
skin	O
damage	O
by	O
ultraviolet	O
irradiation	O
by	O
selecting	O
a	O
drug	O
that	O
increases	O
expression	O
of	O
SCCA-1	B-GENE
and	O
/	O
or	O
SCCA-2	B-GENE
as	O
a	O
UV	O
resistance	O
enhancer	O
.	O


This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
naturally	O
occurring	O
mammalian	O
intermediary	O
metabolites,	O
Tcell	O
ligands	O
or	O
Tcell	B-GENE
receptor	I-GENE
ligands,	O
preferably	O
glycosylceramides,	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
immune	O
mediated	O
or	O
immune	O
related	O
diseases	O
or	O
disorders	O
.	O
Specifically,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
pulmonary,	O
respiratory	O
or	O
airway	O
diseases	O
or	O
disorders	O
such	O
as	O
asthma	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
wherein	O
each	O
of	O
R1	O
to	O
R4	O
is	O
independently	O
selected	O
from	O
hydrogen,	O
a	O
halogen,	O
a	O
substituted	O
or	O
unsubstituted	O
cyclic	O
and	O
heterocyclic	O
moiety,	O
substituted	O
or	O
unsubstituted,	O
linear	O
or	O
branched	O
alkyl,	O
alkyloxy,	O
alkylcarbonyl,	O
alkyloxycarbonyl,	O
alkenyl,	O
alkenyloxy,	O
alkenylcarbonyl,	O
alkenyloxycarbonyl,	O
alkynyl,	O
alkynyloxy,	O
alkynylcarbonyl,	O
alkynyloxycarbonyl,	O
aryl,	O
benzyl,	O
arlyoxy,	O
arylcarbonyl,	O
aryloxycarbonyl	O
and	O
sulphur	O
equivalents	O
of	O
said	O
oxy,	O
carbonyl	O
and	O
oxycarbonyl	O
moieties,	O
and	O
A	O
is	O
NH,	O
or	O
(	O
CH2	O
)	O
n,	O
where	O
n	O
is	O
preferably	O
0,	O
1	O
or	O
2	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
and	O
their	O
uses	O
as	O
CCK	B-GENE
receptor	I-GENE
ligands	O
and	O
CCK	O
antagonists	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
useful	O
as	O
therapeutic	O
compounds,	O
particularly	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
conditions	O
ameliorated	O
by	O
the	O
modulation	O
of	O
the	O
function	O
of	O
the	O
vanilloid-1	B-GENE
receptor	I-GENE
(	O
VR1	B-GENE
)	O
.	O


This	O
invention	O
concerns	O
substituted	O
diaza-spiro-	O
[	O
5	O
.	O
5	O
]	O
-undecane	O
derivatives	O
having	O
neurokinin	O
antagonistic	O
activity,	O
in	O
particular	O
NK1	B-GENE
antagonistic	O
activity,	O
a	O
combined	O
NK1	B-GENE
/	O
NK2	B-GENE
antagonistic	O
activity,	O
a	O
combined	O
NK1	B-GENE
/	O
NK3	B-GENE
antagonistic	O
activity	O
and	O
a	O
combined	O
NK1	B-GENE
/	O
NK2	B-GENE
/	O
NK3	B-GENE
antagonistic	O
activity,	O
their	O
preparation,	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine,	O
in	O
particular	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
schizophrenia,	O
emesis,	O
anxiety	O
and	O
depression,	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
circadian	O
rhythm	O
disturbances,	O
pre-eclampsia,	O
nociception,	O
pain,	O
in	O
particular	O
visceral	O
and	O
neuropathic	O
pain,	O
pancreatitis,	O
neurogenic	O
inflammation,	O
asthma,	O
COPD	O
and	O
micturition	O
disorders	O
such	O
as	O
urinary	O
incontinence	O
.	O
	O
	O
The	O
compounds	O
according	O
to	O
the	O
invention	O
can	O
be	O
represented	O
by	O
general	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
comprises	O
also	O
the	O
pharmaceutically	O
acceptable	O
acid	O
or	O
base	O
addition	O
salts	O
thereof,	O
the	O
stereochemically	O
isomeric	O
forms	O
thereof,	O
the	O
N-oxide	O
form	O
thereof	O
and	O
prodrugs	O
thereof,	O
wherein	O
all	O
substituents	O
are	O
defined	O
as	O
in	O
Claim	O
1	O
.	O


The	O
invention	O
features	O
a	O
method	O
of	O
treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual,	O
comprising	O
administering	O
an	O
agent	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll-like	B-GENE
receptor	I-GENE
2	I-GENE
(	O
TLR2	B-GENE
)	O
and	O
a	O
high	B-GENE
mobility	I-GENE
group	I-GENE
B	I-GENE
(	O
HMGB	B-GENE
)	O
polypeptide	O
to	O
the	O
individual	O
.	O
The	O
invention	O
also	O
features	O
methods	O
for	O
identifying	O
agents	O
that	O
inhibit	O
the	O
interaction	O
between	O
TLR2	B-GENE
and	O
HMGB	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
inhibit	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP-IV	B-GENE
)	O
and	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes,	O
especially	O
type	O
II	O
diabetes,	O
as	O
well	O
as	O
hyperglycemia,	O
Syndrome	O
X,	O
hyperinsulinemia,	O
obesity,	O
atherosclerosis,	O
and	O
various	O
immunomodulatory	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
m	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
CB1	B-GENE
receptors	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
tumorigenic	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
mammary	O
progenitor	O
cancer	O
cells	O
)	O
,	O
with	O
growth	B-GENE
hormone	I-GENE
receptor	I-GENE
antagonists	O
(	O
e	O
.	O
g	O
.	O
,	O
Pegvisomant	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
compositions	O
for	O
screening	O
growth	B-GENE
hormone	I-GENE
receptor	I-GENE
antagonists	O
for	O
their	O
ability	O
serve	O
as	O
anti-neoplastic	O
agents	O
capable	O
of	O
killing	O
tumorigenic	O
cells	O
.	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
identifying	O
tumorigenic	O
cells,	O
methods	O
of	O
obtaining	O
enriched	O
populations	O
of	O
tumorigenic	O
cells,	O
and	O
methods	O
of	O
causing	O
mammary	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
/	O
or	O
differentiate	O
.	O


Remedies	O
or	O
prophylactics	O
for	O
diseases	O
in	O
association	O
with	O
CCR5	B-GENE
such	O
as	O
AIDS,	O
rheumatoid	O
arthritis	O
or	O
nephritis	O
comprising	O
a	O
cyclic	O
amine	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
C1-C6	O
alkyl	O
addition	O
salt	O
thereof,	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A	O
is	O
a	O
benzene	O
ring	O
optionally	O
having	O
substituents,	O
R1,	O
R2a	O
and	O
R3	O
are	O
each	O
a	O
hydrogen	O
atom,	O
a	O
hydrocarbon	O
group	O
optionally	O
having	O
substituents	O
or	O
a	O
heterocyclic	O
group	O
optionally	O
having	O
substituents,	O
R1	O
and	O
R2a	O
may	O
form	O
a	O
ring	O
via	O
X,	O
when	O
R1	O
and	O
R2a	O
form	O
a	O
ring	O
via	O
X,	O
R1	O
and	O
R2a	O
are	O
each	O
a	O
bond	O
or	O
a	O
divalent	O
C1-5	O
acyclic	O
hydrocarbon	O
group	O
optionally	O
having	O
substituents,	O
and	O
X	O
is	O
a	O
bond,	O
an	O
oxygen	O
atom,	O
an	O
optionally	O
oxidized	O
sulfur	O
atom	O
or	O
an	O
imino	O
group	O
optionally	O
having	O
a	O
substituent,	O
provided	O
that	O
R1,	O
R2a	O
and	O
X	O
are	O
not	O
bonds	O
at	O
the	O
same	O
time,	O
or	O
a	O
salt	O
thereof,	O
and	O
an	O
agent	O
for	O
inhibiting	O
kinase	B-GENE
(	O
phosphorylation	O
enzyme	O
)	O
,	O
which	O
contains	O
this	O
compound	O
or	O
a	O
prodrug	O
thereof	O
.	O
The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
an	O
inhibitory	O
activity	O
against	O
kinase	B-GENE
such	O
as	O
a	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
VEGFR	B-GENE
)	O
and	O
the	O
like,	O
and	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
cancer	O
and	O
the	O
like	O
.	O


[	O
Problem	O
]	O
There	O
is	O
provided	O
a	O
compound	O
which	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diseases	O
in	O
which	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11β-HSD1	B-GENE
)	O
participates,	O
in	O
particular	O
diabetes,	O
insulin	B-GENE
resistance	O
.	O
	O
	O
	O
	O
	O
[	O
Means	O
for	O
Solution	O
]	O
It	O
has	O
been	O
found	O
that	O
a	O
triazole	O
derivative	O
wherein	O
the	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
in	O
the	O
2-position	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
a	O
strong	O
11β-HSD1	B-GENE
inhibitory	O
activity	O
.	O
Moreover,	O
the	O
triazole	O
derivative	O
of	O
the	O
invention	O
exhibits	O
an	O
excellent	O
blood-glucose	O
level-lowering	O
action	O
and	O
hence	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diabetes,	O
insulin	B-GENE
resistance	O
.	O


The	O
disclosure	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Y,	O
Y1,	O
Yo,	O
R1,	O
R2,	O
R2′,	O
p,	O
R3,	O
R3′,	O
A,	O
B	O
and	O
Y2	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
to	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
and	O
use	O
thereof	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors	O
.	O


Disclosed	O
is	O
the	O
identification,	O
provision	O
and	O
use	O
of	O
a	O
panel	O
of	O
biomarkers	O
that	O
predict	O
sensitivity	O
or	O
resistance	O
to	O
gefitinib	O
and	O
other	O
EGFR	B-GENE
inhibitors,	O
and	O
products	O
and	O
processes	O
related	O
thereto	O
.	O
Specifically,	O
a	O
method	O
is	O
described	O
for	O
selecting	O
a	O
cancer	O
patient	O
who	O
is	O
predicted	O
to	O
benefit	O
from	O
therapeutic	O
administration	O
of	O
an	O
EGFR	B-GENE
inhibitor,	O
an	O
agonist	O
thereof,	O
or	O
a	O
drug	O
having	O
substantially	O
similar	O
biological	O
activity	O
as	O
EGFR	B-GENE
inhibitor	O
.	O
Also	O
described	O
is	O
a	O
method	O
to	O
identify	O
molecules	O
that	O
interact	O
with	O
the	O
EGFR	B-GENE
pathway	O
to	O
allow	O
or	O
enhance	O
responsiveness	O
to	O
EGFR	B-GENE
inhibitors,	O
as	O
well	O
as	O
a	O
plurality	O
of	O
polynucleotides	O
or	O
antibodies	O
for	O
the	O
detection	O
of	O
the	O
expression	O
of	O
genes	O
that	O
are	O
indicative	O
of	O
sensitivity	O
or	O
resistance	O
to	O
EGFR	B-GENE
inhibitors,	O
an	O
agonist	O
thereof,	O
or	O
a	O
drug	O
having	O
substantially	O
similar	O
biological	O
activity	O
as	O
EGFR	B-GENE
inhibitors	O
.	O
A	O
method	O
to	O
identify	O
a	O
compound	O
with	O
the	O
potential	O
to	O
enhance	O
the	O
efficacy	O
of	O
EGFR	B-GENE
inhibitors	O
is	O
also	O
described	O
.	O


This	O
invention	O
relates	O
to	O
oligonucleotide	O
sequences	O
and	O
their	O
derivatives	O
.	O
These	O
oligonucleotide	O
sequences	O
are	O
capable	O
of	O
hybridising	O
with	O
the	O
genes	O
or	O
with	O
products	O
of	O
the	O
genes	O
coding	O
for	O
the	O
PKC-beta	B-GENE
1	I-GENE
.	O
This	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
oligonucleotide	O
sequences	O
as	O
a	O
depigmenting	O
or	O
bleaching	O
agent	O
for	O
the	O
skin	O
in	O
a	O
cosmetic	O
composition	O
or	O
in	O
a	O
topical	O
pharmaceutical	O
composition	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
inhibiting	O
secretase	B-GENE
activity	O
.	O
A	O
method	O
for	O
promoting	O
the	O
sensitivity	O
of	O
a	O
secretase	B-GENE
inhibitor,	O
a	O
method	O
for	O
binding	O
synoviolin	B-GENE
to	O
Herp	B-GENE
(	O
homocysteine-inducible	B-GENE
endoplasmic	I-GENE
reticulum	I-GENE
stress-inducible	I-GENE
ubiquitin-like	I-GENE
domain	I-GENE
member	I-GENE
1	I-GENE
)	O
,	O
or	O
the	O
like	O
is	O
employed	O
to	O
inhibit	O
secretase	B-GENE
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
combinations	O
and	O
methods	O
of	O
inhibiting	O
the	O
proliferation	O
of	O
cancerous	O
cells,	O
the	O
abnormal	O
growth	O
of	O
cells,	O
and	O
tumor	O
cell	O
growth	O
using	O
the	O
combination	O
of	O
a	O
hedgehog	B-GENE
inhibitor	O
with	O
chemotherapy	O
and	O
/	O
or	O
radiation	O
therapy	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
enhancing	O
the	O
antiproliferative	O
effect	O
of	O
chemotherapy	O
and	O
/	O
or	O
radiation	O
therapy	O
in	O
a	O
mammalian	O
cancer	O
patient	O
undergoing	O
either	O
chemotherapy	O
or	O
radiation	O
or	O
a	O
combination	O
of	O
radiation	O
and	O
chemotherapy	O
by	O
co-administering	O
a	O
therapeutically	O
amount	O
of	O
a	O
hedgehog	B-GENE
inhibitor,	O
concurrently	O
or	O
sequentially,	O
with	O
the	O
chemotherapy	O
and	O
/	O
or	O
radiation	O
therapy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
of	O
treating,	O
preventing,	O
or	O
lessening	O
the	O
severity	O
of	O
drug-resistant	O
Gram-positive	O
bacterial	O
infections	O
in	O
mammals	O
.	O
The	O
compounds	O
consist	O
of	O
a	O
combination	O
of	O
a	O
gyrase	B-GENE
B	I-GENE
inhibitor	O
and	O
a	O
protein	O
synthesis	O
inhibitor	O
.	O
These	O
compounds	O
demonstrate	O
antibacterial	O
activity	O
against	O
drug-resistant	O
strains	O
of	O
Gram-positive	O
bacteria,	O
and	O
in	O
particular,	O
methicillin-resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
.	O
Methods	O
for	O
inhibiting	O
the	O
activity	O
of	O
strains	O
of	O
Gram-positive	O
bacteria	O
and	O
methods	O
for	O
treating	O
a	O
bacterial	O
infection	O
caused	O
by	O
such	O
organisms	O
are	O
described	O
herein	O
.	O


Imidazo-quinoline,	O
-pyridine,	O
and	O
-naphthyridine	O
ring	O
systems	O
(	O
particularly	O
quinolines,	O
tetrahydroquinolines,	O
pyridines,	O
1,5-naphthyridines,	O
1,5-tetrahydronaphthyridines	O
)	O
substituted	O
at	O
the	O
1-position	O
with	O
a	O
cyclic	O
substituent,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
use	O
of	O
these	O
compounds	O
as	O
immunomodulators,	O
for	O
inducing	O
cytokine	B-GENE
biosynthesis	O
in	O
animals	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
viral	O
and	O
neoplastic	O
diseases	O
are	O
disclosed	O
.	O


CRF	B-GENE
receptor	O
antagonists	O
are	O
disclosed	O
which	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
disorders	O
in	O
mammals,	O
including	O
the	O
treatment	O
of	O
disorders,	O
such	O
as	O
stroke,	O
manifesting	O
hypersecretion	O
of	O
CRF	B-GENE
.	O
The	O
CRF	B-GENE
receptor	O
antagonists	O
of	O
this	O
invention	O
have	O
the	O
following	O
structure	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
including	O
stereoisomers,	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
R1,	O
R2,	O
R5,	O
Ar,	O
and	O
Het	O
are	O
as	O
defined	O
herein	O
.	O
Compositions	O
containing	O
a	O
CRF	B-GENE
receptor	O
antagonist	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
are	O
also	O
disclosed,	O
as	O
well	O
as	O
methods	O
for	O
use	O
of	O
the	O
same	O
.	O


Compositions	O
and	O
methods	O
of	O
using	O
compositions	O
for	O
treatment	O
of	O
inflammatory	O
diseases	O
and	O
immune	O
disorders	O
are	O
provided	O
.	O
Allylamino	O
compounds	O
are	O
disclosed	O
which	O
are	O
inhibitors	O
of	O
semicarbazide-sensitive	B-GENE
amine	I-GENE
oxidase	I-GENE
(	O
SSAO	B-GENE
)	O
and	O
/	O
or	O
vascular	B-GENE
adhesion	I-GENE
protein	I-GENE
1	I-GENE
(	O
VAP-1	B-GENE
)	O
.	O
The	O
compounds	O
have	O
therapeutic	O
utility	O
in	O
suppressing	O
inflammation	O
and	O
inflammatory	O
responses,	O
and	O
in	O
treatment	O
of	O
several	O
disorders,	O
including	O
multiple	O
sclerosis	O
and	O
stroke	O
.	O


This	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
compounds,	O
diagrammed	O
below,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
D	O
and	O
n	O
are	O
defined	O
therein,	O
which	O
are	O
cysteine	B-GENE
protein	I-GENE
inhibitors,	O
including,	O
but	O
not	O
limited	O
to,	O
inhibitors	O
of	O
cathepsins	B-GENE
K,	I-GENE
L,	I-GENE
S	I-GENE
and	I-GENE
B	I-GENE
.	O
These	O
compounds	O
are	O
useful	O
for	O
treating	O
diseases	O
in	O
which	O
inhibition	O
of	O
bone	O
reportion	O
is	O
indicated,	O
such	O
as	O
osteoporosis	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
certain	O
5-phenyl-5,6,7,8-hydroquinoline	O
compounds	O
which	O
are	O
useful	O
as	O
neurokinin-1	B-GENE
(NK-1)	I-GENE
receptor	I-GENE
antagonists,	O
and	O
inhibitors	O
of	O
tachykinin	B-GENE
and	O
in	O
particular	O
substance	B-GENE
P	I-GENE
.	O
The	O
invention	O
is	O
also	O
concerned	O
with	O
pharmaceutical	O
formulations	O
comprising	O
these	O
compounds	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
compounds	O
and	O
their	O
formulations	O
in	O
the	O
treatment	O
of	O
certain	O
disorders,	O
including	O
emesis,	O
urinary	O
incontinence,	O
depression,	O
and	O
anxiety	O
.	O


The	O
present	O
invention	O
provides	O
acid	O
salts,	O
such	O
as	O
sulfate,	O
hydrochloride,	O
and	O
methanesulfonate,	O
of	O
4-	O
(	O
1-	O
(	O
(	O
4-methylbenzothiophen-3-yl	O
)	O
methyl	O
)	O
benzimidazol-2-ylthio	O
)	O
butanoic	O
acid	O
and	O
the	O
crystals	O
thereof	O
.	O
These	O
benzimidazole	O
derivatives	O
and	O
the	O
crystals	O
thereof	O
have	O
an	O
in	O
vivo	O
chymase	B-GENE
inhibitory	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
diseases,	O
allergic	O
diseases,	O
respiratory	O
diseases,	O
circulatory	O
diseases,	O
or	O
bone	O
/	O
cartilage	O
metabolic	O
diseases	O
.	O


Compounds	O
of	O
the	O
present	O
invention,	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
thereof,	O
are	O
useful	O
as	O
modulators	O
of	O
ATP-Binding	B-GENE
Cassette	I-GENE
(“ABC”)	I-GENE
transporters	I-GENE
or	O
fragments	O
thereof,	O
including	O
Cystic	B-GENE
Fibrosis	I-GENE
Transmembrane	I-GENE
Conductance	I-GENE
Regulator	I-GENE
(	O
“CFTR”	O
)	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
ABC	B-GENE
transporter	I-GENE
mediated	O
diseases	O
using	O
compounds	O
of	O
the	O
present	O
invention	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
GPR40	B-GENE
receptor	O
function	O
regulator	O
comprising	O
a	O
fused	O
imidazole	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification,	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O
The	O
GPR40	B-GENE
receptor	O
function	O
regulator	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
obesity,	O
hyperinsulinemia,	O
type	O
2	O
diabetes	O
and	O
the	O
like	O
.	O


According	O
to	O
the	O
present	O
invention,	O
there	O
is	O
provided	O
a	O
method	O
for	O
treating	O
a	O
motor	O
neuron	O
disease,	O
comprising	O
the	O
step	O
of	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
having	O
serotonin	B-GENE
receptor	I-GENE
antagonist	O
activity	O
or	O
its	O
pharmacologically	O
acceptable	O
salt	O
or	O
their	O
solvate	O
optionally	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
to	O
a	O
mammal	O
for	O
which	O
the	O
treatment	O
of	O
said	O
disease	O
is	O
indicated	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
2-phenylthiophene	O
derivative	O
or	O
a	O
salt	O
thereof,	O
wherein	O
the	O
thiophene	O
ring	O
is	O
substituted	O
with	O
a	O
carboxyl	O
group	O
or	O
the	O
like	O
and	O
the	O
benzene	O
ring	O
has	O
an	O
electron-withdrawing	O
group	O
such	O
as	O
a	O
cyano	O
group	O
and	O
an	O
electron-donating	O
group	O
such	O
as	O
a	O
substituted	O
alkoxy	O
group	O
at	O
the	O
same	O
time	O
.	O
Since	O
the	O
compound	O
of	O
the	O
invention	O
has	O
good	O
xanthine	O
oxidase-inhibitory	O
action	O
and	O
uric	O
acid-lowering	O
action	O
and	O
does	O
not	O
have	O
a	O
structure	O
derived	O
from	O
nucleic	O
acid,	O
the	O
compound	O
has	O
advantages	O
of	O
high	O
safety	O
and	O
excellent	O
effects	O
as	O
compared	O
with	O
conventional	O
compounds	O
and	O
is	O
useful	O
as	O
a	O
therapeutic	O
or	O
preventive	O
agent	O
for	O
hyperuricemia,	O
gout,	O
inflammatory	O
bowel	O
diseases,	O
diabetic	O
kidney	O
diseases,	O
diabetic	O
retinopathy,	O
or	O
the	O
like	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R,	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description,	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
dyslipidaemia,	O
atherosclerosis	O
and	O
diabetes,	O
pharmaceutical	O
compositions	O
comprising	O
them,	O
and	O
.	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
.	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
PPARα	B-GENE
and	O
PPARα	B-GENE
isoforms	O
.	O


An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
cerebral	O
infarction	O
suppressant	O
which	O
is	O
effective	O
for	O
brain	O
tissue	O
necrosis	O
attributed	O
to	O
long-time	O
ischemia	O
as	O
in	O
actual	O
cerebral	O
infarction	O
and	O
has	O
fewer	O
side	O
effects	O
.	O
The	O
suppressant	O
for	O
cerebral	O
infarction	O
attributed	O
to	O
long-time	O
ischemia	O
according	O
to	O
the	O
present	O
invention	O
is	O
characterized	O
in	O
that	O
a	O
histidine	O
and	O
an	O
H3-receptor	B-GENE
blocker	O
or	O
a	O
histidine	O
and	O
a	O
histamine	B-GENE
N-methyltransferase	I-GENE
inhibitor	O
are	O
comprised	O
as	O
active	O
ingredients	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
solvate	O
thereof,	O
or	O
a	O
combination	O
thereof,	O
wherein	O
R1,	O
R2,	O
and	O
X	O
are	O
as	O
defined	O
herein	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
progesterone	B-GENE
receptor	I-GENE
modulators	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
hexanoic	O
acid	O
derivatives	O
which	O
are	O
inhibitors	O
of	O
the	O
dipeptidyl	B-GENE
peptidase-IV	I-GENE
enzyme	O
(	O
“DPP-IV	O
inhibitors”	O
)	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
dipeptidyl	B-GENE
peptidase-IV	I-GENE
enzyme	O
is	O
involved,	O
particularly	O
in	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
and	O
conditions	O
that	O
are	O
associated	O
with	O
the	O
same	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
useful	O
in	O
inhibiting	O
DPP-IV	B-GENE
enzyme,	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
hexanoic	O
acid	O
derivatives	O
.	O
Moreover,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
inhibiting	O
DPP-IV	B-GENE
comprising	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
single	O
or	O
a	O
combination	O
of	O
hexanoic	O
acid	O
derivatives	O
of	O
the	O
invention	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
kits	O
and	O
other	O
articles	O
of	O
manufacture	O
for	O
treating	O
disease	O
states	O
associated	O
with	O
DPP-IV	B-GENE
enzyme	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
that	O
has	O
dipeptidyl	B-GENE
peptidase-IV	I-GENE
enzyme	O
inhibition	O
activity,	O
comprising	O
following	O
steps	O
:	O
1	O
.	O
Define	O
the	O
residues	O
of	O
the	O
active	O
site	O
of	O
DPP-IV	B-GENE
2	O
.	O
Define	O
the	O
geometry	O
and	O
force	O
field	O
relationship	O
of	O
the	O
residues	O
identified	O
above	O
in	O
(	O
I	O
)	O
3	O
.	O
Define	O
the	O
physical	O
parameters	O
of	O
the	O
active	O
site	O
identified	O
in	O
(	O
1	O
)	O
4	O
.	O
Validate	O
the	O
model	O
based	O
on	O
mutational	O
analysis	O
and	O
in-vitro	O
inhibitor	O
binding	O
studies	O
5	O
.	O
Screen	O
the	O
library	O
for	O
scaffolds	O
and	O
small	O
molecules	O
that	O
satisfy	O
the	O
model	O
developed	O
in	O
(	O
3	O
)	O
and	O
validated	O
in	O
(	O
4	O
)	O
above	O
.	O
6	O
.	O
Dock	O
each	O
inhibitor	O
identified	O
in	O
(	O
5	O
)	O
above	O
to	O
the	O
active	O
site	O
of	O
DPP-IV	B-GENE
defined	O
in	O
(	O
1	O
)	O
.	O
7	O
.	O
Minimize	O
the	O
energy	O
of	O
the	O
inhibitor	O
and	O
DPP-IV	B-GENE
complex	O
using	O
force	O
fields	O
used	O
in	O
(	O
2	O
)	O
above	O
.	O
8	O
.	O
Compare	O
the	O
energy	O
of	O
interaction	O
of	O
each	O
inhibitor	O
to	O
that	O
of	O
known	O
inhibitors	O
.	O
9	O
.	O
Synthesize	O
and	O
validate	O
in	O
in-vitro	O
assays	O


Compounds	O
and	O
methods	O
for	O
protein	O
kinase	B-GENE
modulation	O
for	O
cancer	O
treatment	O
are	O
disclosed	O
.	O
The	O
compounds	O
and	O
methods	O
disclosed	O
are	O
based	O
on	O
isoalpha	O
acids,	O
commonly	O
found	O
in	O
hops	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
use	O
of	O
inhibitors	O
of	O
bcl-2	B-GENE
/	O
bcl-XI	B-GENE
family	I-GENE
of	O
anti-apoptotic	O
compounds	O
for	O
the	O
treatment	O
of	O
post-angioplasty	O
restenosis	O
and	O
in-stent	O
restenosis	O
.	O
Small	O
molecules	O
of	O
Bcl	B-GENE
inhibitors	O
are	O
incorporated	O
into	O
a	O
stent,	O
typically	O
by	O
a	O
fine	O
polymeric	O
coating	O
over	O
the	O
metal,	O
which	O
would	O
be	O
placed	O
during	O
angioplasty	O
of	O
occluded	O
blood	O
vessels,	O
to	O
act	O
on	O
fibroproliferative	O
in-growth	O
.	O
Hollow	O
organs	O
such	O
as	O
urethras,	O
Fallopian	O
tubes	O
and	O
vascular	O
access	O
grafts	O
could	O
be	O
treated	O
in	O
a	O
similar	O
manner	O
to	O
prevent	O
their	O
closure	O
due	O
to	O
fibrosis	O
.	O
Other	O
iatrogenic	O
fibrosis	O
such	O
as	O
adhesions	O
after	O
surgery	O
could	O
also	O
be	O
blocked	O
by	O
this	O
therapy	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
apoptosis	O
.	O
The	O
invention	O
provides	O
novel	O
therapies,	O
for	O
example,	O
novel	O
combinatorial	O
therapies	O
or	O
novel	O
therapeutic	O
compounds	O
that	O
can	O
work	O
alone,	O
sequentially	O
to,	O
or	O
jointly	O
with	O
Apoptin,	O
especially	O
in	O
those	O
cases	O
wherein	O
p53	B-GENE
is	O
completely	O
or	O
partially	O
non-functional	O
.	O


A	O
method	O
for	O
achieving	O
a	O
chronobiologic	O
effect	O
on	O
a	O
circadian	O
rhythm	O
in	O
a	O
human	O
infant	O
or	O
fetus	O
in	O
utero	O
is	O
described	O
.	O
The	O
method	O
involves	O
the	O
administration	O
of	O
melatonin	O
or	O
dose-equivalent	O
melatonin	O
analogue	O
or	O
melatonin	B-GENE
receptor	I-GENE
agonist	O
to	O
an	O
infant	O
by	O
administering	O
melatonin	O
or	O
dose-equivalent	O
melatonin	O
precursor,	O
melatonin	O
analogue	O
or	O
melatonin	B-GENE
receptor	I-GENE
agonist	O
to	O
the	O
infant	O
'	O
s	O
breast-feeding	O
mother	O
or	O
wet	O
nurse,	O
and	O
to	O
a	O
fetus	O
by	O
administration	O
of	O
melatonin	O
or	O
dose-equivalent	O
melatonin	O
precursor,	O
melatonin	O
analogue	O
or	O
melatonin	B-GENE
receptor	I-GENE
agonist	O
to	O
the	O
pregnant	O
woman	O
.	O
Alternatives	O
wherein	O
melatonin	O
or	O
dose-equivalent	O
melatonin	O
analogue	O
or	O
melatonin	B-GENE
receptor	I-GENE
agonist	O
is	O
administered	O
directly	O
to	O
the	O
infant,	O
such	O
as	O
in	O
formula	O
or	O
in	O
expressed	O
breast	O
milk,	O
are	O
also	O
provided	O
.	O


Disclosed	O
is	O
a	O
method	O
of	O
treating	O
a	O
wart	O
in	O
a	O
subject	O
by	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
containing	O
(	O
1	O
)	O
a	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
or	O
an	O
immunostimulatory	O
fragment	O
thereof,	O
and	O
(	O
2	O
)	O
a	O
protein	O
of	O
a	O
human	O
papilloma	O
virus	O
or	O
an	O
antigenic	O
fragment	O
thereof	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
of	O
treating	O
a	O
human	O
papilloma	O
virus	O
infection	O
in	O
a	O
subject	O
infected	O
or	O
suspected	O
of	O
being	O
infected	O
with	O
a	O
human	O
papilloma	O
virus	O
of	O
a	O
first	O
type	O
by	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
containing	O
(	O
1	O
)	O
a	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
or	O
an	O
antigenic	O
fragment	O
thereof,	O
and	O
(	O
2	O
)	O
a	O
protein	O
of	O
a	O
human	O
papilloma	O
virus	O
of	O
a	O
second	O
type	O
or	O
an	O
antigenic	O
fragment	O
thereof,	O
where	O
the	O
first	O
type	O
and	O
second	O
type	O
are	O
different	O
.	O


The	O
invention	O
discloses	O
a	O
method	O
of	O
administering	O
an	O
anti-diabetic	O
combination	O
comprising	O
a	O
DPP	B-GENE
inhibitor	O
and	O
a	O
slow	O
release	O
biguanide	O
to	O
a	O
mammal	O
in	O
need	O
of	O
thereof	O
.	O
This	O
invention	O
further	O
discloses	O
anti-diabetic	O
combination	O
comprising	O
a	O
DPP	B-GENE
inhibitor	O
and	O
a	O
slow	O
release	O
biguanide	O
for	O
treating	O
diabetes	O
.	O


This	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
agent	O
for	O
preventing	O
metastasis	O
of	O
cancer,	O
which	O
comprises	O
a	O
substance	O
that	O
inhibits	O
expression	O
of	O
macrophage	B-GENE
migration	I-GENE
inhibitory	I-GENE
factor	I-GENE
(	O
MIF	B-GENE
)	O
.	O
Such	O
substance	O
includes	O
siRNA	O
of	O
MIF	B-GENE
.	O


The	O
present	O
invention	O
pertains	O
to	O
a	O
method	O
for	O
treatment	O
of	O
allergic	O
diseases	O
by	O
administering	O
a	O
natriuretic	O
hormone	I-GENE
peptide	I-GENE
(	O
NHP	B-GENE
)	O
,	O
or	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP,	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
concerns	O
an	O
expression	O
vector	O
comprising	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	B-GENE
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
concerns	O
a	O
host	O
cell	O
genetically	O
modified	O
with	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	B-GENE
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
NHP	B-GENE
or	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	B-GENE
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
pertains	O
to	O
novel	O
fragments	O
of	O
atrial	B-GENE
natriuretic	I-GENE
peptide	I-GENE
(	O
ANP	B-GENE
)	O
exhibiting	O
bronchodilatory	O
and	O
anti-inflammatory	O
activity,	O
and	O
isolated	O
nucleic	O
acid	O
sequences	O
encoding	O
the	O
fragments	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
molecules	O
such	O
as	O
peptides,	O
polypeptides	O
and	O
proteins	O
which	O
interact	O
immunologically	O
with	O
T	O
lymphocytes	O
in	O
subjects	O
having	O
peanut	O
allergy,	O
or	O
allergy	O
to	O
other	O
tree	O
nuts,	O
and	O
genetic	O
sequences	O
encoding	O
same	O
.	O
These	O
molecules	O
are	O
preferentially	O
immunointeractive	O
with	O
T	O
cells	O
in	O
subjects	O
having	O
an	O
allergy	O
to	O
the	O
Ara	B-GENE
h	I-GENE
2	I-GENE
allergen	O
.	O
The	O
molecules	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
development	O
of	O
diagnostic,	O
therapeutic	O
and	O
prophylactic	O
agents	O
for	O
conditions	O
characterised	O
by	O
an	O
aberrant,	O
inappropriate	O
or	O
otherwise	O
unwanted	O
immune	O
response	O
to	O
Ara	B-GENE
h	I-GENE
2	I-GENE
or	O
derivative	O
or	O
homologue	O
thereof	O
.	O


Novel	O
HIV	B-GENE
integrase	I-GENE
inhibitor	O
compounds	O
having	O
at	O
least	O
one	O
phosphonate	O
group,	O
protected	O
intermediates	O
thereof,	O
and	O
methods	O
for	O
inhibition	O
of	O
HIV-integrase	B-GENE
are	O
disclosed	O
.	O


The	O
acyclic	O
hydrazides	O
of	O
the	O
invention	O
are	O
antagonists	O
and	O
/	O
or	O
inverse	O
agonists	O
of	O
the	O
Cannabinoid-1	B-GENE
(CB1)	I-GENE
receptor	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
CB1	B-GENE
receptor	I-GENE
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
centrally	O
acting	O
drugs	O
in	O
the	O
treatment	O
of	O
psychosis,	O
memory	O
deficits,	O
cognitive	O
disorders,	O
migraine,	O
neuropathy,	O
neuro-inflammatory	O
disorders	O
including	O
multiple	O
sclerosis	O
and	O
Guillain-Barre	O
syndrome	O
and	O
the	O
inflammatory	O
sequelae	O
of	O
viral	O
encephalitis,	O
cerebral	O
vascular	O
accidents,	O
and	O
head	O
trauma,	O
anxiety	O
disorders,	O
stress,	O
epilepsy,	O
Parkinson	O
'	O
s	O
disease,	O
movement	O
disorders,	O
and	O
schizophrenia	O
.	O
The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
substance	O
abuse	O
disorders	O
(	O
including	O
smoking	O
cessation	O
)	O
,	O
the	O
treatment	O
of	O
obesity	O
or	O
eating	O
disorders,	O
as	O
well	O
as	O
the	O
treatment	O
of	O
asthma,	O
constipation,	O
chronic	O
intestinal	O
pseudo-obstruction,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O


The	O
invention	O
is	O
related	O
to	O
polynucleotide-based	O
cytomegalovirus	O
vaccines	O
.	O
In	O
particular,	O
the	O
invention	O
is	O
plasmids	O
operably	O
encoding	O
HCMV	O
antigens,	O
in	O
which	O
the	O
naturally-occurring	O
coding	O
regions	O
for	O
the	O
HCMV	O
antigens	O
have	O
been	O
modified	O
for	O
improved	O
translation	O
in	O
human	O
or	O
other	O
mammalian	O
cells	O
through	O
codon	O
optimization	O
.	O
HCMV	O
antigens	O
which	O
are	O
useful	O
in	O
the	O
invention	O
include,	O
but	O
are	O
not	O
limited	O
to	O
pp65,	O
glycoprotein	O
B	O
(	O
gB	O
)	O
,	O
IE1,	O
and	O
fragments,	O
variants	O
or	O
derivatives	O
of	O
either	O
of	O
these	O
antigens	O
.	O
In	O
certain	O
embodiments,	O
sequences	O
have	O
been	O
deleted,	O
e	O
.	O
g	O
.	O
,	O
the	O
Arg435-Lys438	O
putative	O
kinase	B-GENE
in	O
pp65	O
and	O
the	O
membrane	O
anchor	O
and	O
endocellular	O
domains	O
in	O
gB	O
.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
to	O
induce	O
an	O
immune	O
response	O
to	O
HCMV	O
in	O
a	O
mammal,	O
for	O
example,	O
a	O
human,	O
comprising	O
delivering	O
a	O
plasmid	O
encoding	O
a	O
codon-optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
plasmids	O
encoding	O
a	O
codon-optimized	O
HCMV	O
antigen	O
as	O
described	O
above,	O
and	O
further	O
comprising	O
adjuvants,	O
excipients,	O
or	O
immune	O
modulators	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
treating	O
disorders	O
related	O
to	O
matrix	B-GENE
metalloproteases	I-GENE
.	O
More	O
particularly,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
treating	O
stroke	O
.	O


Methods	O
for	O
treating	O
MM	O
using	O
anti-CS1	O
antibodies	O
are	O
provided	O
herein	O
.	O


Combination	O
therapy	O
comprising	O
PPAR	B-GENE
modulators	O
and	O
glucose	O
reabsorption	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
Syndrome	O
X	O
are	O
disclosed	O
.	O


Autoimmune	O
disease	O
therapy	O
in	O
a	O
patient	O
treated	O
with	O
apoptosis-inducing	O
agents	O
is	O
enhanced	O
by	O
co-administration	O
of	O
sphingomyelin	O
.	O
The	O
combination	O
most	O
likely	O
enhances	O
an	O
autoimmune	O
disease	O
cell	O
'	O
s	O
ability	O
to	O
undergo	O
ceramide-induced	O
apoptosis	O
by	O
increasing	O
the	O
levels	O
of	O
sphingomyelin	O
in	O
all	O
cellular	O
compartments,	O
thereby	O
providing	O
sufficient	O
substrate	O
for	O
activated	O
sphingomyelinase	B-GENE
.	O
In	O
alternative	O
embodiments,	O
sphingomyelin	O
may	O
be	O
administered	O
alone,	O
in	O
combination	O
with	O
corticosteroids,	O
and	O
/	O
or	O
in	O
combination	O
with	O
a	O
apoptosis-inducing	O
agent	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
(	O
where	O
variables	O
A1,	O
A2,	O
B,	O
J,	O
K,	O
m,	O
n,	O
R4,	O
R5a,	O
R5b	O
and	O
R5c	O
are	O
as	O
defined	O
herein	O
)	O
useful	O
as	O
antagonists	O
of	O
CGRP	B-GENE
receptors	O
and	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
CGRP	B-GENE
is	O
involved,	O
such	O
as	O
headache,	O
migraine	O
and	O
cluster	O
headache	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	B-GENE
is	O
involved	O
.	O


An	O
alkyl	O
ether	O
derivative	O
represented	O
by	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
or	O
salts	O
thereof	O
exhibits	O
synergistically	O
improved	O
anti-hypoxic	O
activity	O
when	O
combined	O
with	O
a	O
compound	O
having	O
an	O
acetylcholine	B-GENE
esterase	I-GENE
inhibitory	O
activity	O
.	O
Therefore,	O
the	O
combination	O
according	O
to	O
the	O
present	O
invention	O
is	O
useful	O
as	O
a	O
method	O
for	O
improving	O
cerebral	O
function	O
.	O
Further,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
relating	O
to	O
the	O
combination	O
according	O
to	O
the	O
present	O
invention	O
is	O
useful	O
for	O
treatment	O
and	O
prevention	O
of	O
dysfunction	O
of	O
cerebral	O
acetylcholine	O
neurons	O
in	O
the	O
sequelae	O
of	O
cerebrovascular	O
dementia,	O
senile	O
dementia,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
ischemic	O
cerebral	O
lesion	O
and	O
in	O
the	O
cerebral	O
apoplexy	O
or	O
the	O
memory	O
impairment	O
caused	O
by	O
selective	O
neuronal	O
death	O
.	O


Compositions	O
and	O
methods	O
for	O
treating	O
noninflammatory	O
pain,	O
including	O
but	O
not	O
limited	O
to,	O
neuropathic	O
pain	O
by	O
using	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptor	I-GENE
a	I-GENE
(	O
PPARa	B-GENE
)	O
agonists	O
to	O
treat	O
a	O
subject	O
having	O
such	O
pain	O
are	O
described	O
.	O
The	O
agonists	O
may	O
be	O
used	O
with	O
additional	O
therapeutic	O
agents	O
such	O
as	O
an	O
inhibitor	O
of	O
fatty	B-GENE
acid	I-GENE
amide	I-GENE
hydrolase	I-GENE
or	O
a	O
cannabinoid	O
CB1	O
or	O
CB2	O
cannabinoid	O
receptor	O
agonist	O
.	O


Compositions	O
and	O
methods	O
are	O
provided	O
for	O
treating	O
diseases	O
associated	O
with	O
aberrant	O
silencing	O
of	O
gene	O
expression	O
such	O
as	O
cancer	O
and	O
hematological	O
disorders	O
by	O
reestablishing	O
the	O
gene	O
expression	O
through	O
inhibition	O
of	O
DNA	O
hypomethylation	O
and	O
histone	B-GENE
deacetylase	I-GENE
.	O
The	O
method	O
comprises	O
:	O
administering	O
to	O
a	O
patient	O
suffering	O
from	O
the	O
disease	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
DNA	O
methylation	O
inhibitor	O
such	O
as	O
a	O
cysteine	O
analog	O
such	O
as	O
decitabine,	O
in	O
combination	O
with	O
an	O
effective	O
amount	O
of	O
histone	B-GENE
deacetylase	I-GENE
inhibitor	O
such	O
as	O
hydroxamic	O
acid,	O
cyclic	O
peptide,	O
benzamide,	O
butyrate,	O
and	O
depudecin	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
comprising	O
quetiapine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
zolmitriptan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
pharmaceutical	O
compositions,	O
processes	O
for	O
its	O
preparation,	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
and	O
a	O
method	O
of	O
treatment	O
of	O
disease	O
and	O
more	O
particularly	O
to	O
a	O
method	O
of	O
treatment	O
of	O
diseases	O
typically	O
treated	O
with	O
5-HT1D	B-GENE
agonists	O
and	O
/	O
or	O
atypical	O
antipsychotics,	O
in	O
particularly,	O
migraine,	O
related	O
conditions	O
and	O
for	O
reducing	O
or	O
eliminating	O
of	O
migraine	O
recurrence	O
.	O


The	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
diseases	O
or	O
disorders	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	B-GENE
activity,	O
particularly	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
the	O
Abl,	O
BCR-Abl,	O
Bmx,	O
CSK,	O
TrkB,	O
FGFR3,	O
Fes,	O
Lck,	O
B-RAF,	O
C-RAF,	O
MKK6,	O
SAPK2α	B-GENE
and	O
SAPK2β	B-GENE
kinases	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazoles,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
.	O
The	O
compounds	O
are	O
glucagon	B-GENE
receptor	I-GENE
antagonists	O
and	O
thus	O
are	O
useful	O
for	O
treating,	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O


The	O
present	O
invention	O
relates	O
to	O
liposomes	O
for	O
drug	O
delivery,	O
wherein	O
a	O
liposome	O
includes	O
molecules	O
of	O
at	O
least	O
one	O
desired	O
drug	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
liposome	O
and	O
wherein	O
the	O
liposome	O
further	O
includes	O
molecules	O
of	O
the	O
same	O
or	O
of	O
another	O
drug	O
attached	O
to	O
either	O
or	O
both	O
sides	O
of	O
the	O
liposomal	O
membrane	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
liposomes,	O
wherein	O
at	O
least	O
a	O
part	O
of	O
the	O
molecules	O
of	O
a	O
desired	O
drug	O
bear	O
a	O
functional	O
group	O
that	O
is	O
reactive	O
with	O
a	O
functional	O
group	O
present	O
in	O
at	O
least	O
one	O
lipid	O
fraction,	O
and	O
wherein	O
the	O
drug	O
is	O
covalently	O
linked	O
to	O
the	O
membrane	O
lipids	O
by	O
chemical	O
bonding,	O
e	O
.	O
g	O
.	O
by	O
ester	O
bonding	O
of	O
a	O
hydroxyl	O
group	O
of	O
a	O
lipid	O
molecule	O
and	O
an	O
acidic	O
residue	O
of	O
the	O
drug	O
.	O
In	O
a	O
preferred	O
embodiment,	O
the	O
desired	O
drug	O
is	O
a	O
glycoprotein	B-GENE
such	O
as	O
erythropoietin	B-GENE
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
manufacture	O
of	O
said	O
liposomes	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
suppression	O
of	O
ultra	O
violet-induced	O
skin	O
pathologies	O
and	O
skin	O
abnormalities,	O
such	O
as	O
abnormal	O
proliferation	O
and	O
mutagenesis,	O
and	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
having	O
Erbb2	B-GENE
or	O
HER2	B-GENE
receptors	O
.	O
The	O
method	O
involves	O
administration	O
of	O
Erbb2	B-GENE
/	O
HER2	B-GENE
inhibitors,	O
either	O
before	O
or	O
after	O
exposure	O
to	O
UV	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
substantially	O
pure	O
biologically	O
active	O
consecutive	O
anti-angiogenic	O
polypeptide	O
comprising	O
the	O
central	O
region	O
of	O
human	B-GENE
Histidine	I-GENE
Rich	I-GENE
Glycoprotein	I-GENE
(	O
HRGP	B-GENE
)	O
.	O
Said	O
polypeptide	O
is	O
shown	O
to	O
comprise	O
a	O
potential	O
endogenous,	O
naturally	O
occurring	O
subfragment	O
of	O
human	O
HRGP,	O
comprising	O
similar	O
anti-angiogenic	O
activities	O
as	O
the	O
mature	O
protein	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
one	O
or	O
more	O
new	O
biologically	O
active	O
subfragments	O
of	O
human	O
HRGP,	O
derived	O
from	O
said	O
central	O
region	O
.	O
Said	O
subfragments	O
are	O
all	O
characterized	O
by	O
having	O
anti-angiogenic	O
activity	O
.	O
One	O
of	O
the	O
active	O
subfragments	O
is	O
referred	O
to	O
as	O
Pep2	B-GENE
.	O
Enscoped	O
by	O
the	O
present	O
invention	O
are	O
also	O
anti-angiogenic	O
subfragments	O
derived	O
from	O
Pep2,	O
one	O
of	O
them	O
comprising	O
a	O
newly	O
identified	O
presently	O
minimal	O
functional	O
entity	O
.	O


Disclosed	O
is	O
a	O
viral	O
vector	O
containing	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
erythropoietin	B-GENE
(	O
Epo	B-GENE
)	O
,	O
in	O
operable	O
linkage	O
with	O
an	O
HRE	B-GENE
expression	O
control	O
sequence,	O
as	O
well	O
as	O
uses	O
of	O
the	O
vector	O
;	O
for	O
instance,	O
in	O
preparing	O
a	O
medicament	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
treating	O
anemia,	O
can	O
involve	O
administering	O
the	O
vector	O
to	O
a	O
patient,	O
wherein	O
expression	O
of	O
Epo	B-GENE
is	O
physiologically	O
regulated	O
such	O
that	O
hematocrit	O
levels	O
of	O
the	O
patient	O
are	O
corrected	O
and	O
maintained	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
N-hydroxyamidino	O
compounds	O
which	O
are	O
modulators	O
of	O
indoleamine	B-GENE
2,3-dioxygenase	I-GENE
(	O
IDO	B-GENE
)	O
,	O
as	O
well	O
as	O
compositions	O
and	O
pharmaceutical	O
methods	O
thereof	O
.	O


A	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
comprising	O
a	O
fixed	O
dose	O
combination	O
of	O
a	O
first	O
solid	O
pharmaceutical	O
composition	O
containing	O
fenofibrate	O
as	O
the	O
active	O
substance	O
and	O
second	O
solid	O
pharmaceutical	O
composition	O
containing	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
such	O
as	O
a	O
statin	O
as	O
the	O
active	O
substance,	O
wherein	O
the	O
first	O
and	O
the	O
second	O
pharmaceutical	O
compositions	O
are	O
present	O
in	O
separate	O
entities	O
in	O
a	O
single	O
solid	O
dosage	O
form	O
.	O
For	O
example	O
a	O
multilayer	O
tablet,	O
a	O
two-layer	O
tablet,	O
or	O
capsules	O
or	O
sachets	O
containing	O
the	O
active	O
ingredients	O
in	O
separate	O
granulates	O
or	O
beads,	O
either	O
granulate	O
or	O
bead	O
optionally	O
being	O
coated	O
with	O
a	O
protective	O
coating	O
or	O
an	O
entero-coating	O
.	O


The	O
application	O
discloses	O
a	O
role	O
of	O
p62	B-GENE
in	O
aging-related	O
disease,	O
such	O
as	O
development	O
of	O
obesity,	O
type	O
2	O
diabetes	O
mellitus,	O
non-alcoholic	O
fatty	O
liver,	O
various	O
tumors,	O
increased	O
male	O
mortality,	O
intracellular	O
inclusion	O
named	O
sequestosome,	O
and	O
redox	O
regulation	O
.	O
In	O
particular	O
the	O
application	O
discloses	O
a	O
method	O
of	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
.	O
Further,	O
transgenic	O
mice	O
containing	O
a	O
mutation	O
in	O
the	O
p62	B-GENE
gene	O
and	O
having	O
a	O
functionally	O
disrupted	O
p62	B-GENE
gene	O
locus	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
functional	O
disorders,	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
dysfunction	O
and	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
deuteropathy	O
thereof,	O
each	O
of	O
which	O
comprises	O
a	O
compound	O
having	O
an	O
effect	O
of	O
increasing	O
ubiquinone	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
;	O
as	O
well	O
as	O
a	O
ubiquinone	O
increasing	O
agent	O
comprising	O
a	O
compound	O
having	O
a	O
squalene	B-GENE
synthase	I-GENE
inhibitory	O
effect	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O


A	O
bone	O
implant	O
composite	O
comprising	O
a	O
collagen	B-GENE
matrix	O
and	O
a	O
calcium-based	O
mineral,	O
the	O
calcium-based	O
mineral	O
having	O
a	O
particle	O
size	O
of	O
25-2000	O
μm	O
and	O
being	O
interspersed	O
in	O
the	O
collagen	B-GENE
matrix	O
;	O
wherein	O
the	O
bone	O
implant	O
composite	O
contains	O
3-60	O
%	O
by	O
weight	O
the	O
collagen	B-GENE
matrix	O
and	O
40-97	O
%	O
by	O
weight	O
the	O
calcium-based	O
mineral,	O
and	O
has	O
a	O
pore	O
size	O
of	O
50-500	O
μm,	O
a	O
density	O
range	O
of	O
0	O
.	O
02-0	O
.	O
8	O
g	O
/	O
cm3,	O
a	O
tensile	O
strength	O
range	O
of	O
0	O
.	O
4-100	O
kg	O
/	O
cm2,	O
and	O
a	O
compression	O
modulus	O
range	O
of	O
0	O
.	O
2-10	O
kg	O
/	O
cm2	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
preparing	O
the	O
above-described	O
composite	O
.	O


Disclosed	O
are	O
compounds	O
which	O
inhibit	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
enzymatic	O
activity	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
as	O
well	O
as	O
methods	O
to	O
treat	O
conditions,	O
particularly	O
proliferative	O
conditions,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
HDAC	B-GENE
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
and	O
is	O
stable	O
even	O
if	O
it	O
is	O
stored	O
for	O
a	O
long	O
time	O
.	O
It	O
is	O
also	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
susceptible	O
to	O
acid,	O
and	O
does	O
not	O
dissolve	O
in	O
the	O
stomach	O
but	O
dissolves	O
in	O
the	O
intestine	O
to	O
release	O
a	O
primary	O
drug	O
product	O
promptly	O
.	O
The	O
object	O
could	O
be	O
achieved	O
by	O
the	O
pharmaceutical	O
composition	O
characterized	O
in	O
that	O
a	O
layer	O
containing	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
and	O
ethyl	O
cellulose,	O
a	O
layer	O
containing	O
an	O
enteric	O
polymer,	O
and	O
if	O
necessary	O
an	O
intermediate	O
layer	O
composed	O
of	O
one	O
or	O
more	O
layers	O
are	O
formed	O
on	O
a	O
pharmacologically	O
inactive	O
core	O
substance	O
.	O
The	O
intermediate	O
layer	O
is	O
composed	O
of	O
a	O
water-insoluble	O
polymer,	O
a	O
water-soluble	O
polymer,	O
a	O
lubricant	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
provides	O
amino	O
ceramide-like	O
compounds	O
which	O
inhibit	O
glucosyl	O
ceramide	O
(	O
GlyCer	O
)	O
formation	O
by	O
inhibiting	O
the	O
enzyme	O
GlyCer	O
synthase,	O
thereby	O
lowering	O
the	O
level	O
of	O
glycosphingolipids	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
have	O
improved	O
GlcCer	B-GENE
synthase	I-GENE
inhibition	O
activity	O
and	O
are	O
therefore	O
useful	O
in	O
therapeutic	O
methods	O
for	O
treating	O
various	O
conditions	O
and	O
diseases	O
associated	O
with	O
altered	O
glycosphingolipid	O
levels	O
.	O


There	O
is	O
provided	O
use	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
a	O
steroid	B-GENE
sulphatase	I-GENE
enzyme	O
(	O
E	O
.	O
C	O
.	O
3	O
.	O
1	O
.	O
6	O
.	O
2	O
)	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting	O
in	O
vivo	O
synthesis	O
of	O
at	O
least	O
one	O
of	O
androstenedione	O
and	O
testosterone,	O
which	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
hirsutism,	O
excess	O
sebum	O
production,	O
benign	O
breast	O
disease,	O
benign	O
ovarian	O
disease,	O
polycystic	O
ovarian	O
disease	O
and	O
female	O
infertility	O
among	O
others	O
.	O


Antisense	O
compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
stearoyl-CoA	B-GENE
desaturase	I-GENE
.	O
The	O
compositions	O
comprise	O
antisense	O
compounds,	O
particularly	O
antisense	O
oligonucleotides,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
stearoyl-CoA	B-GENE
desaturase	I-GENE
.	O
Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
stearoyl-CoA	B-GENE
desaturase	I-GENE
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
stearoyl-CoA	B-GENE
desaturase	I-GENE
are	O
provided	O
.	O


[	O
Object	O
]	O
Is	O
to	O
provide	O
a	O
novel	O
compound	O
having	O
an	O
anti-viral	O
activity,	O
particularly	O
a	O
HIV	B-GENE
integrase	I-GENE
inhibitory	O
activity,	O
and	O
an	O
agent,	O
particularly	O
an	O
anti-HIV	O
agent	O
.	O
	O
[	O
Solving	O
means	O
]	O
A	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
	O
	O
	O
Z1	O
is	O
NR4	O
(	O
R4	O
is	O
hydrogen,	O
optionally	O
substituted	O
lower	O
alkyl	O
etc	O
.	O
)	O
,	O
O	O
or	O
CH2	O
;	O
Z2	O
is	O
optionally	O
substituted	O
lower	O
alkylene	O
or	O
optionally	O
substituted	O
lower	O
alkenylene,	O
each	O
may	O
be	O
intervened	O
by	O
a	O
heteroatom	O
group	O
selected	O
from	O
group	O
consisting	O
O,	O
S,	O
SO,	O
SO2,	O
NR5	O
(	O
R5	O
is	O
selected	O
independently	O
from	O
the	O
same	O
substituent	O
group	O
of	O
R4	O
)	O
—N═	O
and	O
═N—	O
;	O
R1	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
is	O
a	O
single	O
bond,	O
a	O
heteroatom	O
group	O
selected	O
from	O
O,	O
S,	O
SO,	O
SO2	O
and	O
NH,	O
or	O
lower	O
alkylene	O
or	O
lower	O
alkenylene	O
each	O
may	O
be	O
intervened	O
by	O
the	O
heteroatom	O
group	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	O
;	O
R3	O
is	O
hydrogen,	O
halogen,	O
hydroxy,	O
optionally	O
substituted	O
alkyl	O
group	O
etc	O
.	O
)	O


The	O
present	O
invention	O
involves	O
diagnostic	O
and	O
treatment	O
methods	O
for	O
prostate	O
cancer	O
.	O
We	O
have	O
shown	O
that	O
prostate	O
cancer	O
cells	O
overexpress	O
variant	O
isoforms	O
of	O
CD44	B-GENE
(	O
CD44v7-10	B-GENE
)	O
.	O
Overexpression	O
is	O
observed	O
at	O
the	O
messenger	O
RNA	O
and	O
protein	O
levels	O
.	O
The	O
present	O
invention	O
includes	O
using	O
diagnostic	O
procedures	O
such	O
as	O
RT-PCR	O
and	O
in	O
situ	O
hybridization	O
to	O
distinguish	O
prostate	O
cancer	O
cells	O
from	O
benign	O
prostate	O
tissue	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
involves	O
RNA	O
interference	O
(	O
RNAi	O
)	O
targeted	O
to	O
a	O
region	O
of	O
CD44v7-10	B-GENE
and	O
to	O
Muc18	B-GENE
as	O
a	O
treatment	O
method	O
for	O
PC	O
.	O
We	O
have	O
shown	O
that	O
RNAi	O
targeted	O
to	O
CD44v7-10	B-GENE
and	O
to	O
Muc	B-GENE
18	I-GENE
decreased	O
invasiveness	O
of	O
two	O
PC	O
cell	O
lines	O
.	O
Therapeutic	O
methods	O
of	O
the	O
present	O
invention	O
include	O
gene	O
therapy	O
with	O
RNAi,	O
antisense,	O
or	O
ribozymes	O
targeted	O
against	O
CD44v7-10	B-GENE
or	O
Muc18	B-GENE
in	O
cancer	O
cells	O
in	O
vivo	O
.	O


A	O
compound	O
of	O
Formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
enantiomers,	O
diastereomers	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
I,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	B-GENE
kinase	I-GENE
.	O


The	O
present	O
patent	O
application	O
concerns	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
with	O
R1	O
and	O
R2	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
form	O
a	O
saturated	O
nitrogen-containing	O
ring,	O
A	O
is	O
a	O
saturated	O
C1-4	O
alkylene	O
and	O
B	O
a	O
C3-4	O
alkylene	O
or	O
alkenylene	O
chain	O
;	O
their	O
preparation	O
and	O
their	O
use	O
as	O
a	O
H3	B-GENE
receptor	O
ligand	O
for	O
treating	O
e	O
.	O
g	O
.	O
CNS	O
disorders	O
like	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
improving	O
the	O
bioavailability,	O
preferably,	O
oral	O
bioavailability	O
and	O
/	O
or	O
drug	O
disposition,	O
e	O
.	O
g	O
.	O
brain	O
penetration,	O
of	O
an	O
iron	O
chelator,	O
which	O
method	O
comprises	O
co-administering	O
to	O
a	O
mammal,	O
especially	O
a	O
human,	O
in	O
need	O
of	O
such	O
treatment,	O
a	O
combination	O
of	O
an	O
iron	O
chelator	O
and	O
an	O
efflux	B-GENE
protein	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
dosage	O
forms	O
with	O
controlled	O
release	O
of	O
active	O
ingredient	O
which	O
comprise	O
the	O
PDE	B-GENE
5	I-GENE
inhibitor	O
vardenafil	O
and	O
/	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates,	O
solvates	O
and	O
/	O
or	O
polymorphic	O
forms	O
thereof	O
as	O
active	O
ingredient,	O
and	O
to	O
the	O
production	O
thereof	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
these	O
novel	O
pharmaceutical	O
dosage	O
forms	O
as	O
medicaments,	O
and	O
to	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
disorders	O
in	O
humans	O
and	O
animals	O
.	O


Oligonucleotides	O
directed	O
against	O
the	O
Ha-ras	B-GENE
gene	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
Ha-ras	B-GENE
.	O
The	O
compositions	O
comprise	O
oligonucleotides,	O
particularly	O
antisense	O
oligonucleotides,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
the	O
Ha-ras	B-GENE
.	O
Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
Ha-ras	B-GENE
expression	O
and	O
for	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
either	O
overexpression	O
of	O
Ha-ras,	O
expression	O
of	O
mutated	O
Ha-ras	B-GENE
or	O
both	O
are	O
provided	O
.	O
Examples	O
of	O
diseases	O
are	O
cancer	O
such	O
as	O
lung,	O
breast,	O
colon,	O
prostate,	O
pancreas,	O
lung,	O
liver,	O
thyroid,	O
kidney,	O
brain,	O
testes,	O
stomach,	O
intestine,	O
bowel,	O
spinal	O
cord,	O
sinuses,	O
bladder,	O
urinary	O
tract	O
or	O
ovaries	O
cancers	O
.	O
The	O
oligonucleotides	O
may	O
be	O
composed	O
of	O
deoxyribonucleosides	O
or	O
a	O
nucleic	O
acid	O
analogue	O
such	O
as	O
for	O
example	O
locked	O
nucleic	O
acid	O
or	O
a	O
combination	O
thereof	O
.	O


Pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
formula	O
I	O
are	O
provided	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
constituent	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compositions	O
are	O
useful	O
as	O
inhibitors	O
of	O
plasminogen	B-GENE
activator	I-GENE
inhibitor-1	I-GENE
(	O
PAI-1	B-GENE
)	O
for	O
treating	O
conditions	O
resulting	O
from	O
fibrinolytic	O
disorders,	O
such	O
as	O
deep	O
vein	O
thrombosis	O
and	O
coronary	O
heart	O
disease,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
pulmonary	O
fibrosis	O
.	O


Compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R	O
is	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl,	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl	O
or	O
—NR′R′,	O
	O
Q	O
is	O
C	O
(	O
O	O
)	O
,	O
O,	O
NR′,	O
S,	O
S	O
(	O
O	O
)	O
2,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
Y	O
is	O
C	O
(	O
O	O
)	O
,	O
O,	O
NR′,	O
S,	O
S	O
(	O
O	O
)	O
2,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
	O
	O
Z	O
is	O
H	O
or	O
C1-C4	O
alkyl,	O
R′	O
is	O
H,	O
C	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2,	O
C	O
(	O
O	O
)	O
2,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
or	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl,	O
when	O
substituted,	O
aryl,	O
heteroaryl	O
and	O
alkyl	O
are	O
substituted	O
with	O
halogen,	O
C6-C12	O
heteroaryl,	O
—NR′R′	O
or	O
COOZ,	O
which	O
have	O
diagnostic	O
and	O
therapeutic	O
properties,	O
such	O
as	O
the	O
treatment	O
and	O
management	O
of	O
prostate	O
cancer	O
and	O
other	O
diseases	O
related	O
to	O
NAALADase	B-GENE
inhibition	O
.	O
Radiolabels	O
can	O
be	O
incorporated	O
into	O
the	O
structure	O
through	O
a	O
variety	O
of	O
prosthetic	O
groups	O
attached	O
at	O
the	O
X	O
amino	O
acid	O
side	O
chain	O
via	O
a	O
carbon	O
or	O
hetero	O
atom	O
linkage	O
.	O


The	O
present	O
invention	O
is	O
drawn	O
to	O
methods	O
of	O
repairing	O
lytic	O
bone	O
lesions	O
and	O
tumor	O
growth	O
in	O
an	O
individual	O
.	O
In	O
this	O
regard,	O
the	O
present	O
invention	O
discloses	O
use	O
of	O
a	O
Wnt	B-GENE
ligand	O
either	O
alone	O
or	O
in	O
combination	O
with	O
anti-Wnt	O
signaling	O
antagonist	O
therapy	O
.	O
The	O
individuals	O
who	O
might	O
benefit	O
from	O
such	O
method	O
may	O
include	O
but	O
are	O
not	O
limited	O
to	O
the	O
ones	O
with	O
multiple	O
myeloma,	O
osteoporosis,	O
post-menopausal	O
osteoporosis,	O
fractures,	O
metastatic	O
breast	O
cancer	O
or	O
metastatic	O
prostate	O
cancer	O
.	O


Methods	O
for	O
use	O
in	O
mobilizing	O
triacylglycerol	O
(	O
TAG	O
)	O
in	O
order	O
to	O
elevate	O
apoliprotein	B-GENE
B	I-GENE
and	O
Very-Low-Density	O
Lipoprotein	O
(	O
VLDL	O
)	O
are	O
described	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
involves	O
providing	O
betaine	O
in	O
an	O
amount	O
of	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
in	O
order	O
to	O
mobilize	O
TAG	O
.	O
In	O
some	O
embodiments,	O
serum	O
VLDL	O
is	O
elevated	O
as	O
a	O
result	O
of	O
mobilizing	O
hepatic	O
TAG	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
includes	O
restricting	O
methionine	O
intake	O
to	O
less	O
than	O
about	O
1	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
includes	O
feeding	O
L-cysteine	O
at	O
a	O
level	O
of	O
at	O
least	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
includes	O
feeding	O
choline	O
bitartrate	O
at	O
a	O
level	O
of	O
about	O
1	O
.	O
25	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O
Mobilizing	O
hepatic	O
TAG	O
is	O
effective	O
to	O
reduce	O
hepatic	O
steatosis	O
.	O


Objective	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
are	O
described	O
herein	O
.	O
In	O
one	O
embodiment,	O
the	O
diagnostic	O
method	O
involves	O
the	O
determining	O
an	O
expression	O
level	O
of	O
C10orf3	B-GENE
that	O
discriminate	O
between	O
CRC	O
and	O
normal	O
cell	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
CRC,	O
methods	O
of	O
treating	O
CRC	O
and	O
method	O
of	O
vaccinating	O
a	O
subject	O
against	O
CRC	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
2-propene-1-one	O
series,	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives,	O
analogs,	O
tautomeric	O
forms,	O
stereoisomers,	O
polymorphs,	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them,	O
wherein	O
R5,	O
R6,	O
Q	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
preparing	O
such	O
compounds,	O
compositions	O
containing	O
such	O
compounds,	O
and	O
use	O
of	O
such	O
compound	O
and	O
composition	O
in	O
medicine	O
.	O
The	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
induce	O
HSP-70	B-GENE
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
accompanying	O
pathological	O
stress	O
in	O
a	O
living	O
mammalian	O
organism,	O
including	O
a	O
human	O
being,	O
such	O
as	O
stroke,	O
myocardial	O
infarction,	O
inflammatory	O
disorder,	O
hepatotoxicity,	O
sepsis,	O
diseases	O
of	O
viral	O
origin,	O
allograft	O
rejection,	O
tumourous	O
diseases,	O
gastric	O
mucosal	O
damage,	O
brain	O
haemorrhage,	O
endothelial	O
dysfunctions,	O
diabetic	O
complications,	O
neuro-degenerative	O
diseases,	O
post-traumatic	O
neuronal	O
damage,	O
acute	O
renal	O
failure,	O
glaucoma	O
and	O
aging	O
related	O
skin	O
degeneration	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
cancer	O
diagnosis,	O
research	O
and	O
therapy,	O
including	O
but	O
not	O
limited	O
to,	O
cancer	O
markers	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
AGTR1	B-GENE
and	O
LBP	B-GENE
markers	O
for	O
breast	O
cancer	O
.	O


This	O
invention	O
relates	O
to	O
methods	O
for	O
treating,	O
preventing	O
and	O
/	O
or	O
managing	O
cancer	O
in	O
a	O
subject	O
including	O
enhancing	O
the	O
efficacy	O
of	O
a	O
Vascular	O
Disrupting	O
Agent	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
combretastatin	O
or	O
derivative	O
thereof	O
)	O
by	O
administering	O
to	O
the	O
subject	O
a	O
Chemokine	B-GENE
Receptor	I-GENE
Antagonist	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
CXCR4	B-GENE
antagonist	O
)	O
or	O
Chemokine	O
Antagonist	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
SDF-1	B-GENE
antagonist	O
)	O
sequentially	O
or	O
simultaneously	O
in	O
combination	O
with	O
said	O
Vascular	O
Disrupting	O
Agent	O
.	O


The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
method	O
of	O
treating	O
cognition	O
deficits	O
in	O
a	O
patient	O
suffering	O
from	O
schizophrenia	O
by	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
CB1	B-GENE
receptor	I-GENE
antagonist	O
as	O
described	O
herein	O
.	O
In	O
another	O
aspect,	O
this	O
invention	O
also	O
discloses	O
and	O
claims	O
a	O
combination	O
of	O
one	O
or	O
more	O
CB1	B-GENE
receptor	I-GENE
antagonists	O
and	O
of	O
one	O
or	O
more	O
antipsychotic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
disorders	O
.	O
The	O
combination	O
of	O
this	O
invention	O
provides	O
synergistic	O
results	O
in	O
that	O
the	O
combination	O
improves	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia,	O
weight	O
gain	O
and	O
catalepsy	O
.	O


Oligopeptides	O
which	O
can	O
be	O
used	O
to	O
treat	O
bone	O
disease	O
such	O
as	O
osteoporosis	O
are	O
disclosed	O
.	O
Further	O
disclosed	O
are	O
methods	O
of	O
treating	O
bone	O
disease	O
such	O
as	O
osteoporosis	O
.	O
These	O
methods	O
include	O
administration	O
of	O
a	O
polypeptide	O
encoded	O
by	O
the	O
Mesd	O
gene,	O
or	O
an	O
oligopeptide	O
comprising	O
a	O
contiguous	O
subsequence	O
of	O
a	O
Mesd	O
polypeptide	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
inhibition	O
of	O
histone	B-GENE
acetyltransferases	I-GENE
using	O
glycosaminoglycans	O
.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
for	O
treating	O
disorders	O
associated	O
with	O
hyperacetylation	O
by	O
administration	O
of	O
glycosaminoglycans	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O
In	O
one	O
preferred	O
embodiment,	O
the	O
glycosaminoglycan	O
is	O
a	O
heparin	O
or	O
heparan	B-GENE
sulfate	I-GENE
oligosaccharide	O
.	O
Studies	O
show	O
that	O
removal	O
of	O
sulfate	O
residues	O
from	O
the	O
O-positions	O
of	O
either	O
the	O
uronic	O
acid	O
or	O
the	O
glucosamine	O
did	O
not	O
eliminate	O
the	O
inhibitory	O
activity	O
of	O
heparan	B-GENE
sulfate	I-GENE
.	O
Since	O
a	O
majority	O
of	O
heparan	B-GENE
sulfate	I-GENE
binding	I-GENE
proteins	I-GENE
appear	O
to	O
require	O
O-sulfation,	O
molecules	O
without	O
certain	O
O-sulfations	O
can	O
be	O
used	O
to	O
inhibit	O
HATs	B-GENE
while	O
not	O
interacting	O
with	O
most	O
known	O
heparin-binding	O
proteins	O
.	O
In	O
addition,	O
specific	O
sequences	O
of	O
heparin	O
/	O
heparan	B-GENE
sulfate	I-GENE
can	O
be	O
used	O
to	O
specifically	O
inhibit	O
various	O
HATs	B-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
drug	O
delivery	O
device	O
for	O
providing	O
local	O
analgesia,	O
local	O
anesthesia	O
or	O
nerve	O
blockade	O
at	O
a	O
site	O
in	O
a	O
human	O
or	O
animal	O
in	O
need	O
thereof,	O
the	O
device	O
comprising	O
a	O
fibrillar	O
collagen	B-GENE
matrix	O
;	O
and	O
at	O
least	O
one	O
drug	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
amino	O
amide	O
anesthetics,	O
amino	O
ester	O
anesthetics	O
and	O
mixtures	O
thereof,	O
the	O
at	O
least	O
one	O
drug	O
substance	O
being	O
substantially	O
homogeneously	O
dispersed	O
in	O
the	O
collagen	B-GENE
matrix,	O
and	O
the	O
at	O
least	O
one	O
drug	O
substance	O
being	O
present	O
in	O
an	O
amount	O
sufficient	O
to	O
provide	O
a	O
duration	O
of	O
local	O
analgesia,	O
local	O
anesthesia	O
or	O
nerve	O
blockade	O
which	O
lasts	O
for	O
at	O
least	O
about	O
one	O
day	O
after	O
administration	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
selected	O
from	O
substituted	O
oxazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
that	O
selectively	O
modulate,	O
regulate,	O
and	O
/	O
or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and	O
/	O
or	O
mutant	O
tyrosine	B-GENE
kinases	I-GENE
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative,	O
metabolic,	O
allergic,	O
and	O
degenerative	O
disorders	O
.	O
More	O
particularly,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
c-kit,	O
bcr-abl	O
and	O
Fit-3	O
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
heparanases,	O
heparanase	O
splice	O
variants,	O
and	O
to	O
polynucleotides	O
encoding	O
them	O
.	O
Particularly,	O
the	O
invention	O
relates	O
to	O
Spalax	O
heparanases,	O
and	O
to	O
Spalax	O
and	O
human	B-GENE
heparanase	I-GENE
splice	O
variants	O
.	O
Heparanase	B-GENE
splice	O
variants	O
can	O
be	O
used,	O
for	O
example,	O
to	O
modulate	O
the	O
activity	O
of	O
heparanase	O
in	O
diseases	O
disorders	O
or	O
conditions	O
caused	O
by	O
or	O
associated	O
with	O
the	O
enzymatic	O
activity	O
of	O
heparanase	O
.	O
For	O
instance,	O
a	O
splice	O
variant	O
capable	O
of	O
down	O
regulating	O
the	O
activity	O
of	O
heparanase	O
can	O
be	O
used	O
to	O
treat	O
primary	O
tumors	O
and	O
/	O
or	O
to	O
prevent	O
or	O
treat	O
metastasis	O
.	O


The	O
invention	O
is	O
based	O
on	O
the	O
discovery	O
that	O
the	O
human	O
protein	O
referred	O
to	O
herein	O
as	O
INSP181	B-GENE
protein	O
is	O
a	O
lipocalin	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
a	O
method	O
of	O
inhibiting	O
bone	O
resorption	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
with	O
an	O
oral	O
pharmaceutical	O
composition	O
comprising	O
a	O
cathepsin	B-GENE
K	I-GENE
inhibitor,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
mixture	O
thereof,	O
according	O
to	O
a	O
continuous	O
schedule	O
having	O
a	O
dosage	O
interval	O
of	O
once	O
weekly,	O
biweekly,	O
twice	O
monthly	O
or	O
once	O
monthly	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
GFRα3	B-GENE
agonists	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
the	O
retina	O
.	O
A	O
preferred	O
GFRα3	B-GENE
agonist	O
is	O
Neublastin	B-GENE
.	O
Neublastin	B-GENE
may	O
be	O
administered	O
to	O
the	O
eye	O
using	O
protein	O
formulations,	O
in	O
vivo	O
or	O
ex	O
vivo	O
gene	O
therapy,	O
or	O
implantation	O
of	O
encapsulated	O
cells	O
delivering	O
Neublastin	B-GENE
locally	O
to	O
the	O
retina	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
long-acting	O
sustained-release	O
dosage	O
form	O
for	O
treatment	O
of	O
Parkinson	O
Disease,	O
comprising	O
a	O
dopamine	B-GENE
receptor	I-GENE
agonist	O
and	O
a	O
pharmaceutically	O
acceptable	O
biodegradable	O
polymer	O
accessories,	O
wherein	O
the	O
content	O
of	O
the	O
dopamine	B-GENE
receptor	I-GENE
agonist	O
in	O
the	O
sustained-release	O
dosage	O
form	O
is	O
5-50	O
%	O
by	O
weight,	O
and	O
the	O
content	O
of	O
the	O
pharmaceutically	O
acceptable	O
polymer	O
accessories	O
is	O
50-95	O
%	O
by	O
weight	O
.	O


The	O
present	O
invention	O
relates	O
to	O
Sphingosine	B-GENE
kinase	I-GENE
inhibitors	O
that	O
are	O
useful	O
for	O
treating	O
various	O
cancers	O
.	O
The	O
invention	O
further	O
relates	O
to	O
compositions	O
and	O
methods	O
of	O
SPK	B-GENE
inhibitors,	O
including	O
siRNAs,	O
which	O
specifically	O
block	O
gene	O
expression	O
of	O
SPK	B-GENE
and	O
potentiates	O
the	O
effect	O
of	O
radiation	O
in	O
the	O
treatment	O
of	O
various	O
cancers	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
of	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
any	O
stereoisomeric	O
form	O
of	O
the	O
compound	O
of	O
the	O
formula	O
I	O
or	O
a	O
mixture	O
of	O
these	O
forms	O
in	O
any	O
ratio	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
of	O
the	O
compound	O
of	O
the	O
formula	O
I	O
which	O
inhibit	O
the	O
enzyme	O
TAFIa	B-GENE
(	O
activated	B-GENE
thrombin-activatable	I-GENE
fibrinolysis	I-GENE
inhibitor	I-GENE
)	O
,	O
and	O
to	O
a	O
process	O
for	O
their	O
preparation	O
and	O
to	O
their	O
use	O
to	O
treat	O
described	O
diseases	O
where	O
the	O
substituents	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O


Compounds,	O
compositions,	O
and	O
methods	O
of	O
avoiding	O
edema	O
while	O
treating	O
or	O
preventing	O
PPARγ-mediated	O
diseases,	O
including	O
cancer,	O
using	O
derivatives	O
and	O
prodrugs	O
are	O
provided	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
:	O
R1,	O
R2,	O
R3,	O
A	O
and	O
m	O
are	O
each	O
as	O
described	O
herein	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
5-HT4	B-GENE
agonistic	O
activity	O
such	O
as,	O
but	O
not	O
limited	O
to,	O
gastroesophageal	O
reflux	O
disease,	O
gastrointestinal	O
disease,	O
gastric	O
motility	O
disorder,	O
non-ulcer	O
dyspepsia,	O
functional	O
dyspepsia,	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
constipation,	O
dyspepsia,	O
esophagitis,	O
gastroesophageral	O
disease,	O
nausea,	O
central	O
nervous	O
system	O
disease,	O
Alzheimer	O
'	O
s	O
disease,	O
cognitive	O
disorder,	O
emesis,	O
migraine,	O
neurological	O
disease,	O
pain,	O
cardiovascular	O
disorders,	O
cardiac	O
failure,	O
heart	O
arrhythmia,	O
diabetes	O
and	O
apnea	O
syndrome	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
acetyl	O
L-carnitine	O
in	O
association	O
with	O
the	O
biotin	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
Type	O
2	O
insulin-resistant	O
diabetes	O
mellitus	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination,	O
such	O
as	O
a	O
combined	O
preparation	O
or	O
pharmaceutical	O
composition,	O
respectively,	O
comprising	O
of	O
a	O
DPP	B-GENE
IV	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
comprising	O
at	O
least	O
one	O
therapeutic	O
agent	O
selected	O
from	O
an	O
agent	O
interacting	O
with	O
a	O
5-HT3	B-GENE
receptor	I-GENE
and	O
/	O
or	O
an	O
agent	O
interacting	O
with	O
5-HT4	O
receptor,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


A	O
treatment	O
method	O
for	O
restoring	O
of	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
or	O
selected	O
areas	O
of	O
the	O
body	O
is	O
disclosed	O
which	O
includes	O
injecting	O
an	O
injectable	O
composition	O
containing	O
a	O
growth	O
factor	I-GENE
and	O
hyaluronic	O
acid	O
as	O
a	O
carrier	O
into	O
the	O
dermis,	O
the	O
hypodermis,	O
or	O
both,	O
in	O
various	O
areas	O
of	O
the	O
face,	O
or	O
selected	O
areas	O
of	O
the	O
body	O
of	O
a	O
person	O
to	O
stimulate	O
collagen,	O
elastin,	O
or	O
fat	O
cell	O
production,	O
thereby	O
restoring	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
and	O
selected	O
areas	O
of	O
the	O
body	O
.	O
Further	O
disclosed	O
is	O
an	O
injectable	O
composition	O
for	O
restoring	O
of	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
and	O
selected	O
areas	O
of	O
the	O
body,	O
which	O
contains	O
a	O
growth	O
factor	I-GENE
and	O
hyaluronic	O
acid	O
as	O
a	O
carrier	O
for	O
providing	O
time	O
release	O
of	O
the	O
growth	O
factor	I-GENE
into	O
tissues	O
.	O
The	O
growth	O
factor	I-GENE
can	O
be	O
insulin,	O
insulin-like	B-GENE
growth	I-GENE
factor,	O
thyroid	O
hormone,	O
fibroblast	B-GENE
growth	I-GENE
factor,	O
estrogen,	O
retinoic	O
acid,	O
or	O
their	O
combinations	O
.	O


Inhibitors	O
of	O
plasminogen	B-GENE
activator	I-GENE
inhibitor-1	I-GENE
(	O
PAI-I	B-GENE
)	O
are	O
provided,	O
which	O
may	O
also	O
act	O
as	O
anti	O
cancer	O
agents,	O
of	O
formulae	O
(	O
I-V	O
)	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
the	O
G-protein	B-GENE
coupled	I-GENE
orphan	I-GENE
receptor	I-GENE
GPR43	B-GENE
and	O
the	O
identification	O
of	O
short	O
chain	O
fatty	O
acids	O
as	O
natural	O
ligands	O
of	O
the	O
receptor	O
.	O
The	O
invention	O
further	O
relates	O
to	O
assays	O
for	O
the	O
identification	O
of	O
agents	O
that	O
modulate	O
GPR43	B-GENE
ligand	O
binding	O
and	O
signalling	O
activity,	O
as	O
well	O
as	O
compositions	O
consisting	O
essentially	O
of	O
an	O
isolated	O
GPR43	B-GENE
polypeptide	O
and	O
an	O
isolated	O
short	O
chain	O
fatty	O
acid	O
.	O
The	O
invention	O
also	O
relates	O
to	O
diagnostic	O
methods	O
and	O
kits	O
that	O
take	O
advantage	O
of	O
the	O
novel	O
interaction	O
of	O
GPR43	B-GENE
with	O
short	O
chain	O
fatty	O
acids	O
.	O


The	O
present	O
disclosure	O
provides	O
meroduplex	O
ribonucleic	O
acid	O
molecules	O
(	O
mdRNA	O
)	O
capable	O
of	O
decreasing	O
or	O
silencing	O
ERBB	B-GENE
gene	O
expression	O
.	O
An	O
mdRNA	O
of	O
this	O
disclosure	O
comprises	O
at	O
least	O
three	O
strands	O
that	O
combine	O
to	O
form	O
at	O
least	O
two	O
non-overlapping	O
double-stranded	O
regions	O
separated	O
by	O
a	O
nick	O
or	O
gap	O
wherein	O
one	O
strand	O
is	O
complementary	O
to	O
an	O
ERBB	B-GENE
mRNA	O
.	O
In	O
addition,	O
the	O
meroduplex	O
may	O
have	O
at	O
least	O
one	O
uridine	O
substituted	O
with	O
a	O
5-methyluridine,	O
a	O
nucleoside	O
replaced	O
with	O
a	O
locked	O
nucleic	O
acid,	O
or	O
optionally	O
other	O
modifications,	O
and	O
any	O
combination	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
decreasing	O
expression	O
of	O
an	O
ERBB	B-GENE
gene	O
in	O
a	O
cell	O
or	O
in	O
a	O
subject	O
to	O
treat	O
an	O
ERBB-related	O
disease	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
reducing	O
the	O
emetogenic	O
effects	O
of	O
PDE	B-GENE
inhibitors,	O
and	O
more	O
particularly	O
is	O
directed	O
to	O
compounds	O
having	O
PDE4	B-GENE
inhibition	O
activity	O
with	O
little	O
or	O
no	O
emetogenic	O
side-effects,	O
and	O
chemical	O
methods	O
including	O
benzylation	O
for	O
preparing	O
such	O
compounds	O
.	O
A	O
benzyl	O
group	O
may	O
be	O
attached	O
to	O
either	O
a	O
carbon	O
or	O
nitrogen	O
atom	O
of	O
a	O
PDE4	B-GENE
inhibitor	O
.	O
Suitable	O
benzylation	O
chemistry	O
is	O
to	O
extract	O
a	O
hydrogen	O
from	O
a	O
PDE4	B-GENE
inhibitor,	O
preferably	O
with	O
a	O
base,	O
and	O
then	O
react	O
the	O
resulting	O
nucleophilic	O
PDE4	B-GENE
inhibitor	O
with	O
a	O
benzylating	O
agent,	O
e	O
.	O
g	O
.	O
,	O
benzyl	O
bromide	O
or	O
a	O
derivative	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
inducing	O
ovulation	O
in	O
a	O
female	O
host	O
comprising	O
the	O
administration	O
of	O
a	O
non-polypeptide	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
level	O
modulator	O
to	O
the	O
female	O
host	O
.	O
In	O
another	O
aspect,	O
the	O
invention	O
provides	O
for	O
specific	O
administration	O
of	O
the	O
phosphodiesterase	B-GENE
inhibitor	O
prior	O
to	O
the	O
luteal	O
phase	O
of	O
the	O
host	O
'	O
s	O
ovulatory	O
cycle	O
.	O
Preferred	O
non-polypeptide	O
cAMP	O
level	O
modulators	O
include	O
phosphodiesterase	B-GENE
inhibitors,	O
particularly	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
4	I-GENE
isoforms	O
.	O


This	O
invention	O
describes	O
the	O
principles	O
and	O
procedures	O
suitable	O
for	O
developing,	O
testing,	O
manufacturing,	O
and	O
using	O
combinations	O
of	O
various	O
amphipatic,	O
if	O
necessary	O
modified,	O
macromolecules	O
(	O
such	O
as	O
polypeptides,	O
proteins,	O
etc	O
.	O
)	O
or	O
other	O
chain	O
molecules	O
(	O
such	O
as	O
suitable,	O
e	O
.	O
g	O
.	O
partly	O
hydrophobised,	O
polynucleotides	O
or	O
polysaccharides	O
)	O
with	O
the	O
aggregates	O
which	O
comprise	O
a	O
mixture	O
of	O
polar	O
and	O
/	O
or	O
charged	O
amphipats	O
and	O
form	O
extended	O
surfaces	O
that	O
can	O
be	O
freely	O
suspended	O
or	O
supported	O
.	O
The	O
described	O
methods	O
can	O
be	O
utilised	O
for	O
the	O
optimisation	O
of	O
aggregates	O
that,	O
after	O
association	O
with	O
chain	O
molecules	O
exerting	O
some	O
activity	O
or	O
a	O
useful	O
function,	O
are	O
suitable	O
for	O
the	O
application	O
in	O
vitro	O
or	O
in	O
vivo,	O
for	O
example,	O
in	O
the	O
fields	O
of	O
drug	O
delivery,	O
diagnostics	O
or	O
bio	O
/	O
catalysis	O
.	O
As	O
special	O
examples,	O
mixtures	O
of	O
vesicular	O
droplets	O
consisting	O
of	O
lipids	O
loaded	O
(	O
associated	O
)	O
with	O
insulin,	O
interferon,	O
interleukin,	O
nerve	B-GENE
growth	I-GENE
factor,	O
calcitonin,	O
and	O
an	O
immunoglobulin,	O
etc	O
.	O
,	O
are	O
described	O
.	O


A	O
therapeutic	O
method	O
for	O
treating	O
intestinal	O
damage,	O
enteritis,	O
diarrhea,	O
or	O
a	O
combination	O
thereof	O
caused	O
by	O
a	O
C	O
.	O
difficile	O
is	O
provided	O
.	O
The	O
method	O
includes	O
administration	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
an	O
A2A	B-GENE
adenosine	I-GENE
receptor	I-GENE
agonist,	O
optionally	O
in	O
combination	O
with	O
an	O
effective	O
amount	O
of	O
a	O
stable	O
glutamine	O
derivative,	O
e	O
.	O
g	O
.	O
,	O
alanyl-glutamine	O
.	O


Compounds	O
of	O
the	O
formula	O
I,	O
in	O
which	O
R,	O
X,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1,	O
are	O
inhibitors	O
of	O
CHK1	B-GENE
CHK2	B-GENE
and	O
SGK	B-GENE
kinases	O
and	O
can	O
be	O
employed,	O
inter	O
alia,	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
heteroaryl	O
aryl	O
ureas	O
of	O
the	O
formula	O
IA,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
radicals	O
and	O
symbols	O
have	O
the	O
meanings	O
as	O
defined	O
herein,	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
protein	B-GENE
kinase	I-GENE
dependent	O
diseases	O
;	O
to	O
pharmaceutical	O
preparations	O
comprising	O
said	O
heteroaryl	O
aryl	O
ureas,	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
such	O
novel	O
compounds	O
and	O
to	O
methods	O
of	O
treatment	O
comprising	O
the	O
use	O
of	O
such	O
heteroaryl	O
aryl	O
ureas	O
.	O


A	O
pharmaceutical	O
composition	O
for	O
treating	O
the	O
hypertension	O
is	O
provided	O
.	O
The	O
pharmaceutical	O
composition	O
comprises	O
a	O
chemical	O
compound	O
of	O
7-	O
[	O
2-	O
[	O
4-	O
(	O
2-Chlorobenzene	O
)	O
piperazinyl	O
]	O
ethyl	O
]	O
-1,3-dimethyl	O
xanthine	O
and	O
one	O
of	O
a	O
pharmaceutical	O
acceptable	O
salt	O
thereof	O
and	O
a	O
solvate	O
thereof,	O
wherein	O
the	O
chemical	O
compound	O
treats	O
the	O
hypertension	O
by	O
cGMP-dependent	O
inhibition	O
on	O
Rho	B-GENE
kinase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
CKα-5	O
protein	O
which	O
is	O
a	O
member	O
of	O
the	O
alpha	O
chemokine	O
family	O
.	O
In	O
particular,	O
isolated	O
nucleic	O
acid	O
molecules	O
are	O
provided	O
encoding	O
the	O
human	B-GENE
CKα-5	I-GENE
protein	O
.	O
CKα-5	O
polypeptides	O
are	O
also	O
provided,	O
as	O
are	O
vectors,	O
host	O
cells	O
and	O
recombinant	O
methods	O
for	O
producing	O
the	O
same	O
.	O
Antibodies	O
and	O
fragments	O
thereof	O
that	O
specifically	O
bind	O
to	O
CKα-5	O
polypeptides	O
are	O
also	O
disclosed,	O
as	O
are	O
compositions	O
and	O
methods	O
for	O
making	O
such	O
antibodies	O
.	O
The	O
invention	O
further	O
relates	O
to	O
screening	O
methods	O
for	O
identifying	O
agonists	O
and	O
antagonists	O
of	O
CKα-5	O
activity	O
.	O
Also	O
provided	O
are	O
diagnostic	O
methods	O
for	O
detecting	O
immune	O
system-related	O
disorders	O
and	O
therapeutic	O
methods	O
for	O
treating	O
immune	O
system-related	O
disorders	O
.	O


α-Hydroxy	O
amide	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
are	O
bradykinin	B-GENE
B1	I-GENE
antagonists	O
or	O
inverse	O
agonists	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
symptoms	O
such	O
as	O
pain	O
and	O
inflammation	O
associated	O
with	O
the	O
bradykinin	B-GENE
B1	I-GENE
pathway	O
.	O
R2a	O
is	O
selected	O
from	O
(	O
1	O
)	O
a	O
group	O
selected	O
from	O
Ra	O
.	O
(	O
2	O
)	O
(	O
CH2	O
)	O
nNRbC	O
(	O
O	O
)	O
Ra	O
.	O
(	O
3	O
)	O
(	O
CH2	O
)	O
nNRbSO2Rd	O
.	O
(	O
4	O
)	O
(	O
CH2	O
)	O
nNRbCO2Ra	O
.	O
(	O
5	O
)	O
(	O
CH2	O
)	O
k-heterocycle	O
optionally	O
substituted	O
with	O
1	O
to	O
3	O
groups	O
independently	O
selected	O
from	O
halogen	O
.	O
nitro,	O
cyano	O
.	O
ORa	O
.	O
SRa	O
.	O
C1-4	O
alkyl	O
and	O
C1-3	O
haloakyl	O
wherein	O
said	O
heterocycle	O
is	O
(	O
a	O
)	O
a	O
5-membered	O
heteroaromatic	O
ring	O
having	O
a	O
ring	O
heteroatom	O
selected	O
from	O
N	O
.	O
O	O
and	O
S	O
.	O
and	O
optionally	O
having	O
up	O
to	O
3	O
additional	O
ring	O
nitrogen	O
atoms	O
wherein	O
said	O
ring	O
is	O
optionally	O
benzo-fused	O
;	O
or	O
(	O
b	O
)	O
a	O
6-membered	O
heteromatic	O
ring	O
containing	O
from	O
1	O
to	O
3	O
ring	O
nitrogen	O
atoms	O
and	O
N-oxydes	O
thereof	O
.	O
Wherein	O
said	O
ring	O
is	O
optionally	O
benzo-fused	O
.	O
(	O
6	O
)	O
(	O
CH2	O
)	O
kCO2Ra	O
.	O
and	O
(	O
7	O
)	O
(	O
CH2	O
)	O
C	O
(	O
O	O
)	O
NRbRc	O
.	O
R2b	O
is	O
OH	O
or	O
a	O
group	O
selected	O
from	O
R2a	O
;	O
or	O
R2a	O
and	O
R2b	O
together	O
with	O
the	O
carbon	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
3-	O
to	O
7-membered	O
carbocyclic	O
ring	O
optionally	O
substituted	O
with	O
1	O
to	O
4	O
groups	O
independently	O
selected	O
from	O
halogen	O
.	O
ORa	O
.	O
C1-4	O
alkyl	O
and	O
C1-4	O
haloalkyl	O
;	O


Anthracyclines-treated	O
tumor	O
cells	O
are	O
particularly	O
effective	O
in	O
eliciting	O
an	O
anti-cancer	O
immune	O
response,	O
where	O
the	O
rDNA-damaging	O
agents,	O
such	O
as	O
etoposide	O
and	O
mitomycin	O
C	O
do	O
not	O
induce	O
immunogenic	O
cell	O
death	O
.	O
Anthracyclines	O
induce	O
the	O
rapid,	O
pre-apoptotic	O
translocation	O
of	O
calreticulin	B-GENE
(	O
CRT	B-GENE
)	O
to	O
the	O
cell	O
surface	O
.	O
Blockade	O
or	O
knock	O
down	O
of	O
CRT	B-GENE
suppressed	O
the	O
phagocytosis	O
of	O
anthracyclines-treated	O
tumor	O
cells	O
by	O
dendritic	O
cells	O
and	O
abolished	O
their	O
immunogenicity	O
in	O
mammals,	O
such	O
as	O
mice	O
.	O
The	O
anthracyclines-induced	O
CRT	B-GENE
translocation	O
was	O
mimicked	O
by	O
inhibition	O
of	O
the	O
protein	B-GENE
phosphatase1/GADD34	I-GENE
complex	O
.	O
Administration	O
of	O
recombinant	O
CRT	B-GENE
or	O
inhibitors	O
of	O
protein	B-GENE
phosphatase1/GADD34	I-GENE
restored	O
the	O
immunogenicity	O
of	O
cell	O
death	O
elicited	O
by	O
etoposide	O
and	O
mitomycin	O
C,	O
and	O
enhanced	O
their	O
antitumor	O
effects	O
in	O
vivo	O
.	O
These	O
data	O
identify	O
CRT	B-GENE
as	O
a	O
key	O
feature	O
determining	O
anti-cancer	O
immune	O
responses	O
and	O
delineate	O
a	O
possible	O
strategy	O
for	O
immunogenic	O
chemotherapy	O
.	O


The	O
compounds	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1	O
and	O
R2	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
are	O
novel	O
effective	O
PDE2	B-GENE
inhibitors	O
.	O


Substituted	O
imidazo	O
[	O
2,1-b	O
]	O
thiazole	O
compounds	O
corresponding	O
to	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
a	O
method	O
for	O
producing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
the	O
use	O
thereof	O
for	O
regularing	O
mGluR5	B-GENE
receptors,	O
or	O
for	O
treating	O
or	O
inhibiting	O
disorders	O
or	O
disease	O
states	O
at	O
least	O
partially	O
mediated	O
by	O
mGluR5	B-GENE
receptor	O
such	O
as	O
pain,	O
anxiety	O
attacks,	O
drug	O
or	O
alcohol	O
dependency,	O
and	O
others	O
.	O


The	O
present	O
invention	O
relates	O
to	O
dihydroisoxazoles	O
that	O
are	O
useful	O
for	O
treating	O
cellular	O
proliferative	O
diseases,	O
for	O
treating	O
disorders	O
associated	O
with	O
KSP	O
kinesin	B-GENE
activity,	O
and	O
for	O
inhibiting	O
KSP	O
kinesin	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
compositions	O
which	O
comprise	O
these	O
compounds,	O
and	O
methods	O
of	O
using	O
them	O
to	O
treat	O
cancer	O
in	O
mammals	O
.	O


The	O
present	O
invention	O
provides	O
compositions,	O
including	O
pharmaceutical	O
compositions,	O
comprising	O
an	O
amount	O
of	O
an	O
antibody,	O
antibody	O
fragment	O
or	O
antibody	O
conjugate	O
sufficient	O
to	O
treat	O
Group	O
A	O
streptococcus	O
(	O
GAS	O
)	O
infection	O
or	O
complication	O
thereof	O
in	O
a	O
subject	O
or	O
a	O
disease	O
or	O
complication	O
associated	O
with	O
GAS	O
infection	O
in	O
a	O
subject	O
wherein	O
said	O
antibody,	O
antibody	O
fragment	O
or	O
antibody	O
conjugate	O
binds	O
immunospecifically	O
to	O
a	O
B-cell	O
epitope	O
of	O
GAS	O
M-protein	B-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
treatment	O
of	O
infection	O
by	O
GAS	O
and	O
complications	O
thereof	O
comprising	O
administering	O
the	O
compositions	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


Methods	O
of	O
treatment	O
of	O
sepsis	O
are	O
disclosed	O
.	O
These	O
methods	O
comprise	O
administering	O
to	O
a	O
subject	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
siRNA	O
directed	O
against	O
at	O
least	O
one	O
gene	O
encoding	O
a	O
pro-apoptotic	O
polypeptide	O
.	O
The	O
pro-apoptotic	O
polypeptide,	O
in	O
some	O
aspects,	O
can	O
be	O
other	O
than	O
Fas	B-GENE
or	O
caspase-8	B-GENE
.	O
In	O
some	O
embodiments,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
pro-apoptotic	O
component	O
of	O
the	O
mitochondrial	O
pathway,	O
such	O
as	O
a	O
pro-apoptotic	O
bcl-2	B-GENE
protein	O
.	O
In	O
some	O
aspects,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
BH3-only	O
bcl-2	B-GENE
protein,	O
while	O
in	O
other	O
aspects,	O
siRNAs	O
can	O
be	O
directed	O
against	O
multi	O
BH	B-GENE
domain	I-GENE
Bcl-2	B-GENE
family	O
members	O
such	O
as	O
bax	O
and	O
bak	O
.	O
In	O
some	O
embodiments,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
death	B-GENE
receptor	I-GENE
pathway	O
molecule	O
such	O
as	O
FADD	B-GENE
.	O
In	O
various	O
configurations,	O
a	O
composition	O
can	O
also	O
comprise	O
a	O
cationic	O
lipid	O
such	O
as	O
DOTAP,	O
or	O
nanoparticles	O
comprising	O
a	O
cyclodextrin-containing	O
polycation	O
and	O
a	O
polymer	O
such	O
as	O
a	O
poly	O
(	O
ethylene	O
glycol	O
)	O
.	O


Described	O
are	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
VI	O
and	O
(	O
VII	O
)	O
.	O
Also	O
described	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
identified	O
.	O
The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
described	O
are	O
inhibitors	O
of	O
5′-methylthioadenosine/S-adenosylhomocystein	B-GENE
nucleosidase	I-GENE
(	O
MTAN	B-GENE
)	O
and	O
/	O
or	O
5′-methylthioadenosine	B-GENE
phosphorylase	I-GENE
(	O
MTAP	B-GENE
)	O
.	O
Methods	O
of	O
treatment	O
using	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
described	O
are	O
also	O
provided	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
disease	O
states	O
and	O
/	O
or	O
conditions	O
by	O
inhibiting	O
MTAN	B-GENE
and	O
/	O
or	O
MTAP	B-GENE
in	O
patients	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel,	O
non-secosteroidal,	O
diaryl	O
compounds	O
with	O
vitamin	B-GENE
D	I-GENE
receptor	I-GENE
(	O
VDR	B-GENE
)	O
modulating	O
and	O
psoriasis	O
.	O


The	O
invention	O
provides	O
uses	O
and	O
methods	O
for	O
reducing	O
nephropathy	O
in	O
persons	O
with	O
diabetes	O
mellitus	O
(	O
particularly	O
Type	O
2	O
diabetes	O
)	O
,	O
in	O
persons	O
with	O
metabolic	O
syndrome,	O
in	O
persons	O
with	O
triglyceride	O
levels	O
over	O
215	O
mg	O
/	O
dL,	O
and	O
in	O
persons	O
with	O
a	O
cholesterol	O
level	O
over	O
200	O
mg	O
/	O
dL,	O
by	O
administering	O
an	O
inhibitor	O
of	O
soluble	B-GENE
epoxide	I-GENE
hydrolase	I-GENE
(	O
“sEH”	O
)	O
.	O
Optionally,	O
a	O
cis-epoxyeicosantrienoic	O
acid	O
(	O
“EET”	O
)	O
can	O
be	O
administered	O
with	O
the	O
sEH	B-GENE
inhibitor	O
.	O
The	O
invention	O
further	O
provides	O
for	O
using	O
EETs	O
in	O
conjunction	O
with	O
one	O
or	O
more	O
sEH	B-GENE
inhibitors	O
to	O
reduce	O
hypertension,	O
and	O
for	O
compositions	O
of	O
EETs	O
coated	O
with	O
a	O
material	O
insoluble	O
in	O
an	O
acid	O
of	O
pH	O
3	O
but	O
soluble	O
in	O
a	O
solution	O
with	O
a	O
pH	O
of	O
7	O
.	O
4	O
or	O
higher	O
.	O


Diaminoalkanes	O
of	O
Formula	O
I	O
have	O
now	O
been	O
found	O
which	O
are	O
orally	O
active	O
and	O
bind	O
to	O
aspartic	O
proteases	O
to	O
inhibit	O
their	O
activity	O
.	O
They	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
amelioration	O
of	O
diseases	O
associated	O
with	O
elevated	O
levels	O
of	O
aspartic	B-GENE
protease	I-GENE
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
use	O
of	O
the	O
compounds	O
of	O
Formula	O
I	O
in	O
ameliorating	O
or	O
treating	O
aspartic	B-GENE
protease	I-GENE
related	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
.	O


Human	B-GENE
ALDO	I-GENE
genes	I-GENE
are	O
identified	O
as	O
modulators	O
of	O
the	O
IGF	B-GENE
pathway,	O
and	O
thus	O
are	O
therapeutic	O
targets	O
for	O
disorders	O
associated	O
with	O
defective	O
IGF	B-GENE
function	O
.	O
Methods	O
for	O
identifying	O
modulators	O
of	O
IGF,	O
comprising	O
screening	O
for	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ALDO	O
are	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
and	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
inflammatory	O
diseases	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
lymphocyte	O
adhesion	O
to	O
an	O
endothelial	O
cell,	O
or	O
a	O
method	O
for	O
treating	O
an	O
inflammatory	O
disease,	O
which	O
comprises	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	B-GENE
polypeptide	O
.	O
A	O
pharmaceutical	O
composition	O
comprising	O
the	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	B-GENE
polypeptide,	O
and	O
the	O
use	O
of	O
the	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	B-GENE
polypeptide	O
are	O
also	O
disclosed	O
.	O
Further,	O
a	O
method	O
for	O
screening	O
a	O
medicament	O
for	O
inhibiting	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	B-GENE
polypeptide	O
or	O
a	O
medicament	O
for	O
treating	O
an	O
inflammatory	O
disease,	O
which	O
comprises	O
a	O
step	O
of	O
selecting	O
an	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	B-GENE
polypeptide,	O
is	O
disclosed	O
.	O


A	O
method	O
is	O
provided	O
for	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
raf	B-GENE
kinase,	O
which	O
includes	O
administering	O
a	O
guanylhydrazone	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O
A	O
method	O
is	O
also	O
provided,	O
which	O
includes	O
modulating	O
or	O
inhibiting	O
signal	O
transduction	O
in	O
a	O
c-raf	B-GENE
pathway	O
with	O
at	O
least	O
one	O
guanylhydrazone	O
.	O
Another	O
method	O
is	O
provided,	O
which	O
includes	O
contacting	O
one	O
or	O
more	O
human	O
mononuclear	O
cells	O
with	O
at	O
least	O
one	O
guanylhydrazone	O
and	O
at	O
least	O
one	O
lipopolysaccharide	O
to	O
obtain	O
one	O
or	O
more	O
treated	O
cells	O
;	O
contacting	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
including	O
said	O
treated	O
cells,	O
one	O
or	O
more	O
lysates	O
thereof,	O
and	O
combinations	O
thereof,	O
with	O
at	O
least	O
one	O
surface-bound	O
peptide	O
in	O
a	O
surface-bound	O
peptide	O
array	O
;	O
and	O
selectively	O
modulating	O
or	O
inhibiting	O
the	O
phosphorylation	O
of	O
the	O
surface-bound	O
peptide	O
.	O


This	O
invention	O
relates	O
to	O
a	O
novel	O
human	O
deoxyribonuclease,	O
referred	O
to	O
as	O
human	B-GENE
DNase	I-GENE
II	I-GENE
.	O
The	O
invention	O
provides	O
nucleic	O
acid	O
sequences	O
encoding	O
human	B-GENE
DNase	I-GENE
II,	O
thereby	O
enabling	O
the	O
production	O
of	O
human	B-GENE
DNase	I-GENE
II	I-GENE
by	O
recombinant	O
DNA	O
methods	O
in	O
quantities	O
sufficient	O
for	O
clinical	O
use	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
and	O
therapeutic	O
uses	O
of	O
human	B-GENE
DNase	I-GENE
II	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
high	O
affinity	O
compounds,	O
able	O
to	O
bind	O
CB1	B-GENE
and	O
CB2	B-GENE
endocannabinoid	O
receptors	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
find	O
particular	O
application	O
as	O
agents	O
for	O
pain	O
therapy	O
and	O
/	O
or	O
anti-inflammatory	O
and	O
/	O
or	O
anti-stress	O
and	O
/	O
or	O
anti-oxidising	O
and	O
/	O
or	O
hypotensive	O
and	O
/	O
or	O
immune	O
suppressive	O
therapy	O
and	O
/	O
or	O
anti-spastic	O
activity	O
in	O
multiple	O
sclerosis	O
and	O
/	O
or	O
anti-cancer	O
.	O


This	O
invention	O
relates	O
to	O
methods	O
and	O
kits	O
for	O
enhancing	O
the	O
permeability	O
of	O
the	O
blood-brain	O
barrier	O
of	O
abnormal	O
brain	O
tissue	O
or	O
the	O
blood-tumor	O
barrier	O
.	O
Particularly,	O
methods	O
comprising	O
the	O
administration	O
of	O
5-phosphodiesterase	B-GENE
inhibitors,	O
such	O
as	O
sildenafil	O
and	O
vardenafil,	O
to	O
selectively	O
enhance	O
the	O
permeability	O
of	O
the	O
blood-brain	O
barrier	O
of	O
abnormal	O
brain	O
tissue	O
or	O
the	O
blood-tumor	O
barrier	O
are	O
described	O
.	O
This	O
selective	O
enhancement	O
allows	O
for	O
selective	O
delivery	O
of	O
therapeutic	O
agents	O
or	O
imaging	O
to	O
treat	O
the	O
abnormal	O
brain	O
tissue	O
or	O
a	O
tumor,	O
including	O
brain	O
tumors	O
and	O
non-central	O
nervous	O
system	O
tumors	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
novel	O
piperazine	O
amide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
to	O
R11,	O
W,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O
These	O
compounds	O
bind	O
to	O
LXR	B-GENE
alpha	I-GENE
and	O
LXR	B-GENE
beta	I-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


Novel	O
thienopyridine	O
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1,	O
R2,	O
R3	O
and	O
Y	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1,	O
are	O
HSP90	B-GENE
inhibitors	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
the	O
inhibition,	O
regulation	O
and	O
/	O
or	O
modulation	O
of	O
HSP90	B-GENE
plays	O
a	O
role	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
spiro-benzo	O
[	O
C	O
]	O
chromene	O
derivatives,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
one	O
or	O
more	O
estrogen	B-GENE
receptors	I-GENE
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
the	O
depletion	O
of	O
estrogen	O
such	O
as	O
hot	O
flashes,	O
vaginal	O
dryness,	O
osteopenia	O
and	O
osteoporosis	O
;	O
hormone	O
sensitive	O
cancers	O
and	O
hyperplasia	O
of	O
the	O
breast,	O
endometrium,	O
cervix	O
and	O
prostate	O
;	O
endometriosis,	O
uterine	O
fibroids,	O
osteoarthritis	O
and	O
as	O
contraceptive	O
agents,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
progestogen	O
or	O
progestogen	O
antagonist	O
.	O


Substituted	O
N—	O
[	O
N-	O
(	O
sulphonylphenyl	O
)	O
sulfonyl-prolyl	O
]	O
-phenylalanine	O
derivatives	O
of	O
the	O
present	O
invention	O
are	O
antagonists	O
of	O
the	O
VLA-4	B-GENE
integrin	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
VLA-4-binding	O
and	O
cell	O
adhesion	O
and	O
activation	O
.	O
Moreover,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
demonstrate	O
significant	O
receptor	O
occupancy	O
of	O
VLA-4	O
bearing	O
cells	O
after	O
oral	O
administration	O
and	O
are	O
suitable	O
for	O
once-,	O
twice-,	O
or	O
thrice-a-day	O
oral	O
administration	O
.	O
This	O
invention	O
also	O
relates	O
to	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
such	O
compounds	O
.	O


The	O
present	O
specification	O
provides,	O
inter	O
alia,	O
methods	O
of	O
using	O
Wnt	B-GENE
and	O
FZD	B-GENE
proteins,	O
genes,	O
FZD	B-GENE
and	O
Wnt-specific	O
antibodies	O
and	O
probes	O
in	O
diagnosis	O
and	O
treatment	O
of	O
cancer	O
and	O
for	O
screening	O
test	O
compounds	O
for	O
an	O
ability	O
to	O
treat	O
cancer	O
.	O
Also	O
disclosed	O
are	O
compounds	O
useful	O
for	O
treating	O
cancer	O
such	O
as	O
liver	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
episomal	O
structure	O
expressing	O
a	O
functional	O
oncogene,	O
whereby	O
said	O
oncogene	O
is	O
a	O
fusion	O
gene	O
of	O
two	O
chromosomal	O
gene	O
fragments	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
a	O
NUP214-ABL1	B-GENE
fusion	O
product,	O
important	O
in	O
the	O
development	O
of	O
T-cell	O
acute	O
lymphoblastic	O
leukemia,	O
to	O
methods	O
to	O
detect	O
the	O
fusion	O
and	O
to	O
methods	O
to	O
prevent	O
the	O
oncogenic	O
activity	O
of	O
said	O
fusion	O
product	O
.	O


Provided	O
herein	O
are	O
compounds,	O
compositions	O
and	O
methods	O
for	O
decreasing	O
NFκB	B-GENE
DNA-binding	O
activity	O
in	O
a	O
patient	O
comprising	O
administering	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
or	O
composition	O
of	O
the	O
application	O
to	O
the	O
patient	O
to	O
reduce,	O
alleviate	O
or	O
treat	O
various	O
gastrointestinal	O
diseases,	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O


[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
which	O
may	O
be	O
used	O
in	O
treating	O
diseases	O
in	O
which	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11β-HSD1	B-GENE
)	O
is	O
concerned,	O
especially	O
diabetes	O
and	O
insulin	B-GENE
resistance	O
.	O
	O
	O
	O
	O
[	O
Means	O
for	O
Solution	O
]	O
It	O
was	O
found	O
that	O
a	O
triazole	O
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
in	O
which	O
the	O
3-position	O
of	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
and	O
the	O
5-position	O
is	O
substituted	O
with	O
a	O
lower	O
alkyl,	O
cycloalkyl	O
or	O
the	O
like,	O
has	O
a	O
strong	O
11β-HSD1-inhibitory	O
activity	O
.	O
In	O
addition,	O
since	O
the	O
triazole	O
derivative	O
of	O
the	O
present	O
invention	O
shows	O
excellent	O
blood	O
glucose-lowering	O
action,	O
it	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diabetes	O
and	O
insulin	B-GENE
resistance	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
immunologic	O
diseases	O
or	O
pathological	O
conditions	O
involving	O
an	O
immunologic	O
component	O
using	O
certain	O
Lck	B-GENE
inhibitors	O
already	O
known	O
as	O
kinase	B-GENE
inhibitors	O
for	O
therapy	O
in	O
oncology,	O
optionally	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
drugs	O
selected	O
from	O
NSAIDs,	O
steroids,	O
DMARDs,	O
immunsuppressives,	O
biologic	O
response	O
modifiers	O
and	O
antinfectives,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
Lck	B-GENE
inhibitors	O
together	O
with	O
said	O
other	O
drugs,	O
and	O
the	O
use	O
of	O
the	O
Lck	B-GENE
inhibitors	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
immunologic	O
diseases	O
or	O
pathological	O
conditions	O
involving	O
an	O
immunologic	O
component	O
.	O


A	O
method	O
of	O
diagnosing	O
melanoma	O
and	O
/	O
or	O
monitoring	O
melanoma	O
progression,	O
in	O
particular	O
for	O
determining	O
whether	O
the	O
melanoma	O
is	O
likely	O
to	O
have	O
metastatic	O
capabilities,	O
in	O
a	O
subject	O
includes	O
the	O
steps	O
of	O
in	O
a	O
test	O
sample	O
determining	O
the	O
methylation	O
status	O
of	O
FABP5	B-GENE
wherein	O
methylation	O
of	O
the	O
gene	O
indicates	O
a	O
positive	O
diagnosis	O
of	O
melanoma	O
and	O
/	O
or	O
increased	O
methylation	O
of	O
the	O
gene	O
indicates	O
the	O
progression	O
of	O
melanoma	O
.	O
Methods	O
of	O
monitoring	O
melanoma	O
progression	O
may	O
also	O
incorporate	O
measuring	O
the	O
expression	O
levels	O
of	O
FABP5,	O
with	O
low	O
levels	O
of	O
expression	O
indicating	O
a	O
positive	O
diagnosis	O
of	O
melanoma	O
and	O
/	O
or	O
lower	O
levels	O
of	O
expression	O
being	O
indicative	O
of	O
progression	O
of	O
melanoma	O
.	O
Methods	O
of	O
treating	O
melanoma	O
in	O
a	O
subject	O
comprise	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
DNA	B-GENE
methyltransferase	I-GENE
inhibitor	O
or	O
a	O
histone	B-GENE
deacetylase	I-GENE
inhibitor	O
to	O
the	O
subject	O
such	O
that	O
expression	O
of	O
FABP5	B-GENE
is	O
increased	O
.	O
Microarrays	O
for	O
use	O
in	O
these	O
diagnostic	O
methods	O
and	O
compound	O
screening	O
methods	O
based	O
around	O
monitoring	O
methylation	O
and	O
/	O
or	O
expression	O
of	O
FABP5	B-GENE
are	O
also	O
envisaged	O
.	O


The	O
invention	O
described	O
herein	O
relates	O
to	O
diagnostic	O
and	O
treatment	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders,	O
for	O
example	O
cancers,	O
involving	O
cells	O
that	O
overexpress	O
MDR-1,	O
and	O
methods	O
of	O
decreasing	O
the	O
incidence	O
of	O
CNS	O
complications	O
that	O
are	O
often	O
associated	O
with	O
CML	O
patients	O
that	O
have	O
been	O
administered	O
imatinib	O
or	O
other	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitors	O
.	O


This	O
invention	O
provides	O
methods	O
of	O
inducing	O
cell	O
death	O
with	O
Flavivirus	O
or	O
Pestivirus	O
capsid	B-GENE
protein,	O
such	O
as	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
capsid	B-GENE
protein,	O
and	O
functional	O
fragments	O
thereof	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
patients	O
suffering	O
from	O
diseases	O
characterized	O
by	O
hyperproliferating	O
cells	O
by	O
administering	O
pharmaceutical	O
compositions	O
comprising	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
capsid	B-GENE
or	O
other	O
protein	O
or	O
a	O
nucleic	O
acid	O
molecule	O
encoding	O
the	O
same	O
.	O
Methods	O
of	O
identifying	O
compounds	O
which	O
have	O
anti-viral	O
and	O
/	O
or	O
anti-WNV	O
and	O
/	O
or	O
anti-Flavivirus	O
and	O
/	O
or	O
anti-Pestivirus	O
capsid	B-GENE
or	O
other	O
protein	O
activity	O
are	O
disclosed	O
.	O
The	O
invention	O
also	O
provides	O
vaccine	O
compositions	O
comprising	O
capsid	B-GENE
or	O
other	O
proteins,	O
or	O
fragments	O
thereof,	O
or	O
nucleic	O
acids	O
encoding	O
same,	O
from	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
invention	O
also	O
provides	O
diagnostic	O
methods	O
and	O
kits	O
for	O
identifying	O
individuals	O
exposed	O
to	O
WNV	O
or	O
other	O
viruses	O
including	O
Flavivirus	O
or	O
Pestivirus	O
.	O


[	O
Problems	O
to	O
be	O
Solved	O
]	O
An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
methods	O
for	O
regenerating	O
or	O
repairing	O
damaged	O
tissues	O
using	O
adrenomedullin	B-GENE
.	O
Another	O
objective	O
is	O
to	O
provide	O
pharmaceutical	O
agents	O
that	O
comprise	O
adrenomedullin	B-GENE
as	O
an	O
active	O
ingredient	O
for	O
regenerating	O
or	O
repairing	O
damaged	O
tissues	O
.	O
	O
	O
	O
	O
[	O
Means	O
for	O
Solving	O
the	O
Problems	O
]	O
To	O
solve	O
the	O
above	O
problems,	O
the	O
present	O
inventors	O
administered	O
adrenomedullin	B-GENE
(	O
hereinafter	O
indicated	O
as	O
AM	B-GENE
)	O
or	O
physiological	O
saline	O
to	O
C57BL	O
/	O
6	O
mice,	O
and	O
counted	O
the	O
numbers	O
of	O
mononuclear	O
cells	O
and	O
Sca-1-positive	O
cells	O
in	O
the	O
blood	O
.	O
The	O
result	O
showed	O
that	O
AM	B-GENE
increased	O
the	O
numbers	O
of	O
mononuclear	O
cells	O
and	O
stem	O
cell	O
antigen-1-positive	O
cells	O
in	O
the	O
blood	O
.	O
It	O
was	O
also	O
shown	O
that	O
by	O
administering	O
AM	B-GENE
to	O
a	O
mouse	O
model	O
of	O
pulmonary	O
emphysema	O
and	O
a	O
rat	O
model	O
of	O
acute	O
myocardial	O
infarction,	O
the	O
quantity	O
of	O
bone	O
marrow-derived	O
cells	O
that	O
migrated	O
and	O
settled	O
into	O
the	O
damaged	O
tissues	O
increased,	O
and	O
the	O
recruited	O
bone	O
marrow	O
cells	O
differentiated	O
into	O
blood	O
vessels,	O
alveoli,	O
and	O
cardiac	O
muscle	O
at	O
the	O
lesion	O
sites	O
.	O
Further,	O
decrease	O
in	O
infarct	O
size,	O
suppression	O
of	O
the	O
enlargement	O
of	O
alveolar	O
diameter,	O
and	O
improvement	O
of	O
organ	O
functions	O
were	O
confirmed	O
in	O
the	O
models	O
of	O
myocardial	O
infarction	O
and	O
pulmonary	O
emphysema	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
derivatives	O
capable	O
of	O
increasing	O
the	O
synthesis	O
and	O
/	O
or	O
the	O
release	O
of	O
neurotrophic	O
factors,	O
and	O
therefore	O
able	O
to	O
be	O
used	O
as	O
a	O
human	O
or	O
veterinary	O
medicinal	O
product	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
the	O
derivatives	O
and	O
also	O
to	O
the	O
intermediates	O
required	O
for	O
their	O
synthesis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
substituted	O
nicotinamides	O
.	O
These	O
compounds	O
can	O
inhibit	O
histone	B-GENE
deacetylase	I-GENE
and	O
are	O
suitable	O
for	O
use	O
in	O
selectively	O
inducing	O
terminal	O
differentiation,	O
and	O
arresting	O
cell	O
growth	O
and	O
/	O
or	O
apoptosis	O
of	O
neoplastic	O
cells,	O
thereby	O
inhibiting	O
proliferation	O
of	O
such	O
cells	O
.	O
Thus,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
treating	O
a	O
patient	O
having	O
a	O
tumor	O
characterized	O
by	O
proliferation	O
of	O
neoplastic	O
cells	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
may	O
also	O
be	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
TRX-mediated	O
diseases,	O
such	O
as	O
autoimmune,	O
allergic	O
and	O
inflammatory	O
diseases,	O
and	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
such	O
as	O
neurodegenerative	O
diseases	O
.	O
The	O
present	O
invention	O
further	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
instant	O
invention	O
and	O
safe	O
dosing	O
regimens	O
of	O
these	O
pharmaceutical	O
compositions,	O
which	O
are	O
easy	O
to	O
follow,	O
and	O
which	O
result	O
in	O
a	O
therapeutically	O
effective	O
amount	O
of	O
these	O
compounds	O
in	O
vivo	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
VEGF	B-GENE
production	O
or	O
secretion	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
associated	O
with	O
abnormal	O
levels	O
of	O
VEGF	B-GENE
production	O
or	O
secretion	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
which	O
are	O
effective	O
inhibitors	O
of	O
histone	B-GENE
deacetylases	I-GENE
.	O


The	O
present	O
invention	O
describes	O
methods	O
of	O
retarding	O
the	O
development	O
of	O
visceral	O
and	O
somatic	O
hypersensitivities	O
in	O
an	O
individual	O
.	O
Further,	O
the	O
present	O
invention	O
describes	O
a	O
potentially	O
important	O
role	O
for	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
1	O
(	O
TRPV1	B-GENE
)	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
chronic	O
visceral	O
hypersensitivity	O
and	O
its	O
role	O
in	O
development	O
of	O
irritable	O
bowel	O
syndrome	O
.	O


Provided	O
are	O
muscarinic	B-GENE
receptor	I-GENE
antagonists,	O
which	O
can	O
be	O
useful	O
in	O
treating	O
various	O
diseases	O
of	O
the	O
respiratory,	O
urinary	O
and	O
gastrointestinal	O
systems	O
mediated	O
through	O
muscarinic	B-GENE
receptors	I-GENE
.	O
Also	O
provided	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
for	O
treating	O
diseases	O
mediated	O
through	O
muscarinic	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
Tartrate,	O
Mono-Hydrochloride,	O
Malonate	O
and	O
p-Toluenesulfonate	O
Salts	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
solvates	O
thereof,	O
or	O
crystalline	O
forms	O
thereof	O
;	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
the	O
Salts,	O
including	O
crystalline	O
forms	O
thereof,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
;	O
and	O
to	O
the	O
use	O
of	O
the	O
Salts,	O
including	O
crystalline	O
forms	O
thereof,	O
for	O
treating	O
a	O
patient	O
suffering	O
from,	O
or	O
subject	O
to,	O
a	O
pathological	O
condition	O
capable	O
of	O
being	O
ameliorated	O
by	O
inhibiting	O
IKK-2,	O
and	O
methods	O
related	O
thereto	O
.	O


The	O
subject	O
invention	O
provides	O
derivatives	O
of	O
propargylamino	O
indan	O
(	O
PAI	O
)	O
and	O
propargylamino	O
tetralin	O
that	O
selectively	O
inhibit	O
monoamine	B-GENE
oxidase	I-GENE
(	O
MAO	B-GENE
)	O
in	O
the	O
brain,	O
having	O
the	O
structure	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
is	O
OC	O
(	O
O	O
)	O
R9	O
and	O
R2	O
is	O
H,	O
	O
	O
	O
wherein	O
R9	O
is	O
branched	O
or	O
unbranched	O
C1	O
to	O
C6	O
alkyl,	O
aryl,	O
or	O
aralkyl,	O
or	O
	O
R1	O
is	O
OC	O
(	O
O	O
)	O
R4	O
and	O
R2	O
is	O
OC	O
(	O
O	O
)	O
R4,	O
	O
wherein	O
R4	O
is	O
branched	O
or	O
unbranched	O
C1	O
to	O
C6	O
alkyl,	O
aryl,	O
aralkyl	O
or	O
NR5R6,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R5	O
and	O
R6	O
are	O
each	O
independently	O
H,	O
C1	O
to	O
C8	O
alkyl,	O
C6	O
to	O
C12	O
aryl,	O
C6	O
to	O
C12	O
aralkyl	O
or	O
C6	O
to	O
C12	O
cycloalkyl,	O
each	O
optionally	O
substituted	O
;	O
	O
	O
wherein	O
R3	O
is	O
H	O
or	O
C1	O
to	O
C6	O
alkyl	O
;	O
wherein	O
n	O
is	O
0	O
or	O
1	O
;	O
and	O
wherein	O
m	O
is	O
1	O
or	O
2,	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
Additionally,	O
the	O
subject	O
invention	O
provides	O
methods	O
of	O
treating	O
neurological	O
disorders	O
using	O
these	O
compounds,	O
uses	O
of	O
these	O
compounds	O
for	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
neurological	O
disorders	O
and	O
processes	O
for	O
synthesis	O
of	O
these	O
compounds	O
.	O


This	O
invention	O
provides	O
a	O
method	O
for	O
regulating	O
migration	O
of	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
nervous	O
system	O
of	O
a	O
mammal	O
.	O
The	O
method	O
comprises	O
providing	O
a	O
mammal	O
with	O
TNR,	O
a	O
biologically	O
active	O
fragment	O
of	O
TNR,	O
or	O
a	O
TNR	B-GENE
agonist	O
in	O
an	O
amount	O
sufficient	O
to	O
direct	O
migration	O
of	O
the	O
neuronal	O
progenitor	O
cells	O
.	O
The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
neurological	O
diseases	O
by	O
replenishing	O
diseased,	O
damaged,	O
or	O
destroyed	O
neural	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
or	O
in	O
the	O
peripheral	O
nervous	O
system	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
making,	O
delivering	O
and	O
using	O
formulations	O
that	O
combine	O
a	O
therapeutically	O
active	O
agent	O
(	O
s	O
)	O
(	O
such	O
as	O
for	O
example	O
a	O
Rho	B-GENE
antagonist	O
(	O
s	O
)	O
)	O
and	O
a	O
flowable	O
carrier	O
component	O
capable	O
of	O
forming	O
a	O
therapeutically	O
acceptable	O
matrix	O
in	O
vivo	O
(	O
such	O
as	O
for	O
example	O
tissue	O
adhesives	O
)	O
,	O
to	O
injured	O
nerves	O
to	O
promote	O
repair	O
and	O
regeneration	O
and	O
regrowth	O
of	O
injured	O
(	O
mammalian	O
)	O
neuronal	O
cells,	O
e	O
.	O
g	O
.	O
for	O
facilitating	O
axon	O
growth	O
at	O
a	O
desired	O
lesion	O
site	O
.	O
Preferred	O
active	O
agents	O
are	O
known	O
Rho	B-GENE
antagonists	O
such	O
as	O
for	O
example	O
C3,	O
chimeric	O
C3	O
proteins,	O
etc	O
.	O
or	O
substances	O
selected	O
from	O
among	O
known	O
trans-4-amino	O
(	O
alkyl	O
)	O
-1-pyridylcarbamoylcyclohexane	O
compounds	O
or	O
Rho	B-GENE
kinase	I-GENE
inhibitors	O
.	O
The	O
system	O
for	O
example	O
may	O
deliver	O
an	O
antagonist	O
(	O
s	O
)	O
in	O
a	O
tissue	O
adhesive	O
such	O
as,	O
for	O
example,	O
a	O
fibrin	O
glue	O
or	O
a	O
collagen	B-GENE
gel	O
to	O
create	O
a	O
delivery	O
matrix	O
in	O
situ	O
.	O
A	O
kit	O
and	O
methods	O
of	O
stimulating	O
neuronal	O
regeneration	O
are	O
also	O
included	O
.	O


This	O
invention	O
relates	O
to	O
gene	O
polypeptides	O
and	O
polynucleotides	O
that	O
encode	O
proteins	O
of	O
the	O
Nogo-66	B-GENE
receptor	I-GENE
(	O
NgR	B-GENE
)	O
family	O
and	O
are	O
therefore	O
called	O
NgR	B-GENE
homologue	I-GENE
1	I-GENE
(	O
NgRH1	B-GENE
)	O
.	O
The	O
invention	O
further	O
relates	O
to	O
their	O
use	O
in	O
identifying	O
compounds	O
that	O
may	O
be	O
agonists	O
or	O
antagonists	O
that	O
are	O
potentially	O
useful	O
in	O
regeneration	O
and	O
protection	O
of	O
the	O
nervous	O
system,	O
and	O
to	O
production	O
of	O
NgRH1	B-GENE
polypepfldes,	O
derivatives,	O
and	O
antibodies	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
a	O
tautomer	O
or	O
stereoisomer	O
thereof,	O
or	O
a	O
salt	O
thereof,	O
wherein	O
ring	O
B	O
and	O
the	O
pyrimidine	O
to	O
which	O
it	O
is	O
fused,	O
R4,	O
R5,	O
R6	O
and	O
R7	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
and	O
the	O
claims,	O
are	O
effective	O
inhibitors	O
of	O
the	O
Pi3K/Akt	B-GENE
pathway	O
.	O


Provided	O
are	O
tetrakis-quaternary	O
ammonium	O
compounds	O
which	O
are	O
modulators	O
of	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
.	O
Also	O
provided	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
modulating	O
the	O
function	O
of	O
a	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptor,	O
and	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders,	O
substance	O
use	O
and	O
/	O
or	O
abuse,	O
and	O
or	O
gastrointestinal	O
tract	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
designed	O
for	O
the	O
treatment,	O
management	O
or	O
prevention	O
of	O
cancer	O
.	O
The	O
methods	O
of	O
the	O
invention	O
comprise	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
antagonists	O
of	O
Integrin	B-GENE
αVβ3	I-GENE
alone	O
or	O
in	O
combination	O
with	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
other	O
agents	O
useful	O
for	O
cancer	O
therapy	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
antagonists	O
of	O
Integrin	B-GENE
αVβ3	I-GENE
and	O
/	O
or	O
one	O
or	O
more	O
other	O
agents	O
useful	O
for	O
cancer	O
therapy	O
.	O
In	O
particular,	O
the	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
treatment	O
and	O
prevention	O
of	O
cancer	O
by	O
the	O
administration	O
of	O
a	O
therapeutically	O
or	O
prophylactically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
antagonists	O
of	O
Integrin	B-GENE
αVβ3	I-GENE
alone	O
or	O
in	O
combination	O
with	O
standard	O
and	O
experimental	O
therapies	O
for	O
treatment	O
or	O
prevention	O
of	O
cancer	O
.	O
Also	O
included	O
are	O
methods	O
for	O
screening	O
for	O
epitope-specific	O
Integrin	B-GENE
αVβ3	I-GENE
antagonists	O
which	O
can	O
be	O
used	O
according	O
to	O
the	O
methods	O
of	O
the	O
invention	O
.	O
In	O
addition,	O
methods	O
for	O
facilitating	O
the	O
use	O
of	O
Integrin	B-GENE
αVβ3	I-GENE
antagonists	O
in	O
the	O
analysis	O
of	O
Integrin	B-GENE
αVβ3	I-GENE
expression	O
in	O
biopsies	O
of	O
animal	O
model	O
and	O
clinical	O
study	O
samples	O
are	O
also	O
contemplated	O
.	O


Methods	O
for	O
using	O
death	B-GENE
receptor	I-GENE
ligands,	O
such	O
as	O
Apo-2	B-GENE
ligand	I-GENE
/	O
TRAIL	B-GENE
polypeptides	O
or	O
death	B-GENE
receptor	I-GENE
antibodies,	O
and	O
EGFR	B-GENE
inhibitors	O
to	O
treat	O
pathological	O
conditions	O
such	O
as	O
cancer	O
are	O
provided	O
.	O
Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
Apo2L	B-GENE
/	O
TRAIL	B-GENE
or	O
death	B-GENE
receptor	I-GENE
antibodies	O
such	O
as	O
DR5	B-GENE
antibodies	O
and	O
DR4	B-GENE
antibodies	O
in	O
combination	O
with	O
EGFR	B-GENE
inhibitors,	O
such	O
as	O
Tarceva™	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
diagnosing	O
epilepsy	O
in	O
a	O
mammal	O
by	O
detecting	O
ST3	B-GENE
β-galactoside	I-GENE
α-2,3-sialyltransferase	I-GENE
3	I-GENE
(	O
ST3Gal-III	B-GENE
)	O
activity	O
or	O
by	O
detecting	O
for	O
one	O
or	O
more	O
mutations	O
in	O
a	O
ST3Gal-III	B-GENE
gene	I-GENE
that	O
decrease	O
that	O
activity	O
of	O
a	O
ST3Gal-III	B-GENE
polypeptide	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
treating	O
an	O
epileptic	O
condition	O
associated	O
with	O
decreased	O
ST3Gal-III	B-GENE
activity	O
by	O
administering	O
one	O
or	O
more	O
agents	O
that	O
increase	O
the	O
activity	O
of	O
ST3Gal-III	B-GENE
.	O
Also	O
provided	O
are	O
methods	O
of	O
identifying	O
one	O
or	O
more	O
agents	O
that	O
increase	O
the	O
activity	O
of	O
ST3Gal-III	B-GENE
.	O


The	O
present	O
invention	O
discloses	O
Mnk	B-GENE
homologous	O
proteins	O
regulating	O
the	O
energy	O
homeostasis,	O
the	O
metabolism	O
of	O
triglycerides,	O
and	O
/	O
or	O
is	O
contributing	O
to	O
membrane	O
stability	O
and	O
/	O
or	O
function	O
of	O
organelles,	O
and	O
polynucleotides,	O
which	O
identify	O
and	O
encode	O
the	O
proteins	O
disclosed	O
in	O
this	O
invention	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
sequences	O
in	O
the	O
diagnosis,	O
study,	O
prevention,	O
and	O
treatment	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
body-weight	O
regulation	O
and	O
thermogenesis,	O
for	O
example,	O
but	O
not	O
limited	O
to,	O
metabolic	O
diseases	O
such	O
as	O
obesity,	O
as	O
well	O
as	O
related	O
disorders	O
such	O
as	O
eating	O
disorder,	O
cachexia,	O
diabetes	O
mellitus,	O
hypertension,	O
coronary	O
heart	O
disease,	O
hypercholesterolemia,	O
dyslipidemia,	O
osteoarthritis,	O
gallstones,	O
and	O
sleep	O
apnea,	O
and	O
disorders	O
related	O
to	O
ROS	O
defence,	O
such	O
as	O
diabetes	O
mellitus,	O
neurodegenerative	O
disorders,	O
and	O
cancer,	O
e	O
.	O
g	O
.	O
cancers	O
of	O
the	O
reproductive	O
organs,	O
and	O
others	O
.	O


The	O
present	O
invention	O
relates	O
to	O
nucleic	O
acid	O
molecules	O
such	O
as	O
ribozymes,	O
DNAzymes,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
and	O
antisense	O
which	O
modulate	O
the	O
synthesis,	O
expression	O
and	O
/	O
or	O
stability	O
of	O
an	O
mRNA	O
encoding	O
one	O
or	O
more	O
receptors	O
of	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor,	O
such	O
as	O
flt-1	B-GENE
(	O
VEGFR1	B-GENE
)	O
and	O
/	O
or	O
KDR	B-GENE
(	O
VEGFR2	B-GENE
)	O
.	O
Nucleic	O
acid	O
molecules	O
and	O
methods	O
for	O
the	O
inhibition	O
of	O
angiogenesis	O
and	O
treatment	O
of	O
cancer	O
and	O
other	O
conditions	O
associated	O
with	O
VEGF-R	B-GENE
are	O
provided,	O
optionally	O
in	O
conjunction	O
with	O
other	O
therapeutic	O
agents	O
such	O
as	O
interferons	O
.	O


Aromatase	B-GENE
inhibitors	O
(	O
AIs	O
)	O
are	O
disclosed	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
post-menopausal	O
breast	O
cancer	O
.	O
New	O
AIs	O
derived	O
from	O
natural	O
products	O
are	O
disclosed	O
that	O
are	O
evaluated	O
for	O
clinical	O
utility	O
for	O
treating	O
post-menopausal	O
breast	O
cancer	O
and	O
may	O
also	O
act	O
as	O
chemopreventive	O
agents	O
for	O
preventing	O
breast	O
cancer	O
.	O
Several	O
pure	O
compounds	O
demonstrated	O
AI	O
activity	O
using	O
a	O
noncellular,	O
enzyme-based	O
microsomal	O
and	O
a	O
cell-based	O
aromatase	B-GENE
assay	O
.	O
Correlations	O
are	O
made	O
between	O
structural	O
classes	O
with	O
levels	O
of	O
aromatase	B-GENE
inhibition	O
.	O
The	O
disclosure	O
may	O
be	O
utilized	O
to	O
direct	O
synthetic	O
modification	O
of	O
natural	O
product	O
scaffolds	O
to	O
enhance	O
aromatase	B-GENE
inhibition	O
or	O
to	O
standardize	O
botanical	O
dietary	O
supplements	O
for	O
increased	O
aromatase	B-GENE
inhibition	O
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
substituted	O
nitrogen-containing	O
heterobicyclic	O
compounds	O
of	O
general	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
B,	O
X1	O
to	O
X3	O
and	O
R1	O
to	O
R5	O
are	O
defined	O
as	O
in	O
claim	O
1,	O
the	O
tautomers,	O
the	O
enantiomers,	O
the	O
diastereomers,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases,	O
which	O
have	O
valuable	O
properties	O
.	O
	O
	O
	O
	O
The	O
compounds	O
of	O
the	O
above	O
general	O
formula	O
I	O
as	O
well	O
as	O
the	O
tautomers,	O
the	O
enantiomers,	O
the	O
diastereomers,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases,	O
and	O
their	O
stereoisomers	O
have	O
valuable	O
pharmacological	O
properties,	O
particularly	O
an	O
antithrombotic	O
activity	O
and	O
a	O
factor	O
Xa-inhibiting	O
activity	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
sexual	O
dysfunction	O
.	O
The	O
methods	O
include	O
administering	O
an	O
effective	O
amount	O
of	O
nebivolol,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
e	O
.	O
g	O
.	O
a	O
PDE-5	B-GENE
inhibitor,	O
such	O
as	O
sildenafil	O
citrate	O
.	O
The	O
methods	O
of	O
the	O
present	O
invention	O
are	O
particularly	O
suited	O
to	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
arousal	O
disorder	O
.	O


The	O
patent	O
application	O
relates	O
to	O
new	O
heterocyclic	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
n	O
have	O
the	O
definitions	O
elucidated	O
in	O
more	O
detail	O
in	O
the	O
description,	O
to	O
a	O
process	O
for	O
preparing	O
them	O
and	O
to	O
the	O
use	O
of	O
these	O
C	O
compounds	O
as	O
medicaments,	O
particularly	O
as	O
aldosterone	B-GENE
synthase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
discloses	O
oxygenic	O
oxygenic	O
oxysterols	O
.	O
Also	O
disclosed,	O
agents	O
and	O
methods	O
for	O
protecting,	O
blocking	O
or	O
rescuing	O
marrow	O
stromal	O
cells	O
from	O
the	O
inhibitory	O
effects	O
of	O
oxidative	O
stress	O
on	O
their	O
osteoblastic	O
cellular	O
differentiation	O
.	O
Exemplary	O
agents	O
include	O
oxysterols,	O
rhBMP2,	O
alone	O
or	O
in	O
combination	O
which	O
are	O
demonstrated	O
to	O
specifically	O
combat	O
oxidative	O
stress	O
caused	O
by	O
inflammatory	O
oxidized	O
lipids,	O
such	O
as	O
xanthine	O
/	O
xanthine	O
oxidase	O
and	O
minimally	O
oxidized	O
LDL	O
.	O
The	O
synergistic	O
effects	O
of	O
oxysterols	O
and	O
bone	O
morphogenic	O
proteins	O
are	O
disclosed	O
.	O


The	O
invention	O
provides	O
a	O
nucleotide	O
sequence	O
that	O
encodes	O
an	O
HIV-1	B-GENE
gag	I-GENE
protein	I-GENE
or	O
fragment	O
thereof	O
containing	O
a	O
gag	O
epitope	O
and	O
a	O
second	O
HIV	O
antigen	O
or	O
a	O
fragment	O
encoding	O
an	O
epitope	O
of	O
said	O
second	O
HIV	O
antigen,	O
operably	O
linked	O
to	O
a	O
heterologous	O
promoter	O
.	O
Preferred	O
polynucleotide	O
sequences	O
further	O
encodes	O
nef	B-GENE
or	O
a	O
fragment	O
thereof	O
and	O
RT	B-GENE
or	O
a	O
fragment	O
thereof	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
compounds	O
that	O
display	O
retinoid	O
like	O
activities,	O
including	O
HB-EGF	B-GENE
(	O
Heparin	B-GENE
Binding	I-GENE
Epidermal	I-GENE
Growth	I-GENE
Factor	I-GENE
)	O
release	O
from	O
keratinocytes,	O
cell	O
proliferation,	O
and	O
epidermal	O
thickening	O
without	O
the	O
irritation	O
potentials,	O
such	O
as	O
release	O
of	O
interleukin	O
8	O
and	O
inhibition	O
of	O
terminal	O
differentiation	O
of	O
keratinocytes	O
.	O
	O
	O
	O
	O
This	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
a	O
compound	O
for	O
both	O
external	O
and	O
non-external	O
applications	O
.	O


The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
a	O
hepatic	O
disease,	O
for	O
reducing	O
fat	O
deposition	O
in	O
the	O
liver	O
and	O
for	O
inhibiting	O
fibrosis	O
of	O
the	O
liver	O
by	O
administering	O
a	O
compound	O
or	O
agent	O
that	O
modulates	O
an	O
adenosine	O
receptor,	O
in	O
particular,	O
an	O
inhibitor	O
or	O
antagonist	O
of	O
an	O
adenosine	O
receptor,	O
especially	O
an	O
A1	B-GENE
or	I-GENE
A2B	I-GENE
adenosine	B-GENE
receptor	I-GENE
antagonist	O
.	O


This	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
shown	O
below	O
.	O
Each	O
variable	O
in	O
formula	O
(	O
I	O
)	O
is	O
defined	O
in	O
the	O
specification	O
.	O
These	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
a	O
kinesin	B-GENE
Eg5	I-GENE
protein-mediated	O
disorder	O
.	O


Aspects	O
of	O
the	O
present	O
invention	O
relate	O
to	O
the	O
creation	O
of	O
mutant	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS3/4A	B-GENE
genes	O
encoding	O
proteins	O
with	O
altered	O
protease	B-GENE
activity	O
.	O
Embodiments	O
include	O
said	O
NS3/4A	B-GENE
genes,	O
HCV	O
peptides	O
encoded	O
by	O
said	O
nucleic	O
acids,	O
nucleic	O
acids	O
encoding	O
said	O
HCV	O
peptides,	O
antibodies	O
directed	O
to	O
said	O
peptides,	O
compositions	O
containing	O
said	O
nucleic	O
acids	O
and	O
peptides,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
using	O
the	O
aforementioned	O
compositions	O
including,	O
but	O
not	O
limited	O
to,	O
diagnostics	O
and	O
medicaments	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
HCV	O
infection	O
.	O


This	O
invention	O
is	O
in	O
the	O
field	O
of	O
cancer-associated	O
genes	O
.	O
Specifically	O
it	O
relates	O
to	O
methods	O
for	O
detecting	O
cancer	O
or	O
the	O
likelihood	O
of	O
developing	O
cancer	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
expression	O
of	O
a	O
PRLR	B-GENE
gene	O
or	O
protein	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
and	O
molecules	O
for	O
upregulating	O
or	O
downregulating	O
PRLR	B-GENE
gene	O
expression	O
and	O
PRLR	B-GENE
protein	O
activity	O
.	O


Methods	O
of	O
antagonizing	O
MIF	B-GENE
activity	O
using	O
ibudilast	O
are	O
described	O
.	O
Also	O
described	O
are	O
methods	O
of	O
screening	O
for	O
MIF	B-GENE
antagonists	O
.	O
These	O
agents	O
can	O
be	O
used	O
for	O
treating	O
addictions,	O
including	O
drug	O
and	O
behavioral	O
addictions,	O
as	O
well	O
as	O
for	O
treating	O
neuropathic	O
pain	O
.	O


The	O
invention	O
encompasses	O
novel	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
derivatives	O
thereof,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
diseases	O
mediated	O
by	O
B1	B-GENE
bradykinin	I-GENE
receptor	I-GENE
.	O


Methods	O
and	O
products	O
for	O
the	O
attenuation	O
or	O
treatment	O
of	O
pain	O
and	O
the	O
reduction	O
of	O
nociception	O
are	O
described	O
.	O
The	O
methods	O
an	O
products	O
are	O
based	O
on	O
the	O
modulation	O
of	O
neuroglia-derived	O
BDNF	B-GENE
expression	O
or	O
activity	O
.	O
Also	O
described	O
herein	O
are	O
commercial	O
packages	O
and	O
uses	O
based	O
on	O
such	O
modulation	O
.	O
Related	O
methods	O
for	O
identifying	O
or	O
characterizing	O
compounds	O
for	O
the	O
treatment	O
of	O
pain	O
and	O
the	O
reduction	O
of	O
nociception	O
are	O
also	O
described	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
are	O
inhibitors	O
of	O
cysteine	O
proteases,	O
in	O
particular,	O
cathepsins	B-GENE
B,	I-GENE
K,	I-GENE
L,	I-GENE
F,	I-GENE
and	I-GENE
S	I-GENE
and	I-GENE
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
mediated	O
by	O
these	O
proteases	O
.	O
The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
processes	O
for	O
preparing	O
them	O
.	O
Wherein	O
R3	O
is	O
-alkylene-SO2NR5R6	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
T	B-GENE
type	I-GENE
calcium	I-GENE
channel	I-GENE
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
,	O
the	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
in	O
a	O
mammal	O
associated	O
with	O
influx	O
of	O
extracellular	O
calcium	O
via	O
T	B-GENE
type	I-GENE
calcium	I-GENE
channels,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
	O
	O
	O
	O
R1	O
is	O
C1-C4	O
alkyl,	O
hydroxy,	O
or	O
C1-C4	O
alkoxy	O
;	O
	O
	O
	O
	O
Z	O
is	O
NH,	O
NCH3,	O
O,	O
S,	O
or	O
CH2	O
;	O
	O
	O
	O
	O
Y	O
is	O
NH,	O
O,	O
or	O
CH2	O
with	O
the	O
proviso	O
that	O
Y	O
and	O
Z	O
are	O
not	O
the	O
same	O
;	O
	O
	O
	O
	O
R2	O
is	O
H,	O
halo,	O
NH2,	O
C1-C4	O
alkyl,	O
hydroxy,	O
or	O
C1-C4	O
alkoxy	O
;	O
	O
	O
	O
	O
m	O
and	O
n	O
are	O
independently	O
selected	O
from	O
integers	O
ranging	O
from	O
1-5	O
with	O
the	O
proviso	O
that	O
m+n	O
=	O
an	O
integer	O
ranging	O
from	O
2-9	O
;	O
and	O
	O
	O
	O
	O
R3	O
is	O
H,	O
halo,	O
NH2,	O
C1-C4	O
alkyl,	O
hydroxy,	O
or	O
C1-C4	O
alkoxy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
delivery	O
systems	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
microporous	O
scaffolds	O
having	O
thereon	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
extracellular	B-GENE
matrix	I-GENE
proteins,	O
exendin-4	B-GENE
)	O
and	O
biological	O
material	O
(	O
e	O
.	O
g	O
.	O
,	O
pancreatic	O
islet	O
cells	O
)	O
.	O
In	O
some	O
embodiments,	O
the	O
scaffolds	O
are	O
used	O
for	O
transplanting	O
biological	O
material	O
into	O
a	O
subject	O
.	O
In	O
some	O
embodiments,	O
the	O
scaffolds	O
are	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
type	O
1	O
diabetes	O
)	O
,	O
and	O
related	O
methods	O
(	O
e	O
.	O
g	O
.	O
,	O
diagnostic	O
methods,	O
research	O
methods,	O
drug	O
screening	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
first	O
amount	O
of	O
a	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
inhibitor	O
such	O
as	O
suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	O
thereof,	O
and	O
a	O
second	O
amount	O
of	O
one	O
or	O
more	O
anti-cancer	O
agents,	O
including	O
Bortezomib	O
.	O
The	O
HDAC	B-GENE
inhibitor	O
and	O
the	O
anti-cancer	O
agent	O
may	O
be	O
administered	O
to	O
comprise	O
therapeutically	O
effective	O
amounts	O
.	O
In	O
various	O
aspects,	O
the	O
effect	O
of	O
the	O
HDAC	B-GENE
inhibitor	O
and	O
the	O
anti-cancer	O
agent	O
may	O
be	O
additive	O
or	O
synergistic	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
which	O
are	O
appropriate	O
for	O
the	O
treatment	O
of	O
kinase,	O
e	O
.	O
g	O
.	O
PI3K-related,	O
diseases,	O
such	O
as	O
proliferative	O
diseases,	O
inflammatory	O
diseases,	O
obstructive	O
airways	O
disorders	O
and	O
transplantation	O
related	O
diseases	O
.	O


A	O
use	O
of	O
Vanillyl	O
alcohol	O
for	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
is	O
disclosed	O
in	O
accordance	O
with	O
the	O
present	O
invention	O
.	O
The	O
Vanillyl	O
alcohol	O
'	O
s	O
formula	O
is	O
4-hydroxy-3-methoxy-benzyl	O
alcohol	O
and	O
similitude	O
with	O
the	O
human	O
neurotransmitter	O
dopamine	O
.	O
The	O
Vanillyl	O
alcohol	O
has	O
dopamine	B-GENE
receptor	I-GENE
stimulant	O
and	O
which	O
is	O
applied	O
for	O
pharmaceutical	O
preparation	O
of	O
treating	O
Parkinson	O
'	O
s	O
disease	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
/	O
or	O
enantiomers	O
and	O
/	O
or	O
racemates	O
and	O
/	O
or	O
diastereomers	O
and	O
/	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
formed	O
with	O
acids	O
or	O
bases,	O
to	O
the	O
process	O
for	O
their	O
preparation,	O
to	O
the	O
intermediates	O
of	O
the	O
preparation	O
process,	O
to	O
the	O
pharmaceutical	O
formulations	O
containing	O
these	O
compounds	O
and	O
to	O
their	O
use	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
mGluR5	B-GENE
receptor-mediated	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O
These	O
novel	O
compounds	O
possess	O
CHK1	B-GENE
kinase	I-GENE
inhibitory	O
activity,	O
PDK1	B-GENE
inhibitory	O
activity	O
and	O
Pak	B-GENE
kinase	I-GENE
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
cancer	O
.	O


Muscarinic	B-GENE
Acetylcholine	I-GENE
receptor	I-GENE
antagonists	O
and	O
methods	O
of	O
using	O
them	O
are	O
provided	O
.	O


Provided	O
herein	O
are	O
oral	O
skin	O
care	O
supplements	O
and	O
nutraceutical	O
compositions	O
and	O
methods	O
of	O
use	O
for	O
improving	O
the	O
health	O
and	O
appearance	O
of	O
skin	O
.	O
Also	O
provided	O
are	O
nutraceutical	O
compositions	O
that,	O
when	O
orally	O
consumed	O
will	O
provide	O
nourishment	O
and	O
deliver	O
essential	O
skin	O
health	O
nutrition	O
to	O
the	O
skin	O
.	O
These	O
nutraceutical	O
compositions	O
include	O
omega	O
3	O
rich	O
oils,	O
vitamins,	O
lutein,	O
marine	O
collagen	B-GENE
and	O
elastin	B-GENE
.	O
Also	O
provided	O
is	O
a	O
unique	O
microalgae	O
oral	O
delivery	O
system	O
targeting	O
the	O
health	O
and	O
appearance	O
of	O
skin	O
.	O


The	O
present	O
invention	O
relates	O
to	O
phosphodiesterase	B-GENE
(PDE)	I-GENE
type	I-GENE
IV	I-GENE
selective	O
inhibitors	O
.	O
Processes	O
for	O
the	O
preparation	O
of	O
disclosed	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
the	O
disclosed	O
compounds	O
and	O
their	O
use	O
as	O
PDE	B-GENE
type	I-GENE
IV	I-GENE
selective	O
inhibitors	O
are	O
provided	O
.	O
Prepared	O
compounds	O
correspond	O
to	O
structure	O
XIV	O
Formula	O
(	O
XIV	O
)	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
hematological	O
disorders	O
such	O
as	O
anemia	O
and	O
thrombocytopenia,	O
whereby	O
a	O
TPO	B-GENE
mimetic	O
peptide	O
compound	O
is	O
administered	O
using	O
a	O
specified	O
dosing	O
regimen	O
.	O
The	O
dosing	O
regimen	O
involves	O
the	O
administration	O
of	O
the	O
TPO	B-GENE
mimetic	O
peptide	O
compound	O
within	O
a	O
specified	O
time	O
frame	O
surrounding	O
administration	O
of	O
a	O
chemotherapeutic	O
agent	O
.	O
The	O
dosing	O
regimen	O
also	O
involves	O
monitoring	O
subject	O
response	O
in	O
order	O
to	O
determine	O
future	O
course	O
of	O
treatment	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
modulating	O
the	O
activity	O
of	O
the	O
hedgehog	B-GENE
signaling	O
pathway	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
inhibiting	O
aberrant	O
growth	O
states	O
resulting	O
from	O
phenotypes	O
such	O
as	O
Ptc	O
loss-of-function,	O
hedgehog	B-GENE
gain-of-function,	O
smoothened	O
gain-of-function	O
or	O
Gli	O
gain-of-function,	O
comprising	O
contacting	O
a	O
cell	O
with	O
a	O
sufficient	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
use	O
of	O
oxindole	O
derivatives	O
of	O
formula	O
I,	O
as	O
a	O
free	O
base	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
[	O
Chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O
Please	O
see	O
paper	O
copy	O
.	O
]	O
wherein	O
R1,	O
R2,	O
R3,	O
m	O
and	O
n	O
are	O
as	O
defined	O
as	O
in	O
claim	O
1,	O
as	O
well	O
as	O
to	O
new	O
compounds,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
new	O
intermediates	O
used	O
in	O
the	O
preparation	O
thereof,	O
pharmaceutical	O
compositions	O
containing	O
said	O
therapeutically	O
active	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
active	O
compounds	O
in	O
therapy,	O
especially	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
dementia	O
related	O
diseases,	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
conditions	O
associated	O
with	O
glycogen	B-GENE
synthase	I-GENE
kinase-3	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
or	O
a	O
salt	O
thereof,	O
which	O
is	O
useful	O
as	O
a	O
CRTH2	B-GENE
antagonist,	O
especially	O
as	O
a	O
medicament	O
for	O
disorder	O
that	O
participates	O
eosinophil,	O
for	O
example,	O
allergic	O
disorder	O
such	O
as	O
asthma,	O
allergic	O
rhinitis,	O
allergic	O
dermatitis,	O
conjunctival	O
inflammation,	O
hives,	O
eosinophilic	O
bronchitis,	O
food	O
allergy,	O
inflammation	O
of	O
the	O
nasal	O
sinuses,	O
multiple	O
sclerosis,	O
angiitis,	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
the	O
like	O
.	O


A	O
reactive	B-GENE
oxygen	I-GENE
generating	I-GENE
enzyme	I-GENE
inhibitor	O
with	O
NO	O
donor	O
bioactivity,	O
e	O
.	O
g	O
.	O
,	O
nitrated	O
allopurinol,	O
is	O
useful	O
to	O
treat	O
heart	O
failure,	O
stable	O
angina,	O
ischemic	O
disorder,	O
ischemic	O
reperfusion	O
injury,	O
atherosclerosis,	O
sickle	O
cell	O
disease,	O
diabetes,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
ALS	O
and	O
asthma	O
and	O
to	O
obtain	O
proper	O
contraction	O
of	O
heart,	O
skeletal	O
and	O
smooth	O
muscle	O
.	O


This	O
application	O
discloses	O
6-Phenyl-imidazo	O
[	O
1,2-a	O
]	O
pyrazine	O
derivatives	O
according	O
to	O
generic	O
Formulae	O
I-V	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein,	O
variables	O
Q,	O
R,	O
Y1,	O
Y2,	O
Y3,	O
Y4,	O
n,	O
and	O
m	O
are	O
defined	O
as	O
described	O
herein,	O
which	O
inhibit	O
Btk	B-GENE
.	O
The	O
compounds	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
Btk	B-GENE
and	O
treat	O
diseases	O
associated	O
with	O
excessive	O
Btk	B-GENE
activity	O
.	O
The	O
compounds	O
are	O
further	O
useful	O
to	O
treat	O
inflammatory	O
and	O
auto	O
immune	O
diseases	O
associated	O
with	O
aberrant	O
B-cell	O
proliferation	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O
Also	O
disclosed	O
are	O
compositions	O
comprising	O
compounds	O
of	O
Formulae	O
I-V	O
and	O
at	O
least	O
one	O
carrier,	O
diluent	O
or	O
excipient	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
constitutive	O
activity	O
of	O
the	O
Hedgehog	B-GENE
pathway	O
in	O
non-small	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O
A	O
method	O
for	O
diagnosing	O
NSCLC	O
by	O
detecting	O
the	O
level	O
of	O
a	O
component	O
of	O
the	O
Hedgehog	B-GENE
pathway	O
is	O
provided,	O
as	O
is	O
a	O
method	O
for	O
identifying	O
subjects	O
that	O
will	O
respond	O
positively	O
to	O
treatment	O
with	O
a	O
Hedgehog	B-GENE
pathway	O
antagonist	O
.	O
Methods	O
for	O
treating	O
subjects	O
with	O
cancer	O
or	O
cancers	O
resistant	O
to	O
Hedgehog	B-GENE
pathway	O
antagonists	O
are	O
also	O
provided	O
.	O


There	O
are	O
provided	O
a	O
method	O
for	O
identifying	O
a	O
compound	O
having	O
an	O
anti-anxiety	O
effect,	O
an	O
inhibitor	O
of	O
a	O
function	O
of	O
a	O
protein	O
having	O
a	O
function	O
as	O
a	O
G-protein	B-GENE
coupled	I-GENE
receptor,	O
characterized	O
by	O
finding	O
the	O
protein	O
and	O
a	O
gene	O
encoding	O
the	O
protein	O
and	O
using	O
at	O
least	O
one	O
of	O
a	O
DNA	O
represented	O
by	O
the	O
nucleotide	O
sequence	O
of	O
this	O
gene	O
or	O
a	O
complementary	O
strand	O
thereof,	O
a	O
homologue	O
of	O
the	O
DNA,	O
a	O
protein	O
encoded	O
by	O
the	O
DNA,	O
and	O
a	O
cell	O
expressing	O
the	O
protein	O
encoded	O
by	O
the	O
DNA,	O
an	O
agent	O
and	O
a	O
method	O
for	O
improving	O
an	O
anxiety	O
condition,	O
a	O
method	O
and	O
an	O
agent	O
for	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
treatment	O
of	O
an	O
anxiety	O
disorder,	O
and	O
a	O
measurement	O
method	O
for	O
diagnosis	O
and	O
a	O
diagnostic	O
method	O
of	O
an	O
anxiety	O
disorder	O
.	O


Compounds	O
of	O
following	O
formula	O
(	O
I	O
)	O
are	O
provided	O
that	O
have	O
both	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
activity	O
and	O
PPARy	B-GENE
agonist	O
activity	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
treatment	O
of	O
diseases	O
with	O
the	O
compounds	O
including	O
type	O
2	O
diabetes,	O
insulin	B-GENE
resistance,	O
hyperinsulinemia,	O
hyperlipidemia,	O
hypertriglyceridemia,	O
metabolic	O
syndrome,	O
congestive	O
heart	O
failure,	O
and	O
hypertension	O
.	O


Disclosed	O
are	O
dispyrin	O
analogue	O
compounds	O
useful	O
as	O
H3	O
receptor	I-GENE
activity	O
modulators,	O
methods	O
of	O
making	O
same,	O
pharmaceutical	O
compositions	O
comprising	O
same,	O
and	O
methods	O
of	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
associated	O
with	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
activity	O
using	O
same	O
.	O
In	O
one	O
aspect,	O
the	O
disclosed	O
analogues	O
can	O
have	O
a	O
structure	O
represented	O
by	O
a	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
This	O
abstract	O
is	O
intended	O
as	O
a	O
scanning	O
tool	O
for	O
purposes	O
of	O
searching	O
in	O
the	O
particular	O
art	O
and	O
is	O
not	O
intended	O
to	O
be	O
limiting	O
of	O
the	O
present	O
invention	O
.	O


Methods	O
and	O
compositions	O
for	O
detecting	O
and	O
treating	O
diseases,	O
especially	O
cancer,	O
and	O
particularly	O
breast,	O
bladder,	O
colon,	O
gastrointestinal,	O
kidney,	O
liver,	O
lung,	O
melanoma,	O
ovary,	O
pancreatic,	O
pharyngeal,	O
prostate	O
cancer	O
and	O
renal,	O
associated	O
with	O
differential	O
expression	O
of	O
prominin-1	B-GENE
(	O
CD133	B-GENE
)	O
in	O
disease	O
cells	O
compared	O
to	O
healthy	O
cells	O
.	O
Also	O
provided	O
are	O
antagonists	O
or	O
agonists	O
of	O
prominin-1,	O
and	O
methods	O
for	O
screening	O
agents	O
that	O
modulate	O
the	O
prominin-1	B-GENE
level	O
or	O
activity	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O


The	O
present	O
invention	O
relates	O
to	O
agents	O
and	O
methods	O
for	O
growth-factor	B-GENE
receptor	I-GENE
activation	O
by	O
modulating	O
the	O
G-protein	B-GENE
mediated	O
signal	O
transduction	O
pathway	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
interleukin-17	B-GENE
inhibitor	O
and	O
/	O
or	O
of	O
at	O
least	O
one	O
IL-17	B-GENE
receptor	I-GENE
inhibitor,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting,	O
preventing	O
or	O
treating	O
gastric	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
wherein	O
:	O
R1,	O
R2,	O
Z1,	O
t,	O
and	O
ring	O
A	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
JNK,	O
such	O
as	O
diabetes,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
provides	O
a	O
triazole	O
compound	O
of	O
the	O
following	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
a	O
prodrug	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
above-mentioned	O
triazole	O
compound	O
has	O
superior	O
HSD1	B-GENE
inhibitory	O
activity,	O
and	O
is	O
useful	O
as	O
an	O
HSD1	B-GENE
inhibitor,	O
a	O
therapeutic	O
drug	O
of	O
diabetes	O
or	O
a	O
therapeutic	O
drug	O
of	O
obesity	O
or	O
a	O
therapeutic	O
drug	O
of	O
metabolic	O
syndrome	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
a	O
disease	O
caused	O
by	O
infection	O
by	O
a	O
eukaryotic	O
pathogen,	O
wherein	O
the	O
method	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
modulator	O
of	O
a	O
eukaryotic	O
pathogen	O
'	O
s	O
adenylyl	B-GENE
cyclase	I-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
useful	O
for	O
preventing	O
or	O
treating	O
a	O
disease,	O
with	O
the	O
compositions	O
containing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
modulator	O
of	O
a	O
eukaryotic	O
pathogen	O
'	O
s	O
adenylyl	B-GENE
cyclase	I-GENE
.	O
The	O
invention	O
also	O
provides	O
screening	O
methods	O
for	O
identifying	O
selective	O
modulators	O
of	O
a	O
eukaryotic	O
pathogen	O
'	O
s	O
adenylyl	B-GENE
cyclase	I-GENE
that	O
do	O
not	O
substantially	O
modulate	O
an	O
adenylyl	B-GENE
cyclase	I-GENE
of	O
the	O
subject	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
culturing	O
eukaryotic	O
pathogens	O
and	O
methods	O
for	O
inducing	O
the	O
pathogenic	O
state	O
in	O
vitro	O
.	O


Methods	O
are	O
provided	O
for	O
determining	O
in	O
vitro	O
whether	O
or	O
not	O
a	O
patient	O
will	O
respond	O
to	O
steroid	O
treatment	O
based	O
on	O
the	O
levels	O
of	O
interleukin-1	B-GENE
receptor	I-GENE
type	I-GENE
II	I-GENE
(	O
IL-1RII	B-GENE
)	O
in	O
a	O
sample	O
of	O
mononuclear	O
immune	O
cells	O
obtained	O
from	O
the	O
patient	O
before	O
steroid	O
treatment	O
and	O
/	O
or	O
on	O
the	O
change	O
in	O
IL-1RII	B-GENE
in	O
the	O
patient	O
'	O
s	O
mononuclear	O
immune	O
cells	O
in	O
response	O
to	O
an	O
in	O
vitro	O
steroid	O
challenge	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
melanin	B-GENE
concentrating	I-GENE
hormone	I-GENE
antagonist	O
compound	O
of	O
formula	O
I	O
:	O
wherein	O
“	O
-	O
-	O
-	O
”	O
is	O
absent	O
or	O
is	O
optionally	O
a	O
bond	O
;	O
q	O
is	O
1	O
or	O
2	O
;	O
R1	O
is	O
independently	O
selected	O
from	O
hydrogen,	O
—C1-C2	O
alkyl,	O
halo,	O
hydroxy,	O
—C1-C2	O
haloalkyl,	O
—C1-C3	O
alkoxy,	O
cyano,	O
—O—C3-C4	O
cycloalkyl,	O
and	O
—OC1-C2	O
haloalkyl	O
;	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
—C1-C3	O
alkyl,	O
hydroxy,	O
—C1-C3	O
alkoxy,	O
cyano,	O
—C1-C2	O
haloalkyl,	O
—OC1-C2	O
haloalkyl,	O
and	O
halo	O
;	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
—C1-C4	O
alkyl,	O
—C2-C4	O
haloalkyl,	O
—C2-C4	O
alkylOH,	O
—C3-C6	O
cycloalkyl,	O
—CH2C3-C6	O
cycloalkyl,	O
—C2-C4	O
alkyl-O—C1-C4	O
alkyl,	O
—C	O
(	O
O	O
)	O
C1-C4	O
alkyl,	O
—C	O
(	O
O	O
)	O
C1-C4	O
haloalkyl,	O
—CH2-thiazole,	O
phenyl,	O
benzyl,	O
tetrahydrothiopyranyl,	O
and	O
tetrahydropyranyl,	O
wherein	O
the	O
cycloalkyl,	O
tetrahydrothiopyranyl,	O
tetrahydropyranyl	O
and	O
thiazolyl	O
group	O
is	O
optionally	O
substituted	O
with	O
one	O
or	O
two	O
groups	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halo,	O
hydroxy,	O
C1-C2	O
alkyl,	O
and	O
—C1-C2	O
haloalkyl	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
enantiomer,	O
diastereomer	O
or	O
mixture	O
thereof,	O
useful	O
in	O
the	O
treating,	O
preventing	O
or	O
ameliorating	O
of	O
symptoms	O
associated	O
with	O
obesity	O
and	O
related	O
diseases	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
formulations	O
and	O
methods	O
for	O
the	O
improved	O
delivery	O
and	O
administration	O
of	O
hydrophobic	O
therapeutic	O
compounds	O
that	O
are	O
substantially	O
insoluble	O
and	O
/	O
or	O
susceptible	O
to	O
precipitation	O
in	O
aqueous	O
solution	O
at	O
physiological	O
pH,	O
including,	O
e	O
.	O
g	O
.	O
,	O
growth	B-GENE
and	I-GENE
differentiation	I-GENE
factor-5	I-GENE
and	I-GENE
related	O
proteins	O
.	O
Many	O
therapeutic	O
compounds	O
are	O
hydrophobic	O
at	O
physiological	O
pH	O
levels	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
the	O
HIV	B-GENE
NC	I-GENE
protein,	O
and	O
more	O
particularly,	O
it	O
is	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
AIDS	O
having	O
a	O
polypeptide	O
comprising	O
HIV	B-GENE
NC	I-GENE
protein	I-GENE
as	O
an	O
active	O
component	O
and	O
the	O
method	O
of	O
inhibiting	O
HIV	O
proliferation	O
by	O
using	O
the	O
polypeptide	O
.	O
The	O
polypeptide	O
comprising	O
HIV	B-GENE
NC	I-GENE
protein	I-GENE
of	O
the	O
present	O
invention,	O
when	O
it	O
is	O
overexpressed,	O
has	O
the	O
effect	O
on	O
inhibiting	O
HIV	O
proliferation	O
.	O
Accordingly,	O
the	O
present	O
invention	O
provides	O
not	O
only	O
the	O
novel	O
means	O
of	O
inhibition	O
of	O
HIV	O
proliferation,	O
but	O
also	O
the	O
novel	O
method	O
for	O
preventing	O
and	O
treating	O
AIDS	O
.	O


The	O
invention	O
relates	O
to	O
dihydroimidazoles	O
of	O
formula	O
rac-	O
(	O
I	O
)	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
radicals	O
and	O
symbols	O
are	O
as	O
defined	O
herein	O
;	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	B-GENE
protein	O
with	O
a	O
p53-like	O
peptide,	O
new	O
pharmaceutical	O
formulations	O
comprising	O
said	O
compounds,	O
said	O
compounds	O
for	O
use	O
in	O
the	O
therapeutic	O
treatment	O
of	O
warm-blooded	O
animals,	O
especially	O
humans,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
or	O
for	O
the	O
manufacture	O
of	O
pharmaceutical	O
formulations	O
useful	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	B-GENE
protein	O
with	O
a	O
p53-like	O
peptide,	O
a	O
pharmaceutical	O
formulation	O
e	O
.	O
g	O
.	O
useful	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	B-GENE
protein	O
with	O
a	O
p53-like	O
peptide	O
comprising	O
said	O
compound,	O
methods	O
of	O
treatment	O
comprising	O
administration	O
of	O
said	O
compounds	O
to	O
a	O
warm-blooded	O
animal,	O
and	O
/	O
or	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
compounds	O
.	O


The	O
subject	O
matters	O
of	O
this	O
invention	O
are	O
a	O
sequence	O
of	O
double-stranded	O
RNA	O
:	O
ATN-RNA,	O
intervention	O
using	O
interference	O
RNA	O
(	O
iRNAi	O
)	O
,	O
use	O
of	O
a	O
sequence	O
of	O
double-stranded	O
RNA	O
:	O
ATN-RNA,	O
a	O
method	O
of	O
treating	O
a	O
brain	O
tumor	O
and	O
a	O
method	O
of	O
inhibiting	O
a	O
brain	O
tumor	O
cells	O
which	O
express	O
tenascin,	O
a	O
kit	O
for	O
inhibiting	O
cancer	O
cell	O
which	O
expresses	O
tenascin	B-GENE
and	O
a	O
method	O
for	O
a	O
kit	O
preparation	O
in	O
a	O
brain	O
tumor	O
therapy	O
.	O
Malignant	O
gliomas	O
preferentially	O
express	O
a	O
number	O
of	O
surface	O
markers	O
that	O
may	O
be	O
exploited	O
as	O
therapeutic	O
targets,	O
including	O
tenascin-C,	O
an	O
extracellular	O
matrix	O
glycoprotein	O
that	O
is	O
ubiquitously	O
expressed	O
by	O
malignant	O
gliomas	O
and	O
probably	O
contributes	O
to	O
tumor	O
cell	O
adhesion,	O
invasion,	O
migration	O
and	O
proliferation	O
.	O
For	O
tenascin-C	B-GENE
inhibition,	O
RNA	O
interference	O
intervention	O
(	O
iRNAi	O
)	O
approach	O
have	O
been	O
applied	O
.	O


The	O
present	O
invention	O
provides	O
a	O
preparing	O
method	O
of	O
microcapsule	O
containing	O
unsaturated	O
fatty	O
acid	O
comprising	O
the	O
steps	O
of	O
(	O
a	O
)	O
preparing	O
a	O
first	O
coating	O
material	O
by	O
mixing	O
and	O
gelatinating	O
one	O
or	O
more	O
gums	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
xanthan	O
gum,	O
guar	O
gum,	O
and	O
locusbean	O
gum,	O
with	O
poly	O
glycerin	O
esters	O
of	O
fatty	O
acid	O
in	O
sterilized	O
water,	O
adding	O
unsaturated	O
fatty	O
acid	O
to	O
the	O
solution,	O
and	O
homogenizing	O
the	O
solution	O
;	O
(	O
b	O
)	O
preparing	O
a	O
second	O
coating	O
material	O
by	O
mixing	O
and	O
gelatinating	O
starch	O
or	O
modified	O
starch,	O
gelatin	B-GENE
or	O
casein,	O
and	O
poly	O
glycerin	O
esters	O
of	O
fatty	O
acid	O
in	O
sterilized	O
water,	O
adding	O
the	O
first	O
coating	O
material	O
prepared	O
in	O
(	O
a	O
)	O
to	O
the	O
solution,	O
and	O
homogenizing	O
the	O
solution	O
;	O
and	O
(	O
c	O
)	O
spraying	O
the	O
second	O
coating	O
material	O
prepared	O
in	O
(	O
b	O
)	O
in	O
cold	O
sterilized	O
water	O
;	O
a	O
microcapsule	O
prepared	O
by	O
the	O
method	O
;	O
and	O
articles	O
containing	O
the	O
microcapsule	O
.	O
	O
	O
	O
	O
The	O
present	O
microcapsule	O
has	O
effects	O
of	O
preventing	O
the	O
oxidation	O
of	O
unsaturated	O
fatty	O
acid	O
and	O
inhibiting	O
offensive	O
smell	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
treatment	O
of	O
cystic	O
fibrosis	O
.	O
The	O
invention	O
includes	O
a	O
method	O
for	O
treatment	O
of	O
cystic	O
fibrosis	O
in	O
a	O
patient	O
by	O
increasing	O
the	O
activity	O
of	O
sarcoendoplasmic	B-GENE
reticulum	I-GENE
calcium	I-GENE
ATPase	I-GENE
(	O
SERCA	B-GENE
)	O
in	O
a	O
patient	O
.	O
More	O
specifically,	O
the	O
step	O
of	O
increasing	O
SERCA	B-GENE
activity	O
can	O
include	O
but	O
is	O
not	O
limited	O
to,	O
administration	O
of	O
SERCA	B-GENE
protein	O
or	O
its	O
homologues,	O
gene	O
therapy	O
to	O
restore	O
or	O
enhance	O
SERCA	B-GENE
activity,	O
or	O
the	O
administration	O
of	O
compounds	O
stimulating	O
the	O
activity	O
of	O
endogenous	O
SERCA	B-GENE
.	O
Reference	O
herein	O
to	O
SERCA,	O
can	O
include	O
in	O
preferred	O
embodiments,	O
the	O
isoform	O
SERCA2,	O
which	O
is	O
the	O
principal	O
lung	O
isoform	O
of	O
SERCA	B-GENE
.	O
The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
SERCA2	B-GENE
(	O
a	O
calcium	O
pump	I-GENE
)	O
is	O
deficient	O
(	O
not	O
100	O
%	O
)	O
in	O
the	O
lung	O
epithelial	O
cells	O
of	O
cystic	O
fibrosis	O
samples	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
comprising	O
compounds	O
that	O
selectively	O
bind	O
to	O
hexokinases	B-GENE
thereby	O
promoting	O
dissociation	O
of	O
these	O
enzymes	O
from	O
mitochondria,	O
and	O
methods	O
of	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
to	O
induce	O
cell	O
death	O
in	O
diseases	O
and	O
disorders	O
characterized	O
by	O
the	O
high	O
levels	O
of	O
mitochondrial	O
bound	O
hexokinase	B-GENE
.	O
The	O
present	O
invention	O
further	O
discloses	O
methods	O
and	O
assays	O
for	O
detecting	O
and	O
identifying	O
molecules	O
having	O
these	O
activities	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
indazole	O
derivatives	O
having	O
pharmacological	O
activity,	O
processes	O
for	O
their	O
preparation,	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
estrogen	B-GENE
receptor	I-GENE
beta	I-GENE
mediated	O
diseases	O
.	O


A	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
comprises	O
a	O
non-emulsified,	O
aqueous	O
suspension	O
of	O
retinol	O
.	O
The	O
composition	O
may	O
further	O
include	O
at	O
least	O
one	O
protein	O
species,	O
and	O
some	O
proteins	O
used	O
in	O
the	O
composition	O
include	O
collagen	B-GENE
and	O
elastin	B-GENE
.	O
The	O
composition	O
may	O
also	O
include	O
hyaluronic	O
acid	O
.	O
The	O
composition	O
may	O
also	O
include	O
one	O
or	O
more	O
of	O
tocopheryl	O
acetate,	O
propylene	O
glycol,	O
and	O
linseed	O
extract	O
.	O
Also	O
disclosed	O
are	O
methods	O
for	O
making	O
the	O
composition	O
and	O
use	O
of	O
the	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
.	O


Compounds	O
of	O
the	O
present	O
invention	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
mammalian	O
cancers	O
and	O
especially	O
human	O
cancers	O
including,	O
but	O
not	O
limited	O
to,	O
malignant	O
melanomas,	O
solid	O
tumors,	O
glioblastomas,	O
ovarian	O
cancer,	O
pancreatic	O
cancer,	O
prostate	O
cancer,	O
lung	O
cancers,	O
breast	O
cancers,	O
kidney	O
cancers,	O
hepatic	O
cancers,	O
cervical	O
carcinomas,	O
metastasis	O
of	O
primary	O
tumor	O
sites,	O
myeloproliferative	O
diseases,	O
chronic	O
myelogenous	O
leukemia,	O
leukemias,	O
papillary	O
thyroid	O
carcinoma,	O
non-small	O
cell	O
lung	O
cancer,	O
mesothelioma,	O
hypereosinophilic	O
syndrome,	O
gastrointestinal	O
stromal	O
tumors,	O
colonic	O
cancers,	O
ocular	O
diseases	O
characterized	O
by	O
hyperproliferation	O
leading	O
to	O
blindness	O
including	O
various	O
retinopathies,	O
diabetic	O
retinopathy,	O
rheumatoid	O
arthritis,	O
asthma,	O
chronic	O
obstructive	O
pulmonary	O
disease,	O
mastocytosis,	O
mast	O
cell	O
leukemia,	O
and	O
diseases	O
caused	O
by	O
PDGFR-α	B-GENE
kinase,	O
PDGFR-β	B-GENE
kinase,	O
c-KIT	B-GENE
kinase,	O
cFMS	B-GENE
kinase,	O
c-MET	B-GENE
kinase,	O
and	O
oncogenic	O
forms,	O
aberrant	O
fusion	O
proteins	O
and	O
polymorphs	O
of	O
any	O
of	O
the	O
foregoing	O
kinases	O
.	O


This	O
invention	O
is	O
directed	O
towards	O
treatments	O
for	O
multiple	O
sclerosis	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
first	O
agent,	O
such	O
as	O
2-chloro-2′-deoxyadenosine	O
(	O
2-CdA	O
)	O
,	O
that	O
reduces	O
the	O
number	O
of	O
lymphocytes	O
in	O
combination	O
with	O
a	O
second	O
agent,	O
such	O
as	O
an	O
anti-alpha-4	O
integrin	O
antibody,	O
that	O
blocks	O
the	O
adhesion	O
of	O
monocytes	O
and	O
leukocytes	O
to	O
endothelial	O
cells	O
.	O
The	O
use	O
of	O
2-CdA	O
combined	O
with	O
an	O
anti-alpha-4	O
integrin	O
antibody	O
may	O
be	O
more	O
effective	O
than	O
either	O
treatment	O
alone	O
for	O
MS	O
.	O
Furthermore,	O
the	O
combination	O
treatment	O
may	O
allow	O
for	O
a	O
lowering	O
or	O
altering	O
the	O
dose	O
of	O
one	O
or	O
more	O
of	O
the	O
agents	O
in	O
order	O
to	O
limit	O
any	O
adverse	O
effects	O
associated	O
with	O
the	O
individual	O
agents,	O
but	O
maintaining	O
the	O
same	O
therapeutic	O
efficacy	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
novel	O
heterobicyclic	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
V,	O
W,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
These	O
compounds	O
inhibit	O
L-CPT1	B-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


Benzoxazole	O
and	O
benzothiazole	O
compounds	O
and	O
their	O
oxides,	O
esters,	O
prodrugs,	O
solvates,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
disclosed	O
.	O
Compositions	O
of	O
the	O
compounds,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent,	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
and	O
uses	O
of	O
the	O
compounds,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent	O
are	O
also	O
disclosed	O
.	O
The	O
embodiments	O
are	O
useful	O
for	O
inhibiting	O
cellular	O
proliferation,	O
inhibiting	O
the	O
growth	O
and	O
/	O
or	O
metathesis	O
of	O
tumors,	O
treating	O
or	O
preventing	O
cancer,	O
treating	O
or	O
preventing	O
degenerating	O
bone	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis,	O
and	O
/	O
or	O
inhibiting	O
molecules	O
such	O
as	O
CSF	B-GENE
1R	I-GENE
.	O


Certain	O
embodiments	O
disclosed	O
relate	O
to	O
compositions,	O
including	O
therapeutic	O
compositions,	O
methods,	O
devices,	O
and	O
systems	O
that	O
modulate	O
at	O
least	O
one	O
inflammatory	O
response	O
or	O
reaction	O
.	O
According	O
to	O
various	O
embodiments,	O
the	O
compositions,	O
methods,	O
devices,	O
and	O
systems	O
relate	O
to	O
modulating	O
one	O
or	O
more	O
of	O
Toll-like	O
receptors,	O
Src	B-GENE
family	O
kinases,	O
NF-kB	B-GENE
molecules,	O
proteases,	O
or	O
proteasomes	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
TRPV3	B-GENE
(	O
transient	B-GENE
receptor	I-GENE
potential	I-GENE
vanilloid	I-GENE
3	I-GENE
)	O
activity	O
inhibitor,	O
more	O
precisely	O
to	O
a	O
method	O
for	O
inhibiting	O
TRPV3	B-GENE
activity	O
including	O
the	O
step	O
of	O
treating	O
isopentenyl	O
pyrophosphate	O
and	O
a	O
method	O
for	O
treating	O
skin	O
disease	O
containing	O
the	O
step	O
of	O
administering	O
isopentenyl	O
pyrophosphate	O
to	O
a	O
subject	O
with	O
skin	O
disease	O
or	O
applying	O
the	O
same	O
on	O
the	O
skin	O
of	O
the	O
subject	O
.	O
Isopentenyl	O
pyrophosphate	O
of	O
the	O
present	O
invention	O
controls	O
increase	O
of	O
sensory	O
cell	O
reactivity	O
to	O
current	O
or	O
migration	O
and	O
proliferation	O
of	O
skin	O
cells	O
induced	O
by	O
TRPV3,	O
so	O
that	O
it	O
can	O
be	O
effectively	O
used	O
for	O
the	O
development	O
of	O
a	O
pain	O
reliever	O
or	O
a	O
therapeutic	O
agent	O
for	O
skin	O
disease	O
.	O


Disclosed	O
are	O
compositions	O
and	O
methods	O
for	O
reducing	O
the	O
proliferation	O
of	O
ALL	O
cancer	O
cells	O
through	O
targeted	O
interactions	O
with	O
ALL1	B-GENE
fusion	O
proteins	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
trifluoromethylphenyl	O
modulators	O
of	O
calcium-sensing	O
receptor,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
subject	O
application	O
provides	O
for	O
a	O
method	O
for	O
enhancing	O
oxygen	O
delivery	O
to	O
a	O
tissue	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
comprising	O
two	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hemoglobin	B-GENE
based	O
oxygen	O
carrier,	O
a	O
nonhemoglobin	O
based	O
oxygen	O
carrier,	O
a	O
rheologic	O
modulator,	O
a	O
diffusion	O
changing	O
compound,	O
a	O
volume	O
expander,	O
and	O
a	O
vasomodulator	O
.	O
The	O
subject	O
application	O
also	O
provides	O
for	O
a	O
method	O
for	O
enhancing	O
oxygen	O
delivery	O
to	O
a	O
tissue	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
comprising	O
a	O
perfluorocarbon	O
and	O
one	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hemoglobin	B-GENE
based	O
oxygen	O
carrier,	O
a	O
nonhemoglobin	O
based	O
oxygen	O
carrier,	O
a	O
rheologic	O
modulator,	O
a	O
diffusion	O
changing	O
compound,	O
a	O
volume	O
expander,	O
and	O
a	O
vasomodulator	O
.	O


The	O
invention	O
provides	O
an	O
assay	O
for	O
determining	O
whether	O
a	O
test	O
agent	O
is	O
a	O
COX	O
modulator	O
.	O
In	O
general	O
terms,	O
the	O
assay	O
includes	O
:	O
determining	O
whether	O
a	O
test	O
agent	O
modulates	O
binding	O
of	O
a	O
PDZ-containing	B-GENE
polypeptide	I-GENE
to	O
a	O
COX	B-GENE
PL-containing	I-GENE
polypeptide	I-GENE
.	O
The	O
PDZ-containing	B-GENE
polypeptide	I-GENE
may	O
contain	O
the	O
PDZ	B-GENE
domain	I-GENE
of	O
PDZ	B-GENE
domain	I-GENE
of	O
MAGI1,	O
TIP-1,	O
MAST2,	O
PSD95,	O
or	O
SHANK	B-GENE
.	O
The	O
assays	O
may	O
be	O
done	O
in	O
a	O
cell-free	O
environment	O
or	O
in	O
a	O
cellular	O
environment,	O
particularly	O
using	O
a	O
neuronal	O
cell	O
.	O
The	O
invention	O
finds	O
use	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications,	O
including	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
treating	O
cancer,	O
pain,	O
inflammation	O
and	O
neuronal	O
conditions	O
caused	O
by	O
acute	O
insult,	O
e	O
.	O
g	O
.	O
,	O
stroke	O
.	O


Provided	O
herein	O
is	O
a	O
method	O
of	O
screening	O
a	O
tumour	O
cell	O
for	O
resistance	O
to	O
a	O
tubulin-binding	O
agent,	O
the	O
method	O
comprising	O
detecting	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B-GENE
II,	I-GENE
class	B-GENE
III	I-GENE
and	I-GENE
class	B-GENE
IVb	I-GENE
β-tubulin	I-GENE
by	O
the	O
tumour	O
cell,	O
wherein	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B-GENE
II,	I-GENE
class	B-GENE
III	I-GENE
and	I-GENE
class	B-GENE
IVb	I-GENE
β-tubulin	I-GENE
indicates	O
that	O
the	O
tumour	O
cell	O
has	O
resistance	O
or	O
potential	O
resistance	O
to	O
the	O
tubulin-binding	O
agent	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
modulating	O
the	O
sensitivity	O
of	O
a	O
tumour	O
cell	O
.	O
Also	O
provided	O
is	O
a	O
method	O
of	O
modulating	O
the	O
tumorigenesis	O
of	O
a	O
tumour	O
cell	O
.	O


Disclosed	O
are	O
methods	O
involving	O
the	O
administration	O
of	O
an	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
metastasis	O
modifier	O
gene,	O
e	O
.	O
g	O
.	O
,	O
Anakin,	O
Necdin,	O
CentaurinD3	B-GENE
(	O
CentD3	B-GENE
)	O
,	O
Csf1r,	O
Brd4,	O
Pi16,	O
and	O
Luc7l,	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
of	O
tumor	O
growth	O
.	O
Further	O
disclosed	O
are	O
methods	O
of	O
characterizing	O
a	O
tumor	O
or	O
cancer	O
in	O
a	O
subject	O
comprising	O
detecting	O
(	O
i	O
)	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
an	O
Anakin	B-GENE
gene	O
or	O
a	O
Brd4	B-GENE
gene	O
of	O
the	O
subject,	O
(	O
ii	O
)	O
an	O
amino	O
acid	O
substitution	O
in	O
an	O
Anakin	B-GENE
protein	O
in	O
the	O
subject,	O
or	O
(	O
iii	O
)	O
a	O
level	O
of	O
expression	O
of	O
an	O
Anakin	B-GENE
gene	O
or	O
a	O
Brd4	B-GENE
gene	O
in	O
the	O
subject	O
.	O
Methods	O
of	O
screening	O
a	O
compound	O
for	O
anti-cancer	O
activity	O
and	O
use	O
of	O
a	O
compound	O
with	O
anti-cancer	O
activity	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
to	O
treat	O
or	O
prevent	O
cancer	O
in	O
a	O
subject	O
are	O
also	O
disclosed	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Sipa-1	B-GENE
in	O
a	O
subject	O
.	O


Provided	O
herein	O
are	O
methods	O
for	O
reducing	O
or	O
preventing	O
neutrophilic	O
inflammation	O
in	O
a	O
subject	O
comprising	O
selecting	O
a	O
subject	O
with	O
or	O
at	O
risk	O
for	O
neutrophilic	O
inflammation	O
and	O
administering	O
to	O
the	O
subject	O
an	O
agent	O
that	O
inhibits	O
the	O
expression	O
or	O
activity	O
of	O
prolyl	B-GENE
endopeptidase	I-GENE
.	O
Provided	O
herein	O
are	O
also	O
methods	O
for	O
treatment	O
or	O
prevention	O
of	O
diseases	O
associated	O
with	O
neutrophilic	O
inflammation	O
.	O


The	O
present	O
invention	O
discloses	O
an	O
agent	O
for	O
treating	O
a	O
polyglutamine	O
aggregation-caused	O
disease	O
or	O
suppressing	O
its	O
onset,	O
which	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
(	O
1	O
)	O
(	O
i	O
)	O
HGF	O
protein,	O
(	O
ii	O
)	O
a	O
partial	O
peptide	O
of	O
HGF	B-GENE
protein	I-GENE
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	O
protein,	O
or	O
a	O
salt	O
of	O
either	O
of	O
them,	O
or	O
	O
	O
	O
	O
(	O
2	O
)	O
DNA	O
containing	O
(	O
i	O
)	O
DNA	O
encoding	O
HGF	O
protein,	O
(	O
ii	O
)	O
DNA	O
encoding	O
a	O
partial	O
peptide	O
of	O
HGF	B-GENE
protein	I-GENE
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	B-GENE
protein	I-GENE
or	O
(	O
iii	O
)	O
DNA	O
which	O
encodes	O
a	O
protein	O
or	O
a	O
peptide	O
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	B-GENE
protein	I-GENE
and	O
hybridizes	O
with	O
DNA	O
comprising	O
a	O
complementary	O
base	O
sequence	O
of	O
either	O
of	O
the	O
above-mentioned	O
DNAs	O
under	O
a	O
stringent	O
condition	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
AGC	B-GENE
kinase	I-GENE
inhibitors,	O
in	O
particular	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
or	O
a	O
stereoisomer	O
tautomer,	O
racemic,	O
metabolite,	O
pro-	O
or	O
predrug,	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof,	O
wherein	O
Ar1,	O
Ar2,	O
R1,	O
R3,	O
p	O
and	O
n	O
have	O
the	O
meaning	O
defined	O
in	O
the	O
claims	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
more	O
specifically	O
AGC	B-GENE
kinases	I-GENE
inhibitors,	O
compositions,	O
in	O
particular	O
pharmaceuticals,	O
comprising	O
such	O
inhibitors,	O
and	O
to	O
uses	O
of	O
such	O
inhibitors	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
disease	O
.	O


The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
series	O
of	O
substituted	O
N-phenyl-bipyrrolidine	O
carboxamides	O
of	O
formula	O
(	O
I	O
)	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Wherein	O
R,	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O
More	O
specifically,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
modulators	O
of	O
H3	B-GENE
receptors	I-GENE
and	O
are,	O
therefore,	O
useful	O
as	O
pharmaceutical	O
agents,	O
especially	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
variety	O
of	O
diseases	O
modulated	O
by	O
H3	B-GENE
receptors	I-GENE
including	O
diseases	O
associated	O
with	O
the	O
central	O
nervous	O
system	O
.	O
Additionally,	O
this	O
invention	O
also	O
discloses	O
methods	O
of	O
preparation	O
of	O
substituted	O
N-phenyl-bipyrrolidine	O
carboxamides	O
and	O
intermediates	O
therefor	O
.	O


This	O
application	O
provides	O
a	O
method	O
for	O
the	O
use	O
of	O
select	O
quaternary	O
ammonium	O
antagonists	O
to	O
alpha-7	B-GENE
nAChR	I-GENE
for	O
the	O
treatment	O
of	O
cancer	O
and	O
HIV	O
and	O
AIDS	O
.	O


Patients	O
are	O
subject	O
to	O
a	O
post-seizure	O
treatment	O
regime	O
to	O
separately	O
inhibitor	O
consecutive	O
targets	O
of	O
an	O
epileptogenic	O
cascade	O
comprising	O
neurotransmitter	B-GENE
receptor	I-GENE
signaling,	O
kinase	B-GENE
/	O
phosphatase	B-GENE
activity,	O
protein	O
translation,	O
and	O
apoptosis	O
or	O
inflammation	O
.	O


The	O
invention	O
provides	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
which	O
are	O
useful	O
as	O
protein	O
kinase	O
inhibitors,	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O
In	O
some	O
embodiments,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
Alk,	O
Abl,	O
Aurora-A,	O
B-Raf,	O
C-Raf,	O
Bcr-Abl,	O
BRK,	O
Blk,	O
Bmx,	O
BTK,	O
C-Kit,	O
CSK,	O
C-Src,	O
EphB1,	O
EphB2,	O
EphB4,	O
FLT1,	O
Fms,	O
Flt3,	O
Fyn,	O
FRK3,	O
JAK2,	O
KDR,	O
Lck,	O
Lyn,	O
PDGFRα,	O
PDGFRβ,	O
PKCα,	O
SAPK2α,	O
Src,	O
SIK,	O
Syk,	O
Tie2	B-GENE
and	O
TrkB	B-GENE
kinases	O
.	O


The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
cancers	O
associated	O
with	O
overexpression	O
of	O
a	O
BCL2	B-GENE
gene	O
and	O
/	O
or	O
gene	O
product	O
in	O
a	O
subject,	O
and	O
methods	O
and	O
compositions	O
for	O
the	O
improvement	O
of	O
anti-cancer	O
therapy,	O
such	O
as	O
chemotherapy	O
and	O
radiation	O
therapy	O
.	O
The	O
invention	O
also	O
encompasses	O
methods	O
for	O
determining	O
the	O
efficacy	O
of	O
a	O
cancer	O
therapy	O
in	O
a	O
subject	O
and	O
methods	O
for	O
inducing	O
apoptosis	O
of	O
a	O
cell	O
.	O


Methods,	O
devices	O
and	O
kits	O
for	O
treating	O
sleep	O
disorders,	O
anxiety	O
disorders,	O
and	O
developmental	O
disorders,	O
and	O
/	O
or	O
for	O
inducing	O
an	O
arousable	O
state	O
of	O
sedation	O
in	O
a	O
subject,	O
are	O
described	O
.	O
For	O
example,	O
inhalation	O
methods,	O
devices	O
and	O
kits	O
for	O
treating	O
insomnia,	O
anxiety	O
and	O
/	O
or	O
ADHD	O
using	O
one	O
or	O
more	O
α2-adrenergic	B-GENE
agonists	O
such	O
as	O
dexmedetomidine	O
or	O
clonidine	O
are	O
described	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
non-steroidal	O
17beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
inhibitors	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
hormone-dependent,	O
particularly	O
estrogen-dependent,	O
diseases	O
.	O
The	O
invention	O
further	O
relates	O
to	O
suitable	O
inhibitors	O
and	O
to	O
a	O
method	O
for	O
the	O
production	O
thereof	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
simple	O
normal-tension	O
glaucoma	O
model	O
capable	O
of	O
spontaneously,	O
age-dependently	O
and	O
surly	O
developing	O
conditions	O
similar	O
to	O
symptoms	O
of	O
normal-tension	O
glaucoma	O
which	O
occurs	O
more	O
frequently	O
in	O
elder	O
people,	O
and	O
a	O
method	O
of	O
evaluating	O
therapeutic	O
effect	O
on	O
normal-tension	O
glaucoma	O
whereby	O
a	O
drug	O
useful	O
in	O
treating	O
and	O
diagnosing	O
can	O
be	O
conveniently	O
screened	O
by	O
using	O
the	O
normal-tension	O
glaucoma	O
model	O
.	O
A	O
normal-tension	O
glaucoma	O
model	O
comprising	O
a	O
nonhuman	O
mammal,	O
which	O
is	O
deficient	O
in	O
a	O
transcriptional	O
regulator	O
NF-κBp50	B-GENE
and	O
thus	O
spontaneously	O
develops	O
the	O
normal-tension	O
glaucoma	O
symptom	O
age-relatedly,	O
an	O
organ	O
or	O
a	O
tissue	O
thereof	O
or	O
cells	O
collected	O
from	O
any	O
of	O
the	O
same	O
.	O
A	O
method	O
of	O
evaluating	O
therapeutic	O
effect	O
on	O
normal-tension	O
glaucoma	O
of	O
a	O
test	O
substance	O
which	O
comprises	O
administering	O
or	O
adding	O
the	O
test	O
substance	O
to	O
the	O
above-described	O
nonhuman	O
mammal,	O
an	O
organ	O
or	O
a	O
tissue	O
thereof	O
or	O
cells	O
collected	O
from	O
any	O
of	O
the	O
same,	O
and	O
measuring	O
a	O
morphological	O
defect,	O
cell	O
count,	O
pressure,	O
the	O
expression	O
amount	O
or	O
activity	O
strength	O
of	O
a	O
protein,	O
the	O
expression	O
amount	O
of	O
a	O
nucleic	O
acid	O
and	O
/	O
or	O
the	O
activity	O
strength	O
of	O
an	O
antibody	O
in	O
the	O
organ,	O
tissue	O
and	O
/	O
or	O
cells	O
as	O
indication	O
(	O
s	O
)	O
for	O
the	O
evaluation	O
.	O


Disclosed	O
is	O
a	O
novel	O
sirtuin	B-GENE
modulating	O
composition	O
comprising	O
an	O
orally	O
bioavailable	O
SIRT-1	B-GENE
enhancing	O
compound	O
3,5-dimethoxy-3,4′-dihydroxystilbene	O
represented	O
by	O
STR	O
#	O
I	O
.	O
Also	O
disclosed	O
is	O
an	O
anti-acne	O
composition	O
comprising	O
3,5-dimethoxy-	O
3,4′-dihydroxystilbenes	O
represented	O
by	O
STR	O
#	O
I	O
.	O
Further,	O
a	O
novel	O
sirtuin	B-GENE
modulating	O
composition	O
comprising	O
an	O
orally	O
bioavailable	O
SIRT-1	B-GENE
enhancing	O
compound	O
2,3′,5′,	O
6-tetrahydroxy-trans-stilbene	O
represented	O
by	O
STR	O
#	O
II	O
is	O
also	O
disclosed	O
.	O


The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
determining	O
a	O
subject	O
'	O
s	O
adipose	O
tissue	O
activity	O
.	O
In	O
one	O
embodiment,	O
the	O
composition	O
comprises	O
a	O
solid	O
support	O
comprising	O
probes	O
for	O
measuring	O
a	O
biomarker	O
panel	O
comprising,	O
for	O
example,	O
adiponectin,	O
resistin,	O
PAI-1,	O
optionally	O
leptin	B-GENE
and	O
optionally	O
visfatin	B-GENE
.	O
The	O
simultaneous	O
use	O
of	O
multiple	O
biomarkers	O
with	O
independent	O
classification	O
power	O
will	O
increase	O
the	O
performance	O
of	O
the	O
biomarker	O
panel	O
in	O
identifying	O
adipose	O
tissue	O
activity,	O
which	O
is	O
associated	O
with	O
various	O
disease	O
states	O
including	O
chronic	O
or	O
systemic	O
inflammation,	O
atherosclerosis	O
and	O
other	O
cardiovascular	O
risks	O
and	O
complications	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
a	O
subject	O
and	O
determining	O
the	O
efficacy	O
of	O
a	O
therapy	O
through	O
assaying	O
the	O
various	O
biomarkers	O
of	O
a	O
biomarker	O
panel	O
disclosed	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
GPR119	B-GENE
receptor	I-GENE
to	O
identify	O
peptide	B-GENE
YY	I-GENE
(	O
PYY	B-GENE
)	O
secretagogues	O
and	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
modulated	O
by	O
PYY,	O
such	O
as	O
conditions	O
modulated	O
by	O
stimulation	O
of	O
NPY	B-GENE
Y2	I-GENE
receptor	I-GENE
(	O
Y2R	B-GENE
)	O
.	O
Agonists	O
of	O
GPR119	B-GENE
receptor	I-GENE
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
modulated	O
by	O
PYY,	O
such	O
as	O
a	O
condition	O
modulated	O
by	O
stimulation	O
of	O
Y2R	B-GENE
.	O
Conditions	O
modulated	O
by	O
PYY	B-GENE
such	O
as	O
may	O
be	O
a	O
condition	O
modulated	O
by	O
stimulation	O
of	O
Y2R	B-GENE
include	O
bone-related	O
conditions,	O
metabolic	O
disorders,	O
angiogenesis-related	O
conditions,	O
ischemia-related	O
conditions,	O
convulsive	O
disorders,	O
malabsorptive	O
disorders,	O
cancers,	O
and	O
inflammatory	O
disorders	O
.	O


Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	O
trialkyl	O
ammonium-containing	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
alkaline	B-GENE
phosphatase	I-GENE
or	O
other	O
weight	O
loss-inducing	O
drugs	O
or	O
methods	O
to	O
reduce	O
or	O
reverse	O
excess	O
weight	O
gain	O
and	O
obesity	O
as	O
well	O
as	O
reduce	O
the	O
risk	O
of	O
development	O
and	O
help	O
treatment	O
of	O
diseases	O
and	O
unhealthy	O
conditions	O
related	O
to	O
overweight	O
and	O
obesity	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
bcl-2	B-GENE
antisense	O
oligomers	O
to	O
treat	O
and	O
prevent	O
bcl-2	B-GENE
related	O
disorders	O
.	O
These	O
disorders	O
include	O
cancers,	O
tumors,	O
carcinomas	O
and	O
cell-proliferative	O
related	O
disorders	O
.	O
In	O
one	O
embodiment	O
of	O
the	O
invention,	O
a	O
bcl-2	B-GENE
antisense	O
oligomer	O
is	O
administered	O
at	O
high	O
doses	O
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
a	O
bcl-2	B-GENE
related	O
disorder,	O
in	O
particular	O
cancer,	O
comprising	O
administering	O
a	O
bcl-2	B-GENE
antisense	O
oligomer	O
for	O
short	O
periods	O
of	O
time	O
.	O
The	O
present	O
invention	O
is	O
further	O
drawn	O
to	O
the	O
use	O
of	O
bcl-2	B-GENE
antisense	O
oligomers	O
to	O
increase	O
the	O
sensitivity	O
of	O
a	O
subject	O
to	O
cancer	O
therapeutics	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
bcl-2	B-GENE
antisense	O
oligomers,	O
which	O
may	O
comprise	O
one	O
or	O
more	O
cancer	O
therapeutic	O
agents	O
.	O


The	O
present	O
invention	O
concerns	O
products	O
containing	O
(	O
i	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	B-GENE
somatostatin	I-GENE
2	I-GENE
receptor	I-GENE
protein	I-GENE
(	O
sst2	B-GENE
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
1,	O
ortholog	O
or	O
derivative	O
thereof,	O
(	O
ii	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	B-GENE
deoxycytidine	I-GENE
kinase	I-GENE
protein	I-GENE
(	O
dck	B-GENE
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
2,	O
ortholog	O
or	O
derivative	O
thereof,	O
(	O
iii	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	B-GENE
uridine	I-GENE
monophosphate	I-GENE
kinase	I-GENE
protein	I-GENE
(	O
umk	B-GENE
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
3	O
ortholog	O
or	O
derivative	O
thereof,	O
and	O
(	O
iv	O
)	O
gemcitabine,	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous,	O
separate,	O
or	O
sequential	O
use	O
for	O
treating	O
cancer	O
in	O
a	O
subject	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
method	O
of	O
screening	O
a	O
drug	O
with	O
the	O
use	O
of	O
a	O
67	B-GENE
kDa	I-GENE
laminin	I-GENE
receptor	I-GENE
and	O
a	O
drug	O
obtained	O
thereby	O
.	O
A	O
method	O
of	O
screening	O
a	O
drug	O
having	O
an	O
effect	O
on	O
inhibiting	O
cell	O
proliferation,	O
an	O
angiogenesis	O
inhibitory	O
effect,	O
an	O
effect	O
of	O
inhibiting	O
cancer	O
cell	O
metastasis,	O
a	O
neuroprotective	O
effect,	O
and	O
anti-allergic	O
effect,	O
and	O
anti-arteriosclerotic	O
effect	O
and	O
/	O
or	O
an	O
effect	O
of	O
inhibiting	O
infection	O
with	O
Creutzfeldt-Jakob	O
disease	O
which	O
involves	O
the	O
step,	O
of	O
qualitatively	O
or	O
quantitatively	O
measuring	O
the	O
degree	O
of	O
the	O
binding	O
of	O
a	O
test	O
compound	O
to	O
a	O
67	B-GENE
kDa	I-GENE
laminin	I-GENE
receptor,	O
and	O
judging	O
that	O
the	O
test	O
compound	O
is	O
a	O
drug	O
having	O
an	O
effect	O
of	O
inhibiting	O
cell	O
proliferation,	O
and	O
angiogenesis	O
inhibitory	O
effect,	O
an	O
effect	O
of	O
inhibiting	O
cancer	O
cell	O
metastasis,	O
a	O
neuroprotective	O
effect,	O
and	O
anti-allergic-effect,	O
and	O
anti-arteriosclerotic	O
effect	O
and	O
/	O
or	O
an	O
effect	O
of	O
inhibiting	O
infection	O
with	O
Creutzfeldt-Jakob	O
disease	O
in	O
the	O
case	O
where	O
it	O
is	O
found	O
out	O
by	O
the	O
results	O
of	O
the	O
measurement	O
that	O
the	O
test	O
compound	O
binds	O
to	O
the	O
67	B-GENE
kDa	I-GENE
laminin	I-GENE
receptor,	O
and	O
a	O
drug	O
obtained	O
thereby	O
.	O


A	O
method	O
for	O
predicting	O
the	O
likelihood	O
a	O
mammal	O
will	O
respond	O
therapeutically	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
a	O
VEGFR-2	B-GENE
modulator	O
or	O
a	O
dual	O
VEGFR-2	B-GENE
/	O
FGFR-1	B-GENE
modulator	O
wherein	O
the	O
method	O
comprises	O
:	O
(	O
a	O
)	O
measuring	O
in	O
the	O
mammal	O
the	O
level	O
of	O
FGF2	B-GENE
;	O
(	O
b	O
)	O
either	O
comparing	O
the	O
level	O
of	O
FGF2	B-GENE
in	O
the	O
sample	O
relative	O
to	O
a	O
standard	O
to	O
permit	O
assignment	O
of	O
the	O
sample	O
to	O
either	O
being	O
a	O
member	O
of	O
an	O
FGF2	B-GENE
positive	O
class	O
or	O
an	O
FGF2	B-GENE
negative	O
class,	O
or	O
comparing	O
the	O
level	O
of	O
FGF2	B-GENE
in	O
the	O
sample	O
relative	O
to	O
a	O
standard,	O
wherein	O
assignment	O
of	O
the	O
mammal	O
to	O
the	O
FGF2	B-GENE
positive	O
sample	O
class	O
or	O
a	O
determination	O
that	O
the	O
mammal	O
has	O
an	O
elevated	O
level	O
of	O
FGF2,	O
indicates	O
an	O
increased	O
likelihood	O
the	O
patient	O
will	O
respond	O
therapeutically	O
to	O
the	O
cancer	O
treatment	O
.	O
Methods	O
of	O
predicting	O
whether	O
a	O
mammal	O
has	O
received	O
an	O
efficacious	O
dose	O
of	O
a	O
VEGFR-2	B-GENE
modulator	O
or	O
a	O
dual	O
VEGFR-2	B-GENE
/	O
FGFR-1	B-GENE
modulator	O
is	O
also	O
disclosed,	O
in	O
addition	O
to	O
kits	O
comprising	O
these	O
methods	O
.	O


An	O
NR2B	B-GENE
receptor	O
antagonist	O
is	O
useful,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
agents,	O
for	O
promoting	O
wakefulness,	O
treating	O
narcolepsy,	O
excessive	O
daytime	O
sleepiness,	O
enhancing	O
cognition,	O
treating	O
sleepiness	O
associated	O
with	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
fibromyalgia,	O
chronic	O
pain,	O
sleep	O
disorders,	O
autism	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O


Compositions,	O
compounds,	O
and	O
methods	O
for	O
modulating	O
the	O
activity	O
of	O
glutamate	B-GENE
dehydrogenase	I-GENE
are	O
disclosed	O
.	O
In	O
addition,	O
compositions,	O
compounds,	O
and	O
methods	O
for	O
regulating	O
insulin	B-GENE
secretion	O
and	O
treating	O
hyperinsulism	O
/	O
hyperammonemia	O
and	O
/	O
or	O
diabetes	O
are	O
disclosed	O
.	O


Clusterin	B-GENE
possesses	O
an	O
excellent	O
anorexigenic	O
effect	O
and,	O
accordingly,	O
is	O
useful	O
for	O
treating	O
or	O
preventing	O
obesity	O
or	O
an	O
obesity-related	O
disorder	O
.	O
Co-administration	O
of	O
sub-clinical	O
dose	O
of	O
clustrin	B-GENE
potentiates	O
the	O
anorexigenic	O
effect	O
of	O
leptin	B-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
double-stranded	O
compound,	O
preferably	O
an	O
oligoribonucleotide,	O
which	O
down-regulates	O
the	O
expression	O
of	O
a	O
gene	O
of	O
the	O
TGase	B-GENE
family	O
at	O
post-transcriptional	O
level	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound,	O
or	O
a	O
vector	O
capable	O
of	O
expressing	O
the	O
oligoribonucleotide,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
also	O
contemplates	O
a	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
fibrotic	O
disease	O
such	O
as	O
kidney	O
and	O
liver	O
fibrosis	O
and	O
ocular	O
scarring	O
comprising	O
administering	O
to	O
the	O
patient	O
the	O
pharmaceutical	O
composition	O
in	O
a	O
therapeutically	O
effective	O
amount	O
so	O
as	O
to	O
thereby	O
treat	O
the	O
patient	O
.	O
The	O
invention	O
also	O
relates	O
to	O
treatment	O
of	O
fibrotic	O
and	O
other	O
diseases	O
by	O
use	O
of	O
antibodies	O
to	O
TGase	B-GENE
polypeptides	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
fields	O
of	O
genetics	O
and	O
medicine	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
relates	O
to	O
improved	O
methods	O
of	O
treating	O
cancers	O
using	O
a	O
TLR3	B-GENE
agonist,	O
by	O
assessing	O
the	O
expression	O
of	O
a	O
TLR3	B-GENE
receptor	O
by	O
cancer	O
cells	O
.	O


Provided	O
herein	O
are	O
methods	O
for	O
treating	O
a	O
subject	O
having	O
or	O
at	O
risk	O
for	O
an	O
angiogenesis-related	O
disorder	O
.	O
The	O
methods	O
include	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
inhibits	O
JNK3	B-GENE
expression,	O
or	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
inhibits	O
JNK3	B-GENE
activity	O
.	O
Disorders	O
that	O
can	O
be	O
treated	O
by	O
these	O
methods	O
include	O
cancer,	O
rheumatoid	O
arthritis,	O
vascular	O
diseases,	O
and	O
other	O
disorders	O
resulting	O
from	O
excessive	O
angiogenesis	O
.	O
The	O
therapeutic	O
agent	O
may	O
be	O
a	O
compound,	O
small	O
molecule,	O
peptide,	O
antibody,	O
antisense	O
nucleic	O
acid,	O
ribozyme,	O
or	O
the	O
like	O
.	O
Methods	O
of	O
identifying	O
a	O
candidate	O
agent	O
that	O
modulates	O
JNK3	B-GENE
expression	O
are	O
also	O
provided	O
.	O


This	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
disease	O
or	O
disorder	O
of	O
the	O
nervous	O
system,	O
associated	O
with	O
an	O
inflammatory	O
response	O
.	O
This	O
invention	O
further	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising,	O
inter	O
alia,	O
an	O
agent	O
which	O
increases	O
brain	O
levels	O
of	O
interferon-γ	B-GENE
;	O
and	O
an	O
agent	O
which	O
reduces	O
the	O
number	O
of	O
brain	O
T	O
regulatory	O
(	O
Treg	O
)	O
cells,	O
and	O
optionally	O
further	O
comprising	O
an	O
agent	O
which	O
suppresses	O
neurotoxic	O
inflammatory	O
brain	O
responses	O
.	O


The	O
present	O
invention	O
relates	O
to	O
serotonin	B-GENE
receptor	I-GENE
antagonists	O
for	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
comprising	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
serotonin	B-GENE
receptor	I-GENE
antagonist	O
and	O
instructions	O
indicating	O
that	O
the	O
composition	O
is	O
for	O
use	O
in	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
comprising	O
administration	O
of	O
a	O
serotonin	B-GENE
receptor	I-GENE
antagonist	O
.	O
The	O
method	O
is	O
preferably	O
carried	O
out	O
on	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
.	O
The	O
inflammatory	O
arthritis	O
is	O
preferably	O
rheumatoid	O
arthritis	O
.	O


Compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
diseases,	O
and	O
for	O
releasing	O
cells	O
such	O
as	O
stem	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
bone	O
marrow	O
progenitor	O
cells	O
)	O
into	O
circulating	O
blood	O
and	O
enhancing	O
retention	O
of	O
the	O
cells	O
in	O
the	O
blood	O
.	O
More	O
specifically,	O
heterobifunctional	O
compounds	O
that	O
inhibit	O
both	O
E-selectins	B-GENE
and	O
CXCR4	B-GENE
chemokine	O
receptors	O
are	O
described	O
.	O


The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
fibrosis	O
in	O
a	O
subject	O
by	O
administering	O
a	O
5-HT	B-GENE
modulator,	O
e	O
.	O
g	O
.	O
,	O
a	O
5-HT2B	B-GENE
modulator	O
.	O
In	O
particular	O
embodiments,	O
the	O
5-HT	B-GENE
modulator	O
is	O
a	O
piperidinylamino-thieno	O
[	O
2,3-d	O
]	O
pyrimidine	O
compound	O
.	O


Disclosed	O
herein	O
are	O
indolo	O
[	O
3,2-c	O
]	O
quinoline	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R	O
and	O
m	O
are	O
given	O
the	O
definitions	O
as	O
set	O
forth	O
in	O
the	O
Specification	O
and	O
Claims	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
These	O
compounds	O
can	O
be	O
used	O
to	O
inhibit	O
both	O
growth	O
of	O
cancer	O
cells	O
and	O
activity	O
of	O
telomerase	B-GENE
.	O


Disclosed	O
are	O
methods	O
and	O
compositions	O
relating	O
to	O
antagonists	O
of	O
HNF4α	B-GENE
.	O


The	O
present	O
invention	O
provides	O
nucleic	O
acid	O
molecules	O
that	O
inhibit	O
K-ras	B-GENE
expression	O
.	O
Methods	O
of	O
using	O
the	O
nucleic	O
acid	O
molecules	O
are	O
also	O
provided	O
.	O


The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
asthma	O
and	O
bronchial	O
inflammation,	O
e	O
.	O
g	O
.	O
,	O
as	O
induced	O
by	O
an	O
allergen	O
or	O
toxin	O
.	O
In	O
one	O
aspect,	O
the	O
invention	O
provides	O
inhibitors	O
of	O
“Inducible	O
T	O
Cell	I-GENE
Kinase”	O
(	O
ITK	B-GENE
)	O
polypeptides	O
and	O
methods	O
of	O
making	O
and	O
using	O
them,	O
e	O
.	O
g	O
.	O
,	O
as	O
agents	O
and	O
pharmaceutical	O
compositions	O
to	O
treat	O
asthma	O
.	O
In	O
one	O
aspect,	O
the	O
invention	O
is	O
directed	O
to	O
ITK	B-GENE
protein	O
expression	O
and	O
/	O
or	O
activity	O
inhibitors	O
.	O
In	O
one	O
aspect,	O
these	O
ITK	B-GENE
protein	O
expression	O
and	O
/	O
or	O
activity	O
inhibitors	O
are	O
used	O
with	O
targeting	O
agents	O
.	O
In	O
one	O
aspect,	O
the	O
ITK	B-GENE
protein	O
inhibitors	O
of	O
the	O
invention	O
are	O
used	O
to	O
treat	O
asthma	O
.	O
In	O
one	O
aspect,	O
the	O
invention	O
is	O
directed	O
to	O
ITK	B-GENE
protein	O
inhibitors	O
as	O
chimeric	O
proteins	O
comprising	O
fragments	O
or	O
altered	O
or	O
truncated	O
forms	O
of	O
ITK	B-GENE
protein,	O
or	O
equivalent	O
.	O
In	O
other	O
aspects	O
ITK	B-GENE
protein	O
is	O
joined	O
or	O
fused	O
to	O
another	O
moiety	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
targeting	O
domain	O
)	O
or	O
to	O
an	O
antibiotic	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
ITK	B-GENE
protein	O
inhibitors	O
of	O
the	O
invention,	O
and	O
methods	O
of	O
making	O
and	O
using	O
them,	O
including	O
methods	O
for	O
ameliorating	O
or	O
preventing	O
asthma	O
.	O
The	O
invention	O
also	O
provides	O
compositions	O
for	O
transfecting	O
cells	O
with	O
nucleic	O
acids	O
acting	O
as	O
ITK	B-GENE
protein	O
inhibitors	O
and	O
/	O
or	O
the	O
chimeric	O
ITK	B-GENE
protein	O
inhibitors	O
polypeptides	O
of	O
the	O
invention	O
.	O


Disclosed	O
are	O
:	O
a	O
peptide	O
comprising	O
an	O
amino	O
acid	O
sequence	O
composed	O
of	O
contiguous	O
nine	O
amino	O
acid	O
residues	O
derived	O
from	O
a	O
WT1	B-GENE
protein,	O
wherein	O
an	O
amino	O
acid	O
residue	O
at	O
position	O
2	O
in	O
the	O
amino	O
acid	O
sequence	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Ala,	O
Ile,	O
Leu,	O
Val,	O
Phe,	O
Tyr,	O
Ser	O
and	O
Asp	O
and	O
an	O
amino	O
acid	O
residue	O
at	O
position	O
9	O
in	O
the	O
amino	O
acid	O
sequence	O
is	O
Arg	O
;	O
a	O
polynucleotide	O
encoding	O
the	O
peptide	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
peptide	O
;	O
and	O
others	O
.	O


A	O
method	O
of	O
inhibiting	O
replication	O
of	O
a	O
flavivirus	O
in	O
animal	O
cells,	O
and	O
an	O
oligonucleotide	O
compound	O
for	O
use	O
in	O
the	O
method	O
are	O
disclosed	O
.	O
The	O
oligonucleotide	O
analog	O
(	O
i	O
)	O
has	O
a	O
nuclease-resistant	O
backbone,	O
(	O
ii	O
)	O
is	O
capable	O
of	O
uptake	O
by	O
the	O
cells,	O
(	O
iii	O
)	O
contains	O
between	O
8-40	O
nucleotide	O
bases,	O
and	O
(	O
iv	O
)	O
has	O
a	O
sequence	O
of	O
at	O
least	O
8	O
bases	O
complementary	O
to	O
a	O
region	O
of	O
the	O
virus	O
'	O
positive	O
strand	O
RNA	O
genome	O
that	O
includes	O
at	O
least	O
a	O
portion	O
of	O
SEQ	O
ID	O
NOS	O
:	O
1-4	O
.	O
Exposure	O
of	O
cells	O
infected	O
with	O
a	O
flavivirus	O
to	O
the	O
analog	O
is	O
effective	O
to	O
form	O
within	O
the	O
cells,	O
a	O
heteroduplex	O
structure	O
composed	O
of	O
the	O
virus	O
ssRNA	O
and	O
the	O
oligonucleotide,	O
characterized	O
by	O
a	O
Tm	O
of	O
dissociation	O
of	O
at	O
least	O
45°	O
C	O
.	O
,	O
and	O
having	O
disrupted	O
base	O
pairing	O
between	O
the	O
virus	O
'	O
5′	O
and	O
3′	O
cyclization	O
sequences	O
.	O


The	O
present	O
invention	O
concerns	O
compounds	O
and	O
their	O
use	O
to	O
treat	O
cell	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O
In	O
general	O
aspects,	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
tyrphostin-like	O
in	O
structure	O
.	O
Compounds	O
of	O
the	O
present	O
invention,	O
in	O
certain	O
embodiments,	O
display	O
significant	O
potency	O
by	O
causing,	O
for	O
example,	O
inhibition	O
of	O
Stat3	B-GENE
activation,	O
reduction	O
in	O
c-myc	B-GENE
protein	O
levels	O
and	O
/	O
or	O
induction	O
of	O
apoptosis	O
in	O
tumor	O
cells	O
.	O
In	O
general	O
aspects,	O
compounds	O
of	O
the	O
present	O
invention	O
induce	O
one	O
or	O
more	O
of	O
these	O
activities	O
at	O
nanomolar	O
concentrations	O
and	O
typically	O
function	O
through	O
a	O
unique	O
mechanism	O
involving	O
the	O
induction	O
of	O
stress	O
granules	O
that	O
bind	O
specific	O
signaling	O
molecules	O
and	O
prevent	O
them	O
from	O
participating	O
in	O
signal	O
transduction	O
and	O
oncogenesis	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
which	O
is	O
an	O
amide	O
of	O
the	O
formula	O
(	O
1	O
)	O
,	O
or	O
a	O
salt,	O
solvate,	O
N-oxide	O
or	O
tautomer	O
thereof	O
;	O
wherein	O
:	O
a	O
is	O
0	O
or	O
1	O
;	O
b	O
is	O
0	O
or	O
1	O
:	O
provided	O
that	O
the	O
sum	O
of	O
a	O
and	O
b	O
is	O
0	O
or	O
1	O
;	O
T	O
is	O
O	O
or	O
NH	O
Ar1	O
is	O
a	O
monocyclic	O
or	O
bicyclic	O
5-	O
to	O
10-membered	O
aryl	O
or	O
heteroaryl	O
group	O
containing	O
up	O
to	O
4	O
heteroatoms	O
selected	O
from	O
O,	O
N	O
and	O
S,	O
and	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
R1	O
;	O
Ar2	O
Js	O
a	O
monocyclic	O
or	O
bicyclic	O
5-	O
to	O
10-membered	O
aryl	O
or	O
heteroaryl	O
group	O
containing	O
up	O
to	O
4	O
heteroatoms	O
selected	O
from	O
O,	O
N	O
and	O
S	O
and	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
R2	O
;	O
and	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
kinases	O
and	O
in	O
particular	O
FLT3,	O
FLT4	B-GENE
and	O
Aurora	B-GENE
kinases	I-GENE
.	O


Certain	O
novel	O
benzothiazoles	O
and	O
benzoxazoles,	O
e	O
.	O
g	O
.	O
,	O
2-	O
(	O
piperazin-1-yl	O
)	O
benzothiazoles	O
and	O
2-	O
(	O
piperazin-1-yl	O
)	O
benzoxazoles,	O
optionally	O
substituted	O
in	O
the	O
3	O
and	O
/	O
or	O
4	O
positions	O
of	O
the	O
piperazine	O
rings,	O
!	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
having	O
histamine	B-GENE
H3	I-GENE
antagonistic	O
activity	O
can	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
.	O


Treatment	O
of	O
cancer	O
and	O
thromboembolic	O
disorders	O
using	O
inhibitors	O
of	O
Factor	B-GENE
VIIa	I-GENE
are	O
disclosed	O
herein	O
using	O
a	O
compound	O
of	O
Formula	O
I	O
.	O


A	O
method	O
of	O
suppressing	O
undesirable	O
cell	O
proliferation,	O
such	O
as	O
tumour	O
growth,	O
is	O
provided	O
comprising	O
the	O
step	O
of	O
increasing	O
the	O
level	O
of	O
PCL2	B-GENE
in	O
target	O
cells	O
.	O


The	O
disclosure	O
relates	O
to	O
methods	O
for	O
identifying	O
a	O
subject	O
having	O
elevated	O
FGL2	B-GENE
plasma	O
levels,	O
the	O
method	O
comprising	O
the	O
step	O
of	O
assaying	O
a	O
plasma	O
sample	O
from	O
the	O
subject	O
to	O
determine	O
a	O
level	O
of	O
FGL2,	O
wherein	O
a	O
level	O
above	O
control	O
indicates	O
the	O
subject	O
has	O
elevated	O
FGL2	B-GENE
levels	O
.	O
Diagnostic	O
methods,	O
methods	O
of	O
monitoring	O
prognosis	O
and	O
methods	O
of	O
medical	O
treatment	O
relating	O
to	O
viral	O
hepatitis	O
are	O
also	O
provided	O
.	O
The	O
disclosure	O
also	O
provides	O
assays	O
and	O
kits	O
useful	O
in	O
the	O
diagnosis	O
of	O
a	O
viral	O
hepatitis	O
associated	O
with	O
elevated	O
FGL2	B-GENE
.	O


The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
the	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
as	O
well	O
as	O
other	O
invention	O
embodiments	O
related	O
to	O
these	O
compounds	O
.	O
The	O
compounds	O
are	O
e	O
.	O
g	O
.	O
useful	O
in	O
the	O
treatment	O
of	O
the	O
animal	O
or	O
human	O
body	O
in	O
view	O
of	O
their	O
ability	O
to	O
inhibit	O
protein	B-GENE
kinases	I-GENE
such	O
as	O
especially	O
PI3	B-GENE
kinase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating,	O
preventing	O
or	O
ameliorating	O
a	O
chronic	O
neurodegenerative	O
disorder,	O
in	O
particular	O
progressive	O
muscular	O
atrophy	O
(	O
PMA	O
)	O
,	O
said	O
method	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
of	O
such	O
a	O
treatment,	O
prevention	O
or	O
amelioration	O
a	O
specific	O
inhibitor	O
of	O
a	O
caspase	O
I-dependent	O
cytokine	B-GENE
.	O
Also	O
specific	O
inhibitors	O
of	O
a	O
caspase	O
I-dependent	O
cytokine	B-GENE
for	O
treating,	O
preventing	O
or	O
ameliorating	O
a	O
neurodegenerative	O
disorder,	O
in	O
particular	O
PMA,	O
are	O
disclosed	O
herein	O
.	O
Furthermore,	O
the	O
present	O
invention	O
provides	O
for	O
the	O
use	O
of	O
(	O
a	O
)	O
specific	O
inhibitor	O
(	O
s	O
)	O
of	O
a	O
caspase	O
I-dependent	O
cytokine	B-GENE
in	O
the	O
medical	O
or	O
pharmaceutical	O
intervention	O
of	O
neurodegenerative	O
disorders	O
.	O
In	O
particular	O
said	O
cytokine	B-GENE
to	O
be	O
inhibited	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
interleukin-1	B-GENE
(	O
IL-1	B-GENE
)	O
,	O
interleukin-18	B-GENE
(	O
IL-18	B-GENE
)	O
,	O
interleukin-33	B-GENE
and	O
interferon	B-GENE
γ	I-GENE
(	O
IFN-γ	B-GENE
;	O
interferon-gamma	B-GENE
)	O
and	O
most	O
preferably	O
said	O
inhibitor	O
to	O
be	O
employed	O
in	O
context	O
of	O
this	O
invention	O
is	O
a	O
human	O
interleukin-1	B-GENE
receptor	I-GENE
antagonist	O
(	O
IL-1Ra	B-GENE
)	O
,	O
like	O
anakinra	O
.	O


The	O
present	O
invention	O
relates	O
to	O
ACE2	B-GENE
for	O
the	O
therapeutic	O
treatment	O
or	O
prevention	O
of	O
a	O
fibrosis	O
or	O
liver	O
disorder	O
.	O


Gene	O
expression	O
profiling	O
in	O
multiple	O
myeloma	O
patients	O
identifies	O
genes	O
that	O
distinguish	O
between	O
patients	O
with	O
subsequent	O
early	O
death	O
or	O
long	O
survival	O
after	O
treatment	O
.	O
Poor	O
survival	O
is	O
linked	O
to	O
over-expression	O
of	O
genes	O
such	O
as	O
ASPM,	O
OPN3	B-GENE
and	O
CKS1B	B-GENE
which	O
are	O
located	O
in	O
chromosome	O
1q	O
.	O
Given	O
the	O
frequent	O
amplification	O
of	O
1q	O
in	O
many	O
cancers,	O
it	O
is	O
possible	O
that	O
these	O
genes	O
can	O
be	O
used	O
as	O
powerful	O
prognostic	O
markers	O
and	O
therapeutic	O
targets	O
for	O
multiple	O
myeloma	O
and	O
other	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
compounds,	O
in	O
particular	O
2-amino-3,4,5,-trisubstituted	O
thiophenes,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
the	O
uses	O
of	O
said	O
compounds	O
and	O
compositions	O
for	O
diseases	O
related	O
to	O
sphingosine-1-phosphate	B-GENE
(S1P)	I-GENE
receptors,	O
predominantly	O
S1P3	B-GENE
receptors	I-GENE
.	O
The	O
diseases	O
include	O
cardiovascular	O
diseases,	O
atherosclerosis,	O
cancer,	O
pulmonary	O
oedema,	O
autoimmune	O
disorders	O
and	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
.	O


This	O
invention	O
relates	O
to	O
compounds,	O
compositions,	O
and	O
methods	O
useful	O
for	O
modulating	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
and	O
/	O
or	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
PDGFr	B-GENE
)	O
gene	O
expression	O
using	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
molecules	O
.	O
This	O
invention	O
also	O
relates	O
to	O
compounds,	O
compositions,	O
and	O
methods	O
useful	O
for	O
modulating	O
the	O
expression	O
and	O
activity	O
of	O
other	O
genes	O
involved	O
in	O
pathways	O
of	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
and	O
/	O
or	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
PDGFr	B-GENE
)	O
gene	O
expression	O
and	O
/	O
or	O
activity	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
using	O
small	O
nucleic	O
acid	O
molecules	O
.	O
In	O
particular,	O
the	O
instant	O
invention	O
features	O
small	O
nucleic	O
acid	O
molecules,	O
such	O
as	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
double-stranded	O
RNA	O
(	O
dsRNA	O
)	O
,	O
micro-RNA	O
(	O
miRNA	O
)	O
,	O
and	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
molecules	O
and	O
methods	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
and	O
/	O
or	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
PDGFr	B-GENE
)	O
genes,	O
such	O
as	O
PDGF	B-GENE
and	O
/	O
or	O
PDGFr	B-GENE
.	O


Covalent	O
conjugates	O
of	O
an	O
α,α-disubstituted	O
glycine	O
ester	O
and	O
a	O
modulator	O
of	O
the	O
activity	O
of	O
a	O
target	O
intracellular	O
enzyme	O
or	O
receptor,	O
wherein	O
the	O
ester	O
group	O
of	O
the	O
conjugate	O
is	O
hydrolysable	O
by	O
one	O
or	O
more	O
intracellular	O
carboxylesterase	B-GENE
enzymes	O
to	O
the	O
corresponding	O
acid	O
and	O
the	O
α,α-disubstituted	O
glycine	O
ester	O
is	O
conjugated	O
to	O
the	O
modulator	O
at	O
a	O
position	O
remote	O
from	O
the	O
binding	O
interface	O
between	O
the	O
inhibitor	O
and	O
the	O
target	O
enzyme	O
or	O
receptor	O
pass	O
into	O
cells	O
and	O
the	O
active	O
acid	O
hydrolysis	O
product	O
accumulates	O
within	O
the	O
cells	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
fused	O
pyridone	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
(	O
I	O
)	O
that	O
are	O
M1	B-GENE
receptor	I-GENE
positive	O
allosteric	O
modulators	O
and	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
the	O
M1	B-GENE
receptor	I-GENE
is	O
involved,	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
schizophrenia,	O
pain	O
or	O
sleep	O
disorders	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
the	O
M1	B-GENE
receptor	I-GENE
.	O


The	O
adrenergic	O
receptors	O
or	O
adrenoceptors	B-GENE
are	O
a	O
family	O
of	O
G-protein	B-GENE
coupled	I-GENE
receptors	I-GENE
split	O
into	O
α	O
and	O
β	O
subclasses	O
.	O
The	O
adrenoceptors	B-GENE
have	O
important	O
roles	O
in	O
regulating	O
a	O
myriad	O
of	O
physiological	O
conditions	O
and	O
their	O
malfunction	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
a	O
number	O
of	O
diseases	O
.	O
Disclosed	O
herein	O
are	O
a	O
series	O
of	O
novel	O
guanidine	O
and	O
2-aminoimidazoline	O
compounds	O
which	O
are	O
ligands	O
of	O
the	O
alpha2-adrenoceptor	B-GENE
(	O
α2-ARs	B-GENE
)	O
subclass	O
of	O
adrenergic	O
receptors	O
.	O
The	O
invention	O
also	O
provides	O
for	O
pharmaceutical	O
compositions	O
comprising	O
the	O
novel	O
compounds	O
.	O
The	O
compounds	O
are	O
suitable	O
for	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
α2-ARs	B-GENE
associated	O
disorders,	O
such	O
as	O
depression,	O
schizophrenia,	O
glaucoma	O
and	O
analgesia	O
.	O


In	O
this	O
application	O
is	O
described	O
a	O
novel,	O
multiparameter	O
analysis	O
of	O
TCR-coupled	O
signaling	O
and	O
function	O
in	O
resting	O
and	O
activated	O
naive	O
and	O
memory	O
CD4	B-GENE
T	O
cells,	O
revealing	O
a	O
biochemical	O
basis	O
for	O
immunological	O
recall	O
.	O
Results	O
reveal	O
a	O
novel	O
biochemical	O
signature	O
imparted	O
to	O
memory	O
CD4	B-GENE
T	O
cells	O
enabling	O
efficacious	O
responses	O
through	O
increased	O
ZAP-70	B-GENE
expression	O
and	O
reduced	O
accumulation	O
of	O
downstream	O
signaling	O
events	O
.	O


Piperazinyl	O
oxoalkyl	O
tetrahydro-beta-carbolines	O
and	O
related	O
analogues	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
are	O
provided,	O
as	O
are	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
.	O
Such	O
compounds	O
may	O
generally	O
be	O
used	O
to	O
modulate	O
ligand	O
binding	O
to	O
histamine	B-GENE
H3	I-GENE
receptors	I-GENE
in	O
vivo	O
or	O
in	O
vitro,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
disorders	O
in	O
humans,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O
Pharmaceutical	O
compositions	O
and	O
therapeutic	O
methods	O
are	O
provided,	O
as	O
are	O
methods	O
for	O
using	O
such	O
ligands	O
for	O
detecting	O
histamine	B-GENE
H3	I-GENE
receptors	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
receptor	O
localization	O
studies	O
)	O
.	O


The	O
non-toxic	O
proteolytic	O
C	O
fragment	O
of	O
tetanus	B-GENE
toxin	I-GENE
(	O
TTC	B-GENE
peptide	O
)	O
has	O
the	O
same	O
ability	O
to	O
bind	O
nerve	O
cells	O
and	O
be	O
retrogradely	O
transported	O
through	O
a	O
synapse	O
as	O
the	O
native	O
toxin	O
.	O
A	O
hybrid	O
protein	O
encoded	O
by	O
the	O
LacZ-TTC	B-GENE
gene	O
fusion	O
retains	O
the	O
biological	O
functions	O
of	O
both	O
proteins	O
in	O
vivo,	O
i	O
.	O
e	O
.	O
retrograde	O
transynaptic	O
transport	O
of	O
the	O
TTC	B-GENE
fragment	O
and	O
βgal	B-GENE
enzymatic	O
activity	O
.	O
After	O
intramuscular	O
injection,	O
enzymatic	O
activity	O
can	O
be	O
detected	O
in	O
motoneurons	O
and	O
connected	O
neurons	O
of	O
brainstem	O
areas	O
.	O
This	O
strategy	O
is	O
useful	O
for	O
the	O
delivery	O
of	O
a	O
biological	O
activity	O
to	O
neurons	O
from	O
the	O
periphery	O
to	O
the	O
central	O
nervous	O
system	O
.	O
Such	O
a	O
hybrid	O
protein	O
can	O
also	O
be	O
used	O
to	O
map	O
synaptic	O
connections	O
between	O
neural	O
cells	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
and	O
/	O
or	O
energy	O
expenditure	O
in	O
a	O
subject,	O
e	O
.	O
g	O
.	O
,	O
to	O
treat	O
or	O
prevent	O
obesity	O
and	O
/	O
or	O
a	O
related	O
condition	O
and	O
/	O
or	O
to	O
reduce	O
adiposity,	O
the	O
method	O
comprising	O
increasing	O
the	O
level	O
and	O
/	O
or	O
activity	O
of	O
Hypoxia	B-GENE
Induced	I-GENE
Factor	I-GENE
1α	I-GENE
(	O
HIF-1α	B-GENE
)	O
in	O
a	O
cell,	O
tissue	O
or	O
organ	O
of	O
the	O
subject,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
in	O
a	O
subject,	O
the	O
method	O
comprising	O
administering	O
an	O
iron	O
chelating	O
agent	O
to	O
the	O
subject,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
treating	O
diabetes	O
and	O
related	O
disorders,	O
such	O
as	O
metabolic	O
syndromes	O
(	O
which	O
includes	O
insulin	B-GENE
resistance	O
)	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
osteopontin	B-GENE
(	O
OPN	B-GENE
)	O
,	O
which	O
includes	O
an	O
antibody,	O
antibody	O
fragment,	O
siRNA,	O
and	O
aptamer	O
.	O
Also	O
disclosed	O
are	O
methods	O
for	O
increasing	O
glucose	O
uptake	O
by	O
cells	O
in	O
a	O
subject,	O
by	O
administering	O
an	O
inhibitor	O
of	O
OPN	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoline	O
compounds	O
.	O
The	O
compounds	O
possess	O
valuable	O
therapeutic	O
properties	O
and	O
are	O
particularly	O
suitable,	O
for	O
treating	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	O
5-HT6	B-GENE
receptor	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
R	O
is	O
a	O
moiety	O
of	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A,	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
specification,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
n	O
is	O
0,	O
1	O
or	O
2	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
m	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Ra,	O
Rb	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen,	O
CN,	O
C1-C4-alkyl,	O
C1-C4-haloalkyl,	O
C1-C4-alkoxy,	O
C1-C4-haloalkoxy,	O
C	O
(	O
O	O
)	O
Raa,	O
C	O
(	O
O	O
)	O
NRccRbb	O
and	O
NRccRbb	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
X	O
is	O
CH2,	O
C	O
(	O
O	O
)	O
,	O
S,	O
S	O
(	O
O	O
)	O
or	O
S	O
(	O
O	O
)	O
2	O
;	O
which	O
is	O
located	O
in	O
the	O
3-	O
or	O
4-position	O
of	O
the	O
quinoline	O
ring	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Ar	O
is	O
a	O
radical	O
Ar1,	O
Ar2—Ar3	O
or	O
Ar2—O—Ar3,	O
wherein	O
Ar1,	O
Ar2	O
and	O
Ar3	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aryl	O
or	O
hetaryl	O
wherein	O
aryl	O
or	O
hetaryl	O
moieties	O
may	O
be	O
unsubstituted	O
or	O
may	O
carry	O
1,	O
2,	O
3	O
substituents	O
Rx,	O
wherein	O
	O
and	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
and	O
the	O
N-oxides	O
thereof	O
.	O


Provided	O
herein	O
are	O
novel	O
sirtuin-modulating	O
compounds	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
and	O
methods	O
of	O
use	O
thereof	O
.	O
The	O
sirtuin-modulating	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell,	O
and	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including,	O
for	O
example,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress,	O
diabetes,	O
obesity,	O
neurodegenerative	O
diseases,	O
cardiovascular	O
disease,	O
blood	O
clotting	O
disorders,	O
inflammation,	O
cancer,	O
and	O
/	O
or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O
Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
sirtuin-modulating	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
represented	O
by	O
formula	O
1	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein,	O
R1	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
R10,	O
R11,	O
R12,	O
R13	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
in	O
all	O
its	O
stereoisomeric	O
and	O
tautomeric	O
forms	O
and	O
mixtures	O
thereof	O
in	O
all	O
ratios,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutically	O
acceptable	O
solvates,	O
pharmaceutically	O
acceptable	O
polymorphs	O
and	O
prodrugs	O
.	O
These	O
compounds	O
are	O
useful	O
for	O
treatment	O
of	O
inflammatory	O
disorders	O
including	O
those	O
caused	O
by	O
elevated	O
levels	O
of	O
proinflammatory	O
cytokines	O
such	O
as	O
Tumor	B-GENE
Necrosis	I-GENE
Factor	I-GENE
(	O
TNF-α	B-GENE
and	O
/	O
or	O
interleukins	B-GENE
(	O
IL-1β,	O
IL-6,	O
IL-8	B-GENE
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
compounds	O
of	O
formula	O
1	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
pre-eclampsia	O
and	O
eclampsia	O
using	O
compounds	O
that	O
increase	O
VEGF	B-GENE
or	O
PlGF	B-GENE
levels	O
or	O
compounds	O
that	O
decrease	O
sFlt-1	B-GENE
levels	O
.	O
Compounds	O
that	O
inhibit	O
the	O
binding	O
of	O
VEGF	B-GENE
or	O
PlGF	B-GENE
to	O
sFlt1—are	O
also	O
disclosed	O
herein	O
for	O
the	O
treatment	O
of	O
pre-eclampsia	O
or	O
eclampsia	O
.	O


Methods	O
for	O
treating	O
neuroblastoma	O
in	O
a	O
subject	O
are	O
provided	O
.	O
The	O
methods	O
include	O
administering	O
to	O
the	O
subject	O
nucleic	O
acid	O
that	O
is	O
capable	O
of	O
causing	O
a	O
significant	O
reduction	O
of	O
the	O
amount	O
of	O
doublecortin	B-GENE
like	I-GENE
protein	I-GENE
(	O
DCL	B-GENE
)	O
in	O
the	O
subject	O
.	O
The	O
nucleic	O
acids	O
include	O
antisense	O
oligonucleotides	O
and	O
small	O
interfering	O
RNA	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
according	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
where	O
the	O
definitions	O
of	O
the	O
substituents	O
R1,	O
R2,	O
Ar	O
and	O
X	O
are	O
as	O
specified	O
in	O
the	O
description,	O
and	O
to	O
their	O
physiologically	O
tolerated	O
salts,	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
and	O
their	O
use	O
as	O
medicaments	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
These	O
compounds	O
are	O
poly(ADP-ribose)	B-GENE
polymerase	I-GENE
(	O
PARP	B-GENE
)	O
inhibitors	O
.	O


The	O
present	O
invention	O
provides	O
mTOR	B-GENE
inhibitors	O
of	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
intermediates	O
thereof	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O


The	O
present	O
inventors	O
developed	O
5a	O
/	O
2a	O
intergenotypic	O
recombinants	O
in	O
which	O
the	O
JFH1	O
structural	O
genes	O
(	O
Core,	O
E1	B-GENE
and	O
E2	B-GENE
)	O
,	O
p7	B-GENE
and	O
all	O
of	O
or	O
part	O
of	O
NS2	B-GENE
were	O
replaced	O
by	O
the	O
corresponding	O
genes	O
of	O
the	O
genotype	O
5a	O
reference	O
strain	O
SA13	O
.	O
Compared	O
to	O
the	O
J6	O
/	O
JFH	O
control	O
virus,	O
after	O
transfection	O
of	O
in	O
vitro	O
transcripts	O
in	O
Huh7	O
.	O
5	O
cells,	O
production	O
of	O
infectious	O
viruses	O
was	O
delayed	O
.	O
However,	O
in	O
subsequent	O
viral	O
passages	O
efficient	O
spread	O
of	O
infection	O
and	O
HCV	O
RNA	O
titers	O
as	O
high	O
as	O
for	O
J6	O
/	O
JFH	O
were	O
obtained	O
.	O
Infectivity	O
titers	O
were	O
at	O
all	O
time	O
points	O
analyzed	O
comparable	O
to	O
J6	O
/	O
JFH	O
control	O
virus	O
.	O
Sequence	O
analysis	O
of	O
recovered	O
5a	O
/	O
2a	O
recombinants	O
from	O
2	O
serial	O
passages	O
and	O
subsequent	O
reverse	O
genetic	O
studies	O
revealed	O
adaptive	O
mutations	O
in	O
p7,	O
NS2	B-GENE
and	O
/	O
or	O
NS3	B-GENE
.	O
Infectivity	O
of	O
the	O
5a	O
/	O
2a	O
viruses	O
was	O
CD81	B-GENE
and	O
SR-BI	B-GENE
dependant,	O
and	O
the	O
recombinant	O
viruses	O
could	O
be	O
neutralized	O
by	O
chronic	O
phase	O
sera	O
from	O
patients	O
infected	O
with	O
genotype	O
5a	O
.	O
Conclusion	O
:	O
The	O
developed	O
5a	O
/	O
2a	O
viruses	O
provide	O
a	O
robust	O
in	O
vitro	O
tool	O
for	O
research	O
in	O
HCV	O
genotype	O
5,	O
including	O
vaccine	O
studies	O
and	O
functional	O
analyses	O
of	O
an	O
increasingly	O
important	O
genotype	O
in	O
South	O
Africa	O
and	O
Europe	O
.	O


Oral	O
compositions	O
comprising	O
an	O
association	O
of	O
one	O
or	O
of	O
a	O
mixture	O
of	O
phytoestrogens,	O
selective	O
for	O
the	O
estrogen	O
receptor-β,	O
with	O
dietary	O
fibres	O
are	O
described	O
.	O
The	O
compositions	O
thereof	O
can	O
be	O
profitably	O
used	O
for	O
the	O
prophylactic	O
and	O
therapeutic	O
treatment	O
in	O
mammals,	O
including	O
humans,	O
of	O
health	O
conditions	O
characterised	O
by	O
a	O
high	O
risk	O
of	O
onset	O
and	O
recurrence	O
of	O
intestinal	O
adenomas	O
(	O
adenopolyposis	O
coli	O
)	O
,	O
and	O
of	O
adenoma	O
'	O
s	O
progression	O
to	O
colorectal	O
carcinoma	O
.	O
In	O
presence	O
of	O
pre-cancerous	O
lesions	O
in	O
the	O
colon,	O
characterised	O
by	O
mutations	O
of	O
the	O
APC	B-GENE
tumor	O
suppressor	O
and	O
defined	O
as	O
polyps	O
or	O
adenomas,	O
the	O
oral	O
compositions	O
disclosed	O
can	O
be	O
in	O
fact	O
profitably	O
used	O
to	O
reduce	O
the	O
number	O
and	O
volume	O
of	O
polyps,	O
and	O
to	O
prevent	O
their	O
progression	O
to	O
neoplastic	O
transformation,	O
reducing	O
their	O
degree	O
of	O
dysplasia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
2-phenyl-4-cyclopropyl-pyrimidine	O
derivatives	O
and	O
their	O
use	O
as	O
P2Y12	B-GENE
receptor	O
antagonists	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
peripheral	O
vascular,	O
of	O
visceral-,	O
hepatic-	O
and	O
renal-vascular,	O
of	O
cardiovascular	O
and	O
of	O
cerebrovascular	O
diseases	O
or	O
conditions	O
associated	O
with	O
platelet	O
aggregation,	O
including	O
thrombosis	O
in	O
humans	O
and	O
other	O
mammals	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
where	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R9,	O
Ar,	O
Q1,	O
Q2	O
and	O
Q3	O
are	O
each	O
as	O
defined	O
below	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
have	O
antithrombotic	O
activity	O
and	O
inhibit	O
especially	O
protease-activated	B-GENE
receptor	I-GENE
1	I-GENE
(	O
PAR1	B-GENE
)	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
process	O
for	O
preparing	O
the	O
compound	O
of	O
the	O
formula	O
I	O
and	O
to	O
the	O
use	O
thereof	O
as	O
a	O
medicament	O
.	O


This	O
invention	O
relates	O
generally	O
to	O
benzimidazole-based	O
modulators	O
of	O
Liver	B-GENE
X	I-GENE
receptors	I-GENE
(	O
LXRs	B-GENE
)	O
having	O
formula	O
(	O
I	O
)	O
and	O
related	O
methods	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R2	O
is	O
C6-C10	O
aryl	O
or	O
heteroaryl	O
including	O
5-10	O
atoms,	O
each	O
of	O
which	O
is	O
:	O
(	O
i	O
)	O
substituted	O
with	O
1	O
R7,	O
and	O
(	O
ii	O
)	O
optionally	O
substituted	O
with	O
from	O
1-5	O
Re	O
;	O
and	O
R1,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
and	O
Re	O
are	O
defined	O
herein	O
.	O


The	O
invention	O
relates	O
to	O
a	O
viral	O
vector	O
for	O
treating	O
Alzheimers	O
disease,	O
which	O
vector	O
comprises	O
a	O
cholesterol	B-GENE
24-hydroxylase	I-GENE
(	O
CYP46A1	O
)	O
encoding	O
nucleic	O
acid	O
.	O
In	O
a	O
preferred	O
embodiment,	O
the	O
viral	O
vector	O
may	O
be	O
an	O
Adeno-Associated-Virus	O
(	O
AAV	O
)	O
vector,	O
preferably	O
an	O
AVV5	O
vector	O
.	O
The	O
vector	O
may	O
be	O
useful	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
Alzheimers	O
disease	O
in	O
a	O
subject,	O
wherein	O
the	O
vector	O
is	O
to	O
be	O
administered	O
directly	O
into	O
the	O
brain	O
of	O
the	O
subject	O
or	O
by	O
intravenous	O
or	O
intrathecal	O
injection	O
.	O


Methods	O
and	O
compositions	O
comprising	O
an	O
anti-ostepontin	O
agent	O
and	O
/	O
or	O
a	O
PDGF	B-GENE
receptor	I-GENE
blocker	O
or	O
antagonist,	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
anti-connexin	O
agents,	O
for	O
example,	O
one	O
or	O
more	O
anti-connexin	O
polynucleotides	O
and	O
/	O
or	O
one	O
or	O
more	O
anti-connexin	O
peptides	O
or	O
peptidomimetics,	O
are	O
provided	O
for	O
the	O
promotion	O
and	O
/	O
or	O
improvement	O
of	O
wound	O
healing	O
and	O
/	O
or	O
tissue	O
repair,	O
and	O
for	O
anti-scarring,	O
anti-inflammatory,	O
anti-fibrosis	O
and	O
anti-adhesion	O
indications	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
claim	O
1	O
comprising	O
an	O
SGLT2	B-GENE
inhibitor,	O
a	O
DPPIV	B-GENE
inhibitor	O
and	O
a	O
third	O
antidiabetic	O
agent	O
which	O
is	O
suitable	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
one	O
or	O
more	O
conditions	O
selected	O
from	O
type	O
1	O
diabetes	O
mellitus,	O
type	O
2	O
diabetes	O
mellitus,	O
impaired	O
glucose	O
tolerance	O
and	O
hyperglycemia	O
.	O
In	O
addition	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
of	O
metabolic	O
disorders	O
and	O
related	O
conditions	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
a	O
nucleic	O
acid,	O
preferably	O
binding	O
to	O
C5a,	O
selected	O
from	O
the	O
group	O
comprising	O
type	O
A	O
nucleic	O
acids,	O
type	O
B	O
nucleic	O
acids,	O
type	O
C	O
nucleic	O
acids,	O
type	O
D	O
nucleic	O
acids	O
and	O
nucleic	O
acids	O
having	O
a	O
nucleic	O
acid	O
sequence	O
according	O
to	O
any	O
of	O
SEQ	O
.	O
ID	O
.	O
No	O
.	O
73	O
to	O
79	O
.	O


The	O
HIV	O
regulatory	O
proteins	O
Tat	B-GENE
and	O
Rev	B-GENE
accumulate	O
in	O
nucleoli	O
of	O
human	O
cells	O
.	O
No	O
functional	O
role	O
has	O
been	O
attributed	O
to	O
this	O
localization	O
.	O
Recently	O
it	O
was	O
demonstrated	O
that	O
expression	O
of	O
Rev	B-GENE
induces	O
nucleolar	O
re-localization	O
of	O
some	O
nuclear	O
factors	O
involved	O
in	O
Rev	B-GENE
export	O
.	O
Thus,	O
it	O
is	O
likely	O
that	O
the	O
nucleolus	O
plays	O
a	O
critical	O
role	O
in	O
Rev-mediated	O
export	O
of	O
singly	O
spliced	O
and	O
unspliced	O
HIV-1	O
RNAs	O
.	O
As	O
a	O
test	O
for	O
trafficking	O
of	O
HIV-1	O
RNAs	O
into	O
the	O
nucleolus,	O
a	O
hammerhead	O
ribozyme	O
which	O
specifically	O
cleaves	O
HIV-1	O
RNA	O
was	O
joined	O
to	O
the	O
U16	O
snoRNA	O
resulting	O
in	O
accumulation	O
of	O
the	O
ribozyme	O
within	O
nucleoli	O
of	O
human	O
cells	O
.	O
Stably	O
transduced	O
human	O
T-cells	O
expressing	O
this	O
nucleolar	O
localized	O
ribozyme	O
dramatically	O
suppressed	O
HIV-1	O
replication,	O
confirming	O
a	O
possible	O
trafficking	O
of	O
the	O
HIV	O
RNA	O
through	O
the	O
nucleoli	O
of	O
human	O
cells	O
.	O
In	O
addition,	O
a	O
TAR	O
element	O
which	O
binds	O
Tat	B-GENE
was	O
joined	O
to	O
the	O
U16	O
snoRNA,	O
also	O
resulting	O
in	O
localization	O
in	O
the	O
nucleoli	O
and	O
inhibiting	O
HIV	O
replication	O
.	O


Briefly	O
described,	O
embodiments	O
of	O
this	O
disclosure	O
include	O
compositions,	O
pharmaceutical	O
compositions,	O
methods	O
of	O
treating	O
a	O
host	O
infected	O
with	O
a	O
virus	O
from	O
the	O
Flaviviridae	O
family	O
of	O
viruses,	O
methods	O
of	O
treating	O
HCV	O
replication	O
in	O
a	O
host,	O
methods	O
of	O
inhibiting	O
the	O
binding	O
of	O
NS4B	B-GENE
polypeptide	O
to	O
the	O
3′UTR	B-GENE
of	I-GENE
HCV	I-GENE
negative	O
strand	O
RNA	O
in	O
a	O
host,	O
methods	O
of	O
treating	O
liver	O
fibrosis	O
in	O
a	O
host,	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
refers	O
to	O
the	O
use	O
of	O
compounds	O
binding	O
to	O
the	O
sigma	B-GENE
receptor	I-GENE
for	O
the	O
treatment	O
or	O
prevention	O
of	O
neuropathic	O
pain	O
resulting	O
from	O
chemotherapy	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
which	O
are	O
useful	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors,	O
as	O
well	O
as	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O
In	O
some	O
embodiments,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
c-kit,	O
PDGFRα,	O
PDGFRβ,	O
CSF1R,	O
Abl,	O
BCR-Abl,	O
CSK,	O
JNK1,	O
JNK2,	O
p38,	O
p70S6K,	O
TGFβ,	O
SRC,	O
EGFR,	O
trkB,	O
FGFR3,	O
Fes,	O
Lck,	O
Syk,	O
RAF,	O
MKK4,	O
MKK6,	O
SAPK2β,	O
BRK,	O
Fms,	O
KDR,	O
c-raf	B-GENE
or	O
b-raf	B-GENE
kinases	B-GENE
.	O


Provided	O
herein	O
are	O
small	O
molecule	O
compounds	O
that	O
alter	O
the	O
transport	O
activity	O
of	O
solute	O
transporters,	O
particularly	O
urea	B-GENE
transporters	I-GENE
.	O
The	O
compounds	O
described	O
herein	O
belong	O
to	O
the	O
benzenesulfonanilide	O
class	O
of	O
compounds	O
.	O
The	O
compounds	O
described	O
herein	O
are	O
useful	O
for	O
increasing	O
solute	O
clearance	O
in	O
states	O
of	O
fluid	O
overload	O
and	O
for	O
treating	O
cardiovascular,	O
renal,	O
and	O
metabolic	O
diseases,	O
disorders,	O
and	O
conditions	O
.	O
Methods	O
for	O
identifying	O
and	O
using	O
these	O
agents	O
that	O
inhibit	O
urea	B-GENE
transporters	I-GENE
are	O
described	O
herein	O
.	O


This	O
invention	O
relates	O
to	O
a	O
Bicyclic	O
triterpenoid	O
Iripallidal	O
as	O
a	O
novel	O
anti-glioma	O
and	O
anti	O
neoplastic	O
agent,	O
having	O
the	O
composition	O
[	O
(	O
−	O
)	O
(	O
6R,10S,11S,18R,22S	O
)	O
-26	O
Hydroxy-22-α	O
methylcyloirid-16-enal	O
NSC	O
631939	O
]	O
,	O
wherein	O
it	O
binds	O
to	O
Ras	O
GRP3,	O
a	O
phorbol	O
ester	O
receptor	O
that	O
links	O
DAG	O
/	O
phorbolester	O
signaling	O
with	O
Ras	O
activation	O
and	O
induces	O
phosphorylation	O
of	O
ER	B-GENE
K1/2	I-GENE
in	O
a	O
Ras	O
dependent	O
manner,	O
reducing	O
proliferation	O
of	O
cancer	O
cell	O
lines	O
to	O
the	O
extent	O
of	O
50-70	O
%	O
.	O


This	O
invention	O
relates	O
to	O
certain	O
complexes	O
of	O
ascorbic	O
acid	O
and	O
its	O
derivatives	O
with	O
certain	O
natural	O
antioxidant	O
and	O
anti-inflammatory	O
ketones	O
for	O
topical	O
or	O
oral	O
application	O
;	O
said	O
complexes	O
having	O
general	O
chemical	O
formula	O
(	O
I	O
)	O
,	O
its	O
isomers,	O
and	O
salts	O
thereof,	O
including	O
their	O
optically	O
active	O
or	O
racemic	O
forms	O
.	O
This	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
skin	O
condition,	O
including	O
dark	O
skin,	O
age	O
spots,	O
acne,	O
inflammation,	O
loss	O
of	O
cellular	O
antioxidants,	O
collagen	O
loss	O
with	O
aging,	O
loss	O
of	O
skin	O
pliability,	O
loss	O
of	O
skin	O
suppleness,	O
skin	O
wrinkles,	O
oxidation,	O
damage	O
from	O
radiation,	O
malfunction	O
of	O
matrix	O
metalloproteases,	O
malfunction	O
of	O
tyrosinases,	O
damage	O
from	O
free	O
radicals,	O
photo-damage,	O
nutritional	O
deficiency,	O
and	O
combinations	O
thereof	O
;	O


The	O
disclosure	O
provides	O
compounds	O
of	O
Formula	O
I,	O
including	O
pharmaceutically	O
acceptable	O
salts,	O
their	O
pharmaceutical	O
compositions,	O
and	O
their	O
uses	O
in	O
inhibiting	O
β-amyloid	B-GENE
peptide	I-GENE
(	O
β-AP	B-GENE
)	O
production	O
.	O


4-	O
[	O
4-	O
(	O
2-Adamantylcarbamoyl	O
)	O
-5-tert-butyl-pyrazol-1-yl	O
]	O
benzoic	O
acid	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof	O
and	O
a	O
particular	O
crystalline	O
form	O
of	O
the	O
Agent	O
(	O
Form	O
1	O
)	O
;	O
their	O
use	O
in	O
the	O
inhibition	O
of	O
11βHSD1,	O
processes	O
for	O
making	O
them	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
also	O
described	O
.	O


Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
promoting	O
neuroprotection	O
in	O
a	O
subject	O
and	O
for	O
treating	O
a	O
neural	O
disorder	O
associated	O
with	O
protein	O
aggregation	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
agent	O
that	O
increases	O
expression	O
or	O
activity	O
of	O
cathepsin-D	B-GENE
.	O
Also	O
provided	O
are	O
methods	O
of	O
screening	O
for	O
agents	O
that	O
increase	O
expression	O
or	O
activity	O
of	O
cathepsin-D	B-GENE
and	O
methods	O
of	O
screening	O
for	O
neuroprotective	O
agents	O
.	O


The	O
invention	O
provides	O
compounds	O
that	O
inhibit	O
CK2	B-GENE
and	O
/	O
or	O
Pim	B-GENE
kinases	I-GENE
and	O
compositions	O
containing	O
such	O
compounds	O
.	O
These	O
compounds	O
and	O
compositions	O
are	O
useful	O
for	O
treating	O
proliferative	O
disorders	O
such	O
as	O
cancer,	O
as	O
well	O
as	O
other	O
kinase-associated	O
conditions	O
including	O
inflammation,	O
pain,	O
infections,	O
and	O
certain	O
immunological	O
disorders	O
.	O


There	O
is	O
provided	O
a	O
series	O
of	O
novel	O
α-	O
(	O
N-sulfonamido	O
)	O
acetamide	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2	O
and	O
n	O
are	O
defined	O
herein,	O
which	O
are	O
inhibitors	O
of	O
β-amyloid	B-GENE
peptide	I-GENE
(	O
β-AP	B-GENE
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
anti-amyloid	O
activity	O
.	O


The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
the	O
RhoA	B-GENE
gene,	O
and	O
more	O
particularly	O
to	O
the	O
downregulation	O
of	O
RhoA	B-GENE
by	O
chemically	O
modified	O
oligonucleotides	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
capable	O
of	O
inhibiting	O
the	O
mutant	O
huntingtin	B-GENE
protein,	O
inhibiting	O
or	O
reducing	O
polyglutamine-induced	O
protein	O
aggregation,	O
and	O
/	O
or	O
altering	O
huntingtin	B-GENE
protein	O
conformation,	O
which	O
inhibition	O
is	O
useful	O
in	O
the	O
prevention,	O
amelioration	O
and	O
/	O
or	O
treatment	O
of	O
neurodegenerative	O
diseases,	O
and	O
protein	O
aggregation	O
diseases	O
more	O
generally	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
Huntington	O
'	O
s	O
disease	O
.	O
The	O
invention	O
provides	O
polypeptide	O
and	O
nucleic	O
acid	O
TARGETs	O
and	O
siRNA	O
sequences	O
based	O
on	O
these	O


This	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
activators	O
of	O
glucokinase	B-GENE
and	O
thus	O
may	O
be	O
useful	O
for	O
the	O
management,	O
treatment,	O
control,	O
or	O
adjunct	O
treatment	O
of	O
diseases,	O
where	O
increasing	O
glucokinase	B-GENE
activity	O
is	O
beneficial	O
.	O
The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A	O
and	O
B	O
are	O
further	O
defined	O
in	O
the	O
application	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
mutants	O
of	O
HCV	B-GENE
NS3/4A	I-GENE
protease	I-GENE
.	O
More	O
particularly,	O
the	O
present	O
invention	O
identifies	O
mutant	O
of	O
HCV	B-GENE
NS3/4A	I-GENE
protease	I-GENE
that	O
are	O
resistant	O
to	O
drug	O
treatment	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
toxin	O
moiety	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
chlorotoxin	B-GENE
moiety	I-GENE
)	O
as	O
a	O
carrier	O
for	O
therapeutic	O
agents,	O
e	O
.	O
g	O
.	O
,	O
therapeutic	O
agents	O
that	O
require	O
intracellular	O
uptake	O
to	O
exert	O
their	O
effects	O
.	O
For	O
example,	O
in	O
some	O
embodiments,	O
the	O
present	O
invention	O
provides	O
conjugates	O
comprising	O
a	O
toxin	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
chlorotoxin	B-GENE
)	O
moiety	O
and	O
an	O
anti-cancer	O
moiety	O
and	O
methods	O
for	O
using	O
such	O
conjugates	O
to	O
increase	O
cellular	O
uptake	O
and	O
/	O
or	O
increase	O
specificity	O
for	O
cancer	O
cells	O
of	O
the	O
anti-cancer	O
drug	O
.	O
In	O
some	O
embodiments,	O
the	O
present	O
invention	O
provides	O
conjugates	O
comprising	O
a	O
toxin	O
moiety	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
chlorotoxin	B-GENE
moiety	I-GENE
)	O
and	O
a	O
nucleic	O
acid	O
agent	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treatment	O
involving	O
administration	O
of	O
such	O
conjugates,	O
and	O
pharmaceutical	O
compositions	O
and	O
kits	O
useful	O
for	O
carrying	O
out	O
such	O
methods	O
of	O
treatment	O
.	O


The	O
present	O
invention	O
provides	O
azole	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
of	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
their	O
use	O
in	O
treating	O
human	O
or	O
animal	O
disorders	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
can	O
be	O
useful	O
as	O
inhibitors	O
of	O
protein	B-GENE
tyrosine	I-GENE
phosphatases	I-GENE
and	O
thus	O
can	O
be	O
useful	O
for	O
the	O
management,	O
treatment,	O
control,	O
or	O
the	O
adjunct	O
treatment	O
of	O
diseases	O
mediated	O
by	O
PTPase	B-GENE
activity	O
.	O
Such	O
diseases	O
include	O
Type	O
I	O
diabetes	O
and	O
Type	O
II	O
diabetes	O
.	O


The	O
invention	O
relates	O
to	O
a	O
topical	O
composition	O
and	O
a	O
method	O
for	O
treating	O
psoriasis	O
.	O
The	O
topical	O
composition	O
comprises	O
one	O
or	O
more	O
compound	O
that	O
inhibits	O
the	O
production	O
of	O
IL-12	B-GENE
and	O
IL-23	B-GENE
.	O


The	O
present	O
invention	O
provides	O
compounds	O
according	O
to	O
Formulas	O
I,	O
II,	O
III,	O
IV,	O
V,	O
VI,	O
VII	O
or	O
VIII	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
their	O
use	O
as	O
H3	B-GENE
antagonists	O
/	O
inverse	O
agonists,	O
processes	O
for	O
their	O
preparation,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O


This	O
invention	O
is	O
directed	O
to	O
compounds,	O
which	O
are	O
PDE10A	B-GENE
enzyme	O
inhibitors	O
.	O
The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
neurodegenerative	O
disorder	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
psychiatric	O
disorder	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
.	O


This	O
application	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
the	O
degradation	O
of	O
an	O
extracellular	O
matrix	O
associated	O
with	O
islet	O
beta	O
cells,	O
said	O
method	O
comprising	O
contacting	O
said	O
extracellular	O
matrix	O
with	O
an	O
effective	O
amount	O
of	O
a	O
heparanase	B-GENE
inhibitor	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
which	O
are	O
useful	O
for	O
the	O
therapeutic	O
treatment	O
of	O
diseases	O
associated	O
with	O
the	O
modulation	O
or	O
inhibition	O
of	O
11β-HSD1	B-GENE
in	O
mammals	O
.	O


The	O
present	O
invention	O
provides	O
siRNA	O
nucleic	O
acid	O
molecules	O
that	O
inhibit	O
Notch1	B-GENE
expression	O
.	O
Methods	O
of	O
using	O
the	O
nucleic	O
acid	O
molecules	O
are	O
also	O
provided	O
.	O


This	O
disclosure	O
concerns	O
the	O
use	O
of	O
agonists	O
of	O
AMP-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
AMPK	B-GENE
)	O
for	O
improving	O
exercise	O
and	O
modifying	O
energy	O
metabolism	O
in	O
a	O
subject	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
a	O
combination	O
of	O
AMPK	B-GENE
and	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
(PPAR)	I-GENE
δ	I-GENE
agonists	O
for	O
improving	O
exercise	O
performance	O
in	O
a	O
subject,	O
methods	O
for	O
identifying	O
substance-enhanced	O
exercise	O
performance	O
in	O
a	O
subject,	O
and	O
methods	O
for	O
identifying	O
compounds	O
that	O
affect	O
the	O
interaction	O
of	O
PPARδ	B-GENE
with	O
exercise-induced	O
kinases	B-GENE
.	O


Compositions	O
and	O
methods	O
for	O
tissue	O
repair	O
are	O
provided	O
including	O
cell	O
binding	O
peptides	O
and	O
growth	B-GENE
factor	I-GENE
binding	O
peptides	O
.	O
The	O
cell	O
binding	O
peptides	O
bind	O
to	O
one	O
or	O
more	O
of	O
stem	O
cells,	O
fibroblasts,	O
or	O
endothelial	O
cells	O
.	O
The	O
growth	B-GENE
factor	I-GENE
binding	O
peptides	O
include	O
platelet	B-GENE
derived	I-GENE
growth	B-GENE
factor	I-GENE
(	O
PDGF	B-GENE
)	O
binding	O
peptides	O
and	O
growth	B-GENE
differentiation	I-GENE
factor	I-GENE
(	O
GDF	B-GENE
)	O
binding	O
peptides	O
.	O
The	O
tissue	O
for	O
repair	O
includes	O
tendon,	O
muscle,	O
connective	O
tissue,	O
ligament,	O
cardiac	O
tissue,	O
vascular	O
tissue,	O
or	O
dermis	O
.	O
Implantable	O
devices	O
for	O
tissue	O
repair	O
are	O
provided	O
to	O
which	O
the	O
cell	O
and	O
growth	B-GENE
factor	I-GENE
binding	O
peptides	O
are	O
attached,	O
such	O
as	O
acellular	O
extracellular	O
matrix	O
having	O
attached	O
binding	O
peptide	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
selective	O
inhibitors	O
of	O
JAK2	B-GENE
kinase	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
acceptable	O
compositions	O
comprising	O
said	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
diseases,	O
conditions	O
or	O
disorders	O
.	O
The	O
invention	O
also	O
provides	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
6-	O
(	O
1H-imidazo-1-yl	O
)	O
-2-aryl	O
and	O
2-heteroaryl	O
quinazoline	O
and	O
quinolines	O
derivatives,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutical	O
acceptable	O
salts	O
and	O
solvates	O
and	O
corresponding	O
pharmaceutical	O
compositions,	O
that	O
acts	O
as	O
Monoamine	B-GENE
Oxidase	I-GENE
(	O
MAO	B-GENE
)	O
inhibitors	O
and	O
Imidazoline	B-GENE
Receptor	I-GENE
ligands	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
:	O
X	O
is	O
independently	O
selected	O
from	O
—CH	O
group	O
or	O
a	O
nitrogen	O
atom	O
(	O
—N	O
)	O
,	O
W	O
is	O
independently	O
selected	O
from	O
an	O
aryl	O
group,	O
an	O
heteroaryl	O
group,	O
or	O
a	O
benzocondensed	O
heteroaryl	O
group	O
such	O
as	O
1,3-benzodioxole,	O
benzofuran,	O
2,3-dihydrobenzofuran,	O
benzothiophene,	O
2,3-dihydrobenzothiophene,	O
indole,	O
2,3-dihydroindole,	O
benzimidazole,	O
benzoxazole,	O
benzothiazole,	O
2H-3,4-dihydrobenzopyran,	O
[	O
1,4	O
]	O
-benzodioxine,	O
2,3-dihydro-	O
[	O
1,4	O
]	O
-benzodioxine	O
(	O
1,4-benzodioxan	O
)	O
.	O
R1	O
is	O
independently	O
selected	O
from	O
hydrogen	O
(	O
—H	O
)	O
,	O
C1-C4	O
alkyl,	O
hydroxymethyl	O
(	O
—CH2OH	O
)	O
,	O
aminomethyl	O
(	O
—CH2NH2	O
)	O
,	O
alkylaminomethyl	O
[	O
CH2NH	O
(	O
R2	O
)	O
]	O
,	O
or	O
di-alkylaminomethyl	O
[	O
CH2N	O
(	O
R2	O
)	O
2	O
]	O
,	O
trifluoromethyl	O
(	O
—CF3	O
)	O
.	O
	O
	O
	O
	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
elicited	O
a	O
pharmacological	O
profile	O
suitable	O
for	O
the	O
clinical	O
treatment	O
of	O
depression	O
and	O
related	O
disorders,	O
Parkinson	O
disease,	O
drug	O
abuse,	O
and	O
morphine	O
tolerance	O
and	O
dependence	O
.	O


The	O
disclosure	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
including	O
their	O
salts,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O
The	O
compounds	O
are	O
CRF	B-GENE
receptor	I-GENE
antagonists	O
and	O
may	O
be	O
useful	O
for	O
treating	O
disorders	O
associated	O
with	O
abnormal	O
CRF	O
levels	O
or	O
aberrant	O
functioning	O
of	O
CRF	B-GENE
receptors	I-GENE
.	O


The	O
marginal	O
zone	O
(	O
MZ	O
)	O
and	O
B1	O
subsets	O
of	O
B	O
cells,	O
which	O
differ	O
from	O
conventional	O
follicular	O
(	O
FO	O
)	O
B	O
cells	O
both	O
developmentally	O
and	O
functionally,	O
are	O
involved	O
in	O
early	O
responses	O
to	O
infectious	O
pathogens	O
and	O
the	O
production	O
of	O
self-reactive	O
antibodies	O
.	O
A	O
novel	O
gene,	O
mzb1,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
MZ	O
and	O
B1	O
B	O
cells	O
but	O
at	O
low	O
level,	O
if	O
at	O
all,	O
in	O
FOB	O
cells	O
.	O
MZB1	B-GENE
is	O
involved	O
in	O
the	O
regulation	O
of	O
proliferation,	O
BCR-mediated	O
signal	O
transduction,	O
and	O
antibody	O
production	O
in	O
B	O
cells	O
.	O
Inhibitors,	O
activators	O
and	O
enhancers	O
of	O
MZB1	B-GENE
expression	O
or	O
activity	O
can	O
be	O
used	O
as	O
immune	O
modulators	O
for	O
research	O
and	O
therapeutic	O
purposes	O
.	O


In	O
certain	O
aspects,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
inducing	O
utrophin	B-GENE
expression	O
in	O
muscle	O
with	O
an	O
ActRIIB	B-GENE
protein	O
as	O
therapy	O
for	O
muscular	O
dystrophy	O
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
screening	O
compounds	O
that	O
modulate	O
activity	O
of	O
an	O
ActRIIB	B-GENE
protein	O
and	O
/	O
or	O
an	O
ActRIIB	B-GENE
ligand	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
treating	O
disorders	O
associated	O
with	O
selective	O
subtype	O
modulation	O
of	O
alpha	B-GENE
2	I-GENE
adrenergic	I-GENE
receptors	I-GENE
.	O
In	O
particular,	O
the	O
invention	O
provides	O
methods	O
employing	O
well-defined	O
N-	O
[	O
1-	O
(	O
2	O
and	O
/	O
or	O
3-substituted-phenyl	O
)	O
-alkyl	O
]	O
-	O
(	O
4,5-dihydro-1H-imidazol-2-yl	O
)	O
-amines	O
and	O
pharmaceutical	O
compositions	O
thereof	O
to	O
treat	O
disorders	O
associated	O
with	O
selective	O
subtype	O
alpha	B-GENE
2	I-GENE
adrenergic	I-GENE
receptor	I-GENE
modulation,	O
such	O
as	O
ocular	O
disorders,	O
pain	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
motor	O
disorders	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
their	O
synthesis,	O
and	O
their	O
use	O
as	O
CHK-1	B-GENE
inhibitors	O
.	O


Provided	O
herein	O
are	O
novel	O
ergoline	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O
In	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment,	O
prevention,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as,	O
for	O
example,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O
In	O
still	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as,	O
for	O
example,	O
the	O
5-HT1D	B-GENE
and	O
or	O
5-HT1B	B-GENE
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O
In	O
still	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as,	O
for	O
example,	O
the	O
5-HT2B	B-GENE
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O
In	O
still	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
regulating	O
serotonin	O
transport	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O


The	O
invention	O
provides	O
the	O
combination	O
use	O
of	O
antisense	O
oligomers	O
targeting	O
androgen	B-GENE
receptor	I-GENE
mRNA	O
and	O
androgen	B-GENE
receptor	I-GENE
binding	O
inhibitors	O
that	O
reduce	O
androgen	B-GENE
receptor	I-GENE
activity	O
for	O
the	O
treatment	O
of	O
androgen	B-GENE
receptor	I-GENE
related	O
medical	O
disorders,	O
such	O
as	O
cancers,	O
particularly	O
prostate	O
cancers	O
and	O
breast	O
cancers	O
.	O


The	O
invention	O
relates	O
to	O
a	O
double-stranded	O
ribonucleic	O
acid	O
(	O
dsRNA	O
)	O
targeting	O
X-Box	B-GENE
Protein	I-GENE
1	I-GENE
(	O
XBP-1	B-GENE
)	O
,	O
and	O
methods	O
of	O
using	O
the	O
dsRNA	O
to	O
inhibit	O
expression	O
of	O
XBP-1	B-GENE
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
n	O
is	O
0,	O
1	O
or	O
2	O
;	O
G	O
is	O
CH2	O
or	O
CHR3	O
;	O
R1	O
is	O
H,	O
C,-C6-alkyl,	O
C,-C6-alkyl	O
substituted	O
by	O
C3-C6-cycloalkyl,	O
C1-C6-hydroxyalkyl,	O
fluorinated	O
C,-C6-alkyl,	O
C3-C6-cycloalkyl,	O
fluorinated	O
C3-C6-cycloalkyl,	O
C3-C6	O
alkenyl,	O
fluorinated	O
C3-C6-alkenyl,	O
formyl,	O
acetyl	O
or	O
propionyl	O
;	O
R2,	O
R3	O
and	O
R4	O
are,	O
independently	O
of	O
each	O
other,	O
H,	O
methyl,	O
fluoromethyl,	O
difluoromethyl,	O
or	O
trifluoromethyl	O
;	O
A	O
is	O
phenylene,	O
pyridylene,	O
pyrimidylene,	O
pyrazinylene,	O
pyridazinylene	O
or	O
thiophenylene,	O
which	O
can	O
be	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halogen,	O
methyl,	O
methoxy	O
and	O
CF3	O
;	O
E	O
is	O
NR5	O
or	O
CH2,	O
wherein	O
R5	O
is	O
H	O
or	O
C1-C3-alkyl	O
;	O
Ar	O
is	O
a	O
cyclic	O
radical	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phenyl,	O
a	O
5-	O
or	O
6-membered	O
heteroaromatic	O
radical	O
comprising	O
as	O
ring	O
members	O
1,	O
2	O
or	O
3	O
heteroatoms	O
selected	O
from	O
N,	O
O	O
and	O
S	O
and	O
a	O
phenyl	O
ring	O
fused	O
to	O
a	O
saturated	O
or	O
unsaturated	O
5-	O
or	O
6-membered	O
carbocyclic	O
or	O
heterocyclic	O
ring,	O
where	O
the	O
heterocyclic	O
ring	O
comprises	O
as	O
ring	O
members	O
1,	O
2	O
or	O
3	O
heteroatoms	O
selected	O
from	O
N,	O
O	O
and	O
S	O
and	O
/	O
or	O
1,	O
2	O
or	O
3	O
heteroatom-containing	O
groups	O
each	O
independently	O
selected	O
from	O
NR8,	O
where	O
R8	O
is	O
H,	O
C1-C4-alkyl,	O
fluorinated	O
C1-C4-alkyl,	O
C1-C4alkylcarbonyl	O
or	O
fluorinated	O
C1-C4-alkylcarbonyl,	O
and	O
where	O
the	O
cyclic	O
radical	O
Ar	O
may	O
carry	O
1,	O
2	O
or	O
3	O
substituents	O
Ra,	O
wherein	O
the	O
variable	O
Ra	O
has	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
in	O
the	O
description	O
;	O
and	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
a	O
medical	O
disorder	O
susceptible	O
to	O
treatment	O
with	O
a	O
dopamine	B-GENE
D3	I-GENE
receptor	I-GENE
ligand	O
.	O


Stable,	O
extracellular	O
microRNAs	O
and	O
methods	O
for	O
isolating	O
and	O
identifying	O
such	O
microRNAs	O
from	O
a	O
body	O
fluid	O
are	O
provided	O
.	O
The	O
extracellular	O
microRNAs	O
isolated	O
from	O
a	O
bodily	O
fluid	O
of	O
a	O
subject	O
can	O
be	O
used	O
to	O
measure	O
disease	O
and	O
provide	O
sensitive,	O
efficient,	O
and	O
non	O
invasive	O
methods	O
for	O
the	O
detection	O
of	O
disease,	O
including	O
cancer	O
.	O
The	O
extracellular	O
microRNAs	O
can	O
be	O
used	O
to	O
develop	O
new	O
therapeutics	O
for	O
the	O
treatment	O
of	O
disease,	O
including	O
cancer	O
.	O
The	O
examples	O
illustrate	O
diagnosis	O
of	O
prostate	O
and	O
ovarian	O
cancer	O
and	O
differential	O
expression	O
of	O
miR-100,	O
miR-135b,	O
miR-141,	O
miR-148a,	O
miR-200a,	O
miR-200c,	O
miR-210,	O
miR-222,	O
miR-375,	O
miR-425-Sp	B-GENE
and	O
miR-429	B-GENE
.	O


The	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
cosmetic	O
and	O
/	O
or	O
dermatological	O
composition	O
for	O
use	O
in	O
the	O
treatment	O
of	O
skin	O
and	O
/	O
or	O
hair	O
disorders	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
a	O
cosmetic	O
and	O
/	O
or	O
dermatological	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
hydroxymethylglutaryl-coenzyme	B-GENE
A	I-GENE
(HMG-CoA)	I-GENE
reductase,	O
an	O
inhibitor	O
of	O
farnesyl	B-GENE
pyrophosphate	I-GENE
synthase,	O
or	O
an	O
inhibitor	O
of	O
one	O
of	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
and	O
a	O
cosmetic	O
and	O
/	O
or	O
dermatological	O
product	O
.	O
The	O
present	O
invention	O
finds,	O
for	O
example,	O
a	O
very	O
advantageous	O
use	O
in	O
the	O
treatment	O
of	O
the	O
effects	O
of	O
early	O
ageing,	O
in	O
particular	O
in	O
terms	O
of	O
the	O
skin	O
and	O
the	O
hair	O
system	O
.	O


3-	O
(	O
2-amino-ethyl	O
)	O
-5-	O
(	O
3-cyclohexyl-propylidene	O
)	O
-thiazolidine-2,4-dione	O
and	O
derivatives	O
thereof	O
are	O
provided	O
for	O
use	O
as	O
dual	O
inhibitors	O
of	O
the	O
Raf	B-GENE
/	O
MEK	B-GENE
/	O
ERK	B-GENE
and	O
PI3K	B-GENE
/	O
Akt	B-GENE
pathways	O
and	O
for	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
predicting	O
the	O
hypoxia	O
response	O
in	O
tumor	O
cells,	O
methods	O
for	O
predicting	O
the	O
likelihood	O
of	O
cancer	O
metastasis,	O
and	O
methods	O
for	O
inhibiting	O
tumor	O
cell	O
proliferation	O
using	O
a	O
microRNA	O
comprising	O
miR-210	B-GENE
.	O


The	O
present	O
invention	O
embraces	O
Niemann-Pick	B-GENE
C1-like	I-GENE
1	I-GENE
protein	I-GENE
antagonists	O
and	O
agents	O
that	O
inhibit	O
hepatic	O
virus	O
infection	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
hepatic	O
virus	O
infection	O
.	O


Methods	O
and	O
compositions	O
are	O
provided	O
to	O
determine	O
if	O
a	O
cancer	O
is	O
resistant	O
to	O
treatment	O
with	O
anti-mitotic	O
agents,	O
including	O
treatment	O
with	O
T-DM1	O
.	O
The	O
methods	O
relate	O
to	O
determining	O
if	O
the	O
ABCC3	B-GENE
gene	O
is	O
amplified	O
and	O
/	O
or	O
overexpressed	O
in	O
the	O
cancer	O
.	O


Immunogenic	O
HCV	B-GENE
E1E2809	I-GENE
DNA	I-GENE
compositions	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
described	O
.	O
The	O
compositions	O
comprise	O
HCV	B-GENE
E1E2809	I-GENE
DNA	I-GENE
adsorbed	O
to	O
cationic	O
microparticles,	O
such	O
as	O
poly	O
(	O
lactide-co-glycolide	O
)	O
(	O
PLG	O
)	O
microparticles	O
.	O


Described	O
are	O
methods	O
for	O
treating	O
cancers,	O
e	O
.	O
g	O
.	O
,	O
glioblastoma,	O
including	O
administering	O
an	O
inhibitor	O
of	O
Notch	B-GENE
signalling,	O
e	O
.	O
g	O
.	O
,	O
a	O
gamma	B-GENE
secretase	I-GENE
inhibitor,	O
in	O
combination	O
with	O
a	O
chemotherapeutic	O
agent	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
which	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
substituents	O
are	O
as	O
described	O
herein	O
or	O
a	O
pharmaceutically	O
active	O
acid-addition	O
salt	O
thereof	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
both	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
through	O
dual	O
inhibition	O
of	O
NK1	B-GENE
and	O
NK3	B-GENE
receptors	O
.	O
The	O
invention	O
also	O
provides	O
novel	O
compounds	O
with	O
formula	O
I	O
and	O
methods	O
for	O
preparing	O
compounds	O
of	O
the	O
invention	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
and	O
compounds	O
for	O
inhibiting	O
bacterial	O
growth	O
and	O
treating	O
a	O
bacterial	O
infection	O
in	O
a	O
subject	O
.	O
These	O
methods	O
involve	O
providing	O
an	O
inhibitor	O
of	O
intrabacterial	O
pH	O
homeostasis,	O
including	O
inhibitors	O
of	O
the	O
Mycobacterium	O
tuberculosis	O
Rv3671c	B-GENE
gene	O
encoded	O
membrane	O
protease	O
.	O
Methods	O
for	O
identifying	O
novel	O
compounds	O
that	O
disrupt	O
intrabacterial	O
pH	O
homeostasis	O
and	O
their	O
use	O
for	O
inhibiting	O
bacterial	O
growth	O
and	O
treating	O
a	O
bacterial	O
infection	O
in	O
a	O
subject	O
are	O
also	O
disclosed	O
.	O


Compounds	O
which	O
modulate	O
the	O
CB2	B-GENE
receptor	I-GENE
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
treating	O
CB2	O
receptor-mediated	O
diseases	O
such	O
as	O
pain	O
.	O


A	O
method	O
of	O
treating	O
inflammation	O
and	O
joint	O
deterioration	O
in	O
mammals	O
includes	O
administering	O
a	O
therapeutically	O
effective	O
dose	O
of	O
alpha	B-GENE
1A	I-GENE
receptor	I-GENE
antagonists	O
alone	O
or	O
in	O
combination	O
with	O
a	O
beta	B-GENE
2	I-GENE
adrenergic	I-GENE
antagonists	O
or	O
beta	B-GENE
2	I-GENE
adrenergic	I-GENE
antagonists	O
and	O
beta	B-GENE
2	I-GENE
adrenergic	I-GENE
agonists	O
.	O


The	O
invention	O
provides	O
a	O
nanoparticle	O
composition	O
that	O
is	O
decorated	O
with	O
a	O
urea-based	O
small-molecule	O
peptidomimetic	O
inhibitor	O
of	O
prostate	B-GENE
specific	I-GENE
membrane	I-GENE
antigen	I-GENE
(	O
PSMA	B-GENE
)	O
,	O
which	O
is	O
expressed	O
by	O
almost	O
all	O
solid	O
tumors	O
.	O
This	O
strategy	O
takes	O
advantage	O
of	O
both	O
the	O
avidity	O
of	O
the	O
functionalized	O
nanoparticle	O
for	O
binding	O
to	O
PSMA	B-GENE
and	O
the	O
ability	O
of	O
the	O
nanoparticle	O
to	O
be	O
retained	O
for	O
longer	O
periods	O
of	O
time	O
in	O
the	O
tumor	O
due	O
to	O
enhanced	O
leakage	O
via	O
EPR	B-GENE
into	O
the	O
tumor	O
interstitium	O
and	O
poor	O
clearance	O
due	O
to	O
underdeveloped	O
or	O
non-existent	O
lymphatics	O
within	O
the	O
tumor	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
disubstituted	O
azepan	O
and	O
oxazepan	O
amide	O
compounds	O
which	O
are	O
antagonists	O
of	O
orexin	O
receptors,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
and	O
diseases	O
in	O
which	O
orexin	B-GENE
receptors	I-GENE
are	O
involved	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
orexin	B-GENE
receptors	I-GENE
are	O
involved	O
.	O


A	O
series	O
of	O
novel	O
anthra	O
[	O
1,2-d	O
]	O
imidazole-6,11-dione	O
derivatives,	O
and	O
the	O
preparation	O
method	O
and	O
application	O
of	O
said	O
derivatives,	O
wherein	O
said	O
application	O
includes	O
a	O
pharmaceutical	O
composition	O
containing	O
said	O
derivatives	O
for	O
treating	O
cancer,	O
and	O
said	O
application	O
involves	O
effects	O
of	O
said	O
derivatives	O
for	O
inhibiting	O
telomerase	B-GENE
activity,	O
inhibiting	O
the	O
growth	O
of	O
cancer	O
cell,	O
treating	O
cancer	O
and	O
the	O
like	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
4-	O
(	O
indazolyl	O
)	O
-1,4-dihydropyridine	O
og	O
the	O
following	O
formula	O
(	O
I	O
)	O
derivatives	O
having	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitory	O
activity,	O
to	O
a	O
process	O
for	O
the	O
manufacture	O
thereof	O
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
c-Met-mediated	O
diseases	O
or	O
c-Met-mediated	O
conditions,	O
particularly	O
cancer	O
and	O
other	O
proliferative	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
a	O
Cinnamomum	O
subavenium	O
extract	O
for	O
inhibiting	O
melanogenesis	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
composition	O
for	O
inhibiting	O
melanogenesis	O
including	O
compounds	O
inhibit	O
tyrosinase	B-GENE
activity	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
phenethylamide	O
derivatives	O
and	O
their	O
wherein	O
A,	O
B,	O
R1,	O
R2	O
and	O
R3	O
are	O
as	O
described	O
in	O
the	O
application,	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds,	O
or	O
of	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds,	O
as	O
medicaments,	O
especially	O
as	O
orexin	B-GENE
receptor	I-GENE
antagonists	O
.	O


The	O
invention	O
concerns	O
RNA	O
oligonucleotide	O
sequences	O
or	O
sequences	O
that	O
are	O
transcribed	O
into	O
RNA	O
or	O
analogous	O
molecules	O
able	O
to	O
silence	O
the	O
expression	O
of	O
the	O
CYCLIN	B-GENE
D1	I-GENE
/	O
TROP2	B-GENE
chimeric	O
mRNA	O
and	O
their	O
use	O
in	O
the	O
treatment	O
and	O
the	O
prevention	O
of	O
tumors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
diagnosis	O
and	O
therapy	O
of	O
hematological	O
malignancies,	O
such	O
as	O
multiple	O
myeloma,	O
as	O
well	O
as	O
solid	O
tumors	O
based	O
on	O
cytokine	B-GENE
interleukin-16	I-GENE
(	O
IL-16	B-GENE
)	O
and	O
agents	O
specifically	O
targeting	O
this	O
antigen	O
or	O
cells	O
expressing	O
the	O
same,	O
e	O
.	O
g	O
.	O
,	O
antibodies	O
.	O
The	O
inventors	O
were	O
able	O
to	O
prove	O
that	O
IL-16	B-GENE
is	O
expressed	O
and	O
secreted	O
at	O
high	O
levels	O
by	O
myeloma	O
cells	O
.	O
Most	O
importantly,	O
the	O
inventors	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
IL-16	B-GENE
supports	O
the	O
proliferation	O
of	O
the	O
malignant	O
cells	O
.	O
Therefore,	O
this	O
cytokine	O
represents	O
a	O
particularly	O
advantageous	O
target	O
in	O
cancer	O
therapy	O
and	O
diagnosis	O
.	O


This	O
disclosure	O
provides	O
an	O
intracellular	O
fragment	O
of	O
natriuretic	O
peptide	I-GENE
receptor	I-GENE
A	I-GENE
(	O
NPRA	B-GENE
)	O
,	O
referred	O
to	O
herein	O
as	O
soluble	O
natriuretic	O
peptide	I-GENE
receptor-related	O
fragment	O
(	O
sNRF	O
)	O
.	O
It	O
is	O
shown	O
herein	O
that	O
sNRF	O
causes	O
NP	O
resistance	O
.	O
Based	O
on	O
these	O
observations,	O
methods	O
of	O
treating	O
a	O
cardiovascular	O
disorder	O
by	O
inhibiting	O
the	O
activity	O
of	O
sNRF	O
are	O
disclosed	O
.	O
Assays	O
are	O
provided	O
that	O
use	O
sNRF	O
to	O
screen	O
agents	O
for	O
their	O
ability	O
to	O
increase	O
the	O
biological	O
activity	O
of	O
an	O
NPR,	O
for	O
example	O
agents	O
that	O
increase	O
the	O
sensitivity	O
of	O
NPR	O
for	O
NPs	O
(	O
such	O
as	O
atrial	B-GENE
natriuretic	I-GENE
peptide,	O
ANP	B-GENE
)	O
,	O
or	O
that	O
decrease	O
growth	B-GENE
factor	I-GENE
deleterious	O
effects,	O
or	O
combinations	O
thereof	O
.	O
Also	O
provided	O
are	O
agents	O
identified	O
using	O
the	O
disclosed	O
assays,	O
and	O
methods	O
of	O
using	O
the	O
agents,	O
for	O
example	O
to	O
treat	O
or	O
diagnose	O
a	O
cardiovascular	O
disorder,	O
such	O
as	O
heart	O
failure	O
.	O


The	O
invention	O
provides	O
neuregulin	B-GENE
antagonists	O
and	O
methods	O
of	O
using	O
the	O
neuregulin	B-GENE
antagonists	O
in	O
delaying	O
the	O
time	O
to	O
tumor	O
recurrence	O
or	O
preventing	O
resistance	O
of	O
cancer	O
cells	O
to	O
treatment	O
with	O
a	O
therapeutic	O
agent	O
.	O


The	O
present	O
invention	O
provides	O
transient	O
receptor	O
potential	O
vanilloid	O
(	O
TRPV	B-GENE
)	O
modulators	O
of	O
formula	O
(	O
I	O
)	O
.	O
In	O
particular,	O
compounds	O
described	O
herein	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
diseases,	O
conditions	O
and	O
/	O
or	O
disorders	O
modulated	O
by	O
TRPV3	B-GENE
.	O
Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein,	O
intermediates	O
used	O
in	O
their	O
synthesis,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases,	O
conditions	O
and	O
/	O
or	O
disorders	O
modulated	O
by	O
TRPV3	B-GENE
.	O


This	O
invention	O
relates	O
to	O
novel	O
hydroxyethylamino	O
sulfonamides	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
compound	O
with	O
the	O
ability	O
to	O
act	O
as	O
an	O
HIV	B-GENE
(human	I-GENE
immunodeficiency	I-GENE
virus)	I-GENE
protease	I-GENE
inhibitor	O
.	O


The	O
subject	O
of	O
the	O
present	O
invention	O
is	O
a	O
new	O
combination	O
of	O
active	O
ingredients	O
consisting	O
of	O
alfuzosin	O
and	O
PDE	B-GENE
4	I-GENE
inhibitor,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them,	O
for	O
ameliorating	O
and	O
/	O
or	O
treating	O
benign	O
prostatic	O
hyperplasia,	O
urinary	O
disorders,	O
disorders	O
related	O
to	O
bladder	O
dysfunction,	O
lower	O
urinary	O
tract	O
symptoms	O
associated	O
or	O
not	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia,	O
urinary	O
incontinence,	O
bladder	O
outlet	O
obstruction	O
associated	O
or	O
not	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia,	O
interstitial	O
cystitis	O
and	O
overactive	O
bladder	O
.	O


The	O
invention	O
provides	O
a	O
composition	O
comprising	O
a	O
plurality	O
of	O
nanoceria	O
particles,	O
a	O
sufficient	O
amount	O
of	O
at	O
least	O
one	O
inhibitor	O
of	O
human	B-GENE
carbonic	I-GENE
anhydrase	I-GENE
II	I-GENE
associated	O
with	O
said	O
plurality	O
of	O
nanoceria	O
particles,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
containing	O
said	O
plurality	O
of	O
nanoceria	O
particles	O
with	O
associated	O
inhibitor	O
.	O
One	O
preferred	O
inhibitor	O
of	O
human	B-GENE
carbonic	I-GENE
anhydrase	I-GENE
II	I-GENE
comprises	O
4-carboxybenzene	O
sulfonamide	O
.	O
The	O
disclosed	O
composition	O
is	O
useful	O
in	O
treatment	O
of	O
glaucoma	O
.	O


The	O
present	O
invention	O
provides	O
6-substituted	O
2,3,4,5-tetrahydro-1H-benzo	O
[	O
d	O
]	O
azepines	O
of	O
Formula	O
(	O
I	O
)	O
as	O
selective	O
5-HT2c	B-GENE
receptor	O
agonists	O
for	O
the	O
treatment	O
of	O
5-HT2c	B-GENE
associated	O
disorders	O
including	O
obesity,	O
obsessive	O
/	O
compulsive	O
disorder,	O
depression,	O
and	O
anxiety,	O
where,	O
R6	O
is	O
—NR10R11,	O
where	O
R10	O
is	O
substituted	O
phenylalkyl	O
or	O
substituted	O
pyridylalkyl	O
and	O
other	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
inhibitors	O
of	O
sphingosine	B-GENE
kinase	I-GENE
3,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
and	O
conditions,	O
such	O
as	O
inflammatory	O
disorders	O
.	O


Embodiments	O
of	O
the	O
invention	O
relate	O
to	O
methods	O
and	O
compositions	O
for	O
the	O
expansion	O
of	O
hematopoietic	O
stem	O
cell	O
(	O
HSC	O
)	O
self	O
renewal	O
.	O
The	O
microRNA-125a	B-GENE
is	O
a	O
master	O
control	O
of	O
HSC	O
self-renewal	O
.	O
Increased	O
expression	O
of	O
mir-125a	B-GENE
increased	O
HSC	O
self-renewal	O
by	O
6-30	O
folds	O
.	O
Increased	O
expression	O
of	O
mir-125a	B-GENE
can	O
be	O
used	O
to	O
expand	O
HSC	O
ex	O
vivo	O
and	O
in	O
vivo	O
.	O


Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	B-GENE
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
HDAC	B-GENE
inhibitor	O
is	O
present	O
in	O
an	O
amount	O
sufficient	O
to	O
achieve	O
a	O
plasma	O
concentration	O
from	O
about	O
100	O
nM	O
to	O
about	O
2	O
uM	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
same	O
.	O
Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	B-GENE
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
HDAC	B-GENE
inhibitor	O
is	O
present	O
in	O
an	O
amount	O
from	O
0	O
.	O
1	O
mg	O
to	O
100	O
mg	O
.	O
Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	B-GENE
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
wherein	O
the	O
concentration	O
of	O
the	O
HDAC	B-GENE
inhibitor	O
is	O
sufficient	O
to	O
decrease	O
the	O
relative	O
viability	O
of	O
lymphoblastoid	O
cells	O
by	O
at	O
least	O
about	O
50	O
percent	O
and	O
/	O
or	O
is	O
sufficient	O
to	O
decrease	O
the	O
proliferation	O
of	O
lymphoblastoid	O
cells	O
by	O
at	O
least	O
about	O
60	O
percent	O
and	O
/	O
or	O
is	O
sufficient	O
to	O
decrease	O
the	O
relative	O
viability	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
less	O
than	O
about	O
50	O
percent	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
same	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
that	O
Tat	B-GENE
polypeptides	O
may	O
be	O
used	O
as	O
immunoregulators	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
infectious	O
diseases	O
.	O
More	O
particularly,	O
Tat	B-GENE
polypeptides	O
may	O
be	O
used	O
as	O
immunoregulators	O
to	O
enhance	O
immune	O
responses	O
to	O
microbial	O
infections,	O
for	O
example,	O
viral	O
and	O
bacterial	O
infections	O
.	O
In	O
accordance	O
with	O
the	O
present	O
invention,	O
Tat	B-GENE
polypeptides	O
interact	O
with	O
CCR3	B-GENE
to	O
stimulate	O
platelet	O
activation	O
.	O
The	O
novel	O
finding	O
of	O
the	O
present	O
inventors,	O
therefore,	O
presents	O
new	O
applications	O
for	O
which	O
Tat	B-GENE
nucleic	O
and	O
amino	O
acid	O
sequences,	O
and	O
compositions	O
thereof	O
may	O
be	O
used	O
to	O
advantage	O
.	O
Applications	O
for	O
which	O
the	O
Tat	B-GENE
nucleic	O
and	O
amino	O
acid	O
sequences	O
and	O
compositions	O
thereof	O
of	O
the	O
invention	O
may	O
be	O
used	O
include,	O
but	O
are	O
not	O
limited	O
to,	O
various	O
research	O
and	O
therapeutic	O
applications	O
as	O
described	O
herein	O
.	O
Also	O
provided	O
is	O
a	O
kit	O
comprising	O
Tat	B-GENE
nucleic	O
and	O
/	O
or	O
amino	O
acid	O
sequences,	O
Tat	B-GENE
activity	O
compatible	O
buffers,	O
and	O
instruction	O
materials	O
.	O


Substituted	O
pyrrolo-pyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
defined	O
in	O
the	O
specification,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
in	O
therapy	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
dysregulated	O
protein	B-GENE
kinase	I-GENE
activity,	O
like	O
cancer	O
.	O


A	O
nucleic	O
acid	O
construct	O
and	O
construct	O
system	O
are	O
disclosed	O
.	O
The	O
nucleic	O
acid	O
construct	O
and	O
system	O
comprise	O
a	O
regulatory	O
sequence	O
which	O
regulates	O
inducible	O
expression	O
of	O
a	O
polypeptide	O
of	O
interest,	O
the	O
regulatory	O
sequence	O
comprising	O
a	O
choroid	O
plexus	O
specific	O
promoter,	O
with	O
the	O
proviso	O
that	O
the	O
choroid	O
plexus	O
specific	O
promoter	O
is	O
not	O
a	O
transthyretin	B-GENE
promoter	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
same	O
and	O
uses	O
thereof	O
are	O
also	O
disclosed	O
.	O


The	O
invention	O
provides	O
compositions	O
and	O
methods	O
to	O
modulate	O
hair	O
growth	O
in	O
a	O
tissue	O
comprising	O
administering	O
to	O
the	O
tissue	O
an	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
inhibits	O
or	O
augments	O
Bone	B-GENE
Morphogenic	I-GENE
Protein	I-GENE
(	O
BMP	B-GENE
)	O
signaling	O
in	O
the	O
tissue,	O
thereby	O
facilitating	O
or	O
inhibiting	O
hair	O
growth	O
.	O


A	O
ProNGF	B-GENE
inhibitor	O
for	O
preparing	O
a	O
drug,	O
said	O
drug	O
being	O
in	O
particular	O
useful	O
for	O
blocking	O
remote	O
dissemination	O
and	O
cell	O
invasion	O
in	O
patients	O
suffering	O
from	O
cancer,	O
in	O
particular	O
breast,	O
thyroid	O
or	O
lung	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer,	O
tautomer,	O
salt	O
or	O
solvate	O
thereof,	O
wherein	O
the	O
variables	O
are	O
defined	O
herein	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
Bcl-2	B-GENE
family	O
antiapoptotic	O
proteins,	O
compositions	O
containing	O
the	O
compounds	O
and	O
methods	O
of	O
treating	O
diseases	O
using	O
the	O
compounds	O
.	O


Novel	O
polyisoprenylated	O
benzophenone	O
derivatives	O
isolated	O
from	O
the	O
plant	O
Garcinia	O
paucinervis	O
.	O
Among	O
these	O
new	O
compounds,	O
paucinones	O
A-C	O
(	O
Compounds	O
1-3	O
)	O
contains	O
an	O
unexpected	O
cyclohexane-spiro-tetrahydrofuran	O
moiety	O
.	O
A	O
1-methylene-3,3-dimethylcyclohexane	O
group	O
never	O
reported	O
before	O
was	O
found	O
in	O
the	O
structure	O
of	O
paucinone	O
D	O
(	O
Compound	O
4	O
)	O
.	O
Structures	O
of	O
these	O
compounds	O
were	O
elucidated	O
with	O
spectroscopic	O
evidence	O
.	O
The	O
relative	O
stereochemistry	O
of	O
1-4	O
was	O
determined	O
by	O
NOESY	O
correlations	O
.	O
These	O
compounds	O
a	O
potent	O
ability	O
to	O
activate	O
caspase-3	B-GENE
in	O
HeLa-C3	O
cells	O
within	O
72	O
hours	O
at	O
a	O
low	O
concentration	O
and	O
significant	O
cytotoxicity	O
against	O
HeLa-C3	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
alkaloid	O
aminoester	O
compounds	O
which	O
act	O
as	O
muscarinic	B-GENE
receptor	I-GENE
antagonists,	O
processes	O
for	O
their	O
preparation,	O
compositions	O
comprising	O
them,	O
and	O
therapeutic	O
uses	O
thereof	O
.	O


Compounds	O
useful	O
as	O
allosteric	O
potentiators	O
/	O
positive	O
allosteric	O
modulators	O
of	O
the	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
subtype	I-GENE
4	I-GENE
(	O
mGluR4	B-GENE
)	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
oligomer	O
compounds	O
(	O
oligomers	O
)	O
,	O
which	O
target	O
mtGPAT1mRNA	B-GENE
in	O
a	O
cell,	O
leading	O
to	O
reduced	O
expression	O
of	O
mtGPAT1	B-GENE
.	O
Reduction	O
of	O
mtGPAT1	B-GENE
expression	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
certain	O
medical	O
disorders,	O
such	O
as	O
overweight,	O
obesity,	O
fatty	O
liver,	O
hepatosteatosis,	O
non	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
non	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
insulin	B-GENE
resistance,	O
and	O
non	O
insulin	B-GENE
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	O
that	O
modulate	O
the	O
expression	O
of	O
and	O
/	O
or	O
function	O
of	O
Delta-like	B-GENE
(1)	I-GENE
homolog	I-GENE
(	O
DLK1	B-GENE
)	O
,	O
in	O
particular,	O
by	O
targeting	O
natural	O
antisense	O
polynucleotides	O
of	O
Delta-like	B-GENE
(1)	I-GENE
homolog	I-GENE
(	O
DLK1	B-GENE
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
identification	O
of	O
these	O
antisense	O
oligonucleotides	O
and	O
their	O
use	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
the	O
expression	O
of	O
(	O
DLK1	B-GENE
)	O
.	O


Provided	O
herein	O
are	O
small	O
molecule	O
inhibitors	O
of	O
Taspase1	B-GENE
and	O
methods	O
of	O
using	O
the	O
small	O
molecule	O
inhibitors	O
of	O
Taspase1	B-GENE
to	O
treat	O
neoplasm	O
in	O
subjects	O
in	O
need	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
means	O
of	O
restoring	O
the	O
immune	O
system	O
in	O
aging	O
and	O
immunocompromised	O
individuals	O
using	O
an	O
antioxidant	O
nutraceutical	O
.	O
The	O
nutraceutical	O
stimulates	O
the	O
aging	O
immune	O
system	O
through	O
the	O
Nrf2	B-GENE
master	O
gene	O
regulatory	O
pathway	O
.	O
The	O
invention	O
is	O
based	O
in	O
part	O
on	O
the	O
discovery	O
that	O
the	O
Nrf2	B-GENE
has	O
antioxidant	O
and	O
immune	O
restorative	O
activity	O
.	O
The	O
nutraceutical	O
improves	O
function	O
of	O
both	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
.	O


Provided	O
is	O
a	O
GIP-increase	O
inhibitor,	O
which	O
is	O
customary	O
used	O
for	O
food	O
production,	O
is	O
excellent	O
in	O
safety,	O
and	O
is	O
useful	O
for,	O
for	O
example,	O
a	O
medicine	O
or	O
a	O
food	O
.	O
The	O
GIP-increase	O
inhibitor	O
contains	O
catechins	O
as	O
active	O
ingredient	O
.	O


The	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
regulating	O
p110	B-GENE
delta	I-GENE
as	O
an	O
anti-influenza	O
virus	O
therapy	O
.	O
The	O
invention	O
includes	O
inhibiting	O
p110	O
delta,	O
a	O
component	O
of	O
p110	B-GENE
delta	I-GENE
signaling	O
pathway,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
cell	O
as	O
an	O
anti-influenza	O
viral	O
therapeutic	O
approach	O
for	O
treating	O
influenza	O
virus	O
infection	O
.	O
The	O
invention	O
includes	O
a	O
method	O
of	O
modulating	O
p110	B-GENE
delta	I-GENE
in	O
a	O
cell	O
by	O
contacting	O
the	O
cell	O
with	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
p110	B-GENE
delta	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
preparing	O
splice	O
variants	O
of	O
TNFalpha	B-GENE
receptor	I-GENE
(	O
TNFR	B-GENE
)	O
in	O
vivo	O
or	O
in	O
vitro,	O
and	O
the	O
resulting	O
TNFR	B-GENE
protein	O
variants	O
.	O
Such	O
variants	O
may	O
be	O
prepared	O
by	O
controlling	O
the	O
splicing	O
of	O
pre-mRNA	O
molecules	O
and	O
regulating	O
protein	O
expression	O
with	O
splice	O
switching	O
oligonucleotides	O
or	O
splice	O
switching	O
oligomers	O
(	O
SSOs	O
)	O
.	O
The	O
preferred	O
SSOs	O
according	O
to	O
the	O
invention	O
target	O
exon	O
7	O
or	O
8	O
of	O
TNFR1	B-GENE
(	O
TNFRSF1A	B-GENE
)	O
or	O
TNFR2	B-GENE
(	O
TNFRSF1A	B-GENE
)	O
pre-mRNA,	O
typically	O
resulting	O
in	O
the	O
production	O
of	O
TNFR	B-GENE
variants	O
which	O
comprise	O
a	O
deletion	O
in	O
part	O
or	O
the	O
entire	O
exon	O
7	O
or	O
8	O
respectfully	O
.	O
SSOs	O
targeting	O
exon	O
7	O
are	O
found	O
to	O
result	O
in	O
a	O
soluble	O
form	O
of	O
the	O
TNFR,	O
which	O
has	O
therapeutic	O
benefit	O
for	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O
The	O
SSO	O
'	O
s	O
are	O
characterized	O
in	O
that	O
they	O
are	O
substantially	O
incapable	O
or	O
incapable	O
of	O
recruiting	O
RNaseH	B-GENE
.	O


A	O
therapeutic	O
composition	O
for	O
treating	O
glaucoma	O
or	O
for	O
reducing	O
intraocular	O
pressure	O
containing	O
a	O
combination	O
of	O
pharmaceutically	O
effective	O
amounts	O
of	O
drugs	O
including	O
(	O
i	O
)	O
a	O
Rho	B-GENE
kinase	I-GENE
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-N-	O
(	O
1H-pyrrolo	O
[	O
2,3-b	O
]	O
pyridin-4-yl	O
)	O
-4-	O
(	O
1-aminoethyl	O
)	O
benzamide	O
and	O
1-	O
(	O
5-isoquinolinesulfonyl	O
)	O
-homopiperazine,	O
or	O
a	O
salt	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
prostaglandin	O
which	O
is	O
latanoprost	O
or	O
a	O
salt	O
of	O
latanoprost,	O
and	O
(	O
iii	O
)	O
optionally	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
A	O
therapeutic	O
composition	O
for	O
treating	O
glaucoma	O
or	O
for	O
reducing	O
intraocular	O
pressure	O
containing	O
a	O
combination	O
of	O
pharmaceutically	O
effective	O
amounts	O
of	O
drugs	O
comprising	O
(	O
i	O
)	O
a	O
Rho	B-GENE
kinase	I-GENE
which	O
is	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-N-	O
(	O
1H-pyrrolo	O
[	O
2,3-b	O
]	O
pyridin-4-yl	O
)	O
-4-	O
(	O
1-aminoethyl	O
)	O
benzamide	O
or	O
a	O
slat	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
prostaglandin	O
which	O
is	O
isopropyl	O
unoprostone	O
or	O
a	O
salt	O
thereof,	O
and	O
(	O
iii	O
)	O
optionally	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
form	O
(	O
s	O
)	O
of	O
water-soluble	O
salts	O
and	O
of	O
free	O
base	O
of	O
a	O
cdk	B-GENE
inhibitor	O
.	O
Such	O
crystal	O
salts	O
are	O
for	O
example	O
fumarate,	O
L-malate,	O
maleate,	O
succinate,	O
adipate,	O
malonate,	O
glycolate,	O
phosphate,	O
mesylate,	O
L-lactate,	O
hydrochloride,	O
di-hydrochloride,	O
tri-hydrochloride	O
.	O
Hydrates	O
and	O
polymorphs	O
of	O
such	O
new	O
salt	O
forms,	O
a	O
process	O
for	O
their	O
preparation,	O
their	O
utility	O
in	O
therapy	O
and	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
claimed	O
and	O
described	O
in	O
the	O
present	O
application	O
.	O


Substituted	O
spirocyclic	O
amines	O
of	O
structural	O
formula	O
I	O
are	O
selective	O
antagonists	O
of	O
the	O
somatostatin	B-GENE
sub-type	I-GENE
receptor	I-GENE
5	I-GENE
(	O
SSTR5	B-GENE
)	O
and	O
are	O
useful	O
for	O
the	O
treatment,	O
control	O
or	O
prevention	O
of	O
disorders	O
responsive	O
to	O
antagonism	O
of	O
SSTR5,	O
such	O
as	O
Type	O
2	O
diabetes,	O
insulin	B-GENE
resistance,	O
lipid	O
disorders,	O
obesity,	O
atherosclerosis,	O
metabolic	O
syndrome,	O
depression,	O
and	O
anxiety	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
WT1	B-GENE
peptide	O
which	O
has	O
an	O
amino	O
acid	O
sequence	O
consisting	O
of	O
contiguous	O
amino	O
acids	O
derived	O
from	O
a	O
WT1	B-GENE
protein	O
and	O
induces	O
WT1-specific	O
helper	O
T	O
cells	O
by	O
binding	O
to	O
an	O
MHC	B-GENE
class	I-GENE
II	I-GENE
molecule,	O
a	O
pharmaceutical	O
composition	O
comprising	O
them	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
:	O
ring	O
C	O
is	O
an	O
8,	O
9,	O
10,	O
12	O
or	O
13-membered	O
bicyclic	O
or	O
tricyclic	O
moiety	O
which	O
moiety	O
may	O
be	O
saturated	O
or	O
unsaturated,	O
which	O
may	O
be	O
aromatic	O
or	O
non-aromatic,	O
and	O
which	O
optionally	O
may	O
contain	O
1-3	O
heteroatoms	O
selected	O
independently	O
from	O
O,	O
N	O
and	O
S	O
;	O
is	O
—O—	O
—NH—	O
or	O
—S—	O
;	O
is	O
0,	O
1,	O
2,	O
3,	O
4	O
or	O
5	O
;	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
and	O
R2	O
and	O
R1	O
are	O
as	O
defined	O
herein	O
;	O
and	O
salts	O
thereof	O
;	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
production	O
of	O
an	O
antiangiogenic	O
and	O
/	O
or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
warm-blooded	O
animals	O
;	O
processes	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
;	O
pharmaceutical	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
methods	O
of	O
treating	O
disease	O
states	O
involving	O
angiogenesis	O
by	O
administering	O
a	O
compound	O
of	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
inhibit	O
the	O
effects	O
of	O
VEGF,	O
a	O
property	O
of	O
value	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
disease	O
states	O
including	O
cancer	O
and	O
rheumatoid	O
arthritis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
isolated	O
haemoglobin	B-GENE
from	O
worms	O
belonging	O
to	O
the	O
Nereididae	O
family	O
and	O
its	O
use	O
in	O
cell	O
culture	O
medium,	O
in	O
preservation	O
solutions	O
and	O
as	O
artificial	O
oxygen	O
carrier	O
for	O
transfusion	O
.	O


Provided	O
herein	O
is	O
an	O
optically	O
active	O
pyrozolylaminoquinazaline,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O
Also	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating,	O
preventing,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
JAK-mediated	O
condition,	O
disorder,	O
or	O
disease	O
.	O
Further	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating,	O
preventing,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
proliferative	O
disease,	O
inflammatory	O
disease,	O
or	O
renal	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
semi-synthetic	O
macrolides	O
having	O
anti-inflammatory	O
activity	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
14-	O
and	O
15-membered	O
macrolides	O
substituted	O
at	O
the	O
4″	O
position,	O
to	O
their	O
pharmaceutically	O
acceptable	O
derivatives,	O
to	O
processes	O
and	O
intermediates	O
for	O
their	O
preparation,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
activity	O
and	O
use	O
in	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
and	O
conditions	O
in	O
humans	O
and	O
animals,	O
especially	O
those	O
diseases	O
associated	O
with	O
excessive	O
secretion	O
of	O
TNF-α,	O
IL-1,	O
IL-8,	O
IL-2	B-GENE
or	O
IL-5	B-GENE
;	O
and	O
/	O
or	O
inhibitor	O
of	O
excessive	O
lymphocyte	O
proliferation	O
;	O
and	O
/	O
or	O
excessive	O
granulocyte	O
degranulation	O
.	O


A	O
method	O
of	O
inhibiting	O
the	O
inflammatory	O
process,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
suffering	O
from	O
inflammation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
where	O
:	O
	O
R	O
is	O
a	O
C1-C10	O
alkylene	O
group,	O
in	O
which,	O
when	O
the	O
number	O
of	O
carbon	O
atoms	O
is	O
at	O
least	O
2,	O
there	O
are	O
optionally	O
1	O
or	O
2	O
non-adjacent	O
double	O
bonds	O
;	O
1	O
to	O
3	O
non-adjacent	O
methylene	O
groups	O
are	O
optionally	O
replaced	O
by	O
NR1	O
(	O
where	O
R1	O
is	O
H,	O
alkyl,	O
or	O
acyl	O
)	O
,	O
O,	O
or	O
S	O
;	O
and	O
1	O
or	O
2	O
methylene	O
groups	O
are	O
optionally	O
replaced	O
by	O
a	O
carbonyl	O
or	O
hydroxymethylene	O
group	O
and	O
pharmaceutically	O
acceptable	O
esters	O
or	O
salts	O
of	O
the	O
compounds	O
and	O
wherein	O
the	O
inflammatory	O
process	O
results	O
from	O
a	O
disease	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ulcerative	O
colitis,	O
endotoxic	O
shock,	O
rheumatoid	O
arthritis,	O
juvenile	O
arthritis,	O
osteoarthritis,	O
psoriasis,	O
Crohn	O
'	O
s	O
disease,	O
inflammatory	O
bowel	O
disease,	O
multiple	O
sclerosis,	O
insulin	B-GENE
dependent	O
diabetes	O
mellitus,	O
gout,	O
psoriatic	O
arthritis,	O
reactive	O
arthritis,	O
vital	O
or	O
post-viral	O
arthritis	O
and	O
ankylosing	O
spondylarthritis	O
.	O


A	O
composition	O
for	O
preventing	O
and	O
treating	O
fatty	O
liver	O
is	O
disclosed	O
.	O
The	O
composition	O
includes	O
a	O
lactoferrin	B-GENE
and	O
a	O
trivalent	O
chromium	O
compound	O
.	O
The	O
trivalent	O
chromium	O
compound	O
of	O
the	O
present	O
invention	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
chromium	O
(	O
III	O
)	O
chloride	O
hexahydrate,	O
chromium	O
(	O
III	O
)	O
chloride,	O
chromium	O
(	O
III	O
)	O
acetate,	O
chromium	O
(	O
III	O
)	O
sulfate,	O
chromium	O
picolinate,	O
chromium	O
nicotinate,	O
chromium	O
GTF,	O
chromium	O
yeast	O
extract,	O
other	O
inorganic	O
salts	O
of	O
trivalent	O
chromium,	O
other	O
organic	O
salts	O
of	O
trivalent	O
chromium,	O
and	O
combinations	O
thereof	O
.	O
The	O
composition	O
of	O
the	O
present	O
invention	O
can	O
provide	O
a	O
beneficial	O
effect	O
in	O
preventing	O
and	O
treating	O
fatty	O
liver	O
by	O
effectively	O
reducing	O
multiple	O
risk	O
factors	O
of	O
fatty	O
liver	O
disease	O
.	O


The	O
present	O
invention	O
pertains	O
to	O
methods	O
for	O
therapeutic	O
and	O
prophylactic	O
treatment	O
of	O
cats	O
against	O
FIV	O
infection	O
.	O
Methods	O
of	O
the	O
present	O
invention	O
utilize	O
a	O
combination	O
of	O
antiretroviral	O
compounds	O
to	O
treat	O
or	O
prevent	O
FIV	O
infection	O
in	O
a	O
feline	O
animal	O
.	O
In	O
one	O
embodiment,	O
the	O
method	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
AZT	O
and	O
another	O
nucleoside	O
analog,	O
such	O
as,	O
for	O
example,	O
3TC	O
to	O
the	O
animal	O
.	O
In	O
another	O
embodiment,	O
cats	O
are	O
given	O
an	O
effective	O
dose	O
(	O
s	O
)	O
of	O
AZT,	O
3TC,	O
and	O
a	O
retroviral	B-GENE
protease	I-GENE
inhibitor	O
.	O


Provided	O
is	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
which	O
inhibits	O
the	O
activity	O
of	O
PI3K	B-GENE
to	O
regulate	O
many	O
biological	O
processes	O
including	O
the	O
growth,	O
differentiation,	O
survival,	O
proliferation,	O
migration,	O
metabolism,	O
and	O
the	O
like	O
of	O
cells	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prophylaxis	O
/	O
therapy	O
of	O
diseases	O
including	O
inflammatory	O
diseases,	O
arteriosclerosis,	O
vascular	O
/	O
circulatory	O
diseases,	O
cancer	O
/	O
tumors,	O
immune	O
system	O
diseases,	O
cell	O
proliferative	O
diseases,	O
infectious	O
diseases,	O
and	O
the	O
like	O
.	O
The	O
above	O
problem	O
was	O
solved	O
by	O
providing	O
a	O
urea	O
derivative	O
shown	O
in	O
the	O
present	O
specification,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


An	O
extended	O
regimen	O
for	O
treatment	O
of	O
HER-2	B-GENE
/	O
neu	B-GENE
overexpressed	O
/	O
amplified	O
cancer	O
is	O
described,	O
with	O
involves	O
delivering	O
a	O
course	O
of	O
neratinib	O
therapy	O
to	O
HER-2	B-GENE
/	O
neu	B-GENE
overexpressed	O
/	O
amplified	O
cancer	O
patients	O
following	O
the	O
completion	O
of	O
surgical	O
and	O
adjuvant	O
therapy	O
.	O
The	O
neratinib	O
regimen	O
may	O
be	O
continued	O
for	O
upwards	O
of	O
twelve	O
months	O
to	O
five	O
years	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
kits	O
designed	O
to	O
facilitate	O
compliance	O
with	O
the	O
regimen	O
.	O


The	O
invention	O
provides	O
for	O
methods	O
of	O
upregulating	O
endogenous	O
GDNF	B-GENE
by	O
inhibiting	O
Shh	B-GENE
signaling	O
.	O
The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
increasing	O
the	O
production	O
of	O
cholinergic	O
neurons	O
and	O
dopamine	O
neurons	O
by	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
neurogenesis	O
in	O
a	O
subject	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
for	O
treating	O
a	O
neurodegenerative	O
disorder	O
in	O
a	O
subject	O
.	O


Disclosed	O
is	O
a	O
cream	O
formulation	O
containing	O
calamine,	O
an	O
H1	B-GENE
antihistamine,	O
and	O
a	O
corticosteroid	O
for	O
the	O
reduction	O
of	O
inflammation,	O
redness	O
and	O
itching	O
associated	O
with	O
acute	O
and	O
chronic	O
allergic	O
skin	O
disease	O
.	O


Provided	O
herein	O
are	O
methods	O
for	O
treating	O
certain	O
conditions,	O
including	O
fibrosis,	O
inflammatory,	O
and	O
autoimmune	O
conditions,	O
with	O
conjugated	O
compounds	O
having	O
Toll-like	B-GENE
receptor	I-GENE
modulatory	O
activity	O
.	O


The	O
present	O
invention	O
provides	O
a	O
mangiferin-berberine	O
salt	O
and	O
manufacturing	O
method	O
thereof	O
.	O
Otherwise,	O
the	O
present	O
invention	O
also	O
provides	O
the	O
use	O
of	O
mangiferin-berberine	O
salt	O
as	O
AMPK	B-GENE
activator	O
.	O


The	O
present	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
inhibiting	O
kinase	B-GENE
activity	O
to	O
protect	O
against	O
neurodegeneration	O
including	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
or	O
Huntington	O
'	O
s	O
disease,	O
and	O
conditions	O
such	O
as	O
ischemic	O
stroke	O
comprising	O
the	O
step	O
of	O
providing	O
the	O
subject	O
with	O
a	O
therapeutically	O
affective	O
amount	O
of	O
1,4-benzoxazine	O
compounds	O
and	O
derivatives	O
thereof	O
.	O


Methods	O
and	O
compositions	O
of	O
inhibitors	O
of	O
MAPK	B-GENE
kinases	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
(	O
MEK1	B-GENE
and	I-GENE
MEK2,	O
or	O
together,	O
MEK1	B-GENE
/	O
2	O
)	O
,	O
such	O
as	O
ARRY142886,	O
and	O
their	O
use	O
in	O
inhibiting	O
MEK1/2	B-GENE
kinase	B-GENE
activity	O
in	O
mammals	O
for	O
the	O
treatment	O
and	O
/	O
or	O
reversal	O
of	O
the	O
symptoms	O
of	O
pulmonary	O
fibrosis	O
.	O
MEK1/2	B-GENE
inhibitors	O
can	O
selectively	O
inhibit	O
the	O
MAPK	B-GENE
/	O
ERK	B-GENE
pathway	O
in	O
vivo	O
and	O
prevent	O
TGF-α	B-GENE
mediated	O
fibrosis	O
.	O
There	O
are	O
several	O
distinct	O
MAPK	B-GENE
pathways	O
that	O
are	O
important	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation,	O
differentiation,	O
development,	O
inflammation,	O
survival,	O
and	O
migration	O
.	O
The	O
Ras-Raf-MEK-ERK	O
pathway	O
(	O
a	O
key	O
component	O
of	O
the	O
MAPK	B-GENE
pathway	O
)	O
via	O
inhibition	O
of	O
MEK1/2	B-GENE
is	O
an	O
attractive	O
strategy	O
for	O
therapeutic	O
intervention	O
in	O
idiopathic	O
pulmonary	O
fibrosis,	O
because	O
inhibition	O
of	O
MEK1/2	B-GENE
has	O
the	O
potential	O
to	O
block	O
inappropriate	O
signal	O
transduction	O
leading	O
to	O
pulmonary	O
fibrosis,	O
regardless	O
of	O
the	O
upstream	O
position	O
of	O
the	O
aberration	O
causing	O
it	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
salt	O
thereof,	O
which	O
are	O
modulators	O
of	O
the	O
glucocorticoid	B-GENE
receptor	I-GENE
.	O
The	O
compounds	O
and	O
salts	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
glucocorticoid	B-GENE
receptor	I-GENE
activity	O
.	O


Novel	O
alkoxy-thienopyrimidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
and	O
R2	O
have	O
the	O
meaning	O
according	O
to	O
claim	O
1,	O
	O
	O
are	O
inhibitors	O
of	O
TGF-beta	B-GENE
receptor	I-GENE
I	I-GENE
kinase,	O
and	O
can	O
be	O
employed,	O
inter	O
alia,	O
for	O
the	O
treatment	O
of	O
tumors	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof,	O
wherein	O
Q,	O
W,	O
X,	O
R1-R5	O
and	O
n	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	B-GENE
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O


The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
identifying	O
a	O
cancer	O
patient	O
suitable	O
for	O
anti-VEGF	O
therapy	O
.	O
After	O
determining	O
if	O
a	O
patient	O
is	O
likely	O
to	O
be	O
successfully	O
treated,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
the	O
patients	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
quinolinone	O
compounds	O
which	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders	O
associated	O
with	O
phosphodiesterase	B-GENE
2	I-GENE
(	O
PDE2	B-GENE
)	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders,	O
such	O
as	O
schizophrenia,	O
psychosis	O
or	O
Huntington	O
'	O
s	O
disease,	O
and	O
those	O
associated	O
with	O
striatal	O
hypofunction	O
or	O
basal	O
ganglia	O
dysfunction	O
.	O


Matrix	B-GENE
metalloproteases	I-GENE
(	O
MMPs	B-GENE
)	O
play	O
many	O
important	O
roles	O
in	O
normal	O
and	O
pathological	O
remodeling	O
processes	O
including	O
atherothrombotic	O
disease,	O
inflammation,	O
angiogenesis	O
and	O
cancer	O
.	O
This	O
invention	O
relates	O
to	O
the	O
activation	O
of	O
protease-activated	B-GENE
receptor-1	I-GENE
(	O
PAR-1	B-GENE
)	O
by	O
endogenous	O
platelet	O
MMP-1	B-GENE
collagenase	B-GENE
on	O
the	O
surface	O
of	O
platelets	O
.	O
Exposure	O
of	O
platelets	O
to	O
fibrillar	O
collagen	O
converts	O
the	O
surface-bound	O
pro-MMP-1	B-GENE
zymogen	O
to	O
active	O
MMP-1,	O
which	O
promotes	O
aggregation	O
through	O
PAR-1,	O
MMP-1	B-GENE
is	O
shown	O
to	O
cleave	O
the	O
PAR-1	B-GENE
extracellular	I-GENE
domain	I-GENE
at	O
a	O
novel	O
site,	O
which	O
then	O
strongly	O
activates	O
Rho-GTP	O
signaling	O
pathways,	O
cell	O
shape	O
change	O
and	O
motility,	O
and	O
MAPK	B-GENE
signaling	O
.	O
Blockade	O
of	O
MMP-PAR	O
1	O
suppresses	O
thrombogenesis	O
under	O
arterial	O
flow	O
conditions	O
and	O
inhibited	O
thrombosis	O
in	O
animals	O
.	O
These	O
studies	O
provide	O
a	O
link	O
between	O
matrix-dependent	O
activation	O
of	O
metalloproteases	O
and	O
platelet-G	O
protein	O
signaling	O
and	O
identify	O
MMP-1	B-GENE
/	O
PAR-1	B-GENE
as	O
a	O
new	O
target	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
arterial	O
thrombosis	O
and	O
other	O
thrombotic	O
diseases	O
.	O


Methods	O
for	O
treating	O
respiratory	O
and	O
gastrointestinal	O
diseases	O
mediated	O
by	O
a	O
P2X3	B-GENE
and	O
/	O
or	O
a	O
P2X2/3	B-GENE
receptor	I-GENE
antagonist,	O
the	O
methods	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
	O
wherein	O
D,	O
X,	O
Y,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O


One	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
two	O
or	O
more	O
active	O
agents	O
that	O
when	O
taken	O
together	O
can	O
be	O
used	O
to	O
treat,	O
e	O
.	O
g	O
.	O
,	O
insomnia	O
and	O
/	O
or	O
depression	O
.	O
The	O
first	O
component	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
a	O
GABA	B-GENE
receptor	I-GENE
modulating	O
compound	O
.	O
The	O
second	O
component	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
a	O
serotonin	O
reuptake	O
inhibitor,	O
a	O
norepinephrine	O
reuptake	O
inhibitor,	O
a	O
5-HT2A	B-GENE
modulator,	O
or	O
dopamine	O
reuptake	O
inhibitor	O
.	O
In	O
certain	O
embodiments,	O
the	O
pharmaceutical	O
composition	O
comprises	O
eszopiclone	O
.	O
In	O
a	O
preferred	O
embodiment,	O
the	O
pharmaceutical	O
composition	O
comprises	O
eszopiclone	O
and	O
fluoxetine	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
sleep	O
abnormality,	O
treating	O
insomnia,	O
treating	O
depression,	O
augmenting	O
antidepressant	O
therapy,	O
eliciting	O
a	O
dose-sparing	O
effect,	O
reducing	O
depression	O
relapse,	O
improving	O
the	O
efficacy	O
of	O
antidepressant	O
therapy	O
or	O
improving	O
the	O
tolerability	O
of	O
antidepressant	O
therapy,	O
comprising	O
co-administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
GABA-receptor-modulating	O
compound	O
;	O
and	O
a	O
SRI,	O
NRI,	O
5-HT2A	B-GENE
modulator	O
or	O
DRI	O
.	O


Biomarkers	O
relating	O
to	O
glucose	O
disposal	O
rate,	O
insulin	B-GENE
resistance,	O
and	O
/	O
or	O
insulin	B-GENE
resistance-related	O
disorders	O
are	O
provided	O
.	O
Methods	O
based	O
on	O
the	O
same	O
biomarkers	O
are	O
also	O
provided	O
.	O


Embodiments	O
disclosed	O
in	O
the	O
present	O
application	O
relate	O
to	O
a	O
composition	O
that	O
can	O
include	O
a	O
hepatitis	B-GENE
C	I-GENE
viral	I-GENE
polymerase	I-GENE
inhibitor,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
and	O
a	O
hepatitis	B-GENE
C	I-GENE
viral	I-GENE
protease	I-GENE
inhibitor,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O
Additional	O
embodiments	O
disclosed	O
relate	O
to	O
methods	O
for	O
treating	O
a	O
disease	O
condition	O
such	O
as	O
a	O
hepatitis	B-GENE
C	I-GENE
virus	O
infection,	O
liver	O
fibrosis	O
and	O
/	O
or	O
impaired	O
liver	O
function	O
with	O
a	O
hepatitis	B-GENE
C	I-GENE
viral	I-GENE
polymerase	I-GENE
inhibitor,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
and	O
a	O
hepatitis	B-GENE
C	I-GENE
viral	I-GENE
protease	I-GENE
inhibitor,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
deuterated	O
compounds	O
having	O
certain	O
biological	O
activities	O
that	O
include,	O
but	O
are	O
not	O
limited	O
to,	O
inhibiting	O
cell	O
proliferation,	O
modulating	O
protein	B-GENE
kinase	I-GENE
activity	O
and	O
modulating	O
polymerase	B-GENE
activity	O
.	O
The	O
deuterated	O
compounds	O
of	O
the	O
invention	O
can	O
modulate	O
casein	B-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
activity	O
and	O
/	O
or	O
poly(ADP-ribose)polymerase	B-GENE
(	O
PARP	B-GENE
)	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
in	O
part	O
to	O
methods	O
for	O
using	O
such	O
deuterated	O
compounds	O
as	O
therapeutic	O
agents	O
.	O


The	O
present	O
invention	O
provides	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
neurological	O
or	O
neuropsychiatric	O
disorders	O
involving	O
abnormal	O
D1-D2	B-GENE
dopamine	I-GENE
receptor	I-GENE
coupling	O
and	O
/	O
or	O
activation	O
.	O
Methods	O
and	O
agents	O
are	O
provided	O
for	O
modulating	O
dopamine	O
receptor	I-GENE
function	O
arising	O
from	O
D1-D2	O
coupling	O
and	O
/	O
or	O
activation	O
.	O
Agents	O
of	O
the	O
present	O
invention	O
include	O
fragments	O
of	O
D2	B-GENE
receptor	I-GENE
or	O
D1	B-GENE
receptor	I-GENE
that	O
can	O
disrupt	O
D1-D2	O
coupling	O
.	O


Disclosed	O
are	O
a	O
new	O
class	O
of	O
non-lipid	O
small	O
molecule	O
inhibitors	O
which	O
interfere	O
with	O
the	O
interaction	O
between	O
PIP3	O
and	O
pleckstrin	O
homology	O
domains	O
.	O
These	O
molecules	O
target	O
a	O
broad	O
range	O
of	O
PIP3-dependent	O
signaling	O
events	O
in	O
vitro	O
and	O
exert	O
significant	O
anti-tumor	O
activity	O
in	O
vivo	O
.	O
The	O
small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
can	O
be	O
used	O
alone	O
or	O
together	O
with	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	B-GENE
)	O
-related	O
apoptosis-inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
other	O
cancer	O
medicament	O
to	O
treat	O
cancer	O
.	O
Small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
act	O
synergistically	O
in	O
combination	O
with	O
TRAIL	O
in	O
treating	O
cancer	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cancer	O
are	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
phenyl	O
oxadiazole	O
derivatives,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-phosphate	B-GENE
receptors	I-GENE
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
provides	O
provides	O
certain	O
pentafluorosulfur	O
imino	O
heterocyclic	O
compounds,	O
including	O
compounds	O
Formula	O
(	O
I	O
)	O
:	O
and	O
tautomers	O
thereof,	O
and	O
solvates,	O
prodrugs,	O
esters,	O
and	O
deuterates	O
of	O
said	O
compounds	O
and	O
said	O
tautomers,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
said	O
compounds,	O
tautomers,	O
solvates,	O
prodrugs,	O
esters,	O
and	O
deuterates,	O
wherein	O
each	O
of	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R9,	O
R11,	O
ring	O
A,	O
ring	O
B,	O
m,	O
n,	O
p,	O
q,	O
r,	O
-L1-,	O
L2-,	O
and	O
L3-	O
is	O
selected	O
independently	O
and	O
as	O
defined	O
herein	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
such	O
compounds	O
(	O
alone	O
and	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
active	O
agents	O
)	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
in	O
treating	O
pathologies	O
associated	O
with	O
amyloid	B-GENE
beta	I-GENE
(Aβ)	I-GENE
protein,	O
including	O
Alzheimers	O
Disease,	O
are	O
also	O
disclosed	O
.	O


Disclosed	O
herein	O
are	O
compounds,	O
compositions	O
and	O
methods	O
for	O
modulating	O
splicing	O
of	O
SMN2	B-GENE
mRNA	O
in	O
a	O
cell,	O
tissue	O
or	O
animal	O
.	O
Also	O
provided	O
are	O
uses	O
of	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders,	O
including	O
spinal	O
muscular	O
atrophy	O
.	O


Select	O
phytoestrogen	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
for	O
promoting	O
neurological	O
heath	O
and	O
prevention	O
of	O
age-related	O
neurodegeneration,	O
such	O
as	O
AD,	O
have	O
been	O
developed	O
.	O
These	O
select	O
phytoestrogen	O
formulations	O
are	O
composed	O
of	O
a	O
number	O
of	O
plant-derived	O
estrogenic	O
molecules	O
and	O
/	O
or	O
their	O
structural	O
analogues	O
and	O
exhibit	O
binding	O
preference	O
to	O
ERβ	B-GENE
over	O
ERα	B-GENE
and	O
agonist	O
activity	O
in	O
the	O
brain	O
.	O
These	O
ERβ-selective	O
phytoestrogen	O
formulations	O
cross	O
the	O
blood-brain-barrier	O
and	O
promote	O
estrogen-associated	O
neurotrophism	O
and	O
neuroprotections	O
mechanisms	O
in	O
the	O
brain,	O
without	O
activating	O
proliferative	O
mechanisms	O
in	O
the	O
reproductive	O
tissues	O
and	O
are	O
therefore	O
devoid	O
of	O
other	O
estrogen-associated	O
problematic	O
aspects	O
.	O
These	O
are	O
administered	O
enterally,	O
transdermally,	O
transmucosally,	O
intranasally	O
or	O
parenterally,	O
in	O
a	O
dosage	O
effective	O
to	O
prevent	O
or	O
alleviate	O
neuronal	O
damage,	O
effect	O
neuronal	O
regeneration	O
or	O
sustain	O
viability,	O
increase	O
expression	O
of	O
anti-apoptotic	O
proteins,	O
and	O
/	O
or	O
decrease	O
indicators	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
.	O


The	O
present	O
invention	O
provides	O
use	O
of	O
protein	B-GENE
kinase	I-GENE
C-zeta	I-GENE
(	O
PKC-ζ	B-GENE
)	O
as	O
a	O
diagnostic	O
biomarker	O
for	O
breast	O
cancer	O
tumorigenesis	O
.	O
Also	O
provided	O
are	O
uses	O
of	O
PKC-zeta	B-GENE
inhibitors	O
for	O
inhibiting	O
breast	O
cancer	O
tumorigenesis	O
and	O
for	O
treatment	O
of	O
breast	O
cancer	O
.	O


The	O
invention	O
provides	O
compounds	O
and	O
methods	O
for	O
inhibiting	O
proteases	B-GENE
.	O
One	O
aspect	O
of	O
the	O
invention	O
features	O
pro-soft	O
inhibitors	O
which	O
react	O
with	O
an	O
activating	O
protease	B-GENE
to	O
release	O
an	O
active	O
inhibitor	O
moiety	O
in	O
proximity	O
to	O
a	O
target	O
protease	B-GENE
.	O
In	O
certain	O
instances,	O
compounds	O
inhibit	O
proteasomes	B-GENE
and	O
/	O
or	O
post-proline	B-GENE
cleaving	I-GENE
enzymes	I-GENE
(	O
PPCE	B-GENE
)	O
,	O
such	O
as	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
.	O
The	O
compounds	O
of	O
the	O
invention	O
provide	O
a	O
better	O
therapeutic	O
index,	O
owing	O
in	O
part	O
to	O
reduced	O
toxicity	O
and	O
/	O
or	O
improved	O
specificity	O
for	O
the	O
targeted	O
protease	B-GENE
.	O
Another	O
aspect	O
of	O
the	O
invention	O
provides	O
for	O
the	O
use	O
of	O
the	O
disclosed	O
compounds	O
for	O
treating	O
Type	O
II	O
diabetes,	O
insulin	B-GENE
resistance,	O
glucose	O
intolerance,	O
hyperglycemia,	O
hypoglycemia,	O
hyperinsulinemia,	O
obesity,	O
hyperlipidemia,	O
or	O
hyperlipoproteinemia	O
.	O


Described	O
are	O
gastrointestinal	O
cancer	O
specific	O
biomarkers	O
comprising	O
the	O
nucleic	O
acid	O
sequence	O
of	O
the	O
Engrailed-2	B-GENE
(	O
EN2	B-GENE
)	O
gene	O
or	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
encoded	O
EN2	B-GENE
protein	O
.	O
Also	O
described	O
are	O
uses	O
of	O
the	O
biomarkers	O
in	O
the	O
treatment,	O
diagnosis,	O
monitoring	O
and	O
imaging	O
of	O
gastrointestinal	O
cancer	O
.	O


Compounds,	O
compositions,	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
modulate	O
apoptosis	O
including	O
IAP	B-GENE
antagonists	O
are	O
provided	O
herein	O
.	O
Compositions	O
including	O
mimetics	O
of	O
the	O
invention	O
and,	O
optionally,	O
secondary	O
agents,	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
such	O
as,	O
cancer	O
and	O
autoimmune	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
therapeutic	O
methods,	O
compositions	O
and	O
uses	O
thereof,	O
that	O
affect,	O
directly	O
or	O
indirectly,	O
the	O
behavior	O
of	O
LRP	B-GENE
receptors	I-GENE
.	O
These	O
compositions	O
and	O
methods	O
result	O
in	O
the	O
treatment	O
of	O
inflammatory,	O
immunological	O
and	O
metabolic	O
conditions	O
.	O
More	O
particularly,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
are	O
directed	O
to	O
the	O
identification	O
of	O
small	O
molecules,	O
drugs	O
and	O
/	O
or	O
pharmacological	O
agents	O
that	O
affect	O
the	O
Wnt	B-GENE
pathway	O
by	O
affecting	O
normal	O
complex	O
formation	O
among	O
various	O
signaling	O
receptors,	O
the	O
LRP5	B-GENE
and	O
LRP6	B-GENE
receptor,	O
and	O
related	O
ligands	O
.	O


Organic	O
compounds	O
showing	O
the	O
ability	O
to	O
inhibit	O
viral	O
glycoprotein	B-GENE
(	O
GP	O
)	O
-mediated	O
entry	O
of	O
a	O
filovirus	O
into	O
a	O
host	O
cell	O
are	O
disclosed	O
.	O
The	O
disclosed	O
filovirus	O
entry	O
inhibitor	O
compounds	O
are	O
useful	O
for	O
treating,	O
preventing,	O
or	O
reducing	O
the	O
spread	O
of	O
infections	O
by	O
filovirus	O
including	O
the	O
type	O
species	O
Marburg	O
virus	O
(	O
MARV	O
)	O
and	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
.	O
Preferred	O
inhibitors	O
of	O
the	O
invention	O
provide	O
therapeutic	O
agents	O
for	O
combating	O
the	O
Ivory	O
Coast,	O
Sudan,	O
Zaire,	O
Bundibugyo,	O
and	O
Reston	O
Ebola	O
virus	O
strains	O
.	O


The	O
present	O
application	O
describes	O
selective	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
for	O
neuronal	B-GENE
nicotinic	I-GENE
receptors	I-GENE
(	O
NNRs	B-GENE
)	O
,	O
more	O
specifically	O
for	O
the	O
α4β2	B-GENE
NNR	O
subtype,	O
compositions	O
thereof,	O
and	O
methods	O
of	O
using	O
the	O
same,	O
wherein	O
X,	O
R1,	O
X,	O
R2,	O
R3,	O
L1,	O
m,	O
n,	O
p,	O
and	O
q	O
are	O
defined	O
in	O
the	O
specification	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
hepcidin	B-GENE
antagonists	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
the	O
use	O
thereof	O
as	O
medicaments,	O
in	O
particular	O
for	O
treatment	O
of	O
disorders	O
in	O
iron	O
metabolism,	O
such	O
as,	O
in	O
particular,	O
iron	O
deficiency	O
diseases	O
and	O
anaemias,	O
in	O
particular	O
anaemias	O
in	O
connection	O
with	O
chronic	O
inflammatory	O
diseases	O
(	O
ACD	O
:	O
anaemia	O
of	O
chronic	O
disease	O
and	O
AI	O
:	O
anaemia	O
of	O
inflammation	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
neurodegenerative	O
disorders,	O
e	O
.	O
g	O
.	O
,	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
compositions	O
comprising	O
selective	O
antagonists	O
of	O
calcium	B-GENE
ion	I-GENE
channels	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
cav1.3-type	B-GENE
ion	I-GENE
channels	I-GENE
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
to	O
treat	O
or	O
prevent	O
neurodegenerative	O
disorders	O
.	O


The	O
invention	O
provides	O
a	O
microsphere	O
formulation	O
for	O
the	O
sustained	O
delivery	O
of	O
an	O
aptamer,	O
for	O
example,	O
an	O
anti-Vascular	O
Endothelial	O
Growth	I-GENE
Factor	I-GENE
aptamer,	O
to	O
a	O
preselected	O
locus	O
in	O
a	O
mammal,	O
such	O
as	O
the	O
eye	O
.	O
In	O
addition,	O
the	O
invention	O
provides	O
methods	O
for	O
making	O
such	O
formulations,	O
and	O
methods	O
of	O
using	O
such	O
formulations	O
to	O
deliver	O
an	O
aptamer	O
to	O
a	O
preselected	O
locus	O
in	O
a	O
mammal	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
delivering	O
the	O
aptamer	O
to	O
an	O
eye	O
for	O
the	O
treatment	O
of	O
an	O
ocular	O
disorder,	O
for	O
example,	O
age-related	O
macular	O
degeneration	O
.	O


Compounds	O
that	O
selectively	O
inhibit	O
pathological	O
production	O
of	O
human	B-GENE
vascular	I-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O
Compounds	O
that	O
inhibit	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O
Also	O
described	O
are	O
methods	O
of	O
reducing	O
VEGF	B-GENE
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
non-neoplastic	O
conditions	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O
Further	O
described	O
are	O
methods	O
of	O
inhibiting	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
viral	O
infections	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O
The	O
Compounds	O
may	O
be	O
administered	O
as	O
a	O
single	O
agent	O
therapy	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapies	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatments	O
.	O


Described	O
herein	O
is	O
an	O
improved	O
method	O
of	O
treating	O
overactive	O
bladder,	O
wherein	O
the	O
method	O
comprises	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
beta	B-GENE
3	I-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist,	O
an	O
antimuscarinic	O
agent,	O
and	O
an	O
optional	O
selective	O
M2	B-GENE
antagonist	O
.	O
Such	O
combination	O
therapy	O
provides	O
improved	O
efficacy	O
and	O
/	O
or	O
reduced	O
side	O
effects	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
having	O
an	O
excellent	O
DGAT	B-GENE
inhibitory	O
effect	O
and	O
feeding	O
suppressant	O
effect	O
.	O
The	O
present	O
invention	O
provides	O
trans-6-	O
[	O
3-	O
(	O
2,4-difluoro-phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H-isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl-cyclohexyl	O
ester,	O
trans-6-	O
[	O
3-	O
(	O
2-chloro-phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H-isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl-cyclohexyl	O
ester,	O
trans-6-	O
[	O
3-	O
(	O
2,3-difluoro-phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H-isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl-cyclohexyl	O
ester,	O
trans-6-	O
[	O
3-	O
(	O
2,5-difluoro-phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H-isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl-cyclohexyl	O
ester,	O
trans-6-	O
[	O
3-	O
(	O
2,6-difluoro-phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H-isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl-cyclohexyl	O
ester,	O
or	O
the	O
like,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
chemokine-mucin	O
fusions	O
linked	O
to	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-anchors	O
and	O
their	O
use	O
as	O
anti-cancer	O
adjuvants	O
and	O
as	O
agents	O
in	O
tissue	O
regeneration	O
and	O
suppression	O
of	O
vascular	O
damage	O
.	O
GPI-linked	O
chemokines	B-GENE
are	O
incorporated	O
in	O
the	O
surface	O
membrane	O
of	O
tumour	O
cells	O
and	O
effect	O
a	O
recruitment	O
of	O
cytotoxic	O
immune	O
cells	O
to	O
the	O
tumour	O
site	O
following	O
injection	O
in	O
vivo	O
.	O
Leukocytes,	O
cytotoxic	O
T-cells	O
and	O
NK	O
cells	O
target	O
the	O
chemokine-GPI-anchored	O
tumour	O
cells	O
and	O
modulate	O
cell-mediated	O
lysis	O
of	O
the	O
tumour	O
cells	O
.	O
The	O
efficiency	O
of	O
GPI-anchoring	O
and	O
modulation	O
of	O
immune	O
cells	O
can	O
be	O
further	O
enhanced	O
by	O
linking	O
the	O
chemokine	B-GENE
to	O
a	O
mucin	B-GENE
domain	O
followed	O
by	O
the	O
GPI-anchor	O
.	O
The	O
GPI-anchored	O
chemokines,	O
with	O
or	O
without	O
mucin	B-GENE
domain,	O
are	O
remarkably	O
useful	O
for	O
the	O
inhibition	O
of	O
tumour	O
growth,	O
tissue	O
regeneration,	O
and	O
suppression	O
of	O
acute	O
vascular	O
damage	O
to	O
allografts	O
.	O


The	O
invention	O
relates	O
to	O
the	O
treatment	O
and	O
prevention	O
of	O
type	O
I	O
diabetes	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
compounds	O
that	O
treat	O
or	O
prevent	O
the	O
body	O
'	O
s	O
immune	O
system	O
from	O
destroying	O
β-cells	O
(	O
i	O
.	O
e	O
.	O
,	O
insulin-producing	O
cells	O
in	O
the	O
pancreatic	O
islets	O
of	O
Langerhans	O
)	O
by	O
inhibition	O
of	O
JNK2,	O
selective	O
inhibition	O
of	O
JNK2,	O
or	O
inhibition	O
of	O
the	O
expression	O
of	O
the	O
MAPK9	B-GENE
gene	O
or	O
gene	O
product	O
.	O
In	O
one	O
embodiment,	O
the	O
present	O
invention	O
contemplates	O
the	O
diagnosis,	O
identification,	O
production,	O
and	O
use	O
of	O
compounds	O
which	O
modulate	O
MAPK9	B-GENE
gene	O
expression	O
or	O
the	O
activity	O
of	O
the	O
MAPK9	B-GENE
gene	O
product	O
including	O
but	O
not	O
limited	O
to,	O
JNK2,	O
the	O
nucleic	O
acid	O
encoding	O
MAPK9	B-GENE
and	O
homologues,	O
analogues,	O
and	O
deletions	O
thereof,	O
as	O
well	O
as	O
antisense,	O
ribozyme,	O
triple	O
helix,	O
antibody,	O
and	O
polypeptide	O
molecules	O
as	O
well	O
as	O
small	O
inorganic	O
molecules	O
.	O
The	O
present	O
invention	O
contemplates	O
a	O
variety	O
of	O
pharmaceutical	O
formulations	O
and	O
routes	O
of	O
administration	O
for	O
such	O
compounds	O
.	O


This	O
invention	O
provides	O
methods	O
of	O
diagnosing	O
or	O
determining	O
a	O
cause	O
of	O
an	O
autoimmune	O
encephalitis	O
or	O
an	O
epilepsy	O
in	O
a	O
subject	O
and	O
of	O
diagnosing	O
a	O
tumor	O
in	O
a	O
subject,	O
comprising	O
the	O
step	O
of	O
testing	O
a	O
biological	O
sample	O
of	O
the	O
subject	O
for	O
an	O
anti-body	O
to	O
a	O
GABAB	B-GENE
receptor	I-GENE
.	O
This	O
invention	O
further	O
provides	O
methods	O
of	O
treating	O
an	O
autoimmune	O
encephalitis	O
or	O
an	O
epilepsy,	O
comprising	O
the	O
steps	O
of	O
detecting	O
an	O
antibody	O
to	O
a	O
GABAB	B-GENE
receptor	I-GENE
and	O
treating	O
a	O
tumor	O
associated	O
with	O
the	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	B-GENE
of	I-GENE
motor	I-GENE
neuron	I-GENE
1	I-GENE
(	O
SMN1	B-GENE
)	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
ubiquitin	B-GENE
carboxyl-terminal	I-GENE
hydrolase	I-GENE
L1	I-GENE
(	O
UCHL1	B-GENE
)	O
regulator	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	B-GENE
carboxyl-terminal	I-GENE
hydrolase	I-GENE
L1	I-GENE
(	O
UCHL1	B-GENE
)	O
in	O
human	O
fibroblasts	O
comprising	O
detecting	O
protein	O
expression	O
level	O
of	O
survival	B-GENE
of	I-GENE
motor	I-GENE
neuron	I-GENE
1	I-GENE
(	O
SMN1	B-GENE
)	O
.	O


Methods	O
for	O
modulating	O
gene	O
expression	O
in	O
a	O
skin	O
cell	O
by	O
administering	O
to	O
the	O
cell	O
an	O
amount	O
of	O
a	O
therapeutic	O
composition	O
in	O
an	O
amount	O
sufficient	O
to	O
modulate	O
the	O
expression	O
of	O
miR-1,	O
and	O
therapeutic	O
compositions	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
expression	O
and	O
regulating	O
growth	O
factors	O
in	O
chrondrocytes	O
and	O
developing	O
cartilage,	O
particularly	O
granulin-epithelin	B-GENE
precursor	I-GENE
(	O
GEP	B-GENE
)	O
.	O
The	O
invention	O
relates	O
to	O
the	O
modulation	O
and	O
manipulation	O
of	O
these	O
growth	O
factors,	O
GEP,	O
and	O
/	O
or	O
the	O
molecules	O
they	O
interact	O
with,	O
for	O
instance	O
COMP,	O
in	O
cartilage	O
disorders,	O
including	O
arthritis	O
.	O
Assays	O
and	O
screening	O
methods	O
for	O
the	O
determination	O
of	O
the	O
expression	O
and	O
activity	O
of	O
GEP,	O
or	O
of	O
GEP-COMP,	O
are	O
provided,	O
including	O
for	O
screening	O
for	O
the	O
presence	O
or	O
extent	O
of	O
cartilage	O
or	O
arthritic	O
disease	O
and	O
for	O
identifying	O
modulators	O
or	O
compounds	O
/	O
agents	O
for	O
treatment	O
or	O
prevention	O
of	O
cartilage	O
or	O
arthritic	O
diseases	O
.	O


The	O
present	O
application	O
is	O
directed	O
to	O
the	O
discovery	O
that	O
preparations	O
of	O
hedgehog	B-GENE
polypeptides	O
can	O
be	O
used	O
to	O
control	O
the	O
formation	O
and	O
/	O
or	O
maintenance	O
of	O
epithelial	O
tissue	O
.	O


There	O
is	O
disclosed	O
a	O
molecular	O
composition	O
(	O
s	O
)	O
of	O
a	O
novel	O
tissue	O
protective	O
erythropoietin	B-GENE
(EPO)	I-GENE
binding	I-GENE
receptor	I-GENE
protein	I-GENE
complex,	O
termed	O
NEPOR	B-GENE
.	O
Presence	O
of	O
NEPOR	B-GENE
components	O
on	O
a	O
tumour	O
allows	O
EPO	B-GENE
to	O
impinge	O
on	O
the	O
survival	O
of	O
associated	O
cells	O
thereby	O
enhancing	O
tumour	O
progression	O
and	O
negatively	O
effecting	O
patient	O
survival	O
.	O
Presence	O
of	O
NEPOR	B-GENE
represents	O
a	O
prognostic	O
biomarker	O
for	O
poorer	O
patient	O
outcome	O
.	O
Thus,	O
methods	O
are	O
provided	O
for	O
stratifying	O
patients	O
having	O
a	O
tumour	O
as	O
suitable	O
(	O
i	O
.	O
e	O
.	O
NEPOR	B-GENE
not	O
present	O
)	O
or	O
non-suitable	O
(	O
i	O
.	O
e	O
.	O
,	O
NEPOR	B-GENE
present	O
)	O
for	O
EPO	B-GENE
treatment,	O
comprising	O
:	O
(	O
a	O
)	O
isolating	O
a	O
tissue	O
sample	O
from	O
an	O
individual	O
who	O
is	O
receiving	O
or	O
is	O
a	O
candidate	O
for	O
receiving	O
erythropoietin,	O
(	O
b	O
)	O
determining	O
the	O
level	O
of	O
expression	O
of	O
the	O
NEPOR	B-GENE
gene	O
(	O
s	O
)	O
(	O
mRNA	O
)	O
and	O
/	O
or	O
the	O
presence	O
of	O
the	O
NEPOR	B-GENE
gene	O
product	O
(	O
protein	O
)	O
from	O
the	O
isolated	O
tissue,	O
and	O
(	O
c	O
)	O
correlating	O
the	O
presence	O
of	O
an	O
NEPOR	B-GENE
gene	O
expression	O
product	O
or	O
the	O
presence	O
of	O
NEPOR	B-GENE
protein	I-GENE
to	O
a	O
physiological	O
response	O
to	O
the	O
treatment	O
with	O
erythropoietin	O
.	O
Furthermore,	O
by	O
disclosing	O
the	O
molecular	O
compositions	O
of	O
NEPOR	B-GENE
species,	O
there	O
are	O
disclosed	O
methods	O
for	O
rationally	O
identifying	O
/	O
designing	O
NEPOR	B-GENE
modulating	O
therapeutics	O
.	O
Methods	O
also	O
are	O
provided	O
for	O
treating	O
neurological	O
insults	O
such	O
as	O
stroke	O
(	O
via	O
enhancement	O
of	O
NEPOR	B-GENE
activity	O
)	O
and	O
cancer	O
(	O
via	O
down-regulation	O
of	O
cyto-protective	O
signaling	O
from	O
NEPOR	B-GENE
)	O
.	O


A	O
composition	O
comprising	O
an	O
SL0101	O
[	O
kaempferol	O
3-O-	O
(	O
3″,4″-di-O-acetyl-α-L-rhamnopyranoside	O
)	O
]	O
derivative	O
compound	O
that	O
has	O
enhanced	O
ability	O
to	O
inhibit	O
RSK	B-GENE
activity,	O
relative	O
to	O
the	O
parent	O
compound	O
is	O
provided	O
.	O
The	O
compounds	O
have	O
utility	O
for	O
treating	O
any	O
disease	O
or	O
conditions	O
characterized	O
or	O
associated	O
with	O
excess	O
or	O
undesirable	O
RSK	B-GENE
activity	O
.	O
For	O
example	O
the	O
RSK	B-GENE
inhibitors	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
to	O
reduce	O
the	O
proliferation	O
of	O
neoplastic	O
cells	O
or	O
for	O
inhibiting	O
the	O
establishment	O
or	O
maintenance	O
of	O
an	O
intracellular	O
pathogenic	O
infection	O
by	O
pathogens	O
whose	O
pathogenicity	O
derives	O
in	O
part	O
from	O
the	O
pathogen	O
'	O
s	O
ability	O
to	O
impede	O
endosomal	O
/	O
phagosomal	O
maturation	O
in	O
the	O
host	O
cell	O
.	O


The	O
invention	O
is	O
directed	O
to	O
one	O
or	O
more	O
RNase	B-GENE
L	I-GENE
mediated	O
cleavage	O
products	O
.	O
In	O
particular	O
aspects,	O
the	O
RNase	B-GENE
L	I-GENE
mediated	O
cleavage	O
products	O
are	O
RNase	B-GENE
L	I-GENE
mediated	O
cleavage	O
products	O
of	O
a	O
virus,	O
referred	O
to	O
herein	O
as	O
a	O
“suppressor	O
of	O
virus	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
”	O
or	O
“svRNA”	O
and	O
uses	O
thereof	O
.	O


A	O
process	O
for	O
producing	O
a	O
biocompatible	O
material	O
includes	O
the	O
steps	O
of	O
mixing	O
an	O
extract	O
of	O
a	O
fish	O
scale-derived	O
hydroxyapatite	O
(	O
with	O
water	O
content	O
of	O
70	O
to	O
75	O
%	O
by	O
weight	O
)	O
and	O
of	O
a	O
fish	O
scale-derived	O
collagen	B-GENE
(	O
with	O
water	O
content	O
of	O
40	O
to	O
60	O
%	O
by	O
weight	O
)	O
in	O
the	O
weight	O
percent	O
ratio	O
of	O
about	O
8	O
:	O
2,	O
stirring	O
the	O
mixture	O
and	O
drying	O
the	O
mixture	O
by	O
a	O
hot	O
blast	O
in	O
order	O
to	O
obtain	O
a	O
composite	O
.	O


Methods	O
of	O
diagnosing	O
osteoarthritis	O
are	O
carried	O
out	O
by	O
measuring	O
levels	O
of	O
Ihh,	O
and	O
methods	O
of	O
treating	O
osteoarthritis	O
comprise	O
inhibiting	O
Ihh	B-GENE
to	O
reduce	O
or	O
prevent	O
cartilage	O
degradation	O
.	O


DNA	O
aptamers	O
are	O
high	O
affinity	O
ligands	O
selected	O
by	O
genetic	O
enrichment	O
techniques	O
to	O
bind	O
to	O
specific	O
protein	O
targets	O
.	O
Because	O
these	O
represent	O
chemically	O
stable	O
and	O
reproducible	O
molecules,	O
they	O
have	O
application	O
as	O
affinity	O
reagents	O
and	O
/	O
or	O
therapeutic	O
drugs	O
to	O
affect	O
the	O
target	O
protein	O
'	O
s	O
actions	O
.	O
NF-kB	O
is	O
an	O
important	O
mediator	O
of	O
the	O
innate	O
immune	O
response	O
and	O
mediator	O
of	O
tissue	O
inflammation	O
.	O
Although	O
RNA	O
and	O
double	O
stranded	O
DNA	O
aptamers	O
have	O
been	O
identified	O
to	O
bind	O
to	O
the	O
NF-kB	O
family	O
of	O
proteins,	O
the	O
present	O
invention	O
represents	O
the	O
first	O
identification	O
of	O
single	O
stranded	O
DNA	O
aptamers	O
that	O
recognize	O
NFkB	B-GENE
RelA	B-GENE
.	O
The	O
aptamers	O
disclosed	O
herein	O
bind	O
to	O
several	O
distinct	O
regions	O
of	O
RelA	B-GENE
and	O
may	O
be	O
useful	O
to	O
antagonize	O
the	O
DNA	O
binding	O
of	O
RelA	B-GENE
as	O
an	O
inhibitor	O
of	O
cellular	O
inflammation,	O
visualize	O
the	O
location	O
or	O
amount	O
of	O
RelA	B-GENE
in	O
tissues	O
from	O
pathological	O
conditions,	O
or	O
to	O
quantitatively	O
measure	O
the	O
activated	O
state	O
of	O
RelA	B-GENE
by	O
affinity	O
binding	O
.	O


This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cortisol	O
blockers	O
(	O
glucocorticoid	B-GENE
receptor	I-GENE
[	O
GR	B-GENE
]	O
antagonists	O
)	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
stress	O
induced	O
hair	O
loss	O
.	O


The	O
method	O
of	O
treating	O
a	O
person	O
having	O
a	O
cancer	O
selected	O
from	O
carcinoma,	O
sarcoma	O
or	O
hematopoietic	O
cancer	O
by	O
administering	O
(	O
a	O
)	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
anti-cancer	O
drug	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
inhibitor,	O
a	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
VEGFR	B-GENE
)	O
inhibitor	O
and	O
a	O
Raf	B-GENE
kinase	O
inhibitor	O
and	O
(	O
b	O
)	O
an	O
effective	O
amount	O
of	O
5-	O
(	O
4-	O
(	O
6-	O
(	O
4-amino-3,5-dimethyl-phenoxy	O
)	O
-1-methyl-1H-benzimidazol-2-ylmethoxy	O
)	O
-benzyl	O
)	O
-thiazolidine-2,4-dione	O
.	O
dihydrochloride	O
provided	O
that	O
said	O
carcinoma	O
is	O
not	O
lung	O
cancer	O
when	O
an	O
EGFR	B-GENE
inhibitor	O
is	O
erlotinib	O
.	O
The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
finding	O
that	O
Syndecans	B-GENE
(	O
Sdc	B-GENE
)	O
are	O
receptors	O
of	O
Rspondin-2	B-GENE
(	O
Rspo2	B-GENE
)	O
and	O
Rspondin-3	O
(	O
Rspo3	B-GENE
)	O
.	O
Thus,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
Rspo2,	O
Rspo3	B-GENE
and	O
/	O
or	O
Sdc	B-GENE
activity	O
modulators	O
by	O
determining	O
if	O
a	O
test	O
compound	O
has	O
the	O
ability	O
to	O
modulate	O
the	O
binding	O
of	O
an	O
Rspo2	B-GENE
and	O
/	O
or	O
Rspo3	B-GENE
polypeptide	O
to	O
an	O
Sdc	B-GENE
polypeptide	O
.	O
Further,	O
the	O
invention	O
refers	O
to	O
novel	O
uses	O
for	O
antagonists	O
of	O
Rspo2	B-GENE
and	O
/	O
or	O
Rspo3	B-GENE
in	O
the	O
treatment	O
of	O
Sdc-associated	O
disorders	O
and	O
for	O
Sdc	B-GENE
antagonists	O
in	O
the	O
treatment	O
of	O
Rspo2-	O
and	O
/	O
or	O
Rspo3-associated	O
disorders	O
.	O


Diclosed	O
are	O
CCR1	B-GENE
receptor	O
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Ar1,	O
Ar2,	O
R1,	O
X	O
and	O
G	O
are	O
disclosed	O
herein	O
.	O
Also	O
disclosed	O
are	O
compositions,	O
methods	O
of	O
making	O
and	O
using	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
.	O


Disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
HIV	B-GENE
integrase	I-GENE
strand	O
transfer	O
inhibitor	O
.	O
More	O
particularly,	O
oral	O
pharmaceutical	O
compositions	O
of	O
raltegravir	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
and	O
process	O
for	O
preparing	O
and	O
use	O
of	O
the	O
same	O
are	O
disclosed	O
.	O


Provided	O
are	O
compounds	O
that	O
are	O
capable	O
of	O
modulating	O
the	O
activity	O
of	O
the	O
influenza	O
A	O
virus	O
via	O
interaction	O
with	O
the	O
M2	B-GENE
transmembrane	I-GENE
protein	I-GENE
.	O
Also	O
provided	O
are	O
methods	O
for	O
treating	O
an	O
influenza	O
A-affected	O
disease	O
state	O
or	O
infection	O
comprising	O
administering	O
a	O
composition	O
comprising	O
one	O
or	O
more	O
compounds	O
that	O
have	O
been	O
identified	O
as	O
being	O
capable	O
of	O
interaction	O
with	O
the	O
M2	B-GENE
protein	I-GENE
.	O


Disclosed	O
herein	O
are	O
methods	O
of	O
treating	O
a	O
condition	O
associated	O
with	O
elevated	O
cholesterol	O
levels	O
are	O
provided,	O
comprising	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
a	O
safe	O
and	O
effective	O
amount	O
of	O
a	O
cholesterol	O
biosynthesis	O
inhibitor	O
and	O
a	O
soluble	O
fiber	O
.	O
Further	O
disclosed	O
herein	O
are	O
kits	O
comprising	O
a	O
first	O
composition	O
comprising	O
a	O
cholesterol	O
biosynthesis	O
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
HMG	B-GENE
CoA	I-GENE
reductase	I-GENE
inhibitors,	O
HMG	B-GENE
CoA	I-GENE
synthase	I-GENE
inhibitors,	O
and	O
mixtures	O
thereof	O
;	O
and	O
a	O
second	O
composition	O
comprising	O
a	O
soluble	O
fiber	O
.	O
Even	O
further	O
described	O
are	O
compositions	O
comprising	O
a	O
cholesterol	O
biosynthesis	O
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
HMG	B-GENE
CoA	I-GENE
reductase	I-GENE
inhibitors,	O
HMG	B-GENE
CoA	I-GENE
synthase	I-GENE
inhibitors,	O
and	O
mixtures	O
thereof	O
;	O
and	O
a	O
soluble	O
fiber	O
.	O


The	O
invention	O
relates	O
to	O
1H-	O
[	O
1,2,3	O
]	O
triazolo	O
[	O
4,5-c	O
]	O
pyridine-4-carbonitrile	O
derived	O
Cathepsin	O
S	O
inhibitors	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
H	O
or	O
(	O
C1-3	O
)	O
alkyl	O
;	O
R2	O
is	O
halogen	O
or	O
(	O
C1-4	O
)	O
alkyl,	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
halogens	O
;	O
n	O
is	O
1-3	O
;	O
X	O
is	O
O	O
or	O
CH2	O
;	O
U,	O
V	O
and	O
W	O
are	O
CH	O
;	O
or	O
one	O
of	O
U,	O
V	O
and	O
W	O
is	O
N	O
;	O
Y	O
is	O
a	O
group	O
capable	O
of	O
interacting	O
with	O
the	O
Sn	O
.	O
.	O
.	O
S2	O
substites	O
of	O
the	O
active	O
site	O
of	O
Cathepsin	O
S	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
derivatives	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cathepsin	B-GENE
S	I-GENE
related	O
diseases	O
such	O
as	O
atherosclerosis,	O
obesity,	O
inflammation	O
and	O
immune	O
disorders,	O
such	O
as	O
rheumatoid	O
arthritis,	O
psoriasis,	O
cancer,	O
and	O
chronic	O
pain,	O
such	O
as	O
neuropathic	O
pain	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
diarrhea,	O
both	O
chronic	O
or	O
acute	O
forms,	O
by	O
the	O
administration	O
of	O
a	O
therapeutically	O
or	O
prophylactically	O
effective	O
amount	O
of	O
antibodies	O
and	O
fragments	O
thereof	O
having	O
binding	O
specificity	O
for	O
CGRP	B-GENE
.	O
In	O
particular	O
the	O
methods	O
prevent	O
or	O
reduce	O
diarrhea	O
in	O
conditions	O
or	O
treatments	O
resulting	O
in	O
elevated	O
CGRP	B-GENE
levels,	O
e	O
.	O
g	O
.	O
,	O
in	O
the	O
GI	O
tract	O
(	O
colon	O
)	O
that	O
are	O
associated	O
with	O
diarrhea	O
and	O
/	O
or	O
improper	O
electrolyte	O
and	O
fluid	O
excretion	O
from	O
the	O
bowel	O
or	O
urinary	O
system	O
.	O
More	O
specifically,	O
this	O
invention	O
relates	O
to	O
treatments	O
using	O
the	O
anti-CGRP	O
antibodies	O
and	O
fragments	O
described	O
herein,	O
and	O
binding	O
fragments	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
obesity,	O
diabetes,	O
dyslipidemia,	O
fatty	O
liver	O
or	O
insulin	B-GENE
resistance	O
syndrome,	O
comprising	O
:	O
administering	O
to	O
a	O
mammalian	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
adipic	O
acid	O
.	O
The	O
present	O
composition	O
containing	O
adipic	O
acid	O
as	O
an	O
active	O
ingredient	O
is	O
very	O
effective	O
in	O
preventing	O
or	O
treating	O
obesity,	O
diabetes,	O
dyslipidemia,	O
fatty	O
liver	O
(	O
preferably,	O
non-alcoholic	O
fatty	O
liver	O
)	O
or	O
insulin	B-GENE
resistance	O
syndrome	O
.	O
The	O
composition	O
of	O
the	O
present	O
invention	O
useful	O
as	O
pharmaceuticals	O
compositions	O
or	O
functional	O
food	O
compositions	O
has	O
therapeutic	O
efficacies	O
for	O
obesity,	O
dyslipidemia	O
or	O
fatty	O
liver,	O
and	O
also	O
induces	O
significant	O
decrease	O
in	O
fasting	O
glucose	O
level	O
and	O
blood	O
insulin	B-GENE
level	O
to	O
improve	O
type	O
2	O
diabetes,	O
insulin	B-GENE
resistance	O
and	O
related	O
metabolic	O
diseases	O
.	O


An	O
exosomal	O
composition	O
is	O
provided	O
that	O
comprises	O
a	O
therapeutic	O
agent	O
encapsulated	O
by	O
an	O
exosome	O
.	O
The	O
therapeutic	O
agent	O
can	O
be	O
a	O
phytochemical	O
agent,	O
a	O
chemotherapeutic	O
agent,	O
or	O
a	O
Stat3	B-GENE
inhibitor	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
the	O
exosomal	O
compositions	O
are	O
also	O
provided	O
.	O
Methods	O
for	O
treating	O
an	O
inflammatory	O
disease	O
or	O
a	O
cancer	O
are	O
further	O
provided	O
and	O
include	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
exosomal	O
composition	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
to	O
thereby	O
treat	O
the	O
inflammatory	O
disorder	O
or	O
the	O
cancer	O
.	O


A	O
pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
is	O
disclosed	O
.	O
The	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
comprises	O
:	O
a	O
first	O
pharmaceutical	O
composition	O
comprising	O
a	O
first	O
effective	O
amount	O
of	O
a	O
Mg2+-containing	O
compound	O
;	O
and	O
a	O
second	O
pharmaceutical	O
composition	O
comprising	O
a	O
second	O
effective	O
amount	O
of	O
a	O
COX-2	B-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
splice	O
variant	O
of	O
BANK1,	O
the	O
use	O
of	O
SNPs	O
in	O
BANK1	B-GENE
for	O
diagnostics	O
and	O
the	O
use	O
of	O
antagonists	O
to	O
modulate	O
BANK1	B-GENE
and	O
/	O
or	O
the	O
BANK1	B-GENE
pathway	O
.	O


The	O
present	O
invention	O
relates	O
to	O
4-pyridinone	O
compounds	O
which	O
are	O
inhibitors	O
of	O
catechol	B-GENE
O-methyltransferase	I-GENE
(	O
COMT	B-GENE
)	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
and	O
diseases	O
in	O
which	O
COMT	B-GENE
enzyme	O
is	O
involved	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
COMT	B-GENE
is	O
involved	O
.	O


The	O
invention	O
relates	O
to	O
the	O
synthesis	O
of	O
a	O
second-generation	O
camptothecin	O
glucuronide	O
prodrug	O
(	O
BQC-G	O
)	O
of	O
a	O
potent	O
anticancer	O
camptothecin	O
derivative	O
5,6-dihydro-4H-benzo	O
[	O
de	O
]	O
quinoline-camptothecin	O
(	O
BQC	O
)	O
.	O
BQC-G	O
was	O
over	O
4000	O
times	O
more	O
water	O
soluble	O
than	O
BQC,	O
displayed	O
good	O
stability	O
in	O
human	O
plasma	O
and	O
was	O
an	O
excellent	O
substrate	O
for	O
enzymatic	O
hydrolysis	O
by	O
bacterial	O
and	O
human	B-GENE
β-glucuronidases	I-GENE
.	O
BQC-G	O
was	O
about	O
30	O
times	O
less	O
toxic	O
than	O
BQC,	O
but	O
was	O
as	O
toxic	O
as	O
BQC	O
after	O
hydrolysis	O
of	O
the	O
glucuronide	O
moiety	O
by	O
β-glucuronidase	B-GENE
.	O
In	O
the	O
presence	O
of	O
human	B-GENE
serum	I-GENE
albumin,	O
BQC-G	O
displayed	O
lower	O
cytotoxicity	O
(	O
IC50	O
=	O
1080	O
nM	O
)	O
but	O
could	O
be	O
activated	O
by	O
β-glucuronidase	B-GENE
to	O
display	O
potent	O
activity	O
(	O
IC50	O
=	O
13	O
.	O
3	O
nM	O
)	O
.	O


A	O
method	O
of	O
identifying	O
cancer	O
or	O
an	O
associated	O
disorder	O
comprising	O
identifying	O
and	O
quantifying	O
STAT3	B-GENE
occurring	O
in	O
a	O
biological	O
sample	O
taken	O
from	O
a	O
subject	O
after	O
administering	O
a	O
SFK	B-GENE
inhibitor	O
to	O
said	O
subject	O
.	O


The	O
invention	O
describes	O
a	O
composition	O
for	O
combating	O
beta-lactamase-mediated	O
antibiotic	O
resistance	O
using	O
beta-lactamase	B-GENE
inhibitor	O
useful	O
for	O
injection,	O
capable	O
of	O
pharmaceutical	O
application	O
.	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
composition	O
containing	O
ceftriaxone	O
(	O
normally	O
as	O
ceftriaxone	O
sodium	O
)	O
and	O
sulbactam	O
(	O
normally	O
as	O
sulbactam	O
sodium	O
)	O
.	O
Such	O
compositions	O
are	O
found	O
to	O
be	O
useful	O
for	O
intramuscular	O
or	O
intravenous	O
administration	O
as	O
antibiotics	O
for	O
hospitalized	O
patients	O
with	O
serious	O
infections	O
.	O
Specifically,	O
this	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
further	O
including	O
an	O
aminocarboxylic	O
acid	O
chelating	O
agent,	O
for	O
example,	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
pharmaceutical	O
compositions	O
of	O
this	O
invention	O
have	O
been	O
found	O
normally	O
to	O
enhance	O
resistance	O
to	O
particulate	O
formation	O
in	O
solutions	O
to	O
be	O
administered	O
parenterally	O
.	O
The	O
invention	O
also	O
gives	O
details	O
of	O
the	O
dosage	O
forms	O
stored	O
in	O
sealed	O
containers	O
to	O
be	O
reconstituted	O
before	O
use	O
.	O
The	O
invention	O
also	O
gives	O
a	O
process	O
to	O
manufacture	O
these	O
compositions	O
.	O
The	O
invention	O
gives	O
a	O
method	O
of	O
treating	O
a	O
subject	O
having	O
a	O
condition	O
or	O
disorder,	O
wherein	O
a	O
treatment	O
with	O
ceftriaxone	O
sodium	O
and	O
sulbactam	O
sodium	O
is	O
indicated	O
.	O


Disclosed	O
are	O
neuraminidase	B-GENE
inhibitor	O
compounds	O
and	O
pharmaceutical	O
compositions	O
with	O
improved	O
bioavailability	O
and	O
/	O
or	O
improved	O
efficacy	O
and	O
methods	O
of	O
treating	O
influenza	O
using	O
the	O
compounds	O
and	O
pharmaceuticals	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
determining	O
the	O
redox	O
status	O
of	O
a	O
cell	O
or	O
tissue	O
comprising	O
a	O
step	O
consisting	O
of	O
determining	O
the	O
level	O
of	O
PML	B-GENE
nuclear	O
bodies	O
in	O
said	O
cell	O
or	O
tissue	O
.	O


In	O
a	O
first	O
aspect,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
prevention	O
or	O
treating	O
memory	O
impairment	O
and	O
/	O
or	O
a	O
neurodegenerative	O
condition,	O
disorder	O
or	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
targeting	O
a	O
miRNA	O
or	O
any	O
precursor,	O
or	O
targeting	O
the	O
activity	O
of	O
said	O
miRNA	O
or	O
any	O
precursor	O
thereof	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
wherein	O
the	O
targeted	O
miRNA	O
is	O
miR-34	B-GENE
.	O
Moreover,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
improving	O
memory	O
functionality	O
in	O
a	O
subject	O
suffering	O
from	O
memory	O
loss,	O
said	O
method	O
comprises	O
the	O
reduction	O
or	O
reducing	O
the	O
level	O
of	O
miR-34	B-GENE
levels	O
or	O
precursor	O
molecule	O
levels	O
in	O
brain	O
tissue	O
of	O
said	O
subject	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
targeting	O
miR-34	B-GENE
or	O
any	O
precursor	O
thereof	O
.	O
	O
	O
	O
	O
Moreover,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
inducing	O
memory	O
loss	O
in	O
an	O
individual	O
comprising	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
compounds	O
having	O
the	O
functionality	O
of	O
miR-34,	O
in	O
particular	O
of	O
miR-34c	B-GENE
or	O
any	O
precursor	O
thereof	O
.	O
In	O
addition,	O
a	O
method	O
for	O
diagnosing	O
or	O
predicting	O
memory	O
impairment	O
and	O
/	O
or	O
neurodegenerative	O
condition,	O
disorder	O
or	O
disease	O
is	O
provided	O
.	O
Finally,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
compound	O
targeting	O
miR-34	B-GENE
or	O
precursor	O
molecules	O
thereof	O
.	O


Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
comprising	O
bile	O
acid	O
transport	O
inhibitors	O
and	O
/	O
or	O
enteroendocrine	O
peptide	O
enhancing	O
agents	O
and	O
/	O
or	O
FXR	B-GENE
agonists	O
for	O
the	O
treatment	O
of	O
pancreatitis	O
or	O
prevention	O
of	O
pancreatitis	O
.	O


The	O
invention	O
relates	O
to	O
immunogenic	O
compositions	O
comprising	O
recombinant	O
multimeric	O
influenza	O
proteins	O
or	O
parts	O
thereof	O
fused	O
to	O
a	O
streptavidin	O
affinity	O
tag,	O
preferably	O
recombinant	O
trimeric	O
influenza	B-GENE
virus	I-GENE
hemagglutinin	I-GENE
and	O
/	O
or	O
recombinant	O
tetrameric	O
influenza	B-GENE
virus	I-GENE
neuraminidase,	O
or	O
vectors	O
comprising	O
nucleic	O
acid	O
sequences	O
encoding	O
such	O
influenza	O
proteins	O
.	O
The	O
inventions	O
further	O
relate	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
immunogenic	O
compositions	O
and	O
uses	O
thereof	O
and	O
methods	O
for	O
eliciting	O
an	O
immune	O
response	O
in	O
an	O
individual	O
.	O


Provided	O
are	O
a	O
novel	O
pyridine	O
carboxylic	O
acid	O
based	O
compound	O
used	O
as	O
a	O
P2X1	B-GENE
and	O
P2X3	B-GENE
receptor	I-GENE
antagonist,	O
a	O
production	O
method	O
for	O
the	O
same	O
and	O
a	O
composition	O
comprising	O
the	O
same	O
.	O
The	O
compound	O
according	O
to	O
the	O
present	O
invention	O
is	O
a	O
powerful	O
antagonist	O
of	O
P2X1	B-GENE
and	O
P2X3	O
receptors,	O
and	O
hence	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
diseases	O
involving	O
neurological	O
pain	O
or	O
chronic	O
inflammatory	O
diseases	O
which	O
are	O
diseases	O
caused	O
by	O
P2X1	B-GENE
and	O
P2X3	B-GENE
receptor	I-GENE
activity	O
.	O


Disclosed	O
are	O
compounds	O
having	O
enhanced	O
potency	O
in	O
the	O
modulation	O
of	O
NMDA	B-GENE
receptor	I-GENE
activity	O
.	O
Such	O
compounds	O
are	O
contemplated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
disorders	O
such	O
as	O
learning,	O
cognitive	O
activities,	O
and	O
analgesia,	O
particularly	O
in	O
alleviating	O
and	O
/	O
or	O
reducing	O
neuropathic	O
pain	O
.	O


Provided	O
herein	O
are	O
methods,	O
compounds,	O
and	O
compositions	O
for	O
reducing	O
expression	O
of	O
a	O
CETP	B-GENE
mRNA	O
and	O
protein	O
in	O
an	O
animal	O
.	O
Also	O
provided	O
herein	O
are	O
methods,	O
compounds,	O
and	O
compositions	O
for	O
increasing	O
HDL	O
levels	O
and	O
/	O
or	O
HDL	O
activity	O
and	O
reducing	O
plasma	O
lipids,	O
plasma	O
glucose	O
and	O
atherosclerotic	O
plaques	O
in	O
an	O
animal	O
.	O
Such	O
methods,	O
compounds,	O
and	O
compositions	O
are	O
useful	O
to	O
treat,	O
prevent,	O
delay,	O
or	O
ameliorate	O
any	O
one	O
or	O
more	O
of	O
cardiovascular	O
disease	O
or	O
metabolic	O
disease,	O
or	O
a	O
symptom	O
thereof	O
.	O


Novel	O
biaryl	O
compounds	O
with	O
phosphodiesterase	B-GENE
inhibitory	O
activity	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R3,	O
X,	O
Y,	O
Z1,	O
Z2,	O
Z3,	O
and	O
Z4	O
have	O
the	O
meanings	O
defined	O
herein,	O
as	O
well	O
as	O
their	O
use	O
as	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
and	O
conditions	O
.	O


Heterocyclic	O
compounds,	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
are	O
disclosed	O
as	O
RORγt	B-GENE
modulators	O
that	O
have	O
a	O
formula	O
represented	O
by	O
the	O
following	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
wherein	O
n1,	O
n2,	O
R1,	O
R2,	O
R3,	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O
These	O
compounds	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans,	O
including	O
by	O
way	O
of	O
non-limiting	O
example,	O
inflammatory	O
conditions,	O
autoimmune	O
disorders,	O
cancer,	O
and	O
graft-versus-host	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
N-	O
(	O
3-	O
(	O
2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta	O
[	O
e	O
]	O
[	O
1,3	O
]	O
oxazin-4-yl	O
)	O
-phenyl	O
)	O
-amides	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
having	O
BACE1	B-GENE
inhibitory	O
activity,	O
their	O
manufacture,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
therapeutically	O
active	O
substances	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
treatment	O
of	O
e	O
.	O
g	O
.	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
concerns	O
an	O
adeno-associated	O
viral	O
vector	O
comprising	O
:	O
	O
	O
	O
a	O
U7	O
type	O
modified	O
snRNA	O
sequence	O
;	O
the	O
native	O
U7	O
promoter	O
;	O
at	O
least	O
one	O
antisense	O
sequence	O
directed	O
against	O
at	O
least	O
one	O
splice	O
site	O
of	O
at	O
least	O
one	O
exon,	O
the	O
said	O
exon	O
encoding	O
a	O
dispensable	O
domain	O
of	O
dystrophin	B-GENE
.	O


Novel	O
IL-17	B-GENE
like	O
polypeptides	O
and	O
nucleic	O
acid	O
molecules	O
encoding	O
the	O
same	O
.	O
The	O
invention	O
also	O
provides	O
vectors,	O
host	O
cells,	O
selective	O
binding	O
agents,	O
and	O
methods	O
for	O
producing	O
IL-17	B-GENE
like	O
polypeptides	O
.	O
Also	O
provided	O
for	O
are	O
methods	O
for	O
the	O
treatment,	O
diagnosis,	O
amelioration,	O
or	O
prevention	O
of	O
diseases	O
with	O
IL-17	B-GENE
like	O
polypeptides,	O
agonists,	O
or	O
antagonists	O
thereof	O
.	O


Disclosed	O
is	O
a	O
method	O
for	O
treating	O
a	O
human	O
having	O
a	O
disease	O
associated	O
with	O
leukocyte	O
infiltration	O
of	O
mucosal	O
tissues,	O
comprising	O
administering	O
to	O
said	O
human	O
an	O
effective	O
amount	O
of	O
a	O
human	O
or	O
humanized	O
immunoglobulin	O
or	O
antigen-binding	O
fragment	O
thereof	O
having	O
binding	O
specificity	O
for	O
α4β7	B-GENE
integrin	I-GENE
.	O
Preferably,	O
no	O
more	O
than	O
about	O
8	O
mg	O
immunoglobulin	O
or	O
fragment	O
per	O
kg	O
body	O
weight	O
are	O
administered	O
during	O
a	O
period	O
of	O
about	O
one	O
month	O
.	O


Oligonucleotides	O
are	O
provided	O
which	O
are	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
human	B-GENE
raf	B-GENE
and	O
capable	O
of	O
inhibiting	O
raf	B-GENE
expression	O
.	O
The	O
oligonucleotides	O
may	O
have	O
chemical	O
modifications	O
at	O
one	O
or	O
more	O
positions	O
and	O
may	O
be	O
chimeric	O
oligonucleotides	O
.	O
Methods	O
of	O
inhibiting	O
the	O
expression	O
of	O
human	B-GENE
raf	B-GENE
using	O
oligonucleotides	O
of	O
the	O
invention	O
are	O
also	O
provided	O
.	O
The	O
present	O
invention	O
further	O
comprises	O
methods	O
of	O
inhibiting	O
hyperproliferation	O
of	O
cells	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
conditions,	O
including	O
hyperproliferative	O
conditions,	O
associated	O
with	O
raf	B-GENE
expression	O
.	O


The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
glutathione-reductase	B-GENE
(	O
GSSG	B-GENE
reductase	I-GENE
)	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
HIV-infected	O
patients,	O
seropositive	O
or	O
already	O
affected	O
by	O
AIDS,	O
both	O
for	O
prophylactic	O
and	O
therapeutic	O
use	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
1,3,8-triazaspiro	O
[	O
4	O
.	O
5	O
]	O
decan-4-one	O
derivatives	O
of	O
the	O
general	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
all	O
variables	O
are	O
as	O
defined	O
herein,	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
mediated	O
by	O
the	O
ORL-1	B-GENE
G-protein	B-GENE
coupled	I-GENE
receptor	I-GENE
.	O
More	O
particularly,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
such	O
as	O
anxiety,	O
depression,	O
substance	O
abuse,	O
neuropathic	O
pain,	O
acute	O
pain,	O
migraine,	O
asthma,	O
cough	O
and	O
for	O
improved	O
cognition	O
.	O


The	O
invention	O
relates	O
to	O
a	O
clusianon	O
isomer	O
and	O
to	O
the	O
use	O
thereof,	O
in	O
particular	O
as	O
a	O
pharmaceutical	O
or	O
medical	O
active	O
ingredient,	O
in	O
particular	O
for	O
producing	O
medicaments	O
for	O
the	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
(	O
curative	O
)	O
treatment	O
of	O
tumor	O
or	O
cancer	O
diseases	O
as	O
well	O
as	O
viral	O
diseases	O
.	O
The	O
aforementioned	O
compound	O
can	O
be	O
used	O
in	O
cytostatics	O
and	O
antiviral	O
agents	O
(	O
virostatics	O
)	O
.	O
Said	O
compound	O
acts,	O
in	O
particular,	O
as	O
a	O
topoisomerase	B-GENE
and	O
telomerase	B-GENE
inhibitor	O
and	O
as	O
a	O
regulator	O
in	O
the	O
MAP	B-GENE
kinase	I-GENE
signal	O
transduction	O
.	O
Said	O
compound	O
can	O
thus	O
intervene	O
at	O
the	O
cellular	O
level	O
in	O
the	O
proliferation	O
mechanism	O
of	O
tumor	O
or	O
cancer	O
cells	O
and	O
viruses	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
pharmaceutically	O
acceptable	O
salts	O
and	O
N-oxides	O
thereof	O
in	O
which	O
A,	O
B,	O
D	O
and	O
E	O
are	O
C	O
or	O
N	O
with	O
the	O
proviso	O
that	O
one	O
or	O
more	O
are	O
N,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5	O
and	O
R6	O
are	O
simple	O
substituents,	O
n	O
is	O
0-3	O
and	O
y	O
is	O
an	O
aryl,	O
heteroaryl,	O
carbocyclyl	O
or	O
fused-carbocyclyl	O
group	O
;	O
as	O
VR-1	B-GENE
antagonists	O
for	O
treating	O
conditions	O
or	O
diseases	O
in	O
which	O
pain	O
and	O
/	O
or	O
inflammation	O
predominates	O
;	O
the	O
use	O
of	O
the	O
same	O
for	O
manufacturing	O
medicaments,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
methods	O
of	O
treatment	O
utilizing	O
them	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treating	O
the	O
epithelial	O
toxicity	O
caused	O
by	O
administering	O
to	O
a	O
human	O
cancer	O
patient	O
an	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
inhibitor	O
.	O
The	O
pharmaceutical	O
composition	O
preferably	O
comprises	O
an	O
EGFR	B-GENE
inhibitor	O
and	O
a	O
keratinocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
KGF	B-GENE
)	O
in	O
a	O
pharmaceutically-acceptable	O
carrier	O
.	O
The	O
method	O
of	O
treatment	O
comprises	O
co-administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
KGF	B-GENE
with	O
the	O
EGFR	B-GENE
inhibitor	O
.	O


Provided	O
is	O
a	O
modified	O
human	B-GENE
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
receptor-1	I-GENE
polypeptide	O
or	O
a	O
fragment	O
thereof	O
that	O
binds	O
to	O
a	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
in	O
vivo	O
or	O
ex	O
vivo	O
.	O
The	O
modified	O
human	B-GENE
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
receptor-1	I-GENE
polypeptide	O
or	O
fragment	O
exhibits	O
improved	O
ability	O
to	O
bind	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
and	O
resistance	O
to	O
proteases	B-GENE
.	O


Compounds	O
of	O
structural	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
pharmacologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
possess	O
5α-reductase	B-GENE
inhibitory	O
activity	O
.	O
These	O
compounds	O
inhibit	O
5α-reductase	B-GENE
type	I-GENE
1	I-GENE
and	I-GENE
type	I-GENE
2	I-GENE
.	O
The	O
compounds	O
of	O
structural	O
Formula	O
I	O
are	O
useful	O
in	O
the	O
systemic,	O
including	O
oral,	O
and	O
parenteral,	O
including	O
topical,	O
treatment	O
and	O
prevention	O
of	O
hyperandrogenic	O
conditions	O
including	O
prostatic	O
carcinoma,	O
benign	O
prostatic	O
hyperplasia,	O
acne	O
vulgaris,	O
seborrhea,	O
androgenic	O
alopecia	O
(	O
also	O
called	O
androgenetic	O
alopecia	O
)	O
which	O
includes	O
male-	O
and	O
female-pattern	O
baldness,	O
female	O
hirsutism,	O
and	O
prostatitis	O
.	O
A	O
class	O
of	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
potent	O
antiandrogens	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
novel	O
compositions	O
containing	O
such	O
compounds,	O
methods	O
of	O
their	O
use	O
and	O
methods	O
of	O
their	O
manufacture	O
.	O


The	O
present	O
invention	O
provides	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
of	O
a	O
new	O
type	O
for	O
diabetes	O
mellitus	O
and	O
diabetic	O
complications	O
on	O
the	O
basis	O
of	O
an	O
adenosine	B-GENE
A2	I-GENE
receptor	I-GENE
antagonist	O
action	O
.	O
	O
	O
	O
	O
A	O
purine	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
,	O
its	O
pharmacologically	O
acceptable	O
salt	O
or	O
hydrates	O
thereof	O
has	O
an	O
adenosine	B-GENE
A2	I-GENE
receptor	I-GENE
antagonistic	O
action	O
and	O
is	O
useful	O
for	O
prevention	O
or	O
therapy	O
of	O
diabetes	O
mellitus	O
and	O
diabetic	O
complications	O
.	O
In	O
addition,	O
adenosine	B-GENE
A2	I-GENE
receptor	I-GENE
antagonists	O
having	O
different	O
structures	O
from	O
those	O
of	O
the	O
compounds	O
described	O
above,	O
for	O
example	O
KW6002,	O
are	O
also	O
effective	O
for	O
prevention	O
or	O
therapy	O
of	O
diabetes	O
mellitus	O
and	O
diabetic	O
complications	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
In	O
the	O
formula,	O
W	O
is	O
—CH2CH2—,	O
or	O
—CH═CH—	O
or	O
—C≡C—	O
;	O
R1	O
is	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
in	O
the	O
formula,	O
X	O
is	O
hydrogen	O
atom,	O
hydroxyl	O
group,	O
a	O
lower	O
alkyl	O
group,	O
a	O
lower	O
alkoxy	O
group,	O
etc	O
.	O
;	O
and	O
R5	O
and	O
R6	O
are	O
the	O
same	O
as	O
or	O
different	O
from	O
each	O
other	O
and	O
each	O
represents	O
hydrogen	O
atom,	O
a	O
lower	O
alkyl	O
group,	O
a	O
cycloalkyl	O
group,	O
etc	O
.	O
)	O
and	O
the	O
like	O
;	O
R2	O
is	O
an	O
amino	O
group,	O
etc	O
.	O
which	O
maybe	O
substituted	O
with	O
a	O
lower	O
alkyl	O
group,	O
etc	O
.	O
;	O
R3	O
is	O
a	O
cycloalkyl	O
group,	O
an	O
optionally	O
substituted	O
aryl	O
group,	O
etc	O
.	O
;	O
and	O
R4	O
is	O
a	O
lower	O
alkyl	O
group	O
etc	O
.	O


Methods	O
of	O
treating	O
disorders	O
in	O
which	O
TNFα	B-GENE
activity	O
is	O
detrimental	O
via	O
biweekly,	O
subcutaneous	O
administration	O
of	O
human	O
antibodies,	O
preferably	O
recombinant	O
human	O
antibodies,	O
that	O
specifically	O
bind	O
to	O
human	B-GENE
tumor	I-GENE
necrosis	I-GENE
factor	I-GENE
α	I-GENE
(	O
hTNFα	B-GENE
)	O
are	O
disclosed	O
.	O
The	O
antibody	O
may	O
be	O
administered	O
with	O
or	O
without	O
methotrexate	O
.	O
These	O
antibodies	O
have	O
high	O
affinity	O
for	O
hTNFα	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
Kd	O
=	O
10-8	O
M	O
or	O
less	O
)	O
,	O
a	O
slow	O
off	O
rate	O
for	O
hTNFα	B-GENE
dissociation	O
(	O
e	O
.	O
g	O
.	O
,	O
K¿off	O
?	O
=	O
10	O
?	O
-3	O
sec-1¿	O
or	O
less	O
)	O
and	O
neutralize	O
hTNFα	B-GENE
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
An	O
antibody	O
of	O
the	O
invention	O
can	O
be	O
a	O
full-length	O
antibody	O
or	O
an	O
antigen-binding	O
portion	O
thereof	O
.	O
Kits	O
containing	O
a	O
pharmaceutical	O
composition	O
and	O
instructions	O
for	O
dosing,	O
and	O
preloaded	O
syringes	O
containing	O
pharmaceutical	O
compositions	O
are	O
also	O
encompassed	O
by	O
the	O
invention	O
.	O


The	O
invention	O
concerns	O
substituted	O
tricyclic	O
isoxazoline	O
derivatives,	O
more	O
in	O
particular	O
tricyclic	O
dihydrobenzopyranoisoxazoline,	O
dihydroquinolinoisoxazoline	O
,	O
dihydronaphthalenoisoxazoline	O
and	O
dihydrobenzothiopyranoisoxazoline	O
derivatives	O
substituted	O
on	O
at	O
least	O
one	O
of	O
the	O
C6-	O
and	O
C9-positions	O
of	O
the	O
phenylpart	O
of	O
the	O
tricyclic	O
moiety	O
with	O
a	O
selected	O
radical,	O
according	O
to	O
Formula	O
(	O
I	O
)	O
wherein	O
X	O
=	O
CH2,	O
N-R7,	O
S	O
or	O
O,	O
R1,	O
R2,	O
R14	O
and	O
R15	O
are	O
certain	O
specific	O
substituents,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
R14	O
and	O
R15	O
is	O
not	O
hydrogen,	O
Pir	O
is	O
preferably	O
an	O
optionally	O
substituted	O
piperidinyl	O
or	O
piperazinyl	O
radical	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
aromatic	O
homocyclic	O
or	O
heterocyclic	O
ring	O
system	O
including	O
a	O
partially	O
or	O
completely	O
hydrogenated	O
hydrocarbon	O
chain	O
of	O
maximum	O
6	O
atoms	O
long	O
with	O
which	O
the	O
ring	O
system	O
is	O
attached	O
to	O
the	O
Pir	O
radical	O
and	O
which	O
may	O
contain	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
the	O
group	O
of	O
O,	O
N	O
and	O
S	O
;	O
a	O
process	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
depression,	O
anxiety,	O
movement	O
disorders,	O
psychosis,	O
Parkinson	O
'	O
s	O
disease	O
and	O
body	O
weight	O
disorders	O
.	O
.	O
The	O
compounds	O
according	O
to	O
the	O
invention	O
have	O
surprisingly	O
been	O
shown	O
to	O
have	O
a	O
serotonine	O
(	O
5-HT	O
)	O
reuptake	O
inhibitor	O
activity	O
in	O
combination	O
with	O
additional	O
α2-adrenoceptor	B-GENE
antagonist	O
activity	O
and	O
show	O
a	O
strong	O
anti-depressant	O
activity	O
without	O
being	O
sedative	O
.	O
The	O
invention	O
also	O
relates	O
to	O
novel	O
combination	O
of	O
isoxazoline	O
derivatives	O
according	O
to	O
the	O
invention	O
with	O
one	O
or	O
more	O
other	O
compounds	O
selected	O
from	O
the	O
group	O
of	O
antidepressants,	O
anxiolytics,	O
anti-psychotics	O
and	O
anti-Parkinson	O
'	O
s	O
disease	O
drugs	O
to	O
improve	O
efficacy	O
and	O
/	O
or	O
onset	O
of	O
action	O
.	O


The	O
invention	O
provides	O
nucleic	O
acid	O
therapeutic	O
compositions	O
capable	O
of	O
binding	O
to	O
cytokines,	O
growth	B-GENE
factors	I-GENE
and	O
cell	B-GENE
surface	I-GENE
proteins,	O
individually	O
or	O
in	O
combinations	O
of	O
two	O
or	O
more,	O
and	O
methods	O
for	O
delivering	O
these	O
nucleic	O
acid	O
therapeutics	O
in	O
the	O
treatment	O
of	O
glaucoma	O
and	O
other	O
proliferative	O
diseases	O
of	O
the	O
eye	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
wherein	O
P,	O
P	O
'	O
,	O
W,	O
R1,	O
R2,	O
n,	O
p,	O
q,	O
r,	O
s	O
and	O
t	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
processes	O
for	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
their	O
use	O
as	O
vanilloid	B-GENE
receptor	I-GENE
(	O
VR1	B-GENE
)	O
antagonists	O
in	O
the	O
treatment	O
of	O
pain	O
.	O


A	O
preparation	O
for	O
external	O
percutaneous	O
administration	O
which	O
comprises	O
a	O
non-steroidal	O
anti-inflammatory	O
drug,	O
an	O
alkyl	O
gallate,	O
and	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
.	O
Also	O
provided	O
is	O
an	O
interleukin-1α	B-GENE
production	O
inhibitor	O
which	O
comprises	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
and	O
/	O
or	O
an	O
alkyl	O
gallate	O
.	O


Compounds	O
of	O
formula	O
(	O
A	O
)	O
and	O
formula	O
(	O
B	O
)	O
:	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
compositions	O
comprising	O
them,	O
methods	O
for	O
their	O
use,	O
and	O
their	O
use	O
in	O
the	O
preparation	O
of	O
medicaments	O
.	O
The	O
compounds	O
are	O
antagonists	O
of	O
MCP-1	B-GENE
function,	O
and	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
chronic	O
or	O
acute	O
inflammatory	O
or	O
autoimmune	O
diseases,	O
such	O
as	O
multiple	O
sclerosis,	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
allergic	O
hypersensitivity	O
diseases	O
.	O


This	O
invention	O
relates	O
to	O
substituted	O
tetrahydroquinoline	O
phenylacetic	O
acids	O
and	O
benzoic	O
acids	O
that	O
bind	O
to	O
and	O
/	O
or	O
modulate	O
hepatocyte	B-GENE
factor	I-GENE
4α	I-GENE
receptors	O
and	O
to	O
methods	O
for	O
making	O
and	O
using	O
such	O
compounds	O
.	O


Imidazo-containing	O
compounds	O
(	O
e	O
.	O
g	O
.	O
,	O
imidazoquinolines,	O
imidazonaphthyridines,	O
imidazopyridines	O
)	O
with	O
a	O
hydroxylamine	O
substituent	O
at	O
the	O
1-position,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
intermediates,	O
and	O
methods	O
of	O
use	O
of	O
these	O
compounds	O
as	O
immunomodulators,	O
for	O
inducing	O
cytokine	B-GENE
biosynthesis	O
in	O
animals	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
viral	O
and	O
neoplastic	O
diseases	O
are	O
disclosed	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
method	O
of	O
diagnosing	O
caner	O
with	O
the	O
use	O
of	O
Nox1	B-GENE
gene	O
relating	O
to	O
mutated	O
Ras	B-GENE
oncogen,	O
a	O
method	O
of	O
screening	O
a	O
cancer	O
growth	O
inhibitor	O
and	O
a	O
medicinal	O
composition	O
to	O
be	O
used	O
in	O
treating	O
cancer	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
polypeptide	O
encoded	O
by	O
Nox1	B-GENE
gene,	O
its	O
homolog,	O
a	O
composition	O
for	O
producing	O
an	O
antibody	O
containing	O
such	O
a	O
peptide	O
fragment,	O
an	O
antibody	O
against	O
the	O
polypeptide	O
encoded	O
by	O
Nox1	B-GENE
gene,	O
and	O
a	O
method	O
of	O
detecting	O
mRNA	O
expressing	O
such	O
an	O
antibody	O
or	O
Nox1	B-GENE
.	O


The	O
invention	O
provides	O
use	O
of	O
a	O
compound	O
capable	O
of	O
modulating	O
CB1	B-GENE
receptor	O
signaling,	O
or	O
of	O
a	O
polypeptide	O
with	O
a	O
biospecific	O
affinity	O
for	O
the	O
CB1	B-GENE
receptor,	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
a	O
lymphoproliferative	O
disorder	O
involving	O
cells	O
with	O
abnormal	O
CB1	B-GENE
receptor	O
function	O
.	O
Furthermore,	O
the	O
invention	O
provides	O
methods	O
for	O
identification	O
of	O
a	O
compound	O
capable	O
of	O
modulating	O
CBI	B-GENE
receptor	O
signaling,	O
a	O
method	O
for	O
the	O
diagnosis	O
of	O
a	O
lymphoproliferative	O
disorder	O
involving	O
cells	O
with	O
abnormal	O
CBI	B-GENE
receptor	O
function	O
in	O
a	O
subject,	O
a	O
method	O
for	O
treatment	O
of	O
a	O
lymphoproliferative	O
disorder	O
involving	O
cells	O
with	O
abnormal	O
CB1	B-GENE
receptor	O
function,	O
and	O
a	O
method	O
for	O
elimination	O
of	O
malignant	O
lymphocytes	O
from	O
a	O
cell	O
population	O
.	O


This	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
infections	O
in	O
mammals	O
using	O
Toll-Like	B-GENE
Receptor	I-GENE
(TLR)7	I-GENE
ligands	O
and	O
prodrugs	O
thereof	O
.	O
More	O
particularly,	O
this	O
invention	O
relates	O
to	O
methods	O
of	O
orally	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
prodrugs	O
of	O
TLR7	B-GENE
ligands	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hepatitis	O
C	O
viral	O
infection	O
.	O
Oral	O
administration	O
of	O
these	O
TLR7	B-GENE
immunomodulating	O
ligands	O
and	O
prodrugs	O
thereof	O
to	O
a	O
mammal	O
provides	O
therapeutically	O
effective	O
amounts	O
and	O
reduced	O
undesirable	O
side	O
effects	O
.	O


This	O
invention	O
relates	O
to	O
a	O
novel	O
series	O
of	O
chemical	O
compounds	O
useful	O
as	O
Human	B-GENE
immunodeficiency	I-GENE
Virus	I-GENE
(HIV)	I-GENE
protease	I-GENE
inhibitors	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
as	O
antiviral	O
agents	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
antiviral	O
agents,	O
and	O
their	O
uses	O
and	O
materials	O
for	O
their	O
synthesis	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
promoting	O
collagen	B-GENE
synthesis	O
and	O
a	O
composition	O
for	O
external	O
application	O
to	O
skin	O
which	O
includes	O
the	O
collagen	B-GENE
synthesis	O
promoting	O
composition	O
.	O
The	O
collagen	B-GENE
synthesis	O
promoting	O
composition	O
includes,	O
as	O
an	O
effective	O
component,	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
compounds	O
represented	O
as	O
:	O
wherein	O
R	O
is	O
hydrogen,	O
a	O
methoxy	O
group,	O
or	O
a	O
3-methyl-2-butenyl	O
group	O
.	O
The	O
composition	O
for	O
external	O
application	O
to	O
skin	O
includes	O
at	O
least	O
one	O
collagen	B-GENE
synthesis	O
promoting	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
compounds	O
represented	O
by	O
above	O
.	O


The	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
variable	O
groups	O
are	O
defined	O
within	O
;	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
inhibition	O
of	O
11βHSD1,	O
processes	O
for	O
making	O
them,	O
certain	O
compounds	O
within	O
the	O
definition	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
described	O
.	O


Compounds	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
;	O
salts	O
thereof,	O
solvates	O
thereof,	O
prodrugs	O
thereof	O
or	O
cyclodextrin	O
clathrates	O
thereof	O
.	O
Because	O
of	O
having	O
a	O
potent	O
agonism	O
to	O
EP2	B-GENE
and	O
a	O
potent	O
effect	O
of	O
lowering	O
ocular	O
tension	O
while	O
little	O
irritating	O
the	O
eye,	O
these	O
compounds	O
are	O
useful	O
in	O
treating	O
eye	O
diseases	O
such	O
as	O
glaucoma,	O
ocular	O
hypertension,	O
macular	O
edema,	O
macular	O
degeneration,	O
blood	O
flow	O
loss	O
in	O
retinal	O
and	O
optic	O
nerve	O
papillae,	O
retinal	O
and	O
optic	O
nerve	O
hypertension,	O
myopia,	O
hyperopia,	O
astigma,	O
dry	O
eye,	O
retinal	O
detachment,	O
cataract	O
and	O
so	O
on	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
ABCA1	B-GENE
stabilizer	O
focusing	O
on	O
the	O
HDL	O
neogenesis	O
system	O
which	O
is	O
pharmacologically	O
useful	O
as	O
a	O
preventive	O
/	O
remedy	O
for	O
low	O
HDL	O
cholesterolemia	O
.	O
Namely,	O
an	O
ABCA1	B-GENE
stabilizer,	O
which	O
comprises	O
a	O
bisphenol	O
compound	O
selected	O
from	O
among	O
probucol	O
spiroquinone,	O
probucol	O
diphenoquinone	O
and	O
probucol	O
bisphenol	O
as	O
the	O
active	O
ingredient,	O
enables	O
the	O
continuous	O
and	O
stable	O
express	O
of	O
ABCA1	B-GENE
by	O
a	O
mechanism	O
completely	O
different	O
from	O
those	O
in	O
the	O
conventional	O
art,	O
thereby	O
increasing	O
blood	O
HDL	O
level	O
.	O
Therefore,	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
/	O
remedy	O
for	O
low	O
HDL	O
cholesterolemia,	O
arteriosclerosis,	O
etc	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
combinations	O
comprising	O
a	O
topical	O
anticholinergic	O
drug	O
alone	O
or	O
in	O
combination	O
with	O
topically	O
administered	O
antihistamines,	O
topically	O
or	O
orally	O
administered	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitors	O
or	O
topical	O
corticosteroids	O
for	O
the	O
treatment	O
of	O
rhinitis	O
of	O
various	O
origins	O
.	O
It	O
further	O
comprises	O
presentation	O
of	O
these	O
combinations	O
in	O
locally	O
applied	O
formulations	O
and	O
includes	O
various	O
pharmaceutical	O
formulations	O
suitable	O
for	O
topical	O
application,	O
e	O
.	O
g	O
.	O
nasal	O
sprays,	O
nasal	O
drops,	O
emulsions,	O
pastes,	O
creams	O
and	O
gels	O
.	O


This	O
invention	O
provides	O
a	O
pharmaceutical	O
agent	O
containing,	O
in	O
combination,	O
a	O
sulfonamide	O
compound	O
and	O
other	O
therapeutic	O
agent,	O
preferably,	O
at	O
least	O
one	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
R1-SO2-NH-CO-A1-CH2-R2	O
[	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
at	O
least	O
one	O
pharmaceutical	O
agent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
α-glucosidase	B-GENE
inhibitor,	O
an	O
insulin	B-GENE
secretagogue,	O
a	O
sulfonylurea	O
and	O
a	O
biguanide,	O
which	O
has	O
a	O
superior	O
therapeutic	O
effect	O
.	O


A	O
high	O
through-put	O
in	O
situ	O
hybridization	O
system	O
process	O
has	O
been	O
applied	O
to	O
an	O
epidermis	O
of	O
mouse	O
sole	O
in	O
order	O
to	O
identify	O
a	O
novel	O
gene	O
participating	O
in	O
epidermal	O
differentiation	O
.	O
As	O
a	O
result,	O
about	O
100	O
types	O
of	O
unique	O
mRNA	O
expression	O
patterns	O
in	O
the	O
epidermis	O
have	O
been	O
detected	O
.	O
Two	O
novel	O
secreted	O
proteins,	O
dermokine-α	B-GENE
and	I-GENE
-β,	O
expressed	O
in	O
the	O
epidermal	O
layer	O
resulting	O
from	O
differentiation	O
of	O
a	O
superstratum	O
of	O
basal	O
layer	O
have	O
been	O
successfully	O
identified	O
therefrom	O
.	O
Further,	O
it	O
has	O
been	O
found	O
that	O
the	O
genes	O
coding	O
for	O
these	O
proteins	O
construct	O
a	O
novel	O
gene	O
complex	O
(	O
SSC	O
)	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
remedy	O
for	O
urinary	O
disorder	O
.	O
Namely,	O
a	O
remedy	O
for	O
urinary	O
disorder	O
containing	O
a	O
compound	O
which	O
suppresses	O
the	O
GIRK	B-GENE
channel	I-GENE
activated	O
current	O
while	O
showing	O
no	O
suppressive	O
effect	O
on	O
the	O
glycine	B-GENE
receptor	I-GENE
activated	O
current	O
or	O
NMDA	B-GENE
receptor	I-GENE
activated	O
current	O
.	O


A	O
compound	O
having	O
the	O
activity	O
of	O
glucokinase	B-GENE
activation	O
and	O
being	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes,	O
etc	O
.	O
,	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
[	O
wherein	O
X	O
is	O
a	O
nitrogen	O
atom,	O
etc	O
.	O
;	O
Y	O
is	O
an	O
oxygen	O
atom,	O
etc	O
.	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
5	O
to	O
6-membered	O
heteroaryl	O
group,	O
etc	O
.	O
;	O
R2	O
is	O
a	O
hydrogen	O
atom	O
or	O
a	O
fluorine	O
atom	O
;	O
and	O
the	O
ring	O
A	O
is	O
an	O
optionally	O
substituted	O
monocyclic	O
or	O
bicyclic	O
heteroaryl	O
group	O
of	O
the	O
formula	O
:	O
(	O
II	O
)	O
]	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O


An	O
edible	O
composition	O
having	O
effects	O
of	O
promoting	O
the	O
production	O
and	O
release	O
of	O
a	O
calcitonin	B-GENE
gene-related	I-GENE
peptide	I-GENE
.	O
Namely,	O
an	O
edible	O
composition	O
comprising	O
isoflavone	O
and	O
capsaicin	O
as	O
the	O
essential	O
components	O
and	O
having	O
effects	O
of	O
promoting	O
the	O
production	O
and	O
release	O
of	O
a	O
calcitonin	B-GENE
gene-related	I-GENE
peptide	I-GENE
;	O
and	O
an	O
edible	O
composition	O
comprising	O
the	O
above-described	O
edible	O
composition	O
for	O
preventing	O
and	O
treating	O
gastric	O
mucosal	O
injury,	O
life	O
style-related	O
diseases,	O
obesity,	O
malignant	O
tumor	O
and	O
osteoporosis,	O
relieving	O
rejection	O
accompanying	O
organ	O
transplantation,	O
preventing	O
and	O
relieving	O
organ	O
injury	O
caused	O
by	O
vital	O
invasion	O
reactions	O
against	O
invasive	O
factors	O
such	O
as	O
infection,	O
and	O
stimulating	O
hair	O
(	O
for	O
example,	O
head	O
hair	O
)	O
growth	O
.	O
This	O
edible	O
composition	O
exerts	O
effects	O
of	O
preventing	O
and	O
treating	O
gastric	O
mucosal	O
injury	O
and	O
so	O
on	O
and	O
these	O
effects	O
are	O
mild	O
without	O
any	O
risk	O
of	O
side	O
effect	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof,	O
wherein	O
the	O
symbols	O
have	O
meaning	O
as	O
defined,	O
which	O
are	O
antagonists	O
of	O
CCR-1	B-GENE
and	O
which	O
find	O
use	O
pharmaceutically	O
for	O
treatment	O
of	O
diseases	O
and	O
conditions	O
in	O
which	O
CCR-1	B-GENE
is	O
implicated,	O
e	O
.	O
g	O
.	O
inflammatory	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
including	O
a	O
macrolide	O
compound	O
that	O
inhibits	O
MHC	B-GENE
class	I-GENE
II	I-GENE
expression	O
.	O
The	O
compositions	O
of	O
the	O
invention	O
are	O
used	O
as	O
an	O
immunosuppressive	O
agent	O
in	O
the	O
treatment	O
prior	O
to,	O
during	O
and	O
/	O
or	O
after	O
organ	O
or	O
tissue	O
transplantation,	O
as	O
well	O
as	O
in	O
the	O
treatment	O
of	O
immune-related	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
2-substituted	O
estra-1,3,5	O
(	O
10	O
)	O
-trien-17-ones	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R2	O
is	O
an	O
C1-C8	O
alkyl	O
saturated	O
or	O
unsaturated	O
group,	O
an	O
C1-C5-alkyloxy	O
group,	O
an	O
aralkyl-	O
or	O
alkylaryl	O
rest,	O
an	O
-O-CnFmHo	O
rest,	O
wherein	O
n	O
=	O
1,2,3,4,5	O
or	O
6,	O
m≥1	O
and	O
m	O
=	O
2n+1,	O
or	O
a	O
CH2XY	O
group	O
in	O
which	O
X	O
is	O
an	O
oxygen	O
atom	O
and	O
Y	O
is	O
an	O
alkyl	O
rest	O
containing	O
1	O
to	O
4	O
carbon	O
atoms,	O
a	O
halogen	O
atom	O
and	O
a	O
nitrile	O
group,	O
R13	O
is	O
a	O
hydrogen	O
atom	O
or	O
a	O
methyl	O
group,	O
R16	O
is	O
a	O
hydrogen	O
or	O
fluorine	O
atom,	O
Z	O
is	O
an	O
oxygen	O
or	O
sulfur	O
atom,	O
each	O
R4	O
and	O
R6	O
independently	O
of	O
each	O
other	O
represents	O
α	O
or	O
β	O
hydrogen	O
atom,	O
an	O
C1-C5	O
alkyl,	O
C1-C5-alkyloxy,	O
C1-C5-acyl	O
or	O
hydroxy	O
group	O
or	O
an	O
aralkyl-	O
or	O
alkylaryl	O
rest,	O
R3	O
and	O
R4	O
represent	O
together	O
an	O
oxygen	O
atom,	O
R5	O
and	O
R6	O
represent	O
together	O
an	O
oxygen	O
atom,	O
each	O
R7	O
and	O
R8	O
represents	O
a	O
hydrogen	O
atom	O
or	O
together	O
an	O
oxygen	O
atom,	O
each	O
R7	O
and	O
R8	O
represents	O
a	O
hydrogen	O
atom	O
or	O
together	O
a	O
CH2	O
group	O
.	O
Pharmaceutically	O
acceptable	O
salts	O
of	O
said	O
compounds,	O
the	O
production	O
and	O
use	O
thereof	O
in	O
the	O
form	O
of	O
drags	O
which	O
are	O
usable	O
for	O
preventing	O
and	O
treating	O
estrogen-dependent	O
diseases	O
and	O
are	O
influenced	O
by	O
inhibiting	O
17ß-hydroxysteroiddehydrogenase	B-GENE
of	I-GENE
type	I-GENE
1	I-GENE
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
generally	O
relates	O
to	O
a	O
series	O
of	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
to	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
as	O
therapeutic	O
agents	O
.	O
More	O
specifically,	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
hexahydroazepinoindole	O
and	O
octahydroazepinoindole	O
compounds	O
.	O
These	O
compounds	O
are	O
serotonin	B-GENE
receptor	I-GENE
(	O
5-HT	O
)	O
ligands	O
and	O
are	O
useful	O
for	O
treating	O
diseases,	O
disorders,	O
and	O
conditions	O
wherein	O
modulation	O
of	O
the	O
activity	O
of	O
serotonin	B-GENE
receptors	I-GENE
(	O
5-HT	O
)	O
is	O
desired	O
(	O
e	O
.	O
g	O
.	O
anxiety,	O
depression	O
and	O
obesity	O
)	O
.	O


A	O
compound	O
usable	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
urination	O
disorders	O
.	O
It	O
is	O
a	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
pharmacologically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
hydrate	O
or	O
solvate	O
of	O
either	O
.	O
Also	O
provided	O
are	O
a	O
process	O
for	O
producing	O
the	O
compound	O
and	O
a	O
medicinal	O
composition	O
characterized	O
by	O
containing	O
the	O
compound	O
.	O
The	O
compound	O
has	O
a	O
high	O
affinity	O
especially	O
for	O
the	O
a1A-adrenergic	B-GENE
receptor	I-GENE
subtype	O
among	O
the	O
a1A-,	B-GENE
a1B-,	I-GENE
and	I-GENE
a1D-adrenergic	I-GENE
receptor	I-GENE
subtypes,	O
which	O
are	O
human	B-GENE
a1-adrenergic	I-GENE
receptors	I-GENE
.	O
It	O
can	O
hence	O
be	O
an	O
excellent	O
therapeutic	O
and	O
/	O
or	O
preventive	O
agent	O
for	O
urination	O
disorders	O
.	O
(	O
1	O
)	O
(	O
In	O
the	O
formula,	O
R	O
represents	O
lower	O
alkyl	O
optionally	O
having	O
halogeno,	O
cyano,	O
or	O
aryl	O
.	O
)	O


A	O
drug	O
having	O
anti-HIV	O
activity,	O
especially	O
a	O
drug	O
having	O
integrase	O
inhibitory	O
activity	O
.	O
Also	O
provided	O
is	O
a	O
quinolizinone	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
I	O
]	O
:	O
[	O
I	O
]	O
(	O
wherein	O
the	O
symbols	O
are	O
the	O
same	O
as	O
defined	O
in	O
the	O
description	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
drug	O
is	O
an	O
anti-HIV	O
agent	O
containing	O
the	O
compound	O
or	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
compound	O
has	O
the	O
function	O
of	O
inhibiting	O
HIV	B-GENE
integrase	I-GENE
activity	O
and	O
is	O
useful	O
as	O
an	O
anti-HIV	O
agent	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
AIDs	O
.	O
The	O
anti-HIV	O
agent	O
can	O
be	O
a	O
more	O
effective	O
one	O
when	O
used	O
in	O
combination	O
with	O
other	O
anti-HIV	O
agent	O
such	O
as	O
a	O
protease	B-GENE
inhibitor	O
or	O
reverse	B-GENE
transcriptase	I-GENE
inhibitor	O
.	O
The	O
anti-HIV	O
agent	O
has	O
high	O
inhibitory	O
activity	O
specific	O
for	O
integrases	O
and	O
can	O
hence	O
be	O
a	O
drug	O
safe	O
for	O
the	O
human	O
body	O
and	O
reduced	O
in	O
side	O
effects	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
ketone	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
having	O
Asp2	B-GENE
(	O
β-secretase,	O
BACE1	B-GENE
or	O
Memapsin-2	B-GENE
)	O
inhibitory	O
activity,	O
processes	O
for	O
their	O
preparation,	O
to	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
characterised	O
by	O
elevated	O
β-	B-GENE
amyloid	I-GENE
levels	O
or	O
β-amyloid	B-GENE
deposits,	O
particularly	O
Alzheimer	O
'	O
s	O
disease	O
.	O


A	O
compound	O
with	O
p38MAP	B-GENE
kinase	I-GENE
inhibiting	O
activity	O
useful	O
as	O
a	O
pharmaceutical,	O
represented	O
by	O
the	O
general	O
formula	O
:	O
(	O
I	O
)	O
[	O
wherein	O
all	O
the	O
characters	O
are	O
as	O
defined	O
in	O
the	O
description	O
]	O
,	O
or	O
its	O
salt,	O
N-oxide	O
or	O
solvate,	O
or	O
a	O
prodrug	O
thereof	O
.	O
Further,	O
there	O
are	O
provided	O
a	O
process	O
for	O
producing	O
the	O
same	O
and	O
usage	O
thereof	O
.	O
The	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
has	O
a	O
p38MAP	B-GENE
kinase	I-GENE
inhibiting	O
activity	O
and	O
is	O
useful	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
in	O
which	O
an	O
abnormal	O
production	O
of	O
cytokine,	O
such	O
as	O
inflammatory	O
cytokine	O
or	O
chemokine,	O
or	O
an	O
over-reaction	O
thereto	O
would	O
be	O
instrumental	O
in	O
the	O
cause	O
and	O
aggravation	O
of	O
pathologic	O
condition	O
thereof,	O
namely,	O
cytokine-mediated	O
diseases,	O
for	O
example,	O
inflammatory	O
diseases,	O
respiratory	O
diseases,	O
circulatory	O
diseases,	O
central	O
nervous	O
system	O
diseases,	O
etc	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
drug	O
for	O
inhibiting	O
estrogen-dependent	O
diseases,	O
prostaglandin	O
D	O
(	O
PGD	O
)	O
-dependent	O
gynecological	O
diseases,	O
immunological	O
diseases,	O
cancer	O
and	O
angiogenesis	O
.	O
Namely,	O
a	O
drug	O
aiming	O
at	O
inhibiting	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
estrogen-dependent	O
diseases,	O
PGD-dependent	O
gynecological	O
diseases,	O
immunological	O
diseases,	O
cancer	O
and	O
angiogenesis	O
characterized	O
by	O
containing	O
an	O
ingredient	O
inhibiting	O
the	O
activity	O
of	O
a	O
histamine	B-GENE
release	I-GENE
factor	I-GENE
(	O
HRF	B-GENE
)	O
.	O
By	O
inhibiting	O
the	O
HRF	B-GENE
activity,	O
the	O
expression	O
of	O
genes	O
of,	O
for	O
example,	O
IL-1β	O
receptor,	O
17β	B-GENE
hydroxy	I-GENE
steroid	I-GENE
dehydrogenase	I-GENE
(	O
HSD	B-GENE
)	O
,	O
etc	O
.	O
is	O
inhibited	O
.	O
Thus,	O
the	O
estrogen	O
activity	O
is	O
inhibited	O
and	O
estrogen-dependent	O
diseases	O
can	O
be	O
prevented,	O
treated	O
or	O
ameliorated	O
thereby	O
.	O
As	O
the	O
above-described	O
ingredient	O
inhibiting	O
the	O
RHF	B-GENE
activity,	O
it	O
is	O
preferred	O
to	O
use	O
artemisinin	O
.	O


An	O
URAT1	B-GENE
activity	O
inhibitor	O
which	O
contains	O
a	O
nitrogen-containing	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
1	O
]	O
:	O
[	O
1	O
]	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O
This	O
URAT1	B-GENE
activity	O
inhibitor	O
is	O
useful	O
in,	O
for	O
example,	O
treating	O
pathological	O
conditions	O
in	O
which	O
uric	O
acid	O
participates	O
such	O
as	O
hyperuricemia,	O
gouty	O
node,	O
acute	O
gouty	O
arthritis,	O
chronic	O
gouty	O
arthritis,	O
gouty	O
kidney,	O
urinary	O
calcus,	O
renal	O
dysfunction,	O
coronary	O
artery	O
disease	O
and	O
ischemic	O
heart	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
pharmaceutical	O
uses	O
of	O
4-azasteroid	O
compounds,	O
in	O
particular	O
of	O
Finasteride	O
and	O
Dutasteride	O
and	O
its	O
pharmaceutically	O
acceptable	O
derivatives,	O
and	O
combinations	O
comprising	O
said	O
compounds	O
.	O
The	O
invention	O
also	O
features	O
generally	O
the	O
use	O
of	O
a	O
modulator	O
compound	O
of	O
neuroprotective	O
conditions	O
via	O
beta	O
subunits	O
of	O
shaker-	B-GENE
type	I-GENE
voltage-gated	I-GENE
potassium	I-GENE
channels	I-GENE
and	I-GENE
/	O
or	O
via	O
members	O
of	O
solute	B-GENE
carriers	I-GENE
family	I-GENE
25,	O
in	O
particular	O
Aralar	B-GENE
(member	I-GENE
12)	I-GENE
and	I-GENE
adenine	B-GENE
-nucleotide	I-GENE
translocators	I-GENE
1	I-GENE
&	I-GENE
2	I-GENE
(member	I-GENE
4	I-GENE
&	I-GENE
5	I-GENE
)	O
and	O
/	O
or	O
via	O
a	O
4-nitrophenylphosphatase	B-GENE
domain	I-GENE
and	I-GENE
non-neurona	I-GENE
SNAP25-like	I-GENE
protein	I-GENE
homolog	I-GENE
1	I-GENE
(	O
NIPSNAP	B-GENE
1	I-GENE
)	O
as	O
a	O
neuroprotective	O
medicament,	O
particularly	O
as	O
a	O
medicament	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
neurological	O
diseases	O
such	O
as	O
dementia,	O
Parkinson,	O
Alzheimer,	O
schizophrenia	O
or	O
epilepsy	O
.	O
The	O
demonstrated	O
inhibition	O
of	O
the	O
MPTP	B-GENE
appears	O
to	O
constitute	O
a	O
novel	O
principle	O
applicable	O
to	O
all	O
pathological	O
conditions	O
which	O
have	O
underlying	O
excitotoxic	O
/	O
mitochondrial	O
mechanisms,	O
like	O
:	O
amyotrophic	O
lateral	O
sclerosis,	O
Alzheimer	O
'	O
s	O
disease,	O
depression,	O
epilepsy,	O
multiple	O
sclerosis,	O
pain,	O
Parkinson	O
'	O
s	O
disease,	O
schizophrenia,	O
traumatic	O
brain	O
and	O
spinal	O
chord	O
injury,	O
stroke	O
and	O
other	O
ischemic	O
conditions	O
in	O
the	O
brain	O
.	O


A	O
medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
adhesion	O
which	O
contains	O
a	O
CCR8	B-GENE
inhibitor	O
as	O
the	O
active	O
ingredient	O
.	O
The	O
CCR8	B-GENE
inhibitor	O
is	O
preferably	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
antibody	O
binding	O
to	O
CCR8,	O
a	O
neutralizing	O
antibody	O
against	O
a	O
CCR8	B-GENE
ligand	O
CCL1,	O
aptamers	O
to	O
CCR8	B-GENE
and	O
CCL1,	O
an	O
antagonist	O
to	O
CCR8,	O
antisense	O
oligonucleotides	O
to	O
CCR8	B-GENE
and	O
CCL1	B-GENE
genes	O
and	O
siRNAs	O
thereto	O
.	O
A	O
method	O
of	O
diagnosing	O
adhesion	O
which	O
comprises	O
detecting	O
the	O
expression	O
of	O
a	O
CCR8	B-GENE
gene	O
or	O
a	O
CCL1	B-GENE
gene	O
in	O
test	O
cells	O
or	O
detecting	O
the	O
content	O
of	O
CCR8	B-GENE
or	O
CCL1	B-GENE
in	O
the	O
test	O
cells	O
.	O
A	O
method	O
of	O
screening	O
a	O
substance	O
which	O
is	O
useful	O
in	O
preventing	O
and	O
treating	O
adhesion	O
.	O


Compounds	O
are	O
described	O
that	O
are	O
active	O
on	O
at	O
least	O
one	O
of	O
PPARα,	O
PPARδ,	O
and	O
PPARϜ,	O
which	O
are	O
useful	O
for	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
methods	O
involving	O
modulation	O
of	O
at	O
least	O
one	O
of	O
PPARα,	O
PPARδ,	O
and	O
PPARϜ	B-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
GABAA	O
receptor	I-GENE
agonist,	O
such	O
as	O
an	O
agonist	O
or	O
partial	O
agonist	O
of	O
the	O
2	B-GENE
GABAA	I-GENE
receptors	I-GENE
and/or	I-GENE
3	B-GENE
GABAA	I-GENE
receptors,	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neuropathic,	O
inflammatory	O
and	O
migraine	O
associated	O
pain,	O
and	O
to	O
a	O
method	O
of	O
prevention	O
and	O
treatment	O
of	O
neuropathic,	O
inflammatory	O
and	O
migraine	O
associated	O
pain	O
using	O
a	O
GABAA	O
receptor	I-GENE
agonist	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
such	O
a	O
use,	O
wherein	O
the	O
GABAA	O
receptor	I-GENE
agonist	O
is	O
an	O
anxiolytic	O
compound	O
acting	O
at	O
the	O
GABAA	O
receptor	I-GENE
benzodiazepine	O
binding	O
sites,	O
and	O
preferably	O
having	O
less	O
binding	O
affinity	O
to	O
1	O
or	O
less	O
efficacy	O
of	O
receptor	O
activation	O
at	O
1	B-GENE
GABAA	I-GENE
receptors	I-GENE
compared	O
to	O
2	B-GENE
and/or	I-GENE
3	B-GENE
GABAA	I-GENE
receptors	I-GENE
.	O
Particular	O
compounds	O
considered	O
are	O
1,2,4-triazolo	O
[	O
4,3-b	O
]	O
pyridazines,	O
e	O
.	O
g	O
.	O
L-838,417,	O
TPA	O
023	O
or	O
CL-218,872,	O
1H-	O
pyrido	O
[	O
3,4-b	O
]	O
indole	O
derivatives,	O
e	O
.	O
g	O
.	O
SL	O
651498,	O
and	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyrimidines,	O
e	O
.	O
g	O
.	O
ocinaplon	O
.	O


An	O
anthranilic	O
acid	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
X	O
)	O
[	O
wherein	O
R1	O
represents	O
hydrogen	O
or	O
a	O
carboxy-protecting	O
group	O
;	O
R2	O
represents	O
optionally	O
substituted	O
phenyl,	O
a	O
heterocyclic	O
group,	O
etc	O
.	O
;	O
R3	O
represents	O
optionally	O
substituted	O
phenyl,	O
a	O
monocyclic	O
heterocyclic	O
group,	O
etc	O
.	O
;	O
X1	O
represents	O
carbonyl,	O
etc	O
.	O
;	O
X2	O
represents	O
optionally	O
substituted	O
alkylene,	O
a	O
bond,	O
etc	O
.	O
;	O
X3	O
represents	O
oxygen,	O
a	O
bond,	O
etc	O
.	O
;	O
and	O
X4	O
represents	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
-X5-X6-	O
or	O
-X6-X5-	O
(	O
wherein	O
X5	O
means	O
oxygen,	O
a	O
bond,	O
etc	O
.	O
;	O
and	O
X6	O
means	O
optionally	O
substituted	O
alkylene,	O
a	O
bond,	O
etc	O
.	O
)	O
]	O
or	O
a	O
salt	O
of	O
the	O
derivative	O
.	O
The	O
derivative	O
or	O
salt	O
has	O
an	O
MMP-13	B-GENE
production	O
inhibitory	O
activity	O
and	O
is	O
hence	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
articular	O
rheumatisum,	O
osteoarthritis,	O
cancer,	O
etc	O
.	O


The	O
present	O
invention	O
pertains	O
to	O
certain	O
pyrazines	O
and	O
pyridines,	O
and	O
dervatives	O
thereof,	O
which,	O
inter	O
alia,	O
inhibit	O
RAF	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
B	B-GENE
RAF	B-GENE
)	O
activity,	O
inhibit	O
cell	O
proliferation,	O
treat	O
cancer,	O
etc	O
.	O
,	O
and	O
more	O
particularly	O
to	O
compounds	O
of	O
the	O
formulae	O
:	O
(	O
I	O
)	O
wherein	O
:	O
Q	O
is	O
independently	O
-N	O
=	O
or	O
-CH	O
=	O
;	O
one	O
of	O
RP2	O
and	O
RP3	O
is	O
independently	O
a	O
group	O
of	O
the	O
formula	O
-J1-L1-Z	O
;	O
wherein	O
:	O
if	O
Q	O
is	O
-N	O
=	O
,	O
then	O
-J1-L1-Z	O
is	O
independently	O
:	O
-NH-Z	O
;	O
-O-Z	O
;	O
or	O
S-Z	O
;	O
if	O
Q	O
is	O
-CH	O
=	O
,	O
then	O
-J1-L1-Z	O
is	O
independently	O
:	O
-NH-	O
(	O
CH2	O
)	O
n-Z,	O
wherein	O
n	O
is	O
independently	O
0	O
or	O
1	O
;	O
-O-Z	O
;	O
or	O
-S-Z	O
;	O
Z	O
is	O
independently	O
:	O
C6-14	O
carboaryl,	O
C5-14	O
heteroaryl,	O
C3-12carbocyclic,	O
C3-12	O
heterocyclic	O
;	O
and	O
is	O
independently	O
unsubstituted	O
or	O
substituted	O
;	O
the	O
other	O
of	O
RP2	O
and	O
RP3	O
is	O
independently	O
-H,	O
-NHRN1,	O
or	O
-NHC	O
(	O
=	O
O	O
)	O
RN2	O
;	O
wherein	O
:	O
RN1,	O
if	O
present,	O
is	O
independently	O
-H	O
or	O
aliphatic	O
saturated	O
C1-4alkyl	O
;	O
RN2,	O
if	O
present,	O
is	O
independently	O
-H	O
or	O
aliphatic	O
saturated	O
C1-4alkyl	O
;	O
one	O
of	O
RP5	O
and	O
RP6	O
is	O
independently	O
a	O
group	O
of	O
the	O
formula	O
-W-Y	O
;	O
wherein	O
:	O
W	O
is	O
independently	O
:	O
a	O
covalent	O
bond	O
;	O
-NRN4-,	O
-O-,	O
-S-,	O
-C	O
(	O
=	O
O	O
)	O
-,	O
-CH2-	O
;	O
-NRN4-CH2-,	O
-O-CH2-,	O
-S-CH2-,	O
-C	O
(	O
=	O
O	O
)	O
-CH2-,	O
-	O
(	O
CH2	O
)	O
2-	O
;	O
-CH2-NRN4-,	O
-CH2-O-,	O
-CH2-S-,	O
or	O
-CH2-C	O
(	O
=	O
O	O
)	O
-	O
;	O
wherein	O
RN4,	O
if	O
present,	O
is	O
independently	O
-H	O
or	O
aliphatic	O
saturated	O
C1-4alkyl	O
;	O
Y	O
is	O
independently	O
:	O
C6-14carboaryl,	O
C5-14heteroaryl,	O
C3-12carbocyclic,	O
C3-12heterocyclic	O
;	O
and	O
is	O
independently	O
unsubstituted	O
or	O
substituted	O
;	O
the	O
other	O
of	O
RP5	O
and	O
RP6	O
is	O
independently	O
-H	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
amides,	O
esters,	O
ethers,	O
N-oxides,	O
chemically	O
protected	O
forms,	O
and	O
prodrugs	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions,	O
e	O
.	O
g	O
.	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo,	O
to	O
inhibit	O
RAF	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
B-RAF	B-GENE
)	O
activity,	O
to	O
inhibit	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
RTK	B-GENE
)	O
activity,	O
to	O
inhibit	O
cell	O
proliferation,	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
conditions	O
that	O
are	O
ameliorated	O
by	O
the	O
inhibition	O
of	O
RAF,	O
RTK,	O
etc	O
.	O
,	O
proliferative	O
conditions	O
such	O
as	O
cancer	O
(	O
e	O
.	O
g	O
.	O
,	O
colorectal	O
cancer,	O
melanoma	O
)	O
,	O
etc	O
.	O


The	O
invention	O
concerns	O
benzamide	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1a,	O
R1b,	O
R1c,	O
R2,	O
R3,	O
R4,	O
integer	O
m,	O
integer	O
n	O
and	O
W	O
have	O
any	O
of	O
the	O
meanings	O
defined	O
in	O
the	O
description	O
;	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
as	O
an	O
antiproliferative	O
agent	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
tumours	O
or	O
other	O
proliferative	O
conditions	O
which	O
are	O
sensitive	O
to	O
the	O
inhibition	O
of	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
.	O


Compounds	O
and	O
compositions	O
are	O
provided	O
for	O
modulating	O
the	O
activity	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O
The	O
compounds	O
for	O
use	O
in	O
the	O
compositions	O
and	O
methods	O
provided	O
herein	O
have	O
formulae	O
(	O
I	O
)	O
Protein	B-GENE
tyrosine	I-GENE
hosaphatase,	O
including	O
PTB-1B,	O
mediated	O
diseases	O
and	O
disorders	O
include	O
diabetes	O
including	O
Type	O
1	O
and	O
Type	O
2	O
diabetes	O
(	O
and	O
associated	O
complications	O
such	O
as	O
hypertension,	O
ischemic	O
diseases	O
of	O
the	O
large	O
and	O
small	O
blood	O
vessels,	O
blindness,	O
circulatory	O
problems,	O
kidney	O
failure	O
and	O
atherosclerosis	O
)	O
,	O
syndrome	O
X,	O
methabolic	O
syndrome,	O
glucose	O
intolerance,	O
insulin	B-GENE
resistance,	O
obesity,	O
cancer,	O
neurodegenerative	O
diseases	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
medicine,	O
particularly	O
a	O
pharmaceutical	O
composition	O
useful	O
for	O
preventing	O
or	O
treating	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
infection	O
of	O
a	O
virus	O
of	O
the	O
Herpesviridae	O
family	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
The	O
present	O
invention	O
relates	O
to	O
an	O
anti-herpesvirus	O
agent	O
characterized	O
by	O
combining	O
a	O
helicase-primase	O
inhibitor	O
with	O
a	O
polymerase	O
inhibitor	O
.	O
By	O
combining	O
the	O
helicase-primase	O
inhibitor	O
with	O
the	O
polymerase	O
inhibitor	O
having	O
different	O
action	O
mechanisms,	O
the	O
anti-herpesvirus	O
agent	O
of	O
the	O
present	O
invention	O
achieves	O
a	O
dramatically	O
superior	O
anti-herpesvirus	O
action	O
compared	O
with	O
conventional	O
administration	O
of	O
a	O
polymerase	O
inhibitor	O
alone	O
.	O
Therefore,	O
it	O
is	O
particularly	O
effective	O
in	O
a	O
case	O
in	O
which	O
a	O
sufficient	O
therapeutic	O
effect	O
cannot	O
be	O
achieved	O
only	O
with	O
a	O
polymerase	O
inhibitor	O
.	O
Further,	O
the	O
doses	O
of	O
both	O
agents	O
can	O
be	O
kept	O
low,	O
therefore	O
it	O
is	O
also	O
possible	O
to	O
perform	O
treatment	O
by	O
lowering	O
the	O
effect	O
of	O
an	O
adverse	O
reaction	O
to	O
be	O
concerned	O
.	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
and	O
a	O
salt	O
thereof	O
.	O
(	O
In	O
the	O
formula,	O
the	O
ring	O
A	O
represents	O
an	O
optionally	O
substituted	O
five-membered	O
aromatic	O
heterocyclic	O
ring	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
optionally	O
substituted	O
hydrocarbon	O
group	O
;	O
W	O
represents	O
an	O
oxygen	O
atom	O
or	O
a	O
sulfur	O
atom	O
;	O
X1	O
and	O
X2	O
may	O
be	O
the	O
same	O
as	O
or	O
different	O
from	O
each	O
other	O
and	O
respectively	O
represent	O
a	O
hydrogen	O
atom,	O
an	O
optionally	O
substituted	O
hydrocarbon	O
group	O
or	O
heterocyclic	O
group,	O
or	O
alternatively	O
X1	O
and	O
X2	O
combine	O
together	O
and	O
form	O
an	O
oxygen	O
atom,	O
a	O
sulfur	O
atom	O
or	O
a	O
=	O
NR2	O
group	O
;	O
the	O
ring	O
B	O
represents	O
an	O
aromatic	O
ring	O
which	O
may	O
have	O
a	O
further	O
substituent	O
;	O
Y	O
represents	O
a	O
bonding	O
hand	O
or	O
an	O
optionally	O
substituted	O
C1-6	O
alkylene,	O
C2-6	O
alkenylene	O
or	O
C2-6	O
alkynylene	O
;	O
and	O
Z	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
-SOnR3	O
or	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
-COR4	O
.	O
Such	O
a	O
compound	O
and	O
a	O
salt	O
thereof	O
are	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
having	O
a	O
GnRH	B-GENE
antagonist	O
action	O
.	O


Therapeutically	O
active	O
heteroaryl	O
carboxylic	O
acid	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
W,	O
X,	O
Y	O
and	O
Z	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
processes	O
for	O
the	O
preparation	O
of	O
said	O
derivatives,	O
pharmaceutical	O
formulations	O
containing	O
the	O
active	O
compounds	O
and	O
the	O
use	O
of	O
the	O
compounds	O
in	O
therapy,	O
particularly	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
under-activation	O
of	O
the	O
HM74A	B-GENE
receptor	I-GENE
contributes	O
to	O
the	O
disease	O
or	O
in	O
which	O
activation	O
of	O
the	O
receptor	O
will	O
be	O
beneficial,	O
are	O
disclosed	O
.	O


It	O
is	O
intended	O
to	O
conveniently	O
and	O
efficiently	O
provide	O
a	O
specific	O
compound	O
originating	O
in	O
a	O
natural	O
material	O
and	O
a	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B-GENE
resistance	O
syndrome	O
characterized	O
by	O
containing	O
the	O
above	O
compound	O
as	O
the	O
active	O
ingredient	O
.	O
Namely,	O
a	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B-GENE
resistance	O
syndrome	O
which	O
contains,	O
as	O
the	O
active	O
ingredient,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
,	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
and	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
5	O
)	O
or	O
a	O
salt	O
or	O
an	O
ester	O
of	O
the	O
same	O
.	O


The	O
invention	O
provides	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
description,	O
processes	O
and	O
intermediates	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
mGluR5	B-GENE
.	O


Disclosed	O
is	O
a	O
hair	O
cosmetic	O
comprising	O
a	O
substance	O
having	O
an	O
inhibitory	O
effect	O
against	O
testosterone	O
5α-reductase,	O
an	O
effect	O
of	O
promoting	O
the	O
hair	O
papilla	O
cell	O
growth,	O
an	O
effect	O
of	O
promoting	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor-7	I-GENE
production,	O
an	O
effect	O
of	O
promoting	O
the	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
production	O
or	O
an	O
effect	O
of	O
promoting	O
the	O
bone	B-GENE
forming	I-GENE
factor-2	I-GENE
production	O
.	O
Also	O
disclosed	O
is	O
a	O
medicated	O
hair	O
tonic,	O
a	O
testosterone	B-GENE
5α-reductase	I-GENE
inhibitor,	O
a	O
hair	O
papilla	O
cell	O
growth	O
promoter,	O
a	O
fibroblast	B-GENE
growth	I-GENE
factor-7	I-GENE
production	O
promoter,	O
a	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
production	O
promoter	O
or	O
a	O
bone	B-GENE
forming	I-GENE
factor-2	I-GENE
production	O
promoter	O
comprising	O
the	O
substance	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
hair	O
cosmetic	O
has	O
corosolic	O
acid	O
blended	O
therein	O
.	O
The	O
medicated	O
hair	O
tonic,	O
testosterone	B-GENE
5α-reductase	I-GENE
inhibitor,	O
hair	O
papilla	O
cell	O
growth	O
promoter,	O
fibroblast	B-GENE
growth	I-GENE
factor-7	I-GENE
production	O
promoter,	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
production	O
promoter	O
or	O
bone	B-GENE
forming	I-GENE
factor-2	I-GENE
production	O
promoter	O
comprises	O
corosolic	O
acid	O
as	O
an	O
active	O
ingredient	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
Focusing	O
on	O
the	O
multidrug	O
therapy,	O
a	O
medicine	O
is	O
designed	O
by	O
using	O
a	O
novel	O
phenylpropionic	O
acid	O
derivative	O
serving	O
as	O
a	O
PPARα	B-GENE
activator	O
(	O
for	O
example,	O
(	O
S	O
)	O
-2-ethyl-3-	O
[	O
4-methoxy-3-	O
[	O
N-	O
[	O
[	O
4-	O
(	O
4-fluorophenoxy	O
)	O
phenyl	O
]	O
methyl	O
]	O
carbamoyl	O
]	O
phenyl	O
]	O
propionic	O
acid	O
(	O
KRP-101	O
)	O
)	O
together	O
with	O
a	O
statin	O
drug	O
serving	O
as	O
an	O
antihyperlipidemic	O
or	O
blending	O
them	O
to	O
synergistically	O
or	O
additionally	O
enhance	O
the	O
lipid-lowering	O
effect,	O
thereby	O
providing	O
a	O
novel	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O


The	O
instant	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
PDE7	B-GENE
inhibitor	O
and	O
an	O
alpha-2-delta	O
ligand,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
pain,	O
particularly	O
inflammatory,	O
neuropathic,	O
visceral	O
and	O
nociceptive	O
pain	O
.	O


Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
modulating	O
the	O
activity	O
of	O
sirtuin	B-GENE
deacetylase	I-GENE
protein	I-GENE
family	O
members	O
;	O
p53	B-GENE
activity	O
;	O
apoptosis	O
;	O
lifespan	O
and	O
sensitivity	O
to	O
stress	O
of	O
cells	O
and	O
organisms	O
.	O
Exemplary	O
methods	O
comprise	O
contacting	O
a	O
cell	O
with	O
an	O
activating	O
compound,	O
such	O
as	O
a	O
flavone,	O
stilbene,	O
flavanone,	O
isoflavone,	O
catechin,	O
chalcone,	O
tannin	O
or	O
anthocyanidin	O
;	O
or	O
an	O
inhibitory	O
compound,	O
such	O
as	O
a	O
sphingolipid,	O
e	O
.	O
g	O
.	O
,	O
sphingosine	O
.	O
Also	O
disclosed	O
herein	O
are	O
methods	O
for	O
treating,	O
preventing	O
or	O
diagnosing	O
a	O
disease	O
associated	O
with	O
neuronal	O
cell	O
death,	O
e	O
.	O
g	O
.	O
,	O
a	O
neurodegenerative	O
disease	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
(	O
S	O
)	O
-l-	O
{	O
[	O
2-	O
(	O
5-Methyl-2-phenyl-oxazol-4-yl	O
)	O
-	O
ethylamino	O
]	O
-acetyl	O
}	O
-pyrrolidine-2-carbonitrile	O
mesylate	O
and	O
crystalline	O
polymorphs	O
of	O
this	O
compound	O
.	O
This	O
compound	O
and	O
its	O
polymorphic	O
forms	O
exhibits	O
superior	O
properties	O
compared	O
to	O
the	O
previously	O
known	O
compounds	O
and	O
can	O
be	O
used	O
as	O
medicament	O
for	O
the	O
treatment	O
of	O
disorders	O
which	O
are	O
associated	O
with	O
DPP-IV	B-GENE
.	O


Methods	O
of	O
treating	O
an	O
SCD-mediated	O
disease	O
or	O
condition	O
in	O
a	O
mammal,	O
preferebly	O
a	O
human,	O
are	O
disclosed,	O
wherein	O
the	O
methods	O
comprise	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
where	O
x,	O
y,	O
G,	O
J,	O
K,	O
L,	O
M,	O
W,	O
R2,	O
R3,	O
R5	O
,	O
R5a,	O
R6,	O
R6a,	O
R7,	O
R7a,	O
R8	O
and	O
R8a	O
are	O
difined	O
herein	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
also	O
disclosed	O
.	O


Disclosed	O
is	O
a	O
highly	O
safe	O
composition	O
for	O
enhancing	O
expression	O
and	O
activity	O
of	O
a	O
protease	B-GENE
in	O
the	O
liver	O
.	O
Specifically	O
disclosed	O
is	O
a	O
composition	O
containing	O
coenzyme	B-GENE
Q10	I-GENE
as	O
an	O
active	O
constituent	O
.	O
This	O
composition	O
enhances	O
expression	O
and	O
activity	O
of	O
a	O
protease	B-GENE
in	O
the	O
liver	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
with	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
Formula	O
(	O
I	O
)	O
;	O
wherein	O
R1	O
is	O
an	O
optionally	O
fused	O
pyridine	O
ring	O
and	O
R2	O
and	O
R3	O
together	O
form	O
a	O
heterocyclic	O
ring	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
the	O
11-β-hsd-1	B-GENE
enzyme	O
.	O


Disclosed	O
is	O
a	O
compound	O
having	O
an	O
inhibitory	O
effect	O
on	O
both	O
EGF	B-GENE
receptor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
and	O
HER2	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
of	O
either	O
of	O
them	O
.	O
[	O
In	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
represents	O
a	O
C1-3	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
group	O
represented	O
by	O
the	O
following	O
formula	O
:	O
(	O
wherein	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
an	O
optionally	O
substituted	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
Ar1	O
represents	O
an	O
allylene	O
or	O
heteroallylene	O
;	O
R6	O
represents	O
an	O
optionally	O
substituted	O
alkyl	O
group,	O
an	O
alkoxycarbonyl	O
group	O
or	O
the	O
like	O
;	O
R	O
'	O
s	O
independently	O
represent	O
an	O
optionally	O
substituted	O
alkyl	O
group,	O
an	O
alkyloxy	O
group	O
or	O
the	O
like	O
;	O
and	O
n	O
represents	O
an	O
integer	O
of	O
0-2	O
)	O
;	O
Y	O
represents	O
-O-,	O
-S-,	O
-N	O
(	O
R20	O
)	O
-	O
or	O
the	O
like	O
;	O
R20	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
alkyl	O
group,	O
an	O
acyl	O
group	O
or	O
the	O
like	O
;	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
phenyl	O
group	O
or	O
the	O
like	O
.	O
]	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
screening	O
for	O
compounds	O
that	O
modulate	O
the	O
expression	O
of	O
the	O
cannabinoid	O
CBl	B-GENE
and	O
CB2	B-GENE
receptors,	O
and	O
methods	O
for	O
modulating	O
receptor	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
CB	B-GENE
1	I-GENE
and	O
CB2	B-GENE
receptors	O
and	O
/	O
or	O
binding	O
partners	O
for	O
identification	O
of	O
pharmacologically	O
active	O
agents,	O
and	O
their	O
use	O
for	O
enhancing	O
wound	O
healing	O
and	O
treating	O
wound	O
healing	O
disorders	O
.	O


As	O
a	O
result	O
of	O
a	O
large	O
scale	O
SNP	O
analysis	O
on	O
a	O
group	O
of	O
Perkinson	O
disease	O
patients	O
and	O
a	O
control	O
group	O
of	O
normal	O
persons,	O
it	O
has	O
succeeded	O
in	O
the	O
identification	O
of	O
a	O
gene	O
involved	O
in	O
Perkinson	O
disease	O
(	O
GRK5	B-GENE
)	O
.	O
It	O
is	O
now	O
found	O
that	O
the	O
increase	O
in	O
the	O
expression	O
of	O
the	O
GRK5	B-GENE
gene	O
induces	O
the	O
enhancement	O
of	O
the	O
phosphorylation	O
of	O
α-synuclein,	O
which	O
in	O
turn	O
induces	O
the	O
enhancement	O
of	O
the	O
formation	O
of	O
a	O
soluble	O
α-synuclein	B-GENE
oligomer,	O
leading	O
to	O
the	O
development	O
of	O
Perkinson	O
disease	O
.	O
It	O
becomes	O
possible	O
to	O
diagnose	O
Perkinson	O
disease	O
and	O
screen	O
a	O
therapeutic	O
agent	O
for	O
Perkinson	O
disease	O
by	O
using	O
the	O
expression	O
of	O
the	O
GRK5	B-GENE
gene	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
pyrrolidine	O
and	O
thiazolidine	O
DPP-IV	B-GENE
inhibitor	O
compounds	O
.	O
The	O
present	O
invention	O
also	O
provides	O
synthetic	O
methods	O
for	O
preparation	O
of	O
such	O
compounds,	O
methods	O
of	O
inhibiting	O
DPP-IV	B-GENE
using	O
such	O
compounds	O
and	O
pharmaceutical	O
formulations	O
containing	O
them	O
for	O
treatment	O
of	O
DPP-IV	B-GENE
mediated	O
diseases,	O
in	O
particular,	O
Type-2	O
diabetes	O
.	O


Provided	O
are	O
quinazoline	O
derivatives	O
of	O
the	O
compound	O
(	O
I	O
)	O
,	O
and	O
its	O
preparation	O
process	O
and	O
application	O
as	O
a	O
medicine	O
of	O
inhibit	O
tumor	O
growth	O
.	O
The	O
group	O
X,	O
Y,	O
Z,	O
R1,	O
R2,	O
R3,	O
R4	O
of	O
compound	O
(	O
I	O
)	O
are	O
defined	O
in	O
the	O
description	O
.	O
Compounds	O
of	O
the	O
invention	O
can	O
specially	O
inhibit	O
tyrosine	O
kinase	O
activity,	O
adjust	O
VEGF	B-GENE
secretion,	O
thus	O
to	O
achieve	O
the	O
purpose	O
of	O
treating	O
malignant	O
tumor	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
N-oxides	O
which	O
are	O
useful	O
as	O
hypoxic	O
selective	O
cytotoxic	O
agents	O
that	O
mediate	O
and	O
/	O
or	O
inhibit	O
cell	O
proliferation,	O
for	O
example,	O
through	O
the	O
activity	O
of	O
protein	B-GENE
kinases	I-GENE
.	O
The	O
invention	O
is	O
further	O
related	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
compositions,	O
and	O
to	O
methods	O
of	O
treating	O
cancer	O
as	O
well	O
as	O
other	O
disease	O
states	O
associated	O
with	O
unwanted	O
ahgiogenesis	O
and	O
/	O
or	O
cellular	O
proliferation	O
by	O
administering	O
effective	O
amounts	O
of	O
such	O
compounds	O
.	O


Disclosed	O
are	O
substituted	O
benzo	O
[	O
d	O
]	O
isoxazol-3-yl	O
amine	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
pain	O
while	O
being	O
provided	O
with	O
an	O
excellent	O
affinity	O
to	O
the	O
KCNQ2/3	B-GENE
K+	I-GENE
channel	I-GENE
and	O
thus	O
being	O
suitable	O
for	O
the	O
treatment	O
of	O
disorders	O
or	O
diseases	O
that	O
are	O
transmitted	O
at	O
least	O
in	O
part	O
through	O
KCNQ2/3	B-GENE
K+	I-GENE
channels	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
to	O
R3	O
are	O
as	O
described	O
herein,	O
processes	O
for	O
preparing	O
the	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
GHSR	B-GENE
receptor-related	O
disorder	O
.	O
Examples	O
of	O
such	O
disorders	O
are	O
obesity	O
and	O
related	O
disorders	O
such	O
as	O
diabetes	O
type	O
II,	O
dyslipidemia	O
and	O
the	O
metabolic	O
syndrome	O
Prader-Willi	O
syndrome,	O
cardiovascular	O
diseases	O
such	O
as	O
atherosclerotic	O
vascular	O
disease,	O
angina	O
pectoris,	O
myocardial	O
infarction	O
and	O
stroke,	O
intestinal	O
inflammation	O
that	O
is	O
associated	O
with	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
such	O
as	O
Crohn	O
'	O
s	O
disease	O
and	O
ulcerative	O
colitis,	O
acromegaly	O
and	O
cancer,	O
in	O
particular	O
breast,	O
lung,	O
prostate,	O
thyroid	O
and	O
endocrine	O
pituary	O
carcinomas	O
.	O


Disclosed	O
are	O
methods	O
for	O
detecting	O
adriamycin	O
resistance	O
in	O
a	O
test	O
neoplastic	O
cell	O
from	O
a	O
non-hematological	O
cancer	O
.	O
The	O
methods	O
include	O
detecting	O
a	O
level	O
of	O
pl6	B-GENE
expression	O
in	O
the	O
test	O
neoplastic	O
cell	O
of	O
a	O
given	O
origin	O
or	O
cell	O
type,	O
and	O
comparing	O
the	O
level	O
of	O
pl6	B-GENE
expression	O
detected	O
in	O
the	O
test	O
neoplastic	O
cell	O
to	O
the	O
level	O
of	O
pl6	B-GENE
expression	O
in	O
a	O
nonresistant	O
neoplastic	O
cell	O
of	O
the	O
same	O
origin	O
or	O
cell	O
type,	O
wherein	O
the	O
test	O
neoplastic	O
cell	O
is	O
adriamycin	O
resistant	O
if	O
the	O
level	O
of	O
pl6	B-GENE
expression	O
is	O
greater	O
than	O
the	O
level	O
of	O
pl6	B-GENE
expression	O
in	O
the	O
nonresistant	O
neoplastic	O
cell	O
of	O
the	O
same	O
origin	O
or	O
cell	O
type	O
.	O
Also	O
disclosed	O
are	O
therapeutic	O
compositions	O
comprising	O
an	O
agent	O
that	O
inhibits	O
pl6	B-GENE
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


This	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
anti-cancer	O
compounds	O
which	O
comprises	O
a	O
)	O
an	O
orally	O
effective	O
taxane,	O
and	O
b	O
)	O
a	O
thymidylate	B-GENE
synthase	I-GENE
inhibitor,	O
and	O
optionally	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
carrier	O
for	O
simultaneous,	O
separate	O
or	O
sequential	O
use	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
useful,	O
for	O
example,	O
for	O
modulating	O
insulin	B-GENE
levels	O
in	O
a	O
subject,	O
having	O
the	O
general	O
formula	O
I	O
:	O
wherein	O
Q	O
is	O
an	O
optionally	O
substituted	O
phenyl	O
;	O
L	O
is	O
a	O
bond	O
or	O
O	O
;	O
P	O
is	O
a	O
benzene	O
or	O
an	O
optionally	O
substituted	O
thiazole	O
ring	O
;	O
and	O
R1	O
has	O
the	O
values	O
provided	O
herein	O
.	O
The	O
present	O
invention	O
also	O
provides	O
compositions,	O
uses,	O
and	O
methods	O
for	O
use	O
of	O
the	O
compounds,	O
for	O
instance,	O
for	O
treatment	O
of	O
type	O
II	O
diabetes	O
.	O


A	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
a	O
motor	O
disorder	O
comprising,	O
as	O
an	O
active	O
ingredient,	O
a	O
triazolopyrimidine	O
derivative	O
having	O
an	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
antagonistic	O
effect	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	O
group	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
heterocyclic	O
group	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
-WR4	O
or	O
the	O
like	O
;	O
and	O
Q1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
3,4-dimethoxybenzyl	O
;	O
and	O
others	O
.	O


The	O
present	O
invention	O
relates	O
to	O
improved	O
methods	O
for	O
treating	O
anemia	O
.	O
Compounds	O
which	O
stabilise	O
HIF-alpha	B-GENE
useful	O
for	O
treating	O
anemia,	O
wherein	O
the	O
anemia	O
treatment	O
is	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
thrombosis	O
or	O
hypertension	O
compared	O
to	O
that	O
observed	O
with	O
rhEPO	B-GENE
therapy,	O
are	O
provided	O
.	O


The	O
present	O
invention	O
uses	O
NF-κB	B-GENE
as	O
target	O
point,	O
and	O
utilizes	O
the	O
NF-κB	B-GENE
inhibitor	O
to	O
treat	O
several	O
diseases	O
of	O
mammal,	O
e	O
.	O
g	O
.	O
virusinfection,	O
cancer,	O
chronic	O
inflammation	O
and	O
autoimmune	O
diseases	O
.	O
The	O
said	O
inhibitor	O
includes	O
the	O
compounds	O
and	O
derivates	O
which	O
can	O
inhibit	O
NF-κB,	O
such	O
as	O
quinazoline	O
derivative,	O
celastrol,	O
phenylethyl	O
caffeiatc,	O
(	O
E	O
)	O
3-	O
(	O
(	O
4-methylphenyl	O
)	O
ulfonyl	O
)	O
-2-acrylonitrile,	O
Rocaglamide	O
and	O
7-methoxy-5,11,12-trihydroxy-benzofuran	O
coumarin	O
.	O
They	O
can	O
be	O
used	O
alonely	O
or	O
be	O
combined	O
with	O
known	O
clinical	O
treatment	O
to	O
treat	O
viral	O
diseases,	O
especially	O
viral	O
infection	O
caused	O
by	O
retrovirus	O
and	O
AIDS	O
caused	O
by	O
HIV,	O
cancer,	O
chronic	O
inflammation	O
and	O
autoimmune	O
diseases	O
.	O


The	O
present	O
invention	O
discloses	O
sulfonamide	O
CA	O
IX-selective	O
inhibitors,	O
which	O
selectively	O
bind	O
to	O
the	O
enzyme	O
under	O
hypoxic	O
conditions	O
and	O
are	O
able	O
to	O
reverse	O
the	O
tumor	O
acidification	O
mediated	O
by	O
the	O
enzyme	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
anticancer	O
therapies	O
based	O
on	O
tumor-associated	O
CA	B-GENE
isozyme	I-GENE
inhibition	O
as	O
well	O
as	O
for	O
hypoxic	O
tumor	O
imaging	O
.	O
The	O
inhibitors	O
contain	O
a	O
fluorescent	O
moiety,	O
preferably	O
fluorescein	O
.	O


This	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
forms	O
thereof	O
useful	O
as	O
inhibitors	O
of	O
cPLA2	B-GENE
and	O
a	O
method	O
for	O
preventing,	O
treating	O
or	O
ameliorating	O
a	O
cPLA2	B-GENE
mediated	O
inflammatory	O
related	O
disease,	O
disorder	O
or	O
condition	O
using	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
and,	O
more	O
particularly,	O
for	O
preventing,	O
treating	O
or	O
ameliorating	O
a	O
cPLA2	B-GENE
mediated	O
inflammatory	O
related	O
disease,	O
disorder	O
or	O
condition	O
which	O
results	O
from	O
the	O
cellular	O
secretion	O
of	O
TXB2	O
or	O
LTB4	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
is	O
independently	O
H1	O
-OR3,	O
-NHR4	O
;	O
C1-C4	O
alkyl	O
;	O
or,	O
when	O
n	O
is	O
2,	O
adjacent	O
R1	O
together	O
define	O
an	O
olefin	O
ic	O
bond	O
;	O
R2	O
is	O
H	O
;	O
or	O
when	O
the	O
gem	O
R1	O
is	O
C1-C4	O
alkyl,	O
that	O
R2	O
may	O
also	O
be	O
C1-C4	O
alkyl	O
;	O
or	O
when	O
the	O
gem	O
R1	O
is	O
-OR3,	O
that	O
R2	O
may	O
also	O
be	O
-C	O
(	O
=	O
O	O
)	O
OH	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester	O
thereof	O
;	O
R3	O
is	O
independently	O
H,	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester	O
thereof	O
;	O
R4	O
is	O
independently	O
H	O
or	O
a	O
pharmaceutically	O
acceptable	O
amide	O
thereof	O
;	O
R5	O
and	O
R6	O
are	O
H	O
or	O
an	O
amine	O
prodrug	O
moiety	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
have	O
utility	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
HIV,	O
especially	O
reverse	B-GENE
transcriptase	I-GENE
mutants	O
which	O
allow	O
an	O
obligate	O
chain	O
terminating	O
nucleoside-	O
or	O
nucleotide	O
phosphate	O
to	O
be	O
excised	O
from	O
the	O
nascent	O
DNA	O
strand	O
by	O
ATP-	O
or	O
pyrophosphate-mediated	O
excision	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof,	O
process	O
for	O
their	O
preparation,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
tachykinins	B-GENE
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
phosphodiesterase	B-GENE
(PDE)	I-GENE
type	I-GENE
5	I-GENE
inhibitors	O
or	O
their	O
pharmaceutically	O
compatible	O
salts	O
for	O
producing	O
a	O
medicament	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
diseases	O
or	O
health	O
disorders,	O
which	O
are	O
associated	O
with	O
an	O
excessive	O
proliferation	O
of	O
adipose	O
tissue	O
in	O
the	O
body	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
phosphodiesterase	B-GENE
type	I-GENE
5	I-GENE
inhibitors	O
for	O
preventing	O
and	O
treating	O
adiposity	O
.	O
In	O
addition,	O
the	O
invention	O
relates	O
to	O
special	O
dispensing	O
systems	O
for	O
the	O
vaginal	O
and	O
sub-cutaneous	O
administration	O
of	O
PDE5	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
benzylpiperazine	O
derivatives	O
such	O
as	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
have	O
activity	O
as	O
agonists	O
of	O
the	O
GPR38	B-GENE
receptor	O
and	O
the	O
use	O
of	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
thereof	O
in	O
the	O
preparation	O
of	O
medicaments	O
suitable	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O


Compounds	O
active	O
on	O
the	O
receptor	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinases	I-GENE
c-kit	B-GENE
and	O
c-fms	B-GENE
are	O
provided	O
herewith	O
.	O
Also	O
provided	O
herewith	O
are	O
compositions	O
useful	O
for	O
treatment	O
of	O
c-kit	B-GENE
mediated	O
diseases	O
or	O
condition	O
and	O
c-fms-mediated	O
diseases	O
or	O
condition,	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders,	O
for	O
improving	O
glycemic	O
control,	O
for	O
preventing	O
progression	O
from	O
impaired	O
glucose	O
tolerance,	O
insulin	B-GENE
resistance	O
and	O
/	O
or	O
from	O
metabolic	O
syndrome	O
to	O
type	O
2	O
diabetes	O
mellitus,	O
for	O
preventing	O
or	O
treating	O
of	O
complications	O
of	O
diabetes	O
mellitus,	O
for	O
reducing	O
the	O
weight,	O
for	O
preventing	O
or	O
treating	O
the	O
degeneration	O
of	O
pancreatic	O
beta	O
cells,	O
for	O
treating	O
hyperinsulinemia	O
and	O
insulin	B-GENE
resistance	O
and	O
diabetes	O
type	O
1,	O
in	O
patients	O
in	O
need	O
thereof	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pyrazole-O-glycoside	O
as	O
defined	O
in	O
claim	O
1	O
,	O
or	O
a	O
prodrug	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
which	O
mimic	O
peptides	O
with	O
a	O
C-terminal	O
penultimate	O
proline,	O
such	O
compounds	O
being	O
useful	O
as	O
protease	B-GENE
inhibitors,	O
particularly	O
as	O
inhibitors	O
of	O
serine	O
proteases,	O
and	O
more	O
particularly	O
as	O
inhibitors	O
of	O
the	O
NS3	B-GENE
serine	B-GENE
protease	B-GENE
from	O
hepatitis	O
C	O
.	O
The	O
compounds	O
find	O
utility	O
as	O
antiviral	O
agents	O
directed	O
at	O
hepatitis	O
C	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
employing	O
such	O
inhibitors,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents,	O
to	O
treat	O
hepatitis	O
C	O
infection	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
.	O


The	O
present	O
invention	O
provides	O
thioether	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
useful	O
in	O
treatment	O
of	O
a	O
CNS	O
disorder	O
related	O
to	O
or	O
affected	O
by	O
the	O
5-HT6	B-GENE
receptor	O
.	O
Pharmacological	O
profile	O
of	O
these	O
compounds	O
includes	O
high	O
affinity	O
binding	O
with	O
5-HT6	B-GENE
receptor	O
along	O
with	O
selectivity	O
towards	O
the	O
said	O
receptor	O
.	O
The	O
present	O
invention	O
also	O
includes	O
the	O
stereoisomers,	O
the	O
salts,	O
methods	O
of	O
preparation	O
and	O
medicine	O
containing	O
the	O
said	O
thioether	O
derivatives	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
corresponding	O
enantiomeric,	O
diastereomeric	O
and	O
/	O
or	O
tautomeric	O
forms	O
thereof	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
the	O
prodrugs	O
of	O
said	O
compounds	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compounds	O
as	O
binding	O
partners	O
for	O
5-HT5	B-GENE
receptors	O
for	O
treating	O
diseases	O
that	O
are	O
modulated	O
by	O
a	O
5-HT5	B-GENE
receptor	O
activity,	O
in	O
particular,	O
for	O
treating	O
neurodegenerative	O
and	O
neuropsychiatric	O
disorders	O
as	O
well	O
as	O
signs,	O
symptoms	O
and	O
dysfunctions	O
.	O


The	O
invention	O
addresses	O
the	O
current	O
need	O
for	O
selective	O
and	O
potent	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitors	O
by	O
providing	O
potent	O
inhibitors	O
of	O
c-fms	B-GENE
kinase	I-GENE
.	O
The	O
invention	O
is	O
directed	O
to	O
the	O
novel	O
compounds	O
of	O
Formula	O
I	O
:	O
or	O
a	O
solvate,	O
hydrate,	O
tautomer	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
:	O
W,	O
A,	O
Y,	O
n,	O
Z,	O
and	O
R102	O
are	O
described	O
in	O
the	O
specification	O
.	O


The	O
invention	O
relates	O
to	O
4-oxy-N-	O
[	O
1	O
,3,4	O
]	O
-thiadiazol-2-yl-benzene	O
sulfonamides	O
and	O
to	O
their	O
physiologically	O
acceptable	O
salts	O
and	O
physiologically	O
functional	O
derivatives	O
showing	O
PPARalpha,	O
PPARdelta	B-GENE
and	O
PPARgamma	B-GENE
agonist	O
activity	O
.	O
What	O
is	O
described	O
are	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
the	O
radicals	O
are	O
as	O
defined,	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
and	O
processes	O
for	O
their	O
preparations	O
.	O
The	O
compounds	O
are	O
suitable	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
disorders	O
of	O
fatty	O
acid	O
metabolism	O
and	O
glucose	O
utilization	O
disorders	O
as	O
well	O
as	O
of	O
disorders	O
in	O
which	O
insulin	B-GENE
resistance	O
is	O
involved	O
and	O
demyelinating	O
and	O
other	O
neurodegenerative	O
disorders	O
of	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
agent	O
for	O
treating	O
diabetes,	O
particularly	O
an	O
agent	O
for	O
treating	O
diabetes	O
capable	O
of	O
being	O
administered	O
orally,	O
which	O
has	O
high	O
safety	O
even	O
if	O
it	O
is	O
administered	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
diabetes	O
comprising	O
an	O
anionic	O
polyamino	O
acid,	O
preferably	O
a	O
metal-polyamino	O
acid	O
complex	O
which	O
can	O
be	O
produced	O
from	O
poly-gamma-glutamic	O
acid	O
and	O
a	O
metal	O
compound	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
diabetes	O
comprising	O
an	O
anionic	O
polyamino	O
acid,	O
preferably	O
a	O
metal-polyamino	O
acid	O
complex	O
which	O
can	O
be	O
produced	O
from	O
poly-gamma-glutamic	O
acid	O
and	O
a	O
metal	O
compound	O
and	O
having	O
at	O
least	O
one	O
action	O
of	O
a	O
hypoglycemic	O
action,	O
a	O
glucose	O
tolerance	O
improving	O
action,	O
a	O
blood	O
pressure-lowering	O
action	O
and	O
an	O
insulin	B-GENE
resistance	O
improving	O
action	O
.	O
Further,	O
the	O
invention	O
relates	O
to	O
a	O
food	O
composition	O
comprising	O
an	O
anionic	O
polyamino	O
acid,	O
preferably	O
a	O
metal-polyamino	O
acid	O
complex	O
which	O
can	O
be	O
produced	O
from	O
poly-gamma-glutamic	O
acid	O
and	O
a	O
metal	O
compound	O
.	O


The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
Liver	B-GENE
X	I-GENE
Receptor	I-GENE
(	O
LXR	B-GENE
)	O
modulators	O
that	O
have	O
been	O
identified	O
to	O
downregulate	O
5-lipoxygenase	B-GENE
gene	O
expression	O
in	O
order	O
to	O
treat	O
various	O
diseases	O
and	O
disorders	O
that	O
involve	O
the	O
function	O
of	O
the	O
5-LO	B-GENE
protein	O
in	O
intracellular	O
signaling	O
(	O
or	O
other	O
cellular	O
processes	O
)	O
or	O
the	O
function	O
of	O
protein	O
products	O
downstream	O
of	O
5-LO	B-GENE
in	O
intracellular	O
signaling	O
(	O
i	O
.	O
e	O
.	O
,	O
leukotrienes	O
)	O
.	O


(	O
The	O
disclosure	O
relates	O
to	O
compositions	O
for	O
and	O
methods	O
of	O
inhibiting	O
the	O
mammalian	O
Hedgehog	B-GENE
signaling	O
pathway	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
I	O
:	O
[	O
(	O
C	O
)	O
-	O
(	O
L	O
'	O
)	O
]	O
n-	O
(	O
A	O
)	O
-	O
[	O
(	O
L	O
)	O
-	O
(	O
B	O
)	O
]	O
m	O
wherein	O
(	O
A	O
)	O
is	O
a	O
thioglycosylated	O
cysteine	O
of	O
formula	O
IIa	O
or	O
IIb	O
:	O
IIa	O
IIb	O
;	O
(	O
B	O
)	O
is	O
a	O
melanogenosis-inhibiting	O
peptide	O
comprising	O
peptide	O
sequence	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
:	O
(	O
i	O
)	O
.	O
Glu-Asp-Tyr-His-Ser-Leu-Tyr-Gln-Ser-His-Leu	O
;	O
(	O
ii	O
)	O
.	O
Ser-Gly-Gly-Tyr-Leu-Pro-Pro-Leu	O
;	O
and	O
(	O
iii	O
)	O
.	O
His-Ser-C	O
(	O
O	O
)	O
-NH-	O
(	O
CH2	O
)	O
k-CH2-C	O
(	O
O	O
)	O
-NH-Ser-His	O
;	O
(	O
C	O
)	O
is	O
a	O
tyrosinase	B-GENE
inhibitor	O
;	O
n	O
is	O
0	O
or	O
1	O
;	O
m	O
is	O
0	O
or	O
1	O
;	O
m	O
+	O
n	O
is	O
1	O
or	O
2	O
;	O
k	O
is	O
2-10	O
;	O
X1	O
is	O
O	O
or	O
NH	O
;	O
R1,	O
R2,	O
R7,	O
and	O
R8	O
are	O
each,	O
independently,	O
selected	O
from	O
H,	O
and	O
a	O
bond	O
in	O
a	O
linkage	O
group	O
between	O
(	O
A	O
)	O
and	O
(	O
L	O
)	O
;	O
R3,	O
R4,	O
R5,	O
R6,	O
R9,	O
R10,	O
R11,	O
and	O
R12	O
are	O
each,	O
independently,	O
selected	O
from	O
H,	O
a	O
saccharide,	O
and	O
a	O
bond	O
in	O
a	O
linkage	O
group	O
between	O
(	O
A	O
)	O
and	O
(	O
L	O
'	O
)	O
;	O
(	O
L	O
)	O
is	O
a	O
linker	O
which	O
forms	O
linkage	O
groups	O
with	O
thioglycosylated	O
cysteine	O
(	O
A	O
)	O
and	O
melanogenosis-inhibiting	O
peptide	O
(	O
B	O
)	O
;	O
and	O
(	O
L	O
'	O
)	O
is	O
a	O
linker	O
which	O
forms	O
linkage	O
groups	O
with	O
thioglycosylated	O
cysteine	O
(	O
A	O
)	O
and	O
tyrosinase	B-GENE
inhibitor	O
(	O
C	O
)	O
.	O


This	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
B,	O
G,	O
A,	O
E,	O
R1,	O
R2,	O
R3,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein,	O
which	O
are	O
useful	O
as	O
type	B-GENE
I	I-GENE
receptor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitors,	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
in	O
mammals	O
.	O


Disclosed	O
is	O
a	O
cyclohexane	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
,	O
which	O
can	O
bind	O
specifically	O
to	O
an	O
NR1	B-GENE
/	O
NR2B	B-GENE
receptor	O
and	O
therefore	O
can	O
be	O
used	O
as	O
an	O
analgesic	O
agent	O
(	O
a	O
therapeutic	O
agent	O
for	O
pain	O
)	O
:	O
(	O
I	O
)	O
wherein	O
A1	O
represents	O
a	O
(	O
substituted	O
)	O
aromatic	O
cyclic	O
group	O
having	O
-NH-	O
in	O
the	O
ring	O
or	O
the	O
like	O
;	O
A2	O
represents	O
a	O
(	O
substituted	O
)	O
phenyl	O
or	O
the	O
like	O
;	O
R1,	O
R2a,	O
R2b	O
and	O
R2c	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
hydroxy	O
or	O
the	O
like	O
;	O
m	O
represents	O
0	O
or	O
1	O
;	O
X	O
represents	O
-CONH	O
(	O
CR3R4	O
)	O
n-,	O
-NHCO	O
(	O
CR3R4	O
)	O
n-,	O
-A3-	O
(	O
CR3R4	O
)	O
n-	O
or	O
the	O
like	O
;	O
R3	O
and	O
R4	O
independently	O
represent	O
a	O
hydrogen	O
or	O
a	O
(	O
substituted	O
)	O
lower	O
alkyl	O
;	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
4	O
;	O
A3	O
represents	O
a	O
phenylene	O
or	O
the	O
like	O
;	O
and	O
Y	O
represents	O
a	O
single	O
bond,	O
a	O
lower	O
alkylene	O
or	O
the	O
like	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
protein	B-GENE
tyrosine	I-GENE
phosphatases	I-GENE
(	O
PTPases	B-GENE
)	O
and,	O
thus,	O
may	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
PTPase	B-GENE
activity	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
also	O
be	O
employed	O
as	O
inhibitors	O
of	O
other	O
enzymes	O
characterized	O
with	O
a	O
phosphotyrosine	O
binding	O
region	O
such	O
as	O
the	O
SH2	B-GENE
domain	I-GENE
.	O
Accordingly,	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
may	O
be	O
employed	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
insulin	B-GENE
resistance	O
associated	O
with	O
obesity,	O
glucose	O
intolerance,	O
diabetes	O
mellitus,	O
hypertension	O
and	O
ischemic	O
diseases	O
of	O
the	O
large	O
and	O
small	O
blood	O
vessels,	O
conditions	O
that	O
accompany	O
type-2	O
diabetes,	O
including	O
hyperlipidemia,	O
hypertriglyceridemia,	O
atherosclerosis,	O
vascular	O
restenosis,	O
irritable	O
bowel	O
syndrome,	O
pancreatitis,	O
adipose	O
cell	O
tumors	O
and	O
carcinomas	O
such	O
as	O
liposarcoma,	O
dyslipidemia,	O
and	O
other	O
disorders	O
where	O
insulin	B-GENE
resistance	O
is	O
indicated	O
.	O
In	O
addition,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
employed	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
cancer,	O
osteoporosis,	O
neurodegenerative	O
and	O
infectious	O
diseases,	O
and	O
diseases	O
involving	O
inflammation	O
and	O
the	O
immune	O
system	O
.	O


The	O
present	O
disclosure	O
provides	O
compounds	O
that	O
inhibit	O
protein	O
kinases,	O
such	O
as	O
JAK,	O
AxI,	O
or	O
Syk	B-GENE
kinases,	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
to	O
inhibit	O
protein	O
kinase	B-GENE
and	O
treat	O
and	O
/	O
or	O
prevent	O
diseases	O
associated	O
with	O
inappropriate	O
kinase	B-GENE
activity	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
isoxazol-4-yl-oxadiazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen,	O
halogen,	O
aryl,	O
heterocyclyl,	O
heteroaryl,	O
cyano,	O
lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-cycloalkyl,	O
-	O
(	O
CH2	O
)	O
n-N	O
(	O
R	O
)	O
2,	O
-	O
(	O
CH2	O
)	O
n-O-lower	O
alkyl	O
or	O
-	O
(	O
CH2	O
)	O
n-OH	O
;	O
n	O
is	O
0,1	O
or	O
2	O
R	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
R2	O
is	O
cycloalkyl,	O
aryl,	O
heteroaryl	O
or	O
heterocyclyl,	O
which	O
are	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen,	O
cyano,	O
nitro,	O
lower	O
alkyl,	O
lower	O
alkoxy,	O
lower	O
alkoxy	O
substituted	O
by	O
halogen,	O
lower	O
alkyl	O
substituted	O
by	O
halogen,	O
C	O
(	O
O	O
)	O
O-lower	O
alkyl,	O
lower	O
alkylsulfonyl,	O
-NRaRb,	O
-C	O
(	O
O	O
)	O
-NRaRb,	O
-C	O
(	O
O	O
)	O
-heterocyclyl,	O
benzyloxy,	O
heterocyclyl	O
optionally	O
substituted	O
by	O
hydroxy,	O
halogen	O
or	O
lower	O
alkyl,	O
or	O
is	O
heteroaryl	O
optionally	O
substituted	O
by	O
lower	O
alkyl	O
;	O
Ra	O
and	O
Rb	O
are	O
independently	O
hydrogen,	O
lower	O
alkylsulfonyl,	O
-C	O
(	O
O	O
)	O
H,	O
-	O
(	O
CH2	O
)	O
n-N	O
(	O
R	O
)	O
2,	O
-	O
(	O
CH2	O
)	O
n-O-lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-S-lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-S	O
(	O
O	O
)	O
2-lower	O
alkyl,	O
heteroarylsulfonyl,	O
lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-heterocyclyl,	O
optionally	O
substituted	O
by	O
lower	O
alkyl,	O
or	O
is	O
-	O
(	O
CH2	O
)	O
n-cycloalkyl,	O
-	O
(	O
CH2	O
)	O
n-heteroaryl,	O
-	O
(	O
CH2	O
)	O
n-OH,	O
-	O
(	O
CO	O
)	O
-R	O
'	O
,	O
wherein	O
R	O
'	O
is	O
lower	O
alkyl,	O
cycloalkyl	O
or	O
heteroaryl	O
;	O
R3	O
is	O
aryl	O
or	O
heteroaryl,	O
which	O
are	O
optionally	O
substituted	O
by	O
halogen	O
or	O
lower	O
alkyl	O
substituted	O
by	O
halogen	O
;	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O
It	O
has	O
been	O
found	O
that	O
this	O
class	O
of	O
compounds	O
show	O
high	O
affinity	O
and	O
selectivity	O
for	O
GABA	B-GENE
α5	I-GENE
receptor	O
binding	O
sites	O
and	O
might	O
be	O
useful	O
as	O
cognitive	O
enhancer	O
or	O
for	O
the	O
treatment	O
of	O
cognitive	O
disorders	O
like	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
necessities	O
of	O
life,	O
and	O
more	O
particularly	O
to	O
the	O
field	O
of	O
cosmetology	O
and	O
dermatology	O
.	O
It	O
relates	O
more	O
particularly	O
to	O
novel	O
cosmetological	O
and	O
/	O
or	O
dermatological	O
compositions	O
which	O
bring	O
about	O
a	O
very	O
significant	O
increase	O
in	O
the	O
deposition	O
of	O
collagen	B-GENE
type	I-GENE
(III)	I-GENE
in	O
the	O
extracellular	O
matrix,	O
characterized	O
in	O
that	O
they	O
contain,	O
as	O
active	O
ingredient,	O
a	O
combination	O
of	O
a	O
4-hydroxyproline	O
fatty	O
acid	O
amido	O
ester,	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1	O
and	O
R’1	O
are	O
identical	O
or	O
different	O
aliphatic	O
chains	O
containing	O
from	O
10	O
to	O
24	O
carbon	O
atoms	O
that	O
are	O
in	O
a	O
straight	O
line	O
or	O
branched,	O
and	O
of	O
an	O
extract	O
of	O
the	O
epicarp	O
of	O
the	O
Opuntia	O
ficus-indica	O
(	O
Barbary	O
fig	O
)	O
fruit	O
in	O
an	O
inert,	O
nontoxic	O
excipient	O
or	O
carrier	O
suitable	O
for	O
topical	O
use	O
.	O
Use	O
in	O
the	O
form	O
of	O
a	O
fatty	O
cream	O
or	O
gel	O
for	O
the	O
increased	O
production	O
of	O
collagen,	O
without	O
amplifying	O
that	O
of	O
procollagen	B-GENE
(III)	I-GENE
or	O
of	O
enzymes	O
of	O
the	O
metalloproteinase	B-GENE
family	O
.	O


A	O
method	O
of	O
screening	O
reagents	O
for	O
preventing	O
or	O
treating	O
Alzheimer’s	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O
The	O
method	O
comprises	O
:	O
(	O
a	O
)	O
stimulating	O
a	O
receptor	O
and	O
identifying	O
its	O
degree	O
of	O
internalization,	O
wherein	O
the	O
receptor	O
is	O
a	O
G	B-GENE
protein-coupled	I-GENE
receptor	I-GENE
combining	O
with	O
PS1	B-GENE
;	O
(	O
b	O
)	O
stimulating	O
the	O
receptor	O
as	O
step	O
(	O
a	O
)	O
in	O
the	O
presence	O
of	O
a	O
reagent,	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
again	O
;	O
(	O
c	O
)	O
comparing	O
the	O
difference	O
between	O
the	O
internalizing	O
degrees	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
;	O
(	O
d	O
)	O
repeating	O
steps	O
(	O
a	O
)	O
-	O
(	O
c	O
)	O
if	O
the	O
difference	O
is	O
less	O
than	O
the	O
least	O
value	O
.	O
And	O
use	O
of	O
the	O
receptor	O
antagonist	O
for	O
preparing	O
a	O
drug	O
for	O
preventing	O
or	O
treating	O
Alzheimer’s	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O
The	O
receptor	O
antagonist	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
internalization	O
of	O
the	O
G	B-GENE
protein-coupled	I-GENE
receptor	I-GENE
combing	O
with	O
PS1	B-GENE
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
aryl-isoxazol-4-yl-imidazo	O
[	O
1,5-a	O
]	O
pyridine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
is	O
hydrogen,	O
halogen,	O
hydroxy,	O
lower	O
alkyl,	O
benzyloxy	O
or	O
-O-	O
(	O
CH2	O
)	O
-	O
(	O
CO	O
)	O
-5	O
or	O
6	O
membered	O
heteroaryl	O
optionally	O
substituted	O
by	O
aryl	O
and	O
lower	O
alkyl	O
;	O
R2	O
is	O
hydrogen,	O
lower	O
alkyl,	O
or	O
-	O
(	O
CO	O
)	O
-Ra	O
;	O
R3	O
is	O
hydrogen,	O
halogen,	O
cyano,	O
lower	O
alkyl,	O
or	O
-	O
(	O
CO	O
)	O
-Ra	O
;	O
Ra	O
is	O
hydroxy,	O
lower	O
alkoxy,	O
NR	O
'	O
R	O
'	O
'	O
,	O
wherein	O
R	O
'	O
and	O
R	O
'	O
'	O
are	O
each	O
independently	O
hydrogen,	O
cycloalkyl,	O
5	O
or	O
6-membered	O
heterocycloalkyl	O
or	O
lower	O
alkyl	O
optionally	O
substituted	O
by	O
cycloalkyl,	O
cyano,	O
5	O
or	O
6-membered	O
heterocycloalkyl	O
or	O
5	O
or	O
6-membered	O
heteroaryl	O
;	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O
It	O
has	O
been	O
found	O
that	O
this	O
class	O
of	O
compounds	O
show	O
high	O
affinity	O
and	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
α5	I-GENE
receptor	I-GENE
binding	O
sites	O
and	O
might	O
be	O
useful	O
as	O
cognitive	O
enhancer	O
or	O
for	O
the	O
treatment	O
of	O
cognitive	O
disorders	O
like	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
includes	O
the	O
use	O
of	O
at	O
least	O
one	O
agent	O
which	O
induces	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
together	O
with	O
at	O
least	O
one	O
agent	O
which	O
gives	O
rise	O
to	O
inhibition	O
of	O
protein	B-GENE
disulfide	I-GENE
isomerase	I-GENE
(	O
PDI	B-GENE
)	O
or	O
GRP78	B-GENE
function	O
for	O
the	O
preparation	O
of	O
a	O
medicament,	O
more	O
particularly	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cancer,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
agent	O
which	O
induces	O
ER	O
stress	O
together	O
with	O
at	O
least	O
one	O
agent	O
which	O
gives	O
rise	O
to	O
inhibition	O
of	O
PDI	B-GENE
or	O
GRP78	B-GENE
function,	O
and	O
which	O
together	O
provide	O
a	O
therapeutic	O
effect	O
.	O


The	O
invention	O
relates	O
to	O
thiazole	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
Formula	O
(	O
II	O
)	O
and	O
compositions	O
thereof	O
useful	O
for	O
treating	O
diseases	O
mediated	O
by	O
protein	B-GENE
kinase	I-GENE
B	I-GENE
(	O
PKB	B-GENE
)	O
where	O
the	O
variables	O
have	O
the	O
definitions	O
provided	O
herein	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
therapeutic	O
use	O
of	O
such	O
thiazole	O
compounds	O
and	O
compositions	O
thereof	O
in	O
treating	O
disease	O
states	O
associated	O
with	O
abnormal	O
cell	O
growth,	O
cancer,	O
inflammation,	O
and	O
metabolic	O
disorders	O
.	O


It	O
is	O
known	O
that	O
a	O
conventional	O
anticholinergic	O
agent	O
for	O
inhalation	O
administration	O
is	O
antagonistic	O
to	O
muscarinic	B-GENE
receptor	I-GENE
in	O
the	O
airway	O
smooth	O
muscle	O
and	O
further	O
migrates	O
from	O
airway	O
to	O
blood	O
.	O
As	O
a	O
result,	O
it	O
is	O
concerned	O
that	O
there	O
is	O
a	O
possibility	O
that	O
dysuria	O
is	O
aggravated	O
by	O
prostatic	O
hyperplasia	O
via	O
blood	O
.	O
A	O
long-acting	O
inhaled	O
anticholinergic	O
agent	O
with	O
no	O
possibility	O
of	O
such	O
a	O
side	O
effect	O
has	O
been	O
demanded	O
.	O
A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
(	O
wherein	O
all	O
symbols	O
represent	O
the	O
same	O
meaning	O
as	O
in	O
the	O
description	O
)	O
,	O
a	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
exerts	O
an	O
effect	O
in	O
a	O
target	O
region,	O
is	O
inactivated	O
rapidly	O
and	O
is	O
excellent	O
in	O
long-acting	O
property,	O
therefore,	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
a	O
muscarinic	O
receptor-mediated	O
disease	O
with	O
fewer	O
side	O
effects	O
.	O


The	O
invention	O
provides	O
compounds	O
represented	O
by	O
the	O
formula	O
I,	O
each	O
of	O
which	O
compounds	O
may	O
have	O
sphingosine-1	B-GENE
-phosphate	I-GENE
receptor	I-GENE
agonist	O
and	O
or	O
antagonist	O
biological	O
activity	O
:	O
and	O
wherein	O
the	O
variables	O
Y,	O
R4,	O
n,	O
A,	O
X,	O
Z,	O
R1,	O
o,	O
R3,	O
R2	O
and	O
p	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
These	O
compounds	O
are	O
useful	O
for	O
treating	O
a	O
disease	O
or	O
condition	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
glaucoma,	O
dry	O
eye,	O
angiogenesis,	O
cardiovascular	O
conditions	O
and	O
diseases,	O
and	O
wound	O
healing	O
.	O


The	O
invention	O
relates	O
to	O
a	O
new	O
class	O
of	O
compounds	O
with	O
inhibitory	O
action	O
on	O
carnitine	B-GENE
palmitoyl	I-GENE
transferase	I-GENE
(	O
CPT	B-GENE
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
SNC	O
)	O
,	O
derived	O
from	O
trimetazidine	O
and	O
perhexiline,	O
preferentially	O
selective	O
for	O
the	O
hepatic	O
form	O
of	O
CPT1	B-GENE
(	O
CPT1L	B-GENE
)	O
,	O
pharmaceutical	O
compounds	O
which	O
contain	O
at	O
least	O
one	O
new	O
compound	O
according	O
to	O
the	O
invention,	O
and	O
their	O
therapeutic	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
in	O
the	O
prevention	O
of	O
obesity,	O
hyperglycaemia,	O
diabetes	O
and	O
disorders	O
associated	O
with	O
them,	O
such	O
as,	O
for	O
example,	O
diabetic	O
retinopathy,	O
diabetic	O
neuropathy	O
and	O
cardiovascular	O
disorders	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
used	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
heart	O
disorders	O
such	O
as	O
CHF	O
(	O
congestive	O
heart	O
failure	O
)	O
.	O


Provided	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
ocular	O
conditions	O
characterized	O
by	O
the	O
presence	O
of	O
unwanted	O
choroidal	O
neovasculature,	O
for	O
example,	O
neovascular	O
age-related	O
macular	O
degeneration	O
.	O
The	O
selectivity	O
and	O
sensitivity	O
of,	O
for	O
example,	O
a	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
-based	O
approach	O
can	O
be	O
enhanced	O
by	O
combining	O
the	O
PDT	O
with	O
an	O
ansamycin	O
analog	O
or	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
inhibitor,	O
for	O
example,	O
17-allylamino-17-demethoxygeldanamycin	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
diphenylurea	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
chloride	O
channel	O
blockers	O
or	O
BKCa	B-GENE
channel	I-GENE
modulators	O
.	O
In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O


The	O
present	O
invention	O
describes	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
W,	O
X,	O
Y,	O
Z,	O
and	O
Q	O
are	O
defined	O
herein,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
for	O
the	O
prophylaxis,	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
related	O
to	O
thrombin	B-GENE
activity	O
in	O
a	O
mammal	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
a	O
method	O
of	O
modulating	O
β	B-GENE
amyloid	I-GENE
peptide	O
production	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
modulating	O
β	B-GENE
amyloid	I-GENE
peptide	O
production	O
by	O
downregulating	O
cleavage	O
of	O
the	O
β	B-GENE
amyloid	I-GENE
precursor	O
protein	O
to	O
produce	O
the	O
β	B-GENE
amyloid	I-GENE
protein	O
.	O
The	O
method	O
of	O
the	O
present	O
invention	O
is	O
useful,	O
inter	O
alia,	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
conditions	O
characterised	O
by	O
aberrant,	O
unwanted	O
or	O
otherwise	O
inappropriate	O
Aβ	B-GENE
amyloidosis	O
including,	O
but	O
not	O
limited	O
to,	O
Alzheimer	O
'	O
s	O
disease,	O
Down	O
'	O
s	O
Syndrome	O
and	O
cerebral	O
amyloid	O
angiopathy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
G	O
and	O
R	O
to	O
R	O
and	O
R	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
obesity,	O
eating	O
disorders,	O
and	O
sexual	O
dysfunction	O
.	O
The	O
methods	O
comprise	O
administering	O
to	O
a	O
mammalian	O
host	O
suffering	O
from	O
obesity,	O
an	O
eating	O
disorder,	O
or	O
sexual	O
dysfunction	O
an	O
effective	O
dose	O
of	O
a	O
compound	O
of	O
the	O
invention	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
potentiating	O
the	O
effect	O
of	O
an	O
MC4	B-GENE
receptor	I-GENE
agonist	O
in	O
a	O
mammalian	O
host	O
.	O
In	O
some	O
cases	O
the	O
methods	O
comprise	O
administering	O
to	O
the	O
host	O
a	O
compound	O
that	O
lowers	O
the	O
EC50	O
of	O
the	O
agonist	O
.	O
In	O
other	O
cases	O
the	O
methods	O
comprise	O
administering	O
to	O
the	O
host	O
a	O
compound	O
that	O
increases	O
the	O
maximum	O
effect	O
of	O
the	O
agonist	O
.	O


Methods	O
and	O
compositions	O
for	O
modulating	O
blood-neural	O
barrier	O
(	O
BNB	O
)	O
for	O
the	O
treatment	O
of	O
CNS	O
conditions	O
such	O
as	O
edema,	O
and	O
for	O
increased	O
drug	O
delivery	O
efficacy	O
across	O
the	O
BNB	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
improved	O
tPA	B-GENE
treatment	O
of	O
ischemic	O
cerebrovascular	O
and	O
related	O
diseases	O
in	O
combination	O
with	O
antagonism	O
of	O
the	O
PDGF	B-GENE
signaling	I-GENE
pathway	O
.	O
The	O
inventive	O
method	O
and	O
composition	O
is	O
particularly	O
suitable	O
for	O
conjunctive	O
therapy	O
of	O
ischemic	O
stroke	O
using	O
tPA	B-GENE
and	O
an	O
anti-PDGF-C	O
antagonist	O
or	O
an	O
anti-PDGFR-α	O
antagonist	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
functional	O
muscarinic	B-GENE
M1/M4	I-GENE
receptor	I-GENE
agonist	O
such	O
as	O
the	O
functional	O
muscarinic	B-GENE
M1/M4	I-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
in	O
particular	O
sabcomeline	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
for	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
and	O
to	O
combination	O
therapies	O
for	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
which	O
the	O
functional	O
muscarinic	B-GENE
M1/M4	I-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
in	O
particular	O
sabcomeline	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
at	O
least	O
one	O
other	O
neuroprotective	O
agent	O
and	O
/	O
or	O
neuroleptic	O
and	O
/	O
or	O
atypical	O
antipsyhcotic	O
agent	O
are	O
administered	O
adjunctively	O
or	O
simultaneously	O
.	O
The	O
invention	O
provides	O
methods	O
of	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
utilising	O
such	O
therapies	O
and	O
such	O
adjunctive	O
or	O
simultaneous	O
therapeutic	O
combination	O
therapies,	O
therapeutic	O
combinations	O
for	O
use	O
therein	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
com-	O
prising	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
7-dehydrocholesterol	B-GENE
reductase	I-GENE
(	O
DHCR7	B-GENE
)	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
ex-	O
cipient	O
.	O
This	O
pharmaceutical	O
composition	O
is	O
active	O
against	O
various	O
types	O
of	O
cancer,	O
in	O
particular	O
but	O
not	O
limited	O
to	O
adenocarcinomas	O
of	O
the	O
upper	O
gastro-intestinal	O
tract	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
preparing	O
a	O
pharmaceutical	O
composition	O
suitable	O
for	O
the	O
treatment	O
of	O
an	O
adenocarcinoma	O
.	O


Disclosed	O
herein	O
are	O
non-competitive	O
NMDA	B-GENE
receptor	I-GENE
antagonists	O
having	O
chemical	O
structures	O
similar	O
to	O
that	O
of	O
phencyclidine	O
(	O
PCP	O
)	O
.	O
These	O
antagonists	O
contain	O
a	O
polycyclic	O
ring	O
structure	O
in	O
place	O
of	O
the	O
cycloalkyl	O
ring	O
of	O
PCP	O
.	O
The	O
antagonists	O
also	O
differ	O
from	O
PCP	O
in	O
that	O
they	O
include	O
an	O
electron	O
withdrawing	O
group,	O
a	O
hydroxyl	O
group,	O
or	O
an	O
amine	O
group	O
at	O
the	O
para	O
position	O
of	O
the	O
phenyl	O
ring	O
.	O
The	O
antagonists	O
disclosed	O
herein	O
are	O
useful	O
for	O
treating	O
or	O
ameliorating	O
a	O
symptom	O
of	O
ailments	O
associated	O
with	O
over	O
excitation	O
of	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
neurons	O
)	O
that	O
express	O
NMDA	B-GENE
receptors	I-GENE
.	O
Examples	O
of	O
ailments	O
that	O
can	O
be	O
treated	O
and	O
for	O
which	O
symptoms	O
can	O
be	O
ameliorated	O
include	O
epilepsy,	O
neurodegenerative	O
disease	O
(	O
e	O
.	O
g	O
.	O
,	O
Alzheimer	O
'	O
s	O
and	O
Parkinson	O
'	O
s	O
diseases	O
)	O
,	O
drug	O
addiction,	O
neuropathic	O
pain,	O
and	O
neuronal	O
and	O
glutamate-	O
dependent	O
tumors	O
.	O


The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activity	O
and	O
the	O
uPA	B-GENE
/	O
plasmin	O
pathway,	O
in	O
particular	O
by	O
regulating	O
pro-uPA	O
activation	O
by	O
hepsin	O
.	O


The	O
invention	O
pertains	O
to	O
heteroaromatic	O
compounds	O
of	O
the	O
formula	O
I,	O
as	O
defined	O
herein,	O
that	O
serve	O
as	O
effective	O
phosphodiesterase	B-GENE
(	O
PDE	B-GENE
)	O
inhibitors	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
said	O
compounds	O
which	O
are	O
selective	O
inhibitors	O
of	O
PDE10	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
;	O
and	O
the	O
use	O
of	O
said	O
compounds	O
in	O
a	O
method	O
for	O
treating	O
certain	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
or	O
other	O
disorders	O
.	O


Methods	O
for	O
identifying	O
subjects	O
who	O
could	O
benefit	O
therapeutically	O
from	O
administration	O
of	O
a	O
high	O
specificity	O
cytokine	B-GENE
inhibitor	O
are	O
provided	O
.	O
Subjects	O
that	O
are	O
identified	O
include	O
those	O
that	O
are	O
eligible,	O
based	O
on	O
pre-determined	O
criteria,	O
for	O
a	O
spinal	O
device	O
or	O
fusion	O
procedure,	O
such	O
as	O
the	O
implantation	O
of	O
a	O
nucleus	O
replacement	O
device,	O
an	O
annular	O
repair	O
device,	O
or	O
a	O
fusion	O
device	O
.	O
Methods	O
of	O
preventing	O
such	O
procedures	O
or	O
improving	O
the	O
outcome	O
of	O
such	O
procedures	O
are	O
also	O
provided,	O
and	O
include	O
administering	O
a	O
TAT	O
to	O
the	O
subject	O
by	O
any	O
route	O
or	O
regimen	O
of	O
administration,	O
including	O
the	O
regimens	O
described	O
herein	O
.	O


The	O
use	O
of	O
substituted	O
amides	O
for	O
modulating	O
the	O
activity	O
of	O
11β-hydroxysteroid	O
dehydrogenase	O
type	I-GENE
1	I-GENE
(	O
11βHSD1	B-GENE
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutical	O
compositions,	O
are	O
described	O
.	O
Also	O
a	O
novel	O
class	O
of	O
substituted	O
amides,	O
of	O
the	O
general	O
formula	O
I	O
.	O
Their	O
use	O
in	O
therapy,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
.	O
The	O
present	O
compounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSDI	B-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	O
is	O
desirable	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
breast	O
cancer	O
which	O
comprises	O
administration	O
of	O
fulvestrant	O
and	O
simultaneous,	O
separate	O
or	O
sequential	O
treatment	O
with	O
an	O
aromatase	B-GENE
inhibitor,	O
for	O
example	O
anastrozole,	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
wherein	O
the	O
patient	O
has	O
hormone	O
receptor	O
positive	O
early	O
breast	O
cancer	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
method	O
of	O
enhancing	O
the	O
numbers	O
and	O
activity	O
of	O
naturally	O
occurring	O
CD4+CD25+	O
regulatory	O
T	O
cells	O
using	O
statins,	O
e	O
.	O
g	O
.	O
atorvastatin	O
.	O
Treatment	O
with	O
statins	O
increases	O
the	O
number	O
of	O
Tregs	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
concomitant	O
upregulation	O
of	O
their	O
master	O
transcriptional	O
activator	O
foxp3	B-GENE
.	O
The	O
invention	O
further	O
concerns	O
a	O
method	O
of	O
treatment	O
of	O
diseases	O
which	O
are	O
characterized	O
by	O
an	O
impaired	O
function	O
of	O
Tregs	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
the	O
formula	O
(	O
1	O
)	O
or	O
salts,	O
solvates	O
or	O
tautomers	O
thereof	O
;	O
wherein	O
Y1	O
and	O
Y2	O
are	O
both	O
N+-O-	O
or	O
one	O
of	O
Y1	O
and	O
Y2	O
is	O
N	O
and	O
the	O
other	O
is	O
N+-O-	O
;	O
G	O
is	O
CH2,	O
O,	O
NH,	O
NHCO	O
or	O
CONH	O
;	O
A	O
is	O
a	O
group	O
(	O
CH2	O
)	O
n	O
where	O
n	O
is	O
1	O
to	O
4	O
provided	O
that	O
when	O
G	O
is	O
O	O
or	O
NH,	O
n	O
is	O
at	O
least	O
2	O
;	O
Q	O
is	O
N	O
or	O
N+-O-	O
;	O
V2	O
is	O
nitrogen	O
or	O
a	O
group	O
CR5	O
;	O
V3	O
is	O
nitrogen	O
or	O
a	O
group	O
CR5	O
;	O
V4	O
is	O
nitrogen	O
or	O
CH	O
;	O
provided	O
that	O
no	O
more	O
than	O
two	O
of	O
V2,	O
V3	O
and	O
V4	O
are	O
nitrogen	O
;	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
is	O
hydrogen	O
or	O
a	O
substituent	O
R6	O
;	O
R3	O
and	O
R4	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
is	O
hydrogen	O
or	O
C1-4	O
alkyl	O
;	O
or	O
R3	O
and	O
R4	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
azetidine,	O
pyrrolidine,	O
piperidine,	O
piperazine,	O
N-methylpiperazine	O
or	O
morpholine	O
group	O
;	O
provided	O
that	O
when	O
Q	O
is	O
N+-O-,	O
then	O
R3	O
and	O
R4	O
are	O
both	O
other	O
than	O
hydrogen	O
;	O
R5	O
is	O
hydrogen	O
or	O
a	O
substituent	O
R6	O
;	O
and	O
R6	O
is	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
are	O
reduced	O
under	O
hypoxic	O
conditions	O
such	O
as	O
those	O
found	O
in	O
solid	O
tumour	O
cells	O
to	O
give	O
compounds	O
that	O
inhibit	O
or	O
modulate	O
Chk-1	B-GENE
kinase	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
and	O
formula	O
II,	O
their	O
preparation,	O
a	O
their	O
use	O
as	O
pharmaceutically	O
active	O
immunosuppressive	O
agents	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disorders,	O
organ	O
transplant	O
rejection,	O
disorders	O
associated	O
with	O
an	O
activated	O
immune	O
system,	O
as	O
well	O
as	O
other	O
disorders	O
modulated	O
by	O
lymphopenia	O
or	O
SlP	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
provides	O
an	O
antiretroviral	O
solid	O
oral	O
composition	O
comprising	O
one	O
or	O
more	O
antiretroviral	O
drugs,	O
for	O
example	O
protease	B-GENE
inhibitors	O
such	O
as	O
lopinavir,	O
ritonavir	O
or	O
a	O
combination	O
thereof	O
with	O
one	O
or	O
more	O
excipients	O
.	O
The	O
invention	O
provides	O
a	O
composition	O
which	O
is	O
smaller	O
for	O
a	O
given	O
amount	O
of	O
said	O
active	O
substance	O
and	O
possesses	O
taste	O
masking	O
property	O
and	O
a	O
process	O
for	O
preparing	O
the	O
composition	O
.	O
The	O
present	O
invention	O
also	O
provides	O
an	O
antiretroviral	O
solid	O
oral	O
composition	O
comprising	O
one	O
or	O
more	O
antiretroviral	O
drugs,	O
for	O
example	O
protease	B-GENE
inhibitors	O
such	O
as	O
lopinavir,	O
ritonavir	O
or	O
a	O
combination	O
thereof	O
with	O
at	O
least	O
one	O
water	O
insoluble	O
polymer,	O
wherein	O
the	O
ratio	O
of	O
drug	O
to	O
polymer	O
in	O
the	O
composition	O
ranges	O
from	O
about	O
1	O
:	O
1	O
to	O
about	O
1	O
:	O
6,	O
and	O
a	O
process	O
for	O
preparing	O
the	O
composition	O
.	O


A	O
composition	O
for	O
treating,	O
controlling,	O
reducing,	O
ameliorating,	O
or	O
alleviating	O
infections	O
and	O
their	O
inflammatory	O
sequelae	O
comprises	O
a	O
dissociated	O
glucocorticoid	B-GENE
receptor	I-GENE
agonist	O
(	O
'	O
DIGRA	O
'	O
)	O
and	O
an	O
anti-infective	O
agent,	O
such	O
as	O
an	O
antibacterial,	O
antiviral,	O
antifungal,	O
antiprotozoal	O
agent,	O
or	O
a	O
combination	O
thereof	O
.	O
The	O
composition	O
can	O
be	O
formulated	O
for	O
topical	O
application,	O
injection,	O
or	O
implantation	O
.	O


Methods	O
and	O
compositions	O
for	O
promoting	O
coupling	O
between	O
bone	O
formation	O
and	O
bone	O
resorption	O
are	O
provided	O
.	O
The	O
method	O
related	O
to	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
rho	O
inhibitor,	O
a	O
Transforming	B-GENE
Growth	I-GENE
Factor	I-GENE
ß	I-GENE
receptor	I-GENE
I	I-GENE
(	O
TßRI	B-GENE
)	O
inhibitor	O
or	O
a	O
combination	O
thereof	O
to	O
a	O
subject	O
.	O
The	O
methods	O
and	O
compositions	O
are	O
useful,	O
for	O
example,	O
in	O
a	O
subject	O
with	O
a	O
disorder	O
linked	O
to	O
an	O
imbalance	O
between	O
bone	O
formation	O
and	O
bone	O
resorption	O
.	O


The	O
invention	O
relates	O
to	O
an	O
inhibitor	O
of	O
pulmonary	O
emphysematous	O
lesions	O
containing	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
having	O
an	O
action	O
of	O
promoting	O
the	O
degradation	O
of	O
CSPG,	O
an	O
action	O
of	O
inhibiting	O
the	O
synthesis	O
of	O
CSPG,	O
or	O
an	O
action	O
of	O
inhibiting	O
the	O
sulfation	O
of	O
CSPG,	O
for	O
example,	O
chondroitinase	B-GENE
ABC,	O
a	O
C6ST	O
antisense	O
agent,	O
a	O
GalNAc	O
antisense	O
agent	O
or	O
the	O
like,	O
an	O
inhibitor	O
of	O
emphysematous	O
lesions	O
suitable	O
for	O
treating	O
or	O
preventing	O
COPD,	O
a	O
therapeutic	O
or	O
preventive	O
agent	O
for	O
COPD,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
emphysematous	O
lesions	O
and	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
COPD	O
.	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below,	O
which	O
selectively	O
accelerates	O
biosynthesis	O
of	O
a	O
proteoglycan,	O
particularly	O
a	O
chondroitin	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
or	O
a	O
heparan	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
.	O
Also	O
disclosed	O
is	O
a	O
pharmaceutical	O
product	O
containing	O
such	O
a	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O
(	O
I	O
)	O
(	O
In	O
the	O
formula,	O
R	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
optionally	O
substituted	O
alkyl,	O
an	O
optionally	O
substituted	O
aryl,	O
an	O
optionally	O
substituted	O
heteroaryl,	O
or	O
a	O
peptide	O
residue	O
composed	O
of	O
a	O
natural	O
or	O
non-natural	O
amino	O
acid	O
;	O
and	O
X	O
and	O
Y	O
represent	O
a	O
halogen	O
atom,	O
a	O
hydroxy	O
group	O
or	O
an	O
alkoxy	O
group	O
.	O
In	O
this	O
connection,	O
at	O
least	O
one	O
of	O
X	O
and	O
Y	O
represents	O
a	O
hydroxy	O
group,	O
but	O
both	O
X	O
and	O
Y	O
are	O
not	O
hydroxy	O
groups	O
at	O
the	O
same	O
time	O
.	O
)	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
to	O
intermediates	O
for	O
their	O
preparation,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
as	O
modulators	O
of	O
the	O
dopamine	B-GENE
D3	I-GENE
receptor,	O
particularly	O
as	O
psychotherapeutic	O
agents	O
.	O


The	O
inventor	O
found	O
for	O
the	O
first	O
time	O
that	O
renal	O
fibrosis	O
can	O
be	O
efficiently	O
inhibited	O
by	O
inhibiting	O
the	O
formation	O
or	O
accumulation	O
of	O
chondroitin	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
.	O
That	O
is,	O
by	O
administering	O
chondroitinase	B-GENE
ABC	I-GENE
which	O
is	O
an	O
enzyme	O
degrading	O
chondroitin	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
and	O
inhibiting	O
the	O
expression	O
of	O
C4ST-1,	O
C6ST-1	B-GENE
or	O
C6ST-2,	O
which	O
is	O
a	O
chondroitin	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
sulfotransferase,	O
using	O
siRNA,	O
fibrosis	O
in	O
renal	O
tissue	O
could	O
be	O
inhibited	O
.	O
A	O
compound	O
such	O
as	O
a	O
nucleic	O
acid	O
to	O
be	O
used	O
for	O
such	O
an	O
siRNA	O
can	O
be	O
used	O
as	O
an	O
agent	O
for	O
inhibiting	O
renal	O
fibrosis	O
.	O
Further,	O
this	O
makes	O
it	O
possible	O
to	O
find	O
the	O
agent	O
for	O
inhibiting	O
renal	O
fibrosis	O
by	O
screening	O
a	O
compound	O
inhibiting	O
the	O
formation	O
or	O
accumulation	O
of	O
chondroitin	B-GENE
sulfate	I-GENE
proteoglycan	I-GENE
.	O


We	O
provide	O
a	O
composition	O
comprising	O
a	O
first	O
agent	O
which	O
is	O
an	O
antagonist	O
of	O
mTOR	B-GENE
activity,	O
together	O
with	O
a	O
second	O
agent	O
comprising	O
an	O
angiogenesis	O
inhibitor	O
.	O
The	O
first	O
agent	O
may	O
comprise	O
rapamycin,	O
and	O
the	O
second	O
agent	O
may	O
comprise	O
an	O
inhibitor	O
of	O
VEGF	B-GENE
activity	O
such	O
as	O
Bevacizumab	O
(	O
Avastin	O
)	O
.	O
Such	O
a	O
composition	O
may	O
be	O
used	O
for	O
preventing	O
the	O
growth	O
or	O
proliferation,	O
or	O
both,	O
of	O
a	O
cell	O
or	O
tissue	O
.	O
The	O
composition	O
may	O
also	O
be	O
used	O
to	O
treat	O
or	O
prevent	O
cancer,	O
such	O
as	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
imidazopyridine	O
and	O
imidazopyrimidine	O
derivatives	O
that	O
act	O
as	O
cannabinoid	B-GENE
receptor	I-GENE
ligands,	O
e	O
.	O
g	O
.	O
,	O
CB2	B-GENE
ligands	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds,	O
compositions	O
containing	O
the	O
compounds,	O
and	O
to	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
.	O


Provided	O
herein	O
is	O
a	O
novel	O
treatment	O
for	O
HIV-associated	O
adipose	O
redistribution	O
syndrome	O
(	O
HARS	O
)	O
comprising	O
combination	O
of	O
agents,	O
said	O
combination	O
of	O
agents	O
comprising	O
a	O
first	O
agent	O
which	O
binds	O
to	O
and	O
initiates	O
signaling	O
of	O
the	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
(hGH)	I-GENE
receptor	I-GENE
or	O
a	O
substance	O
which	O
stimulates	O
release	O
or	O
potentiates	O
the	O
activity	O
of	O
endogenous	O
hGH	B-GENE
;	O
and	O
a	O
second	O
agent	O
which	O
increases	O
insulin	B-GENE
sensitivity	O
in	O
said	O
patient	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
2-alkyl-6-	O
(	O
pyrazolopyridin-	O
4-yl	O
)	O
pyridazinone	O
derivative	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
having	O
a	O
phosphodiesterase-inhibiting	O
activity	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
2-alkyl-6-	O
(	O
pyrazolopyridin-4-yl	O
)	O
pyridazinone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
(	O
a	O
specific	O
example	O
:	O
6-	O
(	O
7-methoxy-2-	O
trifluoromethylpyrazolo	O
[	O
1,5-a	O
]	O
pyridin-4-yl	O
)	O
-5-methyl-2-	O
[	O
3-	O
[	O
4-	O
(	O
4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-	O
yl	O
)	O
phenoxy	O
]	O
propyl	O
]	O
-4,5-dihydro-2H-	O
pyridazin-3-one	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
modulators	O
of	O
IRAK	B-GENE
kinases	O
of	O
formula	O
(	O
I	O
)	O
and	O
provides	O
compositions	O
comprising	O
such	O
modulators,	O
as	O
well	O
as	O
methods	O
therewith	O
for	O
treating	O
IRAK-	O
mediated	O
or	O
IRAK	B-GENE
-associated	O
conditions	O
or	O
diseases	O
.	O


Disclosed	O
herein	O
is	O
the	O
use	O
of	O
LXR	B-GENE
agonists	O
for	O
preventing	O
and	O
treating	O
osteoarthritis	O
as	O
well	O
as	O
methods	O
of	O
detecting	O
an	O
osteoarthritic	O
phenotype	O
in	O
a	O
subject	O
and	O
methods	O
of	O
identifying	O
an	O
LXR	B-GENE
ligand	O
capable	O
of	O
reducing	O
an	O
osteoarthritic	O
effect	O
in	O
cartilage	O
.	O


This	O
invention	O
provides	O
novel	O
methods	O
of	O
treatment	O
to	O
ameliorate	O
or	O
prevent	O
cognitive	O
disorder	O
/	O
dysfunction	O
in	O
pre-	O
or	O
asymptomatic	O
subject	O
having	O
one	O
or	O
more	O
mutations	O
in	O
the	O
Huntington	B-GENE
gene	O
.	O
The	O
methods	O
involve	O
increasing	O
the	O
expression	O
or	O
activity	O
of	O
the	O
neurotrophin	O
BDNS	O
in	O
the	O
brain	O
of	O
said	O
subject	O
.	O


Compounds	O
are	O
provided	O
which	O
are	O
useful	O
as	O
platelet	O
ADP	B-GENE
receptor	I-GENE
inhibitors,	O
for	O
treating	O
thrombosis	O
and	O
for	O
reducing	O
the	O
likelihood	O
and	O
/	O
or	O
severity	O
of	O
a	O
secondary	O
ischemic	O
event	O
in	O
a	O
patient	O
.	O


This	O
invention	O
relates	O
to	O
the	O
field	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinases	I-GENE
and	O
inhibitors	O
thereof	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
inhibitors	O
of	O
JAK-2,	O
pharmaceutical	O
compositions	O
of	O
the	O
compounds	O
for	O
inhibiting	O
JAK-2,	O
methods	O
of	O
inhibiting	O
JAK-2	B-GENE
in	O
a	O
cell,	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
JAK-2	B-GENE
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
according	O
to	O
the	O
invention	O
.	O
The	O
also	O
comprises	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
that	O
involves	O
JAK-2	B-GENE
comprising	O
administering	O
to	O
a	O
patient	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
according	O
to	O
the	O
invention	O
.	O


Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
energy	O
metabolism	O
disorders	O
by	O
administering	O
a	O
composition	O
containing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
fatty	B-GENE
acid	I-GENE
amide	I-GENE
hydrolase	I-GENE
inhibitor	O
.	O
The	O
composition	O
can	O
also	O
be	O
administered	O
to	O
reduce	O
body	O
fat,	O
body	O
weight,	O
or	O
caloric	O
intake	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
EGFR	B-GENE
kinase	I-GENE
inhibitor	O
and	O
at	O
least	O
one	O
additional	O
active	O
compound	O
selected	O
from	O
beta-2	O
mimetics,	O
steroids,	O
PDE-IV	B-GENE
inhibitors,	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
inhibitors,	O
NK1	B-GENE
antagonists,	O
anticholinergics	O
and	O
endothelin	O
antagonists,	O
processes	O
for	O
preparing	O
the	O
compositions	O
and	O
the	O
use	O
thereof	O
as	O
medicament	O
in	O
the	O
treatment	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints,	O
as	O
well	O
as	O
inflammatory	O
diseases	O
of	O
the	O
joints,	O
the	O
skin	O
or	O
the	O
eyes	O
.	O


Methods	O
for	O
treating	O
delirium,	O
including	O
postoperative	O
delirium,	O
sepsis-associated	O
delirium,	O
and	O
drug	O
or	O
alcohol	O
withdrawal-associated	O
delirium	O
with	O
ibudilast	O
are	O
disclosed	O
.	O
Treatment	O
may	O
further	O
comprise	O
administration	O
of	O
one	O
or	O
more	O
other	O
agents,	O
such	O
as	O
analgesics,	O
anti-inflammatory	O
and	O
central	B-GENE
nervous	I-GENE
system	I-GENE
(CNS)-partitioning	I-GENE
phosphodiesterase	I-GENE
inhibitors,	O
antidepressants,	O
neuroleptics,	O
benzodiazepines,	O
and	O
procholinergic	O
agents	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
fragile	O
X	O
syndrome	O
and	O
/	O
or	O
other	O
neurodevelopmental	O
disorders	O
by	O
administering	O
small	O
molecule	O
p21	B-GENE
-activated	I-GENE
kinase	I-GENE
(	O
PAK	B-GENE
)	O
inhibitors	O
to	O
a	O
patient	O
suffering	O
from,	O
susceptible	O
to,	O
and	O
/	O
or	O
exhibiting	O
one	O
or	O
more	O
symptoms	O
of	O
FXS	O
and	O
/	O
or	O
other	O
neurodevelopmental	O
disorders	O
.	O
The	O
present	O
invention	O
provides	O
specific	O
small	O
molecule	O
PAK	B-GENE
inhibitors	O
and	O
pharmaceutical	O
compositions	O
comprising	O
small	O
molecule	O
PAK	B-GENE
inhibitors	O
.	O


The	O
presently	O
disclosed	O
subject	O
matter	O
is	O
directed	O
to	O
metallo-oxidoreductase	B-GENE
inhibitors	O
having	O
metal	O
binding	O
moities	O
linked	O
to	O
a	O
targeting	O
moiety	O
through	O
a	O
linking	O
group	O
or	O
a	O
direct	O
bond,	O
methods	O
for	O
screening	O
for	O
metallo-oxidoreductase	B-GENE
inhibitors,	O
and	O
methods	O
of	O
treating	O
an	O
oxidoreductase	B-GENE
related	O
disorder	O
by	O
administering	O
a	O
metallo-	B-GENE
oxidoreductase	B-GENE
inhibitor	O
to	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
thereof	O
.	O


5-	O
[	O
(	O
2R	O
)	O
-	O
[	O
2-	O
[	O
2-	O
[	O
2-	O
(	O
2,2,2-trifluoroethoxy	O
)	O
phenoxy	O
]	O
ethyl	O
]	O
amino	O
]	O
propyl	O
]	O
-2-methoxybenzenesulfonamide,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound,	O
and	O
the	O
synthesis	O
method	O
thereof	O
.	O
The	O
compound	O
has	O
strong	O
antagonism	O
toward	O
α1-adrenoceptor	B-GENE
and	O
has	O
high	O
selectivity	O
toward	O
smooth	O
muscle	O
of	O
urethra	O
.	O


The	O
present	O
invention	O
relates	O
to	O
controlled-release	O
beads	O
comprising	O
diquinoline-	O
substituted	O
piperazine-piperidine	O
compounds,	O
such	O
as	O
5-fluoro-8-	O
{	O
4-	O
[	O
4-	O
[	O
(	O
6-methoxyquinolin-	O
8-yl	O
)	O
piperazin-l-yl	O
]	O
piperidin-l-yl	O
}	O
quinoline,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
to	O
multiple	O
particulate	O
formulations	O
comprising	O
such	O
beads	O
;	O
to	O
methods	O
of	O
preparing	O
such	O
beads	O
;	O
and	O
to	O
methods	O
of	O
treating	O
5-HTiA-related	O
disorders	O
using	O
such	O
beads	O
and	O
/	O
or	O
multiple	O
particulate	O
formulations	O
.	O


A	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
obesity	O
or	O
related	O
eating	O
disorders	O
and	O
/	O
or	O
reducing	O
food	O
consumption,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
MTP	B-GENE
inhibitor	O
in	O
conjunction	O
with	O
an	O
increased-fat	O
diet	O
.	O


The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
neuronal	B-GENE
nicotinic	I-GENE
receptor	I-GENE
ligand	O
and	O
an	O
α4β2	O
positive	O
allosteric	O
modulator,	O
a	O
method	O
of	O
using	O
the	O
same,	O
and	O
a	O
related	O
article	O
of	O
manufacture	O
.	O


Use	O
of	O
lactoferrin	O
or	O
metal	O
ion	O
lactoferrin,	O
preferably	O
iron	O
lactoferrin,	O
preferably	O
bovine	O
lactoferrin,	O
preferably	O
iron	O
bovine	O
lactoferrin,	O
or	O
a	O
metal	O
ion	O
functional	O
variant	O
or	O
functional	O
fragment	O
thereof	O
and	O
at	O
least	O
one	O
anti-tumour	O
food	O
factor	O
selected	O
from	O
soy	O
protein	O
and	O
vitamin	O
D	O
inhibits	O
tumour	O
formation	O
or	O
growth,	O
maintains	O
or	O
improves	O
one	O
or	O
both	O
of	O
the	O
white	O
blood	O
cell	O
count	O
and	O
red	O
blood	O
cell	O
count,	O
stimulates	O
the	O
immune	O
system,	O
and	O
/	O
or	O
treats	O
or	O
prevents	O
cancer	O
.	O
Dietary	O
(	O
foods	O
or	O
food	O
supplements	O
)	O
,	O
nutraceutical	O
or	O
pharmaceutical	O
compositions	O
may	O
be	O
used	O
.	O


Compounds	O
active	O
on	O
protein	O
kinases	B-GENE
are	O
described,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
protein	O
kinases	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
increased	O
intraocular	O
pressure	O
in	O
a	O
subject	O
by	O
administering	O
a	O
protein	B-GENE
kinase	I-GENE
C-delta	I-GENE
(	O
PKCδ	B-GENE
)	O
inhibitor	O
.	O
In	O
further	O
embodiments,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
glaucoma	O
by	O
administering	O
a	O
PKCδ	B-GENE
inhibitor	O
.	O


The	O
present	O
dislcosure	O
provides	O
amide-based,	O
non-nucleoside	O
compounds	O
having	O
an	O
inhibitory	O
activity	O
against	O
endogenous	O
polymerases,	O
such	O
as	O
polymerase	B-GENE
alpha	I-GENE
and	O
polymerase	B-GENE
gamma	I-GENE
.	O
This	O
disclosure	O
further	O
provides	O
uses	O
of	O
treating	O
hyperproliferative	O
diseases	O
or	O
disorders,	O
such	O
as	O
benign	O
or	O
malignant	O
neoplasms,	O
and	O
more	O
specifically	O
cancers	O
that	O
are	O
sensitive	O
to	O
inhibition	O
of	O
polymerase	B-GENE
alpha	I-GENE
and	O
polymerase	B-GENE
gamma	I-GENE
.	O


N3-Heteroaryl	O
substituted	O
triazoles	O
and	O
N5-heteroaryl	O
substituted	O
triazoles	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
are	O
disclosed	O
as	O
being	O
useful	O
in	O
inhibiting	O
the	O
activity	O
of	O
the	O
receptor	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinase	I-GENE
Axl	I-GENE
.	O
Methods	O
of	O
using	O
the	O
compounds	O
in	O
treating	O
diseases	O
or	O
conditions	O
associated	O
with	O
Axl	O
activity	O
are	O
also	O
disclosed	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
semicarbazide	O
and	O
carbonylhydrazide	O
derivatives	O
that	O
are	O
found	O
to	O
be	O
potent	O
modulators	O
of	O
potassium	B-GENE
channels	I-GENE
and,	O
as	O
such,	O
they	O
are	O
valuable	O
candidates	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
which	O
are	O
responsive	O
to	O
modulation	O
of	O
potassium	B-GENE
channels	I-GENE
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
A	O
:	O
(	O
A	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
hydrate,	O
or	O
prodrug	O
thereof	O
.	O
The	O
compounds	O
of	O
Formula	O
A	O
are	O
TGR5	B-GENE
modulators	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases,	O
including	O
obesity,	O
insulin	B-GENE
sensitivity,	O
inflammation,	O
cholestasis,	O
and	O
bile	O
desaturation	O
.	O


The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R8	O
and	O
R11	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description,	O
the	O
salts	O
thereof,	O
the	O
N-oxides	O
of	O
the	O
compounds	O
and	O
the	O
salts	O
thereof,	O
and	O
the	O
stereoisomers	O
of	O
the	O
compounds,	O
the	O
salts,	O
the	O
N-oxides	O
of	O
the	O
compounds	O
and	O
the	O
N-oxides	O
of	O
the	O
salts	O
thereof	O
are	O
effective	O
inhibitors	O
of	O
the	O
type	B-GENE
5	I-GENE
phosphodiesterase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
phenylmorpholine	O
and	O
phenyl	O
thiomorpholine	O
compounds	O
useful	O
as	O
alpha2C	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonists,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,-	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
diseases	O
associated	O
with	O
the	O
alpha2C	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonists,	O
such	O
as	O
allergic	O
rhinitis,	O
congestion,	O
pain,	O
diarrhea,	O
glaucoma,	O
congestive	O
heart	O
failure,	O
cardiac	O
ischemia,	O
manic	O
disorders,	O
depression,	O
anxiety	O
and	O
schizophrenia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
an	O
amyloidosis	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
characterized	O
in	O
that	O
it	O
comprises	O
administering	O
an	O
agonist	O
of	O
the	O
P	O
/	O
Q	O
type	O
voltage-gated	B-GENE
presynaptic	I-GENE
calcium	I-GENE
channel	I-GENE
to	O
said	O
subject	O
.	O


The	O
present	O
invention	O
relates	O
to	O
breast	O
cancer	O
and	O
methods	O
for	O
identifying	O
therapeutics	O
and	O
diagnosis	O
.	O
In	O
general,	O
methods	O
for	O
identifying	O
therapeutic	O
agents	O
directed	O
to	O
calcium	O
flow	O
are	O
disclosed	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
diagnosis	O
of	O
breast	O
cancer	O
and	O
/	O
or	O
a	O
predisposition	O
to	O
breast	O
cancer	O
and	O
methods	O
of	O
treatment	O
of	O
breast	O
cancer	O
.	O
The	O
methods	O
include	O
identifying	O
therapeutic	O
agents	O
which	O
modulate	O
a	O
CRAC	B-GENE
channel	O
and	O
/	O
or	O
a	O
glycoprotein	O
activator	O
of	O
a	O
CRAC	B-GENE
channel	O
.	O
Also	O
provided	O
are	O
diagnostic	O
methods	O
that	O
ultilise	O
a	O
CRAC	B-GENE
channel	O
and	O
/	O
or	O
a	O
glycoprotein	O
activator	O
of	O
a	O
CRAC	B-GENE
channel	O
.	O


Bridged	O
phenanthridine	O
compounds	O
having	O
the	O
structure	O
of	O
formula	O
I	O
or	O
of	O
formula	O
II	O
are	O
provided	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
cannabinoid	B-GENE
receptor	I-GENE
ligands	O
and	O
can	O
be	O
prepared	O
as	O
pharmaceutical	O
compositions	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
variety	O
of	O
diseases,	O
disorders	O
and	O
conditions	O
including	O
inflammatory	O
pain,	O
visceral	O
pain,	O
postoperative	O
pain,	O
cancer	O
pain,	O
neuropathic	O
pain,	O
musculoskeletal	O
pain,	O
dysmenorrhea,	O
menstrual	O
pain,	O
migraine,	O
headache	O
as	O
well	O
as	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis,	O
systemic	O
lupus	O
erythematosus,	O
Crohn	O
'	O
s	O
disease,	O
psoriasis,	O
eczema,	O
multiple	O
sclerosis,	O
diabetes	O
and	O
thyroiditis	O
.	O
The	O
compounds	O
can	O
also	O
be	O
used	O
in	O
the	O
treatment	O
of	O
skin	O
disorders,	O
lung	O
disorders,	O
ophthalmic	O
disorders,	O
gastrointestinal	O
disorders,	O
cardiovascular	O
disorders,	O
as	O
well	O
as	O
neurodegenerative,	O
neuroinflammatory	O
and	O
certain	O
psychiatric	O
disorders	O
.	O


The	O
present	O
disclosure	O
provides	O
meroduplex	O
ribonucleic	O
acid	O
molecules	O
(	O
mdRNA	O
)	O
capable	O
of	O
decreasing	O
or	O
silencing	O
BCR-ABL	O
gene	O
expression	O
.	O
An	O
mdRNA	O
of	O
this	O
disclosure	O
comprises	O
at	O
least	O
three	O
strands	O
that	O
combine	O
to	O
form	O
at	O
least	O
two	O
non-overlapping	O
double-stranded	O
regions	O
separated	O
by	O
a	O
nick	O
or	O
gap	O
wherein	O
one	O
strand	O
is	O
complementary	O
to	O
a	O
BCR-ABL	O
mRNA	O
.	O
In	O
addition,	O
the	O
meroduplex	O
may	O
have	O
at	O
least	O
one	O
uridine	O
substituted	O
with	O
a	O
5-methyluridine,	O
a	O
nucleoside	O
replaced	O
with	O
a	O
locked	O
nucleic	O
acid,	O
or	O
optionally	O
other	O
modifications,	O
and	O
any	O
combination	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
decreasing	O
expression	O
of	O
a	O
BCR-ABL	O
gene	O
in	O
a	O
cell	O
or	O
in	O
a	O
subject	O
to	O
treat	O
a	O
BCR-ABL-related	O
disease	O
.	O


A	O
CPT	B-GENE
inhibitor	O
compound	O
is	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
A	O
pharmaceutical	O
composition	O
comprises	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
A	O
method	O
of	O
treating	O
a	O
subject	O
having	O
cancer	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
PLK1	B-GENE
inhibitor	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O
Useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
cell	O
proliferative	O
disorders,	O
particularly	O
oncological	O
disorders	O
.	O
These	O
compounds	O
and	O
formulations	O
containing	O
such	O
compounds	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
solid	O
tumors,	O
such	O
as,	O
for	O
example,	O
breast,	O
colon,	O
lung	O
and	O
prostate	O
tumors	O
and	O
other	O
oncological	O
diseases	O
such	O
as	O
non-Hodgkin	O
'	O
s	O
lymphomas	O
.	O


Described	O
herein	O
arenew	O
retrosteroidal	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
representing	O
progesterone	B-GENE
receptor	I-GENE
modulators,	O
and	O
their	O
production,	O
and	O
pharmaceutical	O
preparations	O
containing	O
these	O
compounds	O
.	O
Saidcompounds	O
are	O
preferably	O
used	O
for	O
the	O
treatment	O
of	O
benign	O
gynecological	O
disorders	O
such	O
as	O
endometriosis	O
and	O
uterine	O
fibroids,	O
as	O
well	O
as	O
for	O
female	O
birth	O
control	O
and	O
for	O
HRT	O
.	O


This	O
invention	O
describes	O
compounds	O
and	O
pharmaceutical	O
compositions	O
useful	O
as	O
ubiquitin	O
agent	O
inhibitors,	O
particularly	O
ubiquitin	B-GENE
ligase	I-GENE
inhibitors	O
.	O
The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
the	O
biochemical	O
pathways	O
of	O
organisms	O
in	O
which	O
ubiquitination	O
is	O
involved,	O
such	O
as	O
signal	O
transduction	O
pathways	O
.	O
The	O
invention	O
also	O
comprises	O
the	O
use	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
for	O
the	O
treatment	O
of	O
conditions	O
that	O
require	O
inhibition	O
of	O
ubiquitination	O
.	O
Furthermore,	O
the	O
invention	O
comprises	O
methods	O
of	O
inhibiting	O
ubiquitination	O
in	O
a	O
cell	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
ubiquitination	O
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
invention	O
.	O
Particularly,	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful	O
to	O
inhibit	O
the	O
ubiquitin	B-GENE
ligase	I-GENE
activity	O
of	O
TRAF6	B-GENE
.	O


Novel	O
heterocyclic	O
compounds	O
of	O
formula	O
I	O
:	O
A-B-D	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
:	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
moiety	O
having	O
general	O
Formula	O
II	O
and	O
a	O
moiety	O
having	O
general	O
Formula	O
III	O
:	O
Formula	O
II	O
Formula	O
III	O
B	O
is	O
a	O
moiety	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
O	O
D	O
is	O
a	O
moiety	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
N	O
and	O
which	O
exhibit	O
a	O
dopamine	B-GENE
receptor	I-GENE
(	O
preferably	O
a	O
D4	B-GENE
receptor	I-GENE
)	O
and	O
/	O
or	O
a	O
serotonine	B-GENE
receptor	I-GENE
(	O
preferably	O
5HTAi	O
agonistic	O
activity	O
)	O
,	O
processes	O
of	O
preparing	O
same,	O
pharmaceutical	O
compositions	O
containing	O
same	O
and	O
uses	O
thereof	O
in	O
the	O
treatment	O
of	O
medical	O
conditions	O
associated	O
with	O
the	O
dopaminergic	O
and	O
/	O
or	O
serotonergic	O
systems	O
(	O
e	O
.	O
g	O
.	O
,	O
sexual	O
disorders,	O
dyskinesia,	O
anxiety	O
)	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
forms	O
of	O
(	O
R	O
)	O
-N-methylnaltrexone,	O
and	O
compositions	O
thereof,	O
useful	O
as	O
a	O
peripheral	O
mu	B-GENE
opioid	I-GENE
receptor	I-GENE
antagonist	O
.	O


The	O
instant	O
invention	O
is	O
directed	O
towards	O
steroid	O
compounds	O
and	O
compositions,	O
methods	O
of	O
inhibiting	O
Tdpl	B-GENE
activity,	O
and	O
methods	O
of	O
treating	O
Tdpl	B-GENE
-associated	O
disorders	O
including	O
cancer,	O
using	O
steroid	O
derivatives	O
.	O


Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
that	O
target	O
a	O
mammalian	B-GENE
thymidylate	I-GENE
synthase	I-GENE
gene	O
(	O
TS	B-GENE
)	O
,	O
and	O
which	O
are	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
their	O
target	O
gene,	O
are	O
provided	O
The	O
siRNA	O
molecules	O
are	O
also	O
capable	O
of	O
sensitizing	O
cells	O
to	O
the	O
effects	O
of	O
other	O
anti-cancer	O
agents,	O
particularly	O
chemotherapeutic	O
agents	O
that	O
target	O
TS	B-GENE
Methods	O
of	O
treating	O
cancer	O
using	O
the	O
TS	B-GENE
siRNA	O
in	O
combination	O
with	O
another	O
anti-cancer	O
agent	O
are	O
also	O
provided	O
Methods	O
of	O
enhancing	O
the	O
effect	O
of	O
a	O
TS	B-GENE
siRNA	O
on	O
cancer	O
cell	O
proliferation	O
by	O
combining	O
the	O
TS	B-GENE
siRNA	O
with	O
a	O
siRNA	O
targeting	O
a	O
cell	O
survival	O
gene	O
such	O
as	O
Bcl-2	B-GENE
are	O
further	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
modulating,	O
disrupting	O
or	O
enhancing	O
the	O
clearance	O
of	O
copper/zinc	B-GENE
superoxide	I-GENE
dismutase	I-GENE
1	I-GENE
(	O
SOD1	B-GENE
)	O
aggregates	O
in	O
astrocytes	O
or	O
motor	O
neurons	O
in	O
a	O
subject,	O
by	O
administering	O
a	O
medicament	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
cyclohexanehexol	O
derivative	O
.	O
In	O
another	O
aspect,	O
the	O
invention	O
provides	O
a	O
medicament	O
comprising	O
at	O
least	O
one	O
cyclohexanehexol	O
derivative	O
of	O
formula	O
III	O
or	O
IV	O
useful	O
in	O
preventing	O
or	O
treating	O
amyothropic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
improving	O
motor	O
neuron	O
function	O
and	O
slowing	O
the	O
degeneration	O
or	O
death	O
of	O
motor	O
neurons	O
in	O
brain	O
stem,	O
spinal	O
cord	O
or	O
motor	O
cortex	O
.	O
These	O
medicaments	O
may	O
be	O
administered	O
orally,	O
intravenously,	O
intraperitoneal,	O
subcutaneous,	O
intramuscular,	O
intranasal	O
or	O
transdermal	O
.	O


The	O
present	O
study	O
has	O
demonstrated	O
that	O
heparanase	B-GENE
expression	O
and	O
activity	O
was	O
increased	O
in	O
human	O
microvascular	O
endothelial	O
cells	O
and	O
rat	O
kidney	O
epithelial	O
cells	O
growing	O
under	O
hyperglycemia	O
condition,	O
as	O
found	O
in	O
diabetic	O
nephropathy	O
disease	O
.	O
Oligotide	O
was	O
able	O
to	O
:	O
-downregulate	O
the	O
heparanase	B-GENE
gene	O
expression	O
;	O
-downregulate	O
the	O
cell	O
surface	O
protein	O
expression	O
;	O
-decrease	O
the	O
heparanase	B-GENE
enzymatic	O
activity	O
.	O
Since	O
heparanase	B-GENE
is	O
a	O
critical	O
factor	O
in	O
maintaining	O
glomerular	O
basement	O
membrane	O
integrity	O
and	O
is	O
elevated	O
in	O
renal	O
diseases,	O
as	O
for	O
instance	O
diabetic	O
nephropathies,	O
Oligotide	O
should	O
be	O
considered	O
for	O
the	O
management	O
of	O
these	O
diseases	O
.	O


The	O
invention	O
provides	O
compounds	O
which	O
are	O
pyrimidines	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
group	O
-NR-	O
(	O
CHR	O
)	O
m-X	O
;	O
R2	O
is	O
a	O
substituted	O
indolyl	O
group	O
;	O
R	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
;	O
m	O
is	O
1,	O
2,	O
3	O
or	O
4	O
;	O
and	O
X	O
is	O
a	O
pyridyl	O
ring	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
PI3K	B-GENE
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B-GENE
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


Methods	O
and	O
compositions	O
for	O
contributing	O
to	O
the	O
treatment	O
of	O
cancers,	O
especially	O
ovarian	O
tumors,	O
are	O
disclosed	O
.	O
The	O
methods	O
and	O
compositions	O
utilize	O
an	O
endothelin	B-GENE
B	I-GENE
agonist	O
(	O
ETB	O
)	O
to	O
enhance	O
the	O
delivery	O
and	O
resulting	O
efficacy	O
of	O
chemotherapeutic	O
agent	O
(	O
s	O
)	O
(	O
e	O
.	O
g	O
.	O
,	O
cisplatin	O
and	O
/	O
or	O
cyclophosphamide	O
)	O
.	O


Disclosed	O
is	O
a	O
method	O
for	O
improving	O
the	O
activity	O
of	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
-scavenging	O
enzyme,	O
which	O
has	O
a	O
mechanism	O
of	O
action	O
based	O
on	O
scientific	O
grounds,	O
is	O
highly	O
safe,	O
is	O
inexpensive,	O
and	O
is	O
widely	O
applicable	O
.	O
An	O
organism	O
having	O
an	O
ROS-scavenging	O
enzyme	O
(	O
e	O
.	O
g	O
.	O
,	O
superoxide	O
dismutase,	O
catalase,	O
peroxidase	B-GENE
)	O
is	O
administered	O
with	O
one	O
or	O
more	O
substances	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
erythritol,	O
mannitol,	O
sorbitol	O
and	O
xylitol	O
at	O
a	O
dosage	O
concentration	O
of	O
0	O
.	O
01	O
to	O
10	O
%	O
to	O
thereby	O
induce	O
the	O
increase	O
in	O
the	O
amount	O
or	O
the	O
enhancement	O
of	O
the	O
activity	O
of	O
the	O
ROS-scavenging	O
enzyme	O
in	O
the	O
organism	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
benzoxazole	O
compounds	O
which	O
are	O
ltgands	O
at	O
the	O
NPY	B-GENE
Y5	I-GENE
receptor	O
.	O
The	O
invention	O
further	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
This	O
invention	O
also	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
depression,	O
anxiety	O
or	O
obesity	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
subject	O
invention	O
.	O
Furthermore,	O
this	O
invention	O
also	O
provides	O
uses	O
of	O
a	O
compound	O
of	O
the	O
invention	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
depression,	O
anxiety	O
or	O
obesity	O
.	O


A	O
proliferation	O
of	O
cells	O
can	O
be	O
reduced	O
by	O
contacting	O
the	O
cells	O
with	O
a	O
compound	O
having	O
formula	O
(	O
I	O
)	O
.	O
where	O
R	O
and	O
R	O
are	O
each	O
alkyl	O
groups,	O
R	O
'	O
is	O
hydrogen	O
or	O
an	O
alkyl	O
group	O
and	O
X3,	O
X4	O
and	O
X5	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
benzyl,	O
t-butyldimethylsiloxy	O
radical	O
and	O
triphenylmethyl	O
.	O
Accordingly,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
for	O
treatment	O
of	O
tumors	O
including	O
melanoma	O
.	O
Also	O
a	O
secretion	O
of	O
a	O
matrix	B-GENE
metalloproteinase	I-GENE
(	O
MMP	B-GENE
)	O
enzyme	O
by	O
cells	O
can	O
be	O
reduced	O
by	O
contacting	O
the	O
cells	O
with	O
the	O
compound	O
having	O
formula	O
(	O
I	O
)	O
.	O
Accordingly,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
for	O
treatment	O
physiological	O
conditions	O
associated	O
with	O
an	O
elevated	O
MMP	B-GENE
level,	O
such	O
as	O
tumors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
(	O
a	O
)	O
ICA512,	O
pro-ICA512,	O
ICA512-TMF	O
or	O
ICA512-CCF,	O
each	O
devoid	O
of	O
the	O
C-terminus	O
or	O
PHOGRIN	B-GENE
devoid	O
of	O
the	O
C-terminus,	O
wherein	O
said	O
ICA512,	O
pro-ICA512,	O
ICA512-	O
TMF,	O
ICA512-CCF	O
or	O
PHOGRIN	B-GENE
does	O
not	O
comprise	O
a	O
functional	O
domain	O
involved	O
in	O
the	O
binding	O
to	O
the	O
PDZ	B-GENE
domain	I-GENE
of	O
β2-syntrophin,	O
or	O
a	O
mimetic	O
of	O
the	O
C-terminus	O
of	O
ICA512,	O
pro-ICA512,	O
ICA512-TMF,	O
ICA512-CCF	O
or	O
PHOGRIN	B-GENE
;	O
(	O
b	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
protease	O
that	O
cleaves	O
the	O
C-terminus	O
of	O
ICA512,	O
pro-ICA512,	O
ICA512-TMF	O
or	O
ICA512-CCF	O
or	O
PHOGRIN,	O
wherein	O
the	O
removed	O
C-terminal	O
fragment	O
includes	O
the	O
functional	O
domain	O
involved	O
in	O
the	O
binding	O
to	O
the	O
PDZ	B-GENE
domain	I-GENE
of	O
β2-syntrophin	B-GENE
or	O
a	O
portion	O
of	O
said	O
functional	O
domain	O
wherein	O
said	O
portion	O
is	O
sufficient	O
to	O
hinder	O
binding	O
of	O
ICA512,	O
pro-ICA512,	O
ICA512-TMF	O
or	O
ICA512-CCF	O
or	O
PHOGRIN	B-GENE
to	O
β2-syntrophin	B-GENE
;	O
(	O
c	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine/threonine	B-GENE
kinase	I-GENE
which	O
phosphorylates	O
β2-	B-GENE
syntrophin	I-GENE
on	O
serine	O
residue	O
95	O
;	O
(	O
d	O
)	O
a	O
compound	O
interfering	O
with	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine/threonine	B-GENE
phosphatase	I-GENE
which	O
dephosphorylates	O
β2-syntrophin	B-GENE
on	O
serine	O
residue	O
95	O
;	O
(	O
e	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine/threonine	B-GENE
phosphatase	I-GENE
which	O
dephosphorylates	O
β2-syntrophin	B-GENE
on	O
serine	O
residue	O
110	O
;	O
or	O
(	O
f	O
)	O
a	O
compound	O
interfering	O
with	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine/threonine	B-GENE
kinase	I-GENE
which	O
phosphorylates	O
β2-syntrophin	B-GENE
on	O
serine	O
residue	O
110	O
.	O


Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
involving	O
disturbances	O
in	O
glutathione	O
(	O
GSH	O
)	O
metabolism	O
and	O
oxidative	O
stress,	O
especially	O
respiratory	O
diseases	O
or	O
disorders,	O
and	O
most	O
especially	O
asthma	O
.	O
In	O
particular	O
embodiments,	O
methods	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
or	O
disorders,	O
involving	O
the	O
step	O
of	O
administering	O
an	O
agent	O
that	O
inhibits	O
gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
(	O
GGT	B-GENE
)	O
activity	O
in	O
lung	O
and	O
airway	O
lining	O
fluid	O
.	O


Disclosed	O
are	O
a	O
substance	O
and	O
a	O
pharmaceutical	O
product	O
inhibiting	O
activation	O
of	O
a	O
G	B-GENE
protein-coupled	I-GENE
receptor	I-GENE
.	O
Specifically	O
disclosed	O
is	O
a	O
G	B-GENE
protein-coupled	I-GENE
receptor	I-GENE
inhibitor	O
containing	O
a	O
specific	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
.	O


Disclosed	O
is	O
a	O
novel	O
aralkyl	O
carboxylic	O
acid	O
compound	O
which	O
has	O
an	O
agonistic	O
activity	O
on	O
GPR-120	B-GENE
and	O
/	O
or	O
GPR-40,	O
particularly	O
GPR-120,	O
and	O
is	O
therefore	O
useful	O
as	O
an	O
appetite	O
regulator,	O
an	O
anti-obesity	O
agent,	O
a	O
therapeutic	O
agent	O
for	O
diabetes,	O
a	O
pancreatic	O
beta	O
differentiating	O
cell	O
growth	O
enhancer,	O
a	O
therapeutic	O
agent	O
for	O
metabolic	O
syndrome,	O
a	O
therapeutic	O
agent	O
for	O
a	O
gastrointestinal	O
disease,	O
a	O
therapeutic	O
agent	O
for	O
a	O
neuropathy,	O
a	O
therapeutic	O
agent	O
for	O
a	O
mental	O
disorder,	O
a	O
therapeutic	O
agent	O
for	O
a	O
pulmonary	O
disease,	O
a	O
therapeutic	O
agent	O
for	O
a	O
pituitary	O
hormone	O
secretion	O
disorder	O
or	O
a	O
lipid	O
flavoring	O
/	O
seasoning	O
agent	O
.	O
The	O
aralkyl	O
carboxylic	O
acid	O
compound	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
.	O
(	O
I	O
)	O
wherein	O
the	O
ring	O
Q	O
represents	O
a	O
pyridyl	O
or	O
the	O
like	O
;	O
R1	O
represents	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-4	O
alkyl	O
group	O
or	O
a	O
C1-4	O
alkoxy	O
group	O
;	O
m	O
and	O
n	O
independently	O
represent	O
an	O
integer	O
of	O
1	O
to	O
5	O
;	O
and	O
X	O
represents	O
an	O
oxygen	O
atom,	O
a	O
sulfur	O
atom	O
or	O
-NR3-	O
[	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-4	O
alkyl	O
group	O
]	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pyrimidine	O
compounds	O
that	O
are	O
useful	O
as	O
agents	O
for	O
the	O
treatment	O
of	O
kinase	B-GENE
related	O
disorders	O
such	O
as	O
proliferative	O
disorders	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
heterocycloalkyl	O
substituted	O
pyrimidine	O
compounds,	O
methods	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
.	O
These	O
compounds	O
may	O
be	O
useful	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
a	O
number	O
of	O
kinase	B-GENE
related	O
disorders	O
such	O
as	O
proliferative	O
disorders	O
including	O
tumours	O
and	O
cancers	O
as	O
well	O
as	O
other	O
disorders	O
or	O
conditions	O
related	O
to	O
or	O
associated	O
with	O
kinases	B-GENE
.	O


Compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof	O
are	O
provided	O
:	O
wherein	O
X,	O
Y,	O
Z,	O
R1,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Processes	O
for	O
preparation,	O
pharmaceutical	O
compositions,	O
and	O
uses	O
thereof	O
as	O
a	O
medicament,	O
for	O
example	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
a	O
reduction	O
or	O
imbalance	O
in	O
glutamate	B-GENE
receptor	I-GENE
function,	O
such	O
as	O
schizophrenia	O
or	O
cognition	O
impairment,	O
are	O
also	O
disclosed	O
.	O


Compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmacologically	O
acceptable	O
salts	O
and	O
pro-drugs	O
thereof	O
:	O
wherein	O
A	O
and	O
B	O
are	O
CH2	O
or	O
CH2CH2,	O
R1	O
is	O
hydrogen,	O
alkyl,	O
cycloalkyl,	O
aryl,	O
aralkyl	O
or	O
heteroaralkyl,	O
D,	O
E	O
and	O
G	O
are	O
CR2	O
or	O
nitrogen,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
D,	O
E	O
and	O
G	O
is	O
nitrogen,	O
R2,	O
R3	O
and	O
R4	O
are	O
hydrogen,	O
alkyl,	O
halogen,	O
haloalkyl,	O
alkoxy,	O
alkoxycarbonyl,	O
carboxyl,	O
hydroxyl	O
or	O
cyano,	O
X	O
is	O
R5SO2,	O
R5R7NCO,	O
R5R7NSO2or	O
R5SO2NR7CO,	O
Y	O
is	O
R6CO,	O
R6SO2,	O
R6R7NCO,	O
R6R7NSO2,	O
R6SO2NR7CO	O
or	O
CO2R8,	O
R5	O
and	O
R6	O
are	O
hydrogen,	O
alkyl,	O
aryl,	O
aralkyl,	O
heteroaryl	O
or	O
heteroaralkyl,	O
R7	O
is	O
hydrogen,	O
alkyl,	O
aryl	O
or	O
aralkyl,	O
and	O
R8	O
is	O
alkyl,	O
aryl,	O
aralkyl,	O
alkoxyalkyl,	O
heteroaryl	O
or	O
heteroarylalkyl,	O
are	O
of	O
use	O
inthe	O
prophylaxis	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
in	O
which	O
Kv1.x	B-GENE
channels	I-GENE
are	O
involved,	O
such	O
as	O
lower	O
urinary	O
tract	O
disorders,	O
cardiovascular	O
diseases,	O
inflammatory	O
and	O
immunological	O
diseases	O
and	O
pain	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
having	O
pharmacological	O
activity	O
towards	O
the	O
sigma	B-GENE
(σ)	I-GENE
receptor,	O
and	O
more	O
particularly	O
to	O
some	O
thieno-pyrano-pyrazole	O
derivatives,	O
to	O
processes	O
of	O
preparation	O
of	O
such	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them,	O
and	O
to	O
their	O
use	O
in	O
therapy	O
and	O
prophylaxis,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
psychosis	O
or	O
pain	O
.	O


Disclosed	O
is	O
a	O
novel	O
pyrazolone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
below,	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
having	O
phosphodiesterase	B-GENE
inhibitory	O
activity	O
.	O
(	O
1	O
)	O
R1,	O
R2	O
:	O
C1-6	O
alkyl	O
R3,	O
R4	O
:	O
H,	O
X,	O
C1-6	O
alkoxy	O
Z	O
:	O
O,	O
S	O
A	O
:	O
AA,	O
BB	O
(	O
R5	O
:	O
H,	O
C1-6	O
alkyl	O
;	O
R6,	O
R7	O
:	O
C1-6	O
alkyl	O
)	O


This	O
invention	O
provides	O
potassium	B-GENE
channel	I-GENE
modulators	O
which	O
are	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
formula	O
I	O
)	O
,	O
where	O
at	O
least	O
one	O
of	O
W	O
and	O
Z	O
is	O
N	O
;	O
where	O
the	O
moiety	O
(	O
formula	O
II	O
)	O
,	O
is	O
one	O
of	O
Groups	O
A	O
or	O
B	O
below	O
(	O
formula	O
A	O
)	O
,	O
where	O
Ar	O
is	O
a	O
1,2-fused,	O
six	O
membered	O
ring	O
aromatic	O
group,	O
bearing	O
substituents	O
R1	O
and	O
R2	O
as	O
defined	O
below,	O
and	O
containing	O
zero	O
or	O
one	O
ring	O
nitrogen	O
atom	O
;	O
and	O
where	O
other	O
substituents	O
are	O
defined	O
herein	O
.	O
The	O
invention	O
also	O
provides	O
a	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
i	O
)	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
and	O
ii	O
)	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester,	O
or	O
prodrug	O
thereof	O
.	O
The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
a	O
disease	O
or	O
disorder	O
which	O
is	O
affected	O
by	O
activities	O
of	O
potassium	O
channels,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
or	O
a	O
salt,	O
ester,	O
or	O
prodrug	O
thereof	O
.	O


The	O
invention	O
discloses	O
use	O
of	O
aniline	O
quinazoline	O
compounds	O
of	O
formula	O
I,	O
especially	O
N-	O
{	O
4-	O
[	O
3-chloro-4-	O
(	O
3-fluoro-benzyloxy	O
)	O
phenylamino	O
]	O
-quinazoline-6-yl	O
}	O
-acrylamide	O
and	O
N-	O
{	O
4-	O
[	O
3-chloro-4-	O
(	O
3-fluoro-benzyloxy	O
)	O
phenylamino	O
]	O
-7-methoxyl-	O
quinazoline-6-	O
yl	O
}	O
-acrylamide,	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
cancer	O
with	O
high	O
expression	O
of	O
erb-B1	B-GENE
and	O
/	O
or	O
erb-B2,	O
such	O
as	O
lung	O
cancer,	O
ovarian	O
cancer,	O
and	O
breast	O
cancer	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
multimers	O
thereof	O
are	O
inhibitors	O
of	O
human	B-GENE
neutrophil	I-GENE
elastase	I-GENE
activity,	O
and	O
of	O
utility	O
in	O
the	O
treatment	O
of,	O
e	O
.	O
g	O
.	O
,	O
COPD	O
:	O
wherein	O
all	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
,	O
(	O
Ia	O
)	O
,	O
(	O
Ib	O
)	O
,	O
(	O
Ic	O
)	O
,	O
(	O
Id	O
)	O
,	O
(	O
Ie	O
)	O
,	O
(	O
If	O
)	O
,	O
(	O
Ig	O
)	O
,	O
(	O
Ih	O
)	O
;	O
(	O
Ii	O
)	O
;	O
(	O
Ij	O
)	O
,	O
(	O
Ik	O
)	O
,	O
(	O
II	O
)	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
which	O
are	O
useful	O
for	O
the	O
therapeutic	O
treatment	O
of	O
diseases	O
associated	O
with	O
the	O
modulation	O
or	O
inhibition	O
of	O
11	B-GENE
β-HSD1	I-GENE
in	O
mammals	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
of	O
the	O
novel	O
compounds	O
and	O
methods	O
for	O
their	O
use	O
in	O
the	O
reduction	O
or	O
control	O
of	O
the	O
production	O
of	O
cortisol	O
in	O
a	O
cell	O
or	O
the	O
inhibition	O
of	O
the	O
conversion	O
of	O
cortisone	O
to	O
cortisol	O
in	O
a	O
cell	O
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
6-substituted	O
sulfonyl-1,3,3-trialkyl-6-azabicyclo	O
[	O
3	O
.	O
2	O
.	O
1	O
]	O
octane	O
compounds	O
useful	O
to	O
inhibit	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type-I,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
conditions	O
associated	O
with	O
the	O
expression	O
of	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type-I	I-GENE
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O


The	O
present	O
invention	O
related	O
to	O
a	O
combination	O
of	O
(	O
a	O
)	O
a	O
compound	O
which	O
is	O
a	O
MPO	B-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
b	O
)	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
which	O
is	O
used	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
PD	O
or	O
Multiple	O
Sclerosis	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
combination	O
and	O
to	O
methods	O
of	O
treating	O
Neuroinflammatory	O
and	O
Neurodegenerative	O
Disorder	O
(	O
s	O
)	O
,	O
such	O
as	O
PD	O
and	O
Multiple	O
Sclerosis	O
in	O
mammals	O
by	O
administrating	O
said	O
combination	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
kit	O
comprising	O
the	O
combination	O
and	O
use	O
of	O
said	O
kit	O
in	O
treatment	O
of	O
Neuroinflammatory	O
Disorder	O
(	O
s	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
PPAR	O
agonists,	O
and	O
their	O
use	O
in	O
therapy	O
including	O
the	O
treatment	O
of	O
disease	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
flavonoid	O
compounds	O
which	O
are	O
PPAR-gamma	B-GENE
agonists	O
and	O
/	O
or	O
PPAR	B-GENE
alpha/gamma	I-GENE
dual	O
agonists	O
.	O


A	O
therapeutic	O
agent	O
for	O
cancers	O
having	O
resistance	O
to	O
protease	B-GENE
inhibitors	O
which	O
contains,	O
as	O
a	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
(	O
Hsp90	B-GENE
)	O
family	O
protein	O
inhibitor,	O
either	O
a	O
benzoyl	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1-5	O
;	O
R1	O
represents	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl,	O
CONR7R8	O
(	O
wherein	O
R7	O
and	O
R8	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl,	O
etc	O
.	O
)	O
,	O
etc	O
.	O
;	O
R2	O
represents	O
(	O
un	O
)	O
substituted	O
aryl,	O
etc	O
.	O
;	O
R3	O
and	O
R5	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl,	O
etc	O
.	O
;	O
R4	O
represents	O
hydrogen,	O
etc	O
.	O
;	O
and	O
R6	O
represents	O
hydrogen,	O
halogeno,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl,	O
etc	O
.	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
substituted	O
indolyl	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives,	O
their	O
stereoisomers,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
above	O
said	O
novel	O
compounds,	O
their	O
derivatives,	O
their	O
stereoisomers,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O
This	O
invention	O
also	O
relates	O
to	O
the	O
novel	O
intermediates	O
involved	O
therein	O
and	O
process	O
of	O
their	O
preparation	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
that	O
are	O
related	O
to	O
5-HT6	B-GENE
receptor	O
functions	O
.	O


The	O
invention	O
provides	O
a	O
glucocorticoid	B-GENE
receptor	I-GENE
agonist	O
consisting	O
of	O
a	O
1,3,3-trimethyl-7-phenyl-3,4-dihydro-1H	O
-quinoxalin-2-one	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
and	O
novel	O
pharmacological	O
effects	O
of	O
the	O
agonist	O
:	O
[	O
Chemical	O
formula	O
1	O
]	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
1	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
2a	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
4a	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
3a	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
5a	O
)	O
	O
wherein	O
R1	O
is	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
(	O
2a	O
)	O
,	O
(	O
3a	O
)	O
,	O
(	O
4a	O
)	O
or	O
(	O
5a	O
)	O
;	O
R2	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
from	O
each	O
other	O
and	O
are	O
each	O
hydrogen,	O
halogeno,	O
lower	O
alkyl,	O
hydroxy,	O
esterified	O
hydroxy,	O
or	O
the	O
like	O
;	O
R4	O
is	O
lower	O
alkyl	O
;	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
each	O
halogeno,	O
lower	O
alkyl,	O
hydroxy,	O
lower	O
alkoxy,	O
or	O
the	O
like	O
;	O
and	O
m,	O
n,	O
p	O
and	O
q	O
are	O
each	O
0,	O
1	O
or	O
2	O
.	O


Provided	O
herein	O
are	O
alkylthio	O
substituted	O
pyrimidine	O
compounds	O
having	O
CRTH2	B-GENE
(	O
G-	B-GENE
protein-coupled	I-GENE
chemoattractant	I-GENE
receptor,	O
expressed	O
on	O
Th2	O
cells	O
)	O
antagonistic	O
activity,	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
associated	O
with	O
CRTH2	B-GENE
activity,	O
including	O
the	O
treatment	O
of	O
allergic	O
diseases,	O
eosinophil-related	O
diseases	O
and	O
basophil-related	O
diseases	O
.	O


This	O
application	O
describes	O
quinone	O
derivatives	O
which	O
target	O
the	O
redox	O
site	O
of	O
Ape1	B-GENE
/	O
Ref1	B-GENE
.	O
Also	O
included	O
in	O
the	O
invention	O
are	O
pharmaceutical	O
formulations	O
containing	O
the	O
derivatives	O
and	O
therapeutic	O
uses	O
of	O
the	O
derivatives	O
.	O


The	O
use	O
of	O
Kit	B-GENE
Ligand	I-GENE
and,	O
optionally,	O
a	O
steroid	O
such	O
as	O
Dexamethasone	O
in	O
the	O
treatment	O
of	O
β-Thalassaemias	O
is	O
provided,	O
as	O
are	O
methods	O
of	O
treating	O
β-Thalassaemias	O
.	O


This	O
invention	O
relates	O
to	O
a	O
combination	O
product,	O
as	O
defined	O
herein,	O
comprising	O
a	O
MEK	B-GENE
inhibitor	O
and	O
a	O
mTOR-selective	O
inhibitor,	O
and	O
to	O
methods	O
for	O
the	O
production	O
of	O
an	O
anti-cancer	O
effect	O
in	O
a	O
patient,	O
which	O
is	O
accordingly	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient	O
.	O
More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
;	O
a	O
combination	O
product,	O
as	O
defined	O
herein,	O
comprising	O
a	O
MEK	B-GENE
inhibitor	O
and	O
a	O
mTOR-selective	O
inhibitor	O
;	O
a	O
combination	O
product,	O
as	O
defined	O
herein,	O
comprising	O
a	O
kit	O
of	O
parts	O
comprising	O
a	O
MEK	B-GENE
inhibitor	O
and	O
a	O
mTOR-selective	O
inhibitor	O
;	O
use	O
of	O
the	O
combination	O
product,	O
as	O
defined	O
herein,	O
in	O
the	O
treatment	O
of	O
cancer	O
;	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
the	O
combination	O
product,	O
as	O
defined	O
herein,	O
to	O
a	O
patient	O
.	O
The	O
combination	O
product,	O
as	O
defined	O
herein,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
the	O
activity	O
of	O
MEK,	O
and	O
/	O
or	O
mTOR	B-GENE
.	O


The	O
subject	O
matter	O
of	O
the	O
instant	O
invention	O
is	O
pertinent	O
to	O
the	O
field	O
of	O
hormone	O
therapy	O
.	O
More	O
specifically,	O
the	O
subject	O
matter	O
of	O
the	O
instant	O
invention	O
concerns	O
methods	O
of	O
treating	O
dysfunctional	O
uterine	O
bleeding	O
.	O
The	O
instant	O
invention	O
is	O
also	O
relevant	O
to	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
anemia	O
in	O
patients	O
with	O
dysfunctional	O
uterine	O
bleeding	O
.	O
Compositions	O
for	O
practicing	O
the	O
methods,	O
comprising	O
progesterone	O
antagonists	O
are	O
also	O
disclosed	O
.	O
Embodiments	O
of	O
the	O
instant	O
invention	O
also	O
disclose	O
methods	O
for	O
identifying	O
new	O
selective	O
progesterone	B-GENE
receptor	I-GENE
modulators	O
for	O
practicing	O
disclosed	O
methods	O
of	O
treatment	O
.	O


The	O
present	O
disclosure	O
concerns	O
a	O
new	O
class	O
of	O
selective	O
estrogen	B-GENE
receptor	I-GENE
modulators	O
(	O
SERMs	O
)	O
.	O
The	O
disclosure	O
also	O
includes	O
the	O
identification	O
of	O
a	O
previously	O
unknown	O
membrane	O
associated	O
estrogen	B-GENE
receptor	I-GENE
.	O
Methods	O
for	O
making	O
and	O
using	O
the	O
disclosed	O
SERMs	O
are	O
disclosed,	O
including	O
pharmaceutical	O
formulations	O
of	O
the	O
disclosed	O
novel	O
compounds	O
in	O
useful	O
compositions	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
4,5-dihydroisoxazoles	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
their	O
use	O
as	O
estrogen	B-GENE
receptor	I-GENE
modulators,	O
and	O
to	O
methods	O
of	O
their	O
preparation	O
.	O


Morpholino	O
pyrimidines	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
selected	O
from	O
-Y-R6	O
and	O
-NR4R5	O
;	O
R2	O
is	O
a	O
N-containing	O
monocyclic	O
heteroaryl	O
group	O
which	O
is	O
selected	O
from	O
pyridyl,	O
isoxazolyl,	O
imidazolyl,	O
pyrazolyl,	O
pyrrolyl,	O
thiazolyl,	O
pyridazinyl,	O
pyrimidinyl,	O
pyrazinyl,	O
oxazolyl,	O
furanyl,	O
thienyl,	O
triazolyl	O
and	O
tetrazolyl	O
and	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
by	O
halo,	O
-CN,	O
-NR10R11,	O
-OR10,	O
-C	O
(	O
O	O
)	O
R10,	O
-NR10C	O
(	O
O	O
)	O
R11,	O
-	O
N	O
(	O
C	O
(	O
O	O
)	O
R11	O
)	O
2,	O
-NR10C	O
(	O
O	O
)	O
NR10R11,	O
-SO2R10R11,	O
-SO2NR10R11,	O
-C	O
(	O
=	O
O	O
)	O
OR10,	O
-C	O
(	O
=	O
O	O
)	O
NR10R11,	O
halo-C1	O
-C6	O
alkyl	O
and	O
unsubstituted	O
C1-C12	O
alkyl	O
;	O
R3	O
is	O
selected	O
from	O
H,	O
C1-C6	O
alkyl	O
and	O
C1-C6	O
alkoxy	O
;	O
Y	O
is	O
selected	O
from	O
a	O
direct	O
bond,	O
-	O
(	O
CR2	O
)	O
m-,	O
C2-C6	O
alkenylene,	O
C2-C6	O
alkynylene,	O
-	O
(	O
CR2	O
)	O
p-O-	O
(	O
CR2	O
)	O
t-,	O
-	O
(	O
CR2	O
)	O
p-NR-	O
(	O
CR2	O
)	O
t,	O
-	O
(	O
CR2	O
)	O
p-NR-	O
(	O
CR2	O
)	O
n-C	O
(	O
O	O
)	O
-,	O
-	O
(	O
CR2	O
)	O
p-NR-C	O
(	O
O	O
)	O
-	O
(	O
CR2	O
)	O
n-,	O
-	O
(	O
CR2	O
)	O
p-C	O
(	O
O	O
)	O
-NR-	O
(	O
CR2	O
)	O
t,	O
-	O
(	O
CR2	O
)	O
p-C	O
(	O
O	O
)	O
-	O
(	O
CR2	O
)	O
n-NR-	O
(	O
CR2	O
)	O
t,-	O
and	O
-	O
(	O
CR2	O
)	O
p-	O
C	O
(	O
O	O
)	O
-	O
(	O
CR2	O
)	O
n-	O
;	O
R6	O
is	O
selected	O
from	O
an	O
unsaturated	O
5-	O
to	O
12-membered	O
carbocyclic	O
or	O
heterocyclic	O
ring,	O
a	O
saturated	O
5-,	O
6-	O
or	O
7-	O
membered	O
N-containing	O
heterocyclic	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted,	O
C1-C6	O
alkyl,	O
-NR2,	O
-OR,	O
-NR	O
(	O
CO	O
)	O
R	O
and	O
-	O
C	O
(	O
O	O
)	O
NR2	O
;	O
R4	O
and	O
R5,	O
which	O
are	O
the	O
same	O
or	O
different,	O
are	O
both	O
C1-C6	O
alkyl	O
which	O
is	O
unsubstituted	O
or	O
substituted,	O
or	O
R4	O
and	O
R5	O
together	O
form,	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
a	O
saturated	O
5-,	O
6-	O
or	O
7-	O
membered	O
N-containing	O
heterocyclic	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
each	O
R,	O
which	O
are	O
the	O
same	O
or	O
different	O
when	O
more	O
than	O
one	O
is	O
present	O
in	O
a	O
given	O
group,	O
is	O
independently	O
H,	O
C1-C6	O
alkyl	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
or	O
a	O
5-	O
to	O
12-membered	O
aryl	O
or	O
heteroaryl	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
R10	O
and	O
R11,	O
which	O
are	O
the	O
same	O
or	O
different,	O
are	O
independently	O
selected	O
from	O
H,	O
C1-C6	O
alkyl,	O
C2-C6	O
alkenyl,	O
C2-C6	O
alkynyl	O
and	O
C3-C8	O
cycloalkyl	O
;	O
n	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
p	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
and	O
t	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6,	O
with	O
the	O
proviso	O
that	O
t	O
is	O
an	O
integer	O
of	O
2	O
to	O
6	O
when	O
R6	O
is	O
linked	O
to	O
Y	O
through	O
a	O
constituent	O
O	O
or	O
N	O
atom	O
of	O
R6	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
subject	O
to	O
various	O
provisos,	O
have	O
activity	O
as	O
inhibitors	O
of	O
PI3K	B-GENE
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour,	O
particularly	O
that	O
associated	O
with	O
PI3	B-GENE
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
disorders	O
and	O
neurological	O
disorders	O
.	O
Processes	O
for	O
synthesizing	O
the	O
compounds	O
are	O
also	O
described	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
preparation	O
of	O
the	O
non-steroidal	O
aromatase	B-GENE
inhibitor	O
drug,	O
Letrozole	O
of	O
formula	O
(	O
I	O
)	O
and	O
its	O
intermediates,	O
4-	O
[	O
1-	O
(	O
1,2,4-triazolyl	O
)	O
methyl	O
]	O
-benzonitrile	O
of	O
formula	O
(	O
IV	O
)	O
and	O
4-	O
[	O
1-	O
(	O
1,2,4-triazolyl	O
)	O
methyl	O
]	O
-benzonitrile	O
hydrochloride	O
of	O
formula	O
(	O
VII	O
)	O
,	O
all	O
having	O
a	O
purity	O
of	O
≥99	O
%	O
,	O
which	O
is	O
simple,	O
convenient,	O
economical,	O
does	O
not	O
use	O
hazardous	O
chemicals	O
and	O
industrially	O
viable	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
modulators	O
of	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
pathway	O
for	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
such	O
as	O
alcohol	O
abuse	O
.	O
The	O
modulators	O
include	O
small	O
molecule	O
inhibitors	O
such	O
as	O
Erlotinib	O
(	O
TARCEVA®,	O
N-	O
(	O
3-ethynylphenyl	O
)	O
-6,7-bis	O
(	O
2-methoxyethoxy	O
)	O
-4-	O
quinazolineamine	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
Gefitinib	O
[	O
IRES	O
S	O
A®,	O
N-	O
(	O
3	O
-chloro-4-fluoro-phenyl	O
)	O
-7-methoxy-6-	O
(	O
3	O
-morpholin-4-	O
ylpropoxy	O
)	O
quinazolin-4-amine	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
various	O
macromolecular	O
inhibitors	O
of	O
the	O
EGFR	B-GENE
pathway	O
such	O
as	O
siRNAs	O
and	O
antibodies	O
that	O
target	O
genes	O
or	O
proteins	O
in	O
the	O
EGFR	B-GENE
/	O
ERK	B-GENE
pathway	O
such	O
as	O
one	O
of	O
the	O
EGFR	B-GENE
/	O
ErbB	B-GENE
protein	O
or	O
a	O
homolog	O
thereof	O
.	O


It	O
is	O
intended	O
to	O
amplify	O
CD34-positive	O
cells	O
in	O
vitro	O
more	O
efficiently	O
and	O
in	O
a	O
shorter	O
time	O
than	O
conventional	O
by	O
using	O
a	O
low-molecular	O
compound	O
which	O
can	O
be	O
produced	O
biologically	O
safely	O
at	O
low	O
cost	O
.	O
It	O
is	O
also	O
intended	O
to	O
provide	O
an	O
amplification	O
agent	O
for	O
CD34-positive	O
cells	O
useful	O
as	O
a	O
method	O
for	O
treating	O
various	O
hematopoietic	O
diseases	O
accompanying	O
dysfunction	O
of	O
hematopoietic	O
stem	O
cells	O
and	O
/	O
or	O
hematopoietic	O
progenitor	O
cells	O
.	O
An	O
amplification	O
method	O
for	O
CD34-positive	O
cells	O
characterized	O
by	O
culturing	O
CD34-positive	O
cells	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
A,	O
B,	O
L1,	O
L2,	O
L3,	O
L4,	O
R1,	O
R2,	O
R3,	O
X,	O
and	O
Y	O
are	O
defined	O
in	O
the	O
specification	O
)	O
,	O
a	O
tautomer	O
thereof,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
.	O


Chemokine	B-GENE
receptor	I-GENE
antagonists,	O
in	O
particular,	O
compounds	O
of	O
Formula	O
(	O
I-	O
A	O
)	O
that	O
act	O
as	O
antagonists	O
of	O
the	O
chemokine	B-GENE
CCR2	B-GENE
receptor,	O
including	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
to	O
treat	O
or	O
prevent	O
diseases	O
associated	O
with	O
monocyte	O
accumulation,	O
lymphocyte	O
accumulation	O
or	O
leukocyte	O
accumulation	O
are	O
described	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
TRAIL	B-GENE
protein	O
to	O
treat	O
various	O
cancers	O
in	O
mammals	O
.	O
The	O
invention	O
provides	O
a	O
variant	O
TRAIL	B-GENE
protein,	O
which	O
has	O
superior	O
selectivity	O
for	O
the	O
death	B-GENE
receptor	I-GENE
5,	O
for	O
treating	O
a	O
mammal	O
diagnosed	O
with	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
aminotriazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A,	O
E,	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description,	O
their	O
preparation	O
and	O
their	O
use	O
as	O
pharmaceutically	O
active	O
compounds	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases,	O
which	O
respond	O
to	O
the	O
modulation	O
of	O
the	O
ALX	B-GENE
receptor	I-GENE
such	O
as	O
inflammatory	O
diseases	O
.	O


The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
obesity	O
or	O
fatty	O
liver	O
disease,	O
using	O
icaritin	O
as	O
active	O
ingredient	O
.	O
Icaritin	O
is	O
an	O
effective	O
fatty	B-GENE
acid	I-GENE
synthetase	I-GENE
inhibitor,	O
and	O
can	O
suppress	O
food	O
intake	O
and	O
reduce	O
weight	O
in	O
DIO	O
mice,	O
depress	O
hepatic	O
fatty	O
degeneration,	O
and	O
relieve	O
ischemia-reperfusion	O
injure	O
in	O
liver	O
with	O
fatty	O
degeneration	O
.	O
Further,	O
icaritin	O
shows	O
no	O
toxicity	O
on	O
mice	O
in	O
acute	O
toxicity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
Acetyl	B-GENE
Coenzyme	I-GENE
A	I-GENE
Carboxylase	I-GENE
(	O
ACC	B-GENE
)	O
inhibitors	O
according	O
to	O
formula	O
(	O
I	O
)	O
,	O
or	O
an	O
enantiomer	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
where	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
E,	O
L,	O
Z	O
and	O
n	O
are	O
as	O
defined	O
herein,	O
to	O
processes	O
for	O
preparing	O
such	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them,	O
to	O
the	O
use	O
of	O
such	O
inhibitors	O
and	O
to	O
methods	O
for	O
th	O
eir	O
therapeutic	O
use,	O
particularly	O
in	O
the	O
treatments	O
of	O
obesity	O
and	O
diabetes	O
mellitus	O
.	O


Provided	O
herein	O
are	O
compounds	O
which	O
are	O
CDC2-Like	B-GENE
Kinase	I-GENE
(	O
CLK	B-GENE
)	O
inhibiting	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O
.	O
The	O
CLK-inhibiting	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell,	O
and	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including,	O
for	O
example,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress,	O
diabetes,	O
obesity,	O
neurodegenerative	O
diseases,	O
cardiovascular	O
disease,	O
blood	O
clotting	O
disorders,	O
inflammation,	O
ocular	O
disorders,	O
and	O
/	O
or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benfit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O
Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
Clk-inhibiting	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O


This	O
invention	O
relates	O
generally	O
to	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyrimidine-based	O
modulators	O
of	O
Liver	B-GENE
X	I-GENE
receptors	I-GENE
(	O
LXRs	B-GENE
)	O
having	O
formula	O
(	O
I	O
)	O
and	O
related	O
methods	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
R2	O
is	O
C6-C10	O
aryl	O
or	O
heteroaryl	O
including	O
5-10	O
atoms,	O
each	O
of	O
which	O
is	O
:	O
(	O
i	O
)	O
substituted	O
with	O
1	O
R6,	O
and	O
(	O
ii	O
)	O
optionally	O
substituted	O
with	O
from	O
1-5	O
Re	O
;	O
and	O
R1,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
Re	O
are	O
defined	O
herein	O
.	O


The	O
present	O
invention	O
provides	O
imidazopyridines	O
of	O
formula	O
(	O
I	O
)	O
.	O
The	O
compounds	O
show	O
inhibitory	O
activity	O
against	O
protein	O
kinase,	O
especially	O
VEGFR2,	O
FLT3,	O
and	O
C-KIT	B-GENE
receptors	O
and	O
so	O
on,	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicament	O
for	O
treating	O
diseases	O
associated	O
with	O
abnormal	O
high	O
level	O
of	O
kinase	B-GENE
activity,	O
such	O
as	O
cancer	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
2-Aminoquinoline	O
derivatives	O
as	O
5-HT5A	B-GENE
receptor	O
antagonists,	O
their	O
manufacture,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
depression,	O
anxiety	O
disorders,	O
schizophrenia,	O
panic	O
disorders,	O
agoraphobia,	O
social	O
phobia,	O
obsessive	O
compulsive	O
disorders,	O
post-traumatic	O
stress	O
disorders,	O
pain,	O
memory	O
disorders,	O
dementia,	O
disorders	O
of	O
eating	O
behaviors,	O
sexual	O
dysfunction,	O
sleep	O
disorders,	O
abuse	O
of	O
drugs,	O
motor	O
disorders	O
such	O
as	O
Parkinson	O
'	O
s	O
disease,	O
psychiatric	O
disorders	O
or	O
gastrointestinal	O
disorders	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
is	O
concerned	O
with	O
compounds	O
of	O
the	O
general	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
-Z-Ar1	O
are	O
as	O
described	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
preventive	O
and	O
therapeutic	O
veterinary	O
medicine	O
.	O
In	O
particular,	O
it	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
sweet	O
itch	O
in	O
equine	O
species,	O
horses,	O
ponies,	O
donkeys	O
.	O
Provided	O
is	O
the	O
use	O
of	O
ubiquitin,	O
or	O
ubiquitin-related	O
molecule,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
sweet	O
itchin	O
an	O
equine	O
mammal	O
.	O
Also	O
provided	O
is	O
a	O
composition	O
comprising	O
pharmaceutically	O
active	O
quantities	O
of	O
ubiquitin	B-GENE
or	O
ubiquitin-	O
related	O
molecule	O
and	O
tocopherol,	O
together	O
with	O
an	O
acceptable	O
carrier	O
.	O


The	O
disclosure	O
generally	O
relates	O
to	O
the	O
novel	O
compounds	O
of	O
formula	O
I,	O
including	O
their	O
salts,	O
which	O
are	O
CGRP	B-GENE
receptor	I-GENE
antagonists	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
using	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
CGRP	O
related	O
disorders	O
including	O
migraine	O
and	O
other	O
headaches,	O
neurogenic	O
vasodilation,	O
neurogenic	O
inflammation,	O
thermal	O
injury,	O
circulatory	O
shock,	O
flushing	O
associated	O
with	O
menopause,	O
airway	O
inflammatory	O
diseases	O
such	O
as	O
asthma,	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O
(	O
I	O
)	O


Methods	O
of	O
treating	O
patients	O
with	O
an	O
HDAC	B-GENE
inhibitor	O
and	O
an	O
HMT	B-GENE
inhibitor	O
are	O
provided	O
.	O


Compounds,	O
pharmaceutical	O
compositions	O
and	O
methods	O
are	O
provided	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
CDK4-mediated	O
disorders,	O
such	O
as	O
cancer	O
.	O
The	O
subject	O
compounds	O
are	O
gem-disubstituted	O
or	O
spirocyclic	O
pyridine,	O
pyrimidine	O
and	O
triazine	O
derivatives	O
.	O


Effective	O
treatments	O
of	O
pain	O
and	O
/	O
or	O
inflammation	O
are	O
provided	O
.	O
Through	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
beta	B-GENE
adrenergic	I-GENE
agonist	O
at	O
or	O
near	O
a	O
target	O
site,	O
one	O
can	O
reduce,	O
prevent	O
or	O
treat	O
pain	O
and	O
/	O
or	O
inflammation	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
for	O
the	O
regulation	O
of	O
phosphoinositides	B-GENE
3-kinases	I-GENE
activity	O
and	O
related	O
diseases	O
.	O


Disclosed	O
is	O
a	O
novel	O
LXRβ	B-GENE
agonist	O
which	O
is	O
useful	O
as	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
arteriosclerosis	O
such	O
as	O
atherosclerosis	O
and	O
arteriosclerosis	O
associated	O
with	O
diabetes,	O
dyslipidemia,	O
hypercholesterolemia,	O
lipid-related	O
diseases,	O
inflammatory	O
diseases	O
induced	O
by	O
an	O
inflammatory	O
cytokine,	O
skin	O
diseases	O
such	O
as	O
allergic	O
skin	O
diseases,	O
diabetes	O
or	O
Alzheimer’s	O
disease	O
.	O
	O
Specifically	O
disclosed	O
is	O
a	O
quinoline	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
salt	O
thereof,	O
or	O
a	O
solvate	O
of	O
the	O
quinoline	O
compound	O
or	O
the	O
salt	O
.	O


Tablets	O
containing	O
1-	O
[	O
(	O
4,6-dimethyl-5-pyrimidinyl	O
)	O
carbonyl	O
]	O
-4-	O
[	O
4-	O
[	O
2-methoxy-1	O
(	O
R	O
)	O
-	O
[	O
4-	O
(	O
trifluoromethyl	O
)	O
phenyl	O
]	O
ethyl	O
]	O
-3-	O
(	O
S	O
)	O
-methyl-1-piperazinyl	O
]	O
-4-methyl-piperi	O
dine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
are	O
disclosed	O
.	O
Methods	O
of	O
making	O
such	O
tablets	O
with	O
satisfactory	O
processability	O
are	O
also	O
disclosed	O
.	O
In	O
addition,	O
methods	O
for	O
treating	O
HIV	O
as	O
well	O
as	O
inflammatory	O
diseases	O
with	O
an	O
antagonist	O
of	O
chemokine	B-GENE
(C-C	I-GENE
motif)	I-GENE
receptor	I-GENE
5	I-GENE
(	O
CCR5	B-GENE
)	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
administering	O
compositions	O
comprising	O
a	O
progesterone	B-GENE
receptor	I-GENE
antagonist	O
for	O
use	O
in	O
treating	O
estrogen-dependent	O
conditions	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
methods	O
for	O
treating	O
pain	O
associated	O
with	O
endometriosis	O
.	O
The	O
compositions	O
may	O
be	O
administered	O
to	O
females	O
with	O
endometriosis	O
as	O
well	O
as	O
to	O
females	O
undergoing	O
estrogen	O
and	O
/	O
or	O
selective	O
estrogen	B-GENE
receptor	I-GENE
modulator	O
(	O
SERM	O
)	O
therapy	O
.	O
In	O
certain	O
embodiments,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
suppressing	O
endometrial	O
proliferation	O
.	O


A	O
method	O
is	O
disclosed	O
utilizing	O
a	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2-receptor-selective	O
agonist	O
for	O
treating	O
or	O
preventing	O
lower	O
urinary	O
tract	O
dysfunction,	O
including	O
overactive	O
bladder,	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
detrusor	O
overactivity	O
.	O


A	O
single	O
nucleotide	O
G	O
>	O
A	O
polymorphism	O
at	O
position	O
-126	O
in	O
the	O
promoter	O
of	O
the	O
human	B-GENE
myeloid	B-GENE
cell	I-GENE
leukemia-1	I-GENE
gene	I-GENE
is	O
associated	O
with	O
a	O
reduced	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro-apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O
The	O
G	O
>	O
;	O
A	O
polymorphism	O
is	O
in	O
an	O
ELK4	B-GENE
transcription	O
factor	O
binding	O
site,	O
which	O
results	O
in	O
reduced	O
myeloid	B-GENE
cell	I-GENE
leukemia-1	I-GENE
gene	I-GENE
expression	O
.	O
Elevated	O
levels	O
of	O
ELK4	B-GENE
and	O
Mcl-1	B-GENE
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
an	O
increased	O
predisposition	O
to	O
cancer	O
and	O
an	O
decreased	O
responsiveness	O
to	O
pro-apoptotic	O
agents	O
.	O
Reduced	O
levels	O
of	O
ELK4	B-GENE
and	O
Mcl-1	B-GENE
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
less	O
of	O
a	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro-apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O
Methods	O
of	O
cancer	O
diagnosis	O
and	O
/	O
or	O
therapy	O
which	O
target	O
ELK4	B-GENE
and	O
/	O
or	O
Mcl-1	B-GENE
protein	O
and	O
/	O
or	O
nucleic	O
acids	O
are	O
particularly	O
applicable	O
to	O
cancers	O
such	O
as	O
glioma,	O
colon	O
cancer,	O
lung	O
cancer,	O
thyroid	O
cancer,	O
kidney	O
cancer	O
and	O
/	O
or	O
melanoma	O
.	O
Such	O
methods	O
and	O
compositions	O
may	O
sensitize	O
or	O
improve	O
responsiveness	O
of	O
cancer	O
cells	O
to	O
pro-apoptotic	O
agents	O
.	O


The	O
present	O
invention	O
provides	O
a	O
use	O
of	O
tanshinone	O
IIA,	O
physiologically	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates	O
or	O
mixtures	O
thereof	O
in	O
preparing	O
medicine	O
for	O
treating	O
obesity	O
and	O
insulin	B-GENE
resistance	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
losing	O
weight	O
by	O
using	O
tanshinone	O
IIA	O
or	O
a	O
composition	O
thereof,	O
and	O
a	O
medical	O
use	O
of	O
a	O
composition	O
which	O
includes	O
tanshinone	O
IIA	O
and	O
other	O
materials,	O
said	O
materials	O
could	O
prevent,	O
control	O
or	O
treat	O
diabetes	O
and	O
/	O
or	O
symptoms	O
or	O
diseases	O
associated	O
with	O
obesity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
protein	O
kinases,	O
such	O
as	O
inhibitors	O
of	O
GSK-3	B-GENE
.	O
The	O
invention	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O
The	O
invention	O
provides	O
processes	O
for	O
preparing	O
compounds	O
of	O
the	O
invention	O
.	O
The	O
invention	O
provides	O
methods	O
of	O
identifying	O
compounds	O
useful	O
for	O
treatment	O
of	O
diabetes,	O
diabetic	O
neuropathy,	O
osteoporosis,	O
Alzheimer	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
AIDS-associated	O
dementia,	O
bipolar	O
disorder,	O
amyotrophic	O
lateral	O
sclerosis,	O
multiple	O
sclerosis,	O
schizophrenia,	O
leukocytopenia,	O
cardiomyocyte	O
hypertrophy,	O
stroke,	O
post-stroke,	O
spinal	O
cord	O
injury,	O
traumatic	O
brain	O
injury,	O
Charcot-Marie-Tooth,	O
peripheral	O
nerve	O
regeneration,	O
and	O
rheumatoid	O
arthritis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
phosphodiesterase	O
inhibitors	O
(	O
PDEs	B-GENE
)	O
,	O
in	O
particular	O
phosphodiesterase	B-GENE
type	I-GENE
4	I-GENE
inhibitors,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O
These	O
novel	O
PDEs	B-GENE
are	O
useful	O
in	O
treating	O
allergic	O
and	O
inflammatory	O
diseases	O
(	O
such	O
as	O
asthma,	O
COPD,	O
allergic	O
rhinitis,	O
allergic	O
conjunctivitis,	O
respiratory	O
distress	O
syndrome,	O
chronic	O
bronchitis,	O
nephritis,	O
rheumatoid	O
spondylitis,	O
osteoarthritis,	O
atopic	O
dermatitis,	O
eosinophilic	O
granuloma,	O
psoriasis,	O
rheumatoid	O
septic	O
shock,	O
ulcerative	O
colitis,	O
multiple	O
sclerosis,	O
chronic	O
inflammation,	O
Crohn	O
'	O
s	O
syndrome	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
)	O
and	O
for	O
inhibiting	O
the	O
production	O
of	O
Tumor	B-GENE
Necrosis	I-GENE
Factor	I-GENE
(	O
TNF-α	B-GENE
)	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
hydrate	O
or	O
solvate	O
thereof,	O
where	O
R	O
1,	O
R	O
2,	O
R	O
3,	O
R	O
4,	O
R	O
5,	O
R	O
6,	O
R	O
7,	O
R	O
8,	O
R	O
9	O
and	O
R	O
10	O
have	O
the	O
meanings	O
as	O
indicated	O
in	O
the	O
specification,	O
is	O
useful	O
for	O
treating	O
diseases	O
which	O
respond	O
to	O
the	O
blockade	O
of	O
the	O
epithelial	B-GENE
sodium	I-GENE
channel	I-GENE
.	O
Pharmaceutical	O
compositions	O
that	O
contain	O
the	O
compounds	O
and	O
processes	O
for	O
preparing	O
the	O
compounds	O
are	O
also	O
described	O
.	O


Disclosed	O
are	O
:	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
others,	O
which	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
diseases	O
induced	O
by	O
the	O
production,	O
secretion	O
and	O
/	O
or	O
deposition	O
of	O
amyloid-β	B-GENE
protein	I-GENE
.	O
[	O
In	O
the	O
formula,	O
the	O
ring	O
A	O
represents	O
a	O
carbocyclic	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
a	O
heterocyclic	O
group	O
which	O
may	O
have	O
a	O
substituent	O
;	O
R1	O
represents	O
a	O
lower	O
alkyl	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
;	O
R2a	O
and	O
R2b	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
lower	O
alkyl	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
;	O
and	O
R3a	O
and	O
R3c	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
halogen,	O
a	O
hydroxy,	O
a	O
lower	O
alkyl	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
.	O
]	O


A	O
pharmaceutical	O
combination	O
product	O
is	O
disclosed	O
that	O
comprises	O
a	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitor	O
and	O
a	O
fatty	B-GENE
acid	I-GENE
synthase	I-GENE
inhibitor,	O
and	O
to	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cancer	O
.	O


Compounds	O
active	O
on	O
Fms	B-GENE
and	O
/	O
or	O
Kit	B-GENE
protein	I-GENE
kinases	I-GENE
are	O
described,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
Fms	B-GENE
and	O
/	O
or	O
Kit	B-GENE
protein	I-GENE
kinases	I-GENE
.	O


Histone	B-GENE
deacetylase	I-GENE
inhibitors	O
and	O
uses	O
thereof	O
.	O
The	O
histone	B-GENE
deacetylase	I-GENE
inhibitors	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
tumor	O
and	O
the	O
diseases	O
associated	O
with	O
differentiation	O
and	O
proliferation	O
.	O
The	O
histone	B-GENE
deacetylase	I-GENE
inhibitors	O
are	O
the	O
compounds	O
or	O
salts	O
thereof	O
represented	O
as	O
the	O
formula	O
illustrated	O
below	O
.	O


The	O
invention	O
relates	O
to	O
bi-	O
and	O
polycyclic	O
substituted	O
isoquinoline	O
and	O
isoquinolinones	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R12	O
are	O
as	O
defined	O
in	O
the	O
application	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
associated	O
with	O
Rho-kinase	B-GENE
and	O
/	O
or	O
Rho-kinase	B-GENE
mediated	O
phosphorylation	O
of	O
myosin	B-GENE
light	I-GENE
chain	I-GENE
phosphatase,	O
and	O
compositions	O
containing	O
such	O
compounds	O
.	O


An	O
immune	O
composition	O
containing	O
Globo	O
H	O
or	O
its	O
fragment	O
(	O
e	O
.	O
g	O
.	O
,	O
SSEA3	O
)	O
and	O
an	O
adjuvant,	O
e	O
.	O
g	O
.	O
,	O
α	O
-GalCer,	O
for	O
eliciting	O
immune	O
responses	O
against	O
Globo	O
H	O
or	O
its	O
fragment	O
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
of	O
treating	O
cancer	O
by	O
inhibiting	O
the	O
activity	O
of	O
one	O
of	O
FUT1	B-GENE
and	O
FUT2,	O
both	O
of	O
which	O
involve	O
in	O
Globo	O
H	O
biosynthesis	O
.	O


The	O
invention	O
relates	O
to	O
the	O
novel	O
products	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
:	O
n	O
=	O
0,1	O
or	O
2	O
;	O
X	O
is	O
H,	O
Hal	O
or	O
alk	O
;	O
R	O
is	O
H,	O
NH2,	O
NHalk	O
or	O
N	O
(	O
alk	O
)	O
2	O
;	O
Ra	O
is	O
H,	O
Hal,	O
-O-cycloalkyl,	O
-O-alkyl,	O
-O-aryl,	O
-O-heteroaryl,	O
‑NRd	O
(	O
cycloalkyl	O
)	O
,	O
‑NRd	O
(	O
alkyl	O
)	O
,	O
-NRd	O
(	O
aryl	O
)	O
,	O
-NRd	O
(	O
heteroaryl	O
)	O
,	O
alkyl,	O
cycloalkyl,	O
heterocycloalkyl,	O
aryl	O
or	O
heteroaryl,	O
all	O
optionally	O
substituted	O
;	O
Rb	O
is	O
H,	O
Rc,	O
-COORc-CO-Rc	O
or	O
-CO-NRcRd	O
;	O
where	O
Rc	O
is	O
alkyl,	O
cycloalkyl,	O
heterocycloalkyl,	O
aryl	O
and	O
heteroaryl,	O
all	O
optionally	O
substituted	O
;	O
Rd	O
is	O
H,	O
alk	O
or	O
cycloalkyl	O
;	O
these	O
products	O
being	O
in	O
all	O
the	O
isomer	O
forms	O
and	O
the	O
salts,	O
as	O
medicaments,	O
in	O
particular	O
as	O
MET	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
Ar,	O
Hetaryl,	O
m	O
and	O
n	O
are	O
as	O
described	O
in	O
the	O
description	O
and	O
claims	O
.	O
The	O
compounds	O
are	O
orexin	B-GENE
receptor	I-GENE
antagonists	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
disorders,	O
in	O
which	O
orexin	O
pathways	O
are	O
involved	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
having	O
pharmacological	O
activity	O
towards	O
the	O
5-HT7	B-GENE
receptor	I-GENE
;	O
to	O
a	O
method	O
for	O
identifying	O
them	O
as	O
5-HT7	B-GENE
ligands,	O
especially	O
as	O
agonists,	O
by	O
using	O
a	O
pharmacophore	O
and	O
a	O
descriptor	O
'	O
s	O
profile	O
filter	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
;	O
and	O
to	O
their	O
use	O
in	O
therapy,	O
in	O
particular	O
for	O
the	O
treatment	O
and	O
or	O
prophylaxis	O
of	O
a	O
disease	O
in	O
which	O
5-HT7	B-GENE
is	O
involved,	O
such	O
as	O
CNS	O
disorders	O
.	O


Provided	O
herein	O
is	O
a	O
method	O
of	O
treating	O
postangiplasty	O
or	O
instent	O
restenosis	O
in	O
an	O
individual	O
in	O
need	O
of	O
such	O
treatment,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
dose	O
of	O
morelloflavone	O
.	O
Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
postangiplasty	O
or	O
instent	O
restenosis	O
in	O
an	O
individual	O
in	O
need	O
of	O
such	O
treatment,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
dose	O
of	O
morelloflavone	O
and	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
.	O


Mimetics	O
of	O
nitro	O
linoleic	O
acid	O
are	O
potent	O
agonists	O
of	O
PPAR-γ,	O
a	O
receptor	O
that	O
regulates	O
adipocyte	O
differentiation,	O
glucose	O
homeostasis	O
and	O
insulin	B-GENE
sensitivity	O
.	O
Thus,	O
10-LNO2	O
and	O
12-LN-NO2	O
are	O
potent,	O
selective	O
activators	O
of	O
the	O
PPAR-γ,	O
as	O
are	O
mimetics	O
of	O
LNO2	O
that	O
bind	O
in	O
a	O
manner	O
similar	O
to	O
LNO2	O
.	O
High-resolution	O
crystallographic	O
data	O
on	O
the	O
binding	O
of	O
LNO2	O
by	O
PPAR-γ	B-GENE
thus	O
inform	O
the	O
design	O
of	O
such	O
mimetics	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
is	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
disease	O
or	O
medical	O
condition	O
mediated	O
through	O
glucokinase	B-GENE
(	O
GLK	B-GENE
or	O
GK	B-GENE
)	O
,	O
leading	O
to	O
a	O
decreased	O
glucose	O
threshold	O
for	O
insulin	B-GENE
secretion	O
.	O


Compositions	O
and	O
methods	O
are	O
provided	O
having	O
unexpected	O
anti-inflammatory	O
and	O
other	O
properties	O
based	O
on	O
unprecedented	O
synergistic	O
effects	O
of	O
administering	O
two	O
or	O
more	O
of	O
(	O
i	O
)	O
an	O
opiate	O
antagonist,	O
partial	O
antagonist,	O
or	O
reverse	O
agonist,	O
(	O
ii	O
)	O
a	O
cAMP-phosphodiesterase	B-GENE
(	O
PDE	B-GENE
)	O
inhibitor,	O
(	O
iii	O
)	O
an	O
adenylate	O
cyclase	O
activator,	O
and	O
(	O
iv	O
)	O
a	O
nicotinamide	B-GENE
adenine	I-GENE
dinucleotide	I-GENE
(phosphate)	I-GENE
(NAD(P)H)	I-GENE
oxidase	I-GENE
inhibitor	O
.	O
Invention	O
embodiments	O
are	O
useful	O
for	O
treating	O
or	O
reducing	O
one	O
or	O
more	O
of	O
tissue	O
inflammation,	O
inflammation-associated	O
cellular	O
proliferation,	O
oxidative	O
stress	O
or	O
neuronal	O
death	O
or	O
dysfunction,	O
or	O
for	O
treating	O
or	O
preventing	O
gray	O
hair	O
or	O
restoring	O
hair	O
color	O
.	O


Macrocyclic	O
derivative	O
compounds	O
that	O
inhibit	O
protein	B-GENE
kinase	B-GENE
enzymes	O
are	O
disclosed	O
along	O
with	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
for	O
synthesizing	O
the	O
same	O
.	O
Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
resulting	O
from	O
unregulated	O
and	O
/	O
or	O
disturbed	O
kinase	B-GENE
activity	O
such	O
as	O
cancers,	O
psoriasis,	O
viral	O
and	O
bacterial	O
infections,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
use	O
in	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
septicaemia	O
and	O
septic	O
shock	O
.	O
The	O
invention	O
further	O
provides	O
compositions	O
and	O
methods	O
for	O
the	O
suppression	O
of	O
Toll-like	B-GENE
Receptor	I-GENE
14	I-GENE
interaction	O
with	O
CD14	B-GENE
during	O
Toll-like	B-GENE
Receptor	I-GENE
mediated	O
signalling	O
.	O
The	O
invention	O
further	O
provides	O
screening	O
assays	O
to	O
identify	O
compounds	O
which	O
have	O
utility	O
in	O
preventing	O
the	O
association	O
of	O
Toll-like	B-GENE
Receptor	I-GENE
14	I-GENE
and	O
CD14	B-GENE
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
azanitrile	O
compounds	O
as	O
inhibitors	O
of	O
α2C	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonists,	O
methods	O
of	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
such	O
compounds,	O
methods	O
of	O
preparing	O
pharmaceutical	O
formulations	O
comprising	O
one	O
or	O
more	O
such	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
conditions	O
associated	O
with	O
the	O
α2C	B-GENE
adrenergic	I-GENE
receptors	I-GENE
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O


Compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
through	O
the	O
inhibition	O
of	O
sodium	O
ion	O
flux	O
through	O
voltage-gated	B-GENE
sodium	I-GENE
channels	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
GCH1	B-GENE
(	O
GTP	B-GENE
cyclohydrolase	I-GENE
1	I-GENE
)	O
-targeted	O
siRNA,	O
a	O
recombinant	O
vector	O
containing	O
the	O
siRNA,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
recombinant	O
vector	O
for	O
treating	O
and	O
preventing	O
neuropathic	O
pain	O
.	O
The	O
GCH1-targeted	O
siRNA	O
of	O
the	O
present	O
invention	O
down-regulates	O
the	O
expression	O
of	O
GCH1,	O
and	O
the	O
recombinant	O
vector	O
containing	O
the	O
siRNA	O
may	O
deliver	O
siRNA	O
to	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O
Thus,	O
neuropathic	O
pain	O
caused	O
by	O
nerve	O
injury	O
can	O
be	O
inhibited,	O
and	O
inflammatory	O
response	O
at	O
the	O
spine	O
caused	O
by	O
nerve	O
injury	O
can	O
also	O
be	O
inhibited	O
by	O
using	O
the	O
recombinant	O
vector	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
hepatitis	O
C,	O
dyslipidemia,	O
insulin	B-GENE
resistance,	O
and	O
inflammation,	O
with	O
flavonoid-	O
sugar	O
complexes	O
.	O


Disclosed	O
are	O
ethoxy	O
diphenyl	O
ethane	O
derivates,	O
preparation	O
processes	O
and	O
uses	O
thereof	O
.	O
Diphenyl	O
ethane	O
is	O
chemically	O
modified	O
by	O
ethoxy	O
substituted	O
on	O
the	O
4	O
'	O
-position	O
of	O
its	O
B	O
aryl	O
ring	O
and	O
is	O
changed	O
into	O
their	O
soluble	O
prodrugs	O
of	O
phosphates	O
or	O
the	O
like	O
by	O
modifying	O
the	O
hydroxyl	O
on	O
the	O
3	O
'	O
-position	O
of	O
their	O
B	O
aryl	O
ring	O
.	O
Similarly,	O
side	O
chain	O
of	O
amino	O
acid	O
can	O
be	O
introduced	O
to	O
3	O
'	O
-amino	O
to	O
form	O
soluble	O
prodrug	O
of	O
amino	O
acidamide	O
.	O
The	O
structure	O
of	O
the	O
said	O
compounds	O
is	O
showed	O
as	O
formula	O
(	O
I	O
)	O
.	O
Ethoxy	O
diphenyl	O
ethane	O
derivates	O
and	O
prodrugs	O
thereof	O
	O
are	O
characterized	O
by	O
the	O
following	O
:	O
possessing	O
potent	O
tubulin	B-GENE
polymerizaion	O
inhibitory	O
activity	O
;	O
possessing	O
obvious	O
target	O
damage	O
of	O
tumour	O
vessel	O
;	O
resulting	O
in	O
dysfunction	O
and	O
structural	O
damage	O
of	O
tumour	O
vessel	O
selectively	O
;	O
evoking	O
die	O
of	O
vessel	O
endothelium	O
cell	O
;	O
making	O
the	O
tumor	O
cell	O
lose	O
nourishment	O
and	O
oxygen	O
;	O
and	O
killing	O
tumor	O
cell	O
or	O
inhibiting	O
tumor	O
metastasis	O
.	O


The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
enzyme	O
AKR1C3	B-GENE
is	O
capable	O
of	O
exhibiting	O
nitroreductase	B-GENE
activity	O
and	O
activating	O
nitroaromatic	O
prodrugs	O
to	O
release	O
the	O
cytotoxic	O
effector	O
.	O
AKR1C3-activated	O
nitroaromatic	O
prodrugs	O
include	O
dinitrobenzamide	O
mustards	O
such	O
as	O
2-	O
(	O
(	O
2-bromoethyl	O
)	O
-2-	O
{	O
[	O
(	O
2-hydroxyethyl	O
)	O
amino	O
]	O
carbonyl	O
}	O
-4,6-dinitroanilino	O
)	O
ethyl	O
methanesulfonate	O
(	O
PR-104A	O
)	O
,	O
and	O
the	O
corresponding	O
pre-prodrug	O
2-	O
[	O
(	O
2-	O
(	O
bromoethyl	O
)	O
-2,4-dinitro-6-	O
[	O
[	O
[	O
2-	O
(	O
phosphonooxy	O
)	O
ethyl	O
]	O
amino	O
]	O
carbonyl	O
]	O
anilino	O
]	O
ethyl	O
methanesulfonate	O
(	O
PR-104	O
)	O
.	O
The	O
invention	O
provides	O
methods	O
and	O
procedures	O
to	O
determine	O
drug	O
sensitivity	O
in	O
patients	O
to	O
allow	O
the	O
identification	O
of	O
individualized	O
patient	O
profiles	O
which	O
will	O
aid	O
in	O
treating	O
diseases	O
and	O
disorders,	O
such	O
as	O
cancer	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
treatment	O
which	O
are	O
based	O
upon	O
such	O
biomarker-related	O
profiles,	O
as	O
well	O
as	O
compounds	O
suitable	O
for	O
use	O
in	O
such	O
methods	O
and	O
compositions	O
comprising	O
"such	O
compounds	O
.	O


Disclosed	O
are	O
compounds	O
and	O
compositions	O
of	O
the	O
formula	O
I	O
as	O
described	O
herein	O
which	O
are	O
inhibitors	O
of	O
MMP-13	B-GENE
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
using	O
and	O
making	O
compounds	O
of	O
the	O
formula	O
I	O
.	O


6-morpholin-4-yl-pyrazolo	O
[	O
3,4-d	O
]	O
pyrimidine	O
and	O
2-morpholin-4-yl-7H-	O
pyrrolo	O
[	O
2,3-d	O
]	O
pyrimidine	O
derivatives	O
have	O
unexpected	O
drug	O
properties	O
as	O
inhibitors	O
of	O
PI3	B-GENE
and	O
/	O
or	O
mTOR	B-GENE
kinases	O
and	O
are	O
useful	O
in	O
treating	O
disorders	O
related	O
to	O
abnormal	O
PI3K	B-GENE
/	O
mT0R	B-GENE
activities	O
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
disorders	O
and	O
neurological	O
disorders	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X,	O
Z,	O
A,	O
B,	O
D,	O
E,	O
R1-R4	O
and	O
m	O
are	O
as	O
defined	O
in	O
the	O
claims,	O
exhibit	O
alpha2C	B-GENE
antagonistic	O
activity	O
and	O
are	O
thus	O
useful	O
as	O
alpha2C	B-GENE
antagonists	O
.	O


The	O
present	O
invention	O
relates	O
to	O
(	O
a	O
pharmaceutical	O
composition	O
comprising	O
)	O
a	O
combination	O
of	O
bifeprunox	O
(	O
a	O
D2	B-GENE
/	O
5-HT1A	B-GENE
receptor	O
ligand	O
)	O
and	O
at	O
least	O
one	O
D2	B-GENE
/	O
5-HT2A	B-GENE
receptor	O
antagonistic	O
ligand	O
and	O
pharmaceutically	O
acceptable	O
auxiliaries	O
for	O
use	O
in	O
the	O
treatment	O
of	O
various	O
CNS	O
disorders,	O
particularly	O
psychotic	O
disorders	O
like	O
schizophrenia	O
and	O
related	O
psychiatric	O
conditions,	O
including	O
bipolar	O
disorder,	O
bipolar	O
depression,	O
mania	O
and	O
atypical	O
depression	O
.	O


A	O
pyrimidine	O
derivative	O
or	O
a	O
pyridine	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
pyrimidine	O
derivative	O
or	O
the	O
pyridine	O
derivative,	O
which	O
can	O
inhibit	O
the	O
activity	O
of	O
PI3K	B-GENE
to	O
control	O
many	O
biological	O
processes	O
including	O
growth,	O
differentiation,	O
survival,	O
proliferation,	O
migration	O
and	O
metabolism	O
of	O
cells	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
diseases	O
including	O
inflammatory	O
diseases,	O
arteriosclerosis,	O
vascular	O
/	O
cardiovascular	O
diseases,	O
cancer	O
/	O
tumors,	O
immune	O
diseases,	O
cell	O
proliferative	O
diseases	O
and	O
infectious	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
radicals	O
R1	O
to	O
R6	O
have	O
the	O
meaning	O
according	O
to	O
claim	O
1,	O
and	O
/	O
or	O
physiologically	O
acceptable	O
salts	O
thereof,	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
treatment	O
and	O
/	O
or	O
monitoring	O
of	O
physiological	O
and	O
/	O
or	O
pathological	O
conditions	O
that	O
are	O
associated	O
with	O
the	O
activity	O
of	O
AMP-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
AMPK	B-GENE
)	O
.	O
Another	O
object	O
of	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
said	O
compounds	O
for	O
enhancing	O
glucose	O
homeostasis,	O
improving	O
podocytopathy	O
and	O
/	O
or	O
decreasing	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
in-vitro	O
diagnosing	O
diabetic	O
nephropathy	O
and	O
a	O
method	O
for	O
screening	O
compounds	O
that	O
reduce	O
podocytopathy,	O
in	O
each	O
case	O
by	O
applying	O
synaptopodin	B-GENE
as	O
biomarker	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
thereof,	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
any	O
of	O
a	O
number	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
/	O
scatter	B-GENE
factor	I-GENE
(	O
HGF	B-GENE
/	O
SF	B-GENE
)	O
or	O
the	O
activities	O
thereof,	O
or	O
agonists	O
or	O
antagonists	O
thereof,	O
have	O
a	O
therapeutically	O
useful	O
role	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
anti-cancer	O
treatments	O
and	O
compositions	O
using	O
combinations	O
of	O
at	O
least	O
one	O
agonist	O
of	O
the	O
RXR-PPARγ	O
heterodimer	O
complex	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
a	O
RXRα	B-GENE
agonist,	O
a	O
RXRβ	B-GENE
agonist,	O
a	O
RXRγ	B-GENE
agonist,	O
a	O
PPARγ	B-GENE
agonist	O
or	O
a	O
RXR-PPARγ	O
heterodimer	O
agonist	O
and	O
a	O
growth	O
factor	O
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
form	O
thereof,	O
wherein	O
Q1,	O
Q2,	O
Q3,	O
and	O
Q4	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
has	O
ALK	B-GENE
and	O
/	O
or	O
JAK2	B-GENE
inhibitory	O
activity,	O
and	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
.	O


The	O
invention	O
is	O
directed	O
to	O
inhibitors	O
of	O
cystathionine	B-GENE
beta	I-GENE
synthase	I-GENE
which,	O
among	O
other	O
biochemical	O
effects,	O
allow	O
reduction	O
of	O
the	O
neurotoxic	O
overproduction	O
of	O
endogenous	O
hydrogen	O
sulphide	O
.	O
These	O
compounds	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neurotoxic	O
and	O
cognitive	O
disorders	O
such	O
as	O
cognitive	O
disorders	O
in	O
Down	O
syndrome	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
neurotoxic	O
and	O
cognitive	O
disorders	O
including	O
cognitive	O
disorders	O
in	O
Down	O
Syndrome	O
.	O


Pyrazolo	O
[	O
1,5-a	O
]	O
pyridine	O
derivatives	O
of	O
formula	O
I,	O
wherein	O
the	O
meaning	O
for	O
R1,	O
R2	O
and	O
R3	O
is	O
as	O
disclosed	O
in	O
the	O
description	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
JAK3	B-GENE
kinase	I-GENE
inhibitors	O
.	O


Provided	O
are	O
3-substituted	O
oxindole	O
derivatives	O
which	O
are	O
agonists	O
of	O
the	O
CB2	B-GENE
receptor,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same,	O
and	O
methods	O
of	O
treatment	O
related	O
to	O
CB2-mediated	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
pain,	O
cancer	O
etc	O
.	O
)	O
using	O
the	O
3-substituted	O
oxindole	O
derivatives	O
and	O
compositions	O
described	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
eyesight-protecting	O
composition	O
having	O
preventive	O
and	O
therapeutic	O
efficacy	O
in	O
diabetes	O
or	O
diabetes	O
complications	O
.	O
In	O
particular,	O
the	O
eyesight-protecting	O
composition	O
essentially	O
comprises	O
functional	O
components	O
such	O
as	O
calcium,	O
vitamin	O
A,	O
vitamin	O
C	O
and	O
vitamin	O
D,	O
and	O
additionally	O
at	O
least	O
one	O
plant	O
extract	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lycii	O
fructus	O
extract,	O
astragalus	O
extract,	O
cassia	O
tora	O
extract,	O
polygonatum	O
odoratum	O
extract	O
and	O
rubus	O
coreanus	O
extract	O
.	O
A	O
composition	O
containing	O
functional	O
components	O
of	O
the	O
present	O
invention	O
significantly	O
inhibits	O
the	O
expression	O
of	O
inflammatory	O
factors,	O
inhibits	O
/	O
regulates	O
the	O
expression	O
of	O
cytokines	B-GENE
of	O
Th1	O
/	O
Th2	O
cells	O
via	O
a	O
JAK-STAT	O
pathway,	O
and	O
also	O
significantly	O
inhibits	O
the	O
expression	O
of	O
STAT3	B-GENE
in	O
diabetic	O
retinopathy,	O
which	O
is	O
one	O
of	O
the	O
complications	O
of	O
diabetes,	O
such	O
that	O
the	O
composition	O
can	O
advantageously	O
be	O
used	O
as	O
an	O
eyesight-protecting	O
composition	O
efficacious	O
for	O
prevention	O
and	O
treatment	O
of	O
diabetes	O
complications	O
.	O


Inhibitors	O
of	O
poly(ADP-ribose)polymerase	B-GENE
having	O
a	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
,	O
ways	O
to	O
make	O
them	O
and	O
methods	O
of	O
treating	O
patients	O
using	O
them	O
are	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
abnormalities	O
characterized	O
by	O
abnormal	O
glucose	O
metabolism,	O
including	O
diabetes	O
mellitus	O
and	O
new	O
onset	O
diabetes	O
mellitus	O
through	O
the	O
use	O
of	O
fibroblast	B-GENE
activation	I-GENE
protein	I-GENE
(	O
FAP	B-GENE
)	O
selective	O
inhibitors	O
.	O


The	O
present	O
invention	O
provides	O
bumetanide,	O
furosemide,	O
piretanide,	O
azosemide,	O
and	O
torsemide	O
analogs	O
and	O
compositions	O
comprising	O
such	O
analogs	O
.	O
The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
these	O
bumetanide,	O
furosemide,	O
piretanide,	O
azosemide,	O
and	O
torsemide	O
analogs	O
and	O
methods	O
for	O
their	O
use	O
.	O
All	O
of	O
these	O
analogs	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
conditions	O
that	O
involve	O
the	O
Na+K+Cl-	B-GENE
co-transporter	I-GENE
or	O
GABAA	B-GENE
receptor	I-GENE
including	O
but	O
not	O
limited	O
to	O
addictive	O
disorders,	O
Alzheimer	O
'	O
s	O
Disease,	O
anxiety	O
disorders,	O
ascites,	O
autism,	O
bipolar	O
disorder,	O
cancer,	O
depression,	O
endothelial	O
corneal	O
dystrophy,	O
edema,	O
epilepsy,	O
glaucoma,	O
Huntington	O
'	O
s	O
Disease,	O
insomnia,	O
ischemia,	O
migraine,	O
migraine	O
with	O
aura,	O
neuropathic	O
pain,	O
nociceptive	O
neuralgia,	O
nociceptive	O
pain,	O
ocular	O
diseases,	O
pain,	O
Parkinson	O
'	O
s	O
disease,	O
personality	O
disorders,	O
postherpetic	O
neuralgia,	O
psychosis,	O
schizophrenia,	O
seizure	O
disorders,	O
tinnitus,	O
and	O
withdrawal	O
syndromes	O
.	O


ABSTRACT	O
This	O
invention	O
provides	O
for	O
certain	O
bridged	O
and	O
fused	O
compounds	O
of	O
the	O
formula	O
G-L-A	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester	O
of	O
solvate	O
thereof	O
wherein	O
:	O
A	O
is	O
:	O
(	O
I	O
)	O
and	O
the	O
other	O
variables	O
are	O
defined	O
herein	O
;	O
the	O
inventive	O
compounds	O
are	O
agonists	O
of	O
the	O
G-protein	B-GENE
coupled	I-GENE
receptor	I-GENE
40	I-GENE
(	O
GPR40,	O
also	O
known	O
as	O
free	B-GENE
fatty	I-GENE
acid	I-GENE
receptor	I-GENE
FFAR	B-GENE
)	O
.	O
This	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
and	O
the	O
use	O
of	O
these	O
compounds	O
to	O
regulate	O
insulin	B-GENE
levels	O
in	O
a	O
mammal	O
.	O
The	O
compounds	O
may	O
be	O
used,	O
for	O
example	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
Type	O
2	O
diabetes	O
mellitus	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
conditions	O
related	O
to	O
Type	O
2	O
diabetes	O
mellitus,	O
such	O
as	O
insulin	B-GENE
resistance,	O
obesity	O
and	O
lipid	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
hydrazino-cyclobut-3-ene-1,2-dione	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
as	O
selective	O
CXCR2	B-GENE
antagonists,	O
pharmaceutical	O
compositions	O
containing	O
the	O
novel	O
compounds,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
or	O
preventing	O
chemokine	O
mediated	O
diseases	O
or	O
conditions	O
in	O
human	O
and	O
non-human	O
animals	O
using	O
the	O
novel	O
compounds	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
CXCR2	B-GENE
receptor	O
antagonists	O
or	O
inhibitors	O
of	O
CXCR2	B-GENE
receptor	O
gene	O
expression	O
for	O
the	O
treatment	O
or	O
the	O
prevention	O
of	O
insulin	B-GENE
resistance	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
diagnosing	O
and	O
/	O
or	O
prognosing	O
insulin	B-GENE
resistance	O
in	O
a	O
subject	O
comprising	O
detecting	O
the	O
presence	O
and	O
/	O
or	O
quantifying	O
CXCL5	O
in	O
a	O
biological	O
sample	O
obtained	O
from	O
said	O
subject	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
product	O
that	O
contains	O
sucrose	O
and	O
a	O
berry	O
polyphe-	O
nolic	O
compound	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
use	O
of	O
a	O
polyphenolic	O
compound	O
for	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
use	O
of	O
the	O
product	O
for	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
.	O
In	O
addition,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
of	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
by	O
administering	O
a	O
polyphenolic	O
compound	O
and	O
/	O
or	O
the	O
product	O
to	O
the	O
subject	O
.	O


A	O
process	O
for	O
efficiently	O
producing,	O
at	O
low	O
cost	O
through	O
few	O
steps,	O
a	O
phenyl-substituted	O
heterocyclic	O
derivative	O
represented	O
by	O
formula	O
(	O
3	O
)	O
which	O
comprises	O
subjecting	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
to	O
coupling	O
reaction	O
with	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
2	O
)	O
in	O
the	O
presence	O
of	O
a	O
nickel	O
compound,	O
the	O
derivative	O
being	O
either	O
a	O
xanthine	B-GENE
oxidase	I-GENE
inhibitor,	O
which	O
is	O
a	O
therapeutic	O
agent	O
for	O
hyperuricemia,	O
or	O
an	O
intermediate	O
therefor	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
tetrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
found	O
to	O
be	O
modulators	O
of	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
.	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-	O
degeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
kynurenic	O
acid	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
hydroxy,	O
NHR2,	O
NR2R2	O
or	O
C1-10	O
straight	O
or	O
branched	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
hydrogen	O
atom	O
or	O
C1-10	O
straight	O
or	O
branched	O
alkyl	O
group	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
hydrogen	O
atom,	O
halogen	O
atom,	O
C1-10	O
alkyl,	O
C2-10	O
alkenyl	O
or	O
alkynyl	O
group	O
optionally	O
substituted	O
with	O
a	O
halogen	O
atom,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester	O
or	O
amide	O
thereof	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and	O
/	O
or	O
vacuolization	O
and	O
/	O
or	O
destruction	O
of	O
pancreatic	O
tissue	O
and	O
/	O
or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	B-GENE
α-amylase	I-GENE
.	O
Prefereably,	O
in	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
R1	O
is	O
a	O
hydroxy,	O
NH2,	O
NH-	O
(	O
C1-5	O
straight	O
or	O
branched	O
alkyl	O
)	O
or	O
C1-5	O
straight	O
or	O
branched-	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
a	O
hydrogen	O
atom	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
a	O
hydrogen	O
atom,	O
halogen	O
atom	O
or	O
CF3	O
group	O
.	O
In	O
the	O
most	O
preferred	O
embodiment,	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
kynurenic	O
acid	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and	O
/	O
or	O
vacuolization	O
and	O
/	O
or	O
destruction	O
of	O
pancreatic	O
tissue	O
and	O
/	O
or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	B-GENE
α-amylase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
bone	O
regeneration	O
including	O
a	O
hyaluronic	O
acid	O
and	O
a	O
mesenchymal	O
stem	O
cell	O
into	O
which	O
a	O
bone	O
regeneration	O
inducing	O
factor	O
is	O
introduced,	O
and	O
a	O
manufacturing	O
method	O
thereof	O
.	O
The	O
composition	O
for	O
bone	O
regeneration	O
can	O
include	O
a	O
stem	O
cell	O
into	O
which	O
a	O
gene	O
coding	O
a	O
protein	O
with	O
a	O
bone	O
formation	O
function	O
is	O
introduced	O
or	O
cells	O
differentiated	O
from	O
the	O
stem	O
cell	O
and	O
the	O
hyaluronic	O
acid	O
.	O
The	O
protein	O
with	O
the	O
bone	O
formation	O
function	O
can	O
be	O
a	O
bone	B-GENE
morphogenic	I-GENE
protein	I-GENE
(	O
BMP	B-GENE
)	O
.	O
The	O
stem	O
cell	O
can	O
be	O
a	O
mesenchymal	O
stem	O
cell,	O
and	O
it	O
can	O
be	O
a	O
stem	O
cell	O
into	O
which	O
a	O
suicide	O
gene	O
is	O
additionally	O
introduced	O
.	O
An	O
average	O
molecular	O
weight	O
of	O
the	O
hyaluronic	O
acid	O
can	O
be	O
from	O
50,000	O
to	O
300,000	O
daltons	O
.	O


EphB3	B-GENE
kinase	O
inhibitor	O
compounds,	O
including	O
certain	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyridine	O
and	O
imidazo	O
[	O
1,2-a	O
]	O
pyridine	O
compounds,	O
inhibit	O
EphB3	B-GENE
kinase	O
.	O
The	O
EphB3	B-GENE
kinase	O
inhibitor	O
compounds	O
can	O
have	O
greater	O
potency	O
for	O
the	O
inhibition	O
of	O
EphB3	B-GENE
kinase	O
than	O
general	O
kinase	O
inhibitors	O
.	O
Pharmaceutical	O
compositions,	O
such	O
as	O
neuroprotective	O
agents,	O
comprising	O
the	O
EphB3	B-GENE
kinase	O
inhibitor	O
compounds	O
are	O
also	O
provided	O
.	O
The	O
EphB3	B-GENE
kinase	O
inhibitor	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful,	O
for	O
example,	O
to	O
provide	O
neuroprotection	O
and	O
/	O
or	O
repair	O
of	O
neuronal	O
tissue	O
damaged	O
during	O
an	O
ischemic	O
event,	O
such	O
as	O
a	O
stroke	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
benzimidazole	O
modulators	O
of	O
H1	B-GENE
receptor	I-GENE
activity	O
and	O
/	O
or	O
inhibitors	O
of	O
NS4B	B-GENE
protein	I-GENE
activity,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
provides	O
compositions	O
and	O
methods	O
useful	O
for	O
treating	O
wounds	O
and	O
enhancing	O
wound	O
healing	O
.	O
The	O
present	O
invention	O
discloses	O
a	O
continuous	O
polymer	O
coating	O
system	O
to	O
provide	O
sustained	O
localized	O
delivery	O
of	O
bioactive	O
agents	O
.	O
The	O
data	O
demonstrate	O
the	O
efficacy	O
of	O
a	O
bioactive	O
coating	O
comprising	O
the	O
polymer	O
PLAGA	O
and	O
the	O
agent	O
FTY720,	O
a	O
selective	O
agonist	O
for	O
sphingosine	B-GENE
1-phosphate	I-GENE
receptors,	O
and	O
biologically	O
active	O
derivatives	O
and	O
analogs	O
thereof,	O
for	O
use	O
in	O
wound	O
healing	O
.	O
In	O
vitro	O
drug	O
release	O
studies	O
validated	O
64	O
%	O
loading	O
efficiency	O
with	O
complete	O
release	O
of	O
compound	O
following	O
14	O
days	O
.	O
Mechanical	O
evaluation	O
of	O
healing	O
bone	O
showed	O
significant	O
enhancement	O
of	O
mechanical	O
stability	O
in	O
FTY720	O
treatment	O
groups	O
.	O
Superior	O
osseous	O
integration	O
across	O
the	O
host-graft	O
interface,	O
significant	O
enhancement	O
in	O
smooth	O
muscle	O
cell	O
investment,	O
and	O
reduction	O
in	O
leukocyte	O
recruitment	O
were	O
evident	O
in	O
FTY720	O
treated	O
groups	O
.	O
The	O
present	O
invention	O
is	O
useful	O
for	O
enhancing	O
angiogenesis	O
for	O
wound	O
healing	O
.	O


Disclosed	O
is	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
which	O
is	O
useful	O
as	O
an	O
active	O
ingredient	O
for	O
a	O
pharmaceutical	O
composition,	O
in	O
particular	O
a	O
pharmaceutical	O
composition	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O
The	O
inventors	O
have	O
intensively	O
studied	O
on	O
compounds	O
having	O
JAK	B-GENE
inhibitory	O
activity,	O
and	O
found	O
that	O
the	O
compound	O
of	O
the	O
present	O
invention,	O
namely	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
has	O
excellent	O
JAK	B-GENE
inhibitory	O
activity	O
and	O
is	O
thus	O
useful	O
as	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
decreasing	O
the	O
level	O
of	O
pro-	B-GENE
AD	I-GENE
AM	I-GENE
10	I-GENE
and	O
/	O
or	O
BACE	B-GENE
protein	O
in	O
a	O
subject,	O
the	O
method	O
comprising	O
administering	O
a	O
heterocyclic	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate	O
or	O
prodrug	O
thereof	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


A	O
combination	O
of	O
compounds	O
is	O
described	O
that	O
target	O
protein	B-GENE
kinases	I-GENE
and	O
is	O
more	O
effective	O
than	O
the	O
individual	O
compounds	O
against	O
cancer	O
where	O
EGFR	B-GENE
is	O
upregulated	O
and	O
c-met	B-GENE
is	O
activated,	O
for	O
example,	O
epithelial	O
cell	O
tumors,	O
and	O
particularly,	O
non	O
small	O
cell	O
lung	O
carcinomas	O
(	O
NSCLC	O
)	O
.	O


This	O
invention	O
relates	O
to	O
3-azabicyclo	O
[	O
4	O
.	O
1	O
.	O
0	O
]	O
heptane	O
derivatives	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
orexin	B-GENE
receptor	O
antagonists	O
.	O


Described	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
non-localized	O
inflammatory	O
condition	O
(	O
or	O
any	O
symptoms	O
associated	O
with	O
such	O
inflammation	O
)	O
,	O
including	O
systemic	O
inflammation,	O
and	O
inflammatory	O
conditions	O
affecting	O
the	O
large	O
portions	O
of	O
or	O
the	O
whole	O
body,	O
or	O
sepsis	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan-HDAC	O
inhibitor	O
.	O
Also	O
described	O
herein	O
are	O
methods	O
for	O
decreasing	O
iNOS	B-GENE
and	O
cytokine	B-GENE
expression	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan-HDAC	O
inhibitor	O
.	O


This	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
I	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
Such	O
compounds	O
possess	O
both	O
muscarinic	B-GENE
receptor	I-GENE
antagonist	O
and	O
β2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist	O
activities	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
processes	O
and	O
intermediates	O
for	O
preparing	O
such	O
compounds,	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
as	O
bronchodilating	O
agents	O
to	O
treat	O
pulmonary	O
disorders	O
.	O


A	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof,	O
which	O
has	O
a	O
β2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist	O
activity	O
and	O
a	O
muscarin	B-GENE
receptor	I-GENE
antagonist	O
activity	O
.	O
R1	O
is	O
H	O
or	O
a	O
C1-8	O
alkyl	O
.	O
R4	O
is	O
a	O
C1-10	O
alkylene	O
.	O
R2	O
is	O
a	O
single	O
bond,	O
a	O
(	O
substituted	O
)	O
C1-8	O
alkylene,	O
a	O
C2-4	O
alkenylene,	O
or	O
an	O
O-	O
(	O
C1-4	O
alkylene	O
)	O
.	O
X	O
is	O
a	O
single	O
bond,	O
O,	O
CONR3,	O
NR3CO,	O
or	O
NR3COCH2O	O
(	O
wherein	O
R3	O
is	O
H	O
or	O
a	O
C1-8	O
alkyl	O
)	O
.	O
A1	O
is	O
a	O
single	O
bond,	O
a	O
(	O
substituted	O
)	O
C6-10	O
arylene,	O
etc	O
.	O
R8	O
and	O
R9	O
each	O
is	O
X,	O
CN,	O
a	O
C1-6	O
alkyl,	O
etc	O
.	O
a	O
and	O
b	O
each	O
is	O
0-3	O
.	O
W-	O
is	O
an	O
anion	O
.	O
Y	O
is	O
any	O
of	O
formulae	O
(	O
1	O
)	O
to	O
(	O
9	O
)	O
.	O
Q	O
is	O
any	O
of	O
formulae	O
(	O
10	O
)	O
to	O
(	O
12	O
)	O
(	O
wherein	O
R6	O
and	O
R7	O
each	O
is	O
a	O
(	O
substituted	O
)	O
C1-6	O
alkyl	O
or	O
a	O
(	O
substituted	O
)	O
C8-10	O
phenoxyalkyl	O
;	O
n	O
is	O
0-2	O
;	O
m	O
is	O
0-3	O
;	O
and	O
R5	O
is	O
a	O
(	O
substituted	O
)	O
C1-6	O
alkyl	O
(	O
two	O
of	O
R5	O
to	O
R8	O
may	O
form	O
a	O
ring	O
structure	O
)	O
)	O
.	O


Disclosed	O
are	O
:	O
a	O
compound	O
represented	O
by	O
structural	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
;	O
a	O
histone	B-GENE
acetylase	I-GENE
inhibitor	O
;	O
a	O
nuclear	B-GENE
receptor	I-GENE
transcription	O
activation	O
inhibitor	O
;	O
a	O
deuteromycetes	O
belonging	O
to	O
the	O
genus	O
Penicillium,	O
which	O
can	O
produce	O
the	O
compound	O
;	O
a	O
process	O
for	O
producing	O
the	O
compound,	O
which	O
comprises	O
a	O
culturing	O
step	O
of	O
culturing	O
the	O
microorganism	O
and	O
a	O
collection	O
step	O
of	O
collecting	O
the	O
compound	O
from	O
a	O
culture	O
produced	O
in	O
the	O
culturing	O
step	O
;	O
and	O
others	O
.	O


Diastereomeric	O
pyrrolidine	O
compounds	O
and	O
methods	O
of	O
preparation,	O
as	O
can	O
be	O
used	O
en	O
route	O
to	O
the	O
preparation	O
of	O
a	O
range	O
of	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
comprising	O
isolated	O
elastin	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
human	B-GENE
elastin	I-GENE
is	O
substantially	O
insoluble	O
in	O
water	O
with	O
a	O
molecular	O
weight	O
greater	O
than	O
100	O
kDa	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
and	O
kits	O
for	O
soft	O
tissue	O
augmentation	O
.	O


Provided	O
herein	O
are	O
pharmaceutical	O
formulations,	O
methods,	O
and	O
systems	O
for	O
the	O
cosmetic	O
alteration	O
of	O
fat	O
deposits	O
.	O
Methods	O
comprise	O
administering	O
a	O
pharmaceutical	O
formulation	O
of	O
a	O
long-acting	O
beta-2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist,	O
for	O
example,	O
salmeterol,	O
that	O
is	O
suitable	O
for	O
subcutaneous	O
administration	O
.	O
Methods	O
further	O
comprise	O
administering	O
a	O
pharmaceutical	O
formulation	O
that	O
is	O
suitable	O
for	O
subcutaneous	O
injection	O
comprising	O
:	O
(	O
a	O
)	O
a	O
lipophilic	O
long-acting	O
selective	O
beta-2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist	O
and	O
/	O
or	O
glucocorticosteroid,	O
or	O
a	O
salt,	O
optical	O
isomer,	O
racemate,	O
solvate,	O
or	O
polymorph	O
thereof	O
;	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
subcutaneously	O
acceptable	O
inactive	O
ingredient	O


The	O
invention	O
relates	O
to	O
imidazo	O
[	O
1,5-a	O
]	O
quinoxaline	O
derivatives	O
which	O
are	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
10	I-GENE
(	O
PDE10	B-GENE
)	O
useful	O
in	O
treating	O
central	O
nervous	O
system	O
diseases	O
such	O
as	O
psychosis	O
and	O
also	O
in	O
treating,	O
for	O
example,	O
obesity,	O
type	O
2	O
diabetes,	O
metabolic	O
syndrome,	O
glucose	O
intolerance,	O
and	O
pain	O
.	O


The	O
present	O
invention	O
pertains	O
to	O
4-	O
(	O
4-methylpiperazin-1-ylmethyl	O
)	O
-N-	O
[	O
4-methyl-3-	O
(	O
4-pyridin-3-yl	O
)	O
pyrimidin-2-ylamino	O
)	O
phenyl	O
]	O
-benzamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
4-methyl-3-	O
[	O
[	O
4-	O
(	O
3-pyridinyl	O
)	O
-2-pyrimidinyl	O
]	O
amino	O
]	O
-Λ	O
/	O
-	O
[	O
5-	O
(	O
4-methyl-1	O
H-imidazol-1-yl	O
)	O
-3-	O
(	O
trifluoro-	O
methyl	O
)	O
phenyl	O
]	O
benzamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
for	O
the	O
treatment	O
of	O
ophthalmologic	O
disorders	O
mediated	O
by	O
alpha-carbonic	B-GENE
anhydrase	I-GENE
isoforms	O
.	O


A	O
novel	O
C-aryl	O
glucoside	O
compound,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
prodrug	O
thereof	O
having	O
an	O
inhibitory	O
activity	O
against	O
sodium-dependent	B-GENE
glucose	I-GENE
cotransporter	I-GENE
2	I-GENE
(	O
SGLT2	B-GENE
)	O
being	O
present	O
in	O
the	O
intestine	O
and	O
kidney	O
;	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient,	O
which	O
is	O
useful	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders,	O
particularly,	O
diabetes,	O
are	O
provided	O
.	O


Use	O
of	O
puerarin	O
in	O
preparing	O
medicine	O
for	O
treating	O
P2X3-mediated	O
pain	O
and	O
nervous	O
system	O
disease	O
.	O
Experiment	O
verified	O
that	O
puerarin	O
treats	O
acute	O
or	O
chronic	O
pain	O
by	O
blocking	O
transfer	O
of	O
pain	O
sensation	O
information	O
mediated	O
by	O
primary	O
sensory	O
neuron	O
P2X3	B-GENE
receptor	O
.	O
Puerarin	O
has	O
antagonistic	O
effect	O
on	O
P2X3	B-GENE
receptor	O
and	O
therefore	O
can	O
prevent	O
and	O
treat	O
P2X3	B-GENE
receptor-mediated	O
nervous	O
system	O
disease	O
.	O


Provided	O
is	O
a	O
crystalline	O
form	O
of	O
the	O
ethylenediamine	O
salt	O
of	O
[	O
4,6-bis	O
(	O
dimethylamino	O
)	O
-2-	O
(	O
4-	O
{	O
[	O
4-	O
(	O
trifluoromethyl	O
)	O
benzoyl	O
]	O
amino	O
}	O
benzyl	O
)	O
pyrimidin-5-yl	O
]	O
acetic	O
acid,	O
processes	O
for	O
its	O
preparation,	O
pharmaceutical	O
compositions	O
comprising	O
it,	O
and	O
methods	O
of	O
its	O
use	O
for	O
treating,	O
preventing,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
CRTH2-mediated	O
disorder	O
or	O
disease	O
.	O


Disclosed	O
is	O
an	O
agent	O
for	O
inhibiting	O
increase	O
in	O
postprandial	O
blood	O
insulin	B-GENE
level,	O
which	O
contains	O
a	O
polyglutamic	O
acid	O
as	O
an	O
active	O
ingredient	O
.	O


Methods,	O
uses,	O
compositions,	O
combinations	O
and	O
kits	O
relating	O
to	O
the	O
decrease	O
of	O
Tau	B-GENE
protein	I-GENE
levels,	O
and	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
or	O
disorders	O
associated	O
with	O
Tau	B-GENE
protein	I-GENE
(	O
Tauophathies	O
)	O
,	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
using	O
a	O
curcuminoid	O
and	O
a	O
mammalian	O
target	O
of	O
rapamycin	B-GENE
(	O
mTOR	B-GENE
)	O
inhibitor,	O
are	O
described	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
tautomers	O
and	O
salts	O
thereof	O
wherein	O
R1	O
is	O
methyl	O
or	O
ethyl,	O
R2	O
is	O
n-butyl	O
or	O
o-methoxyphenyl,	O
R3	O
is	O
hydrogen	O
or	O
hydroxy	O
;	O
and	O
R4	O
is	O
hydrogen	O
or	O
methyl	O
.	O
These	O
compounds	O
are	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
EphB4	B-GENE
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
angiogenesis	O
dependent	O
cancers	O
and	O
intraocular	O
neovascular	O
syndromes	O
.	O


Disclosed	O
is	O
a	O
therapeutic	O
pharmaceutical	O
composition	O
comprising	O
a	O
thrombolytic	O
agent	O
and	O
an	O
inhibitor	O
capable	O
of	O
inhibiting	O
a	O
signaling	O
that	O
is	O
mediated	O
by	O
a	O
receptor	O
of	O
a	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
.	O
The	O
therapeutic	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
severe	O
ischemic	O
events	O
including	O
cerebral	O
infarction,	O
cardiac	O
infarction	O
and	O
pulmonary	O
embolism	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
diabetes,	O
obesity	O
or	O
disorders	O
related	O
to	O
diabetes	O
or	O
obesity	O
.	O
The	O
compositions	O
comprise	O
a	O
combination	O
of	O
a	O
selective	O
PPARγ	B-GENE
modulator	O
and	O
an	O
incretin	O
.	O
The	O
methods	O
include	O
the	O
administration	O
of	O
the	O
combination	O
of	O
a	O
selective	O
PPARγ	B-GENE
modulator	O
and	O
an	O
incretin	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
cancer,	O
such	O
methods	O
involving	O
the	O
determination	O
of	O
the	O
expression	O
level	O
of	O
C12orf32	B-GENE
genes	O
.	O
These	O
genes	O
were	O
discovered	O
to	O
discriminate	O
cancer	O
cells	O
from	O
normal	O
cells	O
.	O
Furthermore,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
substances	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O
Moreover,	O
the	O
present	O
invention	O
provides	O
siRNAs	O
targeting	O
C12orf32	B-GENE
genes,	O
all	O
of	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O


Disclosed	O
is	O
a	O
compound	O
having	O
an	O
activity	O
of	O
modulating	O
a	O
histamine-H4	B-GENE
receptor	I-GENE
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
Ra	O
and	O
Rb	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group,	O
or	O
the	O
like	O
;	O
X	O
represents	O
-O-	O
or	O
-S	O
(	O
O	O
)	O
p-	O
;	O
p	O
represents	O
an	O
integer	O
of	O
0	O
to	O
2	O
;	O
Y	O
represents	O
=	O
O	O
or	O
=	O
S	O
;	O
R1	O
represents	O
a	O
halogen	O
atom,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group,	O
or	O
the	O
like	O
;	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
4	O
;	O
and	O
R2	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group,	O
or	O
the	O
like	O
]	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
.	O


Disclosed	O
are	O
a	O
diamide-phenyl	O
derivative	O
which	O
inhibits	O
soluble	B-GENE
epoxy	I-GENE
hydrolase	I-GENE
(	O
sEH	B-GENE
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
diamide-phenyl	O
derivative	O
.	O
Specifically	O
disclosed	O
are	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O
(	O
In	O
the	O
formula,	O
A	O
represents	O
a	O
group	O
represented	O
by	O
formula	O
(	O
a	O
)	O
(	O
wherein	O
Ra1,	O
Ra2	O
and	O
Ra3	O
each	O
independently	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R1	O
represents	O
a	O
C1-6	O
alkyl	O
group	O
(	O
which	O
is	O
substituted	O
by	O
a	O
C1-4	O
alkoxy	O
group	O
(	O
which	O
may	O
be	O
substituted	O
by	O
a	O
C1-4	O
alkoxy	O
group	O
)	O
,	O
a	O
C1-4	O
alkylsulfonyl	O
group	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
and	O
R2	O
represents	O
an	O
optionally	O
substituted	O
C1-6	O
alkyl	O
group	O
or	O
an	O
optionally	O
substituted	O
C3-6	O
cycloalkyl	O
group	O
.	O
)	O


Fused	O
heteroaryl	O
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X,	O
R1,	O
R2	O
and	O
R3	O
are	O
defined	O
as	O
in	O
the	O
description	O
are	O
disclosed	O
.	O
The	O
method	O
for	O
preparing	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
phosphoinositide	B-GENE
3-kinase	I-GENE
(	O
PI3K	B-GENE
)	O
inhibitors	O
and	O
anticancer	O
agents	O
are	O
also	O
disclosed	O
.	O


Novel	O
substituted	O
carbonyl	O
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
salts	O
thereof,	O
which	O
exhibit	O
excellent	O
bronchodilating	O
effect	O
that	O
relies	O
on	O
potent	O
EP2	B-GENE
agonist	O
activity	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O
In	O
general	O
formula	O
(	O
I	O
)	O
,	O
R1	O
is	O
-OR5,	O
-O	O
(	O
CH2CH2O	O
)	O
mR6	O
or	O
-NR7R8	O
(	O
wherein	O
R5	O
is	O
C7-22	O
alkyl	O
or	O
the	O
like	O
;	O
R6	O
is	O
H	O
or	O
benzyl	O
;	O
m	O
is	O
1	O
to	O
4	O
;	O
and	O
R7	O
and	O
R8	O
are	O
each	O
H,	O
C1-12	O
alkyl,	O
or	O
the	O
like	O
)	O
;	O
R2	O
and	O
R3	O
are	O
each	O
H	O
or	O
C1-6	O
alkyl	O
;	O
Y	O
is	O
a	O
(	O
substituted	O
)	O
bicyclic	O
heteroaromatic	O
ring,	O
-Q1-Q2,	O
or	O
the	O
like	O
(	O
wherein	O
Q1	O
is	O
arylene	O
or	O
the	O
like	O
;	O
and	O
Q2	O
is	O
a	O
(	O
substituted	O
)	O
5-	O
or	O
6-memebred	O
heterocycle,	O
or	O
the	O
like	O
)	O
;	O
and	O
Z	O
is	O
(	O
substituted	O
)	O
aryl	O
or	O
a	O
(	O
substituted	O
)	O
5-	O
or	O
6-memeberd	O
heteroaromatic	O
ring	O
.	O


The	O
invention	O
features	O
compositions	O
comprising	O
microRNAs	O
that	O
are	O
capable	O
of	O
repressing	O
vIL6	B-GENE
or	O
hIL6,	O
and	O
related	O
methods	O
of	O
using	O
the	O
microRNAs	O
for	O
treating	O
Kaposi	O
'	O
s	O
sarcoma-	O
associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
infections	O
or	O
diseases	O
caused	O
by	O
KSHV	O
.	O


A	O
phosphoproteomic	O
method	O
termed	O
SH2	B-GENE
profiling	O
to	O
characterize	O
phosphotyrosine	O
(	O
pTyr	O
)	O
signaling	O
in	O
lung	O
cancer	O
.	O
This	O
method	O
provides	O
quantitative	O
values	O
for	O
the	O
phosphorylated	O
binding	O
sites	O
for	O
Src	B-GENE
Homology	I-GENE
2	I-GENE
(SH2)	I-GENE
domains,	O
which	O
the	O
cell	O
uses	O
to	O
relay	O
signals	O
from	O
tyrosine	B-GENE
kinases	I-GENE
.	O
Lung	O
cancer	O
cell	O
lines	O
with	O
known	O
mutational	O
status	O
of	O
the	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
and	O
Ras	B-GENE
were	O
profiled	O
.	O
Changes	O
in	O
SH2	B-GENE
domain	I-GENE
binding	O
were	O
characterized	O
in	O
response	O
to	O
the	O
EGFR	B-GENE
inhibitor	O
erlotinib,	O
and	O
the	O
SRC/multi-kinase	B-GENE
inhibitor	O
dasatinib	O
.	O
Cell	O
lines	O
grouped	O
based	O
on	O
SH2	B-GENE
binding	O
patterns	O
.	O
Clusters	O
correlated	O
with	O
EGFR	B-GENE
mutation	O
status	O
or	O
MET	B-GENE
activation	O
.	O
Binding	O
of	O
specific	O
SH2	B-GENE
domains	I-GENE
correlated	O
with	O
EGFR	B-GENE
mutation	O
and	O
erlotinib	O
sensitivity	O
.	O
SH2	B-GENE
domain	I-GENE
profiling	O
identifies	O
subsets	O
of	O
lung	O
cancer	O
cells	O
with	O
distinct	O
patterns	O
of	O
pTyr	O
signaling	O
and	O
provides	O
a	O
powerful	O
molecular	O
diagnostic	O
tool	O
for	O
classification	O
and	O
biomarker	O
identification	O
.	O
This	O
analysis	O
has	O
therapeutic	O
importance	O
for	O
personalized	O
use	O
of	O
tyrosine	B-GENE
kinase	I-GENE
inhibitors	O
in	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
quinolone	O
antibiotic	O
compound	O
of	O
formula	O
(	O
1	O
)	O
capable	O
of	O
promoting	O
the	O
production	O
of	O
G-CSF	B-GENE
in	O
the	O
body,	O
and	O
the	O
medicament	O
for	O
treatment	O
of	O
neutropenia	O
and	O
early	O
recovery	O
of	O
immunocytes,	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
discloses	O
the	O
uses	O
of	O
CRISPLD2	B-GENE
protein	O
and	O
agonists	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
septicemia	O
and	O
septic	O
shock	O
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
septicemia	O
and	O
septic	O
shock,	O
and	O
kits	O
for	O
the	O
prediction	O
of	O
susceptibility	O
to	O
septicemia	O
and	O
septic	O
shock	O
.	O


Provided	O
are	O
compositions	O
and	O
uses	O
of	O
the	O
benzimidazole	O
pyridyl	O
ether	O
{	O
1-methyl-5-	O
[	O
2-	O
(	O
5-tri-fluoromethyl-1H-imidazol-2-yl	O
)	O
-pyridin-4-yloxy	O
]	O
-1H-benzoimidazol-2-yl	O
}	O
-	O
(	O
4-trifluoromethylphenyl	O
)	O
-amine	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
in	O
combination	O
with	O
an	O
activator	O
of	O
AMPK	B-GENE
(	O
AMP-activated	B-GENE
protein	I-GENE
kinase	I-GENE
)	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
RNA-binding	O
protein	O
modulating	O
agents	O
to	O
treat	O
of	O
cancer,	O
particularly	O
patients	O
that	O
are	O
susceptible	O
to	O
or	O
diagnosed	O
with	O
estrogen	O
receptor-negative	O
breast	O
cancer,	O
such	O
as	O
methods	O
of	O
inhibiting	O
the	O
growth	O
or	O
metastasis	O
of	O
cancer	O
cells	O
comprising	O
contacting	O
cells	O
with	O
a	O
therapeutically-effective	O
amount	O
of	O
an	O
HuR-modulating	O
agent	O
.	O
The	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
therapeutically-effective	O
amounts	O
of	O
an	O
HuR-modulating	O
agent	O
.	O


Disclosed	O
are	O
:	O
an	O
antisense	O
nucleotide	O
which	O
contains	O
a	O
sequence	O
complementary	O
to	O
IFN-α	B-GENE
mRNA,	O
especially	O
a	O
sequence	O
complementary	O
to	O
a	O
base	O
sequence	O
in	O
the	O
SL1	O
and	O
/	O
or	O
SL2	O
region	O
of	O
IFN-α	B-GENE
mRNA,	O
and	O
which	O
is	O
capable	O
of	O
enhancing	O
the	O
expression	O
of	O
IFN-α	B-GENE
;	O
an	O
IFN-α	B-GENE
expression	O
enhancer	O
and	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
viral	O
infectious	O
diseases	O
or	O
cancer,	O
each	O
containing	O
the	O
antisense	O
nucleotide	O
;	O
a	O
sense	O
oligonucleotide	O
which	O
contains	O
a	O
sequence	O
complementary	O
to	O
endogenous	O
asRNA	O
for	O
IFN-α	B-GENE
mRNA,	O
especially	O
a	O
sequence	O
homologous	O
to	O
a	O
base	O
sequence	O
in	O
the	O
SL1	O
or	O
SL2	O
region	O
of	O
IFN-α	B-GENE
mRNA,	O
and	O
which	O
is	O
capable	O
of	O
modulating	O
the	O
expression	O
of	O
IFN-α	B-GENE
;	O
and	O
an	O
IFN-α	B-GENE
expression	O
modulator	O
which	O
contains	O
the	O
sense	O
oligonucleotide	O
.	O


A	O
composition	O
for	O
aiding	O
an	O
anti-cancer	O
agent	O
or	O
radiation	O
therapy	O
including	O
a	O
nuclear	B-GENE
factor	I-GENE
E2	I-GENE
factor	I-GENE
related-factor	I-GENE
2	I-GENE
(	O
Nrf2	B-GENE
)	O
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
benzo-heterocycle	O
derivatives,	O
and	O
more	O
particularly,	O
to	O
a	O
composition	O
for	O
preventing	O
and	O
treating	O
cancer,	O
comprising	O
benzo-heterocycle	O
derivatives	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
as	O
active	O
ingredients	O
.	O
The	O
inventors	O
of	O
the	O
present	O
invention	O
have	O
found	O
that	O
KRS	B-GENE
interacts	O
with	O
67LR	B-GENE
to	O
promote	O
the	O
migration	O
of	O
cancer	O
(	O
or	O
tumor	O
)	O
cells	O
and	O
thus	O
affects	O
the	O
metastasis	O
of	O
cancer,	O
and	O
also	O
have	O
identified	O
that	O
the	O
substance	O
which	O
inhibits	O
the	O
interaction	O
between	O
the	O
KRS	B-GENE
and	O
67LR	B-GENE
suppresses	O
the	O
metastasis	O
of	O
cancer	O
cells,	O
and	O
thus	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O
Accordingly,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
suppresses	O
the	O
metastasis	O
of	O
cancer,	O
and	O
therefore	O
provides	O
a	O
novel	O
means	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
medicaments,	O
their	O
methods	O
of	O
preparation,	O
as	O
well	O
as	O
methods	O
of	O
diagnosis	O
and	O
imaging	O
of	O
mammalian	O
tumors	O
with	O
[	O
131I	O
]	O
-MIBG	O
and	O
/	O
or	O
[	O
123I	O
]	O
-MIBG	O
.	O
A	O
method	O
for	O
treating	O
a	O
mammalian	O
tumor	O
which	O
comprises	O
administering	O
to	O
a	O
mammal	O
having	O
a	O
tumor,	O
a	O
composition	O
comprising	O
a	O
histone	B-GENE
deacetylase	I-GENE
inhibitor,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof,	O
in	O
an	O
effective	O
amount	O
for	O
at	O
least	O
about	O
forty-eight	O
hours,	O
and	O
followed	O
by	O
administering	O
to	O
the	O
mammal	O
a	O
composition	O
comprising	O
an	O
effective	O
amount	O
of	O
[	O
131I	O
]	O
-MIBG	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof	O
is	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
humans,	O
including	O
four	O
active	O
principles	O
selected	O
as	O
:	O
a	O
non-nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitor	O
(	O
NNRTI	O
)	O
selected	O
from	O
nevirapine,	O
efavirenz	O
and	O
etravirine	O
;	O
a	O
nucleoside	O
reverse	B-GENE
transcriptase	I-GENE
inhibitor	O
(	O
NARTI	O
)	O
selected	O
from	O
lamivudine	O
and	O
emtricitabine	O
;	O
and	O
two	O
different	O
nucleoside	O
or	O
nucleotide	O
reverse	B-GENE
transcriptase	I-GENE
inhibitors	O
(	O
NARTI	O
)	O
selected	O
from	O
didanosine,	O
abacavir	O
and	O
tenofovir	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
Ia	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
invention	O
also	O
provides	O
use	O
of	O
the	O
compounds	O
or	O
salts	O
as	O
modulators	O
of	O
Kv3.1	B-GENE
and	O
/	O
or	O
Kv3	O
.	O
2,	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
where	O
a	O
modulator	O
of	O
Kv3.1	B-GENE
and	O
/	O
or	O
Kv3.2	B-GENE
is	O
required,	O
such	O
as	O
depression	O
and	O
mood	O
disorders,	O
hearing	O
disorders,	O
schizopherenea,	O
substance	O
abuse	O
disorders,	O
sleep	O
disorders	O
or	O
epilepsy	O
.	O


Aminoalkyipyrimidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
meaning	O
of	O
the	O
different	O
substituents	O
are	O
those	O
indicated	O
in	O
the	O
description	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
histamine	B-GENE
H4	I-GENE
receptor	I-GENE
antagonists	O
.	O


Disclosed	O
is	O
a	O
novel	O
compound	O
which	O
has	O
excellent	O
IκB	B-GENE
kinase	I-GENE
inhibitory	O
activity	O
and	O
TNFα	B-GENE
production	O
inhibitory	O
activity,	O
and	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
for	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
associated	O
with	O
NF-κB	B-GENE
and	O
TNFα	B-GENE
.	O
Specifically	O
disclosed	O
is	O
a	O
novel	O
dihydrothieno	O
[	O
2,3-e	O
]	O
indazole	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
.	O
Also	O
specifically	O
disclosed	O
are	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
dihydrothieno	O
[	O
2,3-e	O
]	O
indazole	O
compound,	O
and	O
use	O
of	O
the	O
dihydrothieno	O
[	O
2,3-e	O
]	O
indazole	O
compound	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
.	O


The	O
instant	O
invention	O
relates	O
to	O
new	O
chemical	O
entities	O
which	O
comprise	O
corticosteroids,	O
phosphorylated	O
β-agonists	O
and	O
muscarinic	B-GENE
(M3)	I-GENE
antagonists	O
for	O
use	O
in	O
therapy	O
and	O
compositions	O
comprising	O
and	O
processes	O
for	O
preparing	O
the	O
same	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
A,	O
Cy,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
NURR-1	B-GENE
nuclear	O
receptor	O
modulators	O
.	O


The	O
present	O
invention	O
provides	O
for	O
novel	O
benzene	O
compounds	O
and	O
saccharide	O
compounds	O
and	O
for	O
the	O
use	O
of	O
said	O
compounds	O
for	O
binding,	O
titration	O
(	O
quantification	O
)	O
,	O
removing,	O
purifying	O
or	O
separating	O
the	O
glycoprotein	O
gp120,	O
gp120	O
comprising	O
viruses	O
or	O
cells	O
infected	O
with	O
gp120	O
comprising	O
viruses	O
.	O
The	O
invention	O
also	O
provides	O
for	O
a	O
method	O
for	O
the	O
detection,	O
binding,	O
titration	O
(	O
quantification	O
)	O
,	O
removal,	O
purification	O
or	O
separation	O
of	O
(	O
or	O
directing	O
therapeutic	O
or	O
other	O
agents	O
to	O
)	O
gp120,	O
gp120	O
comprising	O
viruses	O
or	O
cells	O
infected	O
with	O
gp120	O
comprising	O
viruses	O
.	O
The	O
invention	O
further	O
provides	O
for	O
the	O
use	O
of	O
the	O
compounds	O
and	O
for	O
methods	O
using	O
the	O
compounds	O
for	O
directing	O
anti	O
-viral	O
drugs	O
or	O
other	O
agents	O
to	O
gp120	O
comprising	O
viruses	O
or	O
to	O
gp120	O
comprising	O
virus	O
-	O
infected	O
cells	O
.	O
The	O
present	O
invention	O
also	O
provides	O
processes	O
for	O
the	O
preparation	O
of	O
said	O
novel	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
chromium-carbonyl	O
complexes	O
and	O
a	O
method	O
for	O
the	O
preparation	O
of	O
the	O
latter	O
as	O
well	O
as	O
use	O
of	O
the	O
inventive	O
chromium-carbonyl	O
complexes	O
to	O
inhibit	O
NOD1	B-GENE
and	O
/	O
or	O
NOD2	B-GENE
in	O
the	O
immune	O
system	O
of	O
vertebrates	O
.	O
In	O
a	O
further	O
aspect,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
inventive	O
chromium-carbonyl	O
complexes	O
as	O
pharmaceutical	O
active	O
ingredients	O
in	O
a	O
pharmaceutical	O
composition	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
cinchonine	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
obesity,	O
dyslipidemia,	O
fatty	O
liver,	O
or	O
insulin	B-GENE
resistance	O
syndrome	O
.	O
The	O
composition	O
of	O
the	O
present	O
invention	O
containing	O
cinchonine	O
as	O
an	O
active	O
ingredient	O
may	O
inhibit	O
the	O
differentiation	O
of	O
fat	O
cells,	O
reduce	O
body	O
fat	O
mass,	O
reduce	O
visceral	O
fat,	O
reduce	O
a	O
total	O
cholesterol	O
concentration,	O
reduce	O
plasma	O
triglyceride	O
and	O
liver	O
triglyceride,	O
normalize	O
liver	O
function	O
marker	O
enzyme	O
expression,	O
and	O
eventually	O
promote	O
the	O
prevention	O
or	O
treatment	O
of	O
obesity,	O
dyslipidemia,	O
or	O
fatty	O
liver	O
.	O
In	O
addition,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
may	O
induce	O
a	O
significant	O
reduction	O
in	O
the	O
fasting	O
blood	O
sugar	O
level	O
and	O
blood	O
insulin	B-GENE
concentration	O
level	O
resulting	O
in	O
the	O
effect	O
of	O
improving	O
type	O
2	O
diabetes	O
or	O
insulin	B-GENE
resistance,	O
in	O
addition	O
to	O
the	O
metabolic	O
diseases	O
closely	O
related	O
thereto	O
.	O


There	O
are	O
described	O
4-difluoromethoxyphenyl	O
pyrazolo	O
[	O
5	O
.	O
1-b	O
]	O
oxazole	O
derivatives	O
useful	O
as	O
corticotropin	B-GENE
releasing	I-GENE
factor	I-GENE
(CRF1)	I-GENE
receptor	I-GENE
antagonists	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
inhibitors	O
of	O
S100	B-GENE
protein	O
binding	O
interactions,	O
such	O
as,	O
for	O
example,	O
the	O
annexin	O
A2-S100A10	O
protein	O
binding	O
interaction	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
concerns	O
certain	O
substituted	O
pyrrole	O
derivatives	O
of	O
the	O
general	O
formula	O
I	O
or	O
II	O
as	O
defined	O
herein,	O
as	O
well	O
as	O
processes	O
for	O
preparing	O
these	O
derivatives,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment,	O
prevention	O
or	O
delay	O
of	O
progression	O
of	O
diseases	O
in	O
which	O
S100	B-GENE
protein	O
binding	O
interactions	O
are	O
implicated	O
(	O
such	O
as	O
cancer	O
)	O
.	O


An	O
ultrasound-mediated	O
gene	O
transfer	O
method	O
named	O
Ultrasound	O
Targeted	O
Microbubble	O
Destruction	O
(	O
UTMD	O
)	O
for	O
the	O
delivery	O
of	O
human	B-GENE
vascular	I-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
hVEGF	B-GENE
)	O
gene	O
to	O
transplanted	O
islets	O
and	O
the	O
surrounding	O
tissue	O
is	O
described	O
herein	O
.	O
The	O
delivery	O
of	O
hVEGF	B-GENE
promotes	O
islet	O
revascularization	O
and	O
survival	O
.	O
The	O
inventors,	O
first	O
transplanted	O
human	O
islets	O
were	O
transplanted	O
into	O
diabetic	O
nude	O
mice	O
liver	O
followed	O
by	O
the	O
induction	O
of	O
non-viral	O
plasmid	O
vectors	O
encoding	O
hVEGF	B-GENE
or	O
Green	O
Fluorescent	O
Protein	O
(	O
GFP	O
)	O
gene	O
in	O
the	O
host	O
liver	O
by	O
UTMD	O
.	O
Transplantation	O
without	O
gene	O
delivery	O
was	O
also	O
performed	O
as	O
a	O
control	O
.	O
Blood	O
glucose,	O
serum	O
human	O
insulin,	O
C-peptide	O
levels	O
and	O
the	O
revascularization	O
in	O
graft	O
islets	O
were	O
evaluated	O
.	O
The	O
findings	O
of	O
the	O
method	O
of	O
the	O
present	O
invention	O
indicated	O
that	O
hVEGF	B-GENE
gene	O
delivery	O
to	O
host	O
liver	O
using	O
UTMD	O
promoted	O
islet	O
revascularization	O
after	O
islet	O
transplantation	O
and	O
improved	O
the	O
restoration	O
of	O
euglycemia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
indirubin-3	O
'	O
-oxime	O
derivative	O
as	O
potent	O
cyclin	B-GENE
dependent	I-GENE
kinase	I-GENE
inhibitor	O
with	O
anti-cancer	O
activity	O
.	O
More	O
particularly,	O
this	O
invention	O
relates	O
to	O
an	O
indirubin-3	O
'	O
-oxime	O
derivative	O
as	O
potent	O
cyclin	B-GENE
dependent	I-GENE
kinase	I-GENE
inhibitor	O
having	O
excellent	O
anti-cancer	O
activity	O
against	O
human	O
lung	O
cancer	O
cell,	O
human	O
fibro	O
sarcoma	O
cell,	O
human	O
colon	O
cancer	O
cell,	O
human	O
leukemia	O
cell,	O
human	O
stomach	O
cancer	O
cell,	O
human	O
nasopharyngeal	O
cancer	O
cell	O
and	O
/	O
or	O
human	O
breast	O
cancer	O
cell	O
.	O


Compounds	O
represented	O
by	O
the	O
formulae	O
:	O
wherein	O
R	O
is	O
individually	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
H,	O
aliphatic	O
acyl,	O
aromatic	O
acyl	O
group,	O
fluoro,	O
chloro,	O
bromo,	O
iodo,	O
alkoxy,	O
alkyl,	O
haloalkyl,	O
alkenyl,	O
haloalkenyl,	O
alkynyl,	O
amino,	O
monoalkylamino,	O
dialkylamino,	O
cyano,	O
aryl	O
and	O
nitro	O
;	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
prodrugs	O
thereof,	O
solvates	O
thereof	O
and	O
mixtures	O
thereof	O
;	O
are	O
used	O
as	O
inhibitors	O
of	O
DNA	B-GENE
methytransferase	I-GENE
and	O
for	O
treating	O
patients	O
suffering	O
from	O
diseases	O
resulting	O
from	O
or	O
related	O
to	O
aberrant	O
DNA	O
methylation	O
such	O
as	O
myelodysplastic	O
syndromes	O
and	O
other	O
cancers	O
.	O


This	O
invention	O
relates	O
crystalline	O
hydrates	O
of	O
N-	O
[	O
3-fluoro-4-	O
(	O
{	O
6-	O
(	O
methyloxy	O
)	O
-7-	O
[	O
(	O
3-	O
morpholin-4-ylpropyl	O
)	O
oxy	O
]	O
quinolin-4-yl	O
}	O
oxy	O
)	O
phenyl	O
]	O
-N	O
'	O
-	O
(	O
4-fluorophenyl	O
)	O
cyclopropane-1,1-dicarboxamide,	O
Compound	O
(	O
I	O
)	O
.	O
The	O
invention	O
provides	O
methods	O
for	O
treatment	O
of	O
cancer	O
by	O
exploiting	O
the	O
modulation	O
of	O
protein	B-GENE
kinase	I-GENE
activity	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
a	O
crystalline	O
hydrate	O
of	O
Compound	O
(	O
I	O
)	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O


The	O
invention	O
relates	O
to	O
nucleic	O
acid	O
molecules	O
and	O
compositions	O
for	O
specific	O
post-transcriptional	O
inhibition	O
of	O
PKM2	B-GENE
expression	O
.	O
Methods	O
for	O
specific	O
inhibition	O
of	O
PKM2	B-GENE
expression	O
in	O
a	O
target	O
cell,	O
for	O
example	O
a	O
cancer	O
cell,	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
identification	O
of	O
a	O
compound	O
which	O
inhibits	O
the	O
enzyme	O
NMPRTase	B-GENE
and	O
glioma	O
cancer	O
cell	O
growth	O
and	O
further	O
used	O
for	O
glioma	O
therapy	O
.	O
Pre-B-	B-GENE
cell	I-GENE
colony	I-GENE
enhancing	I-GENE
factor	I-GENE
1	I-GENE
gene	I-GENE
(	O
PBEF1	B-GENE
)	O
encodes	O
nicotinamide	B-GENE
phosphoribosyltransferase	I-GENE
(	O
NMPRTase	B-GENE
)	O
,	O
which	O
catalyses	O
the	O
rate	O
limiting	O
step	O
in	O
the	O
salvage	O
pathway	O
of	O
NAD	O
metabolism	O
in	O
mammalian	O
cells	O
.	O
PBEF1	B-GENE
transcript	O
and	O
protein	O
levels	O
have	O
been	O
shown	O
to	O
be	O
elevated	O
in	O
glioblastoma	O
and	O
a	O
chemical	O
inhibitor	O
of	O
NMPRTase	B-GENE
has	O
been	O
shown	O
to	O
specifically	O
inhibit	O
cancer	O
cells	O
.	O
Here	O
a	O
structure	O
based	O
drug	O
discovery	O
approach	O
has	O
been	O
reported	O
with	O
an	O
aim	O
to	O
develop	O
novel	O
inhibitors	O
for	O
glioblastoma	O
therapy	O
.	O
Present	O
invention	O
relates	O
to	O
virtual	O
screening	O
using	O
docking	O
of	O
ligands	O
from	O
a	O
large	O
library	O
of	O
13,000	O
compounds	O
against	O
NMPRTase	B-GENE
as	O
the	O
macromolecular	O
target	O
resulting	O
in	O
short	O
listing	O
of	O
34	O
possible	O
ligands,	O
of	O
which	O
six	O
were	O
tested	O
experimentally,	O
using	O
the	O
NMPRTase	B-GENE
enzyme	O
inhibition	O
assay	O
and	O
further	O
with	O
the	O
glioma	O
cell	O
viability	O
assays	O
.	O
Of	O
these,	O
two	O
compounds	O
were	O
found	O
to	O
be	O
significantly	O
efficacious	O
in	O
inhibiting	O
the	O
conversion	O
of	O
nicotinamide	O
to	O
NAD,	O
and	O
out	O
of	O
which	O
one	O
compound,	O
3-amino-2-benzyl-7-nitro-4-	O
(	O
2-quinolyl-	O
)	O
-l,2-	O
dihydroisoquinolin-l	O
-one,	O
was	O
found	O
to	O
inhibit	O
the	O
growth	O
of	O
a	O
PBEF1	B-GENE
over	O
expressing	O
glioma	O
derived	O
cell	O
line	O
U87	O
also	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
macrolide	O
inhibitors	O
of	O
mTOR,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
(	O
Formula	O
I	O
)	O
.	O


Substituted	O
bicyclic	O
heteroaryls	O
and	O
compositions	O
containing	O
them,	O
for	O
the	O
treatment	O
of	O
general	O
inflammation,	O
arthritis,	O
rheumatic	O
diseases,	O
osteoarthritis,	O
inflammatory	O
bowel	O
disorders,	O
inflammatory	O
eye	O
disorders,	O
inflammatory	O
or	O
unstable	O
bladder	O
disorders,	O
psoriasis,	O
skin	O
complaints	O
with	O
inflammatory	O
components,	O
chronic	O
inflammatory	O
conditions,	O
including	O
but	O
not	O
restricted	O
to	O
autoimmune	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosis	O
(	O
SLE	O
)	O
,	O
myestenia	O
gravis,	O
rheumatoid	O
arthritis,	O
acute	O
disseminated	O
encephalomyelitis,	O
idiopathic	O
thrombocytopenic	O
purpura,	O
multiples	O
sclerosis,	O
Sjoegren	O
'	O
s	O
syndrome	O
and	O
autoimmune	O
hemolytic	O
anemia,	O
allergic	O
conditions	O
including	O
all	O
forms	O
of	O
hypersensitivity,	O
The	O
present	O
invention	O
also	O
enables	O
methods	O
for	O
treating	O
cancers	O
that	O
are	O
mediated,	O
dependent	O
on	O
or	O
associated	O
with	O
p110	B-GENE
activity,	O
including	O
but	O
not	O
restricted	O
to	O
leukemias,	O
such	O
as	O
Acute	O
Myeloid	O
leukaemia	O
(	O
AML	O
)	O
Myelo-dysplastic	O
syndrome	O
(	O
MDS	O
)	O
myelo-proliferative	O
diseases	O
(	O
MPD	O
)	O
Chronic	O
Myeloid	O
Leukemia	O
(	O
CML	O
)	O
T-cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
T-ALL	O
)	O
B-cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
B-ALL	O
)	O
Non	O
Hodgkins	O
Lymphoma	O
(	O
NHL	O
)	O
B-cell	O
lymphoma	O
and	O
solid	O
tumors,	O
such	O
as	O
breast	O
cancer	O
.	O


A	O
medication	O
that	O
has	O
excellent	O
agonist	O
effects	O
on	O
CaSR	B-GENE
and	O
enables	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes	O
or	O
obesity	O
is	O
provided	O
by	O
means	O
of	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
defined	O
in	O
the	O
description,	O
or	O
a	O
composition	O
comprising	O
a	O
salt	O
thereof	O
.	O


Two	O
new	O
compounds	O
with	O
anticancer	O
effects	O
of	O
N-	O
[	O
4-chloro-3-	O
(	O
trifluoromethyl	O
)	O
phenyl	O
]	O
-	O
[	O
4-	O
(	O
N-methyl-formamide	O
)	O
(	O
4-pyridyloxy	O
)	O
phenyl	O
]	O
-thiourea	O
and	O
N-	O
[	O
4-chloro-3-	O
(	O
trifluoromethyl	O
)	O
phenyl	O
]	O
-	O
[	O
4-	O
(	O
N-methyl-formamide	O
)	O
(	O
4-pyridylthio	O
)	O
phenyl	O
]	O
-thiourea,	O
and	O
salts	O
thereof	O
are	O
disclosed	O
.	O
Preparation	O
methods	O
of	O
the	O
two	O
new	O
compounds	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
new	O
compounds	O
are	O
further	O
disclosed	O
.	O
Experimental	O
studies	O
show	O
that	O
the	O
two	O
new	O
compounds	O
can	O
effectively	O
inhibit	O
the	O
activity	O
of	O
Raf	B-GENE
and	O
VEGFR	B-GENE
protein	O
kinase,	O
widely	O
inhibit	O
growth	O
of	O
various	O
types	O
of	O
human	O
tumor	O
cell	O
lines	O
and	O
further	O
induce	O
apoptosis	O
of	O
tumor	O
cells	O
.	O
Human	O
tumor	O
heterograft	O
model	O
investigation	O
proves	O
that	O
the	O
two	O
new	O
compounds	O
are	O
effective	O
antineoplastic	O
agents,	O
and	O
can	O
sharply	O
inhibit	O
growth	O
of	O
human	O
liver	O
cancer	O
cells,	O
lung	O
cancer	O
cells	O
and	O
intestinal	O
cancer	O
cells	O
in	O
vivo	O
.	O
Furthermore,	O
the	O
anticancer	O
effects	O
of	O
the	O
compounds	O
are	O
much	O
better	O
than	O
that	O
of	O
sorafenib	O
.	O


Therapeutic	O
compounds	O
are	O
disclosed	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders,	O
including	O
type	O
II	O
diabetes	O
.	O
The	O
compounds	O
have	O
activity	O
as	O
agonists	O
of	O
GPR119	B-GENE
.	O
Compounds	O
having	O
the	O
stereochemistry	O
of	O
formula	O
(	O
la	O
)	O
may	O
also	O
demonstrate	O
DPP-IV	B-GENE
inhibitory	O
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
tricarbonyl	O
technetium-99m	O
or	O
rhenium-188	O
label	O
ring	O
RGD	O
derivative,	O
a	O
preparation	O
method	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
derivative	O
as	O
an	O
active	O
ingredient	O
for	O
use	O
in	O
the	O
diagnosis	O
or	O
treatment	O
of	O
angiogenesis-related	O
diseases	O
.	O
The	O
tricarbonyl	O
technetium-99m	O
or	O
rhenium-188	O
label	O
ring	O
RGD	O
derivative	O
of	O
the	O
present	O
invention	O
has	O
a	O
high	O
subnanomolar	O
affinity	O
to	O
αvβ3	B-GENE
integrin	I-GENE
(	O
also	O
called	O
as	O
a	O
vitronectin	B-GENE
receptor	I-GENE
that	O
is	O
activated	O
in	O
an	O
angiogenic	O
action	O
induced	O
by	O
a	O
tumor,	O
reflects	O
a	O
high	O
tumor	O
image	O
after	O
an	O
animal	O
in	O
which	O
cancer	O
cells	O
are	O
transplanted	O
received	O
an	O
initial	O
intake	O
of	O
the	O
tricarbonyl	O
technetium-99m	O
label	O
ring	O
RGD	O
derivative,	O
and	O
acts	O
exclusively	O
upon	O
cancer	O
cells	O
having	O
selectively	O
activated	O
αvβ3	B-GENE
integrin	I-GENE
because	O
of	O
a	O
substantially	O
low	O
intake	O
into	O
the	O
liver	O
and	O
intestines,	O
compared	O
to	O
existing	O
known	O
radioactive	O
isotope	O
label	O
ring	O
RGD	O
derivatives	O
.	O
These	O
results	O
show	O
that	O
the	O
rhenium-188	O
label	O
derivative,	O
a	O
therapeutic	O
nuclide	O
using	O
the	O
same	O
precursor	O
as	O
used	O
in	O
the	O
technetium-99m	O
label,	O
effectively	O
inhibits	O
the	O
growth	O
of	O
a	O
tumor	O
and	O
demonstrates	O
therapeutic	O
efficacy	O
when	O
administered	O
via	O
tail	O
vein	O
injection	O
to	O
an	O
animal	O
model	O
of	O
a	O
tumor,	O
compared	O
to	O
a	O
case	O
where	O
only	O
saline	O
has	O
been	O
injected,	O
thereby	O
making	O
it	O
useful	O
as	O
a	O
medicine	O
for	O
the	O
diagnosis	O
or	O
treatment	O
of	O
angiogenesis-related	O
diseases	O
.	O


Provided	O
herein	O
are	O
PAK	B-GENE
inhibitors	O
and	O
methods	O
of	O
utilizing	O
PAK	B-GENE
inhibitors	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O
such	O
as	O
neuropsychiatric	O
disoders	O
.	O


Described	O
herein	O
is	O
the	O
LPAl	B-GENE
antagonist	O
{	O
4	O
'	O
-	O
[	O
3-methyl-4-	O
(	O
(	O
R	O
)	O
-l-phenyl-ethoxycarbonylamino	O
)	O
-isoxazol-5-yl	O
]	O
-biphenyl-4-yl	O
}	O
-acetic	O
acid	O
(	O
Compound	O
1	O
)	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
Also	O
described	O
are	O
methods	O
of	O
preparing	O
the	O
LPAl	B-GENE
antagonist,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
suitable	O
for	O
administration	O
to	O
a	O
mammal	O
that	O
include	O
the	O
LPAl	B-GENE
antagonist,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
methods	O
of	O
using	O
such	O
pharmaceutical	O
compositions	O
for	O
treating	O
LPA-dependent	O
or	O
LPA-mediated	O
diseases	O
or	O
conditions	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
wherein	O
A	O
is	O
selected	O
from	O
the	O
groups	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
:	O
formula	O
(	O
II	O
)	O
or	O
formula	O
(	O
III	O
)	O
(	O
b	O
)	O
or	O
is	O
cycloalkyl,	O
(	O
c	O
)	O
optionally	O
substituted	O
by	O
lower	O
alkyl	O
(	O
c	O
)	O
;	O
Ar1	O
is	O
phenyl	O
or	O
a	O
six	O
membered	O
heteroaryl	O
;	O
X1	O
is	O
N	O
or	O
CH	O
;	O
X2	O
is	O
N-R1	O
or	O
O	O
;	O
R1	O
is	O
S	O
(	O
O	O
)	O
2-lower	O
alkyl,	O
C	O
(	O
O	O
)	O
-cycloalkyl	O
substituted	O
by	O
lower	O
alkyl,	O
or	O
is	O
C	O
(	O
O	O
)	O
-lower	O
alkyl,	O
lower	O
alkyl,	O
cyano,	O
cycloalkyl	O
or	O
is	O
a	O
six	O
membered	O
heteroaryl	O
substituted	O
by	O
lower	O
alkyl,	O
cyano,	O
C	O
(	O
O	O
)	O
-lower	O
alkyl,	O
halogen,	O
lower	O
alkyl	O
substituted	O
by	O
halogen	O
or	O
lower	O
alkoxy	O
;	O
or	O
is	O
phenyl	O
substituted	O
by	O
cyano	O
or	O
halogen	O
;	O
R2	O
is	O
lower	O
alkyl,	O
halogen,	O
pyrazolyl,	O
3-methyl-	O
[	O
1,2,4	O
]	O
oxazolyl,	O
5-methyl-	O
[	O
1,2,4	O
]	O
oxadiazol-3-yl,	O
pyridyl	O
substituted	O
by	O
cyano,	O
or	O
is	O
phenyl	O
substituted	O
by	O
halogen,	O
or	O
is	O
cyano,	O
lower	O
alkoxy,	O
or	O
is	O
piperidin-2-one	O
;	O
or	O
to	O
pharmaceutically	O
active	O
salts,	O
sterioisomeric	O
forms,	O
including	O
individual	O
diastereoisomers	O
and	O
enantiomers	O
of	O
the	O
compound	O
of	O
formula	O
I	O
as	O
well	O
as	O
racemic	O
and	O
non-racemic	O
mixtures	O
thereof	O
.	O
.	O
It	O
has	O
been	O
found	O
that	O
the	O
present	O
compounds	O
are	O
high	O
potential	O
NK-3	B-GENE
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
depression,	O
pain,	O
psychosis,	O
Parkinsons	O
disease,	O
schizophrenia,	O
anxiety	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O


Amide	O
substituted	O
indazoles	O
and	O
benzotriazoles	O
as	O
inhibitors	O
of	O
the	O
enzyme	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
(	O
PARP	B-GENE
)	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
mono-therapies	O
in	O
tumors	O
with	O
specific	O
defects	O
in	O
DNA-repair	O
pathways,	O
as	O
enhancers	O
of	O
certain	O
DNA-damaging	O
agents	O
such	O
as	O
anticancer	O
agents	O
and	O
radiotherapy,	O
for	O
reducing	O
cell	O
necrosis	O
(	O
in	O
stroke	O
and	O
myocardial	O
infarction	O
)	O
,	O
regulating	O
inflammation	O
and	O
tissue	O
injury,	O
treating	O
retroviral	O
infections,	O
and	O
protecting	O
against	O
the	O
toxicity	O
of	O
chemotherapy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
family	O
of	O
cyclic	O
polyethers	O
of	O
general	O
formula	O
(	O
I	O
)	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
tau-	O
and	O
β-amyloid-linked	O
neurodegenerative	O
diseases	O
and	O
to	O
a	O
method	O
for	O
synthesizing	O
said	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
relates	O
to	O
substituted	O
pyridine	O
compounds	O
of	O
Formula	O
I	O
:	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
prodrug,	O
or	O
solvate	O
thereof,	O
wherein	O
A1,	O
X,	O
A2,	O
R1a,	O
R1b,	O
R1c,	O
G,	O
and	O
z	O
are	O
defined	O
as	O
set	O
forth	O
in	O
the	O
specification	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
I	O
to	O
treat	O
a	O
disorder	O
responsive	O
to	O
the	O
blockade	O
of	O
sodium	B-GENE
channels	I-GENE
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
especially	O
useful	O
for	O
treating	O
pain	O
.	O


A	O
nitrogenated	O
aromatic	O
heterocyclic	O
ring	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
W	O
represents	O
CR3	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R9	O
represents	O
a	O
pyrazolyl	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
;	O
and	O
R12	O
and	O
R13	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
(	O
wherein	O
N-	O
[	O
2-chloro-4-	O
(	O
6,7-dimethoxy-4-	O
quinolyloxy	O
)	O
phenyl	O
]	O
-N	O
'	O
-	O
(	O
5-methyl-3-isooxazolyl	O
)	O
urea	O
is	O
excluded	O
from	O
the	O
derivative	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
FGFR	B-GENE
inhibitor	O
or	O
the	O
like	O
which	O
comprises	O
the	O
derivative	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O


Imidazoline	O
derivatives	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmacologically	O
acceptable	O
salts	O
thereof,	O
which	O
exhibit	O
high	O
selectivity	O
for	O
α1L	B-GENE
and	O
are	O
useful	O
as	O
drugs	O
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O
.	O
In	O
general	O
formula	O
(	O
I	O
)	O
,	O
either	O
X	O
or	O
Y	O
is	O
hydrogen,	O
and	O
the	O
other	O
is	O
NR1R2	O
;	O
R1	O
and	O
R2	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
are	O
each	O
hydrogen	O
or	O
methyl	O
;	O
and	O
Z	O
is	O
chloro	O
or	O
methyl	O
.	O


[	O
Problem	O
]	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
preparation	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
various	O
diseases,	O
which	O
comprises	O
a	O
compound	O
capable	O
of	O
increasing	O
a	O
translation	O
initiation	O
factor	O
or	O
a	O
transcription	O
elongation	O
factor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O
[	O
Solution	O
]	O
The	O
present	O
inventors	O
made	O
extensive	O
studies	O
for	O
the	O
purpose	O
of	O
solving	O
the	O
problem,	O
and	O
it	O
is	O
found	O
for	O
the	O
first	O
time	O
that	O
the	O
increase	O
in	O
a	O
translation	O
initiation	O
factor	O
(	O
e	O
.	O
g	O
.	O
,	O
eIF4A1	B-GENE
)	O
or	O
a	O
translation	O
elongation	O
factor	O
(	O
e	O
.	O
g	O
.	O
,	O
eEF1A1	B-GENE
)	O
is	O
involved	O
in	O
the	O
NGF-induced	O
neurite	O
elongation	O
potentiating	O
activity	O
of	O
minocycline	O
or	O
cilostazol,	O
and	O
the	O
invention	O
has	O
been	O
accomplished	O
.	O


Benzohydrol	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method,	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
use	O
thereof	O
are	O
disclosed	O
in	O
the	O
invention	O
.	O
The	O
derivatives	O
can	O
be	O
used	O
as	O
rennin	B-GENE
inhibitors	O
to	O
prepare	O
the	O
drugs	O
for	O
the	O
treatment	O
of	O
the	O
diseases	O
related	O
with	O
rennin,	O
such	O
as	O
antihypertensive	O
drugs	O
.	O


Objective	O
methods	O
for	O
diagnosing	O
a	O
predisposition	O
to	O
developing	O
cancer,	O
including	O
bladder	O
cancer,	O
lung	O
cancer,	O
AML,	O
CML,	O
esophageal	O
cancer,	O
breast	O
cancer,	O
cervical	O
cancer	O
and	O
osteosarcoma	O
caner	O
is	O
described	O
herein	O
.	O
The	O
present	O
invention	O
provides	O
a	O
diagnostic	O
method	O
that	O
utilizes	O
the	O
expression	O
level	O
of	O
EHMT2	B-GENE
as	O
an	O
index	O
of	O
cancer	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
substances	O
for	O
the	O
treatment	O
of	O
EHMT2-associated	O
disease,	O
such	O
as	O
a	O
cancer,	O
e	O
.	O
g	O
.	O
bladder	O
cancer,	O
lung	O
cancer,	O
AML,	O
CML,	O
esophageal	O
cancer,	O
breast	O
cancer,	O
cervical	O
cancer	O
and	O
osteosarcoma	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
inhibiting	O
cell	O
growth	O
and	O
treating	O
or	O
alleviating	O
one	O
or	O
more	O
symptoms	O
of	O
EHMT2-associated	O
diseases	O
.	O
The	O
invention	O
also	O
features	O
double-stranded	O
molecules	O
that	O
inhibit	O
EHMT2	B-GENE
expression,	O
vectors	O
encoding	O
the	O
double-stranded	O
molecule	O
and	O
compositions	O
containing	O
them	O
.	O


Provided	O
are	O
a	O
hydrochloride	O
of	O
a	O
tricyclic	O
pyrazolopyrimidine	O
compound	O
that	O
inhibits	O
the	O
action	O
of	O
Hsp90	B-GENE
and	O
a	O
crystal	O
thereof	O
.	O
The	O
present	O
invention	O
provides	O
a	O
hydrochloride	O
of	O
2-	O
{	O
4-amino-2-	O
[	O
(	O
3-chloro-4-methoxy-5-methylpyridine-2-yl	O
)	O
methyl	O
]	O
-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo	O
[	O
cd	O
]	O
azulene-8-yl	O
}	O
-N-methylacetamide	O
that	O
inhibits	O
the	O
activity	O
of	O
Hsp90	B-GENE
ATPase	B-GENE
and	O
has	O
antitumor	O
activity,	O
a	O
crystal	O
thereof,	O
and	O
a	O
medicine,	O
anticancer	O
agent,	O
and	O
the	O
like	O
containing	O
the	O
same	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
that	O
has	O
the	O
effect	O
of	O
suppressing	O
matrix-metalloproteinase	B-GENE
activity	O
.	O
Specifically,	O
the	O
present	O
invention	O
pertains	O
to	O
a	O
composition	O
which	O
suppresses	O
matrix-metalloproteinase	B-GENE
activity	O
and	O
contains,	O
as	O
an	O
active	O
ingredient,	O
a	O
glucose-metabolism	O
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
a	O
PPAR	B-GENE
δ	I-GENE
agonist,	O
and	O
more	O
particularly,	O
to	O
a	O
fetal	O
reprogramming	O
effect	O
of	O
a	O
PPAR	B-GENE
δ	I-GENE
agonist	O
.	O
According	O
to	O
the	O
present	O
invention,	O
a	O
PPAR	B-GENE
δ	I-GENE
agonist	O
adjusts	O
calcium	O
ion	O
during	O
embryo	O
genesis	O
and	O
a	O
early	O
fetal	O
development	O
period	O
to	O
increase	O
slow	O
muscle	O
fiber	O
and	O
to	O
thus	O
improve	O
muscle	O
endurance,	O
thereby	O
improving	O
lipid	O
and	O
glucose	O
metabolism	O
and	O
reprogramming	O
the	O
metabolism	O
of	O
the	O
entire	O
body,	O
thus	O
preventing	O
/	O
inhibiting	O
the	O
occurrence	O
of	O
metabolic	O
diseases,	O
such	O
as	O
obesity	O
and	O
diabetes	O
in	O
an	O
adult	O
body	O
caused	O
by	O
a	O
high-fat	O
diet	O
and	O
a	O
lack	O
of	O
exercise,	O
and	O
improving	O
memory	O
for	O
an	O
adult	O
.	O
In	O
addition,	O
fetal	O
reprogramming	O
using	O
a	O
PPAR	B-GENE
δ	I-GENE
agonist	O
prevents	O
/	O
inhibits	O
the	O
occurrence	O
of	O
diabetes	O
in	O
a	O
mouse	O
model	O
for	O
diabetes	O
.	O
Therefore,	O
the	O
PPAR	B-GENE
δ	I-GENE
agonist	O
may	O
be	O
used	O
in	O
a	O
pharmaceutical	O
composition	O
for	O
enhancing	O
the	O
endurance	O
of	O
a	O
human	O
and	O
an	O
animal	O
by	O
embryonic	O
/	O
fetal	O
reprogramming,	O
preventing	O
/	O
inhibiting	O
metabolic	O
diseases	O
such	O
as	O
obesity,	O
diabetes,	O
arteriosclerosis	O
and	O
fatty	O
liver,	O
and	O
enhancing	O
memory	O
.	O
The	O
PPAR	B-GENE
δ	I-GENE
agonist	O
may	O
also	O
be	O
used	O
in	O
a	O
nutritional	O
supplement	O
for	O
pregnant	O
women,	O
in	O
food	O
additives,	O
in	O
a	O
functional	O
food	O
supplement	O
or	O
functional	O
beverage	O
composition,	O
in	O
pharmaceutical	O
compositions	O
for	O
animals,	O
in	O
an	O
endurance	O
enhancer	O
for	O
animals,	O
in	O
dry	O
milk	O
and	O
baby	O
formula	O
compositions,	O
in	O
an	O
animal	O
feed	O
composition,	O
etc	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
polymorphs	O
and	O
salts	O
of	O
a	O
compound	O
which	O
is	O
an	O
inhibitor	O
of	O
kinase	B-GENE
activity	O
.	O


Provided	O
is	O
an	O
inhibitor	O
of	O
HMGB	O
protein-mediated	O
immune	O
response	O
activation,	O
comprising	O
one	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phosphorothioate	O
oligonucleotides	O
and	O
derivatives	O
thereof	O
.	O
Also	O
provided	O
is	O
a	O
method	O
for	O
screening	O
an	O
inhibitor	O
or	O
promoter	O
of	O
HMGB	O
protein-mediated	O
immune	O
response	O
activation,	O
comprising	O
:	O
a	O
mixing	O
step	O
of	O
mixing	O
an	O
HMGB	B-GENE
protein	I-GENE
and	O
a	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
test	O
substance	O
;	O
a	O
assaying	O
step	O
of	O
assaying	O
the	O
HMGB	B-GENE
protein	I-GENE
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
;	O
and	O
a	O
determination	O
step	O
of	O
determining	O
that	O
the	O
test	O
substance	O
is	O
an	O
inhibitor	O
of	O
HMGB	O
protein-mediated	O
immune	O
response	O
activation	O
in	O
the	O
case	O
that	O
the	O
quantity	O
of	O
the	O
HMGB	B-GENE
protein	I-GENE
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
of	O
the	O
test	O
substance	O
is	O
less	O
than	O
the	O
quantity	O
of	O
the	O
HMGB	B-GENE
protein	I-GENE
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance,	O
and	O
determining	O
that	O
the	O
test	O
substance	O
is	O
a	O
promoter	O
of	O
HMGB	O
protein-mediated	O
immune	O
response	O
activation	O
in	O
the	O
case	O
that	O
the	O
quantity	O
of	O
the	O
HMGB	B-GENE
protein	I-GENE
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
of	O
the	O
test	O
substance	O
is	O
greater	O
than	O
the	O
quantity	O
of	O
the	O
HMGB	B-GENE
protein	I-GENE
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
.	O


[	O
insert	O
compound	O
of	O
Formula	O
I	O
]	O
This	O
invention	O
relates	O
to	O
novel	O
substituted	O
azaindoles	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
compound	O
showing	O
selective	O
inhibitory	O
activity	O
of	O
oncogenic	O
B-RafV600E	O
protein	O
kinase	B-GENE
.	O


Provided	O
herein	O
are	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
various	O
ocular	O
diseases	O
characterized	O
by	O
unwanted	O
cellular	O
proliferation	O
.	O
The	O
pharmaceutical	O
compositions	O
may	O
comprise	O
one	O
or	O
more	O
MDM2	B-GENE
inhibitors,	O
and	O
may	O
further	O
comprise	O
one	O
or	O
more	O
additional	O
therapeutic	O
agents	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
use	O
of	O
MDM2	B-GENE
inhibitors	O
and	O
/	O
or	O
formulations	O
thereof	O
for	O
the	O
treatment	O
of	O
ocular	O
diseases	O
characterized	O
by	O
unwanted	O
cellular	O
proliferation	O
.	O


The	O
present	O
invention	O
provides	O
treating	O
LAL	B-GENE
deficiency	O
(	O
e	O
.	O
g	O
.	O
Wolman	O
'	O
s	O
disease,	O
CESD	O
)	O
comprising	O
administering	O
to	O
a	O
mammal	O
a	O
therapeutically	O
effective	O
amount	O
o	O
lysosomal	B-GENE
acid	I-GENE
lipase	I-GENE
with	O
an	O
effective	O
dosage	O
frequency	O
.	O
Methods	O
of	O
improving	O
growth	O
and	O
liver	O
function,	O
increasing	O
LAL	B-GENE
tissue	O
concentration,	O
and	O
increasing	O
LAL	B-GENE
activity	O
in	O
a	O
human	O
patient	O
suffering	O
from	O
LAL	B-GENE
deficiency	O
are	O
also	O
provided	O


Disclosed	O
are	O
a	O
compound	O
inhibitory	O
of	O
HIF-1	B-GENE
activity,	O
a	O
method	O
for	O
preparing	O
the	O
same,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
compound	O
has	O
anticancer	O
activity	O
which	O
is	O
attributable	O
to	O
its	O
inhibitory	O
activity	O
against	O
HIF-1,	O
but	O
not	O
to	O
non-selective	O
cellular	O
toxicity	O
.	O
Thus,	O
having	O
inhibitory	O
activity	O
against	O
HIF-1,	O
the	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
can	O
be	O
used	O
as	O
an	O
ingredient	O
in	O
an	O
anticancer	O
agent	O
for	O
various	O
cancers	O
including	O
large	O
intestine	O
cancer,	O
hepatic	O
cancer,	O
stomach	O
cancer	O
and	O
breast	O
cancer	O
.	O
Further,	O
the	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
applicable	O
to	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
or	O
arthritis	O
which	O
is	O
aggravated	O
upon	O
the	O
activation	O
of	O
VEGFA	B-GENE
by	O
HIF-1	B-GENE
.	O


This	O
invention	O
relates	O
generally	O
to	O
a	O
therapeutic	O
use	O
of	O
TLR3	B-GENE
and	O
TLR7	B-GENE
inhibitors	O
to	O
treat	O
or	O
reduce	O
pruritus	O
in	O
a	O
subject	O
.	O


A	O
method	O
for	O
treating	O
an	O
ATP	O
analog-induced	O
side	O
effect	O
in	O
a	O
subject	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
adenosine	B-GENE
receptor	I-GENE
antagonist	O
to	O
the	O
subject	O
.	O
A	O
method	O
for	O
treating	O
cancer	O
in	O
a	O
subject	O
comprises	O
administering	O
a	O
nucleobase	O
and	O
/	O
or	O
nucleoside	O
prior	O
to	O
administering	O
an	O
ATP	O
analog	O
.	O


Compounds	O
of	O
Formula	O
I	O
are	O
disclosed	O
:	O
wherein	O
L,	O
A,	O
R1,	O
R2,	O
R3A,	O
R3B,	O
R4A,	O
R4B,	O
R5,	O
R6	O
and	O
R7	O
are	O
defined	O
herein	O
.	O
The	O
compounds	O
encompassed	O
by	O
Formula	O
I	O
include	O
compounds	O
which	O
are	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
and	O
other	O
compounds	O
which	O
can	O
be	O
metabolized	O
in	O
vivo	O
to	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
.	O
The	O
compounds	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
are	O
useful	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
infection	O
by	O
HIV	O
and	O
the	O
prophylaxis,	O
treatment,	O
or	O
delay	O
in	O
the	O
onset	O
of	O
AIDS	O
.	O
The	O
compounds	O
and	O
their	O
salts	O
can	O
be	O
employed	O
as	O
ingredients	O
in	O
pharmaceutical	O
compositions,	O
optionally	O
in	O
combination	O
with	O
other	O
antivirals,	O
immunomodulators,	O
antibiotics	O
or	O
vaccines	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds,	O
processes	O
for	O
making	O
said	O
compounds,	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
Αβ-related	O
diseases	O
.	O


The	O
invention	O
generally	O
relates	O
to	O
methods	O
of	O
improving	O
thyroid	O
hormone	O
sensitivity	O
or	O
treating	O
a	O
thyroid	O
hormone	O
resistance	O
related	O
disorder	O
in	O
a	O
patient	O
in	O
need	O
thereof,	O
comprising	O
administering	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
MetAP-2	B-GENE
inhibitor	O
.	O
Such	O
methods	O
may	O
include	O
administering	O
a	O
MetAP-2	B-GENE
inhibitor	O
at	O
a	O
dose	O
that	O
does	O
not	O
substantially	O
modulate	O
angiogenesis	O
.	O


Disclosed	O
are	O
methods	O
to	O
treat	O
allergic	O
conditions,	O
including	O
pulmonary	O
and	O
non-	O
pulmonary	O
conditions,	O
in	O
a	O
subject	O
by	O
administering	O
a	O
composition	O
that	O
inhibits	O
Pirn	B-GENE
kinase	I-GENE
.	O
Also	O
disclosed	O
are	O
methods	O
to	O
treat	O
allergic	O
conditions	O
in	O
a	O
subject	O
by	O
administering	O
a	O
composition	O
that	O
induces	O
expression	O
of	O
Runx3	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
styraxlignolide	O
A	O
or	O
the	O
aglycone	O
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
or	O
treating	O
asthma	O
.	O
More	O
particularly,	O
the	O
styraxlignolide	O
A	O
compound	O
is	O
separated	O
from	O
the	O
stem	O
and	O
bark	O
of	O
Styrax	O
japonica,	O
and	O
the	O
styraxlignolide	O
A	O
or	O
homoegonol,	O
which	O
is	O
the	O
aglycone	O
of	O
styraxlignolide	O
A	O
and	O
which	O
has	O
improved	O
safety,	O
has	O
the	O
effect	O
of	O
attenuating	O
weight	O
loss	O
and	O
hypersensitivity	O
of	O
the	O
airway,	O
inhibiting	O
the	O
generation	O
of	O
active	O
oxygen	O
in	O
the	O
airway,	O
inhibiting	O
the	O
generation	O
of	O
IgE,	O
TGF-â1,	O
and	O
IL-17	B-GENE
in	O
the	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid,	O
inhibiting	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
bronchial	O
tubes,	O
and	O
inhibiting	O
the	O
formation	O
of	O
a	O
mucous	O
plug	O
and	O
subepithelial	O
fibrosis	O
in	O
an	O
asthmatic	O
mouse	O
model	O
.	O
Therefore,	O
the	O
above-described	O
styraxlignolide	O
or	O
homoegonol	O
can	O
be	O
effectively	O
used	O
as	O
the	O
active	O
ingredient	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
bronchial	O
asthma	O
in	O
which	O
airway	O
remodeling	O
has	O
progressed	O
.	O


Provided	O
is	O
an	O
insulin	B-GENE
secretagogue	O
which	O
is	O
effective	O
in	O
preventing	O
diabetes	O
and	O
the	O
like	O
and	O
which	O
is	O
very	O
safe	O
and	O
free	O
of	O
concern	O
of	O
side	O
effects	O
even	O
when	O
ingested	O
continuously	O
.	O
This	O
insulin	B-GENE
secretagogue	O
contains,	O
as	O
an	O
active	O
ingredient,	O
any	O
of	O
a	O
phospholipid,	O
a	O
sucrose	O
fatty	O
acid	O
ester,	O
an	O
HLB-4	O
to	O
15	O
polyglycerin	O
fatty	O
acid	O
ester,	O
or	O
glycerin	O
mono	O
fatty	O
acid	O
ester,	O
and	O
is	O
therefore	O
very	O
safe	O
and	O
free	O
of	O
concern	O
of	O
side	O
effects	O
even	O
when	O
ingested	O
continuously	O
.	O
The	O
phospholipid	O
is	O
preferably	O
lecithin	O
derived	O
from	O
soybeans	O
.	O
The	O
HLB	O
of	O
the	O
sucrose	O
fatty	O
acid	O
ester	O
is	O
preferably	O
4	O
to	O
16	O
.	O
The	O
carbon	O
number	O
of	O
the	O
constituent	O
fatty	O
acid	O
of	O
the	O
glycerin	O
mono	O
fatty	O
acid	O
ester	O
is	O
preferably	O
8	O
to	O
12	O
.	O


The	O
invention	O
relates	O
to	O
thieno	O
[	O
3,4-b	O
]	O
pyrazine	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
treating,	O
preventing	O
and	O
/	O
or	O
managing	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
inadequate	O
insulin	B-GENE
secretion	O
such	O
as	O
diabetes,	O
related	O
disorders	O
and	O
metabolic	O
syndrome	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
treating,	O
preventing	O
and	O
/	O
or	O
managing	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
which	O
are	O
affected	O
or	O
facilitated	O
by	O
the	O
modulation	O
of	O
GLP-1	B-GENE
receptor	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
provides	O
N-	O
(	O
1-	O
(	O
substituted-phenyl	O
)	O
ethyl	O
)	O
-9H-purin-6-amines	O
derivatives	O
that	O
modulate	O
the	O
activity	O
of	O
phosphoinositide	B-GENE
3-kinases	I-GENE
(	O
PI3Ks	B-GENE
)	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
the	O
activity	O
of	O
PI3Ks	B-GENE
including,	O
for	O
example,	O
inflammatory	O
disorders,	O
immune-based	O
disorders,	O
cancer,	O
and	O
other	O
diseases	O
.	O


of	O
formula	O
4	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
acting	O
as	O
protein	B-GENE
kinase	I-GENE
(	O
PK	B-GENE
)	O
and	O
receptor	B-GENE
kinase	I-GENE
(	O
RK	B-GENE
)	O
signaling	O
modulators	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
including	O
such	O
compounds,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
and	O
compositions,	O
especially	O
as	O
anti-cancer	O
agents	O
for	O
preventions	O
and	O
treatments	O
of	O
PK-	O
and	O
RK-related	O
disorders,	O
in	O
particular	O
cancer	O
.	O
(	O
I	O
)	O
wherein	O
A	O
is	O
H	O
or	O
CN	O
;	O
Z	O
is	O
S,	O
SO	O
or	O
S02	O
;	O
X1,	O
X2,	O
X3,	O
X4,	O
X5,Y1	O
and	O
Y2	O
are	O
each	O
independently	O
selected	O
from	O
H,	O
halogen,	O
alkyl,	O
haloalkyl	O
and	O
OR1	O
;	O
and	O
Y3	O
and	O
Y4	O
are	O
each	O
OR1,	O
wherein	O
each	O
R1	O
is	O
independently	O
H,	O
C1-C4	O
alkyl,	O
acyl,	O
-	O
(	O
CH2CH20	O
)	O
n	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
to	O
20,	O
or	O
a	O
functional	O
group	O
that	O
gives	O
rise	O
to	O
hydroxyl	O
upon	O
hydrolysis	O
.	O


This	O
invention	O
describes	O
substituted	O
pyrazole	O
derivatives	O
of	O
Formula	O
I,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O
These	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
modification	O
of	O
the	O
activity	O
of	O
ERK	B-GENE
would	O
have	O
a	O
positive	O
therapeutic	O
outcome,	O
for	O
instance	O
various	O
cancers,	O
psoriasis	O
and	O
actinic	O
keratosis	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
one	O
of	O
X	O
and	O
Y	O
is	O
N	O
and	O
the	O
other	O
is	O
an	O
optionally	O
substituted	O
carbon	O
atom,	O
and	O
Z2-Z5	O
represent	O
one	O
or	O
two	O
nitrogen	O
atoms,	O
as	O
further	O
described	O
herein,	O
including	O
pharmaceutically	O
acceptable	O
salts,	O
enantiomers,	O
stereoisomers,	O
rotamers,	O
tautomers,	O
diastereomers,	O
or	O
racemates	O
thereof	O
.	O
These	O
compounds	O
inhibit	O
the	O
activity	O
of	O
CDK9	B-GENE
and	O
are	O
thus	O
useful	O
as	O
pharmaceuticals	O
and	O
as	O
components	O
of	O
pharmaceutical	O
compositions	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
CDK9	B-GENE
using	O
the	O
compounds	O
described	O
herein	O
or	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O


To	O
study	O
different	O
types	O
of	O
thrombolytic	O
agents,	O
both	O
thrombolysis	O
and	O
stimulation	O
of	O
fucoidan	O
were	O
studied	O
in	O
a	O
mouse	O
model	O
of	O
ferric	O
chloride-induced	O
arterial	O
thrombosis	O
and	O
were	O
compared	O
with	O
those	O
of	O
a	O
heparin	O
and	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t-PA	B-GENE
)	O
.	O
Thrombosis	O
was	O
induced	O
by	O
applying	O
a	O
filter	O
paper	O
saturated	O
with	O
5	O
%	O
FeCl3	O
to	O
the	O
left	O
carotid	O
artery	O
.	O
20	O
minutes	O
after	O
complete	O
occlusion,	O
several	O
test	O
preparations	O
including	O
a	O
fucoidan	O
source	O
from	O
Undaria	O
pinnatifida	O
sporophylls	O
were	O
intravenously	O
injected	O
to	O
each	O
mouse	O
group	O
by	O
various	O
dosages	O
of	O
10-200	O
mg	O
/	O
kg-1	O
.	O
To	O
study	O
the	O
stimulation	O
effect	O
of	O
fucoidan	O
with	O
respect	O
to	O
t-PA,	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t-PA	B-GENE
was	O
injected	O
by	O
a	O
dose	O
of	O
1-10	O
mg	O
/	O
kg	O
.	O
Then,	O
the	O
time	O
to	O
reperfusion	O
was	O
measured	O
.	O
As	O
a	O
result,	O
an	O
occluded	O
aorta	O
was	O
dose-dependently	O
reperfused,	O
and	O
the	O
reperfusion	O
was	O
observed	O
at	O
37	O
.	O
5±12	O
.	O
4	O
minutes	O
after	O
the	O
administration	O
of	O
100	O
mg	O
/	O
kg-1	O
of	O
unfractionated	O
fucoidan	O
.	O
The	O
time	O
to	O
reperfusion	O
was	O
retarded	O
to	O
55	O
.	O
0±8	O
.	O
0	O
minutes	O
when	O
a	O
large	O
amount	O
of	O
fucoidan	O
such	O
as	O
1	O
g	O
/	O
kg-1	O
was	O
administered	O
to	O
a	O
mouse	O
provided	O
with	O
low	O
molecular	O
weight	O
fucoidan	O
(	O
LMWF	O
)	O
.	O
Reperfusion	O
occurred	O
at	O
16	O
.	O
67	O
minutes	O
after	O
administration	O
in	O
a	O
mouse	O
of	O
a	O
control	O
group	O
provided	O
with	O
20	O
mg	O
/	O
kg-1	O
of	O
t-PA	B-GENE
.	O
On	O
the	O
contrary,	O
reperfusion	O
was	O
not	O
observed	O
in	O
an	O
occluded	O
mouse	O
provided	O
with	O
heparin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
occluded	O
artery	O
was	O
recovered	O
without	O
reperfusion	O
at	O
17	O
.	O
2	O
minutes	O
after	O
injection	O
if	O
the	O
least	O
amount	O
of	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t-PA	B-GENE
was	O
provided	O
.	O
All	O
the	O
data	O
show	O
that	O
fucoidan	O
can	O
serve	O
as	O
both	O
a	O
thrombolytic	O
agent	O
and	O
a	O
stimulant	O
with	O
respect	O
to	O
thrombolysis	O
activation	O
of	O
t-PA	B-GENE
in	O
a	O
thrombosis	O
model,	O
differently	O
from	O
heparin	O
.	O


A	O
dual	O
H1	B-GENE
/	O
5-HT2A	B-GENE
receptor	I-GENE
antagonist	O
of	O
the	O
formula	O
:	O
,	O
its	O
uses,	O
and	O
methods	O
for	O
its	O
preparation	O
are	O
described	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
benzimidazole	O
derivatives,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
modulated	O
by	O
TRP	O
M8,	O
including	O
for	O
example,	O
inflammatory	O
pain,	O
inflammatory	O
hyperalgesia,	O
inflammatory	O
hypersensitivity	O
condition,	O
neuropathic	O
pain,	O
neuropathic	O
cold	O
allodynia,	O
inflammatory	O
somatic	O
hyperalgesia,	O
inflammatory	O
visceral	O
hyperalgesia,	O
cardiovascular	O
disease	O
aggravated	O
by	O
cold	O
and	O
pulmonary	O
disease	O
aggravated	O
by	O
cold	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
class	O
of	O
compounds	O
useful	O
for	O
the	O
modulation	O
of	O
beta-secretase	B-GENE
enzyme	O
(	O
BACE	B-GENE
)	O
activity	O
.	O
The	O
compounds	O
have	O
a	O
general	O
Formula	O
I,	O
wherein	O
variables	O
A1,	O
A3,	O
A4,	O
A5,	O
A6,	O
A8,	O
R2,	O
R7,	O
X,	O
Y	O
and	O
Z	O
of	O
Formula	O
I	O
are	O
defined	O
herein	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
corresponding	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
disorders	O
and	O
/	O
or	O
conditions	O
related	O
to	O
plaque	O
formation	O
and	O
deposition,	O
resulting	O
from	O
the	O
activity	O
of	O
BACE	B-GENE
.	O
Such	O
BACE	B-GENE
mediated	O
disorders	O
include,	O
for	O
example,	O
Alzheimer	O
'	O
s	O
Disease,	O
cognitive	O
deficits	O
and	O
impairments,	O
schizophrenia	O
and	O
other	O
central	O
nervous	O
system	O
conditions	O
and	O
disorders	O
.	O
The	O
invention	O
further	O
provides	O
compounds	O
of	O
Formulas	O
II	O
and	O
III,	O
and	O
of	O
sub-formulas	O
of	O
Formulas	O
I,	O
II	O
and	O
III,	O
intermediates	O
and	O
processes	O
and	O
methods	O
useful	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
Formulas	O
I-III	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound,	O
or	O
a	O
stereoisomer,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11β-HSD1	B-GENE
)	O
comprising	O
the	O
same	O
.	O
The	O
invention	O
provides	O
a	O
compound,	O
which	O
has	O
excellent	O
activity	O
and	O
solubility	O
and	O
is	O
more	O
efficiently	O
formulated	O
and	O
delivered,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
comprising	O
the	O
same	O
.	O


The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
human	O
RPT4	B-GENE
protein	O
/	O
gene	O
can	O
function	O
as	O
a	O
therapeutic	O
target	O
for	O
solid	O
tumour	O
type	O
cancers,	O
especially	O
solid	O
tumours	O
of	O
the	O
colon,	O
and	O
that	O
reducing	O
the	O
abundance	O
of	O
RPT4	B-GENE
in	O
tumour	O
cells	O
causes	O
a	O
significant	O
increase	O
in	O
cancer	O
cell	O
death,	O
and	O
potently	O
decreases	O
the	O
survival	O
and	O
proliferation	O
of	O
cancer	O
cells	O
in	O
tumour	O
growth	O
assays	O
(	O
Figs	O
3	O
and	O
4	O
)	O
.	O
A	O
further,	O
but	O
linked,	O
aspect	O
of	O
the	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
inhibitors	O
of	O
RPT4	B-GENE
significantly	O
decrease	O
the	O
viability	O
of	O
chemotherapeutic-resistant	O
tumours,	O
especially	O
solid	O
tumours,	O
especially	O
colorectal	O
solid	O
tumours	O
(	O
Fig	O
.	O
5	O
)	O
.	O
A	O
further,	O
but	O
linked,	O
aspect	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
efficacy	O
of	O
conventional	O
chemotherapeutic	O
therapy,	O
for	O
example	O
5-FU	O
/	O
oxaliplatin	O
therapy,	O
is	O
significantly	O
improved	O
when	O
combined	O
with	O
treatment	O
with	O
a	O
RPT4	B-GENE
inhibitor	O
(	O
Fig	O
.	O
6	O
)	O
.	O
A	O
further,	O
but	O
linked,	O
aspect	O
of	O
the	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
levels	O
of	O
RPT4	B-GENE
in	O
solid	O
tumours	O
such	O
as	O
colorectal	O
cancer	O
can	O
function	O
as	O
a	O
prognostic	O
variable	O
of	O
outcome	O
/	O
survival	O
(	O
Fig	O
.	O
2	O
)	O
.	O


TRPVl	B-GENE
antagonists	O
and	O
associated	O
methods	O
are	O
provided	O
.	O
A	O
TRPVl	B-GENE
channel	O
antagonist	O
can	O
have	O
the	O
structure	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
can	O
be	O
-CH3,	O
-	O
(	O
CH2	O
)	O
X	O
(	O
CH	O
)	O
YCH3	O
where	O
x	O
+	O
y	O
=	O
1-20,	O
an	O
aromatic,	O
a	O
(	O
CH2	O
)	O
n	O
aromatic	O
where	O
n	O
can	O
be	O
less	O
than	O
or	O
equal	O
to	O
6,	O
a	O
lipid,	O
or	O
a	O
linker,	O
and	O
wherein	O
R2	O
can	O
be	O
either	O
Formula	O
(	O
II	O
)	O
or	O
Formula	O
(	O
III	O
)	O
Additionally,	O
R3	O
can	O
be	O
-O-R4	O
or	O
-NH-R4	O
and	O
R4	O
can	O
be	O
-H,	O
-CH3,	O
an	O
ester,	O
a	O
cyclic	O
ester,	O
or	O
an	O
amide	O
.	O


The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
CHODL	B-GENE
gene	O
are	O
overexpressed	O
in	O
cancer	O
and	O
associated	O
with	O
cancer	O
prognosis,	O
and	O
involved	O
in	O
cancer	O
cell	O
survival	O
.	O
The	O
present	O
invention	O
features	O
methods	O
for	O
assessing	O
or	O
predicting	O
the	O
prognosis	O
of	O
a	O
subject	O
with	O
cancer,	O
using	O
CHODL	B-GENE
gene	O
as	O
a	O
prognostic	O
marker	O
.	O
The	O
present	O
invention	O
also	O
features	O
a	O
double-stranded	O
molecule	O
against	O
CHODL	B-GENE
gene,	O
a	O
method	O
or	O
composition	O
for	O
treating	O
or	O
preventing	O
cancer	O
using	O
such	O
double-stranded	O
molecules	O
or	O
vectors	O
encoding	O
such	O
double-stranded	O
molecule	O
.	O


The	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
and	O
effective	O
anti-wrinkle	O
agent	O
.	O
The	O
invention	O
relates	O
to	O
a	O
matrix	B-GENE
metalloproteinase	I-GENE
(	O
MMP	B-GENE
)	O
inhibitor	O
and	O
/	O
or	O
laminin	O
5	O
production	O
promoter,	O
as	O
well	O
as	O
an	O
anti-wrinkle	O
agent,	O
each	O
of	O
which	O
comprises	O
1-piperidine	O
propionate	O
and	O
/	O
or	O
a	O
salt	O
thereof	O
.	O


Disclosed	O
herein	O
are	O
KCNQ	B-GENE
potassium	B-GENE
channels	I-GENE
modulators	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
ring	O
G1,	O
R1,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Compositions	O
comprising	O
such	O
compounds	O
;	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
described	O
.	O


The	O
present	O
invention	O
relates	O
to	O
diagnostic,	O
therapeutic	O
and	O
prognostic	O
methods	O
for	O
thyroid	O
cancers	O
.	O
In	O
one	O
embodiment,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
a	O
an	O
anaplastic	O
thyroid	O
cancer	O
(	O
ATC	O
)	O
patient	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
the	O
patient	O
an	O
effective	O
amount	O
of	O
an	O
anaplastic	B-GENE
lymphoma	I-GENE
kinase	I-GENE
(	O
ALK	B-GENE
)	O
inhibitor	O
.	O
In	O
another	O
embodiment,	O
a	O
method	O
for	O
diagnosing	O
ATC	O
in	O
patient	O
comprises	O
the	O
step	O
of	O
performing	O
an	O
assay	O
on	O
a	O
biological	O
sample	O
from	O
the	O
patient	O
to	O
identify	O
the	O
presence	O
or	O
absence	O
of	O
a	O
C3592T	O
and	O
/	O
or	O
a	O
G3602A	O
mutation	O
in	O
exon	O
23	O
of	O
the	O
ALK	B-GENE
gene	I-GENE
according	O
to	O
SEQ	O
ID	O
NO	O
:	O
6,	O
wherein	O
the	O
presence	O
of	O
either	O
of	O
both	O
of	O
the	O
mutations	O
correlates	O
with	O
a	O
diagnosis	O
of	O
ATC	O
in	O
the	O
patient	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
CFTR	B-GENE
potentiator	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
spinal	O
muscular	O
atrophy	O
and	O
other	O
related	O
neuromuscular	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
said	O
method	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
ERK	B-GENE
inhibitor,	O
such	O
as	O
Selumetinib	O
to	O
said	O
subject	O
.	O


This	O
disclosure	O
relates	O
to	O
pharmaceutical	O
compositions	O
useful	O
for	O
inhibiting	O
insulin-degrading	B-GENE
enzyme	I-GENE
(	O
IDE	B-GENE
)	O
and	O
methods	O
of	O
treating	O
disorders	O
involving	O
the	O
same	O
or	O
peptide	O
substrates	O
of	O
the	O
same	O
.	O
For	O
example,	O
provided	O
herein	O
are	O
methods	O
of	O
treating	O
diabetes,	O
promotion	O
of	O
wound	O
healing,	O
and	O
improvement	O
of	O
memory	O
.	O


﻿The	O
present	O
invention	O
relates	O
to	O
a	O
heterocyclic	O
[	O
b	O
]	O
pyridone	O
compound	O
of	O
the	O
following	O
formula	O
(	O
I	O
)	O
.	O
,and	O
the	O
heterocyclic	O
[	O
b	O
]	O
pyridone	O
compound	O
is	O
used	O
as	O
tyrosine	B-GENE
kinase	I-GENE
inhibitors,	O
particularly	O
as	O
the	O
c-Met	B-GENE
inhibitors	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
intermediates	O
of	O
the	O
preparation	O
of	O
the	O
heterocyclic	O
[	O
b	O
]	O
pyridone	O
compound	O
as	O
well	O
as	O
the	O
method	O
of	O
preparation	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
pharmaceutical	O
composition	O
containing	O
such	O
compounds	O
as	O
the	O
active	O
ingredient,	O
and	O
disclose	O
the	O
purpose	O
of	O
heterocyclic	O
[	O
b	O
]	O
pyridone	O
compound	O
as	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
the	O
disease	O
associated	O
with	O
tyrosine	O
kinase,	O
especially	O
cancer	O
associated	O
with	O
c-Met	B-GENE
.	O


The	O
present	O
patent	O
application	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
transient	B-GENE
receptor	I-GENE
potential	I-GENE
ankyrin-1	I-GENE
receptor	I-GENE
(	O
"TRPA1"	O
)	O
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
regulation	O
of	O
macrophage	O
activation	O
by	O
delivering	O
of	O
miRNAs,	O
for	O
example	O
miR-125b	B-GENE
or	O
anti-miR-125b,	O
to	O
macrophages	O
.	O
For	O
example,	O
in	O
some	O
embodiments,	O
macrophage	O
activation	O
can	O
be	O
elevated	O
or	O
reduced	O
by	O
administering	O
miR-125b	B-GENE
or	O
anti-miR-125b	O
oligonucleotides	O
.	O
Also	O
disclosed	O
are	O
methods	O
for	O
promoting	O
T	O
cell	O
activation	O
and	O
method	O
for	O
treating	O
various	O
disorders	O
such	O
as	O
tumor	O
and	O
autoimmune	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
hepatitis	O
C	O
(	O
HCV	O
)	O
infection	O
by	O
the	O
combination	O
treatment	O
with	O
a	O
miR-122	O
inhibitor	O
and	O
a	O
HCV	O
NS5B	B-GENE
RNA	I-GENE
dependant	I-GENE
RNA	I-GENE
polymerase	I-GENE
inhibitor	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
comprising	O
non-peptide	O
prokineticin	B-GENE
receptors	I-GENE
antagonists	O
and	O
agents	O
that	O
modulate	O
or	O
inhibit	O
the	O
activity	O
of	O
prokineticin	B-GENE
receptors	I-GENE
for	O
use	O
in	O
the	O
treatment	O
of	O
immune-mediated	O
diseases	O
of	O
the	O
central	O
nervous	O
system,	O
peripheral	O
nervous	O
system	O
and	O
neuromuscular	O
junctions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
in	O
therapy,	O
to	O
compositions	O
comprising	O
said	O
compounds,	O
and	O
to	O
methods	O
of	O
treating	O
diseases	O
comprising	O
administration	O
of	O
said	O
com-	O
pounds	O
.	O
The	O
compounds	O
referred	O
to	O
are	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
of	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
α7	I-GENE
receptor	I-GENE
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
X,	O
R3	O
and	O
R4	O
have	O
meanings	O
given	O
in	O
the	O
description	O
(	O
and	O
which	O
compounds	O
are	O
optionally	O
substituted	O
as	O
indicated	O
in	O
the	O
description	O
)	O
,	O
and	O
pharmaceutically-acceptable	O
esters,	O
amides,	O
solvates	O
or	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	O
or	O
lipid	O
kinase	O
(	O
e	O
.	O
g	O
.	O
a	O
PIM	B-GENE
family	I-GENE
kinase,	O
such	O
as	O
PIM-1,	O
PIM-2	B-GENE
and	O
/	O
or	O
PIM-3	B-GENE
)	O
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O
There	O
is	O
also	O
provided	O
combinations	O
comprising	O
the	O
compounds	O
of	O
formula	O
I	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts,	O
wherein	O
R1,	O
R2,	O
R3,	O
A,	O
B,	O
and	O
n	O
are	O
defined	O
in	O
the	O
description	O
.	O
The	O
present	O
invention	O
relates	O
also	O
to	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	B-GENE
such	O
as	O
wee-1	O
and	O
methods	O
of	O
treating	O
diseases	O
such	O
as	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
spirocyclic	O
compounds	O
of	O
formula	O
I,	O
namely	O
spirocyclic	O
(	O
1H-pyrazol-4-yl	O
)	O
-3-	O
(	O
1-	O
(	O
2,6-dichloro-3-	O
fiuorophenyl	O
)	O
ethoxy	O
)	O
pyridin-2-amines	O
having	O
protein	B-GENE
kinase	I-GENE
inhibitory	O
activity,	O
and	O
methods	O
of	O
synthesizing	O
and	O
using	O
such	O
compounds	O
.	O
Preferred	O
compounds	O
are	O
c-Met	B-GENE
and	O
/	O
or	O
ALK	B-GENE
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth,	O
such	O
as	O
cancers	O
.	O


Pyridazine	O
derivatives	O
that	O
activate	O
the	O
excitatory	B-GENE
amino	I-GENE
acid	I-GENE
transporter	I-GENE
2	I-GENE
(	O
EAAT2	B-GENE
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
treating	O
or	O
preventing	O
diseases,	O
disorders,	O
and	O
conditions	O
associated	O
with	O
glutamate	O
excitotoxicity	O
.	O


Therapeutic	O
agents	O
targeted	O
to	O
voltage	B-GENE
gated	I-GENE
calcium	I-GENE
channels	O
and	O
compositions	O
comprising	O
such	O
therapeutic	O
agents	O
are	O
provided,	O
as	O
is	O
the	O
use	O
of	O
such	O
agents	O
and	O
compositions	O
to	O
modulate	O
the	O
function	O
of	O
haematopoietic	O
cells	O
expressing	O
the	O
voltage	B-GENE
gated	I-GENE
calcium	I-GENE
channel	I-GENE
.	O
Also	O
provided	O
are	O
methods	O
of	O
screening	O
for	O
agents	O
that	O
target	O
a	O
given	O
voltage	B-GENE
gated	I-GENE
calcium	I-GENE
channel	I-GENE
that	O
are	O
suitable	O
for	O
use	O
as	O
therapeutics	O
to	O
modulate	O
the	O
activity	O
of	O
cells	O
expressing	O
the	O
targeted	O
voltage	B-GENE
gated	I-GENE
calcium	I-GENE
channel	I-GENE
.	O
The	O
agent	O
can	O
be,	O
for	O
example,	O
an	O
antibody,	O
an	O
aptamer,	O
a	O
peptide	O
or	O
a	O
small	O
molecule	O
capable	O
of	O
binding	O
to	O
an	O
ectodomain	O
of	O
the	O
target	O
voltage	B-GENE
gated	I-GENE
calcium	I-GENE
channel	I-GENE
and	O
thus	O
of	O
modulating	O
the	O
function	O
of	O
the	O
calcium	O
channel	I-GENE
.	O


A	O
method	O
for	O
treating	O
a	O
p62-mediated	O
disease	O
(	O
e	O
.	O
g	O
.	O
,	O
multiple	O
myeloma	O
)	O
in	O
a	O
subject,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
p62-ZZ	O
inhibitor	O
compound	O
.	O


Novel	O
tricyclic	O
pyrimidine	O
compounds	O
and	O
tricyclic	O
pyridine	O
compounds	O
having	O
JAK	B-GENE
inhibitory	O
activities	O
are	O
provided	O
.	O
A	O
tricyclic	O
heterocyclic	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
Ia	O
)	O
:	O
wherein	O
the	O
rings	O
Aa	O
and	O
Ba,	O
Xa,	O
Ya,	O
R1a,	O
R2a,	O
R3a,	O
L1a,	O
L2a,	O
L3a	O
and	O
na	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O


The	O
primary	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
heterocyclic	O
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
Examples	O
of	O
the	O
present	O
invention	O
can	O
include	O
a	O
heterocyclic	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
tautomer	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
(	O
In	O
the	O
formula,	O
R1	O
and	O
R2	O
are	O
identical	O
or	O
different	O
and	O
represent	O
an	O
aromatic	O
ring	O
or	O
the	O
like,	O
and	O
the	O
ring	O
(	O
A	O
)	O
represents	O
a	O
heterocycle	O
.	O
)	O
This	O
compound	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
high	O
mPGES-1	B-GENE
inhibitory	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
prophylactic	O
agent	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
involving	O
mPGES-1,	O
e	O
.	O
g	O
.	O
,	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
temporomandibular	O
joint	O
disease,	O
low	O
back	O
pain,	O
endometriosis,	O
dysmenorrhea,	O
overactive	O
bladder,	O
malignancy,	O
or	O
neurodegenerative	O
disease	O
.	O


Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
vitamin	O
B12	O
to	O
influence	O
amyloid-beta	B-GENE
peptide	O
aggregation	O
.	O
A	O
preferred	O
method	O
comprises	O
contacting	O
at	O
least	O
one	O
amyloid-beta	B-GENE
peptide	O
oligomer	O
formed	O
from	O
a	O
plurality	O
of	O
amyloid-beta	B-GENE
peptide	O
monomers	O
with	O
an	O
effective	O
amount	O
of	O
vitamin	O
B12,	O
the	O
effective	O
amount	O
being	O
sufficient	O
to	O
stimulate	O
dissociation	O
of	O
the	O
amyloid-beta	B-GENE
peptide	O
monomers	O
from	O
the	O
amyloid-beta	B-GENE
peptide	O
oligomer	O
or	O
fibril	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
and	O
diagnostic	O
tests	O
for	O
detecting	O
the	O
presence	O
of	O
amyloid-beta	B-GENE
peptides	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
predicting	O
if	O
a	O
squamous	O
cell	O
neoplasm	O
in	O
a	O
subject	O
will	O
be	O
susceptible	O
to	O
treatment	O
with	O
a	O
PI3K	B-GENE
inhibitor,	O
a	O
method	O
for	O
selecting	O
a	O
subject	O
with	O
a	O
squamous	O
cell	O
neoplasm	O
for	O
PI3K	B-GENE
inhibitor	O
treatment,	O
and	O
a	O
method	O
for	O
treating	O
a	O
squamous	O
cell	O
neoplasm	O
in	O
a	O
subject,	O
and	O
to	O
kits	O
related	O
to	O
said	O
methods	O
.	O


The	O
invention	O
is	O
directed	O
to	O
T	O
cells	O
and	O
other	O
cells	O
that	O
express	O
chimeric	O
NKp30	B-GENE
receptors	O
(	O
"chimeric	O
NKp30	B-GENE
T	O
cells"	O
)	O
,	O
methods	O
of	O
making	O
and	O
using	O
chimeric	O
NKp30	B-GENE
T	O
cells,	O
and	O
methods	O
of	O
using	O
these	O
chimeric	O
NKp30	B-GENE
T	O
cells	O
to	O
address	O
diseases	O
and	O
disorders	O
.	O
In	O
one	O
aspect,	O
the	O
disclosure	O
broadly	O
relates	O
to	O
chimeric	O
NKp30	B-GENE
T	O
cells,	O
isolated	O
populations	O
thereof,	O
and	O
compositions	O
comprising	O
the	O
same	O
.	O
In	O
another	O
aspect,	O
said	O
chimeric	O
NKp30	B-GENE
T	O
cells	O
are	O
further	O
designed	O
to	O
express	O
a	O
functional	O
non-TCR	O
receptor	O
.	O
The	O
disclosure	O
also	O
pertains	O
to	O
methods	O
of	O
making	O
said	O
chimeric	O
NKp30	B-GENE
T	O
cells,	O
and	O
methods	O
of	O
reducing	O
or	O
ameliorating,	O
or	O
preventing	O
or	O
treating,	O
diseases	O
and	O
disorders	O
using	O
said	O
chimeric	O
NKp30	B-GENE
T	O
cells,	O
populations	O
thereof,	O
or	O
compositions	O
comprising	O
the	O
same	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
osteoporosis	O
by	O
co-	O
administration	O
of	O
a	O
vitamin	O
D	O
and	O
a	O
3-hydroxy-3-methyl-glutaryl-Co	B-GENE
A	I-GENE
reductase	I-GENE
(	O
HMG	B-GENE
Co	I-GENE
A	I-GENE
reductase	I-GENE
)	O
inhibitor	O
.	O
Also	O
provided	O
are	O
compositions	O
and	O
kits	O
useful	O
for	O
treating	O
osteoporosis	O
comprising	O
a	O
vitamin	O
D	O
and	O
an	O
HMG	B-GENE
Co	I-GENE
A	I-GENE
reductase	I-GENE
inhibitor	O
.	O


A	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
(	O
in	O
the	O
formula,	O
Ra	O
represents	O
an	O
optionally	O
substituted	O
alkyl	O
group,	O
an	O
optionally	O
substituted	O
alkenyl	O
group,	O
an	O
optionally	O
substituted	O
cycloalkyl	O
group,	O
an	O
optionally	O
substituted	O
aryl	O
group,	O
an	O
optionally	O
substituted	O
saturated	O
heterocyclyl	O
group,	O
or	O
an	O
optionally	O
substituted	O
unsaturated	O
heterocyclyl	O
group	O
;	O
Rb	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
alkyl	O
group	O
;	O
R1,	O
R2,	O
R5,	O
and	O
R6	O
represent	O
a	O
hydrogen	O
atom,	O
fluorine	O
atom,	O
or	O
alkyl	O
group	O
;	O
R4,	O
R7,	O
and	O
R8	O
represent	O
a	O
hydrogen	O
atom	O
or	O
alkyl	O
group	O
;	O
and	O
R3	O
and	O
R9	O
represent	O
a	O
hydrogen	O
atom	O
or	O
a	O
prodrug	O
group	O
.	O
)	O
,	O
which	O
has	O
TAFIa	B-GENE
enzyme	O
inhibitory	O
activity	O
and	O
is	O
useful	O
as	O
a	O
therapeutic	O
drug	O
for	O
myocardial	O
infarction,	O
angina	O
pectoris,	O
acute	O
coronary	O
syndrome,	O
stroke,	O
deep	O
vein	O
thrombosis,	O
pulmonary	O
embolism,	O
or	O
the	O
like	O
;	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O


Cycloalkylnitrile	O
pyrazole	O
carboxamides	O
as	O
JAK	B-GENE
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
JAK-mediated	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis,	O
asthma,	O
COPD	O
and	O
cancer	O
are	O
provided	O
.	O


Disclosed	O
are	O
compounds	O
with	O
the	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
and	O
R2	O
are	O
as	O
disclosed	O
herein,	O
which	O
are	O
eIF4E	B-GENE
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
cancers	O
.	O
Also	O
disclosed	O
are	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
compounds	O
.	O


The	O
invention	O
provides	O
compounds	O
which	O
are	O
inhibitor	O
of	O
ricin,	O
abrin,	O
Shiga	B-GENE
or	O
saporin	B-GENE
and	O
which	O
have	O
a	O
bipartite	O
configuration	O
comprising	O
an	O
aromatic	O
heterocyclic	O
structure	O
resembling	O
an	O
adenine	O
moiety	O
in	O
size	O
and	O
shape	O
connected	O
at	O
the	O
C8	O
position	O
to	O
an	O
aromatic	O
or	O
non-	O
aromatic	O
cyclic	O
ring	O
structure	O
resembling	O
a	O
ribose	O
moiety	O
in	O
size	O
and	O
shape	O
.	O
More	O
particularly,	O
the	O
inhibitors	O
have	O
the	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
where	O
X	O
=	O
-S-,	O
-O-,	O
-CH	O
2	O
-,	O
-NH-,	O
-PH-,	O
-O-Y-,	O
-CH	O
2	O
-Y-,	O
-NH-Y-,	O
-PH-Y,	O
or	O
-S-Y	O
;	O
Y	O
=	O
-S-,	O
-O-,	O
-CH	O
2	O
-,	O
-NH-,	O
or	O
-PH-	O
;	O
and	O
W	O
=	O
a	O
5-	O
or	O
6-membered	O
aromatic	O
or	O
non-aromatic	O
cyclic	O
ring	O
.	O
Uses	O
of	O
these	O
compounds	O
in	O
manufacturing	O
a	O
medicament	O
and	O
in	O
treating	O
a	O
subject	O
are	O
also	O
described,	O
as	O
is	O
a	O
method	O
of	O
identifying	O
suitable	O
inhibitors	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
substituted	O
amide	O
compounds	O
that	O
are	O
inhibitors	O
of	O
Fatty	B-GENE
Acid	I-GENE
Amide	I-GENE
Hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
,	O
their	O
stereoisomers,	O
tautomers,	O
prodrugs,	O
polymorphs,	O
solvates,	O
pharmaceutically	O
acceptable	O
salts,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment,	O
prevention,	O
prophylaxis,	O
management,	O
or	O
adjunct	O
treatment	O
of	O
all	O
medical	O
conditions	O
related	O
to	O
inhibition	O
of	O
Fatty	B-GENE
Acid	I-GENE
Amide	I-GENE
Hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
,	O
such	O
as	O
pain	O
including	O
acute	O
and	O
post	O
operative	O
pain,	O
chronic	O
pain,	O
cancer	O
pain,	O
cancer	O
chemotherapy	O
induced	O
pain,	O
neuropathic	O
pain,	O
nociceptive	O
pain,	O
inflammatory	O
pain,	O
back	O
pain,	O
pain	O
due	O
to	O
disease	O
of	O
various	O
origin	O
such	O
as	O
:	O
diabetic	O
neuropathy,	O
neurotropic	O
viral	O
disease	O
including	O
human	O
immunodeficient	O
virus	O
(	O
HIV	O
)	O
,	O
herpes	O
zoster	O
such	O
as	O
post	O
herpetic	O
neuralgia	O
;	O
polyneuropathy,	O
neurotoxicity,	O
mechanical	O
nerve	O
injury,	O
carpal	O
tunnel	O
syndrome,	O
immunologic	O
mechanisms	O
like	O
multiple	O
sclerosis	O
;	O
sleep	O
disorders,	O
anxiety	O
and	O
depression	O
disorders,	O
inflammatory	O
disorders,	O
weight	O
and	O
eating	O
disorders,	O
Parkinson	O
'	O
s	O
disease,	O
addiction,	O
spasticity,	O
hypertension	O
or	O
other	O
disorders	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
the	O
process	O
of	O
preparation	O
of	O
the	O
amide	O
compounds	O
.	O
Formula	O
(	O
1	O
)	O
.	O
The	O
present	O
disclosure	O
also	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


Provided	O
is	O
a	O
promoter	O
capable	O
of	O
promoting	O
the	O
inhibition	O
of	O
the	O
expression	O
of	O
mRNA	O
by	O
RNA	O
interference	O
.	O
The	O
promoter	O
according	O
to	O
the	O
present	O
invention	O
is	O
characterized	O
by	O
comprising	O
at	O
least	O
one	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
resveratrol,	O
a	O
resveratrol	O
derivative,	O
a	O
tautomer,	O
a	O
geometric	O
isomer	O
and	O
a	O
stereoisomer	O
of	O
resveratrol	O
or	O
the	O
resveratrol	O
derivative,	O
and	O
salts	O
thereof,	O
wherein	O
the	O
active	O
ingredient	O
can	O
promote	O
the	O
transcription	O
of	O
a	O
nucleic	O
acid	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
mRNA	O
by	O
RNA	O
interference	O
and	O
/	O
or	O
the	O
expression	O
of	O
Argonaute-2	B-GENE
(	O
Ago2	B-GENE
)	O
.	O
The	O
nucleic	O
acid	O
is	O
preferably	O
miRNA	O
.	O
The	O
promoter	O
according	O
to	O
the	O
present	O
invention	O
is	O
applicable	O
to,	O
for	O
example,	O
a	O
method	O
for	O
treating	O
a	O
disease	O
utilizing	O
RNA	O
interference,	O
a	O
medicinal	O
agent,	O
a	O
food	O
additive,	O
the	O
analysis	O
of	O
a	O
gene	O
by	O
means	O
of	O
knock	O
down,	O
and	O
others	O


Disclosed	O
are	O
hybrid	O
compounds	O
that	O
release	O
both	O
nitric	O
oxide	O
and	O
a	O
moiety	O
that	O
inhibits	O
poly	B-GENE
(ADP-ribose)	I-GENE
polymerase	I-GENE
(	O
PARP	B-GENE
)	O
,	O
e	O
.	O
g	O
.	O
,	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1-4	O
and	O
m-p	O
are	O
as	O
described	O
herein	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
including	O
treating	O
cancer	O
and	O
enhancing	O
the	O
chemotherapeutic	O
treatment	O
of	O
chemotherapeutic	O
agents	O
and	O
high	O
energy	O
radiation	O
.	O


Compounds	O
having	O
methyltransferase	B-GENE
inhibitory	O
activity	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
amino	O
acids,	O
esters	O
and	O
amides	O
having	O
a	O
common	O
core	O
based	O
on	O
adenosine	O
or	O
deazaadenosine	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
similar	O
diseases	O
associated	O
with	O
inappropriate	O
methyltransferase	B-GENE
activity	O
.	O


[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
having	O
sEH	B-GENE
inhibitory	O
activity	O
and	O
to	O
provide	O
a	O
pharmaceutical	O
that	O
actualizes	O
a	O
therapeutic	O
effect	O
based	O
on	O
the	O
mechanism	O
against	O
hypertension	O
and	O
other	O
such	O
cardiovascular	O
diseases	O
.	O
[	O
Solution	O
]	O
The	O
invention	O
provides	O
a	O
diazaspirourea	O
derivative	O
represented	O
by	O
the	O
following	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
Nox4	B-GENE
inhibitors,	O
pharmaceutical	O
composition	O
thereof	O
and	O
to	O
their	O
use	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
osteoporosis	O
or	O
an	O
osteoclastogenesis	O
dysfunction,	O
in	O
particular	O
osteoporotic	O
and	O
pre-osteoporotic	O
osteoclastogenesis	O
dysfunction	O
.	O


Provided	O
is	O
a	O
puncture	O
pain	O
alleviating	O
external	O
preparation	O
which	O
causes	O
little	O
pain	O
and	O
which	O
can	O
be	O
easily	O
used	O
.	O
The	O
puncture	O
pain	O
alleviating	O
external	O
preparation	O
of	O
the	O
present	O
invention	O
is	O
to	O
be	O
applied	O
in	O
the	O
vicinity	O
of	O
the	O
site	O
to	O
be	O
punctured,	O
and	O
comprises	O
:	O
at	O
least	O
one	O
aliphatic	O
alcohol	O
selected	O
from	O
methanol,	O
ethanol,	O
isopropanol,	O
and	O
normal	O
propanol	O
;	O
menthol	O
;	O
and	O
at	O
least	O
one	O
or	O
more	O
substance	O
that	O
stimulates	O
the	O
TRPM8	B-GENE
receptor	O
activation	O
channel	O
selected	O
from	O
the	O
group	O
of	O
compounds	O
represented	O
by	O
the	O
following	O
chemical	O
formula	O
.	O
(	O
In	O
the	O
formula,	O
R1	O
and	O
R2	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hydrogen	O
or	O
halogen	O
atom	O
;	O
a	O
hydroxy,	O
cyano,	O
nitro,	O
mercapto,	O
carbonyl,	O
sulfone,	O
or	O
carboxy	O
group	O
;	O
or	O
an	O
optionally	O
substituted	O
alkyl,	O
alkenyl,	O
alkoxy,	O
alkylthio,	O
aryl,	O
aryloxy,	O
arylthio,	O
amino,	O
siloxy,	O
ester,	O
or	O
heterocycle	O
group	O
.	O
)	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
the	O
chemical	O
and	O
pharmaceutical	O
industry	O
and	O
medicine	O
and	O
concerns	O
compounds	O
which	O
can	O
be	O
used	O
to	O
produce	O
agents	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
diseases	O
.	O
A	O
novel	O
compound	O
of	O
formula	O
I	O
is	O
proposed	O
which	O
exhibits	O
the	O
properties	O
of	O
an	O
exogenous	O
nitric	O
oxide	O
donor	O
and	O
thus	O
a	O
thrombocyte	O
aggregation	O
inhibitor,	O
as	O
well	O
as	O
displaying	O
antihypertensive	O
activity	O
and	O
activating	O
activity	O
towards	O
the	O
enzyme	O
soluble	B-GENE
guanylyl	I-GENE
cyclase	I-GENE
.	O
Variants	O
of	O
methods	O
for	O
synthesizing	O
the	O
above	O
compound	O
are	O
also	O
proposed	O
.	O


Disclosed	O
are	O
a	O
phthalic	O
hydrazide	O
(	O
phthalazine	O
ketone	O
)	O
compound,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
.	O
As	O
a	O
DNA	O
repair	O
enzyme	O
poly	B-GENE
(ADP-ribozyme)	I-GENE
polymerase	I-GENE
inhibitor,	O
the	O
compound	O
and	O
the	O
pharmaceutical	O
composition	O
can	O
effectively	O
treat	O
diseases	O
involving	O
PARP	B-GENE
enzymatic	O
activity,	O
including	O
cancer,	O
neural	O
degenerative	O
diseases,	O
inflammation	O
and	O
the	O
like	O
.	O


Provided	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
.	O
Compared	O
to	O
prior	O
art,	O
the	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
dual	O
structure	O
of	O
sulfonylurea	O
and	O
aminoguanidine	O
;	O
the	O
sulfonylurea	O
can	O
reduce	O
blood	O
sugar	O
level	O
by	O
enhancing	O
the	O
secretion	O
of	O
endogenous	O
insulin,	O
and	O
the	O
aminoguanidine	O
structure	O
has	O
significant	O
prevention	O
and	O
treatment	O
effects	O
for	O
various	O
complications	O
of	O
diabetic	O
patients	O
.	O
Each	O
substituent	O
of	O
X,	O
R1,	O
R2,	O
R3	O
and	O
R4	O
is	O
as	O
defined	O
in	O
the	O
specification	O
.	O


A	O
pharmacological	O
treatment	O
of	O
both	O
familial	O
early	O
onset	O
and	O
sporadic	O
late	O
onset	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
AD-related	O
disorders	O
and	O
Down	O
'	O
s	O
syndrome-coupled	O
neuropathies	O
involves	O
the	O
use	O
of	O
a	O
class	O
of	O
drugs,	O
the	O
calcilytics,	O
which	O
by	O
inhibiting	O
the	O
calcium-sensing	B-GENE
receptor	I-GENE
(	O
CaSR	B-GENE
)	O
signaling	O
in	O
all	O
types	O
of	O
brain	O
cells	O
prevent	O
:	O
(	O
i	O
)	O
the	O
overproduction	O
of	O
cell-harming	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
peroxynitrite	O
(	O
ONOO-	O
)	O
,	O
and	O
most	O
importantly	O
(	O
ii	O
)	O
the	O
intracellular	O
overproduction,	O
accumulation,	O
and	O
secretion	O
of	O
Amyloid	B-GENE
β	I-GENE
(	O
Aβ	B-GENE
)	O
peptides	O
in	O
response	O
to	O
the	O
extracellular	O
presence	O
of	O
exogenous	O
Aβpeptides	B-GENE
and	O
/	O
or	O
proinflammatory	O
cytokines,	O
and	O
(	O
iii	O
)	O
the	O
Aβ	B-GENE
peptide-related	O
hyperphosphorylation	O
of	O
the	O
Tau	B-GENE
(	O
τ	O
)	O
protein	O
on	O
the	O
part	O
of	O
an	O
Aβ	B-GENE
/	O
Ca	O
SR-signaling	O
activated	O
glycogen	B-GENE
synthase	I-GENE
kinase-(GSK)-3β	I-GENE
w	O
i	O
t	O
h	O
the	O
resulting	O
formation	O
of	O
neurofibrillary	O
tangles	O
(	O
NTFs	O
)	O
,	O
the	O
latter	O
known	O
to	O
cause	O
such	O
severe	O
dysfunctioning	O
of	O
the	O
microtubular	O
cytoskeleton	O
as	O
to	O
eventually	O
favor	O
(	O
iv	O
)	O
the	O
death	O
of	O
human	O
cerebral	O
cortex	O
neurons	O
.	O


Bivalent	O
ligands	O
that	O
contain	O
two	O
pharmacophores	O
linked	O
through	O
a	O
spacer,	O
one	O
of	O
which	O
interacts	O
with	O
the	O
μ-opioid	B-GENE
receptor	I-GENE
(	O
MOR	B-GENE
)	O
and	O
the	O
other	O
of	O
which	O
interacts	O
with	O
the	O
co-receptor	O
CC	B-GENE
chemokine	I-GENE
receptor	I-GENE
5	I-GENE
(	O
CCR5	B-GENE
)	O
,	O
are	O
used	O
for	O
the	O
treatment	O
of	O
neurological	O
disorders	O
such	O
as	O
those	O
associated	O
with	O
AIDS	O
.	O


The	O
present	O
invention	O
relates	O
methods	O
to	O
increase	O
the	O
expression	O
of	O
fatty	B-GENE
acid	I-GENE
desaturases	I-GENE
(	O
FADS	B-GENE
)	O
and	O
increase	O
cellular	O
and	O
tissue	O
levels	O
of	O
highly	O
unsaturated	O
fatty	O
acids	O
(	O
HUFA	O
)	O
by	O
modulating	O
one	O
or	O
more	O
of	O
the	O
FADS	B-GENE
via	O
the	O
action	O
of	O
specific	O
classes	O
of	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
statins	O
and	O
LXR	B-GENE
agonists	O
)	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
conditions	O
(	O
e	O
.	O
g	O
.	O
,	O
tumor	O
and	O
cancer	O
)	O
involving	O
deficient	O
function	O
of	O
FADS	B-GENE
by	O
administering	O
statins	O
and	O
/	O
or	O
LXR	B-GENE
agonists	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
determining	O
the	O
need	O
for	O
statins	O
or	O
dietary	O
LCPUFA	O
in	O
subjects	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
thiadiazolidmediones	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
any	O
pharmaceutically	O
acceptable	O
salt,	O
solvate	O
or	O
prodrug	O
thereof,	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
in	O
which	O
glycogen	B-GENE
synthase	I-GENE
kinase	I-GENE
3	I-GENE
(	O
GSK-3	B-GENE
)	O
is	O
involved,	O
particularly	O
neurodegenerative	O
diseases,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cardiovascular	O
disorders	O
.	O
Additionally,	O
there	O
is	O
provided	O
a	O
process	O
for	O
preparing	O
such	O
compounds,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
in	O
one	O
embodiment	O
to	O
a	O
pharmaceutical	O
combination	O
of	O
a	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
5	I-GENE
(	O
mGluR5	B-GENE
)	O
negative	O
allosteric	O
modulator	O
and	O
levodopa	O
or	O
a	O
dopamine	O
agonist,	O
and	O
at	O
least	O
one	O
of	O
a	O
dopa	O
decarboxylase	O
inhibitor	O
or	O
a	O
catechol-O-methyl	B-GENE
transferase	I-GENE
inhibitor	O
for	O
the	O
treatment	O
of	O
PD-LID	O
.	O
In	O
this	O
exemplary	O
pharmaceutical	O
combination,	O
the	O
mGluR5	B-GENE
negative	O
allosteric	O
modulator	O
will	O
have	O
similar	O
pharmacokinetic	O
parameters	O
to	O
levodopa	O
or	O
to	O
a	O
dopamine	O
agonist	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
compounds	O
(	O
e	O
.	O
g	O
.	O
,	O
imidazopyrazine,	O
imidazopyridine,	O
imidazopyridazine	O
and	O
imidazpyrimidine	O
compounds	O
)	O
that	O
act	O
as	O
inhibitors	O
of	O
the	O
MAP	B-GENE
kinase	I-GENE
interacting	O
kinases	O
MNK2a,	O
MNK2b,	O
MNK1a,	O
and	O
MNK1b	B-GENE
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
proliferative	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
cancer	O
)	O
,	O
inflammatory	O
diseases,	O
Alzheimer	O
'	O
s	O
disease	O
)	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
these	O
diseases	O
.	O


Compounds	O
useful	O
as	O
kinase	B-GENE
inhibitors	O
are	O
provided	O
herein,	O
as	O
well	O
as	O
salts,	O
pharmaceutical	O
compositions,	O
methods	O
of	O
medical	O
treatment	O
and	O
methods	O
of	O
synthesis	O
thereof	O
.	O


Methods	O
and	O
compositions	O
for	O
treating	O
various	O
indications	O
by	O
lessening	O
oxidative	O
stress	O
in	O
a	O
patient	O
are	O
provided	O
.	O
A	O
pharmaceutical	O
composition	O
comprises	O
between	O
about	O
0	O
.	O
001	O
%	O
to	O
about	O
10	O
.	O
0	O
%	O
)	O
,	O
or	O
more	O
specifically	O
between	O
about	O
0	O
.	O
015	O
%	O
to	O
about	O
5	O
%	O
,	O
sodium	O
iodine	O
or	O
catalase	B-GENE
by	O
weight	O
.	O
The	O
iodine	O
ion	O
or	O
the	O
catalase	B-GENE
dissociates	O
hydrogen	O
peroxide	O
into	O
water	O
and	O
molecular	O
oxygen	O
to	O
interrupt	O
biological	O
events	O
that	O
result	O
in	O
negative	O
side	O
effects	O
.	O
The	O
pharmaceutical	O
composition	O
further	O
comprises	O
in	O
some	O
cases	O
a	O
reducing	O
agent	O
or	O
various	O
carrier	O
materials	O
.	O
The	O
pharmaceutical	O
composition	O
is	O
in	O
some	O
cases	O
formulated	O
for	O
a	O
variety	O
of	O
delivery	O
methods	O
.	O


The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
EPl	B-GENE
receptor	I-GENE
ligands	O
.	O
More	O
specifically	O
it	O
refers	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
having	O
great	O
affinity	O
and	O
selectivity	O
for	O
the	O
EPl	B-GENE
receptor	I-GENE
.	O
The	O
invention	O
also	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation,	O
to	O
their	O
use	O
as	O
medicament	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
or	O
disorders	O
mediated	O
by	O
the	O
EPl	B-GENE
receptor	I-GENE
as	O
well	O
as	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
amidopyridine	O
derivative	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
provides	O
a	O
medicinal	O
agent	O
which	O
is	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases,	O
which	O
is	O
based	O
on	O
the	O
production	O
of	O
cytokines	B-GENE
from	O
T	O
cells,	O
and	O
which	O
has,	O
as	O
an	O
active	O
ingredient,	O
the	O
amidopyridine	O
derivative	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O
Provided	O
are	O
the	O
amidopyridine	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
(	O
in	O
general	O
formula	O
(	O
I	O
)	O
,	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
)	O
.	O


Certain	O
2-carbamo	O
(	O
thio	O
)	O
yl-1,3-dioxopropyl	O
derivatives,	O
or	O
the	O
tautomers	O
and	O
pharmacologically	O
acceptable	O
addition	O
salts	O
thereof	O
are	O
found	O
to	O
be	O
toxic	O
to	O
cancer	O
cells,	O
in	O
part,	O
by	O
inhibiting	O
DNA	B-GENE
topoisomerase	I-GENE
II	I-GENE
enzyme	O
making	O
them	O
candidates	O
for	O
pharmaceutical	O
use	O
as	O
anticancer	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
immunotherapies	O
that	O
are	O
based	O
on	O
depletion	O
of	O
CD37-positive	O
cells	O
such	O
as	O
B-cells	O
.	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
reduction	O
of	O
CD37-positive	O
cells	O
such	O
as	O
B-cells	O
in	O
an	O
individual	O
/	O
patient	O
using	O
a	O
combination	O
of	O
CD37	B-GENE
antibody	O
/	O
antibodies	O
and	O
bendamustine	O
.	O
The	O
combination	O
of	O
CD37	B-GENE
antibodies	O
and	O
bendamustine	O
is	O
shown	O
to	O
have	O
a	O
synergistic	O
effect	O
.	O
The	O
application	O
further	O
provides	O
materials	O
and	O
methods	O
for	O
treatment	O
of	O
diseases	O
involving	O
aberrant	O
B-cell	O
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pyrrolopyridinone	O
derivatives	O
which	O
have	O
blocking	O
activities	O
of	O
voltage	B-GENE
gated	I-GENE
sodium	I-GENE
channels	I-GENE
as	O
the	O
TTX-S	O
channels,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
and	O
diseases	O
in	O
which	O
voltage	B-GENE
gated	I-GENE
sodium	I-GENE
channels	I-GENE
are	O
involved	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
voltage	B-GENE
gated	I-GENE
sodium	I-GENE
channels	I-GENE
are	O
involved	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
for	O
controlling	O
a	O
chromatin	O
structure	O
.	O
A	O
composition	O
of	O
the	O
present	O
invention	O
contains	O
:	O
(	O
1	O
)	O
a	O
polymer	O
which	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
amphoteric	O
polymers,	O
anionic	O
polymers	O
and	O
nonionic	O
polymers	O
having	O
a	O
specific	O
main	O
chain	O
skeleton	O
;	O
or	O
(	O
2	O
)	O
a	O
carrier	O
which	O
encloses	O
two	O
or	O
more	O
kinds	O
of	O
substances	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
expression	O
vectors	O
containing	O
a	O
gene	O
such	O
as	O
a	O
gene	O
encoding	O
histone	B-GENE
acetyltransferase	I-GENE
and	O
inhibitors	O
such	O
as	O
histone	O
acetylation	O
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
described	O
herein	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
acceptable	O
salts	O
thereof,	O
which	O
modulate	O
the	O
activity	O
of	O
calcium	B-GENE
release-	I-GENE
activated	I-GENE
calcium	B-GENE
(CRAC)	I-GENE
channel	I-GENE
.	O
The	O
invention	O
also	O
describes	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
thereof	O
for	O
treating,	O
managing,	O
and	O
/	O
or	O
lessening	O
the	O
severity	O
of	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
the	O
modulation	O
of	O
calcium	B-GENE
release-activated	I-GENE
calcium	B-GENE
(CRAC)	I-GENE
channel	I-GENE
.	O


The	O
current	O
disclosure	O
describes	O
materials	O
and	O
methods	O
for	O
identifying	O
subjects	O
that	O
would	O
benefit	O
from	O
treatment	O
with	O
a	O
DNA	B-GENE
topoisomerase	I-GENE
1	I-GENE
inhibitor,	O
based	O
on	O
the	O
levels	O
of	O
cullin	B-GENE
4B	I-GENE
gene,	O
RNA	O
and	O
protein	O
levels	O
in	O
the	O
subject	O
.	O
The	O
disclosure	O
identifies	O
CUL4B	B-GENE
as	O
a	O
predictive	O
biomarker	O
for	O
cancer	O
diagnosis	O
and	O
the	O
subsequent	O
treatment	O
with	O
directed	O
therapeutic	O
agents	O
.	O
The	O
current	O
disclosure	O
also	O
identifies	O
novel	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
level	O
of	O
CUL4B	B-GENE
expression,	O
and	O
sensitize	O
a	O
subject	O
to	O
treatment	O
with	O
a	O
second	O
therapeutic	O
agent	O
.	O


The	O
present	O
disclosure	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
modulator	O
of	O
retinoid-related	B-GENE
orphan	I-GENE
receptor	I-GENE
gamma	I-GENE
t	I-GENE
(	O
RORϒt	B-GENE
)	O
.	O
These	O
compounds	O
prevent,	O
inhibit,	O
or	O
suppress	O
the	O
action	O
of	O
RORϒt	B-GENE
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
RORϒt	B-GENE
mediated	O
disease,	O
disorder,	O
syndrome	O
or	O
condition	O
such	O
as	O
pain,	O
inflammation,	O
COPD,	O
asthma,	O
rheumatoid	O
arthritis,	O
colitis,	O
multiple	O
sclerosis,	O
neurodegenerative	O
diseases	O
or	O
cancer	O
.	O


Aspects	O
of	O
the	O
invention	O
provide	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B-GENE
genes	O
(	O
HBB,	O
HBD,	O
HBEl,	O
HBG1	B-GENE
or	O
HBG2	B-GENE
)	O
.	O
Further	O
aspects	O
provide	O
compositions	O
and	O
kits	O
comprising	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B-GENE
genes	O
.	O
Methods	O
for	O
modulating	O
expression	O
of	O
hemoglobin	B-GENE
genes	O
using	O
the	O
single	O
stranded	O
oligonucleotides	O
are	O
also	O
provided	O
.	O
Further	O
aspects	O
of	O
the	O
invention	O
provide	O
methods	O
for	O
selecting	O
a	O
candidate	O
oligonucleotide	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B-GENE
genes	O
.	O


The	O
invention	O
provides	O
a	O
dinucleoside	O
polyphosphate	O
analogue,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
for	O
use	O
in	O
the	O
inhibition	O
(	O
or	O
down-regulation	O
)	O
of	O
a	O
pain,	O
via	O
a	O
transducing	O
ATP	O
-gated	O
P2X3	B-GENE
receptor,	O
often	O
by	O
means	O
of	O
high-affinity	O
desensitisation	O
(	O
HAD	O
)	O
mechanism	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
and	O
the	O
pharmaceutical-chemical	O
industry,	O
and	O
specifically	O
to	O
the	O
field	O
of	O
neurology,	O
and	O
concerns	O
new	O
compositions	O
containing	O
memantine	O
and	O
melatonin	O
.	O
It	O
has	O
been	O
established	O
that	O
a	O
strengthening	O
of	O
the	O
effect	O
of	O
memantine	O
takes	O
place	O
when	O
it	O
is	O
combined	O
with	O
melatonin	O
.	O
The	O
invention	O
may	O
be	O
realized	O
through	O
the	O
preparation	O
of	O
a	O
finished	O
pharmaceutical	O
product	O
such	O
as	O
capsules,	O
preferably	O
hard	O
gelatin	B-GENE
capsules	O
.	O


This	O
application	O
is	O
directed	O
to	O
α-neuronal	B-GENE
nicotinic	I-GENE
receptor	I-GENE
agonists	O
selective	O
for	O
α7-subtype	O
that	O
are	O
useful	O
for	O
improving	O
cognition	O
impairment	O
in	O
patients	O
having	O
schizophrenia,	O
a	O
schizophreniform	O
disorder	O
or	O
a	O
related	O
schizophrenia	O
spectrum	O
psychotic	O
disorder	O
.	O
Compounds	O
and	O
compositions	O
containing	O
such	O
compounds,	O
and	O
methods	O
of	O
using	O
such	O
compound	O
and	O
compositions	O
are	O
described	O
herein	O
.	O


Provided	O
is	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
mild	O
cognitive	O
impairment,	O
which	O
can	O
improve	O
interstitial	O
flow	O
in	O
cerebral	O
blood	O
vessels	O
and	O
the	O
like	O
to	O
achieve	O
the	O
sufficient	O
clearance	O
of	O
harmful	O
proteins	O
accumulated	O
in	O
the	O
brain	O
.	O
The	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
comprises	O
6-	O
[	O
4-	O
(	O
1-cyclohexyl-1H-tetrazol-5-yl	O
)	O
butoxy	O
]	O
3,4-	O
dihydrocarbostyril	O
or	O
a	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
can	O
improve	O
the	O
flow	O
of	O
an	O
interstitial	O
fluid	O
around	O
blood	O
vessels	O
in	O
a	O
drainage	O
pathway	O
to	O
excrete	O
harmful	O
proteins	O
.	O
The	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
mild	O
cognitive	O
impairment	O
according	O
to	O
the	O
present	O
invention	O
may	O
take	O
the	O
form	O
of	O
a	O
preparation	O
for	O
oral	O
administration,	O
a	O
liquid	O
preparation	O
for	O
oral	O
administration,	O
or	O
an	O
injectable	O
preparation	O
.	O
The	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
mild	O
cognitive	O
impairment	O
according	O
to	O
the	O
present	O
invention	O
can	O
be	O
used	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
cerebral	O
amyloid	B-GENE
angiopathy,	O
and	O
can	O
also	O
be	O
used	O
for	O
the	O
amelioration	O
of	O
dementia	O
with	O
Lewy	O
bodies,	O
Down	O
'	O
s	O
syndrome	O
or	O
macular	O
degeneration	O
.	O


The	O
present	O
invention	O
relates	O
to	O
uses	O
for	O
:	O
restricting	O
apoptosis	O
of	O
miRNA	O
of	O
Epstein-Barr	O
virus,	O
especially	O
miR-BART3-5p,	O
miR-BART3-3p,	O
miR-BART21-5p,	O
miR-BART21-3p,	O
miR-BART18-5p,	O
miR-BART18-3p,	O
miR-BART7-5p,	O
miR-BART7-3p,	O
miR-BART8-5p,	O
miR-BART8-3p,	O
miR-BART9-5p,	O
miR-BART22-5p,	O
miR-BART22-3p,	O
miR-BART19-5p,	O
miR-BART19-3p,	O
miR-BART13-5p,	O
miR-BART13-3p,	O
miR-BART14-5p,	O
miR-BART2-3p,	O
miR-BART1-3p,	O
miR-BART9-3p,	O
miR-BART10-5p,	O
miR-BART10-3p,	O
miR-BART14-3p	B-GENE
and	O
their	O
mimics	O
;	O
and	O
promoting	O
cell	O
proliferation	O
.	O


Provided	O
herein	O
are	O
novel	O
compositions	O
and	O
methods	O
to	O
inhibit	O
Olig2	B-GENE
activity	O
.	O
The	O
Olig2	B-GENE
inhibitors	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
useful,	O
inter	O
alia,	O
for	O
treating	O
cancer	O
.	O
In	O
particular	O
the	O
Olig2	B-GENE
inhibitors	O
may	O
be	O
used	O
to	O
treat	O
glioblastoma	O
.	O
Further,	O
provided	O
are	O
peptide	O
compositions	O
capable	O
of	O
inhibiting	O
Olig	B-GENE
2	I-GENE
.	O


The	O
invention	O
provides	O
novel	O
compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
A,	O
E	O
and	O
n	O
are	O
as	O
described	O
herein,	O
compositions	O
including	O
the	O
compounds	O
and	O
use	O
thereof	O
as	O
fatty-acid	B-GENE
binding	I-GENE
protein	I-GENE
(FABP)	I-GENE
4/5	I-GENE
inhibitors	O
in	O
the	O
treatment	O
of	O
e	O
.	O
g	O
.	O
type	O
2	O
diabetes,	O
atherosclerosis	O
or	O
cancer	O
.	O


A	O
method	O
for	O
treating	O
a	O
neuroendocrine	O
tumor,	O
particularly	O
pancreatic	O
neuroendocrine	O
tumor,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
therapeutic	O
agent,	O
wherein	O
said	O
neuroendocrine	O
tumor	O
is	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B-GENE
inhibitor	O
;	O
uses	O
of	O
said	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
neuroendocrine	O
tumor	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B-GENE
inhibitor	O
;	O
uses	O
of	O
said	O
compound	O
for	O
treating	O
said	O
disease	O
;	O
and	O
related	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
package	O
thereof	O
.	O


5-Azaindazole	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
including	O
stereoisomers,	O
geometric	O
isomers,	O
tautomers,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
are	O
useful	O
for	O
inhibiting	O
Pim	O
kinase,	O
and	O
for	O
treating	O
disorders	O
such	O
as	O
cancer	O
mediated	O
by	O
Pim	B-GENE
kinase	I-GENE
.	O
Methods	O
of	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis,	O
prevention	O
or	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells,	O
or	O
associated	O
pathological	O
conditions,	O
are	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
AKR1C3	B-GENE
inhibitors	O
and	O
methods	O
for	O
the	O
production	O
thereof,	O
the	O
use	O
thereof	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
diseases,	O
and	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
diseases,	O
in	O
particular	O
menstrual	O
pain	O
and	O
endometriosis	O
.	O


Disclosed	O
are	O
novel	O
heteroaryl	O
and	O
heterocycle	O
compounds	O
of	O
formula	O
I-1,	O
I-2	O
or	O
I-3	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them,	O
uses	O
and	O
methods	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
PI3K	B-GENE
and	O
for	O
treating	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O


Provided	O
is	O
a	O
piperazinotrizole	O
compound	O
represented	O
by	O
general	O
formula	O
I	O
or	O
an	O
isomer,	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester,	O
prodrug	O
or	O
hydrate	O
thereof	O
.	O
Also	O
provided	O
are	O
a	O
method	O
for	O
preparing	O
the	O
compound,	O
a	O
drug	O
composition	O
containing	O
the	O
compound,	O
and	O
a	O
use	O
thereof	O
as	O
a	O
high-selectivity	O
poly(ADP-ribose)	B-GENE
polymerase-1	O
(	O
PARP1	B-GENE
)	O
inhibitor	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
PARP-related	O
diseases	O
.	O


The	O
use	O
of	O
ORL-1	B-GENE
receptor	O
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
is	O
described	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
and	O
salts	O
thereof	O
.	O
In	O
some	O
embodiments,	O
the	O
invention	O
relates	O
to	O
inhibitors	O
or	O
modulators	O
of	O
Pim-1	B-GENE
and	O
/	O
or	O
Pim-2,	O
and	O
/	O
or	O
Pim-3	B-GENE
protein	O
kinase	O
activity	O
or	O
enzyme	O
function	O
.	O
In	O
still	O
further	O
embodiments,	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
disclosed	O
herein,	O
and	O
their	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
Pim	B-GENE
kinase	I-GENE
related	O
conditions	O
and	O
diseases,	O
preferably	O
cancer	O
.	O


Provided	O
herein	O
are	O
curcumin	O
analogues	O
that	O
are	O
able	O
to	O
interact	O
with	O
amyloid	B-GENE
β	I-GENE
(	O
Aβ	B-GENE
)	O
and	O
to	O
attenuate	O
the	O
copper-induced	O
crosslinking	O
of	O
Aβ	B-GENE
.	O
Also	O
provided	O
herein	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
Disease	O
or	O
a	O
related	O
disorder	O
.	O


The	O
invention	O
relates	O
to	O
buffer	O
substances	O
for	O
the	O
phase-appropriate	O
treatment	O
of	O
wounds,	O
said	O
treatment	O
comprising	O
the	O
suppression	O
of	O
fibrin	B-GENE
formation	O
and	O
/	O
or	O
fibrin	B-GENE
cross-linking	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
wound	O
dressing	O
product	O
containing	O
said	O
buffer	O
substances	O
to	O
suppress	O
fibrin	B-GENE
formation	O
and	O
/	O
or	O
fibrin	B-GENE
cross-linking	O
.	O


Novel	O
compounds	O
of	O
the	O
structural	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
AMP-protein	B-GENE
kinase	I-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
AMPK	B-GENE
activated	O
protein	O
kinase	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Type	O
2	O
diabetes,	O
hyperglycemia,	O
metabolic	O
syndrome,	O
obesity,	O
hypercholesterolemia,	O
and	O
hypertension	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
metastatic	O
cancer	O
.	O
Certain	O
example	O
embodiments	O
of	O
the	O
present	O
disclosure	O
provide	O
a	O
method	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
a	O
metastatic	O
cancer	O
in	O
a	O
subject	O
.	O
The	O
method	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
a	O
chemokine	B-GENE
receptor	I-GENE
CCX-CKR	I-GENE
.	O


This	O
invention	O
is	O
directed	O
to	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient,	O
particularly	O
a	O
patient	O
with	O
lung	O
adenocarcinoma,	O
and	O
more	O
particularly	O
a	O
patient	O
with	O
KIF5B-RET	O
fusion-positive	O
non-small	O
cell	O
lung	O
cancer,	O
with	O
an	O
inhibitor	O
of	O
MET,	O
VEGF,	O
and	O
RET	B-GENE
which	O
is	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
anti-aging	O
or	O
skin	O
moisturizing	O
composition	O
.	O
The	O
composition	O
according	O
to	O
the	O
present	O
invention	O
contains,	O
as	O
an	O
active	O
ingredient,	O
a	O
material	O
for	O
controlling	O
the	O
expression	O
of	O
ABH	O
antigen,	O
and	O
therefore,	O
has	O
superior	O
anti-aging	O
and	O
skin	O
moisturizing	O
effects	O
.	O
Further,	O
the	O
composition	O
of	O
the	O
preset	O
invention	O
may	O
inhibit	O
the	O
expression	O
of	O
MMP-1,	O
and	O
therefore,	O
can	O
be	O
effectively	O
used	O
in	O
reducing	O
wrinkles	O
or	O
improving	O
the	O
appearance	O
thereof	O
.	O


﻿The	O
subject	O
of	O
the	O
present	O
invention	O
is	O
nα-acyl	O
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	B-GENE
endopeptidase	I-GENE
and	O
dipeptidyl	O
peptidase-iv,	O
having	O
hypoglycemic,	O
antihypoxic,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
.	O


Novel	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
(	O
PTP	B-GENE
)	O
inhibitor	O
compounds	O
synthesized	O
from	O
phosphonodifluoromethyl	O
phenylalanine	O
(	O
F2Pmp	O
)	O
are	O
provided	O
.	O
Use	O
of	O
these	O
compounds	O
for	O
inhibiting	O
a	O
PTP	B-GENE
enzyme	O
(	O
such	O
as	O
PTP-MEG2	O
)	O
,	O
as	O
well	O
as	O
treating	O
a	O
disease,	O
disorder,	O
or	O
condition	O
associated	O
with	O
inappropriate	O
activity	O
of	O
a	O
PTP	B-GENE
(	O
such	O
as	O
type	O
2	O
diabetes	O
)	O
,	O
is	O
also	O
provided	O
.	O


Disclosed	O
is	O
an	O
application	O
of	O
a	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
following	O
structure	O
formula	O
(	O
I	O
)	O
.	O
It	O
is	O
proved	O
through	O
a	O
biological	O
activity	O
test,	O
the	O
compound	O
has	O
an	O
obvious	O
activity	O
of	O
inhibiting	O
the	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
.	O
Therefore,	O
the	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
the	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
for	O
curing	O
cancers	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
cancers	O
expressing	O
the	O
type	B-GENE
1	I-GENE
insulin-like	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
IGF1R	B-GENE
)	O
or	O
a	O
constituent	O
of	O
an	O
IGF1R	B-GENE
signaling	O
pathway,	O
in	O
particular	O
melanoma,	O
using	O
the	O
microRNA	O
miR-7-5p	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
increasing	O
the	O
sensitivity	O
of	O
such	O
cancers	O
to	O
therapeutic	O
agents	O
.	O


The	O
present	O
disclosure	O
relates	O
generally	O
to	O
alpha-helix	O
mimetic	O
structures	O
and	O
specifically	O
to	O
alpha-helix	O
mimetic	O
structures	O
that	O
are	O
inhibitors	O
of	O
β-catenin	B-GENE
.	O
The	O
disclosure	O
also	O
relates	O
to	O
applications	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
and	O
pre-cancerous	O
skin	O
conditions	O
including	O
actinic	O
keratosis	O
and	O
psoriasis,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
alpha	O
helix	O
mimetic	O
β-catenin	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
(	O
e	O
.	O
g	O
.	O
,	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates,	O
polymorphs,	O
co-crystals,	O
tautomers,	O
stereoisomers,	O
isotopically	O
labeled	O
derivatives,	O
prodrugs,	O
and	O
compositions	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
and	O
kits	O
comprising	O
the	O
inventive	O
compounds,	O
or	O
compositions	O
thereof,	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
fungal	O
or	O
protozoan	O
infection,	O
inhibiting	O
the	O
activity	O
of	O
a	O
fungal	O
or	O
protozoan	O
enzyme,	O
killing	O
a	O
fungus	O
or	O
protozoan,	O
or	O
inhibiting	O
the	O
growth	O
of	O
a	O
fungus	O
or	O
protozoan	O
.	O
The	O
fungus	O
may	O
be	O
a	O
Candida	O
species,	O
Sacchawmyces	O
species,	O
or	O
other	O
pathogenic	O
fungal	O
species	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
activity	O
of	O
fungal	O
or	O
protozoan	O
mitochondrial	B-GENE
phosphate	I-GENE
carrier	I-GENE
protein	I-GENE
.	O


Provided	O
are	O
bifunctional	O
small	O
molecules	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
M	O
represents	O
a	O
small	O
organic	O
molecule	O
which	O
binds,	O
covalently	O
or	O
non-covalently,	O
a	O
kinase,	O
such	O
as	O
Her3	B-GENE
protein	O
kinase	B-GENE
;	O
L1	O
represents	O
a	O
linker	O
;	O
and	O
RH	O
represents	O
a	O
hydrophobic	O
group	O
.	O
An	O
example	O
of	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
is	O
a	O
compound	O
of	O
Formula	O
(	O
II	O
)	O
:	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
for	O
treating	O
proliferative	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates,	O
polymorphs,	O
co-crystals,	O
tautomers,	O
stereoisomers,	O
isotopically	O
labeled	O
derivatives,	O
prodrugs,	O
and	O
compositions	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
and	O
kits	O
involving	O
the	O
inventive	O
compounds	O
or	O
compositions	O
for	O
treating	O
or	O
preventing	O
proliferative	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
cancers	O
(	O
e	O
.	O
g	O
.	O
,	O
leukemia,	O
lymphoma,	O
melanoma,	O
multiple	O
myeloma,	O
breast	O
cancer,	O
Ewing	O
'	O
s	O
sarcoma,	O
osteosarcoma,	O
brain	O
cancer,	O
neuroblastoma,	O
lung	O
cancer	O
)	O
,	O
benign	O
neoplasms,	O
angiogenesis,	O
inflammatory	O
diseases,	O
autoinflammatory	O
diseases,	O
and	O
autoimmune	O
diseases	O
)	O
in	O
a	O
subject	O
.	O
Treatment	O
of	O
a	O
subject	O
with	O
a	O
proliferative	O
disease	O
using	O
a	O
compound	O
or	O
composition	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
aberrant	O
activity	O
of	O
a	O
kinase,	O
such	O
as	O
cyclin-dependent	B-GENE
kinase	B-GENE
(	O
CDK	B-GENE
)	O
(	O
e	O
.	O
g	O
.	O
,	O
cyclin-dependent	B-GENE
kinase	B-GENE
7	I-GENE
(	O
CDK7	B-GENE
)	O
)	O
,	O
and	O
therefore,	O
induce	O
cellular	O
apoptosis	O
and	O
/	O
or	O
inhibit	O
transcription	O
in	O
the	O
subject	O
.	O


Disclosed	O
herein	O
are	O
compositions	O
comprising	O
a	O
galectin-1	B-GENE
-targeting	O
compound	O
in	O
a	O
therapeutically	O
effective	O
composition	O
for	O
treating	O
cancer	O
.	O
In	O
an	O
aspect,	O
a	O
galectin-1	B-GENE
-targeting	O
compound	O
is	O
OTX-008	O
.	O
Also	O
disclosed	O
herein	O
are	O
methods	O
of	O
making	O
and	O
using	O
such	O
compositions	O
.	O


The	O
present	O
invention	O
provides	O
tricyclic	O
fused	O
thiophene	O
derivatives,	O
as	O
well	O
as	O
their	O
compositions	O
and	O
methods	O
of	O
use,	O
that	O
modulate	O
the	O
activity	O
of	O
Janus	B-GENE
kinase	I-GENE
(	O
JAK	B-GENE
)	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
the	O
activity	O
of	O
JAK	B-GENE
including,	O
for	O
example,	O
inflammatory	O
disorders,	O
autoimmune	O
disorders,	O
cancer,	O
and	O
other	O
diseases	O
.	O


Compositions	O
comprising	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
that	O
modulate	O
pyruvate	B-GENE
kinase	I-GENE
are	O
described	O
herein	O
.	O
Also	O
described	O
herein	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
that	O
modulate	O
pyruvate	B-GENE
kinase	I-GENE
in	O
the	O
treatment	O
of	O
diseases	O
.	O


The	O
instant	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
which	O
are	O
PI3K-delta	B-GENE
inhibitors,	O
and	O
as	O
such	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
PI3K-delta-mediated	O
diseases	O
such	O
as	O
inflamation,	O
asthma,	O
COPD	O
and	O
cancer	O
.	O


The	O
inhibitory	O
oligonucleotides	O
(	O
ODNs	O
)	O
which	O
strongly	O
block	O
NF-	B-GENE
κ	I-GENE
B	I-GENE
activation	O
induced	O
by	O
TLR9	B-GENE
agonists	O
and	O
TLR7	B-GENE
agonists	O
are	O
provided	O
.	O
The	O
production	O
of	O
proinflammatory	O
cytokines,	O
such	O
as	O
interleukin-6	B-GENE
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha,	O
is	O
inhibited	O
by	O
the	O
inhibitory-ODNs	O
.	O
Interferon	B-GENE
production	O
from	O
human	O
PBMC	O
induced	O
by	O
TLR9	B-GENE
agonist	O
is	O
prevented	O
by	O
the	O
inhibitory-ODNs	O
.	O
These	O
ODNs	O
can	O
be	O
used	O
as	O
a	O
remedy	O
for	O
the	O
treatment	O
of	O
immune-mediated	O
disorders	O
such	O
as	O
rheumatoid	O
arthritis,	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
sepsis,	O
multiple	O
organ	O
dysfunction	O
syndromes	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
stabilizing	O
a	O
fusion	O
protein	O
of	O
a	O
bioactive	O
protein	O
and	O
an	O
Fc	O
domain,	O
and	O
relates	O
to	O
a	O
method	O
for	O
stabilizing	O
a	O
fusion	O
protein	O
of	O
a	O
protein	O
and	O
an	O
Fc	B-GENE
domain	I-GENE
by	O
using	O
a	O
composition	O
containing	O
an	O
ammonium	O
salt,	O
or	O
an	O
ammonium	O
salt	O
and	O
a	O
succinate	O
.	O
The	O
composition	O
containing	O
an	O
ammonium	O
salt,	O
or	O
an	O
ammonium	O
salt	O
and	O
a	O
succinate,	O
according	O
to	O
the	O
present	O
invention,	O
effectively	O
inhibits	O
the	O
aggregation	O
of	O
an	O
Fc-fusion	O
protein,	O
thereby	O
enabling	O
the	O
fusion	O
protein	O
to	O
be	O
stored	O
for	O
a	O
long	O
time,	O
and	O
thus	O
can	O
be	O
widely	O
used	O
in	O
the	O
medical	O
field	O
using	O
an	O
Fc-fusion	B-GENE
protein	I-GENE
.	O


A	O
TARP	O
γ8	O
dependant	O
AMPA	B-GENE
receptor	I-GENE
antagonist	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
its	O
pharmaceutically	O
acceptable	O
salts,	O
uses,	O
and	O
methods	O
for	O
its	O
preparation	O
are	O
described	O
.	O


Provided	O
herein	O
are	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
inhibitor	B-GENE
of	I-GENE
apoptosis	I-GENE
proteins	I-GENE
(	O
IAPs	B-GENE
)	O
,	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
comprising	O
the	O
compounds	O
.	O


In	O
the	O
present	O
invention,	O
a	O
CBP	B-GENE
/	O
β-catenin	B-GENE
inhibitor	O
exhibits	O
a	O
superior	O
defibrinating	O
effect	O
with	O
respect	O
to	O
Cre	O
/	O
loxP	O
/	O
HCV-MxCre	O
transgenic	O
mice,	O
which	O
are	O
an	O
experimental	O
animal	O
model	O
for	O
hepatic	O
fibrosis,	O
and	O
is	O
useful	O
as	O
a	O
prevention	O
or	O
treatment	O
drug	O
for	O
hepatic	O
fibrosis	O
.	O


Compounds	O
having	O
the	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
compounds,	O
are	O
CETP	B-GENE
inhibitors	O
and	O
may	O
be	O
useful	O
for	O
raising	O
HDL-cholesterol	O
and	O
reducing	O
LDL-cholesterol	O
in	O
human	O
patients	O
and	O
for	O
treating	O
or	O
preventing	O
atherosclerosis	O
.	O
The	O
chemical	O
compounds	O
that	O
are	O
disclosed	O
cholesterol	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
(	O
CETP	B-GENE
)	O
and	O
are	O
expected	O
to	O
have	O
utility	O
in	O
raising	O
HDL-C,	O
lowering	O
LDL-C,	O
and	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerosis	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
ALK	B-GENE
inhibitors	O
of	O
Formula	O
I	O
:	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
ALK	B-GENE
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
DNA	O
aptamer	O
that	O
can	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
tyrosinase	B-GENE
for	O
the	O
conversion	O
of	O
tyrosine	O
into	O
L-DOPA	O
and	O
dopaquinone,	O
and	O
to	O
the	O
dermatological	O
and	O
cosmetic	O
uses	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
stereoisomers,	O
regioisomers,	O
tautomeric	O
forms	O
and	O
novel	O
intermediates	O
involved	O
in	O
their	O
synthesis,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
of	O
preparing	O
novel	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
stereoisomers,	O
regioisomers,	O
their	O
tautomeric	O
forms,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutically	O
acceptable	O
solvates,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
novel	O
intermediates	O
involved	O
in	O
their	O
synthesis	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
PARP-1	B-GENE
inhibitors	O
for	O
the	O
treatment	O
of,	O
e	O
.	O
g	O
.	O
cancer	O
.	O


The	O
Invention	O
relates	O
to	O
pyrazolyl-based	O
carboxamide	O
compounds	O
of	O
formula	O
(	O
l	O
)	O
useful	O
as	O
ICRAC	B-GENE
inhibitors,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
to	O
these	O
compounds	O
for	O
the	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
and	O
/	O
or	O
disorders,	O
in	O
particular	O
inflammatory	O
diseases	O
and	O
/	O
or	O
inflammatory	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
for	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
various	O
embodiments	O
thereof,	O
and	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
various	O
embodiments	O
thereof	O
.	O
(	O
I	O
)	O
In	O
compounds	O
of	O
Formula	O
I,	O
the	O
groups	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
R7	O
have	O
the	O
meaning	O
as	O
described	O
herein	O
.	O
The	O
present	O
invention	O
also	O
provides	O
for	O
methods	O
of	O
using	O
compounds	O
of	O
Formula	O
I	O
and	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
as	O
DLK	B-GENE
inhibitors	O
and	O
for	O
treating	O
neurodegeneration	O
diseases	O
and	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoxaline	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
as	O
positive	O
allosteric	O
modulators	O
for	O
modulating	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
subtype	I-GENE
4	I-GENE
(	O
mGluR4	B-GENE
)	O
and	O
/	O
or	O
altering	O
glutamate	O
level	O
or	O
glutamatergic	O
signalling	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazoles,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-	B-GENE
phosphate	I-GENE
receptors	I-GENE
.	O
Claimed	O
are	O
compounds	O
of	O
Markush	O
formula	O
(	O
I	O
)	O
:	O
[	O
Formula	O
should	O
be	O
inserted	O
here	O
]	O
A	O
typical	O
example	O
for	O
a	O
Markush	O
formula	O
(	O
I	O
)	O
compound	O
is	O
example	O
7	O
:	O
Example	O
7	O
[	O
Formula	O
should	O
be	O
inserted	O
here	O
]	O


Compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
aberrant	O
activity	O
of	O
the	O
protein	O
kinases	O
ΙΚΚε	B-GENE
and	O
/	O
or	O
TBK-1	B-GENE
in	O
which	O
one	O
of	O
V	O
and	O
W	O
is	O
N,	O
and	O
the	O
other	O
of	O
V	O
and	O
W	O
is	O
C-H	O
;	O
and	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
invention	O
also	O
provides	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
provides	O
novel	O
compounds	O
having	O
the	O
general	O
formula	O
(	O
1	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R9,	O
R10,	O
R11	O
and	O
A	O
are	O
as	O
described	O
herein,	O
compositions	O
including	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
aldosterone	B-GENE
synthase	I-GENE
(	O
CYP11B2	B-GENE
or	O
CYP11B1	B-GENE
)	O
inhibitors	O
for	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
chroman-6-yloxy-cycloalkanes	O
of	O
the	O
formula	O
(	O
I	O
)	O
in	O
which	O
Ar,	O
R1	O
to	O
R4,	O
p	O
and	O
q	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
the	O
sodium-calcium	B-GENE
exchanger	I-GENE
(	O
NCX	B-GENE
)	O
,	O
especially	O
of	O
the	O
sodium-calcium	B-GENE
exchanger	I-GENE
of	I-GENE
subtype	I-GENE
1	I-GENE
(	O
NCX1	B-GENE
)	O
,	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diverse	O
disorders	O
in	O
which	O
intracellular	O
calcium	O
homeostasis	O
is	O
disturbed,	O
such	O
as	O
arrhythmias,	O
heart	O
failure	O
and	O
stroke	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
pharmaceuticals,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


Methods	O
of	O
altering	O
microenvironmental	O
levels	O
of	O
Vascular	B-GENE
Endothelial	I-GENE
Growth	I-GENE
Factor	I-GENE
in	O
a	O
subject	O
are	O
disclosed	O
.	O
The	O
methods	O
include	O
providing	O
a	O
Granzyme	B-GENE
B	I-GENE
(	O
GzmB	B-GENE
)	O
inhibitor	O
to	O
an	O
area	O
of	O
inflammation	O
.	O
The	O
area	O
of	O
inflammation	O
can	O
be	O
associated	O
with	O
conditions	O
that	O
have	O
an	O
associated	O
increase	O
in	O
vascular	O
permeability,	O
including	O
for	O
example,	O
rheumatoid	O
arthritis,	O
myocardial	O
infarction,	O
ocular	O
disease,	O
skin	O
conditions,	O
such	O
as	O
psoriasis,	O
and	O
dermatitis,	O
cancer,	O
transplantation,	O
and	O
/	O
or	O
arthrosclerosis,	O
and	O
the	O
like	O
.	O
The	O
Granzyme	B-GENE
B	I-GENE
inhibitor	O
can	O
be	O
comprised	O
of,	O
but	O
not	O
limited	O
to,	O
a	O
nucleic	O
acid,	O
a	O
polypeptide,	O
a	O
Granzyme	B-GENE
B	I-GENE
specific	O
antibody,	O
a	O
Granzyme	B-GENE
B	I-GENE
antibody	O
derivative,	O
or	O
a	O
small	O
molecule	O
.	O


The	O
invention	O
relates	O
to	O
microRNA	O
mimics,	O
corresponding	O
to	O
the	O
miR-15/107	B-GENE
family,	O
and	O
to	O
methodology	O
for	O
using	O
microRNA	O
mimics	O
to	O
treat	O
malignant	O
pleural	O
mesothelioma	O
(	O
MPM	O
)	O
by	O
restoring	O
regulation	O
of	O
the	O
expression	O
of	O
target	O
genes	O
of	O
the	O
miR-15/107	B-GENE
family	O
in	O
MPM	O
tumor	O
cells	O
.	O


The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
β-aminocarbonyl	O
compound	O
as	O
represented	O
by	O
general	O
formula	O
I,	O
or	O
tautomer,	O
enantiomer,	O
racemate	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
preparation	O
method	O
and	O
pharmaceutical	O
composition	O
thereof,	O
and	O
use	O
thereof	O
as	O
a	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP-4	B-GENE
)	O
inhibitor	O
.	O
The	O
compound	O
or	O
pharmaceutical	O
composition	O
thereof	O
can	O
be	O
used	O
as	O
a	O
DPP-4	B-GENE
inhibitor	O
to	O
treat	O
type	O
II	O
diabetes,	O
hyperglycaemia,	O
obesity,	O
or	O
insulin-resistance	O
syndromes	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
Bub1	O
kinase,	O
processes	O
for	O
their	O
production	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
isolated	O
EGF	B-GENE
receptor	I-GENE
agonist	O
for	O
use	O
in	O
the	O
treatment	O
of	O
chronic	O
liver	O
diseases	O
associated	O
with	O
a	O
low	O
hepcidin	B-GENE
expression	O
such	O
as	O
alcoholic	O
liver	O
disease,	O
chronic	O
hepatitis	O
C,	O
or	O
genetic	O
hemochromatosis	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
and	O
a	O
treatment	O
method	O
therefor	O
.	O
A	O
pharmaceutical	O
composition	O
containing	O
siRNA	O
inhibiting	O
the	O
expression	O
of	O
a	O
CD98	B-GENE
heavy	O
chain	O
was	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O
As	O
a	O
result,	O
a	O
novel	O
treatment	O
method	O
can	O
be	O
provided	O
that	O
uses	O
the	O
siRNA	O
for	O
inflammatory	O
bowel	O
disease	O
for	O
which	O
there	O
has	O
conventionally	O
been	O
no	O
appropriate	O
treatment	O
method	O
.	O


Treating	O
Sonic	O
Hedgehog-Associated	O
Medulloblastoma	O
comprises	O
inhibiting	O
the	O
synthesis	O
or	O
biologic	O
activity	O
of	O
leukotrienes	O
that	O
drive	O
Nestin	B-GENE
expression	O
in	O
cancerous	O
or	O
precancerous	O
granule	O
neuron	O
precursors	O
and	O
that	O
further	O
drive	O
growth	O
and	O
proliferation	O
of	O
medulloblastoma	O
cells	O
through	O
Nestin-mediated	O
aberrant	O
Sonic	B-GENE
Hedgehog	I-GENE
signaling	O
.	O


The	O
present	O
invention	O
encompasses	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
groups	O
ring	O
A	O
and	O
Cy	O
are	O
defined	O
herein,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
BTK,	O
process	O
of	O
making,	O
pharmaceutical	O
preparations	O
which	O
contain	O
compounds	O
and	O
their	O
methods	O
of	O
use	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
salt	O
forms	O
of	O
(	O
S	O
)	O
-Quinuclidin-3-yl	O
(	O
2-	O
(	O
2-	O
(	O
4-fluorophenyl	O
)	O
thiazol-4-yl	O
)	O
propan-2-yl	O
)	O
carbamate	O
useful	O
as	O
an	O
inhibitor	O
of	O
glucosylceramide	B-GENE
synthase	I-GENE
(	O
GCS	B-GENE
)	O
and	O
for	O
the	O
treatment	O
metabolic	O
diseases,	O
such	O
as	O
lysosomal	O
storage	O
diseases,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
enzyme	O
replacement	O
therapy,	O
and	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
can	O
modulate	O
the	O
activity	O
of	O
one	O
or	O
more	O
SIP	B-GENE
receptors	I-GENE
and	O
/	O
or	O
the	O
activity	O
of	O
autotaxin	B-GENE
(	O
ATX	B-GENE
)	O
.	O
Formula	O
(	O
1	O
)	O


The	O
invention	O
refers	O
to	O
an	O
oligonucleotide	O
consisting	O
of	O
10	O
to	O
18	O
nucleotides	O
of	O
selected	O
regions	O
of	O
the	O
TGF-beta2	B-GENE
nucleic	O
acid	O
sequence,	O
which	O
comprises	O
modified	O
nucleotides	O
such	O
as	O
LNA,	O
ENA,	O
polyalkylene	O
oxide-,	O
2	O
'	O
-fluoro,	O
2	O
'	O
-O-methoxy	O
and	O
/	O
or	O
2	O
'	O
-O-methyl	O
modified	O
nucleotides	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
oligonucleotide,	O
wherein	O
the	O
composition	O
or	O
the	O
oligonucleotide	O
is	O
used	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
malignant	O
and	O
/	O
or	O
benign	O
tumor,	O
an	O
immunologic	O
disease,	O
fibrosis,	O
or	O
an	O
ophthalmic	O
disease	O
such	O
as	O
dry	O
eye,	O
glaucoma	O
or	O
posterior	O
capsular	O
opacification	O
(	O
PCO	O
)	O
.	O


Small	O
molecule	O
LRRK2	B-GENE
and	O
ERK5	B-GENE
inhibitors	O
are	O
provided,	O
as	O
well	O
as	O
methods	O
for	O
their	O
use	O
in	O
treating	O
or	O
preventing	O
cancer	O
and	O
/	O
or	O
neurodegenerative	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
SGLT2	B-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
form	O
thereof	O
for	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
metabolic	O
disorder	O
of	O
an	O
equine	O
animal	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
the	O
SGLT2	B-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
form	O
thereof	O
for	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
insulin	B-GENE
resistance,	O
hyperinsulinemia,	O
impaired	O
glucose	O
tolerance,	O
dyslipidemia,	O
dysadipokinemia,	O
subclinical	O
inflammation,	O
systemic	O
inflammation,	O
low	O
grade	O
systemic	O
inflammation,	O
obesity,	O
and	O
/	O
or	O
regional	O
adiposity	O
in	O
an	O
equine	O
animal	O
.	O


A	O
promoter	O
sequence	O
of	O
the	O
human	B-GENE
p55	I-GENE
TNF-R	O
gene	O
is	O
provided	O
.	O
Also	O
provided	O
are	O
sequence	O
motifs	O
and	O
motif	O
regions	O
contained	O
within	O
the	O
promoter	O
sequence	O
.	O
Methods	O
for	O
preparing	O
these	O
motifs	O
or	O
motif	O
regions	O
and	O
their	O
use	O
in	O
the	O
modulation	O
of	O
TNF	B-GENE
function	O
are	O
also	O
provided	O
.	O


Substituted	O
carbamates	O
of	O
tricyclic	O
compounds	O
which	O
have	O
a	O
cyclic	O
sulfer	O
atom,	O
having	O
the	O
formula	O
:	O
(	O
See	O
formula	O
I	O
)	O
wherein	O
R1	O
is	O
H	O
or	O
a	O
linear	O
or	O
branched	O
chain	O
C1-	O
C10	O
alkyl	O
group	O
;	O
and	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
linear	O
or	O
branched	O
chain	O
-C1-C10	O
alkyl	O
group,	O
and	O
(	O
See	O
formula	O
I	O
)	O
wherein	O
R3	O
and	O
R4	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
H	O
and	O
a	O
linear	O
or	O
branched	O
chain	O
C1-C10	O
-alkyl	O
group	O
;	O
and	O
with	O
the	O
proviso	O
that	O
when	O
one	O
of	O
R1	O
or	O
R2	O
is	O
a	O
H	O
or	O
a	O
methyl	O
group	O
the	O
other	O
of	O
R1	O
or	O
R2	O
is	O
not	O
H	O
and	O
optical	O
isomers	O
of	O
the	O
3aS	O
series,	O
provide	O
highly	O
potent	O
and	O
selective	O
cholinergic	O
agonist	O
and	O
blocking	O
activity	O
and	O
are	O
useful	O
as	O
pharmaceutical	O
agents	O
.	O
Cholinergic	O
disease	O
are	O
treated	O
with	O
these	O
compounds	O
such	O
as	O
glaucoma,	O
Myasthenia	O
Gravis,	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Methods	O
for	O
inhibiting	O
esterases,	O
acetylcholinesterase	B-GENE
and	O
butyryl-cholinesterase	B-GENE
are	O
also	O
provided	O
.	O


Methods	O
of	O
improving	O
tolerance	O
of	O
transplanted	O
xenograft	O
tissue	O
or	O
allograft	O
tissue	O
in	O
mammals,	O
including	O
humans,	O
by	O
the	O
administration	O
of	O
LFA-3	B-GENE
or	O
CD2	B-GENE
binding	I-GENE
proteins	I-GENE
.	O


Novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
described	O
herein	O
.	O
These	O
compounds	O
inhibit	O
the	O
production	O
of	O
Tumor	B-GENE
Necrosis	I-GENE
Factor	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disease	O
states	O
mediated	O
or	O
exacerbated	O
by	O
TNF	B-GENE
production	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
useful	O
in	O
the	O
mediation	O
or	O
inhibition	O
of	O
enzymatic	O
or	O
catalytic	O
activity	O
of	O
phosphodiesterase	B-GENE
IV	I-GENE
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
disease	O
states	O
in	O
need	O
of	O
mediation	O
or	O
inhibition	O
thereof	O
.	O


This	O
invention	O
relates	O
to	O
.	O
beta	O
.	O
-alanine	O
derivatives	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
which	O
is	O
glycoprotein	O
IIb	O
/	O
IIIa	O
antagonist,	O
inhibitor	O
of	O
blood	O
platelets	O
aggregation	O
and	O
inhibitor	O
of	O
the	O
binding	O
of	O
fibrinogen	O
to	O
blood	O
platelets,	O
to	O
processes	O
for	O
the	O
preparation	O
thereof,	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
and	O
to	O
a	O
method	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
indicated	O
in	O
the	O
specification	O
to	O
a	O
human	O
being	O
or	O
an	O
animal	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds,	O
compositions	O
and	O
methods	O
of	O
inhibiting	O
and	O
treating	O
HIV	O
and	O
related	O
viruses,	O
and	O
methods	O
for	O
cocrystallizing	O
reverse	B-GENE
transcriptase	I-GENE
in	O
vitro,	O
inhibition	O
of	O
the	O
replication	O
of	O
HIV	O
and	O
related	O
viruses	O
thereof	O
.	O


The	O
invention	O
pertains	O
to	O
a	O
eutrophic	O
drug	O
composition	O
containing	O
transferrins,	O
particularly	O
human	B-GENE
transferrin	I-GENE
.	O
It	O
allows	O
the	O
toxic	O
effects	O
of	O
cytotoxic	O
drugs	O
when	O
used	O
at	O
high	O
dosages	O
or	O
over	O
prolonged	O
times,	O
e	O
.	O
g	O
.	O
,	O
cyclosporin,	O
to	O
be	O
alleviated	O
or	O
even	O
suppressed	O
.	O


Compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts	O
and	O
solvates	O
are	O
PAF	B-GENE
antagonists	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
or	O
disorders	O
mediated	O
by	O
PAF	B-GENE
.	O
Pharmaceutical	O
compositions	O
including	O
these	O
compounds	O
and	O
processes	O
for	O
their	O
preparation	O
are	O
also	O
provided	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
which	O
R1	O
and	O
R2	O
are	O
independently	O
H	O
or	O
methyl	O
(	O
for	O
example	O
N,N-dimethyl-1-	O
[	O
1-	O
(	O
4-chlorophenyl	O
)	O
cyclobutyl	O
]	O
-3-methylbutylamine	O
hydrochloride	O
optionally	O
in	O
the	O
form	O
of	O
its	O
monohydrate	O
)	O
is	O
used	O
for	O
improving	O
the	O
glucose	O
tolerance	O
of	O
humans	O
having	O
impaired	O
glucose	O
tolerance	O
or	O
non-insulin	O
dependent	O
diabetes	O
mellitus	O
.	O


Compounds	O
having	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
B	O
is	O
NR5R11,	O
wherein	O
R5	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
lower	O
alkyl,	O
lower	O
alkenyl,	O
lower	O
alkynyl	O
and	O
aryl,	O
and	O
R11	O
is	O
selected	O
from	O
a	O
3	O
to	O
8	O
member	O
heterocyclyl	O
radical	O
in	O
which	O
at	O
least	O
one	O
member	O
of	O
the	O
ring	O
is	O
carbon	O
and	O
in	O
which	O
1	O
to	O
about	O
4	O
members	O
are	O
heteroatoms	O
independently	O
selected	O
from	O
oxygen,	O
nitrogen	O
and	O
sulfur	O
and	O
said	O
heterocyclyl	O
radical	O
may	O
be	O
optionally	O
substituted,	O
useful	O
as	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
amides	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
wherein	O
R1	O
is	O
an	O
optionally	O
substituted	O
linear	O
or	O
branched	O
hydrocarbon	O
radical,	O
or	O
a	O
group	O
of	O
formula	O
(	O
II	O
)	O
or	O
(	O
III	O
)	O
:	O
	O
	O
	O
wherein	O
R4	O
is	O
an	O
optionally	O
substituted	O
linear	O
hydrocarbon	O
radical,	O
R7	O
is	O
H	O
or	O
a	O
linear	O
or	O
branched	O
alkyl,	O
and	O
the	O
residues	O
	O
	O
are	O
glycosaminic	O
residues	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
amide	O
;	O
and	O
a	O
use	O
of	O
the	O
amide	O
as	O
a	O
CB2	B-GENE
receptor	I-GENE
modulator	O
.	O


Phenoxyethylamine	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
having	O
high	O
affinity	O
for	O
	O
the	O
5-HT1Areceptor,	O
methods	O
for	O
preparing	O
same,	O
pharmaceutical	O
compositions	O
containing	O
said	O
derivatives,	O
and	O
their	O
use,	O
in	O
particular	O
as	O
gastric	O
acid	O
secretion	O
inhibitors	O
or	O
as	O
antiemetics,	O
are	O
disclosed	O
.	O
In	O
general	O
formula	O
(	O
I	O
)	O
,	O
Ar	O
is	O
phenyl	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
;	O
and	O
R	O
is	O
a	O
C1-1-	O
hydrocarbon	O
radical	O
selected	O
from	O
straight	O
or	O
branched	O
alkyl,	O
alkenyl	O
or	O
alkynyl	O
radicals,	O
saturated	O
or	O
unsaturated	O
mono-or	O
polycyclic	O
cycloalkyl,	O
cycloalkylalkyl	O
or	O
alkylcycloalkyl	O
radicals	O
;	O
a	O
pyridyl	O
or	O
isoquinolyl	O
radical,	O
phenyl	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituent,	O
and	O
salts	O
thereof	O
.	O


A	O
mixture	O
of	O
betasitosterol	O
and	O
betasitosteryl	O
glycoside	O
in	O
a	O
ratio	O
of	O
between	O
1	O
:	O
1	O
and	O
500	O
:	O
1	O
is	O
administered	O
to	O
an	O
HIV	O
infected	O
individual	O
.	O
This	O
has	O
the	O
effect	O
of	O
stabilizing	O
CD4	B-GENE
cell	O
numbers,	O
decreases	O
the	O
plasma	O
viral	O
load,	O
degree	O
of	O
apoptosis	O
in,	O
and	O
the	O
serum	O
levels	O
of	O
1	B-GENE
L6	I-GENE
in	O
the	O
peripheral	O
blood	O
.	O


Use	O
of	O
an	O
antibacterial	O
system	O
comprising	O
lactoperoxidase	O
and	O
a	O
peroxide	O
donor	O
for	O
preparing	O
a	O
preparation	O
for	O
prophylactic	O
of	O
therapeutic	O
treatment	O
"in	O
vivo"	O
of	O
an	O
infection	O
caused	O
by	O
the	O
bacteria	O
Helicobacter	O
pylori	O
existing	O
in	O
the	O
oral	O
cavity,	O
in	O
the	O
throat	O
and	O
in	O
the	O
stomach	O
which	O
preparation	O
is	O
completed	O
by	O
the	O
presence	O
of	O
thiocyanate	O
in	O
an	O
antibacterial	O
level,	O
and	O
eventually	O
in	O
the	O
presence	O
of	O
lactoferrin	B-GENE
.	O
A	O
daily	O
dose	O
for	O
human	O
treatment	O
is	O
1	O
.	O
2-1	O
.	O
6	O
gram	O
of	O
the	O
system	O
taken	O
3	O
times	O
a	O
day	O
.	O


Disclosed	O
is	O
a	O
chimeric	O
isoprenoid	B-GENE
synthase	I-GENE
polypeptide	O
including	O
a	O
first	O
domain	O
from	O
a	O
first	O
isoprenoid	B-GENE
synthase	I-GENE
joined	O
to	O
a	O
second	O
domain	O
from	O
a	O
second,	O
heterologous	O
isoprenoid	O
synthase,	O
whereby	O
the	O
chimeric	O
isoprenoid	B-GENE
synthase	I-GENE
is	O
capable	O
of	O
catalyzing	O
the	O
production	O
of	O
isoprenoid	O
reaction	O
products	O
that	O
are	O
not	O
produced	O
in	O
the	O
absence	O
of	O
the	O
second	O
domain	O
of	O
the	O
second,	O
heterologous	O
isoprenoid	B-GENE
synthase	I-GENE
.	O
Also	O
disclosed	O
is	O
a	O
chimeric	O
isoprenoid	B-GENE
synthase	I-GENE
polypeptide	O
including	O
an	O
asymmetrically	O
positioned	O
homologous	O
domain,	O
whereby	O
the	O
chimeric	O
isoprenoid	B-GENE
synthase	I-GENE
is	O
capable	O
of	O
catalyzing	O
the	O
production	O
of	O
isoprenoid	O
reaction	O
products	O
that	O
are	O
not	O
produced	O
when	O
the	O
domain	O
is	O
positioned	O
at	O
its	O
naturally-occurring	O
site	O
in	O
the	O
isoprenoid	B-GENE
synthase	I-GENE
polypeptide	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
preparing	O
functional	O
recombinant	O
tissue	B-GENE
factor	I-GENE
in	O
a	O
prokaryotic	O
host	O
organism	O
.	O


A	O
family	O
of	O
compounds	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
prenyl	B-GENE
transferases	I-GENE
.	O
The	O
compounds	O
are	O
covered	O
by	O
one	O
of	O
the	O
two	O
formulas	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
.	O
Each	O
of	O
the	O
R	O
groups	O
is	O
defined	O
in	O
the	O
disclosure	O
.	O


Disclosed	O
herein	O
are	O
selected	O
indolocarbazole	O
derivatives	O
which	O
are	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
enhancing	O
the	O
function	O
and	O
/	O
or	O
survival	O
of	O
a	O
trophic	O
factor	O
responsive	O
cell	O
.	O
They	O
inhibit	O
interleukin-2	B-GENE
production	O
and	O
have	O
immunosuppressive	O
activity	O
.	O


A	O
compound,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
hydrate	O
thereof	O
having	O
PGD2-antagonistic	O
activities,	O
inhibitory	O
activities	O
against	O
infiltration	O
of	O
eosinophils,	O
and	O
being	O
useful	O
as	O
a	O
drug	O
for	O
treating	O
diseases,	O
such	O
as	O
systemic	O
mastocytosis	O
and	O
disorder	O
of	O
systemic	O
mast	O
cell	O
activation,	O
as	O
well	O
as	O
tracheal	O
contraction,	O
asthma,	O
allergic	O
rhinitis,	O
allergic	O
conjunctivitis,	O
urticaria,	O
ischemic	O
reperfusion	O
injury,	O
inflammation	O
and	O
atopic	O
dermatitis	O
,	O
which	O
is	O
shown	O
by	O
formula	O
(	O
I	O
)	O
,	O
is	O
provided	O
.	O


Pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
involving	O
cognitive	O
dysfunction	O
in	O
a	O
mammal	O
comprising	O
an	O
estrogen	O
agonist	O
or	O
antagonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
an	O
acetyl	B-GENE
cholinesterase	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
estrogen	O
agonists	O
or	O
antagonists	O
and	O
acetylcholinesterase	B-GENE
inhibitors	O
are	O
present	O
in	O
amounts	O
that	O
render	O
the	O
composition	O
effective	O
in	O
the	O
treatment	O
of	O
diseases	O
of	O
cognitive	O
dysfunction	O
including	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Dementia	O
.	O
The	O
method	O
of	O
using	O
these	O
composition	O
is	O
also	O
disclosed	O
.	O
The	O
compositions	O
may	O
help	O
memory	O
inhancement	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
oxazolidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2	O
and	O
R3	O
have	O
the	O
meaning	O
cited	O
in	O
Claim	O
1	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
salts	O
thereof	O
and	O
to	O
a	O
method	O
for	O
the	O
production	O
of	O
the	O
inventive	O
compounds	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
act	O
as	O
5-HT2A	B-GENE
antagonists	O
having	O
a	O
reuptake-inhibiting,	O
antidepressant	O
or	O
anxiolytic	O
effect	O
and	O
can	O
be	O
used	O
in	O
the	O
production	O
of	O
medicaments	O
.	O


The	O
invention	O
relates	O
to	O
LH-RH	B-GENE
peptide	I-GENE
analogues	O
with	O
excellent	O
affinity	O
for	O
LH-RH	O
receptors,	O
of	O
formula	O
(	O
I	O
)	O
:	O
A1-A2-A3-A4-A5-A6-HAA-A7-Pro-Z	O
in	O
which	O
Z,	O
A1	O
to	O
A7	O
are	O
specified	O
in	O
the	O
description	O
and	O
HAA	O
is	O
a	O
non-aromatic	O
hydrophobic	O
amino	O
acid	O
having	O
from	O
7	O
to	O
20	O
carbon	O
atoms	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
said	O
peptide	O
analogues	O
and	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
Ca2+	B-GENE
channel	I-GENE
blockers	O
and	O
more	O
particularly	O
to	O
the	O
R-type	B-GENE
Ca2+	B-GENE
channel	I-GENE
blockers	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
Ca2+	B-GENE
channel	I-GENE
blockers	O
activity	O
of	O
Mandevilla	O
velutina	O
and	O
Mandevilla	O
illustris	O
.	O
The	O
present	O
invention	O
further	O
concerns	O
saponin-like	O
compounds	O
isolated	O
from	O
Mandevilla	O
species	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
treatment	O
of	O
several	O
pathologies	O
that	O
involve	O
the	O
nifedipine-insensitive	O
but	O
isradipine	O
sensitive	O
steady-state	O
R-type	B-GENE
Ca2+	B-GENE
channel	I-GENE
and	O
the	O
use	O
of	O
steady-state	O
R-type	B-GENE
Ca2+	B-GENE
channel	I-GENE
blockers	O
in	O
the	O
treatment	O
of	O
these	O
pathologies	O
.	O


Methods	O
and	O
formulations	O
for	O
treating	O
female	O
sexual	O
dysfunction	O
are	O
provided	O
.	O
A	O
pharmaceutical	O
composition	O
formulated	O
so	O
as	O
to	O
contain	O
a	O
selected	O
vasoactive	O
agent	O
is	O
administered	O
to	O
the	O
vagina,	O
vulvar	O
area	O
or	O
urethra	O
of	O
the	O
individual	O
undergoing	O
treatment	O
.	O
Suitable	O
vasoactive	O
agents	O
are	O
vasodilators,	O
including	O
endothelial-derived	O
relaxation	O
factors,	O
vasoactive	B-GENE
intestinal	I-GENE
polypeptide	I-GENE
agonists,	O
smooth	O
muscle	O
relaxants,	O
leukotriene	O
inhibitors,	O
and	O
others	O
.	O
The	O
formulations	O
are	O
also	O
useful	O
for	O
preventing	O
the	O
occurrence	O
of	O
yeast	O
infections,	O
improving	O
vaginal	O
muscle	O
tone	O
and	O
tissue	O
health,	O
enhancing	O
vaginal	O
lubrication,	O
and	O
minimizing	O
excess	O
collagen	B-GENE
deposition	O
.	O
A	O
clitoral	O
drug	O
delivery	O
device	O
is	O
also	O
provided	O
.	O


Methods	O
are	O
provided	O
for	O
treating	O
proliferative	O
diseases,	O
especially	O
cancers,	O
comprising	O
administering	O
(	O
1	O
)	O
a	O
famesyl	B-GENE
protein	I-GENE
transferase	I-GENE
inhibitor	O
in	O
conjunction	O
with	O
(	O
2	O
)	O
an	O
antineoplastic	O
agent	O
and	O
/	O
or	O
radiation	O
therapy	O
.	O


Compounds	O
of	O
the	O
structure	O
shown	O
below,	O
having	O
a	O
certain	O
benzoxazine	O
ring	O
system	O
and	O
their	O
precursors	O
are	O
disclosed	O
which	O
are	O
useful	O
for	O
enhancing	O
synaptic	O
responses	O
mediated	O
by	O
AMPA	B-GENE
receptors	I-GENE
.	O
Also	O
disclosed	O
are	O
methods	O
for	O
preparing	O
such	O
compounds,	O
and	O
methods	O
for	O
their	O
use	O
in	O
treating	O
subjects	O
suffering	O
from	O
impaired	O
nervous	O
or	O
intellectual	O
functioning	O
due	O
to	O
deficiencies	O
in	O
the	O
number	O
of	O
excitatory	O
synapses	O
or	O
in	O
the	O
number	O
of	O
AMPA	B-GENE
receptors	I-GENE
.	O
The	O
invention	O
compounds	O
can	O
also	O
be	O
used	O
for	O
the	O
treatment	O
of	O
non-impaired	O
subjects	O
for	O
enhancing	O
performance	O
in	O
sensory-motor	O
and	O
cognitive	O
tasks	O
which	O
depend	O
on	O
brain	O
networks	O
utilizing	O
AMPA	B-GENE
receptors	I-GENE
and	O
for	O
improving	O
memory	O
encoding	O
.	O
(	O
see	O
formula	O
1	O
)	O
or	O
(	O
see	O
formula	O
2	O
)	O


The	O
present	O
invention	O
concerns	O
enzymatic	O
aromatic	O
hydroxylation-activated	O
prodrugs,	O
particularly	O
and-tumour	O
prodrugs	O
and	O
those	O
which	O
are	O
specifically	O
activated	O
by	O
the	O
hydroxylation	O
activity	O
of	O
the	O
enzyme	O
CYP1B1	B-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
eletriptan,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
composition	O
thereof,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
of	O
migraine	O
recurrence	O
and	O
to	O
the	O
use	O
of	O
a	O
5-HT1B/1D	B-GENE
receptor	O
agonist,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
composition	O
thereof,	O
for	O
the	O
manufacture	O
of	O
a	O
dual-,	O
sustained-,	O
delayed-,	O
controlled-	O
or	O
pulsed-release	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
of	O
migraine	O
recurrence	O
.	O


Compounds	O
of	O
general	O
structural	O
formula	O
(	O
I	O
)	O
wherein	O
A	O
represents	O
a	O
5-	O
or	O
6-membered	O
heteroaryl	O
group	O
containing	O
at	O
least	O
one	O
heteroatom	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
oxygen,	O
nitrogen,	O
and	O
sulphur	O
;	O
and	O
use	O
of	O
the	O
compounds	O
and	O
salts	O
and	O
solvates	O
thereof,	O
as	O
therapeutic	O
agents	O
are	O
disclosed	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
carboline	O
derivatives	O
which	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
cGMP-specific	B-GENE
PDE	I-GENE
.	O


This	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
Fc	B-GENE
receptor	I-GENE
modulating	O
compound	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
treating	O
a	O
variety	O
of	O
diseases	O
using	O
a	O
Fc	B-GENE
receptor	I-GENE
modulating	O
compound	O
.	O


Cholesteryl	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
inhibitors,	O
of	O
the	O
Formula	O
(	O
I	O
)	O
,	O
prodrug	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
said	O
compound	O
or	O
of	O
said	O
prodrug,	O
pharmaceutical	O
compositions	O
containing	O
such	O
inhibitors	O
and	O
the	O
use	O
of	O
such	O
inhibitors	O
to	O
elevate	O
certain	O
plasma	O
lipid	O
levels	O
including	O
high	O
density	O
lipoprotein-cholesterol	O
and	O
to	O
lower	O
certain	O
other	O
plasma	O
lipid	O
levels,	O
such	O
as	O
LDL-cholesterol	O
and	O
triglycerides	O
and	O
accordingly	O
to	O
treat	O
diseases	O
which	O
are	O
exacerbated	O
by	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
/	O
or	O
high	O
levels	O
of	O
LDL-cholesterol	O
and	O
triglycerides,	O
such	O
as	O
atherosclerosis	O
and	O
cardiovascular	O
diseases	O
in	O
some	O
mammals,	O
including	O
humans	O
.	O


Carboxymethylgalactose	O
derivatives	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
;	O
	O
	O
	O
and	O
salts	O
thereof,	O
which	O
exhibit	O
reactivity	O
to	O
selectins	B-GENE
and	O
are	O
useful	O
as	O
inhibitors	O
against	O
selectin-related	O
diseases	O
such	O
as	O
various	O
inflammations	O
and	O
cancerous	O
metastasis	O
;	O
In	O
said	O
formula,	O
R	O
is	O
a	O
group	O
represented	O
by	O
formula	O
(	O
1a	O
)	O
,	O
(	O
1b	O
)	O
or	O
(	O
1c	O
)	O
.	O


The	O
present	O
invention	O
is	O
to	O
offer	O
a	O
hydantoin	O
derivative	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
hypoalbuminaemia	O
with	O
high	O
safety	O
.	O
	O
This	O
invention	O
relates	O
to	O
an	O
improving	O
agent	O
for	O
hypoalbuminaemia	O
containing	O
a	O
hydantoin	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
effective	O
ingredient	O
.	O
(	O
see	O
formula	O
I	O
)	O
[	O
In	O
the	O
formula,	O
each	O
of	O
R1	O
and	O
R2,	O
which	O
may	O
be	O
the	O
same	O
or	O
different,	O
represents	O
hydrogen,	O
an	O
alkyl	O
group	O
or	O
a	O
cycloalkyl	O
group	O
;	O
and	O
each	O
of	O
X	O
and	O
Y,	O
which	O
may	O
be	O
the	O
same	O
or	O
different,	O
represents	O
hydrogen,	O
a	O
hydroxyl	O
group,	O
an	O
alkyl	O
group	O
or	O
an	O
alkoxy	O
group,	O
or	O
X	O
and	O
Y	O
together	O
represent	O
an	O
oxo	O
group	O
.	O
]	O
	O
It	O
is	O
apparent	O
from	O
the	O
above-mentioned	O
clinical	O
test	O
that	O
the	O
administration	O
of	O
the	O
compound	O
of	O
the	O
present	O
invention	O
gave	O
an	O
increase	O
of	O
serum	B-GENE
albumin	I-GENE
value	O
of	O
patients	O
suffering	O
from	O
hypoalbuminaemia	O
and,	O
therefore,	O
an	O
improving	O
effect	O
of	O
the	O
compound	O
of	O
the	O
present	O
invention	O
for	O
hypoalbuminaemia	O
was	O
shown	O
.	O
Consequently,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
very	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
hypoalbuminaemia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
which	O
inhibit,	O
regulate	O
and	O
/	O
or	O
modulate	O
tyrosine	B-GENE
kinase	I-GENE
signal	O
transduction,	O
compositions	O
which	O
contain	O
these	O
compounds,	O
and	O
methods	O
of	O
using	O
them	O
to	O
treat	O
tyrosine	O
kinase-dependent	O
diseases	O
and	O
conditions,	O
such	O
as	O
angiogenesis,	O
cancer,	O
tumor	O
growth,	O
atherosclerosis,	O
age	O
related	O
macular	O
degeneration,	O
diabetic	O
retinopathy,	O
inflammatory	O
diseases,	O
and	O
the	O
like	O
in	O
mammals	O
.	O
(	O
see	O
formula	O
I	O
)	O


This	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
which	O
is	O
useful	O
for	O
inhibiting	O
the	O
activity	O
of	O
Factor	O
Xa,	O
by	O
contacting	O
said	O
compound	O
with	O
a	O
composition	O
containing	O
Factor	B-GENE
Xa	I-GENE
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
compositions	O
containing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
methods	O
for	O
their	O
preparation,	O
their	O
use,	O
such	O
as	O
in	O
inhibit-ing	O
the	O
formation	O
of	O
thrombin	B-GENE
or	O
for	O
treating	O
a	O
patient	O
suffering	O
from,	O
or	O
subject	O
to,	O
a	O
disease	O
state	O
associated	O
with	O
a	O
physiologically	O
detri-mental	O
excess	O
amount	O
of	O
thrombin	B-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
pseudopolymorph	O
of	O
(	O
-	O
)	O
-cis-2-	O
(	O
2-chlorophenyl	O
)	O
-5,	O
7--dihydroxy-8-	O
[	O
4R-	O
(	O
3S-hydroxy-1-methyl	O
)	O
piperidinyl	O
]	O
-4H-1-benzopyran-4-one	O
hydrochloride,	O
a	O
method	O
of	O
making	O
the	O
same,	O
a	O
pharmaceutical	O
composition	O
and	O
its	O
use	O
for	O
treating	O
cancer	O
and	O
inhibiting	O
protein	B-GENE
kinases	I-GENE
or	O
cyclin	B-GENE
dependant	I-GENE
kinases	I-GENE
in	O
a	O
patient	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
nuclear	B-GENE
factor	I-GENE
kB	I-GENE
(NFkB)-inducing	I-GENE
factor	I-GENE
polypeptides	I-GENE
(	O
NFIF	B-GENE
polypeptides	I-GENE
)	O
which	O
are	O
capable	O
of	O
inducing	O
NKkB	B-GENE
.	O
The	O
present	O
invention	O
includes	O
within	O
its	O
scope	O
NFIF	O
polypeptides,	O
including	O
NFIF-14b	O
and	O
NFIF-7a,	O
DNA,	O
including	O
cDNA,	O
encoding	O
these	O
polypeptides,	O
and	O
expression	O
vectors	O
capable	O
of	O
expressing	O
NFIF	B-GENE
polypeptides	I-GENE
.	O
Also	O
included	O
are	O
methods	O
and	O
compositions	O
for	O
increasing	O
NFkB	B-GENE
induction	O
in	O
a	O
patient,	O
methods	O
and	O
compositions	O
for	O
lowering	O
NFkB	B-GENE
induction	O
in	O
a	O
patient,	O
methods	O
for	O
inhibiting	O
inflammation,	O
and	O
methods	O
for	O
manufacture	O
of	O
a	O
medicament	O
intended	O
for	O
the	O
treament	O
and	O
/	O
or	O
prevention	O
of	O
an	O
NFkB-regulated	O
inflammatory	O
response	O
.	O
In	O
addition,	O
methods	O
for	O
determining	O
whether	O
a	O
test	O
compound	O
inhibits	O
or	O
enhances	O
the	O
activity	O
of	O
NFIF	B-GENE
polypeptides	I-GENE
are	O
provided	O
.	O


Heparin	O
reduces	O
ischemia-reperfusion	O
injury	O
to	O
myocardium	O
.	O
This	O
effect	O
has	O
been	O
attributed	O
complement	O
inhibition,	O
but	O
heparin	O
also	O
has	O
other	O
activities	O
that	O
might	O
diminish	O
ischemia-reperfusion	O
.	O
To	O
further	O
probe	O
these	O
mechanisms,	O
we	O
compared	O
heparin	O
and	O
an	O
O-desulfated	O
nonanticoagulant	O
heparin	O
with	O
greatly	O
reduced	O
anti-complement	O
activity	O
.	O
Given	O
at	O
the	O
time	O
of	O
coronary	O
artery	O
reperfusion	O
in	O
a	O
canine	O
model	O
of	O
myocardial	O
infarction,	O
both	O
heparin	O
and	O
O-desulfated	O
heparin	O
equally	O
reduced	O
neutrophil	O
adherence	O
to	O
ischemic-reperfused	O
coronary	O
artery	O
endothelium,	O
influx	O
of	O
neutrophils	O
into	O
ischemic-reperfused	O
myocardium,	O
myocardial	O
necrosis	O
and	O
release	O
of	O
creatine	B-GENE
kinase	I-GENE
into	O
plasma	O
.	O
Heparin	O
and	O
O-desulfated	O
heparin	O
also	O
prevented	O
dysfunction	O
of	O
endothelial-dependent	O
coronary	O
relaxation	O
following	O
ischemic	O
injury	O
.	O
In	O
addition,	O
heparin	O
and	O
O-desulfated	O
heparin	O
inhibited	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF-.KAPPA.B	B-GENE
from	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
human	O
endothelial	O
cells	O
and	O
decreased	O
NF-.KAPPA.B	B-GENE
DNA	O
binding	O
in	O
human	O
endothelium	O
and	O
ischemic-reperfused	O
rat	O
myocardium	O
.	O
Thus,	O
heparin	O
and	O
nonanticoagulant	O
heparin	O
decrease	O
ischemia-reperfusion	O
injury	O
by	O
disrupting	O
multiple	O
levels	O
of	O
the	O
inflammatory	O
cascade,	O
including	O
the	O
novel	O
observation	O
that	O
heparins	O
inhibit	O
activation	O
of	O
the	O
pro-inflammatory	O
transcription	O
factor	O
NF-	O
.	O
KAPPA	O
.	O
B	O
.	O


The	O
invention	O
provided	O
a	O
method	O
of	O
enhancing	O
the	O
action	O
of	O
a	O
pharmaceutical	O
agent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
group	O
comprising	O
antimicrobial	O
agents,	O
the	O
anthelmintic	O
agents	O
and	O
the	O
anti-ectoparasitic	O
agents,	O
but	O
excluding	O
coal	O
tar	O
solution	O
and	O
H1-antagonist	O
antihistamines,	O
characterised	O
in	O
that	O
the	O
agent	O
is	O
formulated	O
with	O
an	O
administration	O
medium	O
which	O
comprises	O
a	O
solution	O
of	O
nitrous	O
oxide	O
gas	O
in	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
solvent	O
for	O
the	O
gas	O
and	O
which	O
administration	O
medium	O
includes	O
at	O
least	O
one	O
fatty	O
acid	O
or	O
ester	O
or	O
other	O
suitable	O
derivative	O
thereof	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
oleic	O
acid,	O
linoleic	O
acid,	O
alpha-linolenic	O
acid,	O
gamma-linolenic	O
acid,	O
arachidonic	O
acid,	O
eicosapentaenoic	O
acid	O
[	O
C20	O
:	O
5w3	O
]	O
,	O
decosahexaenoic	O
acid	O
[	O
C22	O
:	O
60	O
]	O
,	O
ricinoleic	O
acid	O
and	O
derivatives	O
thereof	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
C1	O
to	O
C6	O
alkyl	O
esters	O
thereof,	O
the	O
glycerol-polyethylene	O
glycol	O
esters	O
thereof	O
and	O
the	O
reaction	O
product	O
of	O
hydrogenated	O
natural	O
oils	O
composed	O
largely	O
of	O
ricinoleic	O
acid	O
based	O
oils,	O
such	O
as	O
castor	O
oil	O
with	O
ethylene	O
oxide	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
which	O
are	O
IP	B-GENE
receptor	I-GENE
antagonists	O
and	O
which	O
are	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
wherein	O
G2	O
is	O
a	O
heteroaryl	O
group	O
containing	O
one	O
or	O
two	O
nitrogen	O
atoms	O
and	O
substituted	O
with	O
a	O
carboxylic	O
acid	O
group,	O
and	O
G1	O
is	O
as	O
defined	O
in	O
the	O
specification	O
;	O
or	O
individual	O
isomers,	O
racemic	O
or	O
non-racemic	O
mixtures	O
of	O
isomers,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds,	O
their	O
use	O
as	O
therapeutic	O
agents,	O
and	O
methods	O
of	O
preparation	O
thereof	O
.	O


In	O
one	O
embodiment,	O
this	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
compounds	O
as	O
antagonists	O
of	O
the	O
MCH	O
receptor,	O
methods	O
of	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds,	O
methods	O
of	O
preparing	O
pharmaceutical	O
formulations	O
comprising	O
one	O
or	O
more	O
such	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention	O
or	O
amelioration	O
or	O
one	O
or	O
more	O
of	O
diseases	O
associated	O
with	O
the	O
MCH	B-GENE
receptor	I-GENE
.	O
An	O
illustrative	O
inventive	O
compound	O
is	O
shown	O
here	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Phosphodiesterase	B-GENE
IV	I-GENE
inhibitors	O
and	O
/	O
or	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
in	O
the	O
production	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
osteoporosis,	O
tumors,	O
tumor	O
metastases,	O
atherosclerosis,	O
rheumatoid	O
arthritis,	O
multiple	O
sclerosis,	O
diabetes	O
mellitus,	O
ulzerative	O
colitis	O
and	O
AIDS	O
.	O


A	O
combination	O
therapy	O
for	O
treating	O
patients	O
suffering	O
from	O
pre-malignant	O
colon	O
lesions	O
(	O
e	O
.	O
g	O
.	O
polyps	O
)	O
and	O
colon	O
cancer,	O
as	O
well	O
as	O
other	O
malignancies,	O
is	O
disclosed	O
.	O
The	O
patient	O
is	O
treated	O
concurrently	O
with	O
a	O
cycloocygenase-2	B-GENE
inhibitor	O
and	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
microtubule	B-GENE
interfering	O
agent,	O
an	O
epithelial	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
tyrosine	I-GENE
protein	I-GENE
kinase	I-GENE
inhibitor	O
and	O
a	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitor	O
.	O


Several	O
studies	O
have	O
demonstrated	O
that	O
bovine	O
whey	O
produced	O
by	O
cheese	O
maker	O
industry	O
contains	O
several	O
bioactive	O
factors	O
promoting	O
health	O
and	O
preventing	O
disease	O
.	O
Although	O
many	O
efforts	O
have	O
been	O
made	O
over	O
the	O
years	O
to	O
show	O
that	O
immunoglobulins,	O
lactoperoxidase,	O
lactoferrin,	O
lysosyme	B-GENE
and	O
small	O
peptides	O
present	O
in	O
whey	O
have	O
antimicrobial	O
activities	O
against	O
several	O
pathogenic	O
microorganisms,	O
such	O
activity	O
has	O
not	O
been	O
investigated	O
so	O
far	O
for	O
the	O
lipid	O
fraction	O
of	O
whey	O
.	O
There,	O
is	O
disclosed	O
a	O
method	O
of	O
inhibiting	O
the	O
germination	O
of	O
Candida	O
albicans	O
using	O
free	O
fatty	O
acids	O
derived	O
from	O
whey	O
cream	O
.	O
Further	O
fractionation	O
by	O
HPLC	O
demonstrates	O
that	O
this	O
activity	O
can	O
be	O
mainly	O
attributed	O
to	O
lauric,	O
myristoleic,	O
linoleic	O
and	O
arachidonic	O
acids	O
.	O


Derivatives	O
of	O
GLP-1	B-GENE
and	O
analogues	O
thereof	O
having	O
a	O
lipophilic	O
substituent	O
have	O
interesting	O
pharmacological	O
properties,	O
in	O
particular	O
they	O
have	O
a	O
more	O
protracted	O
profile	O
of	O
action	O
than	O
GLP-1	B-GENE
(	O
7-37	O
)	O
.	O


A	O
method	O
of	O
promoting	O
neurogenesis	O
by	O
administering	O
a	O
therapeutic	O
amount	O
of	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
compound	O
to	O
a	O
patient	O
in	O
need	O
of	O
neurogenesis	O
promotion	O
.	O
A	O
compound	O
for	O
providing	O
neurogenesis	O
having	O
an	O
effective	O
amount	O
of	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
sufficient	O
to	O
promote	O
neurogenesis	O
.	O
A	O
phosphodiesterase	B-GENE
inhibitor	O
for	O
promoting	O
neurogenesis	O
.	O
A	O
method	O
of	O
augmenting	O
the	O
production	O
of	O
brain	O
cells	O
and	O
facilitating	O
cellular	O
structural	O
and	O
receptor	O
changes	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
compound	O
to	O
a	O
site	O
in	O
need	O
of	O
augmentation	O
.	O
A	O
method	O
of	O
increasing	O
both	O
neurological	O
and	O
cognitive	O
function	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
compound	O
to	O
a	O
patient	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
which	O
inhibit	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP-IV	B-GENE
)	O
and	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes,	O
especially	O
type	O
II	O
diabetes,	O
as	O
well	O
as	O
hyperglycemia,	O
Syndrome	O
X,	O
hyperinsulinemia,	O
obesity,	O
atherosclerosis,	O
and	O
various	O
immunomodulatory	O
diseases	O
.	O
Or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
prodrugs	O
thereof,	O
wherein	O
X,R,R1,R2	O
and	O
R3	O
have	O
the	O
definitions	O
given	O
in	O
the	O
description	O
.	O


Described	O
herein	O
are	O
compounds	O
that	O
are	O
useful	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
Ring	O
B,	O
Z1,	O
Z2,	O
U,	O
p,	O
Q,	O
R1,	O
R2,	O
R3,	O
and	O
R3	O
are	O
as	O
defined	O
herein	O
.	O
These	O
compounds,	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
thereof,	O
are	O
useful	O
for	O
treating	O
or	O
lessening	O
the	O
severity	O
of	O
a	O
variety	O
of	O
disorders,	O
including	O
stroke,	O
inflammatory	O
disorders,	O
autoimmune	O
diseases	O
such	O
as	O
SLE	O
lupus	O
and	O
psoriasis,	O
proliferative	O
disorders	O
such	O
as	O
cancer,	O
and	O
conditions	O
associated	O
with	O
organ	O
transplantation	O
.	O


This	O
invention	O
relates	O
to	O
chroman	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof	O
which	O
are	O
useful	O
as	O
active	O
ingredients	O
of	O
pharmaceutical	O
preparations	O
.	O
The	O
chroman	O
derivatives	O
of	O
the	O
present	O
invention	O
have	O
an	O
excellent	O
activity	O
as	O
BETA	B-GENE
3	I-GENE
antagonists	O
and	O
are	O
useful	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
associated	O
with	O
BETA	B-GENE
3	I-GENE
activity,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
urological	O
disorder	O
or	O
disease,	O
such	O
as	O
detrusor	O
overactivity	O
(	O
overactive	O
bladder	O
)	O
,	O
urinary	O
incontinence,	O
neurogenic	O
detrusor	O
overactivity	O
(	O
detrusor	O
hyperflexia	O
)	O
,	O
idiopathic	O
detrusor	O
overactivity	O
(	O
detrusor	O
instability	O
)	O
,	O
benign	O
prostatic	O
hyperplasia,	O
and	O
lower	O
urinary	O
tract	O
symptoms	O
;	O
and	O
inflammatory	O
disorders,	O
such	O
as	O
asthma	O
and	O
COPD	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
known	O
1-	O
[	O
2H-1-benzopyran-2-one-8-yl	O
]	O
~	O
piperazine	O
derivatives,	O
broad	O
spectrum	O
5-HT	B-GENE
receptor	I-GENE
binding	O
compounds,	O
having	O
amongst	O
other	O
functional	O
serotonin	O
receptor	O
activities,	O
potent	O
5-HT1A	B-GENE
receptor	I-GENE
agonistic	O
activity,	O
5-HT1D	B-GENE
receptor	I-GENE
antagonistic	O
activity	O
and	O
5-HT7	B-GENE
receptor	I-GENE
agonistic	O
activity	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating,	O
ameliorating	O
or	O
preventing	O
movement	O
disorders	O
.	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
(	O
1	O
)	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
of	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
provided	O
:	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
agonists	O
or	O
partial	O
agonists	O
of	O
the	O
2C	B-GENE
subtype	I-GENE
of	I-GENE
brain	I-GENE
serotonin	I-GENE
receptors	I-GENE
.	O
The	O
compounds,	O
and	O
compositions	O
containing	O
the	O
compounds,	O
can	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
central	O
nervous	O
system	O
disorders	O
such	O
as	O
schizophrenia	O
.	O


The	O
present	O
invention	O
provides	O
cycloalkylfused	O
indole,	O
benzothiophene,	O
benzofuran,	O
and	O
indene	O
derivatives,	O
and	O
methods	O
for	O
using	O
them	O
to,	O
for	O
example,	O
treat,	O
prevent	O
and	O
/	O
or	O
ameliorate	O
central	O
nervous	O
system	O
diseases	O
by	O
antagonizing	O
5-HT1A	B-GENE
receptors	O
and	O
modulating	O
serotonin	O
levels	O
.	O


Disclosed	O
is	O
a	O
novel	O
benzyloxypropylamine	O
derivative	O
having	O
an	O
excellent	O
tachykinin	B-GENE
receptor	I-GENE
antagonistic	O
effect	O
.	O
This	O
compound	O
shows	O
a	O
good	O
transfer	O
into	O
the	O
blood	O
and	O
a	O
long	O
blood	O
half-life	O
in	O
the	O
blood	O
kinetic	O
test	O
using	O
a	O
guinea	O
pig	O
orally	O
administered	O
with	O
the	O
compound	O
and	O
is	O
stable	O
in	O
an	O
animal	O
plasma	O
.	O
The	O
compound	O
also	O
shows	O
a	O
high	O
transfer	O
to	O
the	O
central	O
nervous	O
system	O
when	O
it	O
is	O
orally	O
administered	O
to	O
a	O
guinea	O
pig	O
at	O
a	O
certain	O
dose	O
.	O
Accordingly,	O
the	O
benzyloxypropylamine	O
derivative	O
is	O
quite	O
useful	O
as	O
a	O
novel	O
anti-tachykinin	O
agent	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
blocking	O
entry	O
of	O
Shigella	O
into	O
a	O
cell	O
of	O
an	O
animal,	O
to	O
therefore	O
providing	O
protection	O
against,	O
or	O
reduce	O
the	O
severity	O
of	O
Shigella	O
infections	O
.	O
More	O
particularly	O
it	O
relates	O
to	O
the	O
use	O
of	O
the	O
IpaD	B-GENE
protein	I-GENE
obtained	O
from	O
natural	O
sources	O
and	O
/	O
or	O
through	O
synthesis	O
or	O
recombinant	O
technology,	O
and	O
conjugates	O
thereof	O
to	O
induce	O
neutralizing	O
antibodies	O
having	O
protective	O
activity	O
against	O
several	O
serotypes	O
of	O
Shigella,	O
in	O
particular	O
S	O
.	O
flexneri	O
.	O
The	O
composition	O
of	O
the	O
invention	O
is	O
useful	O
to	O
prevent	O
and	O
/	O
or	O
treat	O
shigellosis	O
caused	O
by	O
a	O
bacterium	O
of	O
the	O
Shigella	O
family	O
.	O


An	O
isolated	O
polypeptide	O
comprises	O
an	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
No	O
.	O
1	O
or	O
2	O
or	O
a	O
variant	O
or	O
fragment	O
thereof	O
.	O
The	O
variant	O
may	O
comprise	O
an	O
amino	O
acid	O
sequence	O
that	O
is	O
at	O
least	O
70	O
%	O
or	O
95	O
%	O
identical	O
to	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
No	O
.	O
1	O
or	O
2	O
.	O
A	O
fragment	O
thereof	O
may	O
be	O
a	O
peptide	O
comprising	O
at	O
least	O
12	O
contiguous	O
amino	O
acids	O
of	O
SEQ	O
ID	O
No	O
.	O
1	O
or	O
2	O
.	O
The	O
polypeptide	O
exhibits	O
toll-like	B-GENE
receptor	I-GENE
activity	O
.	O
The	O
TLR	B-GENE
has	O
been	O
named	O
TLRl	O
4	O
.	O
TLR	B-GENE
receptors	I-GENE
recognise	O
a	O
range	O
of	O
ligands	O
and	O
activate	O
a	O
series	O
of	O
signalling	O
pathways	O
that	O
lead	O
to	O
the	O
induction	O
of	O
immune	O
and	O
inflammatory	O
genes	O
.	O


Methods	O
and	O
systems	O
are	O
described	O
that	O
release	O
one	O
or	O
both	O
of	O
a	O
neurotrophin	B-GENE
and	O
an	O
inhibitor	O
of	O
the	O
degradation	O
of	O
the	O
neurotrophin	B-GENE
within	O
or	O
in	O
the	O
vicinity	O
of	O
a	O
highly	O
innervated	O
tissue	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
includes	O
regulating	O
the	O
release	O
of	O
the	O
neurotrophin	B-GENE
and	O
the	O
inhibitor	O
of	O
degradation	O
over	O
time	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
includes	O
monitoring	O
the	O
concentration	O
of	O
the	O
neurotrophin	B-GENE
over	O
time	O
.	O
The	O
system	O
may	O
include	O
a	O
device	O
or	O
multiple	O
devices	O
for	O
the	O
release	O
of	O
the	O
neurotrophin	B-GENE
and	O
the	O
inhibitor	O
as	O
well	O
as	O
a	O
controller	O
.	O
In	O
some	O
embodiments	O
the	O
system	O
may	O
include	O
a	O
sensor	O
device	O
and	O
/	O
or	O
an	O
imaging	O
device	O
capable	O
of	O
detecting	O
the	O
concentration	O
of	O
the	O
neurotrophin	B-GENE
over	O
time	O
.	O
The	O
release	O
of	O
the	O
neurotrophin	B-GENE
and	O
inhibitor	O
of	O
degradation	O
may	O
be	O
part	O
of	O
a	O
controlled	O
release	O
system	O
and	O
regulated	O
over	O
time	O
.	O


A	O
method	O
for	O
preventing	O
or	O
reducing	O
boar	O
taint,	O
a	O
method	O
of	O
screening	O
pigs	O
to	O
determine	O
those	O
more	O
likely	O
to	O
have	O
reduced	O
boar	O
taint	O
and	O
a	O
method	O
for	O
screening	O
substances	O
that	O
enhance	O
skatole	O
metabolism	O
or	O
androstenone	O
in	O
a	O
pig,	O
are	O
disclosed	O
These	O
methods	O
involve	O
the	O
use	O
of	O
the	O
nuclear	O
receptors	O
constitutive	O
androstane	O
receptor,	O
pregnane	B-GENE
X	I-GENE
receptor	I-GENE
and	O
farnesoid	B-GENE
X	I-GENE
receptor,	O
which	O
have	O
been	O
found	O
to	O
modulate	O
the	O
activity	O
of	O
the	O
enzymes	O
involved	O
in	O
skatole	O
and	O
/	O
or	O
androsterone	O
metabolism	O


The	O
invention	O
relates	O
to	O
a	O
system	O
which	O
can	O
kill	O
tumour	O
cells	O
by	O
means	O
of	O
caspase-independent	O
apoptosis	O
activation,	O
consisting	O
of	O
:	O
I	O
.	O
a	O
cyanogenic	O
system	O
comprising	O
the	O
enzymatic	O
activity	O
exerted	O
by	O
linamarase	O
on	O
linamarin	O
and	O
an	O
oxidative	O
stress-inducing	O
system	O
comprising	O
the	O
oxidative	O
activity	O
of	O
the	O
enzyme	O
glucose	O
oxidase,	O
which	O
are	O
combined	O
in	O
one	O
composition	O
;	O
or	O
II	O
.	O
a	O
cyanogenic	O
system	O
comprising	O
the	O
enzymatic	O
activity	O
exerted	O
by	O
linamarase	O
on	O
linamarin	O
and	O
an	O
oxidative	O
stress-inducing	O
system	O
comprising	O
the	O
oxidative	O
activity	O
exerted	O
by	O
the	O
enzyme	O
glucose	O
oxidase,	O
which	O
are	O
present	O
in	O
independent	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
that	O
certain	O
compounds	O
inhibit,	O
regulate	O
and	O
/	O
or	O
modulate	O
tyrosine	B-GENE
and	I-GENE
serine/threonine	I-GENE
kinase	I-GENE
and	I-GENE
kinase-like	O
proteins,	O
such	O
as	O
RAF	B-GENE
kinase,	O
a	O
serine/threonine	O
kinase	I-GENE
that	O
functions	O
in	O
the	O
MAP	B-GENE
kinase	I-GENE
signaling	O
pathway,	O
and	O
is	O
concerned	O
with	O
compositions	O
which	O
contain	O
these	O
compounds,	O
and	O
methods	O
of	O
using	O
them	O
to	O
treat	O
tyrosine	B-GENE
and	I-GENE
serine/threonine	I-GENE
kinase	I-GENE
and	I-GENE
kinase-like	O
dependent	O
diseases,	O
such	O
as	O
angiogenesis,	O
cancer	O
and	O
cardiac	O
hypertrophy	O
.	O
(	O
Formula	O
I	O
)	O
.	O


Inhibitors	O
of	O
microbial	O
heme	B-GENE
oxygenase	I-GENE
and	O
their	O
use	O
for	O
treatment	O
of	O
microbial	O
infections	O
and	O
bioremediation	O
.	O
The	O
inhibitors	O
of	O
microbial	O
heme	B-GENE
oxygenase	I-GENE
are	O
useful	O
against	O
a	O
new	O
class	O
of	O
antimicrobial	O
agents	O
to	O
target	O
infections	O
that	O
are	O
persistently	O
difficult	O
to	O
combat	O
with	O
the	O
current	O
spectrum	O
of	O
antimicrobial	O
agents	O
.	O
Screening	O
methods	O
for	O
selecting	O
inhibitors	O
of	O
microbial	O
heme	B-GENE
oxygenase	I-GENE
.	O


Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
bone	O
loss	O
.	O
The	O
methods	O
comprise	O
providing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
chelating	O
agent	O
to	O
a	O
subject	O
.	O
The	O
methods	O
further	O
comprise	O
providing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
estrogen	O
or	O
at	O
least	O
one	O
estrogen	O
analogue	O
to	O
a	O
subject	O
.	O
Compositions	O
disclosed	O
herein	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
bone	O
loss	O
comprise	O
a	O
chelator	O
and	O
estrogen	O
or	O
at	O
least	O
one	O
estrogen	O
analogue	O
.	O
The	O
compositions	O
further	O
comprise	O
at	O
least	O
one	O
of	O
a	O
bisphosphonate,	O
a	O
selective	O
estrogen	B-GENE
receptor	I-GENE
modulator,	O
or	O
a	O
hormone	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
modulating	O
repair	O
of	O
a	O
wound	O
.	O
The	O
method	O
includes	O
modulating	O
expression	O
and	O
/	O
or	O
activity	O
of	O
Flightless	B-GENE
I	I-GENE
in	O
cells	O
involved	O
in	O
repair	O
of	O
the	O
wound	O
.	O


Disclosed	O
is	O
a	O
fused	O
heterocyclic	O
compound	O
having	O
tyrosine	B-GENE
kinase	I-GENE
inhibitory	O
activity	O
.	O
Formula	O
(	O
I	O
)	O
(	O
In	O
the	O
formula,	O
R1	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
or	O
an	O
optionally	O
substituted	O
group	O
which	O
is	O
bonded	O
through	O
a	O
carbon	O
atom,	O
a	O
nitrogen	O
atom	O
or	O
an	O
oxygen	O
atom,	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
optionally	O
substituted	O
group	O
which	O
is	O
bonded	O
through	O
a	O
carbon	O
atom	O
or	O
a	O
sulfur	O
atom,	O
or	O
alternatively	O
R1	O
and	O
R2	O
or	O
R2	O
and	O
R3	O
are	O
respectively	O
bonded	O
together	O
to	O
form	O
an	O
optionally	O
substituted	O
ring	O
structure	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
optionally	O
substituted	O
aliphatic	O
hydrocarbon	O
group,	O
or	O
alternatively	O
R3	O
is	O
bonded	O
with	O
a	O
carbon	O
atom	O
of	O
ring	O
A	O
to	O
form	O
an	O
optionally	O
substituted	O
ring	O
structure	O
;	O
ring	O
A	O
represents	O
an	O
optionally	O
substituted	O
benzene	O
ring	O
;	O
and	O
ring	O
B	O
represents	O
(	O
i	O
)	O
an	O
optionally	O
substituted	O
fused	O
ring,	O
or	O
(	O
ii	O
)	O
a	O
pyridine	O
ring	O
having	O
an	O
optionally	O
substituted	O
carbamoyl	O
(	O
which	O
pyridine	O
ring	O
may	O
be	O
further	O
substituted	O
)	O
.	O
)	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
an	O
NK1	B-GENE
receptor	I-GENE
antagonist	O
and	O
a	O
sodium	O
channel	O
blocker	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
are	O
independently	O
hydrogen,	O
C1-6alkyl	O
or	O
C3-6cycloalkylC1-6alkyl	O
;	O
or	O
R1	O
and	O
R2,	O
together	O
with	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached,	O
may	O
form	O
an	O
unsubstitued	O
3-,	O
4-,	O
5-	O
or	O
6-membered	O
saturated	O
ring	O
;	O
R3	O
is	O
C1-6alkyl,	O
C1-6haloalkyl,	O
C1-3alkoxyC1-3alkyl	O
or	O
C1-3haloalkoxyC1-3alkyl	O
;	O
or	O
R1	O
and	O
R3,	O
together	O
with	O
the	O
interconnecting	O
atoms,	O
form	O
a	O
saturated	O
or	O
unsaturated	O
4-	O
to	O
6-membered	O
ring	O
;	O
X	O
is	O
carbon	O
or	O
nitrogen	O
;	O
n	O
is	O
0,	O
1	O
or	O
2,	O
wherein	O
when	O
present	O
each	O
R4	O
is	O
independently	O
selected	O
from	O
the	O
list	O
consisting	O
of	O
C1-3alkyl,	O
halogen,	O
cyano,	O
haloC1-3alkyl,	O
hydroxy,	O
C1-3alkoxy	O
and	O
C1-3haloalkoxy	O
;	O
q	O
is	O
1	O
or	O
2	O
;	O
either	O
R5	O
or	O
R6	O
is	O
-O-R7	O
or	O
-OCH2R7,	O
wherein	O
the	O
other	O
R5	O
or	O
R6	O
is	O
hydrogen	O
or	O
R4	O
;	O
and	O
wherein	O
R7	O
is	O
either	O
a	O
phenyl	O
ring	O
or	O
a	O
5-	O
or	O
6-membered	O
aromatic	O
heterocyclic	O
ring	O
(	O
independently	O
containing	O
one	O
or	O
more	O
nitrogen,	O
sulphur	O
or	O
oxygen	O
atoms	O
)	O
wherein	O
either	O
the	O
phenyl	O
ring	O
or	O
the	O
heterocyclic	O
ring	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
list	O
consisting	O
of	O
C1-3alkyl,	O
halogen,	O
cyano,	O
haloC1-3alkyl,	O
hydroxy,	O
C1-3alkoxy	O
and	O
C1-3haloalkoxy	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
;	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous	O
or	O
sequential	O
administration,	O
and	O
to	O
the	O
use	O
of	O
such	O
compositions	O
in	O
the	O
treatment	O
of	O
certain	O
disorders,	O
including	O
epilepsy	O
and	O
mood	O
disorders	O
.	O


Disclosed	O
are	O
inactivators	O
of	O
O6-alkylguanine-DNA	B-GENE
alkyltransferase	I-GENE
(	O
AGT	B-GENE
)	O
having	O
the	O
formula	O
:	O
(	O
I	O
)	O
wherein	O
R,	O
R1	O
and	O
R3	O
are	O
as	O
described	O
herein	O
.	O
The	O
inactivators	O
are	O
highly	O
water	O
soluble	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
an	O
inactivator	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
and	O
a	O
method	O
of	O
use	O
of	O
the	O
inactivator	O
in	O
enhancing	O
the	O
chemotherapeutic	O
treatment	O
of	O
tumor	O
cells	O
in	O
a	O
mammal,	O
e	O
.	O
g	O
.	O
,	O
a	O
human,	O
with	O
an	O
antineoplastic	O
alkylating	O
agent	O
that	O
causes	O
cytotoxic	O
lesions	O
at	O
the	O
O6-position	O
of	O
guanine	O
.	O


The	O
present	O
invention	O
relates	O
to	O
crystalline	O
forms	O
of	O
[	O
3-	O
(	O
4-	O
{	O
2-butyl-1-	O
[	O
4-	O
(	O
4-chloro-phenoxy	O
)	O
-phenyl	O
]	O
-1H-imidazol-4-yl	O
}	O
-phenoxy	O
)	O
-propyl	O
]	O
-diethylamine	O
(	O
"COMPOUND	O
I"	O
)	O
useful	O
in	O
the	O
treatment	O
of	O
RAGE	B-GENE
mediated	O
diseases	O
.	O


Particles	O
comprising	O
an	O
opioid	B-GENE
receptor	I-GENE
antagonist	O
as	O
well	O
as	O
methods	O
of	O
their	O
use	O
and	O
methods	O
of	O
their	O
preparation	O
are	O
provided	O
herein	O
Such	O
particles	O
may	O
be	O
used	O
for	O
treating	O
and	O
preventing	O
opioid-induced	O
side	O
effects	O
in	O
patients,	O
and	O
may	O
be	O
provided	O
to	O
chronic	O
opioid	O
users	O
as	O
well	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
novel	O
hydroxy-methyl	O
isoxazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2	O
and	O
R3	O
are	O
as	O
described	O
herein,	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
have	O
affinity	O
and	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
a5	I-GENE
receptor	O
.	O
Further	O
the	O
present	O
invention	O
is	O
concerned	O
with	O
the	O
manufacture	O
of	O
the	O
active	O
compounds	O
of	O
formula	O
I,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O


Provided	O
herein	O
are	O
8-substituted	O
quinolines	O
and	O
related	O
analogues	O
as	O
sirtuin-modulating	O
compounds	O
of	O
Structural	O
Formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
use	O
thereof	O
.	O
The	O
sirtuin-modulating	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell,	O
and	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including,	O
for	O
example,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress,	O
diabetes,	O
obesity,	O
neurodegenerative	O
diseases,	O
cardiovascular	O
disease,	O
blood	O
clotting	O
disorders,	O
inflammation,	O
cancer,	O
and	O
/	O
or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O
Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
sirtuin-modulating	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
which	O
are	O
able	O
to	O
modulate	O
b-raf	B-GENE
kinases,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
various	O
diseases,	O
disorders	O
or	O
conditions	O
.	O


The	O
application	O
relates	O
to	O
an	O
aqueous	O
pharmaceutical	O
formulation	O
comprising	O
200	O
	O
1000	O
U	O
/	O
mL	O
[	O
equimolar	O
to	O
200	O
1000	O
IU	O
human	O
insulin	B-GENE
]	O
of	O
insulin	B-GENE
glargine,	O
with	O
the	O
proviso	O
that	O
the	O
concentration	O
of	O
said	O
formulation	O
is	O
not	O
684	O
U	O
/	O
mL	O
of	O
insulin	B-GENE
glargine,	O
and	O
its	O
use	O
.	O


By	O
oral	O
administration	O
of	O
a	O
compound	O
represented	O
by	O
the	O
following	O
Formula	O
(	O
I	O
)	O
:	O
the	O
blood	O
level	O
of	O
Compound	O
(	O
IV	O
)	O
:	O
which	O
has	O
an	O
excellent	O
inhibitory	O
action	O
against	O
blood	O
coagulation	B-GENE
factor	I-GENE
VIIa	I-GENE
and	O
the	O
anticoagulant	O
action,	O
reaches	O
a	O
level	O
sufficient	O
for	O
expression	O
of	O
its	O
pharmacological	O
actions	O
.	O
Therefore,	O
the	O
compound	O
of	O
the	O
present	O
invention	O
is	O
useful	O
as	O
a	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
agent	O
for	O
diseases	O
caused	O
by	O
thrombus	O
formation	O
.	O


Compositions	O
and	O
methods	O
for	O
treating	O
a	O
bacterial	O
infection,	O
or	O
disorder	O
associated	O
with	O
a	O
bacterial	O
infection,	O
in	O
a	O
patient	O
being	O
treated	O
for	O
another	O
disorder	O
with	O
a	O
drug	O
metabolized	O
by	O
CYP450,	O
are	O
disclosed	O
.	O
The	O
methods	O
involve	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
rifalazil	O
or	O
rifalazil	O
analogs	O
that	O
does	O
not	O
modulate	O
CYP450	B-GENE
.	O
The	O
bacterial	O
infection	O
may	O
be	O
caused	O
by	O
a	O
bacteria	O
with	O
an	O
active	O
and	O
inactive,	O
latent	O
form,	O
and	O
the	O
rifalazil	O
is	O
administered	O
in	O
an	O
amount	O
and	O
for	O
a	O
duration	O
sufficient	O
to	O
treat	O
both	O
the	O
active	O
and	O
the	O
inactive,	O
latent	O
form	O
of	O
the	O
bacterial	O
infection,	O
which	O
duration	O
is	O
longer	O
than	O
is	O
needed	O
to	O
treat	O
the	O
active	O
form	O
of	O
the	O
bacterial	O
infection	O
.	O
One	O
such	O
bacterial	O
infection	O
is	O
tuberculosis,	O
and	O
the	O
method	O
can	O
be	O
used	O
to	O
treat	O
immunocompromised	O
tuberculosis	O
patients,	O
including	O
those	O
being	O
treated	O
with	O
protease	B-GENE
inhibitors	O
and	O
/	O
or	O
NNRTI	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
fluorinated	O
piperidine	O
derivatives	O
having	O
antagonistic	O
activity	O
at	O
the	O
5-HT2B	B-GENE
receptor,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
their	O
use	O
as	O
a	O
medicine	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
pulmonary	O
arterial	O
hypertension,	O
pulmonary	O
fibrosis	O
or	O
irritable	O
bowel	O
syndrome	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
which	O
can	O
modulate	O
the	O
activity	O
of	O
protein	B-GENE
kinases	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
composition	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
method	O
for	O
synthesizing	O
and	O
using	O
such	O
compound	O
for	O
preventing	O
or	O
treating	O
ALK	B-GENE
or	O
cMet	B-GENE
mediated	O
disorders	O
or	O
conditions	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
iminosugar	O
derivatives	O
and	O
processes	O
for	O
the	O
preparation	O
thereof	O
.	O
The	O
disclosed	O
compounds	O
have	O
glycosidase	B-GENE
inhibiting	O
properties,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
diseases,	O
such	O
as	O
type	O
2	O
diabetes,	O
neurodegenerative	O
diseases	O
or	O
lysosomal	O
storage	O
disorders	O
.	O
The	O
present	O
disclosure	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
disclosed	O
compounds	O
and	O
to	O
their	O
use	O
as	O
biochemical	O
tools	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
comprising	O
AZD5363,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
at	O
least	O
one	O
androgen	B-GENE
receptor	I-GENE
signalling	O
modulator	O
selected	O
from	O
MDV-3100	O
(	O
also	O
known	O
as	O
enzalutamide	O
)	O
,	O
AZD3514,	O
abiraterone	O
(	O
or	O
an	O
ester	O
prodrug	O
thereof	O
:	O
e	O
.	O
g	O
.	O
abiraterone	O
acetate	O
)	O
,	O
and	O
bicalutamide	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
Each	O
of	O
these	O
combinations	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
combinations,	O
and	O
further	O
relates	O
to	O
methods	O
of	O
treatment	O
comprising	O
the	O
simultaneous,	O
sequential	O
or	O
separate	O
administration	O
of	O
AZD5363,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
with	O
at	O
least	O
one	O
androgen	B-GENE
receptor	I-GENE
signalling	O
modulator	O
as	O
described	O
above,	O
to	O
warm-blooded	O
animal,	O
such	O
as	O
a	O
human	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
comprising	O
such	O
combinations	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
or	O
preventing	O
a	O
metabolic	O
disorder	O
in	O
a	O
subject,	O
methods	O
of	O
treating	O
or	O
preventing	O
coronorary	O
artery	O
disease	O
in	O
a	O
subject	O
with	O
a	O
metabolic	O
disorder,	O
as	O
well	O
as	O
methods	O
of	O
reducing	O
hepatic	O
glucose	O
production	O
in	O
a	O
subject	O
.	O
Such	O
methods	O
include,	O
but	O
are	O
not	O
limited	O
to,	O
the	O
administration	O
to	O
the	O
subject	O
of	O
inhibitors	O
of	O
CaMKII,	O
IP3Rs,	O
calcineurin,	O
p38,	O
MK2	O
/	O
3,	O
or	O
any	O
combination	O
thereof	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
a	O
compound	O
that	O
inhibits	O
the	O
activity	O
of	O
CaMKII,	O
IP3Rs,	O
calcineurin,	O
p38,	O
or	O
MK2	O
/	O
3,	O
or	O
reduces	O
the	O
activity	O
and	O
/	O
or	O
activation	O
of	O
CaMKII,	O
IP3Rs,	O
calcineurin,	O
p38,	O
or	O
MK2	O
/	O
3	O
.	O


There	O
is	O
disclosed	O
a	O
methylated	O
intermediate	O
which	O
may	O
be	O
demethylated	O
to	O
provide	O
an	O
inhibitor	O
of	O
catechol-O-methyltransferase	B-GENE
useful	O
in	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
and	O
using	O
said	O
intermediate	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
composition	O
prepared	O
from	O
a	O
combination	O
of	O
plant	O
oil	O
and	O
/	O
or	O
fish	O
oil	O
and	O
a	O
compound	O
comprising	O
non	O
ss-oxidizable	O
fatty	O
acid	O
analogues,	O
and	O
the	O
use	O
of	O
said	O
composition	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
or	O
nutritional	O
composition	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
insulin	B-GENE
resistance,	O
obesity,	O
diabetes,	O
fatty	O
liver,	O
hypercholesterolemia,	O
dyslipidemia,	O
atherosclerosis,	O
coronary	O
heart	O
disease,	O
thrombosis,	O
stenosis,	O
secondary	O
stenosis,	O
myocardial	O
infarction,	O
stroke,	O
elevated	O
blood	O
pressure,	O
endothelial	O
dysfunction,	O
procoagulant	O
state,	O
polycystic	O
ovary	O
syndrome,	O
the	O
metabolic	O
syndrome,	O
cancer,	O
inflammatory	O
disorders	O
and	O
proliferate	O
skin	O
disorders	O
.	O
The	O
present	O
invention	O
also	O
concerns	O
an	O
animal	O
feed	O
prepared	O
from	O
a	O
combination	O
of	O
plant	O
oil	O
and	O
/	O
or	O
fish	O
oil	O
and	O
a	O
compound	O
comprising	O
non	O
ss-oxidizable	O
fatty	O
acid	O
analogues,	O
the	O
use	O
of	O
said	O
feed	O
for	O
improving	O
the	O
body	O
composition	O
of	O
an	O
animal,	O
and	O
a	O
product	O
produced	O
from	O
said	O
animal	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
using	O
tasepi	O
alkali	O
to	O
prepare	O
the	O
drug	O
that	O
restrains	O
the	O
growth	O
of	O
tumor	O
vessel,	O
which	O
provides	O
the	O
method	O
for	O
building	O
chicken	O
blast	O
allantois	O
membrane	O
non-small-cell	O
lung	O
cancer	O
A549	O
tumor	O
transplant	O
cancer	O
model	O
.	O
The	O
invention	O
uses	O
said	O
test	O
model,	O
ELISA,	O
immunity	O
protein	O
label,	O
and	O
Real	O
Time	O
RCR	O
test	O
method	O
to	O
research	O
the	O
effects	O
of	O
tasepi	O
alkali	O
on	O
the	O
CAM	O
vessel	O
structure,	O
the	O
growth	O
of	O
tumor,	O
the	O
shape	O
change	O
and	O
the	O
fresh	O
vessel	O
distribution	O
of	O
tumor,	O
the	O
protein	O
expression	O
of	O
VEGF	B-GENE
and	O
bFGF,	O
the	O
gene	O
expressions	O
of	O
VEGF	B-GENE
acceptors	O
as	O
flt-1	B-GENE
and	O
flk-1	B-GENE
/	O
KDR,	O
the	O
protein	O
expressions	O
of	O
AKT	B-GENE
and	O
Erk1	O
/	O
2,	O
and	O
the	O
phosphorylation	O
level,	O
to	O
prove	O
the	O
function	O
of	O
tasepi	O
alkali	O
for	O
restraining	O
the	O
growth	O
of	O
tumor	O
vessel	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
application	O
of	O
indirubin	O
derivative	O
(	O
IO	O
)	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
curing	O
neural	O
retrograde	O
disease,	O
specially,	O
it	O
relates	O
to	O
an	O
application	O
of	O
indirubin	O
derivative	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
curing	O
Parkinson	O
'	O
s	O
disease	O
.	O
Said	O
invention	O
uses	O
the	O
indirubin	O
derivative	O
as	O
inhibitor	O
and	O
utilizes	O
three	O
kinds	O
of	O
mediated	O
and	O
died	O
kinases	O
of	O
JNK	B-GENE
/	O
CDK5	B-GENE
/	O
GSK3	B-GENE
beta	I-GENE
which	O
are	O
inhibited	O
by	O
said	O
indirubin	O
derivative	O
as	O
clear	O
target	O
to	O
develop	O
the	O
invented	O
new	O
medicine	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
tungstate	O
lithium	O
for	O
preparing	O
a	O
medicine,	O
in	O
particular	O
an	O
application	O
for	O
preparing	O
drug	O
for	O
treating	O
neurodegenerative	O
disease,	O
neuropathy	O
caused	O
by	O
diabetes,	O
and	O
cerebral	O
ischemia	O
including	O
cerebral	O
dysfunction	O
.	O
Both	O
of	O
activity	O
of	O
anion	O
and	O
cation	O
of	O
the	O
tungstate	O
lithium	O
can	O
perform	O
synergistic	O
reaction	O
to	O
inhibit	O
activity	O
of	O
a	O
GSK-3	B-GENE
much	O
better	O
.	O
By	O
inhibiting	O
activity	O
of	O
a	O
GSK-3	B-GENE
alpha,	O
generation	O
of	O
the	O
A	B-GENE
beta	I-GENE
is	O
reduced	O
to	O
decrease	O
SP	O
;	O
by	O
inhibiting	O
activity	O
of	O
a	O
GSK-3	B-GENE
beta,	O
hyperphosphorylation	O
of	O
tau	B-GENE
protein	I-GENE
is	O
inhibitted	O
to	O
reduce	O
NFT	O
.	O
Thereby,	O
survival	O
and	O
wound	O
repair	O
of	O
neurocyte	O
are	O
promoted	O
even	O
in	O
a	O
state	O
of	O
ischemia	O
and	O
anoxia	O
to	O
improve	O
learning	O
and	O
memory	O
dysfunction	O
by	O
increasing	O
content	O
of	O
BDNF	B-GENE
in	O
cortical	O
neurons	O
.	O


The	O
invention	O
discloses	O
a	O
making	O
method	O
of	O
separated	O
and	O
purified	O
new	O
bis-flavonoid	O
from	O
dragon	O
'	O
s	O
blood,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
adopting	O
dragon	O
'	O
s	O
blood	O
as	O
raw	O
material	O
;	O
extracting	O
through	O
ligarine,	O
acetone,	O
acetic	O
ester	O
solvent	O
sequently	O
;	O
separating	O
and	O
recrystallizing	O
the	O
acetic	O
ester	O
solvent	O
extract	O
through	O
silica	O
gel	O
column	O
or	O
rapid	O
silica	O
gel	O
column	O
to	O
chromatograph	O
;	O
obtaining	O
the	O
product	O
named	O
8-	O
(	O
3-	O
(	O
4-hydroxy-2-methoxybenzene	O
)	O
-1-	O
(	O
4-hydroxy	O
benzene	O
)	O
propyl	O
)	O
-2-	O
(	O
4-hydroxy	O
phenyl	O
)	O
-7-methoxy	O
-4H-benzopyranyl	O
-4-ketone	O
to	O
inhibit	O
alpha-glucosidase	B-GENE
acitivty	O
and	O
reduce	O
blood	O
sugar	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
salt	O
or	O
zwitterionic	O
form,	O
wherein	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
,	O
R	O
<	O
3	O
>	O
,	O
R	O
<	O
4	O
>	O
and	O
R	O
<	O
5	O
>	O
have	O
the	O
meanings	O
as	O
indicated	O
in	O
the	O
specification,	O
are	O
useful	O
for	O
treating	O
conditions	O
that	O
are	O
mediated	O
by	O
the	O
muscarinic	B-GENE
M3	I-GENE
receptor	I-GENE
.	O
Pharmaceutical	O
compositions	O
that	O
contain	O
the	O
compounds	O
and	O
a	O
process	O
for	O
preparing	O
the	O
compounds	O
are	O
also	O
described	O
.	O


The	O
invention	O
relates	O
to	O
the	O
chemical	O
engineering	O
field,	O
which	O
relates	O
to	O
a	O
small	O
molecule	O
compound	O
with	O
anti-HIV	O
activity,	O
the	O
preparation	O
method	O
and	O
the	O
application	O
.	O
The	O
CyPA	B-GENE
can	O
combine	O
with	O
Gag	B-GENE
polyprotein	I-GENE
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
.	O
Adoption	O
of	O
the	O
RNAi	O
technology	O
silences	O
CypA	B-GENE
or	O
inhibits	O
the	O
activity	O
of	O
the	O
CypA	B-GENE
which	O
can	O
disturb	O
the	O
replication	O
of	O
the	O
HIV-1	O
virus	O
.	O
The	O
small	O
molecule	O
compound	O
of	O
the	O
invention	O
is	O
CyPA	B-GENE
inhibitor	O
and	O
has	O
the	O
function	O
of	O
resisting	O
the	O
HIV-1	O
virus,	O
which	O
is	O
designed	O
aiming	O
at	O
the	O
cell	O
targets,	O
does	O
not	O
easily	O
form	O
drug	O
resistance	O
and	O
is	O
suitable	O
for	O
the	O
requirements	O
of	O
the	O
drug	O
use	O
for	O
long	O
life	O
of	O
AIDS	O
sufferers	O
.	O
Therefore,	O
the	O
small	O
molecule	O
compound	O
can	O
be	O
developed	O
as	O
the	O
novel	O
drug	O
resisting	O
the	O
AIDS	O
and	O
provides	O
a	O
novel	O
approach	O
and	O
means	O
for	O
treating	O
and	O
healing	O
the	O
AIDS	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pentacyclic	O
triterpanoid	O
derivative	O
of	O
multiple-oxide	O
substitution	O
of	O
the	O
A	O
ring	O
and	O
the	O
medicine	O
salt	O
or	O
solvate	O
of	O
the	O
derivative,	O
and	O
the	O
present	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method,	O
the	O
drug	O
combination,	O
and	O
medical	O
use	O
of	O
the	O
derivative	O
.	O
The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
the	O
functions	O
of	O
inhibiting	O
the	O
activity	O
of	O
six	O
human	O
tumor	O
cell	O
strains	O
in	O
vitro,	O
such	O
as	O
human	O
prostate	O
cancer	O
cell	O
(	O
PC-3	O
)	O
,	O
nasopharyngeal	O
carcinoma	O
cells	O
(	O
CNE	O
)	O
,	O
oral	O
squamous	O
carcinoma	O
cell	O
(	O
KB	O
)	O
,	O
human	O
lung	O
cancer	O
cell	O
(	O
A549	O
)	O
,	O
human	O
hepatoma	O
cell	O
(	O
BEL-7404	O
)	O
,	O
and	O
human	O
cervix	O
cancer	O
cell	O
(	O
Hela	O
)	O
,	O
and	O
the	O
function	O
of	O
the	O
invention	O
is	O
at	O
the	O
same	O
magnitude	O
of	O
the	O
positive	O
control	O
of	O
cisplatin,	O
thereby	O
the	O
compound	O
can	O
be	O
used	O
as	O
expected	O
antitumor	O
drug	O
.	O
The	O
compound	O
of	O
the	O
present	O
invention	O
also	O
inhibits	O
the	O
alpha	B-GENE
glucosidase	I-GENE
strongly,	O
and	O
the	O
inhibiting	O
effect	O
is	O
greater	O
than	O
the	O
positive	O
control	O
of	O
acarbose,	O
thereby	O
the	O
compound	O
can	O
be	O
used	O
as	O
expected	O
medicine	O
for	O
preventing	O
and	O
treating	O
diabetes	O
and	O
the	O
treatment	O
of	O
the	O
virus	O
diseases	O
.	O


A	O
combination	O
preparation	O
for	O
remedying	O
the	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
and	O
the	O
functional	O
dyspepsia	O
is	O
characterized	O
in	O
that	O
the	O
prescription	O
of	O
the	O
combination	O
preparation	O
consists	O
of	O
a	O
proton	B-GENE
pump	I-GENE
depressor	O
and	O
a	O
gastrointestinal	O
power	O
drug	O
of	O
itopride	O
;	O
the	O
proton	B-GENE
pump	I-GENE
depressor	O
is	O
selected	O
from	O
one	O
of	O
a	O
Pantoprazole,	O
a	O
Omeprazole,	O
a	O
Esomeprazole,	O
a	O
Lansoprazole,	O
a	O
Rabeprazole,	O
a	O
Tenatoprazole	O
and	O
a	O
Leminorazole,	O
wherein	O
the	O
Pantoprazole	O
is	O
preferential,	O
and	O
at	O
the	O
same	O
time	O
the	O
neutral	O
form	O
of	O
the	O
basic	O
salt	O
of	O
the	O
proton	B-GENE
pump	I-GENE
depressor	O
is	O
also	O
included,	O
such	O
as	O
Naplus,	O
Mg2plus,	O
Ca2plus,	O
Kplus	O
or	O
Li	O
plus	O
salt	O
and	O
a	O
pure	O
optical	O
stereoisomer	O
of	O
the	O
proton	B-GENE
pump	I-GENE
depressor	O
or	O
an	O
active	O
metabolite	O
of	O
the	O
proton	B-GENE
pump	I-GENE
depressor	O
;	O
the	O
gastrointestinal	O
power	O
drug	O
is	O
the	O
itopride	O
and	O
a	O
ramification	O
of	O
the	O
itopride	O
or	O
one	O
of	O
the	O
medicinal	O
salts	O
of	O
the	O
itopride	O
;	O
in	O
the	O
combination	O
preparation,	O
the	O
weight	O
ratio	O
of	O
the	O
Pantoprazole	O
and	O
the	O
itopride	O
is	O
2	O
to	O
5	O
to	O
2	O
to	O
7	O
.	O
The	O
invention	O
has	O
important	O
affect	O
for	O
remedying	O
the	O
gastroesophageal	O
reflux	O
disease	O
and	O
the	O
functional	O
dyspepsia,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
and	O
convenient	O
;	O
the	O
cost	O
is	O
low	O
;	O
the	O
invention	O
is	O
fit	O
for	O
being	O
orally	O
taken	O
by	O
the	O
patient	O
;	O
the	O
invention	O
has	O
good	O
conformance	O
performance,	O
high	O
curative	O
effect,	O
low	O
recrudescence	O
rate	O
and	O
little	O
adverse	O
reaction	O
.	O


The	O
present	O
invention	O
discloses	O
an	O
anti-TLP2	O
antibody	O
.	O
Said	O
anti-TLR2	O
antibody	O
can	O
inhibit	O
tumor,	O
specially	O
can	O
inhibit	O
the	O
metastasis	O
of	O
B16	O
melanin	O
tumor	O
.	O
Said	O
anti-TLR2	O
antibody	O
not	O
only	O
can	O
block	O
TLR2	B-GENE
activity,	O
but	O
also	O
can	O
obviously	O
reduce	O
number	O
of	O
metastatic	O
foci	O
of	O
lung	O
.	O
At	O
the	O
same	O
time,	O
said	O
invention	O
finds	O
that	O
the	O
bleomycin	O
and	O
said	O
anti-TLR2	O
antibody	O
have	O
good	O
synergistic	O
action	O
.	O


The	O
invention	O
relates	O
to	O
SOD	B-GENE
health	O
protecting	O
Huoliwang	O
wine,	O
which	O
is	O
suitable	O
for	O
men	O
and	O
women	O
.	O
The	O
wine	O
is	O
prepared	O
from	O
the	O
main	O
composition	O
of	O
SOD	B-GENE
and	O
a	O
proper	O
amount	O
of	O
high	O
quality	O
five	O
grain	O
type	O
wine	O
.	O
The	O
invention	O
is	O
characterized	O
in	O
that	O
active	O
ingredient	O
of	O
SOD,	O
ginseng	O
extracts,	O
worm	O
grass	O
extracts,	O
microelement,	O
mineral	O
matter	O
is	O
included	O
in	O
every	O
500	O
ml	O
high	O
quality	O
five	O
grain	O
type	O
wine	O
.	O
The	O
invention	O
aims	O
at	O
providing	O
SOD	B-GENE
health	O
protecting	O
Huoliwang	O
wine	O
which	O
is	O
healthy,	O
does	O
not	O
include	O
the	O
objectionable	O
constituent	O
of	O
irritant,	O
stimulant,	O
hormone	O
and	O
other	O
objectionable	O
constituent	O
which	O
are	O
forbidden	O
by	O
the	O
International	O
Olympic	O
Committee,	O
and	O
has	O
the	O
functions	O
of	O
antiaging,	O
cell	O
healing	O
and	O
the	O
fully	O
adjusting	O
of	O
the	O
balance	O
of	O
the	O
human	O
body	O
.	O


The	O
invention	O
discloses	O
a	O
short	O
interfering	O
RNA	O
(	O
short	O
interfering	O
RNA,	O
siRNA	O
)	O
used	O
in	O
curing	O
oncogene	O
aiming	O
at	O
the	O
OPN	B-GENE
genes	O
of	O
human	O
beings	O
.	O
The	O
siRNA	O
uses	O
RNA	O
interfering	O
technology	O
and	O
makes	O
use	O
of	O
double	O
strand	O
RNA	O
of	O
short	O
bit	O
to	O
cause	O
mRNA	O
degradation	O
of	O
specified	O
genes	O
to	O
differentially	O
interrupt	O
the	O
expressions	O
of	O
the	O
specified	O
genes	O
with	O
high	O
efficiency	O
and	O
lead	O
cells	O
to	O
show	O
the	O
silent	O
phenotypes	O
of	O
the	O
specified	O
genes	O
that	O
can	O
be	O
applied	O
in	O
diseases	O
curing	O
field	O
by	O
researchers	O
.	O
The	O
OPN	B-GENE
genes	O
express	O
a	O
multi-functional	O
protein,	O
which	O
attends	O
the	O
production	O
and	O
diversion	O
of	O
tumours	O
of	O
human	O
beings	O
.	O
The	O
invention	O
widely	O
exists	O
in	O
the	O
tissues	O
and	O
the	O
body	O
fluid	O
of	O
normal	O
adults	O
.	O
Being	O
proved	O
by	O
the	O
experiment,	O
the	O
growth	O
of	O
tumour	O
cells	O
is	O
obviously	O
restricted	O
after	O
the	O
expression	O
of	O
the	O
OPN	B-GENE
genes	O
is	O
controlled	O
.	O


The	O
invention	O
discloses	O
a	O
target	O
antitumor	O
prodrug	O
which	O
is	O
mediated	O
by	O
a	O
folic	O
acid-polypeptide	O
composite	O
;	O
the	O
constructive	O
general	O
formula	O
of	O
the	O
invention	O
is	O
X-ASGP-Cyt	O
'	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
typical	O
prodrug	O
of	O
folic	O
acid-polypeptide-adriamycin	O
.	O
Meanwhile,	O
the	O
invention	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
prodrug	O
.	O
Specificity	O
substrate	O
alanyl-seryl-glycyl-proline	O
(	O
ASGP	O
)	O
polypeptide	O
is	O
utilized	O
as	O
connexin,	O
free	O
carboxyl	O
is	O
used	O
for	O
modifying	O
the	O
free	O
amino-group	O
of	O
adriamycin	O
and	O
other	O
antitumor	O
drugs,	O
and	O
the	O
free	O
amino-group	O
is	O
connected	O
to	O
the	O
carboxyl	O
of	O
folic	O
acid	O
so	O
as	O
to	O
synthesize	O
the	O
enzyme	O
activation	O
type	O
target	O
antitumor	O
prodrug	O
carrying	O
polypeptide,	O
which	O
can	O
be	O
selectively	O
hydrolyzed	O
around	O
tumorous	O
interstitial	O
cells,	O
and	O
folic	O
acid,	O
which	O
has	O
high	O
affinity	O
with	O
the	O
folate	B-GENE
receptors	I-GENE
on	O
tumorous	O
interstitial	O
cells,	O
thus	O
accelerating	O
the	O
active	O
enrichment	O
of	O
the	O
antitumor	O
drug	O
toward	O
specific	O
tumor	O
tissues	O
and	O
achieving	O
the	O
aim	O
of	O
hydrolyzing	O
and	O
releasingthe	O
target	O
cytotoxia	O
drug	O
surrounding	O
tumor	O
tissues	O
.	O


The	O
invention	O
discloses	O
a	O
drug	O
used	O
for	O
antitumor,	O
belonging	O
to	O
technical	O
field	O
of	O
medication	O
chemistry,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
2-substituted-3-hydroxy-2,	O
3-xylylenimine-1-ketone	O
(	O
I	O
)	O
,	O
6-substituted-5-hydroxy-5,	O
6-dihydropyrrolo	O
[	O
3,	O
4-b	O
]	O
pyridine-7-ketone	O
(	O
II	O
)	O
,	O
6-substituted-5,	O
6-dihydropyrrolo	O
[	O
3,	O
4-b	O
]	O
pyridine-7-ketone	O
(	O
III	O
)	O
,	O
6-substituted-5,	O
6-dihydropyrrolo	O
[	O
3,	O
4-d	O
]	O
pyrimidine	O
-7-ketone	O
(	O
IV	O
)	O
;	O
the	O
general	O
formula	O
of	O
the	O
structure	O
is	O
as	O
above	O
.	O
The	O
drug	O
used	O
for	O
antitumor	O
has	O
the	O
advantages	O
of	O
having	O
higher	O
protein	B-GENE
kinase	I-GENE
inhibitory	O
activity,	O
easily	O
preparing,	O
conveniently	O
getting	O
raw	O
material,	O
easily	O
realizing	O
industrialization	O
and	O
meeting	O
requirements	O
of	O
preparing	O
drugs	O
treating	O
cancers	O
clinically	O
.	O


A	O
sustained	O
release	O
implant	O
for	O
treating	O
solid	O
cancer	O
is	O
characterized	O
in	O
that	O
the	O
sustained	O
release	O
implant	O
comprises	O
nimustine,	O
sustained	O
release	O
excipients	O
and	O
a	O
release	O
regulator	O
with	O
an	O
effective	O
amount	O
for	O
anti-cancer	O
.	O
The	O
sustained	O
release	O
excipients	O
essentially	O
include	O
macromolecule	O
polymer	O
which	O
has	O
a	O
biotic	O
capacitability	O
and	O
can	O
be	O
degraded	O
and	O
absorbed,	O
mainly	O
relating	O
to	O
PLA,	O
and	O
PLGA	O
;	O
the	O
release	O
regulator	O
is	O
selected	O
from	O
one	O
or	O
combination	O
of	O
mannitol,	O
sorbitol,	O
xylitol,	O
oligosaccharide,	O
chitin,	O
potassium	O
salt,	O
sodium	O
salt,	O
hyaluronic	O
acid,	O
collagen,	O
chondroitin,	O
gelatin	O
and	O
albumin	B-GENE
.	O
The	O
sustained	O
release	O
implant	O
can	O
slowly	O
release	O
carmustine	O
in	O
partial	O
knub	O
during	O
the	O
process	O
of	O
degrading	O
and	O
absorbing	O
;	O
thereby	O
being	O
able	O
to	O
maintain	O
effective	O
medicine	O
concentration	O
on	O
partial	O
knub	O
simultaneously	O
when	O
remarkably	O
reducing	O
the	O
general	O
toxicity	O
reaction	O
;	O
consequently,	O
the	O
invention	O
can	O
be	O
widely	O
applied	O
for	O
the	O
treatment	O
of	O
the	O
solid	O
knub	O
in	O
various	O
stages	O
by	O
single	O
or	O
cooperated	O
with	O
non	O
operative	O
treatments	O
like	O
chemotherapy	O
medicines	O
and	O
radiotherapy,	O
which	O
can	O
not	O
only	O
selectively	O
enhance	O
medicine	O
concentration	O
on	O
partial	O
knub	O
,	O
but	O
also	O
enhance	O
the	O
curing	O
effects	O
of	O
non	O
operative	O
treatments	O
like	O
medicine	O
chemotherapy	O
and	O
radiotherapy	O
.	O


The	O
invention	O
relates	O
to	O
a	O
mouthwash	O
fluid,	O
in	O
particular	O
to	O
a	O
compound	O
mouthwash	O
fluid	O
for	O
preventing	O
stomatitis,	O
and	O
a	O
preparation	O
method	O
thereof,	O
which	O
comprises	O
a	O
plurality	O
of	O
medicines	O
.	O
The	O
content	O
of	O
each	O
medicine	O
is	O
as	O
follows	O
:	O
250ml	O
of	O
normal	O
saline,	O
1	O
.	O
2	O
million	O
Mu	O
of	O
gentamicin,	O
10,000mcg	O
of	O
Vit	O
B12	O
.	O
,	O
10mg	O
of	O
dexamethasone,	O
1,000Mu	O
of	O
alpha-	B-GENE
chymotrypsin	I-GENE
and	O
8ml	O
of	O
1	O
percent	O
tetracaine	O
.	O
The	O
stable	O
mouthwash	O
liquid	O
is	O
prepared	O
by	O
:	O
sawing	O
off	O
the	O
ampoules	O
of	O
all	O
the	O
medicines	O
with	O
an	O
aseptic	O
operation,	O
pumping	O
the	O
medicines	O
with	O
an	O
injector,	O
thus	O
obtaining	O
the	O
stable	O
mouthwash	O
fluid	O
after	O
adding	O
into	O
a	O
bottle	O
of	O
normal	O
saline	O
for	O
airproof	O
storage	O
.	O
The	O
mouthwash	O
liquid	O
of	O
the	O
invention	O
can	O
prevent	O
and	O
treat	O
radiation	O
stomatitis,	O
has	O
remarkable	O
pharmacological	O
action	O
on	O
various	O
oral	O
inflammation	O
or	O
abiogenetic	O
oral	O
ulcer,	O
which	O
is	O
a	O
perfect	O
medicine	O
for	O
preventing	O
and	O
treating	O
stomatitis	O
.	O


The	O
invention	O
discloses	O
a	O
nucleotide	O
sequence	O
which	O
aims	O
at	O
the	O
specificity	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
of	O
relative	O
antigen	O
of	O
diffuse	O
large	O
b-cell	O
lymphoma	O
and	O
the	O
application,	O
TCR	B-GENE
V	I-GENE
beta	I-GENE
13	I-GENE
sub-family	I-GENE
in	O
peripheral	O
blood	O
of	O
DLBL	O
patients	O
is	O
scanned	O
and	O
analyzed	O
to	O
take	O
obvious	O
monoclone	O
through	O
RT-PCR	O
gens,	O
a	O
V-NDN-J	O
area	O
of	O
specificity	O
TCR	O
sequence	O
for	O
sequencing	O
PCR	O
products	O
namely	O
a	O
complementary-determining	O
region	O
3	O
is	O
a	O
portion	O
which	O
combines	O
with	O
antigen	O
specificity	O
recognition,	O
which	O
expresses	O
specificity	O
TCR	O
which	O
is	O
produced	O
by	O
the	O
stimulation	O
of	O
TCR	O
of	O
clonal	O
T	B-GENE
cell	I-GENE
for	O
relative	O
antigen	O
of	O
DLBL	O
.	O
The	O
nucleotide	O
sequence	O
is	O
a	O
base	O
and	O
a	O
key	O
for	O
adoptive	O
cellular	O
immunotherapy	O
of	O
DLBL	O
molecular	O
target	O
through	O
TCR	O
transgenic	O
technology	O
.	O
The	O
nucleotide	O
sequence	O
of	O
the	O
specificity	O
TCR	O
is	O
an	O
important	O
base	O
for	O
further	O
developing	O
specific	O
cell	O
immunization	O
therapy	O
which	O
aims	O
at	O
lymphoma	O
.	O


A	O
slow	O
release	O
anticancer	O
injection	O
carrying	O
clofarabine	O
and	O
a	O
synergist	O
thereof	O
comprises	O
slow	O
release	O
microspheres	O
and	O
a	O
solvent,	O
wherein	O
the	O
slow	O
release	O
microspheres	O
comprise	O
effective	O
anticancer	O
ingredients	O
and	O
slow	O
release	O
adjuvants,	O
and	O
the	O
solvent	O
is	O
a	O
special	O
solvent	O
containing	O
a	O
suspending	O
agent	O
.	O
The	O
effective	O
anticancer	O
ingredients	O
comprise	O
the	O
clofarabine	O
and	O
a	O
clofarabine	O
synergist	O
selected	O
from	O
phosphoinositol-3-kinase	B-GENE
inhibitor,	O
pyrimidine	O
analogues	O
and	O
/	O
or	O
DNA	B-GENE
repairase	I-GENE
inhibitor	O
;	O
the	O
slow	O
release	O
adjuvants	O
comprise	O
biocompatible	O
polymers	O
such	O
as	O
polylactic	O
acid	O
(	O
PLA	O
)	O
and	O
copolymers	O
thereof,	O
polylactic	O
acid-polyethylene	O
glycol	O
(	O
PEG	O
)	O
-COOH	O
copolymers,	O
fatty	O
acid	O
dimmer-sebacic	O
acid	O
copolymers,	O
polys	O
(	O
erucic	O
acid	O
dimmer-sebacic	O
acid	O
)	O
,	O
polys	O
(	O
fumaric	O
acid-sebacic	O
acid	O
)	O
,	O
polifeprosan,	O
polylactic	O
acid	O
and	O
EVAc	O
;	O
the	O
suspending	O
agent	O
has	O
viscosity	O
of	O
100-3,000cp	O
(	O
at	O
20-30	O
DEG	O
C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethyl	O
cellulose,	O
etc	O
.	O
The	O
effective	O
anticancer	O
ingredients	O
and	O
the	O
slow	O
release	O
microspheres	O
can	O
also	O
be	O
made	O
into	O
slow	O
release	O
implant,	O
and	O
the	O
slow	O
release	O
injection	O
and	O
implant	O
can	O
be	O
injected	O
into	O
tumor	O
or	O
around	O
tumor	O
to	O
effectively	O
inhibit	O
tumor	O
growth	O
and	O
remarkably	O
strengthen	O
the	O
effect	O
of	O
non-surgery	O
treatments	O
as	O
chemotherapy	O
or	O
the	O
like	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I-A	O
)	O
medicaments	O
containing	O
them	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutically	O
active	O
agents	O
.	O
The	O
compounds	O
exhibit	O
activity	O
as	O
Raf	B-GENE
kinase	I-GENE
inhibitors	O
and	O
therefore	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
said	O
kinases,	O
especially	O
as	O
anticancer	O
agents	O
.	O


The	O
invention	O
relates	O
to	O
a	O
medicine	O
with	O
icaritin	O
as	O
active	O
component	O
for	O
treating	O
obesity	O
or	O
fatty	O
livers	O
.	O
The	O
pharmacological	O
experiment	O
shows	O
that	O
the	O
icaritin	O
is	O
an	O
effective	O
fatty	B-GENE
acid	I-GENE
synthetase	I-GENE
inhibitor	O
;	O
can	O
inhibit	O
food	O
intake	O
and	O
reduce	O
weight	O
of	O
DIO	O
mice	O
;	O
reduce	O
adipose	O
degeneration	O
of	O
the	O
livers	O
;	O
and	O
reduce	O
the	O
degree	O
of	O
ischemia	O
/	O
reperfusion	O
injuries	O
of	O
the	O
livers	O
with	O
adipose	O
degeneration	O
.	O
The	O
acute	O
toxicity	O
test	O
of	O
the	O
icaritin	O
on	O
the	O
mice	O
shows	O
that	O
the	O
icaritin	O
has	O
no	O
toxicity	O
.	O
Therefore,	O
the	O
icaritin	O
has	O
wide	O
development	O
prospect,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
new	O
drugs	O
for	O
treating	O
obesity	O
or	O
fatty	O
liver	O
.	O


The	O
invention	O
discloses	O
the	O
application	O
of	O
thunder	O
god	O
vine	O
monomeric	O
compound	O
in	O
improving	O
the	O
efficiency	O
of	O
the	O
adeno-associated	O
virus	O
vector	O
mediated	O
gene	O
expression,	O
and	O
also	O
discloses	O
the	O
application	O
of	O
the	O
thunder	O
god	O
vine	O
monomeric	O
compound	O
in	O
the	O
adjuvant	O
therapy	O
for	O
neurodegenerative	O
diseases	O
.	O
The	O
thunder	O
god	O
vine	O
monomeric	O
compound,	O
in	O
particular	O
to	O
Triptolide,	O
can	O
remarkably	O
improve	O
the	O
transduction	O
efficiency	O
of	O
2-typed	O
recombinant	O
adeno-associated	O
virus	O
on	O
a	O
plurality	O
of	O
nerve	O
cell	O
systems,	O
primary	O
nerve	O
cells	O
and	O
midbrain	O
nervous	O
tissues	O
of	O
rats	O
.	O
In	O
addition,	O
the	O
thunder	O
god	O
vine	O
monomeric	O
compound	O
can	O
inhibit	O
the	O
activation	O
of	O
microglia,	O
reduce	O
the	O
production	O
of	O
proinflammatory	O
cytokine,	O
increase	O
the	O
generation	O
of	O
neurotrophic	B-GENE
factors	I-GENE
and	O
have	O
protection	O
effect	O
on	O
dopaminergic	O
neuron	O
and	O
can	O
be	O
used	O
for	O
adjuvant	O
therapy	O
for	O
neurodegenerative	O
diseases	O
.	O
The	O
invention	O
effectively	O
overcomes	O
the	O
bottleneck	O
problem	O
in	O
the	O
gene	O
treatment	O
of	O
AAV-mediated	O
neuropathy,	O
fully	O
combines	O
the	O
protection	O
effect	O
of	O
the	O
thunder	O
god	O
vine	O
monomeric	O
compound	O
on	O
nerve	O
cells	O
with	O
the	O
assistant	O
synergy	O
effect	O
on	O
virus	O
vector	O
and	O
reduces	O
the	O
potential	O
immune	O
side	O
effect	O
and	O
application	O
cost	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
3-hydroxy	O
fatty	O
acid	O
and	O
derivatives	O
thereof	O
in	O
the	O
preparation	O
of	O
calcium	B-GENE
ion	I-GENE
channel	I-GENE
regulator	O
.	O
An	O
in	O
vitro	O
test	O
indicates	O
that	O
the	O
calcium	B-GENE
ion	I-GENE
channel	I-GENE
regulator	O
promotes	O
neuroglia	O
cell	O
growth	O
and	O
activates	O
cell	O
calcium	B-GENE
ion	I-GENE
channel	I-GENE
;	O
and	O
can	O
be	O
used	O
for	O
treating	O
disease	O
correlated	O
to	O
insufficient	O
activation	O
of	O
the	O
calcium	B-GENE
ion	I-GENE
channel,	O
and	O
used	O
for	O
culturing	O
cell	O
in	O
vitro,	O
particularly	O
neuroglia	O
cell	O
.	O


Disclosed	O
is	O
a	O
method	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
rheumatoid	O
arthritis,	O
which	O
is	O
characterized	O
by	O
administering	O
an	O
IL-1beta	B-GENE
inhibitor	O
and	O
a	O
calcineurin	B-GENE
inhibitor	O
.	O
Also	O
disclosed	O
is	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
rheumatoid	O
arthritis,	O
which	O
comprises	O
a	O
combination	O
of	O
an	O
IL-1beta	B-GENE
inhibitor	O
and	O
a	O
calcineurin	B-GENE
inhibitor	O
.	O
A	O
therapeutic	O
agent	O
for	O
rheumatoid	O
arthritis	O
and	O
a	O
method	O
for	O
treatment	O
of	O
rheumatoid	O
arthritis	O
can	O
be	O
provided	O
which	O
produce	O
little	O
adverse	O
side	O
effects	O
and	O
have	O
an	O
excellent	O
arthritis-preventive	O
effect	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
medicinal	O
technical	O
field	O
and	O
particularly	O
relates	O
to	O
a	O
target	O
protein	O
for	O
screening	O
antituberculosis	O
drugs	O
.	O
The	O
target	O
protein	O
is	O
an	O
indole-3-glycerophosphoric	B-GENE
acid	I-GENE
synthetase	I-GENE
IGPS	B-GENE
sourcing	O
from	O
tubercule	O
bacillus	O
H37Rv	O
.	O
A	O
inhibitor	O
compound	O
I	O
(	O
N-phenyl-6-piperidino-N	O
'	O
-quinine-8-	O
pyridazine-1,3,5-triazine-2,4-diamine	O
)	O
and	O
a	O
compound	O
II	O
(	O
5-	O
[	O
3-	O
(	O
3,5-dimethyl-1-hydrogen-pyrazole	O
)	O
-2-hydroxy-propoxy	O
]	O
-2-methyl-1-	O
(	O
p-benzyl	O
)	O
indole-3-carboxylic	O
acid	O
)	O
of	O
the	O
target	O
protein	O
of	O
the	O
target	O
protein	O
can	O
remarkably	O
inhibit	O
the	O
growth	O
of	O
tubercule	O
bacillus	O
in	O
a	O
in-vitro	O
inhibition	O
experiment	O
for	O
the	O
growth	O
of	O
tubercule	O
bacillus,	O
wherein	O
the	O
compound	O
I	O
has	O
a	O
minimal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
625	O
mu	O
g	O
/	O
ml	O
concerning	O
the	O
tubercule	O
bacillus	O
H37Rv,	O
the	O
compound	O
II	O
has	O
a	O
minimal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
mu	O
g	O
/	O
ml	O
concerning	O
the	O
tubercule	O
bacillus	O
H37Rv,	O
the	O
compound	O
I	O
and	O
the	O
compound	O
II	O
both	O
have	O
a	O
minimal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
1mu	O
g	O
/	O
ml	O
concerning	O
the	O
standard	O
strain	O
H37Rv,	O
and	O
the	O
compound	O
I	O
and	O
the	O
compound	O
II	O
both	O
have	O
a	O
minimal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
1mu	O
g	O
/	O
ml	O
concerning	O
the	O
clinical	O
drug-resistant	O
strain	O
of	O
tubercule	O
bacillus	O
.	O


The	O
invention	O
relates	O
to	O
a	O
constitutional	O
formula	O
of	O
receptor	O
antagonist	O
and	O
/	O
or	O
inverse	O
agonist	O
of	O
novel	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
1	I-GENE
(	O
CB1	B-GENE
)	O
receptor	O
shown	O
in	O
the	O
right	O
formula	O
(	O
I	O
)	O
,	O
the	O
preparation	O
method	O
and	O
the	O
application	O
thereof	O
.	O
The	O
compounds	O
can	O
be	O
used	O
for	O
curing,	O
preventing	O
or	O
relieving	O
CB1	B-GENE
receptor	I-GENE
mediated	O
diseases	O
.	O
The	O
compounds	O
and	O
the	O
pharmaceutically-acceptable	O
salts	O
thereof	O
can	O
be	O
used	O
for	O
curing,	O
preventing	O
or	O
relieving	O
obesity,	O
diabetes,	O
drug	O
dependence,	O
cognitive	O
deficit,	O
neurological	O
disease,	O
gastrointestinal	O
tract	O
disease	O
and	O
liver	O
cirrhosis	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
pharmaceutical	O
field,	O
and	O
relates	O
to	O
a	O
derivative	O
of	O
7-Alpha-substituted	O
phenyl-tetrahydrothebaine	O
shown	O
in	O
formula	O
(	O
I	O
)	O
and	O
the	O
pharmaceutically-accepted	O
salts	O
thereof	O
.	O
The	O
derivative	O
shown	O
in	O
formula	O
(	O
I	O
)	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
:	O
reacting	O
with	O
substituted	O
styrene	O
reagent	O
via	O
thebaine,	O
and	O
then	O
subjecting	O
to	O
the	O
related	O
conversion	O
.	O
According	O
to	O
the	O
results	O
of	O
the	O
animal	O
experiment,	O
the	O
compound	O
has	O
analgesic	O
activity,	O
wherein	O
7-Alpha-	O
(	O
4	O
'	O
-amino-phenyl	O
)	O
-6-Alpha,	O
14-Alpha-endo-vinylidene-tetrahydrothebaine	O
hydrochloride	O
(	O
LQ004C	O
)	O
has	O
an	O
activity	O
to	O
the	O
isolated	O
tissue,	O
which	O
is	O
similar	O
to	O
butophanol	O
tartrate,	O
and	O
is	O
a	O
typical	O
Kappa	B-GENE
excitant	O
;	O
and	O
the	O
compound	O
exhibits	O
remarkable	O
analgesic	O
activity	O
in	O
the	O
mice	O
acetic	O
acid	O
writhing	O
method	O
and	O
the	O
mice	O
heat	O
radiation	O
tail-flick	O
method,	O
and	O
can	O
be	O
further	O
prepared	O
into	O
low-addiction	O
analgetics	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medical	O
technology,	O
in	O
particular	O
to	O
a	O
medical	O
usage	O
of	O
ophiopogonin	O
D,	O
namely	O
the	O
usage	O
of	O
the	O
ophiopogonin	O
D	O
as	O
tissue	B-GENE
factor	I-GENE
pathway	O
inhibitor	O
agent	O
.	O
The	O
ophiopogonin	O
D	O
can	O
be	O
used	O
for	O
curing	O
cardiovascular	O
and	O
cerebrovascular	O
diseases,	O
coagulopathy,	O
invasive	O
therapeutic	O
procedures,	O
tumor	O
metastasis,	O
diabetes	O
and	O
so	O
on	O
.	O


The	O
invention	O
discloses	O
a	O
livestock	O
used	O
compound	O
cordate	O
houttuynia	O
herba	O
injection	O
solution	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
invention	O
aims	O
to	O
provide	O
the	O
beast	O
used	O
compound	O
cordate	O
houttuynia	O
herba	O
injection	O
solution	O
for	O
remedying	O
mastitis	O
and	O
central	O
prolactin	B-GENE
hyposecretion	O
which	O
can	O
cure	O
both	O
the	O
symptoms	O
and	O
root	O
cause	O
of	O
the	O
diseases,	O
and	O
the	O
preparation	O
method	O
which	O
has	O
simple	O
technology	O
and	O
is	O
easy	O
to	O
be	O
realized	O
.	O
For	O
every	O
100L,	O
the	O
injection	O
solution	O
is	O
made	O
from	O
the	O
following	O
components	O
of	O
100-300kg	O
of	O
cordate	O
houttuynia	O
herba,	O
0	O
.	O
1-1kg	O
of	O
hydrochloric	O
acid	O
metoclopramide	O
paspertin,	O
0	O
.	O
2kg	O
of	O
hydrosulphite	O
of	O
sodium,	O
0	O
.	O
01kg	O
of	O
EDTA-2Na	O
and	O
injection	O
water	O
for	O
the	O
surplus	O
proportions	O
.	O
The	O
invention	O
is	O
the	O
compound	O
preparation	O
of	O
the	O
cordate	O
houttuynia	O
herba	O
and	O
the	O
hydrochloric	O
acid	O
metoclopramide	O
paspertin	O
which	O
is	O
used	O
to	O
stimulate	O
the	O
central	O
prolactin	B-GENE
to	O
secrete	O
latex	O
.	O
The	O
combination	O
use	O
of	O
the	O
cordate	O
houttuynia	O
herba	O
and	O
the	O
hydrochloric	O
acid	O
metoclopramide	O
paspertin	O
has	O
high	O
efficiency	O
to	O
livestock	O
mastitis	O
and	O
central	O
prolactin	B-GENE
hyposecretion,	O
can	O
avoid	O
the	O
adverse	O
effect	O
to	O
pups,	O
can	O
reduce	O
the	O
incidence	O
rate	O
of	O
diseases,	O
and	O
can	O
improve	O
milkability	O
.	O


The	O
invention	O
provides	O
the	O
application	O
of	O
the	O
compound	O
MG132	O
in	O
preparing	O
the	O
drug	O
to	O
synergistically	O
promote	O
the	O
retinoic	O
acid	O
drug	O
for	O
the	O
differentiation	O
induction	O
therapy	O
of	O
leukemia	O
.	O
The	O
molecular	O
formula	O
of	O
the	O
compound	O
MG132	O
is	O
C26H41N3O5,	O
the	O
concentration	O
of	O
the	O
compound	O
MG132	O
is	O
1	O
*	O
10	O
<	O
-8	O
>	O
to	O
1	O
*	O
10	O
<	O
-6	O
>	O
M,	O
and	O
the	O
concentration	O
of	O
the	O
retinoic	O
acid	O
is	O
1	O
*	O
10	O
<	O
-9	O
>	O
to	O
1	O
*	O
10	O
<	O
-5	O
>	O
M	O
.	O
The	O
compound	O
MG132	O
with	O
the	O
single	O
effect	O
can	O
not	O
induce	O
the	O
leukemia	O
cells	O
to	O
be	O
differentiated,	O
but	O
promote	O
the	O
differentiation	O
induction	O
effect	O
of	O
the	O
retinoic	O
acid	O
drug	O
on	O
the	O
leukemia	O
cells,	O
which	O
is	O
presented	O
as	O
the	O
promotion	O
of	O
the	O
anti-proliferative	O
effect	O
and	O
the	O
cell	O
cycle	O
arresting	O
effect	O
of	O
the	O
retinoic	O
acid	O
drug	O
on	O
the	O
leukemia	O
cells,	O
promote	O
the	O
expression	O
of	O
the	O
differentiation	O
specific	O
antigen	O
CD11b	B-GENE
on	O
the	O
leukemia	O
cell	O
surface,	O
and	O
increasing	O
the	O
number	O
of	O
segmented	O
cells	O
.	O
The	O
invention	O
opens	O
up	O
the	O
new	O
drug	O
application	O
field	O
of	O
the	O
compound	O
MG132	O
.	O


The	O
invention	O
belongs	O
to	O
a	O
nasal	O
cavity	O
preparation	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
temperature-sensitive	O
type	O
in-situ	O
gel	O
nasal	O
administration	O
preparation	O
for	O
curing	O
osteoporosis	O
.	O
The	O
temperature-sensitive	O
type	O
high	O
molecular	O
compound	O
material	O
is	O
soaked	O
in	O
a	O
proper	O
amount	O
of	O
a	O
potassium	O
biphthalate	O
buffer	O
solution	O
with	O
the	O
pH	O
value	O
being	O
2	O
.	O
5	O
to	O
4	O
.	O
5	O
for	O
20	O
to	O
24	O
hours	O
at	O
the	O
room	O
temperature,	O
then	O
an	O
absorption	O
enhancer,	O
a	O
solubilizing	O
agent,	O
a	O
conserving	O
agent,	O
an	O
odour	O
counteracting	O
agent	O
and	O
an	O
enzyme	O
inhibitor	O
are	O
added	O
and	O
uniformly	O
stirred,	O
then	O
are	O
shocked	O
by	O
an	O
ultrasonoscope	O
for	O
5	O
to	O
10	O
minutes	O
to	O
be	O
fully	O
dissolved,	O
then	O
the	O
formula	O
dosage	O
of	O
vitamin	O
K	O
and	O
osteogenic	B-GENE
growth	I-GENE
peptide	I-GENE
raw	O
materials	O
are	O
added	O
to	O
the	O
solution	O
to	O
be	O
uniformly	O
stirred,	O
the	O
volume	O
is	O
measured,	O
and	O
then	O
canning	O
and	O
sealing	O
are	O
performed	O
to	O
obtain	O
the	O
nasal	O
cavity	O
preparation	O
.	O
The	O
compound	O
preparation	O
has	O
the	O
advantages	O
that	O
the	O
administration	O
is	O
convenient,	O
the	O
drug	O
is	O
not	O
easy	O
to	O
run	O
off	O
from	O
the	O
nasal	O
cavity,	O
the	O
detention	O
time	O
of	O
the	O
drug	O
in	O
the	O
nasal	O
cavity	O
can	O
be	O
prolonged,	O
and	O
the	O
bioavailability	O
of	O
the	O
osteogenic	B-GENE
growth	I-GENE
peptide	I-GENE
is	O
enhanced,	O
while	O
the	O
vitamin	O
K	O
can	O
obviously	O
enhance	O
and	O
promote	O
the	O
osteogenesis	O
effect	O
of	O
the	O
osteogenic	B-GENE
growth	I-GENE
peptide	I-GENE
to	O
ensure	O
that	O
the	O
osteogenesis	O
effect	O
of	O
the	O
osteogenic	B-GENE
growth	I-GENE
peptide	I-GENE
can	O
be	O
greatly	O
enhanced	O
.	O


The	O
invention	O
relates	O
to	O
a	O
target	O
protein	O
for	O
resisting	O
cataract	O
and	O
the	O
application	O
thereof	O
.	O
The	O
change	O
rule	O
of	O
a	O
crystallin	B-GENE
beta	I-GENE
B2	I-GENE
with	O
special	O
expression	O
and	O
special	O
distribution	O
along	O
with	O
the	O
body	O
aging	O
process	O
is	O
discovered	O
according	O
to	O
the	O
phase	O
change	O
of	O
the	O
crystallin,	O
and	O
the	O
crystallin	O
is	O
determined	O
as	O
the	O
more	O
appropriate	O
target	O
protein	O
for	O
resisting	O
cataract	O
.	O
Also	O
discovered	O
is	O
that	O
dithiothreitol	O
is	O
the	O
substance	O
capable	O
of	O
effectively	O
inhibiting	O
denaturation	O
by	O
heat	O
of	O
crystallins	B-GENE
such	O
as	O
beta	O
B2	I-GENE
.	O
Accordingly,	O
corresponding	O
anti-cataract	O
products	O
can	O
be	O
prepared	O
by	O
selecting	O
the	O
target	O
protein	O
as	O
the	O
target	O
point	O
and	O
using	O
dithiothreitol	O
and	O
composition	O
thereof	O
as	O
the	O
raw	O
materials	O
.	O
Cataract	O
disease	O
is	O
an	O
important	O
pathogenic	O
reason	O
influencing	O
the	O
quality	O
of	O
life	O
of	O
Chinese	O
people	O
.	O
The	O
beta	O
B2	I-GENE
is	O
determined	O
as	O
the	O
target	O
protein	O
with	O
wide	O
application,	O
and	O
provides	O
the	O
direction	O
for	O
the	O
development	O
of	O
new	O
drugs	O
.	O
The	O
developed	O
product	O
is	O
mainly	O
used	O
for	O
prevention,	O
and	O
is	O
used	O
externally	O
in	O
combination	O
.	O
A	O
novel	O
drug	O
resource	O
is	O
provided,	O
and	O
is	O
the	O
effective	O
product	O
for	O
preventing,	O
diagnosing	O
and	O
treating	O
denaturation	O
of	O
crystallin	O
or	O
cataract	O
and	O
other	O
related	O
diseases,	O
thereby	O
generating	O
remarkable	O
social	O
and	O
economic	O
benefits	O
.	O


The	O
invention	O
discloses	O
compounds	O
of	O
formula	O
I,	O
wherein	O
one	O
of	O
R1	O
and	O
R2	O
is	O
thienyl	O
which	O
is	O
substituted	O
by	O
halogen	O
and	O
the	O
other	O
of	O
R1	O
and	O
R2	O
is	O
substituted	O
phenyl,	O
wherein	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
claims,	O
with	O
the	O
proviso	O
that	O
the	O
phenyl	O
group	O
is	O
substituted	O
by	O
at	O
least	O
a	O
cyano,	O
carboxy	O
or	O
(	O
C1-4	O
)	O
alkyloxycarbonyl	O
group	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
CCR9	B-GENE
activity	O
and	O
are	O
useful	O
for	O
therapeutic	O
treatment	O
.	O


The	O
invention	O
relates	O
to	O
a	O
process	O
formula,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
a	O
nutritional	O
weight-reduction	O
tablet	O
candy	O
.	O
The	O
total	O
components	O
are	O
considered	O
as	O
100	O
based	O
on	O
dry	O
weight,	O
the	O
raw	O
and	O
subsidiary	O
materials	O
of	O
the	O
formula	O
are	O
as	O
follows	O
:	O
0	O
.	O
2-0	O
.	O
5	O
part	O
of	O
sucralose	O
;	O
90-10	O
parts	O
of	O
dietary	O
fiber	O
;	O
5-90	O
parts	O
of	O
a	O
kidney	B-GENE
bean	I-GENE
extract	I-GENE
alpha-amylase	I-GENE
blocker	O
and	O
0	O
.	O
1-0	O
.	O
5	O
part	O
of	O
citrus	O
essence	O
.	O
After	O
the	O
raw	O
and	O
auxiliary	O
materials	O
are	O
respectively	O
sieved,	O
weighed	O
and	O
mixed	O
according	O
to	O
a	O
preferable	O
formula	O
in	O
the	O
range,	O
2	O
%	O
-5	O
%	O
of	O
hydroxypropyl	O
emthylcellulose	O
aqueous	O
solution	O
is	O
taken	O
as	O
an	O
adhesive	O
for	O
granulation,	O
and	O
1-4	O
parts	O
of	O
magnesium	O
stearate	O
is	O
added	O
as	O
a	O
glidant,	O
and	O
then	O
the	O
finished	O
product	O
is	O
obtained	O
by	O
tabletting	O
.	O
The	O
candy	O
has	O
excellent	O
taste,	O
can	O
be	O
taken	O
as	O
a	O
daily	O
nutritional	O
dietary	O
fiber	O
supplement,	O
and	O
has	O
the	O
functions	O
of	O
reducing	O
blood	O
lipid	O
and	O
blood	O
sugar,	O
reducing	O
weight,	O
relaxing	O
the	O
bowels,	O
etc	O
.	O
The	O
candy	O
has	O
the	O
advantages	O
of	O
being	O
convenient	O
and	O
simple	O
to	O
carry,	O
operate	O
and	O
store,	O
and	O
has	O
long	O
service	O
life,	O
and	O
is	O
a	O
favorable	O
nutritional	O
weight-reduction	O
tablet	O
candy	O
.	O


The	O
invention	O
discloses	O
a	O
shikimic	O
acid	O
used	O
for	O
the	O
new	O
usage	O
of	O
preparing	O
the	O
medicine	O
for	O
treating	O
ulcerative	O
colitis	O
.	O
By	O
utilizing	O
rat	O
ethanoic	O
acid	O
colitis	O
model,	O
the	O
function	O
of	O
shikimic	O
acid	O
for	O
treating	O
ulcerative	O
colitis	O
is	O
inspected,	O
and	O
the	O
shikimic	O
acid	O
is	O
found	O
to	O
have	O
the	O
function	O
of	O
effectively	O
improving	O
the	O
symptoms	O
such	O
as	O
rat	O
diarrhoea,	O
bloody	O
stool,	O
weight	O
lose	O
and	O
colon	O
histomorphology	O
change	O
;	O
the	O
shikimic	O
acid	O
has	O
scavenging	O
action	O
on	O
neutrophilic	O
granulocyte	O
of	O
colonic	O
structure,	O
can	O
obviously	O
reduce	O
the	O
content	O
of	O
MDA	O
and	O
NO	O
in	O
the	O
rat	O
colonic	O
structure	O
of	O
colonitis	O
and	O
the	O
activity	O
of	O
T-NOS	O
and	O
iNOS,	O
and	O
enhance	O
the	O
level	O
of	O
SOD	B-GENE
.	O
Therefore,	O
the	O
shikimic	O
acid	O
can	O
be	O
used	O
for	O
preparing	O
the	O
medicine	O
for	O
treating	O
ulcerative	O
colitis	O
.	O


The	O
invention	O
discloses	O
a	O
protein	O
segment	O
of	O
programmed	B-GENE
death	I-GENE
protein	I-GENE
2	I-GENE
analog,	O
namely,	O
the	O
protein	O
of	O
region	O
1,	O
and	O
the	O
application	O
of	O
the	O
protein	O
of	O
the	O
region	O
1	O
in	O
preparing	O
drugs	O
for	O
curing	O
bacterial	O
inflammation	O
of	O
the	O
programmed	B-GENE
death	I-GENE
protein	I-GENE
2	I-GENE
analog	O
.	O
The	O
protein	O
of	O
region	O
1	O
of	O
the	O
death	O
programmed	B-GENE
protein	I-GENE
2	I-GENE
analog	O
realizes	O
the	O
function	O
of	O
restraining	O
the	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
Alpha	I-GENE
of	O
a	O
pro-inflammatory	O
cytokine	O
caused	O
by	O
bacterial	O
LPS,	O
thereby	O
restraining	O
the	O
generating	O
and	O
developing	O
of	O
the	O
inflammations	O
caused	O
by	O
bacteria	O
.	O


The	O
invention	O
relates	O
a	O
powder	O
preparation	O
of	O
Docetaxel	O
nanoparticles	O
which	O
is	O
stabilized	O
by	O
albumin	B-GENE
and	O
the	O
application	O
thereof	O
in	O
curing	O
tumor	O
sensitive	O
to	O
Docetaxel	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
3,14,9-acetyl	O
andrographolide	O
in	O
the	O
preparation	O
of	O
an	O
proinflammatory	O
cytokine,	O
wherein,	O
the	O
proinflammatory	O
cytokine	B-GENE
comprises	O
any	O
one	O
of	O
TNF-Alpha,	O
IL-1Alpha,	O
IL-1Beta,	O
IL-2,	O
IL-4,	O
IL-6,	O
IL-8,	O
IL-10,	O
IFN-Gamma	B-GENE
and	O
NO	O
.	O


The	O
invention	O
relates	O
to	O
neuronal	B-GENE
nicotinic	I-GENE
receptor	I-GENE
ligands,	O
methods	O
of	O
identifying	O
such	O
ligands	O
for	O
neuronal	B-GENE
nicotinic	I-GENE
receptor	I-GENE
modulation,	O
particularly	O
such	O
ligands	O
demonstrating	O
beneficial	O
side	O
effect	O
tolerability,	O
and	O
methods	O
of	O
using	O
such	O
neuronal	B-GENE
nicotinic	I-GENE
receptor	I-GENE
ligands	O
to	O
provide	O
pharmaceutical	O
compositions	O
and	O
products	O
.	O


The	O
invention	O
relates	O
to	O
a	O
use	O
of	O
a	O
pharmaceutical	O
composition	O
containing	O
an	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitor	O
and	O
a	O
vitamin	O
in	O
vitamin	O
B	O
family	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
body	O
injuries	O
and	O
the	O
related	O
diseases	O
caused	O
by	O
hyperhomocysteinemia	O
(	O
brain	O
stroke,	O
ischemic	O
heart	O
disease,	O
deep	O
vein	O
thrombosis,	O
and	O
the	O
like	O
)	O
,	O
in	O
particular	O
to	O
the	O
drugs	O
for	O
treating	O
the	O
brain	O
stroke	O
.	O
The	O
combined	O
use	O
of	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitor	O
and	O
the	O
vitamin	O
in	O
the	O
vitamin	O
B	O
family	O
can	O
further	O
inhibit	O
the	O
proliferation	O
of	O
VSMC,	O
improve	O
the	O
symptoms	O
of	O
cerebral	O
ischemia	O
and	O
be	O
better	O
than	O
the	O
single	O
use	O
of	O
the	O
drug,	O
thereby	O
showing	O
that	O
the	O
combined	O
use	O
of	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitor	O
and	O
the	O
vitamin	O
in	O
the	O
vitamin	O
B	O
can	O
be	O
acted	O
on	O
the	O
different	O
routes	O
and	O
the	O
links	O
for	O
delaying	O
/	O
treating	O
the	O
body	O
injuries	O
and	O
the	O
related	O
diseases	O
caused	O
by	O
Hcy	O
and	O
further	O
having	O
the	O
overlapping	O
effect	O
or	O
the	O
synergy	O
.	O
At	O
present,	O
the	O
single	O
use	O
of	O
folic	O
acid	O
does	O
not	O
have	O
ideal	O
effect	O
in	O
the	O
clinical	O
treatment	O
of	O
high	O
Hcy,	O
the	O
compound	O
drug	O
can	O
be	O
a	O
better	O
choice	O
and	O
can	O
provide	O
a	O
more	O
effective	O
treatment	O
proposal	O
for	O
treating	O
the	O
hyperhomocysteinemia	O
.	O
The	O
use	O
belongs	O
to	O
the	O
field	O
of	O
pharmacy	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
medical	O
technology	O
field,	O
more	O
particularly	O
relates	O
to	O
a	O
dipeptidase-IV	B-GENE
depressor	O
derivative	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
salt	O
thereof	O
acceptable	O
in	O
pharmacy,	O
or	O
isomers	O
thereof	O
;	O
wherein,	O
Ar,	O
X,	O
Y,	O
Z,	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
and	O
R	O
<	O
3	O
>	O
are	O
defined	O
in	O
the	O
specification	O
;	O
the	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compounds,	O
the	O
medicine	O
combination	O
containing	O
the	O
compounds	O
and	O
the	O
application	O
of	O
the	O
compounds	O
for	O
preparing	O
medicines	O
used	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
diabetes,	O
non-insulin-dependent	O
diabetes,	O
high	O
blood-sugar	O
and	O
insulin	B-GENE
resistance	O
.	O


Macrocyclic	O
compounds	O
having	O
the	O
structures	O
described	O
herein	O
are	O
useful	O
for	O
inhibiting	O
replication	O
of	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
.	O
In	O
preferred	O
embodiments,	O
the	O
compounds	O
are	O
active	O
against	O
both	O
the	O
NS3	B-GENE
protease	I-GENE
and	O
the	O
NS3	B-GENE
helicase	I-GENE
of	O
HCV	O
.	O
Formulae	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
and	O
(	O
V	O
)	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
chemical	O
synthesis,	O
and	O
relates	O
to	O
an	O
inhibitor	O
compound	O
containing	O
benzo	O
2-amino-imidazole	O
skeleton,	O
a	O
method	O
for	O
preparing	O
the	O
same	O
and	O
application	O
thereof	O
.	O
The	O
inhibitor	O
compound	O
contains	O
a	O
new	O
core	O
skeleton	O
of	O
1,	O
2,	O
5-trisubstituted-benzo-2-amino-imidazole	O
.	O
The	O
invention	O
optimizes	O
the	O
effect	O
on	O
activity	O
through	O
different	O
substituents	O
by	O
comparing	O
the	O
time	O
under	O
the	O
guidance	O
of	O
in	O
vivo	O
activity	O
selection	O
and	O
preferably	O
selects	O
a	O
compound	O
which	O
generates	O
obvious	O
inhibition	O
on	O
thrombin	B-GENE
.	O
The	O
synthesis	O
method	O
has	O
simple	O
steps,	O
operations	O
and	O
separations,	O
the	O
reagents	O
used	O
in	O
the	O
method	O
are	O
commonly	O
used	O
reagents,	O
the	O
route	O
is	O
shorter,	O
and	O
each	O
step	O
has	O
higher	O
yield	O
.	O
The	O
obtained	O
target	O
compound	O
has	O
effect	O
on	O
inhibiting	O
the	O
generation	O
of	O
the	O
thrombin	B-GENE
through	O
an	O
activity	O
test	O
.	O


The	O
invention	O
relates	O
to	O
a	O
sodium	B-GENE
ion	I-GENE
channel	I-GENE
blocker	O
compound,	O
a	O
derivative	O
thereof	O
and	O
the	O
new	O
application	O
of	O
medical	O
salts	O
and	O
esters	O
thereof	O
in	O
removing	O
the	O
vivotoxin	O
and	O
biotoxin,	O
in	O
particular	O
to	O
the	O
new	O
application	O
of	O
the	O
compound	O
in	O
removing	O
various	O
harmful	O
chemical	O
components	O
remained	O
in	O
human	O
bodies	O
and	O
organisms	O
.	O
The	O
sodium	B-GENE
ion	I-GENE
channel	I-GENE
blocker	O
mainly	O
refers	O
to	O
:	O
1	O
.	O
an	O
amino	O
perhydro-quinazoline	O
compound	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
;	O
and	O
2	O
.	O
a	O
bi-guanidino	O
hydrogenated	O
purine	O
ring	O
compound	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
The	O
harmful	O
components	O
in	O
the	O
human	O
bodies	O
and	O
organisms	O
removed	O
by	O
the	O
invention	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
the	O
residue	O
of	O
various	O
antibiotics	O
;	O
(	O
2	O
)	O
the	O
residue	O
of	O
various	O
pesticides	O
;	O
(	O
3	O
)	O
the	O
residue	O
of	O
various	O
exogenous	O
hormones	O
;	O
and	O
(	O
4	O
)	O
various	O
inorganic	O
and	O
organic	O
chemical	O
matters	O
harmful	O
to	O
the	O
human	O
bodies	O
.	O


The	O
invention	O
relates	O
to	O
cancer	O
therapy	O
drug	O
sustained-release	O
injection	O
containing	O
gemcitabine	O
.	O
The	O
injection	O
comprises	O
sustained-release	O
microspheres	O
and	O
dissolvent,	O
wherein,	O
the	O
sustained-release	O
microspheres	O
comprise	O
active	O
ingredients	O
for	O
cancer	O
therapy	O
and	O
sustained-release	O
auxiliary	O
materials,	O
and	O
the	O
dissolvent	O
is	O
special	O
dissolvent	O
containing	O
suspending	O
agent	O
.	O
The	O
active	O
ingredients	O
for	O
cancer	O
therapy	O
comprise	O
antimetabolite	O
of	O
gemcitabine	O
or	O
antimetabolite	O
selected	O
from	O
zalcitabine,	O
emtritabine,	O
galocitabine,	O
ibacitabine,	O
ancitabine,	O
decitabine,	O
flurocitabine,	O
enocitabine,	O
imidazoletabine,	O
capecitabine,	O
gemcitabine,	O
fludarabine	O
or	O
cladribine,	O
and	O
/	O
or	O
antimetabolite	O
synergist	O
selected	O
from	O
phosphoinositide	B-GENE
3-kinase	I-GENE
inhibitor,	O
pyrimidine	O
analogs	O
and	O
/	O
or	O
DNA	O
repair	O
enzyme	O
inhibitor	O
;	O
the	O
sustained-release	O
auxiliary	O
materials	O
comprise	O
polifeprosan,	O
bi-fatty	O
acid,	O
decanedioic	O
copolymer,	O
polylactic	O
copolymer	O
and	O
EVAc	O
;	O
the	O
viscocity	O
of	O
the	O
suspending	O
agent	O
is	O
100cp	O
to	O
3000cp	O
(	O
at	O
20	O
to	O
30	O
DEG	O
C	O
)	O
and	O
the	O
suspending	O
agent	O
is	O
selected	O
from	O
sodium	O
carboxymethyl	O
cellulose	O
.	O
The	O
sustained-release	O
microspheres	O
can	O
also	O
be	O
produced	O
into	O
sustained-release	O
implant,	O
and	O
by	O
injecting	O
or	O
positioning	O
the	O
sustained	O
release	O
agent	O
in	O
tumor	O
or	O
tumor	O
margin,	O
the	O
efficacy	O
of	O
non-operative	O
treatment	O
such	O
as	O
radiation	O
treatment	O
and	O
chemical	O
treatment	O
can	O
be	O
enhanced	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
bioflavonoids	O
or	O
polyphenol	O
compounds	O
to	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
.	O
The	O
bioflavonoids	O
or	O
polyphenol	O
compounds	O
can	O
be	O
selected	O
from	O
kaempferol-3-O-rutinoside,	O
dehydrated	O
carthamin	O
yellow	O
B,	O
6-hydroxyl	O
kaempferol-3,	O
6-dioxygen	O
glucoside,	O
(	O
2S	O
)	O
-4	O
'	O
,	O
5-dihydroxyl-6,	O
7-dioxygen	O
flavonone	O
glucoside,	O
rutin,	O
quercetin,	O
vanillina	O
or	O
isovanillin	O
.	O
Through	O
large	O
amount	O
of	O
experiments,	O
the	O
bioflavonoids	O
or	O
polyphenol	O
compounds	O
have	O
activity	O
of	O
interacting	O
with	O
protein	B-GENE
DJ-1	I-GENE
related	O
to	O
the	O
Parkinson	O
diseases	O
.	O
Through	O
further	O
experiments,	O
the	O
bioflavonoids	O
or	O
polyphenol	O
compounds	O
have	O
pharmaceutical	O
activities	O
for	O
resisting	O
oxidative	O
stress,	O
preventing	O
apoptosis	O
of	O
PC12	O
cells	O
or	O
primary	O
nerve	O
cells	O
induced	O
by	O
the	O
oxidative	O
stress,	O
inhibiting	O
active	O
oxygen	O
generation	O
in	O
cells,	O
improving	O
activity	O
of	O
tyrosine	O
hydroxylase,	O
and	O
the	O
like,	O
and	O
can	O
be	O
used	O
for	O
preventing	O
or	O
treating	O
the	O
Parkinson	O
diseases	O
.	O


The	O
invention	O
discloses	O
preparation	O
and	O
application	O
of	O
total	O
alkaloids	O
extract	O
and	O
effective	O
components	O
in	O
peganum	O
plant	O
seeds	O
.	O
The	O
peganum	O
plant	O
(	O
comprising	O
harmel,	O
multisectum	O
peganum	O
and	O
peganum	O
nigellastrum	O
)	O
seeds	O
are	O
heated,	O
refluxed	O
and	O
extracted	O
by	O
ethanol,	O
dissolved	O
along	O
with	O
heat,	O
acidulated	O
by	O
added	O
2	O
to	O
10	O
percent	O
hydrochloric	O
acid,	O
and	O
basified	O
by	O
ammonia	O
water	O
to	O
separate	O
out	O
sediment	O
;	O
and	O
the	O
sediment	O
is	O
dried	O
to	O
obtain	O
the	O
total	O
alkaloids	O
extract	O
mainly	O
containing	O
dehydrogenized	O
peganine	O
and	O
peganine	O
according	O
to	O
a	O
proportion	O
of	O
between	O
0	O
.	O
18	O
to	O
1	O
and	O
4	O
.	O
30	O
to	O
1,	O
wherein	O
the	O
content	O
of	O
the	O
total	O
alkaloids	O
is	O
more	O
than	O
50	O
percent	O
.	O
The	O
total	O
alkaloids	O
extract	O
is	O
separated	O
by	O
chromatography	O
to	O
obtain	O
ten	O
effective	O
monomer	O
components	O
such	O
as	O
the	O
dehydrogenized	O
peganine,	O
the	O
peganine,	O
and	O
the	O
like	O
.	O
Through	O
thin	O
layer	O
chromatography	O
and	O
biological	O
self-developing	O
analysis,	O
the	O
total	O
alkaloids	O
extract	O
and	O
the	O
effective	O
monomer	O
components	O
thereof	O
have	O
the	O
effect	O
of	O
resisting	O
activity	O
of	O
acetylcholine	O
esterase,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicament	O
for	O
resisting	O
the	O
activity	O
of	O
the	O
acetylcholine	B-GENE
esterase	I-GENE
and	O
medicament	O
for	O
treating	O
neurodegenerative	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
somatostatin	O
receptor-mediated	O
tumor	O
targeted	O
pharmaceutical	O
composition	O
which	O
adopts	O
a	O
targeted	O
somatostatin	B-GENE
receptor	I-GENE
functional	O
polypeptide	O
and	O
polyethylene	O
glycol	O
for	O
simultaneously	O
modifying	O
a	O
pharmaceutical	O
carrier,	O
and	O
an	O
anti-tumor	O
drug	O
or	O
/	O
and	O
an	O
anti-angiogenic	O
drug	O
is	O
delivered	O
to	O
the	O
tumor	O
part,	O
thereby	O
enhancing	O
the	O
tumor	O
treatment	O
effect	O
.	O


The	O
present	O
invention	O
relates	O
to	O
4-	O
[	O
5-	O
(	O
2-Amino-ethanesulfonyl	O
)	O
-isoquinolin-7-yl	O
]	O
-phenol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
or	O
the	O
salt	O
thereof	O
as	O
Akt	B-GENE
inhibitors	O
ceptable	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
or	O
the	O
salt	O
thereof	O
as	O
Akt	B-GENE
inhibitors	O
that	O
are	O
antineoplastic	O
and	O
/	O
or	O
antiviral	O
agents	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
composition	O
comprising	O
these	O
compounds	O
and	O
methods	O
for	O
applying	O
these	O
compounds	O
.	O


The	O
invention	O
provides	O
antihypertensive	O
compounds,	O
methods	O
for	O
preparing	O
the	O
same,	O
the	O
pharmaceutical	O
compositions	O
of	O
the	O
same	O
and	O
the	O
uses	O
of	O
the	O
same	O
.	O
The	O
antihypertensive	O
compounds	O
are	O
compounds	O
ofa	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
polycrystals,	O
antipodes	O
or	O
a	O
racemic	O
mixture	O
of	O
the	O
same,	O
wherein	O
R1,	O
R2,	O
R3,	O
and	O
R4	O
are	O
H,	O
substituted	O
alkyls,	O
substituted	O
cyclohexyls,	O
substituted	O
alkylthios,	O
substituted	O
alkoxyls,	O
substituted	O
aryls,	O
substituted	O
aralkyls	O
independently,	O
or	O
R1	O
and	O
R2	O
form	O
substituted	O
cyclohexyls	O
together,	O
or	O
R2	O
and	O
R3	O
form	O
substituted	O
heterocyclyls	O
.	O
The	O
compounds	O
are	O
absorbed	O
by	O
gastrointestinal	O
tracts	O
through	O
the	O
active	O
transportation	O
of	O
a	O
PepT1	O
transporter,	O
and	O
decomposed	O
by	O
enzymes	O
in	O
intestinal	O
tracts	O
and	O
the	O
liver	O
to	O
form	O
iosartan	O
slowly,	O
so	O
the	O
iosartan	O
is	O
kept	O
in	O
the	O
blood	O
for	O
a	O
longer	O
time	O
and	O
stable	O
blood	O
concentration	O
contributes	O
to	O
the	O
improvement	O
of	O
curative	O
effects	O
and	O
reduction	O
of	O
side	O
reactions	O
.	O


The	O
invention	O
relates	O
to	O
an	O
amino	O
acid	O
saccharide	O
compound	O
and	O
application	O
thereof	O
.	O
The	O
design	O
of	O
the	O
amino	O
acid	O
saccharide	O
compound	O
is	O
based	O
on	O
a	O
PTP-1B	B-GENE
double	O
binding	O
site,	O
and	O
the	O
amino	O
acid	O
saccharide	O
compound	O
is	O
obtained	O
by	O
modifying	O
small	O
molecular	O
monosaccharides	O
.	O
An	O
in	O
vitro	O
bioactivity	O
test	O
shows	O
that	O
the	O
amino	O
acid	O
saccharide	O
compound	O
has	O
good	O
activity	O
of	O
inhibiting	O
PTP-1B	B-GENE
and	O
anti-tumor	O
activity	O
.	O
Therefore,	O
the	O
designed	O
and	O
synthesized	O
amino	O
acid	O
saccharide	O
compound	O
has	O
development	O
prospect	O
on	O
novel	O
medicines	O
for	O
treating	O
diabetes	O
and	O
resisting	O
tumor	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
CSAG1	B-GENE
gene	O
which	O
is	O
used	O
for	O
preparing	O
products	O
for	O
diagnosing	O
liver	O
cancer	O
and	O
medicines	O
for	O
treating	O
the	O
cancer	O
.	O
The	O
CSAG1	B-GENE
gene	O
of	O
the	O
invention	O
can	O
be	O
used	O
as	O
the	O
peculiar	O
marker	O
gene	O
for	O
diagnosing	O
liver	O
cancer,	O
facilitates	O
the	O
diagnosis	O
on	O
the	O
liver	O
cancer	O
to	O
be	O
more	O
accurate	O
and	O
rapid	O
and	O
provides	O
new	O
therapeutic	O
targets	O
and	O
effective	O
medicines	O
for	O
preventing	O
and	O
treating	O
liver	O
cancer	O
.	O


The	O
invention	O
discloses	O
3-	O
(	O
2-carboxylbenzoyl	O
)	O
-oleanolic	O
acid	O
or	O
physiologically	O
acceptable	O
salt	O
of	O
the	O
same,	O
application	O
of	O
the	O
same	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
.	O
The	O
compound	O
has	O
inhibition	O
effect	O
on	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
1B	I-GENE
(	O
PTP1B	B-GENE
)	O
and	O
11beta-hydroxysteriod	B-GENE
dehydrogenase	I-GENE
1	I-GENE
(	O
11beta-HSD1	B-GENE
)	O
,	O
has	O
antagonism	O
effect	O
on	O
a	O
glucocorticoid	B-GENE
receptor	I-GENE
(	O
GR	B-GENE
)	O
,	O
has	O
agonistic	O
effect	O
on	O
nuclear	O
receptor	O
LXRa	B-GENE
:	O
RXRa	B-GENE
heterodimer,	O
and	O
can	O
also	O
strengthen	O
the	O
expression	O
of	O
glucose	B-GENE
transporter	I-GENE
4	I-GENE
(	O
Glut4	B-GENE
)	O
at	O
the	O
same	O
time	O
.	O
A	O
whole	O
animal	O
experiment	O
shows	O
that	O
the	O
compound	O
has	O
hypoglycemic	O
activity	O
.	O
Therefore,	O
the	O
3-	O
(	O
2-carboxylbenzoyl	O
)	O
-oleanolic	O
acid	O
or	O
the	O
physiologically	O
acceptable	O
salt	O
of	O
the	O
same	O
can	O
be	O
used	O
for	O
treating	O
diabetes,	O
obesity	O
and	O
complicating	O
diseases	O
thereof	O
caused	O
by	O
insulin	B-GENE
resistance	O
.	O


The	O
invention	O
provides	O
an	O
intensive	O
antitumor	O
medicament,	O
namely	O
bestatin	O
deanol	O
ester,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
bestatin	O
deanol	O
ester	O
not	O
only	O
can	O
effectively	O
inhibit	O
ectopic	O
expression	O
of	O
aminopeptidase	B-GENE
N	I-GENE
activity,	O
but	O
also	O
greatly	O
improve	O
the	O
water	O
solubility	O
of	O
the	O
parent	O
drug	O
bestatin	O
of	O
the	O
bestatin	O
deanol	O
ester,	O
has	O
slow	O
release	O
effect,	O
is	O
more	O
excellent	O
than	O
the	O
parent	O
drug	O
bestatin	O
either	O
from	O
healing	O
effect	O
or	O
preparation,	O
and	O
has	O
wide	O
application	O
.	O
Particularly,	O
the	O
invention	O
mainly	O
relates	O
to	O
the	O
following	O
three	O
aspects	O
:	O
(	O
1	O
)	O
design	O
and	O
synthesis	O
of	O
the	O
bestatin	O
deanol	O
ester	O
;	O
(	O
2	O
)	O
N	O
'	O
N	O
deanol	O
which	O
is	O
a	O
micromolecule	O
fragment,	O
can	O
be	O
connected	O
with	O
other	O
medicaments	O
containing	O
carboxyl,	O
improves	O
the	O
pharmacokinetic	O
property	O
of	O
the	O
medicaments,	O
and	O
improveswater	O
solubility	O
;	O
and	O
(	O
3	O
)	O
a	O
method	O
for	O
synthesizing	O
an	O
ester	O
substance	O
to	O
which	O
the	O
invention	O
relates	O
with	O
wide	O
application	O
and	O
mild	O
condition	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
as	O
a	O
JAK-STAT3	O
signal	O
passage	O
inhibitor,	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
a	O
compound	O
with	O
a	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
in	O
the	O
process	O
of	O
preparing	O
an	O
anti-tumor	O
medicament	O
.	O
The	O
application	O
provides	O
a	O
novel	O
treating	O
candidate	O
medicament	O
for	O
a	O
tumor	O
patient,	O
thereby	O
probably	O
further	O
improving	O
the	O
treatment	O
effect	O
on	O
the	O
patient	O
and	O
improving	O
the	O
prognosis	O
of	O
the	O
patient	O
.	O
The	O
compound	O
with	O
the	O
formula	O
I	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
has	O
the	O
effect	O
on	O
various	O
tumor	O
cells,	O
which	O
indicates	O
that	O
the	O
compound	O
can	O
be	O
used	O
for	O
treating	O
various	O
cancers	O
including	O
cerebral	O
tumor,	O
genitourinary	O
system	O
tumor,	O
lymphatic	O
system	O
tumor,	O
stomach	O
cancer,	O
laryngeal	O
cancer,	O
nasopharyngeal	O
cancer,	O
skin	O
cancer,	O
bone	O
cancer,	O
blood	O
cancer,	O
leukemia,	O
breast	O
cancer	O
and	O
histiocytic	O
lymphoma,	O
non-small	O
cell	O
lung	O
cancer,	O
small-cell	O
lung	O
cancer,	O
lung	O
adenocarcinoma,	O
lung	O
squamous	O
cell	O
cancer,	O
pancreatic	O
cancer,	O
prostatic	O
cancer,	O
liver	O
cancer,	O
epithelial	O
cell	O
cancer	O
and	O
the	O
like	O
.	O
The	O
definition	O
of	O
genes	O
in	O
the	O
formula	O
refers	O
to	O
description	O
for	O
details	O
.	O


The	O
invention	O
discloses	O
a	O
composition	O
having	O
effect	O
of	O
enhancing	O
immunity	O
function,	O
which	O
is	O
prepared	O
by	O
mixing	O
marine	O
protein	O
peptide	O
and	O
nucleotide	O
according	O
to	O
the	O
weight	O
ratio	O
of	O
45	O
:	O
8	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicine,	O
health-care	O
food	O
or	O
food	O
that	O
can	O
enhance	O
immunity	O
function	O
.	O
The	O
obtained	O
preparation	O
has	O
the	O
characteristics	O
of	O
easy	O
and	O
rapid	O
absorption,	O
low	O
viscosity,	O
good	O
water	O
solubility,	O
etc	O
.	O
The	O
preparation	O
can	O
remarkably	O
enhance	O
the	O
mouse	O
delayed-type	O
hypersensitivity	O
(	O
DTH	O
)	O
capability	O
and	O
T	O
lymphopoiesis	O
stimulated	O
by	O
ConA,	O
and	O
obviously	O
increases	O
the	O
quantity	O
of	O
antibody-producing	O
cells	O
.	O
The	O
result	O
proves	O
that	O
the	O
compatibility	O
of	O
the	O
marine	O
protein	O
peptide	O
and	O
the	O
nucleotide	O
can	O
enhance	O
the	O
enhancing	O
immunity	O
function	O
.	O


The	O
invention	O
relates	O
to	O
usage	O
of	O
3-carbonyl-12-alkene-ursane	O
compound	O
for	O
inhibiting	O
gastric	O
cancer	O
cell	O
SGC-7901	O
and	O
hepatoma	O
cancer	O
cell	O
BEL-7404	O
.	O
Experiment	O
shows	O
that	O
the	O
3-carbonyl-12-alkene-ursane	O
compound	O
is	O
effective	O
to	O
inhibit	O
cell	O
proliferation	O
of	O
the	O
gastric	O
cancer	O
cell	O
SGC-7901	O
and	O
the	O
hepatoma	O
cancer	O
cell	O
BEL-7404	O
and	O
can	O
be	O
used	O
for	O
preparing	O
antitumor	O
medicine	O
.	O
Electrophoretic	O
detection	O
shows	O
that	O
the	O
3-carbonyl-12-alkene-ursane	O
compound	O
can	O
accelerate	O
apoptosis	O
of	O
the	O
hepatoma	O
cancer	O
cell	O
BEL-7404	O
by	O
accelerating	O
increase	O
of	O
apoptosis	O
relative	O
gene	O
Bax	B-GENE
expression	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
opiate	O
resistance	O
and	O
dependency	O
by	O
employing	O
pharmaceutically	O
effective	O
dose	O
of	O
ephrinB-EphB	O
signal	O
transmission	O
blocker	O
on	O
individuals	O
requiring	O
the	O
therapy	O
.	O
Preferably,	O
opiate	O
resistance	O
and	O
dependency	O
are	O
mostly	O
caused	O
by	O
long-time	O
morphine	O
therapy	O
and	O
abstinence	O
.	O


It	O
is	O
an	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
the	O
crystalline	O
form	O
of	O
a	O
thiazolidinedione	O
compound,	O
which	O
is	O
effective	O
as	O
a	O
pharmaceutical	O
ingredient	O
for	O
manufacturing	O
a	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
(	O
PPAR	B-GENE
)	O
activator	O
and	O
an	O
anticancer	O
pharmaceutical	O
composition	O
.	O
The	O
present	O
invention	O
relates	O
to	O
a	O
crystalline	O
form	O
of	O
a	O
hydrate	O
of	O
5-	O
(	O
4-	O
{	O
[	O
6-	O
(	O
4-amino-3,5-dimethylphenoxy	O
)	O
-1-methyl-1-H-benzimidazol-2-yl	O
]	O
methoxy	O
}	O
benzyl	O
)	O
-1,3-thiazolidine-2,4-dione	O
dihydrochloride	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicaments	O
relevant	O
to	O
infection,	O
in	O
particular	O
to	O
a	O
hydroxamic	O
acid	O
derivative	O
or	O
salt	O
thereof	O
containing	O
a	O
1,3-diazine	O
five-membered	O
bi-heterocyclic	O
ring	O
with	O
the	O
effect	O
of	O
restraining	O
peptide	B-GENE
deformylase	I-GENE
(	O
PDF	B-GENE
)	O
to	O
generate	O
antibacterial	O
performance,	O
a	O
preparation	O
method,	O
a	O
medical	O
composition	O
thereof	O
and	O
an	O
application	O
in	O
preparing	O
a	O
antibacterial	O
medicament,	O
wherein	O
the	O
definition	O
of	O
each	O
group	O
is	O
disclosed	O
in	O
the	O
specification	O
.	O


The	O
invention	O
provides	O
a	O
new	O
pharmaceutical	O
application	O
of	O
D-cycloserine,	O
in	O
particular	O
to	O
application	O
which	O
utilizes	O
D-cycloserine	O
to	O
promote	O
the	O
decay	O
or	O
oblivion	O
of	O
disgust	O
memories	O
and	O
fear	O
memories	O
and	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicine	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
mental	O
sickness	O
and	O
/	O
or	O
symptoms	O
correlative	O
to	O
BDNF	B-GENE
gene	O
variation	O
.	O
The	O
mental	O
sickness	O
and	O
/	O
or	O
symptoms	O
comprise	O
anxiety	O
neurosis,	O
melancholia,	O
post-traumatic	O
stress	O
syndrome,	O
and	O
the	O
like	O
correlative	O
to	O
the	O
BDNF	B-GENE
gene	O
variation,	O
and	O
the	O
BDNF	B-GENE
gene	O
variation	O
stated	O
herein	O
comprises	O
that	O
valine	O
at	O
the	O
66th	O
position	O
of	O
the	O
BDNF	B-GENE
is	O
mutated	O
into	O
methionine	O
.	O
The	O
invention	O
provides	O
an	O
effective	O
medicine	O
for	O
clinically	O
and	O
individually	O
treating	O
the	O
mental	O
sickness	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
used	O
as	O
a	O
seven-pass	O
transmembrane	O
protein	O
and	O
based	O
on	O
an	O
SAG	B-GENE
structure,	O
which	O
has	O
a	O
general	O
formula	O
I,	O
wherein	O
R,	O
X	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description	O
.	O
The	O
invention	O
also	O
provides	O
a	O
synthesis	O
path	O
and	O
a	O
preparing	O
method	O
of	O
the	O
compound,	O
and	O
the	O
use	O
of	O
the	O
compound	O
and	O
the	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparing	O
the	O
medicament	O
used	O
for	O
treating	O
tumor	O
.	O


The	O
present	O
invention	O
is	O
useful	O
as	O
endurance	O
improving	O
agents	O
or	O
antifatigue	O
agents	O
for	O
physical	O
activities	O
in	O
broad	O
sense,	O
such	O
as	O
exercises	O
requiring	O
endurance,	O
labor	O
requiring	O
repeated	O
muscle	O
exercise,	O
and	O
the	O
like	O
.	O
The	O
present	O
invention	O
relates	O
to	O
endurance	O
improving	O
agents,	O
antifatigue	O
agents	O
and	O
AMPK	B-GENE
activators,	O
all	O
of	O
which	O
contain	O
catechins	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
invention	O
relates	O
to	O
a	O
marine	O
oligosaccharide	O
compound	O
with	O
type	O
II	O
diabetes	O
resisting	O
activity,	O
which	O
is	O
a	O
compound	O
which	O
is	O
formed	O
by	O
following	O
steps	O
:	O
taking	O
D-polymannose	O
aldehydic	O
oligosaccharide	O
which	O
comes	O
from	O
sea	O
and	O
contains	O
carboxyl	O
in	O
each	O
oligosaccharide	O
ring,	O
reacting	O
with	O
dilute	O
alkali	O
and	O
chromium	O
salt	O
solution	O
and	O
introducing	O
trivalent	O
chromium	O
ions	O
which	O
is	O
closely	O
relative	O
to	O
the	O
generation	O
and	O
the	O
development	O
of	O
diabetes	O
into	O
oligosaccharide	O
molecules	O
.	O
A	O
pharmacological	O
experiment	O
proves	O
that	O
the	O
product	O
has	O
remarkable	O
effect	O
on	O
accelerating	O
insulin	B-GENE
secretion,	O
is	O
not	O
influenced	O
by	O
amylin	B-GENE
and	O
has	O
effects	O
on	O
lightening	O
glucose	O
load,	O
improving	O
blood-lipoid	O
metabolism,	O
insulin	B-GENE
sensitivity	O
and	O
certain	O
kidney	O
protection	O
and	O
lightening	O
pancreatic	O
injury	O
for	O
type	O
II	O
diabetes	O
rats	O
and	O
mouse	O
.	O
The	O
product	O
of	O
the	O
invention	O
comes	O
from	O
marine	O
natural	O
species,	O
has	O
the	O
advantages	O
of	O
good	O
security,	O
unique	O
structure,	O
low	O
molecular	O
weight,	O
high	O
chromium	O
binding	O
ratio,	O
good	O
oral	O
absorption	O
effect,	O
and	O
the	O
like,	O
can	O
play	O
a	O
hypoglycemic	O
role	O
in	O
a	O
plurality	O
of	O
links	O
and	O
has	O
favorable	O
market	O
application	O
prospect	O
on	O
the	O
aspect	O
of	O
preventing	O
and	O
treating	O
type	O
II	O
diabetes	O
.	O


Thiazolopyrimidines	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
W	O
represents	O
a	O
thiazole	O
ring	O
;	O
R1	O
and	O
R2	O
form,	O
together	O
with	O
the	O
N	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
a	O
group	O
of	O
the	O
following	O
formula	O
(	O
IIa	O
)	O
:	O
in	O
which	O
A	O
is	O
a	O
ring	O
system	O
;	O
m	O
is	O
0,	O
1	O
or	O
2	O
;	O
R3	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
;	O
and	O
R4	O
is	O
an	O
indole	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
inhibitors	O
of	O
PI3K	B-GENE
and	I-GENE
are	O
selective	O
for	O
the	O
p110d	O
isoform,	O
which	O
is	O
a	O
class	B-GENE
Ia	I-GENE
PD	I-GENE
kinase,	O
over	O
both	O
other	O
class	B-GENE
Ia	I-GENE
and	I-GENE
class	B-GENE
Ib	I-GENE
kinases	I-GENE
.	O
The	O
compounds	O
may	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B-GENE
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
diazo	O
bicyclic	O
mimetics	O
of	O
Smac	B-GENE
which	O
function	O
as	O
inhibitors	O
of	O
Inhibitor	B-GENE
of	I-GENE
Apoptosis	I-GENE
Proteins	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
mimetics	O
for	O
inducing	O
apoptotic	O
cell	O
death	O
and	O
for	O
sensitizing	O
cells	O
to	O
inducers	O
of	O
apoptosis	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicaments	O
related	O
to	O
diabetes,	O
in	O
particular	O
to	O
2-type	B-GENE
sodium	I-GENE
galactosyl	I-GENE
transporter	I-GENE
(	O
SGLT2	B-GENE
)	O
inhibitors	O
with	O
an	O
N-pyrazolyl	O
glycosides	O
structure	O
as	O
well	O
as	O
a	O
preparation	O
method,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
2-type	B-GENE
sodium	I-GENE
galactosyl	I-GENE
transporter	I-GENE
(	O
SGLT2	B-GENE
)	O
inhibitors	O
and	O
application	O
thereof	O
in	O
preparing	O
medicaments	O
for	O
treating	O
diabetes,	O
wherein	O
the	O
group	O
definition	O
is	O
stated	O
as	O
an	O
instruction	O
.	O


The	O
invention	O
discloses	O
a	O
medicine	O
composite	O
for	O
treating	O
B	O
type	O
diabetes,	O
which	O
comprises	O
a	O
trypsin	B-GENE
class	O
medicine	O
and	O
an	O
antiallergic	O
medicine,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
trypsin	B-GENE
class	O
medicine	O
to	O
the	O
antiallergic	O
medicine	O
is	O
1	O
:	O
(	O
1	O
.	O
5-1700	O
)	O
.	O
When	O
being	O
taken,	O
the	O
medicine	O
composite	O
can	O
be	O
prepared	O
into	O
various	O
medicament	O
forms,	O
such	O
as	O
an	O
oral	O
microsphere	O
preparation	O
or	O
injection	O
and	O
the	O
like	O
.	O
The	O
trypsin	B-GENE
class	O
medicine	O
is	O
any	O
one	O
of	O
recombinant	O
human	O
trypsin,	O
pig	B-GENE
trypsin	B-GENE
and	O
dulcin	O
trypsin	B-GENE
.	O
The	O
antiallergic	O
medicine	O
is	O
sodium	O
cromoglyate	O
or	O
/	O
and	O
ketotifen	O
fumarate	O
.	O
Animal	O
experiments	O
prove	O
that	O
the	O
trypsin	B-GENE
class	O
medicine	O
and	O
the	O
antiallergic	O
medicine	O
are	O
combined	O
according	O
to	O
a	O
certain	O
proportion,	O
which	O
not	O
only	O
can	O
prevent	O
the	O
generation	O
of	O
trypsin	B-GENE
allergy	O
but	O
also	O
can	O
enhance	O
the	O
blood	O
sugar	O
control	O
action	O
of	O
trypsin	B-GENE
and	O
lighten	O
the	O
obesity	O
degree	O
.	O
The	O
action	O
mechanism	O
of	O
the	O
medicine	O
composite	O
is	O
to	O
regulate	O
the	O
excessive	O
mast	O
cells	O
of	O
the	O
fat	O
tissues	O
of	O
patients	O
with	O
obesity	O
and	O
diabetes	O
by	O
two	O
antiallergic	O
medicines	O
of	O
the	O
sodium	O
cromoglyate	O
and	O
the	O
ketotifen	O
fumarate,	O
thereby	O
exerting	O
a	O
synergistic	O
action	O
with	O
the	O
trypsin	B-GENE
and	O
preventing	O
and	O
relieving	O
the	O
anaphylactic	O
reaction	O
of	O
the	O
trypsin	B-GENE
.	O


The	O
invention	O
provides	O
an	O
acetamide	O
derivative	O
with	O
the	O
structural	O
formula	O
as	O
follows	O
:	O
R	O
represents	O
-X-Ar,	O
-X-COOH,	O
-CO-Ar,	O
-SO2-Ar,	O
-X-Het	O
.	O
,	O
or	O
-X-NR1R2,	O
wherein	O
X	O
represents	O
alkylene	O
with	O
1-8	O
carbon	O
atoms	O
and	O
the	O
alkylene	O
is	O
not	O
substituted	O
or	O
is	O
substituted	O
by	O
straight	O
chain	O
hydrocarbon	O
or	O
branched	O
hydrocarbon	O
with	O
1-5	O
carbon	O
atoms	O
;	O
and	O
Ar	O
represents	O
phenyl,	O
pyridyl,	O
naphthyl,	O
pyrimidyl	O
and	O
quinolyl	O
.	O
The	O
derivative	O
can	O
cause	O
apoptosis	O
by	O
acting	O
on	O
Caspase-3	B-GENE
zymogen	O
in	O
cancer	O
cells	O
and	O
can	O
be	O
widely	O
applied	O
in	O
cancer	O
treatment	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
oxyresveratrol	O
in	O
the	O
preparation	O
of	O
medicaments,	O
foods	O
or	O
health-care	O
products	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
alpha-glucosidase,	O
the	O
use	O
of	O
the	O
oxyresveratrol	O
in	O
the	O
preparation	O
of	O
hypoglycaemic	O
medicaments,	O
foods	O
or	O
health-care	O
products,	O
and	O
the	O
use	O
of	O
the	O
oxyresveratrol	O
in	O
the	O
preparation	O
of	O
medicaments,	O
foods	O
or	O
health-care	O
products	O
for	O
treating	O
and	O
preventing	O
diabetes	O
and	O
complications	O
of	O
the	O
diabetes	O
.	O
Therefore,	O
in	O
the	O
invention,	O
the	O
oxyresveratrol	O
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
the	O
medicaments,	O
foods	O
or	O
health-care	O
products	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
the	O
alpha-glucosidase,	O
the	O
preparation	O
of	O
the	O
hypoglycaemic	O
medicaments,	O
foods	O
or	O
health-care	O
products	O
and	O
the	O
medicaments,	O
foods	O
or	O
health-care	O
products	O
for	O
treating	O
and	O
preventing	O
diabetes	O
and	O
complications	O
of	O
the	O
diabetes,	O
thereby	O
bringing	O
good	O
news	O
for	O
diabetics	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
biotechnology	O
and	O
the	O
medical	O
field	O
and	O
discloses	O
a	O
new	O
human	O
epididymal	O
specific	O
expression	O
sperm	O
binding	O
protein	O
HEL-215	B-GENE
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O
.	O
The	O
invention	O
discloses	O
an	O
amino	O
acid	O
sequence	O
of	O
the	O
HEL-215	B-GENE
protein	I-GENE
and	O
provides	O
a	O
recombinant	O
expression	O
vector	O
which	O
carries	O
a	O
DNA	O
sequence	O
used	O
for	O
encoding	O
the	O
protein	O
.	O
The	O
protein	O
is	O
located	O
in	O
the	O
back	O
part	O
of	O
the	O
head	O
of	O
a	O
mature	O
sperm	O
and	O
the	O
neck	O
region	O
of	O
the	O
mature	O
sperm	O
and	O
has	O
higher	O
expression	O
level	O
at	O
the	O
head	O
and	O
the	O
body	O
part	O
of	O
an	O
epididymis	O
.	O
A	O
band	O
of	O
about	O
16	O
KD	O
is	O
detected	O
in	O
the	O
epididymis	O
by	O
using	O
Western	O
blot	O
.	O
The	O
HEL-215	B-GENE
protein	I-GENE
can	O
be	O
used	O
as	O
a	O
target	O
protein	O
for	O
developing	O
an	O
immunological	O
contraceptive	O
and	O
clinically	O
diagnosing	O
and	O
treating	O
male	O
infertility	O
.	O
A	O
method	O
for	O
detecting	O
a	O
corresponding	O
gene	O
or	O
protein	O
based	O
on	O
development	O
of	O
the	O
HEL-215	B-GENE
protein	I-GENE
can	O
be	O
widely	O
used	O
for	O
the	O
research	O
field	O
of	O
reproductive	O
medicine	O
.	O


The	O
invention	O
discloses	O
a	O
compound	O
capable	O
of	O
being	O
used	O
for	O
restoring	O
the	O
wound	O
of	O
the	O
skin	O
.	O
The	O
compound	O
has	O
a	O
structure	O
shown	O
as	O
the	O
formula	O
(	O
I	O
)	O
:	O
the	O
compound	O
has	O
a	O
very	O
excellent	O
effect	O
for	O
promoting	O
the	O
restoration	O
of	O
the	O
wound	O
of	O
the	O
skin	O
and	O
can	O
also	O
promote	O
the	O
migration	O
of	O
skin	O
cells	O
obviously	O
;	O
cicatrization	O
after	O
being	O
wounded	O
is	O
reduced	O
;	O
the	O
protein	O
degradation	O
of	O
beta-catenin	B-GENE
is	O
promoted	O
;	O
and	O
the	O
secretion	O
of	O
substrate	O
metalloprotease	O
in	O
the	O
cells	O
is	O
promoted	O
.	O
The	O
compound	O
has	O
favorable	O
effect	O
and	O
low	O
cost	O
of	O
preparation,	O
storage	O
and	O
transportation	O
and	O
can	O
be	O
completely	O
synthesized	O
by	O
a	O
manual	O
mode	O
.	O


The	O
invention	O
relates	O
to	O
medicine	O
application	O
of	O
20	O
(	O
S	O
)	O
-ginsenoside	O
Rg3,	O
in	O
particular	O
to	O
application	O
of	O
20	O
(	O
S	O
)	O
-ginsenoside	O
Rg3	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
a	O
non-small	O
cell	O
lung	O
cancer	O
.	O
In	O
the	O
invention,	O
selecting	O
a	O
human	O
non-small	O
cell	O
lung	O
cancer	O
cell	O
strain	O
(	O
A549	O
lung	O
adenocarcinoma,	O
H460	O
large	O
cell	O
lung	O
cancer	O
and	O
LTEP-78	O
lung	O
squamous	O
carcinoma	O
)	O
to	O
be	O
inoculated	O
under	O
the	O
skin	O
of	O
a	O
naked	O
mouse,	O
and	O
observing	O
the	O
influence	O
of	O
the	O
SPG-Rg3	O
on	O
the	O
non-small	O
cell	O
lung	O
cancer	O
;	O
and	O
carrying	O
out	O
CD34	B-GENE
immunohistochemistry	O
staining	O
and	O
TUNEL	O
immunofluorescence	O
staining	O
on	O
tumor	O
tissues,	O
and	O
observing	O
the	O
influence	O
of	O
the	O
SPG-Rg3	O
on	O
tumor	O
angiogenesis	O
and	O
apoptosis	O
.	O
The	O
inclusion	O
proves	O
that	O
the	O
20	O
(	O
S	O
)	O
-ginsenoside	O
Rg3	O
can	O
remarkably	O
inhibit	O
the	O
growth	O
of	O
the	O
non-small	O
cell	O
lung	O
cancer,	O
has	O
the	O
action	O
mechanism	O
related	O
with	O
the	O
promotion	O
of	O
the	O
tumor	O
apoptosis	O
and	O
the	O
inhibition	O
of	O
the	O
tumor	O
angiogenesis	O
and	O
unobvious	O
cooperation	O
action	O
when	O
being	O
combined	O
with	O
cyclophosphamide	O
for	O
application,	O
and	O
can	O
be	O
used	O
for	O
the	O
clinical	O
chemotherapy	O
of	O
the	O
non-small	O
cell	O
lung	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
a	O
manchette	B-GENE
binding	I-GENE
protein	I-GENE
and	O
effects	O
thereof	O
during	O
spermiogenesis,	O
and	O
discloses	O
application	O
of	O
rab	B-GENE
interaction	I-GENE
molecule	I-GENE
binding	I-GENE
protein	I-GENE
3	I-GENE
(	O
RIM-BP3	B-GENE
)	O
or	O
an	O
accelerator	O
or	O
an	O
inhibitor	O
thereof	O
in	O
preparing	O
a	O
composition	O
for	O
regulating	O
the	O
spermioteleosis	O
of	O
male	O
mammals	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
compound	O
for	O
regulating	O
the	O
spermioteleosis	O
of	O
the	O
male	O
mammals,	O
which	O
comprises	O
the	O
RIM-BP3	B-GENE
and	O
Hook1	B-GENE
protein	I-GENE
.	O
The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
selecting	O
the	O
potential	O
substance	O
for	O
regulating	O
the	O
spermioteleosis	O
of	O
the	O
male	O
mammals	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
Raf	B-GENE
protein	I-GENE
kinase	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
compositions	O
thereof,	O
and	O
methods	O
of	O
treating	O
Raf-mediated	O
diseases	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
:	O
Cy1	O
is	O
an	O
optionally	O
substituted	O
phenyl	O
or	O
an	O
optionally	O
substituted	O
5-6	O
membered	O
saturated,	O
partially	O
unsaturated,	O
or	O
aromatic	O
ring	O
having	O
1-3	O
heteroatoms	O
independently	O
selected	O
from	O
nitrogen,	O
oxygen,	O
or	O
sulfur	O
;	O
Cy2	O
is	O
an	O
optionally	O
substituted	O
5-10	O
membered	O
saturated,	O
partially	O
unsaturated,	O
or	O
aromatic	O
monocyclic	O
or	O
bicyclic	O
ring	O
having	O
0-4	O
heteroatoms,	O
independently	O
selected	O
from	O
nitrogen,	O
oxygen,	O
or	O
sulfur	O
;	O
L1	O
is	O
a	O
direct	O
bond	O
of	O
an	O
optionally	O
substituted,	O
straight	O
or	O
branched	O
C1-6	O
alkylene	O
chain	O
;	O
L2	O
is	O
a	O
direct	O
bond,	O
or	O
is	O
an	O
optionally	O
substituted,	O
straight	O
or	O
branched	O
C1-6	O
alkylene	O
chain	O
wherein	O
1	O
or	O
2	O
methylene	O
units	O
of	O
L2	O
are	O
optionally	O
and	O
independently	O
replaced	O
by	O
-O-,	O
-S-,	O
-N	O
(	O
R	O
)	O
-,	O
-C	O
(	O
O	O
)	O
-,	O
-C	O
(	O
O	O
)	O
N	O
(	O
R	O
)	O
-,	O
-N	O
(	O
R	O
)	O
C	O
(	O
O	O
)	O
N	O
(	O
R	O
)	O
-,	O
-N	O
(	O
R	O
)	O
C	O
(	O
O	O
)	O
-,	O
-N	O
(	O
R	O
)	O
C	O
(	O
O	O
)	O
O-,	O
-OC	O
(	O
O	O
)	O
N	O
(	O
R	O
)	O
-,	O
-SO2-,	O
-SO2N	O
(	O
R	O
)	O
-,	O
-N	O
(	O
R	O
)	O
SO2-,	O
-OC	O
(	O
O	O
)	O
-,	O
-C	O
(	O
O	O
)	O
O-,	O
or	O
a	O
3-6	O
membered	O
cycloalkylene	O
;	O
each	O
R	O
is	O
independently	O
hydrogen	O
or	O
an	O
optionally	O
substituted	O
C1-6	O
aliphatic	O
group	O
.	O


The	O
invention	O
discloses	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
promoting	O
nerve	O
cell	O
proliferation	O
and	O
protecting	O
nerve	O
cells	O
;	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
improving	O
passive	O
avoidance	O
response	O
and	O
impaired	O
spatial	O
learning	O
and	O
memory	O
and	O
enhancing	O
learning	O
and	O
memory	O
;	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
increasing	O
the	O
total	O
protein	O
content	O
in	O
cerebral	O
cortex	O
tissue	O
;	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
reducing	O
the	O
activity	O
of	O
acetylcholin	B-GENE
esterase	I-GENE
in	O
cerebral	O
cortex	O
and	O
hippocampus	O
brain	O
tissue	O
;	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
improving	O
the	O
activity	O
of	O
superoxide	B-GENE
dismutase	I-GENE
in	O
cerebral	O
cortex	O
and	O
hippocampus	O
brain	O
tissue,	O
and	O
reducing	O
the	O
malonaldehyde	O
content	O
and	O
the	O
monoamine	B-GENE
oxidase	I-GENE
activity	O
in	O
cerebral	O
cortex	O
and	O
hippocampus	O
brain	O
tissue	O
;	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
reducing	O
the	O
content	O
of	O
inflammatory	O
factor	O
TNF-alpha	B-GENE
and	O
IL-6	B-GENE
in	O
the	O
brain	O
tissue	O
of	O
cerebral	O
cortex	O
;	O
and	O
the	O
application	O
of	O
forsythiaside	O
in	O
preparing	O
medicine	O
treating	O
mild	O
cognitive	O
impairment,	O
especially	O
senile	O
dementia	O
.	O


The	O
invention	O
discloses	O
4-arylthioquinazoline	O
derivatives,	O
preparation	O
methods	O
and	O
pharmaceutical	O
uses	O
thereof	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
for	O
treating	O
acute	O
myeloid	O
leukemia	O
.	O
The	O
inventor	O
found	O
out	O
that	O
the	O
4-arylthioquinazoline	O
derivative	O
have	O
very	O
strong	O
FLT3	B-GENE
inhibitory	O
activity,	O
and	O
the	O
preparation	O
methods	O
have	O
the	O
advantages	O
that	O
the	O
reaction	O
steps	O
are	O
short,	O
the	O
required	O
raw	O
material	O
reagents	O
are	O
cheap	O
and	O
easy	O
to	O
get,	O
the	O
column	O
chromatography	O
is	O
not	O
needed,	O
and	O
the	O
whole	O
process	O
only	O
needs	O
one-time	O
re-crystallization	O
to	O
obtain	O
high-purity	O
target	O
products	O
.	O


The	O
invention	O
discloses	O
a	O
hemostat	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
A	O
finished	O
product	O
liquor	O
per	O
1000	O
g	O
comprises	O
10-16	O
g	O
of	O
termite	O
fungus	O
garden	O
composition	O
powder,	O
4-6	O
g	O
of	O
collagen,	O
0	O
.	O
02-0	O
.	O
04	O
g	O
of	O
ternary	O
acid,	O
7-9	O
g	O
of	O
bactericidal	O
agent	O
and	O
the	O
balance	O
of	O
water	O
.	O
The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
termite	O
fungus	O
garden	O
composition	O
powder	O
containing	O
rich	O
nutrient	O
contents	O
is	O
utilized	O
in	O
the	O
prescription,	O
the	O
functions	O
of	O
detumescence,	O
convergence	O
and	O
hemostasis	O
are	O
achieved,	O
meanwhile	O
the	O
weak	O
body	O
is	O
tonified	O
without	O
any	O
side	O
effect	O
;	O
the	O
collagen	B-GENE
has	O
very	O
strong	O
affinity	O
with	O
different	O
cells,	O
and	O
also	O
has	O
ideal	O
affinity	O
with	O
growth	B-GENE
factors	I-GENE
which	O
play	O
a	O
key	O
role	O
in	O
the	O
process	O
of	O
wound	O
healing,	O
after	O
blood	O
coagulation,	O
the	O
collagen	B-GENE
can	O
also	O
prevent	O
bleeding	O
again	O
through	O
stimulating	O
the	O
regeneration	O
and	O
the	O
repair	O
of	O
tissues	O
.	O
The	O
hemostat	O
is	O
not	O
fastidious	O
about	O
the	O
using	O
object,	O
has	O
fast	O
hemostasis	O
effect,	O
excellent	O
functions	O
of	O
anti-inflammatory,	O
detumescence	O
and	O
acesodyne	O
without	O
toxic	O
or	O
side	O
effect,	O
or	O
untoward	O
reaction	O
of	O
stimulations	O
.	O
The	O
preparation	O
method	O
has	O
less	O
technical	O
steps	O
and	O
non-rigorous	O
preparation	O
condition,	O
and	O
can	O
be	O
suitable	O
for	O
the	O
industrial	O
mass	O
production	O
.	O


The	O
invention	O
discloses	O
a	O
solid	O
pharmaceutical	O
composition	O
containing	O
5-HT	B-GENE
receptor	I-GENE
agonist,	O
which	O
is	O
used	O
for	O
curing	O
migraine	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
fields	O
of	O
medicaments	O
and	O
foods	O
and	O
relates	O
to	O
an	O
artocarpus	O
hypargyreus	O
hance	O
extract	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
In	O
the	O
artocarpus	O
hypargyreus	O
hance	O
extract,	O
the	O
content	O
of	O
an	O
isopentenyl-substituted	O
flavonoid	O
compound	O
is	O
20	O
to	O
40	O
weight	O
percent	O
.	O
The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
;	O
extracting	O
stems	O
and	O
branches	O
of	O
artocarpus	O
hypargyreus	O
hance	O
serving	O
as	O
a	O
raw	O
material	O
by	O
a	O
solvent	O
to	O
prepare	O
a	O
total	O
extract	O
;	O
dissolving	O
the	O
total	O
extract	O
in	O
water,	O
extracting	O
with	O
a	O
halogenated	O
solvent	O
and	O
an	O
ester	O
solvent	O
in	O
sequence	O
;	O
and	O
taking	O
an	O
extraction	O
phase	O
of	O
the	O
ester	O
solvent,	O
and	O
drying	O
after	O
reclaiming	O
the	O
solvent	O
to	O
obtain	O
the	O
artocarpus	O
hypargyreus	O
hance	O
extract	O
.	O
Through	O
activity	O
tests	O
such	O
as	O
tyrosinase	B-GENE
in	O
vitro,	O
B16	O
melanoma	O
cells,	O
DPPH	O
clearing	O
and	O
the	O
like,	O
results	O
show	O
that	O
the	O
artocarpus	O
hypargyreus	O
hance	O
extract	O
has	O
strong	O
effects	O
of	O
inhibiting	O
the	O
generation	O
of	O
the	O
tyrosinase	B-GENE
and	O
melanin	O
and	O
clearing	O
free	O
radicals,	O
can	O
be	O
used	O
as	O
a	O
melanin	O
inhibitor,	O
a	O
whitening	O
agent	O
or	O
a	O
natural	O
antioxidant,	O
and	O
is	O
applied	O
to	O
the	O
fields	O
of	O
medicament,	O
daily	O
chemical	O
engineering	O
and	O
food	O
.	O


The	O
invention	O
relates	O
to	O
a	O
taxol	O
nano	O
targeting	O
slow-release	O
long-circulating	O
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
taxol	O
nano	O
targeting	O
slow-release	O
long-circulating	O
liposome	O
of	O
the	O
invention	O
mediates	O
the	O
structure	O
of	O
polyethylene	O
glycol	O
modificatory	O
chitosan	O
derivative	O
by	O
folate	B-GENE
receptor	I-GENE
;	O
and	O
the	O
invention	O
utilizes	O
the	O
chitosan	O
derivative	O
as	O
an	O
auxiliary	O
material	O
to	O
prepare	O
a	O
novel	O
taxol	O
preparation	O
by	O
a	O
reverse	O
phase	O
evaporation	O
method	O
or	O
film	O
dispersion	O
method,	O
and	O
the	O
prepared	O
taxol	O
nano	O
targeting	O
slow-release	O
long-circulating	O
liposome	O
has	O
the	O
grain	O
size	O
smaller	O
than	O
100nm,	O
can	O
freely	O
run	O
in	O
the	O
blood,	O
penetrates	O
the	O
endothelial	O
cell	O
of	O
a	O
target	O
tissue,	O
can	O
be	O
uptaken	O
by	O
a	O
tumor	O
cell	O
to	O
enter	O
the	O
cell,	O
releases	O
the	O
contained	O
taxol	O
in	O
the	O
cell,	O
and	O
greatly	O
improves	O
the	O
utilization	O
efficiency	O
of	O
medicaments	O
.	O
In	O
addition,	O
the	O
surface	O
of	O
the	O
prepared	O
taxol	O
nano	O
targeting	O
slow-release	O
long-circulating	O
liposome	O
is	O
also	O
covered	O
by	O
a	O
layer	O
of	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
which	O
can	O
prolong	O
the	O
dwell	O
time	O
of	O
liposome	O
in	O
the	O
blood,	O
reduce	O
the	O
uptaken	O
amount	O
of	O
liposome	O
by	O
liver	O
and	O
spleen	O
reticuloendothelial	O
systems,	O
and	O
is	O
beneficial	O
to	O
the	O
absorption	O
of	O
tumor	O
tissues	O
and	O
lesion	O
parts	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
nutrition	O
combination	O
in	O
the	O
preparation	O
of	O
a	O
medicine	O
for	O
promoting	O
the	O
proliferation	O
of	O
liver	O
stem	O
cells	O
.	O
The	O
nutrition	O
combination	O
can	O
promote	O
the	O
proliferation	O
of	O
hemopoietic	O
stem	O
cells	O
and	O
the	O
synthesis	O
of	O
hemoglobin,	O
can	O
provide	O
conditions	O
for	O
awakening	O
dormant	O
adult	O
liver	O
stem	O
cells	O
and	O
can	O
further	O
promote	O
the	O
proliferation	O
of	O
the	O
adult	O
liver	O
stem	O
cells	O
.	O
The	O
invention	O
solves	O
all	O
kinds	O
of	O
problems	O
existing	O
in	O
the	O
existing	O
orthotopic	O
liver	O
transplantation	O
and	O
the	O
donator	O
liver	O
stem	O
cell	O
transplantation,	O
and	O
has	O
the	O
advantages	O
of	O
high	O
effectiveness,	O
high	O
safety,	O
great	O
convenience,	O
economy,	O
no	O
immunological	O
rejection	O
and	O
the	O
like	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
and	O
relates	O
to	O
a	O
1,	O
2,	O
3-triazole	O
compound,	O
comprising	O
4-	O
(	O
2-bromophenyl	O
)	O
-1H-1,	O
2,	O
3-triazole	O
and	O
4-	O
(	O
2-chlorphenyl	O
)	O
-1H-1,	O
2,	O
3-triazole	O
.	O
The	O
result	O
of	O
an	O
inhibitory	O
activity	O
test	O
of	O
indoleamine	B-GENE
2,	I-GENE
3-dioxygenase	I-GENE
indicates	O
that	O
the	O
disclosed	O
1,	O
2,	O
3-triazole	O
compound	O
used	O
as	O
the	O
indoleamine	B-GENE
2,	I-GENE
3-dioxygenase	I-GENE
inhibitor	O
has	O
broad	O
prospect	O
of	O
application	O
and	O
can	O
be	O
applied	O
to	O
the	O
treatment	O
of	O
diseases	O
with	O
indoleamine	B-GENE
2,	I-GENE
3-dioxygenase-mediated	O
tryptophan	O
metabolic	O
pathway	O
pathological	O
characteristics,	O
including	O
cancer,	O
AIDS	O
(	O
Acquired	O
Immure	O
Deficiency	O
Syndrome	O
)	O
,	O
Alzheimer	O
disease,	O
tristimania,	O
cataract	O
and	O
other	O
critical	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
and	O
discloses	O
medical	O
application	O
of	O
taraxasterol	O
.	O
The	O
taraxasterol	O
has	O
inhibiting	O
effect	O
on	O
alpha-glucosidase	B-GENE
and	O
alpha-amylase,	O
and	O
the	O
inhibiting	O
effect	O
of	O
the	O
taraxasterol	O
is	O
5-60	O
times	O
of	O
the	O
inhibiting	O
effect	O
of	O
acarbose	O
.	O
Thus,	O
the	O
taraxasterol	O
can	O
be	O
used	O
for	O
preparing	O
alpha-glucosidase	B-GENE
inhibitors,	O
alpha-amylase	B-GENE
inhibitors	O
and	O
medicines	O
for	O
treating	O
diabetes	O
.	O
The	O
taraxasterol	O
has	O
the	O
advantages	O
of	O
wide	O
range	O
of	O
existence	O
in	O
plants,	O
easy	O
acquisition,	O
relatively	O
stable	O
properties,	O
safety,	O
economy	O
and	O
high	O
popularization	O
and	O
application	O
values	O
.	O


The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
piprazine	O
compound	O
containing	O
polysulfide	O
bond	O
and	O
an	O
application	O
thereof	O
.	O
Fungus	O
oidiodendron	O
truncatum	O
GW3-13	O
which	O
is	O
separated	O
from	O
the	O
soil	O
of	O
Antarctic	O
Great	O
Wall	O
Station	O
is	O
used	O
for	O
producing	O
the	O
piprazine	O
compound	O
containing	O
the	O
polysulfide	O
bond	O
with	O
novel	O
structure	O
.	O
The	O
piprazine	O
compound	O
is	O
proved	O
to	O
be	O
used	O
as	O
cell	O
proliferation	O
inhibitor	O
or	O
hypoxia-inducible	B-GENE
factor-1	I-GENE
(	O
HIF-1	B-GENE
)	O
targeting	O
antineoplastic	O
agent	O
.	O


The	O
invention	O
relates	O
to	O
indole	O
carbazole	O
and	O
bisindole	O
maleimide	O
alkaloid,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
In	O
the	O
preparation	O
method,	O
the	O
compound	O
of	O
the	O
type	O
with	O
a	O
novel	O
structure	O
is	O
prepared	O
by	O
a	O
chemical	O
reaction	O
starting	O
from	O
indole	O
and	O
indoleacetic	O
acid	O
.	O
An	O
experiment	O
confirms	O
that	O
the	O
compound	O
has	O
tumor	O
cytotoxin	O
activeness	O
and	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
inhibitory	O
activity,	O
so	O
the	O
compound	O
can	O
be	O
used	O
as	O
an	O
cell	O
proliferation	O
inhibitor	O
or	O
an	O
antitumor	O
agent	O
.	O


The	O
invention	O
proves	O
that	O
forsythiaside	O
A	O
has	O
the	O
function	O
of	O
inhibiting	O
platelet	O
aggregation	O
and	O
simultaneously	O
has	O
the	O
obvious	O
anticoagulation	O
role	O
by	O
studying	O
the	O
impacts	O
of	O
the	O
forsythiaside	O
A	O
on	O
ADP-induced	O
platelet	O
aggregation	O
in	O
vitro	O
of	O
rats,	O
the	O
impacts	O
on	O
plasma	O
prothrombin	B-GENE
time	O
(	O
PT	O
)	O
of	O
the	O
rats	O
and	O
the	O
impacts	O
on	O
plasma	O
thrombin	B-GENE
time	O
(	O
TT	O
)	O
of	O
the	O
rats	O
.	O
The	O
forsythiaside	O
A	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
.	O
The	O
forsythiaside	O
A	O
can	O
also	O
be	O
used	O
as	O
a	O
food	O
additive	O
for	O
preparing	O
functional	O
foods	O
for	O
preventing	O
and	O
treating	O
the	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
.	O


The	O
invention	O
discloses	O
spiro	O
compounds	O
(	O
comprising	O
racemes,	O
enantiomers	O
and	O
other	O
stereoisomers	O
)	O
of	O
formulas	O
(	O
I	O
and	O
II	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates,	O
solvates	O
or	O
prodrugs	O
thereof,	O
and	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
and	O
application	O
of	O
the	O
compounds	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
protein	B-GENE
kinase	I-GENE
such	O
as	O
tyrosine	B-GENE
kinase	I-GENE
of	O
c-Met	B-GENE
and	O
the	O
like,	O
and	O
can	O
be	O
used	O
for	O
treating	O
diseases,	O
such	O
as	O
tumors	O
and	O
the	O
like,	O
caused	O
by	O
abnormal	O
activity	O
of	O
the	O
tyrosine	O
kinase,	O
or	O
preparing	O
medicaments	O
of	O
treating	O
these	O
diseases	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
a	O
kind	O
of	O
coumaroyl	O
spermidine	O
type	O
compounds	O
shown	O
as	O
a	O
formula	O
I	O
or	O
plant	O
extracts	O
containing	O
the	O
coumaroyl	O
spermidine	O
type	O
compounds	O
to	O
the	O
preparation	O
of	O
alpha	B-GENE
1-adrenoreceptor	I-GENE
antagonist	O
health-care	O
food,	O
cyclooxygenase-2	B-GENE
inhibiting	O
health-care	O
food	O
and	O
prostate	B-GENE
specific	I-GENE
antigen	I-GENE
(	O
PSA	B-GENE
)	O
inhibiting	O
health-care	O
food,	O
or	O
the	O
preparation	O
of	O
health-care	O
food	O
for	O
preventing	O
and	O
treating	O
prostatoplasia,	O
prostatitis	O
or	O
prostatic	O
cancer	O
.	O
The	O
application	O
of	O
the	O
invention	O
develops	O
the	O
new	O
application	O
field	O
of	O
the	O
compounds,	O
and	O
simultaneously	O
provides	O
a	O
novel	O
path	O
for	O
the	O
relevant	O
health	O
care	O
in	O
the	O
field	O
.	O


The	O
invention	O
relates	O
to	O
chromone	O
ketoside	O
compounds	O
which	O
have	O
beta-secretase	B-GENE
inhibition	O
.	O
The	O
structural	O
formula	O
of	O
the	O
compounds	O
is	O
shown	O
in	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
.	O
The	O
chromone	O
ketoside	O
compounds	O
are	O
separated	O
from	O
aloe	O
plants	O
by	O
a	O
plurality	O
of	O
separation	O
means,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
senile	O
dementia	O
.	O


The	O
invention	O
relates	O
to	O
a	O
medicament	O
composition	O
containing	O
calcium	B-GENE
channel	I-GENE
blockers	O
and	O
biguanide	O
antidiabetic	O
medicine	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
applications	O
of	O
the	O
medicament	O
composition	O
in	O
the	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
or	O
treating	O
diabetes	O
mellitus	O
with	O
hypertension	O
.	O
The	O
implementation	O
of	O
the	O
invention	O
provides	O
the	O
medicine	O
composition	O
with	O
specific	O
applications,	O
and	O
the	O
medicament	O
composition	O
not	O
only	O
has	O
a	O
precise	O
curative	O
effect,	O
but	O
also	O
can	O
improve	O
the	O
compliance	O
of	O
patients	O
.	O
The	O
patients	O
can	O
take	O
the	O
medicament	O
conveniently,	O
and	O
the	O
medical	O
expense	O
is	O
reduced	O
.	O
The	O
invention	O
has	O
a	O
better	O
market	O
prospect,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
pharmacy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrazole	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
thereof	O
that	O
modulate	O
the	O
activity	O
of	O
the	O
5-HT2A	B-GENE
serotonin	O
receptor	O
.	O
Compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
directed	O
to	O
methods	O
useful	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
platelet	O
aggreagation,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
transient	O
ischemic	O
attack,	O
angina,	O
stroke,	O
atrial	O
fibrillation,	O
reducing	O
the	O
risk	O
of	O
blood	O
clot	O
formation,	O
asthma	O
or	O
symptoms	O
thereof,	O
agitation	O
or	O
a	O
symptom,	O
behavioral	O
disorders,	O
drug	O
induced	O
psychosis,	O
excitative	O
psychosis,	O
Gilles	O
de	O
la	O
Tourette	O
'	O
s	O
syndrome,	O
manic	O
disorder,	O
organic	O
or	O
NOS	O
psychosis,	O
psychotic	O
disorder,	O
psychosis,	O
acute	O
schizophrenia,	O
chronic	O
schizophrenia,	O
NOS	O
schizophrenia	O
and	O
related	O
disorders,	O
and	O
sleep	O
disorders,	O
sleep	O
disorders,	O
diabetic-related	O
disorders	O
and	O
the	O
like	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
prophylaxis	O
or	O
treatment	O
of	O
5-HT2A	B-GENE
serotonin	O
receptor	O
mediated	O
disorders	O
in	O
combination	O
with	O
a	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
antagonist	O
such	O
as	O
haloperidol,	O
administered	O
separately	O
or	O
together	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pyrro-quinoline	O
quinine	O
(	O
PQQ	O
)	O
sodium	O
salt	O
derivative	O
and	O
a	O
preparation	O
method	O
thereof,	O
belonging	O
to	O
the	O
field	O
of	O
pharmacy	O
.	O
In	O
the	O
preparation	O
method,	O
PQQ	O
is	O
used	O
as	O
a	O
raw	O
material,	O
and	O
an	O
acid-base	O
neutralization	O
reaction	O
with	O
PQQ	O
is	O
carried	O
out	O
in	O
a	O
basic	O
solvent	O
of	O
sodium	O
hydroxide	O
to	O
prepare	O
the	O
PQQ	O
sodium	O
salt	O
derivative	O
represented	O
in	O
the	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2	O
and	O
R3	O
can	O
be	O
identical	O
or	O
different	O
and	O
respectively	O
represents	O
H,	O
ammonium	O
ion	O
(	O
NH3	O
)	O
,	O
potassium	O
ion,	O
sodium	O
ion,	O
magnesium	O
ion,	O
calcium	O
ion	O
or	O
zinc	O
ion,	O
and	O
at	O
least	O
one	O
of	O
R1,	O
R2	O
and	O
R3	O
is	O
sodium	O
ion	O
.	O
The	O
invention	O
has	O
mild	O
reaction	O
conditions,	O
easy	O
product	O
refining	O
and	O
purification,	O
simple	O
preparation	O
steps	O
and	O
high	O
yield	O
more	O
than	O
80	O
%	O
.	O
The	O
PQQ	O
sodium	O
salt	O
derivative	O
has	O
the	O
functions	O
of	O
inhibiting	O
GSK-3	B-GENE
activity,	O
reducing	O
senile	O
pigment	O
formation	O
in	O
a	O
transgenic	O
mouse	O
brain,	O
reducing	O
tau	B-GENE
protein	O
phosphorylation	O
and	O
the	O
like	O
.	O
Thus,	O
the	O
PQQ	O
sodium	O
salt	O
derivative	O
can	O
be	O
medically	O
used	O
for	O
treating	O
senile	O
dementia	O
and	O
other	O
diseases	O
.	O


The	O
invention	O
discloses	O
4-alkyl-6-aryl-2-acylamino-1,3-thiazine-5-formic	O
ether	O
having	O
the	O
following	O
chemical	O
structural	O
formula	O
shown	O
in	O
the	O
specification	O
.	O
The	O
preparation	O
method	O
of	O
the	O
4-alkyl-6-aryl-2-acylamino-1,3-thiazine-5-formic	O
ether	O
(	O
I	O
)	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
adding	O
2-benzal-2-acyl	O
acetate	O
and	O
thiourea	O
in	O
organic	O
solvent,	O
stirring	O
at	O
55-80	O
DEG	O
C	O
under	O
acid	O
catalysis,	O
filtering	O
and	O
washing	O
after	O
reacting	O
completely,	O
and	O
drying	O
to	O
obtain	O
4-alkyl-6-aryl-2-amino-1,3-thiazine-5-formic	O
ether	O
salt	O
;	O
neutralizing	O
the	O
4-alkyl-6-aryl-2-amino-1,3-thiazine-5-formic	O
ether	O
salt	O
with	O
alkali	O
to	O
obtain	O
4-alkyl-6-aryl-2-amino-1,3-thiazine-5-formic	O
ether	O
;	O
and	O
acylating	O
the	O
4-alkyl-6-aryl-2-amino-1,3-thiazine-5-formic	O
ether	O
to	O
obtain	O
the	O
4-alkyl-6-aryl-2-acylamino-1,3-thiazine-5-formic	O
ether	O
(	O
I	O
)	O
.	O
The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
the	O
4-alkyl-6-aryl-2-acylamino-1,3-thiazine-5-formic	O
ether	O
in	O
preparing	O
the	O
drug	O
of	O
neuraminidase	B-GENE
inhibitor	O
.	O


The	O
invention	O
discloses	O
a	O
ginkgo	O
flavone	O
complex	O
preparation	O
for	O
treating	O
dyslipidemia,	O
which	O
is	O
composed	O
of	O
the	O
following	O
components	O
:	O
ginkgo	O
flavone	O
and	O
any	O
HMG-COA	B-GENE
reductase	I-GENE
inhibitor	O
.	O
The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
ginkgo	O
flavone	O
complex	O
preparation	O
fully	O
performs	O
the	O
complementary	O
synergistic	O
effect	O
of	O
drugs	O
according	O
to	O
drug	O
medication,	O
is	O
favourable	O
for	O
roundly	O
regulating	O
dyslipidemia	O
and	O
reduces	O
adverse	O
reaction	O
relevant	O
to	O
certain	O
dose	O
enhancement	O
;	O
and	O
the	O
effective	O
ingredients	O
of	O
the	O
natural	O
vegetable	O
drug	O
ginkgo	O
flavone	O
are	O
combined	O
with	O
other	O
chemical	O
drugs	O
for	O
lowering	O
blood	O
fat	O
so	O
as	O
to	O
lower	O
TC,	O
LDL-C	O
and	O
TG,	O
improve	O
HDL-C,	O
effectively	O
regulate	O
dyslipidemia	O
and	O
cause	O
the	O
blood	O
fat	O
to	O
reach	O
the	O
standard	O
.	O
The	O
complex	O
preparation	O
of	O
the	O
invention	O
has	O
the	O
characteristics	O
of	O
short	O
course	O
of	O
treatment,	O
quick	O
response,	O
small	O
side	O
effect	O
and	O
low	O
cost	O
.	O


The	O
invention	O
relates	O
to	O
a	O
composition	O
of	O
cefazedone	O
sodium	O
sterile	O
and	O
clavulanate	O
potassium	O
and	O
a	O
proportion	O
thereof	O
.	O
The	O
composition	O
is	O
characterized	O
by	O
consisting	O
of	O
cefazedone	O
sodium	O
sterile	O
and	O
clavulanate	O
potassium	O
in	O
a	O
weight	O
ratio	O
of	O
1	O
:	O
1-8	O
:	O
1	O
.	O
In	O
infectious	O
diseases	O
caused	O
by	O
bacteria,	O
certain	O
bacteria	O
generate	O
beta-lactamase	B-GENE
which	O
has	O
medicament	O
resistance	O
to	O
cefazedone,	O
so	O
the	O
treatmentis	O
not	O
effective	O
.	O
After	O
the	O
cefazedone	O
sodium	O
sterile	O
and	O
the	O
clavulanate	O
potassium	O
are	O
applied	O
in	O
combination,	O
different	O
proportions	O
of	O
the	O
composition	O
have	O
different	O
and	O
relatively	O
strong	O
antibacterial	O
activities	O
to	O
gram	O
negative	O
bacilli	O
and	O
gram	O
positive	O
coccus	O
which	O
generates	O
beta-lactamase	B-GENE
.	O
Tests	O
show	O
that	O
the	O
composition	O
is	O
sensitive	O
to	O
the	O
bacteria	O
strain	O
generating	O
beta-lactamase,	O
so	O
thatthe	O
antibiotic	O
action	O
of	O
the	O
cefazedone	O
sodium	O
sterile	O
can	O
be	O
increased	O
by	O
times	O
and	O
the	O
enzyme-generating	O
strain	O
is	O
restored	O
to	O
be	O
sensitive	O
to	O
the	O
cefazedone	O
sodium	O
sterile	O
.	O
The	O
test	O
bases	O
are	O
enough	O
;	O
the	O
clinical	O
antibacterial	O
effect	O
is	O
clear	O
;	O
and	O
the	O
happening	O
of	O
adverse	O
reactions	O
is	O
not	O
increased	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
a	O
B	O
/	O
E	O
ring	O
substituted	O
silybin	O
for	O
preparing	O
a	O
medicament	O
for	O
treating	O
virus	O
hepatitis	O
B,	O
in	O
particular	O
to	O
the	O
application	O
of	O
a	O
B	O
ring	O
ethoxy	O
and	O
E	O
ring	O
methoxy	O
substituted	O
silybin	O
ester	O
or	O
medicinal	O
salts	O
thereof	O
for	O
preparing	O
the	O
medicament	O
for	O
eliminating	O
hepatitis	O
B	O
virus	O
surface	O
antigens	O
and	O
hepatitis	O
B	O
e	O
antigen	O
and	O
inhibiting	O
HBV	O
and	O
DNA	O
replication	O
.	O
The	O
medicament	O
has	O
accurate	O
activity	O
of	O
inhibiting	O
HBsAg	B-GENE
and	O
HbeAg,	O
and	O
respective	O
intensity	O
of	O
18	O
.	O
5	O
%	O
and	O
23	O
.	O
0	O
%	O
in	O
eliminating	O
HBsAg	B-GENE
and	O
HbeAg	B-GENE
at	O
the	O
concentration	O
of	O
100	O
microgram	O
/	O
ml,	O
which	O
exceeds	O
the	O
positive	O
control	O
medicament	O
of	O
an	O
alpha-interferon	O
;	O
and	O
meanwhile,	O
23	O
.	O
3	O
%	O
inhibition	O
ratio	O
on	O
HBV	O
and	O
DNA	O
is	O
displayed	O
at	O
the	O
concentration	O
of	O
100	O
microgram	O
/	O
ml	O
;	O
and	O
therefore,	O
flavonoid	O
lignans	O
or	O
a	O
medicinal	O
salt	O
thereof	O
are	O
proved	O
to	O
have	O
the	O
efficacy	O
of	O
inhibiting	O
HbsAg,	O
HbeAg,	O
HBV	O
and	O
DNA	O
.	O
The	O
application	O
is	O
predictably	O
used	O
for	O
preparing	O
the	O
non-nucleoside	O
medicament	O
for	O
eliminating	O
HBsAg	B-GENE
and	O
HbeAg,	O
inhibiting	O
HBV	O
and	O
DNA	O
replication	O
and	O
treating	O
hepatitis	O
B	O
virus	O
infectious	O
diseases	O
.	O


This	O
invention	O
provides	O
novel	O
compounds	O
that	O
are	O
modulators	O
of	O
gamma	B-GENE
secretase	I-GENE
.	O
The	O
compounds	O
have	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R2	O
is	O
a	O
fused	O
bicyclic	O
ring	O
of	O
the	O
formula	O
(	O
II	O
)	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
modulating	O
gamma	B-GENE
secretase	I-GENE
activity	O
and	O
methods	O
of	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
using	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
discloses	O
new	O
application	O
of	O
imatinib	O
mesylate	O
.	O
The	O
invention	O
provides	O
application	O
of	O
imatinib	O
mesylate	O
in	O
preparing	O
products	O
for	O
inhibiting	O
neuronal	O
apoptosis,	O
and	O
the	O
application	O
of	O
imatinib	O
mesylate	O
in	O
preparing	O
products	O
for	O
treating	O
neurodegenerative	O
diseases	O
.	O
The	O
neuron	O
is	O
hippocampal	O
neuron	O
.	O
The	O
experiments	O
of	O
the	O
invention	O
show	O
that	O
STI571	O
serving	O
as	O
a	O
c-Abl	B-GENE
specific	O
inhibitor	O
can	O
be	O
used	O
as	O
a	O
new	O
medicine	O
candidate	O
for	O
treating	O
cerebral	O
ischemia	O
and	O
neurodegenerative	O
diseases,	O
and	O
has	O
good	O
application	O
prospect	O
;	O
and	O
the	O
clinical	O
indications	O
of	O
STI571	O
can	O
be	O
expanded	O
greatly	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
composition	O
containing	O
nitrobrate,	O
which	O
is	O
formed	O
by	O
using	O
the	O
nitrobrate	O
and	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
as	O
active	O
components	O
to	O
be	O
combined	O
with	O
pharmaceutically	O
acceptable	O
assistant	O
materials	O
.	O
The	O
composition	O
can	O
be	O
prepared	O
into	O
oral	O
preparations	O
of	O
granules,	O
tablets,	O
capsules,	O
soft	O
capsules,	O
chewable	O
tablets,	O
orally	O
disintegrating	O
tablets,	O
buccal	O
tablets,	O
pills	O
and	O
the	O
like,	O
and	O
can	O
be	O
used	O
for	O
controlling	O
and	O
reducing	O
the	O
level	O
of	O
blood	O
fat	O
for	O
long	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
application	O
of	O
puerarin	O
to	O
the	O
pharmacy	O
field,	O
i	O
.	O
e	O
.	O
application	O
of	O
puerarin	O
to	O
preparing	O
a	O
medicine	O
for	O
treating	O
a	O
P2X3	B-GENE
receptor	O
mediated	O
nerve	O
system	O
disease	O
.	O
Experiments	O
show	O
that	O
the	O
puerarin	O
can	O
inhibit	O
algesthesia	O
behavior	O
reaction	O
;	O
observed	O
from	O
technologies	O
of	O
applying	O
immunohistochemistry,	O
in-situ	O
hybridization,	O
RT-PCR,	O
Western	O
blotting	O
and	O
the	O
like,	O
the	O
puerarin	O
can	O
inhibit	O
nerve	O
pathological	O
pain	O
model	O
rat	O
dorsal	O
root	O
ganglion,	O
burn	O
model	O
rat	O
dorsal	O
root	O
ganglion,	O
sensory	O
nerve	O
ending	O
P2X3	B-GENE
receptor	O
mRNA	O
and	O
protein	O
expression	O
;	O
and	O
observed	O
from	O
whole	O
cell	O
patch	O
clamp	O
technologies,	O
the	O
puerarin	O
can	O
remarkably	O
reduce	O
activating	O
current	O
of	O
a	O
neuron	O
P2X3	B-GENE
receptor	O
stimulant	O
of	O
the	O
pathological	O
pain	O
model	O
rat	O
dorsal	O
root	O
ganglion	O
.	O
Experiments	O
show	O
that	O
the	O
puerarin	O
has	O
the	O
inhibition	O
function	O
on	O
acute	O
and	O
chronic	O
pains	O
for	O
inhibiting	O
the	O
primary	O
sensory	O
neuron	O
P2X3	B-GENE
receptor	O
mediated	O
algesthesia	O
information	O
transfer	O
.	O
The	O
invention	O
verifies	O
a	O
new	O
method	O
for	O
controlling	O
the	O
acute	O
and	O
the	O
chronic	O
pains,	O
presents	O
the	O
puerarin	O
has	O
the	O
function	O
of	O
a	O
P2X3	B-GENE
receptor	O
antagonist,	O
and	O
contributes	O
to	O
the	O
medicine	O
control	O
application	O
of	O
the	O
P2X3	B-GENE
receptor	O
related	O
to	O
the	O
nerve	O
system	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
4-cinnamoyl	O
chloride	O
substituted	O
silybin	O
to	O
preparing	O
glycosidase	B-GENE
inhibitors	O
and	O
in	O
particular	O
discloses	O
application	O
of	O
4-cinnamoyl	O
chloride	O
substituted	O
silybin	O
ester	O
flavonolignans	O
or	O
pharmaceutical	O
salt	O
thereof	O
to	O
preparing	O
drugs	O
for	O
inhibiting	O
alpha-glycosidase	B-GENE
and	O
preventing	O
and	O
treating	O
type	O
II	O
diabetes	O
.	O
The	O
flavonolignans	O
has	O
extremely	O
obvious	O
activity	O
for	O
inhibiting	O
alpha-glycosidase	B-GENE
and	O
the	O
intensity	O
of	O
activity	O
of	O
the	O
40mcg	O
/	O
ml	O
flavonolignans	O
for	O
inhibiting	O
alpha-glycosidase	B-GENE
reaches	O
92	O
.	O
1	O
%	O
.	O
The	O
measured	O
half-inhibitory	O
concentration	O
of	O
the	O
flavonolignans	O
shows	O
that	O
the	O
intensity	O
of	O
activity	O
of	O
the	O
flavonolignans	O
for	O
inhibiting	O
alpha-glycosidase	B-GENE
is	O
30	O
times	O
that	O
of	O
the	O
positive	O
control	O
drug	O
acarbose	O
.	O
The	O
pharmacodynamics	O
result	O
shows	O
that	O
the	O
flavonolignans	O
or	O
pharmaceutical	O
salt	O
thereof	O
can	O
be	O
expected	O
to	O
be	O
applied	O
to	O
preparing	O
glycosidase	B-GENE
inhibitors,	O
especially	O
the	O
drugs	O
for	O
preventing	O
and	O
treating	O
type	O
II	O
diabetes	O
.	O


The	O
invention	O
discloses	O
a	O
structure	O
of	O
medical	O
compounds	O
from	O
mesembrianthemum	O
plants,	O
which	O
is	O
obtained	O
by	O
a	O
plurality	O
of	O
extract	O
methods	O
.	O
The	O
compounds	O
can	O
be	O
used	O
as	O
a	O
serotonin	O
uptake	O
inhibitor	O
and	O
a	O
phosphodiesterase-4	B-GENE
inhibitor	O
and	O
used	O
for	O
curing	O
depression,	O
psychology	O
and	O
nerve	O
system	O
disease	O
related	O
to	O
the	O
depression,	O
alcoholism,	O
drug	O
addiction,	O
cigarette	O
and	O
various	O
narcotics	O
addiction,	O
asthma,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
psoriasis	O
and	O
psoriasis	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicaments,	O
and	O
relates	O
to	O
application	O
of	O
a	O
phenylamine	O
acid	O
compound	O
in	O
preparing	O
a	O
medicament	O
for	O
inducing	O
activation	O
of	O
HIV	O
latent	O
cells	O
.	O
The	O
phenylamine	O
acid	O
compound	O
comprises	O
MGCD0103	O
or	O
MS275	O
.	O
One	O
important	O
reason	O
that	O
the	O
HIV	O
is	O
difficult	O
to	O
be	O
completely	O
cleared	O
in	O
vivo	O
is	O
that	O
the	O
HIV-1	O
can	O
be	O
concealed	O
in	O
resting	O
memory	O
CD4+T	O
cells	O
.	O
The	O
phenylamine	O
acid	O
compound	O
has	O
the	O
effect	O
of	O
inducing	O
the	O
activation	O
of	O
HIV	O
latent	O
cells	O
;	O
when	O
being	O
added	O
into	O
cell	O
culture	O
solution,	O
the	O
phenylamine	O
acid	O
compound	O
can	O
induce	O
the	O
activation	O
of	O
HIV	O
latent	O
cells	O
;	O
and	O
the	O
phenylamine	O
acid	O
compound	O
also	O
can	O
form	O
an	O
anti-HIV	O
medicinal	O
composition	O
together	O
with	O
methyltransferase	B-GENE
inhibitor	O
or	O
cytokine	B-GENE
or	O
NF-kB	B-GENE
signal	O
activating	O
agent,	O
and	O
also	O
can	O
be	O
used	O
with	O
the	O
conventional	O
HIV	O
medicament	O
to	O
well	O
inhibit	O
and	O
eliminate	O
HIV	O
viruses	O
.	O
Compared	O
with	O
similar	O
compounds,	O
the	O
phenylamine	O
acid	O
compound	O
has	O
good	O
effect	O
of	O
inducing	O
the	O
activation	O
of	O
HIV	O
latent	O
cells,	O
and	O
mainly	O
has	O
low	O
toxicity	O
to	O
cells	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
scutellarin	O
shown	O
as	O
a	O
formula	O
I	O
to	O
the	O
treatment	O
of	O
microglia-mediated	O
diseases	O
.	O
Typically,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
scutellarin	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
the	O
microglia-mediated	O
diseases,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
scutellarin	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
microglia-mediated	O
neurotoxicity-caused	O
neural	O
immune	O
inflammatory	O
diseases	O
.	O
The	O
scutellarin	O
has	O
the	O
novel	O
functions	O
of	O
remarkably	O
inhibiting	O
the	O
generation	O
of	O
inflammatory	O
mediators,	O
namely	O
nitric	O
oxide	I-GENE
(	O
NO	O
)	O
,	O
a	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(TNF)	I-GENE
alpha	I-GENE
and	O
interleukin	B-GENE
(IL)-1beta	I-GENE
which	O
activate	O
microglia,	O
inhibiting	O
the	O
expression	O
of	O
inducible	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
(	O
iNOS	B-GENE
)	O
,	O
TNF	B-GENE
alpha	I-GENE
and	O
IL-1beta	B-GENE
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
,	O
inhibiting	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
microglia,	O
reducing	O
the	O
activation	O
of	O
nuclear	B-GENE
factor	I-GENE
(NF)-kappa	I-GENE
B	I-GENE
and	O
remarkably	O
alleviating	O
the	O
cytotoxicity	O
of	O
the	O
microglia	O
to	O
neurons	O
.	O
Therefore,	O
the	O
scutellarin	O
can	O
be	O
applied	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
brain	O
immune	O
inflammatory	O
related	O
diseases	O
such	O
as	O
Parkinson	O
'	O
s	O
disease	O
and	O
the	O
like	O
.	O
The	O
formula	O
I	O
is	O
shown	O
in	O
the	O
specifications	O
.	O


The	O
invention	O
relates	O
to	O
an	O
antitumor	O
medicine	O
composition	O
and	O
application	O
thereof	O
.	O
The	O
composition	O
comprises	O
maslinic	O
acid	O
or	O
physiologically	O
acceptable	O
salts	O
or	O
derivatives	O
thereof	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
used	O
in	O
combination	O
.	O
The	O
acting	O
effects	O
of	O
the	O
composition	O
are	O
superior	O
to	O
the	O
added	O
effects	O
of	O
each	O
medicine	O
used	O
individually	O
.	O
The	O
combination	O
use	O
can	O
effectively	O
reduce	O
the	O
toxic	O
and	O
side	O
effects	O
produced	O
by	O
the	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
used	O
individually,	O
so	O
that	O
the	O
composition	O
used	O
in	O
combination	O
can	O
be	O
used	O
for	O
treating	O
tumor	O
and	O
related	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
1,4-disulfide-7-azaspiro	O
[	O
4,4	O
]	O
nonane-8-carboxylic	O
acid	O
derivative	O
histone	B-GENE
deacetylase	I-GENE
inhibitor,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
compound	O
has	O
a	O
structure	O
shown	O
by	O
a	O
formula	O
(	O
I	O
)	O
,	O
and	O
is	O
prepared	O
by	O
using	O
(	O
S	O
)	O
-7-	O
(	O
butyloxycarbonyl	O
)	O
-1,4-disulfide-7-azaspiro	O
[	O
4,4	O
]	O
nonane-8-carboxylic	O
acid	O
and	O
6-amino	O
n-hexoic	O
acid	O
methyl	O
ester	O
hydrochloride	O
as	O
intermediates	O
.	O
The	O
invention	O
provides	O
a	O
potent	O
histone	B-GENE
deacetylase	I-GENE
inhibitor,	O
which	O
is	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
or	O
treating	O
mammal	O
diseases	O
associated	O
with	O
the	O
abnormal	O
expression	O
of	O
histone	B-GENE
deacetylase	I-GENE
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
medicinal	O
composite	O
containing	O
the	O
compound	O
with	O
the	O
structure	O
of	O
the	O
formula	O
(	O
I	O
)	O
.	O


Fused	O
pyridines	O
of	O
formula	O
(	O
I	O
)	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
have	O
activity	O
as	O
inhibitors	O
of	O
c-Met	B-GENE
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
various	O
diseases	O
and	O
disorders	O
including	O
cancer	O
.	O
Processes	O
for	O
synthesizing	O
the	O
compounds	O
are	O
also	O
described	O
.	O


The	O
invention	O
relates	O
to	O
4,5-dihydro-thiazinogeldanamycin	O
which	O
is	O
a	O
new	O
geldanamycin	O
derivative	O
obtained	O
by	O
genetic	O
engineering	O
technology,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
new	O
derivative	O
is	O
obtained	O
by	O
constructing	O
a	O
geldanamycin	O
producing	O
strain	O
streptomyces	O
hygrocopicus	O
17997	O
P450	B-GENE
monooxygenase	I-GENE
gene	O
(	O
gdmP	B-GENE
)	O
blocked	O
mutant	O
and	O
performing	O
fermentation	O
and	O
extraction	O
;	O
and	O
a	O
research	O
result	O
shows	O
that	O
the	O
4,5-dihydro-thiazinogeldanamycin	O
has	O
antiviral	O
activity	O
and	O
extremely	O
high	O
water	O
solubility	O
and	O
is	O
expected	O
to	O
be	O
developed	O
into	O
a	O
clinically	O
useful	O
antiviral	O
medicament	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry,	O
in	O
particular	O
to	O
optical	O
isomers	O
of	O
indene	O
quinazoline,	O
a	O
preparation	O
method	O
and	O
medicinal	O
application	O
thereof	O
.	O
The	O
structural	O
formulas	O
of	O
the	O
optical	O
isomers	O
are	O
I,	O
II,	O
III	O
and	O
IV	O
.	O
Pharmacological	O
experiments	O
prove	O
that	O
affinity	O
and	O
selectivity	O
of	O
the	O
optical	O
isomers	O
on	O
a	O
k-receptor	B-GENE
are	O
superior	O
to	O
those	O
of	O
a	O
racemic	O
body	O
MB-1C,	O
and	O
the	O
analgesic	O
activity	O
of	O
the	O
optical	O
isomers	O
is	O
9	O
to	O
10	O
times	O
that	O
of	O
the	O
racemic	O
body	O
MB-1C	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
novel	O
imidazolidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
to	O
R3,	O
A,	O
D	O
and	O
E	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
These	O
compounds	O
bind	O
to	O
LXR	B-GENE
alpha	I-GENE
and	O
LXR	B-GENE
beta	I-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


The	O
invention	O
discloses	O
a	O
fistula	O
affused	O
liquid	O
medicine	O
for	O
treating	O
anal	O
fistula	O
.	O
A	O
formula	O
of	O
the	O
liquid	O
medicine	O
comprises	O
a	O
pre-decay-cleaning	O
fistula	O
affused	O
liquid	O
medicine	O
and	O
an	O
after-decay-cleaning	O
fistula	O
affused	O
liquid	O
medicine	O
.	O
The	O
pre-decay-cleaning	O
fistula	O
affused	O
liquid	O
medicine	O
comprises	O
the	O
components	O
of	O
tinidazole,	O
hydrogen	O
peroxide,	O
iodophor,	O
ceftriaxone	O
sodium	O
and	O
gentamicin,	O
and	O
the	O
after-	O
decay-cleaning	O
fistula	O
affused	O
liquid	O
medicine	O
comprises	O
the	O
components	O
of	O
recombinant	O
alkalinity	O
fibroblast	B-GENE
growth	I-GENE
factor,	O
the	O
tinidazole,	O
glucose,	O
hemorrhoid	O
injection	O
and	O
the	O
ceftriaxone	O
sodium	O
.	O
The	O
two	O
sets	O
of	O
liquid	O
medicines	O
are	O
respectively	O
and	O
uniformly	O
mixed	O
and	O
are	O
successively	O
affused	O
from	O
an	O
outer	O
opening	O
of	O
the	O
anal	O
fistula	O
to	O
achieve	O
an	O
inner	O
opening	O
through	O
a	O
fistula,	O
a	O
yarn	O
piece	O
is	O
utilized	O
for	O
covering	O
the	O
outer	O
opening	O
of	O
the	O
anal	O
fistula,	O
and	O
the	O
anal	O
fistula	O
is	O
cured	O
after	O
a	O
certain	O
time	O
.	O
The	O
fistula	O
affused	O
liquid	O
medicine	O
for	O
treating	O
the	O
anal	O
fistula	O
has	O
the	O
advantages	O
of	O
simple	O
method,	O
low	O
treatment	O
cost	O
and	O
short	O
treatment	O
time,	O
keeps	O
the	O
perianal	O
tissue	O
structure	O
intact	O
and	O
ensures	O
that	O
pain	O
is	O
less,	O
recovery	O
is	O
quick,	O
and	O
recurrence	O
rate	O
is	O
low	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
quinazoline	O
derivative,	O
and	O
preparation	O
method	O
and	O
application	O
thereof,	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
chemistry	O
and	O
relates	O
to	O
a	O
quinazoline	O
derivative	O
which	O
is	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
.	O
In	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1,	O
R2,	O
R3,	O
A,	O
X,	O
m	O
and	O
n	O
have	O
meanings	O
defined	O
in	O
the	O
specifications	O
respectively	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
derivative,	O
physiologically	O
acceptable	O
salt	O
which	O
is	O
prepared	O
from	O
the	O
derivative,	O
inorganic	O
or	O
organic	O
acid	O
or	O
alkali	O
and	O
a	O
medicinal	O
composition	O
which	O
comprises	O
the	O
derivative	O
and	O
the	O
physiologically	O
acceptable	O
salt	O
.	O
A	O
compound	O
has	O
a	O
valuable	O
pharmacological	O
property,	O
and	O
particularly	O
plays	O
a	O
role	O
in	O
suppressing	O
signal	O
transduction	O
caused	O
by	O
tyrosine	B-GENE
kinase	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
application	O
of	O
the	O
derivative	O
to	O
the	O
treatment	O
of	O
diseases,	O
particularly	O
tumor	O
disease	O
and	O
the	O
preparation	O
method	O
of	O
the	O
derivative	O
.	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof,	O
which	O
can	O
be	O
used	O
as	O
an	O
activator	O
for	O
a	O
PPAR	B-GENE
.	O
(	O
In	O
the	O
formula,	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
an	O
alkyl	O
group	O
having	O
1	O
to	O
8	O
carbon	O
atoms,	O
an	O
alkyl	O
group	O
having	O
1	O
to	O
8	O
carbon	O
atoms	O
and	O
substituted	O
by	O
a	O
halogen	O
atom,	O
or	O
the	O
like	O
;	O
R3,	O
R4,	O
R5	O
and	O
R6	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
an	O
alkyl	O
group	O
having	O
1	O
to	O
8	O
carbon	O
atoms,	O
or	O
the	O
like	O
;	O
X	O
represents	O
a	O
sulfur	O
atom	O
or	O
the	O
like	O
;	O
Y	O
represents	O
an	O
oxygen	O
atom,	O
a	O
bond	O
or	O
the	O
like	O
;	O
p	O
represents	O
a	O
number	O
of	O
0	O
or	O
1	O
;	O
A	O
represents	O
an	O
oxygen	O
atom,	O
CH2,	O
N-NH2	O
or	O
the	O
like	O
;	O
B	O
represents	O
a	O
benzene	O
ring	O
which	O
may	O
have	O
a	O
substituent	O
when	O
p	O
is	O
1,	O
or	O
B	O
represents	O
a	O
fused	O
ring	O
selected	O
from	O
a	O
benzisoxazole	O
ring	O
which	O
may	O
have	O
a	O
substituent	O
and	O
others	O
when	O
p	O
is	O
0	O
;	O
m	O
represents	O
an	O
integer	O
of	O
1	O
to	O
4	O
;	O
and	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
5	O
.	O
)	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
the	O
treatment	O
of	O
superficial	O
bladder	O
cancer	O
and	O
inflammatory	O
diseases	O
of	O
the	O
bladder	O
which	O
employs	O
certain	O
Toll-like	B-GENE
Receptor	I-GENE
(	O
TLR	B-GENE
)	O
-agonists	O
.	O


The	O
invention	O
relates	O
to	O
a	O
5-amino-4-hydroxy-7-benzyl-8-methylnonanamide	O
derivative,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
in	O
medicines	O
.	O
Specifically,	O
the	O
invention	O
relates	O
to	O
a	O
novel	O
5-amino-4-hydroxy-7-benzyl-8-methylnonanamide	O
derivative	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
in	O
the	O
specification,	O
a	O
preparation	O
method	O
thereof,	O
and	O
medicinal	O
composition	O
containing	O
the	O
derivative	O
as	O
well	O
as	O
application	O
of	O
the	O
medicinal	O
composition	O
as	O
a	O
therapeutical	O
agent,	O
particularly	O
as	O
a	O
Renin	B-GENE
inhibitor	O
and	O
medicaments	O
for	O
treating	O
and	O
resisting	O
high	O
blood	O
pressure	O
and	O
diseases	O
related	O
to	O
Renin	B-GENE
activities,	O
wherein	O
all	O
substituent	O
groups	O
in	O
the	O
general	O
formula	O
(	O
1	O
)	O
are	O
identical	O
to	O
those	O
defined	O
in	O
the	O
specification	O
.	O


The	O
invention	O
provides	O
novel	O
compounds	O
that	O
are	O
inhibitors	O
of	O
PDKI	B-GENE
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds,	O
and	O
methods	O
of	O
treating	O
proliferative	O
diseases,	O
such	O
as	O
cancers,	O
with	O
the	O
compounds	O
or	O
composition	O
.	O


The	O
invention	O
concerns	O
the	O
combinations	O
of	O
an	O
mGluR	B-GENE
modulator,	O
e	O
.	O
g	O
.	O
an	O
mGluR5	B-GENE
modulator	O
and	O
at	O
least	O
one	O
of	O
L-dopa,	O
a	O
dopamine	O
modulator,	O
e	O
.	O
g	O
.	O
a	O
dopamine	O
agonist,	O
a	O
dopa	B-GENE
decarboxylase	I-GENE
inhibitor	O
or	O
a	O
catechol-O-methyl	B-GENE
transferase	I-GENE
inhibitor	O
.	O
The	O
invention	O
is	O
used	O
for	O
treating	O
parkinson	O
'	O
s	O
disease	O
and	O
related	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
the	O
anticancer	O
effect	O
of	O
an	O
antagonist	O
of	O
a	O
neurokinin	O
receptor,	O
in	O
particular	O
to	O
a	O
method	O
of	O
treating	O
cancers	O
in	O
subjects,	O
relieving	O
cancer	O
symptoms	O
in	O
the	O
subjects,	O
or	O
inhibiting	O
the	O
proliferation	O
of	O
cancer	O
cells,	O
use	O
of	O
the	O
antagonist	O
of	O
the	O
neurokinin	B-GENE
receptor	I-GENE
in	O
the	O
preparation	O
of	O
medicines,	O
medicaments	O
or	O
pharmaceutical	O
compositions	O
for	O
treating	O
the	O
cancers,	O
relieving	O
the	O
cancer	O
symptoms,	O
or	O
inhibiting	O
the	O
proliferation	O
of	O
the	O
cancer	O
cells,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
product	O
which	O
comprises	O
the	O
antagonist	O
of	O
the	O
neurokinin	B-GENE
receptor	I-GENE
as	O
an	O
active	O
component,	O
and	O
aspecification	O
comprising	O
the	O
pharmaceutical	O
product	O
.	O


The	O
invention	O
relates	O
to	O
a	O
sorafenib	O
tosylate-hydroxypropyl-beta-cyclodextrin	O
clathrate	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
Sorafenib	O
plays	O
the	O
role	O
of	O
anticancer	O
by	O
inhibiting	O
RAS	B-GENE
/	O
RAF	B-GENE
/	O
MEK	B-GENE
(	O
methyl	O
ethyl	O
ketone	O
)	O
/	O
ERK	B-GENE
(	O
extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
)	O
signal	O
conducting	O
channels	O
and	O
inhibiting	O
tumor	O
angiogenesis,	O
and	O
is	O
directed	O
to	O
cancer	O
cells	O
instead	O
of	O
normal	O
cells	O
.	O
The	O
sorafenib	O
is	O
almost	O
insoluble	O
in	O
water,	O
and	O
the	O
average	O
relative	O
bioavailability	O
of	O
oral	O
administration	O
is	O
38	O
%	O
to	O
49	O
%	O
.	O
According	O
to	O
the	O
preparation	O
method	O
of	O
the	O
invention,	O
the	O
sorafenib	O
tosylate-hydroxypropyl-beta-cyclodextrin	O
clathrate	O
compound	O
is	O
prepared	O
based	O
on	O
the	O
clathrate	O
compound-forming	O
property	O
of	O
hydroxypropyl-beta-cyclodextrin,	O
thereby	O
increasing	O
medicine	O
dissolvability,	O
improving	O
medicine	O
dissolution	O
and	O
raising	O
medicine	O
bioavailability	O
.	O


The	O
invention	O
discloses	O
a	O
resveratrol	O
analogue	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
to	O
treatment	O
of	O
diseases	O
related	O
to	O
aging	O
and	O
SIRTI	B-GENE
enzyme	O
activity	O
.	O
The	O
resveratrol	O
analogue	O
disclosed	O
by	O
the	O
invention	O
has	O
an	O
eliminating	O
effect	O
on	O
DPPH	O
radical	O
(	O
DPPH	O
.	O
)	O
,	O
superoxide	O
anion	O
radical	O
(	O
O2	O
<	O
.	O
-	O
>	O
)	O
,	O
hydroxide	O
anion	O
radical	O
(	O
OH	O
.	O
)	O
and	O
nitrogen	O
peroxide	O
radical	O
(	O
OHOO	O
.	O
)	O
and	O
has	O
excellent	O
antioxidation	O
activity	O
.	O
Some	O
derivatives	O
of	O
the	O
resveratrol	O
analogue	O
are	O
SIRTI	B-GENE
enzyme	O
activating	O
agents	O
while	O
others	O
are	O
excellent	O
SIRT1	B-GENE
enzyme	O
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
application	O
of	O
taurochenodeoxycholic,	O
and	O
particularly	O
relates	O
to	O
novel	O
application	O
of	O
the	O
taurochenodeoxycholic	O
acid	O
in	O
treating	O
adverse	O
reactions	O
of	O
glucocorticoid	O
medicaments	O
.	O
Through	O
studying	O
on	O
the	O
taurochenodeoxycholic	O
acid,	O
the	O
inventor	O
discovers	O
that	O
the	O
taurochenodeoxycholic	O
acid	O
can	O
resist	O
apoptosis	O
of	O
suprarenal	O
gland	O
cells	O
and	O
promote	O
multiplication	O
of	O
adrenal	O
cortex	O
stem	O
cells	O
so	O
as	O
to	O
recover	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
inhibition	O
caused	O
by	O
the	O
glucocorticoid	O
medicaments,	O
promotes	O
osteoblast	O
to	O
secrete	O
osteocalcin	B-GENE
and	O
improve	O
the	O
reduced	O
bone	O
mineral	O
density	O
so	O
as	O
to	O
recover	O
osteoporosis	O
caused	O
by	O
the	O
glucocorticoid	O
medicaments,	O
and	O
can	O
reinforce	O
the	O
mucosal	O
immunity	O
function	O
and	O
promote	O
multiplication	O
of	O
small	O
intestine	O
stem	O
cells	O
;	O
therefore,	O
the	O
taurochenodeoxycholic	O
acid	O
can	O
be	O
directly	O
administrated	O
or	O
made	O
into	O
various	O
preparations	O
or	O
mixtures	O
for	O
preventing	O
and	O
treating	O
adverse	O
reactions	O
caused	O
by	O
the	O
glucocorticoid	O
medicaments	O
.	O


The	O
invention	O
relates	O
to	O
a	O
preparation	O
for	O
preventing	O
and	O
treating	O
osteoporosis	O
and	O
osteoarthrosis,	O
which	O
comprises	O
calcium	O
carbonate,	O
glucosamine	O
hydrochloride,	O
chondroitin	O
sulfate,	O
casein	O
phosphopeptide,	O
ossein,	O
manganese	O
chloride	O
and	O
vitamin	O
D3	O
serving	O
as	O
main	O
raw	O
materials	O
.	O
The	O
preparation	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
components	O
in	O
part	O
by	O
mass	O
:	O
200	O
to	O
300	O
parts	O
of	O
calcium	O
carbonate,	O
100	O
to	O
200	O
parts	O
of	O
glucosamine	O
hydrochloride,	O
40	O
to	O
100	O
parts	O
of	O
chondroitin	O
sulfate,	O
10	O
to	O
30	O
parts	O
of	O
casein	O
phosphopeptide,	O
60	O
to	O
120	O
parts	O
of	O
ossein,	O
1	O
to	O
3	O
parts	O
of	O
manganese	O
chloride,	O
atrace	O
amount	O
of	O
vitamin	O
D3	O
and	O
a	O
proper	O
amount	O
of	O
pharmaceutic	O
adjuvant	O
(	O
such	O
as	O
dextrin,	O
magnesium	O
stearate	O
and	O
the	O
like	O
)	O
;	O
and	O
the	O
preparation	O
is	O
prepared	O
into	O
capsules,	O
tablets	O
or	O
granules	O
by	O
a	O
production	O
process	O
of	O
mixing,	O
granulating,	O
drying,	O
filling	O
or	O
tabletting	O
and	O
the	O
like	O
.	O
The	O
preparation	O
has	O
the	O
advantages	O
that	O
by	O
different	O
mechanisms,	O
the	O
absorption	O
of	O
calcium	O
and	O
the	O
deposition	O
of	O
thecalcium	O
on	O
skeletons	O
are	O
promoted,	O
the	O
dissolution	O
and	O
loss	O
of	O
the	O
calcium	O
are	O
inhibited,	O
and	O
the	O
formation	O
of	O
bone	O
matrixes	O
is	O
promoted,	O
so	O
that	O
bone	O
density	O
is	O
increased	O
comprehensively	O
and	O
the	O
osteoarthrosis	O
is	O
prevented	O
.	O


The	O
invention	O
discloses	O
a	O
RNA	O
has-miR-29c	B-GENE
related	O
to	O
Hepatitis	O
B	O
Virus	O
(	O
HBV	O
)	O
and	O
liver	O
cancer	O
and	O
its	O
uses	O
in	O
inhibiting	O
HBV	O
infection	O
and	O
preventing	O
liver	O
cancer	O
from	O
generation	O
.	O
The	O
invention	O
is	O
directed	O
to	O
the	O
field	O
of	O
biology	O
technology	O
research	O
.	O
Based	O
on	O
qRT-PCR	O
technology,	O
it	O
is	O
found	O
that	O
compared	O
to	O
a	O
hepatocyte	O
lineage	O
HepG2,	O
the	O
has-miR-29c	B-GENE
has	O
a	O
down-regulation	O
of	O
expression	O
in	O
a	O
hepatoma	O
cell	O
line	O
.	O
A	O
bioinformatics	O
method	O
and	O
double	O
fluorescence	O
detection	O
are	O
used	O
to	O
determine	O
that	O
the	O
target	O
gene	O
of	O
has-miR-29c	B-GENE
is	O
Tnfaip3	B-GENE
.	O
The	O
has-miR-29c	B-GENE
expression	O
carrier	O
is	O
externally	O
transfected	O
.	O
It	O
is	O
observed	O
that	O
miR-29c	B-GENE
can	O
inhibit	O
the	O
growth	O
of	O
tumor	O
cells	O
for	O
a	O
short	O
period	O
and	O
has	O
a	O
certain	O
inhibition	O
effect	O
to	O
the	O
duplication	O
and	O
expression	O
of	O
HBV	O
DNA	O
.	O
The	O
target	O
gene	O
Tnfaip3	B-GENE
has	O
a	O
down-regulation	O
of	O
expression	O
both	O
on	O
mRNA	O
and	O
the	O
level	O
of	O
protein	O
.	O
The	O
research	O
result	O
shows	O
miR-29c	B-GENE
possibly	O
participates	O
in	O
the	O
generation	O
and	O
development	O
process	O
of	O
liver	O
cancer	O
related	O
to	O
HBV	O
through	O
its	O
target	O
gene	O
Tnfaip3	B-GENE
.	O
Therefore,	O
miR-29c	B-GENE
can	O
be	O
used	O
as	O
a	O
regulation	O
and	O
control	O
molecule	O
for	O
inhibiting	O
HBV	O
infection	O
and	O
preventing	O
liver	O
cancer	O
from	O
generation,	O
thereby	O
providing	O
a	O
theoretical	O
and	O
experimental	O
basis	O
for	O
clinic	O
prevention	O
and	O
treatment	O
.	O


The	O
invention	O
relates	O
to	O
a	O
medical	O
application	O
of	O
EB	B-GENE
(Epstein-Barr)	I-GENE
virus	I-GENE
miR-BART3	I-GENE
antisense	O
oligonucleotides,	O
in	O
particular	O
relating	O
to	O
an	O
application	O
of	O
EB	B-GENE
virus	I-GENE
miR-BART3	I-GENE
antisense	O
oligonucleotides	O
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
nasopharyngeal	O
darcinoma,	O
wherein	O
the	O
sequence	O
of	O
the	O
EB	B-GENE
virus	I-GENE
miR-BART3	I-GENE
antisense	O
oligonucleotides	O
is	O
ACACCUGGUGACUAGUGGUGCG	B-GENE
(	O
SEQ	O
ID	O
NO	O
:	O
1	O
)	O
.	O
The	O
EB	B-GENE
virus	I-GENE
miR-BART3	I-GENE
antisense	O
oligonucleotides	O
can	O
be	O
effectively	O
combined	O
with	O
mature	O
miRNA	O
of	O
the	O
EB	B-GENE
virus	I-GENE
to	O
block	O
the	O
expression	O
of	O
the	O
miRNA	O
and	O
corresponding	O
regulation	O
action	O
thereof,	O
thus	O
restraining	O
the	O
invasion	O
and	O
metastasis	O
of	O
nasopharyngeal	O
darcinoma	O
cells	O
;	O
and	O
the	O
miRNA	O
has	O
no	O
immunogenifcity,	O
thus	O
being	O
favorable	O
for	O
being	O
further	O
applied	O
in	O
preventing	O
the	O
recurrence	O
and	O
metastasis	O
of	O
the	O
nasopharyngeal	O
darcinoma	O
.	O
The	O
medicament	O
can	O
be	O
used	O
for	O
protecting	O
the	O
antisense	O
oligonucleotides	O
from	O
being	O
degraded	O
by	O
nuclease	O
and	O
prolonging	O
the	O
action	O
time,	O
has	O
higher	O
transfection	O
effciciency	O
than	O
that	O
of	O
commodity	O
liposome,	O
and	O
is	O
favorable	O
for	O
further	O
practical	O
clinical	O
development	O
and	O
application	O
.	O


The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
promoting	O
fracture	O
union	O
and	O
repairing	O
injured	O
nerves,	O
which	O
comprises	O
nerve	B-GENE
growth	I-GENE
factors,	O
neurotrophic	B-GENE
factors	I-GENE
and	O
antipyretic	O
analgesic	O
anti-inflammatory	O
agents	O
such	O
as	O
diclofenac	O
and	O
vitamin	O
B12	O
.	O
The	O
medicinal	O
composition	O
has	O
a	O
good	O
union	O
promoting	O
effect	O
on	O
patients	O
who	O
suffer	O
from	O
fractures	O
;	O
and	O
after	O
the	O
medicinal	O
composition	O
is	O
used	O
bythe	O
patients,	O
the	O
effect	O
is	O
obviously	O
superior	O
to	O
that	O
of	O
using	O
the	O
nerve	B-GENE
growth	I-GENE
factors	I-GENE
or	O
the	O
neurotrophic	B-GENE
factors	I-GENE
independently,	O
and	O
neurons	O
can	O
be	O
nourished	O
and	O
the	O
repair	O
of	O
the	O
injured	O
nerves	O
can	O
be	O
promoted	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
series	O
of	O
thiadiazole	O
histone	B-GENE
deacetylase	I-GENE
inhibitors	O
and	O
an	O
application	O
thereof	O
.	O
The	O
series	O
of	O
compounds	O
have	O
the	O
structure	O
in	O
a	O
general	O
formula	O
I,	O
has	O
the	O
inhibitory	O
activity	O
on	O
histone	B-GENE
deacetylase	I-GENE
and	O
proliferation	O
of	O
multiple	O
kinds	O
of	O
tumor	O
cells	O
as	O
is	O
shown	O
in	O
an	O
activity	O
screening	O
experiment,	O
and	O
can	O
be	O
possibly	O
used	O
for	O
treating	O
diseases	O
caused	O
by	O
disorder	O
of	O
activity	O
of	O
the	O
histone	B-GENE
deacetylase	I-GENE
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
application	O
of	O
a	O
composition	O
of	O
the	O
compounds	O
with	O
the	O
general	O
formula	O
I	O
.	O


Provided	O
herein	O
are	O
Heteroaryl	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
herein,	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
a	O
Heteroaryl	O
Compound	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
inflammatory	O
conditions	O
or	O
cancer,	O
and	O
conditions	O
treatable	O
or	O
preventable	O
by	O
inhibition	O
of	O
a	O
kinase	B-GENE
or	O
a	O
kinase	B-GENE
pathway	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
Heteroaryl	O
Compound	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
applications	O
of	O
8-oxy-8H-acenaphtho	O
(	O
1,2-b	O
)	O
pyrrole	O
derivatives	O
with	O
the	O
following	O
structures	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
cancer	O
treatment,	O
in	O
particular	O
to	O
applications	O
of	O
the	O
pyrrole	O
derivatives	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
colon	O
cancer,	O
liver	O
cancer,	O
stomach	O
cancer,	O
cervical	O
cancer,	O
ovarian	O
cancer,	O
lung	O
cancer,	O
breast	O
cancer,	O
prostate	O
cancer,	O
bladder	O
cancer	O
and	O
hematological	O
malignancies	O
.	O
In	O
addition,	O
the	O
invention	O
relates	O
to	O
applications	O
of	O
the	O
pyrrole	O
derivatives	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
FGFR1	B-GENE
selective	O
inhibitors	O
.	O
The	O
pyrrole	O
derivatives	O
have	O
strong	O
inhibition	O
effects	O
against	O
a	O
plurality	O
of	O
tumor	O
cells,	O
wherein,	O
some	O
compounds	O
are	O
Fibroblast	B-GENE
Growth	I-GENE
Factor	I-GENE
Receptor	I-GENE
(FGFR)	I-GENE
1	I-GENE
selective	O
inhibitors,	O
and	O
testing	O
results	O
show	O
that	O
there	O
is	O
a	O
structure-effective	O
relationship	O
between	O
the	O
inhibitory	O
activities	O
against	O
FGFR1	B-GENE
and	O
the	O
structures	O
of	O
the	O
compounds	O
.	O
The	O
study	O
confirms	O
that	O
the	O
FGFR1	B-GENE
inhibitors	O
can	O
obviously	O
prevent	O
migration	O
of	O
vascular	O
endothelial	O
cells,	O
formation	O
of	O
lumen	O
and	O
generation	O
of	O
newborn	O
blood	O
vessels	O
of	O
chicken	O
chorioallantoic	O
membrane	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicaments,	O
and	O
specifically	O
relates	O
to	O
1-naphthyl	O
benzophenone	O
derivatives	O
with	O
a	O
structural	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
salts	O
thereof,	O
stereochemical	O
isomers	O
thereof,	O
hydrates	O
and	O
solvates	O
thereof,	O
polycrystals	O
or	O
eutectic	O
crystals	O
thereof,	O
precursors	O
and	O
derivatives	O
with	O
identical	O
biological	O
functions	O
thereof,	O
a	O
preparation	O
method	O
thereof,	O
a	O
composition	O
containing	O
one	O
or	O
more	O
the	O
1-naphthyl	O
benzophenone	O
derivatives	O
and	O
application	O
thereof	O
in	O
the	O
relating	O
drugs	O
for	O
treating	O
AIDS	O
(	O
acquired	O
immune	O
deficiency	O
syndrome	O
)	O
and	O
the	O
like	O
.	O
Pharmacological	O
experiment	O
results	O
show	O
that	O
most	O
of	O
the	O
1-naphthyl	O
benzophenone	O
derivatives	O
have	O
strong	O
inhibition	O
activity	O
(	O
nanomolar	O
level	O
)	O
to	O
the	O
duplication	O
of	O
wile-type	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
-1strain	O
(	O
IIIB	O
)	O
,	O
and	O
partial	O
1-naphthyl	O
benzophenone	O
derivatives	O
have	O
strong	O
inhibition	O
activity	O
to	O
multiple	O
drug-resistant	O
HIV-1	O
strain	O
(	O
K103N	B-GENE
+	O
Y181C	B-GENE
)	O
,	O
so	O
that	O
the	O
1-naphthyl	O
benzophenone	O
derivatives	O
can	O
be	O
used	O
as	O
anti-HIV	O
drug	O
candidates	O
.	O


The	O
invention	O
relates	O
to	O
an	O
injection	O
oxytocin	O
for	O
loach	O
.	O
The	O
oxytocin	O
is	O
mixed	O
from	O
three	O
hormones	O
of	O
DOM,	O
LRHA	B-GENE
and	O
chorionic	O
gonadotropin,	O
wherein	O
an	O
amount	O
of	O
the	O
DOM	B-GENE
is	O
45-55mg	O
/	O
kg	O
;	O
an	O
amount	O
of	O
the	O
LRHA	B-GENE
is	O
90-110	O
[	O
mu	O
]	O
g	O
/	O
kg,	O
and	O
an	O
amount	O
of	O
the	O
chorionic	B-GENE
gonadotropin	I-GENE
is	O
7000-8000IU	O
/	O
kg	O
.	O
According	O
to	O
the	O
invention,	O
the	O
three	O
hormones	O
are	O
reasonably	O
proportioned	O
to	O
realize	O
an	O
objective	O
of	O
low	O
usage	O
amount	O
and	O
high	O
induction	O
efficiency	O
.	O


The	O
invention	O
which	O
relates	O
to	O
alcohol	O
compounds	O
provides	O
o-aminoalcohol	O
compounds,	O
a	O
preparation	O
method	O
thereof	O
and	O
an	O
application	O
thereof	O
.	O
Eight	O
natural	O
products	O
of	O
o-aminoalcohols	O
having	O
important	O
physiological	O
activities	O
and	O
derivatives	O
thereof	O
are	O
prepared	O
through	O
carrying	O
out	O
a	O
single	O
stereoselective	O
synthesis	O
and	O
a	O
four-step	O
process	O
on	O
an	O
amino	O
acid	O
which	O
is	O
cheap	O
and	O
easily	O
available	O
and	O
is	O
treated	O
as	O
a	O
raw	O
material	O
.	O
A	O
one-bottle	O
/	O
two-step	O
process	O
which	O
is	O
adopted	O
in	O
oxidative	O
addition	O
allows	O
a	O
target	O
of	O
single	O
stereoselectivity	O
to	O
be	O
realized	O
and	O
C-2	O
racemization	O
not	O
to	O
be	O
generated	O
in	O
asymmetric	O
synthesis	O
.	O
The	O
activity	O
of	O
the	O
compounds	O
as	O
an	O
FAAH	B-GENE
enzyme	O
inhibitor	O
is	O
analyzed	O
through	O
active	O
experiments,	O
so	O
results	O
provide	O
reliable	O
and	O
valuable	O
basis	O
for	O
medicinal	O
development	O
.	O
The	O
synthetic	O
process	O
which	O
has	O
the	O
advantages	O
of	O
generality,	O
concision,	O
high	O
efficiency,	O
single	O
selectivity,	O
cheap	O
and	O
easily	O
available	O
raw	O
materials,	O
and	O
simplicity	O
of	O
operation	O
and	O
separation	O
of	O
each	O
step	O
is	O
suitable	O
for	O
industrial	O
large-scale	O
production	O
.	O


The	O
invention	O
relates	O
to	O
a	O
thiazolidone	O
compound	O
which	O
can	O
be	O
used	O
as	O
a	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
(PPAR)	I-GENE
gamma	I-GENE
activator	O
.	O
The	O
thiazolidone	O
compound	O
and	O
the	O
PPAR	B-GENE
gamma	I-GENE
have	O
high	O
affinity	O
;	O
and	O
in	O
the	O
nanogram	O
molecular	O
concentration	O
level,	O
the	O
thiazolidone	O
compound	O
can	O
specifically	O
activate	O
the	O
PPAR	O
gamma,	O
thereby	O
being	O
an	O
ideal	O
PPAR	B-GENE
gamma	I-GENE
activator	O
.	O
The	O
thiazolidone	O
compound	O
and	O
salt	O
thereof	O
or	O
a	O
medical	O
composition	O
containing	O
the	O
same	O
can	O
achieve	O
a	O
favorable	O
effect	O
when	O
used	O
for	O
preventing	O
and	O
treating	O
diabetes	O
(	O
especially	O
Type	O
2	O
diabetes	O
)	O
,	O
obesity	O
and	O
metabolic	O
syndromes	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
nano	O
administration,	O
and	O
discloses	O
bufalin-loaded	O
valine-arginine-glycine-aspartic	B-GENE
acid-glutamic	I-GENE
acid	I-GENE
cyclic	O
peptide	O
(	O
VRGDG,	O
cRGD	B-GENE
)	O
-modified	O
polyethylene	O
glycol	O
monomethyl	O
ether-polylactic	O
acid	O
glycolic	O
acid-polylysine	O
(	O
bufalin-mPEG-PLGA-PLL-cRGD	O
)	O
nanoparticles,	O
a	O
preparation	O
method	O
of	O
the	O
nanoparticles,	O
and	O
application	O
of	O
the	O
nanoparticles	O
to	O
the	O
preparation	O
of	O
an	O
anti-tumor	O
medicine	O
.	O
The	O
preparation	O
method	O
of	O
the	O
nanoparticles	O
is	O
simple	O
and	O
convenient	O
and	O
suitable	O
for	O
large-scale	O
production	O
.	O


The	O
invention	O
relates	O
to	O
motifilin,	O
AK4,	O
NDRG2,	O
enolase	O
2,	O
myosin,	O
heme	B-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
and	O
application	O
of	O
three	O
new	O
proteins	O
in	O
the	O
aspect	O
of	O
screening	O
medicaments	O
for	O
preventing,	O
treating	O
and	O
alleviating	O
brain	O
ageing	O
.	O
The	O
invention	O
also	O
relates	O
to	O
application	O
of	O
UCH-L1	B-GENE
in	O
the	O
aspect	O
of	O
screening	O
and	O
preparing	O
the	O
medicament	O
for	O
preventing,	O
treating	O
and	O
alleviating	O
diseases	O
related	O
to	O
tau	B-GENE
protein	I-GENE
phosphorylation,	O
such	O
as	O
brain	O
ageing	O
.	O
The	O
invention	O
also	O
relates	O
to	O
application	O
of	O
a	O
UCH-L1	B-GENE
agonist	O
in	O
the	O
aspect	O
of	O
preparing	O
a	O
medicament	O
for	O
preventing,	O
treating	O
and	O
alleviating	O
diseases	O
related	O
to	O
tau	B-GENE
protein	I-GENE
phosphorylation,	O
such	O
as	O
brain	O
ageing	O
.	O
The	O
invention	O
also	O
relates	O
to	O
application	O
of	O
UCH-L3	B-GENE
in	O
the	O
aspect	O
of	O
screening	O
and	O
preparing	O
a	O
medicament	O
for	O
preventing,	O
treating	O
and	O
alleviating	O
diseases	O
related	O
to	O
tau	B-GENE
protein	I-GENE
phosphorylation,	O
such	O
as	O
brain	O
ageing,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
the	O
like	O
and	O
also	O
relates	O
to	O
application	O
of	O
a	O
UCH-L3	B-GENE
agonist	O
in	O
the	O
aspect	O
of	O
screening	O
and	O
preparing	O
a	O
medicament	O
for	O
preventing,	O
treating	O
and	O
alleviating	O
diseases	O
related	O
to	O
tau	B-GENE
protein	I-GENE
phosphorylation,	O
such	O
as	O
brain	O
ageing,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
the	O
like	O
.	O


The	O
invention	O
discloses	O
a	O
compound	O
medicament	O
containing	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitor	O
and	O
glucocorticoid	O
and	O
used	O
for	O
treating	O
dermatosis	O
.	O
The	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitor	O
consisting	O
of	O
glucocorticoid	O
and	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitor	O
which	O
serve	O
as	O
active	O
components,	O
and	O
one	O
or	O
more	O
auxiliary	O
materials	O
for	O
dermatologic	O
medicines,	O
is	O
one	O
of	O
roflumilast,	O
cilomilast,	O
CP	O
80633,	O
CGH	O
2466,	O
RS	O
25344,	O
YM976	O
and	O
salts	O
thereof,	O
preferentially,	O
one	O
of	O
CGH	O
2466,	O
RS	O
25344	O
and	O
salts	O
thereof	O
.	O


Disclosed	O
is	O
a	O
novel	O
excellent	O
prophylactic	O
or	O
therapeutic	O
method	O
for	O
rejections	O
in	O
various	O
types	O
of	O
organ	O
transplantation,	O
allergic	O
diseases,	O
autoimmune	O
diseases,	O
hematologic	O
tumors	O
and	O
others,	O
which	O
relies	O
on	O
a	O
selective	O
inhibitory	O
activity	O
on	O
PI3Kd	B-GENE
and	O
/	O
or	O
an	O
inhibitory	O
activity	O
on	O
the	O
production	O
of	O
IL-2	B-GENE
and	O
/	O
or	O
an	O
inhibitory	O
activity	O
on	O
the	O
proliferation	O
of	O
B	O
cells	O
(	O
including	O
an	O
inhibitory	O
activity	O
on	O
the	O
activation	O
of	O
B	O
cells	O
)	O
.	O
It	O
is	O
found	O
that	O
a	O
tri-substituted	O
triazine	O
derivative	O
or	O
a	O
tri-substituted	O
pyrimidine	O
derivative	O
has	O
a	O
selective	O
inhibitory	O
activity	O
on	O
PI3Kd	B-GENE
and	O
/	O
or	O
an	O
inhibitory	O
activity	O
on	O
the	O
production	O
of	O
IL-2	B-GENE
and	O
/	O
or	O
an	O
inhibitory	O
activity	O
on	O
the	O
proliferation	O
of	O
B	O
cells	O
(	O
including	O
an	O
inhibitory	O
activity	O
on	O
the	O
activation	O
of	O
B	O
cells	O
)	O
and	O
can	O
be	O
used	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
rejections	O
in	O
various	O
types	O
of	O
organ	O
transplantation,	O
allergic	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
asthma,	O
atopic	O
dermatitis	O
)	O
,	O
autoimmune	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
rheumatoid	O
arthritis,	O
psoriasis,	O
ulcerative	O
colitis,	O
Crohn	O
diseases,	O
systemic	O
lupus	O
erythematosus	O
)	O
,	O
hematologic	O
tumors	O
(	O
e	O
.	O
g	O
.	O
,	O
leukemia	O
)	O
and	O
others	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
a	O
compound	O
ainsliaidimer	O
A	O
in	O
preparing	O
a	O
nucleolus	O
transcription	O
factor	O
inhibitor	O
medicament	O
.	O
The	O
inventor	O
carries	O
out	O
experiments	O
of	O
detecting	O
activity	O
of	O
NF	B-GENE
(nuclear	I-GENE
factor)-kappa	I-GENE
B	I-GENE
by	O
adopting	O
EMSA	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
,	O
detecting	O
differences	O
of	O
NF-kappa	B-GENE
B	I-GENE
in	O
cells	O
by	O
immunochemical	O
luminescent	O
assay,	O
detecting	O
expression	O
of	O
the	O
NF-kappa	O
in	O
ainsliaidimer	O
A	O
acting	O
HL-60	O
cells	O
by	O
a	O
Western	O
blot	O
method,	O
detecting	O
expression	O
of	O
apoptosis	O
related	O
protein	O
in	O
lymphoma	O
cell	O
CA46	O
cell	O
after	O
action	O
of	O
the	O
ainsliaidimer	O
A	O
by	O
the	O
Western	O
blot	O
method,	O
detecting	O
influence	O
of	O
the	O
ainsliaidimer	O
A	O
on	O
HL-60	O
cell	O
secretion	O
VEGF	B-GENE
(	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
)	O
and	O
the	O
like	O
.	O
Results	O
prove	O
that	O
the	O
ainsliaidimer	O
A	O
has	O
a	O
good	O
inhibition	O
effect	O
to	O
the	O
activity	O
of	O
the	O
NF-kappa	B-GENE
B	I-GENE
abnormally	O
activated	O
by	O
tumor	O
cells,	O
so	O
that,	O
the	O
compound	O
ainsliaidimer	O
A	O
serving	O
as	O
an	O
active	O
component	O
can	O
be	O
used	O
for	O
preparing	O
a	O
nucleolus	O
transcription	O
factor	O
inhibitor	O
medicament	O
.	O
The	O
medicament	O
can	O
be	O
used	O
as	O
novel	O
application	O
for	O
treating	O
leukemia,	O
autoimmune	O
diseases,	O
renal	O
diseases,	O
heart	O
cerebrovascular	O
diseases,	O
various	O
inflammations,	O
neurodegenerative	O
disorders	O
and	O
eye	O
disorders	O
of	O
animals	O
and	O
humans	O
caused	O
by	O
abnormally	O
activation	O
of	O
the	O
NF-kappa	B-GENE
B	I-GENE
factor,	O
thereby	O
providing	O
a	O
new	O
method	O
for	O
treating	O
the	O
diseases	O
and	O
disorders,	O
and	O
having	O
higher	O
clinical	O
application	O
value	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
arctigenin	O
as	O
shown	O
in	O
general	O
formula	O
(	O
1	O
)	O
and	O
its	O
derivative	O
in	O
preparing	O
medicaments	O
for	O
improving	O
body	O
tolerance	O
(	O
resisting	O
fatigue	O
)	O
,	O
and	O
application	O
of	O
pharmaceutical	O
compositions	O
containing	O
arctigenin	O
and	O
its	O
derivative	O
for	O
improving	O
body	O
tolerance	O
(	O
resisting	O
fatigue	O
)	O
.	O
The	O
arctigenin	O
and	O
its	O
derivative	O
play	O
a	O
promoting	O
role	O
in	O
AMPK	B-GENE
phosphorylation	O
.	O
Whole	O
animal	O
tests	O
show	O
that	O
compounds	O
of	O
the	O
invention	O
can	O
enhance	O
fatigue	O
tolerance	O
and	O
can	O
be	O
used	O
for	O
anti-fatigue	O
treatment	O
.	O


The	O
invention	O
discloses	O
an	O
ezrin	B-GENE
phosphorylation-based	O
material	O
and	O
application	O
thereof	O
.	O
The	O
invention	O
provides	O
application	O
of	O
the	O
material	O
for	O
inhibiting	O
phosphorylation	O
of	O
threonine	O
at	O
a	O
567th	O
site	O
of	O
Ezrin	B-GENE
to	O
preparation	O
of	O
products	O
with	O
functions	O
of	O
inhibiting	O
tumors	O
.	O
The	O
material	O
for	O
inhibiting	O
the	O
phosphorylation	O
of	O
the	O
threonine	O
at	O
the	O
567th	O
site	O
of	O
the	O
Ezrin	B-GENE
is	O
one	O
of	O
1	O
:	O
a	O
coding	O
gene	O
or	O
recombination	O
vector	O
or	O
recombination	O
adenovirus	O
;	O
and	O
2	O
:	O
a	O
material	O
for	O
inhibiting	O
a	O
signal	O
channel	O
of	O
mediating	O
the	O
phosphorylation	O
of	O
the	O
threonine	O
at	O
the	O
567th	O
site	O
of	O
the	O
Ezrin	B-GENE
.	O
Experiments	O
prove	O
that	O
the	O
phosphorylation	O
of	O
the	O
threonine	O
at	O
the	O
567th	O
site	O
of	O
the	O
Ezrin,	O
generated	O
in	O
liver	O
cancer	O
transfer	O
is	O
controlled	O
by	O
Rho	B-GENE
kinase	I-GENE
(	O
ROCK	B-GENE
)	O
,	O
and	O
the	O
Rho	B-GENE
kinase	I-GENE
is	O
knocked	O
out	O
or	O
the	O
activity	O
of	O
the	O
ROCK	B-GENE
is	O
inhibited	O
so	O
that	O
the	O
generation	O
of	O
the	O
liver	O
cancer	O
can	O
be	O
reduced	O
.	O
The	O
ezrin	B-GENE
phosphorylation-based	O
material	O
develops	O
an	O
important	O
role	O
in	O
the	O
field	O
of	O
medicines	O
and	O
pharmacy,	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
.	O


The	O
invention	O
provides	O
a	O
coumarone	O
compound,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
in	O
the	O
medical	O
and	O
chemical	O
field,	O
the	O
structural	O
formula	O
of	O
the	O
coumarone	O
compound	O
is	O
shown	O
as	O
a	O
following	O
formula	O
:	O
;	O
the	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
the	O
application	O
of	O
the	O
compound	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
inhibiting	O
tumor	O
cells	O
biological	O
activity	O
.	O
According	O
to	O
the	O
invention,	O
a	O
traditional	O
PPAR	B-GENE
agonist	O
hydrophobic	O
tail	O
hydrophobic	O
tail	O
and	O
a	O
flexible	O
intermediate	O
coupling	O
chain	O
are	O
taken	O
as	O
a	O
mother	O
nucleus,	O
a	O
cis-structure	O
of	O
CombretastinA-4	O
is	O
referred	O
so	O
that	O
the	O
good	O
antineoplastic	O
activity	O
is	O
presented,	O
the	O
coumarone	O
structure	O
is	O
taken	O
as	O
an	O
aromatic	O
ring	O
center	O
between	O
an	O
acidic	O
head	O
and	O
the	O
flexible	O
coupling	O
chain	O
in	O
the	O
PPAR	B-GENE
agonist,	O
the	O
preparation	O
method	O
of	O
compound	O
is	O
established	O
and	O
optimized,	O
and	O
the	O
prepared	O
novel	O
compound	O
is	O
carried	O
out	O
an	O
experiment	O
for	O
screening	O
the	O
tumor	O
cells	O
.	O
The	O
preliminary	O
antineoplastic	O
tests	O
confirm	O
that	O
the	O
prepared	O
partial	O
novel	O
compound	O
has	O
specific	O
and	O
exclusive	O
tumor	O
inhibition	O
activity	O
aimed	O
at	O
human	O
prostatic	O
cancer	O
cells,	O
the	O
coumarone	O
compound	O
can	O
be	O
used	O
for	O
preparing	O
the	O
antitumor	O
medicines	O
and	O
medicines	O
for	O
treating	O
and	O
preventing	O
tumor	O
.	O


Disclosed	O
is	O
a	O
novel	O
compound	O
which	O
inhibits	O
the	O
interaction	O
between	O
the	O
Mdm2	O
(	O
murine	B-GENE
double	I-GENE
minute	I-GENE
2	I-GENE
)	O
protein	O
and	O
the	O
p53	B-GENE
protein	I-GENE
and	O
has	O
an	O
antitumor	O
activity	O
.	O
Specifically	O
disclosed	O
is	O
an	O
imidazothiazole	O
derivative,	O
which	O
is	O
represented	O
by	O
formula	O
(	O
1	O
)	O
and	O
has	O
various	O
substituents	O
.	O
The	O
imidazothiazole	O
derivative	O
inhibits	O
interaction	O
between	O
the	O
Mdm2	B-GENE
protein	I-GENE
and	O
the	O
p53	B-GENE
protein,	O
and	O
has	O
an	O
antitumor	O
activity	O
.	O
(	O
In	O
formula	O
(	O
1	O
)	O
,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
Ar1	O
and	O
Ar2	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
)	O


Disclosed	O
are	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
:	O
n	O
is	O
zero	O
or	O
an	O
integer	O
selected	O
from	O
1	O
through	O
4	O
;	O
R1	O
is	O
cycloalkyl,	O
aryl,	O
heteroaryl,	O
or	O
heterocyclyl,	O
each	O
optionally	O
substituted	O
with	O
one	O
to	O
five	O
substituents	O
independently	O
selected	O
from	O
C1	O
to	O
C6	O
alkyl,	O
C1	O
to	O
C4	O
haloalkyl,	O
benzyl,	O
OR4,	O
and	O
/	O
or	O
halogen	O
;	O
and	O
R2,	O
R3,	O
R4,	O
and	O
n	O
are	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
using	O
such	O
compounds	O
as	O
selective	O
agonists	O
for	O
G	O
protein-coupled	O
receptor	O
S1P1,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
treating,	O
preventing,	O
or	O
slowing	O
the	O
progression	O
of	O
diseases	O
or	O
disorders	O
in	O
a	O
variety	O
of	O
therapeutic	O
areas,	O
such	O
as	O
autoimmune	O
diseases	O
and	O
vascular	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
a	O
reagent	O
and	O
a	O
method	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
diseases	O
.	O
According	O
to	O
the	O
invention,	O
it	O
is	O
revealed	O
for	O
the	O
first	O
time	O
that	O
chemotactic	O
factor	O
MCP-1	B-GENE
is	O
closely	O
related	O
to	O
aggregation	O
and	O
/	O
or	O
activation	O
of	O
microglia	O
and	O
neuronal	O
injury,	O
and	O
therefore,	O
MCP-1	B-GENE
can	O
be	O
used	O
as	O
a	O
drug	O
target	O
for	O
development	O
of	O
medicines	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
a	O
pyrrolopyrimidine	O
compound	O
and	O
a	O
use	O
thereof	O
.	O
Specifically	O
that	O
the	O
present	O
invention	O
provides	O
a	O
class	O
of	O
pyrrolopyrimidine	O
compounds	O
with	O
the	O
inhibitory	O
activity	O
of	O
JAK	B-GENE
kinase	I-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
drug	O
composition	O
containing	O
the	O
pyrrolopyrimidine	O
compound,	O
and	O
an	O
application	O
of	O
the	O
drug	O
composition	O
in	O
treatments	O
of	O
inflammatory	O
diseases,	O
cancer	O
and	O
other	O
diseases	O
.	O


Disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder,	O
which	O
has	O
a	O
novel	O
mechanism	O
of	O
action	O
that	O
is	O
difference	O
from	O
those	O
of	O
conventional	O
central	O
nervous	O
system	O
stimulating	O
agents	O
.	O
Specifically	O
disclosed	O
is	O
an	O
excellent	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder,	O
which	O
comprises	O
a	O
BEC1	B-GENE
potassium	I-GENE
channel	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient,	O
particularly	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
inattention,	O
impulsivity,	O
hyperactivity	O
and	O
the	O
like	O
in	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O


The	O
invention	O
discloses	O
acceptor	O
protein,	O
and	O
a	O
coding	O
gene	O
and	O
application	O
thereof	O
.	O
The	O
acceptor	O
protein	O
provided	O
in	O
the	O
invention	O
is	O
protein	O
as	O
described	O
by	O
1	O
)	O
or	O
2	O
)	O
:	O
1	O
)	O
protein	O
composed	O
of	O
an	O
amino	O
acid	O
sequence	O
as	O
represented	O
by	O
sequence	O
2	O
in	O
a	O
sequence	O
table	O
and	O
2	O
)	O
protein	O
which	O
is	O
derived	O
from	O
1	O
)	O
,	O
has	O
the	O
same	O
function	O
as	O
1	O
)	O
does	O
and	O
is	O
obtained	O
by	O
carrying	O
out	O
replacement	O
and	O
/	O
or	O
deletion	O
and	O
/	O
or	O
addition	O
of	O
one	O
amino	O
acid	O
residue	O
or	O
more	O
amino	O
acid	O
residues	O
on	O
the	O
amino	O
acid	O
sequence	O
as	O
represented	O
by	O
sequence	O
2	O
in	O
the	O
sequence	O
table	O
.	O
The	O
invention	O
provides	O
application	O
of	O
the	O
protein	O
ininhibiting	O
migration	O
and	O
/	O
or	O
proliferation	O
of	O
cancer	O
cells	O
or	O
application	O
of	O
the	O
coding	O
gene	O
in	O
inhibiting	O
migration	O
and	O
/	O
or	O
proliferation	O
of	O
cancer	O
cells	O
.	O
According	O
to	O
results	O
of	O
experiments	O
in	O
the	O
invention,	O
the	O
invention	O
provides	O
the	O
acceptor	O
protein	O
CCR18	B-GENE
of	O
CCL18,	O
and	O
medicines	O
for	O
inhibiting	O
migration	O
of	O
cancer	O
cells	O
can	O
be	O
prepared	O
through	O
inhibition	O
of	O
the	O
activity	O
of	O
the	O
acceptor	O
protein	O
CCR18	B-GENE
;	O
such	O
a	O
discovery	O
plays	O
an	O
important	O
role	O
in	O
the	O
fields	O
of	O
medical	O
science	O
and	O
pharmacy	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
2-gylcosyl	O
chinoline	O
compound	O
in	O
preparing	O
acetylcholine	B-GENE
esterase	I-GENE
resisting	O
medicines	O
.	O
The	O
2-gylcosyl	O
chinoline	O
compound	O
is	O
of	O
a	O
structural	O
formula	O
as	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R3	O
and	O
R4	O
independently	O
choose	O
-H,	O
-OCH3	O
or	O
-Br	O
.	O
A	O
preparation	O
method	O
of	O
the	O
2-gylcosyl	O
chinoline	O
compound	O
can	O
be	O
produced	O
according	O
to	O
the	O
prior	O
art	O
.	O
The	O
2-gylcosyl	O
chinoline	O
compound	O
is	O
strong	O
in	O
dissolubility	O
in	O
water,	O
high	O
in	O
biological	O
utilization,	O
strong	O
in	O
restrain	O
activity	O
on	O
acetylcholine	B-GENE
esterase	I-GENE
and	O
wide	O
in	O
application	O
prospect	O
on	O
preparing	O
acetylcholine	B-GENE
esterase	I-GENE
resisting	O
medicines	O
.	O
The	O
2-gylcosyl	O
chinoline	O
compound	O
is	O
simple	O
in	O
preparation	O
path,	O
low	O
in	O
cost,	O
small	O
in	O
environment	O
pollution	O
and	O
suitable	O
for	O
large-scale	O
industrial	O
production	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
(	O
E	O
)	O
-N-	O
[	O
2-	O
(	O
3,4-dimethoxyphenyl	O
)	O
ethyl	O
]	O
-3-phenylacrylamide	O
compound	O
1	O
in	O
preparation	O
for	O
a	O
medicine	O
resisting	O
Alzheimer	O
disease	O
.	O
An	O
animal	O
experiment	O
for	O
the	O
nerve	O
cells	O
of	O
a	O
primary	O
SD	O
rat	O
displays	O
that	O
:	O
the	O
compound	O
1	O
can	O
be	O
bound	O
with	O
alpha7nAChR,	O
and	O
the	O
binding	O
site	O
is	O
as	O
the	O
same	O
as	O
the	O
binding	O
site	O
of	O
bungatotoxin	O
.	O
Anti-inflammatory	O
activity	O
experiment	O
prompts	O
that	O
the	O
compound	O
1	O
has	O
good	O
anti-inflammatory	O
activity	O
.	O
The	O
compound	O
1	O
remarkably	O
improves	O
the	O
toxicity	O
of	O
the	O
nerve	O
cells	O
of	O
the	O
primary	O
SD	O
rat,	O
and	O
has	O
a	O
neuroprotective	O
effect	O
.	O
Moreover,	O
the	O
compound	O
1	O
can	O
directly	O
act	O
on	O
amyloid	O
protein,	O
so	O
as	O
to	O
achieve	O
reduction	O
for	O
the	O
toxic	O
effect	O
on	O
the	O
nerve	O
cells	O
acted	O
by	O
beta-amyloid	B-GENE
.	O
An	O
experiment	O
of	O
treating	O
a	O
mouse	O
by	O
scopolamine	O
indicates	O
that	O
the	O
compound	O
1	O
can	O
effectively	O
improve	O
the	O
learning	O
ability	O
and	O
the	O
memory	O
ability	O
of	O
experimental	O
animal	O
.	O
The	O
experiment	O
shows	O
that	O
the	O
compound	O
1	O
can	O
effectively	O
treat	O
the	O
senile	O
dementia	O
induced	O
by	O
beta-amyloid	B-GENE
by	O
means	O
of	O
exciting	O
alpha7-acetylcholine	O
receptor,	O
depolymerizing	O
beta-amyloid	B-GENE
and	O
the	O
like	O
.	O
Therefore,	O
the	O
compound	O
1	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicine	O
resisting	O
Alzheimer	O
disease,	O
and	O
has	O
great	O
clinical	O
application	O
value	O
.	O


The	O
invention	O
relates	O
to	O
piles	O
and	O
anus	O
internal	O
epithelium	O
and	O
rectum	O
mucous	O
epithelium	O
cell	O
anti-inflammation	O
celltrex	O
made	O
of	O
marine	O
organisms,	O
which	O
is	O
used	O
for	O
curing	O
general	O
diseases	O
of	O
piles,	O
anus	O
cryptitis,	O
anal	O
fissure,	O
anus	O
ache	O
(	O
abscess	O
around	O
anus	O
rectum	O
)	O
,	O
anal	O
fistula,	O
rectocele,	O
rectal	O
polyp,	O
aproctia	O
piles	O
and	O
the	O
like	O
.	O
After	O
the	O
celltrex	O
is	O
used,	O
cells	O
at	O
the	O
nidus	O
positions	O
of	O
skin	O
around	O
the	O
anus	O
and	O
anus	O
internal	O
epithelium	O
and	O
rectum	O
mucous	O
epithelium	O
can	O
get	O
rid	O
of	O
the	O
stale	O
and	O
take	O
in	O
the	O
fresh	O
to	O
repair	O
and	O
maintain	O
cells	O
at	O
the	O
nidus	O
in	O
targeted	O
mode,	O
and	O
symptom	O
of	O
pain,	O
swelling,	O
itching	O
and	O
the	O
like	O
of	O
patients	O
can	O
be	O
alleviated	O
.	O
The	O
piles	O
and	O
anus	O
internal	O
epithelium	O
and	O
rectum	O
mucous	O
epithelium	O
cell	O
anti-inflammation	O
celltrex	O
has	O
the	O
advantages	O
of	O
being	O
convenient	O
to	O
use,	O
safe,	O
free	O
of	O
toxic	O
and	O
odor,	O
hygienic,	O
convenient	O
to	O
carry,	O
free	O
of	O
stimulation	O
on	O
skin	O
mucosa	O
and	O
the	O
like	O
.	O
A	O
formula	O
of	O
the	O
piles	O
and	O
anus	O
internal	O
epithelium	O
and	O
rectum	O
mucous	O
epithelium	O
cell	O
anti-inflammation	O
celltrex	O
is	O
as	O
follows	O
(	O
constituents	O
and	O
by	O
weight	O
percentage	O
)	O
:	O
1	O
.	O
0	O
to	O
2	O
.	O
0	O
of	O
beta-chitosan	O
quaternary	O
ammonium	O
hyaluronic	O
acid	O
derivatives,	O
0	O
.	O
5	O
to	O
1	O
.	O
0	O
of	O
seaweed	O
polyose	O
derivatives,	O
6	O
.	O
0	O
to	O
8	O
.	O
0	O
of	O
marine	O
organism	O
alpha-spiral	O
cecropin,	O
0	O
.	O
5	O
to	O
1	O
.	O
5	O
of	O
biological	O
enzyme,	O
0	O
.	O
5	O
to	O
1	O
.	O
0	O
of	O
bornol	O
and	O
deionized	O
water	O
.	O
The	O
weight	O
percentage	O
of	O
the	O
deionized	O
water	O
can	O
be	O
added	O
to	O
100	O
with	O
weight	O
percentage	O
of	O
other	O
constituents	O
.	O


The	O
invention	O
relates	O
to	O
a	O
biphenyl	O
methylene-2-sulpho-4-thiazolone	O
compound	O
with	O
a	O
structure	O
shown	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound,	O
as	O
well	O
as	O
a	O
medicine	O
composition	O
containing	O
the	O
compound	O
.	O
A	O
biological	O
activity	O
test	O
proves	O
that	O
the	O
compound	O
can	O
obviously	O
inhibit	O
the	O
activity	O
of	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
(	O
PTP	O
)	O
-1B	O
.	O
Therefore,	O
the	O
biphenyl	O
methylene-2-sulpho-4-thiazolone	O
compound	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
for	O
the	O
PTP-1B	B-GENE
for	O
preventing	O
or	O
symptomatically	O
treating	O
diabetes	O
mellitus	O
or	O
adiposis	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
chemistry,	O
and	O
relates	O
to	O
a	O
quinazoline	O
derivate	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
the	O
preparation	O
method	O
and	O
the	O
application	O
thereof,	O
wherein	O
both	O
R1	O
and	O
R2	O
have	O
meanings	O
defined	O
in	O
an	O
instruction	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
derivative	O
.	O
The	O
derivative	O
and	O
inorganic	O
and	O
organic	O
acid	O
or	O
alkali	O
form	O
salt	O
which	O
is	O
acceptable	O
physiologically,	O
and	O
drug	O
combinations	O
containing	O
the	O
derivative	O
.	O
The	O
compound	O
has	O
valuable	O
pharmacological	O
properties	O
and	O
especially	O
plays	O
a	O
role	O
in	O
restraining	O
signal	O
transduction	O
aroused	O
by	O
tyrosine	B-GENE
kinase	I-GENE
;	O
and	O
particularly,	O
a	O
mutant	B-GENE
EGFR	I-GENE
(	O
Epidermal	B-GENE
Growth	I-GENE
Factor	I-GENE
Receptor	I-GENE
)	O
(	O
L858R	B-GENE
/	O
T790M	B-GENE
)	O
and	O
HER	B-GENE
2	I-GENE
have	O
higher	O
inhibitory	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
treating	O
diseases,	O
in	O
particular	O
to	O
diseases	O
characterized	O
in	O
abnormal	O
erbB	B-GENE
PTK	B-GENE
(	O
protein	B-GENE
tyrosine	B-GENE
kinase	I-GENE
)	O
activity	O
.	O
The	O
general	O
formula	O
(	O
I	O
)	O
is	O
as	O
follows	O
.	O


The	O
invention	O
discloses	O
a	O
nucleotide	O
analogue	O
and	O
a	O
synthesis	O
and	O
a	O
application	O
thereof	O
.	O
The	O
constitutional	O
formula	O
of	O
the	O
nucleotide	O
analogue	O
is	O
that	O
:	O
Tetra-O-Acetyl-D-Ribose	O
is	O
adopted	O
as	O
a	O
raw	O
material	O
and	O
generates	O
the	O
nucleotide	O
analogue	O
containing	O
a	O
triazole	O
ring	O
formwork	O
through	O
four	O
steps	O
of	O
reaction,	O
wherein	O
R	O
is	O
C2-C15	O
saturated	O
or	O
unsaturated	O
alkyl,	O
or	O
C2-C10	O
saturated	O
or	O
unsaturated	O
alkyl	O
containing	O
hetero	O
atoms	O
;	O
or	O
R	O
is	O
R1	O
which	O
is	O
hydroxyl,	O
alkoxy,	O
amino	O
or	O
substituent	O
amido	O
;	O
or	O
R	O
is	O
R2	O
which	O
is	O
aryl	O
or	O
saturated	O
or	O
unsaturated	O
alkyl	O
;	O
or	O
R	O
is	O
R3	O
which	O
is	O
halogen,	O
amono,	O
methoxyl,	O
methyl	O
or	O
other	O
substituent	O
.	O
The	O
nucleotide	O
analogue	O
can	O
restrain	O
the	O
growth	O
of	O
microorganism	O
such	O
as	O
escherichia	O
coli,	O
and	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
dehydrogenase	B-GENE
such	O
as	O
malate	B-GENE
dehydrogenase	B-GENE
.	O


A	O
pharmaceutical	O
composition	O
of	O
a	O
tubulin	B-GENE
polymerisation	O
inhibitor	O
and	O
an	O
mTOR	B-GENE
inhibitor	O
and	O
a	O
method	O
of	O
treating	O
proliferative	O
disease	O
with	O
a	O
combination	O
of	O
a	O
tubulin	B-GENE
polymerisation	O
inhibitor	O
and	O
an	O
mTOR	B-GENE
inhibitor	O


The	O
invention	O
relates	O
to	O
tanshinone	O
derivatives	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
tanshinone	O
derivatives	O
are	O
substituted	O
by	O
different	O
groups	O
on	O
A	O
ring,	O
B	O
ring,	O
C	O
ring,	O
and	O
D	O
ring	O
.	O
The	O
invention	O
also	O
relates	O
to	O
medicine	O
compositions	O
with	O
the	O
derivatives	O
as	O
active	O
components,	O
preparation	O
methods	O
of	O
the	O
medicines,	O
and	O
applications	O
thereof	O
in	O
preparing	O
a	O
1-type	B-GENE
11beta-hydroxysteroid	I-GENE
dehydrogenase	I-GENE
(	O
11beta-HSD1	B-GENE
)	O
inhibiting	O
agent	O
.	O
The	O
invention	O
also	O
provides	O
applications	O
of	O
the	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
preparations	O
of	O
medicines	O
used	O
for	O
treating	O
diabetes	O
and	O
related	O
metabolic	O
diseases	O
(	O
such	O
as	O
hypertension,	O
obesity,	O
senile	O
dementia,	O
and	O
the	O
like	O
)	O
.	O


The	O
invention,	O
belonging	O
to	O
the	O
pharmaceutical	O
field,	O
relates	O
to	O
a	O
novel	O
levo-meptazinol	O
bi-molecular	O
derivative	O
and	O
/	O
or	O
its	O
salt,	O
and	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O
The	O
levo-meptazinol	O
bi-molecular	O
derivative	O
and	O
/	O
or	O
its	O
salt	O
have	O
/	O
has	O
a	O
structure	O
having	O
general	O
formula	O
(	O
I	O
)	O
.	O
Experiments	O
show	O
that	O
the	O
compound	O
disclosed	O
herein	O
when	O
tested	O
in	O
vitro	O
exhibits	O
inhibitory	O
activities	O
against	O
acetylcholinesterase	B-GENE
and	O
metal	O
ion	O
chelation	O
activity,	O
can	O
be	O
further	O
developed	O
into	O
a	O
medicine	O
with	O
a	O
dual	O
function	O
for	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
.	O
In	O
addition,	O
the	O
compound	O
of	O
the	O
invention	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
preventing	O
or	O
treating	O
neurodegenerative	O
diseases	O
caused	O
by	O
free	O
radicals	O
oxidative	O
damage,	O
wherein	O
the	O
neurodegenerative	O
diseases	O
comprise	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
disease	O
and	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
discloses	O
a	O
4-	O
(	O
4-aminobenzene	O
sulfonamide	O
)	O
phenylacetic	O
acid	O
derivative	O
with	O
a	O
general	O
formula	O
shown	O
as	O
the	O
accompanying	O
drawing	O
.	O
The	O
4-	O
(	O
4-aminobenzene	O
sulfonamide	O
)	O
phenylacetic	O
acid	O
derivative	O
structurally	O
comprises	O
a	O
benzene	O
sulfonamide	O
structural	O
unit	O
and	O
a	O
phenylacetic	O
acid	O
structural	O
unit	O
.	O
According	O
to	O
in-vitro	O
antidiabetic	O
activity	O
determination	O
results,	O
the	O
compounds	O
have	O
a	O
certain	O
activity	O
of	O
stimulating	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptors	I-GENE
(	O
PPARs	B-GENE
)	O
.	O
The	O
PPAR	B-GENE
relative	O
stimulating	O
rate	O
of	O
partial	O
compounds	O
(	O
taking	O
pioglitazone	O
as	O
a	O
reference	O
)	O
exceeds	O
58	O
percent	O
and	O
reaches	O
81	O
.	O
79	O
percent	O
high	O
.	O
The	O
compounds	O
can	O
be	O
used	O
for	O
preparing	O
antidiabetic	O
drugs	O
and	O
can	O
also	O
be	O
used	O
as	O
pilot	O
molecules	O
of	O
novel	O
antidiabetic	O
drugs	O
for	O
deep	O
research	O
.	O
The	O
invention	O
additionally	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
through	O
multiple	O
lines,	O
the	O
method	O
is	O
simple	O
and	O
efficient	O
and	O
the	O
yield	O
is	O
high	O
.	O


The	O
invention	O
discloses	O
a	O
hydroxamic	O
acid	O
compound	O
and	O
a	O
preparation	O
method	O
as	O
well	O
as	O
application	O
of	O
the	O
compound	O
.	O
The	O
invention	O
also	O
discloses	O
a	O
medicine	O
combination	O
for	O
restraining	O
the	O
activity	O
of	O
histone	B-GENE
deacetylase	I-GENE
.	O
The	O
hydroxamic	O
acid	O
compound	O
provided	O
by	O
the	O
invention	O
has	O
good	O
inhibitory	O
effect	O
on	O
the	O
HDAC	B-GENE
in	O
vitro,	O
can	O
also	O
enter	O
tumor	O
cells	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
HDAC	B-GENE
in	O
the	O
tumor	O
cells	O
and	O
enhance	O
the	O
expression	O
of	O
acetylated	O
histone	O
and	O
cycle-related	O
proteins	O
and	O
has	O
the	O
anti-tumor	O
effect	O
;	O
and	O
the	O
anti-tumor	O
effect	O
of	O
the	O
hydroxamic	O
acid	O
compound	O
is	O
obviously	O
superior	O
to	O
that	O
of	O
SAHA	O
.	O


The	O
invention	O
relates	O
to	O
CXCR1	B-GENE
and	O
/	O
or	O
CXCR2	B-GENE
inhibitors	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
as	O
an	O
adjuvant	O
in	O
the	O
transplant	O
of	O
pancreatic	O
islets	O
in	O
Type	O
1	O
diabetes	O
patients	O
.	O
In	O
particular,	O
the	O
compounds	O
that	O
can	O
be	O
used	O
according	O
to	O
the	O
invention	O
have	O
the	O
following	O
formula	O
(	O
I	O
)	O
in	O
which	O
R	O
and	O
R	O
'	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
biomedicines,	O
in	O
particular	O
to	O
a	O
compound	O
medicine	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
fat	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
compound	O
medicine	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
fat	O
consists	O
of	O
a	O
thiazine	O
hypotensor	O
and	O
a	O
3-hydroxy-3-methylglutaryl	B-GENE
coenzyme	I-GENE
A	I-GENE
(HMG-CoA)	I-GENE
reductase	I-GENE
inhibitor,	O
and	O
can	O
simultaneously	O
treat	O
hypertension	O
and	O
hyperlipidemia	O
;	O
the	O
hypotensor	O
and	O
a	O
hypolipidemic	O
are	O
not	O
required	O
to	O
be	O
taken	O
simultaneously	O
;	O
the	O
compound	O
medicine	O
is	O
used	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
fat	O
by	O
synergistic	O
effect	O
of	O
the	O
thiazine	O
hypotensor	O
and	O
the	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor,	O
improves	O
compliance	O
of	O
patients	O
and	O
reduces	O
adverse	O
reaction	O
;	O
the	O
compound	O
medicine	O
has	O
a	O
good	O
therapeutic	O
effect	O
on	O
hypertension	O
and	O
hyperlipidemia	O
in	O
clinical	O
trials	O
;	O
and	O
moreover,	O
the	O
invention	O
also	O
provides	O
the	O
preparation	O
method	O
thereof,	O
technical	O
bottleneck	O
problems	O
are	O
solved,	O
the	O
thiazine	O
hypotensor	O
and	O
the	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
can	O
be	O
stably	O
used	O
in	O
the	O
compound	O
medicine,	O
respective	O
properties	O
of	O
the	O
thiazine	O
hypotensor	O
and	O
the	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
are	O
not	O
affected,	O
and	O
patients	O
suffering	O
from	O
hypertension	O
and	O
hyperlipidemia	O
are	O
simultaneously	O
effectively	O
treated	O
.	O


The	O
invention	O
discloses	O
2,7-substituted	O
3H-imidazole	O
[	O
4,5-b	O
]	O
pyridine	O
compounds	O
shown	O
as	O
the	O
structural	O
formula	O
I,	O
or	O
pharmaceutically	O
acceptable	O
salt,	O
ester	O
and	O
precursors,	O
and	O
/	O
or	O
hydrate	O
and	O
medicinal	O
compositions	O
thereof,	O
and	O
a	O
preparation	O
method	O
for	O
the	O
compounds	O
.	O
The	O
compounds,	O
or	O
pharmaceutically	O
acceptable	O
salt,	O
ester	O
and	O
precursors,	O
and	O
/	O
or	O
hydrate	O
and	O
medicinal	O
compositions	O
thereof	O
can	O
serve	O
as	O
antagonists	O
of	O
CR4	B-GENE
and	O
are	O
used	O
for	O
treating	O
or	O
preventing	O
CXCR4	B-GENE
receptor	O
activation	O
related	O
diseases	O
.	O


2-substituted-isoindol-1,	O
3-dione	O
compound	O
shown	O
in	O
the	O
following	O
formula	O
(	O
I	O
)	O
can	O
significantly	O
inhibit	O
activity	O
of	O
ribosomal	B-GENE
S6kinase2	I-GENE
(	O
RSK2	B-GENE
)	O
,	O
and	O
the	O
RSK2	B-GENE
plays	O
an	O
important	O
role	O
in	O
tumor	O
cell	O
proliferation,	O
and	O
differentiation	O
processes	O
.	O
Thus,	O
the	O
compound	O
of	O
the	O
invention	O
can	O
function	O
as	O
a	O
drug	O
for	O
treating	O
potential	O
tumors	O
and	O
related	O
diseases	O
.	O


The	O
invention	O
discloses	O
a	O
thiazolidone	O
compound,	O
which	O
has	O
a	O
chemical	O
structure	O
shown	O
as	O
a	O
general	O
formula	O
(	O
I	O
)	O
in	O
the	O
specification,	O
wherein	O
R1,	O
R2	O
and	O
R3	O
are	O
independently	O
selected	O
from	O
substituted	O
or	O
unsubstituted	O
C1-C6	O
alkyl	O
groups,	O
substituted	O
or	O
unsubstituted	O
C1-C6	O
unsaturated	O
hydrocarbyl	O
groups,	O
substituted	O
or	O
unsubstituted	O
C3-C8	O
naphthenic	O
groups,	O
substituted	O
or	O
unsubstituted	O
aryl	O
groups,	O
substituted	O
or	O
unsubstituted	O
aralkyl	O
groups,	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
groups,	O
substituted	O
or	O
unsubstituted	O
five-membered	O
to	O
seven-membered	O
heteroaralkyl	O
groups	O
and	O
substituted	O
or	O
unsubstituted	O
five-membered	O
to	O
seven-membered	O
heterocyclic	O
groups	O
respectively	O
.	O
The	O
thiazolidone	O
compound	O
can	O
be	O
used	O
for	O
selectively	O
and	O
effectively	O
killing	O
lung	O
cancer	O
cells	O
with	O
resistance	O
against	O
taxol	O
and	O
lung	O
cancer	O
cells	O
with	O
over-expressed	O
P	B-GENE
glycoprotein	I-GENE
but	O
has	O
no	O
serious	O
killing	O
effect	O
on	O
human	O
normal	O
fibroblast	O
;	O
and	O
the	O
thiazolidone	O
compound	O
is	O
expected	O
to	O
become	O
the	O
potential	O
anti-cancer	O
medicament	O
for	O
selectively	O
inducing	O
apoptosis	O
of	O
lung	O
cancer	O
tumor	O
and	O
effectively	O
treating	O
stubborn	O
lung	O
cancer	O
and	O
has	O
a	O
broad	O
clinical	O
application	O
prospect	O
.	O


The	O
invention	O
discloses	O
a	O
purpose	O
of	O
oleanolic	O
acid	O
and	O
belongs	O
to	O
an	O
application	O
of	O
oleanolic	O
acid	O
to	O
medicine	O
for	O
treating	O
obesity	O
.	O
The	O
oleanolic	O
acid	O
is	O
injected	O
into	O
the	O
abdominal	O
cavities	O
of	O
db	O
/	O
db	O
mice	O
with	O
obesity	O
and	O
diabetes,	O
the	O
blood	O
sugar	O
level	O
can	O
be	O
obviously	O
reduced,	O
the	O
body	O
weight	O
increase	O
is	O
obviously	O
decelerated,	O
and	O
the	O
internal	O
organ	O
fat	O
content	O
is	O
obviously	O
reduced	O
.	O
The	O
oleanolic	O
acid	O
is	O
added	O
in	O
the	O
primary	O
adipocyte	O
culture	O
liquid,	O
and	O
the	O
decomposition	O
of	O
triglyceride	O
can	O
be	O
obviously	O
promoted	O
.	O
Therefore,	O
the	O
oleanolic	O
acid	O
can	O
be	O
used	O
in	O
medicine	O
for	O
treating	O
the	O
obesity	O
and	O
relevant	O
diseases	O
caused	O
by	O
the	O
obesity,	O
and	O
in	O
addition,	O
side	O
effects	O
of	O
possibly	O
existing	O
blood	O
circulation	O
free	O
fatty	O
acid	O
increase	O
during	O
the	O
body	O
weight	O
reduction,	O
or	O
even	O
the	O
insulin	B-GENE
resistance	O
and	O
the	O
like	O
of	O
the	O
traditional	O
weight	O
reducing	O
medicine	O
can	O
be	O
overcome	O
.	O


The	O
invention	O
discloses	O
a	O
mesenchymal	O
stem	O
cell	O
and	O
the	O
application	O
thereof	O
in	O
resisting	O
HIV-1	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
mesenchymal	O
stem	O
cell	O
of	O
a	O
secreted-expression	O
high-concentration	O
keratinocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
KGF	B-GENE
)	O
,	O
and	O
the	O
mesenchymal	O
stem	O
cell	O
is	O
produced	O
through	O
a	O
micro-carrier	O
culturing	O
system	O
.	O
According	O
to	O
the	O
invention,	O
the	O
mesenchymal	O
stem	O
cell	O
can	O
be	O
used	O
for	O
promoting	O
the	O
development	O
of	O
the	O
thymus	O
gland,	O
maintaining	O
the	O
functions	O
of	O
the	O
thymus	O
gland,	O
and	O
enhancing	O
the	O
immunologic	O
function	O
of	O
specific	O
T	O
cells	O
through	O
increasing	O
the	O
output	O
of	O
T	O
lymphocytes	O
to	O
peripheral	O
blood,	O
thereby	O
achieving	O
an	O
effect	O
of	O
treating	O
HIV-1	O
infection,	O
and	O
providing	O
an	O
effective	O
new	O
strategy	O
for	O
the	O
clinical	O
treatment	O
of	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O


The	O
invention	O
provides	O
application	O
of	O
retinoic	O
acid	O
and	O
its	O
derivatives	O
in	O
preparation	O
of	O
drugs	O
preventing	O
and	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Retinoic	O
acid	O
and	O
its	O
derivatives	O
are	O
drug	O
candidate	O
molecules	O
that	O
can	O
be	O
used	O
for	O
controlling	O
Alzheimer	O
'	O
s	O
disease	O
.	O
According	O
to	O
the	O
invention,	O
retinoic	O
acid	O
and	O
its	O
derivatives	O
can	O
inhibit	O
amyloid	O
protein	O
induced	O
inflammatory	O
response	O
during	O
Alzheimer	O
'	O
s	O
disease	O
attacks	O
by	O
specifically	O
inhibiting	O
the	O
activity	O
of	O
transcription	B-GENE
factor	I-GENE
AP-1,	O
thus	O
delaying	O
the	O
occurrence	O
and	O
development	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Retinoic	O
acid	O
and	O
its	O
derivatives	O
can	O
substantially	O
improve	O
dyskinesias	O
of	O
SAM-P	O
/	O
8	O
mice,	O
obviously	O
enhance	O
brain	O
tissue	O
SOD	B-GENE
activity	O
of	O
SAM-P	O
/	O
8	O
mice,	O
reduce	O
brain	O
tissue	O
MDA	O
content,	O
lower	O
brain	O
tissue	O
cholinesterase	B-GENE
activity,	O
strengthen	O
the	O
activity	O
of	O
brain	O
tissue	O
Na	O
<	O
+	O
>	O
-K	O
<	O
+	O
>	O
-ATP	O
enzyme	O
and	O
Ca	O
<	O
2+	O
>	O
-ATP	O
enzyme	O
.	O
Application	O
of	O
retinoic	O
acid	O
and	O
its	O
derivatives	O
in	O
preparation	O
of	O
drugs	O
preventing	O
and	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
can	O
realize	O
inhibition	O
of	O
Alzheimer	O
'	O
s	O
disease	O
attack	O
processes	O
on	O
an	O
animal	O
level	O
.	O
Meanwhile,	O
the	O
small	O
molecular	O
drugs	O
adopted	O
in	O
the	O
invention	O
are	O
characterized	O
by	O
easy	O
acquisition,	O
low	O
price,	O
stable	O
property,	O
as	O
well	O
as	O
convenient	O
storage	O
and	O
transport	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
salidroside	O
in	O
preventing	O
and	O
treating	O
amyotrophy	O
diseases	O
.	O
Experiments	O
prove	O
that	O
salidroside	O
can	O
inhibit	O
the	O
expression	O
of	O
amyotrophy	B-GENE
peculiar	I-GENE
factor	I-GENE
Atrogin-1,	O
myotube	O
atrophy	O
and	O
reduction	O
of	O
skeletal	O
muscle	O
fiber	O
cross	O
section	O
area	O
during	O
the	O
amyotrophy	O
generating	O
process,	O
and	O
has	O
the	O
functions	O
of	O
increasing	O
the	O
content	O
of	O
slow-twitch	O
fiber	O
protein	I-GENE
in	O
skeletal	O
muscle	O
and	O
inhibiting	O
fast-twitch	B-GENE
fiber	I-GENE
protein	I-GENE
expression,	O
and	O
thus	O
the	O
amyotropy	O
is	O
prevented	O
and	O
resisted	O
.	O


The	O
invention	O
relates	O
to	O
a	O
7-	O
(	O
N-	O
(	O
2-pyridyl	O
)	O
sulfonamide	O
or	O
amido	O
)	O
-N-hydroxy	O
heptamide	O
derivative,	O
its	O
preparation	O
method	O
and	O
an	O
application	O
thereof,	O
and	O
provides	O
a	O
compound,	O
the	O
structure	O
of	O
which	O
is	O
as	O
shown	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
which	O
is	O
defined	O
in	O
the	O
specification	O
.	O
The	O
compound	O
provided	O
by	O
the	O
invention	O
has	O
a	O
good	O
activity	O
for	O
inhibiting	O
HDAC	B-GENE
and	O
will	O
be	O
hopefully	O
developed	O
into	O
a	O
novel	O
antitumor	O
drug	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines,	O
and	O
particularly	O
discloses	O
a	O
pyridazine	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
(HIV)-1	I-GENE
reverse	I-GENE
transcriptase	I-GENE
inhibitor,	O
a	O
preparation	O
method	O
and	O
the	O
application	O
of	O
the	O
composition	O
containing	O
one	O
or	O
more	O
compounds	O
in	O
preparation	O
of	O
medicines	O
for	O
resisting	O
HIV	O
.	O


The	O
invention	O
relates	O
to	O
a	O
cyclohexane	O
derivative,	O
its	O
preparation	O
method	O
and	O
its	O
application	O
in	O
medicines	O
.	O
Concretely	O
speaking,	O
the	O
invention	O
relates	O
to	O
the	O
novel	O
cyclohexane	O
derivative	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
its	O
preparation	O
method,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
derivative	O
and	O
a	O
use	O
of	O
the	O
derivative	O
as	O
a	O
therapeutic	O
agent,	O
especially	O
a	O
GPR119	B-GENE
agonist,	O
and	O
an	O
application	O
of	O
the	O
derivative	O
in	O
preparing	O
drugs	O
for	O
treating	O
diabetes,	O
metabolic	O
disorders,	O
and	O
other	O
diseases	O
.	O
Various	O
substituents	O
in	O
the	O
formula	O
(	O
I	O
)	O
are	O
the	O
same	O
as	O
the	O
definitions	O
in	O
the	O
instruction	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
use	O
of	O
a	O
small	O
molecule	O
inhibitor,	O
and	O
specifically	O
to	O
a	O
use	O
of	O
a	O
CDK	B-GENE
small	O
molecule	O
selective	O
inhibitor	O
6-	O
(	O
benzylamino	O
)	O
-2-	O
[	O
[	O
1-	O
(	O
hydroxymethyl	O
)	O
propyl	O
]	O
amino	O
]	O
-9-isopropylpurine	O
or	O
a	O
pharmaceutically-acceptable	O
salt	O
thereof	O
in	O
preparation	O
of	O
drugs	O
for	O
treatment	O
of	O
hand-foot-mouth	O
disease	O
virus	O
infection-related	O
diseases	O
caused	O
by	O
EV71	O
and	O
the	O
like	O
.	O


The	O
invention	O
provides	O
an	O
allopurinol	O
derivative	O
shown	O
in	O
a	O
formula	O
I	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O
The	O
allopurinol	O
derivative	O
can	O
effectively	O
inhibit	O
tumor	O
growth,	O
and	O
has	O
a	O
good	O
antitumor	O
effect	O
;	O
the	O
allopurinol	O
derivative	O
can	O
also	O
effectively	O
inhibit	O
xanthine	B-GENE
oxidase	I-GENE
activity,	O
can	O
be	O
used	O
for	O
gout	O
treatment,	O
and	O
provides	O
a	O
new	O
pharmaceutical	O
option	O
for	O
clinically	O
treating	O
cancer	O
and	O
gout	O
;	O
and	O
moreover,	O
the	O
preparation	O
method	O
of	O
the	O
compound	O
is	O
simple,	O
is	O
lower	O
in	O
cost,	O
and	O
has	O
high	O
yield	O
and	O
a	O
good	O
industrial	O
application	O
prospect	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
particularly	O
relates	O
to	O
2-indolone	O
derivatives	O
and	O
application	O
of	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
to	O
preparation	O
of	O
antioxidant	O
medicines	O
.	O
Pharmacological	O
experiments	O
on	O
the	O
2-indolone	O
derivatives	O
show	O
that	O
the	O
2-indolone	O
derivatives	O
can	O
enhance	O
the	O
antioxidant	O
capacity	O
of	O
cells	O
by	O
stabilizing	O
the	O
stability	O
of	O
an	O
Nrf2	B-GENE
protein,	O
activating	O
an	O
antioxidant	O
signal	O
passage	O
of	O
Nrf2	B-GENE
/	O
ARE,	O
increasing	O
expression	O
of	O
SOD,	O
NQO1,	O
HO-1,	O
a	O
Gamma-GCS	B-GENE
and	O
other	O
genes	O
and	O
enhancing	O
the	O
SOD	B-GENE
activity	O
;	O
the	O
2-indolone	O
derivatives	O
have	O
a	O
significant	O
protective	O
effect	O
on	O
oxidative	O
stress	O
damaging	O
agent	O
6-OHDA-induced	O
death	O
of	O
a	O
neuroblast	O
SH-SY5Y,	O
namely	O
have	O
an	O
anti-oxidative	O
damage	O
protective	O
effect	O
on	O
the	O
SH-SY5Y	O
cell	O
simulating	O
a	O
brain	O
neurocyte	O
;	O
in	O
addition,	O
the	O
2-indolone	O
derivatives	O
can	O
also	O
effectively	O
prevent	O
hydrogen	O
peroxide-induced	O
liver	O
cell	O
damage	O
and	O
inhibit	O
radiation-induced	O
cell	O
death	O
and	O
chromosome	O
aberration	O
;	O
therefore,	O
the	O
2-indolone	O
derivatives	O
have	O
positive	O
effects	O
of	O
resisting	O
the	O
oxidative	O
stress	O
damage	O
and	O
protecting	O
oxidative	O
resistance	O
of	O
a	O
brain	O
cell	O
tissue	O
and	O
can	O
be	O
expected	O
to	O
be	O
applied	O
to	O
preparation	O
of	O
2-indolone	O
derivative	O
medicines	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
ethoxy	O
sanguinarine	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
or	O
Sanguinarine	O
citrate	O
in	O
preparation	O
of	O
a	O
drug	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
cancer	O
.	O
Ethoxy	O
sanguinarine	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
or	O
Sanguinarine	O
citrate,	O
as	O
a	O
compound	O
which	O
can	O
effectively	O
lower	O
CIP2A	B-GENE
protein	O
and	O
inhibit	O
cancer	O
cell	O
proliferation,	O
has	O
latent	O
advantages	O
of	O
little	O
toxic	O
and	O
side	O
effect,	O
significant	O
effect	O
of	O
inhibiting	O
cancer	O
cell	O
proliferation,	O
broad-spectrum	O
anti-cancer	O
effect,	O
wide	O
source,	O
low	O
cost	O
and	O
the	O
like,	O
and	O
has	O
a	O
wide	O
anticancer	O
application	O
prospect	O
in	O
clinic	O
.	O


The	O
invention	O
discloses	O
a	O
Golgi	O
apparatus	O
membrane	O
protein	O
GP73	B-GENE
nucleic	O
acid	O
aptamer	O
of	O
which	O
the	O
nucleotide	O
sequence	O
is	O
shown	O
in	O
SEQ	O
ID	O
No	O
.	O
1	O
.	O
The	O
Golgi	O
apparatus	O
membrane	O
protein	O
GP73	B-GENE
nucleic	O
acid	O
aptamer	O
can	O
be	O
well	O
combined	O
with	O
Golgi	O
apparatus	O
membrane	O
protein	O
GP73,	O
has	O
high	O
specificity	O
and	O
sensitivity,	O
can	O
be	O
preserved	O
for	O
a	O
long	O
time	O
and	O
is	O
lower	O
in	O
cost	O
.	O
The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
aptamer	O
and	O
the	O
application	O
of	O
the	O
aptamer	O
in	O
preparing	O
diagnostic	O
or	O
therapeutic	O
hepatocellular	O
carcinoma	O
medicines	O
.	O


The	O
invention	O
provides	O
a	O
substituent	O
bis-aryl	O
methylene	O
naphthenic	O
base	O
derivative	O
with	O
the	O
structure	O
of	O
a	O
general	O
formula	O
I,	O
as	O
well	O
as	O
medical	O
salt	O
or	O
hydrate	O
thereof	O
.	O
The	O
class	O
of	O
compound	O
can	O
be	O
used	O
as	O
micromolecule	O
tubulin	B-GENE
inhibitor,	O
has	O
a	O
canaliculus	O
resistant	O
function,	O
also	O
has	O
an	O
obvious	O
anti-tumor	O
activity	O
function	O
and	O
has	O
the	O
advantages	O
of	O
small	O
molecular	O
weight,	O
simple	O
synthesis	O
and	O
small	O
toxic	O
and	O
side	O
effects	O
.	O
The	O
invention	O
also	O
provides	O
a	O
synthesis	O
method	O
for	O
the	O
substituent	O
bis-aryl	O
methylene	O
naphthenic	O
base	O
derivative,	O
and	O
an	O
anti-tumor	O
medicine	O
composition	O
which	O
takes	O
the	O
substituent	O
bis-aryl	O
methylene	O
naphthenic	O
base	O
derivative	O
and	O
the	O
medical	O
salt	O
of	O
the	O
substituent	O
bis-aryl	O
methylene	O
naphthenic	O
base	O
derivative	O
as	O
active	O
ingredients	O
.	O


The	O
invention	O
relates	O
to	O
bifunctional	O
small	O
interfering	O
ribonucleic	O
acid	O
(	O
siRNA	O
)	O
(	O
triphosphate-siRNA,	O
3p-siRNA	O
)	O
for	O
efficiently	O
and	O
specifically	O
inhibiting	O
the	O
expression	O
of	O
a	O
tumor-related	O
survivin	O
gene	O
and	O
inhibiting	O
the	O
proliferation	O
of	O
tumor	O
cells,	O
and	O
application	O
of	O
the	O
bifunctional	O
siRNA	O
.	O
The	O
anti-tumor	O
3p-siRNA	O
specifically	O
silences	O
the	O
expression	O
of	O
a	O
tumor	O
target	O
gene	O
survivin	O
through	O
a	O
RNA	O
interference	O
(	O
RNAi	O
)	O
mechanism,	O
can	O
also	O
activate	O
the	O
expression	O
activity	O
of	O
cell	O
factors	O
such	O
as	O
interferon	B-GENE
(	O
IFN	O
)	O
through	O
a	O
retinoic-acid-inducible	B-GENE
gene	I-GENE
I	I-GENE
(	O
RIG-I	B-GENE
)	O
dependency	O
mechanism	O
and	O
exert	O
the	O
antitumor	O
effect	O
through	O
the	O
antitumor	O
innate	O
immune	O
response	O
of	O
cells,	O
and	O
is	O
novel	O
bifunctional	O
anti-tumor	O
3p-siRNA	O
which	O
can	O
perform	O
RNAi	O
and	O
activate	O
the	O
innate	O
immune	O
response	O
of	O
cell	O
IFN	O
.	O
The	O
anti-tumor	O
3p-siRNA	O
has	O
low	O
toxicity,	O
can	O
efficiently	O
activate	O
the	O
expression	O
of	O
a	O
RIG-I-mediated	O
host	O
IFN,	O
can	O
remarkably	O
inhibit	O
the	O
expression	O
of	O
survivin	O
protein	O
in	O
the	O
tumor	O
cells	O
and	O
the	O
proliferation	O
of	O
the	O
tumor	O
cells	O
at	O
the	O
same	O
time,	O
and	O
can	O
promote	O
the	O
apoptosis	O
of	O
the	O
tumor	O
cells	O
.	O
The	O
anti-tumor	O
bifunctional	O
3p-siRNA	O
is	O
prepared	O
by	O
an	O
in-vitro	O
transcription	O
method	O
and	O
an	O
artificial	O
chemical	O
synthesis	O
method,	O
and	O
can	O
be	O
applied	O
to	O
the	O
research	O
and	O
development	O
of	O
medicines	O
for	O
treating	O
human	O
tumors	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
an	O
active	O
substance	O
to	O
treatment	O
of	O
hepatitis	O
C	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
active	O
substance	O
is	O
a	O
non-structural	B-GENE
protein	I-GENE
5A	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically-acceptable	O
salt	O
thereof,	O
is	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
(	O
1	O
)	O
C42H50N8O6,	O
and	O
is	O
762	O
.	O
39	O
in	O
mass	O
.	O
The	O
active	O
substance	O
has	O
the	O
advantage	O
of	O
applicability	O
to	O
treatment	O
of	O
hepatitis	O
C	O
.	O
The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
and	O
practicable	O
operation,	O
mild	O
conditions,	O
mature	O
process,	O
high	O
yield	O
and	O
purity	O
and	O
suitability	O
for	O
industrial	O
mass	O
production	O
.	O


The	O
invention	O
provides	O
a	O
dehydration-resistant	O
oral	O
liquid	O
which	O
comprises	O
sodium	O
chloride,	O
potassium	O
chloride,	O
potassium	O
hydrogen	O
phosphate,	O
sodium	O
citrate,	O
sodium	O
lactate,	O
glucose,	O
maltodextrin	O
and	O
mannitol	O
.	O
The	O
invention	O
has	O
the	O
following	O
advantages	O
:	O
oral	O
liquid	O
provided	O
by	O
the	O
invention	O
can	O
provide	O
stable	O
buffer	O
capacity,	O
which	O
is	O
favorable	O
for	O
maintaining	O
stabilization	O
of	O
a	O
pH	O
value	O
of	O
cell	O
sap	O
;	O
the	O
digestible	O
sugar	O
maltodextrin	O
which	O
does	O
not	O
cause	O
amplification	O
of	O
insulin	B-GENE
response	O
is	O
added	O
while	O
application	O
amount	O
of	O
glucose	O
is	O
reduced,	O
which	O
enables	O
the	O
possibility	O
of	O
amplification	O
of	O
insulin	B-GENE
response	O
to	O
be	O
reduced	O
;	O
drug	O
storage	O
stability	O
is	O
improved,	O
and	O
precipitation	O
and	O
deposition	O
of	O
crystals	O
are	O
reduced	O
;	O
vitamin	O
B	O
substances	O
are	O
added	O
so	O
as	O
to	O
allow	O
energy	O
of	O
a	O
body	O
to	O
be	O
released	O
and	O
a	O
mental	O
state	O
to	O
be	O
enhanced	O
;	O
distribution	O
of	O
all	O
the	O
components	O
in	O
a	O
solid	O
preparation	O
reaches	O
high	O
level	O
of	O
uniformity	O
.	O


The	O
present	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
provides	O
a	O
pramipexole	O
oral	O
liquid	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
Pramipexole	O
is	O
a	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
agonist	O
for	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
;	O
early	O
symptoms	O
of	O
the	O
Parkinson	O
'	O
s	O
disease	O
comprise	O
static	O
tremor,	O
myotonia,	O
bradykinesia,	O
and	O
abnormal	O
posture	O
and	O
gait	O
;	O
and	O
moderate	O
and	O
advanced	O
symptoms	O
of	O
the	O
Parkinson	O
'	O
s	O
disease	O
patients	O
often	O
comprise	O
difficult	O
chewing	O
and	O
swallowing	O
.	O
With	O
the	O
pramipexole	O
oral	O
liquid	O
of	O
the	O
present	O
invention,	O
medication	O
compliance	O
of	O
patients	O
is	O
easily	O
improved,	O
and	O
a	O
therapeutic	O
effect	O
is	O
improved	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
bone	O
disease	O
comprising	O
a	O
glyceollin	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
glyceollin	O
constituting	O
the	O
active	O
ingredient	O
of	O
the	O
present	O
invention	O
promotes	O
breakdown	O
of	O
the	O
Runx2	B-GENE
protein	O
in	O
osteoblasts,	O
reduces	O
the	O
Rankl	B-GENE
mRNA	I-GENE
level	O
and	O
so	O
suppresses	O
the	O
differentiation	O
of	O
osteoclasts,	O
and	O
has	O
greatly	O
alleviated	O
the	O
signs	O
of	O
osteoporosis	O
in	O
an	O
animal	O
model	O
of	O
osteoporosis	O
induced	O
by	O
the	O
administration	O
of	O
a	O
large	O
dose	O
of	O
vitamin	O
D	O
.	O
The	O
composition	O
of	O
the	O
present	O
invention	O
has	O
very	O
high	O
potential	O
to	O
be	O
developed	O
as	O
a	O
drug	O
or	O
food	O
for	O
the	O
prevention	O
or	O
treatment	O
of,	O
inter	O
alia,	O
osteoporosis	O
and	O
bone	O
disease	O
caused	O
by	O
bone	O
metastasis	O
of	O
cancer	O
cells	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines,	O
and	O
particularly	O
relates	O
to	O
a	O
pyridopyrimidine	O
mammalian	B-GENE
target	I-GENE
of	I-GENE
rapamycin	I-GENE
(	O
mTOR	B-GENE
)	O
inhibitor	O
which	O
is	O
shown	O
as	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
stereoisomers	O
thereof,	O
and	O
deuterated	O
pyridopyrimidine	O
mammalian	B-GENE
mTOR	B-GENE
inhibitors,	O
wherein	O
Z	O
<	O
1	O
>	O
,	O
Z	O
<	O
2	O
>	O
,	O
Z	O
<	O
3	O
>	O
,	O
R	O
<	O
1	O
>	O
,	O
R	O
<	O
2	O
>	O
,	O
R	O
<	O
3	O
>	O
,	O
X	O
and	O
W	O
are	O
defined	O
in	O
the	O
specifications	O
.	O
The	O
invention	O
also	O
relates	O
to	O
preparation	O
methods	O
for	O
the	O
compounds,	O
medicinal	O
inhibitors	O
and	O
medicinal	O
compositions	O
which	O
contain	O
the	O
compounds,	O
and	O
the	O
application	O
of	O
the	O
compounds	O
to	O
preparation	O
of	O
medicines	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
post-transplant	O
lymphoproliferative	O
diseases	O
which	O
have	O
response	O
to	O
inhibition	O
of	O
mTOR	B-GENE
activity	O
.	O


The	O
invention	O
relates	O
to	O
new	O
use	O
of	O
B	O
Salvianolic	O
acid	O
.	O
The	O
B	O
Salvianolic	O
acid	O
has	O
a	O
strong	O
inhibition	O
effect	O
to	O
tyrosinase,	O
thereby	O
being	O
used	O
for	O
whitening	O
skin,	O
removing	O
freckle,	O
resisting	O
wrinkle,	O
and	O
treating	O
hyperpigmentation	O
diseases,	O
and	O
being	O
applicable	O
to	O
food	O
additives	O
.	O
The	O
inhibition	O
of	O
the	O
B	O
Salvianolic	O
acid	O
to	O
the	O
activity	O
of	O
the	O
tyrosinase	B-GENE
is	O
detected,	O
the	O
B	O
Salvianolic	O
acid	O
is	O
very	O
high	O
in	O
the	O
activity	O
of	O
the	O
tyrosinase,	O
and	O
is	O
better	O
in	O
stability,	O
and	O
the	O
B	O
Salvianolic	O
acid	O
can	O
effectively	O
inhibit	O
the	O
generation	O
of	O
the	O
melanin,	O
and	O
can	O
be	O
taken	O
as	O
the	O
natural	O
skin-whitening	O
agent	O
for	O
cosmetics	O
.	O
Meanwhile,	O
the	O
B	O
Salvianolic	O
acid	O
can	O
more	O
preferably	O
promote	O
the	O
skin	O
cell	O
proliferation	O
function,	O
and	O
has	O
the	O
functions	O
of	O
beautifying	O
and	O
resisting	O
wrinkle,	O
thereby	O
being	O
applicable	O
to	O
the	O
cosmetics	O
with	O
the	O
functions	O
of	O
beautifying	O
and	O
resisting	O
wrinkle	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
phthalazinone	O
compounds	O
and	O
isomer	O
thereof,	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
chemically	O
protected	O
forms,	O
and	O
prodrugs	O
;	O
which	O
can	O
be	O
used	O
as	O
PARP	B-GENE
inhibitor	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
novel	O
phthalazinone	O
compounds	O
;	O
wherein	O
A,	O
R1	O
and	O
X	O
are	O
defined	O
as	O
shown	O
.	O
The	O
medicine	O
is	O
used	O
for	O
the	O
treatment	O
of	O
:	O
vascular	O
diseases,	O
neurotoxicity,	O
or	O
diseases	O
improved	O
through	O
the	O
inhibition	O
of	O
PARP	B-GENE
activity	O
;	O
or	O
used	O
as	O
adjuvants	O
for	O
the	O
treatment	O
of	O
cancers,	O
or	O
used	O
for	O
enhancing	O
the	O
therapeutic	O
effect	O
of	O
radiation	O
or	O
chemotherapeutic	O
agents	O
on	O
tumor	O
cells,	O
wherein	O
the	O
cancers	O
includes	O
breast	O
cancer,	O
ovarian	O
cancer,	O
colon	O
cancer,	O
melanoma,	O
lung	O
cancer,	O
gastrointestinal	O
stromal	O
tumor,	O
brain	O
cancer,	O
cervical	O
cancer,	O
pancreatic	O
cancer,	O
prostate	O
cancer,	O
gastric	O
cancer,	O
chronic	O
myeloid	O
leukocytes	O
hypercytosis,	O
liver	O
canser,	O
lymphoma,	O
peritoneal	O
cancer,	O
soft	O
tissue	O
sarcoma,	O
neuroendocrine	O
tumors,	O
advanced	O
solid	O
tumors,	O
and	O
glioblastoma	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
expanding	O
human	O
umbilical	O
cord	O
blood	O
stem	O
cells	O
and	O
methods	O
for	O
stimulating	O
growth	B-GENE
factor	I-GENE
production	O
by	O
cord	O
blood	O
stem	O
cells	O
using	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
comprising	O
a	O
lithium	O
salt	O
.	O
The	O
present	O
invention	O
also	O
provides	O
in	O
vivo	O
methods	O
for	O
enhancing	O
the	O
survival	O
and	O
growth	O
of	O
transplanted	O
cord	O
blood	O
stem	O
cells	O
by	O
treating	O
the	O
cells	O
with	O
a	O
lithium	O
salt	O
prior	O
to	O
transplantation	O
.	O
In	O
vivo	O
methods	O
for	O
reducing	O
rejection	O
of	O
transplanted	O
cord	O
blood	O
stem	O
cells	O
by	O
administering	O
a	O
lithium	O
salt	O
after	O
transplantation	O
are	O
also	O
provided	O
.	O


The	O
invention	O
provides	O
application	O
of	O
a	O
liver	B-GENE
X	I-GENE
receptor	I-GENE
activator	O
in	O
anti-nerve	O
inflammatory	O
reaction	O
.	O
The	O
liver	B-GENE
X	I-GENE
receptor	I-GENE
activator	O
is	O
T0901317	O
.	O
The	O
invention	O
also	O
relates	O
to	O
application	O
of	O
T0901317	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
senile	O
dementia	O
.	O
The	O
liver	B-GENE
X	I-GENE
receptor	I-GENE
activator	O
T0901317	O
can	O
directly	O
pass	O
through	O
a	O
blood	O
brain	O
barrier,	O
and	O
has	O
the	O
characteristic	O
of	O
low	O
side	O
effect	O
;	O
and	O
the	O
effect	O
of	O
the	O
anti-nerve	O
inflammatory	O
reaction	O
of	O
the	O
liver	B-GENE
X	I-GENE
receptor	I-GENE
activator	O
is	O
systematically	O
analyzed,	O
the	O
liver	B-GENE
X	I-GENE
receptor	I-GENE
activator	O
is	O
expected	O
to	O
be	O
used	O
as	O
a	O
specific	O
medicament	O
for	O
clinically	O
treating	O
the	O
intra-cephalic	O
inflammatory	O
reaction	O
of	O
the	O
senile	O
dementia,	O
and	O
experimental	O
data	O
are	O
provided	O
for	O
clinical	O
treatment	O
of	O
the	O
senile	O
dementia	O
.	O


The	O
invention	O
relates	O
to	O
3-piperazine-4-indol	O
maleimide	O
compound	O
.	O
The	O
structural	O
formula	O
is	O
shown	O
as	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
methyl,	O
2-ethoxy	O
or	O
4-substituted	O
benzoyl,	O
and	O
the	O
substituent	O
group	O
of	O
the	O
4-substituted	O
benzoyl	O
adopts	O
hydrogen,	O
chlorine,	O
bromine,	O
methoxyl	O
group	O
or	O
nitryl	O
.	O
The	O
preparation	O
comprises	O
the	O
steps	O
that	O
firstly,	O
3-bromine-4-	O
(	O
1H-indol-3-group	O
)	O
-1H-pyrrole-2,5-diketone	O
and	O
alkali	O
are	O
dissolved	O
in	O
N,N-dimethyl	O
formamide	O
solution,	O
substituted	O
piperazidine	O
is	O
added	O
after	O
stirring	O
and	O
dissolving,	O
the	O
piperazidine	O
is	O
stirred	O
at	O
90	O
to	O
100	O
DEG	O
C	O
to	O
be	O
reacted	O
for	O
1	O
to	O
48h,	O
H2O	O
is	O
added	O
after	O
the	O
reaction,	O
and	O
stirring	O
is	O
performed	O
for	O
5	O
to	O
20min	O
;	O
and	O
secondly,	O
solution	O
obtained	O
in	O
step	O
I	O
is	O
extracted	O
through	O
ethyl	O
acetate,	O
then	O
is	O
washed	O
through	O
saturated	O
NaCl	O
solution,	O
dried	O
through	O
anhydrous	O
Na2SO4	O
and	O
concentrated,	O
and	O
finally	O
the	O
compound	O
is	O
obtained	O
through	O
column	O
chromatography	O
isolation	O
.	O
The	O
compound	O
belongs	O
to	O
novel	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitor,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
drug	O
for	O
preventing	O
or	O
curing	O
tumors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
vascular	B-GENE
endothelial	I-GENE
cell	I-GENE
growth	I-GENE
factor-2	I-GENE
receptor	I-GENE
antagonist	O
of	O
a	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
.	O
The	O
compound	O
can	O
inhibit	O
the	O
activity	O
of	O
vascular	B-GENE
endothelial	I-GENE
cell	I-GENE
growth	I-GENE
factor-2	I-GENE
receptors	I-GENE
and	O
effectively	O
achieve	O
an	O
effect	O
of	O
resisting	O
breast	O
cancer	O
and	O
the	O
like	O
.	O
The	O
compound	O
has	O
a	O
strong	O
effect	O
of	O
antagonizing	O
the	O
vascular	B-GENE
endothelial	I-GENE
cell	I-GENE
growth	I-GENE
factor-2	I-GENE
receptors	I-GENE
in	O
vitro,	O
and	O
can	O
effectively	O
inhibit	O
the	O
vascular	B-GENE
endothelial	I-GENE
cell	I-GENE
growth	I-GENE
factor-2	I-GENE
receptors	I-GENE
and	O
antagonize	O
the	O
angiogenesis	O
generating	O
process	O
so	O
as	O
to	O
treat	O
the	O
breast	O
cancer	O
depending	O
on	O
angiogenesis	O
.	O


The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
containing	O
glucocorticoid	O
and	O
an	O
NOS	B-GENE
(	O
Nitric	B-GENE
Oxide	I-GENE
Synthase	I-GENE
)	O
inhibitor	O
for	O
treating	O
nasal	O
inflammation	O
.	O
The	O
medicinal	O
composition	O
contains	O
the	O
glucocorticoid	O
serving	O
as	O
an	O
active	O
ingredient,	O
amino	O
acid	O
derivatives	O
serving	O
as	O
the	O
NOS	B-GENE
inhibitor,	O
one	O
or	O
more	O
of	O
medicinal	O
auxiliaries	O
for	O
medicine	O
administration	O
at	O
a	O
nose,	O
and	O
the	O
balance	O
of	O
water	O
.	O


The	O
invention	O
discloses	O
an	O
injection	O
medicine	O
composition	O
containing	O
glucocorticoid	O
and	O
NOS	B-GENE
(	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
)	O
inhibitor,	O
containing	O
glucocorticoid	O
which	O
is	O
used	O
as	O
an	O
active	O
ingredient,	O
NOS	B-GENE
inhibitor,	O
and	O
one	O
or	O
more	O
pharmaceutical	O
excipients	O
suitable	O
for	O
injection	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
expressed	O
by	O
a	O
general	O
formula	O
I,	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt,	O
and	O
an	O
analyzed	O
enantiomer	O
and	O
a	O
purified	O
diastereomer,	O
wherein	O
R	O
<	O
1	O
>	O
is	O
H	O
or	O
C1-12	O
alkyl	O
groups	O
;	O
R	O
<	O
2	O
>	O
is	O
H,	O
-C	O
(	O
O	O
)	O
R	O
<	O
1a	O
>	O
,	O
-C	O
(	O
O	O
)	O
OR	O
<	O
1a	O
>	O
or	O
-S	O
(	O
O	O
)	O
2R	O
<	O
1b	O
>	O
,	O
wherein	O
R	O
<	O
1a	O
>	O
is	O
H	O
or	O
C1-6	O
alkyl	O
groups,	O
R	O
<	O
1b	O
>	O
is	O
selected	O
from	O
H	O
or	O
C1-6	O
alkyl	O
groups	O
halogenated	O
hydrocarbon,	O
phenyl	O
or	O
aryl	O
group	O
;	O
R	O
<	O
3	O
>	O
is	O
selected	O
from	O
C1-4	O
alkyl	O
groups	O
substituted	O
amino,	O
halogen,	O
hydroxyl,	O
sulfydryl,	O
guanidyl,	O
nitryl	O
or	O
cyano	O
group	O
;	O
and	O
R	O
<	O
4	O
>	O
is	O
-	O
(	O
CH2	O
)	O
nCO2H,	O
-	O
(	O
CH2	O
)	O
nP	O
(	O
O	O
)	O
(	O
OH	O
)	O
2,	O
-	O
(	O
CH2	O
)	O
nCO2R	O
<	O
1a	O
>	O
and	O
-	O
(	O
CH2	O
)	O
nP	O
(	O
O	O
)	O
(	O
OR	O
<	O
1a	O
>	O
)	O
2,	O
wherein	O
R	O
<	O
1a	O
>	O
is	O
H	O
or	O
C1-6	O
alkyl	O
groups,	O
n	O
is	O
an	O
integer	O
between	O
0	O
and	O
4,	O
or	O
a	O
salt	O
of	O
the	O
above	O
groups	O
.	O
The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
cyclohexene	O
compound	O
expressed	O
by	O
the	O
general	O
formula	O
I,	O
and	O
an	O
application	O
of	O
the	O
cyclohexene	O
compound	O
taken	O
as	O
an	O
influenza	B-GENE
virus	I-GENE
neuraminidase	I-GENE
inhibitor	O
for	O
preparing	O
the	O
medicines	O
to	O
prevent	O
or	O
treat	O
the	O
influenza	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
with	O
beta1-epinephrine	B-GENE
receptor	I-GENE
analgesia	O
activity	O
in	O
the	O
chemical	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compound	O
has	O
strong	O
activity	O
of	O
in-vitro	O
agonizing	O
beta1-epinephrine	O
receptor,	O
and	O
the	O
EC50	O
is	O
in	O
an	O
nM	O
level,	O
wherein	O
the	O
EC50	O
of	O
the	O
compound	O
with	O
the	O
strongest	O
activity	O
is	O
24	O
.	O
34+	O
/	O
-0	O
.	O
94nM,	O
so	O
that	O
the	O
compound	O
can	O
be	O
used	O
as	O
a	O
neuroprotective	O
agent	O
for	O
treating	O
Alzheimer	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts,	O
wherein	O
A,	O
B,	O
R1,	O
R2,	O
R3,	O
R4a,	O
R5,	O
and	O
Z	O
are	O
defined	O
in	O
the	O
description	O
.	O
The	O
present	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
making	O
said	O
compounds,	O
and	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	B-GENE
such	O
as	O
aurora	B-GENE
.	O


The	O
invention	O
discloses	O
application	O
of	O
salvianolic	O
acid	O
B	O
salt	O
in	O
preparing	O
a	O
medicament	O
for	O
inhibiting	O
hepatic	O
stellate	O
cell	O
migration	O
.	O
A	O
screening	O
platform	O
of	O
PDGF	B-GENE
(	O
platelet	B-GENE
derived	I-GENE
growth	I-GENE
factor	I-GENE
)	O
induced	O
human	O
hepatic	O
stellate	O
cell	O
strain	O
(	O
LX-2	O
)	O
migration	O
is	O
designed,	O
and	O
the	O
fact	O
that	O
the	O
salvianolic	O
acid	O
B	O
salts	O
with	O
the	O
concentrations	O
of	O
10	O
<	O
-4	O
>	O
and	O
10	O
<	O
-7	O
>	O
mol	O
/	O
L	O
both	O
can	O
be	O
used	O
for	O
inhibiting	O
migration	O
of	O
a	O
PDGF	B-GENE
induced	O
hepatic	O
stellate	O
cell	O
(	O
HSC	O
)	O
is	O
discovered	O
.	O


A	O
flavone-N-	O
methyl	O
hydroxamic	O
acid	O
compound	O
has	O
the	O
following	O
general	O
structural	O
formula	O
:	O
The	O
flavone-N-methyl	O
hydroxamic	O
acid	O
compound	O
has	O
a	O
good	O
inhibition	O
effect	O
for	O
urease,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
such	O
as	O
anti-gastritis	O
drugs,	O
anti-gastrohelcosis	O
drugs	O
and	O
anti-lithangiuria	O
durgs	O
.	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
flavone-N-methyl	O
hydroxamic	O
acid	O
compound	O
.	O


The	O
invention	O
relates	O
to	O
a	O
noradrenaline	B-GENE
and	I-GENE
selective	I-GENE
serotonin	I-GENE
receptor	I-GENE
blocking	O
agent	O
and	O
an	O
application	O
thereof	O
.	O
The	O
noradrenaline	B-GENE
and	I-GENE
selective	I-GENE
serotonin	I-GENE
receptor	I-GENE
blocking	O
agent	O
is	O
a	O
compound	O
in	O
the	O
formula	O
I,	O
or	O
an	O
isomer,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
solvate	O
of	O
the	O
compound,	O
wherein	O
R1	O
is	O
selected	O
from	O
C1-6	O
alkyl,	O
C1-6	O
alkoxy,	O
C6-10	O
aralkyl,	O
C6-10	O
aralkoxy,	O
halogenated	O
C1-6	O
alkyl,	O
and	O
halogenated	O
C1-6	O
alkoxy	O
;	O
R2	O
is	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
following	O
groups	O
:	O
hydrogen,	O
halogen,	O
C1-6	O
alkyl,	O
C1-6	O
alkoxy,	O
nitro,	O
cyan,	O
amino,	O
hydroxyl,	O
halogenated	O
C1-6	O
alkyl,	O
and	O
halogenated	O
C1-6	O
alkoxy	O
;	O
and	O
R3	O
is	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
following	O
groups	O
:	O
hydrogen,	O
halogen,	O
C1-6	O
alkyl,	O
C1-6	O
alkoxy,	O
nitro,	O
cyan,	O
amino,	O
hydroxyl,	O
halogenated	O
C1-6	O
alkyl,	O
and	O
halogenated	O
C1-6	O
alkoxy	O
.	O
The	O
compound	O
disclosed	O
by	O
the	O
invention	O
is	O
the	O
effective	O
noradrenaline	B-GENE
and	I-GENE
selective	I-GENE
serotonin	I-GENE
receptor	I-GENE
blocking	O
agent	O
.	O


Disclosed	O
is	O
a	O
compound	O
which	O
is	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
and	O
has	O
an	O
inhibitory	O
effect	O
on	O
ADAM17,	O
a	O
salt	O
thereof,	O
or	O
a	O
solvate	O
thereof	O
.	O
In	O
formula	O
(	O
I	O
)	O
,	O
X	O
represents	O
a	O
phenylene	O
group,	O
Y	O
represents	O
a	O
hydrogen	O
atom,	O
-	O
(	O
CH2	O
)	O
mR1,	O
or	O
the	O
like,	O
R1	O
represents	O
-NR5COR2,	O
-NR5SO2R2,	O
or	O
-NR3R4,	O
R2	O
represents	O
a	O
C1-C6	O
alkyl	O
group,	O
an	O
aryl	O
group,	O
or	O
a	O
C1-C6	O
alkoxy	O
group,	O
R3	O
and	O
R4	O
each	O
represent	O
a	O
C1-C6	O
alkyl	O
group	O
or	O
the	O
like,	O
R5	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-C6	O
alkyl	O
group,	O
or	O
the	O
like,	O
m	O
represents	O
an	O
integer	O
of	O
0	O
to	O
4,	O
and	O
Z	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-C6	O
alkyl	O
group	O
.	O


The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
multivalent	O
immunostimulation	O
nanoformula	O
.	O
The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
(	O
1	O
)	O
providing	O
a	O
nanogold	O
aqueous	O
solution	O
;	O
(	O
2	O
)	O
modifying	O
the	O
3	O
'	O
terminal	O
of	O
CpG	O
ODN	O
(	O
oligodeoxynucleotides	O
)	O
by	O
using	O
polyadenylic	O
acid	O
to	O
obtain	O
CpG	B-GENE
ODN-polyA	I-GENE
;	O
and	O
(	O
3	O
)	O
assembling	O
the	O
CpG	B-GENE
ODN-polyA	I-GENE
to	O
nanogold	O
to	O
form	O
the	O
multivalent	O
immunostimulation	O
nanoformula	O
.	O
The	O
invention	O
further	O
provides	O
the	O
multivalent	O
immunostimulation	O
nanoformula	O
obtained	O
by	O
the	O
preparation	O
method	O
and	O
application	O
of	O
the	O
multivalent	O
immunostimulation	O
nanoformula	O
.	O
Compared	O
with	O
the	O
traditional	O
CpG	O
ODN,	O
the	O
multivalent	O
immunostimulation	O
nanoformula	O
has	O
very	O
high	O
stability,	O
no	O
influence	O
on	O
cell	O
activity,	O
high	O
cellular	O
uptake	O
rate,	O
low	O
administration	O
dosage,	O
good	O
immunostimulation	O
activity	O
and	O
remarkable	O
effect	O
during	O
administration	O
of	O
low	O
dosage	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
discloses	O
a	O
preparation	O
method	O
of	O
(	O
3S,2	O
'	O
S	O
)	O
,	O
(	O
3S,2	O
'	O
R	O
)	O
,	O
(	O
3R,2	O
'	O
R	O
)	O
and	O
(	O
3R,2	O
'	O
S	O
)	O
four	O
type	O
chiral	O
monomers	O
of	O
muscarine	B-GENE
receptor	I-GENE
antagonist	O
racemic	O
medicine	O
glycopyrronium	O
bromide	O
.	O
The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
resolving	O
racemic	O
alpha-cyclopentylmandelic	O
acid	O
by	O
a	O
chemical	O
resolution	O
method	O
by	O
using	O
L-Tyrosine	O
methyl	O
ester	O
and	O
(	O
R	O
)	O
-alpha-phenylethylamine	O
as	O
resolution	O
reagents	O
to	O
respectively	O
prepare	O
(	O
S	O
)	O
-alpha-cyclopentylmandelic	O
acid	O
and	O
(	O
R	O
)	O
-alpha-cyclopentylmandelic	O
acid	O
;	O
and	O
carrying	O
out	O
esterification	O
reaction	O
to	O
respectively	O
obtain	O
chiral	O
intermediates	O
(	O
S	O
)	O
/	O
(	O
R	O
)	O
-alpha-cyclopentylmethyl	O
mandelate	O
.	O
L	O
/	O
D-malic	O
acid	O
used	O
as	O
the	O
raw	O
material	O
is	O
subjected	O
to	O
four	O
reaction	O
steps,	O
including	O
condensation,	O
carbonyl	O
reduction,	O
catalytic	O
hydrogenation	O
or	O
transfer	O
hydrogenation	O
reduction	O
debenzylation,	O
and	O
reduction	O
alkylation	O
or	O
alkylogen	O
alkylation,	O
in	O
a	O
chiral	O
synthesis	O
mode	O
to	O
obtain	O
another	O
important	O
chiral	O
intermediate	O
(	O
S	O
)	O
/	O
(	O
R	O
)	O
-N-methyl-3-hydroxypyrrolidine	O
.	O
The	O
chiral	O
intermediate	O
is	O
subjected	O
to	O
ester	O
exchange	O
and	O
quaterisation	O
to	O
respectively	O
obtain	O
the	O
four	O
(	O
3S,2	O
'	O
S	O
)	O
,	O
(	O
3S,2	O
'	O
R	O
)	O
,	O
(	O
3R,2	O
'	O
R	O
)	O
and	O
(	O
3R,2	O
'	O
S	O
)	O
type	O
glycopyrronium	O
bromide	O
chiral	O
monomers	O
.	O
The	O
result	O
indicates	O
that	O
the	O
(	O
3R,2	O
'	O
S	O
)	O
-glycopyrronium	O
bromide	O
has	O
the	O
strongest	O
cholinergic	O
antagonistic	O
action	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
drug-resistant	O
cisplatin	O
mineralization	O
liquid	O
.	O
The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
cisplatin	O
is	O
added	O
in	O
an	O
improved	O
DMEM	O
culture	O
medium,	O
and	O
is	O
reacted	O
under	O
the	O
similar	O
physiological	O
conditions	O
to	O
obtain	O
substituted	O
midbody	O
solution	O
;	O
(	O
2	O
)	O
calcium-contained	O
inorganic	O
salt	O
is	O
added	O
in	O
the	O
obtained	O
substituted	O
midbody	O
solution,	O
and	O
is	O
reacted	O
under	O
the	O
similar	O
physiological	O
conditions	O
to	O
obtain	O
a	O
nano	O
cured	O
midbody	O
system	O
;	O
and	O
(	O
3	O
)	O
bovine	B-GENE
serum	I-GENE
albumin	I-GENE
is	O
added	O
in	O
the	O
obtained	O
nano	O
cured	O
midbody	O
system	O
to	O
obtain	O
the	O
cisplatin	O
mineralization	O
liquid	O
.	O
The	O
invention	O
further	O
discloses	O
the	O
cisplatin	O
mineralization	O
liquid	O
produced	O
by	O
the	O
preparation	O
method,	O
and	O
application	O
thereof,	O
wherein	O
the	O
cisplatin	O
mineralization	O
liquid	O
has	O
stronger	O
lethality	O
to	O
tumor	O
cells,	O
and	O
has	O
remarkable	O
curative	O
effect	O
on	O
tumors	O
which	O
are	O
difficultly	O
cured	O
by	O
the	O
cisplatin	O
and	O
have	O
obvious	O
drug	O
resistance	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
with	O
the	O
structure	O
shown	O
by	O
a	O
general	O
formula	O
I	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
the	O
compound	O
has	O
obvious	O
pharmacological	O
activity	O
.	O
The	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
human	O
diabetes	O
as	O
an	O
11beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I	I-GENE
(	O
11b-HSD1	B-GENE
)	O
inhibitor	O
.	O


The	O
invention	O
relates	O
to	O
heterocycle	O
quinoline	O
derivatives	O
as	O
well	O
as	O
medicinal	O
salts,	O
a	O
preparation	O
method	O
and	O
a	O
medicinal	O
application	O
thereof	O
and	O
particularly	O
relates	O
to	O
heterocycle	O
quinoline	O
derivatives	O
shown	O
as	O
a	O
general	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
medicinal	O
salts,	O
a	O
preparation	O
method	O
and	O
a	O
medicinal	O
application	O
of	O
the	O
heterocycle	O
quinoline	O
derivatives	O
as	O
a	O
cancer	O
therapeutic	O
agent	O
and	O
especially	O
an	O
mTOR	B-GENE
and	O
/	O
or	O
PI3-kinase	B-GENE
inhibitor,	O
wherein	O
all	O
substituent	O
groups	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
are	O
defined	O
as	O
same	O
as	O
those	O
in	O
the	O
specification	O
.	O


The	O
invention	O
relates	O
to	O
beta-glucan	O
GFPBW1	O
with	O
a	O
structural	O
formula	O
shown	O
as	O
the	O
following,	O
its	O
preparation	O
method	O
and	O
application	O
of	O
the	O
beta-glucan	O
in	O
preparation	O
of	O
drugs	O
treating	O
tumors	O
.	O
The	O
beta-glucan	O
GFPBW1	O
provided	O
in	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
separation	O
extraction	O
from	O
mushroom	O
Grifola	O
frondosa	O
S	O
.	O
F	O
.	O
Gray	O
and	O
purification	O
by	O
means	O
of	O
a	O
simple	O
and	O
effective	O
polysaccharide	O
extraction	O
process	O
and	O
method	O
.	O
Pharmacological	O
experiments	O
show	O
that	O
GFPBW1	O
can	O
activate	O
primary	O
macrophages	O
through	O
a	O
Dectin-1	B-GENE
receptor	I-GENE
to	O
release	O
cytokines,	O
and	O
in	O
vivo	O
anti-tumor	O
experiments	O
also	O
further	O
show	O
that	O
GFPBW1	O
has	O
an	O
immunoregulation	O
function	O
and	O
corresponding	O
antitumor	O
activity	O
.	O


The	O
invention	O
discloses	O
quinazoline	O
arylurea	O
compounds	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof,	O
wherein	O
the	O
quinazoline	O
arylurea	O
compounds	O
have	O
a	O
general	O
formula	O
I	O
.	O
The	O
new	O
compound	O
with	O
quinazolinyl	O
and	O
aryl-substituted	O
urea	O
shows	O
extremely	O
high	O
activity	O
in	O
suppressing	O
the	O
growth	O
of	O
tumor	O
cells,	O
and	O
particularly	O
realizes	O
an	O
obvious	O
effect	O
in	O
suppressing	O
the	O
growth	O
of	O
VEGFR	B-GENE
high-expression	O
HUVEC	O
cells,	O
wherein	O
half	O
of	O
the	O
suppression	O
IC50	O
values	O
can	O
reach	O
1	O
.	O
8	O
mu	O
g	O
/	O
mL	O
.	O
The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
.	O


The	O
invention	O
provides	O
a	O
(	O
2E,	O
5E	O
)	O
-2,	O
5-benzal	O
cyclopentanone	O
analogue	O
which	O
comprises	O
a	O
compound	O
with	O
a	O
structure	O
shown	O
as	O
formula	O
II	O
and	O
pharmaceutically	O
acceptable	O
salt	O
.	O
The	O
analogue	O
has	O
remarkable	O
pharmacological	O
activity	O
.	O
In	O
addition,	O
the	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
an	O
application	O
thereof	O
as	O
a	O
11beta-hydroxyoxysterooid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I,	O
11b-HSD1	B-GENE
inhibitor	O
for	O
preventing	O
and	O
treating	O
human	O
diabetes	O
.	O


The	O
invention	O
discloses	O
a	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase	O
inhibitor	O
capable	O
of	O
treating	O
chronic	O
granulocytic	O
leukemia	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase	O
inhibitor	O
capable	O
of	O
treating	O
chronic	O
granulocytic	O
leukemia	O
obtained	O
by	O
a	O
large	O
number	O
of	O
experimental	O
screenings	O
not	O
only	O
can	O
effectively	O
inhibit	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase,	O
and	O
still	O
has	O
a	O
good	O
inhibitory	O
effect	O
to	O
mutated	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase,	O
so	O
that	O
the	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase	O
inhibitor	O
is	O
a	O
novel	O
Bcr	B-GENE
/	O
Abl	B-GENE
tyrosine	O
kinase	O
inhibitor	O
for	O
effectively	O
treating	O
chronic	O
granulocytic	O
leukemia	O
.	O


Provided	O
is	O
a	O
fat	O
and	O
oil	O
composition	O
for	O
promoting	O
insulin	B-GENE
secretion,	O
the	O
composition	O
being	O
very	O
safe,	O
devoid	O
of	O
concerns	O
of	O
side	O
effects	O
even	O
when	O
ingested	O
continuously,	O
and	O
effective	O
in	O
preventing	O
diabetes	O
and	O
other	O
uses	O
.	O
This	O
fat	O
and	O
oil	O
composition	O
for	O
promoting	O
insulin	B-GENE
secretion	O
is	O
characterized	O
in	O
containing	O
a	O
triacylglycerol	O
and	O
an	O
emulsifier	O
as	O
active	O
ingredients,	O
the	O
triacylglycerol	O
having	O
one	O
or	O
two	O
medium-chain	O
fatty	O
acid	O
residues	O
in	O
a	O
molecule	O
and	O
containing,	O
as	O
constituent	O
fatty	O
acids,	O
a	O
C6-12	O
medium-chain	O
fatty	O
acid	O
and	O
a	O
C16-24	O
long-chain	O
fatty	O
acid	O
;	O
and	O
the	O
emulsifier	O
being	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
phospholipid,	O
a	O
sucrose	O
fatty	O
acid	O
ester,	O
a	O
polyglycerol	O
fatty	O
acid	O
ester,	O
and	O
a	O
monoglycerol	O
fatty	O
acid	O
ester	O
.	O


The	O
invention	O
relates	O
to	O
a	O
dexlansoprazole	O
composition	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
The	O
dexlansoprazole	O
composition	O
contains	O
an	O
active	O
ingredient	O
and	O
adjuvants,	O
wherein	O
the	O
active	O
ingredient	O
is	O
dexlansoprazole	O
or	O
a	O
dexlansoprazole	O
salt	O
or	O
a	O
dexlansoprazole	O
aqueous	O
crystal	O
substance	O
;	O
and	O
the	O
adjuvants	O
comprise	O
an	O
excipient	O
and	O
a	O
pH	O
regulator,	O
and	O
especially,	O
the	O
dexlansoprazole	O
composition	O
for	O
injection	O
also	O
contains	O
sustained	O
release	O
microspheres	O
containing	O
the	O
active	O
ingredient,	O
wherein	O
the	O
sustained	O
release	O
microspheres	O
contain	O
5-20	O
percent	O
of	O
active	O
ingredient,	O
60-95	O
percent	O
of	O
biodegradable	O
carrier	O
material	O
and	O
0	O
.	O
1-15	O
percent	O
of	O
stabilizer	O
by	O
taking	O
the	O
total	O
weight	O
of	O
the	O
sustained	O
release	O
microspheres	O
as	O
reference	O
.	O
The	O
dexlansoprazole	O
composition	O
for	O
injection	O
is	O
a	O
dual	O
delayed	O
release	O
proton	B-GENE
pump	I-GENE
inhibitor	O
which	O
is	O
released	O
at	O
twice	O
;	O
and	O
during	O
clinical	O
use,	O
after	O
being	O
diluted	O
by	O
using	O
normal	O
saline,	O
the	O
dexlansoprazole	O
composition	O
is	O
injected	O
to	O
a	O
human	O
body	O
to	O
form	O
a	O
pharmacokinetic	O
curve	O
which	O
is	O
similar	O
to	O
a	O
dexlansoprazole	O
delayed	O
release	O
capsule	O
in	O
the	O
market	O
.	O


A	O
skin	O
drug	O
composition	O
containing	O
methylprednisolone	O
aceponate	O
and	O
an	O
amino	O
acid	O
comprises	O
the	O
methylprednisolone	O
aceponate	O
which	O
serves	O
as	O
an	O
active	O
ingredient,	O
an	O
amino	O
acid	O
derivative	O
which	O
serves	O
as	O
a	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
inhibitor,	O
one	O
or	O
more	O
types	O
of	O
drug	O
auxiliary	O
materials	O
applicable	O
to	O
skin,	O
and	O
the	O
balance	O
water	O
.	O


A	O
medicine	O
composition	O
containing	O
mometasone	O
furoate	O
and	O
a	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
inhibitor	O
and	O
for	O
treating	O
nose	O
inflammation	O
comprises	O
the	O
mometasone	O
furoate	O
serving	O
as	O
an	O
active	O
constituent,	O
an	O
amino	O
acid	O
derivative	O
serving	O
as	O
the	O
NOS	B-GENE
inhibitor,	O
one	O
or	O
more	O
types	O
of	O
medicine	O
auxiliary	O
materials	O
suitable	O
for	O
nose	O
medicine	O
dosing	O
and	O
the	O
balance	O
water	O
.	O


A	O
medicine	O
composition	O
containing	O
budesonide	O
and	O
a	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
inhibitor	O
and	O
for	O
treating	O
nose	O
inflammation	O
comprises	O
the	O
budesonide	O
serving	O
as	O
an	O
active	O
constituent,	O
an	O
amino	O
acid	O
derivative	O
serving	O
as	O
the	O
NOS	B-GENE
inhibitor,	O
one	O
or	O
more	O
types	O
of	O
medicine	O
auxiliary	O
materials	O
suitable	O
for	O
nose	O
medicine	O
dosing	O
and	O
the	O
balance	O
water	O
.	O


The	O
invention	O
discloses	O
nerve	O
regeneration	O
biogum	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O
The	O
nerve	O
regeneration	O
biogum	O
is	O
prepared	O
from	O
fibrinogen,	O
NaCl,	O
hemopexin	B-GENE
and	O
12	O
neurotrophic	O
factors,	O
wherein	O
the	O
fibrinogen,	O
the	O
hemopexin	B-GENE
and	O
the	O
NaCl	O
form	O
a	O
base	O
support	O
matrix	O
.	O
The	O
biogum	O
disclosed	O
by	O
the	O
invention	O
can	O
promote	O
regeneration	O
and	O
intramedullary	O
extension	O
of	O
a	O
nerve	O
cell,	O
and	O
can	O
increase	O
the	O
contact	O
frequency	O
of	O
damaged	O
nerve	O
cynapse	O
and	O
normal	O
nerve	O
synapse	O
by	O
verification	O
of	O
an	O
in-vitro	O
cell	O
test	O
and	O
an	O
animal	O
test	O
.	O
A	O
plurality	O
of	O
neurotrophic	B-GENE
factors	I-GENE
in	O
the	O
biogum	O
have	O
important	O
roles	O
in	O
regeneration	O
and	O
extension	O
of	O
the	O
nerve	O
cell,	O
building	O
of	O
synaptic	O
connection	O
and	O
forming	O
of	O
a	O
blood	O
vessel,	O
can	O
be	O
further	O
used	O
for	O
clinically	O
repairing	O
spinal	O
nerve	O
trauma	O
and	O
treating	O
patients	O
with	O
spinal	O
cord	O
injury	O
.	O
The	O
nerve	O
regeneration	O
biogum	O
can	O
be	O
gradually	O
applied	O
to	O
other	O
central	O
nervous	O
system	O
diseases,	O
such	O
as	O
injury	O
of	O
brain	O
tissue,	O
optic	O
nerve	O
injury	O
and	O
the	O
like	O
.	O


The	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
containing	O
a	O
hepatic	B-GENE
cell	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
cMet	B-GENE
)	O
inhibitor	O
and	O
a	O
Bcl-2	B-GENE
inhibitor	O
and	O
an	O
application	O
of	O
the	O
medicine	O
composition	O
in	O
preparing	O
medicine	O
for	O
treating	O
colon	O
cancers,	O
liver	O
cancers,	O
lung	O
cancers,	O
kidney	O
cancers,	O
stomach	O
cancers,	O
brain	O
tumors,	O
sarcoma,	O
glioma,	O
pancreatic	O
cancers,	O
ovarian	O
cancers,	O
breast	O
cancers	O
or	O
prostate	O
cancers	O
.	O
The	O
medicine	O
composition	O
containing	O
the	O
cMet	B-GENE
inhibitor	O
and	O
the	O
Bcl-2	B-GENE
inhibitor	O
has	O
a	O
remarkable	O
synergistic	O
effect,	O
and	O
thereby	O
the	O
curative	O
effect	O
of	O
medicine	O
is	O
improved,	O
the	O
medicine	O
dosage	O
is	O
reduced	O
and	O
the	O
side	O
effect	O
is	O
reduced	O
.	O


The	O
invention	O
provides	O
an	O
injection	O
sustained-release	O
preparation	O
adjuvant	O
containing	O
cyanoacrylate	O
and	O
ethyl	O
oleate	O
.	O
In	O
addition,	O
the	O
invention	O
further	O
provides	O
an	O
injection	O
sustained-release	O
preparation	O
which	O
comprises	O
the	O
injection	O
sustained-release	O
preparation	O
adjuvant	O
and	O
active	O
pharmaceutical	O
ingredients	O
(	O
including	O
small	O
molecular	O
drugs	O
and	O
protein	O
such	O
as	O
pacilitaxel	O
and	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
)	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medical	O
chemical	O
industry,	O
and	O
especially	O
relates	O
to	O
a	O
compound	O
with	O
tyrosine	B-GENE
kinase	I-GENE
inhibition	O
effect	O
;	O
the	O
compound	O
name	O
is	O
N-	O
[	O
5-	O
[	O
5-fluoro-2-oxo-1,2-dihydro-indol-	O
(	O
3Z	O
)	O
-methylene	O
]	O
-2,4-dimethyl-1H-pyrrole-3-yl	O
]	O
-3-	O
(	O
piperazine-1-yl	O
)	O
propionamide	O
;	O
the	O
compound	O
has	O
very	O
high	O
tyrosine	B-GENE
kinase	I-GENE
inhibition	O
effect	O
;	O
the	O
inventor	O
also	O
finds	O
that	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvent	O
compositions	O
of	O
the	O
compound	O
have	O
same	O
tyrosine	B-GENE
kinase	I-GENE
inhibition	O
effect,	O
and	O
have	O
extremely	O
high	O
social	O
and	O
scientific	O
value	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine,	O
and	O
particularly	O
relates	O
to	O
indolinone	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
deuterium	O
of	O
the	O
derivatives,	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
derivatives	O
or	O
stereoisomer	O
of	O
the	O
derivatives,	O
wherein	O
the	O
indolinone	O
derivatives	O
serve	O
as	O
tyrosine	B-GENE
kinase	I-GENE
inhibitors,	O
and	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
n,	O
X	O
and	O
cycle	O
A	O
are	O
defined	O
as	O
in	O
the	O
description	O
.	O
The	O
invention	O
further	O
relates	O
to	O
preparation	O
methods	O
of	O
the	O
compounds,	O
a	O
pharmaceutical	O
preparation	O
comprising	O
the	O
compounds,	O
and	O
applications	O
of	O
the	O
compounds,	O
wherein	O
the	O
applications	O
of	O
the	O
compounds	O
include	O
prevention	O
or	O
treatment	O
of	O
fibrosis	O
diseases,	O
treatment	O
of	O
excessive	O
hyperplasia	O
diseases,	O
especially	O
breast	O
cancer,	O
colorectal	O
cancer	O
and	O
non-small	O
cell	O
lung	O
cancer,	O
anti-angiogenesis	O
and	O
/	O
or	O
reduction	O
of	O
vascular	O
permeability	O
.	O


The	O
invention	O
relates	O
to	O
application	O
of	O
drug	O
composition	O
in	O
curing	O
diseases	O
of	O
the	O
respiratory	O
system	O
.	O
The	O
drug	O
composition	O
is	O
obvious	O
in	O
effect	O
of	O
curing	O
tracheaectasy	O
concurrent	O
infection	O
caused	O
by	O
escherichia	O
coli	O
capable	O
of	O
producing	O
beta-lactam	O
enzyme,	O
klebsiella	O
pneumoniae	O
and	O
proteus	O
mirabilis	O
and	O
bacterial	O
pneumonia	O
.	O


The	O
invention	O
relates	O
to	O
an	O
(	O
S	O
)	O
-2-	O
(	O
2,3-dihydrobenzofuran-3-radical	O
)	O
acetic	O
acid	O
derivative,	O
a	O
preparation	O
method	O
of	O
the	O
derivative,	O
a	O
medicine	O
composition	O
containing	O
the	O
derivative	O
and	O
the	O
application	O
of	O
the	O
derivative	O
serving	O
as	O
a	O
therapeutic	O
agent,	O
particularly	O
GPR40	B-GENE
/	O
FFA1,	O
and	O
particularly	O
provides	O
the	O
(	O
S	O
)	O
-2-	O
(	O
2,3-dihydrobenzofuran-3-radical	O
)	O
acetic	O
acid	O
derivative	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
derivative	O
or	O
a	O
prodrug	O
of	O
the	O
derivative	O
.	O
The	O
compound	O
is	O
an	O
agonist	O
of	O
a	O
GPR40	B-GENE
/	O
FFA1	B-GENE
receptor	O
and	O
has	O
a	O
good	O
preventive	O
and	O
therapeutic	O
effect	O
on	O
lots	O
of	O
GPR40-mediated	O
diseases,	O
especially	O
diabetes	O
mellitus	O
.	O
The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
.	O


The	O
invention	O
discloses	O
a	O
cimicifuga	O
triterpenoid	O
compound	O
and	O
application	O
thereof	O
in	O
preparation	O
of	O
anti-tumor	O
drugs	O
.	O
Shown	O
by	O
targeted	O
screening	O
results	O
directed	O
at	O
tumor-specific	O
mutation	O
gene	O
products,	O
at	O
the	O
concentration	O
of	O
being	O
non-toxic	O
to	O
wild-type	O
normal	O
mouse	O
embryonic	O
fibroblast,	O
a	O
compound	O
KY40	O
can	O
selectively	O
kill	O
tumor	O
cells	O
with	O
tumor-specific	O
mutation	O
genes	O
;	O
and	O
shown	O
by	O
a	O
GFP	O
(	O
Green	O
Fluorescent	O
Protein	O
)	O
reporting	O
vector	O
screening	O
system	O
of	O
a	O
gene	O
p16	O
promoter,	O
the	O
compound	O
KY40	O
can	O
act	O
on	O
the	O
p16	O
promoter,	O
and	O
shown	O
by	O
the	O
characteristics,	O
the	O
novel	O
cimicifuga	O
triterpenoid	O
compound	O
and	O
pharmaceutical	O
compositions	O
taking	O
the	O
cimicifuga	O
triterpenoid	O
compound	O
as	O
an	O
effective	O
treatment	O
amount	O
have	O
application	O
potential	O
in	O
the	O
preparation	O
of	O
individualized	O
treatment	O
drugs	O
directed	O
at	O
tumor-specific	O
mutation	O
genes	O
p53	B-GENE
and	O
tumor	O
suppressor	O
genes	O
p16	O
.	O


A	O
compound	O
represented	O
by	O
formula	O
(	O
A	O
)	O
[	O
wherein	O
Q	O
represents	O
-CH-	O
or	O
a	O
nitrogen	O
atom	O
;	O
R1a	O
and	O
R1b	O
independently	O
represent	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R1c	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R2a,	O
R2b,	O
R2c	O
and	O
R2d	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
the	O
like	O
;	O
R3a,	O
R3b	O
and	O
R3c	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
the	O
like	O
;	O
and	O
R3d	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
which	O
has	O
an	O
antagonistic	O
activity	O
on	O
an	O
orexin	O
receptor,	O
and	O
therefore	O
can	O
be	O
used	O
as	O
a	O
therapeutic	O
agent	O
for	O
sleep	O
disorders,	O
such	O
as	O
insomnia,	O
on	O
which	O
the	O
antagonistic	O
activity	O
on	O
an	O
orexin	B-GENE
receptor	I-GENE
is	O
effective	O
.	O


The	O
invention	O
provides	O
a	O
transient	B-GENE
receptor	I-GENE
potential	I-GENE
vanillin	I-GENE
3	I-GENE
(	O
TRPV3	B-GENE
)	O
modifier	O
of	O
a	O
formula	O
(	O
I	O
)	O
.	O
Particularly,	O
a	O
compound	O
is	O
used	O
for	O
curing	O
or	O
preventing	O
diseases,	O
symptoms	O
and	O
/	O
or	O
obstacles,	O
wherein	O
the	O
diseases,	O
the	O
symptoms	O
and	O
/	O
or	O
the	O
obstacles	O
are	O
modified	O
by	O
the	O
TRPV3	B-GENE
.	O
The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
compound,	O
a	O
midbody	O
used	O
in	O
composition,	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
method	O
for	O
curing	O
or	O
preventing	O
diseases,	O
the	O
symptoms	O
and	O
/	O
or	O
the	O
obstacles,	O
wherein	O
the	O
diseases,	O
the	O
symptoms	O
and	O
/	O
or	O
the	O
obstacles	O
are	O
modified	O
by	O
the	O
TRPV3	B-GENE
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
letrozole	O
(	O
LE	O
)	O
in	O
preparation	O
of	O
a	O
drug	O
used	O
for	O
inducing	O
follicular	O
development	O
of	O
a	O
calf	O
by	O
hormone	O
.	O
According	O
to	O
the	O
invention,	O
influence	O
of	O
LE	O
on	O
internal	O
secretion	O
and	O
paracrine	O
and	O
an	O
ovary	O
follicle	O
collecting	O
effect	O
are	O
utilized,	O
FSH	B-GENE
(	O
follicle-stimulating	B-GENE
hormone	I-GENE
)	O
is	O
used	O
in	O
the	O
conventional	O
hormone	O
inducing	O
method	O
while	O
LE	O
is	O
combined,	O
follicular	O
development	O
of	O
the	O
calf	O
is	O
promoted,	O
ovocyte	O
acquisition	O
efficiency	O
is	O
improved,	O
abundant	O
germplasm	O
resources	O
before	O
a	O
follicle	O
of	O
a	O
fine	O
calf	O
is	O
locked	O
are	O
fully	O
excavated,	O
fine	O
calf	O
breeding	O
and	O
a	O
propagation	O
expanding	O
technology	O
system	O
is	O
sped	O
up,	O
and	O
breeding	O
efficiency	O
and	O
technological	O
level	O
are	O
greatly	O
improved	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
sulfonamide	O
compounds	O
in	O
preparing	O
medicines	O
inhibiting	O
medicine	O
resistant	O
bacteria	O
activities,	O
and	O
especially	O
relates	O
to	O
the	O
application	O
of	O
sulfonamide	O
compounds	O
in	O
preparing	O
medicines	O
inhibiting	O
the	O
activities	O
of	O
NDM-1-producing	O
medicine	O
resistant	O
bacteria	O
.	O
The	O
sulfonamide	O
compounds	O
have	O
a	O
general	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A	O
ring	O
represents	O
C5-C10	O
aryl	O
ring	O
or	O
a	O
5-10-element	O
heteroaryl	O
ring	O
;	O
R1	O
is	O
selected	O
from	O
hydrogen,	O
hydroxyl,	O
halogen,	O
C1-C6	O
alkyl,	O
and	O
C1-C4	O
alkoxy	O
or	O
nitro	O
;	O
R2	O
is	O
selected	O
from	O
C1-C6	O
alkyl,	O
C3-C6	O
cycloalkyl,	O
C5-C10	O
aryl	O
group,	O
or	O
a	O
C5-C10	O
aryl-C1-C4	O
alkyl	O
group	O
.	O
The	O
aralkyl	O
group	O
is	O
not	O
substituted,	O
or	O
is	O
substituted	O
by	O
any	O
one	O
or	O
more	O
groups	O
selected	O
from	O
the	O
following	O
:	O
halogen,	O
C1-C4	O
alkyl,	O
halogenated	O
C1-C4	O
alkyl,	O
C1-C4	O
alkoxy,	O
C1-C4	O
alkanoyl,	O
and	O
C1-C4	O
alkanoyloxy	O
or	O
nitro	O
.	O
The	O
compounds	O
have	O
the	O
effect	O
for	O
inhibiting	O
NDM-1	B-GENE
activity	O
.	O


The	O
invention	O
discloses	O
liver	O
protecting	O
application	O
of	O
a	O
piperic	O
acid	O
and	O
application	O
of	O
the	O
piperic	O
acid	O
in	O
medicaments	O
or	O
health-care	O
products	O
for	O
reducing	O
alanine	B-GENE
transaminase	I-GENE
(	O
ALT	B-GENE
)	O
and	O
aspartate	B-GENE
aminotransferase	I-GENE
(	O
AST	B-GENE
)	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
Aphanamixoid	O
A	O
and	O
especially	O
relates	O
to	O
a	O
use	O
of	O
Aphanamixoid	O
A	O
in	O
a	O
drug	O
for	O
treating	O
the	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Aphanamixoid	O
A	O
has	O
an	O
acetylcholinesterase	B-GENE
inhibitory	O
activity	O
and	O
a	O
nerve	O
cell	O
protection	O
effect	O
and	O
can	O
be	O
used	O
as	O
a	O
multi-effect	O
target	O
compound	O
for	O
preparation	O
of	O
an	O
Alzheimer	O
'	O
s	O
disease-resistant	O
drug	O
.	O
The	O
invention	O
discloses	O
the	O
use	O
of	O
Aphanamixoid	O
A	O
in	O
a	O
drug	O
for	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
first	O
.	O
Aphanamixoid	O
A	O
has	O
a	O
novel	O
skeleton	O
type,	O
a	O
strong	O
acetylcholinesterase	B-GENE
inhibitory	O
activity,	O
and	O
outstanding	O
and	O
substantive	O
features,	O
is	O
not	O
prompted	O
by	O
other	O
compounds,	O
and	O
obviously	O
improves	O
effects	O
of	O
preventing	O
and	O
treating	O
the	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
discloses	O
a	O
mesenchymal	O
stem	O
cell,	O
which	O
is	O
used	O
as	O
a	O
target	O
cell	O
for	O
gene	O
treatment,	O
and	O
used	O
for	O
a	O
carrier	O
of	O
expressing,	O
storing	O
and	O
releasing	O
a	O
transgenic	O
drug	O
.	O
An	O
exogenous	O
promoter	O
and	O
a	O
target	O
gene	O
are	O
led	O
to	O
the	O
mesenchymal	O
stem	O
cell	O
by	O
a	O
virus	O
carrier	O
;	O
and	O
the	O
target	O
gene	O
is	O
integrated	O
into	O
a	O
genome	O
of	O
a	O
host	O
cell,	O
so	O
as	O
to	O
stabilize	O
that	O
the	O
endogenously	O
expressed	O
target	O
gene	O
is	O
not	O
lost	O
and	O
used	O
for	O
gene	O
treatment	O
.	O
It	O
is	O
fully	O
verified	O
that	O
the	O
mesenchymal	O
stem	O
cell	O
can	O
be	O
used	O
as	O
a	O
storage	O
cavern	O
for	O
expressing,	O
storing	O
and	O
releasing	O
a	O
target	O
drug,	O
and	O
has	O
the	O
characteristics	O
of	O
being	O
efficient,	O
safe,	O
reliable	O
and	O
the	O
like	O
by	O
an	O
insulin	B-GENE
gene	O
treatment	O
experiment	O
.	O


The	O
invention	O
provides	O
a	O
new	O
use	O
of	O
a	O
polyene	O
phosphatidyl	O
choline	O
medicine	O
in	O
the	O
treatment	O
of	O
obesity	O
and	O
insulin	B-GENE
resistance	O
syndromes	O
(	O
metabolic	O
syndromes	O
)	O
.	O
A	O
hepatic	O
protector	O
polyene	O
phosphatidyl	O
choline	O
commonly	O
used	O
clinically	O
is	O
used	O
as	O
a	O
new	O
medicine	O
for	O
treating	O
obesity	O
and	O
insulin	B-GENE
resistance	O
syndromes	O
(	O
metabolic	O
syndromes	O
)	O
.	O
Cell	O
experiments	O
prove	O
that	O
polyene	O
phosphatidyl	O
choline	O
makes	O
the	O
proportion	O
of	O
adipocytes	O
in	O
a	O
G1	O
/	O
S	O
phase	O
be	O
substantially	O
increased,	O
the	O
proportion	O
of	O
cells	O
in	O
an	O
S	O
phase	O
be	O
substantially	O
reduced	O
and	O
the	O
growth	O
of	O
the	O
adipocytes	O
be	O
stopped	O
in	O
the	O
G1	O
phase,	O
so	O
the	O
propagation	O
of	O
the	O
adipocytes	O
is	O
inhibited,	O
thereby	O
the	O
obesity	O
degree	O
can	O
be	O
reduced,	O
and	O
polyene	O
phosphatidyl	O
choline	O
can	O
be	O
used	O
for	O
treating	O
the	O
obesity	O
.	O
Polyene	O
phosphatidyl	O
choline	O
makes	O
the	O
GLUT4	B-GENE
expression	O
of	O
adipocyte	O
membranes	O
be	O
increased,	O
so	O
polyene	O
phosphatidyl	O
choline	O
has	O
an	O
insulin	B-GENE
resistance	O
and	O
can	O
be	O
used	O
for	O
treating	O
the	O
insulin	B-GENE
resistance	O
syndromes	O
(	O
metabolic	O
syndromes	O
)	O
.	O
Polyene	O
phosphatidyl	O
choline	O
is	O
a	O
medicine	O
having	O
the	O
advantages	O
of	O
moderate	O
price,	O
small	O
side	O
effects,	O
safety	O
and	O
reliability,	O
and	O
can	O
be	O
used	O
for	O
treating	O
the	O
obesity	O
and	O
insulin	B-GENE
resistance	O
syndromes	O
(	O
metabolic	O
syndromes	O
)	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
a	O
carbon	O
nanomaterial-immunostimulatory	O
sequence	O
compound	O
.	O
The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
1	O
)	O
modifying	O
a	O
carbon	O
nanomaterial	O
through	O
polylysine	O
to	O
obtain	O
a	O
polylysine-modified	O
carbon	O
nanomaterial	O
;	O
and	O
(	O
2	O
)	O
mixing	O
the	O
polylysine-modified	O
carbon	O
nanomaterial	O
obtained	O
from	O
the	O
step	O
(	O
1	O
)	O
with	O
an	O
immunostimulatory	O
sequence	O
in	O
a	O
water	O
solution,	O
oscillating	O
for	O
0	O
.	O
5-3	O
hours	O
at	O
20-37	O
DEG	O
C,	O
and	O
centrifuging,	O
collecting	O
and	O
depositing	O
to	O
obtain	O
the	O
carbon	O
nanomaterial-immunostimulatory	O
sequence	O
compound	O
.	O
According	O
to	O
the	O
carbon	O
nanomaterial-immunostimulatory	O
sequence	O
compound,	O
the	O
carbon	O
nanomaterial	O
serves	O
as	O
a	O
carrier	O
for	O
intracellular	O
transport	O
of	O
the	O
immunostimulatory	O
sequence	O
(	O
CpG	B-GENE
DNA	I-GENE
)	O
,	O
so	O
as	O
to	O
remarkably	O
improve	O
the	O
cellular	O
uptake	O
efficiency	O
of	O
the	O
CpG	O
DNA,	O
protect	O
the	O
CpG	B-GENE
DNA	I-GENE
from	O
being	O
degraded	O
by	O
nuclease	O
and	O
enhance	O
the	O
immunocompetence	O
of	O
an	O
organism	O
for	O
a	O
long	O
time,	O
so	O
the	O
carbon	O
nanomaterial-immunostimulatory	O
sequence	O
compound	O
has	O
a	O
good	O
medical	O
application	O
prospect	O
.	O


The	O
invention	O
discloses	O
a	O
drug	O
novel	O
use	O
of	O
fucoidan	O
polysaccharide	O
sulfate	O
.	O
The	O
use	O
is	O
the	O
application	O
of	O
the	O
fucoidan	O
polysaccharide	O
sulfate	O
in	O
preparing	O
the	O
following	O
products	O
:	O
(	O
1	O
)	O
,	O
a	O
product	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
diabetic	O
cardiomyopathy	O
;	O
(	O
2	O
)	O
,	O
a	O
product	O
for	O
inhibiting	O
diabetic	O
myocardial	O
oxidative	O
stress	O
;	O
and	O
(	O
3	O
)	O
,	O
a	O
product	O
for	O
inhibiting	O
expression	O
and	O
activation	O
of	O
PKC	B-GENE
(Protein	I-GENE
Kinase	I-GENE
C)	I-GENE
beta	I-GENE
in	O
diabetic	O
cardiomyopathy	O
;	O
and	O
(	O
4	O
)	O
,	O
a	O
product	O
for	O
relieving	O
cardiac	O
interstitial	O
fibrosis	O
of	O
a	O
diabetic	O
.	O
The	O
fucoidan	O
polysaccharide	O
sulfate	O
is	O
preferably	O
LMWF	O
(	O
Fucoidan	O
Polysaccharide	O
Sulfate	O
)	O
with	O
weight-average	O
molecular	O
weight	O
of	O
3-30KD	O
.	O
According	O
to	O
the	O
pharmacodynamic	O
experiment,	O
the	O
LMWF	O
can	O
be	O
used	O
for	O
generating	O
beneficial	O
interference	O
to	O
the	O
development	O
of	O
pathogenetic	O
condition	O
of	O
the	O
diabetic	O
cardiomyopathy	O
by	O
strengthening	O
the	O
myocardial	O
systolic	O
function	O
and	O
relieving	O
cardiac	O
fibrosis	O
.	O
More	O
importantly,	O
the	O
LMWF	O
can	O
be	O
used	O
for	O
effectively	O
inhibiting	O
oxidative	O
stress	O
by	O
regulating	O
the	O
activity	O
of	O
antioxidase,	O
and	O
can	O
be	O
used	O
for	O
inhibiting	O
the	O
expression	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
beta	I-GENE
(	O
PKCbeta	B-GENE
)	O
subtype	O
.	O
The	O
LMWF	O
is	O
from	O
the	O
natural	O
existing	O
kelp,	O
so	O
that	O
the	O
availability	O
and	O
safety	O
of	O
the	O
kelp	O
are	O
beneficial	O
to	O
using	O
the	O
fucoidan	O
polysaccharide	O
sulfate	O
as	O
a	O
potential	O
clinical	O
treatment	O
drug	O
and	O
preventing	O
the	O
diabetic	O
cardiomyopathy	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
punicalin	O
in	O
preparation	O
of	O
medicine	O
for	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
infection	O
.	O
An	O
antivirus	O
test	O
is	O
performed	O
by	O
selecting	O
basically	O
non-toxic	O
medicine	O
concentration,	O
the	O
influence	O
of	O
punicalin	O
on	O
copy	O
of	O
hepatitis	O
C	O
virus	O
is	O
detected,	O
and	O
the	O
compound	O
has	O
obvious	O
hepatitis	O
C	O
virus	O
resistant	O
activity	O
and	O
has	O
a	O
dose-dependent	O
effect	O
.	O
The	O
further	O
experiment	O
proves	O
that	O
the	O
punicalin	O
can	O
prevent	O
HCV	O
from	O
being	O
adsorbed	O
and	O
invading	O
the	O
target	O
cells,	O
so	O
that	O
the	O
entrance	O
and	O
reinfection	O
of	O
HCV	O
are	O
inhibited	O
;	O
and	O
meanwhile,	O
the	O
compound	O
also	O
can	O
obviously	O
reduce	O
the	O
activity	O
of	O
HCVNS3	B-GENE
serine	I-GENE
protease	I-GENE
.	O
Thus,	O
when	O
being	O
independently	O
used	O
or	O
combined	O
with	O
other	O
anti-HCV	O
medicines,	O
the	O
punicalin	O
can	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
preventing	O
or	O
treating	O
hepatitis	O
C	O
virus	O
infection	O
.	O


The	O
invention	O
discloses	O
a	O
novel	O
tetrahydropyrrole	O
derivative	O
which	O
is	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
below	O
and	O
is	O
a	O
selective	O
antagonist	O
of	O
a	O
muscarine	B-GENE
type	I-GENE
acetylcholinergic	I-GENE
receptor,	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
C1-3	O
straight-chain	O
or	O
branched-chain	O
alkyl	O
;	O
and	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
halogen	O
.	O
Besides,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
and	O
application	O
of	O
the	O
derivative	O
as	O
a	O
muscarine	B-GENE
acetylcholinergic	I-GENE
receptor	I-GENE
antagonist	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
organisms,	O
particularly	O
relates	O
to	O
the	O
field	O
of	O
a	O
molecular	O
medicine,	O
and	O
more	O
particularly	O
relates	O
to	O
medical	O
application	O
of	O
an	O
RNA	O
(	O
ribonucleic	O
acid	O
)	O
molecule	O
.	O
The	O
invention	O
provides	O
a	O
microRNA	O
molecule	O
related	O
to	O
tumor	O
cell	O
autophagy	O
and	O
application	O
thereof	O
in	O
preparation	O
of	O
a	O
cancer	O
medicine	O
.	O
Particularly,	O
a	O
nucleotide	O
sequence	O
of	O
miR-556	B-GENE
is	O
miR-556-3p	B-GENE
sequence	O
SEQ	O
ID	O
NO	O
:	O
1,	O
or	O
miR-556	B-GENE
precursor	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
2,	O
or	O
homologous	O
complementary	O
variant	O
miR-556-5p	B-GENE
sequence	O
SEQ	O
ID	O
NO	O
:	O
3	O
.	O


The	O
invention	O
provides	O
an	O
application	O
of	O
an	O
isoprenaline	O
hydrochloride	O
and	O
sprycel	O
composition	O
in	O
preparation	O
of	O
a	O
sprycel	O
liver	O
toxicity	O
treatment	O
drug,	O
wherein	O
an	O
amount	O
ratio	O
of	O
the	O
isoprenaline	O
hydrochloride	O
to	O
the	O
sprycel	O
in	O
the	O
composition	O
is	O
1	O
:	O
6	O
.	O
25	O
*	O
10	O
<	O
6	O
>	O
,	O
and	O
the	O
application	O
is	O
that	O
8	O
ng	O
/	O
kg	O
of	O
the	O
isoprenaline	O
hydrochloride	O
and	O
50	O
mg	O
/	O
kg	O
of	O
the	O
sprycel	O
are	O
applied	O
per	O
day	O
.	O
According	O
to	O
the	O
present	O
invention,	O
a	O
p38	B-GENE
specific	O
agonist	O
isoprenaline	O
is	O
adopted	O
to	O
up-regulate	O
a	O
p38	B-GENE
expression	O
level	O
and	O
induce	O
liver	O
cell	O
autophagy	O
generation	O
so	O
as	O
to	O
achieve	O
a	O
purpose	O
of	O
liver	O
protection	O
.	O
With	O
the	O
present	O
invention,	O
theoretical	O
basis	O
is	O
provided	O
for	O
prevention	O
and	O
treatment	O
of	O
tinib	O
drug	O
liver	O
toxicity,	O
and	O
high	O
clinical	O
practicality	O
is	O
provided	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O
An	O
acetohydroxyacid	B-GENE
synthase	I-GENE
(	O
AHAS	B-GENE
)	O
can	O
be	O
used	O
as	O
an	O
important	O
new	O
target	O
enzyme	O
of	O
anti-tuberculosis	O
drugs	O
.	O
In	O
an	O
in	O
vitro	O
AHAS	B-GENE
enzyme	O
activity	O
inhibition	O
experiment	O
and	O
an	O
anti-tuberculosis	O
activity	O
experiment,	O
the	O
substituted	O
benzoate	O
compositions	O
provided	O
by	O
the	O
invention	O
express	O
strong	O
AHAS	B-GENE
inhibition	O
activity	O
and	O
strong	O
growth	O
inhibition	O
effect	O
on	O
mycobacterium	O
tuberculosis,	O
thereby	O
having	O
good	O
drug	O
application	O
prospect	O
.	O
A	O
carrier	O
of	O
the	O
composition	O
drug	O
comprises	O
the	O
following	O
conventional	O
additives	O
in	O
the	O
pharmacy	O
field	O
:	O
a	O
thinner,	O
an	O
excipient,	O
filler,	O
an	O
adhesive,	O
a	O
humectant,	O
a	O
disintegrating	O
agent,	O
a	O
sorbefacient,	O
a	O
surfactant,	O
an	O
adsorption	O
carrier,	O
a	O
lubricant,	O
a	O
synergist,	O
and	O
the	O
like	O
.	O
The	O
drugs	O
can	O
be	O
prepared	O
to	O
injection,	O
tablets,	O
pills,	O
capsules,	O
suspending	O
agents	O
or	O
emulsion,	O
and	O
the	O
administration	O
route	O
can	O
be	O
oral	O
administration,	O
subcutaneous	O
injection,	O
intravenous	O
injection	O
or	O
intramuscular	O
injection	O
.	O


The	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
ribonucleases	B-GENE
and	O
cantharidin	O
.	O
Specifically,	O
the	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
comprising	O
:	O
ribonucleases	B-GENE
as	O
an	O
active	O
component	O
(	O
a	O
)	O
;	O
cantharidin	O
or	O
derivatives	O
or	O
pharmaceutical	O
acceptable	O
salts	O
of	O
the	O
cantharidin	O
as	O
an	O
active	O
component	O
(	O
b	O
)	O
;	O
and	O
pharmaceutical	O
acceptable	O
carriers	O
as	O
active	O
components	O
(	O
c	O
)	O
.	O
The	O
pharmaceutical	O
composition	O
of	O
the	O
invention	O
maycooperatively	O
and	O
effectively	O
increase	O
inhibition	O
effects	O
on	O
the	O
growth	O
of	O
tumor	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazolo	O
[	O
4,3-	O
/	O
h	O
]	O
quinazoline	O
compounds	O
which	O
modulate	O
the	O
activity	O
of	O
protein	B-GENE
kinases	I-GENE
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
caused	O
by	O
dysregulated	O
protein	B-GENE
kinase	I-GENE
activity,	O
in	O
particular	O
PIM	B-GENE
kinases	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
preparing	O
these	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
methods	O
of	O
treating	O
diseases	O
utilizing	O
such	O
these	O
compounds	O
or	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
provides	O
a	O
substituted	O
pyridine	O
compound	O
with	O
a	O
structure	O
as	O
shown	O
in	O
a	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and	O
a	O
pharmaceutical	O
preparation	O
thereof	O
.	O
The	O
substituted	O
pyridine	O
compound	O
is	O
used	O
for	O
regulating	O
the	O
activity	O
of	O
protein	B-GENE
kinase	I-GENE
and	O
regulating	O
signal	O
response	O
between	O
cells	O
or	O
in	O
the	O
cells	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
provided	O
by	O
the	O
invention	O
and	O
a	O
method	O
of	O
utilizing	O
the	O
pharmaceutical	O
composition	O
to	O
treat	O
mammal	O
and	O
especially	O
human	O
high	O
hyperplastic	O
diseases	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
X,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
using	O
the	O
compounds	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
LRRK2	B-GENE
receptor,	O
such	O
as	O
Parkinson	O
'	O
s	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
a	O
ranitidine	O
hydrochloride	O
powder	O
injection	O
for	O
injection,	O
specifically	O
to	O
a	O
pharmaceutical	O
composition	O
.	O
The	O
ranitidine	O
hydrochloride	O
powder	O
injection	O
contains	O
ranitidine,	O
a	O
freeze-drying	O
excipient	O
and	O
an	O
optional	O
acidifying	O
or	O
alkalizing	O
agent	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
pharmaceutical	O
composition	O
.	O
The	O
pharmaceutical	O
composition,	O
which	O
is	O
used	O
as	O
an	O
excellent	O
and	O
potent	O
histamine	B-GENE
H2	I-GENE
receptor	I-GENE
antagonist,	O
can	O
be	O
used	O
to	O
effectively	O
inhibit	O
gastric	O
acid	O
secretion	O
caused	O
by	O
stimulation	O
of	O
histamine,	O
pentagastrin	O
and	O
carbechal,	O
reduce	O
gastric	O
acid	O
and	O
gastric	O
enzyme	O
activity,	O
and	O
is	O
an	O
excellent	O
gastropathy	O
medicine	O
for	O
treating	O
hyperacidity	O
and	O
heartburn	O
.	O
The	O
powder	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
good	O
pharmaceutical	O
properties	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
composed	O
of	O
aspirin	O
and	O
vitamin	O
C	O
and	O
used	O
for	O
preventing	O
and	O
treating	O
lung	O
injury	O
caused	O
by	O
smoking	O
.	O
A	O
composite	O
preparation	O
prepared	O
from	O
the	O
pharmaceutical	O
composition	O
has	O
a	O
good	O
prevention	O
and	O
treatment	O
effect	O
on	O
lung	O
injury	O
caused	O
by	O
smoking	O
.	O
Research	O
results	O
show	O
that	O
an	O
A-C	O
mixture	O
composed	O
of	O
aspirin	O
and	O
vitamin	O
C	O
in	O
the	O
best	O
proportion	O
of	O
1	O
:	O
2	O
has	O
an	O
obvious	O
protection	O
function	O
for	O
pathological	O
tissue	O
change	O
of	O
mice	O
lung	O
tissue	O
caused	O
by	O
long-term	O
smoking,	O
namely,	O
lung	O
tissue	O
is	O
not	O
infiltrated	O
by	O
inflammatory	O
cells,	O
obvious	O
congestion	O
and	O
alveoli	O
bleeding	O
are	O
not	O
generated,	O
the	O
pulmonary	O
alveoli	O
is	O
similar	O
to	O
a	O
normal	O
group,	O
SOD	B-GENE
activity	O
is	O
obviously	O
improved,	O
and	O
contents	O
of	O
MDA	O
and	O
HYP	O
are	O
remarkably	O
reduced	O
.	O
The	O
effect	O
of	O
the	O
A-C	O
mixture	O
group	O
is	O
better	O
than	O
that	O
of	O
single	O
aspirin	O
or	O
vitamin	O
C	O
control	O
drug	O
group	O
at	O
the	O
same	O
dosage	O
.	O
The	O
pharmaceutical	O
composition	O
composed	O
of	O
aspirin	O
and	O
vitamin	O
C	O
in	O
a	O
proportion	O
of	O
1	O
:	O
2	O
can	O
be	O
prepared	O
into	O
medicine	O
tablets,	O
enteric	O
coatel	O
tablets,	O
capsules,	O
granular	O
formation,	O
medicinal	O
granules,	O
oral	O
liquids	O
and	O
the	O
like	O
of	O
various	O
specifications,	O
and	O
can	O
be	O
selected	O
based	O
on	O
the	O
smoking	O
history	O
and	O
lung	O
injury	O
degree	O
.	O


The	O
invention	O
discloses	O
a	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
having	O
a	O
weight	O
average	O
molecular	O
weight	O
of	O
23000	O
daltons	O
.	O
A	O
preparation	O
method	O
comprises	O
the	O
steps	O
:	O
with	O
lycium	O
barbarum	O
as	O
raw	O
material,	O
firstly,	O
adding	O
water	O
for	O
decoction,	O
performing	O
alcohol	O
precipitation	O
to	O
obtain	O
a	O
raw	O
lycium	O
barbarum	O
polysaccharide,	O
then	O
decolorizing	O
the	O
raw	O
lycium	O
barbarum	O
polysaccharide	O
and	O
removing	O
hybrid	O
proteins	O
by	O
a	O
macroporous	O
adsorption	O
resin,	O
further	O
adding	O
the	O
treated	O
raw	O
lycium	O
barbarum	O
polysaccharide	O
on	O
a	O
DEAE-52	O
cellulose	O
column,	O
eluting	O
successively	O
with	O
deionized	O
water	O
and	O
0	O
.	O
05,	O
0	O
.	O
10	O
and	O
0	O
.	O
5	O
M	O
sodium	O
chloride	O
solutions,	O
collecting	O
an	O
eluted	O
part	O
of	O
the	O
0	O
.	O
5	O
M	O
sodium	O
chloride	O
solution,	O
dialyzing	O
after	O
concentrating,	O
and	O
drying	O
to	O
obtain	O
the	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
.	O
The	O
invention	O
also	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
and	O
an	O
application	O
of	O
the	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
in	O
preparing	O
drugs	O
for	O
treating	O
glucose	O
and	O
lipid	O
metabolism	O
disorders	O
and	O
insulin	B-GENE
resistance	O
in	O
diabetes	O
.	O
The	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
has	O
definite	O
effect	O
of	O
treatment	O
;	O
and	O
compared	O
with	O
conventional	O
lycium	O
barbarum	O
polysaccharide	O
extracts	O
and	O
formulations,	O
the	O
lycium	O
barbarum	O
polysaccharide	O
homogeneous	O
fraction	O
IV	O
has	O
fewer	O
impurities,	O
higher	O
content	O
of	O
effective	O
substances,	O
more	O
controllable	O
product	O
quality	O
and	O
less	O
potential	O
security	O
risk	O
.	O
The	O
preparation	O
method	O
is	O
simple,	O
and	O
has	O
short	O
production	O
cycle	O
and	O
low	O
cost	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
butylphthalide	O
or	O
derivatives	O
thereof	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
or	O
preventing	O
radiation	O
brain	O
damage	O
.	O
The	O
mechanism	O
of	O
action	O
for	O
treating	O
the	O
radiation	O
brain	O
damage	O
by	O
using	O
the	O
butylphthalide	O
is	O
that	O
oxygen	O
free	O
radical	O
balance	O
in	O
brain	O
tissues	O
subjected	O
to	O
radiation	O
damage	O
can	O
be	O
improved	O
and	O
the	O
damage	O
effect	O
of	O
oxygen	O
free	O
radicals	O
can	O
be	O
relieved	O
by	O
the	O
butylphthalide	O
;	O
the	O
permeability	O
of	O
blood-brain	O
barrier	O
of	O
a	O
rat	O
with	O
radioactive	O
brain	O
damage	O
can	O
be	O
reduced	O
by	O
reducing	O
the	O
number	O
of	O
circulating	O
endothelial	O
cells	O
of	O
the	O
rat	O
after	O
whole	O
brain	O
irradiation,	O
and	O
the	O
radioactive	O
brain	O
damage	O
is	O
protected,	O
i	O
.	O
e	O
.	O
,	O
acting	O
target	O
cells	O
of	O
the	O
butylphthalide	O
are	O
mainly	O
vascular	O
endothelial	O
cells	O
;	O
and	O
the	O
AQP4	B-GENE
(	O
Aquaporin	B-GENE
4	I-GENE
)	O
effect	O
can	O
be	O
adjusted	O
so	O
as	O
to	O
protect	O
the	O
blood-brain	O
barrier	O
.	O


The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines,	O
especially	O
relates	O
to	O
an	O
application	O
of	O
deacetylase	B-GENE
inhibitors	O
in	O
preparation	O
of	O
medicaments	O
for	O
promoting	O
insulin	B-GENE
secretion,	O
and	O
wherein	O
the	O
deacetylase	B-GENE
inhibitor	O
is	O
nicotinamide	O
(	O
NAM	O
)	O
or	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O
The	O
rat	O
islet	O
cells	O
are	O
co-incubated	O
with	O
the	O
deacetylase	B-GENE
inhibitor	O
NAM	O
for	O
1	O
h,	O
and	O
insulin	B-GENE
secretion	O
stimulated	O
by	O
glucose	O
is	O
improved	O
by	O
about	O
50	O
%	O
;	O
by	O
using	O
the	O
deacetylase	B-GENE
inhibitor	O
TSA	O
to	O
treat	O
islet	O
cells	O
for	O
12	O
h	O
while	O
the	O
glucose	O
concentration	O
is	O
3	O
.	O
3	O
mmol	O
/	O
L,	O
insulin	B-GENE
secretion	O
can	O
be	O
improved,	O
and	O
insulin	B-GENE
secretion	O
is	O
improved	O
obviously	O
after	O
16	O
h	O
;	O
and	O
insulin	B-GENE
secretion	O
is	O
mildly	O
up-regulated	O
after	O
islet	O
cells	O
are	O
treated	O
by	O
NAM	O
for	O
16	O
h	O
.	O
Therefore,	O
the	O
inhibitors	O
NAM	O
and	O
TSA	O
are	O
applicable	O
to	O
preparation	O
of	O
the	O
medicaments	O
for	O
promoting	O
insulin	B-GENE
secretion,	O
and	O
the	O
medicaments	O
will	O
have	O
good	O
treatment	O
effect	O
in	O
diabetes	O
treatment	O
.	O
Also,	O
more	O
scientific	O
bases	O
are	O
provided	O
for	O
more	O
reasonable	O
clinic	O
use	O
of	O
the	O
deacetylase	B-GENE
inhibitors	O
NAM	O
and	O
TSA	O
.	O


The	O
invention	O
provides	O
a	O
tyrosinase	B-GENE
retardant,	O
a	O
melanin	O
inhibitor,	O
a	O
skin	O
lightener	O
and	O
cosmetics	O
with	O
excellent	O
tyrosinase	B-GENE
activity	O
blocking	O
function	O
.	O
The	O
active	O
component	O
of	O
the	O
tyrosinase	B-GENE
retardant	O
is	O
isopropyl	O
Methylphenol	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
sulfur	O
derivatives,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
chemokine	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
an	O
allosteric	O
mTOR	B-GENE
inhibitor	O
and	O
a	O
catalytic	O
mTOR	B-GENE
inhibitor	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
neurodegenerative	O
diseases,	O
for	O
example	O
Huntington	O
'	O
s	O
Disease,	O
and	O
products	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
a	O
combination	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
neurodegenerative	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
hydroxamic	O
acid	O
derivative,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
hydroxamic	O
acid	O
derivative	O
of	O
pyrazolopyrimidine	O
and	O
a	O
medical	O
application	O
thereof	O
.	O
The	O
hydroxamic	O
acid	O
derivative	O
meanwhile	O
has	O
inhibiting	O
effects	O
on	O
histone	B-GENE
deacetylase	I-GENE
1,	O
two	O
types	O
of	O
tyrosine	B-GENE
kinase	I-GENE
(	O
vascular	B-GENE
endothelial	I-GENE
cell	I-GENE
growth	I-GENE
factor	I-GENE
receptors	I-GENE
)	O
and	O
a	O
platelet	O
derived	O
growth	O
factor	I-GENE
receptor,	O
so	O
that	O
the	O
hydroxamic	O
acid	O
derivative	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
associated	O
with	O
the	O
three	O
enzymes	O
.	O
The	O
compounds	O
cannot	O
only	O
adequately	O
exert	O
synergistic	O
effect	O
to	O
enhance	O
the	O
biological	O
activity,	O
but	O
also	O
can	O
avoid	O
problems	O
caused	O
by	O
heterogeneity	O
and	O
metabolism,	O
so	O
that	O
the	O
novel	O
hydroxamic	O
acid	O
derivative	O
has	O
better	O
practicality	O
and	O
good	O
prospect	O
.	O


The	O
invention	O
discloses	O
a	O
novel	O
purpose	O
of	O
cinnamyl	O
aldehyde,	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
the	O
cinnamyl	O
aldehyde	O
which	O
is	O
used	O
as	O
a	O
cough	O
motivation	O
agonist,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
researches	O
.	O
The	O
cinnamyl	O
aldehyde	O
is	O
used	O
for	O
activating	O
a	O
TRPA1	B-GENE
receptor	O
in	O
a	O
TRP	B-GENE
protein	I-GENE
family	I-GENE
as	O
the	O
cough	O
agonist	O
.	O
A	O
novel	O
path	O
is	O
provided	O
for	O
deep	O
research	O
of	O
the	O
cough	O
mechanism,	O
theoretical	O
foundation	O
is	O
provided	O
for	O
novel	O
cough	O
relieving	O
medicine	O
development	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
chrysin	O
in	O
treatment	O
of	O
Guillain-Barre	O
snydrome	O
.	O
A	O
great	O
many	O
of	O
experiments	O
are	O
conducted	O
regarding	O
to	O
the	O
typical	O
pathology	O
characteristics	O
of	O
the	O
Guillain-Barre	O
snydrome,	O
and	O
the	O
chrysin	O
is	O
proven	O
to	O
have	O
remarkable	O
experimental	O
treatment	O
effect	O
for	O
autoimmunity	O
neuritis,	O
and	O
can	O
effectively	O
alleviate	O
the	O
lowering	O
tendency	O
of	O
the	O
nerve	O
conduction	O
rate	O
and	O
the	O
increasing	O
tendency	O
of	O
the	O
amplitude	O
and	O
the	O
latent	O
period	O
;	O
the	O
experiment	O
data	O
shows	O
that	O
infiltration	O
of	O
a	O
neuritis	O
cell	O
and	O
demyelination	O
of	O
peripheral	O
sciatic	O
nerve	O
are	O
both	O
alleviated	O
through	O
taking	O
chrysin,	O
the	O
expression	O
of	O
induction	B-GENE
type	I-GENE
nitric	I-GENE
oxide	I-GENE
synthetase	I-GENE
(	O
iNOS	B-GENE
)	O
,	O
epoxidase	B-GENE
(	O
COX-2	B-GENE
)	O
,	O
and	O
nuclear	B-GENE
transcription	I-GENE
factor	I-GENE
Kappa	I-GENE
B	I-GENE
(	O
NF-Kappa	B-GENE
B	I-GENE
)	O
at	O
peripheral	O
nerves,	O
and	O
the	O
expression	O
of	O
cell	O
factor	O
IL-2,	O
IL-6,	O
IFN-Gamma	B-GENE
and	O
TNF-Alpha	B-GENE
are	O
reduced,	O
so	O
that	O
the	O
chrysin	O
is	O
proven	O
to	O
have	O
treatment	O
effect	O
on	O
the	O
Guillain-Barre	O
snydrome	O
.	O


The	O
invention	O
provides	O
application	O
of	O
cerebrosides	O
in	O
preparation	O
of	O
analgesic	O
drugs	O
.	O
An	O
animal	O
experiment	O
on	O
pharmacology	O
verifies	O
that	O
the	O
cerebrosides	O
are	O
administrated	O
through	O
the	O
ways	O
such	O
as	O
intraperitoneal	O
injection,	O
gavage	O
and	O
skin	O
smearing	O
;	O
all	O
the	O
three	O
ways	O
can	O
improve	O
the	O
threshold	O
values	O
of	O
a	O
mouse	O
to	O
pains	O
caused	O
by	O
heat	O
and	O
mechanical	O
stimulation	O
in	O
a	O
dose-dependent	O
manner	O
;	O
the	O
cerebrosides	O
can	O
remarkably	O
relieve	O
a	O
neuropathic	O
pain,	O
an	O
inflammatory	O
pain	O
and	O
an	O
acetic-acid-induced	O
visceral	O
pain	O
.	O
A	O
cerebroside	O
A	O
or	O
a	O
cerebroside	O
B	O
can	O
inhibit	O
the	O
activity	O
of	O
a	O
vanilloid	O
receptor	O
TRPV1,	O
so	O
that	O
the	O
cerebrosides	O
can	O
increase	O
an	O
algesia	O
threshold	O
value	O
and	O
achieve	O
the	O
purpose	O
of	O
abirritation	O
by	O
lowering	O
the	O
activity	O
of	O
the	O
vanilloid	O
receptor	O
TRPV1	B-GENE
.	O
According	O
to	O
the	O
invention,	O
the	O
application	O
of	O
the	O
cerebrosides	O
serving	O
as	O
internal	O
and	O
external	O
analgesic	O
drugs	O
is	O
developed	O
.	O


The	O
invention	O
relates	O
to	O
3-pyrrole	O
carboxylic	O
acid	O
derivatives,	O
and	O
a	O
preparing	O
method	O
and	O
an	O
application	O
thereof,	O
and	O
particularly	O
relates	O
to	O
the	O
3-pyrrole	O
carboxylic	O
acid	O
derivatives	O
having	O
a	O
structure	O
represented	O
by	O
formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
the	O
preparing	O
method	O
of	O
the	O
derivatives,	O
pharmaceutical	O
compositions	O
with	O
the	O
3-pyrrole	O
carboxylic	O
acid	O
derivatives	O
having	O
the	O
structure	O
represented	O
by	O
the	O
formula	O
I	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
3-pyrrole	O
carboxylic	O
acid	O
derivatives	O
as	O
active	O
ingredients,	O
and	O
applications	O
of	O
the	O
pharmaceutical	O
compositions	O
in	O
prevention	O
or	O
treatment	O
of	O
diseases	O
related	O
with	O
an	O
arginine	B-GENE
vasopressin	I-GENE
V1a	I-GENE
receptor,	O
an	O
arginine	B-GENE
vasopressin	I-GENE
V1b	I-GENE
receptor,	O
an	O
arginine	B-GENE
vasopressin	I-GENE
V2	I-GENE
receptor,	O
a	O
sympathetic	O
nervous	O
system	O
or	O
a	O
renin-angiotensin-aldosterone	O
system	O
.	O


The	O
invention	O
relates	O
to	O
preparation	O
and	O
application	O
of	O
an	O
egg	O
yolk	O
antibody	O
containing	O
florfenicol	B-GENE
drug	I-GENE
resistance	I-GENE
gene	I-GENE
protein	I-GENE
(	O
FloR	B-GENE
)	O
.	O
Riemerella	O
anatipestifer	O
(	O
CCTCC	O
No	O
:	O
M208128	O
)	O
resistant	O
to	O
florfenicol	O
is	O
separated	O
from	O
a	O
duck	O
dies	O
clinically	O
;	O
PCR	O
is	O
adopted	O
to	O
amplify	O
a	O
section	O
of	O
the	O
drug	O
resistance	I-GENE
gene	I-GENE
(	O
floR	B-GENE
)	O
;	O
the	O
section	O
of	O
the	O
drug	O
resistance	I-GENE
gene	I-GENE
is	O
cloned	O
to	O
an	O
expression	O
plasmid	O
pET28a	O
(	O
+	O
)	O
for	O
transfecting	O
host	O
bacteria	O
BL21	O
(	O
DE3	O
)	O
.	O
The	O
recombination	O
strain	O
is	O
subject	O
to	O
induction	O
expression,	O
and	O
fusion	O
protein	O
containing	O
the	O
target	O
gene	O
section	O
and	O
having	O
a	O
HIS	O
label	O
is	O
prepared	O
;	O
the	O
fusion	O
protein	O
exists	O
in	O
the	O
form	O
of	O
an	O
inclusion	O
body	O
;	O
the	O
inclusion	O
body	O
is	O
extracted	O
for	O
the	O
preparation	O
of	O
an	O
immunogen	O
;	O
the	O
immunogen	O
is	O
used	O
for	O
immunizing	O
a	O
laying	O
hen,	O
so	O
as	O
to	O
obtain	O
the	O
egg	O
yolk	O
antibody	O
capable	O
of	O
improving	O
the	O
sensitivity	O
of	O
the	O
drug	O
resistance	I-GENE
strain	O
to	O
florfenicol	O
;	O
the	O
egg	O
yolk	O
antibody	O
is	O
used	O
in	O
combination	O
with	O
florfenicol	O
to	O
remarkably	O
improve	O
the	O
treatment	O
effect	O
on	O
a	O
duck	O
infected	O
with	O
a	O
drug-resistant	O
riemerella	O
anatipestifer	O
strain	O
;	O
as	O
other	O
strains	O
resistant	O
to	O
florfenicol	O
are	O
also	O
mediated	O
through	O
a	O
floR	B-GENE
gene,	O
the	O
egg	O
yolk	O
antibody	O
can	O
be	O
applied	O
to	O
the	O
veterinary	O
clinical	O
treatment	O
on	O
livestock	O
and	O
poultry	O
infected	O
with	O
strains	O
resistant	O
to	O
florfenicol	O
.	O


The	O
invention	O
relates	O
to	O
a	O
matrix	B-GENE
metalloproteinase	I-GENE
inhibitor	O
and	O
a	O
purpose	O
thereof	O
.	O
Particularly,	O
the	O
matrix	B-GENE
metalloproteinase	I-GENE
inhibitor	O
is	O
a	O
compound	O
with	O
a	O
structure	O
shown	O
as	O
in	O
Formula	O
(	O
I	O
)	O
as	O
shown	O
in	O
the	O
specification,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O
The	O
inhibitor	O
can	O
be	O
used	O
for	O
preventing	O
or	O
treating	O
matrix	B-GENE
metalloproteinase	I-GENE
regulated	O
diseases,	O
particularly	O
acute	O
lung	O
injury	O
induced	O
by	O
suffocating	O
gas	O
or	O
a	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
caused	O
by	O
other	O
reasons	O
.	O


The	O
invention	O
discloses	O
2-fuloro	O
fumarate	O
(	O
formula	O
I	O
)	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O
Experiments	O
show	O
that	O
:	O
the	O
kinds	O
of	O
compounds	O
are	O
capable	O
of	O
effectively	O
inhibiting	O
NF-kB	B-GENE
transcriptional	O
activity	O
introduced	O
by	O
TNF-alpha,	O
and	O
further	O
are	O
capable	O
of	O
treating	O
diseases	O
introduced	O
by	O
NF-kB,	O
such	O
as	O
psoriasis,	O
multiple	O
sclerosis,	O
arthritis,	O
eye	O
inflammation	O
or	O
allergy,	O
asthma	O
and	O
lupus	O
erythematosus,	O
and	O
can	O
be	O
used	O
as	O
an	O
immunosuppressant	O
for	O
organ	O
transplantation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
as	O
formula	O
(	O
I	O
)	O
capable	O
of	O
modulating	O
the	O
stability	O
and	O
/	O
or	O
activity	O
of	O
hypoxia	B-GENE
inducible	I-GENE
factor	I-GENE
(	O
HIF	B-GENE
)	O
.	O


Provided	O
are	O
modulators	O
of	O
TLRs	B-GENE
of	O
Formula	O
II,	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
compositions	O
containing	O
such	O
compounds,	O
and	O
therapeutic	O
methods	O
that	O
include	O
the	O
administration	O
of	O
such	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
applications	O
of	O
a	O
cysteinyl	B-GENE
leukotriene	I-GENE
receptor	I-GENE
antagonist	O
(	O
CysLT1R	B-GENE
)	O
on	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
the	O
Alzheimer	O
disease	O
.	O
Research	O
finds	O
that	O
intracerebral	O
CysLT1R	B-GENE
mediates	O
A	O
beta	O
aggregation	O
and	O
dysmnesia	O
;	O
and	O
by	O
oral	O
medication,	O
CysLT1R	B-GENE
antagonists	O
such	O
as	O
pranlukast,	O
zafirlukast	O
and	O
montelukast	O
can	O
improve	O
mice	O
memory	O
impairment	O
caused	O
by	O
A	O
beta	O
.	O
The	O
CysLT1R	B-GENE
antagonists	O
such	O
as	O
pranlukast,	O
zafirlukast	O
and	O
montelukast,	O
and	O
analogs	O
thereof	O
such	O
as	O
iralukast,	O
ablukast,	O
imitrodast,	O
pobilukast,	O
cinalukast,	O
verlukast,	O
pemirolast	O
and	O
ibudilast,	O
have	O
significant	O
protection	O
effect	O
on	O
primarily-cultured	O
mice	O
neuron	O
damage	O
caused	O
by	O
A	O
beta	O
.	O
The	O
CysLT1R	B-GENE
antagonists	O
such	O
as	O
pranlukast,	O
zafirlukast	O
and	O
montelukast,	O
and	O
the	O
analogs	O
thereof	O
such	O
as	O
iralukast,	O
ablukast,	O
imitrodast,	O
pobilukast,	O
cinalukast,	O
verlukast,	O
pemirolast	O
and	O
ibudilast,	O
can	O
be	O
used	O
for	O
preparing	O
anti-AD	O
medicaments	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
taken	O
as	O
a	O
potassium	B-GENE
channel	I-GENE
regulator	O
.	O
The	O
compound	O
taken	O
as	O
the	O
potassium	B-GENE
channel	I-GENE
regulator	O
is	O
a	O
compound	O
shown	O
in	O
a	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
the	O
compound	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
an	O
effect	O
of	O
treating	O
and	O
preventing	O
diseases	O
and	O
symptoms	O
which	O
can	O
be	O
influenced	O
by	O
activity	O
of	O
a	O
potassium	B-GENE
ion	I-GENE
channel	I-GENE
.	O


The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
containing	O
a	O
neurokinin	B-GENE
1(NK-1)	I-GENE
receptor	I-GENE
antagonist,	O
a	O
5-hydroxytryptamine	B-GENE
3	I-GENE
(5HT-3)	I-GENE
receptor	I-GENE
antagonist	O
and	O
adrenocortical	O
hormone	O
.	O
The	O
medicinal	O
composition	O
adopts	O
a	O
NK-1	B-GENE
receptor	I-GENE
antagonist,	O
a	O
5HT-3	B-GENE
receptor	I-GENE
antagonist	O
and	O
adrenocortical	O
hormone	O
as	O
active	O
components,	O
is	O
added	O
with	O
certain	O
auxiliaries	O
with	O
specific	O
spices	O
and	O
proportion	O
to	O
prepare	O
and	O
develop	O
an	O
oral	O
preparation	O
according	O
to	O
a	O
technical	O
means	O
specified	O
in	O
the	O
invention	O
.	O
The	O
medicinal	O
composition	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
nausea	O
and	O
emesis	O
caused	O
by	O
cancer	O
radiotherapy,	O
chemotherapy	O
and	O
operation	O
.	O
The	O
invention	O
aims	O
to	O
provide	O
a	O
medicinal	O
composition	O
preparation	O
which	O
can	O
prevent	O
and	O
treat	O
emesis	O
more	O
conveniently	O
by	O
utilizing	O
the	O
NK-1	B-GENE
receptor	I-GENE
antagonist,	O
the	O
5HT-3	B-GENE
receptor	I-GENE
antagonist	O
and	O
adrenocortical	O
hormone,	O
thereby	O
improving	O
the	O
compliance	O
of	O
a	O
patient	O
.	O


The	O
invention	O
relates	O
to	O
three	O
non-clinical	O
antitumor	O
drugs	O
which	O
are	O
found	O
to	O
have	O
anti-tumor	O
effects	O
and	O
mainly	O
can	O
inhibit	O
the	O
proliferation	O
of	O
lung	O
cancer	O
A549	O
cells	O
or	O
cervical	O
cancer	O
Hela	O
cells	O
.	O
The	O
technical	O
problem	O
to	O
be	O
solved	O
is	O
that	O
some	O
clinical	O
drugs	O
are	O
screened	O
by	O
using	O
the	O
lung	O
cancer	O
A549	O
cells	O
and	O
the	O
cervical	O
cancer	O
Hela	O
cells,	O
so	O
as	O
to	O
obtain	O
the	O
non-clinical	O
antitumor	O
drugs	O
with	O
the	O
antitumor	O
effects	O
.	O
Key	O
points	O
of	O
technical	O
schemes	O
for	O
solving	O
the	O
problems	O
are	O
as	O
follows	O
:	O
the	O
lung	O
cancer	O
A549	O
cells	O
and	O
the	O
cervical	O
cancer	O
Hela	O
cells	O
are	O
processed	O
for	O
48	O
hours	O
by	O
using	O
drugs	O
of	O
saturated	O
concentration,	O
and	O
the	O
changes	O
of	O
the	O
morphology	O
and	O
quantity	O
of	O
the	O
cells	O
are	O
observed	O
by	O
a	O
microscope	O
;	O
for	O
drugs	O
with	O
inhibitory	O
actions,	O
survival	O
rate	O
and	O
LDH	B-GENE
(	O
Lactate	O
Dehydrogenase	O
)	O
activity	O
detection	O
is	O
further	O
carried	O
out	O
on	O
the	O
cells,	O
and	O
Hoechst33258	O
is	O
applied	O
to	O
cell	O
apoptosis	O
detection	O
.	O
Main	O
purposes	O
:	O
the	O
non-clinical	O
anticancer	O
drugs	O
for	O
remarkably	O
inhibiting	O
the	O
proliferation	O
of	O
the	O
lung	O
cancer	O
A549	O
cells	O
or	O
cervical	O
cancer	O
Hela	O
cells	O
are	O
found	O
and	O
are	O
applied	O
to	O
the	O
clinical	O
treatment	O
of	O
patients	O
with	O
lung	O
cancer	O
or	O
cervical	O
cancer	O
.	O


The	O
invention	O
provides	O
a	O
phenoxy	O
phenylacetic	O
acid	O
endothelin	B-GENE
antagonist	O
shown	O
in	O
a	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
benzene	O
oxygen	O
phenylacetic	O
acid	O
endothelin	B-GENE
antagonist	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
an	O
application	O
thereof	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
cardiovascular	O
and	O
cerebrovascular	O
diseases,	O
tumors,	O
diabetes	O
mellitus,	O
nephrosis,	O
asthma	O
or	O
hyperthyroidism	O
.	O


The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines,	O
concretely	O
relates	O
to	O
a	O
compound	O
for	O
treating	O
cancer,	O
a	O
composition	O
and	O
an	O
application	O
of	O
the	O
composition	O
and	O
particularly	O
relates	O
to	O
a	O
PI3	B-GENE
kinase	I-GENE
regulator	O
as	O
well	O
as	O
a	O
use	O
method	O
and	O
application	O
of	O
the	O
PI3	B-GENE
kinase	I-GENE
regulator	O
.	O
The	O
invention	O
provides	O
a	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
accepted	O
salt	O
of	O
the	O
compound	O
and	O
a	O
pharmaceutical	O
preparation	O
of	O
the	O
compound,	O
wherein	O
the	O
compound	O
is	O
used	O
for	O
regulating	O
the	O
activity	O
of	O
protein	B-GENE
kinase	I-GENE
and	O
intercellular	O
or	O
intracellular	O
signal	O
response	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
and	O
a	O
method	O
for	O
treating	O
high-proliferative	O
diseases	O
of	O
mammals	O
and	O
particularly	O
human	O
beings	O
by	O
using	O
the	O
pharmaceutical	O
composition	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
discloses	O
a	O
diterpenoid	O
compound	O
as	O
well	O
as	O
an	O
application	O
thereof	O
based	O
on	O
an	O
anti-tumor	O
effect	O
.	O
The	O
invention	O
provides	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
or	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
(	O
II	O
)	O
.	O
The	O
compound	O
shown	O
as	O
the	O
formula	O
(	O
I	O
)	O
is	O
named	O
as	O
a	O
compound	O
Cyafrin	O
D,	O
and	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
(	O
II	O
)	O
is	O
named	O
as	O
a	O
compound	O
Cyafrin	O
E	O
.	O
The	O
compounds	O
Cyafrin	O
D	O
and	O
E	O
have	O
remarkable	O
killing	O
effects	O
to	O
various	O
tumor	O
cell	O
lines,	O
and	O
can	O
effectively	O
inhibit	O
growth	O
of	O
a	O
human	O
colon	O
cancer	O
cell	O
HCT116	O
and	O
a	O
Bax	B-GENE
protein	O
deleted	O
human	O
colon	O
cancer	O
cell	O
bax-	O
/	O
-HCT116	O
in	O
a	O
nude	O
mouse	O
.	O
The	O
Bax	B-GENE
protein	O
has	O
a	O
promoting	O
effect	O
to	O
apoptosis,	O
and	O
deletion	O
or	O
mutation	O
deactivation	O
of	O
the	O
Bax	B-GENE
protein	O
is	O
always	O
one	O
of	O
the	O
reasons	O
of	O
drug	O
resistance	O
of	O
tumor	O
cells	O
.	O
The	O
invention	O
provides	O
a	O
lead	O
compound	O
for	O
developing	O
novel	O
anti-tumor	O
drugs,	O
and	O
has	O
a	O
significant	O
value	O
for	O
treating	O
tumors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
calcium	O
supplementing	O
composition,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
200-1000	O
parts	O
of	O
edible	O
calcium,	O
200-2000	O
parts	O
of	O
bamboo	O
leaf,	O
200-2000	O
parts	O
of	O
poria	O
cocos,	O
100-3000	O
parts	O
of	O
taurine,	O
300-3000	O
parts	O
of	O
bifidus	O
factor,	O
and	O
1-6	O
parts	O
of	O
casein	B-GENE
phosphopeptides	O
.	O
Experiments	O
prove	O
that	O
the	O
calcium	O
supplementing	O
composition	O
provided	O
by	O
the	O
invention	O
supplements	O
calcium	O
based	O
on	O
the	O
regulation	O
of	O
intestinal	O
functions	O
and	O
body	O
functions	O
;	O
the	O
calcium	O
absorbing	O
effect	O
is	O
prominent	O
.	O


The	O
invention	O
discloses	O
an	O
application	O
of	O
an	O
urushiol-silicon	O
polymer	O
(	O
code	O
:	O
GQ-5	O
)	O
in	O
preparation	O
of	O
a	O
medicine	O
for	O
inhibiting	O
Smad3	B-GENE
phosphorylation	O
.	O
The	O
in-vitro	O
experiment	O
shows	O
that	O
the	O
urushiol-silicon	O
polymer	O
is	O
able	O
to	O
inhibit	O
TGF	B-GENE
(Transforming	I-GENE
Growth	I-GENE
Factor)	I-GENE
beta	I-GENE
1	I-GENE
mediated	O
Smad3	B-GENE
phosphorylation	O
and	O
also	O
can	O
inhibit	O
the	O
expression	O
of	O
mRNA	O
(	O
Messenger	O
Ribose	O
Nucleic	O
Acid	O
)	O
of	O
alpha-SMA	O
(	O
Smooth	O
Muscle	O
Actine	O
)	O
,	O
type	O
I	O
collagen	O
and	O
fibronectin	B-GENE
at	O
downstream	O
.	O
The	O
in-vivo	O
experiment	O
also	O
shows	O
the	O
same	O
result	O
.	O
Therefore,	O
the	O
GQ-5	O
has	O
the	O
effect	O
of	O
specifically	O
inhibiting	O
Smad3	B-GENE
phosphorylation	O
and	O
also	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicine	O
for	O
inhibiting	O
Smad3	B-GENE
phosphorylation	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
that	O
relate	O
to	O
the	O
inhibition,	O
resolution	O
and	O
/	O
or	O
prevention	O
of	O
an	O
array	O
of	O
the	O
manifestations	O
of	O
metabolic	O
syndromes,	O
including	O
Type	O
2	O
diabetes,	O
hyperlipidemia,	O
weight	O
gain,	O
obesity,	O
insulin	B-GENE
resistance,	O
hypertension,	O
atherosclerosis,	O
fatty	O
liver	O
diseases	O
and	O
certain	O
chronic	O
inflammatory	O
states	O
that	O
lead	O
to	O
these	O
manifestations,	O
among	O
others	O
.	O
In	O
additional	O
aspects,	O
the	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
which	O
may	O
be	O
used	O
to	O
treat,	O
inhibit	O
or	O
reduce	O
the	O
likelihood	O
of	O
hepatitis	O
viral	O
infections,	O
including	O
Hepatitis	O
B	O
and	O
Hepatitis	O
C	O
viral	O
infections,	O
as	O
well	O
as	O
the	O
secondary	O
disease	O
states	O
and	O
/	O
or	O
conditions	O
which	O
are	O
often	O
associated	O
with	O
such	O
viral	O
infections,	O
including	O
hepatic	O
steatosis	O
(	O
steatohepatitis	O
)	O
,	O
cirrhosis,	O
fatty	O
liver	O
and	O
hepatocellular	O
cancer,	O
among	O
other	O
disease	O
states	O
or	O
conditions	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
Formula	O
I	O
for	O
use	O
in	O
the	O
treatment,	O
amelioration	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
CETP	B-GENE
activity,	O
such	O
as	O
atherosclerosis	O
and	O
dyslipidemia,	O
in	O
a	O
subject	O
with	O
high	O
triglyceride	O
level	O
;	O
wherein	O
R1,	O
X1,	O
R7,	O
R5,	O
C,	O
L	O
and	O
p	O
are	O
defined	O
herein	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
combination	O
of	O
pharmacologically	O
active	O
agents	O
for	O
use	O
in	O
the	O
treatment,	O
amelioration	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
CETP	B-GENE
activity,	O
such	O
as	O
atherosclerosis	O
and	O
dyslipidemia,	O
in	O
a	O
subject	O
with	O
high	O
triglyceride	O
levels	O
.	O


The	O
invention	O
discloses	O
application	O
of	O
HM-3	O
and	O
platinum,	O
paclitaxel	O
or	O
capecitabine	O
medicine	O
for	O
preparing	O
a	O
solid	O
tumor	O
medicine,	O
belonging	O
to	O
the	O
field	O
of	O
medicines	O
for	O
treating	O
tumor	O
.	O
Platinum,	O
paclitaxel	O
or	O
capecitabine	O
antimetabolites	O
serve	O
as	O
active	O
components	O
and	O
accompanied	O
by	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
to	O
be	O
prepared	O
into	O
various	O
pharmaceutically	O
acceptable	O
preparations	O
.	O
A	O
plurality	O
of	O
experiments	O
show	O
that	O
an	O
integrin	B-GENE
blocker	O
HM-3	O
is	O
clear	O
in	O
target	O
;	O
the	O
integrin	B-GENE
blocker	O
HM-3	O
is	O
reasonably	O
used	O
together	O
with	O
the	O
platinum,	O
paclitaxel	O
or	O
capecitabine	O
for	O
effectively	O
suppressing	O
growth	O
of	O
tumors	O
in	O
lung	O
cancer,	O
liver	O
cancer,	O
stomach	O
cancer,	O
breast	O
cancer,	O
cervical	O
cancer,	O
ovarian	O
cancer,	O
intestinal	O
cancer,	O
and	O
the	O
like	O
.	O
The	O
combined	O
medicine	O
serves	O
as	O
a	O
medicine	O
and	O
is	O
capable	O
of	O
effectively	O
treating	O
tumors	O
;	O
the	O
combined	O
medicine	O
is	O
scientific,	O
reasonable,	O
feasible	O
and	O
effective,	O
so	O
that	O
the	O
treatment	O
spectrum	O
for	O
treating	O
the	O
tumors	O
is	O
greatly	O
expanded	O
;	O
the	O
toxic	O
and	O
side	O
effects	O
are	O
reduced	O
;	O
the	O
HM-3	O
and	O
platinum,	O
paclitaxel	O
or	O
capecitabine	O
medicine	O
is	O
prominent	O
in	O
social	O
value	O
and	O
market	O
value	O
.	O


The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicaments,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
shown	O
in	O
Formula	O
I,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
a	O
novel	O
DPP-4	B-GENE
inhibitor	O
medicament,	O
especially	O
application	O
in	O
preparation	O
of	O
antidiabetic	O
medicaments	O
.	O
In	O
vivo	O
/	O
in	O
vitro	O
pharmacodynamic	O
experiment	O
results	O
indicate	O
that	O
the	O
compound	O
shown	O
in	O
Formula	O
I	O
has	O
obvious	O
inhibiting	O
action	O
on	O
DPP-4,	O
shows	O
superior	O
blood	O
sugar	O
reducing	O
effect	O
and	O
has	O
higher	O
acting	O
effect	O
in	O
comparison	O
with	O
a	O
similar	O
medicament	O
linagliptin	O
.	O
Meanwhile,	O
the	O
compound	O
provided	O
by	O
the	O
invention	O
is	O
short	O
in	O
preparation	O
route,	O
accessible	O
in	O
raw	O
materials,	O
simple	O
in	O
process	O
and	O
suitable	O
for	O
industrial	O
large-scale	O
production,	O
and	O
has	O
great	O
developing	O
prospects	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
having	O
BACE1	B-GENE
and	O
/	O
or	O
BACE2	B-GENE
inhibitory	O
activity,	O
their	O
manufacture,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
therapeutically	O
active	O
substances	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
treatment	O
of	O
e	O
.	O
g	O
.	O
Alzheimer	O
'	O
s	O
disease	O
and	O
type	O
2	O
diabetes	O
.	O


The	O
invention	O
discloses	O
a	O
preparation	O
used	O
for	O
healing	O
wound,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
preparation	O
used	O
for	O
healing	O
wound	O
comprises	O
a	O
cell	O
culture	O
fluid	O
which	O
is	O
used	O
to	O
culture	O
human	O
adipose-derived	O
stem	O
cells	O
before	O
.	O
The	O
preparation	O
used	O
for	O
healing	O
wound	O
is	O
rich	O
in	O
multiple	O
nutritional	O
factors	O
such	O
as	O
bFGF,	O
VEGF,	O
TGF-beta,	O
GM-CSF,	O
HGF,	O
PDGF,	O
IL2,	O
IL10	B-GENE
and	O
the	O
like	O
.	O
The	O
preparation	O
used	O
for	O
healing	O
wound	O
gives	O
play	O
to	O
good	O
effect	O
on	O
wound	O
restoration	O
.	O


Disclosed	O
is	O
a	O
hybridoma	O
cell	O
line	O
which	O
produces	O
human	O
antibodies	O
capable	O
of	O
binding	O
to	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
E2	B-GENE
glycoprotein	I-GENE
and	O
capable	O
of	O
neutralizing	O
HCV	O
infection	O
in	O
vivo	O
in	O
an	O
animal	O
model,	O
as	O
well	O
as	O
antibodies	O
produced	O
by	O
the	O
cell	O
line	O
.	O
Also	O
disclosed	O
are	O
various	O
uses	O
of	O
said	O
antibodies	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
HCV	O
infection	O
.	O
Peripheral	O
blood	O
lymphocytes	O
obtained	O
from	O
human	O
donors	O
having	O
a	O
high	O
titer	O
of	O
anti	O
HCV	O
E2	O
antibodies	O
are	O
transformed	O
in	O
vitro	O
by	O
Epstein-Barr	O
virus	O
and	O
then	O
fused	O
with	O
heteromyeloma	O
cells	O
to	O
generate	O
hybridomas	O
secreting	O
human	O
antibodies	O
having	O
ahigh	O
affinity	O
and	O
specificity	O
to	O
HCV	O
E2	B-GENE
glycoprotein	I-GENE
.	O


A	O
medicinal	O
mixture	O
for	O
treating	O
the	O
ulcer	O
in	O
digestive	O
system	O
contains	O
at	O
least	O
one	O
histamine	B-GENE
receptor	I-GENE
antagon	O
chosen	O
from	O
cimetidine,	O
ranitidine,	O
famotidine,	O
etc	O
and	O
at	O
least	O
one	O
H/K-ATP	B-GENE
enzyme	I-GENE
(	O
proton	B-GENE
pump	I-GENE
)	O
inhibitor	O
chosen	O
from	O
omeprazole,	O
lansoprazole,	O
etc	O
.	O


An	O
anti-inflammatory	O
and	O
antirheumatic	O
compound	O
medicine	O
is	O
proportionally	O
prepared	O
from	O
the	O
one	O
or	O
more	O
of	O
proply	O
gallate	O
compounds	O
and	O
the	O
non-steroidal	O
anti-inflammatory	O
and	O
antirheumatic	O
medicine	O
for	O
non-specific	O
suppression	O
to	O
epoxidase	B-GENE
II	I-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
SARS	B-GENE
coronavirus	I-GENE
3CL	I-GENE
protease	I-GENE
inhibitor	O
and	O
its	O
use,	O
wherein	O
a	O
reversed	O
phase	O
high	O
pressure	O
liquid	O
chromatography	O
method	O
is	O
employed	O
to	O
carry	O
out	O
SARS	B-GENE
coronavirus	I-GENE
3CL	I-GENE
prolease	I-GENE
activity	O
test	O
to	O
a	O
group	O
of	O
compounds	O
having	O
the	O
general	O
formula	O
I,	O
which	O
has	O
proved	O
the	O
inhibitory	O
action	O
to	O
SARS	B-GENE
coronavirus	I-GENE
3CL	I-GENE
proteinase,	O
thus	O
can	O
be	O
used	O
for	O
prevention	O
and	O
treatment	O
of	O
SARS	O
virus	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
sustained-release	O
preparation	O
composed	O
of	O
glipizide	O
and	O
metformin	O
hydrochloride,	O
and	O
its	O
preparing	O
method	O
.	O
The	O
weight	O
ratio	O
of	O
glipizide	O
to	O
metformin	O
hydrochloride	O
is	O
1	O
:	O
100-200,	O
the	O
best	O
ratio	O
is	O
1	O
:	O
100	O
and	O
it	O
adds	O
a	O
proper	O
amount	O
of	O
medicinal	O
auxiliary	O
to	O
the	O
preparation	O
.	O
The	O
compound	O
sustained-release	O
tablet	O
can	O
not	O
only	O
make	O
advantages	O
complementation	O
on	O
glipizide	O
and	O
metformin	O
hydrochloride,	O
promote	O
and	O
increase	O
secretion	O
of	O
beta-cell	O
insulin,	O
and	O
raise	O
the	O
utilization	O
of	O
glucose	O
in	O
tissues,	O
such	O
as	O
muscle,	O
etc,	O
but	O
also	O
reduce	O
the	O
stimulus	O
of	O
metformin	O
hydrochloride	O
to	O
stomach	O
intestine,	O
and	O
largely	O
strengthen	O
curative	O
effect	O
and	O
drug	O
application	O
safety	O
.	O


The	O
present	O
invention	O
discloses	O
a	O
preparation	O
process	O
of	O
slowly	O
releasing	O
orally	O
taken	O
hypoglycemic	O
gliclazide	O
capsule,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicinal	O
technology	O
field	O
.	O
The	O
capsule	O
consists	O
of	O
gliclazide	O
10-40	O
wt	O
%	O
,	O
calcium	O
biphosphate	O
40-70	O
wt	O
%	O
,	O
HPMC4000cp	O
0-20	O
wt	O
%	O
,	O
HPMC100cp	O
0-20	O
wt	O
%	O
,	O
EC100cp	O
0-9	O
.	O
3	O
wt	O
%	O
,	O
magnesium	O
stearate	O
0-2	O
wt	O
%	O
and	O
talcum	O
powder	O
0-2	O
wt	O
%	O
.	O
The	O
preparation	O
process	O
includes	O
60-100	O
mesh	O
sieving	O
the	O
first	O
mentioned	O
five	O
medicine	O
materials,	O
mixing,	O
adding	O
50-75	O
%	O
concentration	O
alcohol	O
as	O
wetting	O
agent	O
and	O
stirring	O
to	O
making	O
soft	O
material,	O
14-20	O
mesh	O
sieve	O
pelletizing,	O
drying	O
at	O
50-60	O
deg	O
.	O
c	O
of	O
1-2	O
hr,	O
14-20	O
mesh	O
sieve	O
finishing,	O
adding	O
magnesium	O
stearate	O
and	O
talcum	O
powder,	O
and	O
capsulizing	O
.	O
The	O
capsule	O
is	O
used	O
in	O
treating	O
non-insulin	O
dependent	O
diabetes	O
(	O
type-II	O
)	O
,	O
is	O
especially	O
suitable	O
for	O
adult	O
diabetes,	O
diabetes	O
accompanied	O
by	O
obesity	O
or	O
blood	O
vessel	O
pathologic	O
change,	O
and	O
has	O
the	O
features	O
of	O
being	O
safe	O
and	O
long	O
in	O
effect	O
.	O


The	O
invention	O
provides	O
a	O
sustained	O
release	O
medicine	O
for	O
artificially	O
inducing	O
sex	O
reversal	O
of	O
grouper	O
and	O
its	O
preparation	O
method,	O
wherein	O
the	O
medicine	O
comprises	O
aromatase	B-GENE
inhibitor	O
1	O
.	O
5-15	O
%	O
,	O
synthetic	O
rubber	O
base	O
material	O
for	O
medical	O
purpose	O
75-90	O
%	O
,	O
hardening	O
agent	O
8	O
.	O
5-10	O
%	O
,	O
the	O
process	O
for	O
preparing	O
the	O
medicament	O
comprises	O
mixing	O
homogeneously,	O
dry	O
forming,	O
and	O
refrigerated	O
preservation	O
.	O


Production	O
of	O
1,3-dihydroxy-5-alkylamine	O
compound	O
with	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
1B	I-GENE
inhibiting	O
activity	O
extracted	O
and	O
separated	O
from	O
branches	O
and	O
leaves	O
of	O
Lumnitzera	O
racemosa	O
Willd	O
and	O
its	O
use	O
are	O
disclosed	O
.	O
R1	O
and	O
R2	O
is	O
H	O
or	O
Ac,	O
R3	O
is	O
H	O
or	O
CH3,	O
n	O
=	O
8	O
or	O
10	O
.	O
It	O
is	O
carried	O
out	O
by	O
drying	O
and	O
breaking	O
branches	O
and	O
leaves	O
of	O
Lumnitzera	O
racemosa,	O
extracting	O
by	O
methyl	O
alcohol,	O
extracting	O
the	O
subsection	O
of	O
light	O
petroleum,	O
acetic	O
ether	O
and	O
(	O
n-	O
)	O
butanol,	O
silica	O
gel	O
column	O
and	O
Sephadex	O
LH-20	O
gel	O
column	O
chromatographing	O
the	O
part	O
of	O
acetic	O
ether,	O
separating	O
to	O
obtain	O
monomer	O
compound,	O
analyzing	O
by	O
wave	O
spectrum,	O
determining	O
1,3-dihydroxy-5-alkylamine	O
compound,	O
acetylating	O
and	O
methylating	O
reacting,	O
and	O
obtaining	O
acetylate	O
and	O
methylate	O
.	O
It	O
has	O
PTP1B	B-GENE
inhibiting	O
activity	O
and	O
can	O
be	O
used	O
for	O
diabetes	O
mellitus	O
and	O
obesity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
ibuprofen	O
sugar	O
derivative	O
and	O
its	O
preparation	O
process	O
and	O
application	O
.	O
The	O
present	O
invention	O
prepares	O
the	O
target	O
compound	O
through	O
crosslinking	O
unprotected	O
alpha-methyl-D-glucoside	O
and	O
2-	O
(	O
4	O
'	O
-isobutylphenyl	O
)	O
-propanoic	O
acid	O
with	O
immobilized	O
lipase	B-GENE
.	O
The	O
present	O
invention	O
has	O
simplified	O
operation	O
steps,	O
mild	O
reaction	O
condition	O
and	O
high	O
product	O
purity,	O
and	O
may	O
be	O
used	O
in	O
industrial	O
production	O
.	O
The	O
ibuprofen	O
sugar	O
derivative	O
of	O
the	O
present	O
invention	O
may	O
be	O
used	O
in	O
preparing	O
medicine	O
for	O
treating	O
rheumarthritis	O
and	O
rheumatoid	O
arthritis	O
.	O
Its	O
general	O
structural	O
expression	O
is	O
also	O
given	O
.	O


The	O
present	O
invention	O
comprises	O
the	O
use	O
of	O
insulin	B-GENE
receptor	I-GENE
activating	O
compounds,	O
optionally	O
in	O
conjunction	O
with	O
insulin,	O
for	O
the	O
treatment	O
of	O
HIV	O
protease	O
inhibitor-induced	O
metabolic	O
disorders	O
.	O
Any	O
insulin	B-GENE
receptor	I-GENE
activating	O
compounds	O
is	O
suitable	O
for	O
the	O
practice	O
of	O
the	O
invention	O
.	O
In	O
addition,	O
preferred	O
compounds	O
are	O
disclosed	O
.	O
Methods	O
of	O
treating	O
a	O
person	O
suffering	O
from	O
HIV	O
protease	O
inhibitor-induced	O
metabolic	O
disorders	O
such	O
as	O
lipodystrophy,	O
hypertriglyceridemia,	O
insulin	B-GENE
resistance,	O
hyperglycemia,	O
diabetes	O
and	O
ketoacidosis	O
are	O
also	O
provided	O
.	O


The	O
invention	O
relates	O
to	O
quinazoline	O
derivatives	O
having	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
mixture	O
of	O
their	O
optically	O
active	O
body	O
or	O
racemic	O
body,	O
and	O
diastereoisomer,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
hydrate	O
or	O
solvate,	O
wherein	O
R1,	O
R2,	O
A,	O
X	O
and	O
Q1	O
are	O
defined	O
in	O
the	O
specification	O
.	O
The	O
derivatives	O
can	O
be	O
used	O
for	O
preparing	O
protein	B-GENE
tyrosine	I-GENE
coyness	I-GENE
inhibitor,	O
and	O
for	O
preparing	O
medicament	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
cancer	O
and	O
other	O
hyperplasia	O
diseases	O
.	O


The	O
present	O
invention	O
discloses	O
the	O
new	O
application	O
of	O
benzydalysine,	O
and	O
is	O
especially	O
the	O
application	O
of	O
benzydalysine	O
in	O
preparing	O
medicine	O
for	O
treating	O
diabetic	O
peripheral	O
neural	O
lesion	O
.	O
Pharmacodynamic	O
experiment	O
research	O
shows	O
that	O
benzydalysine	O
has	O
obvious	O
functions	O
of	O
lowering	O
blood	O
sugar,	O
saccharifying	O
haemoglobin	O
and	O
promoting	O
insulin	O
secretion,	O
can	O
raise	O
the	O
activity	O
of	O
sciatic	O
nerve	O
GSH-PX,	O
inhibit	O
the	O
activity	O
of	O
COX-2,	O
and	O
has	O
antioxidant	O
and	O
antiphlogistic	O
effect,	O
the	O
effect	O
of	O
lowering	O
AGES	O
content	O
in	O
nerve	O
and	O
serum,	O
etc	O
.	O
Benzydalysine	O
and	O
some	O
supplementary	O
material	O
may	O
be	O
prepared	O
into	O
oral	O
preparation	O
for	O
preventing	O
and	O
treating	O
diabetic	O
peripheral	O
neural	O
lesion	O
.	O


The	O
present	O
invention	O
relates	O
to	O
recipe	O
and	O
compounding	O
process	O
of	O
beautifying	O
health	O
article	O
.	O
The	O
compound	O
recipe	O
for	O
replenishing	O
collagen	B-GENE
has	O
collagen	B-GENE
as	O
main	O
component	O
and	O
other	O
antioxidant	O
matter	O
and	O
skin	O
elasticity	O
raising	O
matter	O
.	O
Specifically,	O
the	O
compound	O
recipe	O
contains	O
collagen	B-GENE
10-99	O
wt	O
%	O
,	O
zinc	O
gluconate	O
0	O
.	O
01-20	O
wt	O
%	O
,	O
vitamin	O
C	O
0	O
.	O
01-20	O
wt	O
%	O
,	O
calcium	O
gluconate	O
0	O
.	O
01-50	O
wt	O
%	O
,	O
horsetail	O
extract	O
0	O
.	O
01-40	O
wt	O
%	O
,	O
and	O
elastin	O
0	O
.	O
01-40	O
wt	O
%	O
.	O
The	O
horsetail	O
extract	O
is	O
obtained	O
through	O
the	O
process	O
including	O
stoving	O
horsetail	O
at	O
lower	O
temperature,	O
crushing,	O
thrice	O
heated	O
alcohol	O
solution	O
reflux,	O
merging	O
the	O
extracted	O
liquid,	O
purification,	O
concentrating	O
and	O
stoving	O
at	O
lower	O
temperature	O
.	O
The	O
compound	O
recipe	O
has	O
obvious	O
beautifying	O
effect	O
and	O
hair	O
cure,	O
body	O
strengthening	O
and	O
other	O
effects	O
.	O


This	O
invention	O
is	O
a	O
medicine	O
combination	O
for	O
curing	O
peptic	O
ulcer	O
.	O
Its	O
feature	O
is	O
that	O
it	O
contains	O
fade	O
melanin	O
or	O
L-tryptophan,	O
and	O
at	O
least	O
one	O
kind	O
of	O
pylorus	O
spirabacteria	O
inhibitor	O
or	O
gastric	O
acid	O
secretion	O
inhibitor	O
.	O
Pylorus	O
spirabacteria	O
inhibitor	O
is	O
selected	O
from	O
penicillin,	O
ampicillin,	O
metronidazole	O
furazolidone	O
etc	O
.	O
And	O
gastric	O
acid	O
secretion	O
inhibitor	O
is	O
histamine	O
accepter	O
antagon,	O
proton	B-GENE
pump	I-GENE
inhibitor	O
and	O
/	O
or	O
antacid,	O
they	O
are	O
selected	O
from	O
lafutidine,	O
famotidine,	O
roxatidine,	O
tenatoprazole,	O
latamoxef	O
sodium,	O
rabeprazole,	O
pantoloc,	O
aluminum	O
hydroxide,	O
magnesium	O
hydroxide,	O
baking	O
soda	O
and	O
calcium	O
carbonate	O
.	O
The	O
compound	O
can	O
be	O
make	O
into	O
granule,	O
effervesce	O
agent,	O
tablet,	O
capsule,	O
molasses,	O
injection,	O
suspensoid	O
injection,	O
suppository	O
or	O
sustained-release	O
preparations	O
.	O
It	O
is	O
taken	O
by	O
oral	O
administration	O
or	O
non-oral	O
administration	O
path	O
.	O
It	O
achieves	O
the	O
goal	O
of	O
preventing	O
and	O
curing	O
gastric	O
ulcer	O
and	O
duodenal	O
ulcer	O
by	O
effectively	O
clear	O
oxygen-derived	O
free	O
radicals,	O
inhibiting	O
grown	O
of	O
pylorus	O
spirabacteria	O
and	O
gastric	O
acid	O
secretion	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
application	O
of	O
polymannuronic	O
acid	O
sulfate	O
in	O
preparation	O
of	O
medicine	O
for	O
preventing	O
and	O
curing	O
diabetes	O
.	O
The	O
compound	O
used	O
by	O
said	O
invention	O
has	O
the	O
action	O
of	O
inhibiting	O
formation	O
of	O
amylopsin	O
and	O
obviously	O
stimulating	O
islet	O
cells	O
to	O
release	O
insuline,	O
so	O
that	O
it	O
can	O
produce	O
good	O
effect	O
for	O
preventing	O
and	O
curing	O
diabetes	O
.	O


The	O
present	O
invention	O
discloses	O
one	O
kind	O
of	O
compound,	O
citioaldehyde	O
.	O
The	O
compound,	O
citioaldehyde	O
has	O
very	O
high	O
combination	O
activity,	O
KD	O
=	O
0	O
.	O
197	O
microM,	O
with	O
HIV-1	O
integrase,	O
and	O
effective	O
inhibition	O
of	O
the	O
combination	O
of	O
the	O
integrase	O
to	O
the	O
substrate,	O
IC50	O
=	O
9	O
.	O
6	O
microM,	O
in	O
substrate	O
competition	O
test	O
.	O
Therefore,	O
the	O
compound	O
will	O
find	O
its	O
application	O
in	O
preventing	O
and	O
treating	O
AIDS	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
nonglandular	O
purine	O
in	O
promoting	O
wound	O
healing,	O
and	O
nonglandular	O
purine,	O
such	O
as	O
guanosine,	O
guanine	O
and	O
inosine,	O
may	O
be	O
used	O
in	O
treating	O
wound	O
and	O
promoting	O
wound	O
healing	O
.	O
The	O
nonglandular	O
purine	O
can	O
promote	O
the	O
healing	O
of	O
damaged	O
skin	O
of	O
white	O
mouse,	O
health	O
and	O
suffering	O
from	O
congenital	O
diabetes	O
.	O
During	O
promoting	O
wound	O
healing,	O
the	O
nonglandular	O
purine	O
acts	O
via	O
activating	O
the	O
intracellular	O
biological	O
enzyme	O
while	O
the	O
natto	B-GENE
kinase	I-GENE
inhibitor	O
inhibits	O
the	O
biological	O
effect	O
of	O
the	O
compound	O
.	O


Thalidomide	O
analogs	O
that	O
modulate	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TNF-a	B-GENE
)	O
activity	O
and	O
angiogenesis	O
are	O
disclosed	O
.	O
In	O
particularly	O
disclosed	O
embodiments,	O
the	O
thalidomide	O
analogs	O
are	O
isosteric	O
sulfur-containing	O
analogs	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
a	O
subject	O
with	O
the	O
analogs	O
.	O


The	O
invention	O
relates	O
to	O
a	O
composition	O
of	O
Matrine	O
and	O
Thymopentin,	O
as	O
well	O
as	O
the	O
process	O
for	O
preparation,	O
wherein	O
the	O
composition	O
can	O
be	O
used	O
for	O
treating	O
hepatitis,	O
especially	O
for	O
treating	O
viral	O
hepatitis	O
.	O
The	O
composition	O
comprises	O
0	O
.	O
1-500	O
weight	O
parts	O
of	O
Thmopentin,	O
10-1000	O
weight	O
parts	O
of	O
Matrine,	O
and	O
can	O
be	O
made	O
into	O
freeze-dried	O
forms	O
or	O
injections	O
.	O


The	O
invention	O
relates	O
to	O
a	O
sodium	O
alginate	O
micro	O
ball	O
vessel	O
suppository	O
which	O
contains	O
soluble	O
medicine,	O
and	O
relative	O
preparation	O
and	O
application,	O
wherein	O
said	O
agent	O
can	O
be	O
divided	O
into	O
two	O
kinds	O
as	O
wet	O
ball	O
and	O
dry	O
ball	O
made	O
from	O
degradable	O
biological	O
material	O
;	O
said	O
carrier	O
comprises	O
sodium	O
alginate,	O
blood	O
serum	O
albumin,	O
chitose,	O
or	O
transparent	O
sodium	O
solution,	O
via	O
the	O
static	O
to	O
be	O
solidified	O
with	O
calcium	O
ion,	O
to	O
be	O
made	O
into	O
the	O
micro	O
ball	O
at	O
20	O
mum-1000	O
mum	O
.	O
The	O
inventive	O
material	O
has	O
high	O
mechanical	O
strength,	O
biological	O
compatibility,	O
biological	O
degradability	O
and	O
stability	O
.	O
The	O
invention	O
can	O
be	O
used	O
to	O
cure	O
the	O
vessel	O
suppository	O
of	O
variable	O
cancers	O
.	O


An	O
oral	O
liquid	O
of	O
donkey-hide	O
gelatin-iron	O
for	O
nourishing	O
blood,	O
supplementing	O
Fe	O
to	O
human	O
body	O
and	O
treating	O
iron-deficiency	O
anemia	O
is	O
prepared	O
from	O
NaFeEDTA,	O
granular	O
white	O
sugar,	O
and	O
5	O
Chinese-medicinal	O
materials	O
including	O
donkey-hide	O
gelatin,	O
prepared	O
rehmannia	O
root,	O
astragalus	O
root,	O
pilose	O
asiabell	O
root,	O
etc	O
.	O
Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
3,	O
4-dihydro-1H-2-benzopyran-1-ketone	O
compounds,	O
and	O
provides	O
the	O
preparation	O
process	O
of	O
these	O
compounds	O
.	O
These	O
compounds	O
have	O
LAR	B-GENE
and	O
PTPsigma	B-GENE
inhibiting	O
effect,	O
and	O
may	O
be	O
used	O
in	O
treating	O
various	O
types	O
of	O
diabetes,	O
obesity	O
and	O
their	O
complication	O
as	O
well	O
as	O
other	O
diseases	O
caused	O
by	O
excessive	O
activity	O
or	O
over	O
expression	O
of	O
PTP-LAR	B-GENE
and	O
/	O
or	O
PTPsigma,	O
such	O
as	O
tumor	O
and	O
nervous	O
degenerative	O
disease	O
.	O


Disclosed	O
is	O
an	O
anticancer	O
slow	O
release	O
injection	O
carrying	O
both	O
tetrazole	O
lonone	O
and	O
its	O
synergistic	O
agent,	O
which	O
comprises	O
slow	O
release	O
micro-balloons	O
and	O
dissolvent,	O
wherein	O
the	O
slow	O
release	O
microballoons	O
comprise	O
anti-cancer	O
active	O
constituents	O
and	O
slow	O
release	O
auxiliary	O
materials,	O
the	O
dissolvent	O
being	O
specific	O
dissolvent	O
containing	O
suspension	O
adjuvant	O
.	O
The	O
anticancer	O
active	O
constituents	O
include	O
tetrazole	O
lonone	O
and	O
cytotoxic	O
drugs	O
selected	O
from	O
phosphoinositide	B-GENE
3-kinase	I-GENE
inhibitor,	O
of	O
pyrimidine	O
analogues	O
and	O
/	O
or	O
DNA	O
restoring	O
enzyme	O
inhibitor,	O
the	O
slow	O
release	O
auxiliary	O
materials	O
include	O
polylactic	O
acid	O
and	O
its	O
copolymer,	O
polyethylene	O
glycol,	O
PLA-COOH	O
copolymer,	O
di-aliphatic	O
acid	O
and	O
sebacylic	O
acid	O
copolymer,	O
poly	O
(	O
erucic	O
aciddipolymer-sebacylic	O
acid	O
)	O
,	O
poly	O
(	O
fumaric	O
acid-sebacylic	O
acid	O
)	O
,	O
Polifeprosan,	O
poly	O
(	O
lactic	O
acid	O
)	O
,	O
biological	O
compatible	O
EVAc,	O
the	O
suspending	O
agent	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
with	O
a	O
viscosity	O
of	O
100-3000cp	O
(	O
at	O
20-30	O
deg	O
C	O
)	O
.	O
The	O
anticancer	O
active	O
constituents	O
and	O
the	O
slow	O
release	O
microspheres	O
can	O
also	O
be	O
prepared	O
into	O
slow	O
release	O
implanting	O
agent	O
to	O
be	O
used	O
independently	O
for	O
effectively	O
suppressing	O
tumor	O
accretion,	O
or	O
used	O
in	O
combination	O
with	O
non-operative	O
treatment	O
methods	O
such	O
as	O
chemotherapy	O
.	O


The	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
compound	O
collagen	B-GENE
gel,	O
which	O
is	O
the	O
mixture	O
of	O
collagen	B-GENE
and	O
antibiotics	O
.	O
For	O
every	O
gram	O
gel,	O
there	O
is	O
1-100mg	O
collagen,	O
which	O
is	O
extracted	O
from	O
tendon	O
of	O
the	O
rat	O
tails,	O
swine,	O
or	O
ox,	O
1-100mg	O
antibiotics,	O
0	O
.	O
1-1	O
.	O
0mg	O
medical	O
antiseptics,	O
10-500mg	O
thickening	O
agents,	O
and	O
water	O
.	O
The	O
antibiotics	O
and	O
collagen	B-GENE
act	O
cooperatively	O
to	O
be	O
used	O
in	O
the	O
treatment	O
of	O
the	O
following	O
diseases	O
:	O
different	O
kinds	O
of	O
open	O
wound,	O
anabrosis	O
caused	O
by	O
diabetes,	O
skin	O
damage	O
because	O
of	O
venereal	O
disease,	O
hyperkeratesis,	O
cuticularized	O
skin	O
problems	O
such	O
as	O
keratosis	O
palmaris	O
ET	O
plantaris,	O
winter	O
cutitis	O
and	O
ichthyosis	O
.	O
Since	O
the	O
collagen	B-GENE
protein	O
in	O
the	O
gel	O
can	O
be	O
easily	O
absorbed	O
to	O
provide	O
threpsis	O
to	O
the	O
diseased	O
region,	O
so	O
it	O
can	O
promote	O
the	O
agglutination	O
very	O
effectively	O
as	O
well	O
as	O
extend	O
the	O
time	O
of	O
releasing	O
time	O
of	O
the	O
antibiotics	O
.	O


The	O
present	O
invention	O
discloses	O
an	O
antagonist	O
of	O
human	B-GENE
leukocyte	I-GENE
antigen	I-GENE
DR4	I-GENE
subtype	I-GENE
protein	I-GENE
.	O
Said	O
invention	O
also	O
provides	O
its	O
chemical	O
structure	O
formula	O
and	O
its	O
concrete	O
application	O
range	O
.	O


This	O
invention	O
relates	O
to	O
a	O
cyclooxygenase	B-GENE
[	O
b	O
]	O
symphyso-pyrrole	O
derivate	O
of	O
formula	O
I	O
that	O
possesses	O
selective	O
restraining	O
activity	O
for	O
cyclooxygenase-2,	O
containing	O
medicine	O
combination	O
of	O
mentioned	O
compound,	O
and	O
the	O
usage	O
of	O
mentioned	O
compound	O
which	O
is	O
used	O
for	O
preparing	O
medicine	O
to	O
cure	O
inflammation	O
such	O
as	O
rheumatic	O
arthritis,	O
osteoarthritis,	O
pain	O
and	O
tumor,	O
among	O
them,	O
n	O
is	O
1	O
or	O
2	O
;	O
R1	O
is	O
methyl	O
or	O
amino	O
group	O
;	O
R2	O
is	O
C4-C7	O
saturation	O
cyclane	O
group,	O
aromatic	O
heterocycle	O
or	O
benzene	O
ring	O
which	O
is	O
substituted	O
by	O
1,2	O
or	O
more	O
substituted	O
group,	O
mentioned	O
substituted	O
group	O
is	O
respectively	O
selected	O
from	O
halogen,	O
methyl,	O
methoxy	O
group	O
or	O
methylthio	O
.	O


Isolated	O
human	O
monoclonal	O
antibodies	O
which	O
specifically	O
bind	O
to	O
human	O
EGFR,	O
and	O
related	O
antibody-based	O
compositions	O
and	O
molecules,	O
are	O
disclosed	O
.	O
The	O
human	O
antibodies	O
can	O
be	O
produced	O
by	O
a	O
transgenic	O
mouse,	O
capable	O
of	O
producing	O
multiple	O
isotypes	O
of	O
human	O
nonoclonal	O
antibodies	O
by	O
undergoing	O
V-D-J	O
recombination	O
and	O
isotypes	O
of	O
human	O
monoclonal	O
antibodies	O
by	O
undergoing	O
V-D-J	O
recombination	O
and	O
isotype	O
switching	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
human	O
antibodies,	O
non-human	O
transgenic	O
animals	O
and	O
hybridomas	O
which	O
produce	O
the	O
human	O
antibodies,	O
and	O
therapeutic	O
and	O
diagnostic	O
methods	O
for	O
using	O
the	O
human	O
antibodies	O
.	O


The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
veterinary	O
medicine	O
technology,	O
and	O
is	O
especially	O
lung	O
targeting	O
ofloxacin	O
microsphere	O
for	O
animal	O
and	O
its	O
preparation	O
process	O
.	O
The	O
ofloxacin	O
microsphere	O
is	O
prepared	O
with	O
ofloxacin	O
as	O
medicine	O
component	O
and	O
gelatin	B-GENE
as	O
carrier	O
in	O
the	O
weight	O
ratio	O
of	O
1	O
to	O
2,	O
and	O
through	O
dissolving	O
ofloxacin	O
in	O
gelatin	B-GENE
solution	O
and	O
adding	O
Span-80	O
and	O
liquid	O
paraffin	O
through	O
stirring	O
to	O
obtain	O
emulsion	O
;	O
cooling	O
in	O
icy	O
bath	O
to	O
below	O
5	O
deg	O
.	O
c	O
and	O
adding	O
glutaraldehyde	O
through	O
stirring	O
for	O
cross-linking	O
and	O
curing	O
;	O
dewatering	O
with	O
isopropyl	O
alcohol	O
and	O
suction	O
filtering	O
;	O
washing	O
with	O
isopropyl	O
alcohol	O
and	O
ethyl	O
ether	O
to	O
eliminate	O
glutaraldehyd,	O
washing	O
with	O
petroleum	O
ether	O
to	O
eliminate	O
liquid	O
paraffin	O
in	O
the	O
surface	O
of	O
microsphere	O
and	O
vacuum	O
drying	O
at	O
room	O
temperature	O
to	O
obtain	O
ofloxacin	O
microsphere	O
.	O
The	O
medicine	O
has	O
raised	O
tissue	O
selectivity,	O
delayed	O
release,	O
raised	O
curative	O
effect	O
and	O
lowered	O
toxic	O
side	O
effect	O
.	O


The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
biphenyl	O
cyclo-octadiene	O
lignans	O
for	O
preparing	O
tyrosinase	B-GENE
restrainer,	O
wherein	O
said	O
drug	O
is	O
cancer	O
treater	O
or	O
tyrosinase-abnormal	O
treater	O
.	O
Said	O
drug	O
can	O
be	O
the	O
monomer	O
of	O
biphenyl	O
cyclo-octadiene	O
lignans,	O
or	O
the	O
mixture	O
of	O
biphenyl	O
cyclo-octadiene	O
lignans	O
.	O
The	O
invention	O
can	O
improve	O
sensitivity	O
of	O
tyrosinase	B-GENE
restrainer	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
EGFL7	B-GENE
antagonist	O
to	O
modulate	O
vascular	O
development	O
.	O
Also	O
provided	O
herein	O
are	O
methods	O
of	O
screening	O
for	O
modulators	O
of	O
EGFL7	B-GENE
activity	O
.	O
Furthermore,	O
methods	O
of	O
treatment	O
using	O
EGFL7	B-GENE
antagonists	O
are	O
provided	O
.	O


Preventing	O
the	O
blocking	O
of	O
5-hydroxytryptamine-3	B-GENE
receptor	I-GENE
in	O
organ	O
transplant	O
rejection	O
reaction	O
in	O
transplanted	O
organs	O
such	O
as	O
heart,	O
lungs,	O
kidney	O
or	O
liver	O
comprises	O
administration	O
of	O
tropisetron	O
(	O
I	O
)	O
(	O
5-10	O
mg	O
)	O
.	O
-	O
ACTIVITY	O
:	O
Immunosuppressive	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
5-Hydroxytryptamine-3	B-GENE
receptor	I-GENE
antagonist	O
.	O


(	O
S	O
)	O
-4-Cyclohexyl-3-	O
[	O
(	O
S	O
)	O
-fluoro-	O
(	O
4-trifluoromethyl-phenyl	O
)	O
-methyl	O
]	O
-2-i	O
sopropyl-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol	O
(	O
I	O
)	O
and	O
its	O
salt,	O
and	O
solvate	O
and	O
its	O
salt,	O
is	O
new	O
.	O
(	O
S	O
)	O
-4-Cyclohexyl-3-	O
[	O
(	O
S	O
)	O
-fluoro-	O
(	O
4-trifluoromethyl-phenyl	O
)	O
-methyl	O
]	O
-2-i	O
sopropyl-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol	O
of	O
formula	O
(	O
I	O
)	O
and	O
its	O
salt,	O
and	O
solvate	O
and	O
its	O
salt,	O
is	O
new	O
.	O
Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
(	O
1	O
)	O
a	O
medicine	O
(	O
A	O
)	O
comprising	O
(	O
I	O
)	O
in	O
combination	O
with	O
an	O
inert	O
and	O
non-toxic	O
auxiliary	O
material	O
;	O
(	O
2	O
)	O
preparation	O
of	O
(	O
I	O
)	O
;	O
and	O
(	O
3	O
)	O
a	O
fluoro-cyclopentyl-pyridine	O
compound	O
of	O
formula	O
(	O
VII	O
)	O
,	O
where	O
the	O
hydroxy	O
protecting	O
group	O
from	O
(	O
VII	O
)	O
is	O
removed	O
to	O
give	O
(	O
I	O
)	O
and	O
(	O
I	O
)	O
reacts	O
with	O
a	O
solvent	O
and	O
/	O
or	O
acid	O
or	O
base	O
to	O
give	O
its	O
salt,	O
and	O
solvate	O
and	O
its	O
salt	O
.	O
[	O
Image	O
]	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Cardiant	O
;	O
Antilipemic	O
;	O
Antidiabetic	O
;	O
Antiarteriosclerotic	O
;	O
Vasotropic	O
;	O
Anorectic	O
;	O
Cerebroprotective	O
;	O
Neuroprotective	O
;	O
Nootropic	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Cholesterol	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
inhibitor	O
.	O
The	O
ability	O
of	O
(	O
I	O
)	O
to	O
inhibit	O
cholesterol	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
was	O
tested	O
using	O
biological	O
assays	O
.	O
The	O
results	O
showed	O
that	O
(	O
I	O
)	O
exhibited	O
a	O
median	O
inhibitory	O
concentration	O
value	O
of	O
42	O
nM	O
.	O


Preparing	O
prenylated	O
aromatic	O
compounds	O
(	O
I	O
)	O
,	O
comprises	O
incubating	O
at	O
least	O
an	O
aromatic	O
substrate	O
and	O
at	O
least	O
a	O
prenylating	O
substance	O
with	O
prenyltransferase	B-GENE
Fnq26	I-GENE
.	O
An	O
independent	O
claim	O
is	O
included	O
for	O
compounds,	O
produced	O
by	O
the	O
process	O
.	O


Topical	O
product	O
(	O
I	O
)	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
relapses	O
by	O
herpes	O
simplex	O
I,	O
comprises	O
histone	B-GENE
deacetylase	I-GENE
activator	O
comprising	O
resveratrol,	O
quercetin	O
and	O
/	O
or	O
luteolin,	O
where	O
(	O
I	O
)	O
further	O
comprises	O
vitamin	O
B12,	O
vitamin	O
B6,	O
folic	O
acid	O
and	O
betaine	O
.	O
-	O
ACTIVITY	O
:	O
Virucide	O
;	O
Analgesic	O
;	O
Antiinflammatory	O
;	O
Antimicrobial	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Histone	B-GENE
deacetylase	I-GENE
activator	O
.	O
No	O
biological	O
data	O
given	O
.	O


Use	O
and	O
composition	O
of	O
pharmaceutical	O
formulations	O
for	O
metabolic	O
activation	O
of	O
analgesic	O
effects	O
in	O
chronic	O
pain,	O
is	O
claimed	O
.	O
Polyphenolic	O
flavonoids	O
are	O
used	O
in	O
suitable	O
pharmaceutical	O
formulations	O
and	O
reduce	O
interstitial	O
dysiony	O
of	O
damaged	O
cells	O
and	O
consecutively	O
influence	O
the	O
actual	O
membrane	O
potential	O
of	O
afferent	O
neurons	O
.	O
-	O
ACTIVITY	O
:	O
Analgesic	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Mitochondrial	O
proton	O
F0F1-ATPase	B-GENE
;	O
ATP	B-GENE
synthase	I-GENE
inhibitor	O
.	O
No	O
biological	O
data	O
given	O
.	O


Bromocriptine	O
initiating,	O
without	O
concurrent	O
medication,	O
prolactin	B-GENE
increase	O
in	O
male	O
and	O
female	O
depressed	O
patients	O
for	O
the	O
normalization	O
of	O
mood,	O
in	O
a	O
relapse-free	O
treatment	O
for	O
30	O
days,	O
is	O
new	O
.	O
-	O
ACTIVITY	O
:	O
Neuroprotective	O
;	O
Antidepressant	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Prolactin	B-GENE
inhibitor	O
.	O


Medicine	O
for	O
treating	O
cancer,	O
heart	O
attack	O
and	O
tuberculosis,	O
comprises	O
an	O
active	O
ingredient	O
comprising	O
:	O
theobromine,	O
which	O
is	O
an	O
alkaloid	O
obtained	O
from	O
cocoa	O
;	O
lichenin,	O
which	O
is	O
an	O
antibiotic	O
derived	O
from	O
oats	O
;	O
caffeine	O
which	O
is	O
an	O
alkaloid	O
obtained	O
from	O
coffee	O
;	O
pepsin	B-GENE
which	O
is	O
an	O
enzyme	O
obtained	O
from	O
the	O
pig	O
stomach	O
;	O
and	O
nicotine	O
which	O
is	O
an	O
alkaloid	O
obtained	O
from	O
tobacco	O
.	O
ACTIVITY	O
:	O
Cytostatic	O
;	O
Cardiant	O
;	O
Antitubercular	O
;	O
Tuberculostatic	O
.	O
No	O
biological	O
data	O
given	O
.	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O


Product	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
comprising	O
sphingomyelin	O
and	O
/	O
or	O
an	O
activator	O
of	O
endogenous	O
sphingomyelin	O
synthesis	O
and	O
/	O
or	O
an	O
inhibitor	O
of	O
endogenous	O
sphingomyelin	O
degradation,	O
is	O
new	O
.	O
-	O
ACTIVITY	O
-	O
Nootropic	O
;	O
Neuroprotective	O
.	O
No	O
biological	O
data	O
given	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
-	O
Inhibitor	O
of	O
A	O
beta	O
peptide	O
formation	O
;	O
Activator	O
of	O
endogenous	O
sphingomyelin	O
synthesis	O
;	O
Inhibitor	O
of	O
endogenous	O
sphingomyelin	O
degradation	O
.	O
-	O
Incubating	O
SPA4CT-transfected	O
mouse	O
neurons	O
with	O
sphingomyelin	O
(	O
10-100	O
micro	O
M	O
)	O
reduced	O
A	O
beta	O
peptide	O
levels	O
by	O
20-50	O
%	O
.	O


A	O
compound	O
which	O
comprises	O
a	O
prodrug	O
of	O
a	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitor	O
(	O
PTKi	O
)	O
linked	O
to	O
a	O
protecting	O
group,	O
said	O
group	O
being	O
capable	O
of	O
being	O
cleaved	O
from	O
said	O
compound	O
to	O
release	O
the	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitor	O
.	O
Protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibitors	O
include	O
tyrphostins,	O
preferably	O
those	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
X	O
represents	O
carbon,	O
a	O
nitrogen	O
or	O
a	O
group	O
N→O,	O
n	O
is	O
an	O
integer	O
from	O
1	O
to	O
3	O
;	O
each	O
group	O
R1,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
is	O
hydrogen,	O
hydroxy,	O
mercapto,	O
carboxy,	O
formyl,	O
C¿1-4	O
?	O
alkyl,	O
C2-4	O
alkenyl,	O
C1-4alkoxy,	O
C1-4alkylthio,	O
carboxy,	O
C1-4alkyl,	O
carboxyC2-4	O
alkenyl,	O
C1-4alkylsulphoxy,	O
halo	O
(	O
i	O
.	O
e	O
.	O
fluoro,	O
chloro,	O
bromo	O
or	O
iodo	O
)	O
,	O
nitro,	O
amino,	O
C1-4alkylamino,	O
or	O
C1-4dialkylamino,	O
or	O
when	O
n	O
is	O
2	O
or	O
3	O
two	O
R	O
?	O
1¿	O
groups	O
may	O
together	O
form	O
a	O
methylenedioxy	O
or	O
ethylenedioxy	O
group	O
;	O
R2	O
is	O
hydrogen,	O
hydroxy,	O
C¿1-4	O
?	O
alkyl	O
or	O
together	O
with	O
position	O
2	O
of	O
the	O
ring	O
to	O
which	O
the	O
group	O
(	O
s	O
)	O
R	O
?	O
1¿	O
is	O
(	O
are	O
)	O
attached	O
forms	O
a	O
5	O
or	O
6	O
membered	O
aliphatic	O
or	O
heterocyclic	O
ring,	O
said	O
5	O
or	O
6	O
membered	O
ring	O
optionally	O
containing	O
a	O
ketone	O
group	O
;	O
and	O
R3	O
is	O
cyano,	O
carboxy,	O
carbamoyl,	O
thiocarbamoyl,	O
a	O
group	O
C	O
(	O
O	O
)	O
HNCH¿2	O
?	O
CN,	O
a	O
group	O
C	O
(	O
NH2	O
)	O
=	O
C	O
(	O
CN2	O
)	O
,	O
an	O
alpha	O
keto	O
group	O
C	O
(	O
O	O
)	O
R	O
?	O
4¿	O
where	O
R4	O
is	O
3,4-dihydroxyphenyl	O
or	O
2-thiophene	O
or	O
an	O
alpha	O
amido	O
group	O
C	O
(	O
O	O
)	O
NHR5	O
where	O
R5	O
is	O
benzyl,	O
phenyl,	O
or	O
2,4-dimethoxyphenyl	O
;	O
provided	O
that	O
at	O
least	O
one	O
of	O
the	O
groups	O
R	O
?	O
1	O
and	O
R2¿	O
are	O
mercapto,	O
hydroxy	O
or	O
amino	O
.	O


A	O
method	O
for	O
selectively	O
killing	O
nervous	O
system	O
and	O
peripheral	O
neoplastic	O
cells	O
is	O
provided	O
.	O
Viral	O
vectors	O
are	O
used	O
to	O
selectively	O
express	O
a	O
cytochrome	B-GENE
P450	I-GENE
gene	O
in	O
neoplastic	O
cells,	O
whose	O
gene	O
product	O
targets	O
the	O
cells	O
for	O
selective	O
killing,	O
by	O
rendering	O
the	O
cells	O
sensitive	O
to	O
a	O
chemotherapeutic	O
agent	O
.	O


Peptides	O
capable	O
of	O
interacting	O
with	O
the	O
GAP	B-GENE
protein	I-GENE
SH3	I-GENE
domain,	O
nucleic	O
acid	O
sequences	O
coding	O
therefor,	O
and	O
pharmaceutical	O
compositions	O
containing	O
same,	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
improvement	O
in	O
a	O
method	O
of	O
weight	O
and	O
/	O
or	O
body-fat	O
reduction	O
comprising	O
a	O
(	O
preferably	O
moderate	O
)	O
reduction	O
in	O
the	O
caloric	O
intake	O
of	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
in	O
combination	O
with	O
administration	O
to	O
said	O
subject	O
of	O
a	O
prolactin	B-GENE
inhibitor	O
.	O
Additionally,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
an	O
improvement	O
in	O
a	O
method	O
for	O
altering	O
and	O
/	O
or	O
resetting	O
prolactin	B-GENE
profiles	O
(	O
and	O
thereby	O
controlling	O
one	O
or	O
more	O
metabolic	O
disorders	O
such	O
as	O
obesity,	O
excessive	O
body	O
fat,	O
hyperlipidemia,	O
hyperlipoproteinemia,	O
hyperglycemia,	O
hypercholesterolemia,	O
hyperinsulinemia,	O
insulin	B-GENE
resistance,	O
glucose	O
intolerance,	O
and	O
Type	O
II	O
diabetes	O
)	O
comprising	O
administration	O
to	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
of	O
a	O
prolactin	B-GENE
inhibitor	O
at	O
a	O
predetermined	O
time	O
or	O
times	O
during	O
a	O
24-hour	O
period	O
in	O
combination	O
with	O
a	O
(	O
preferably	O
moderate	O
)	O
reduction	O
of	O
the	O
caloric	O
intake	O
of	O
said	O
subject	O
.	O


6-Aryl	O
pyrido	O
[	O
2,3-d	O
]	O
pyrimidine	O
7-imines,	O
7-ones,	O
and	O
7-thiones	O
o	O
f	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinases,	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
cellular	O
proliferation	O
mediated	O
thereby	O
.	O
The	O
compounds	O
are	O
especially	O
useful	O
in	O
treating	O
cancer,	O
atherosclerosis,	O
restenosis,	O
and	O
psoriasis	O
.	O


This	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
the	O
growth	O
of	O
neoplasms,	O
in	O
a	O
mammal	O
having	O
a	O
prolactin	B-GENE
profile	O
.	O
This	O
method	O
involves	O
comparing	O
the	O
prolactin	B-GENE
profile	O
of	O
the	O
afflicted	O
mammal	O
to	O
a	O
standard	O
prolactin	B-GENE
profile	O
for	O
healthy	O
mammals	O
of	O
the	O
same	O
species	O
and	O
sex	O
and	O
adjusting	O
the	O
prolactin	B-GENE
profile	O
of	O
the	O
afflicted	O
mammal	O
to	O
conform	O
to	O
or	O
approach	O
the	O
standard	O
prolactin	B-GENE
profile	O
for	O
a	O
mammal	O
of	O
the	O
same	O
species	O
and	O
sex	O
of	O
the	O
afflicted	O
mammal,	O
thereby	O
inhibiting	O
the	O
neoplastic	O
growth	O
.	O


An	O
analgesic	O
composition	O
comprising	O
a	O
sub-analgesic	O
dosage	O
of	O
a	O
ν-opioid	B-GENE
agonist	O
or	O
analog	O
or	O
derivative	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
a	O
sub-analgesic	O
dosage	O
of	O
a	O
λ2	B-GENE
opioid	I-GENE
agonist	O
or	O
analog	O
or	O
derivative	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O


New	O
LH-RH	B-GENE
antagonists	O
are	O
disclosed,	O
in	O
particular	O
peptidomimetics	O
and	O
peptides	O
modified	O
in	O
a	O
side	O
chain,	O
their	O
salts	O
with	O
pharmaceutically	O
acceptable	O
acids	O
and	O
a	O
process	O
for	O
preparing	O
these	O
LH-RH	B-GENE
antagonists	O
and	O
their	O
salts	O
.	O
The	O
disclosed	O
peptides	O
represent	O
analogues	O
of	O
the	O
luteinising	B-GENE
hormone	I-GENE
releasing	I-GENE
hormone	I-GENE
(	O
LH-RH	B-GENE
)	O
.	O
The	O
disclosed	O
compounds	O
have	O
a	O
high	O
antagonistic	O
power	O
and	O
are	O
free	O
of	O
undesirable	O
side	O
effects,	O
in	O
particular	O
edematogenic	O
effects	O
.	O


HIV	B-GENE
protease	I-GENE
inhibitors	O
inhibit	O
or	O
block	O
the	O
biological	O
activity	O
of	O
the	O
HIV	B-GENE
protease	I-GENE
enzyme,	O
causing	O
the	O
replication	O
of	O
the	O
HIV	O
virus	O
to	O
terminate	O
.	O
These	O
compounds	O
can	O
be	O
prepared	O
by	O
the	O
novel	O
methods	O
of	O
the	O
present	O
invention	O
using	O
the	O
novel	O
inventive	O
intermediates	O
.	O


The	O
application	O
concerns	O
a	O
method	O
of	O
identifying	O
compounds	O
that	O
can	O
be	O
used	O
to	O
inhibit	O
undesired	O
human	O
CD4+	O
T	O
cell	O
immune	O
responses	O
by	O
identifying	O
compounds	O
that	O
block	O
the	O
interaction	O
of	O
CD4	B-GENE
and	O
class	B-GENE
II	I-GENE
MHC	I-GENE
gene	I-GENE
products	O
and	O
a	O
method	O
of	O
treatment	O
which	O
comprises	O
administering	O
such	O
an	O
identified	O
compound	O
.	O
The	O
compounds	O
that	O
inhibit	O
undesired	O
human	O
CD4+	O
T	O
cell	O
immune	O
responses	O
can	O
be	O
used	O
to	O
treat	O
disease	O
such	O
as	O
multiple	O
sclerosis	O
and	O
to	O
prevent	O
graft	O
rejection	O
and	O
graft	O
versus	O
host	O
disease	O
.	O
More	O
specifically,	O
the	O
application	O
concerns	O
compounds	O
having	O
molecular	O
weights	O
between	O
about	O
500	O
and	O
150	O
daltons	O
that	O
bind	O
to	O
the	O
GFCC	O
'	O
C	O
'	O
'	O
portion	O
of	O
the	O
D1	B-GENE
domain	I-GENE
of	O
human	B-GENE
CD4	B-GENE
lymphocyte	O
cell	O
surface	O
antigen	O
.	O


Novel	O
medicines	O
comprising	O
Rho	B-GENE
kinase	I-GENE
inhibitors,	O
such	O
as	O
hypertension	O
remedy,	O
angina	O
remedy,	O
cerebrovascular	O
twitching	O
inhibitor,	O
asthma	O
remedy,	O
premature	O
birth	O
preventive,	O
arteriosclerosis	O
remedy,	O
anticancer	O
drug,	O
anti-phlogistic,	O
immunosuppressive,	O
autoimmune	O
disease	O
remedy,	O
anti-AIDS	O
drug,	O
contraceptive,	O
digestive	O
infection	O
preventive,	O
osteoporosis	O
remedy,	O
retinopathy	O
remedy,	O
and	O
cerebral	O
function	O
ameliorant	O
;	O
and	O
reagents	O
and	O
diagnostic	O
agents	O
comprising	O
Rho	B-GENE
kinase	I-GENE
inhibitors	O
.	O


Disclosed	O
are	O
methods	O
and	O
compositions	O
for	O
regulating	O
the	O
melanin	O
content	O
of	O
mammalian	O
melanocytes	O
;	O
regulating	O
pigmentation	O
in	O
mammalian	O
skin,	O
hair,	O
wool	O
or	O
fur	O
;	O
treating	O
or	O
preventing	O
various	O
skin	O
and	O
proliferative	O
disorders	O
;	O
increasing	O
the	O
differentiation	O
of	O
mammalian	O
neuronal	O
cells	O
for	O
purposes	O
of	O
treating	O
neurodegenerative	O
diseases	O
or	O
nerve	O
damage	O
;	O
and	O
stimulating	O
cellular	O
nitric	O
oxide	O
(	O
NO	O
)	O
synthesis,	O
cyclic	O
guanosine	O
monophosphate	O
levels	O
(	O
cGMP	O
)	O
,	O
and	O
protein	B-GENE
kinase	I-GENE
G	I-GENE
(	O
PKG	B-GENE
)	O
activity	O
for	O
purposes	O
of	O
treating	O
diseases	O
mediated	O
by	O
deficiencies	O
in	O
the	O
NO	O
/	O
cGMP	O
/	O
PKG	B-GENE
signal	O
transduction	O
pathway	O
;	O
by	O
administration	O
of	O
various	O
compounds,	O
including	O
alcohols,	O
diols	O
and	O
/	O
or	O
triols	O
and	O
their	O
analogues	O
.	O


TSHR	B-GENE
compositions	O
and	O
methods	O
of	O
use	O
are	O
disclosed,	O
useful	O
for	O
diagnostic	O
and	O
therapeutic	O
purposes	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
(	O
C¿2	O
?	O
-C9	O
)	O
heteroaryl	O
;	O
R	O
?	O
2¿	O
is	O
optionally	O
substituted	O
phenyl-	O
(	O
CH¿2	O
?	O
)	O
m-,	O
naphthyl-	O
(	O
CH2	O
)	O
m-,	O
(	O
C3-C10	O
)	O
cycloalkyl-	O
(	O
CH2	O
)	O
m-,	O
(	O
C1-C6	O
)	O
alkyl	O
or	O
(	O
C2-C9	O
)	O
heteroaryl-	O
(	O
CH2	O
)	O
m-,	O
m	O
is	O
an	O
integer	O
from	O
zero	O
to	O
four	O
;	O
R	O
?	O
3¿	O
is	O
hydrogen,	O
or	O
optionally	O
substituted	O
(	O
C¿1	O
?	O
-C10	O
)	O
alkyl,	O
(	O
C3-C10	O
)	O
cycloalkyl-	O
(	O
CH2	O
)	O
n-,	O
(	O
C2-C9	O
)	O
heterocycloalkyl-	O
(	O
CH2	O
)	O
n-,	O
(	O
C2-C9	O
)	O
heteroaryl-	O
(	O
CH2	O
)	O
n-	O
or	O
aryl-	O
(	O
CH2	O
)	O
n-,	O
n	O
is	O
an	O
integer	O
from	O
zero	O
to	O
six	O
;	O
or	O
R	O
?	O
3¿	O
and	O
the	O
carbon	O
to	O
which	O
it	O
is	O
attached	O
form	O
an	O
optionally	O
substituted	O
and	O
/	O
or	O
fused	O
five	O
to	O
seven	O
membered	O
carbocyclic	O
ring	O
;	O
R4	O
is	O
hydrogen,	O
(	O
C¿1	O
?	O
-C6	O
)	O
alkyl,	O
hydroxy,	O
(	O
C1-C6	O
)	O
alkoxy,	O
hydroxy	O
(	O
C1-C6	O
)	O
alkyl,	O
(	O
C1-C6	O
)	O
alkoxyCO,	O
(	O
C3-C10	O
)	O
cycloalkyl-	O
(	O
CH2	O
)	O
p-,	O
or	O
optionally	O
substituted	O
(	O
C2-C9	O
)	O
heterocycloalkyl-	O
(	O
CH2	O
)	O
p-,	O
(	O
C2-C9	O
)	O
heteroaryl-	O
(	O
CH2	O
)	O
p-,	O
phenyl-	O
(	O
CH2	O
)	O
p-	O
or	O
naphthyl-	O
(	O
CH2	O
)	O
p-,	O
p	O
is	O
an	O
integer	O
from	O
zero	O
to	O
four	O
;	O
or	O
R	O
?	O
4	O
and	O
R5¿	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
(	O
C¿2	O
?	O
-C9	O
)	O
heterocycloalkyl	O
group	O
;	O
R	O
?	O
5¿	O
is	O
hydrogen,	O
(	O
C¿1	O
?	O
-C6	O
)	O
alkyl	O
or	O
amino	O
.	O
The	O
present	O
compounds	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MIP-1-alpha	B-GENE
.	O
binding	O
to	O
its	O
receptor	O
CCR1,	O
and	O
are	O
thus	O
useful	O
to	O
treat	O
inflammation	O
and	O
other	O
immune	O
disorders	O
.	O


The	O
soporific	O
activity	O
of	O
cis-9,10-octadecenoamide	O
and	O
other	O
soporific	O
fatty-acid	O
primary	O
amides	O
is	O
neutralized	O
by	O
hydrolysis	O
in	O
the	O
presence	O
of	O
fatty-acid	B-GENE
amide	I-GENE
hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
.	O
Hydrolysis	O
of	O
cis-9,10-octadecenoamide	O
by	O
FAAH	B-GENE
leads	O
to	O
the	O
formation	O
of	O
oleic	O
acid,	O
a	O
compound	O
without	O
soporific	O
activity	O
.	O
FAAH	B-GENE
has	O
been	O
isolated	O
and	O
the	O
gene	O
encoding	O
FAAH	B-GENE
has	O
been	O
cloned,	O
sequenced,	O
and	O
used	O
to	O
express	O
recombinant	O
FAAH	B-GENE
.	O
Inhibitors	O
of	O
FAAH	B-GENE
are	O
disclosed	O
to	O
block	O
the	O
hydrolase	O
activity	O
.	O


Thienyl-,	O
furyl-	O
and	O
pyrrolyl-sulfonamides,	O
pharmaceutically-acceptable	O
salts	O
of	O
sulfonamides,	O
formulations	O
of	O
salts	O
and	O
the	O
sulfonamides,	O
and	O
methods	O
for	O
modulating	O
or	O
altering	O
the	O
activity	O
of	O
the	O
endothelin	B-GENE
family	I-GENE
of	O
peptides	O
using	O
the	O
formulations	O
and	O
sulfonamides	O
are	O
provided	O
.	O
In	O
particular,	O
formulations	O
of	O
sodium	O
salts	O
of	O
N-	O
(	O
isoxazolyl	O
)	O
thienylsulfonamides,	O
N-	O
(	O
isoxazolyl	O
)	O
furylsulfonamides	O
and	O
N-	O
(	O
isoxazolyl	O
)	O
pyrrolylsulfonamides	O
are	O
provided	O
.	O
A	O
process	O
of	O
preparing	O
an	O
alkali	O
metal	O
salt	O
of	O
a	O
hydrophobic	O
sulfonamide	O
is	O
provided	O
.	O
The	O
process	O
includes	O
the	O
step	O
of	O
dissolving	O
a	O
free	O
sulfonamide	O
in	O
an	O
organic	O
solvent	O
in	O
the	O
presence	O
of	O
a	O
saturated	O
alkali	O
metal	O
salt	O
solution	O
and	O
recovering	O
the	O
formed	O
sulfonamide	O
salt	O
from	O
the	O
organic	O
phase	O
.	O


Aryl-substituted	O
and	O
aryl	O
and	O
(	O
3-oxo-1-propenyl	O
)	O
-substituted	O
benzopyran,	O
benzothiopyran,	O
1,2-dihydroquinoline,	O
and	O
5,6-dihydronaphthalene	O
derivatives	O
have	O
retinoid	O
negative	O
hormone	O
and	O
/	O
or	O
antagonist-like	O
biological	O
activities	O
.	O
The	O
invented	O
RAR	B-GENE
antagonists	O
can	O
be	O
administered	O
to	O
mammals,	O
including	O
humans,	O
for	O
the	O
purpose	O
of	O
preventing	O
or	O
diminishing	O
action	O
of	O
RAR	B-GENE
agonists	O
on	O
the	O
bound	O
receptor	O
sites	O
.	O
Specifically,	O
the	O
RAR	B-GENE
agonists	O
are	O
administered	O
or	O
coadministered	O
with	O
retinoid	O
drugs	O
to	O
prevent	O
or	O
ameliorate	O
toxicity	O
or	O
side	O
effects	O
caused	O
by	O
retinoids	O
or	O
vitamin	O
A	O
or	O
vitamin	O
A	O
precursors	O
.	O
The	O
retinoid	O
negative	O
hormones	O
can	O
be	O
used	O
to	O
potentiate	O
the	O
activities	O
of	O
other	O
retinoids	O
and	O
nuclear	B-GENE
receptor	I-GENE
agonists	O
.	O
For	O
example,	O
the	O
retinoid	O
negative	O
hormone	O
called	O
AGN	O
193109	O
effectively	O
increased	O
the	O
effectiveness	O
of	O
other	O
retinoids	O
and	O
steroid	O
hormones	O
in	O
in	O
vitro	O
transactivation	O
assays	O
.	O
Additionally,	O
transactivation	O
assays	O
can	O
be	O
used	O
to	O
identify	O
compounds	O
having	O
negative	O
hormone	O
activity	O
.	O
These	O
assays	O
are	O
based	O
on	O
the	O
ability	O
of	O
negative	O
hormones	O
to	O
down-regulate	O
the	O
activity	O
of	O
chimeric	O
retinoid	B-GENE
receptors	I-GENE
engineered	O
to	O
possess	O
a	O
constitutive	O
transcription	O
activator	O
domain	O
.	O


A	O
method	O
for	O
the	O
treatment	O
of	O
diabetes	O
mellitus	O
and	O
conditions	O
associated	O
with	O
diabetes	O
mellitus	O
in	O
a	O
mammal,	O
which	O
method	O
comprises	O
administering	O
an	O
effective	O
non-toxic	O
and	O
pharmaceutically	O
acceptable	O
amount	O
of	O
an	O
insulin	B-GENE
sensitiser	O
and	O
a	O
sub-maximal	O
amount	O
of	O
an	O
insulin	B-GENE
secretagogue,	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
;	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
use	O
in	O
such	O
method	O
.	O


Novel	O
proteins	O
IR1B1	B-GENE
and	O
IR1B4	B-GENE
have	O
been	O
isolated	O
which	O
bind	O
to	O
the	O
type	B-GENE
I	I-GENE
IFN	I-GENE
receptor	I-GENE
IFNAR1	I-GENE
and	O
function	O
in	O
the	O
cellular	O
response	O
to	O
IFNs	B-GENE
.	O
DNA	O
encoding	O
such	O
proteins	O
in	O
either	O
the	O
sense	O
or	O
anti-sense	O
orientation	O
can	O
be	O
administered	O
to	O
either	O
enhance	O
or	O
inhibit	O
the	O
cellular	O
response	O
to	O
IFNs	B-GENE
.	O
Antibodies	O
to	O
the	O
proteins	O
can	O
be	O
used	O
for	O
isolation	O
of	O
the	O
new	O
protein	O
or	O
for	O
immunodetection	O
thereof	O
.	O


Use	O
of	O
flunarizine,	O
a	O
calcium	B-GENE
channel	I-GENE
blocking	O
agent	O
known	O
for	O
use	O
as	O
cerebral	O
and	O
peripheral	O
vasodilator,	O
in	O
the	O
treatment	O
of	O
glaucoma	O
by	O
topical	O
administration	O
.	O
Differently	O
from	O
other	O
calcium	B-GENE
channel	I-GENE
blockers	O
already	O
tested	O
for	O
use	O
as	O
antiglaucoma	O
agents,	O
flunarizine	O
is	O
highly	O
active	O
in	O
lowering	O
the	O
intraocular	O
pressure	O
when	O
administered	O
by	O
the	O
topical	O
ophthalmic	O
route	O
.	O
The	O
invention	O
also	O
comprises	O
anti-glaucoma	O
preparations	O
containing	O
flunarizine,	O
or	O
combinations	O
of	O
flunarizine	O
with	O
beta-blockers	O
such	O
as	O
timolol	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
inhibition	O
of	O
blood	O
clotting	O
proteins,	O
and	O
more	O
particularly,	O
to	O
indole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R	O
?	O
1a,	O
R1b,	O
R1c	O
R1d,	O
R2,	O
R3,	O
R4¿	O
and	O
A	O
are	O
defined	O
as	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
the	O
blood	O
clotting	O
enzyme	O
factor	B-GENE
Xa	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
methods	O
of	O
inhibiting	O
factor	B-GENE
Xa	I-GENE
activity	O
and	O
of	O
inhibiting	O
blood	O
clotting,	O
to	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
diseases	O
which	O
can	O
be	O
cured	O
or	O
prevented	O
by	O
the	O
inhibition	O
of	O
factor	B-GENE
Xa	I-GENE
activity	O
such	O
as	O
thromboembolic	O
diseases,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
preparation	O
of	O
medicaments	O
to	O
be	O
applied	O
in	O
such	O
diseases	O
.	O
The	O
invention	O
further	O
relates	O
to	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
admixture	O
or	O
otherwise	O
in	O
association	O
with	O
an	O
inert	O
carrier,	O
in	O
particular	O
pharmaceutical	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
together	O
with	O
pharmaceutically	O
acceptable	O
carrier	O
substances	O
and	O
/	O
or	O
auxiliary	O
substances	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
sulfonamide	O
substituted	O
chroman	O
derivatives	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
beta-3	B-GENE
receptor	I-GENE
mediated	O
conditions	O
.	O


Compositions	O
for	O
the	O
treatment	O
of	O
symptoms	O
of	O
inflammatory	O
disorders	O
may	O
include	O
gamma-linolenic	O
acid	O
or	O
dihomogammalinolenic	O
acid,	O
an	O
inhibitor	O
of	O
	O
DELTA	B-GENE
<5>	I-GENE
desaturase,	O
and	O
stearidonic	O
acid	O
or	O
	O
omega	O
-3	O
arachidonic	O
acid	O
.	O
Preferred	O
formulations	O
may	O
be	O
in	O
the	O
form	O
of	O
a	O
good	O
tasting,	O
preferably	O
milk	O
based	O
drink,	O
or	O
a	O
dried	O
powder	O
.	O
Compositions	O
reduce	O
inflammation	O
and	O
inhibit	O
increase	O
in	O
serum	O
arachidonic	O
acid	O
associated	O
with	O
gamma-linolenic	O
acid	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrazole	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
that	O
are	O
p-38	B-GENE
MAP	I-GENE
kinase	I-GENE
inhibitors,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
methods	O
for	O
their	O
use,	O
and	O
methods	O
for	O
preparing	O
these	O
compounds	O
.	O


Novel	O
preventives	O
/	O
remedies	O
for	O
hepatic	O
cirrhosis	O
or	O
bile	O
duct	O
disappearance	O
syndrome	O
which	O
contain	O
as	O
the	O
active	O
ingredient	O
a	O
Fas	B-GENE
antagonist	O
;	O
and	O
a	O
preventive	O
/	O
therapeutic	O
method	O
.	O


A	O
method	O
for	O
the	O
inhibition	O
of	O
the	O
binding	O
of	O
α4β1	B-GENE
integrin	O
to	O
its	O
receptors,	O
for	O
example	O
VCAM-1	B-GENE
(	O
vascular	B-GENE
cell	I-GENE
adhesion	I-GENE
molecule-1	I-GENE
)	O
and	O
fibronectin	B-GENE
;	O
compounds	O
that	O
inhibit	O
this	O
binding	O
;	O
pharmaceutically	O
active	O
compositions	O
comprising	O
such	O
compounds	O
;	O
and	O
the	O
use	O
of	O
such	O
compounds	O
either	O
as	O
above,	O
or	O
in	O
formulations	O
for	O
the	O
control	O
or	O
preventions	O
of	O
diseases	O
states	O
in	O
which	O
α4β1	B-GENE
is	O
involved	O
.	O


The	O
hydrogel	O
for	O
the	O
treatment	O
of	O
aneurysms	O
acts	O
as	O
a	O
carrier	O
for	O
both	O
a	O
radiopaque	O
agent	O
allowing	O
the	O
hydrogel	O
to	O
be	O
visualized	O
under	O
fluoroscopy	O
and	O
a	O
therapeutic	O
agent	O
such	O
as	O
one	O
or	O
more	O
human	B-GENE
growth	I-GENE
factors	I-GENE
.	O
The	O
hydrogel	O
is	O
delivered	O
through	O
a	O
catheter	O
into	O
the	O
aneurysm,	O
where	O
the	O
hydrogel	O
becomes	O
more	O
viscous	O
upon	O
reaching	O
body	O
temperature,	O
or	O
upon	O
exposure	O
to	O
bodily	O
fluids,	O
to	O
block	O
blood	O
flow	O
into	O
the	O
aneurysm	O
.	O
In	O
addition	O
to	O
stopping	O
blood	O
flow	O
into	O
the	O
aneurysm,	O
the	O
delivery	O
of	O
human	B-GENE
growth	I-GENE
factors	I-GENE
to	O
the	O
aneurysm	O
site	O
promotes	O
the	O
growth	O
of	O
a	O
cellular	O
layer	O
across	O
the	O
neck	O
of	O
the	O
aneurysm	O
.	O
The	O
hydrogel	O
may	O
be	O
of	O
a	O
type	O
that	O
dissolves	O
over	O
time	O
or	O
one	O
which	O
remains	O
as	O
a	O
permanent	O
occlusive	O
agent	O
within	O
the	O
aneurysm	O
.	O


An	O
oxindole	O
of	O
Formula	O
(	O
1	O
)	O
or	O
a	O
prodrug	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
useful	O
for	O
growth	B-GENE
hormone	I-GENE
releaser	O
wherein	O
R	O
?	O
1,	O
R2,	O
R3,	O
and	O
R4¿	O
are	O
independently	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
;	O
R5	O
is	O
optionally	O
substituted	O
aryl	O
or	O
optionally	O
substituted	O
heteroaryl	O
;	O
Z	O
is	O
-O-	O
or	O
-NH-	O
;	O
one	O
of	O
W	O
?	O
1	O
and	O
W2¿	O
is	O
hydrogen,	O
alkyl	O
or	O
-Y-CON	O
(	O
R10	O
)	O
R11	O
;	O
the	O
other	O
of	O
W	O
?	O
1	O
and	O
W2¿	O
is	O
(	O
a	O
)	O
;	O
n	O
is	O
1,	O
2	O
or	O
3	O
;	O
m	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
Y	O
is	O
single	O
bond	O
or	O
C¿1	O
?	O
-C3	O
alkylene	O
;	O
R	O
?	O
6	O
and	O
R7¿	O
are	O
independently	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
;	O
R	O
?	O
8	O
and	O
R9¿	O
are	O
independently	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
;	O
R	O
?	O
10	O
and	O
R11¿	O
are	O
independently	O
hydrogen,	O
alkyl	O
etc	O
.	O


Disclosed	O
are	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
non-toxic	O
salts	O
thereof	O
where	O
R1-R4	O
and	O
A	O
are	O
defined	O
herein,	O
which	O
compounds	O
are	O
highly	O
selective	O
agonists,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAa	B-GENE
brain	I-GENE
receptors	I-GENE
or	O
prodrugs	O
of	O
agonists,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAa	B-GENE
brain	I-GENE
receptors	I-GENE
and	O
are,	O
therefore,	O
useful	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
anxiety,	O
Down	O
Syndrome,	O
depression,	O
sleep,	O
cognitive	O
and	O
seizure	O
disorders,	O
overdose	O
with	O
benzodiazepine	O
drugs	O
and	O
for	O
enhancement	O
of	O
altertness	O
.	O


A	O
method	O
is	O
provided	O
for	O
treating	O
diabetes	O
and	O
related	O
diseases,	O
especially	O
Type	O
II	O
diabetes,	O
employing	O
an	O
aP2	B-GENE
inhibitor	O
or	O
a	O
combination	O
of	O
an	O
aP2	B-GENE
inhibitor	O
and	O
another	O
antidiabetic	O
agent	O
such	O
as	O
metformin,	O
glyburide,	O
troglitazone	O
and	O
/	O
or	O
insulin	B-GENE
.	O


A	O
multiple-plasmid	O
system	O
for	O
heterologous	O
expression	O
of	O
polyketides	O
facilitates	O
combinatorial	O
biosynthesis	O
.	O
The	O
method	O
can	O
be	O
extended	O
to	O
any	O
modular	O
polyketide	B-GENE
synthase	I-GENE
(	O
PKS	B-GENE
)	O
or	O
non-ribosomal	B-GENE
peptide	I-GENE
synthase	I-GENE
(	O
NRPS	B-GENE
)	O
and	O
has	O
the	O
potential	O
to	O
produce	O
thousands	O
of	O
novel	O
natural	O
products,	O
including	O
ones	O
derived	O
from	O
further	O
modification	O
of	O
the	O
PKS	B-GENE
or	O
NRPS	B-GENE
products	O
by	O
tailoring	O
enzymes	O
.	O


A	O
composition	O
for	O
topical	O
administration	O
exhibiting	O
an	O
excellent	O
ocular	O
tension	O
lowering	O
effect,	O
which	O
contains	O
an	O
angiotensin	B-GENE
II	I-GENE
antagonist,	O
a	O
borate,	O
and	O
an	O
ethylenediaminetetraacetate	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
?	O
1,	O
R2,	O
R3,	O
R4,	O
R5¿,	O
X,	O
Y,	O
Z,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy,	O
especially	O
for	O
the	O
treatment	O
of	O
chemokine	B-GENE
receptor	I-GENE
related	O
diseases	O
and	O
conditions	O
.	O


The	O
invention	O
concerns	O
biphenyl	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
Ra	O
to	O
Rg	O
and	O
n	O
are	O
as	O
defined	O
in	O
Claim	O
1	O
.	O
The	O
invention	O
also	O
concerns	O
their	O
isomers	O
and	O
their	O
salts,	O
in	O
particular	O
their	O
physiologically	O
acceptable	O
salts	O
.	O
Said	O
compounds	O
are	O
useful	O
inhibitors	O
of	O
the	O
triglycerides	O
microsomal	B-GENE
transfer	I-GENE
protein	I-GENE
(	O
MTP	B-GENE
)	O
.	O
The	O
invention	O
further	O
concerns	O
medicines	O
containing	O
said	O
compounds,	O
and	O
the	O
use	O
and	O
production	O
thereof	O
.	O


Novel	O
water	B-GENE
channel	I-GENE
openers	O
capable	O
of	O
opening	O
the	O
water	B-GENE
channel	I-GENE
of	O
AQP	O
and	O
medicinal	O
compositions	O
for	O
ophthalmic	O
use	O
(	O
in	O
particular,	O
lacrimal	O
secretion	O
promoters	O
)	O
containing	O
the	O
same	O
as	O
the	O
active	O
ingredient	O
.	O
	O
Water	B-GENE
channel	I-GENE
opener	O
compositions	O
comprising	O
compounds	O
having	O
an	O
activity	O
of	O
binding	O
to	O
lipocalin	O
ligands	O
(	O
in	O
particular,	O
odorant-binding	B-GENE
proteins	I-GENE
)	O
and	O
medicinal	O
compositions	O
for	O
ophthalmic	O
use	O
(	O
in	O
particular,	O
lacrimal	O
secretion	O
promoters	O
)	O
containing	O
the	O
same	O
as	O
the	O
active	O
ingredient	O
.	O


Two	O
types	O
of	O
compositions	O
having	O
an	O
eye-drop	O
delivery	O
system	O
are	O
used	O
during	O
or	O
after	O
an	O
orthokeratology	O
procedure	O
to	O
prevent	O
or	O
retard	O
relaxation	O
of	O
corneal	O
tissue	O
back	O
to	O
the	O
original	O
anterior	O
curvature	O
of	O
the	O
cornea	O
.	O
Each	O
composition	O
functions	O
independently	O
from	O
the	O
others	O
and	O
is	O
a	O
different	O
approach	O
of	O
preparing	O
a	O
stabilizing	O
agent	O
.	O
The	O
first	O
composition	O
is	O
directed	O
to	O
a	O
biologically	O
compatible	O
composition	O
comprising	O
fibril	O
associated	O
collogens	B-GENE
with	O
interrupted	O
triple	O
helices	O
(	O
FACITs	O
)	O
and	O
/	O
or	O
small	B-GENE
leucine-rich	I-GENE
repeat	I-GENE
proteoglycans	I-GENE
(	O
SLRPs	B-GENE
)	O
.	O
The	O
fibril	O
associated	O
collogen	B-GENE
family	O
includes	O
various	O
types	O
of	O
collogens,	B-GENE
such	I-GENE
as	I-GENE
type	I-GENE
VI,	I-GENE
type	I-GENE
XX,	I-GENE
type	I-GENE
XII,	I-GENE
and	I-GENE
type	I-GENE
XIV	I-GENE
.	O
The	O
small	B-GENE
leucine-rich	I-GENE
repeat	I-GENE
proteoglycans	I-GENE
family	O
includes	O
decorin,	O
keratocan,	O
biglycan,	O
epiphycan,	O
lumican,	O
mimecan,	O
and	O
fibromodulin	B-GENE
.	O
The	O
second	O
composition	O
includes	O
the	O
enzyme	O
found	O
as	O
a	O
normal	O
component	O
of	O
tissues,	O
plasma,	O
or	O
epidermis,	O
such	O
as	I-GENE
transglutaminase	B-GENE
.	O


A	O
class	O
of	O
novel	O
indole	O
is	O
disclosed	O
together	O
with	O
the	O
use	O
of	O
such	O
compounds	O
for	O
inhibiting	O
sPLA2	B-GENE
mediated	O
release	O
of	O
fatty	O
acids	O
for	O
treatment	O
of	O
Inflammatory	O
Diseases	O
such	O
as	O
septic	O
shock	O
.	O


N	O
<	O
6	O
>	O
heterocyclic	O
8	O
modified	O
adenosine	O
derivatives	O
that	O
are	O
selective,	O
partial	O
or	O
full	O
adenosine	B-GENE
A1	I-GENE
receptor	I-GENE
partial	O
or	O
full	O
agonists,	O
and	O
as	O
such,	O
are	O
useful	O
for	O
modifying	O
cardiac	O
activity,	O
modifying	O
adipocyte	O
function,	O
treating	O
central	O
nervous	O
system	O
disorders,	O
and	O
treating	O
diabetic	O
disorders	O
and	O
obesity	O
in	O
mammals,	O
and	O
especially	O
in	O
humans	O
.	O


This	O
invention	O
relates	O
to	O
treating	O
an	O
inflammatory	O
disease	O
by	O
administering	O
a	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitor	O
in	O
combiantion	O
with	O
an	O
inhibitor	O
of	O
prostaglandin	O
synthesis,	O
NSAIDs	O
being	O
exemplary	O
.	O


Novel	O
compounds	O
having	O
an	O
excellent	O
Na+	B-GENE
channel	I-GENE
inhibiting	O
activity,	O
which	O
are	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
salts	O
thereof,	O
or	O
hydrates	O
of	O
both,	O
wherein	O
A	O
is	O
a	O
ring	O
of	O
the	O
general	O
formula	O
(	O
IA	O
)	O
,	O
(	O
II	O
)	O
	O
(	O
wherein	O
R1	O
is	O
hydrogen	O
or	O
the	O
like	O
;	O
and	O
R2	O
is	O
hydrogen	O
or	O
the	O
like	O
)	O
,	O
or	O
the	O
like	O
;	O
W	O
is	O
optionally	O
substituted	O
C¿1-6	O
?	O
alkylene	O
or	O
the	O
like	O
;	O
Z	O
is	O
an	O
optionally	O
substituted	O
C6-14	O
aromatic	O
carbocyclic	O
group	O
or	O
the	O
like	O
;	O
and	O
l	O
is	O
an	O
integer	O
of	O
0	O
to	O
6	O
.	O


Methods	O
of	O
using	O
one	O
or	O
more	O
agonists	O
or	O
antagonists	O
to	O
modulate	O
activity	O
of	O
the	O
members	O
of	O
the	O
TNF	B-GENE
and	O
TNFR	B-GENE
families	O
referred	O
to	O
as	O
TALL-1,	O
APRIL,	O
TACI,	O
and	O
BCMA	B-GENE
are	O
provided	O
.	O
The	O
methods	O
include	O
in	O
vitro,	O
in	O
situ,	O
and	O
/	O
or	O
in	O
vivo	O
diagnosis	O
and	O
/	O
or	O
treatment	O
of	O
mammalian	O
cells	O
or	O
pathological	O
conditions	O
associated	O
with	O
TALL-1,	O
APRIL,	O
TACI,	O
or	O
BCMA,	O
using	O
one	O
or	O
more	O
agonist	O
or	O
antagonist	O
molecules	O
.	O
The	O
methods	O
of	O
treatment	O
disclosed	O
by	O
the	O
invention	O
include	O
methods	O
of	O
treating	O
immune	O
related	O
diseases	O
and	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
highly	O
penis-specific	O
PDE	B-GENE
V	I-GENE
inhibitor,	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
for	O
the	O
production	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
in	O
males,	O
without	O
the	O
previous	O
circulatory	O
side	O
effects	O
caused	O
by	O
PDE	B-GENE
V	I-GENE
inhibitors,	O
in	O
particular,	O
with	O
concomitant	O
administration	O
of	O
vasodilators,	O
whose	O
mode	O
of	O
action	O
is	O
by	O
means	O
of	O
the	O
NO	O
/	O
cGMP	O
system	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
group	O
of	O
novel	O
4,5-dihydro-1H-pyrazole	O
derivatives	O
which	O
are	O
potent	O
antagonists	O
of	O
the	O
cannabis	O
CB1-receptor	B-GENE
.	O
The	O
compounds	O
have	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
and	O
R1	O
are	O
the	O
same	O
or	O
different	O
and	O
represent	O
phenyl,	O
thienyl	O
or	O
pyridyl	O
which	O
groups	O
may	O
be	O
substituted	O
with	O
1,	O
2	O
or	O
3	O
substituents	O
Y	O
or	O
R	O
and	O
/	O
or	O
R1	O
represent	O
naphtyl,	O
R2	O
represents	O
hydrogen,	O
hydroxy,	O
C1-3-alkoxy,	O
acetyloxy	O
or	O
propionyloxy,	O
Aa	O
represents	O
one	O
of	O
the	O
groups	O
(	O
i	O
)	O
,	O
(	O
ii	O
)	O
,	O
(	O
iii	O
)	O
,	O
(	O
iv	O
)	O
or	O
(	O
v	O
)	O
,	O
Bb	O
represents	O
sulfonyl	O
or	O
carbonyl,	O
R3	O
represents	O
benzyl,	O
phenyl,	O
thienyl	O
or	O
pyridyl	O
which	O
may	O
be	O
substituted	O
with	O
1,	O
2	O
or	O
3	O
substituents	O
Y	O
or	O
R3	O
represents	O
C1-8	O
branched	O
or	O
unbranched	O
alkyl	O
or	O
C3-8	O
cycloalkyl,	O
or	O
R3	O
represents	O
naphtyl	O
.	O


Tetrahydroisoquinoline	O
analogs	O
are	O
provided	O
which	O
are	O
useful	O
in	O
stimulating	O
endogenous	O
production	O
or	O
release	O
of	O
growth	B-GENE
hormone	I-GENE
and	O
in	O
treating	O
obesity,	O
osteoporosis	O
(	O
improving	O
bone	O
density	O
)	O
and	O
in	O
improving	O
muscle	O
mass	O
and	O
muscle	O
strength	O
.	O
The	O
tetrahydroisoquinoline	O
analogs	O
thereof	O
have	O
the	O
structure	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R3a,	O
X1,	O
X2,	O
X3,	O
X4,	O
m	O
and	O
n	O
are	O
as	O
described	O
herein	O
.	O


A	O
ligand	O
to	O
GPR8,	O
its	O
DNA,	O
etc	O
.	O
More	O
particularly	O
speaking,	O
a	O
polypeptide	O
capable	O
of	O
binding	O
to	O
GPR8	B-GENE
or	O
its	O
amide	O
or	O
ester	O
or	O
salts	O
thereof,	O
DNA	O
thereof,	O
etc	O
.	O
are	O
provided	O
.	O
	O
The	O
ligand	O
to	O
GPR8	B-GENE
as	O
described	O
above	O
is	O
useful	O
in	O
developing	O
a	O
receptor-binding	O
assay	O
system	O
with	O
the	O
use	O
of	O
a	O
GPR8	B-GENE
expression	O
system,	O
screening	O
candidate	O
compounds	O
for	O
drugs	O
such	O
as	O
preventives	O
and	O
remedies	O
for	O
obesity,	O
appetite	O
stimulating	O
agents	O
and	O
prolactin	B-GENE
production	O
inhibitors,	O
etc	O
.	O


A	O
nucleic	O
acid	O
molecule	O
which	O
interacts	O
with	O
reverse	O
transcriptase	I-GENE
of	O
a	O
retrovirus	O
.	O
The	O
nucleic	O
acid	O
molecule	O
comprises	O
a	O
nucleotide	O
sequence	O
essentially	O
composed	O
of	O
two	O
stem-loop	O
structures	O
and	O
a	O
short	O
bridge	O
between	O
the	O
two	O
stems,	O
which	O
molecule	O
for	O
the	O
purposes	O
of	O
the	O
interaction	O
with	O
reverse	O
transcriptase	I-GENE
is	O
analogous	O
to	O
the	O
dihydrouridine	O
(	O
D	O
)	O
-stem-loop	O
and	O
anticodon	O
(	O
A	O
)	O
-stem-loop	O
of	O
a	O
mammalian	O
transfer	O
RNA	O
(	O
tRNA	O
)	O
.	O
Optionally,	O
in	O
the	O
nucleic	O
acid	O
molecule,	O
some	O
or	O
all	O
of	O
the	O
normal	O
phosphodiester	O
nucleoside	O
linkages	O
have	O
been	O
substituted	O
with	O
phosphorothioate	O
linkages	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
said	O
nucleic	O
acid	O
molecule	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
inhibition	O
of	O
the	O
interaction	O
of	O
HIV-1	B-GENE
and	I-GENE
HIV-2	I-GENE
reverse	I-GENE
transcriptase	I-GENE
with	O
tRNALys3	O
.	O


The	O
invention	O
provides	O
for	O
a	O
non-steroidal	O
compound	O
having	O
the	O
formula	O
[	O
I	O
]	O
,	O
wherein	O
R	O
?	O
e	O
and	O
'	O
Re¿	O
are	O
OH,	O
optionally	O
independently	O
etherified	O
or	O
esterified	O
;	O
Z	O
is	O
-CH¿2	O
?	O
-	O
or	O
-CH2CH2-	O
;	O
R	O
?	O
1¿	O
is	O
H,	O
halogen,	O
CF¿3	O
?	O
,	O
or	O
(	O
1C-4C	O
)	O
alkyl	O
;	O
R	O
?	O
2,	O
R3	O
and	O
R4¿	O
are	O
independently	O
H,	O
halogen,	O
-CF¿3	O
?	O
,	O
-OCF3,	O
(	O
1C-8C	O
)	O
Alkyl,	O
hydroxy,	O
(	O
1C-8C	O
)	O
alkyloxy,	O
aryloxy,	O
aryl	O
(	O
1C-8C	O
)	O
alkyl,	O
halo	O
(	O
1C-8C	O
)	O
alkyl,	O
-O	O
(	O
CH2	O
)	O
mX,	O
wherein	O
X	O
is	O
halogen	O
or	O
phenyl	O
and	O
m	O
=	O
2-4	O
;	O
-O	O
(	O
CH2	O
)	O
mNRaRb,	O
-S	O
(	O
CH2	O
)	O
mNRaRb	O
or	O
-	O
(	O
CH2	O
)	O
mNRaRb,	O
wherein	O
m	O
=	O
2-4	O
and	O
Ra,	O
Rb	O
are	O
independently	O
(	O
1C-8C	O
)	O
alkyl,	O
(	O
2C-8C	O
)	O
alkenyl,	O
(	O
2C-8C	O
)	O
alkynyl,	O
or	O
aryl,	O
optionally	O
substituted	O
with	O
halogen,	O
-CF3,	O
-OCF3,	O
-CN,	O
-NO2,	O
-OH,	O
(	O
1C-8C	O
)	O
alkoxy,	O
aryloxy,	O
carboxyl,	O
(	O
1C-8C	O
)	O
alkylthio,	O
carboxylate,	O
(	O
1C-8C	O
)	O
alkyl,	O
aryl,	O
aryl	O
(	O
1C-8C	O
)	O
alkyl,	O
halo	O
(	O
1C-8C	O
)	O
alkyl	O
or	O
Ra	O
and	O
Rb	O
form	O
a	O
3-8	O
membered	O
ring	O
structure,	O
optionally	O
substituted	O
with	O
halogen,	O
-CF3,	O
-OCF3,	O
-CN,	O
-NO2,	O
hydroxy,	O
hydroxy	O
(	O
1C-4C	O
)	O
alkyl,	O
(	O
1C-8C	O
)	O
alkoxy,	O
aryloxy,	O
(	O
1C-8C	O
)	O
alkylthio,	O
carboxyl,	O
carboxylate,	O
(	O
1C-8C	O
)	O
alkyl,	O
aryl,	O
aryl	O
(	O
1C-8C	O
)	O
alkyl,	O
halo	O
(	O
1C-8C	O
)	O
alkyl	O
.	O
The	O
compounds	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
a	O
medicine,	O
in	O
particular	O
for	O
use	O
in	O
estrogen-receptor-related	O
treatments	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
proliferation	O
of	O
astrocytes	O
and	O
astrocytic	O
tumor	O
cells	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
for	O
treating	O
a	O
condition	O
associated	O
with	O
a	O
defect	O
in	O
astrocyte	O
proliferation	O
in	O
a	O
subject,	O
and	O
methods	O
for	O
treating	O
a	O
condition	O
associated	O
with	O
astrocytic	O
tumor	O
cell	O
proliferation	O
in	O
a	O
subject	O
.	O
Additionally,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
CD81	B-GENE
protein	O
or	O
nucleic	O
acid	O
and	O
a	O
pharmaceutically-acceptable	O
carrier	O
.	O
Finally,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
determining	O
whether	O
a	O
subject	O
has	O
an	O
astrocytoma,	O
and	O
a	O
method	O
for	O
assessing	O
the	O
efficacy	O
of	O
astrocytoma	O
therapy	O
in	O
a	O
subject	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
certain	O
farnesyl	B-GENE
protein	I-GENE
transferaseinhibitors	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
selective	O
dopamine	B-GENE
D4	I-GENE
receptor	I-GENE
agonists	O
and	O
to	O
compositions	O
containing	O
selective	O
dopamine	B-GENE
D4	I-GENE
receptor	I-GENE
agonists	O
for	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O
.	O


The	O
invention	O
relates	O
to	O
low	O
molecular	O
heparin	O
for	O
producing	O
medicaments	O
for	O
the	O
prophylaxis	O
and	O
therapy	O
of	O
diseases	O
in	O
the	O
course	O
of	O
which	O
increased	O
activity	O
of	O
at	O
least	O
one	O
of	O
the	O
matrix-metalloproteinases	B-GENE
:	O
	O
neutrophilic	O
collagenase,	O
aggrecanase,	O
hADAMTSI	O
and	O
gelatine	O
A	O
are	O
involved	O
.	O


Isoindolin-1-one-substituted	O
propionamide	O
glucokinase	B-GENE
activators	O
which	O
increase	O
insulin	B-GENE
secretion	O
in	O
the	O
treatment	O
of	O
type	O
II	O
diabetes	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
A	O
is	O
unsubstituted	O
phenyl	O
or	O
phenyl	O
which	O
is	O
mono-	O
or	O
di-substituted	O
with	O
halo	O
or	O
mono-substituted	O
with	O
lower	O
alkyl	O
sulfonyl,	O
lower	O
alkyl	O
thio	O
or	O
nitro	O
;	O
R1	O
is	O
cycloalkyl	O
having	O
from	O
3	O
to	O
9	O
carbon	O
atoms	O
or	O
lower	O
alkyl	O
having	O
from	O
2	O
to	O
4	O
carbon	O
atoms	O
;	O
R2	O
is	O
an	O
unsubstituted	O
or	O
mono-substituted	O
five-	O
or	O
six-membered	O
heteroaromatic	O
ring	O
connected	O
by	O
a	O
ring	O
carbon	O
atom	O
to	O
the	O
amine	O
group	O
shown,	O
which	O
five-	O
or	O
six-	O
membered	O
heteroaromatic	O
ring	O
contains	O
from	O
1	O
to	O
3	O
heteroatoms	O
selected	O
from	O
sulfur,	O
oxygen	O
or	O
nitrogen,	O
with	O
one	O
heteroatom	O
being	O
nitrogen	O
which	O
is	O
adjacent	O
to	O
the	O
connecting	O
ring	O
carbon	O
atom,	O
which	O
ring	O
may	O
be	O
monocyclic	O
or	O
fused	O
with	O
phenyl	O
at	O
two	O
of	O
its	O
ring	O
carbons,	O
said	O
monosubstituted	O
heteroaromatic	O
ring	O
being	O
monosubstituted	O
at	O
a	O
position	O
on	O
a	O
ring	O
carbon	O
atom	O
other	O
than	O
adjacent	O
to	O
said	O
connecting	O
carbon	O
atom	O
with	O
a	O
substituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halo,	O
lower	O
alkyl,	O
nitro,	O
cyano,	O
perfluoro-lower	O
alkyl	O
;	O
hydroxy	O
-	O
(	O
CH¿2	O
)	O
n-OR	O
?	O
3,	O
-	O
(	O
CH¿2	O
?	O
)	O
n-C	O
(	O
O	O
)	O
-OR	O
?	O
3¿,	O
-	O
(	O
CH¿2	O
?	O
)	O
n-C	O
(	O
O	O
)	O
-NH-R	O
?	O
3¿,	O
-C	O
(	O
O	O
)	O
C	O
(	O
O	O
)	O
-or3,	O
or	O
-	O
(	O
CH¿2	O
?	O
)	O
n-NHR	O
?	O
3	O
;	O
¿	O
where	O
R3	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
and	O
n	O
is	O
0,	O
1,	O
2,	O
3	O
or	O
4	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salts	O
or	O
N-oxides	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
phenol	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
a	O
hydrocarbon	O
group	O
containing	O
up	O
to	O
12	O
carbon	O
atoms	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
;	O
wherein	O
R	O
?	O
1	O
and	O
R2¿	O
may	O
optionally	O
form	O
a	O
carbocyclic	O
5-	O
or	O
6-membered	O
ring	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
;	O
R	O
?	O
4¿	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
or	O
a	O
halogen	O
atom	O
;	O
R	O
?	O
5¿	O
represents	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
;	O
and	O
R	O
?	O
6¿	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
or	O
a	O
C2	O
or	O
C3	O
alkenyl	O
group,	O
under	O
the	O
proviso	O
that	O
R	O
?	O
2	O
and	O
R4¿	O
can	O
only	O
both	O
represent	O
a	O
hydrogen	O
atom	O
if	O
both	O
R	O
?	O
1	O
and	O
R5¿	O
represent	O
a	O
C¿1	O
?	O
-C7	O
alkyl	O
group	O
and	O
R	O
?	O
3¿	O
represents	O
a	O
halogen	O
atom	O
.	O
The	O
composition	O
is	O
particularly	O
useful	O
for	O
the	O
blockade	O
of	O
sodium	B-GENE
channels	I-GENE
and	O
/	O
or	O
influencing	O
the	O
kinetics	O
of	O
sodium	B-GENE
channels	I-GENE
and	O
thus	O
can	O
be	O
used	O
as	O
local	O
anesthetic,	O
antidysrhythmic,	O
anticonvulsant	O
/	O
antiepileptic	O
and	O
spasmolytic	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
antagonists	O
of	O
gonadotropin	B-GENE
releasing	I-GENE
hormone	I-GENE
(	O
GnRH	B-GENE
)	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
formulations,	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
present	O
invention	O
in	O
the	O
manufacture	O
of	O
a	O
medicament,	O
a	O
method	O
of	O
therapeutic	O
treatment	O
using	O
such	O
a	O
compound	O
and	O
processes	O
for	O
producing	O
the	O
compounds	O
.	O


Genetic	O
evidence	O
that	O
an	O
imbalance	O
in	O
the	O
activity	O
of	O
serine	B-GENE
proteases	I-GENE
can	O
cause	O
severe	O
skin	O
disease	O
has	O
recently	O
been	O
presented	O
.	O
The	O
serine	B-GENE
protease	I-GENE
SCCE	B-GENE
is	O
preferentially	O
expressed	O
in	O
cornifying	O
epithelia	O
.	O
Increased	O
expression	O
of	O
SCCE	B-GENE
in	O
psoriasis	O
has	O
previously	O
been	O
reported	O
.	O
Increased	O
SCCE	B-GENE
expression	O
also	O
in	O
chronic	O
lesions	O
of	O
atopic	O
dermatitis	O
is	O
described	O
herein	O
.	O
Transgenic	O
mice	O
expressing	O
human	B-GENE
SCCE	B-GENE
in	O
suprabasal	O
epidermal	O
keratinocytes	O
were	O
found	O
to	O
develop	O
pathological	O
skin	O
changes	O
with	O
increased	O
epidermal	O
thickness,	O
hyperkeratosis,	O
dermal	O
inflammation,	O
and	O
severe	O
pruritus	O
.	O
The	O
results	O
strengthen	O
the	O
idea	O
that	O
SCCE	B-GENE
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
skin	O
diseases,	O
and	O
may	O
offer	O
a	O
new	O
therapeutic	O
target	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
triazolo-pyridines	O
of	O
the	O
formula	O
I	O
wherein	O
Het	O
is	O
an	O
optionally	O
substituted	O
5-membered	O
heterocycle	O
containing	O
one	O
to	O
two	O
heteroatoms	O
selected	O
from	O
nitrogen,	O
sulfur	O
and	O
oxygen	O
wherein	O
at	O
least	O
one	O
of	O
said	O
heteroatoms	O
atoms	O
must	O
be	O
nitrogen	O
;	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
(	O
C¿1	O
?	O
-C6	O
)	O
alkyl	O
or	O
other	O
suitable	O
substituents	O
;	O
R	O
?	O
3¿	O
is	O
selected	O
	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen,	O
(	O
C¿1	O
?	O
-C6	O
)	O
alkyl	O
or	O
other	O
suitable	O
substituents	O
;	O
s	O
is	O
an	O
integer	O
from	O
0-5	O
;	O
to	O
intermediates	O
for	O
their	O
preparation,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potent	O
inhibitors	O
of	O
MAP	O
kinases,	O
preferably	O
p38	B-GENE
kinase	I-GENE
.	O
They	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
inflammation,	O
osteoarthritis,	O
rheumatoid	O
arthritis,	O
cancer,	O
repurfusion	O
or	O
ischemia	O
in	O
stroke	O
or	O
heart	O
attack,	O
autoimmune	O
diseases	O
and	O
other	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
targeted	O
cancer	O
therapy,	O
and	O
concerns	O
specifically	O
the	O
use	O
of	O
small	O
matrix	B-GENE
metalloproteinase	I-GENE
inhibitors	O
in	O
improving	O
targeting	O
of	O
liposomes	O
to	O
cancer	O
cells,	O
and	O
in	O
enhancing	O
the	O
uptake	O
thereof	O
to	O
such	O
cells	O
.	O
The	O
invention	O
thus	O
provides	O
a	O
method	O
for	O
treating	O
cancer,	O
as	O
well	O
as	O
a	O
method	O
for	O
improving	O
targeting	O
of	O
liposomes	O
to	O
tumor	O
cells,	O
a	O
method	O
for	O
enhancing	O
the	O
uptake	O
of	O
liposomes	O
by	O
tumor	O
cells,	O
and	O
a	O
method	O
for	O
selected	O
liposomal	O
delivery	O
of	O
chemotherapeutic	O
agents	O
into	O
tumor	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
imidazolidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
A,	O
E,	O
Z,	O
R	O
?	O
1,	O
R2,	O
R3,	O
R4	O
and	O
R5¿	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
valuable	O
pharmaceutical	O
active	O
compounds	O
which	O
are	O
suitable,	O
for	O
example,	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases,	O
for	O
example	O
of	O
rheumatoid	O
arthritis,	O
or	O
of	O
allergic	O
diseases	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
the	O
adhesion	O
and	O
migration	O
of	O
leukoxytes	O
and	O
/	O
or	O
antagonists	O
of	O
the	O
adhesion	B-GENE
receptor	I-GENE
VLA-4	B-GENE
belonging	O
to	O
teh	O
integrins	B-GENE
group	O
.	O
They	O
are	O
generally	O
suitable	O
for	O
teh	O
treatment	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
an	O
undesired	O
extend	O
of	O
leukocyte	O
adhesion	O
and	O
or	O
leukocyte	O
migration	O
or	O
are	O
associated	O
therewith	O
or	O
in	O
which	O
cell-cell	O
or	O
cell-matrix	O
interactions	O
which	O
are	O
based	O
on	O
the	O
interactions	O
of	O
VLA-4	B-GENE
receptors	O
with	O
their	O
ligands	O
play	O
a	O
role	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
and	O
pharmaceutical	O
preparations	O
which	O
contain	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O


Dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DP	B-GENE
4	I-GENE
)	O
inhibiting	O
compounds	O
are	O
provided	O
having	O
the	O
formula	O
where	O
n	O
is	O
0	O
or	O
1	O
;	O
X	O
is	O
H	O
or	O
CN	O
;	O
Y	O
is	O
N,	O
NH	O
or	O
O	O
;	O
Z	O
is	O
CH2	O
when	O
Y	O
is	O
O	O
or	O
N-H,	O
with	O
Y-Z	O
forming	O
a	O
single	O
bond,	O
and	O
Z	O
is	O
CH	O
when	O
Y	O
is	O
N,	O
with	O
Y-Z	O
forming	O
a	O
double	O
bond	O
;	O
and	O
wherein	O
R	O
?	O
1,	O
R2,	O
R3	O
and	O
R4¿	O
are	O
as	O
described	O
herein	O
.	O
A	O
method	O
is	O
also	O
provided	O
for	O
treating	O
diabetes	O
and	O
related	O
diseases,	O
especially	O
Type	O
II	O
diabetes,	O
and	O
other	O
diseases	O
as	O
set	O
out	O
herein,	O
employing	O
such	O
DP	B-GENE
4	I-GENE
inhibitor	O
or	O
a	O
combination	O
of	O
such	O
DP	B-GENE
4	I-GENE
inhibitor	O
and	O
one	O
or	O
more	O
of	O
another	O
antidiabetic	O
agent	O
such	O
as	O
metformin,	O
glyburide,	O
troglitazone,	O
pioglitazone,	O
rosiglitazone	O
and	O
/	O
or	O
insulin	B-GENE
and	O
/	O
or	O
one	O
or	O
more	O
of	O
a	O
hypolipidemic	O
agent	O
and	O
/	O
or	O
anti-obesity	O
agent	O
and	O
/	O
or	O
other	O
therapeutic	O
agent	O
.	O


Compounds	O
of	O
general	O
structural	O
formula	O
(	O
I	O
)	O
and	O
use	O
of	O
the	O
compounds	O
and	O
salts	O
and	O
solvates	O
thereof,	O
as	O
therapeutic	O
agents	O
as	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
5	I-GENE
cardiovascular	O
disorders	O
.	O


This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
vitronectin	B-GENE
receptor	I-GENE
antagonist	O
to	O
inhibit	O
adhesion	O
formation	O
.	O


Human	O
papillomavirus	O
(	O
HPV	O
)	O
protein	O
expression	O
is	O
downregulated	O
in	O
patients	O
infected	O
with	O
HPV	O
by	O
administration	O
of	O
PPARη	B-GENE
ligand,	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	B-GENE
(	O
COX-2	B-GENE
)	O
,	O
diaryl	O
heterocycle,	O
inhibitor	O
of	O
HPV	O
protein	O
from	O
a	O
natural	O
source	O
and	O
/	O
or	O
certain	O
non-steroidal	O
anti-inflammatory	O
drugs	O
.	O


This	O
invention	O
generally	O
pertains	O
to	O
the	O
field	O
of	O
psychiatry	O
.	O
In	O
particular,	O
this	O
invention	O
pertains	O
to	O
the	O
discovery	O
that	O
agents	O
which	O
inhibit	O
the	O
binding	O
of	O
cortisol	O
to	O
its	O
receptors	O
can	O
be	O
used	O
in	O
methods	O
for	O
treating	O
delirium	O
.	O
Mifepristone,	O
a	O
potent	O
specific	O
glucocorticoid	B-GENE
receptor	I-GENE
antagonist,	O
can	O
be	O
used	O
in	O
these	O
methods	O
.	O
The	O
invention	O
also	O
provides	O
a	O
kit	O
for	O
treating	O
delirium	O
in	O
a	O
human	O
including	O
a	O
glucocorticoid	B-GENE
receptor	I-GENE
antagonist	O
and	O
instructional	O
material	O
teaching	O
the	O
indications,	O
dosage	O
and	O
schedule	O
of	O
administration	O
of	O
the	O
glucocorticoid	B-GENE
receptor	I-GENE
antagonist	O
.	O


Disclosed	O
are	O
methods	O
of	O
treating	O
certain	O
cytokine	B-GENE
mediated	O
diseases	O
or	O
conditionsusing	O
novel	O
aromatic	O
heterocyclic	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
Ar1,	O
Ar2,	O
L,	O
Q	O
and	O
X	O
are	O
described	O
herein	O
.	O


Reverse	O
hydroxamic	O
acid	O
derivatives	O
having	O
specific	O
structures	O
represented	O
by	O
the	O
general	O
formula	O
(	O
Ia	O
)	O
:	O
(	O
Ia	O
)	O
(	O
wherein	O
A	O
represents	O
hydrogen,	O
etc	O
.	O
;	O
Ar1	O
represents	O
arylene,	O
etc	O
.	O
;	O
Ar2	O
represents	O
optionally	O
substituted	O
aryl,	O
heteroaryl,	O
etc	O
.	O
;	O
R1	O
represents	O
hydrogen,	O
alkyl,	O
etc	O
.	O
;	O
and	O
R2a	O
represents	O
substituted	O
cycloalkyl,	O
heterocycloalkyl,	O
etc	O
.	O
)	O
and	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
(	O
wherein	O
A,	O
Ar1,	O
ar2,	O
and	O
R1	O
are	O
the	O
same	O
as	O
defined	O
above	O
and	O
R2	O
represents	O
hydrogen,	O
R2a,	O
etc	O
.	O
)	O
and	O
salts	O
of	O
the	O
derivatives	O
.	O
They	O
have	O
TNF-α	B-GENE
converting	I-GENE
enzyme	I-GENE
(	O
TACE	B-GENE
)	O
inhibitory	O
activity	O
.	O


A	O
novel	O
class	O
of	O
substituted	O
piperidines,	O
of	O
formula	O
I	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
use	O
thereof	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
the	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
.	O
More	O
particularly,	O
the	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
and	O
disorders	O
in	O
which	O
an	O
interaction	O
with	O
the	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
is	O
beneficial	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
bacterial	O
infections,	O
preferably	O
infections	O
caused	O
by	O
FimH	B-GENE
expressing	O
bacteria,	O
comprising	O
administering	O
a	O
tyrosine	O
kinase	O
inhibitor	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatment,	O
more	O
particularly	O
a	O
non	O
toxic,	O
potent	O
and	O
selective	O
c-kit	B-GENE
inhibitor,	O
wherein	O
said	O
inhibitor	O
is	O
unable	O
to	O
promote	O
death	O
of	O
IL-3	B-GENE
dependent	O
cells	O
cultured	O
in	O
presence	O
of	O
IL-3	B-GENE
.	O


Pyrazolopyrimidinone	O
derivatives	O
represented	O
by	O
the	O
general	O
formula	O
(	O
IA	O
)	O
or	O
(	O
IB	O
)	O
:	O
(	O
IA	O
)	O
(	O
IB	O
)	O
or	O
the	O
general	O
formula	O
(	O
IA’	O
)	O
or	O
(	O
IB’	O
)	O
:	O
(	O
IA’	O
)	O
(	O
IB’	O
)	O
(	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
)	O
.	O
The	O
compounds	O
can	O
enhance	O
the	O
intracellular	O
cAMP	O
level	O
by	O
virtue	O
of	O
their	O
selective	O
inhibitory	O
activity	O
against	O
PDE7,	O
and	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
various	O
allergic	O
diseases	O
and	O
inflammatory	O
and	O
immunologic	O
diseases	O
through	O
their	O
inhibiting	O
the	O
activation	O
of	O
T	O
cells	O
.	O


Compositions	O
and	O
methods	O
for	O
treating	O
rhinitis	O
with	O
H1	B-GENE
antagonists	O
/	O
antiallergics	O
and	O
safe	O
steroids	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
usefull	O
as	O
inhibitors	O
of	O
protein	B-GENE
kinases	I-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositioins	O
comprising	O
said	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disease,	O
conditions,	O
or	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
5-substituted	O
7-azaindole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
in	O
the	O
inhibition	O
of	O
c-Jun	B-GENE
N-terminal	I-GENE
kinases,	O
their	O
use	O
in	O
medicine	O
and	O
particularly	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
neurodegenerative	O
disorders	O
related	O
to	O
apoptosis	O
and	O
/	O
or	O
inflammation	O
.	O
The	O
invention	O
also	O
provides	O
processes	O
for	O
manufacture	O
of	O
said	O
compounds,	O
compositions	O
containing	O
them	O
and	O
processes	O
for	O
manufacturing	O
such	O
compositions	O
.	O


Use	O
ofpyridoxal-5	O
'	O
-phosphate,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof,	O
or	O
a	O
mixture	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
insulin-dependent	O
or	O
non-insulin-dependent	O
diabetes	O
mellitus,	O
related	O
conditions,	O
symptoms	O
of	O
insulin-dependent	O
or	O
non-insulin-dependent	O
diabetes	O
mellitus,	O
or	O
related	O
conditions,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
mammal	O
.	O


To	O
efficiently	O
treat	O
diseases	O
such	O
as	O
cancer	O
in	O
which	O
hIGF	B-GENE
participates,	O
there	O
have	O
been	O
required	O
antibodies	O
which	O
strongly	O
bind	O
to	O
both	O
of	O
hIGF-I	B-GENE
and	O
hIGF-II	B-GENE
and	O
inhibit	O
their	O
functions	O
and	O
fragments	O
of	O
these	O
antibodies	O
.	O
It	O
is	O
intended	O
to	O
provide	O
antibodies	O
which	O
can	O
specifically	O
bind	O
respectively	O
to	O
human	B-GENE
IGF-I	I-GENE
and	O
human	B-GENE
IGF-II	I-GENE
to	O
thereby	O
inhibit	O
the	O
functions	O
of	O
human	B-GENE
IGF-I	I-GENE
and	O
human	B-GENE
IGF-II	I-GENE
and	O
have	O
binding	O
activity	O
with	O
a	O
binding	O
constant	O
of	O
5x10	O
<	O
9	O
>	O
M	O
<	O
-1	O
>	O
or	O
more	O
measured	O
with	O
a	O
biosensor	O
BIACORE	O
.	O
It	O
is	O
also	O
intended	O
to	O
provide	O
diagnostics,	O
preventives	O
and	O
remedies	O
comprising	O
the	O
above	O
antibodies	O
for	O
an	O
hIGF-mediated	O
disease	O
and	O
a	O
disease	O
showing	O
pathological	O
progressing	O
due	O
to	O
abnormally	O
accelerated	O
hIGF	B-GENE
production	O
.	O


The	O
invention	O
describes	O
the	O
use	O
of	O
vasopeptidase	B-GENE
inhibitors	O
of	O
the	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
nephropathy	O
in	O
diabetic	O
or	O
non-diabetic	O
patients,	O
including	O
diabetic	O
or	O
non-diabetic	O
nephropathy,	O
glomerulonephritis,	O
glomerular	O
sclerosis,	O
nephrotic	O
syndome,	O
hypertensive	O
nephrosclerosis,	O
microalbuminuria	O
or	O
end	O
stage	O
renal	O
disease,	O
or	O
insulin	B-GENE
resistence	O
or	O
of	O
metabolic	O
diseases	O
associated	O
with	O
advanced	O
glycation	O
end-products,	O
such	O
as	O
diabetic	O
complications,	O
diabetic	O
neuropathy,	O
diabetic	O
nephropathy,	O
diabetic	O
retinopathy,	O
cataracts,	O
myocardial	O
infarction	O
and	O
/	O
or	O
diabetic	O
cardiomyopathy,	O
or	O
atherosclerosis	O
or	O
endothelial	O
dysfunction	O
.	O


Compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof,	O
wherein	O
R1	O
is	O
aryl	O
;	O
R2	O
is	O
hydrogen,	O
alkyl	O
or	O
cycloalkyl	O
;	O
R3	O
is	O
hydrogen,	O
alkyl,	O
aralkyl,	O
aryl,	O
alkylcarbonyl,	O
arylcarbonyl,	O
alkyl-S	O
(	O
O	O
)	O
2-	O
or	O
aryl-S	O
(	O
O	O
)	O
2-	O
;	O
R4	O
is	O
aralkyl	O
;	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
independently	O
selected	O
from	O
hydrogen,	O
alkyl	O
or	O
cycloalkyl	O
;	O
and	O
n	O
is	O
1,2,3,4	O
or	O
5,	O
are	O
useful	O
as	O
insulin	B-GENE
sensititers,	O
particularly	O
PPAR	B-GENE
activators	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
compositions	O
comprising	O
novel	O
anticholinergic	O
agents	O
and	O
PDE-IV	B-GENE
inhibitors,	O
method	O
for	O
production	O
and	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O


Phenylalanine	O
enamide	O
derivatives	O
of	O
formula	O
(	O
1	O
)	O
are	O
described	O
:	O
wherein	O
R1	O
is	O
a	O
-CH3,	O
-	O
(	O
CH2	O
)	O
3CH3,	O
-CH2CH20H,	O
-CH2CH20CH3,	O
-CH2CH20CH2CH20H,	O
-CH2CH20CH2CH20CH3,	O
Formula	O
(	O
II	O
)	O
group	O
;	O
and	O
the	O
salts,	O
solvates	O
and	O
N-oxides	O
thereof	O
.	O
Compounds	O
according	O
to	O
the	O
invention	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
oA	O
integrins	B-GENE
.	O
The	O
compounds	O
are	O
of	O
use	O
in	O
modulating	O
cell	O
adhesion	O
and	O
in	O
particular	O
are	O
of	O
use	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
or	O
disorders	O
including	O
inflammation	O
in	O
which	O
the	O
extravasation	O
of	O
leukocytes	O
plays	O
a	O
role	O
and	O
the	O
invention	O
extends	O
to	O
such	O
a	O
use	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
such	O
diseases	O
or	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
diseases	O
caused	O
by	O
and	O
/	O
or	O
associated	O
with	O
an	O
altered	O
protein	B-GENE
kinase	I-GENE
activity	O
which	O
comprises	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
pyrazole-tetrahydro	O
pyridine	O
derivative	O
.	O
The	O
invention	O
also	O
provides	O
specific	O
pyrazole-tetrahydro	O
pyridines,	O
a	O
library	O
comprising	O
at	O
least	O
two	O
of	O
them,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
the	O
pharmaceutical	O
compositions	O
containing	O
them,	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
caused	O
by	O
and	O
/	O
or	O
associated	O
with	O
an	O
altered	O
protein	B-GENE
kinase	I-GENE
activity	O
such	O
as	O
cancer,	O
cell	O
proliferative	O
disorders,	O
viral	O
infections,	O
autoimmune	O
diseases	O
and	O
neurodegenerative	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
and	O
methods	O
for	O
using	O
them	O
to	O
treat	O
diseases	O
with	O
aminothiophene	O
inhibitors	O
of	O
IKK-ß	B-GENE
phosphorylation	O
of	O
I	O
:	O
B	O
.	O
In	O
so	O
doing	O
these	O
aminothiophene	O
inhibitors	O
block	O
pathological	O
activation	O
of	O
transcription	O
factor	O
NF-:B	B-GENE
in	O
which	O
diseases	O
excessive	O
activation	O
of	O
NF-:B	B-GENE
is	O
implicated	O
.	O


Disclosed	O
are	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
A,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
X1	O
are	O
as	O
disclosed	O
herein	O
.	O
The	O
compounds	O
have	O
affinity	O
for	O
the	O
ORL1	B-GENE
receptor	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
chronic	O
and	O
acute	O
pain	O
.	O


A	O
method	O
of	O
treating,	O
preventing,	O
or	O
inhibiting	O
ALS,	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment,	O
inhibition	O
or	O
prevention	O
.	O
The	O
method	O
comprises	O
administering	O
to	O
a	O
subject	O
one	O
or	O
more	O
cyclooxygenase-2	B-GENE
selective	O
inhibitor	O
(	O
s	O
)	O
or	O
isomer	O
(	O
s	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
(	O
s	O
)	O
,	O
ester	O
(	O
s	O
)	O
,	O
or	O
prodrug	O
(	O
s	O
)	O
thereof,	O
in	O
combination	O
with	O
one	O
or	O
more	O
second	O
drugs,	O
wherein	O
the	O
amount	O
of	O
the	O
cyclooxygenase-2	B-GENE
selective	O
inhibitor	O
(	O
s	O
)	O
or	O
isomer	O
(	O
s	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
(	O
s	O
)	O
,	O
ester	O
(	O
s	O
)	O
,	O
or	O
prodrug	O
(	O
s	O
)	O
thereof	O
in	O
combination	O
with	O
the	O
amount	O
of	O
second	O
drug	O
(	O
s	O
)	O
constitutes	O
an	O
ALS	O
treatment,	O
inhibition	O
or	O
prevention	O
effective	O
amount	O
.	O


This	O
invention	O
discloses	O
amino	O
acid	O
derivatives	O
which	O
display	O
inhibitory	O
effects	O
on	O
the	O
serine	O
protease	O
factor	B-GENE
Xa	I-GENE
.	O
The	O
invention	O
also	O
discloses	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
compounds,	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
or	O
their	O
salts,	O
methods	O
for	O
the	O
preparation	O
of	O
the	O
compounds,	O
and	O
methods	O
of	O
using	O
them	O
as	O
therapeutic	O
agents	O
for	O
treating	O
or	O
preventing	O
disease	O
states	O
in	O
mammals	O
characterized	O
by	O
abnormal	O
thrombosis	O
.	O


Nicotinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
agonists	O
of	O
formula	O
I	O
wherein	O
a,	O
b,	O
c,	O
D	O
and	O
R	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
enantiomers,	O
pharmaceutically-	O
acceptable	O
salts,	O
methods	O
of	O
making,	O
pharmaceutical	O
compositions	O
containing	O
and	O
methods	O
for	O
using	O
the	O
same	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
psychotic	O
disorders,	O
intellectual	O
impairment	O
disorders,	O
Alzheimer’s	O
disease,	O
leaning	O
deficit,	O
cognition	O
deficit,	O
attention	O
deficit,	O
memory	O
loss,	O
Lewy	O
Body	O
Dementia,	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder,	O
anxiety,	O
schizophrenia,	O
mania	O
or	O
manic	O
depression,	O
Parkinson’s	O
disease,	O
Huntington’s	O
disease,	O
Tourette’s	O
syndrome,	O
neurodegenerative	O
disorders	O
in	O
which	O
there	O
is	O
a	O
loss	O
of	O
cholinergic	O
synapse,	O
jetlag,	O
cessation	O
of	O
smoking,	O
nicotine	O
addiction,	O
pain,	O
ulcerative	O
colitis	O
or	O
irritable	O
bowel	O
syndrome	O
.	O


A	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
:	O
	O
	O
	O
	O
	O
wherein	O
R1	O
represents	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
and	O
the	O
like	O
;	O
R2	O
represents	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group	O
and	O
the	O
like	O
;	O
and	O
R3	O
represents	O
-O-X-C	O
(	O
A1	O
)	O
(	O
A11	O
)	O
-C	O
(	O
A2	O
)	O
(	O
A21	O
)	O
-N	O
(	O
A31	O
)	O
(	O
A3	O
)	O
(	O
X	O
represents	O
propylene	O
group	O
etc	O
.	O
,	O
A11	O
and	O
A21	O
represent	O
hydrogen	O
atom,	O
or	O
a	O
C1-6	O
alkyl	O
group,	O
A31	O
represents	O
a	O
C1-6	O
alkyl	O
group	O
substituted	O
with	O
hydroxyl	O
group,	O
or	O
hydrogen	O
atom,	O
and	O
A1,	O
A2,	O
and	O
A3	O
represent	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group	O
and	O
the	O
like	O
)	O
and	O
the	O
like,	O
which	O
has	O
an	O
inhibitory	O
activity	O
on	O
the	O
phosphorylation	O
of	O
myosin	B-GENE
regulatory	I-GENE
light	I-GENE
chain,	O
and	O
is	O
useful	O
for	O
treatment	O
of	O
diseases	O
relating	O
to	O
contraction	O
of	O
various	O
cells	O
and	O
the	O
like	O
.	O


Certain	O
appropriately	O
substituted	O
forms	O
of	O
pyrimidine	O
and	O
triazine	O
are	O
useful	O
in	O
the	O
treatment	O
to	O
conditions	O
associated	O
with	O
enhanced	O
TGFβ	B-GENE
activity	O
.	O


Methods	O
and	O
formulations	O
are	O
described	O
for	O
improving	O
health	O
and	O
survival	O
in	O
animals	O
suffering	O
from	O
heaves,	O
encompassing	O
the	O
administration	O
of	O
the	O
optically	O
pure	O
R	O
(	O
-	O
)	O
-isomer	O
of	O
albuterol,	O
while	O
minimizing	O
or	O
eliminating	O
unwanted	O
activities	O
of	O
the	O
corresponding	O
S	O
(	O
+	O
)	O
-isomer	O
of	O
albuterol	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
favorable	O
oral	O
administration	O
of	O
R	O
(	O
-	O
)	O
-albuterol	O
to	O
animals	O
and	O
to	O
food	O
compositions	O
for	O
animals	O
suffering	O
from	O
heaves,	O
comprising	O
the	O
optically	O
active	O
adrenergic	B-GENE
beta-receptor	I-GENE
agonist	O
R	O
(	O
-	O
)	O
-albuterol	O
.	O


The	O
present	O
invention	O
relates	O
to	O
genes	O
and	O
genes	O
clusters	O
which	O
are	O
expressed	O
in	O
a	O
tissue	O
specific	O
manner	O
.	O
For	O
example,	O
the	O
invention	O
relates	O
to	O
a	O
group	O
of	O
genes	O
encoding	O
GPCR-like	B-GENE
receptors	I-GENE
that	O
are	O
involved	O
in	O
the	O
function	O
and	O
activity	O
of	O
the	O
immune	O
system	O
.	O
These	O
genes	O
are	O
organized	O
into	O
a	O
discrete	O
cluster	O
at	O
chromosomal	O
location	O
1q22	O
(	O
the	O
“immune	O
gene	O
complex”	O
)	O
and	O
span	O
about	O
700	O
kb	O
of	O
DNA	O
.	O
The	O
region	O
closest	O
to	O
the	O
centromere	O
comprises	O
genes	O
that	O
are	O
expressed	O
predominantly	O
in	O
the	O
thymus,	O
while	O
the	O
distal	O
region	O
comprises	O
genes	O
which	O
are	O
expressed	O
predominantly	O
in	O
the	O
bone	O
marrow	O
and	O
other	O
hematopoietic	O
cells	O
.	O
Another	O
cluster	O
of	O
GPCR	B-GENE
genes	O
is	O
located	O
at	O
chromosomal	O
band	O
11q24	O
.	O
These	O
genes	O
are	O
expressed	O
predominantly	O
in	O
pancreatic	O
tissue,	O
establishing	O
this	O
region	O
of	O
chromosome	O
11	O
as	O
a	O
unique	O
gene	O
complex	O
involved	O
in	O
pancreatic	O
function	O
.	O
A	O
cluster	O
of	O
transmembrane	O
and	O
GPCR-type	B-GENE
receptor	I-GENE
genes	O
is	O
also	O
located	O
at	O
chromosomal	O
band	O
11q12	O
.	O
2	O
.	O
These	O
genes	O
are	O
expressed	O
predominantly	O
in	O
the	O
spleen	O
(	O
hence,	O
“spleen	O
gene”	O
cluster	O
)	O
,	O
as	O
well	O
as	O
other	O
tissues	O
of	O
the	O
immune	O
and	O
reticuloendothelial	O
system	O
(	O
RES	O
)	O
,	O
indicating	O
that	O
establishing	O
this	O
region	O
of	O
the	O
chromosome	O
is	O
involved	O
is	O
spleen,	O
lymphoid,	O
and	O
/	O
or	O
reticuloendothelial	O
function	O
.	O
Finally,	O
genes	O
coding	O
for	O
membrane	O
proteins	O
have	O
been	O
identified	O
which	O
are	O
expressed	O
selectively	O
in	O
bone	O
marrow,	O
kidney,	O
pancreas,	O
and	O
retina	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
involving	O
melanocytes	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
involving	O
RAB38	B-GENE
and	O
mutant	O
RAB38,	O
suitable	O
for	O
use	O
in	O
modulation	O
of	O
pigmentation	O
and	O
for	O
use	O
in	O
determining	O
the	O
means	O
to	O
diagnose	O
and	O
/	O
or	O
treat	O
conditions	O
associated	O
with	O
disorders	O
in	O
pigmentation	O
.	O


A	O
method	O
of	O
treating	O
conditions	O
associated	O
with	O
pain	O
and	O
alleviating	O
the	O
symptoms	O
associated	O
therewith	O
which	O
comprises	O
administering	O
to	O
a	O
mammal,	O
including	O
man,	O
a	O
vanilloid	B-GENE
VR-1	I-GENE
antagonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
and	O
an	O
NSAID	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof,	O
wherein	O
said	O
VR-1	O
antagonist	O
or	O
said	O
NSAID	O
may	O
optionally	O
be	O
administered	O
as	O
a	O
sub-maximal	O
amount	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
designed	O
for	O
the	O
treatment,	O
management,	O
or	O
prevention	O
of	O
cancer,	O
particularly,	O
metastatic	O
cancer	O
.	O
The	O
methods	O
of	O
the	O
invention	O
comprise	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
antibodies	O
that	O
bind	O
to	O
and	O
agonize	O
EphA2,	O
thereby	O
increasing	O
EphA2	B-GENE
phosphorylation	O
and	O
decreasing	O
EphA2	B-GENE
levels	O
in	O
cells	O
which	O
EphA2	B-GENE
has	O
been	O
agonized	O
.	O
The	O
invention	O
also	O
encompasses	O
antibodies	O
that	O
preferentially	O
bind	O
an	O
EphA2	B-GENE
epitope	O
exposed	O
on	O
cancer	O
cells	O
but	O
not	O
non-cancer	O
cells	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
EphA2	B-GENE
antibodies	O
of	O
the	O
invention	O
either	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
agents	O
useful	O
for	O
cancer	O
therapy	O
.	O


Use	O
of	O
galectin-2	B-GENE
or	O
of	O
a	O
nucleic	O
acid	O
coding	O
for	O
galectin-2	B-GENE
or	O
of	O
its	O
complementary	O
strand,	O
or	O
of	O
a	O
nucleic	O
acid	O
hybridizing	O
to	O
such	O
coding	O
nucleic	O
acid	O
or	O
its	O
complementary	O
strand,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
patient	O
having	O
a	O
disease	O
with	O
impaired	O
apoptosis	O
of	O
T-cells,	O
macrophages	O
and	O
/	O
or	O
antigen-presenting	O
cells,	O
e	O
.	O
g	O
.	O
autoimmune	O
diseases	O
or	O
malignant	O
T-cell	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
diseases	O
caused	O
by	O
and	O
/	O
or	O
associated	O
with	O
an	O
altered	O
protein	B-GENE
kinase	I-GENE
activity	O
which	O
comprises	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
tetracyclic	O
pyrazole	O
.	O
The	O
invention	O
also	O
provides	O
specific	O
tetracyclic	O
pyrazole	O
derivatives,	O
useful	O
intermediates,	O
a	O
library	O
comprising	O
at	O
least	O
two	O
of	O
them,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
the	O
pharmaceutical	O
compositions	O
containing	O
them,	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
caused	O
by	O
and	O
/	O
or	O
associated	O
with	O
an	O
altered	O
protein	B-GENE
kinase	I-GENE
activity	O
such	O
as	O
cancer,	O
cell	O
proliferative	O
disorders,	O
viral	O
infections,	O
autoimmune	O
diseases	O
and	O
neurodegenerative	O
disorders	O
.	O


The	O
present	O
application	O
describes	O
lactam-containing	O
cyclic	O
diamines	O
and	O
derivatives	O
thereof	O
of	O
Formula	O
I	O
:	O
or	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof,	O
wherein	O
M	O
is	O
a	O
non-aromatic	O
carbocycle	O
or	O
heterocycle	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
trysin-like	B-GENE
serine	I-GENE
proteases,	O
specifically	O
factor	B-GENE
Xa	I-GENE
.	O


Disclosed	O
are	O
compounds	O
of	O
formula	O
I	O
as	O
modulators	O
of	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptors	I-GENE
(	O
PPARs	B-GENE
)	O
for	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
such	O
as	O
obesity	O
:	O
wherein	O
Ar1	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
monocyclic	O
heteroarornatic	O
ring	O
structure	O
and	O
a	O
bicyclic	O
heteroaromatic	O
ring	O
structure	O
;	O
Ar2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
monocyclic,	O
a	O
bicyclic,	O
and	O
a	O
tricyclic	O
carbocyclic	O
aryl	O
ring	O
structure	O
R1	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alkyl,	O
optionally	O
substituted	O
a	O
five-membered	O
or	O
six-membered	O
heteroarylring	O
or	O
a	O
six-membered	O
aryl	O
ring,	O
optionally	O
substituted	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
;	O
alkyl,	O
optionally	O
substituted	O
a	O
five-membered	O
or	O
six-membered	O
heteroaryl	O
ring	O
or	O
a	O
six-membered	O
aryl	O
ring,	O
optionally	O
substituied	O
cyano	O
;	O
nitro	O
;	O
an	O
amino	O
;	O
an	O
amido	O
;	O
perhaloalkyl	O
;	O
and	O
halogen	O
;	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
;	O
alkyl,	O
optionally	O
substituted	O
and	O
B	O
is	O
a	O
five-membered	O
or	O
six-membered	O
heteroaryl	O
ring,	O
or	O
-	O
(	O
CH2	O
)	O
j-C	O
(	O
O	O
)	O
OR4,	O
wherein	O
j	O
is	O
0	O
or	O
I	O
1	O
when	O
Ar2	O
is	O
a	O
bicyclic	O
or	O
tricyclic	O
carbocyclic	O
ring	O
structure	O
and	O
j	O
is	O
1	O
when	O
Ar2	O
is	O
a	O
monocyclic	O
carbocyclic	O
ring	O
structure	O
;	O
and	O
R4	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
;	O
alkyl,	O
optionally	O
substituted	O
a	O
five-membered	O
or	O
six-membered	O
heteroaryl	O
ring	O
or	O
a	O
six-membered	O
aryl	O
ring,	O
optionally	O
substituted	O
.	O
The	O
obtional	O
substituents	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O


Disclosed	O
are	O
once-daily	O
formulations	O
containing	O
tetracyclines,	O
especially	O
doxycycline	O
.	O
Such	O
formulations	O
are	O
useful,	O
for	O
instance,	O
for	O
the	O
treatment	O
of	O
collagenase	B-GENE
destructive	O
enzyme-dependent	O
diseases,	O
such	O
as	O
periodontal	O
disease	O
and	O
acne,	O
and	O
acute	O
and	O
chronic	O
inflammatory	O
disease	O
states,	O
such	O
as	O
rosacea	O
and	O
arthritis	O
.	O


The	O
instant	O
invention	O
pertains	O
to	O
the	O
discovery	O
of	O
two	O
novel	O
regulatory	O
mechanisms	O
of	O
NF-kB	B-GENE
.	O
The	O
instant	O
invention	O
demonstrates	O
that	O
NF-kB	B-GENE
is	O
regulated	O
by	O
PinI-catalyzed	O
prolyl	O
isomerization	O
and	O
ubiquitin-mediated	O
proteolysis	O
of	O
p65	B-GENE
.	O
Accordingly,	O
the	O
instant	O
invention	O
provides	O
methods	O
for	O
regulating	O
NF-kB,	O
and	O
diseases	O
and	O
disorders	O
associated	O
with	O
NF-kB	B-GENE
.	O
Further,	O
the	O
invention	O
provides	O
compositions	O
capable	O
of	O
modulating	O
the	O
activity	O
or	O
expression	O
of	O
NF-kB,	O
Pinl,	O
and	O
/	O
or	O
the	O
proteolysis	O
of	O
p65	B-GENE
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
isomers,	O
salts,	O
hydrates,	O
solvates,	O
and	O
prodrug	O
derivatives	O
thereof,	O
wherein	O
R1,	O
R6,	O
R7,	O
R8,	O
Pg,	O
and	O
n	O
are	O
those	O
defined	O
herein	O
.	O
The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
for	O
using	O
the	O
same	O
.	O
In	O
particular,	O
compounds	O
of	O
Formula	O
I	O
are	O
useful	O
in	O
modulating	O
TGF-ß	B-GENE
activity	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
the	O
formula	O
:	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
R10	O
and	O
R16	O
are	O
as	O
defined	O
herein	O
which	O
are	O
useful	O
as	O
modulators	O
of	O
chemokine	B-GENE
receptor	I-GENE
activity	O
.	O
In	O
particular,	O
these	O
compounds	O
are	O
useful	O
as	O
modulators	O
of	O
the	O
chemokine	B-GENE
receptor	I-GENE
CCR-2	I-GENE
.	O


The	O
present	O
invention	O
refers	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
sildenafil	O
and	O
a	O
large	B-GENE
conductance	I-GENE
Ca(2+)	I-GENE
activated	I-GENE
K+	I-GENE
channels	I-GENE
activator	O
and	O
its	O
use	O
for	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O
in	O
man	O
and	O
woman,	O
sexual	O
disorders	O
in	O
man,	O
erectile	O
dysfunction	O
or	O
impotence	O
.	O


A	O
unique	O
DHA	O
product,	O
10,	O
17S-docosatriene	O
(	O
'	O
Neuroprotectin	O
D1	O
'	O
or	O
'	O
NPD1	O
'	O
)	O
,	O
was	O
found	O
to	O
provide	O
surprisingly	O
effective	O
neuroprotection	O
when	O
administered	O
right	O
after	O
an	O
experimental	O
stroke	O
.	O
Moreover,	O
both	O
nerve	O
cells	O
and	O
retinal	O
pigment	O
epithelial	O
(	O
RPE	O
)	O
cells	O
were	O
found	O
to	O
synthesize	O
10,175-docosatriene	O
(	O
NPD	O
1	O
)	O
from	O
DHA	O
.	O
NPD	O
1	O
also	O
potently	O
counteracted	O
H2O2	O
/	O
TNFα	B-GENE
oxidative	O
stress-mediated	O
cell	O
apoptotic	O
damage	O
.	O
Under	O
the	O
same	O
oxidative-stress	O
conditions,	O
NPDI	O
up-regulated	O
the	O
anti-apoptotic	O
Bcl-2	B-GENE
proteins,	O
Bcl-2	B-GENE
and	O
Bcl-xL,	O
and	O
decreased	O
expression	O
of	O
the	O
pro-apoptotic	O
proteins,	O
Bad	B-GENE
and	O
Bax	B-GENE
.	O
Moreover,	O
in	O
RPE	O
cells	O
NPD1	O
inhibited	O
oxidative	O
stress-induced	O
caspase-3	B-GENE
activation,	O
IL-lß-stimulated	O
human	O
COX-2	B-GENE
promoter	O
expression,	O
and	O
apoptosis	O
due	O
to	O
N-retinylidene-N-retinylethanolamine	O
(	O
A2E	O
)	O
.	O
Overall,	O
NPD1	O
protected	O
both	O
nerve	O
and	O
retinal	O
pigment	O
epithelial	O
cells	O
from	O
cellular	O
apoptosis	O
and	O
damage	O
due	O
to	O
oxidative	O
stress	O
.	O
NPD1	O
concentration	O
in	O
the	O
brain	O
of	O
Alzheimer	O
'	O
s	O
patients	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
from	O
that	O
of	O
controls	O
.	O
In	O
cultured	O
human	O
brain	O
cells,	O
NPD1	O
synthesis	O
was	O
up-regulated	O
by	O
neuroprotective	O
soluble	O
ß	O
amyloid,	O
and	O
NPD	O
1	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
toxic	O
ß	B-GENE
amyloid	I-GENE
peptides	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
the	O
3-chromancarboxylic	O
acid	O
derivatives,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
prodrugs	O
which	O
are	O
useful	O
for	O
treatment	O
and	O
control	O
of	O
non-insulin	O
dependent	O
diabetes	O
mellitus	O
(	O
type	O
II	O
diabetes	O
)	O
and	O
its	O
related	O
vascular	O
disease	O
as	O
well	O
as	O
obesity	O
and	O
lipid	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
group	O
of	O
thiazole	O
derivatives,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
these	O
compounds	O
as	O
active	O
ingredient,	O
as	O
well	O
to	O
the	O
use	O
of	O
these	O
compositions	O
for	O
the	O
treatment	O
of	O
psychiatric	O
and	O
neurological	O
disorders	O
and	O
other	O
diseases	O
involving	O
cannabinoid	B-GENE
CB	B-GENE
neurotransmission	O
.	O
'	O
The	O
thiazole	O
derivatives	O
of	O
the	O
invention	O
are	O
either	O
cannabinoid	B-GENE
(CB)	I-GENE
receptor	I-GENE
antagonists,	O
CB	B-GENE
receptor	I-GENE
antagonists,	O
CB	B-GENE
receptor	I-GENE
inverse	O
agonists	O
or	O
CB	B-GENE
receptor	I-GENE
partial	O
agonists	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
l	O
)	O
wherein	O
R,	O
R1	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
salts	O
and	O
physiologically	O
functional	O
derivatives	O
thereof,	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
substituent	O
	O
	O
	O
	O
	O
	O
	O
is	O
attached	O
to	O
the	O
5-	O
or	O
6-	O
position	O
of	O
the	O
benzazole	O
;	O
	O
X	O
independently	O
represents	O
S,	O
O,	O
SO,	O
SO2	O
;	O
Y	O
independently	O
represents	O
S,	O
O,	O
NR2,	O
SO,	O
SO2	O
;	O
A	O
independently	O
represents	O
←CO-,	O
←CS-,	O
←SO-,	O
←SO2-,	O
←CO2-,	O
←CONR8-,	O
←NR8CO-,	O
←NR8CONR9-,	O
←NR8COO-,	O
←NR8NR9CO-,	O
←NR8OCO-,	O
←ONR8CO-,	O
←NR8SO2-,	O
where	O
←	O
indicates	O
the	O
point	O
of	O
attachment	O
to	O
R3	O
;	O
	O
and	O
wherein	O
R1	O
to	O
R19	O
in	O
formula	O
(	O
I	O
)	O
represent	O
independently	O
of	O
each	O
other	O
a	O
variety	O
of	O
different	O
substituents	O
comprising	O
alkyl,	O
aryl,	O
aralkyl,	O
alkylaryl,	O
heteroaryl	O
groups	O
and	O
monofunctional	O
moieties	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors	O
in	O
the	O
treatment	O
of	O
i	O
.	O
a	O
.	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
phosphinic	O
acid	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
aryl	O
or	O
heteroaryl,	O
R2	O
is	O
(	O
C1-C5	O
)	O
-alkyl	O
or	O
phenyl,	O
R3	O
is	O
hydrogen,	O
(	O
C1-C5	O
)	O
-alky,	O
O-	O
(	O
C1-C5	O
)	O
-alkyl	O
or	O
phenyl,	O
R4	O
is	O
(	O
C1-C6	O
)	O
-alkyl,	O
(	O
C3-C6	O
)	O
-cycloalkyl,	O
phenyl,	O
pyridyl	O
or	O
indolyl,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
disease	O
related	O
to	O
the	O
inhibition	O
of	O
beta-secretase,	O
inter	O
alia	O
for	O
the	O
treatment	O
of	O
Alzheimer’s	O
disease	O
.	O


A	O
method	O
to	O
increase	O
the	O
efficiency	O
of	O
transduction	O
of	O
hematopoietic	O
and	O
other	O
cells	O
by	O
retroviruses	O
includes	O
infecting	O
the	O
cells	O
in	O
the	O
presence	O
of	O
fibronectin	B-GENE
or	O
fibronectin	B-GENE
fragments	O
.	O
The	O
fibronectin	B-GENE
and	O
fibronectin	B-GENE
fragments	O
significantly	O
enhance	O
retroviral-mediated	O
gene	O
transfer	O
into	O
the	O
cells,	O
particularly	O
hematopoietic	O
cells	O
including	O
committed	O
progenitors	O
and	O
primitive	O
hematopoietic	O
stem	O
cells	O
.	O
The	O
invention	O
also	O
provides	O
improved	O
methods	O
for	O
somatic	O
gene	O
therapy	O
capitalizing	O
on	O
enhanced	O
gene	O
transfer,	O
hematopoietic	O
cellular	O
populations,	O
and	O
novel	O
constructs	O
for	O
enhancing	O
retroviral-mediated	O
DNA	O
transfer	O
into	O
cells	O
and	O
their	O
use	O
.	O


The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing,	O
as	O
an	O
active	O
ingredient,	O
a	O
compound	O
that	O
specifically	O
binds	O
to	O
KSRP	B-GENE
or	O
a	O
functional	O
fragment	O
thereof,	O
and	O
a	O
screening	O
method	O
for	O
the	O
compound	O
.	O
KSRP	B-GENE
is	O
a	O
novel	O
target	O
protein	O
for	O
anticancer	O
agents	O
;	O
a	O
compound	O
capable	O
of	O
regulating	O
the	O
expression	O
and	O
activity	O
of	O
such	O
a	O
protein	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
it	O
are	O
highly	O
useful	O
for	O
proliferative	O
diseases,	O
particularly	O
as	O
anticancer	O
agents	O
.	O
By	O
providing	O
the	O
novel	O
target	O
protein,	O
the	O
mechanism	O
behind	O
the	O
anticancer	O
effect	O
that	O
has	O
conventionally	O
been	O
unexplainable	O
can	O
be	O
elucidated	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
or	O
inhibiting	O
osteoclast	O
development	O
Induced	O
by	O
the	O
receptor	B-GENE
for	I-GENE
activation	I-GENE
of	I-GENE
nuclear	I-GENE
factor	I-GENE
kappa	I-GENE
B	I-GENE
ligand	I-GENE
(	O
RANKL	B-GENE
)	O
,	O
comprising	O
the	O
step	O
of	O
contacting	O
said	O
osteoclast,	O
or	O
a	O
precursor	O
of	O
the	O
osteoclast,	O
with	O
a	O
pharmacologically	O
effective	O
dose	O
of	O
compounds	O
such	O
as	O
diferuloylmethane,	O
guggulsterone,	O
1	O
'	O
­-Acetoxychavicol	O
or	O
analogues	O
thereof	O
.	O


A	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
is	O
disclosed	O
as	O
an	O
HIV	B-GENE
protease	I-GENE
inhibitor	O
.	O
Methods	O
and	O
compositions	O
for	O
inhibiting	O
an	O
HIV	O
infection	O
are	O
also	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
substituted	O
quinazolinone	O
compunds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
Y	O
is	O
C	O
or	O
S	O
;	O
m	O
is	O
1	O
when	O
Y	O
is	O
C	O
and	O
m	O
is	O
2	O
when	O
Y	O
is	O
S	O
;	O
n	O
is	O
1	O
or	O
2	O
;	O
p	O
is	O
from	O
0	O
to	O
3	O
;	O
q	O
is	O
from	O
1	O
to	O
3	O
;	O
Z	O
is	O
-	O
(	O
CRaRb	O
)	O
r-	O
or	O
-SO2-,	O
wherein	O
r	O
is	O
from	O
0	O
to	O
2	O
and	O
each	O
of	O
Ra	O
and	O
Rb	O
is	O
independently	O
hydrogen	O
or	O
alkyl	O
;	O
X	O
is	O
CH	O
or	O
N	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	O
or	O
optionally	O
substituted	O
heteroaryl	O
;	O
preferably	O
R2	O
is	O
aryl,	O
and	O
more	O
preferably	O
phenyl	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
trifluoromethyl,	O
halo,	O
cyano,	O
C1-C6	O
alkyl	O
or	O
C1-C6	O
alkoxy	O
;	O
A	O
is	O
-NR3-	O
or	O
-O-	O
wherein	O
R3	O
is	O
:	O
hydrogen	O
;	O
alkyl,	O
acyl,	O
amidoalkyl,	O
hydroxyalkyl	O
or	O
alkoxyalkyl	O
;	O
the	O
other	O
substituents	O
are	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
are	O
modulators	O
of	O
the	O
5-hydroxytryptamine	B-GENE
receptor	I-GENE
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
such	O
as	O
psychoses,	O
schizophrenia,	O
manic	O
depressions,	O
neurological	O
disorders,	O
memory	O
disorders,	O
attention	O
deficit	O
disorder,	O
Parkinson’s	O
disease,	O
amyotrophic	O
lateral	O
sclerosis,	O
Alzheimer’s	O
disease,	O
food	O
uptake	O
disorders,	O
and	O
Huntington’s	O
disease	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
certain	O
hydroisoindoline	O
compounds	O
of	O
formula	O
I	O
which	O
are	O
useful	O
as	O
neurokinin-1	B-GENE
(NK-1)	I-GENE
receptor	I-GENE
antagonists,	O
and	O
inhibitors	O
of	O
tachykinin	B-GENE
and	O
in	O
particular	O
substance	B-GENE
P	I-GENE
.	O
The	O
invention	O
is	O
also	O
concerned	O
with	O
pharmaceutical	O
formulations	O
comprising	O
these	O
compounds	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
compounds	O
and	O
their	O
formulations	O
in	O
the	O
treatment	O
of	O
certain	O
disorders,	O
including	O
emesis,	O
urinary	O
incontinence,	O
depression,	O
and	O
anxiety	O
.	O


The	O
present	O
invention	O
includes	O
compounds,	O
comprising	O
a	O
portion	O
capable	O
of	O
converting	O
a	O
substrate,	O
for	O
example	O
ethanol,	O
to	O
acetaldehyde	O
and	O
a	O
means	O
of	O
directing	O
the	O
compounds	O
to	O
selected	O
cells,	O
and	O
their	O
use	O
in	O
therapeutic	O
compositions	O
and	O
methods	O
.	O
The	O
compounds	O
may	O
be	O
administered	O
with	O
the	O
substrate,	O
for	O
example	O
ethanol,	O
and	O
an	O
inhibitor	O
of	O
aldehyde	B-GENE
dehydrogenase	I-GENE
.	O
As	O
an	O
example,	O
acetaldehyde	O
may	O
be	O
produced	O
locally	O
in	O
tumours	O
as	O
a	O
result	O
of	O
the	O
presence	O
of	O
the	O
enzyme	O
alcohol	B-GENE
dehydrogenase	I-GENE
within	O
the	O
tumour	O
targeted	O
there	O
by	O
either	O
antibody	O
delivery	O
systems,	O
liposomes	O
or	O
gene	O
therapy	O
delivery	O
systems,	O
or	O
any	O
other	O
suitable	O
system	O
to	O
allow	O
the	O
localisation	O
of	O
a	O
suitable	O
enzymatically	O
active	O
component	O
at	O
the	O
tumour	O
site	O
.	O
When	O
the	O
substrate	O
is	O
pyruvate	O
(	O
i	O
.	O
e	O
.	O
the	O
portion	O
capable	O
of	O
converting	O
a	O
substrate	O
to	O
acetaldehyde	O
is	O
a	O
catalytically	O
active	O
portion	O
of	O
pyruvate	B-GENE
decarboxylase	I-GENE
)	O
,	O
the	O
substrate	O
may	O
preferably	O
be	O
endogenous,	O
i	O
.	O
e	O
.	O
present	O
naturally	O
in	O
the	O
body,	O
particularly	O
in	O
or	O
in	O
the	O
vicinity	O
of	O
the	O
target	O
cells	O
.	O


This	O
invention	O
describes	O
a	O
method	O
to	O
kill	O
cancer	O
cells	O
by	O
acute	O
elevation	O
of	O
cellular	O
malonyl	O
Coenzyme	O
A	O
(	O
Malonyl	O
CoA	O
)	O
which	O
leads	O
to	O
apoptosis	O
.	O
Elevation	O
of	O
malonyl	O
CoA	O
may	O
be	O
induced	O
by	O
inhibition	O
of	O
fatty	B-GENE
acid	I-GENE
synthase	I-GENE
(	O
FAS	B-GENE
)	O
,	O
or	O
by	O
other	O
manipulation	O
of	O
fatty	B-GENE
acid	I-GENE
metabolism	O
tht	O
does	O
not	O
involve	O
inhibition	O
of	O
FAS	B-GENE
.	O
Alternatively,	O
growth	O
of	O
tumor	O
cells	O
may	O
be	O
induced	O
by	O
a	O
combination	O
of	O
effects	O
including	O
FAS	B-GENE
inhibition	O
in	O
conjunction	O
with	O
other	O
interventions	O
which	O
affect	O
fatty	B-GENE
acid	I-GENE
metabolism,	O
including	O
inhibition	O
of	O
camitine	B-GENE
palmitoyltransferase-1	I-GENE
(	O
CPT-1	B-GENE
)	O
.	O
Any	O
combination	O
of	O
drugs	O
which	O
produces	O
an	O
analogous	O
physiologic	O
effect	O
(	O
s	O
)	O
may	O
be	O
expected	O
to	O
lead	O
to	O
the	O
same	O
effect	O
on	O
susceptible	O
tumor	O
cells	O
.	O
For	O
example,	O
combination	O
therapy	O
with	O
drug	O
(	O
s	O
)	O
that	O
inhibit	O
the	O
fatty	B-GENE
acid	I-GENE
synthesis	O
by	O
inhibiting	O
acetyl	B-GENE
CoA	I-GENE
carboxylase	I-GENE
(	O
the	O
first	O
enzyme	O
in	O
the	O
fatty	B-GENE
acid	I-GENE
synthesis	O
pathway	O
)	O
and	O
drug	O
(	O
s	O
)	O
that	O
inhibit	O
CPT-1	B-GENE
may	O
be	O
expected	O
to	O
induce	O
apoptosis	O
in	O
tumor	O
cells	O
.	O
Therefore,	O
this	O
invention	O
encompasses	O
any	O
method	O
to	O
systemically	O
modify	O
fatty	B-GENE
acid	I-GENE
metabolism	O
in	O
cancer	O
cells	O
including	O
but	O
not	O
limited	O
to	O
direct	O
inhibition	O
of	O
CPT-1	B-GENE
through	O
small	O
molecule	O
inhibitors	O
such	O
as	O
etomoxir,	O
as	O
well	O
as	O
inhibition	O
of	O
CPT-1	B-GENE
incidental	O
to	O
increasing	O
the	O
level	O
of	O
malonyl	O
CoA	O
in	O
cancer	O
cells	O
.	O


Prevention	O
or	O
treatment	O
of	O
cerebral	O
edemas	O
comprises	O
administration	O
of	O
benzamide	O
compounds	O
(	O
I	O
)	O
and	O
their	O
salts	O
.	O
Prevention	O
or	O
treatment	O
of	O
cerebral	O
edemas	O
comprises	O
administration	O
of	O
benzamide	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts	O
.	O
X	O
:	O
O	O
or	O
S,	O
where	O
alkyl	O
chain	O
-	O
(	O
CH2	O
)	O
n-	O
can	O
be	O
linear	O
or	O
branched	O
;	O
a	O
:	O
a	O
single	O
or	O
double	O
bond	O
;	O
n	O
:	O
1-3	O
;	O
b,	O
c	O
:	O
0-1	O
;	O
NR1NH	O
group	O
or	O
a	O
heterocycle	O
with	O
5-6	O
atoms	O
comprising	O
1-2	O
heteroatoms	O
of	O
O	O
or	O
N,	O
heterocycle	O
substituted	O
by	O
at	O
least	O
one	O
hydroxyl	O
or	O
oxide	O
group	O
;	O
and	O
R2-R6H,	O
halo,	O
OH,	O
1-4C	O
alkyl,	O
CF3	O
or	O
NO2	O
.	O
Provided	O
that	O
when	O
b	O
is	O
0	O
then	O
a	O
is	O
a	O
double	O
bond	O
and	O
when	O
b	O
is	O
1	O
then	O
a	O
is	O
single	O
bond	O
;	O
and	O
when	O
NR1	O
is	O
NH	O
then	O
c	O
is	O
1	O
and	O
when	O
NR1	O
is	O
a	O
heterocycle	O
then	O
c	O
is	O
0	O
.	O
An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
composition	O
comprising	O
(	O
I	O
)	O
and	O
a	O
corticoid	O
(	O
preferably	O
glucocorticoid	O
)	O
,	O
glycerol,	O
mannitol,	O
a	O
diuretic	O
(	O
preferably	O
furosemide	O
)	O
,	O
a	O
barbiturate,	O
tetracosactide,	O
an	O
antibiotic,	O
cytidine	O
5	O
'	O
-diphosphocholine,	O
vinpocetine,	O
a	O
calcium	O
inhibitor	O
or	O
an	O
N-methyl-D	O
aspartate	O
antagonist	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Antiinflammatory	O
;	O
Cerebroprotective	O
;	O
Vasotropic	O
.	O
The	O
effect	O
of	O
(	O
I	O
)	O
(	O
moclobemide	O
)	O
was	O
studied	O
on	O
the	O
ambulatory	O
activity	O
disrupted	O
by	O
triethyltin	O
(	O
TET	O
)	O
in	O
the	O
rat	O
.	O
The	O
rat	O
received	O
orally	O
over	O
5	O
days,	O
moclobemide	O
2	O
times	O
per	O
day	O
and	O
TET	O
at	O
3	O
mg	O
/	O
kg	O
/	O
day	O
.	O
The	O
ambulatory	O
activity	O
value	O
of	O
moclobemide	O
(	O
2	O
x	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
844+-88	O
instead	O
of	O
2000+-224	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Monoamine	B-GENE
oxidase	I-GENE
inhibitor	O
.	O


Heterologous	O
lipidated	O
proteins	O
formed	O
recombinantly	O
are	O
disclosed	O
and	O
claimed	O
.	O
The	O
expression	O
system	O
can	O
be	O
E	O
.	O
coli	O
.	O
The	O
heterologous	O
lipidated	O
protein	O
has	O
a	O
leader	O
sequence	O
which	O
does	O
not	O
naturally	O
occur	O
with	O
the	O
protein	O
portion	O
of	O
the	O
lipidated	O
protein	O
.	O
The	O
lipidated	O
protein	O
can	O
have	O
the	O
Borrelia	O
OspA	B-GENE
leader	O
sequence	O
.	O
The	O
protein	O
portion	O
can	O
be	O
OspC,	O
PspA,	O
UreA,	O
UreB,	O
or	O
a	O
fragment	O
thereof	O
.	O
Methods	O
and	O
compositions	O
for	O
forming	O
and	O
employing	O
the	O
proteins	O
are	O
also	O
disclosed	O
and	O
claimed	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
or	O
prodrugs	O
thereof,	O
wherein	O
A,	O
W,	O
X,	O
Y,	O
Z	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O
These	O
compounds	O
inhibit	O
IKK	B-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


Use	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5	O
and	O
R6	O
have	O
the	O
definitions	O
illustrated	O
in	O
detail	O
in	O
the	O
description,	O
as	O
beta-secretase,	O
cathepsin	O
D,	O
plasmepsin	B-GENE
II	I-GENE
and	O
/	O
or	O
HIV	B-GENE
protease	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
that	O
specifically	O
binds	O
to	O
MFP-2	B-GENE
or	O
a	O
functional	O
fragment	O
thereof	O
and	O
a	O
screening	O
method	O
for	O
the	O
compound	O
;	O
the	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
are	O
highly	O
useful	O
as	O
anti-inflammatory	O
agents	O
and	O
anti-allergic	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
1,2,4,5-tetrasubstituted	O
imidazole	O
derivatives	O
as	O
selective	O
cannabinoid	B-GENE
CB1	B-GENE
receptor	I-GENE
modulators,	O
in	O
particular	O
CB1	B-GENE
receptor	I-GENE
antagonists	O
or	O
inverse	O
agonists	O
having	O
a	O
high	O
CB1	B-GENE
/	O
CB2	B-GENE
receptor	I-GENE
subtype	O
selectivity,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
and	O
to	O
novel	O
intermediates	O
useful	O
for	O
the	O
synthesis	O
of	O
said	O
imidazole	O
derivatives	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
disclosed	O
herein	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
giving	O
a	O
beneficial	O
effect	O
.	O
A	O
beneficial	O
effect	O
is	O
disclosed	O
herein	O
or	O
apparent	O
to	O
a	O
person	O
skilled	O
in	O
the	O
art	O
from	O
the	O
specification	O
and	O
general	O
knowledge	O
in	O
the	O
art	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
invention	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
or	O
condition	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
a	O
new	O
use	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
disclosed	O
herein	O
or	O
apparent	O
to	O
a	O
person	O
skilled	O
in	O
the	O
art	O
from	O
the	O
specification	O
and	O
general	O
knowledge	O
in	O
the	O
art	O
.	O
In	O
embodiments	O
of	O
the	O
invention	O
specific	O
compounds	O
disclosed	O
herein	O
are	O
used	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
and	O
neurological	O
disorders	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
altering	O
the	O
fate	O
of	O
a	O
cell,	O
tissue	O
or	O
organ	O
type	O
by	O
altering	O
Notch	B-GENE
pathway	O
function	O
in	O
the	O
cell	O
.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
for	O
altering	O
the	O
fate	O
of	O
a	O
cell,	O
tissue	O
or	O
organ	O
type	O
by	O
simultaneously	O
changing	O
the	O
activation	O
state	O
of	O
the	O
Notch	B-GENE
pathway	O
and	O
one	O
or	O
more	O
cell	O
fate	O
control	O
gene	O
pathways	O
.	O
The	O
invention	O
can	O
be	O
utilized	O
for	O
cells	O
of	O
any	O
differentiation	O
state	O
.	O
The	O
resulting	O
cells	O
may	O
be	O
expanded	O
and	O
used	O
in	O
cell	O
replacement	O
therapy	O
to	O
repopulate	O
lost	O
cell	O
populations	O
and	O
help	O
in	O
the	O
regeneration	O
of	O
diseased	O
and	O
/	O
or	O
injured	O
tissues	O
.	O
The	O
resulting	O
cell	O
populations	O
can	O
also	O
be	O
made	O
recombinant	O
and	O
used	O
for	O
gene	O
therapy	O
or	O
as	O
tissue	O
/	O
organ	O
models	O
for	O
research	O
.	O
The	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
macular	O
degeneration	O
comprising	O
altering	O
Notch	B-GENE
pathway	O
function	O
in	O
retinal	O
pigment	O
epithelium	O
cells	O
or	O
retinal	O
neuropithelium	O
or	O
both	O
tissues	O
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
kits	O
utilizing	O
the	O
methods	O
of	O
the	O
invention	O
to	O
generate	O
cells,	O
tissues	O
or	O
organs	O
of	O
altered	O
fates	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
screening	O
for	O
agonists	O
or	O
antagonists	O
of	O
Notch	B-GENE
or	O
cell	O
fate	O
control	O
gene	O
pathway	O
functions	O
.	O


This	O
invention	O
is	O
concerned	O
with	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
one	O
of	O
R6,	O
R7,	O
R8	O
and	O
R9	O
is	O
formula	O
(	O
II	O
)	O
,	O
and	O
X,	O
R1	O
to	O
R12,	O
m,	O
n	O
and	O
o	O
are	O
as	O
defined	O
in	O
the	O
description,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
/	O
or	O
esters	O
thereof	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds,	O
to	O
a	O
process	O
for	O
their	O
preparation	O
and	O
to	O
their	O
use	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
which	O
are	O
modulated	O
by	O
PPARδ	B-GENE
and	O
/	O
or	O
PPARα	B-GENE
agonists	O
.	O


As	O
suppressor	O
of	O
binding	O
between	O
selectin	B-GENE
binding	O
sugar	O
chain	O
and	O
selectin	B-GENE
or	O
cell	O
killing	O
agent,	O
(	O
1	O
)	O
siRNA	O
suppressing	O
expression	O
of	O
genes	O
which	O
relates	O
to	O
cell	O
surface	O
antigen	O
CD43	B-GENE
and	O
selectin	B-GENE
ligand	O
sugar	O
chain	O
by	O
RNA	O
interference	O
;	O
(	O
2	O
)	O
an	O
inhibitor	O
of	O
sugar	O
chain	O
synthesis	O
such	O
as	O
analogue	O
of	O
substrates	O
in	O
sugar	O
chain	O
synthesis	O
;	O
(	O
3	O
)	O
an	O
enzyme	O
severing	O
cell	O
surface	O
antigen	O
CD43	B-GENE
and	O
selectin	B-GENE
ligand	O
sugar	O
chain	O
;	O
and	O
(	O
4	O
)	O
antibodies	O
of	O
cell	O
surface	O
antigen	O
CD43	B-GENE
and	O
selectin	B-GENE
ligand	O
sugar	O
chain	O
are	O
used	O
to	O
selectin	B-GENE
ligand	O
sugar	O
chain	O
expressed	O
in	O
cell	O
surface	O
antigen	O
CD43	B-GENE
to	O
provide	O
a	O
suppressor	O
of	O
infiltration	O
which	O
is	O
able	O
to	O
suppression	O
of	O
infiltration	O
to	O
tissues	O
by	O
leukocytes	O
and	O
a	O
method	O
of	O
suppression	O
thereof,	O
and	O
a	O
cell	O
killing	O
agent	O
of	O
CD43	B-GENE
expressing	O
cell	O
and	O
a	O
cell	O
killing	O
method	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
represents	O
H,	O
CF3	O
;	O
R1	O
represents	O
H,	O
CF3,	O
a	O
(	O
C1-C6	O
)	O
-alkyl,	O
a	O
phenyl,	O
a	O
phenoxy	O
;	O
R2	O
represents	O
H,	O
a	O
(	O
C1-C4	O
)	O
-alkyl,	O
O-	O
(	O
C1-C4	O
)	O
-alkyl,	O
CF3	O
;	O
or	O
R1	O
and	O
R2	O
represent,	O
together	O
with	O
the	O
phenyl-ring,	O
a	O
condensed	O
naphthyl	O
;	O
R3	O
represents	O
a	O
(	O
C1-C6	O
)	O
-alkyl	O
;	O
R4	O
represents	O
a	O
(	O
C1-C6	O
)	O
-alkyl,	O
benzyl	O
;	O
R5	O
represents	O
H,	O
a	O
(	O
C1-C6	O
)	O
-alkyl	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
physiologically	O
compatible	O
salts	O
thereof,	O
solvates	O
and	O
physiologically	O
functional	O
derivatives	O
.	O
The	O
inventive	O
compounds	O
are	O
suitable	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
disorders	O
of	O
the	O
fatty	O
acid	O
metabolism	O
and	O
disorders	O
of	O
glucose	O
utilization	O
in	O
addition	O
to	O
disorders,	O
in	O
which	O
insulin	B-GENE
resistance	O
plays	O
a	O
part	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1-9,	O
Z,	O
n,	O
X,	O
A,	O
and	O
Rb	O
have	O
the	O
meaning	O
as	O
cited	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O
Said	O
compounds	O
are	O
useful	O
as	O
DPP-IV	B-GENE
inhibitors	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
such	O
compounds	O
as	O
well	O
as	O
the	O
production	O
and	O
use	O
thereof	O
as	O
medicament	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus,	O
obesity	O
and	O
lipid	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
2-substituted-1	O
-deaza	O
purine	O
derivatives	O
as	O
adenosine	B-GENE
receptor	I-GENE
modulating	O
agents,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
and	O
to	O
novel	O
intermediates	O
useful	O
for	O
the	O
synthesis	O
of	O
sai	O
d	O
purine	O
derivatives	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O


An	O
antipsychotic	O
and	O
GlyT1	B-GENE
inhibitor	O
combination	O
is	O
disclosed	O
.	O
The	O
antipsychotic	O
and	O
GlyT1	B-GENE
inhibitor	O
combination	O
may	O
be	O
employed	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
symptoms	O
of	O
schizophrenia	O
.	O
Pharmaceutical	O
compositions	O
and	O
treatments	O
comprising	O
an	O
antipsychotic	O
and	O
a	O
GlyT1	B-GENE
inhibitor	O
for	O
treating	O
symptoms	O
of	O
schizophrenia	O
are	O
thus	O
also	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
chemical	O
compounds,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
(	O
A	O
chemical	O
formula	O
should	O
be	O
inserted	O
here	O
-	O
please	O
see	O
paper	O
copy	O
enclosed	O
herewith	O
)	O
(	O
I	O
)	O
which	O
possess	O
B	B-GENE
Raf	I-GENE
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
for	O
their	O
anti	O
cancer	O
activity	O
and	O
thus	O
in	O
methods	O
of	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
chemical	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
of	O
use	O
in	O
the	O
production	O
of	O
an	O
anti-cancer	O
effect	O
in	O
a	O
warm	O
blooded	O
animal	O
such	O
as	O
man	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
when	O
X	O
is	O
NR5,	O
Y	O
is	O
absent	O
or	O
is	O
CH2	O
;	O
when	O
X	O
is	O
CH2,	O
Y	O
is	O
absent,	O
CH2,	O
NR6,	O
O,	O
S,	O
S	O
(	O
O	O
)	O
or	O
S	O
(	O
O	O
)	O
2	O
;	O
Z	O
is	O
a	O
5-	O
or	O
6-membered	O
heterocyclyl	O
ring	O
;	O
compositions	O
comprising	O
them,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
in	O
medical	O
therapy	O
(	O
for	O
example	O
modulating	O
CCR5	B-GENE
receptor	O
activity	O
in	O
a	O
warm	O
blooded	O
animal	O
)	O
.	O


ABSTRACT	O
The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
quinoline	O
derivatives,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
related	O
to	O
ion	O
channels	O
such	O
as	O
potassium	B-GENE
channels	I-GENE
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
certain	O
novel	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
X	O
and	O
R1	O
to	O
R10	O
are	O
as	O
described	O
in	O
the	O
specification,	O
and	O
where	O
either	O
R5	O
is	O
OH,	O
-NRdORa	O
or	O
NRd-NRbRc,	O
or	O
R7	O
is	O
-NRdORa	O
or	O
NRd-NRbRc,	O
or	O
C	O
=	O
R7R8	O
is	O
C	O
=	O
NORa	O
or	O
C	O
=	O
N-NRbRc,	O
which	O
may	O
be	O
useful	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
for	O
treating	O
disorders	O
mediated	O
by	O
lipoxygenases	B-GENE
.	O
They	O
may	O
also	O
be	O
useful	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
formulations	O
for	O
the	O
treatment	O
of	O
lipoxygenase	B-GENE
mediated	O
disorders	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
wherein	O
R1,	O
R3,	O
R4,	O
R5,	O
R6,	O
R14,	O
X,	O
W	O
and	O
Z	O
are	O
as	O
defined	O
in	O
the	O
specification	O
and	O
optical	O
isomers,	O
racemates	O
and	O
tautomers	O
thereof,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
human	O
neutrophil	B-GENE
elastase	I-GENE
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
compound	O
useful	O
as	O
a	O
GnRH	B-GENE
receptor	O
antagonist	O
.	O
The	O
inventors	O
further	O
investigated	O
propane-1,3-dione	O
derivatives	O
.	O
As	O
a	O
result,	O
they	O
confirmed	O
that	O
a	O
compound	O
having	O
a	O
benzene	O
ring	O
or	O
a	O
thiophene	O
ring	O
substituted	O
with	O
a	O
group	O
represented	O
by	O
-SO2-R3	O
in	O
a	O
propane-1,3-dione	O
derivative	O
having	O
2-	O
(	O
1,3-dihydro-2H-benzimidazol-2-ylidene	O
)	O
has	O
an	O
excellent	O
GnRH	B-GENE
receptor	O
antagonistic	O
effect	O
and	O
accomplished	O
the	O
present	O
invention	O
.	O
Because	O
the	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
potent	O
GnRH	B-GENE
receptor	O
antagonistic	O
effect,	O
it	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
sex	O
hormone-dependent	O
diseases,	O
particularly	O
GnRH-related	O
diseases	O
.	O
Further,	O
because	O
the	O
compound	O
of	O
the	O
present	O
invention	O
has	O
an	O
excellent	O
metabolic	O
stability	O
in	O
human	O
and	O
few	O
drug	O
interactions,	O
therefore	O
it	O
has	O
preferable	O
characteristics	O
as	O
a	O
pharmaceutical	O
used	O
for	O
the	O
above-mentioned	O
diseases	O
.	O


The	O
invention	O
is	O
a	O
method	O
of	O
treatment	O
of	O
the	O
symptoms	O
related	O
to	O
inflammation	O
that	O
accompanies	O
the	O
release	O
of	O
Tumor	B-GENE
Necrosis	I-GENE
Factor	I-GENE
-	I-GENE
alpha	I-GENE
in	O
diseases	O
such	O
as	O
viral	O
infection	O
such	O
as	O
those	O
affecting	O
the	O
respiratory	O
tract	O
by	O
providing	O
systemic	O
glutathione	O
(	O
reduced	O
)	O
by	O
oral	O
administration	O
of	O
glutathione	O
(	O
reduced	O
)	O
in	O
a	O
liposome	O
encapsulation	O
or	O
by	O
the	O
intravenous	O
administration	O
of	O
reduced	O
glutathione	O
.	O
The	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
oral	O
liposomal	O
glutathione	O
(	O
reduced	O
)	O
results	O
in	O
improvement	O
of	O
symptoms	O
of	O
disease	O
induced	O
by	O
the	O
release	O
of	O
TNF-	B-GENE
a	I-GENE
in	O
infectious	O
disease	O
states	O
such	O
as	O
respiratory	O
and	O
other	O
viruses	O
.	O
The	O
product	O
is	O
novel	O
in	O
that	O
it	O
is	O
stable	O
across	O
the	O
temperature	O
ranges	O
encountered	O
in	O
shipping	O
and	O
does	O
not	O
need	O
to	O
be	O
refrigerated	O
for	O
storage	O
.	O
Compounds	O
enhancing	O
the	O
effect	O
of	O
the	O
liposomal	O
glutathione	O
as	O
well	O
as	O
intravenous	O
glutathione	O
are	O
contemplated	O
such	O
as	O
Selenium	O
.	O


Pharmaceutical	O
composition	O
for	O
oral	O
administration	O
comprises	O
ethyl	O
3-	O
(	O
2-	O
(	O
4-	O
(	O
hexyloxycarbonylamidino	O
)	O
phenylaminomethyl	O
)	O
-1-methyl-1H-benzi	O
midazole-5-carbonyl	O
)	O
-2-pyridylamino	O
)	O
propionate	O
(	O
I	O
)	O
,	O
or	O
a	O
salt	O
of	O
(	O
I	O
)	O
,	O
and	O
an	O
organic	O
acid	O
(	O
II	O
)	O
with	O
a	O
water-solubility	O
of	O
more	O
than	O
1	O
g	O
/	O
250	O
ml	O
at	O
20	O
[	O
deg	O
]	O
C	O
.	O
Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
(	O
1	O
)	O
production	O
of	O
such	O
a	O
composition	O
by	O
forming	O
cores	O
from	O
(	O
II	O
)	O
,	O
optionally	O
with	O
addition	O
of	O
binders	O
or	O
other	O
additives,	O
by	O
:	O
(	O
a	O
)	O
granulation,	O
pelletization	O
or	O
extrusion	O
/	O
spheronization	O
;	O
(	O
b	O
)	O
coating	O
the	O
cores	O
with	O
an	O
insulating	O
layer	O
comprising	O
a	O
water-soluble	O
polymer	O
and	O
optionally	O
plasticizer,	O
release	O
agent	O
and	O
/	O
or	O
pigment	O
;	O
(	O
c	O
)	O
applying	O
a	O
dispersion	O
containing	O
(	O
I	O
)	O
,	O
binder	O
and	O
optionally	O
release	O
agent	O
and	O
simultaneously	O
or	O
subsequently	O
drying	O
the	O
dispersion	O
;	O
(	O
d	O
)	O
optionally	O
applying	O
a	O
coating	O
of	O
film	O
former,	O
plasticizer	O
and	O
optionally	O
pigment	O
;	O
and	O
(	O
e	O
)	O
filling	O
hard	O
capsules	O
with	O
the	O
resulting	O
pellets	O
;	O
(	O
2	O
)	O
the	O
methanesulfonate	O
salt	O
of	O
(	O
I	O
)	O
.	O
-	O
ACTIVITY	O
:	O
Anticoagulant	O
.	O
Hard	O
gelatin	O
capsules	O
were	O
filled	O
with	O
pellets	O
comprising	O
a	O
core	O
of	O
tartaric	O
acid	O
(	O
61	O
.	O
3	O
wt	O
.	O
pts	O
.	O
)	O
and	O
gum	O
arabic	O
(	O
3	O
.	O
1	O
wt	O
.	O
pts	O
.	O
)	O
,	O
an	O
insulating	O
layer	O
of	O
gum	O
arabic	O
(	O
2	O
.	O
8	O
wt	O
.	O
pts	O
.	O
)	O
and	O
talc	O
(	O
5	O
.	O
6	O
wt	O
.	O
pts	O
.	O
)	O
and	O
a	O
drug	O
layer	O
of	O
talc	O
(	O
3	O
.	O
2	O
wt	O
.	O
pts	O
.	O
)	O
,	O
hydroxypropyl	O
cellulose	O
(	O
4	O
wt	O
.	O
pts	O
.	O
)	O
and	O
ethyl	O
3-	O
(	O
2-	O
(	O
4-	O
(	O
hexyloxycarbonylamidino	O
)	O
phenylaminomethyl	O
)	O
-1-methyl-1H-benzimidazole-5-carbonyl	O
)	O
-2-pyridylamino	O
)	O
propionate	O
mesylate	O
(	O
20	O
wt	O
.	O
pts	O
.	O
)	O
.	O
The	O
capsules	O
contained	O
57	O
.	O
7	O
mg	O
of	O
the	O
mesylate,	O
corresponding	O
to	O
50	O
mg	O
drug	O
free	O
base	O
.	O
In	O
clinical	O
trials,	O
the	O
relative	O
bioavailability	O
in	O
subjects	O
treated	O
with	O
pantoprazol	O
to	O
raise	O
their	O
gastric	O
pH	O
compared	O
with	O
subjects	O
not	O
so	O
treated	O
was	O
94	O
%	O
,	O
compared	O
with	O
18	O
%	O
for	O
conventional	O
tablets	O
not	O
containing	O
tartaric	O
acid	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Thrombin	B-GENE
inhibitor	O
.	O


The	O
invention	O
provides	O
novel	O
compounds	O
of	O
formulae	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
:	O
that	O
are	O
monoamine	B-GENE
oxidase-B	I-GENE
inhibitors,	O
which	O
can	O
be	O
useful	O
in	O
treating	O
obesity,	O
diabetes,	O
and	O
/	O
or	O
cardiometabolic	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
hypertension,	O
dyslipidemias,	O
high	O
blood	O
pressure,	O
and	O
insulin	B-GENE
resistance	O
)	O
.	O


The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
inhibiting	O
FLT3	B-GENE
tyrosine	O
kinase	O
activity	O
or	O
expression	O
or	O
reducing	O
FLT3	B-GENE
kinase	O
activity	O
or	O
expression	O
in	O
a	O
cell	O
or	O
a	O
subject	O
comprising	O
the	O
administration	O
of	O
a	O
farnesyl	O
transferase	O
inhibitor	O
and	O
a	O
FLT3	B-GENE
kinase	O
inhibitor	O
selected	O
from	O
aminoquinoline	O
and	O
aminoquinazoline	O
compounds	O
of	O
Formula	O
(	O
I’	O
)	O
:	O
where	O
R1,	O
R2,	O
R3,	O
B,	O
Z,	O
Q,	O
p,	O
q	O
and	O
X	O
are	O
as	O
defined	O
herein	O
.	O
Included	O
within	O
the	O
present	O
invention	O
is	O
both	O
prophylactic	O
and	O
therapeutic	O
methods	O
for	O
treating	O
a	O
subject	O
at	O
risk	O
of	O
(	O
or	O
susceptible	O
to	O
)	O
developing	O
a	O
cell	O
proliferative	O
disorder	O
or	O
a	O
disorder	O
related	O
to	O
FLT3	B-GENE
.	O


This	O
invention	O
relates	O
to	O
compounds	O
which	O
bind	O
to	O
serotonin	B-GENE
receptors	I-GENE
inside	O
or	O
outside	O
the	O
central	O
nervous	O
system,	O
in	O
particular	O
compounds	O
which	O
bind	O
to	O
the	O
5-HT2	B-GENE
or	O
5-HT7	B-GENE
receptors,	O
their	O
preparation	O
and	O
use,	O
compositions	O
containing	O
them,	O
and	O
methods	O
of	O
treatment	O
using	O
them	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
E	O
is	O
an	O
optionally	O
substituted	O
cyclic	O
group	O
;	O
D	O
is	O
a	O
carbonyl	O
group	O
or	O
a	O
sulfonyl	O
group	O
;	O
A	O
is	O
CH	O
or	O
N	O
;	O
ring	O
P	O
is	O
an	O
optionally	O
further	O
substituted	O
5-	O
to	O
7-membered	O
ring	O
;	O
ring	O
Q	O
is	O
an	O
optionally	O
further	O
substituted	O
5-	O
to	O
7-membered	O
nonaromatic	O
ring	O
;	O
and	O
ring	O
R	O
is	O
an	O
optionally	O
further	O
substituted	O
and	O
optionally	O
condensed	O
5-	O
to	O
7-membered	O
nonaromatic	O
ring,	O
or	O
a	O
salt	O
thereof	O
.	O
The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
an	O
ACC	B-GENE
inhibitory	O
activity,	O
is	O
useful	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
obesity,	O
diabetes,	O
hypertension,	O
hyperlipidemia,	O
cardiac	O
failure,	O
diabetic	O
complications,	O
metabolic	O
syndrome,	O
sarcopenia	O
and	O
the	O
like,	O
and	O
has	O
superior	O
properties	O
in	O
the	O
efficacy,	O
duration	O
of	O
activity,	O
specificity,	O
low	O
toxicity	O
and	O
the	O
like	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
were	O
synthesized	O
.	O
They	O
were	O
found	O
to	O
down-	O
regulate	O
or	O
inhibit	O
the	O
expression	O
or	O
function	O
of	O
the	O
IGF-I	B-GENE
receptor	I-GENE
.	O


The	O
invention	O
provides	O
activator	O
compounds	O
for	O
improving	O
attentive	O
cognition	O
comprising	O
administering	O
a	O
compound	O
that	O
potentiates	O
intraneuronal	O
carbonic	B-GENE
anhydrase	I-GENE
activity	O
thereby	O
improving	O
establishment	O
of	O
a	O
theta	O
rhythm	O
.	O


A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof,	O
an	O
N-oxide	O
thereof,	O
a	O
solvate	O
thereof,	O
or	O
a	O
prodrug	O
thereof	O
:	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
X,	O
Y,	O
and	O
W	O
each	O
independently	O
represent	O
a	O
carbon	O
atom	O
or	O
a	O
nitrogen	O
atom	O
;	O
Z	O
represents	O
CH	O
or	O
a	O
nitrogen	O
atom	O
;	O
R1	O
represents	O
(	O
1	O
)	O
C3-10	O
branched	O
alkyl	O
which	O
may	O
be	O
substituted	O
or	O
(	O
2	O
)	O
-	O
(	O
CH2	O
)	O
m-NR4R5	O
;	O
R2	O
and	O
R3	O
each	O
independently	O
represent	O
(	O
1	O
)	O
a	O
hydrogen	O
atom,	O
(	O
2	O
)	O
C1-4	O
alkyl	O
which	O
may	O
be	O
substituted	O
with	O
a	O
halogen	O
atom,	O
hydroxy	O
which	O
may	O
be	O
protected,	O
amino	O
which	O
may	O
be	O
protected,	O
or	O
carboxyl	O
which	O
may	O
be	O
protected,	O
(	O
3	O
)	O
C2-4	O
alkenyl,	O
(	O
4	O
)	O
C2-4	O
alkynyl,	O
(	O
5	O
)	O
nitrile,	O
(	O
6	O
)	O
COOR6,	O
(	O
7	O
)	O
CONR7R8,	O
(	O
8	O
)	O
COR101,	O
(	O
9	O
)	O
S	O
(	O
O	O
)	O
nR102,	O
or	O
(	O
10	O
)	O
a	O
halogen	O
atom,	O
in	O
which	O
R6	O
represents	O
a	O
hydrogen	O
atom	O
or	O
C1-4	O
alkyl,	O
R7	O
and	O
R8	O
each	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
C1-4	O
alkyl,	O
R101	O
represents	O
a	O
hydrogen	O
atom	O
or	O
C1-4	O
alkyl,	O
R102	O
represents	O
C1-4	O
alkyl,	O
n	O
represents	O
1	O
or	O
2	O
;	O
and	O
Ar	O
represents	O
an	O
aromatic	O
ring	O
which	O
may	O
be	O
substituted,	O
is	O
useful	O
as	O
a	O
pharmacologically	O
active	O
ingredient	O
having	O
a	O
CRF	B-GENE
antagonist	O
action	O
in	O
preventing	O
and	O
/	O
or	O
treating	O
neuropsychiatric	O
diseases,	O
diseases	O
of	O
peripheral	O
organs	O
or	O
the	O
like	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
all	O
of	O
the	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
in	O
free	O
form	O
or	O
in	O
salt	O
form,	O
to	O
their	O
preparation,	O
to	O
their	O
use	O
as	O
medicaments	O
and	O
to	O
medicaments	O
comprising	O
them	O
.	O
The	O
compounds	O
(	O
I	O
)	O
are	O
antagonists	O
of	O
VRl	B-GENE
receptors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
mGluRl	B-GENE
and	O
niGluR5	B-GENE
receptor	O
subtype	O
preferring	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
X	O
represents	O
a	O
group	O
selected	O
from	O
(	O
CH2	O
)	O
n,	O
CH	O
=	O
CH,	O
NH,	O
N	O
(	O
CH3	O
)	O
,	O
NHCH2,	O
N	O
(	O
CH3	O
)	O
CH2,	O
O,	O
OCH2,	O
CH2COO,	O
NHCH2COO	O
;	O
n	O
is	O
an	O
integer	O
of	O
O	O
to	O
2	O
;	O
Y	O
represents	O
a	O
subtituent	O
selected	O
from	O
H,	O
CH3,	O
F,	O
Cl,	O
Br	O
;	O
Z	O
is	O
H	O
or	O
CH3	O
;	O
R	O
is	O
alkyl,	O
cycloalkyl,	O
an	O
optionally	O
substituted	O
phenyl	O
or	O
an	O
optionally	O
substituted	O
heteroaryl,	O
and	O
/	O
or	O
geometric	O
isomers	O
and	O
/	O
or	O
salts	O
and	O
/	O
or	O
hydrates	O
and	O
/	O
or	O
solvates	O
thereof,	O
to	O
the	O
processes	O
for	O
producing	O
the	O
same,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
and	O
to	O
their	O
use	O
in	O
therapy	O
and	O
/	O
or	O
prevention	O
of	O
pathological	O
conditions	O
which	O
require	O
the	O
modulation	O
of	O
mGluRl	B-GENE
mGluR5	B-GENE
receptors	O
such	O
as	O
neurological	O
disorders,	O
psychiatric	O
disorders,	O
acute	O
and	O
chronic	O
pain	O
and	O
neuromuscular	O
dysfunctions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
improving	O
the	O
pharmacokinetics	O
of	O
an	O
HIV	B-GENE
integrase	I-GENE
inhibiting	O
compound	O
by	O
administering	O
food	O
and	O
/	O
or	O
ritonavir	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
with	O
the	O
HIV	B-GENE
integrase	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein,	O
Y	O
is	O
a	O
methylene	O
group,	O
and	O
the	O
like	O
;	O
A	O
is	O
an	O
optionally	O
substituted	O
heterocyclic	O
group,	O
and	O
the	O
like	O
;	O
B	O
is	O
an	O
optionally	O
substituted	O
heterocyclic	O
group,	O
and	O
the	O
like	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
alkyl	O
group,	O
wherein	O
the	O
alkyl	O
group	O
further	O
may	O
optionally	O
be	O
substituted	O
by	O
an	O
optionally	O
substituted	O
homocyclic	O
group,	O
and	O
the	O
like	O
;	O
and	O
R2	O
is	O
an	O
optionally	O
substituted	O
amino	O
group,	O
and	O
the	O
like	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof,	O
which	O
has	O
an	O
inhibitory	O
activity	O
against	O
cholesteryl	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
(	O
CETP	B-GENE
)	O
,	O
thereby	O
being	O
useful	O
for	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
arteriosclerotic	O
diseases,	O
hyperlipemia	O
or	O
dyslipidemia,	O
and	O
the	O
like	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
identifying	O
peptide	O
epitopes	O
that	O
activate	O
CD4+	O
T	O
cells	O
involved	O
in	O
the	O
pathogenesis	O
of	O
diseases,	O
e	O
.	O
g	O
.	O
,	O
autoimmune	O
disease,	O
susceptibility	O
to	O
which	O
is	O
determined	O
by	O
expression	O
of	O
particular	O
class	B-GENE
II	I-GENE
MHC	I-GENE
genes	O
.	O
The	O
invention	O
includes	O
peptides	O
derived	O
from	O
the	O
IA-2	B-GENE
polypeptide	O
by	O
such	O
a	O
method,	O
altered	O
peptide	O
ligands,	O
and	O
methods	O
of	O
therapy	O
involving	O
the	O
use	O
of	O
altered	O
peptide	O
legends	O
.	O


This	O
invention	O
provides	O
α-glucosidase	B-GENE
inhibitors	O
isolated	O
from	O
Oroxylum	O
indicum	O
an	O
Indian	O
medicinal	O
plant	O
.	O
Particularly,	O
this	O
invention	O
provides	O
hexane	O
and	O
acetone	O
fraction	O
of	O
Oroxylum	O
indicum	O
wherein	O
the	O
hexane	O
fraction	O
comprises	O
α-glucosidase	B-GENE
active	O
compounds	O
of	O
oroxylin	O
A,	O
chrysin	O
and	O
baicalain	O
and	O
acetone	O
fraction	O
comprises	O
the	O
compounds	O
of	O
oroxylin	O
A,	O
chrysin,	O
baicalain,	O
methoxy	O
chrysin	O
and	O
oroxyloside	O
methyl	O
ester	O
.	O
This	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
isolation	O
of	O
α-glucosidase	B-GENE
inhibitory	O
active	O
compounds	O
from	O
the	O
above	O
said	O
hexane	O
and	O
acetone	O
fraction	O
of	O
Oroxylum	O
indicum	O
.	O
This	O
invention	O
also	O
provides	O
the	O
use	O
of	O
potent	O
intestinal	B-GENE
α-glucosidase	B-GENE
inhibitors	O
as	O
active	O
ingredients	O
that	O
can	O
be	O
used	O
in	O
pharmaceuticals,	O
food	O
products,	O
health	O
foods	O
and	O
specialized	O
health	O
care	O
foods	O
as	O
anti	O
hyperglycemic	O
agent	O
for	O
prevention	O
and	O
treatment	O
of	O
post	O
prandial	O
hyperglycemia,	O
hyperglycemia	O
and	O
related	O
conditions	O
in	O
diabetes	O
mellitus,	O
obesity	O
and	O
disease	O
conditions	O
requiring	O
hyperglycemic	O
control	O
as	O
well	O
as	O
inhibition	O
of	O
α-glucosidase	B-GENE
activity	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
tetracyclic	O
indole	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
either	O
as	O
in	O
vivo	O
imaging	O
agents	O
or	O
as	O
therapeutic	O
agents	O
.	O
A	O
method	O
for	O
the	O
preparation	O
of	O
the	O
in	O
vivo	O
imaging	O
agent	O
compound	O
is	O
also	O
provided	O
by	O
the	O
invention,	O
as	O
well	O
as	O
a	O
precursor	O
for	O
use	O
in	O
said	O
method	O
.	O
Pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
additionally	O
provided	O
.	O
Where	O
the	O
pharmaceutical	O
composition	O
comprises	O
a	O
compound	O
suitable	O
for	O
in	O
vivo	O
imaging,	O
a	O
kit	O
is	O
provided	O
for	O
the	O
preparation	O
of	O
the	O
pharmaceutical	O
composition	O
.	O
In	O
a	O
further	O
aspect,	O
use	O
of	O
the	O
compound	O
for	O
in	O
vivo	O
imaging	O
or	O
treatment	O
of	O
conditions	O
associated	O
with	O
PBR	B-GENE
is	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
wherein	O
R1	O
is	O
-	O
(	O
CH2	O
)	O
n-aryl	O
or	O
-	O
(	O
CH2	O
)	O
n-heteroaryl,	O
wherein	O
such	O
groups	O
are	O
unsubstituted	O
or	O
substituted	O
by	O
one	O
or	O
more	O
substituents,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen,	O
lower	O
alkyl	O
substituted	O
by	O
halogen,	O
lower	O
alkoxy,	O
lower	O
alkyl,	O
cyano,	O
nitro,	O
-O-lower	O
alkyl	O
substituted	O
by	O
halogen	O
or	O
morpholinyl	O
;	O
R2	O
is	O
-	O
(	O
CH2	O
)	O
n-aryl	O
or	O
-	O
(	O
CH2	O
)	O
n-heteroaryl,	O
wherein	O
such	O
groups	O
are	O
unsubstituted	O
or	O
substituted	O
by	O
one	O
or	O
more	O
substituents,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lower	O
alkyl,	O
lower	O
alkoxy,	O
halogen	O
or	O
-N	O
(	O
lower	O
alkyl	O
)	O
2	O
;	O
R3	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
R4	O
is	O
-	O
(	O
CH2	O
)	O
n-aryl	O
or	O
-	O
(	O
CH2	O
)	O
n-heteroaryl,	O
wherein	O
such	O
groups	O
are	O
unsubstituted	O
or	O
substituted	O
by	O
one	O
or	O
more	O
substituents,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
or	O
lower	O
alkoxy,	O
or	O
is	O
lower	O
alkyl,	O
-	O
(	O
CH2	O
)	O
n-cycloalkyl	O
;	O
or	O
R3	O
and	O
R4	O
form	O
together	O
with	O
the	O
N-atom	O
a	O
heterocyclic	O
ring	O
;	O
n	O
is	O
0,	O
1	O
or	O
2	O
;	O
and	O
to	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O
It	O
has	O
been	O
found	O
that	O
the	O
compounds	O
of	O
general	O
formula	O
I	O
or	O
their	O
tautomeric	O
forms	O
are	O
good	O
inhibitors	O
of	O
the	O
glycine	B-GENE
transporter	I-GENE
1	I-GENE
(	O
GIyT-1	B-GENE
)	O
,	O
and	O
that	O
they	O
have	O
a	O
good	O
selectivity	O
to	O
glycine	B-GENE
transporter	I-GENE
2	I-GENE
(	O
GIyT-2	B-GENE
)	O
inhibitors,	O
useful	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
metal	O
complexes	O
of	O
formulae	O
(	O
I	O
)	O
,	O
(	O
IIa	O
)	O
or	O
(	O
IIb	O
)	O
which	O
interaction	O
with	O
quadruplex	O
DNA	O
and	O
act	O
as	O
inhibitors	O
of	O
telomerase	B-GENE
activity,	O
the	O
synthesis	O
of	O
these	O
complexes	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
substance	O
characterised	O
by	O
the	O
general	O
structural	O
formula	O
(	O
I	O
)	O
for	O
producing	O
an	O
agent	O
that	O
inhibits	O
enzymatic	O
activity	O
of	O
the	O
NO-synthase,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
/	O
or	O
R5	O
represent	O
hydrogen,	O
an	O
alkyl	O
group,	O
an	O
aryl	O
group	O
or	O
a	O
heterocyclic	O
group	O
and	O
n	O
is	O
2	O
or	O
3	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
are	O
inhibitors	O
of	O
MARK,	O
and	O
hence	O
useful	O
for	O
treatment	O
of	O
disorders	O
involving	O
10	O
hyperphosphorylation	O
of	O
tau	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
having	O
an	O
excellent	O
inhibitory	O
action	O
on	O
activation	O
of	O
STAT6	B-GENE
and	O
a	O
pharmaceutical	O
composition	O
thereof	O
.	O
In	O
particular,	O
it	O
provides	O
a	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
them	O
.	O
	O
	O
	O
	O
	O
	O
	O
In	O
the	O
formula,	O
the	O
groups	O
X,Y,Z,R1-R4	O
and	O
n	O
are	O
defined	O
as	O
in	O
claim	O
1	O
.	O


This	O
invention	O
relates	O
to	O
a	O
composition	O
suitable	O
for	O
use	O
in	O
the	O
prevention	O
of	O
secondary	O
infections	O
following	O
a	O
viral	O
infection	O
characterised	O
by	O
neuraminidase	B-GENE
activity	O
comprising	O
a	O
sialylated	O
oligosaccharide	O
and	O
N-acetyl-lactosamine	O
and	O
/	O
or	O
an	O
oligosaccharide	O
containing	O
N-acetyl-lactosamine	O
The	O
invention	O
further	O
extends	O
to	O
the	O
use	O
of	O
such	O
a	O
composition	O
in	O
the	O
prevention	O
of	O
secondary	O
infections	O
such	O
as	O
otitis	O
media	O
.	O


The	O
present	O
application	O
describes	O
modulators	O
of	O
MIP-1α	B-GENE
or	O
CCR-1	B-GENE
of	O
formula	O
(	O
I	O
)	O
or	O
stereoisomers	O
or	O
prodrugs	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
n,	O
ring	O
A,	O
T,	O
V,	O
X,	O
R1,	O
R2	O
and	O
R8,	O
are	O
defined	O
herein	O
.	O
In	O
addition,	O
methods	O
of	O
treating	O
and	O
preventing	O
inflammatory	O
diseases	O
such	O
as	O
asthma	O
and	O
allergic	O
diseases,	O
as	O
well	O
as	O
autoimmune	O
pathologies	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
transplant	O
rejection	O
using	O
modulators	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
.	O


This	O
invention	O
concerns	O
sulfonylpyrazoline	O
carboxamidine	O
derivatives	O
as	O
antagonists	O
of	O
5-HT6	B-GENE
receptors,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
and	O
to	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compounds	O
and	O
compositions,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
chorea,	O
schizophrenia,	O
anxiety,	O
depression,	O
manic	O
depression,	O
psychoses,	O
epilepsy,	O
obsessive	O
compulsive	O
disorders,	O
mood	O
disorders,	O
migraine,	O
Alzheimer	O
'	O
s	O
disease,	O
age	O
related	O
cognitive	O
decline,	O
mild	O
cognitive	O
impairment,	O
sleep	O
disorders,	O
eating	O
disorders,	O
anorexia,	O
bulimia,	O
binge	O
eating	O
disorders,	O
panic	O
attacks,	O
akathisia,	O
attention	O
deficit	O
hyperactivity	O
disorder,	O
attention	O
deficit	O
disorder,	O
withdrawal	O
from	O
abuse	O
of	O
cocaine,	O
ethanol,	O
nicotine	O
or	O
benzodiazepines,	O
pain,	O
disorders	O
associated	O
with	O
spinal	O
trauma	O
or	O
head	O
injury,	O
hydrocephalus,	O
functional	O
bowel	O
disorder,	O
Irritable	O
Bowel	O
Syndrome,	O
obesity	O
and	O
type-2	O
diabetes	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O


A	O
small	O
nucleic	O
acid	O
molecule	O
that	O
down-regulates	O
expression	O
of	O
Wrap53	B-GENE
gene	O
via	O
RNA	O
interference	O
(	O
RNAi	O
)	O
,	O
wherein	O
at	O
least	O
one	O
strand	O
of	O
said	O
small	O
nucleic	O
acid	O
molecule	O
is	O
about	O
15	O
to	O
about	O
30	O
nucleotides	O
in	O
length	O
;	O
and	O
wherein	O
at	O
least	O
one	O
strand	O
of	O
said	O
small	O
nucleic	O
acid	O
molecule	O
comprises	O
a	O
nucleotide	O
sequence	O
having	O
sufficient	O
complementarity	O
to	O
an	O
RNA	O
of	O
said	O
Wrap53	B-GENE
gene	O
for	O
the	O
small	O
nucleic	O
acid	O
molecule	O
to	O
direct	O
cleavage	O
of	O
said	O
RNA	O
via	O
RNA	O
interference,	O
for	O
use	O
as	O
a	O
medicament	O
.	O


Glucagon	B-GENE
receptor	I-GENE
antagonist	O
compounds	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
treating	O
type	O
2	O
diabetes	O
and	O
related	O
conditions	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
are	O
also	O
included	O
.	O
(	O
I	O
)	O


The	O
invention	O
is	O
concerned	O
with	O
novel	O
indazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
These	O
compounds	O
inhibit	O
L-CPT1	B-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


The	O
invention	O
relates	O
to	O
bicyclic	O
heterocycles	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
to	O
the	O
tautomers,	O
stereoisomers,	O
mixtures	O
and	O
salts	O
thereof,	O
especially	O
the	O
physiologically	O
compatible	O
salts	O
with	O
inorganic	O
or	O
organic	O
acids,	O
said	O
compounds	O
having	O
valuable	O
pharmacological	O
properties,	O
especially	O
an	O
inhibiting	O
action	O
on	O
the	O
signal	O
transduction	O
induced	O
by	O
tyrosine	B-GENE
kinases	I-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compounds	O
for	O
treating	O
diseases,	O
especially	O
tumour	O
diseases,	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
and	O
diseases	O
of	O
the	O
lungs	O
and	O
respiratory	O
tract,	O
and	O
to	O
the	O
production	O
of	O
said	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
heterocyclic	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
their	O
use	O
and	O
preparation,	O
methods	O
of	O
making	O
the	O
compounds,	O
compositions	O
containing	O
at	O
least	O
one	O
of	O
said	O
compounds,	O
and	O
methods	O
of	O
treatment	O
using	O
at	O
least	O
one	O
compound	O
.	O
In	O
particular,	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
are	O
useful	O
for	O
inhibiting	O
glycogen	B-GENE
synthase	I-GENE
kinase	I-GENE
3	I-GENE
(	O
GSK-3	B-GENE
)	O
,	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
modulators	O
of	O
cannabinoid	B-GENE
receptor	I-GENE
CB1,	O
useful	O
for	O
the	O
treatment	O
of	O
obesity	O
and	O
diseases	O
for	O
which	O
obesity	O
is	O
a	O
risk	O
factor	O
:	O
(	O
I	O
)	O
wherein	O
:	O
X	O
is	O
a	O
bond,	O
Or-C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
-	O
*	O
.	O
-C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
-O-	O
*	O
,	O
-C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
CH2-	O
*	O
,	O
-C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
CH2-O-	O
*	O
,	O
-CH2C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
-	O
*	O
,	O
-CH2C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
-O-	O
*	O
,	O
or	O
-CH2-O-C	O
(	O
R10	O
)	O
(	O
R11	O
)	O
-	O
*	O
;	O
Y	O
is	O
=	O
O,	O
=	O
N	O
(	O
R9	O
)	O
,	O
=	O
N	O
(	O
OR9	O
)	O
,	O
=	O
CH	O
(	O
CN	O
)	O
,	O
=	O
C	O
(	O
CN	O
)	O
2	O
or	O
=	O
N	O
(	O
CN	O
)	O
;	O
Z	O
is	O
a	O
bond,	O
-O-	O
or	O
-NH-	O
;	O
R1	O
and	O
R2	O
are	O
hydrogen,	O
(	O
CrC3	O
)	O
alkyl,	O
(	O
C3-C6	O
)	O
cycloalkyl	O
or	O
monocyclic	O
heterocyclic	O
;	O
or	O
R1	O
and	O
R2	O
taken	O
together	O
with	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
cyclic	O
amino	O
ring	O
;	O
R3	O
is	O
hydrogen	O
or	O
a	O
radical	O
of	O
formula	O
-	O
(	O
O	O
)	O
a-	O
AIk3	O
wherein	O
a	O
and	O
AIk3	O
are	O
as	O
defined	O
in	O
the	O
claims	O
;	O
R4	O
is	O
a	O
radical	O
of	O
formula	O
-	O
(	O
O	O
)	O
b-	O
(	O
Alk1	O
)	O
p-	O
(	O
Q	O
)	O
r-	O
(	O
L	O
)	O
s-Q2	O
wherein	O
b,	O
p,	O
r,	O
s	O
AIk1,	O
L,	O
Q1	O
and	O
Q2	O
are	O
as	O
defined	O
in	O
the	O
claims	O
;	O
or	O
R3	O
and	O
R4	O
taken	O
together	O
with	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
cyclic	O
amino	O
ring	O
;	O
R5	O
is	O
hydrogen	O
-F,	O
-Cl,	O
-Br,	O
-CN,	O
(	O
C1-C3	O
)	O
alkyl,	O
(	O
C1-C3	O
)	O
fluoroalkyl,	O
cyclopropyl,	O
-COOH,	O
tetrazole	O
or	O
-OR9	O
;	O
R6,	O
R7	O
and	O
R8	O
are	O
hydrogen	O
-F,	O
-Cl,	O
-Br,	O
-CN,	O
(	O
C1-C3	O
)	O
alkyl,	O
(	O
C1-C3	O
)	O
fluoroalkyl,	O
cyclopropyl,	O
or	O
-OR9	O
;	O
and	O
R9	O
R10	O
and	O
R11	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O


One	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
heterocyclic	O
compounds	O
that	O
bind	O
to	O
bcl	B-GENE
proteins	I-GENE
and	O
inhibit	O
BcI	B-GENE
function	O
.	O
Another	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
a	O
heterocyclic	O
compound	O
of	O
the	O
invention	O
.	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
and	O
modulating	O
disorders	O
associated	O
with	O
hyperproliferation,	O
such	O
as	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
bicyclic	O
lactams	O
derivatives,	O
and	O
analogues	O
thereof,	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer,	O
tautomer,	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
or	O
prodrug	O
thereof,	O
wherein	O
the	O
variables	O
A,	O
B,	O
C,	O
W,	O
Y,	O
Z1,	O
Z2,	O
Z3,	O
Z4,	O
R8,	O
and	O
R9	O
are	O
as	O
defined	O
herein	O
.	O
These	O
compounds	O
are	O
selective	O
inhibitors	O
of	O
factor	B-GENE
VIIa	I-GENE
which	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


The	O
present	O
invention	O
relates	O
in	O
general	O
to	O
an	O
inhibitor	O
of	O
a	O
glutaminyl	B-GENE
peptide	I-GENE
cyclotransferase,	O
and	O
use	O
thereof	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
disease	O
or	O
disorder	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
inflammatory	O
diseases	O
selected	O
from	O
a	O
.	O
neurodegenerative	O
diseases,	O
e	O
.	O
g	O
.	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
,	O
Alzheimer	O
'	O
s	O
disease,	O
neurodegeneration	O
in	O
Down	O
Syndrome,	O
Familial	O
British	O
Dementia,	O
Familial	O
Danish	O
Dementia,	O
multiple	O
sclerosis,	O
b	O
.	O
chronic	O
and	O
acute	O
inflammations,	O
e	O
.	O
g	O
.	O
rheumatoid	O
arthritis,	O
atherosclerosis,	O
restenosis,	O
pancreatitis,	O
c	O
.	O
fibrosis,	O
e	O
.	O
g	O
.	O
lung	O
fibrosis,	O
liver	O
fibrosis,	O
renal	O
fibrosis,	O
d	O
.	O
cancer,	O
e	O
.	O
g	O
.	O
cancer	O
/	O
hemangioendothelioma	O
proliferation,	O
gastric	O
carcinomas,	O
e	O
.	O
metabolic	O
diseases,	O
e	O
.	O
g	O
.	O
hypertension,	O
f	O
.	O
and	O
other	O
inflammatory	O
diseases,	O
e	O
.	O
g	O
.	O
neuropathic	O
pain,	O
graft	O
rejection	O
/	O
graft	O
failure	O
/	O
graft	O
vasculopathy,	O
HIV	O
infections	O
/	O
AIDS,	O
gestosis,	O
tuberous	O
sclerosis	O
.	O
Further,	O
the	O
invention	O
relates	O
to	O
a	O
respective	O
diagnostic	O
method,	O
assay	O
and	O
kit	O
.	O


7-Butynyl-8-	O
(	O
3-amino-1-piperidinyl	O
)	O
xanthine	O
derivatives	O
(	O
I	O
)	O
are	O
new	O
.	O
7-Butynyl-8-	O
(	O
3-amino-1-piperidinyl	O
)	O
xanthine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
tautomers,	O
isomers	O
and	O
salts	O
are	O
new	O
.	O
R	O
:	O
benzyl,	O
2-fluorobenzyl,	O
3-fluorobenzyl,	O
4-fluorobenzyl,	O
2,6-difluoro-benzyl,	O
3,4-difluoro-benzyl,	O
2-chlorobenzyl,	O
3-chlorobenzyl	O
or	O
4-chlorobenzyl,	O
2-trifluoromethyl-benzyl,	O
3-trifluoromethyl-benzyl	O
or	O
4-trifluoromethyl-benzyl,	O
3-trifluoromethoxy-benzyl	O
or	O
4-trifluoromethoxy-benzyl,	O
2-cyanobenzyl,	O
3-cyanobenzyl	O
or	O
4-cyanobenzyl,	O
2,6-dicyanobenzyl,	O
3,4-dicyanobenzyl,	O
3,5-dicyanobenzyl,	O
2-trifluoromethyl-4-cyano-benzyl,	O
3-nitro-4-cyano-benzyl,	O
2-cyano-3-methoxy-benzyl,	O
2-cyano-4-methoxy-benzyl,	O
2-cyano-5-methoxy-benzyl,	O
2-cyano-4-fluoro-benzyl,	O
2-cyano-5-fluoro-benzyl,	O
2-cyano-6-fluoro-benzyl,	O
3-cyano-4-fluoro-benzyl,	O
4-cyano-3-fluorobenzyl,	O
2-fluoro-4-cyano-benzyl,	O
2-cyano-3-chlorobenzyl,	O
2-chloro-4-cyano-benzyl	O
or	O
2-cyano-4-bromobenzyl,	O
2-methoxy-benzyl,	O
3-methoxy-benzyl,	O
4-methoxy-benzyl,	O
2-fluoro-3-methoxybenzyl,	O
2-fluoro-4-methoxy-benzyl,	O
2-fluoro-5-methoxy-benzyl,	O
3-fluoro-4-methoxybenzyl,	O
3,4-dimethoxy-benzyl,	O
3,5-dimethoxybenzyl	O
or	O
3,4-dimethoxy-6-fluorobenzyl,	O
(	O
benzo	O
[	O
1,3	O
]	O
dioxol-5-yl	O
)	O
methyl,	O
[	O
(	O
4-cyano-benzo	O
[	O
1,3	O
]	O
dioxol-5-yl	O
)	O
methyl,	O
2-	O
(	O
3-cyclopropyloxy-phenyl	O
)	O
-2	O
-oxo-ethyl,	O
2-	O
(	O
3-cyclopropylmethoxy-phenyl	O
)	O
-2oxo-ethyl	O
or	O
2-	O
(	O
3-cyclobutyloxy-phenyl	O
)	O
-2-oxo-ethyl,	O
2-oxo-2-	O
[	O
2-	O
(	O
pyridin-3-yl	O
)	O
-phe	O
nyl	O
]	O
-ethyl	O
or	O
2-oxo-2-	O
[	O
2-	O
(	O
pyridin-4-yl	O
)	O
-phenyl	O
]	O
ethyl,	O
(	O
3-cyano-1-naphthyl	O
)	O
methyl,	O
(	O
1,4-dicyano-2-naphthyl	O
)	O
methyl	O
or	O
(	O
2,4-dimethoxy-1-naphthyl	O
)	O
methyl,	O
(	O
furan-2-yl	O
)	O
methyl,	O
(	O
furan-3-yl	O
)	O
methyl,	O
(	O
5-bromo-furan-2-yl	O
)	O
methyl,	O
(	O
5-methylfuran-2-yl	O
)	O
methyl,	O
(	O
5-cyano-furan-2-yl	O
)	O
methyl	O
or	O
(	O
5-methoxycarbonyl-furan-2yl	O
)	O
methyl,	O
(	O
pyridin-2-yl	O
)	O
methyl,	O
(	O
6-fluoro-pyridin-2-yl	O
)	O
methyl	O
or	O
(	O
5-methoxy-pyridin-2-yl	O
)	O
methyl,	O
(	O
3-cyanopyridin-2-yl	O
)	O
methyl,	O
(	O
6-cyanopyridin-2-	O
yl	O
)	O
methyl,	O
(	O
5-cyano-pyridin-2-yl	O
)	O
methyl,	O
(	O
4-cyano-pyridin-2-yl	O
)	O
methyl,	O
(	O
4-cyano-pyridin-3-yl	O
)	O
methyl,	O
(	O
3-cyanopyridin-4-yl	O
)	O
methyl,	O
(	O
2-cyano-pyridin-3-yl	O
)	O
methyl,	O
(	O
2-cyano-pyridin-4-yl	O
)	O
methyl,	O
(	O
5cyano-pyridin-3-yl	O
)	O
methyl,	O
(	O
6-cyano-pyridin-3-yl	O
)	O
methyl	O
or	O
(	O
5-cyano-6-methoxypyridin-2-yl	O
)	O
methyl,	O
(	O
6-phenyl-pyridin-2-yl	O
)	O
methyl	O
or	O
(	O
[	O
2,2	O
'	O
]	O
bipyridinyl-6-yl	O
)	O
methyl,	O
(	O
pyrimidin-2-yl	O
)	O
methyl,	O
(	O
4-methyl-pyrimidin-2-yl	O
)	O
methyl	O
or	O
(	O
4,6-dimethylpyrimidin-2-yl	O
)	O
methyl,	O
(	O
2-phenyl-pyrimidin-4-yl	O
)	O
methyl	O
or	O
(	O
4-phenyl-pyrimidin-2-yl	O
)	O
methyl,	O
[	O
(	O
1-methyl-1H-benzotriazol-5-yl	O
)	O
methyl	O
]	O
,	O
(	O
6-fluoro-quinolin-2-yl	O
)	O
met	O
hyl,	O
(	O
7-fluoro-quinolin-2-yl	O
)	O
methyl,	O
(	O
2-methyl-quinolin-4-yl	O
)	O
methyl,	O
(	O
3-cyano-quinolin-2-yl	O
)	O
methyl,	O
(	O
3-cyano-4-methyl-quinolin-2-yl	O
)	O
methyl,	O
(	O
4-cyano-quinolin-2-yl	O
)	O
methyl,	O
(	O
5-cyano-quinolin-2-yl	O
)	O
methyl,	O
(	O
6-cyano-quinolin-2-yl	O
)	O
methyl,	O
(	O
6-amino-quinolin-2-yl	O
)	O
methyl,	O
(	O
8-amino-quinolin-2-y1	O
)	O
methyl,	O
(	O
4-methoxy-quinolin-2-yl	O
)	O
methyl,	O
(	O
6-methoxy-quinolin-2-yl	O
)	O
methyl,	O
(	O
6,7-dimethoxyquinolin-2-yl	O
)	O
methyl	O
or	O
(	O
8-cyano-quinolin-7-yl	O
)	O
methyl,	O
(	O
1-cyano-isoquinolin-3-yl	O
)	O
methyl,	O
(	O
4-cyano-isoquinolin-1-yl	O
)	O
methyl,	O
(	O
4-cyanoisoquinolin-3-yl	O
)	O
methyl	O
or	O
[	O
(	O
4-	O
(	O
pyridin-2-yl	O
)	O
-isoquinolin-1-yl	O
)	O
methyl,	O
(	O
quinazolin-6-yl	O
)	O
methyl,	O
(	O
quinazolin-7-yl	O
)	O
methyl,	O
(	O
2-methyl-quinazolin-4yl	O
)	O
methyl,	O
(	O
4,5-dimethyl-quinazolin-2-yl	O
)	O
methyl,	O
(	O
4-ethyl-quinazolin-2-yl	O
)	O
methyl,	O
(	O
4-cyclopropyl-quinazolin-2-yl	O
)	O
methyl,	O
(	O
2-phenyl-quinazolin-4-yl	O
)	O
met	O
hyl,	O
(	O
4-cyanoquinazolin-2-yl	O
)	O
methyl,	O
(	O
4-phenylamino-quinazolin-2-yl	O
)	O
m	O
ethyl	O
or	O
(	O
4-benzylaminoquinazolin-2-yl	O
)	O
methyl,	O
(	O
quinoxalin-5-yl	O
)	O
methyl,	O
(	O
quinoxalin-6-yl	O
)	O
methyl	O
or	O
(	O
2,3-dimethyl-quinoxalin-6-yl	O
)	O
methyl,	O
or	O
(	O
[	O
1,5	O
]	O
naphthyridin-3-yl	O
)	O
methyl	O
.	O
An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
process	O
for	O
preparing	O
(	O
I	O
)	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Antidiabetic	O
;	O
Antiarthritic	O
;	O
Anorectic	O
;	O
Osteopathic	O
;	O
Tranquilizer	O
;	O
Hypotensive	O
;	O
Nephrotropic	O
;	O
Antiinflammatory	O
;	O
Antiulcer	O
;	O
Immunosuppressive	O
;	O
Virucide	O
;	O
Anti-HIV	O
;	O
Neuroprotective	O
;	O
Nootropic	O
;	O
Cytostatic	O
;	O
Cerebroprotective	O
;	O
Vasotropic	O
;	O
Antiparkinsonian	O
;	O
Antimigraine	O
;	O
Dermatological	O
;	O
Antipsoriatic	O
;	O
Antidepressant	O
;	O
Neuroleptic	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP	B-GENE
IV	I-GENE
)	O
inhibitor	O
.	O
1-	O
(	O
4-Benzylamino-4-quinazolinylmethyl	O
)	O
-3-methyl-7-	O
(	O
2-butyn-1-yl	O
)	O
-8-	O
(	O
3	O
-amino-1-piperidinyl	O
)	O
xanthine	O
had	O
an	O
IC50	O
of	O
6	O
nM	O
against	O
DPP	B-GENE
IV	I-GENE
activity	O
in	O
Caco-2	O
cell	O
extracts	O


The	O
present	O
invention	O
provides	O
a	O
selective	O
M4	B-GENE
receptor	I-GENE
antagonist,	O
levorotatory	O
demethylated	O
phencynonate	O
or	O
its	O
nontoxic	O
pharmaceutically	O
acceptable	O
salt,	O
a	O
pharmaceutical	O
composition	O
comprising	O
this	O
compound,	O
and	O
a	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
motion	O
dysfunction,	O
such	O
as,	O
tremor,	O
rigor	O
and	O
the	O
like	O
caused	O
by	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O
The	O
structure	O
of	O
the	O
compound	O
is	O
shown	O
in	O
Formula	O
IIa	O
:	O


The	O
invention	O
provides	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
diseases	O
or	O
disorders	O
associated	O
with	O
the	O
activity	O
of	O
GPR119	B-GENE
.	O


This	O
invention	O
relates	O
to	O
novel	O
aromatic	O
heterocyclic	O
carboxylic	O
acid	O
amide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
that	O
are	O
found	O
to	O
be	O
potent	O
modulators	O
of	O
potassium	B-GENE
channels	I-GENE
and,	O
as	O
such,	O
are	O
valuable	O
candidates	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
which	O
are	O
responsive	O
to	O
the	O
modulation	O
of	O
potassium	B-GENE
channels	I-GENE
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds,	O
compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
viral	O
infections,	O
in	O
particular,	O
HIV,	O
HBV,	O
and	O
HCV,	O
in	O
human	O
patients	O
or	O
other	O
animal	O
hosts	O
.	O
The	O
compounds	O
are	O
3	O
'	O
-azido-2	O
'	O
,3	O
'	O
-dideoxy	O
purine	O
nucleosides	O
or	O
phosphonates,	O
and	O
pharmaceutically	O
acceptable,	O
salts,	O
prodrugs,	O
and	O
other	O
derivatives	O
thereof	O
.	O
In	O
particular,	O
the	O
compounds	O
show	O
potent	O
antiviral	O
activity	O
against	O
HIV-1	O
resistance	O
mutants	O
including	O
HIV-1K65R,	O
HTV-1K70E,	O
HIV-1L74V,	O
HIV-1M184V,	O
HIV-1Q151M	O
and	O
inhibitory	O
activity	O
against	O
HIV-1	B-GENE
RT	I-GENE
harboring	O
TAMS	O
or	O
insertion	O
mutations	O
including	O
HIV-1AZT3,	O
HIV-1AZT7,	O
HIV-1AZT9,	O
HIV-	O
1Q151M,	O
or	O
HIV-169insertion	O
.	O
In	O
one	O
embodiment,	O
the	O
compounds	O
are	O
3	O
'	O
-azido-ddA,	O
3	O
'	O
-azido-ddG,	O
or	O
combinations	O
thereof,	O
administered	O
with	O
one	O
or	O
more	O
additional	O
antiviral	O
agents	O
that	O
select	O
for	O
TAM	O
mutations	O
and	O
/	O
or	O
the	O
M	B-GENE
184V	I-GENE
mutation,	O
along	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


The	O
invention	O
relates	O
to	O
N-substituted	O
azaindolyl	O
compounds	O
of	O
Formula	O
I	O
with	O
anti-cancer	O
and	O
/	O
or	O
anti-inflammatory	O
activity	O
and	O
more	O
specifically	O
to	O
N-substituted	O
azaindolyl	O
compounds	O
which	O
inhibit	O
MEK	B-GENE
kinase	I-GENE
activity	O
.	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
useful	O
for	O
inhibiting	O
abnormal	O
cell	O
growth	O
or	O
treating	O
a	O
hyperproliferative	O
disorder,	O
or	O
treating	O
an	O
inflammatory	O
disease	O
in	O
a	O
mammal	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis	O
or	O
treatment	O
of	O
mammalian	O
cells,	O
or	O
associated	O
pathological	O
conditions	O
.	O


The	O
invention	O
relates	O
to	O
2-aza-bicyclo	O
[	O
3	O
.	O
3	O
.	O
0	O
]	O
octane	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
A,	O
B,	O
and	O
R1	O
are	O
as	O
described	O
in	O
the	O
description,	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds,	O
or	O
of	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds,	O
as	O
medicaments,	O
especially	O
as	O
orexin	B-GENE
receptor	I-GENE
antagonists	O
.	O


The	O
present	O
invention	O
provides	O
compound	O
having	O
the	O
general	O
structure	O
A	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
Het-L-P	O
(	O
A	O
)	O
wherein	O
Het	O
is	O
an	O
aromatic	O
moiety	O
comprising	O
a	O
heterocyclic	O
structure	O
mimicking	O
ATP,	O
P	O
is	O
a	O
docking	O
site	O
derived	O
peptide	O
or	O
a	O
docking	O
site	O
peptide	O
mimetic,	O
and	O
L	O
is	O
a	O
linking	O
moiety,	O
wherein	O
L	O
links	O
the	O
ATP	O
mimetic	O
to	O
the	O
docking	O
site	O
peptide	O
moiety	O
.	O
The	O
compounds	O
having	O
the	O
general	O
structure	O
A	O
can	O
serve	O
as	O
inhibitors	O
of	O
kinases,	O
such	O
as	O
the	O
kinases	B-GENE
JNK,	O
Erk	B-GENE
and	O
P38	B-GENE
.	O


Novel	O
sulfonamide	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
related	O
to	O
the	O
production	O
of	O
beta-amyloid	B-GENE
are	O
described,	O
as	O
are	O
routes	O
to	O
their	O
preparation	O
.	O
The	O
sulfonamide	O
compounds	O
are	O
of	O
the	O
following	O
structure,	O
wherein	O
R4-R3	O
are	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
/	O
or	O
prodrugs	O
of	O
these	O
compounds	O
and	O
a	O
physiologically	O
compatible	O
carrier	O
.	O
These	O
compounds	O
are	O
specifically	O
useful	O
for	O
inhibiting	O
beta	B-GENE
amyloid	I-GENE
production,	O
and	O
treating	O
Alzheimer	O
'	O
s	O
Disease,	O
amyloid	O
angiopathy,	O
cerebral	O
amyloid	O
angiopathy,	O
systemic	O
amyloidosis,	O
hereditary	O
cerebral	O
hemorrhage	O
with	O
amyloidosis	O
of	O
the	O
Dutch	O
type,	O
inclusion	O
body	O
myositis,	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
and	O
Down	O
'	O
s	O
syndrome	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
cancers,	O
e	O
.	O
g	O
.	O
,	O
mesothelioma	O
or	O
lymphoma	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
mesothelioma	O
or	O
diffuse	O
large	O
B-cell	O
lymphoma	O
(	O
DLBCL	O
)	O
,	O
by	O
administration	O
of	O
pharmaceutical	O
compositions	O
comprising	O
HDAC	B-GENE
inhibitors,	O
e	O
.	O
g	O
.	O
,	O
suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
.	O
The	O
oral	O
formulations	O
of	O
the	O
pharmaceutical	O
compositions	O
have	O
favorable	O
pharmacokinetic	O
profiles	O
such	O
as	O
high	O
bioavailability	O
and	O
surprisingly	O
give	O
rise	O
to	O
high	O
blood	O
levels	O
of	O
the	O
active	O
compounds	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
safe,	O
daily	O
dosing	O
regimen	O
of	O
these	O
pharmaceutical	O
compositions,	O
which	O
is	O
easy	O
to	O
follow,	O
and	O
which	O
results	O
in	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
HDAC	B-GENE
inhibitors	O
in	O
vivo	O
.	O


Provided	O
herein	O
are	O
compounds	O
of	O
formulae	O
I	O
to	O
II	O
that	O
bind	O
to	O
androgen	B-GENE
receptors	I-GENE
and	O
/	O
or	O
modulate	O
activity	O
of	O
androgen	B-GENE
receptors	I-GENE
;	O
and	O
to	O
methods	O
for	O
making	O
and	O
using	O
such	O
compounds	O
.	O
Also	O
provided	O
are	O
compositions	O
including	O
such	O
compounds	O
and	O
methods	O
for	O
making	O
and	O
using	O
such	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
forms	O
of	O
bosentan	O
and	O
processes	O
for	O
their	O
preparation	O
.	O
Further,	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
crystalline	O
forms	O
and	O
use	O
of	O
said	O
compositions	O
in	O
the	O
treatment	O
of	O
patientssuffering	O
from	O
endothelin	B-GENE
receptor	I-GENE
mediated	O
disorders,	O
for	O
example,cardiovascular	O
disorders	O
such	O
as	O
hypertension,	O
pulmonary	O
hypertension,	O
ischemia,	O
vasospasm	O
and	O
angina	O
pectoris	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
N-aryl	O
-N-piperidin-4	O
-yl	O
-propionamide	O
derivatives	O
(	O
I	O
)	O
useful	O
as	O
opioid	B-GENE
receptor	I-GENE
ligands	O
.	O
In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy,	O
such	O
as	O
for	O
the	O
treatment	O
of	O
pain,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
combination	O
treatment	O
of	O
cancer,	O
especially	O
lung	O
cancer	O
with	O
an	O
anti-IGF-1R	O
antibody	O
in	O
combination	O
with	O
erlotinib	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
urea	O
for	O
increasing	O
the	O
expression	O
of	O
at	O
least	O
one	O
gene	O
encoding	O
an	O
antimicrobial	O
peptide,	O
preferably	O
a	O
defensin,	O
a	O
cathelicidin	B-GENE
such	O
as	O
LL-37	B-GENE
or	O
a	O
psoriasin	B-GENE
.	O
Furthermore	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
said	O
compositions	O
for	O
the	O
treatment	O
of	O
microbial	O
infections,	O
preferably	O
microbial	O
infections	O
of	O
the	O
skin	O
.	O


The	O
invention	O
relates	O
to	O
serotonin	O
5-HT3	B-GENE
receptor	O
antagonists	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
vestibular	O
deficit	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
n1	O
is	O
0,	O
1,	O
or	O
2	O
;	O
n2	O
is	O
0,	O
1,	O
or	O
2	O
;	O
X	O
is	O
a	O
bond,	O
O,	O
S,	O
or	O
NR1	O
;	O
and	O
Ar1	O
is	O
a	O
5-membered	O
aromatic	O
ring,	O
6-membered	O
aromatic	O
ring,	O
or	O
a	O
fused	O
bicycloheterocycle	O
.	O
The	O
compounds	O
are	O
useful	O
in	O
treating	O
conditions	O
or	O
disorders	O
prevented	O
by	O
or	O
ameliorated	O
by	O
α7	B-GENE
nAChR	I-GENE
ligands	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
having	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
and	O
compositions	O
.	O


The	O
present	O
invention	O
provides,	O
for	O
example,	O
methods	O
for	O
treating	O
or	O
preventing	O
colorectal	O
cancer	O
with	O
an	O
anti-IGF1R	O
antibody	O
in	O
association	O
with	O
sunitinib	O
or	O
a	O
combination	O
of	O
leucovorin	O
and	O
5-fluorouracil	O
.	O


This	O
invention	O
provides	O
androgen	B-GENE
receptor	I-GENE
targeting	O
agents	O
(	O
ARTA	O
)	O
.	O
The	O
agents	O
define	O
a	O
new	O
subclass	O
of	O
compounds,	O
which	O
are	O
selective	O
androgen	B-GENE
receptor	I-GENE
modulators	O
(	O
SARM	O
)	O
.	O
Several	O
of	O
the	O
SARM	O
compounds	O
have	O
been	O
found	O
to	O
have	O
an	O
unexpected	O
androgenic	O
and	O
anabolic	O
activity	O
of	O
a	O
nonsteroidal	O
ligand	O
for	O
the	O
androgen	B-GENE
receptor	I-GENE
.	O
Other	O
SARM	O
compounds	O
have	O
been	O
found	O
to	O
have	O
an	O
unexpected	O
antiandrogenic	O
activity	O
of	O
a	O
nonsteroidal	O
ligand	O
for	O
the	O
androgen	B-GENE
receptor	I-GENE
.	O
The	O
SARM	O
compounds,	O
either	O
alone	O
or	O
as	O
a	O
composition,	O
are	O
useful	O
for	O
a	O
)	O
mate	O
contraception	O
;	O
b	O
)	O
treatment	O
of	O
a	O
variety	O
of	O
hormone-related	O
conditions,	O
for	O
example	O
conditions	O
associated	O
with	O
Androgen	O
Decline	O
in	O
Aging	O
Male	O
(	O
ADAM	O
)	O
,	O
such	O
as	O
fatigue,	O
depression,	O
decreased	O
libido,	O
sexual	O
dysfunction,	O
erectile	O
dysfunction,	O
hypogonadism,	O
osteoporosis,	O
hair	O
loss,	O
anemia,	O
obesity,	O
sarcopenia,	O
osteopenia,	O
osteoporosis,	O
benign	O
prostate	O
hyperplasia,	O
alterations	O
in	O
mood	O
and	O
cognition	O
and	O
prostate	O
cancer	O
;	O
c	O
)	O
treatment	O
of	O
conditions	O
associated	O
with	O
Androgen	O
Decline	O
in	O
Female	O
(	O
ADIF	O
)	O
,	O
such	O
as	O
sexual	O
dysfunction,	O
decreased	O
sexual	O
libido,	O
hypogonadism,	O
sarcopenia,	O
osteopenia,	O
osteoporosis,	O
alterations	O
in	O
cognition	O
and	O
mood,	O
depression,	O
anemia,	O
hair	O
loss,	O
obesity,	O
endometriosis,	O
breast	O
cancer,	O
uterine	O
cancer	O
and	O
ovarian	O
cancer	O
;	O
d	O
)	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
acute	O
and	O
/	O
or	O
chronic	O
muscular	O
wasting	O
conditions	O
;	O
e	O
)	O
preventing	O
and	O
/	O
or	O
treating	O
dry	O
eye	O
conditions	O
;	O
f	O
)	O
oral	O
androgen	O
replacement	O
therapy	O
;	O
and	O
/	O
or	O
g	O
)	O
decreasing	O
the	O
incidence	O
of,	O
halting	O
or	O
causing	O
a	O
regression	O
of	O
prostate	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
series	O
of	O
2-substituted-di-	O
tri	O
or	O
tetra-hydro-8H-cyclopentaoxazolo	O
[	O
3,2-a	O
]	O
pyrimidin-8-ones	O
and	O
2-substituted-di-,	O
tetra-,	O
or	O
hexa-hydro-cyclohexaoxazolo	O
[	O
3,2-a	O
]	O
pyrimidin-9-ones	O
of	O
formula	O
(	O
I	O
)	O
.	O
Wherein	O
p,	O
n,	O
A,	O
B,	O
X,	O
Y,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O
This	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
making	O
these	O
compounds	O
including	O
novel	O
intermediates	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
are	O
modulators	O
of	O
metabotropic	B-GENE
glutamate	I-GENE
receptors	I-GENE
(	O
mGluR	B-GENE
)	O
,	O
particularly,	O
mGluR2	B-GENE
receptor	O
.	O
Therefore,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
useful	O
as	O
pharmaceutical	O
agents,	O
especially	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
variety	O
of	O
central	O
nervous	O
system	O
disorders	O
(	O
CNS	O
)	O
,	O
including	O
but	O
not	O
limited	O
to	O
acute	O
and	O
chronic	O
neurodegenerative	O
conditions,	O
psychoses,	O
convulsions,	O
anxiety,	O
depression,	O
migraine,	O
pain,	O
sleep	O
disorders	O
and	O
emesis	O
.	O


There	O
are	O
disclosed	O
a	O
method	O
of	O
screening	O
a	O
cell	O
death	O
inhibitor,	O
which	O
comprises	O
using	O
macrophage	B-GENE
migration	I-GENE
inhibitory	I-GENE
factor,	O
a	O
kit	O
for	O
screening	O
a	O
cell	O
death	O
inhibitor,	O
comprising	O
macrophage	B-GENE
migration	I-GENE
inhibitory	I-GENE
factor	I-GENE
and	O
a	O
method	O
for	O
quantification	O
of	O
macrophage	B-GENE
migration	I-GENE
inhibitory	I-GENE
factor,	O
which	O
comprises	O
using	O
a	O
substance	O
capable	O
of	O
binding	O
to	O
macrophage	B-GENE
migration	I-GENE
inhibitory	I-GENE
factor	I-GENE
.	O


Tumor	O
metastases	O
in	O
cancer	O
patients	O
are	O
inhibited	O
by	O
administration	O
of	O
a	O
combination	O
therapy	O
including	O
effective	O
amounts	O
of	O
Interleukin-2	B-GENE
and	O
a	O
methylol	O
transfer	O
agent	O
such	O
as	O
taurolidine,	O
taurultam	O
or	O
mixtures	O
thereof	O
.	O


Described	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
certain	O
retinol-related	O
diseases	O
and	O
conditions	O
by	O
modulation	O
of	O
transthyretin	B-GENE
(	O
TTR	B-GENE
)	O
and	O
retinol	B-GENE
binding	I-GENE
protein	I-GENE
(	O
RBP	B-GENE
)	O
availability	O
in	O
the	O
subject	O
.	O
For	O
example,	O
the	O
methods	O
and	O
compositions	O
provide	O
for	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
age-related	O
macular	O
degeneration	O
and	O
/	O
or	O
dystrophies,	O
metabolic	O
disorders,	O
idiopathic	O
intracranial	O
hypertension,	O
hyperostosis,	O
and	O
protein	O
misfolding	O
and	O
aggregation	O
diseases	O
.	O
The	O
compositions	O
disclosed	O
may	O
be	O
used	O
as	O
single	O
agent	O
therapy	O
or	O
in	O
combination	O
with	O
other	O
agents	O
or	O
therapies	O
.	O
In	O
addition,	O
described	O
herein	O
are	O
methods	O
and	O
assays	O
for	O
selecting	O
appropriate	O
agents	O
that	O
can	O
modulate	O
the	O
TTR	B-GENE
and	O
RBP	B-GENE
availability	O
in	O
a	O
subject	O
.	O


The	O
present	O
invention	O
is	O
included	O
in	O
the	O
field	O
of	O
pharmacology	O
and	O
medical	O
chemistry	O
and	O
relates	O
to	O
novel	O
molecules	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
especially	O
the	O
one	O
called	O
FM19G11,	O
as	O
well	O
as	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O
Said	O
pharmacologically	O
optimized	O
compositions	O
are	O
capable	O
of	O
modulating	O
and	O
/	O
or	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
modulated	O
by	O
the	O
hypoxia-inducible	B-GENE
transcription	I-GENE
factor	I-GENE
(	O
HIF	B-GENE
)	O
and	O
which	O
are	O
directly	O
and	O
/	O
or	O
indirectly	O
involved	O
in	O
pathological	O
processes	O
related	O
to	O
cancer,	O
inflammation,	O
tissue	O
repair,	O
stem	O
cell	O
differentiation	O
and	O
regenerative	O
therapy	O
.	O
	O
	O
	O
	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
synthesis	O
of	O
said	O
molecules	O
(	O
I	O
)	O
and	O
to	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
the	O
mentioned	O
pathological	O
processes	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
an	O
AT1	B-GENE
receptor	O
antagonist	O
or	O
or	O
an	O
AT2	B-GENE
receptor	O
modulator,	O
respectively,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
for	O
producing	O
a	O
pharmaceutical	O
preparation	O
for	O
the	O
treatment	O
of	O
conditions	O
or	O
diseases	O
associated	O
with	O
the	O
increase	O
of	O
AT1	B-GENE
receptors	O
in	O
the	O
sub-epithelial	O
area	O
or	O
increase	O
of	O
AT2	B-GENE
receptors	O
in	O
the	O
epithelia	O
.	O


A	O
melanocortin	B-GENE
receptor	I-GENE
agonist	O
cyclic	O
peptide	O
of	O
the	O
formula	O
where	O
R,	O
x	O
and	O
y	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
compositions	O
and	O
formulations	O
including	O
the	O
peptide	O
of	O
the	O
foregoing	O
formula,	O
and	O
methods	O
of	O
preventing,	O
ameliorating	O
or	O
treating	O
melanocortin	O
receptor-mediated	O
diseases,	O
indications,	O
conditions	O
and	O
syndromes,	O
including	O
sexual	O
dysfunction	O
such	O
as	O
male	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
dysfunction	O
.	O


Phenethylsulfones	O
substituted	O
alpha	O
to	O
the	O
phenyl	O
group	O
with	O
a	O
1-oxoisoindoline	O
or	O
1,3-dioxoisoindoline	O
reduce	O
the	O
levels	O
of	O
TNF	B-GENE
alpha	I-GENE
in	O
a	O
mammal	O
.	O
A	O
typical	O
embodiment	O
is	O
2-	O
[	O
1-	O
(	O
3-ethoxy-4-methoxyphenyl	O
)	O
-2-methylsulfonylethyl	O
]	O
-4-aminoisoindoline-1,3-dione	O
.	O


The	O
invention	O
includes	O
a	O
combination	O
of	O
a	O
compound	O
of	O
formula	O
I	O
	O
	O
as	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
inhibitor	O
with	O
an	O
anti-inflammatory,	O
bronchodilatory	O
or	O
antihistamine	O
drug	O
substance,	O
said	O
agent	O
of	O
the	O
invention	O
and	O
said	O
drug	O
substance	O
being	O
in	O
the	O
same	O
or	O
different	O
pharmaceutical	O
composition	O
.	O


The	O
present	O
invention	O
aims	O
at	O
provision	O
of	O
a	O
method	O
for	O
inhibiting	O
remnant	O
lipoprotein	O
production	O
and	O
a	O
remnant	O
lipoprotein	O
production	O
inhibitor,	O
which	O
includes	O
administering	O
a	O
compound	O
having	O
a	O
CETP	B-GENE
inhibitory	O
activity	O
to	O
an	O
administration	O
subject	O
.	O
The	O
remnant	O
lipoprotein	O
production	O
inhibitor	O
of	O
the	O
present	O
invention	O
contains	O
a	O
compound	O
having	O
a	O
CETP	B-GENE
inhibitory	O
activity	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
condition	O
or	O
disease	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hypertension,	O
(	O
acute	O
and	O
chronic	O
)	O
congestive	O
heart	O
failure,	O
left	O
ventricular	O
dysfunction	O
and	O
hypertrophic	O
cardiomyopathy,	O
myocardial	O
infarction	O
and	O
its	O
sequelae,	O
supraventricular	O
and	O
ventricular	O
arrhythmias,	O
atrial	O
fibrillation	O
or	O
atrial	O
flutter,	O
atherosclerosis,	O
angina	O
(	O
whether	O
stable	O
or	O
unstable	O
)	O
,	O
renal	O
insufficiency	O
(	O
diabetic	O
and	O
non-diabetic	O
)	O
,	O
heart	O
failure,	O
angina	O
pectoris,	O
diabetes,	O
hypertension	O
in	O
patients	O
with	O
NIDDM,	O
secondary	O
aldosteronism,	O
primary	O
and	O
secondary	O
pulmonary	O
hyperaldosteronism,	O
primary	O
and	O
pulmonary	O
hypertension,	O
renal	O
failure	O
conditions,	O
such	O
as	O
diabetic	O
nephropathy,	O
glomerulonephritis,	O
scleroderma,	O
glomerular	O
sclerosis,	O
proteinuria	O
of	O
primary	O
renal	O
disease,	O
and	O
also	O
renal	O
vascular	O
hypertension,	O
diabetic	O
retinopathy,	O
the	O
management	O
of	O
other	O
vascular	O
disorders,	O
such	O
as	O
migraine,	O
Raynaud	O
'	O
s	O
disease,	O
luminal	O
hyperplasia,	O
cognitive	O
dysfunction	O
(	O
such	O
as	O
Alzheimer	O
'	O
s	O
)	O
,	O
and	O
stroke,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
combination	O
of	O
(	O
i	O
)	O
the	O
AT1-antagonists	O
valsartan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
Calcium	B-GENE
channel	I-GENE
blocker	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
and	O
to	O
corresponding	O
pharmaceutical	O
combination	O
composition	O
.	O


Use	O
of	O
alkyl	O
phenol	O
and	O
monocyclic	O
monoterpene-derived	O
compounds	O
in	O
the	O
treatment	O
of	O
neuronal	O
damage	O
and	O
in	O
inhibiting	O
activity	O
of	O
TRPC	B-GENE
and	O
non-thermo-TRPM	O
channels,	O
and	O
use	O
of	O
bicyclic	O
monoterpene-derived	O
compounds	O
in	O
activating	O
TRPC	B-GENE
and	O
non-thermo-TRPM	O
channels	O
.	O


3,4-diarylpyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful,	O
in	O
therapy,	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
a	O
disregulated	O
protein	B-GENE
kinase	I-GENE
activity,	O
like	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
pyrazole	O
carboxamide	O
inhibitors	O
of	O
factor	O
Xa,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
triazolopyridine	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
which	O
are	O
Monopolar	B-GENE
Spindle	I-GENE
1	I-GENE
kinase	I-GENE
(	O
Mps-1	B-GENE
or	O
TTK	B-GENE
)	O
inhibitors	O
:	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R4,	O
and	O
R5	O
are	O
as	O
given	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
to	O
methods	O
of	O
preparing	O
said	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
and	O
combinations	O
comprising	O
said	O
compounds,	O
to	O
the	O
use	O
of	O
said	O
compounds	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
proliferative	O
diseases,	O
as	O
well	O
as	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
.	O


Disclosed	O
are	O
methods,	O
compounds,	O
and	O
compositions	O
comprising	O
botanically	O
based	O
drugs,	O
medical	O
foods,	O
and	O
dietary	O
supplements	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
disorders,	O
in	O
particular	O
obesity,	O
weight	O
gain,	O
insulin	B-GENE
resistance	O
syndromes,	O
diabetes,	O
fasting	O
hyperlipidemia	O
and	O
osteoarthritis	O
.	O
More	O
specifically,	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
therapeutic	O
methods	O
and	O
compositions	O
utilizing	O
phytochemicals,	O
natural	O
plant	O
extracts	O
and	O
combinations	O
to	O
modify	O
adipocyte	O
physiology	O
to	O
enhance	O
thermogenesis	O
and	O
modify	O
cytokine	O
secretion	O
.	O


CTLA-8	B-GENE
antigen	O
from	O
a	O
primate,	O
reagents	O
related	O
thereto	O
including	O
purified	O
proteins,	O
specific	O
antibodies,	O
and	O
nucleic	O
acids	O
encoding	O
the	O
antigen	O
.	O
Uses	O
of	O
the	O
reagents	O
are	O
also	O
provided	O
.	O


Pharmaceutical	O
composition	O
comprising	O
an	O
antibody	O
specifically	O
recognizing	O
CD38	B-GENE
and	O
cyclophosphamide	O
.	O


Bicyclic	O
pyrazole	O
and	O
isoxazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
defined	O
in	O
the	O
specification,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
in	O
therapy	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
HSP90	B-GENE
protein,	O
like	O
cancer	O
and	O
neurodegenerative	O
disorders	O
.	O


In	O
one	O
aspect,	O
the	O
present	O
invention	O
relates	O
to	O
use	O
of	O
an	O
ACE	B-GENE
inhibitor	O
and	O
/	O
or	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
dermatological	O
disorder,	O
particularly	O
by	O
topical	O
application	O
of	O
said	O
ACE	B-GENE
inhibitor	O
and	O
/	O
or	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
.	O
The	O
present	O
invention	O
also	O
provides	O
cosmetic	O
methods	O
for	O
improving	O
and	O
/	O
or	O
maintaining	O
the	O
skin	O
tone	O
of	O
an	O
individual	O
suffering	O
from,	O
or	O
at	O
risk	O
of	O
suffering	O
from,	O
a	O
dermatological	O
disorder,	O
said	O
method	O
comprising	O
contacting	O
the	O
skin	O
of	O
said	O
individual	O
with	O
an	O
ACE	B-GENE
inhibitor	O
and	O
/	O
or	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
m,	O
n,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
using	O
the	O
compounds	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
the	O
P2X7	B-GENE
purinergic	O
receptor	O
.	O


The	O
invention	O
features	O
methods	O
and	O
compositions	O
for	O
treatment	O
of	O
conditions	O
associated	O
with	O
decreased	O
nitric	O
oxide	O
bioavailability,	O
such	O
as	O
a	O
condition	O
associated	O
with	O
elevated	O
arginase	B-GENE
activity,	O
using	O
an	O
arginine-based	O
therapy,	O
including	O
combination	O
therapy	O
with	O
an	O
arginase	B-GENE
inhibitor	O
and	O
/	O
or	O
magnesium	O


Tocopheryl	O
succinate	O
derivatives	O
according	O
to	O
formula	O
(	O
I	O
)	O
are	O
described	O
.	O
These	O
compounds	O
increase	O
the	O
activity	O
of	O
protein	B-GENE
phosphatase	I-GENE
2A,	O
can	O
be	O
included	O
in	O
pharmaceutical	O
compositions,	O
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
androgen	O
receptor-dependent	O
cancers	O
such	O
as	O
prostate	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
modulating	O
melanin	O
production,	O
secretion	O
and	O
/	O
or	O
accumulation	O
in	O
human	O
skin	O
cells	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
A3	B-GENE
adenosine	I-GENE
receptor	I-GENE
antagonists	O
in	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
and	O
amelioration	O
of	O
hyper-pigmentation	O
conditions	O
and	O
for	O
the	O
lightening	O
of	O
skin,	O
and	O
to	O
the	O
use	O
of	O
A3	B-GENE
adenosine	I-GENE
receptor	I-GENE
agonists	O
in	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
and	O
amelioration	O
of	O
hypo-pigmentation	O
conditions	O
and	O
for	O
the	O
tanning	O
of	O
skin	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof,	O
wherein	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
the	O
application	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
a	O
process	O
for	O
the	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body,	O
in	O
particular	O
with	O
regard	O
to	O
C-Met	B-GENE
tyrosine	I-GENE
kinase	I-GENE
mediated	O
disease	O
;	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
for	O
manufacturing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
such	O
diseases	O
;	O
pharamaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
optionally	O
in	O
the	O
presence	O
of	O
a	O
combination	O
partner	O
;	O
processes	O
for	O
the	O
preparation	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O


A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
wherein	O
Z	O
represents	O
nitrogen	O
atom	O
or	O
C-X	O
;	O
X	O
represents	O
hydrogen	O
atom	O
or	O
fluorine	O
atom	O
;	O
R1	O
is	O
hydrogen	O
atom	O
or	O
a	O
C1-C3	O
alkyl	O
group	O
;	O
L	O
represents	O
single	O
bond	O
or	O
a	O
C1-C6	O
alkylene	O
group	O
which	O
may	O
be	O
substituted	O
;	O
Y	O
represents	O
single	O
bond,	O
sulfur	O
atom,	O
oxygen	O
atom,	O
NH,	O
or	O
the	O
like	O
;	O
R2	O
represents	O
hydrogen	O
atom	O
or	O
a	O
cyclic	O
group	O
which	O
may	O
be	O
substituted,which	O
is	O
used	O
for	O
preventive	O
and	O
/	O
or	O
therapeutic	O
treatment	O
of	O
a	O
disease	O
caused	O
by	O
abnormal	O
activity	O
of	O
tau	B-GENE
protein	I-GENE
kinase	I-GENE
1	I-GENE
such	O
as	O
a	O
neurodegenerative	O
diseases	O
(	O
e	O
.	O
g	O
.	O
Alzheimer	O
disease	O
)	O
.	O


The	O
present	O
invention,	O
relates	O
to	O
methods	O
including	O
compounds,	O
derivatives,	O
antibodies,	O
interfering	O
RNA,	O
biologies,	O
polypeptides,	O
dominant	O
negative	O
effectors,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
by	O
inhibition	O
of	O
transient	B-GENE
receptor	I-GENE
potential	I-GENE
(TRP)	I-GENE
channels	I-GENE
.	O
In	O
another	O
embodiment,	O
this	O
invention	O
relates	O
to	O
inhibitors,	O
antagonists,	O
and	O
agonists	O
of	O
TRPC4	B-GENE
.	O
TRPC4	B-GENE
therapeutic	O
agents	O
and	O
modulators	O
include	O
but	O
are	O
not	O
limited	O
to	O
small	O
molecule	O
inhibitors,	O
compounds,	O
amino	O
acid	O
derivatives,	O
polypeptides,	O
RNA	O
interference	O
agents,	O
natural	O
chemicals,	O
ligand	O
derivatives,	O
and	O
ions	O
.	O
TRPC4	B-GENE
therapeutic	O
agents	O
and	O
modulators	O
are	O
developed	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain,	O
including	O
but	O
not	O
limited	O
to	O
pain	O
sensations	O
such	O
as	O
nociception,	O
hyperalgesia,	O
allodynia,	O
and	O
loss	O
of	O
sensory	O
function	O
.	O


This	O
application	O
relates	O
to	O
compounds	O
having	O
inverse	O
agonist	O
functional	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
receptors	I-GENE
containing	O
the	O
α5	B-GENE
subunit	O
for	O
use	O
as	O
a	O
medicament	O
in	O
the	O
treatment	O
of	O
cognitive	O
impairments	O
in	O
subjects	O
suffering	O
from	O
Down	O
syndrome	O
.	O
The	O
present	O
application	O
also	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
having	O
inverse	O
agonist	O
functional	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
receptors	I-GENE
containing	O
the	O
α5	B-GENE
subunit	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
in	O
the	O
treatment	O
of	O
cognitive	O
impairments	O
in	O
subjects	O
suffering	O
from	O
Down	O
syndrome	O
.	O
The	O
application	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
treating	O
cognitive	O
impairments	O
in	O
subjects	O
suffering	O
from	O
Down	O
syndrome	O
comprising	O
a	O
compound	O
having	O
inverse	O
agonist	O
functional	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
receptors	I-GENE
containing	O
the	O
α5	B-GENE
subunit,	O
or	O
suitable	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
a	O
polyethoxylated	O
castor	O
oil	O
and	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
.	O
The	O
present	O
application	O
also	O
describes	O
methods	O
for	O
enhancing	O
cognitive	O
function,	O
or	O
treating	O
or	O
lessening	O
the	O
severity	O
of	O
cognitive	O
impairments,	O
in	O
subjects	O
suffering	O
from	O
Down	O
syndrome	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
compounds	O
having	O
inverse	O
agonist	O
functional	O
selectivity	O
for	O
GABA	B-GENE
A	I-GENE
receptors	I-GENE
containing	O
the	O
α5	B-GENE
subunit	O
.	O
More	O
particularly,	O
the	O
present	O
application	O
is	O
concerned	O
with	O
the	O
treatment	O
of	O
cognitive	O
impairments,	O
such	O
as	O
impairment	O
in	O
memory,	O
learning	O
capacity	O
or	O
both,	O
in	O
subjects	O
suffering	O
from	O
Down	O
syndrome	O
.	O


Methods	O
of	O
treating	O
a	O
wound,	O
an	O
ulcer	O
and	O
/	O
or	O
a	O
burn	O
responsive	O
to	O
inhibition	O
of	O
xanthine	B-GENE
oxidoreductase	I-GENE
to	O
thereby	O
reduce	O
uric	O
acid	O
in	O
an	O
animal	O
are	O
provided	O
wherein	O
the	O
methods	O
include	O
topical	O
administration	O
of	O
a	O
therapeutic	O
agent	O
effective	O
for	O
treatment	O
of	O
the	O
wound,	O
the	O
ulcer	O
and	O
/	O
or	O
the	O
burn	O
wherein	O
the	O
therapeutic	O
agent	O
inhibits	O
xanthine	B-GENE
oxidoreductase	I-GENE
to	O
thereby	O
reduce	O
uric	O
acid	O
in	O
the	O
wound,	O
ulcer	O
and	O
/	O
or	O
burn	O
.	O
Also	O
provided	O
are	O
methods	O
and	O
kits	O
for	O
determining	O
the	O
severity	O
of	O
a	O
wound,	O
a	O
burn	O
and	O
/	O
or	O
an	O
ulcer	O
including	O
the	O
step	O
of	O
detecting	O
one	O
or	O
more	O
of	O
(	O
i	O
)	O
a	O
level	O
of	O
uric	O
acid	O
;	O
(	O
ii	O
)	O
a	O
level	O
of	O
one	O
or	O
more	O
uric	O
acid	O
precursors	O
;	O
and	O
(	O
iii	O
)	O
a	O
presence,	O
or	O
absence	O
of,	O
or	O
level	O
of	O
xanthine	B-GENE
oxidoreductase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
combination	O
of	O
1-benzyl-3-hydroxymethyl-indazole	O
derivative,	O
a	O
pressure	O
lowering	O
agent	O
selected	O
from	O
ACE-inhibitors,	O
renin	B-GENE
inhibitors,	O
ARBs	O
and	O
CCBs,	O
and	O
/	O
or	O
a	O
cholesterol	O
lowering	O
agent	O
selected	O
from	O
statin	O
derivatives	O
.	O
The	O
combination	O
showed	O
an	O
additive	O
and	O
synergistic	O
activity	O
in	O
reducing	O
MCP-1	B-GENE
levels,	O
thus	O
significantly	O
improving	O
inflammatory	O
response	O
inhibition	O
and	O
consequently	O
reducing	O
complications	O
occurring	O
in	O
patients	O
suffering	O
from	O
inflammatory	O
diseases	O
.	O


Described	O
herein	O
are	O
novel	O
beta-secretase	B-GENE
inhibitors	O
and	O
methods	O
for	O
their	O
use,	O
including	O
methods	O
of	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
is	O
concerned	O
with	O
novel	O
bicyclic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A,	O
L,	O
E,	O
F,	O
G,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
V,	O
W	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O
These	O
compounds	O
are	O
antagonists	O
of	O
CCR2	B-GENE
receptor,	O
CCR5	B-GENE
receptor	O
and	O
/	O
or	O
CCR3	B-GENE
receptor	O
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


The	O
present	O
invention	O
concerns	O
the	O
field	O
of	O
cancer	O
therapy	O
.	O
In	O
particular,	O
it	O
relates	O
to	O
an	O
antagonist	O
of	O
a	O
B-type	B-GENE
plexin	I-GENE
which	O
prevents	O
the	O
interaction	O
of	O
the	O
B-type	B-GENE
plexin	I-GENE
with	O
ErbB-2	B-GENE
for	O
use	O
as	O
a	O
medicament,	O
in	O
particular,	O
for	O
treating	O
metastasizing	O
cancer	O
.	O
The	O
present	O
invention	O
also	O
contemplates	O
a	O
method	O
for	O
identifying	O
an	O
antagonist	O
which	O
prevents	O
the	O
interaction	O
of	O
a	O
B-type	B-GENE
plexin	I-GENE
with	O
ErbB-2	B-GENE
.	O
Finally,	O
the	O
invention	O
provides	O
for	O
a	O
polynucleotide	O
encoding	O
a	O
B-type	B-GENE
plexin	I-GENE
polypeptide	O
which	O
lacks	O
a	O
functional	O
intracellular	O
domain	O
and	O
the	O
said	O
polypeptide	O
.	O


This	O
invention	O
relates	O
to	O
modulation	O
of	O
the	O
α7	B-GENE
nicotinic	I-GENE
acetylcholine	I-GENE
receptor	I-GENE
(	O
nAChR	B-GENE
)	O
by	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


3-	O
(	O
5,	O
6-Dichloro-pyridin-3-yl	O
)	O
-IS,	O
5S-3,	O
6-diazabicyclo	O
[	O
3	O
.	O
2	O
.	O
0	O
]	O
heptane	O
(	O
SOFINICLINE,	O
ABT-894	O
)	O
and	O
salts	O
thereof	O
are	O
effective	O
nicotinic	B-GENE
receptor	I-GENE
agonist	O
compounds	O
that	O
demonstrated	O
pharmacological	O
effect	O
for	O
symptoms	O
associated	O
with	O
attention-def	O
icit	O
/	O
hyperactivity	O
disorder	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I,	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
microsomal	B-GENE
prostaglandin	I-GENE
E2	I-GENE
synthase-1	I-GENE
(	O
mPGES-1	B-GENE
)	O
,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
inflammatory	O
diseases	O
and	O
associated	O
conditions	O
such	O
as	O
inflammatory	O
/	O
nociceptive	O
pain	O
.	O
A,	O
M,	O
R1,	O
R2,	O
R7	O
'	O
Ra,	O
Rb,	O
Q3,	O
Q4,	O
Q6,	O
Z2,	O
Z4,	O
Z5,	O
Z6	O
and	O
W	O
have	O
meanings	O
given	O
in	O
the	O
description	O
.	O


Compound	O
of	O
formula	O
I	O
are	O
antagonists	O
of	O
the	O
PGD2	O
receptor,	O
CRTH2,	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
CRTH2-mediated	O
diseases	O
such	O
as	O
asthma	O
in	O
combination	O
with	O
a	O
second	O
active	O
ingredient	O
such	O
as	O
a	O
leukotriene	O
antagonist	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
potent	O
inhibitors	O
of	O
Aurora	B-GENE
A	I-GENE
kinase,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O


Compounds	O
of	O
structure	O
(	O
I	O
)	O
:	O
including	O
stereoisomers	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
X,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
herein	O
.	O
Such	O
compounds	O
have	O
activity	O
as	O
SHIP1	B-GENE
modulators,	O
and	O
thus	O
may	O
be	O
used	O
to	O
treat	O
any	O
of	O
a	O
variety	O
of	O
diseases,	O
disorders	O
or	O
conditions	O
that	O
would	O
benefit	O
from	O
SHIP1	B-GENE
modulation	O
.	O
Compositions	O
comprising	O
a	O
compound	O
of	O
structure	O
(	O
I	O
)	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
diluent	O
are	O
also	O
disclosed,	O
as	O
are	O
methods	O
of	O
SHIP1	B-GENE
modulation	O
by	O
administration	O
of	O
such	O
compounds	O
to	O
an	O
animal	O
in	O
need	O
thereof	O
.	O


Compounds	O
and	O
compositions	O
comprising	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
are	O
described	O
herein	O
.	O
The	O
compounds	O
and	O
compositions	O
can	O
be	O
used	O
to	O
modulate	O
an	O
isocitrate	B-GENE
dehydrogenase	I-GENE
(	O
IDH	B-GENE
)	O
mutant	O
(	O
e	O
.	O
g	O
.	O
,	O
IDHIm	B-GENE
or	O
IDH2m	B-GENE
)	O
having	O
alpha	O
hydroxyl	O
neoactivity	O
.	O


The	O
present	O
invention	O
encompasses	O
novel	O
piperin	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
m	O
and	O
n	O
are	O
defined	O
as	O
in	O
claim	O
1,	O
which	O
are	O
suitable	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
mediated	O
by	O
modulation	O
of	O
GABAA	B-GENE
receptor	I-GENE
and	O
the	O
use	O
thereof	O
for	O
preparing	O
a	O
medicament	O
having	O
the	O
above	O
mentioned	O
properties	O
.	O


The	O
invention	O
encompasses	O
pyrazolo	O
[	O
1,5-a	O
]	O
pyrimidine	O
derivatives	O
which	O
selectively	O
inhibit	O
microtubule	B-GENE
affinity	I-GENE
regulating	I-GENE
kinase	I-GENE
(	O
MARK	B-GENE
)	O
and	O
are	O
therefore	O
useful	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
also	O
included	O
.	O


The	O
present	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
compound	O
(	O
I	O
)	O
shown	O
below,	O
having	O
the	O
anti-virus	O
activity,	O
particularly	O
the	O
HIV	B-GENE
integrase	I-GENE
inhibitory	O
activity,	O
and	O
a	O
drug	O
containing	O
the	O
same,	O
particularly	O
an	O
anti-HIV	O
drug,	O
as	O
well	O
as	O
a	O
process	O
and	O
an	O
intermediate	O
thereof	O
.	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
Z1	O
is	O
NR4	O
;	O
R1	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
is	O
a	O
single	O
bond,	O
a	O
hetero	O
atom	O
group	O
selected	O
from	O
O,	O
S,	O
SO,	O
SO2	O
and	O
NH,	O
or	O
lower	O
alkylene	O
or	O
lower	O
alkenylene	O
in	O
which	O
the	O
hetero	O
atom	O
group	O
may	O
intervene	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	O
;	O
R3	O
is	O
hydrogen,	O
a	O
halogen,	O
hydroxy,	O
optionally	O
substituted	O
lower	O
alkyl	O
etc	O
;	O
and	O
R4	O
and	O
Z2	O
part	O
taken	O
together	O
forms	O
a	O
ring,	O
to	O
form	O
a	O
polycyclic	O
compound,	O
including	O
e	O
.	O
g	O
.	O
,	O
a	O
tricyclic	O
or	O
tetracyclic	O
compound	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
1	O
.	O
or	O
2	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
represents	O
straight-chain	O
or	O
branched	O
C2-C8	O
alkyl,	O
C2-C8	O
alkenyl,	O
optionally	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxyl,	O
amino	O
or	O
C1-C6	O
alkyl	O
amino	O
group,	O
or	O
C2-C4	O
alkynyl,	O
optionally	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxyl,	O
amino	O
or	O
C1-C6	O
alkyl	O
amino	O
group	O
;	O
and	O
R2	O
represents	O
hydroxyl,	O
C1-C6	O
alkyl,	O
C1-C6	O
alkylcarbonyl,	O
di	O
(	O
C1-C6-alkyl	O
)	O
aminomethyl,	O
C3-C6	O
heterocyclylmethyl	O
or	O
arylaminomethyl,	O
wherein	O
the	O
aryl	O
group	O
is	O
optionally	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogens	O
and	O
C1-C6	O
alkoxy	O
as	O
well	O
as	O
associated	O
pharmaceutical	O
compositions	O
and	O
uses	O
of	O
the	O
compound	O
or	O
composition	O
in	O
therapy,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
or	O
a	O
disease	O
susceptible	O
to	O
inhibition	O
of	O
COX-2	B-GENE
.	O


Pharmaceutically	O
acceptable	O
salts	O
of	O
pyrrolo-nitrogenous	O
heterocyclic	O
derivatives,	O
preparation	O
method	O
and	O
medical	O
use	O
thereof	O
are	O
disclosed	O
.	O
More	O
specifically,	O
pharmaceutically	O
acceptable	O
salts	O
of	O
(	O
R,Z	O
)	O
-2-	O
(	O
5-fluoro-2-oxo-1,2-dihydro-indol-3-methylene	O
)	O
-5-	O
(	O
2-hydroxy-3-morpholinyl-4-yl-propyl	O
)	O
-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo	O
[	O
3,2-c	O
]	O
azepin-4-one	O
presented	O
by	O
formula	O
(	O
I	O
)	O
,	O
the	O
preparation	O
method	O
and	O
the	O
use	O
thereof	O
as	O
therapeutic	O
agents,	O
especially	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors,	O
are	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
for	O
increasing	O
telomerase	B-GENE
activity	O
in	O
cells	O
.	O
Such	O
compositions	O
include	O
pharmaceutical,	O
including	O
topical,	O
and	O
nutraceutical	O
formulations	O
.	O
The	O
compositions	O
are	O
useful	O
for	O
treating	O
diseases	O
subject	O
to	O
treatment	O
by	O
an	O
increase	O
in	O
telomerase	B-GENE
activity	O
in	O
cells	O
or	O
tissue	O
of	O
a	O
patient,	O
such	O
as,	O
for	O
example,	O
HIV	O
infection,	O
various	O
degenerative	O
diseases,	O
and	O
acute	O
or	O
chronic	O
skin	O
aliments	O
.	O
They	O
are	O
also	O
useful	O
for	O
enhancing	O
replicative	O
capacity	O
of	O
cells	O
in	O
culture,	O
as	O
in	O
ex	O
vivo	O
cell	O
therapy	O
and	O
proliferation	O
of	O
stem	O
cells	O
.	O


The	O
present	O
invention	O
provides	O
a	O
process	O
for	O
preparing	O
novel	O
intermediates	O
of	O
Formula	O
wherein,	O
R1	O
can	O
be	O
hydrogen,	O
C1-C4	O
alkyl,	O
halogen,	O
nitro,	O
hydroxy,	O
or	O
C1-C4	O
alkoxy	O
;	O
Rx	O
can	O
be	O
selected	O
from	O
hydrophobic	O
residue	O
of	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitors	O
;	O
which	O
can	O
be	O
effectively	O
used	O
for	O
the	O
preparation	O
of	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitors	O
such	O
as	O
rosuvastatin	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O


Disclosed	O
are	O
CCR1	B-GENE
inhibitor	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
autoimmune	O
and	O
other	O
diseases	O
.	O
Also	O
disclosed	O
a	O
pharmaceutical	O
compositions	O
containing	O
the	O
same,	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O
.	O


Provided	O
herein	O
are	O
substituted	O
furanyl	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
methods	O
of	O
their	O
preparation,	O
and	O
methods	O
of	O
their	O
use	O
.	O
The	O
compounds	O
provided	O
herein	O
are	O
useful	O
for	O
the	O
treatment,	O
prevention,	O
and	O
/	O
or	O
amelioration	O
of	O
various	O
disorders,	O
including	O
cancer	O
and	O
proliferative	O
disorders	O
.	O
In	O
one	O
embodiment,	O
the	O
compounds	O
provided	O
herein	O
modulate	O
eIF4E	B-GENE
activity	O
.	O
In	O
one	O
embodiment,	O
the	O
compounds	O
provided	O
herein	O
modulate	O
the	O
Hedgehog	B-GENE
pathway	O
activity	O
.	O
In	O
one	O
embodiment,	O
the	O
compounds	O
provided	O
herein	O
are	O
used	O
in	O
combination	O
with	O
surgery,	O
radiation	O
therapy,	O
immuno	O
therapy	O
and	O
/	O
or	O
one	O
or	O
more	O
additional	O
anticancer	O
drugs	O
for	O
the	O
treatment,	O
prevention,	O
and	O
/	O
or	O
amelioration	O
of	O
cancer	O
and	O
proliferative	O
disorders	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
novel	O
dosage	O
forms	O
of	O
xanthine	B-GENE
oxidoreductase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
[	O
1,8	O
]	O
naphthyridine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
in	O
which	O
the	O
inhibition,	O
regulation	O
and	O
/	O
or	O
modulation	O
of	O
signal	O
transduction	O
by	O
ATP	B-GENE
consuming	I-GENE
proteins	I-GENE
like	O
kinases	B-GENE
plays	O
a	O
role,	O
particularly	O
to	O
inhibitors	O
of	O
TGF-beta	B-GENE
receptor	I-GENE
kinases,	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
the	O
treatment	O
of	O
kinase-induced	O
diseases,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
tumors	O
.	O


Provided	O
are	O
a	O
VEGF	B-GENE
production	O
promoter,	O
a	O
hair	O
quality	O
improver,	O
and	O
an	O
external	O
preparation	O
for	O
skin,	O
each	O
of	O
which	O
has	O
a	O
VEGF	B-GENE
production	O
promoting	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
pharmaceutical	O
agent,	O
a	O
cosmetic,	O
a	O
food,	O
or	O
a	O
material	O
therefor	O
.	O
	O
	O
	O
	O
The	O
VEGF	B-GENE
production	O
promotor,	O
the	O
hair	O
quality	O
improver,	O
and	O
the	O
external	O
preparation	O
for	O
skin	O
each	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
a	O
cycloartane-type	O
glycoside	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
(	O
where	O
R	O
represents	O
a	O
xylose	O
residue	O
or	O
an	O
arabinose	O
residue,	O
and	O
the	O
ring	O
D	O
moiety	O
represents	O
any	O
one	O
of	O
the	O
following	O
moieties	O
a	O
to	O
f	O
(	O
where	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
methyl	O
group,	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
acetyl	O
group,	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
hydroxyl	O
group,	O
R4	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
hydroxyl	O
group,	O
and	O
Ac	O
represents	O
an	O
acetyl	O
group	O
)	O
)	O
.	O


The	O
invention	O
relates	O
to	O
sulfonamide	O
derivatives,	O
to	O
their	O
use	O
i	O
n	O
medicine,	O
to	O
compositions	O
containing	O
them,	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
to	O
intermediates	O
used	O
in	O
such	O
processes	O
.	O
More	O
particularly	O
the	O
invention	O
relates	O
to	O
new	O
sulfonamide	O
Nav1.7	B-GENE
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
Z1,	O
Ra,	O
Rb,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
Nav	B-GENE
1.7	I-GENE
inhibitors	O
are	O
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
disorders,	O
particularly	O
pain	O
.	O


Phage	O
displayed	O
recombinant	O
antibody	O
library	O
was	O
developed	O
and	O
the	O
library	O
was	O
screened	O
against	O
VEGFR-2	B-GENE
.	O
After	O
screening	O
and	O
ELISA	O
experiments	O
two	O
recombinant	O
antibodies	O
showing	O
binding	O
properties	O
to	O
VEGFR-2	B-GENE
was	O
obtained	O
.	O
The	O
difference	O
of	O
the	O
two	O
recombinant	O
antibodies	O
to	O
the	O
recombinant	O
antibodies	O
already	O
developed	O
was	O
demonstrated	O
by	O
DNA	O
sequence	O
analysis	O
.	O
The	O
inhibition	O
effect	O
of	O
the	O
two	O
recombinant	O
antibodies	O
on	O
endothelial	O
cell	O
proliferation	O
was	O
demonstrated	O
with	O
cell	O
assays	O
.	O
Thus	O
these	O
recombinant	O
antibodies	O
might	O
be	O
used	O
as	O
VEGF	B-GENE
related	O
angiogenesis	O
inhibitors	O
.	O


A	O
compound	O
is	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
A	O
pharmaceutical	O
composition	O
comprises	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
A	O
method	O
of	O
treating	O
a	O
subject	O
in	O
need	O
thereof	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
subject	O
has	O
type	O
2	O
diabetes	O
;	O
renal	O
hypertrophy	O
or	O
hyperplasia	O
associated	O
with	O
diabetic	O
nephropathy	O
;	O
Tay-Sachs	O
;	O
Gaucher	O
'	O
s	O
or	O
Fabry	O
'	O
s	O
disease	O
.	O
Methods	O
of	O
decreasing	O
plasma	O
TNF-α,	O
lowering	O
blood	O
glucose	O
levels,	O
decreasing	O
glycated	O
hemoglobin	B-GENE
levels,	O
inhibiting	O
glucosylceramide	O
synthase,	O
and	O
lowering	O
glycosphingolipid	O
concentration	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
respectively	O
comprise	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
recombinant	O
LAG-3	B-GENE
or	O
derivatives	O
thereof	O
in	O
order	O
to	O
boost	O
a	O
monocyte-mediated	O
immune	O
response,	O
in	O
particular	O
to	O
elicit	O
an	O
increase	O
in	O
the	O
number	O
of	O
monocytes	O
in	O
blood	O
.	O
	O
	O
	O
	O
This	O
finds	O
use	O
in	O
the	O
development	O
of	O
novel	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
an	O
infectious	O
disease	O
or	O
cancer	O
.	O


Aminoquinazolinyl	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
described,	O
which	O
are	O
useful	O
as	O
prolyl	B-GENE
hydroxylase	I-GENE
inhibitors	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disease	O
states,	O
disorders,	O
and	O
conditions	O
mediated	O
by	O
prolyl	B-GENE
hydroxylase	I-GENE
activity	O
.	O
Thus,	O
the	O
compounds	O
may	O
be	O
administered	O
to	O
treat,	O
e	O
.	O
g	O
.	O
,	O
anemia,	O
vascular	O
disorders,	O
metabolic	O
disorders,	O
and	O
wound	O
healing	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
modulator	O
of	O
the	O
Smoothened	B-GENE
(Smo)	I-GENE
receptor	I-GENE
capable	O
of	O
altering	O
cellular	O
glucose	O
uptake	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
disease,	O
wherein	O
(	O
a	O
)	O
the	O
modulator	O
is	O
an	O
activator	O
of	O
the	O
Smoothened	B-GENE
(Smo)	I-GENE
receptor	I-GENE
capable	O
of	O
increasing	O
cellular	O
glucose	O
uptake	O
and	O
is	O
for	O
use	O
in	O
the	O
treatment	O
of	O
diabetes,	O
glucose	O
intolerance,	O
hyperglycemia,	O
obesity,	O
overweight,	O
sepsis	O
and	O
diseases	O
associated	O
therewith	O
;	O
or	O
(	O
b	O
)	O
wherein	O
the	O
modulator	O
is	O
an	O
inhibitor	O
of	O
the	O
Smoothened	B-GENE
(Smo)	I-GENE
receptor	I-GENE
capable	O
of	O
decreasing	O
cellular	O
glucose	O
uptake	O
and	O
is	O
for	O
use	O
in	O
the	O
treatment	O
of	O
hypoglycaemia	O
.	O
Further,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
of	O
altering	O
the	O
glucose	O
uptake,	O
the	O
lactate	O
level,	O
the	O
NAD+	O
/	O
NADH	O
ratio	O
and	O
/	O
or	O
the	O
NADP+	O
/	O
NADPH	O
ratio	O
of	O
a	O
cell	O
and	O
a	O
method	O
of	O
identifying	O
a	O
modulator	O
of	O
the	O
Smoothened	B-GENE
(Smo)	I-GENE
receptor	I-GENE
capable	O
of	O
altering	O
the	O
glucose	O
uptake,	O
the	O
lactate	O
level,	O
the	O
NAD+	O
/	O
NADH	O
ratio	O
and	O
/	O
or	O
the	O
NADP+	O
/	O
NADPH	O
ratio	O
of	O
a	O
cell	O
.	O
Also,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
of	O
increasing	O
uptake	O
of	O
glucose	O
or	O
a	O
glucose	O
analogue	O
labelled	O
with	O
a	O
detectable	O
moiety	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
fused	O
tricyclic	O
compounds	O
that	O
are	O
inhibitors	O
of	O
mammalian	B-GENE
Target	I-GENE
of	I-GENE
Rapamycin	I-GENE
(	O
mTOR	B-GENE
)	O
kinase,	O
which	O
is	O
also	O
known	O
as	O
FRAP,	O
RAFT,	O
RAPT	B-GENE
or	O
SEP,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cellular	O
proliferative	O
diseases,	O
for	O
example	O
cancer	O
and	O
other	O
proliferative	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
forms	O
of	O
(	O
4-	O
{	O
4-	O
[	O
5-	O
(	O
6-Trifluoromethyl-pyridin-3-ylamino	O
)	O
-pyridin-2-yl	O
]	O
-phenyl	O
}	O
-cyclohexyl	O
)	O
-acetic	O
acid,	O
sodium	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
condition	O
or	O
a	O
disorder	O
associated	O
with	O
DGAT1	B-GENE
activity	O
in	O
animals,	O
particularly	O
humans	O
.	O
It	O
also	O
relates	O
processes	O
for	O
making	O
such	O
novel	O
crystalline	O
forms	O
.	O


The	O
methods	O
and	O
compositions	O
of	O
the	O
present	O
invention	O
are	O
directed	O
to	O
the	O
treatment	O
or	O
amelioration	O
of	O
muscle	O
cramps	O
using	O
a	O
composition	O
that	O
includes	O
one	O
or	O
more	O
TRPV1	B-GENE
channel	I-GENE
activators,	O
and	O
/	O
or	O
one	O
or	O
more	O
TRPA1	B-GENE
channel	I-GENE
activators,	O
and	O
/	O
or	O
one	O
or	O
more	O
ASIC	B-GENE
channel	I-GENE
activators	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
class	O
of	O
compounds	O
useful	O
for	O
the	O
modulation	O
of	O
beta-secretase	B-GENE
enzyme	O
(	O
BACE	B-GENE
)	O
activity	O
.	O
The	O
compounds	O
have	O
a	O
general	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
variables	O
A1,	O
A3,	O
A4,	O
A5,	O
A6,	O
A8,	O
L,	O
R2,	O
R7,	O
R9,	O
W	O
and	O
Y	O
of	O
Formula	O
(	O
I	O
)	O
are	O
defined	O
herein	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
corresponding	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
disorders	O
and	O
/	O
or	O
conditions	O
related	O
to	O
plaque	O
formation	O
and	O
deposition,	O
resulting	O
from	O
the	O
activity	O
of	O
BACE	B-GENE
.	O
Such	O
BACE	B-GENE
mediated	O
disorders	O
include,	O
for	O
example,	O
Alzheimer	O
'	O
s	O
Disease,	O
cognitive	O
deficits,	O
cognitive	O
impairments,	O
schizophrenia	O
and	O
other	O
central	O
nervous	O
system	O
conditions	O
.	O
The	O
invention	O
further	O
provides	O
compounds	O
of	O
Formulas	O
(	O
II	O
)	O
and	O
(	O
III	O
)	O
,	O
sub-Formula	O
embodiments	O
of	O
Formulas	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
and	O
(	O
III	O
)	O
,	O
intermediates	O
and	O
processes	O
and	O
methods	O
useful	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
Formulae	O
(	O
I-III	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
crystalline	O
anhydrous	O
form	O
of	O
[	O
(	O
5-chlorothiophene-2-	O
ylsulfonylcarbamoyl	O
)	O
-	O
(	O
4-	O
(	O
6-fluoro-7-	O
(	O
methylamino	O
)	O
-2,4-dioxo-1,2-dihydroquinazolin-3	O
(	O
4H	O
)	O
-	O
yl	O
)	O
phenyl	O
)	O
amide,	O
potassium	O
salt,	O
and	O
its	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
condition	O
or	O
a	O
disorder	O
with	O
platelet	O
ADP	B-GENE
receptor	I-GENE
inhibition,	O
in	O
particular,	O
P2Y12	B-GENE
inhibition,	O
in	O
animals,	O
particularly	O
humans	O
.	O
It	O
also	O
relates	O
processes	O
for	O
making	O
such	O
a	O
novel	O
crystalline	O
form	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
solid,	O
oral	O
formulation	O
of	O
this	O
novel	O
crystalline	O
form,	O
its	O
preparation	O
and	O
use	O
thereof	O
.	O


Disclosed	O
are	O
nutritional	O
compositions	O
that	O
include	O
beta-hydroxy-beta-methylbutyrate	O
.	O
The	O
nutritional	O
compositions	O
may	O
be	O
administered	O
to	O
prevent	O
and	O
/	O
or	O
reduce	O
and	O
/	O
or	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
downregulation	O
of	O
serine-threonine	B-GENE
kinase	I-GENE
protein	I-GENE
kinase	I-GENE
B	I-GENE
(	O
Akt	B-GENE
/	O
PKB	B-GENE
)	O
signaling	O
pathways,	O
with	O
the	O
concomitant	O
FOXO	B-GENE
transcription	I-GENE
factors	I-GENE
activation,	O
such	O
as	O
muscle	O
wasting,	O
diabetes,	O
infertility,	O
neurodegeneration,	O
and	O
immune	O
system	O
dysfunction	O
.	O


This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
microsomal	B-GENE
prostaglandin	I-GENE
E2	I-GENE
synthase-1	O
(	O
mPGES-1	B-GENE
)	O
,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
the	O
10	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
inflammatory	O
diseases	O
and	O
associated	O
conditions	O
.	O
A,	O
M,	O
W,	O
R1,	O
R2,	O
R3,	O
R4,	O
R6,	O
R2,R7,	O
R8,	O
R9,	O
Ra,	O
Rb	O
have	O
meanings	O
given	O
in	O
the	O
description	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts,	O
wherein	O
R1,	O
R2,	O
R3,	O
A,	O
B,	O
Z,	O
n,	O
and	O
m	O
are	O
defined	O
in	O
the	O
description	O
.	O
The	O
present	O
invention	O
relates	O
also	O
to	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
ALK	B-GENE
and	O
methods	O
of	O
treating	O
diseases	O
such	O
as	O
cancer	O
.	O


Pharmaceutical	O
compositions	O
comprising	O
an	O
SGLT2	B-GENE
inhibitor	O
with	O
a	O
supply	O
of	O
carbohydrate	O
or	O
an	O
inhibitor	O
of	O
uric	O
acid	O
synthesis	O
or	O
a	O
supply	O
of	O
carbohydrate	O
and	O
an	O
inhibitor	O
of	O
uric	O
acid	O
synthesis	O
are	O
provided	O
in	O
the	O
instant	O
invention	O
and	O
are	O
provided	O
for	O
use	O
in	O
methods	O
for	O
treating	O
hyperuricemia	O
.	O


The	O
invention	O
relates	O
to	O
selective,	O
non-steroidal	O
17beta-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
2	I-GENE
(	O
17beta-HSD2	B-GENE
)	O
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
production	O
and	O
use,	O
notably	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
sex	O
steroid	O
deficient	O
diseases	O
like	O
osteoporosis	O
in	O
men	O
and	O
women	O
.	O


There	O
is	O
provided	O
a	O
compound	O
which	O
is	O
a	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
inhibitor,	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester,	O
amide,	O
solvate	O
or	O
salt	O
thereof,	O
for	O
use	O
in	O
:	O
(	O
I	O
)	O
treating	O
or	O
preventing	O
a	O
pathological	O
condition	O
associated	O
with	O
excess	O
fibrin	O
deposition	O
and	O
/	O
or	O
thrombus	O
formation	O
;	O
and	O
/	O
or	O
(	O
II	O
)	O
potentiating	O
the	O
degradation	O
of	O
fibrin	O
deposits	O
and	O
preventing	O
such	O
deposits	O
associated	O
with	O
pathological	O
conditions	O
or	O
which	O
may	O
lead	O
to	O
such	O
conditions,	O
wherein	O
the	O
HDAC	B-GENE
inhibitor,	O
and	O
the	O
dose	O
thereof,	O
is	O
as	O
described	O
in	O
the	O
description	O
.	O
There	O
is	O
also	O
provided	O
valproic	O
acid,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
for	O
use	O
in	O
improving	O
or	O
normalizing	O
endogenous	O
fibrinolysis	O
impaired	O
by	O
local	O
or	O
systemic	O
inflammation	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
along	O
with	O
processes	O
for	O
their	O
preparation	O
that	O
are	O
useful	O
for	O
treating,	O
managing	O
and	O
/	O
or	O
lessening	O
the	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
the	O
modulation	O
of	O
calcium	B-GENE
sensing	I-GENE
(Ca	I-GENE
SR)	I-GENE
receptors	I-GENE
.	O
Methods	O
of	O
treating,	O
managing	O
and	O
/	O
or	O
lessening	O
the	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
the	O
modulation	O
of	O
calcium	B-GENE
sensing	I-GENE
(Ca	I-GENE
SR)	I-GENE
receptors	I-GENE
of	O
Formula	O
(	O
I	O
)	O
.	O


Disclosed	O
are	O
the	O
CCR2	B-GENE
antagonists	O
of	O
Formula	O
I	O
:	O
I	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
R7,	O
A,	O
X,	O
B,	O
and	O
n	O
are	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
methods	O
of	O
treatment	O
using	O
the	O
compounds,	O
and	O
compositions	O
to	O
treat	O
diseases	O
or	O
disorders	O
associated	O
with	O
CCR2	B-GENE
activity	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X,	O
R1,	O
R2,	O
T0,	O
o	O
have	O
the	O
meaning	O
as	O
cited	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O
Said	O
compounds	O
are	O
useful	O
as	O
inhibitors	O
of	O
mTOR	B-GENE
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
mTOR	B-GENE
related	O
diseases	O
and	O
disorders	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
including	O
said	O
compounds,	O
the	O
preparation	O
of	O
such	O
compounds	O
as	O
well	O
as	O
the	O
use	O
as	O
medicaments	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrimidinyl-pyrrole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
modulate	O
the	O
activity	O
of	O
protein	B-GENE
kinases	I-GENE
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
caused	O
by	O
dysregulated	O
protein	B-GENE
kinase	I-GENE
activity,	O
in	O
particular	O
Janus	B-GENE
kinases	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
preparing	O
these	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
methods	O
of	O
treating	O
diseases	O
utilizing	O
such	O
compounds	O
or	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
relates	O
to	O
an	O
interleukin-27	B-GENE
(	O
IL-27	B-GENE
)	O
modulator	O
for	O
the	O
treatment	O
of	O
a	O
pathological	O
immune	O
response	O
associated	O
with	O
acute	O
lung	O
disease	O
.	O
The	O
invention	O
therefore	O
relates	O
to	O
IL-27	B-GENE
agonists,	O
preferably	O
IL-27	B-GENE
protein,	O
for	O
the	O
treatment	O
of	O
immunopathology	O
and	O
/	O
or	O
uncontrolled	O
inflammatory	O
lung	O
disease,	O
as	O
well	O
as	O
IL-27	B-GENE
antagonists	O
for	O
the	O
treatment	O
of	O
immune	O
response	O
depression	O
.	O
The	O
IL-27	B-GENE
agonist	O
is	O
preferably	O
administered	O
at	O
a	O
defined,	O
preferably	O
delayed,	O
stage	O
of	O
infection	O
or	O
inflammation	O
.	O


[	O
Problem	O
]	O
	O
	O
	O
	O
To	O
provide	O
a	O
GPR40	B-GENE
activating	O
agent	O
having,	O
as	O
an	O
active	O
ingredient,	O
a	O
novel	O
compound	O
having	O
a	O
GPR40	B-GENE
agonist	O
action,	O
a	O
salt	O
of	O
the	O
compound,	O
a	O
solvate	O
of	O
the	O
salt	O
or	O
the	O
compound,	O
or	O
the	O
like,	O
particularly,	O
an	O
insulin	B-GENE
secretagogues	O
and	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
against	O
diabetes,	O
obesity,	O
or	O
other	O
diseases	O
.	O
	O
	O
	O
	O
[	O
Means	O
of	O
solving	O
the	O
problem	O
]	O
	O
	O
	O
	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
(	O
where	O
n	O
is	O
0	O
to	O
2	O
;	O
p	O
is	O
0	O
to	O
4	O
;	O
his	O
0	O
to	O
3	O
;	O
j	O
is	O
0	O
to	O
3	O
;	O
k	O
is	O
0	O
to	O
2	O
;	O
a	O
ring	O
B	O
is	O
an	O
aryl	O
group	O
or	O
a	O
heteroaryl	O
group	O
;	O
X	O
is	O
O,	O
S,	O
or	O
-NR7-	O
;	O
J1	O
is	O
-CR11aR11b-	O
or	O
-NR11c-	O
;	O
J2	O
is	O
-CR12aR12b-	O
or	O
-NR12c-	O
;	O
and	O
R1	O
to	O
R12c	O
are	O
specific	O
groups	O
)	O
,	O
a	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
solvate	O
of	O
the	O
salt	O
or	O
the	O
compound	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
macrocyclic	O
lactones,	O
in	O
particular	O
avermectins,	O
in	O
the	O
treatment	O
of	O
conditions	O
whose	O
formation,	O
occurrence,	O
development	O
or	O
growth	O
is	O
associated	O
with	O
aberrant	O
Wnt	B-GENE
signalling	O
in	O
particular	O
the	O
treatment	O
of	O
colorectal	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
a	O
4-aminoquinazoline	O
derivative	O
having	O
the	O
chemical	O
structure	O
of	O
the	O
following	O
formula,	O
and	O
the	O
use	O
thereof	O
.	O
It	O
is	O
demonstrated	O
by	O
the	O
pharmacological	O
experiment	O
that,	O
the	O
compound	O
or	O
a	O
salt	O
thereof	O
according	O
to	O
the	O
present	O
invention	O
not	O
only	O
has	O
distinct	O
inhibitory	O
effect	O
on	O
histone	O
deacetylases,	O
but	O
also	O
has	O
stronger	O
differentiation	O
induction	O
and	O
anti-proliferative	O
activities	O
for	O
certain	O
tumor	O
cells	O
.	O
It	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
cancers	O
and	O
diseases	O
related	O
to	O
cell	O
differentiation	O
and	O
proliferation	O
.	O
Excellent	O
efficacy	O
is	O
observed	O
especially	O
for	O
leukemia	O
and	O
a	O
solid	O
tumor	O
.	O
As	O
demonstrated	O
by	O
the	O
animal	O
test,	O
the	O
compound	O
or	O
a	O
salt	O
thereof	O
according	O
to	O
the	O
present	O
invention	O
is	O
less	O
toxic	O
.	O


The	O
invention	O
relates	O
to	O
benzoxazepin	O
compounds	O
of	O
Formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
including	O
stereoisomers,	O
geometric	O
isomers,	O
tautomers,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
:	O
Z1	O
is	O
CR1	O
or	O
N	O
;	O
Z2	O
is	O
CR2	O
or	O
N	O
;	O
Z3	O
is	O
CR3	O
or	O
N	O
;	O
Z4	O
is	O
CR4	O
or	O
N	O
;	O
and	O
B	O
is	O
a	O
pyrazolyl,	O
imidazolyl,	O
or	O
triazolyl	O
ring	O
which	O
compounds	O
have	O
anti-cancer	O
activity,	O
and	O
more	O
specifically,	O
inhibit	O
PI3	B-GENE
kinase	I-GENE
activity	O
.	O


The	O
present	O
invention	O
provides	O
matriptase	B-GENE
inhibitors	O
and	O
compositions	O
for	O
treating	O
and	O
preventing	O
orthomyxovirus	O
infections	O
such	O
as	O
flu	O
infections	O
.	O
The	O
present	O
invention	O
also	O
provides	O
novel	O
compounds,	O
compositions,	O
methods	O
of	O
use,	O
uses	O
and	O
kits	O
thereof	O
for	O
inhibiting	O
matriptase	B-GENE
.	O
Such	O
compounds	O
are	O
useful	O
for	O
treating	O
and	O
preventing	O
orthomyxovirus	O
infections,	O
such	O
as	O
flu	O
infections,	O
and	O
for	O
inhibiting	O
tumor	O
growth,	O
progression	O
and	O
/	O
or	O
metastasis	O
.	O


1H-Indole-3-carboxamide	O
derivatives	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O
1H-Indole-3-carboxamide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
form	O
of	O
base	O
or	O
salt	O
addition	O
with	O
an	O
acid	O
or	O
base	O
or	O
their	O
enantiomers	O
and	O
diastereoisomers	O
including	O
their	O
racemic	O
mixtures,	O
are	O
new	O
.	O
A	O
:	O
bivalent	O
group	O
of	O
formula	O
(	O
Ia	O
)	O
or	O
(	O
Ib	O
)	O
;	O
R1	O
:	O
1-4C	O
alkyl	O
;	O
R2	O
:	O
1-3C	O
alkyl	O
;	O
R3	O
:	O
-NR7R8,	O
where	O
R7	O
and	O
R8	O
are	O
combined	O
together	O
with	O
nitrogen	O
atom	O
to	O
obtain	O
saturated	O
4-6	O
membered	O
heterocycle	O
ring	O
containing	O
another	O
nitrogen	O
atom,	O
and	O
the	O
heterocycle	O
ring	O
is	O
substituted	O
with	O
1-3C	O
alkyl	O
(	O
optionally	O
substituted	O
by	O
two	O
or	O
three	O
halogen	O
atoms	O
or	O
1-3C	O
alkoxy	O
(	O
optionally	O
substituted	O
by	O
two	O
or	O
three	O
halogen	O
atoms	O
)	O
)	O
;	O
and	O
R4	O
:	O
halo	O
.	O
Independent	O
claims	O
are	O
included	O
for	O
:	O
(	O
1	O
)	O
preparing	O
the	O
1H-indole-3-carboxamide	O
derivative	O
;	O
(	O
2	O
)	O
a	O
o-tolyl-vinyl-amine	O
compound	O
of	O
formula	O
(	O
IIA	O
)	O
;	O
and	O
(	O
3	O
)	O
o-tolyl-vinyl-amine	O
compound	O
of	O
formula	O
(	O
IIB	O
)	O
.	O
[	O
Image	O
]	O
[	O
Image	O
]	O
[	O
Image	O
]	O
ACTIVITY	O
:	O
Antianginal	O
;	O
Cardiant	O
;	O
Vasotropic	O
;	O
Anticoagulant	O
;	O
Thrombolytic	O
;	O
Antiarteriosclerotic	O
;	O
Antiinflammatory	O
;	O
Muscular-Gen	O
.	O
;	O
Hemostatic	O
;	O
Gynecological	O
;	O
Antianemic	O
;	O
Antisickling	O
;	O
Nephrotropic	O
;	O
Gastrointestinal-Gen	O
.	O
;	O
Antimigraine	O
;	O
Antiasthmatic	O
.	O
MECHANISM	O
OF	O
ACTION	O
:	O
Purinergic	B-GENE
(P2Y12)	I-GENE
receptor	I-GENE
antagonist	O
.	O


What	O
is	O
described	O
is	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
heterotopic	O
ossification,	O
vascular	O
calcification,	O
and	O
pathologic	O
mineralization,	O
comprising	O
administering	O
an	O
drug,	O
wherein	O
the	O
drug	O
is	O
an	O
antagonist	O
of	O
the	O
Hedgehog	B-GENE
(	O
Hh	B-GENE
)	O
pathway	O
.	O
For	O
example	O
the	O
antagonist	O
consists	O
of	O
arsenic	O
trioxide,	O
sodium	O
arsenite,	O
phenylarsine,	O
GANT-58,	O
GANT-61,	O
zerumbone	O
vismodegib	O
(	O
GDC-	O
0449,Genentech	O
)	O
,	O
bevacizumab,	O
gemcitabine,	O
nab-paclitaxel,	O
FOLFIR,	O
FOLFOX,	O
RO4929097,	O
cixutumumab,	O
cisplatin,	O
etoposide,	O
LDAC,	O
decitabine,	O
daunorubicin,	O
cytarabin,	O
rosiglitazone,	O
goserelin,	O
leuprolide,	O
capecitabine,	O
fluorouracil,	O
leucovorin,	O
oxaliplatin,	O
irinotecan,	O
diclofenac,	O
BMS-833923	O
(	O
XL139	O
)	O
,	O
IPI-926-	O
Infinity	O
Pharmaceuticals,	O
Inc	O
.	O
,	O
LDE225,	O
LEQ506-Novartis	O
Pharmaceuticals,	O
TAK-441	O
Millennium	O
Pharmaceuticals,	O
Inc	O
.	O
,	O
and	O
PF-04449913-Pfizer,	O
alone	O
or	O
in	O
combination	O
therapy	O
.	O
The	O
method	O
targets	O
pluripotent	O
mesenchymal	O
cells,	O
wherein	O
the	O
antagonist	O
inhibits	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
Hh	B-GENE
pathway	O
component,	O
for	O
example	O
by	O
decreasing	O
levels	O
of	O
mRNA	O
encoded	O
Ptch1,	O
Gli1	B-GENE
or	O
HIP	B-GENE
.	O


There	O
is	O
described	O
a	O
novel	O
group	O
of	O
cyclic	O
amine	O
derivative	O
compounds,	O
having	O
an	O
EP4	B-GENE
receptor	I-GENE
antagonistic	O
activity	O
and	O
specifically	O
pharmaceutical	O
compounds	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
alleviation	O
of	O
Prostaglandin	O
E	O
mediated	O
diseases	O
.	O
The	O
present	O
invention	O
therefore	O
relates	O
to	O
novel	O
compounds	O
which	O
are	O
selective	O
antagonists	O
of	O
the	O
EP4	B-GENE
subtype	O
of	O
PGE2	O
receptors	O
with	O
analgesic	O
and	O
antinflammatory	O
activity,	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments,	O
inter	O
alia	O
for	O
the	O
treatment	O
or	O
alleviation	O
of	O
Prostaglandin	O
E	O
mediated	O
diseases	O
such	O
as	O
acute	O
and	O
chronic	O
pain,	O
osteoarthritis,	O
inflammation-associated	O
disorder	O
as	O
arthritis,	O
rheumatoid	O
arthritis,	O
cancer,	O
migraine	O
and	O
endometriosis	O
.	O


In	O
one	O
aspect,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
increasing,	O
decreasing	O
or	O
maintaining	O
the	O
innate	O
immune	O
response	O
in	O
a	O
mammalian	O
subject	O
comprising	O
modulating	O
the	O
expression	O
of	O
DUX4-fl,	O
or	O
modulating	O
the	O
expression	O
of	O
beta-defensin	B-GENE
3	I-GENE
(	O
DEFB103	B-GENE
)	O
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
increasing,	O
decreasing	O
or	O
maintaining	O
myogenesis	O
or	O
muscle	O
differentiation	O
in	O
a	O
mammalian	O
subject	O
comprising	O
modulating	O
the	O
expression	O
of	O
beta-defensin	B-GENE
3	I-GENE
(	O
DEFB103	B-GENE
)	O
.	O
In	O
additional	O
aspects,	O
the	O
present	O
invention	O
involves	O
diagnostic	O
methods	O
based	O
on	O
assessement	O
of	O
identified	O
biomarkers	O
.	O


New	O
pyridin-2	O
(	O
1H	O
)	O
-one	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
Janus	B-GENE
Kinases	I-GENE
(	O
JAK	B-GENE
)	O
.	O


A	O
dibenzoxepin	O
derivative	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
Y	O
is	O
a	O
hydrogen	O
atom	O
and	O
the	O
like,	O
RA	O
is	O
a	O
hydrogen	O
atom	O
and	O
the	O
like,	O
X	O
is	O
the	O
formula	O
(	O
b3	O
)	O
wherein	O
RB	O
is	O
a	O
hydrogen	O
atom	O
and	O
the	O
like,	O
and	O
the	O
like,	O
A	O
is	O
the	O
formula	O
(	O
a18	O
)	O
wherein	O
R1	O
is	O
a	O
hydrogen	O
atom	O
and	O
the	O
like,	O
and	O
RC	O
and	O
RD	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
is	O
a	O
hydrogen	O
atom	O
and	O
the	O
like,	O
and	O
the	O
like,	O
which	O
has	O
a	O
PPARγ	B-GENE
agonist	O
activity	O
and	O
the	O
like,	O
and	O
useful	O
as	O
a	O
therapeutic	O
agent	O
and	O
/	O
or	O
prophylaxis	O
agent	O
and	O
the	O
like	O
for	O
type	O
2	O
diabetes	O
and	O
the	O
like,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
the	O
like	O
is	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
phosphodiesterase	B-GENE
inhibitors,	O
more	O
specifically	O
soft	O
PDE4	B-GENE
inhibitors,	O
compositions,	O
in	O
particular	O
pharmaceuticals,	O
comprising	O
such	O
inhibitors,	O
and	O
to	O
uses	O
of	O
such	O
inhibitors	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
disease	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
new	O
soft	O
PDE4	B-GENE
inhibitors	O
compositions,	O
in	O
particular	O
pharmaceuticals,	O
comprising	O
such	O
inhibitors,	O
and	O
to	O
uses	O
of	O
such	O
inhibitors	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
disease	O
.	O
In	O
addition,	O
the	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
and	O
use	O
of	O
said	O
compounds	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
application	O
to	O
a	O
number	O
of	O
therapeutic	O
indications	O
including	O
inflammatory	O
diseases	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formulae	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
which	O
are	O
useful	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitors,	O
as	O
well	O
as	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O
In	O
some	O
embodiments,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat,	O
ameliorate	O
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
c-kit	B-GENE
or	O
c-kit	B-GENE
and	O
PDGFR	B-GENE
(	O
PDGFRα,	O
PDGFRβ	B-GENE
)	O
kinases	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
cancer	O
therapeutics	O
and	O
treatment	O
of	O
cancer	O
.	O
In	O
particular,	O
it	O
relates	O
to	O
a	O
method	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
natural	O
AHR	B-GENE
ligand-dependent	O
cancer	O
comprising	O
administering	O
to	O
a	O
subject	O
suffering	O
from	O
said	O
cancer	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
AHR	B-GENE
inhibitor	O
.	O
Moreover,	O
contemplated	O
is	O
a	O
AHR	B-GENE
inhibitor	O
for	O
use	O
in	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
natural	O
AHR	B-GENE
ligand-dependent	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
2-	O
(	O
chroman-6-yloxy	O
)	O
-thiazoles	O
of	O
the	O
formula	O
I	O
in	O
which	O
Ar,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
inhibitors	O
of	O
the	O
sodium-calcium	B-GENE
exchanger	I-GENE
(	O
NCX	B-GENE
)	O
,	O
especially	O
of	O
the	O
sodium-calcium	B-GENE
exchanger	I-GENE
of	I-GENE
subtype	I-GENE
1	I-GENE
(	O
NCX1	B-GENE
)	O
,	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diverse	O
disorders	O
in	O
which	O
intracellular	O
calcium	O
homeostasis	O
is	O
disturbed,	O
such	O
as	O
arrhythmias,	O
heart	O
failure	O
and	O
stroke	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I,	O
their	O
use	O
as	O
pharmaceuticals,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
invention	O
relates	O
to	O
AKR1C3	B-GENE
inhibitors	O
and	O
to	O
processes	O
for	O
preparation	O
thereof,	O
to	O
the	O
use	O
thereof	O
for	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
and	O
to	O
the	O
use	O
thereof	O
for	O
production	O
of	O
medicaments	O
for	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases,	O
especially	O
of	O
bleeding	O
problems	O
and	O
endometriosis	O
.	O


The	O
instant	O
application	O
describes	O
novel	O
compounds	O
that	O
modulate	O
(	O
in	O
particular,	O
inhibit	O
)	O
Sirt2,	O
with	O
structures	O
according	O
to	O
Formulas	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
provided	O
herein	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
thereof,	O
methods	O
of	O
treatment	O
(	O
i	O
.	O
e	O
.	O
,	O
cancer	O
and	O
neurodegenerative	O
disease	O
)	O
by	O
administration	O
of	O
the	O
modulating	O
compounds,	O
assay	O
methods	O
for	O
finding	O
modulators	O
of	O
Sirt2,	O
and	O
kits	O
for	O
practicing	O
the	O
assay	O
method	O
.	O


[	O
Problem	O
]	O
A	O
crystal	O
of	O
(	O
2R,5S	O
)	O
-4-	O
(	O
3-chloro-4-cyanophenyl	O
)	O
-N-	O
(	O
2-cyclopropylpyrimidin-5-yl	O
)	O
-2,5-dimethylpiperazine-1-carboxamide	O
with	O
excellent	O
activity	O
as	O
an	O
androgen	B-GENE
receptor	I-GENE
(	O
AR	B-GENE
)	O
antagonistic	O
compound,	O
the	O
salts	O
thereof,	O
or	O
the	O
solvate	O
thereof,	O
which	O
is	O
suitable	O
for	O
industrialization	O
as	O
a	O
bulk	O
drug	O
of	O
pharmaceutical	O
products	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
crystal	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
the	O
pharmaceutical	O
composition	O
which	O
is	O
the	O
AR	B-GENE
antagonistic	O
drug	O
are	O
provided	O
.	O
	O
	O
	O
	O
[	O
Solution	O
]	O
A01-type	O
crystal	O
of	O
monohydrate,	O
A01-type	O
crystal	O
of	O
hydrochloride,	O
A01-type	O
crystal	O
of	O
hydrobromide,	O
and	O
A01-type	O
crystal	O
of	O
methanesulfonate	O
of	O
(	O
2R,	O
5S	O
)	O
-4-	O
(	O
3-chloro-4-cyanophenyl	O
)	O
-N-	O
(	O
2-cyclopropylpyrimidin-5-yl	O
)	O
-2,5-dimethylpiperazine-1-carboxamide,	O
which	O
have	O
certain	O
crystal	O
forms,	O
are	O
provided	O
.	O


The	O
meglumine	O
salt	O
of	O
1-	O
(	O
5,6-dichloro-1H-benzo	O
[	O
d	O
]	O
imidazol-2-yl	O
)	O
-1H-pyrazole-4-carboxylic	O
acid	O
(	O
compound	O
(	O
1	O
)	O
)	O
and	O
pharmaceutically	O
acceptable	O
formulations	O
thereof	O
are	O
described	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disease	O
states,	O
disorders,	O
and	O
conditions	O
mediated	O
by	O
prolyl	B-GENE
hydroxylase	I-GENE
activity	O
.	O


Disclosed	O
is	O
a	O
composition	O
comprising	O
all-cis-5,8,11,14,17-icosapentaenoic	O
acid	O
for	O
use	O
in	O
the	O
prevention	O
of	O
a	O
cardiovascular	O
event	O
in	O
a	O
hypercholesterolemia	O
patient	O
undergoing	O
treatment	O
with	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
and	O
suffering	O
from	O
additional	O
risk	O
factors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
phosphoinositide	O
3-kinase	O
inhibitor	O
compound	O
and	O
(	O
b	O
)	O
a	O
compound	O
which	O
modulates	O
the	O
JAK2-STAT5	O
pathway	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease,	O
especially	O
a	O
solid	O
tumor	O
disease	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
combination	O
;	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
;	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
such	O
a	O
combination	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous,	O
separate	O
or	O
sequential	O
use	O
;	O
and	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
warm-blooded	O
animal,	O
especially	O
a	O
human	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
Phosphodiesterase	B-GENE
4	I-GENE
inhibitors	O
without	O
vomiting,	O
which	O
is	O
compounds	O
or	O
a	O
prodrugs	O
or	O
solvates	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
R1	O
is	O
an	O
independent	O
methoxy,	O
bromine	O
and	O
substituted	O
aryl	O
;	O
X	O
is	O
an	O
optionally	O
substituted	O
six-membered	O
heterocyclic	O
ring	O
;	O
Y	O
is	O
-	O
(	O
CH2	O
)	O
n-,	O
-NH	O
(	O
CH2	O
)	O
n-,	O
and-NH	O
(	O
CH2	O
)	O
n-O-,	O
wherein	O
n	O
is	O
any	O
value	O
among	O
0,	O
1,	O
2	O
and	O
3	O
;	O
Z	O
is	O
an	O
optionally	O
substituted	O
aromatic	O
ring	O
or	O
an	O
optionally	O
substituted	O
heteroaromatic	O
ring	O
.	O
The	O
present	O
invention	O
is	O
relates	O
to	O
a	O
kind	O
of	O
Phosphodiesterase	B-GENE
4	I-GENE
inhibitors	O
without	O
vomiting,	O
which	O
is	O
a	O
novel	O
biphenyl	O
series	O
PDE4D	B-GENE
inhibitor,	O
and	O
can	O
be	O
applied	O
to	O
treat	O
depression	O
and	O
Alzheimer	O
'	O
s	O
disease,	O
improve	O
cognitive	O
ability	O
and	O
avoid	O
vomiting	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
an	O
antisense	O
compound	O
for	O
inducing	O
exon	O
inclusion	O
as	O
a	O
treatment	O
for	O
Spinal	O
Muscle	O
Atrophy	O
(	O
SMA	O
)	O
.	O
More	O
particularly	O
it	O
relates	O
to	O
inducing	O
inclusion	O
of	O
exon	O
7	O
to	O
restore	O
levels	O
of	O
Survival	B-GENE
Motor	I-GENE
Neuron	I-GENE
(SMN)	I-GENE
protein	I-GENE
encoded	O
by	O
the	O
Survival	B-GENE
Motor	I-GENE
Neuron	I-GENE
(SMN)	I-GENE
gene	I-GENE
.	O


Methods	O
for	O
screening	O
for	O
potential	O
modulators	O
of	O
mammalian	B-GENE
target	I-GENE
of	I-GENE
rapamycin	I-GENE
(	O
mTOR	B-GENE
)	O
are	O
provided	O
based	O
on	O
detecting	O
cellular	O
ATP	O
levels	O
.	O
Also	O
provided	O
are	O
compositions	O
useful	O
in	O
treating	O
diseases	O
or	O
conditions	O
dependent	O
on	O
mTOR	B-GENE
signaling,	O
including	O
cancer,	O
rheumatoid	O
arthritis,	O
restinosis	O
and	O
transplant	O
rejection	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
methods	O
of	O
modifying	O
drug	O
clearance	O
and	O
avoiding	O
multi-drug	O
resistance	O
by	O
modifying	O
SXR	B-GENE
activity	O
.	O
SXR	B-GENE
is	O
a	O
transcriptional	O
activator	O
of	O
MDR1,	O
cytochrome	B-GENE
P40-3A4	I-GENE
and	O
cytochrome	B-GENE
P40	I-GENE
2C8	I-GENE
.	O
SXR	B-GENE
activation	O
can	O
significantly	O
increase	O
the	O
metabolic	O
inactivation	O
and	O
efflux	O
of	O
a	O
wide	O
range	O
of	O
chemotherapeutic	O
agents,	O
for	O
example	O
taxanes	O
.	O
Reducing	O
and	O
/	O
or	O
preventing	O
SXR	B-GENE
activation	O
therefore	O
diminishes	O
drug	O
resistance	O
and	O
drug	O
clearance	O
and	O
forms	O
the	O
basis	O
of	O
important	O
therapeutic	O
methods	O
which	O
increase	O
the	O
performance	O
of	O
drugs,	O
such	O
as	O
taxanes	O
.	O
Screening	O
and	O
drug	O
identification	O
methods	O
are	O
described	O
which	O
can	O
identify	O
drugs	O
which	O
are	O
not	O
susceptible	O
to	O
SXR	B-GENE
related	O
inactivation	O
and	O
increased	O
efflux	O
.	O
In	O
addition,	O
drugs	O
which	O
can	O
reduce	O
these	O
effects	O
for	O
other	O
agents	O
are	O
provided	O
.	O


The	O
present	O
invention	O
is	O
provides	O
benzoic	O
acid	O
derivatives	O
and	O
uses	O
thereof	O
.	O
In	O
accordance	O
with	O
one	O
aspect	O
there	O
is	O
provided	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
stereoisomers	O
thereof,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
hydrates	O
thereof,	O
or	O
physiologically	O
acceptable	O
and	O
hydrolysable	O
esters	O
thereof	O
;	O
wherein	O
:	O
R1	O
is	O
H,	O
OH,	O
halogen,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO—	O
;	O
R2	O
is	O
H,	O
OH,	O
halogen,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO—	O
;	O
r3	O
is	O
H,	O
OH,	O
halogen,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO	O
;	O
R4	O
is	O
H,	O
OH,	O
halogen,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO—	O
;	O
R5	O
is	O
H,	O
OH,	O
halogen,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO—	O
;	O
Y	O
is	O
O	O
or	O
—NR′,	O
wherein	O
R′	O
is	O
H	O
or	O
(	O
C1-C4	O
)	O
alkyl	O
;	O
n	O
is	O
0-8	O
;	O
R6	O
is	O
a	O
5	O
to	O
8	O
membered	O
lactone	O
or	O
lactam	O
ring	O
;	O
R7	O
is	O
H,	O
(	O
C1-C4	O
)	O
alkyl,	O
(	O
C1-C4	O
)	O
alkenyl,	O
(	O
C1-C4	O
)	O
alkoxy,	O
phenyl	O
or	O
(	O
C1-C4	O
)	O
alkyl-COO—,	O
wherein	O
the	O
lactam	O
or	O
lactone	O
ring	O
optionally	O
comprises	O
one	O
or	O
more	O
C═C	O
double	O
bonds	O
and	O
the	O
lactam	O
or	O
lactone	O
ring	O
is	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
(	O
C1-C4	O
)	O
alkenyl	O
groups	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
with	O
an	O
etiology	O
associated	O
with	O
or	O
comprising	O
excessive	O
cytokine	B-GENE
release	O
.	O
The	O
compounds	O
are	O
also	O
used	O
in	O
the	O
treatment	O
of	O
cancer,	O
inflammatory	O
disorders	O
and	O
disorders	O
associated	O
with	O
an	O
increased	O
stability	O
of	O
mRNA	O
which	O
has	O
an	O
mRNA	O
instability	O
sequence	O
.	O
The	O
present	O
invention	O
further	O
provides	O
processes	O
for	O
preparing	O
benzoic	O
acid	O
derivatives	O
of	O
Formula	O
I	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
preparation	O
and	O
use	O
as	O
pharmaceutical	O
compositions	O
asintegrin	O
antagonists,	O
especially	O
as	O
α4β	B-GENE
and/or	I-GENE
α4β	B-GENE
7	I-GENE
?and/or	I-GENE
α9β1	I-GENE
intergrin	I-GENE
antagonists	O
and	O
in	O
particular	O
for	O
the	O
production	O
of	O
pharmaceutical	O
compositions	O
suitable	O
for	O
the	O
inhibition	O
or	O
the	O
prevention	O
of	O
cell	O
adhesion	O
and	O
cell-adhesion	O
mediated	O
disorders	O
.	O
Examples	O
are	O
the	O
treatment	O
and	O
the	O
prophylaxis	O
of	O
atherosclerosis,	O
asthma,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
allergies,	O
diabetes,	O
inflammatory	O
bowel	O
disease,	O
multiple	O
sclerosis,	O
myocardial	O
ischemia,	O
rheumatoid	O
arthritis,	O
transplant	O
rejection	O
and	O
other	O
inflammatory,	O
autoimmune	O
and	O
immune	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
mastocytosis	O
comprising	O
administering	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatment,	O
more	O
particularly	O
a	O
non-toxic,	O
selective	O
and	O
potent	O
c-kit	B-GENE
inhibitor,	O
wherein	O
said	O
inhibitor	O
is	O
unable	O
to	O
promote	O
death	O
of	O
IL-3	B-GENE
dependent	O
cells	O
cultured	O
in	O
presence	O
of	O
IL-3	B-GENE
.	O
The	O
invention	O
also	O
contemplates	O
a	O
composition	O
for	O
topical	O
application	O
comprising	O
said	O
inhibitor	O
for	O
treating	O
category	O
I	O
mastocytosis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
derivatives	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
compounds	O
in	O
medicine,	O
particularly	O
in	O
the	O
amelioration	O
of	O
a	O
clinical	O
condition	O
for	O
which	O
a	O
Factor	B-GENE
Xa	I-GENE
inhibitor	O
is	O
indicated	O
.	O


A	O
condensed	O
heterocyclic	O
compound	O
having	O
poly(adenosine	B-GENE
5′-diphospho-ribose)polymerase	I-GENE
(	O
PARP	B-GENE
)	O
inhibitory	O
activity	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
hydrogen,	O
halogen,	O
lower	O
alkyl	O
or	O
lower	O
alkoxy,	O
A	O
and	O
two	O
adjacent	O
carbon	O
atoms	O
of	O
the	O
six	O
membered	O
ring	O
to	O
be	O
bonded	O
with	O
A	O
form	O
benzene	O
ring,	O
pyridine	O
ring,	O
etc,	O
—Y1═Y2—	O
is	O
formula	O
(	O
II	O
)	O
wherein	O
L11,	O
L12,	O
L13	O
and	O
L14	O
is	O
(	O
1	O
)	O
lower	O
alkylene,	O
(	O
2	O
)	O
lower	O
alkenylene,	O
etc,	O
and	O
R21,	O
R22,	O
R23	O
and	O
R24	O
is	O
(	O
1	O
)	O
cyclic	O
amino	O
group,	O
which	O
is	O
substituted	O
with	O
phenyl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
suitable	O
substituent	O
(	O
s	O
)	O
,	O
etc	O
.	O
provided	O
that	O
when	O
A	O
and	O
two	O
adjacent	O
carbon	O
atoms	O
of	O
the	O
six	O
membered	O
ring	O
to	O
be	O
bonded	O
with	O
A	O
form	O
benzene	O
ring,	O
then	O
—Y1═Y2—	O
is	O
formula	O
(	O
III	O
)	O
or	O
its	O
prodrug,	O
or	O
their	O
salts	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
substituted	O
bicyclo	O
[	O
3	O
.	O
3	O
.	O
1	O
]	O
noman-2,4,9-triones,	O
especially	O
clusianon	O
and	O
clusianon	O
derivatives,	O
as	O
pharmaceutical	O
active	O
ingredients	O
or	O
medicamentous	O
active	O
ingredients,	O
especially	O
for	O
producing	O
medicaments	O
for	O
the	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
(	O
curative	O
)	O
treatment	O
of	O
tumour	O
or	O
cancer	O
diseases,	O
and	O
of	O
viral	O
diseases	O
.	O
The	O
above-mentioned	O
compounds	O
can	O
be	O
used	O
in	O
cytostatic	O
agents	O
and	O
antiviral	O
agents	O
(	O
virostatic	O
agents	O
)	O
.	O
They	O
are	O
especially	O
used	O
as	O
inhibitors	O
of	O
topoisomerases	B-GENE
and	O
telomerases	B-GENE
and	O
as	O
regulators	O
during	O
the	O
MAP	B-GENE
kinase	I-GENE
signal	O
transduction	O
and	O
can	O
thus	O
intervene	O
on	O
a	O
cellular	O
scale	O
in	O
the	O
mechanism	O
for	O
multiplication	O
of	O
tumour	O
or	O
cancer	O
cells	O
and	O
viruses	O
.	O


The	O
present	O
invention	O
relates	O
to	O
derivatives	O
of	O
5-cyano-1H-indole	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1,	O
R2,	O
X	O
and	O
n	O
are	O
as	O
defined	O
in	O
claim	O
1,	O
as	O
well	O
as	O
to	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
hydrates	O
.	O
Pharmaceutical	O
compositions	O
containing	O
them,	O
as	O
well	O
as	O
their	O
use	O
for	O
the	O
preparation	O
of	O
medicaments	O
intended	O
for	O
the	O
preventative	O
or	O
curative	O
treatment	O
of	O
illnesses	O
which	O
are	O
dependent	O
upon	O
the	O
activation	O
of	O
the	O
interleukin	B-GENE
CXCR2	I-GENE
receptor	O
and	O
of	O
the	O
chemokines	B-GENE
of	O
the	O
same	O
family,	O
are	O
also	O
subjects	O
of	O
the	O
invention	O
.	O


A	O
neuropeptide	B-GENE
Y	I-GENE
Y5	I-GENE
antagonist	O
is	O
useful,	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
agents,	O
for	O
altering	O
circadian	O
rhythmicity	O
and	O
alleviating	O
circadian	O
rhythm	O
disorders	O
and	O
for	O
enhancing	O
and	O
improving	O
the	O
quality	O
of	O
sleep	O
.	O
The	O
present	O
invention	O
further	O
provides	O
for	O
the	O
use	O
of	O
a	O
medicament	O
for	O
carrying	O
out	O
these	O
methods	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
[	O
Chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O
Please	O
see	O
paper	O
copy	O
]	O
wherein	O
:	O
X	O
is	O
CH2,	O
O,	O
S	O
(	O
O	O
)	O
2	O
or	O
NR10	O
;	O
Y	O
is	O
a	O
bond,	O
CH2,	O
NR35,	O
CH2NH,	O
CH2NHC	O
(	O
O	O
)	O
,	O
CH	O
(	O
OH	O
)	O
,	O
CH	O
(	O
NHCOR33	O
)	O
,	O
CH	O
(	O
NHSO2R34	O
)	O
,	O
CH2O	O
or	O
CH2S	O
;	O
Z	O
is	O
C	O
(	O
O	O
)	O
,	O
or	O
when	O
Y	O
is	O
a	O
bond	O
Z	O
can	O
also	O
be	O
S	O
(	O
O	O
)	O
2	O
;	O
R1	O
is	O
optionally	O
substituted	O
aryl,	O
optionally	O
substituted	O
heterocyclyl	O
or	O
C4-6	O
cycloalkyl	O
fused	O
to	O
a	O
benzene	O
ring	O
;	O
and	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8,	O
R9,	O
R10,	O
R32,	O
R33,	O
R34	O
and	O
R35	O
are	O
as	O
defined	O
herein	O
;	O
are	O
modulators	O
of	O
chemokine	B-GENE
(	O
especially	O
CCR3	B-GENE
)	O
activity	O
(	O
for	O
use	O
in,	O
for	O
example,	O
treating	O
asthma	O
)	O
.	O
The	O
invention	O
also	O
provides	O
a	O
process	O
for	O
making	O
4-	O
(	O
3,4-dichlorophenoxy	O
)	O
piperidine,	O
which	O
is	O
useful	O
as	O
an	O
intermediate	O
for	O
making	O
certain	O
compounds	O
of	O
the	O
invention	O
.	O


Antisense	O
compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
inducible	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
.	O
The	O
compositions	O
comprise	O
antisense	O
compounds,	O
particularly	O
antisense	O
oligonucleotides,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
inducible	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
.	O
Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
inducible	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
inducible	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
are	O
provided	O
.	O


Heterocyclic	O
amides	O
of	O
formula	O
(	O
1	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
:	O
Z	O
is	O
CH	O
or	O
nitrogen	O
;	O
	O
	O
R4	O
and	O
R5	O
together	O
are	O
either	O
—S—C	O
(	O
R6	O
)	O
═C	O
(	O
R7	O
)	O
—	O
or	O
—C	O
(	O
R7	O
)	O
═C	O
(	O
R6	O
)	O
—S—	O
;	O
	O
R6	O
and	O
R7	O
are	O
selected	O
from	O
for	O
example	O
hydrogen,	O
halo,	O
C1-4alkyl,	O
and	O
C1-4alkanoyl	O
;	O
A	O
is	O
phenylene	O
or	O
heteroarylene	O
;	O
n	O
is	O
0,	O
1	O
or	O
2	O
;	O
	O
R1	O
is	O
selected	O
from	O
for	O
example	O
halo,	O
nitro,	O
cyano,	O
hydroxy,	O
carboxy	O
;	O
r	O
is	O
1	O
or	O
2	O
;	O
	O
Y	O
is	O
—NR2R3	O
or	O
—OR3	O
;	O
	O
R2	O
and	O
R3	O
are	O
selected	O
from	O
for	O
example	O
hydrogen,	O
hydroxy,	O
aryl,	O
heterocyclyl	O
and	O
C1-4alkyl	O
(	O
optionally	O
substituted	O
by	O
1	O
or	O
2	O
R8	O
groups	O
)	O
;	O
	O
R4	O
is	O
selected	O
from	O
for	O
example	O
hydrogen,	O
halo,	O
nitro,	O
cyano,	O
hydroxy,	O
C1-4alkyl,	O
and	O
C1-4alkanoyl	O
;	O
	O
R8	O
is	O
selected	O
from	O
for	O
example	O
hydroxy,	O
—COCOOR9,	O
—C	O
(	O
O	O
)	O
N	O
(	O
R9	O
)	O
(	O
R10	O
)	O
,	O
—NHC	O
(	O
O	O
)	O
R9,	O
(	O
R9	O
)	O
(	O
R10	O
)	O
N—	O
and	O
—COOR9	O
;	O
	O
R9	O
and	O
R10	O
are	O
selected	O
from	O
for	O
example	O
hydrogen,	O
hydroxy,	O
C1-4alkyl	O
(	O
optionally	O
substituted	O
by	O
1	O
or	O
2	O
R13	O
)	O
;	O
	O
R13	O
is	O
selected	O
from	O
hydroxy,	O
halo,	O
trihalomethyl	O
and	O
C1-4alkoxy	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
pro-drug	O
thereof	O
;	O
possess	O
glycogen	B-GENE
phosphorylase	I-GENE
inhibitory	O
activity	O
and	O
accordingly	O
have	O
value	O
in	O
the	O
treatment	O
of	O
disease	O
states	O
associated	O
with	O
increased	O
glycogen	B-GENE
phosphorylase	I-GENE
activity	O
.	O
Processes	O
for	O
the	O
manufacture	O
of	O
said	O
heterocyclic	O
amide	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
described	O
.	O


The	O
invention	O
relates	O
to	O
pharmaccutical	O
compositions	O
of	O
activated	B-GENE
protein	I-GENE
C	I-GENE
with	O
a	O
chelating	O
agent	O
.	O
Preferably,	O
the	O
formulation	O
contains	O
activated	B-GENE
protein	I-GENE
C,	O
a	O
chelating	O
agent,	O
a	O
bulking	O
agent,	O
a	O
buffer,	O
and	O
/	O
or	O
a	O
salt	O
with	O
a	O
reconstituted	O
pH	O
between	O
about	O
5	O
.	O
5	O
5	O
and	O
about	O
6	O
.	O
5	O
.	O
Alternatively,	O
the	O
chelating	O
agent	O
is	O
added	O
to	O
the	O
diluent	O
used	O
with	O
the	O
activated	B-GENE
protein	I-GENE
C	I-GENE
pharmaceutical	O
composition	O
.	O
The	O
aPC	B-GENE
pharmaceutical	O
compositions,	O
formulations,	O
and	O
uses	O
of	O
the	O
invention	O
have	O
improved	O
in-use	O
stability	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R0	O
;	O
Q	O
;	O
X	O
;	O
Q′,	O
D,	O
R10	O
and	O
V	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
.	O
They	O
exhibit	O
a	O
strong	O
antithrombotic	O
effect	O
and	O
are	O
suitable,	O
for	O
example,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
cardiovascular	O
disorders	O
like	O
thromboembolic	O
diseases	O
or	O
restenoses	O
.	O
They	O
are	O
reversible	O
inhibitors	O
of	O
the	O
blood	B-GENE
clotting	I-GENE
enzymes	I-GENE
factor	I-GENE
Xa	I-GENE
(	O
FXa	B-GENE
)	O
and	O
/	O
or	O
factor	O
VIIa	I-GENE
(	O
FVIIa	B-GENE
)	O
,	O
and	O
can	O
in	O
general	O
be	O
applied	O
in	O
conditions	O
in	O
which	O
an	O
undesired	O
activity	O
of	O
factor	O
Xa	I-GENE
and	O
/	O
or	O
factor	O
VIIa	I-GENE
is	O
present	O
or	O
for	O
the	O
cure	O
or	O
prevention	O
of	O
which	O
an	O
inhibition	O
of	O
factor	O
Xa	I-GENE
and	O
/	O
or	O
factor	O
VIIa	I-GENE
is	O
intended	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
I,	O
their	O
use,	O
in	O
particular	O
as	O
active	O
ingredients	O
in	O
pharmaceuticals,	O
and	O
pharmaceutical	O
preparations	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treatment	O
and	O
diagnosis	O
of	O
disorders	O
associated	O
with	O
abnormally	O
proliferating	O
cells	O
.	O
In	O
one	O
aspect	O
the	O
invention	O
relates	O
to	O
methods,	O
which	O
are	O
especially	O
useful	O
for	O
the	O
detection	O
of	O
tumors	O
and	O
their	O
precursory	O
stages	O
based	O
on	O
the	O
detection	O
of	O
overexpression	O
of	O
human	B-GENE
transketolase	I-GENE
like-1	I-GENE
gene	I-GENE
in	O
biological	O
samples	O
.	O
In	O
another	O
aspect	O
the	O
invention	O
relates	O
to	O
methods	O
for	O
treatment	O
of	O
disorders	O
associated	O
with	O
the	O
overexpression	O
of	O
human	B-GENE
transketolase	I-GENE
like-1	I-GENE
gene	I-GENE
.	O
Methods	O
for	O
treatment	O
may	O
include	O
gene	O
therapeutic	O
approaches	O
as	O
well	O
as	O
methods	O
for	O
inhibiting	O
or	O
reducing	O
the	O
activity	O
of	O
transketolase	O
like-1	I-GENE
polypeptides	O
.	O


The	O
current	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
hyperlipidemia	O
in	O
mammals,	O
including	O
humans	O
.	O
More	O
specifically,	O
the	O
current	O
invention	O
relates	O
to	O
the	O
use	O
of	O
retinoid	O
or	O
retinoid	O
derivative	O
that	O
is	O
able	O
to	O
act	O
as	O
an	O
antagonist	O
or	O
inverse	O
agonist	O
of	O
a	O
retinoid	B-GENE
receptor	I-GENE
to	O
treat	O
hyperlipidemia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
imidazopyridine	O
compounds	O
which	O
inhibit,	O
regulate	O
and	O
/	O
or	O
modulate	O
tyrosine	B-GENE
kinase	I-GENE
signal	O
transduction,	O
compositions	O
which	O
contain	O
these	O
compounds,	O
and	O
methods	O
of	O
using	O
them	O
to	O
treat	O
tyrosine	O
kinase-dependent	O
diseases	O
and	O
conditions,	O
such	O
as	O
angiogenesis,	O
cancer,	O
tumor	O
growth,	O
atherosclerosis,	O
age	O
related	O
macular	O
degeneration,	O
diabetic	O
retinopathy,	O
inflammatory	O
diseases,	O
and	O
the	O
like	O
in	O
mammals	O
.	O


The	O
present	O
invention	O
discloses	O
Inositol	B-GENE
hexakisphosphate	I-GENE
kinase	I-GENE
or	O
RYK	B-GENE
kinase	I-GENE
homologous	O
proteins	O
regulating	O
the	O
energy	O
homeostasis	O
and	O
the	O
metabolism	O
of	O
energy	O
storage	O
metabolites,	O
and	O
polynucleotides,	O
which	O
identify	O
and	O
encode	O
the	O
proteins	O
disclosed	O
in	O
this	O
invention	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
sequences	O
in	O
the	O
diagnosis,	O
study,	O
prevention,	O
and	O
treatment	O
of	O
metabolic	O
diseases	O
and	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
pharmaceutical	O
formulations	O
of	O
phenylalanine	O
derivatives	O
and	O
to	O
the	O
use	O
thereof	O
as	O
urokinase	B-GENE
inhibitors,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
malignant	O
tumors	O
and	O
of	O
tumor	O
metastases	O
.	O


D-glyceric	O
acid	O
has	O
been	O
found	O
to	O
enhance	O
alcohol	O
metabolism	O
and	O
thereby	O
prevent	O
adverse	O
effects	O
of	O
alcohol	O
consumption	O
.	O
D-glyceric	O
acid	O
is	O
administered	O
concurrently	O
with	O
alcohol,	O
to	O
accelerate	O
the	O
elimination	O
of	O
the	O
alcohol	O
from	O
the	O
body	O
.	O
D-glyceric	O
acid	O
is	O
converted	O
into	O
D-glyceraldehyde	O
and	O
further	O
into	O
glycerol	O
in	O
reactions	O
catalysed	O
by	O
NADH-aldehyde	B-GENE
dehydrogenase	I-GENE
and	O
NADH-alcohol	B-GENE
dehydrogenase	I-GENE
complexes,	O
which	O
are	O
produced	O
in	O
excess	O
during	O
alcohol	O
oxidation,	O
in	O
the	O
cells	O
of	O
alcohol-metabolising	O
tissues	O
.	O
In	O
these	O
reactions,	O
the	O
NADH	B-GENE
complexes	I-GENE
become	O
NAD-aldehyde	B-GENE
dehydrogenase	I-GENE
and	O
NAD-alcohol	B-GENE
dehydrogenase	I-GENE
complexes	I-GENE
.	O
These	O
complexes	O
in	O
turn	O
accelerate	O
the	O
oxidation	O
of	O
alcohol,	O
which	O
is	O
paralleled	O
by	O
enhancement	O
of	O
acetaldehyde	O
oxidation	O
to	O
metabolically	O
harmless	O
acetic	O
acid	O
.	O
D-glyceric	O
acid	O
or	O
its	O
salt	O
or	O
ester	O
is	O
used	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
preparation	O
for	O
enhancing	O
the	O
metabolism	O
of	O
alcohol	O
.	O
A	O
method	O
of	O
enhancing	O
the	O
metabolism	O
of	O
alcohol	O
in	O
a	O
subject	O
by	O
administering	O
said	O
compounds	O
an	O
effective	O
amount	O
of	O
D-glyceric	O
acid	O
or	O
its	O
salt	O
or	O
ester	O
is	O
disclosed	O
.	O
An	O
oral	O
or	O
parenteral	O
preparation	O
comprising	O
said	O
compounds	O
is	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
a	O
novel	O
role	O
of	O
CXCR-4	B-GENE
in	O
cell	O
transformation	O
and	O
aberrant	O
cellular	O
proliferation	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
altered	O
gene	O
expression	O
of	O
CXCR-4	B-GENE
in	O
a	O
number	O
of	O
primary	O
tumors	O
and	O
cell	O
lines	O
derived	O
from	O
tumors,	O
in	O
addition	O
to,	O
the	O
altered	O
gene	O
expression	O
of	O
ligands	O
for	O
CXCR-4	B-GENE
.	O
Further,	O
the	O
present	O
invention	O
relates,	O
in	O
part,	O
to	O
the	O
Applicants	O
'	O
surprising	O
discovery	O
that	O
the	O
inhibition	O
of	O
CXCR-4	B-GENE
gene	O
expression	O
or	O
the	O
inhibition	O
of	O
CXCR-4	B-GENE
activity	O
in	O
transformed	O
cells	O
reverses	O
the	O
transformed	O
phenotype	O
.	O


In	O
one	O
aspect,	O
the	O
invention	O
provides	O
methods	O
for	O
determining	O
the	O
biological	O
activity	O
of	O
heat	B-GENE
shock	I-GENE
proteins	I-GENE
or	O
heat	B-GENE
shock	I-GENE
protein-peptide	O
complexes	O
based	O
on	O
the	O
ATPase	O
activity	O
or	O
the	O
multimeric	O
structure	O
of	O
the	O
heat	B-GENE
shock	I-GENE
proteins	I-GENE
or	O
heal	B-GENE
shock	I-GENE
protein-peptide	O
complexes,	O
and	O
methods	O
for	O
screening	O
agents	O
that	O
modulate	O
the	O
biological	O
activity	O
of	O
heat	B-GENE
shock	I-GENE
proteins	I-GENE
or	O
heat	B-GENE
shock	I-GENE
protein-peptide	O
complexes	O
.	O
In	O
another	O
aspect,	O
the	O
invention	O
provides	O
complexes,	O
compositions	O
and	O
methods	O
for	O
enhancing	O
the	O
immunogenicity	O
of	O
a	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
or	O
a	O
complex	O
comprising	O
a	O
heal	B-GENE
shock	I-GENE
protein	I-GENE
and	O
an	O
antigenic	O
molecule	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
to	O
treat	O
diseases	O
or	O
condition	O
with	O
an	O
α7	B-GENE
nAChR	I-GENE
full	O
agonist	O
and	O
an	O
inhibitor	O
of	O
cholinesterase,	O
and	O
or	O
beta	B-GENE
secretase	I-GENE
and	O
or	O
gamma	B-GENE
secretase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
Formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
hydrate	O
or	O
formulation	O
thereof	O
.	O
These	O
compounds	O
can	O
be	O
used	O
for	O
the	O
inhibition	O
of	O
tryptase	B-GENE
and	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
that	O
are	O
mediated	O
by	O
tryptase	B-GENE
activity	O
.	O


Compounds	O
of	O
formula	O
1	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
M,	O
B1,	O
B2,	O
R2,	O
K1	O
and	O
K2	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
are	O
novel	O
effective	O
tryptase	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
growth	O
factors	O
in	O
improving	O
tissue	O
survival	O
.	O
In	O
particular,	O
the	O
invention	O
describes	O
methods	O
for	O
enhancing	O
organ	O
transplant,	O
musculocutaneous	O
flap	O
or	O
skin	O
graft	O
survival	O
by	O
administering	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
benzophenone	O
compounds	O
useful	O
in	O
the	O
inhibition	O
of	O
HIV	B-GENE
reverse	I-GENE
transcriptase,	O
particularly	O
its	O
resistant	O
varieties	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds,	O
to	O
methods	O
for	O
their	O
preparation,	O
to	O
compositions	O
containing	O
them,	O
and	O
to	O
methods	O
and	O
use	O
for	O
clinical	O
treatment	O
of	O
medical	O
conditions	O
which	O
may	O
benefit	O
from	O
immunomodulation,	O
including	O
rheumatoid	O
arthritis,	O
multiple	O
sclerosis,	O
diabetes,	O
asthma,	O
transplantation,	O
systemic	O
lupus	O
erythematosis	O
and	O
psoriasis	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds,	O
which	O
are	O
CD80	B-GENE
antagonists	O
capable	O
of	O
inhibiting	O
the	O
interactions	O
between	O
CD80	B-GENE
and	O
CD28	B-GENE
.	O


Substituted	O
spiro	O
[	O
isobenzofuran-1,4′-piperidin	O
]	O
-3-ones	O
and	O
3H-spiroisobenzofuran-1,4′-piperidines	O
capable	O
of	O
modulating	O
NPY5	B-GENE
receptor	O
activity	O
are	O
provided	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
to	O
modulate	O
ligand	O
binding	O
to	O
NPY5	B-GENE
receptors	O
in	O
vivo	O
or	O
in	O
vitro,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
eating	O
disorders	O
such	O
as	O
obesity	O
or	O
bulimia,	O
psychiatric	O
disorders,	O
diabetes	O
and	O
cardiovascular	O
disorders	O
such	O
as	O
hypertension	O
)	O
in	O
humans,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
such	O
disorders	O
are	O
provided,	O
as	O
are	O
methods	O
for	O
using	O
such	O
compounds	O
for	O
detecting	O
NPY5	B-GENE
receptors	O
.	O


The	O
present	O
invention	O
provides	O
an	O
agent	O
that	O
inhibits	O
or	O
promotes	O
glucose	O
uptake	O
in	O
the	O
small	O
intestine,	O
etc	O
.	O
,	O
comprising	O
a	O
compound	O
that	O
inhibits	O
or	O
promotes	O
the	O
activity	O
of	O
Na+/glucose	B-GENE
transporter	I-GENE
(	O
SGLT	B-GENE
)	O
homologs	O
.	O


The	O
present	O
invention	O
provides	O
a	O
combination	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
which	O
responds	O
to	O
aromatase	B-GENE
inhibition,	O
in	O
particular	O
a	O
proliferative	O
disease,	O
especially	O
a	O
malignant	O
disease	O
such	O
as	O
breast	O
cancer	O
or	O
similar	O
soft	O
tissue	O
endocrine-sensitive	O
cancer,	O
most	O
preferably	O
breast	O
cancer,	O
comprising	O
an	O
aromatase	B-GENE
inhibitor	O
and	O
a	O
bisphosphonate	O
for	O
simultaneous,	O
concurrent,	O
separate	O
or	O
sequential	O
use	O
in	O
the	O
prevention	O
of	O
bone	O
loss	O
which	O
is	O
caused	O
by	O
the	O
treatment	O
with	O
an	O
aromatase	B-GENE
inhibitor	O
.	O
Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
a	O
disease	O
or	O
condition	O
which	O
responds	O
to	O
aromatase	B-GENE
inhibition	O
comprising	O
administering	O
to	O
the	O
patient	O
an	O
effective	O
amount	O
of	O
a	O
bisphosphonate	O
and	O
an	O
effective	O
amount	O
of	O
an	O
aromatase	B-GENE
inhibitor	O
.	O


An	O
indole	O
derivative	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
the	O
symbols	O
in	O
the	O
formula	O
are	O
as	O
mentioned	O
in	O
the	O
specification	O
)	O
and	O
a	O
salt	O
thereof	O
Since	O
the	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
binds	O
to	O
PGD2	B-GENE
receptors	O
and	O
shows	O
antagonistic	O
activity,	O
they	O
are	O
believed	O
to	O
be	O
useful	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
such	O
as	O
allergic	O
disease	O
(	O
such	O
as	O
allergic	O
rhinitis,	O
allergic	O
conjunctivitis,	O
atopic	O
dermatitis,	O
bronchial	O
asthma	O
and	O
food	O
allergy	O
)	O
,	O
systemic	O
mastocytosis,	O
systemic	O
mast	O
cell	O
activating	O
disorder,	O
anaphylaxis	O
shock,	O
airway	O
contraction,	O
urticaria,	O
eczema,	O
diseases	O
accompanied	O
by	O
itch	O
(	O
such	O
as	O
atopic	O
dermatitis,	O
urticaria	O
)	O
,	O
diseases	O
(	O
such	O
as	O
cataract,	O
retinal	O
detachment,	O
inflammation,	O
infection	O
and	O
sleep	O
disorder	O
)	O
which	O
are	O
generated	O
secondarily	O
as	O
a	O
result	O
of	O
behavior	O
accompanied	O
by	O
itch	O
(	O
such	O
as	O
scratching	O
and	O
beating	O
)	O
,	O
inflammation,	O
chronic	O
obstructive	O
pulmonary	O
diseases,	O
ischemic	O
reperfusion	O
injury,	O
cerebrovascular	O
accident,	O
autoimmune	O
disease,	O
chronic	O
articular	O
rheumatism,	O
pleuritis,	O
ulcerative	O
colitis	O
and	O
irritable	O
bowel	O
syndrome	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
[	O
wherein	O
Ring	O
A	O
represents	O
an	O
optionally	O
substituted	O
5-	O
to	O
8-membered	O
ring,	O
Ring	O
B	O
represents	O
a	O
further	O
optionally	O
substituted	O
4-	O
to	O
10-membered	O
ring,	O
Ring	O
C	O
represents	O
a	O
further	O
optionally	O
substituted	O
benzene	O
ring,	O
X1	O
represents	O
carbon	O
atom,	O
X2	O
represents	O
a	O
carbon	O
atom,	O
an	O
oxygen	O
atom,	O
etc	O
.	O
,	O
W	O
represents	O
a	O
nitrogen	O
atom,	O
etc	O
.	O
,	O
Y11	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
CR2R3′	O
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
nitro	O
group,	O
etc	O
.	O
,	O
and	O
R3′	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
nitro	O
group,	O
etc	O
.	O
,	O
respectively	O
)	O
,	O
Y21	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
CR4R5′	O
(	O
wherein	O
R4	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
nitro	O
group,	O
etc	O
.	O
,	O
and	O
R5′	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
nitro	O
group,	O
etc	O
.	O
,	O
respectively	O
)	O
,	O
etc	O
.	O
,	O
and	O
R1	O
represents	O
an	O
electron-withdrawing	O
group,	O
respectively	O
.	O
The	O
formula	O
	O
	O
	O
	O
	O
	O
	O
represents	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
]	O
or	O
a	O
salt	O
thereof,	O
which	O
is	O
useful	O
as	O
an	O
androgen	B-GENE
receptor	I-GENE
modulator	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
compounds	O
having	O
the	O
general	O
formula	O
:	O
(	O
1	O
)	O
wherein	O
X	O
is	O
O	O
or	O
S	O
which	O
are	O
useful	O
as	O
selective	O
ER-β	B-GENE
ligands	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
Alzheimer	O
'	O
s	O
disease,	O
anxiety	O
disorders,	O
depressive	O
disorders,	O
osteoporosis,	O
cardiovascular	O
disease,	O
rheumatoid	O
arthritis	O
or	O
prostate	O
cancer	O
.	O


Anthranylic	O
compounds	O
having	O
anti-CCK	O
activity	O
of	O
general	O
formula	O
(	O
I	O
)	O
in	O
which,	O
n	O
is	O
a	O
whole	O
number	O
lying	O
between	O
0	O
and	O
7	O
;	O
R1	O
is	O
chosen	O
independently	O
from	O
the	O
groups	O
(	O
II	O
)	O
,	O
in	O
which	O
X1	O
is	O
chosen	O
independently	O
from,	O
S,	O
O,	O
NR2	O
and	O
X2	O
is	O
a	O
group	O
chosen	O
from	O
:	O
H,	O
C1-C4	O
alkyl,	O
F,	O
Cl,	O
CF3,	O
OCH3,	O
OC2H5,	O
CN	O
;	O
R2	O
is	O
chosen	O
from	O
H	O
or	O
CH3	O
;	O
R3	O
is	O
chosen	O
from	O
H,	O
CH3,	O
F,	O
Cl,	O
CF3,	O
OCH3	O
;	O
R4	O
is	O
chosen	O
from	O
the	O
groups	O
:	O
H,	O
—S—	O
(	O
CH2	O
)	O
m-R5,	O
—SO2—	O
(	O
CH2	O
)	O
m-R5	O
(	O
n	O
different	O
from	O
0	O
)	O
,	O
a	O
branched	O
alkyl	O
group,	O
a	O
cyclo	O
alkyl,	O
a	O
cyclo	O
alkenyl,	O
the	O
group	O
1	O
or	O
2	O
adamantile,	O
a	O
phenyl	O
group	O
optionally	O
substituted	O
;	O
R5	O
is	O
chosen	O
from	O
the	O
groups	O
:	O
H,	O
linear	O
or	O
branched	O
alkyl,	O
cyclo	O
alkyl,	O
the	O
group	O
1	O
or	O
2	O
adamantile,	O
a	O
suitably	O
substituted	O
phenyl	O
group	O
.	O


N-	O
(	O
indolethyl-	O
)	O
cycloamine	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1′,	O
R1″	O
X,	O
Ar,	O
and	O
n	O
have	O
a	O
meaning	O
indicated	O
in	O
Claim	O
1,	O
are	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
effectors	O
of	O
the	O
serotonergic	O
receptors	O
5-HT1A	B-GENE
and	O
5-HT2A	B-GENE
.	O
They	O
are	O
therefore	O
suitable	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
various	O
diseases	O
of	O
the	O
central	O
nervous	O
system,	O
such	O
as	O
depression,	O
dyskinesia,	O
Parkinson	O
'	O
s	O
disease,	O
dementia,	O
strokes,	O
schizophrenia,	O
Alzheimer	O
'	O
s	O
disease,	O
Lewy	O
bodies	O
dementia,	O
Huntington	O
'	O
s	O
disease,	O
Tourette	O
'	O
s	O
syndrome,	O
anxiety,	O
learning	O
and	O
memory	O
impairment,	O
pain,	O
sleeping	O
disorders	O
and	O
neurodegenerative	O
diseases	O
.	O


Tertiary	O
amine	O
compounds	O
that	O
bind	O
chemokine	O
receptors	O
such	O
as	O
CXCR4	B-GENE
and	O
CCR5	B-GENE
are	O
disclosed	O
.	O


This	O
invention	O
relates	O
to	O
a	O
remedy	O
for	O
treating	O
allergic	O
contact	O
dermatitis	O
containing	O
a	O
substance	O
having	O
MEK	B-GENE
inhibitory	O
action	O
as	O
its	O
effective	O
component	O
.	O


The	O
present	O
invention	O
relates	O
to	O
formulations	O
containing	O
phosphoprotein,	O
designed	O
for	O
use	O
as	O
oral	O
lubricant	O
or	O
as	O
artificial	O
saliva,	O
methods	O
of	O
using	O
the	O
formulations	O
and	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
formulations	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
ligands	O
to	O
GABAB	B-GENE
receptors	I-GENE
for	O
increasing	O
neurotrophin	B-GENE
levels	O
in	O
the	O
central	O
nervous	O
system	O
.	O


The	O
invention	O
relates	O
to	O
a	O
bispecific	O
molecule	O
comprising	O
a	O
first	O
recognition	O
binding	O
moeity	O
that	O
binds	O
a	O
Cab-like	B-GENE
receptor	I-GENE
cross-linked	O
using	O
a	O
poly-	O
(	O
ethylene	O
glycol	O
)	O
(	O
“PEG”	O
)	O
linker	O
with	O
one	O
or	O
more	O
second	O
recognition	O
binding	O
moieties	O
that	O
bind	O
a	O
molecule	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
producing	O
such	O
bispecific	O
molecules	O
and	O
to	O
therapeutic	O
uses	O
of	O
such	O
bispecific	O
molecules	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
I	O
and	O
the	O
use	O
thereof	O
for	O
the	O
therapeutic	O
treatment	O
of	O
a	O
CNS	O
disorder	O
relating	O
to	O
or	O
affected	O
by	O
the	O
5-HT6	B-GENE
receptor	O
.	O


A	O
method	O
of	O
treating	O
or	O
preventing	O
menorrhagia	O
in	O
an	O
female	O
individual	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
individual	O
at	O
least	O
one	O
agent	O
that	O
prevents	O
PGP2α	B-GENE
having	O
its	O
effect	O
on	O
the	O
FP	B-GENE
receptor	I-GENE
.	O
Optionally,	O
an	O
inhibitor	O
of	O
PGES	B-GENE
and	O
/	O
or	O
an	O
antagonist	O
of	O
EP2	B-GENE
or	O
EP4	B-GENE
is	O
also	O
administered	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
[	O
Chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O
Please	O
see	O
paper	O
copy	O
.	O
]	O
wherein	O
R1,	O
R2,	O
R3,	O
R3a,	O
R4,	O
R4a,	O
R5,	O
and	O
R6	O
are	O
as	O
defined	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
;	O
compositions	O
containing	O
these	O
compounds,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
as	O
modulators	O
of	O
chemokine	B-GENE
activity	O
(	O
especially	O
CCR5	B-GENE
activity	O
)	O
.	O


The	O
present	O
invention	O
relates,	O
inter	O
alia,	O
to	O
novel	O
piperazines	O
of	O
the	O
following	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
to	O
methods	O
of	O
treatment	O
employing	O
these	O
compounds	O
or	O
compositions	O
.	O
The	O
compounds	O
show	O
a	O
high	O
and	O
selective	O
binding	O
affinity	O
for	O
the	O
histamine	B-GENE
H3	I-GENE
receptor,	O
indicating	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
antagonistic,	O
inverse	O
agonistic	O
or	O
agonistic	O
activity	O
.	O
As	O
a	O
result,	O
the	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
related	O
to	O
the	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
.	O


The	O
present	O
invention	O
provide	O
purified	O
Flt4	B-GENE
receptor	O
tyrosine	O
kinase	O
polypeptides	O
and	O
fragments	O
thereof,	O
polynucleotides	O
encoding	O
such	O
polypeptides,	O
antibodies	O
that	O
specifically	O
bind	O
such	O
polypeptides,	O
and	O
uses	O
therefor	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
inhibit	O
the	O
processing	O
of	O
APP	B-GENE
by	O
gamma-secretase,	O
and	O
hence	O
are	O
useful	O
for	O
treatment	O
or	O
prevention	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O


A	O
non-immunosuppressive	O
pipecolic	O
acid	O
derivative	O
having	O
an	O
affinity	O
for	O
FKBP-type	O
immunophilins	O
is	O
provided	O
for	O
inducing	O
chondrogenic	O
differentiation	O
.	O
Composition	O
containing	O
such	O
compounds	O
is	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
treatments	O
for	O
schizophrenia,	O
based	O
on	O
the	O
concept	O
of	O
identifying	O
agents	O
capable	O
of	O
selectively	O
binding	O
to	O
the	O
serotonin	O
5-HT7	B-GENE
and	O
muscarinic	B-GENE
M4	I-GENE
receptors	I-GENE
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
treating	O
schizophrenia	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
novel	O
amidine	O
compounds	O
for	O
treating	O
schizophrenia,	O
a	O
method	O
of	O
manufacturing	O
such	O
compounds,	O
pharmaceutical	O
formulations	O
comprising	O
said	O
compounds,	O
as	O
well	O
as	O
medical	O
uses	O
and	O
methods	O
of	O
treatment	O
using	O
said	O
compounds	O
.	O


A	O
persulfated	O
saccharide	O
compound	O
capable	O
of	O
acting	O
on	O
selectin	O
and	O
chemokine	B-GENE
.	O
According	O
to	O
the	O
present	O
invention,	O
there	O
are	O
provided	O
a	O
saccharide	O
compound	O
capable	O
of	O
interacting	O
with	O
L-selectin,	O
P-selectin	B-GENE
and	O
chemokine	B-GENE
;	O
a	O
pharmaceutical	O
composition	O
;	O
and	O
an	O
agent	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
of	O
which	O
sideration	O
is	O
associated	O
with	O
biological	O
events	O
mediated	O
by	O
any	O
of	O
L-selectin,	O
P-selectin	B-GENE
and	O
chemokine	B-GENE
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
using	O
NFκB	B-GENE
decoys	O
to	O
regulate	O
(	O
suppress	O
)	O
transcription	O
activated	O
by	O
NFκB,	O
and	O
to	O
suppress	O
neointimal	O
formation	O
in	O
grafts	O
.	O
Furthermore,	O
the	O
present	O
invention	O
relates	O
to	O
agents	O
for	O
protection	O
from	O
intimal	O
thickening	O
in	O
vascular	O
grafts	O
that	O
comprise	O
NFκB	B-GENE
decoys	O
.	O


The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
asthma	O
comprising	O
a	O
substance	O
capable	O
of	O
suppressing	O
the	O
function	O
involved	O
in	O
signal	O
transduction	O
of	O
GPR4	B-GENE
as	O
an	O
active	O
ingredient	O
.	O
It	O
also	O
provides	O
an	O
agent	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
asthma	O
which	O
comprises	O
a	O
nitrogen-containing	O
tricyclic	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
quaternary	O
ammonium	O
salt	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
[	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl,	O
or	O
the	O
like	O
;	O
R2	O
represents	O
hydrogen,	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl,	O
or	O
the	O
like	O
;	O
R3	O
and	O
R4	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen,	O
lower	O
alkyl,	O
or	O
the	O
like	O
;	O
n	O
represents	O
0	O
or	O
1	O
;	O
X	O
represents	O
—	O
(	O
CH2	O
)	O
2—,	O
or	O
the	O
like	O
;	O
and	O
Y	O
represents	O
the	O
formula	O
(	O
II	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
W	O
represents	O
CH	O
or	O
a	O
nitrogen	O
atom	O
;	O
Z1	O
and	O
Z2	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen,	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl,	O
or	O
the	O
like	O
;	O
and	O
Z3	O
represents	O
hydrogen,	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl,	O
or	O
the	O
like	O
)	O
]	O
as	O
an	O
active	O
ingredient	O
.	O


A	O
polynucleotide	O
comprising	O
an	O
Skp	B-GENE
2	I-GENE
promoter	I-GENE
sequence	O
is	O
provided	O
.	O
The	O
promoter	O
is	O
useful	O
in	O
tumour	O
and	O
cancer	O
therapy,	O
in	O
particular	O
in	O
therapies	O
that	O
are	O
intended	O
to	O
selectively	O
kill	O
or	O
reduce	O
the	O
growth,	O
division	O
or	O
viability	O
of	O
tumour	O
or	O
cancer	O
cells	O
compared	O
to	O
surrounding,	O
non-tumour	O
or	O
non-cancer	O
cells	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
screening	O
for	O
inhibitors	O
of	O
Skp2	B-GENE
promoter	I-GENE
activity	O
.	O


Human	B-GENE
DYRK	I-GENE
genes	O
are	O
identified	O
as	O
modulators	O
of	O
the	O
APC	B-GENE
and	O
Axin	B-GENE
pathways,	O
and	O
thus	O
are	O
therapeutic	O
targets	O
for	O
disorders	O
associated	O
with	O
defective	O
APC	B-GENE
and	O
Axin	B-GENE
function	O
.	O
Methods	O
for	O
identifying	O
modulators	O
of	O
APC	B-GENE
and	O
Axin,	O
comprising	O
screening	O
for	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
DYRK	O
are	O
provided	O
.	O


Disclosed	O
are	O
novel	O
compounds	O
that	O
are	O
partial	O
and	O
full	O
A1	B-GENE
adenosine	I-GENE
receptor	I-GENE
agonists,	O
useful	O
for	O
treating	O
various	O
disease	O
states,	O
in	O
particular	O
tachycardia	O
and	O
atrial	O
flutter,	O
angina,	O
myocardial	O
infarction	O
and	O
hyperlipidemia	O
.	O


This	O
invention	O
features	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
R1	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
each	O
of	O
R2	O
and	O
R4,	O
independently,	O
is	O
H,	O
halogen,	O
CN,	O
alkyl,	O
ORa,	O
or	O
NRaRb	O
;	O
R3	O
is	O
H,	O
halogen,	O
CN,	O
alkyl,	O
alkenyl,	O
alkynyl,	O
aryl,	O
heteroaryl,	O
cyclyl,	O
heterocyclyl,	O
ORa,	O
OC	O
(	O
O	O
)	O
Ra,	O
OC	O
(	O
O	O
)	O
NRaRb,	O
NRaRb,	O
NRaC	O
(	O
O	O
)	O
Rb,	O
NRaS	O
(	O
O	O
)	O
RbN,	O
RaS	O
(	O
O	O
)	O
2Rb,	O
NRaC	O
(	O
O	O
)	O
NRbRc,	O
NRaC	O
(	O
S	O
)	O
NRbRc,	O
NRaC	O
(	O
NRb	O
)	O
NRcRd,	O
NRaC	O
(	O
O	O
)	O
ORb,	O
S	O
(	O
O	O
)	O
NRaRb,	O
S	O
(	O
O	O
)	O
2NRaRb,	O
S	O
(	O
O	O
)	O
Ra,	O
S	O
(	O
O	O
)	O
2Ra,	O
C	O
(	O
O	O
)	O
Ra,	O
C	O
(	O
O	O
)	O
ORa,	O
or	O
C	O
(	O
O	O
)	O
NRaRb	O
;	O
R5	O
is	O
H	O
or	O
alkyl	O
;	O
n	O
is	O
0,	O
1,	O
2,	O
3,	O
4,	O
5,	O
or	O
6	O
;	O
A	O
is	O
O,	O
S,	O
S	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2,	O
or	O
NRe	O
;	O
B	O
is	O
N	O
or	O
CRf	O
;	O
X	O
is	O
O,	O
S,	O
S	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2,	O
NRe,	O
or	O
C	O
(	O
O	O
)	O
;	O
Y	O
is	O
a	O
covalent	O
bond,	O
C	O
(	O
O	O
)	O
,	O
C═NRa,	O
O,	O
S,	O
S	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2,	O
or	O
NRe	O
;	O
Z	O
is	O
N	O
or	O
CH	O
;	O
each	O
of	O
U	O
and	O
V,	O
independently,	O
is	O
N	O
or	O
CR	O
;	O
and	O
W	O
is	O
O,	O
S,	O
or	O
NRe	O
;	O
in	O
which	O
each	O
of	O
Ra,	O
Rb,	O
Rc,	O
and	O
Rd,	O
independently,	O
is	O
H,	O
alkyl,	O
aryl,	O
heteroaryl,	O
cyclyl,	O
or	O
heterocyclyl	O
;	O
Re	O
is	O
H,	O
alkyl,	O
aryl,	O
acyl,	O
or	O
sufonyl	O
;	O
and	O
Rf	O
is	O
H,	O
alkyl,	O
aryl,	O
acyl,	O
sulfonyl,	O
alkoxyl,	O
amino,	O
ester,	O
amide,	O
CN,	O
or	O
halogen	O
.	O
The	O
compound	O
is	O
useful	O
for	O
treating	O
an	O
interleukin-12	B-GENE
overproduction-related	O
disorder	O
.	O


In	O
accordance	O
with	O
the	O
invention,	O
a	O
compound	O
with	O
a	O
protective	O
action	O
for	O
nerve	O
cell	O
can	O
be	O
reselected	O
by	O
adding	O
PPARδ	B-GENE
agonist	O
to	O
a	O
culture	O
cell	O
system	O
where	O
toxic	O
substances	O
such	O
as	O
thapsigargin,	O
MPP+	O
and	O
staurosporine	O
are	O
preliminarily	O
allowed	O
to	O
react	O
and	O
reselecting	O
a	O
compound	O
improving	O
the	O
survival	O
rate	O
.	O
The	O
compound	O
selected	O
by	O
such	O
method	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
such	O
as	O
cerebral	O
infarction	O
and	O
Parkinson	O
'	O
s	O
disease	O
.	O
Thus,	O
the	O
invention	O
is	O
very	O
useful	O
for	O
research	O
works	O
for	O
creating	O
novel	O
pharmaceutical	O
agent	O
.	O


A	O
therapeutic	O
medical	O
article	O
is	O
provided	O
which	O
comprises	O
a	O
medical	O
article,	O
a	O
precursor	O
compound	O
and	O
an	O
activator	O
compound	O
.	O
The	O
medical	O
article	O
is	O
adapted,	O
upon	O
administration	O
to	O
a	O
patient,	O
to	O
release	O
the	O
precursor	O
compound	O
and	O
the	O
activator	O
compound	O
such	O
that	O
the	O
activator	O
compound	O
interacts	O
with	O
the	O
precursor	O
compound	O
and	O
converts	O
the	O
precursor	O
compound	O
into	O
activated	O
form	O
for	O
local	O
delivery	O
.	O
Specific	O
examples	O
of	O
precursor	O
and	O
activator	O
compound	O
pairs	O
include	O
:	O
(	O
a	O
)	O
a	O
nitrosothiol	O
precursor	O
and	O
a	O
nitric	O
oxide	O
donor,	O
(	O
b	O
)	O
plasminogen	B-GENE
and	O
plasminogen	B-GENE
activator,	O
and	O
(	O
c	O
)	O
fibrinogen	B-GENE
and	O
thrombin	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
enhancement	O
of	O
adiponectin	B-GENE
production,	O
treatment	O
or	O
prevention	O
of	O
hypoadiponectinemia,	O
and	O
the	O
like,	O
comprising	O
as	O
an	O
active	O
ingredient	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
.	O


A	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
prodrugs,	O
salts,	O
hydrates,	O
solvates,	O
crystal	O
forms	O
or	O
diastereomers	O
thereof	O
is	O
described	O
.	O
A	O
method	O
of	O
treating	O
tyrosine	O
kinase-associated	O
disease	O
states	O
in	O
a	O
subject	O
using	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
is	O
also	O
described	O
.	O


A	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
a	O
prodrug	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
either	O
.	O
These	O
are	O
compounds	O
having	O
high	O
DPP-IV	B-GENE
inhibitory	O
activity	O
and	O
improved	O
in	O
safety,	O
nontoxicity,	O
etc	O
.	O
(	O
I	O
)	O
[	O
In	O
the	O
formula,	O
R1	O
represents	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
.	O
;	O
the	O
solid	O
line	O
and	O
dotted	O
line	O
between	O
A1	O
and	O
A2	O
indicate	O
a	O
double	O
bond	O
(	O
A1	O
=	O
A2	O
)	O
,	O
etc	O
.	O
;	O
A1	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
C	O
(	O
R2	O
)	O
,	O
etc	O
.	O
;	O
A2	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
C	O
(	O
R4	O
)	O
,	O
etc	O
.	O
;	O
R2	O
represents	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
.	O
;	O
R4	O
represents	O
hydrogen,	O
optionally	O
substituted	O
alkyl,	O
etc	O
.	O
;	O
R6	O
represents	O
hydrogen,	O
optionally	O
substituted	O
aryl,	O
etc	O
.	O
;	O
and	O
—Y	O
represents,	O
e	O
.	O
g	O
.	O
;	O
a	O
group	O
represented	O
by	O
the	O
formula	O
(	O
A	O
)	O
:	O
(	O
A	O
)	O
(	O
wherein	O
m1	O
is	O
0,	O
1,	O
2,	O
or	O
3	O
;	O
and	O
R7	O
is	O
absent,	O
or	O
one	O
or	O
two	O
R7	O
'	O
s	O
are	O
present	O
and	O
each	O
independently	O
represents	O
optionally	O
substituted	O
alkyl,	O
etc	O
.	O
)	O
.	O
]	O


There	O
is	O
disclosed	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X,	O
Y,	O
W	O
and	O
Q	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
in	O
the	O
manufacture	O
of	O
a	O
medicament,	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
or	O
conditions	O
in	O
which	O
inhibition	O
of	O
the	O
enzyme	O
myeloperoxidase	B-GENE
(	O
MPO	B-GENE
)	O
is	O
beneficial	O
.	O
Certain	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
disclosed,	O
together	O
with	O
processes	O
for	O
their	O
preparation	O
.	O
The	O
compounds	O
of	O
formulae	O
(	O
I	O
)	O
are	O
MPO	B-GENE
inhibitors	O
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
neuroinflammatory	O
disorders	O
.	O


Human-	O
and	O
mouse-derived	O
bHLH	B-GENE
type	I-GENE
transcription	I-GENE
factors	I-GENE
were	O
isolated	O
.	O
These	O
transcription	O
factors	I-GENE
shared	O
homology	O
with	O
the	O
transcription	O
factor	O
DEC1,	O
the	O
expression	O
of	O
which	O
is	O
induced	O
in	O
human	O
cartilage	O
cells	O
when	O
differentiated	O
with	O
cAMP	O
.	O
Thus,	O
these	O
isolated	O
transcription	O
factors	I-GENE
are	O
thought	O
to	O
be	O
novel	O
transcription	O
factors	I-GENE
belonging	O
to	O
the	O
DEC1	B-GENE
subfamily	O
.	O
The	O
transcription	O
factors	I-GENE
of	O
the	O
present	O
invention	O
are	O
also	O
homologous	O
to	O
mouse	B-GENE
Stra13	I-GENE
and	O
rat	B-GENE
SHARP	I-GENE
that	O
are	O
related	O
to	O
neurocyte	O
differentiation	O
.	O
The	O
transcription	O
factors	I-GENE
of	O
the	O
present	O
invention	O
may	O
be	O
used	O
as	O
tools	O
for	O
developing	O
pharmaceutical	O
agents	O
for	O
diseases	O
related	O
to	O
the	O
differentiation	O
and	O
proliferation	O
of	O
cells	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
pyrrolo	O
‘2,1-a’	O
isoquinoline	O
structure-element	O
as	O
an	O
integral	O
part	O
of	O
the	O
overall	O
structure	O
of	O
compounds	O
which	O
inhibit	O
PDE10	B-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
guanine	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
to	O
hydrates	O
or	O
solvents	O
thereof,	O
for	O
use	O
as	O
neuropeptide	O
FF	O
receptor	O
antagonists	O
in	O
the	O
treatment	O
of	O
pains	O
and	O
hyperalgesia,	O
of	O
withdrawal	O
symptoms	O
of	O
addiction	O
to	O
alcohol,	O
psychotropic	O
drugs	O
or	O
nicotine	O
and	O
in	O
the	O
prevention	O
of	O
or	O
recovery	O
from	O
these	O
addictions,	O
for	O
the	O
regulation	O
of	O
insulin	B-GENE
release,	O
food	O
intake,	O
memory	O
functions,	O
blood	O
pressure,	O
electrolyte	O
and	O
energy	O
metabolism,	O
and	O
in	O
the	O
treatment	O
of	O
urinary	O
incontinence	O
.	O


The	O
use	O
of	O
VR4	B-GENE
polypeptides	O
and	O
polynucleotides	O
in	O
the	O
design	O
of	O
protocols	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
cartilage,	O
such	O
as	O
hyaline-,	O
fibro-	O
and	O
elastic-cartilage,	O
or	O
diseases	O
of	O
tissues	O
where	O
such	O
cartilage	O
is	O
found	O
including	O
diseases	O
or	O
disorders	O
affecting	O
the	O
larynx,	O
auditory	O
canal,	O
intervertebral	O
discs,	O
ligaments,	O
tendons	O
and	O
joint	O
capsules,	O
bone	O
development	O
including	O
osteoporosis,	O
diseases	O
involving	O
joint	O
destruction	O
and	O
also	O
pain	O
linked	O
to	O
rheumatoid	O
arthritis	O
and	O
osteoarthritis	O
.	O


The	O
invention	O
relates	O
especially	O
to	O
novel	O
stereospecific	O
derivatives	O
of	O
2,3-benzodiazepine	O
type	O
as	O
inhibitors	O
of	O
phosphodiesterases,	O
especially	O
2	O
and	O
4,	O
and	O
uses	O
thereof	O
in	O
the	O
therapeutic	O
field,	O
most	O
particularly	O
for	O
preventing	O
and	O
treating	O
pathologies	O
involving	O
a	O
central	O
and	O
/	O
or	O
peripheral	O
disorder	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
more	O
particularly	O
correspond	O
to	O
the	O
general	O
formulae	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
:	O


Disclosed	O
are	O
methods	O
of	O
administering	O
BIRB	O
796	O
BS,	O
a	O
p38	B-GENE
MAPK	I-GENE
inhibitor,	O
at	O
particular	O
dosages	O
.	O


Dithiocarbamate,	O
particularly	O
tetraethylthiuram	O
disulfide,	O
and	O
thiocarbamate	O
anions	O
thereof,	O
strongly	O
inhibit	O
the	O
growth	O
of	O
cancer	O
cells	O
of	O
a	O
variety	O
of	O
cell	O
types	O
.	O
Such	O
inhibitory	O
effect	O
is	O
enhanced	O
by	O
heavy	O
metal	O
ions	O
such	O
as	O
copper	O
ions,	O
cytokines	B-GENE
and	O
ceruloplasmin	B-GENE
.	O
A	O
method	O
is	O
presented	O
for	O
using	O
tetraethylthiuram	O
disulfide	O
to	O
reduce	O
tumor	O
growth,	O
and	O
to	O
potentiate	O
the	O
effect	O
of	O
other	O
anticancer	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
useful	O
as	O
dipeptidyl	B-GENE
peptidase	I-GENE
IV	I-GENE
(	O
DPP-IV	B-GENE
)	O
inhibitors	O
of	O
the	O
formula	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
X,	O
Y,	O
a,	O
R1,	O
and	O
R2	O
are	O
as	O
defined	O
herein	O
.	O


Compositions,	O
methods,	O
and	O
pharmaceutical	O
products	O
related	O
to	O
prostaglandin-related	O
compounds	O
and	O
trefoil	B-GENE
factor	I-GENE
family	I-GENE
peptides	O
are	O
disclosed	O
herein	O
.	O
Of	O
particular	O
interest	O
are	O
compositions	O
and	O
methods	O
useful	O
for	O
the	O
treatment	O
of	O
glaucoma	O
with	O
a	O
reduced	O
occurrence	O
of	O
hyperemia	O
.	O


Provided	O
herein	O
is	O
a	O
dietary	O
supplement	O
comprising	O
as	O
its	O
active	O
ingredients	O
soybean,	O
mushroom	O
and	O
mung	O
bean	O
is	O
used	O
in	O
a	O
method	O
to	O
treat	O
non-small	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O
The	O
active	O
components	O
of	O
the	O
dietary	O
supplement	O
include	O
phytoestrogens,	O
β-glucans,	O
saponins,	O
inositol	O
hexaphosphate,	O
and	O
lectins	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
ligands	O
of	O
the	O
peripheral	O
cannabinoid	B-GENE
receptor	I-GENE
CB2,	O
especially	O
(	O
+	O
)	O
-α-pinene	O
derivatives,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treatment	O
and	O
prevention	O
of	O
the	O
onset	O
of	O
genetic	O
neurodegenerative	O
disorders,	O
in	O
particular	O
Huntington	O
'	O
s	O
disease	O
.	O


Objective	O
methods	O
for	O
diagnosing	O
a	O
predisposition	O
to	O
developing	O
prostate	O
cancer	O
(	O
PRC	O
)	O
are	O
described	O
herein	O
.	O
In	O
one	O
embodiment,	O
the	O
diagnostic	O
method	O
involves	O
the	O
determining	O
a	O
expression	O
level	O
of	O
EphA4	B-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
PRC,	O
methods	O
of	O
treating	O
PRC	O
.	O
The	O
invention	O
also	O
features	O
a	O
method	O
for	O
inhibiting	O
growth	O
of	O
a	O
cancer	O
cell	O
by	O
contacting	O
the	O
cell	O
with	O
a	O
composition	O
of	O
a	O
siRNA	O
of	O
EPHA4	B-GENE
.	O
Methods	O
of	O
treating	O
cancer	O
are	O
also	O
within	O
the	O
invention	O
.	O
The	O
invention	O
also	O
features	O
products,	O
including	O
nucleic	O
acid	O
sequences	O
and	O
vectors	O
as	O
well	O
as	O
to	O
compositions	O
comprising	O
them,	O
useful	O
in	O
the	O
provided	O
methods	O
.	O
The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
inhibiting	O
of	O
tumor	O
cell,	O
for	O
example	O
pancreatic	O
cancer	O
cell,	O
particularly	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDACa	O
)	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
substituted	O
N-aryl-1H-pyrazolo	O
[	O
3,4-b	O
]	O
quinolin-4-amines	O
and	O
analogs	O
thereof,	O
represented	O
by	O
the	O
general	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
Q,	O
Y,	O
Z,	O
R4-R7,	O
X	O
and	O
Ar	O
are	O
defined	O
herein	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
discovery	O
that	O
compounds	O
having	O
Formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
caspases	B-GENE
and	O
inducers	O
of	O
apoptosis	O
.	O
Therefore,	O
the	O
activators	O
of	O
caspases	B-GENE
and	O
inducers	O
of	O
apoptosis	O
of	O
this	O
invention	O
can	O
be	O
used	O
to	O
induce	O
cell	O
death	O
in	O
a	O
variety	O
of	O
clinical	O
conditions	O
in	O
which	O
uncontrolled	O
growth	O
and	O
spread	O
of	O
abnormal	O
cells	O
occurs	O
.	O


Compounds	O
having	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
are	O
useful	O
for	O
inhibiting	O
protein	B-GENE
kinases	I-GENE
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
the	O
compounds,	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
in	O
a	O
mammal,	O
particularly	O
a	O
human,	O
with	O
a	O
combination	O
of	O
pharmaceutical	O
agents	O
which	O
comprises	O
:	O
(	O
a	O
)	O
an	O
HDAI	O
;	O
and	O
(	O
b	O
)	O
a	O
death	B-GENE
receptor	I-GENE
ligand	O
.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
:	O
(	O
a	O
)	O
an	O
HDAI	O
;	O
(	O
b	O
)	O
death	B-GENE
receptor	I-GENE
ligand	O
;	O
and	O
(	O
c	O
)	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
:	O
(	O
a	O
)	O
a	O
pharmaceutical	O
formulation	O
of	O
an	O
HDAI	O
;	O
and	O
(	O
b	O
)	O
a	O
pharmaceutical	O
formulation	O
of	O
death	B-GENE
receptor	I-GENE
ligand	O
for	O
simultaneous,	O
concurrent,	O
separate	O
or	O
sequential	O
use	O
.	O


The	O
invention	O
relates	O
to	O
chemical	O
compounds,	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
possess	O
B-Raf	B-GENE
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
for	O
their	O
anti	O
cancer	O
activity	O
and	O
thus	O
in	O
methods	O
of	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
chemical	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
of	O
use	O
in	O
the	O
production	O
of	O
an	O
anti-cancer	O
effect	O
in	O
a	O
warm	O
blooded	O
animal	O
such	O
as	O
man	O
.	O


The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
PPARα	B-GENE
agonists	O
in	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
infection	O
by	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
in	O
mammals,	O
especially	O
humans	O
.	O


Described	O
is	O
a	O
method	O
to	O
predict	O
response	O
of	O
tumour	O
cells	O
to	O
in	O
vivo	O
treatment	O
with	O
a	O
platinum-based	O
chemotherapeutic	O
agent,	O
the	O
method	O
based	O
on	O
the	O
determination	O
of	O
the	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
genes	O
encoding	O
BCRP	B-GENE
protein,	O
wherein	O
enhanced	O
expression	O
of	O
said	O
gene	O
correlates	O
with	O
enhanced	O
resistance	O
to	O
the	O
chemotherapeutic	O
agent	O
.	O
Also	O
described	O
are	O
methods	O
of	O
sensitising	O
cancer	O
cells,	O
particularly	O
colorectal	O
cancer	O
cells	O
to	O
treatment	O
.	O


Disclosed	O
are	O
medicaments,	O
pharmaceutical	O
compositions,	O
pharmaceutical	O
kits,	O
and	O
methods	O
based	O
on	O
combinations	O
of	O
at	O
least	O
one	O
HCV	B-GENE
protease	I-GENE
inhibitor	O
and	O
at	O
least	O
one	O
HCV	B-GENE
polymerase	I-GENE
inhibitor	O
but	O
not	O
HCV-796	O
;	O
for	O
concurrent	O
or	O
consecutive	O
administration	O
in	O
treating	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
HCV,	O
or	O
disorders	O
associated	O
with	O
HCV	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


Disclosed	O
is	O
a	O
method	O
for	O
obtaining	O
glucose-regulated	O
expression	O
of	O
active	O
insulin	B-GENE
in	O
the	O
cells	O
of	O
a	O
mammalian	O
subject	O
.	O
The	O
method	O
involves	O
delivering	O
into	O
the	O
subject	O
a	O
genetic	O
construct	O
comprising	O
a	O
coding	O
sequence	O
for	O
a	O
human	B-GENE
proinsulin	I-GENE
operably	O
connected	O
a	O
promoter	O
functional	O
in	O
the	O
host	O
cells	O
.	O
The	O
construct	O
includes	O
a	O
glucose	O
responsive	O
regulatory	O
module	O
having	O
at	O
least	O
one	O
glucose	O
inducible	O
regulatory	O
element	O
comprising	O
a	O
pair	O
of	O
CACGTG	O
motifs	O
linked	O
by	O
a	O
five	O
base	O
nucleotide	O
sequence,	O
which	O
confers	O
glucose	O
inducible	O
expression	O
of	O
the	O
proinsulin	O
coding	O
sequence	O
.	O
To	O
ensure	O
proper	O
processing	O
of	O
the	O
proinsulin	O
to	O
active	O
insulin,	O
the	O
coding	O
sequence	O
was	O
modified	O
to	O
direct	O
the	O
synthesis	O
of	O
a	O
mutant	O
proinsulin	O
polypeptide	O
having	O
amino	O
acid	O
sequences	O
that	O
can	O
be	O
cleaved	O
to	O
mature	O
insulin	B-GENE
in	O
suitable	O
host	O
cells,	O
such	O
as	O
hepatocytes	O
.	O


The	O
invention	O
concerns	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
cancer	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
combination	O
of	O
a	O
PP2A	B-GENE
methylating	O
agent	O
and	O
an	O
active	O
principle	O
selected	O
among	O
the	O
group	O
consisting	O
of	O
a	O
phosphatase	B-GENE
PP1	I-GENE
inhibitor,	O
a	O
histone	B-GENE
diacetylase	I-GENE
inhibitor,	O
a	O
direct	O
or	O
indirect	O
pyruvate	B-GENE
kinase	I-GENE
activator,	O
a	O
PTEN	B-GENE
agonist,	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor,	O
a	O
PI3	B-GENE
kinase	I-GENE
inhibitor,	O
a	O
glucose	O
competitor,	O
a	O
phosphocnol	B-GENE
pyruvate	B-GENE
carboxykinase	I-GENE
inhibitor,	O
a	O
citrate	B-GENE
synthase	I-GENE
inhibitor	O
and	O
a	O
latctate	B-GENE
dehydro-genase	I-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
and	O
formulations	O
for	O
inhibiting	O
Lipoxygenase	B-GENE
enzymes	O
that	O
function	O
to	O
biosynthesize	O
or	O
metabolize	O
arachidonic	O
acid	O
into	O
its	O
intermediate	O
Leukotriene	O
constituents,	O
as	O
well	O
as	O
a	O
method	O
and	O
formulation	O
for	O
treating	O
and	O
preventing	O
diseases,	O
including	O
inflammatory	O
diseases,	O
and	O
the	O
symptoms	O
associated	O
with	O
such	O
diseases	O
.	O
The	O
present	O
invention	O
methods	O
and	O
formulations	O
effectively	O
function	O
as	O
such	O
through	O
the	O
introduction	O
into	O
the	O
body	O
(	O
e	O
.	O
g	O
.	O
ingesting	O
)	O
a	O
safe,	O
pre-determined	O
dosage	O
of	O
a	O
naturaceutical	O
composition	O
formulated	O
with	O
or	O
comprising	O
one	O
or	O
more	O
processed	O
Morinda	O
citrifolia	O
products	O
for	O
a	O
safe,	O
pre-determined	O
duration,	O
wherein	O
the	O
processed	O
Morinda	O
citrifolia	O
product	O
may	O
comprise	O
one	O
or	O
more	O
isolated	O
active	O
ingredients	O
.	O


A	O
double	O
stranded	O
RNA	O
having	O
a	O
specific	O
nucleotide	O
sequence	O
is	O
useful	O
for	O
treating	O
cellular	O
proliferative	O
disorders	O
.	O
The	O
double	O
stranded	O
RNA	O
acts	O
as	O
siRNA	O
against	O
the	O
Rad51	B-GENE
gene	O
.	O
The	O
double	O
stranded	O
RNA	O
of	O
the	O
present	O
invention	O
inhibits	O
cellular	O
proliferation	O
itself	O
.	O
In	O
addition,	O
co-administration	O
of	O
the	O
double	O
stranded	O
RNA	O
with	O
a	O
chemotherapeutic	O
agent	O
further	O
enhances	O
its	O
pharmacological	O
effect	O
.	O
The	O
combined	O
use	O
of	O
the	O
double	O
stranded	O
RNA	O
with	O
an	O
agent	O
having	O
a	O
nucleic	O
acid	O
synthesis-inhibitory	O
activity	O
or	O
a	O
nucleic	O
acid-impairing	O
activity	O
is	O
particularly	O
effective	O
.	O


A	O
method	O
of	O
treating	O
aging	O
of	O
skin	O
including	O
applying	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
anti-aging	O
dermatological	O
care	O
composition	O
including	O
at	O
least	O
one	O
cosmetic	O
formulation	O
agent	O
and	O
oligogalacturonides	O
having	O
a	O
degree	O
of	O
polymerization	O
between	O
1	O
and	O
5	O
that	O
stimulates	O
adherence	O
of	O
basal	O
keratinocytes	O
to	O
laminin	B-GENE
V	I-GENE
and	O
/	O
or	O
collagen	B-GENE
IV	I-GENE
and	O
reduces	O
communication	O
disturbances	O
between	O
a	O
subject	O
'	O
s	O
dermis	O
and	O
epidermis	O
and	O
reduces	O
diminishment	O
in	O
interkeratinocyte	O
cohesion	O
within	O
the	O
epidermis,	O
to	O
skin	O
.	O


This	O
invention	O
relates	O
to	O
compositions	O
comprising	O
co-crystals	O
of	O
(	O
−	O
)	O
-gossypol	O
with	O
a	O
C1-8	O
carboxylic	O
acid	O
or	O
C1-8	O
sulfonic	O
acid	O
which	O
are	O
useful	O
as	O
inhibitors	O
of	O
Bcl-2	B-GENE
family	I-GENE
proteins	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
co-crystals	O
of	O
(	O
−	O
)	O
-gossypol	O
with	O
a	O
C1-8	O
carboxylic	O
acid	O
or	O
C1-8	O
sulfonic	O
acid	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
and	O
for	O
sensitizing	O
cells	O
to	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
maintaining	O
and	O
promoting	O
hair	O
thickening	O
by	O
increasing	O
the	O
expression	O
of	O
keratinocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
FGF-7	B-GENE
)	O
in	O
hair	O
follicle	O
cells,	O
and	O
preferably	O
dermal	O
papilla	O
cells,	O
a	O
composition	O
for	O
increasing	O
expression	O
of	O
FGF-7	B-GENE
that	O
contains	O
adenosine	O
and	O
/	O
or	O
a	O
derivative	O
thereof,	O
and	O
particularly,	O
an	O
external	O
scalp	O
preparation	O
for	O
maintaining	O
and	O
promoting	O
hair	O
thickening	O
.	O


The	O
invention	O
provides	O
the	O
combination	O
of	O
a	O
5-HT2A	B-GENE
antagonist	O
and	O
gaboxadol	O
for	O
use	O
in	O
treatment	O
or	O
prevention	O
of	O
sleep	O
disorders,	O
schizophrenia	O
or	O
depression	O
.	O


The	O
present	O
invention	O
relates	O
to	O
hydrochloric	O
acid	O
salt	O
and	O
crystalline	O
forms	O
of	O
the	O
5-HT1A	B-GENE
binding	O
agent	O
6-methoxy-8-	O
[	O
4-	O
(	O
1-	O
(	O
5-fluoro	O
)	O
-quinolin-8-yl-piperidin-4-yl	O
)	O
-piperazin-1-yl	O
]	O
-quinoline,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
3,3-diphenyl-1,3-dihydro-indol-2-one	O
compounds,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
mammal	O
.	O
It	O
is	O
postulated	O
that	O
treatment	O
of	O
cancers	O
is	O
achieved	O
in	O
which	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
/	O
or	O
inhibition	O
of	O
activation	O
of	O
the	O
mTOR	B-GENE
pathway	O
is	O
an	O
effective	O
method	O
for	O
reducing	O
cell	O
growth	O
.	O
Examples	O
of	O
such	O
cancers	O
are	O
breast	O
cancer,	O
renal	O
cancer,	O
multiple	O
myeloma,	O
leukemia,	O
glia	O
blastoma,	O
rhabdomyosarcoma,	O
prostate,	O
soft	O
tissue	O
sarcoma,	O
colorectal	O
sarcoma,	O
gastric	O
carcinoma,	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma,	O
uterine,	O
cervical,	O
melanoma,	O
lymphoma,	O
and	O
pancreatic	O
cancer	O
.	O
A	O
particular	O
subclass	O
of	O
compounds	O
are	O
represented	O
by	O
the	O
formula	O
(	O
II	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
at	O
least	O
one	O
of	O
X1	O
and	O
X2	O
is	O
a	O
heteroatom	O
substituent,	O
e	O
.	O
g	O
.	O
6-chloro-3,3-bis-	O
(	O
4-hydroxy-phenyl	O
)	O
-7-methyl-1,3-dihydro-indol-2-one	O
.	O


A	O
method	O
to	O
ameliorate	O
inflammatory	O
effects	O
by	O
providing	O
an	O
anti-platelet	O
derived	O
growth	O
factor	O
(	O
anti-PDGF	O
)	O
agent	O
.	O
In	O
one	O
embodiment	O
the	O
agent	O
is	O
imatinib	O
.	O
In	O
another	O
embodiment	O
the	O
agent	O
is	O
dasatinib	O
.	O
The	O
method	O
reduces	O
the	O
undesirable	O
effects	O
of	O
post-surgical	O
scarring,	O
such	O
as	O
restenosis,	O
because	O
of	O
the	O
anti-inflammatory	O
effect	O
of	O
the	O
anti-PDGF	O
agent	O
.	O
The	O
method	O
may	O
be	O
used	O
in	O
patients	O
undergoing	O
any	O
type	O
of	O
surgery,	O
such	O
as	O
cardiac	O
surgery,	O
ocular	O
surgery,	O
vascular	O
surgery,	O
etc	O
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
discloses	O
novel	O
compounds,	O
as	O
inhibitors	O
of	O
HDM2	B-GENE
protein,	O
methods	O
for	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
including	O
one	O
or	O
more	O
such	O
compounds,	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,	O
of	O
one	O
or	O
more	O
diseases	O
associated	O
with	O
the	O
HDM2	B-GENE
protein	O
or	O
P53	B-GENE
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds,	O
including	O
compounds	O
of	O
Formula	O
I,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester,	O
or	O
prodrug,	O
thereof	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
which	O
inhibit	O
serine	B-GENE
protease	I-GENE
activity,	O
particularly	O
the	O
activity	O
of	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
(HCV)	I-GENE
NS3-NS4A	I-GENE
protease	I-GENE
.	O
Consequently,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
interfere	O
with	O
the	O
life	O
cycle	O
of	O
the	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
and	O
are	O
also	O
useful	O
as	O
antiviral	O
agents	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
aforementioned	O
compounds	O
for	O
administration	O
to	O
a	O
subject	O
suffering	O
from	O
HCV	O
infection	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
an	O
HCV	O
infection	O
in	O
a	O
subject	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
.	O


The	O
present	O
invention	O
refers	O
to	O
an	O
in	O
vitro	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
renal	O
cancer	O
in	O
an	O
individual,	O
for	O
determining	O
the	O
stage,	O
malignancy	O
or	O
severity	O
of	O
said	O
carcinoma	O
in	O
the	O
individual	O
or	O
for	O
monitoring	O
the	O
effect	O
of	O
the	O
therapy	O
administered	O
to	O
an	O
individual	O
having	O
said	O
cancer	O
;	O
to	O
the	O
search,	O
identification,	O
development	O
and	O
assessment	O
of	O
the	O
efficacy	O
of	O
compounds	O
for	O
therapy	O
for	O
said	O
cancer	O
in	O
an	O
attempt	O
to	O
develop	O
new	O
drugs	O
;	O
as	O
well	O
as	O
to	O
agents	O
inducing	O
Plexin-131	B-GENE
protein	O
expression	O
and	O
/	O
or	O
activity,	O
or	O
to	O
agents	O
inhibiting	O
the	O
effects	O
of	O
Plexin-B1	B-GENE
protein	O
expression	O
and	O
/	O
or	O
activity	O
repression	O
.	O


One	O
embodiment	O
is	O
directed	O
toward	O
a	O
method	O
for	O
treating	O
an	O
individual	O
with	O
a	O
disorder	O
affected	O
by	O
androgen	B-GENE
receptor	I-GENE
activity	O
.	O
This	O
method	O
includes	O
administering	O
a	O
therapeutic	O
amount	O
of	O
DL3	O
(	O
6-amino-2-	O
(	O
2-4-tert-butyl-phenoxy	O
)	O
-ethylsulfanyl	O
)	O
-1H-pyrimidin-4-one	O
)	O
to	O
the	O
individual	O
.	O
In	O
an	O
additional	O
embodiment,	O
the	O
disorder	O
affected	O
by	O
androgen	B-GENE
receptor	I-GENE
activity	O
includes	O
cancer	O
.	O
Another	O
embodiment	O
is	O
directed	O
toward	O
a	O
method	O
for	O
treating	O
an	O
individual	O
with	O
prostate	O
cancer	O
.	O
This	O
method	O
includes	O
administering	O
to	O
the	O
individual	O
a	O
therapeutic	O
amount	O
of	O
an	O
androgen	B-GENE
receptor	I-GENE
antagonist	O
which	O
reduces	O
the	O
production	O
of	O
prostate	O
specific	O
antigen	O
and	O
has	O
only	O
negligible	O
androgen	B-GENE
receptor	I-GENE
agonist	O
effects	O
.	O


(	O
1	O
)	O
A	O
preventive	O
and	O
/	O
or	O
a	O
remedy	O
for	O
lower	O
urinary	O
tract	O
diseases	O
such	O
as	O
inflammation	O
in	O
the	O
lower	O
urinary	O
tract,	O
cystitis	O
(	O
interstitial	O
cystitis,	O
etc	O
.	O
)	O
and	O
urethritis	O
;	O
(	O
2	O
)	O
an	O
agent	O
for	O
improving	O
bladder	O
compliance	O
and	O
/	O
or	O
bladder	O
capacity	O
;	O
and	O
(	O
3	O
)	O
an	O
agent	O
for	O
protecting	O
bladder	O
mucosa	O
and	O
/	O
or	O
bladder	O
epithelial	O
cells	O
and	O
/	O
or	O
promoting	O
the	O
regeneration	O
thereof	O
;	O
each	O
containing	O
an	O
EP4	B-GENE
agonist	O
.	O
	O
	O
	O
	O
	O
An	O
EP4	B-GENE
agonist	O
is	O
useful	O
in	O
ameliorating	O
symptoms	O
of	O
lower	O
urinary	O
tract	O
diseases	O
such	O
as	O
(	O
1	O
)	O
frequent	O
urination,	O
(	O
2	O
)	O
urgency	O
of	O
urination,	O
(	O
3	O
)	O
pain	O
in	O
the	O
reproductive	O
organs	O
and	O
/	O
or	O
lower	O
urinary	O
tract	O
(	O
for	O
example,	O
bladder	O
pain,	O
urinary	O
tract	O
pain,	O
vulvar	O
pain,	O
vaginal	O
pain,	O
scrotal	O
pain,	O
perineal	O
pain,	O
pelvic	O
pain,	O
etc	O
.	O
)	O
and	O
/	O
or	O
(	O
4	O
)	O
discomfort	O
in	O
the	O
reproductive	O
organs	O
and	O
/	O
or	O
lower	O
urinary	O
tract	O
.	O
Among	O
all,	O
a	O
selective	O
EP4	B-GENE
agonist	O
is	O
useful	O
as	O
a	O
preventive	O
and	O
/	O
or	O
remedy	O
for	O
lower	O
urinary	O
tract	O
diseases	O
having	O
no	O
side	O
effect	O
.	O


Compounds	O
of	O
Formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
n,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
R10,	O
R15,	O
R16,	O
R17,	O
R18,	O
Y	O
and	O
Z	O
are	O
defined	O
herein	O
)	O
which	O
are	O
modulators	O
of	O
chemokine	B-GENE
receptor	I-GENE
activity	O
and	O
are	O
useful	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
certain	O
inflammatory	O
and	O
immunoregulatory	O
disorders	O
and	O
diseases,	O
allergic	O
diseases,	O
atopic	O
conditions	O
including	O
allergic	O
rhinitis,	O
dermatitis,	O
conjunctivitis,	O
and	O
asthma,	O
as	O
well	O
as	O
autoimmune	O
pathologies	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
atherosclerosis	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
chemokine	O
receptors	O
are	O
involved	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
TNF-α-mediated	O
disorders,	O
the	O
methods	O
generally	O
involving	O
administering	O
to	O
an	O
individual	O
in	O
need	O
thereof	O
effective	O
amounts	O
of	O
pirfenidone	O
or	O
a	O
pirfenidone	O
analog	O
and	O
a	O
second	O
therapeutic	O
agent	O
that	O
reduces	O
TNF-α	B-GENE
synthesis	O
or	O
that	O
reduces	O
TNF-α	B-GENE
binding	O
to	O
a	O
TNF	B-GENE
receptor	I-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
for	O
treating	O
non-alcoholic	O
steatohepatitis,	O
the	O
method	O
generally	O
involving	O
administering	O
to	O
an	O
individual	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
pirfenidone	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
treating	O
end-stage	O
or	O
advanced	O
Type	O
II	O
diabetes,	O
the	O
methods	O
generally	O
involving	O
administering	O
to	O
an	O
individual	O
in	O
need	O
thereof	O
effective	O
amounts	O
of	O
pirfenidone	O
and	O
insulin	O
.	O


The	O
combination	O
of	O
pentraxin	B-GENE
PTX3	I-GENE
with	O
antifungal	O
agents	O
is	O
described	O
for	O
the	O
treatment	O
of	O
fungal	O
infections	O
and	O
particularly	O
for	O
infections	O
caused	O
by	O
Aspergillus	O
fumigatus	O
.	O
Thanks	O
to	O
the	O
synergistic	O
effect	O
of	O
the	O
two	O
drugs,	O
the	O
combination	O
allows	O
the	O
administration	O
of	O
suboptimal	O
doses	O
of	O
antifungal	O
agent	O
.	O


A	O
method	O
of	O
potentiating	O
the	O
activity	O
of	O
a	O
therapeutic	O
drug,	O
like	O
a	O
chemotherapeutic	O
drug	O
or	O
an	O
antibiotic,	O
in	O
a	O
cell	O
or	O
tissue,	O
by	O
inhibiting	O
the	O
efflux	O
capability	O
of	O
a	O
multidrug	B-GENE
transporter	I-GENE
are	O
disclosed	O
.	O
The	O
method	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
cancer	O
by	O
sensitizing	O
tumor	O
cells	O
to	O
a	O
chemotherapeutic	O
agent	O
.	O
Compounds	O
capable	O
of	O
inhibiting	O
an	O
efflux	O
capability	O
of	O
a	O
multidrug	B-GENE
transporter	I-GENE
also	O
are	O
disclosed	O
.	O


The	O
invention	O
provides	O
a	O
human	B-GENE
GPR39	I-GENE
which	O
is	O
associated	O
with	O
the	O
cardiovascular	O
disorders,	O
endocrine	O
system	O
and	O
hormone	O
disorders,	O
cancer	O
disorders,	O
metabolic	O
diseases,	O
gastrointestinal	O
and	O
liver	O
diseases,	O
hematological	O
disorders,	O
neurological	O
disorders	O
and	O
respiratory	O
diseases	O
.	O
The	O
invention	O
also	O
provides	O
assays	O
for	O
the	O
identification	O
of	O
compounds	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
cardiovascular	O
disorders,	O
endocrine	O
system	O
and	O
hormone	O
disorders,	O
cancer	O
disorders,	O
metabolic	O
diseases,	O
gastrointestinal	O
and	O
liver	O
diseases,	O
hematological	O
disorders,	O
neurological	O
disorders	O
and	O
respiratory	O
diseases	O
.	O
The	O
invention	O
also	O
features	O
compounds	O
which	O
bind	O
to	O
and	O
/	O
or	O
activate	O
or	O
inhibit	O
the	O
activity	O
of	O
GPR39	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O


The	O
invention	O
is	O
based	O
upon	O
the	O
discovery	O
that	O
the	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
pathway	O
can	O
increase	O
CA9	B-GENE
expression	O
independently	O
of	O
HIF-1,	O
as	O
well	O
as	O
increasing	O
CA9	B-GENE
expression	O
under	O
HIF-1-dependent	O
pathways	O
initiated	O
by	O
hypoxia	O
or	O
high	O
cell	O
density	O
.	O
Disclosed	O
herein	O
are	O
novel	O
therapeutic	O
methods	O
for	O
treating	O
preneoplastic	O
/	O
neoplastic	O
diseases	O
associated	O
with	O
abnormal	O
MN	O
/	O
CA	B-GENE
IX	I-GENE
expression,	O
using	O
MAPK	B-GENE
pathway	O
inhibitors	O
.	O
Preferably,	O
the	O
MAPK	B-GENE
pathway	O
inhibitors	O
are	O
raf	B-GENE
kinase	I-GENE
inhibitors,	O
particularly	O
the	O
raf	B-GENE
kinase	I-GENE
inhibitor	O
Sorafenib	O
.	O
Further	O
disclosed	O
are	O
methods	O
for	O
patient	O
therapy	O
selection	O
for	O
MAPK	B-GENE
pathway	O
inhibitors,	O
preferably	O
in	O
combination	O
with	O
other	O
cancer	O
therapies,	O
based	O
on	O
detection	O
of	O
abnormal	O
MN	O
/	O
CA9	B-GENE
gene	O
expression	O
in	O
preneoplastic	O
/	O
neoplastic	O
tissues	O
.	O


Disclosed	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
subjects	O
with	O
conditions	O
related	O
to	O
Inositol	B-GENE
1,4,5-trisphosphate	I-GENE
receptor	I-GENE
(	O
InsP3R	B-GENE
)	O
.	O
Described	O
herein	O
are	O
mutants	O
of	O
InsP3R,	O
methods	O
of	O
making	O
mutants,	O
and	O
methods	O
of	O
using	O
InsP3R	B-GENE
mutants	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
p	O
is	O
1,	O
2	O
or	O
3	O
;	O
n	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
m	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
	O
	O
	O
	O
A	O
is	O
CRc,	O
S,	O
NRc	O
or	O
O,	O
where	O
Rc	O
is	O
H	O
or	O
lower	O
alkyl	O
;	O
	O
X,	O
Y	O
and	O
Z	O
are	O
each	O
independently	O
selected	O
from	O
N	O
or	O
C—R3,	O
wherein	O
at	O
least	O
two	O
of	O
X,	O
Y	O
and	O
Z	O
are	O
N	O
;	O
and	O
	O
each	O
Ra	O
is	O
independently	O
selected	O
from	O
hydrogen	O
and	O
lower-alkyl	O
;	O
	O
each	O
Rb	O
is	O
hydrogen	O
or	O
lower-alkyl	O
;	O
G	O
is	O
a	O
group	O
Ar	O
or	O
represents	O
CN	O
or	O
unsubstituted	O
or	O
substituted	O
lower	O
alkyl	O
;	O
Ar	O
is	O
a	O
saturated	O
or	O
unsaturated	O
cyclic	O
group,	O
which	O
is	O
substituted	O
or	O
unsubstituted	O
and	O
maybe	O
a	O
five	O
or	O
six	O
membered	O
monocyclic	O
or	O
a	O
8,	O
9,	O
10,	O
11	O
or	O
12	O
membered	O
bicyclic	O
or	O
tricyclic	O
ring	O
and	O
may	O
contain	O
0,	O
1,	O
2	O
or	O
3	O
heteroatoms	O
selected	O
from	O
O,	O
N	O
and	O
S	O
;	O
	O
and	O
wherein	O
the	O
radicals	O
have	O
R1,	O
R2,	O
R3	O
and	O
R4	O
have	O
the	O
meanings	O
as	O
defined	O
herein,	O
to	O
salts,	O
esters,	O
N-oxides	O
or	O
prodrugs	O
thereof	O
;	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
protein	B-GENE
kinase	I-GENE
dependent	O
diseases,	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
for	O
use	O
in	O
the	O
treatment	O
of	O
said	O
diseases,	O
methods	O
of	O
use	O
of	O
diary	O
urea	O
derivatives	O
in	O
the	O
treatment	O
of	O
said	O
diseases,	O
pharmaceutical	O
preparations	O
comprising	O
these	O
novel	O
diaryl	O
urea	O
derivatives,	O
processes	O
for	O
the	O
manufacture	O
of	O
the	O
novel	O
diaryl	O
urea	O
derivatives,	O
the	O
use	O
or	O
methods	O
of	O
use	O
of	O
the	O
novel	O
diaryl	O
urea	O
derivatives	O
as	O
mentioned	O
above,	O
and	O
/	O
or	O
these	O
novel	O
diaryl	O
urea	O
derivatives	O
for	O
use	O
in	O
the	O
treatment	O
of	O
the	O
animal	O
or	O
human	O
body	O
.	O


Method	O
of	O
diagnosing	O
persistent,	O
chronic	O
synovitis	O
and	O
progressive	O
joint	O
degradation	O
in	O
the	O
joint	O
of	O
a	O
mammal	O
.	O
The	O
method	O
including	O
providing	O
a	O
test	O
sample	O
comprising	O
synovial	O
fluid,	O
cell	O
or	O
tissue	O
from	O
the	O
joint	O
of	O
a	O
mammal	O
;	O
detecting	O
the	O
presence	O
of	O
bacterial	O
DNA,	O
measuring	O
the	O
concentration	O
of	O
one	O
or	O
more	O
biomarkers	O
being	O
cathepsin	O
K,	O
MMP-2	B-GENE
and	I-GENE
-9,	O
cathepsin	O
S,	O
tartrate-resistant	B-GENE
acid	I-GENE
phosphatase,	O
invariant	O
chain,	O
CD4+	O
T-lymphocytes,	O
CD8+	O
T-lymphocytes,	O
CD44+	O
mononuclear	O
cells,	O
Toll-like	O
receptor-2,	O
Toll-like	O
receptor-9,	O
or	O
a	O
combination	O
thereof	O
;	O
and,	O
comparing	O
the	O
concentration	O
of	O
the	O
biomarker	O
from	O
the	O
test	O
sample	O
to	O
a	O
corresponding	O
biomarker	O
concentration	O
in	O
a	O
control	O
sample	O
from	O
healthy	O
dogs,	O
or	O
an	O
internal	O
PBMC	O
control	O
sample,	O
wherein	O
a	O
statistically	O
significant	O
elevated	O
concentration	O
of	O
the	O
biomarker	O
in	O
the	O
test	O
sample	O
indicates	O
that	O
the	O
mammal	O
'	O
s	O
joint	O
is	O
diseased	O
.	O


Novel	O
compositions	O
and	O
methods	O
of	O
treating	O
and	O
preventing	O
a	O
viral	O
infection	O
are	O
provided	O
.	O
A	O
method	O
of	O
blocking	O
a	O
viral	O
infection	O
facilitated	O
by	O
a	O
serine	O
proteolytic	O
(	O
SP	O
)	O
activity	O
is	O
disclosed,	O
which	O
involves	O
administering	O
to	O
a	O
subject	O
suffering	O
or	O
about	O
to	O
suffer	O
from	O
a	O
viral	O
infection	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
substance	O
having	O
serine	O
protease	O
inhibitory	O
activity	O
or	O
serpin	O
activity	O
.	O
Among	O
the	O
substances	O
found	O
to	O
be	O
useful	O
are	O
α1-antitrypsin	B-GENE
(	O
AAT	B-GENE
)	O
,	O
peptide	O
derivatives	O
from	O
the	O
carboxy	O
terminal	O
end	O
of	O
AAT	B-GENE
and	O
synthetic	O
drugs	O
mimicking	O
the	O
action	O
of	O
such	O
substances	O
.	O
The	O
invention	O
is	O
particularly	O
well	O
suited	O
for	O
checking	O
a	O
viral	O
infection	O
mediated	O
by	O
members	O
of	O
herpesviridae	O
family	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
that	O
OLD-35,	O
at	O
least	O
in	O
part	O
through	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species,	O
induces	O
a	O
number	O
of	O
inflammatory	O
cytokines	O
and	O
promotes	O
nuclear	O
translocation	O
and	O
binding	O
of	O
the	O
transcriptional	O
activator	O
NF-κB	B-GENE
.	O
Accordingly,	O
the	O
present	O
invention	O
provides	O
for	O
assay	O
systems	O
(	O
which	O
either	O
utilize	O
the	O
old-35	B-GENE
promoter	O
or	O
the	O
old-35	B-GENE
gene	O
)	O
that	O
may	O
be	O
used	O
to	O
identify	O
new	O
anti-inflammatory	O
agents	O
;	O
model	O
systems	O
of	O
inflammation	O
based	O
on	O
over-expression	O
of	O
the	O
old-35	B-GENE
gene	O
in	O
cells	O
and	O
tissues	O
(	O
including	O
specific	O
model	O
systems	O
for	O
arthritis,	O
atherosclerosis	O
and	O
Alzheimer	O
'	O
s	O
disease	O
)	O
;	O
methods	O
and	O
kits	O
for	O
diagnosing	O
old-35	B-GENE
associated	O
inflammatory	O
conditions,	O
and	O
methods	O
of	O
treatment	O
and	O
anti-inflammatory	O
compositions	O
that	O
utilize	O
agents	O
that	O
antagonize	O
OLD-35	B-GENE
activity	O
.	O


A	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof,	O
an	O
N-oxide	O
thereof,	O
a	O
solvate	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O
)	O
The	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
has	O
the	O
antagonistic	O
activity	O
against	O
CCR5,	O
so	O
they	O
are	O
useful	O
in	O
preventing	O
and	O
/	O
or	O
treating	O
CCR5-related	O
diseases,	O
for	O
example,	O
various	O
inflammatory	O
diseases	O
(	O
asthma,	O
nephritis,	O
nephropathy,	O
hepatitis,	O
arthritis,	O
rheumatoid	O
arthritis,	O
rhinitis,	O
conjunctivitis,	O
inflammatory	O
bowel	O
disease	O
such	O
as	O
ulcerative	O
colitis,	O
etc	O
.	O
)	O
,	O
immunological	O
diseases	O
(	O
autoimmune	O
diseases,	O
rejection	O
in	O
organ	O
transplantation	O
(	O
rejection	O
of	O
graft	O
of	O
solid	O
organ,	O
rejection	O
of	O
graft	O
of	O
pancreatic	O
islet	O
cells	O
in	O
therapy	O
for	O
diabetes,	O
graft-versus-host	O
disease,	O
etc	O
.	O
)	O
,	O
immunosuppression,	O
psoriasis,	O
multiple	O
sclerosis,	O
etc	O
.	O
)	O
,	O
infectious	O
diseases	O
(	O
infection	O
with	O
human	O
immunodeficiency	O
virus,	O
acquired	O
immunodeficiency	O
syndrome,	O
infection	O
with	O
RSV,	O
etc	O
.	O
)	O
,	O
allergic	O
diseases	O
(	O
atopic	O
dermatitis,	O
urticaria,	O
allergic	O
bronchopulmonary	O
aspergillosis,	O
allergic	O
eosinophilic	O
gastroenteritis,	O
etc	O
.	O
)	O
,	O
cardiovascular	O
diseases	O
(	O
arteriosclerosis,	O
ischemic	O
reperfusion	O
injury,	O
etc	O
.	O
)	O
,	O
acute	O
respiratory	O
distress	O
syndrome,	O
shock	O
accompanying	O
bacterial	O
infection,	O
diabetes,	O
cancer	O
metastasis	O
and	O
so	O
on	O
.	O


A	O
novel	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
-cholesterol	O
level	O
elevating	O
agent	O
containing	O
a	O
compound	O
which	O
has	O
a	O
squalene	B-GENE
synthase	I-GENE
inhibitory	O
activity	O
.	O


Treatment	O
of	O
Diseases	O
caused	O
by	O
Disturbances	O
of	O
the	O
Activity	O
of	O
the	O
Androgen	B-GENE
Receptor	I-GENE
uses	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
(	O
as	O
defined	O
herein	O
)	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
caused	O
by	O
disturbances	O
of	O
the	O
activity	O
of	O
androgen	B-GENE
receptor	I-GENE
are	O
provided	O
:	O
Formula	O
(	O
I	O
)	O
.	O
Isolated	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
discloses	O
uses	O
for	O
the	O
MKLP1	B-GENE
gene	O
and	O
/	O
or	O
polypeptide	O
and	O
/	O
or	O
modulators	O
thereof	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
apoptosis-related	O
diseases	O
.	O


The	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
agent	O
for	O
promoting	O
IFN-γ	B-GENE
production,	O
which	O
can	O
be	O
safely	O
applied	O
to	O
living	O
bodies	O
;	O
the	O
present	O
invention	O
solves	O
the	O
problem	O
by	O
providing	O
an	O
agent	O
for	O
promoting	O
IFN-γ	B-GENE
production,	O
which	O
comprises	O
a	O
tri-heterocyclic	O
polymethine	O
cyanine	O
dye	O
(	O
s	O
)	O
,	O
and	O
a	O
method	O
for	O
producing	O
IFN-γ,	O
which	O
comprises	O
a	O
step	O
of	O
allowing	O
the	O
agent	O
to	O
act	O
on	O
immunocompetent	O
cells	O
.	O


The	O
invention	O
concerns	O
a	O
method	O
of	O
treatment	O
or	O
prophylaxis	O
of	O
depression	O
by	O
administering	O
a	O
phenylethanolaminocyclohexylphenyl	O
compound	O
of	O
a	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1	O
represents	O
hydrogen	O
or	O
halogen	O
;	O
R2	O
represents	O
hydrogen,	O
hydroxy,	O
lower	O
alkoxy,	O
lower	O
alkoxy	O
substituted	O
with	O
one	O
or	O
two	O
lower	O
alkoxycarbonyl	O
or	O
carboxy	O
groups,	O
lower	O
alkoxy	O
substituted	O
with	O
lower	O
alkylaminocarbonyl	O
which	O
may	O
be	O
substituted	O
with	O
lower	O
alkoxy,	O
lower	O
alkoxy	O
substituted	O
with	O
cyclic	O
aminocarbonyl	O
of	O
4	O
to	O
6	O
carbon	O
atoms,	O
lower	O
alkoxycarbonyl	O
or	O
carboxy	O
;	O
R3	O
represents	O
hydrogen,	O
hydroxy,	O
lower	O
alkoxy	O
or	O
lower	O
alkoxy	O
substituted	O
with	O
one	O
or	O
two	O
lower	O
alkoxycarbonyl	O
or	O
carboxy	O
groups	O
;	O
R2	O
and	O
R3	O
may	O
be	O
bonded	O
to	O
each	O
other	O
to	O
form	O
methylenedioxy	O
substituted	O
with	O
carboxy	O
or	O
lower	O
alkoxycarbonyl	O
;	O
and	O
m	O
and	O
n	O
are	O
0	O
or	O
1,	O
and	O
their	O
pharmacologically	O
acceptable	O
metabolites	O
or	O
salts,	O
which	O
have	O
selective	O
stimulating	O
activity	O
and	O
binding	O
affinity	O
for	O
β3	B-GENE
adrenergic	I-GENE
receptors	I-GENE
.	O


A	O
means	O
and	O
method	O
for	O
increasing	O
or	O
inhibiting	O
the	O
secretion	O
of	O
cytokines	B-GENE
using	O
gallotannins	O
and	O
ellagitannins	O
is	O
described	O
.	O
The	O
preferred	O
cytokine	B-GENE
release	O
inhibiting	O
compounds	O
are	O
dimeric	O
gallotannins	O
having	O
a	O
linker	O
molecule	O
that	O
misaligns	O
the	O
carbohydrate	O
cores	O
of	O
the	O
compounds	O
.	O
The	O
preferred	O
cytokine	B-GENE
release	O
promoting	O
gallotannins	O
and	O
ellagitannins	O
include	O
a	O
diaryl	O
ether	O
linker	O
unit	O
.	O
In	O
comparison	O
to	O
the	O
more	O
structurally	O
complex	O
ellagitannins,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
structurally	O
simpler,	O
easier	O
to	O
synthesize,	O
and	O
more	O
potent	O
.	O


The	O
application	O
relates	O
to	O
novel	O
substituted	O
piperidines	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R4,	O
W,	O
X,	O
Z,	O
m	O
and	O
n	O
are	O
each	O
as	O
defined	O
in	O
detail	O
in	O
the	O
description,	O
to	O
a	O
process	O
for	O
their	O
preparation	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
as	O
medicines,	O
in	O
particular	O
as	O
renin	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
identification	O
of	O
agents	O
that	O
pay	O
a	O
role	O
in	O
regulating	O
brain	O
amyloid-β	B-GENE
(	O
Aβ	B-GENE
)	O
levels	O
in	O
vivo	O
.	O
The	O
invention	O
provides	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
amyloidogenic	O
conditions	O
.	O
It	O
also	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
screening	O
for	O
and	O
evaluating	O
candidate	O
amyloid	O
inhibiting	O
or	O
therapeutic	O
compounds	O
.	O
In	O
particular,	O
ovariectomy	O
(	O
ovx	O
)	O
and	O
estrogen	O
replacement	O
were	O
found	O
to	O
affect	O
brain	O
Aβ,	O
levels	O
in	O
guinea	O
pigs	O
.	O
Long-term	O
ovx	O
of	O
guinea	O
pigs	O
resulted	O
in	O
increased	O
levels	O
of	O
total	O
brain	O
Aβ,	O
as	O
compared	O
to	O
intact	O
animals,	O
and	O
the	O
Aβ42	O
/	O
Aβ40	O
ratio	O
was	O
also	O
elevated	O
.	O
Treatment	O
of	O
ovx	O
guinea	O
pigs	O
with	O
β17-estradiol	O
for	O
ten	O
days	O
partially	O
reversed	O
the	O
ovx-associated	O
increase	O
in	O
brain	O
Aβ	B-GENE
levels	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
inhibitors	O
of	O
MDM2	B-GENE
Binding	I-GENE
Protein	I-GENE
(	O
MTBP	B-GENE
)	O
activity	O
that	O
may	O
be	O
used	O
as	O
medicaments	O
.	O
Such	O
medicaments	O
may	O
be	O
used	O
to	O
prevent	O
or	O
treat	O
cancers	O
.	O
A	O
preferred	O
inhibitor	O
is	O
an	O
siRNA	O
molecule	O
that	O
is	O
specific	O
for	O
silencing	O
MTBP	B-GENE
expression	O
.	O
The	O
invention	O
further	O
relates	O
to	O
screening	O
methods	O
(	O
e	O
.	O
g	O
.	O
for	O
identifying	O
MTBP	B-GENE
inhibitors	O
that	O
may	O
be	O
used	O
to	O
treat	O
cancers	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
therapy	O
for	O
treating	O
patients	O
suffering	O
from	O
proliferative	O
diseases	O
or	O
diseases	O
associated	O
with	O
persistent	O
angiogenesis	O
.	O
The	O
patient	O
is	O
treated	O
with	O
a	O
VEGF	B-GENE
inhibitor	O
compound	O
;	O
and	O
one	O
or	O
more	O
chemotherapeutic	O
agents	O
.	O


The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
autoimmune	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
.	O
The	O
compositions	O
include	O
a	O
combination	O
of	O
an	O
NMDA	B-GENE
Receptor	I-GENE
antagonist,	O
such	O
as	O
memantine	O
or	O
rimantadine,	O
and	O
a	O
fumarate	O
agent,	O
such	O
as	O
dimethyl	O
fumarate	O
.	O


The	O
present	O
invention	O
is	O
directed	O
at	O
substituted	O
heteroaryl-	O
and	O
phenylsulfamoyl	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
as	O
peroxisome	B-GENE
proliferator	I-GENE
activator	I-GENE
receptor	I-GENE
(	O
PPAR	B-GENE
)	O
agonists	O
.	O
PPAR	B-GENE
alpha	I-GENE
activators,	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
to	O
elevate	O
certain	O
plasma	O
lipid	O
levels,	O
including	O
high	O
density	O
lipoprotein-cholesterol	O
and	O
to	O
lower	O
certain	O
other	O
plasma	O
lipid	O
levels,	O
such	O
as	O
LDL-cholesterol	O
and	O
triglycerides	O
and	O
accordingly	O
to	O
treat	O
diseases	O
which	O
are	O
exacerbated	O
by	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
and	O
/	O
or	O
high	O
levels	O
of	O
LDL-cholesterol	O
and	O
triglycerides,	O
such	O
as	O
atherosclerosis	O
and	O
cardiovascular	O
diseases,	O
in	O
mammals,	O
including	O
humans	O
.	O
The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
negative	O
energy	O
balance	O
(	O
NEB	O
)	O
and	O
associated	O
diseases	O
in	O
ruminants	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
dipyrazole	O
compounds	O
of	O
formula	O
I	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
stereoisomers,	O
tautomers,	O
or	O
solvates	O
thereof	O
.	O
Novel	O
compounds	O
include	O
those	O
of	O
formula	O
I	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
The	O
compounds	O
of	O
this	O
invention	O
modulate	O
AMPA	B-GENE
and	I-GENE
NMDA	I-GENE
receptor	I-GENE
function,	O
and	O
therefore	O
are	O
useful	O
as	O
pharmaceutical	O
agents,	O
especially	O
for	O
the	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
.	O


The	O
present	O
invention	O
includes	O
the	O
use	O
of	O
pelorol,	O
related	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
as	O
modulators	O
of	O
SHIP	B-GENE
1	I-GENE
activity	O
.	O
This	O
invention	O
also	O
provides	O
novel	O
terpene	O
compounds	O
capable	O
of	O
modulating	O
SHIP	B-GENE
1	I-GENE
activity	O
and	O
methods	O
of	O
synthesis	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
the	O
specific	O
inhibition	O
of	O
kinase	B-GENE
suppressor	I-GENE
of	I-GENE
Ras	I-GENE
(	O
KSR	B-GENE
)	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
genetic	O
approaches	O
and	O
nucleic	O
acids	O
for	O
the	O
specific	O
inhibition	O
of	O
KSR,	O
particularly	O
of	O
KSR	B-GENE
expression	O
.	O
The	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	O
and	O
the	O
expression	O
of	O
nucleic	O
acid	O
which	O
is	O
substantially	O
complementary	O
to	O
KSR	B-GENE
RNA	O
.	O
Oligonucleotide	O
and	O
nucleic	O
acid	O
compositions	O
are	O
provided	O
.	O
The	O
invention	O
provides	O
methods	O
to	O
inhibit	O
KSR,	O
including	O
inhibition	O
of	O
KSR	B-GENE
expression	O
.	O
Methods	O
for	O
blocking	O
gfRas	O
mediated	O
tumorigenesis,	O
metastasis,	O
and	O
for	O
cancer	O
therapy	O
are	O
provided	O
.	O
Methods	O
for	O
conferring	O
radiosensitivity	O
to	O
cells	O
are	O
also	O
provided	O
.	O


Compounds	O
are	O
described	O
that	O
are	O
active	O
on	O
PPARs,	O
including	O
pan-active	O
compounds	O
.	O
Also	O
described	O
are	O
methods	O
for	O
developing	O
or	O
identifying	O
compounds	O
having	O
a	O
desired	O
selectivity	O
profile	O
.	O


The	O
invention	O
encompasses	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
cyclooxygenase-2	B-GENE
selective	O
inhibitor	O
selected	O
from	O
rofecoxib	O
and	O
etoricoxib	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
omeprazole,	O
lansoprazole,	O
rabeprazole,	O
pantoprazole,	O
and	O
esomeprazole,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
any	O
of	O
the	O
aforementioned,	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
invention	O
also	O
encompasses	O
a	O
method	O
for	O
treating	O
a	O
cyclooxygenase-2	B-GENE
mediated	O
disease	O
or	O
condition	O
in	O
a	O
human	O
patient	O
at	O
risk	O
of	O
a	O
thrombotic	O
cardiovascular	O
event,	O
wherein	O
the	O
patient	O
is	O
on	O
aspirin	O
therapy	O
to	O
reduce	O
the	O
risk	O
of	O
the	O
thrombotic	O
cardiovascular	O
event,	O
comprising	O
administering	O
to	O
the	O
patient	O
this	O
pharmaceutical	O
composition	O
.	O


Compounds	O
that	O
may	O
be	O
used	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
condition	O
associated	O
with	O
T-cell	O
proliferation	O
or	O
that	O
is	O
mediated	O
by	O
pro-inflammatory	O
cytokines	B-GENE
are	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
is	O
CHR4—OR5	O
or	O
CHR4—SR5,	O
or	O
aryl	O
or	O
heteroaryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
R6	O
;	O
R2	O
is	O
alkyl	O
or	O
is	O
part	O
of	O
a	O
ring	O
with	O
R3	O
;	O
R3	O
is	O
H,	O
alkyl	O
or	O
CH2	O
(	O
when	O
forming	O
part	O
of	O
a	O
ring	O
with	O
R2	O
)	O
;	O
R4	O
is	O
H	O
or	O
alkyl	O
or	O
is	O
part	O
of	O
a	O
ring	O
with	O
R5	O
;	O
R5	O
is	O
aryl	O
or	O
heteroaryl	O
optionally	O
substituted	O
with	O
R7	O
;	O
each	O
R6	O
is	O
independently	O
alkyl,	O
CF3,	O
OH,	O
Oalkyl,	O
OCOalkyl,	O
CONH2,	O
CN,	O
halogen,	O
NH2,	O
NO2,	O
NHCHO,	O
NHCONH2,	O
NHSO2alkyl,	O
CONH2,	O
SOMe,	O
SO2NH2,	O
Salkyl,	O
CH2SO2alkyl	O
or	O
OCONalkyl2	O
;	O
R7	O
is	O
R8	O
or	O
(	O
CH2	O
)	O
nOR8,	O
R9,	O
CF3,	O
OH,	O
OR9,	O
OCOR9,	O
COR9,	O
COOR9,	O
CONH2,	O
CH2CONH2,	O
CN,	O
halogen,	O
NH2,	O
NO2,	O
NHCHO,	O
NHCONH2,	O
NHCONHR7,	O
NHCON	O
(	O
R9	O
)	O
2,	O
NHCOR9,	O
NHCOaryl,	O
NHSO2Me,	O
CONH2,	O
SMe,	O
SOMe	O
Or	O
SO2NH2	O
;	O
R8	O
is	O
(	O
CH2	O
)	O
nOR9,	O
(	O
CH2	O
)	O
nOR9,	O
(	O
CH2	O
)	O
nCOOR9	O
or	O
(	O
CH2	O
)	O
nCOaryl	O
;	O
R9	O
is	O
alkyl	O
or	O
cycloalkyl	O
;	O
and	O
n	O
is	O
1	O
to	O
4	O
;	O
or	O
a	O
salt	O
thereof	O
.	O


Use	O
of	O
a	O
)	O
an	O
HIV	B-GENE
Tat	I-GENE
protein	I-GENE
or	O
polynucleotide	O
;	O
or	O
b	O
)	O
an	O
HIV	B-GENE
Nef	I-GENE
protein	I-GENE
or	O
polynucleotide	O
;	O
or	O
c	O
)	O
an	O
HIV	B-GENE
Tat	I-GENE
protein	I-GENE
or	O
polynucleotide	O
linked	O
to	O
an	O
HIV	B-GENE
Nef	I-GENE
protein	I-GENE
or	O
polynucleotide	O
;	O
and	O
an	O
HIV	B-GENE
gp120	I-GENE
protein	I-GENE
or	O
polynucleotide	O
in	O
the	O
manufacture	O
of	O
a	O
vaccine	O
suitable	O
for	O
a	O
prime-boost	O
delivery	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
immunisation	O
of	O
humans	O
against	O
HIV,	O
wherein	O
the	O
protein	O
or	O
polynucleotide	O
is	O
delivered	O
via	O
a	O
bombardment	O
approach	O
.	O


The	O
present	O
invention	O
provides	O
method	O
for	O
quickly	O
and	O
conveniently	O
determining	O
if	O
a	O
given	O
treatment	O
regimen	O
of	O
IGF1R	B-GENE
inhibitor	O
is	O
sufficient,	O
e	O
.	O
g	O
.	O
,	O
to	O
saturate	O
IGF1R	B-GENE
receptors	O
in	O
the	O
body	O
of	O
a	O
subject	O
.	O
Several	O
clinically	O
relevant	O
determinations	O
may	O
be	O
made	O
based	O
on	O
this	O
point,	O
including,	O
for	O
example,	O
whether	O
the	O
dosage	O
of	O
the	O
regimen	O
is	O
sufficient	O
or	O
should	O
be	O
increased	O
.	O


Described	O
herein	O
are	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
T-cell	O
lymphoma	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
selective	O
inhibitor	O
of	O
histone	B-GENE
deacetylase	I-GENE
8	I-GENE
.	O
Also	O
described	O
herein	O
are	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
T-cell	O
lymphoma	O
by	O
administering	O
to	O
the	O
subject	O
a	O
population	O
of	O
autologous	O
T-cells	O
that	O
have	O
been	O
exposed	O
to	O
a	O
selective	O
HDAC8	B-GENE
inhibitor	O
composition	O
ex	O
vivo	O
.	O


It	O
is	O
intended	O
to	O
identify	O
rheumatoid	O
arthritis	O
susceptibility	O
genes	O
by	O
a	O
highly	O
efficient,	O
low-cost	O
mapping	O
method	O
using	O
microsatellites	O
.	O
In	O
the	O
present	O
invention,	O
novel	O
rheumatoid	O
arthritis	O
susceptibility	O
genes,	O
that	O
is,	O
TNXB,	O
NOTCH4,	O
RAB6A,	O
MPRL48,	O
UCP2,	O
and	O
UCP3	B-GENE
genes,	O
in	O
the	O
human	O
genomic	O
DNA	O
sequence	O
were	O
identified	O
by	O
conducting	O
case-control	O
association	O
analysis	O
on	O
rheumatoid	O
arthritis	O
by	O
use	O
of	O
microsatellite	O
polymorphic	O
markers	O
assigned	O
at	O
approximately	O
100-kb	O
intervals	O
to	O
narrow	O
down	O
candidate	O
regions	O
and	O
then	O
conducting	O
association	O
analysis	O
and	O
linkage	O
analysis	O
with	O
SNP	O
as	O
a	O
marker	O
.	O


A	O
diastereomers	O
of	O
imidazolines	O
as	O
4-position	O
acids	O
are	O
described	O
.	O
The	O
imidazoline	O
diastereomers	O
potentiate	O
the	O
activity	O
of	O
antitumor	O
drugs	O
and	O
are	O
potent	O
inhibitors	O
of	O
the	O
transcription	O
factor	O
NF-κB	B-GENE
.	O


The	O
invention	O
provides	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
diseases	O
or	O
disorders	O
associated	O
with	O
the	O
activity	O
of	O
the	O
Peroxisome	B-GENE
Proliferator-Activated	I-GENE
Receptor	I-GENE
(	O
PPAR	B-GENE
)	O
families,	O
particularly	O
the	O
activity	O
of	O
PPAR	B-GENE
.	O


Synthetic	O
triple-helical	O
peptides	O
(	O
THPs	O
)	O
are	O
used	O
for	O
the	O
design	O
and	O
synthesis	O
of	O
triple-helical	O
transition	O
state	O
analog	O
inhibitors	O
.	O
These	O
inhibitors	O
feature	O
a	O
phosphonate	O
ester	O
or	O
phosphinic	O
moiety	O
in	O
place	O
of	O
the	O
scissle	O
bond	O
.	O
These	O
groups	O
inhibit	O
MMPs,	O
and	O
methods	O
been	O
developed	O
for	O
their	O
convenient	O
incorporation	O
within	O
a	O
peptide	O
sequence	O
by	O
solid-phase	O
methods	O
.	O


The	O
present	O
invention	O
contemplates	O
a	O
method	O
to	O
identify	O
subjects	O
that	O
either	O
have	O
a	O
tumor,	O
or	O
are	O
at	O
risk	O
for	O
tumor	O
development,	O
that	O
are	O
responsive	O
to	O
various	O
inhibitors	O
of	O
an	O
activated-Chk2	B-GENE
protein	O
.	O
Such	O
Chk2	B-GENE
inhibitors	O
may	O
comprise	O
a	O
benzimidazole	O
core	O
structure,	O
and	O
derivatives	O
thereof	O
.	O
Other	O
Chk2	B-GENE
inhibitors	O
may	O
comprise	O
nucleic	O
acids,	O
such	O
as	O
silencing	O
interference	O
RNA	O
'	O
s	O
specific	O
for	O
a	O
Chk2	B-GENE
expression	O
.	O
Other	O
Chk2	B-GENE
inhibitors	O
may	O
comprises	O
proteins,	O
such	O
as	O
antibodies	O
.	O
For	O
example,	O
the	O
present	O
invention	O
contemplates	O
that	O
when	O
a	O
Chk2	B-GENE
inhibitor	O
is	O
administered	O
during,	O
or	O
after,	O
ionizing	O
radiation	O
tumor	O
cell	O
apoptosis	O
is	O
increased	O
.	O


A	O
method	O
of	O
diagnosing	O
and	O
treating	O
a	O
patient	O
with	O
or	O
suspected	O
of	O
having	O
at	O
least	O
one	O
solid	O
tumor	O
that	O
produces	O
folate	B-GENE
receptor	I-GENE
type	I-GENE
α	I-GENE
includes	O
administering	O
a	O
biologically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
folate	B-GENE
receptor	I-GENE
α	I-GENE
inducer,	O
specifically	O
steroid	O
receptor	O
ligands,	O
with	O
or	O
without	O
aid	O
from	O
at	O
least	O
one	O
histone	B-GENE
deacetylase	I-GENE
inhibitor,	O
to	O
increase	O
the	O
level	O
of	O
the	O
folate	B-GENE
receptor	I-GENE
α	I-GENE
on	O
the	O
plasma	O
membrane	O
of	O
cancer	O
cells	O
as	O
well	O
as	O
the	O
folate	B-GENE
receptor	I-GENE
α	I-GENE
in	O
at	O
least	O
one	O
type	O
of	O
body	O
fluid,	O
including,	O
for	O
example,	O
serum,	O
ascites	O
and	O
cerebrospinal	O
fluid	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Ar	O
has	O
the	O
sub-formula	O
(	O
x	O
)	O
or	O
(	O
z	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
wherein	O
R3	O
is	O
optionally	O
substituted	O
C3-8cycloalkyl,	O
optionally	O
substituted	O
C5-7cycloalkenyl,	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
(	O
aa	O
)	O
,	O
(	O
bb	O
)	O
or	O
(	O
cc	O
)	O
,	O
or	O
a	O
bicyclic	O
group	O
(	O
ee	O
)	O
;	O
	O
and	O
wherein	O
R4	O
is	O
H,	O
C1-3alkyl,	O
C1-2fluoroalkyl,	O
cyclopropyl,	O
—CH2OR4a,	O
—CH	O
(	O
Me	O
)	O
OR4a,	O
or	O
—CH2CH2OR4a	O
;	O
and	O
R5	O
is	O
inter	O
alia	O
H,	O
C1-8alkyl,	O
C1-3fluoroalkyl,	O
C3-8cycloalkyl,	O
certain	O
substituted	O
alkyl	O
groups,	O
—	O
(	O
CH2	O
)	O
n	O
13-Het,	O
or	O
optionally	O
substituted	O
phenyl	O
or	O
—CH2-Ph	O
;	O
	O
or	O
R4	O
and	O
R5	O
taken	O
together	O
are	O
—	O
(	O
CH2	O
)	O
p	O
1—	O
or	O
—	O
(	O
CH2	O
)	O
p	O
3—X5—	O
(	O
CH2	O
)	O
p	O
4—	O
;	O
	O
provided	O
that	O
at	O
least	O
one	O
of	O
R4	O
and	O
R5	O
is	O
not	O
a	O
hydrogen	O
atom	O
(	O
H	O
)	O
.	O
	O
	O
	O
	O
	O
The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
compounds	O
as	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
type	I-GENE
IV	I-GENE
(	O
PDE4	B-GENE
)	O
and	O
/	O
or	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
inflammatory	O
and	O
/	O
or	O
allergic	O
diseases	O
such	O
as	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
asthma,	O
rheumatoid	O
arthritis,	O
allergic	O
rhinitis	O
or	O
atopic	O
dermatitis	O
.	O


An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
γ	I-GENE
(	O
PPARγ	B-GENE
)	O
ligand	O
derived	O
from	O
a	O
natural	O
product	O
and	O
to	O
provide	O
a	O
composition	O
for	O
prevention	O
or	O
improvement	O
of	O
insulin	O
resistant	O
syndrome,	O
diabetes	O
mellitus,	O
obesity,	O
or	O
visceral	O
fat	O
obesity,	O
characterized	O
by	O
comprising	O
the	O
ligand	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
present	O
invention	O
provides	O
a	O
PPARγ	B-GENE
ligand	O
comprising	O
as	O
an	O
active	O
ingredient,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
coumaperine	O
and	O
derivatives	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
composition	O
for	O
prevention	O
or	O
improvement	O
of	O
insulin	O
resistant	O
syndrome,	O
diabetes	O
mellitus,	O
obesity,	O
or	O
visceral	O
fat	O
obesity	O
comprising	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
provides	O
a	O
1-thio-D-glucitol	O
compound	O
of	O
the	O
following	O
formula,	O
which	O
shows	O
the	O
action	O
of	O
inhibiting	O
the	O
activity	O
of	O
SGLT2,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
or	O
the	O
salt	O
;	O
and	O
a	O
pharmaceutical	O
comprising	O
such	O
a	O
compound	O
as	O
an	O
active	O
ingredient,	O
especially,	O
a	O
pharmaceutical	O
for	O
preventing	O
or	O
treating	O
diabetes,	O
diabetes-related	O
disease,	O
or	O
diabetic	O
complication	O
.	O
The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
producing	O
the	O
1-thio-D-glucitol	O
compound	O
and	O
its	O
intermediate	O
.	O


A	O
substance	O
that	O
has	O
a	O
potency	O
antagonistic	O
to	O
coupling	O
of	O
histamine	O
with	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
or	O
a	O
potency	O
of	O
inhibiting	O
the	O
constant	O
activity	O
of	O
histamine	B-GENE
H3	I-GENE
receptor	I-GENE
.	O
There	O
is	O
provided	O
a	O
form	O
I	O
crystal	O
of	O
2-methyl	O
3-	O
{	O
4-	O
[	O
3-	O
(	O
1-pyrrolidinyl	O
)	O
propoxy	O
]	O
phenyl	O
}	O
-5-trifluoromethyl-4	O
(	O
3H	O
)	O
-quinazolinone	O
that	O
in	O
the	O
powder	O
X-	O
ray	O
diffractometry,	O
has	O
peaks	O
at	O
6	O
.	O
4°,	O
9	O
.	O
7°,	O
10	O
.	O
2°,	O
12	O
.	O
9°,	O
14	O
.	O
2°,	O
14	O
.	O
7°,	O
16	O
.	O
0°,	O
16	O
.	O
3°,	O
16	O
.	O
8°,	O
17	O
.	O
6°,	O
19	O
.	O
5°,	O
20	O
.	O
3°,	O
20	O
.	O
6°,	O
21	O
.	O
2°,	O
21	O
.	O
8°,	O
22	O
.	O
1°,	O
22	O
.	O
4°,	O
22	O
.	O
6°,	O
24	O
.	O
0°,	O
24	O
.	O
3°,	O
24	O
.	O
9°,	O
25	O
.	O
7°,	O
25	O
.	O
9°,	O
26	O
.	O
5°,	O
26	O
.	O
7°,	O
27	O
.	O
4°,	O
29	O
.	O
1°,	O
29	O
.	O
4°,	O
32	O
.	O
3°	O
and	O
39	O
.	O
0°	O
diffraction	O
angles	O
(	O
2θ±0	O
.	O
2°	O
)	O
.	O


Histamine	B-GENE
H3	I-GENE
inverse	O
agonists	O
or	O
histamine	B-GENE
H3	I-GENE
antagonists	O
are	O
useful,	O
alone	O
or	O
in	O
combination	O
with	O
an	O
anti-stroke	O
agent,	O
for	O
treating	O
stroke	O
.	O


Novel	O
isoindoline	O
compounds	O
are	O
disclosed	O
.	O
Methods	O
of	O
treating,	O
preventing	O
and	O
/	O
or	O
managing	O
cancer,	O
diseases	O
and	O
disorders	O
associated	O
with,	O
or	O
characterized	O
by,	O
undesired	O
angiogenesis,	O
and	O
diseases	O
and	O
disorders	O
mediated	O
by	O
PDE	O
4,	O
using	O
the	O
compounds	O
are	O
also	O
disclosed	O
.	O


A	O
method	O
for	O
treating	O
or	O
preventing	O
symptoms	O
of	O
hormonal	O
variation	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
receptor	O
antagonist	O
to	O
a	O
subject	O
having	O
one	O
or	O
more	O
symptoms	O
of	O
hormonal	O
variations,	O
wherein	O
the	O
receptor	O
antagonist	O
binds	O
to	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
serotonin	B-GENE
type	I-GENE
2A	I-GENE
(	O
5-HT2A	B-GENE
)	O
and	O
a	O
dopamine	B-GENE
type	I-GENE
2	I-GENE
(D2)	I-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
using	O
PARP	B-GENE
inhibitors	O
as	O
radio-sensitization	O
agents	O
of	O
tumors	O
.	O
Specifically	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
radio-sensitization	O
of	O
tumors	O
using	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
form	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
compositions	O
of	O
PARP	B-GENE
inhibitors	O
for	O
radiosensitizing	O
tumors	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
preventing	O
inflammation	O
and	O
retinal	O
edema	O
resulting	O
from	O
an	O
ocular	O
surgical	O
procedure	O
by	O
administering	O
to	O
a	O
patient	O
undergoing	O
surgery	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
an	O
active	O
agent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
RTK	B-GENE
inhibitors	O
and	O
anti-VEGF	O
compounds,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
wherein	O
the	O
RTK	B-GENE
inhibitor	O
blocks	O
tyrosine	O
autophosphorylation	O
of	O
VEGFR-1,	O
VEGFR-2,	O
VEGFR-3,	O
Tie-2,	O
PDGFR,	O
c-KIT,	O
Flt-3,	O
and	O
CSF-1R	B-GENE
.	O


A	O
method	O
of	O
combination	O
cancer	O
therapy	O
in	O
a	O
mammal,	O
especially	O
a	O
human,	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
GST-activated	O
anticancer	O
compound	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
another	O
anticancer	O
therapy,	O
that	O
is,	O
an	O
anticancer	O
therapy	O
that	O
is	O
not	O
a	O
treatment	O
with	O
a	O
GST-	O
activated	O
anticancer	O
compound	O
(	O
including	O
chemotherapy	O
;	O
molecular	O
targeted	O
therapy	O
;	O
biologic	O
therapy	O
;	O
and	O
radiotherapy,	O
used	O
as	O
monotherapy	O
or	O
in	O
combination	O
)	O
.	O
Pharmaceutical	O
compositions,	O
products,	O
and	O
kits	O
for	O
the	O
method	O
.	O
The	O
use	O
of	O
a	O
GST-activated	O
anticancer	O
compound	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
method	O
.	O
A	O
method	O
of	O
potentiating	O
an	O
anticancer	O
therapy	O
in	O
a	O
mammal,	O
especially	O
a	O
human,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
GST-activated	O
anticancer	O
compound	O
to	O
the	O
mammal	O
being	O
treated	O
with	O
the	O
anticancer	O
therapy	O
.	O
The	O
use	O
of	O
a	O
GST-activated	O
anticancer	O
compound	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
method	O
.	O
The	O
GST-activated	O
anticancer	O
compound	O
is	O
preferably	O
a	O
compound	O
of	O
U	O
.	O
S	O
.	O
Pat	O
.	O
No	O
.	O
5,556,942,	O
and	O
more	O
preferably	O
TLK286,	O
especially	O
as	O
the	O
hydrochloride	O
salt	O
.	O


Disclosed	O
are	O
new	O
methods	O
for	O
treatment	O
of	O
angiogenesis-related	O
disorders	O
.	O
Angiogenesis-related	O
disorders	O
are	O
treated	O
by	O
administration	O
of	O
a	O
Tie1	B-GENE
ectodomain-binding	O
agent	O
and	O
a	O
VEGF	B-GENE
antagonist	O
agent	O
.	O


The	O
present	O
invention	O
is	O
a	O
method	O
of	O
inhibiting	O
islet	O
cell	O
transplant	O
rejection	O
particular,	O
to	O
treat	O
diabetes,	O
such	O
as	O
type-1	O
and	O
type-2	O
diabetes,	O
by	O
administering	O
to	O
a	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
soluble	O
CTLA4	B-GENE
mutant	O
molecule	O
.	O
One	O
example	O
of	O
soluble	O
CTLA4	B-GENE
mutant	O
molecule	O
is	O
L104EA29YIg	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
promoting	O
local	O
bone	O
growth	O
by	O
administering	O
a	O
therapeutic	O
amount	O
of	O
a	O
Sost	B-GENE
antagonist	O
to	O
a	O
mammalian	O
patient	O
in	O
need	O
thereof	O
.	O
Preferably,	O
the	O
Sost	B-GENE
antagonist	O
is	O
an	O
antibody	O
or	O
FAB	O
fragment	O
selectively	O
recognizing	O
any	O
one	O
of	O
SEQ	O
ID	O
NOS	O
:	O
1-23	O
.	O
The	O
Sost	B-GENE
antagonist	O
may	O
be	O
coadministered	O
together	O
or	O
sequentially	O
with	O
a	O
matrix	O
conducive	O
to	O
anchoring	O
new	O
bone	O
growth	O
.	O
Orthopedic	O
and	O
Periodontal	O
devices	O
comprising	O
an	O
implantable	O
portion	O
adapted	O
to	O
be	O
permanently	O
implanted	O
within	O
a	O
mammalian	O
body	O
and	O
bearing	O
an	O
external	O
coating	O
of	O
a	O
Sost	B-GENE
antagonist	O
are	O
also	O
disclosed,	O
as	O
it	O
a	O
method	O
of	O
increasing	O
bone	O
density	O
by	O
administering	O
to	O
a	O
mammalian	O
patient	O
a	O
therapeutic	O
amount	O
of	O
a	O
Sost	B-GENE
antagonist	O
together	O
with	O
an	O
antiresorptive	O
drug	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
therapeutic	O
and	O
diagnostic	O
agents	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
provides	O
therapeutic	O
molecules	O
capable	O
of	O
modulating	O
signal	O
transduction	O
such	O
as	O
but	O
not	O
limited	O
to	O
cytokine-mediated	O
signal	O
transduction	O
.	O
The	O
molecules	O
of	O
the	O
present	O
invention	O
are	O
useful,	O
therefore,	O
in	O
modulating	O
cellular	O
responsiveness	O
to	O
cytokines	B-GENE
as	O
well	O
as	O
other	O
mediators	O
of	O
signal	O
transduction	O
such	O
as	O
endogenous	O
or	O
exogenous	O
molecules,	O
antigens,	O
microbes	O
and	O
microbial	O
products,	O
viruses	O
or	O
components	O
thereof,	O
ions,	O
hormones	O
and	O
parasites	O
.	O


Methods	O
are	O
disclosed	O
for	O
inhibiting	O
or	O
disrupting	O
Janus	B-GENE
tyrosine	I-GENE
kinase	I-GENE
3	I-GENE
(	O
Jak3	B-GENE
)	O
dependent	O
function	O
in	O
cells	O
of	O
lymphoid	O
or	O
myeloid	O
origin,	O
especially	O
for	O
blocking	O
proliferation	O
and	O
function	O
of	O
lymphocytes	O
(	O
e	O
.	O
g	O
.	O
,	O
T-cells,	O
B-cells	O
)	O
.	O
A	O
Mannich	O
base	O
compound,	O
or	O
a	O
derivative	O
or	O
modified	O
compound,	O
is	O
employed	O
which	O
is	O
capable	O
of	O
selectively	O
inhibiting	O
Jak3	B-GENE
while	O
affecting	O
other	O
protein	O
tyrosine	O
kinase	I-GENE
activities	O
to	O
a	O
lesser	O
extent	O
or	O
not	O
at	O
all,	O
to	O
provide	O
beneficial	O
effects	O
such	O
as	O
mitigation	O
of	O
transplant	O
rejection	O
and	O
alleviation	O
of	O
allergic	O
responses	O
with	O
fewer	O
side	O
effects	O
than	O
with	O
conventional	O
immunosuppressive	O
agents	O
.	O


The	O
invention	O
involves	O
methods	O
of	O
regulating	O
cell	O
growth	O
and	O
division	O
to	O
control	O
disease	O
processes	O
by	O
manipulating	O
mitochondrial	O
metabolism	O
and	O
the	O
expression	O
of	O
cell	B-GENE
surface	I-GENE
immune	I-GENE
proteins	I-GENE
.	O
The	O
invention	O
also	O
involves	O
related	O
compositions	O
and	O
screening	O
assays	O
.	O


Insulin	B-GENE
or	O
a	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
(	O
PPAR	B-GENE
)	O
agonist	O
provides	O
reliable	O
and	O
effective	O
prevention	O
of	O
scarring	O
in	O
human	O
skin,	O
or	O
at	O
least	O
a	O
reduction	O
in	O
the	O
severity	O
of	O
scarring	O
.	O
The	O
application	O
of	O
insulin	B-GENE
or	O
the	O
PPAR	B-GENE
agonist	O
to	O
wounds	O
topically	O
or	O
by	O
local	O
injection	O
is	O
particularly	O
advantageous	O
since	O
it	O
simultaneously	O
reduces	O
/	O
prevents	O
scarring	O
whilst	O
enhancing	O
re-epithelialisation	O
of	O
the	O
wound	O
and	O
thus	O
provides	O
a	O
dual	O
action	O
wound	O
healing	O
treatment	O
.	O
The	O
present	O
invention	O
accordingly	O
provides	O
a	O
highly	O
effective	O
prophylactic	O
treatment	O
for	O
any	O
individual	O
suffering	O
tissue	O
trauma	O
to	O
reduce	O
and	O
/	O
or	O
prevent	O
normal	O
and	O
/	O
or	O
pathological	O
scarring	O
.	O


Provided	O
is	O
a	O
simple	O
and	O
safe	O
immunization	O
procedure	O
to	O
reduce	O
cancer	O
incidence	O
and	O
increase	O
longevity	O
by	O
modulating	O
IGF-1	B-GENE
levels	O
in	O
the	O
body	O
.	O
Described	O
are	O
cancer	O
preventive	O
vaccines	O
and	O
methods	O
that	O
elicit	O
circulating	O
antibodies	O
specific	O
to	O
insulin-like	B-GENE
growth	I-GENE
factor	I-GENE
1	I-GENE
(	O
IGF-1	B-GENE
)	O
in	O
the	O
body	O
.	O
Many	O
cancers	O
will	O
be	O
less	O
likely	O
to	O
occur	O
and	O
spread	O
in	O
the	O
absence	O
or	O
reduced	O
levels	O
of	O
the	O
stimulatory	O
signals	O
provided	O
by	O
IGF-1	B-GENE
.	O
Longevity	O
also	O
can	O
be	O
extended	O
by	O
immunologically	O
lowering	O
the	O
level	O
of	O
bioavailable	O
IGF-1	B-GENE
in	O
adult	O
animals	O
.	O
This	O
prolongation	O
of	O
lifespan	O
resulting	O
from	O
lower	O
IGF-1	B-GENE
levels	O
is	O
produced	O
independently	O
of	O
the	O
inhibitory	O
effects	O
on	O
carcinogenesis	O
.	O
However,	O
the	O
two	O
IGF-1-mediated	O
processes	O
are	O
linked	O
mechanistically	O
.	O
Methods	O
of	O
active	O
and	O
passive	O
immunization	O
to	O
suppress	O
IGF-1	B-GENE
activity	O
are	O
included	O
.	O
Also	O
described	O
are	O
methods	O
for	O
increasing	O
longevity	O
or	O
reducing	O
one	O
or	O
more	O
symptoms	O
of	O
aging	O
in	O
a	O
warm-blooded	O
animal	O
comprising	O
administering	O
anti-IGF-1	O
antibodies	O
such	O
that	O
IGF-1	B-GENE
is	O
inactivated	O
or	O
suppressed	O
or	O
administering	O
IGF-1	B-GENE
antigen	O
such	O
that	O
the	O
animal	O
produces	O
endogenous	O
antibodies	O
to	O
IGF-1	B-GENE
.	O


The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
diagnosing	O
or	O
prognosing	O
depression,	O
in	O
particular	O
major	O
depression,	O
in	O
a	O
subject,	O
or	O
determining	O
whether	O
a	O
subject	O
is	O
at	O
increased	O
risk	O
of	O
developing	O
depression,	O
in	O
particular	O
major	O
depression,	O
comprising	O
:	O
	O
	O
	O
determining	O
a	O
level,	O
or	O
an	O
activity,	O
or	O
both	O
said	O
level	O
and	O
said	O
activity,	O
of	O
neurotrophin	B-GENE
3	I-GENE
and	O
/	O
or	O
of	O
a	O
transcription	O
product	O
of	O
a	O
gene	O
coding	O
for	O
neurotrophin	B-GENE
3	I-GENE
in	O
a	O
sample	O
from	O
said	O
subject	O
;	O
and	O
comparing	O
said	O
level,	O
or	O
said	O
activity,	O
or	O
both	O
said	O
level	O
and	O
said	O
activity,	O
to	O
a	O
reference	O
value	O
representing	O
a	O
known	O
disease	O
or	O
health	O
status,	O
thereby	O
diagnosing	O
or	O
prognosing	O
depression	O
in	O
said	O
subject,	O
or	O
determining	O
whether	O
said	O
subject	O
is	O
at	O
increased	O
risk	O
of	O
developing	O
said	O
depression	O
.	O


The	O
invention	O
includes	O
a	O
screening	O
assay	O
for	O
the	O
identification	O
of	O
agents	O
that	O
inhibit	O
the	O
interaction	O
of	O
p53	B-GENE
with	O
p53	B-GENE
inhibitory	O
polypeptides,	O
and	O
p53	B-GENE
inhibitory	O
polypeptide	O
variants	O
that	O
are	O
inactive	O
with	O
respect	O
to	O
the	O
inhibition	O
of	O
p53	B-GENE
activity	O
.	O


This	O
invention	O
relates	O
to	O
a	O
group	O
of	O
quinolyl,	O
isoquinolyl	O
and	O
pyridyl	O
ureas,	O
their	O
the	O
use	O
in	O
treating	O
raf	B-GENE
mediated	O
diseases,	O
and	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
ureas	O
for	O
use	O
in	O
such	O
therapy	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates,	O
solvates,	O
geometrical	O
isomers,	O
tautomers,	O
optical	O
isomers,	O
or	O
prodrug	O
forms	O
thereof,	O
wherein	O
X,	O
Y,	O
Z,	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
herein	O
are	O
capable	O
of	O
binding	O
to	O
the	O
active	O
site	O
of	O
protein	B-GENE
kinase	I-GENE
enzymes	O
.	O
In	O
particular,	O
they	O
are	O
inhibitors	O
of	O
a	O
serine/threonine	B-GENE
kinase	I-GENE
more	O
particularly	O
Rho	B-GENE
kinase	I-GENE
(	O
ROK,	O
ROCK	B-GENE
)	O
.	O
The	O
compounds	O
can	O
be	O
used	O
in	O
methods	O
of	O
treatment	O
and	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
application	O
to	O
a	O
number	O
of	O
therapeutic	O
indications	O
including	O
cardiovascular	O
disease	O
(	O
coronary	O
vasospasm,	O
hypertensive	O
disease,	O
arteriosclerosis	O
)	O
,	O
stroke,	O
cancer,	O
erectile	O
dysfunction,	O
asthma,	O
osteoporosis,	O
AIDS	O
or	O
an	O
ocular	O
condition	O
including	O
glaucoma,	O
age	O
related	O
macular	O
degeneration,	O
lacrimal	O
gland	O
disease,	O
or	O
diabetic	O
retinopathy,	O
or	O
suppression	O
of	O
neurite	O
growth	O
and	O
hence	O
a	O
condition	O
requiring	O
nerve	O
cell	O
extension	O
and	O
connectivity,	O
neuronal	O
regeneration,	O
inducing	O
new	O
axonal	O
growth	O
and	O
promotion	O
of	O
axonal	O
(	O
re	O
)	O
wiring,	O
repairing	O
damage	O
to	O
neurons	O
in	O
the	O
CNS	O
caused	O
by	O
trauma	O
(	O
eg	O
stroke,	O
traumatic	O
brain	O
injury	O
etc	O
.	O
)	O
or	O
neurodegeneration	O
(	O
eg	O
Alzheimer	O
'	O
s,	O
Parkinson	O
'	O
s	O
etc	O
)	O
,	O
repair	O
and	O
recovery	O
from	O
and	O
treatment	O
of	O
disorders	O
such	O
as	O
spinal	O
cord	O
injury	O
and	O
in	O
reducing	O
the	O
subsequent	O
effects	O
thereof,	O
or	O
pain	O
caused	O
by	O
nerve	O
cell	O
damage	O
such	O
as	O
following	O
trauma	O
or	O
amputation	O
for	O
example	O
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O


The	O
present	O
invention	O
discloses	O
purified	O
polypeptides	O
that	O
comprise	O
an	O
active	O
ADAM33	B-GENE
catalytic	I-GENE
domain	I-GENE
.	O
In	O
addition,	O
the	O
present	O
invention	O
discloses	O
nucleic	O
acids	O
that	O
encode	O
the	O
polypeptides	O
of	O
the	O
present	O
invention	O
.	O
The	O
present	O
invention	O
also	O
discloses	O
methods	O
of	O
growing	O
X-ray	O
diffractable	O
crystals	O
of	O
polypeptides	O
comprising	O
the	O
active	O
ADAM33	B-GENE
catalytic	I-GENE
domain	I-GENE
.	O
In	O
addition,	O
the	O
present	O
invention	O
discloses	O
methods	O
of	O
using	O
the	O
X-ray	O
diffractable	O
crystals	O
of	O
ADAM33	O
in	O
structure-based	O
drug	O
design	O
to	O
identify	O
compounds	O
that	O
can	O
modulate	O
the	O
enzymatic	O
activity	O
of	O
ADAM33	O
.	O
The	O
present	O
invention	O
also	O
discloses	O
methods	O
of	O
treating	O
respiratory	O
disorders	O
by	O
administering	O
therapeutic	O
amounts	O
of	O
the	O
ADAM33	B-GENE
catalytic	I-GENE
domain	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
multifunctional	O
phosphodiesterase	B-GENE
inhibitor	O
(	O
MPDEI	O
)	O
and	O
at	O
least	O
one	O
adenosine	O
uptake	O
inhibitor	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
cilostazol	O
and	O
dipyridamole	O
and	O
their	O
use	O
.	O


A	O
leukotriene	B-GENE
C4	I-GENE
and	I-GENE
D4	I-GENE
antagonist	O
is	O
used	O
to	O
inhibit	O
tumor	O
metastasis	O
by	O
acting	O
to	O
inhibit	O
tumor	O
cell	O
adhesion	O
to	O
endothelial	O
cells,	O
thereby	O
preventing	O
tumor	O
cell	O
extravasation	O
.	O


Biaryl-substituted	O
tetrahydro-pyrazolo-pyridine	O
compounds	O
are	O
described,	O
which	O
are	O
useful	O
as	O
cathepsin	B-GENE
S	I-GENE
modulators	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disease	O
states,	O
disorders,	O
and	O
conditions	O
mediated	O
by	O
cathepsin	B-GENE
S	I-GENE
activity,	O
such	O
as	O
psoriasis,	O
pain,	O
multiple	O
sclerosis,	O
atherosclerosis,	O
and	O
rheumatoid	O
arthritis	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
osteopontin,	O
or	O
of	O
an	O
agonist	O
of	O
osteopontin	B-GENE
activity,	O
for	O
treatment	O
or	O
prevention	O
of	O
a	O
neurologic	O
diseases	O
.	O


The	O
invention	O
pertains	O
to	O
methods	O
for	O
treating	O
medical	O
disorders	O
characterized	O
by	O
elevated	O
levels	O
or	O
abnormal	O
expression	O
of	O
IL-18	B-GENE
by	O
administering	O
an	O
IL-18	B-GENE
antagonist,	O
such	O
as	O
soluble	O
IL-18	B-GENE
receptor,	O
a	O
soluble	O
IL-18	B-GENE
binding	I-GENE
protein	I-GENE
and	O
/	O
or	O
an	O
antibody	O
.	O


This	O
invention	O
relates	O
to	O
a	O
novel	O
protein,	O
termed	O
INSP152,	O
herein	O
identified	O
as	O
a	O
secreted	O
protein,	O
in	O
particular,	O
as	O
a	O
MAM	B-GENE
domain	I-GENE
containing	O
protein	O
and	O
to	O
the	O
use	O
of	O
this	O
protein	O
and	O
nucleic	O
acid	O
sequence	O
from	O
the	O
encoding	O
gene	O
in	O
the	O
diagnosis,	O
prevention	O
and	O
treatment	O
.	O


Selected	O
compounds	O
are	O
effective	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
diseases,	O
such	O
as	O
c-met	O
mediated	O
diseases	O
and	O
/	O
or	O
HGF	B-GENE
mediated	O
diseases	O
.	O
The	O
invention	O
encompasses	O
novel	O
compounds,	O
analogs,	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
and	O
other	O
maladies	O
or	O
conditions	O
involving,	O
cancer	O
and	O
the	O
like	O
.	O
The	O
subject	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
making	O
such	O
compounds	O
as	O
well	O
as	O
to	O
intermediates	O
useful	O
in	O
such	O
processes	O
.	O


Compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	O
CB1	B-GENE
antagonism	O
and	O
serotonin	O
re-uptake	O
inhibition,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
methods	O
for	O
preparing	O
these	O
compounds,	O
methods	O
for	O
preparing	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis,	O
and	O
methods	O
for	O
preparing	O
these	O
compositions	O
are	O
disclosed	O
.	O
Uses	O
of	O
such	O
compounds	O
and	O
compositions,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
psychosis,	O
anxiety,	O
depression,	O
attention	O
deficits,	O
cognitive	O
disorders,	O
obesity,	O
drug	O
dependence,	O
Parkinson	O
'	O
s	O
disease,	O
Alzheimer	O
'	O
s	O
disease,	O
pain	O
disorders,	O
neuropathic	O
pain	O
disorders	O
and	O
sexual	O
disorders	O
are	O
disclosed	O
.	O
	O
	O
	O
	O
In	O
at	O
least	O
one	O
embodiment,	O
the	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
;	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
substitutents	O
have	O
the	O
definitions	O
given	O
in	O
the	O
specification	O
.	O


Novel	O
phenylquinazoline	O
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1,	O
are	O
HSP90	B-GENE
inhibitors	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
the	O
inhibition,	O
regulation	O
and	O
/	O
or	O
modulation	O
of	O
HSP90	B-GENE
plays	O
a	O
role	O
.	O


3-amino-2-phenylpyrrolidine	O
compounds	O
useful	O
as	O
NK-1	B-GENE
antagonists,	O
with	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
comprising	O
same,	O
are	O
disclosed	O
.	O


HIF-1	B-GENE
inhibitors	O
and	O
methods	O
of	O
use	O
thereof	O
are	O
provided	O
.	O


Novel	O
crystalline	O
salts	O
of	O
(	O
2R	O
)	O
-4-oxo-4-	O
[	O
3-	O
(	O
trifluoromethyl	O
)	O
-5,6-dihydro	O
[	O
1,2,4	O
]	O
triazolo	O
[	O
4,3-a	O
]	O
pyrazin-7	O
(	O
8H	O
)	O
-yl	O
]	O
-1-	O
(	O
2,4,5-trifluorophenyl	O
)	O
butan-2-	O
&	O
agr	O
;	O
amine	O
are	O
potent	O
inhibitors	O
of	O
dipeptidyl	B-GENE
peptidase-IV	I-GENE
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
non-insulin	O
dependent	O
(	O
Type	O
2	O
)	O
diabetes	O
mellitus	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
novel	O
salts,	O
processes	O
to	O
prepare	O
these	O
salts	O
and	O
their	O
pharmaceutical	O
compositions	O
as	O
well	O
as	O
uses	O
thereof	O
for	O
the	O
treatment	O
of	O
Type	O
2	O
diabetes	O
.	O


This	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
neurodegenerative,	O
pulmonary	O
and	O
inflammatory	O
diseases	O
described	O
herein	O
with	O
glutathione	B-GENE
peroxidase	I-GENE
and	O
its	O
mimetics	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
hyaluronidase	B-GENE
inhibitor	O
containing	O
poly-gamma-glutamic	O
acid	O
(	O
PGA	O
)	O
as	O
an	O
active	O
ingredient,	O
a	O
composition	O
for	O
maintaining	O
skin	O
elasticity	O
and	O
a	O
composition	O
for	O
improving	O
allergy,	O
wherein	O
each	O
of	O
the	O
compositions	O
contains	O
PGA	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
inventive	O
compositions	O
containing	O
PGA	O
are	O
effective	O
in	O
maintaining	O
skin	O
moisturization	O
and	O
skin	O
elasticity	O
by	O
effectively	O
inhibiting	O
the	O
activity	O
of	O
hyaluronidase	B-GENE
which	O
is	O
an	O
enzyme	O
that	O
degrades	O
hyaluronic	O
acid	O
present	O
in	O
the	O
skin	O
dermis	O
.	O
Also,	O
the	O
compositions	O
can	O
relieve	O
allergic	O
symptoms	O
by	O
inhibiting	O
the	O
permeability	O
of	O
inflammatory	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds,	O
compositions,	O
and	O
methods	O
for	O
the	O
study,	O
diagnosis,	O
and	O
treatment	O
of	O
traits,	O
diseases	O
and	O
conditions	O
that	O
respond	O
to	O
the	O
modulation	O
of	O
Sterol	B-GENE
Regulatory	I-GENE
Element-Binding	I-GENE
Protein	I-GENE
1	I-GENE
(	O
SREBP1	B-GENE
)	O
gene	O
expression	O
and	O
/	O
or	O
activity	O
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
compounds,	O
compositions,	O
and	O
methods	O
relating	O
to	O
traits,	O
diseases	O
and	O
conditions	O
that	O
respond	O
to	O
the	O
modulation	O
of	O
expression	O
and	O
/	O
or	O
activity	O
of	O
genes	O
involved	O
in	O
Sterol	B-GENE
Regulatory	I-GENE
Element-Binding	I-GENE
Protein	I-GENE
1	I-GENE
(	O
SREBP1	B-GENE
)	O
gene	O
expression	O
pathways	O
or	O
other	O
cellular	O
processes	O
that	O
mediate	O
the	O
maintenance	O
or	O
development	O
of	O
such	O
traits,	O
diseases	O
and	O
conditions	O
.	O
Specifically,	O
the	O
invention	O
relates	O
to	O
double	O
stranded	O
nucleic	O
acid	O
molecules	O
including	O
small	O
nucleic	O
acid	O
molecules,	O
such	O
as	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
double-stranded	O
RNA	O
(	O
dsRNA	O
)	O
,	O
micro-RNA	O
(	O
miRNA	O
)	O
,	O
and	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
molecules	O
capable	O
of	O
mediating	O
RNA	O
interference	O
(	O
RNAi	O
)	O
against	O
Sterol	B-GENE
Regulatory	I-GENE
Element-Binding	I-GENE
Protein	I-GENE
1	I-GENE
(	O
SREBP1	B-GENE
)	O
gene	O
expression,	O
including	O
cocktails	O
of	O
such	O
small	O
nucleic	O
acid	O
molecules	O
and	O
lipid	O
nanoparticle	O
(	O
LNP	O
)	O
formulations	O
of	O
such	O
small	O
nucleic	O
acid	O
molecules	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
small	O
nucleic	O
acid	O
molecules,	O
such	O
as	O
siNA,	O
siRNA,	O
and	O
others	O
that	O
can	O
inhibit	O
the	O
function	O
of	O
endogenous	O
RNA	O
molecules,	O
such	O
as	O
endogenous	O
micro-RNA	O
(	O
miRNA	O
)	O
(	O
e	O
.	O
g,	O
miRNA	O
inhibitors	O
)	O
or	O
endogenous	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
(	O
e	O
.	O
g	O
.	O
,	O
siRNA	O
inhibitors	O
)	O
or	O
that	O
can	O
inhibit	O
the	O
function	O
of	O
RISC	O
(	O
e	O
.	O
g	O
.	O
,	O
RISC	O
inhibitors	O
)	O
,	O
to	O
modulate	O
SREBP1	B-GENE
gene	O
expression	O
by	O
interfering	O
with	O
the	O
regulatory	O
function	O
of	O
such	O
endogenous	O
RNAs	O
or	O
proteins	O
associated	O
with	O
such	O
endogenous	O
RNAs	O
(	O
e	O
.	O
g	O
.	O
,	O
RISC	O
)	O
,	O
including	O
cocktails	O
of	O
such	O
small	O
nucleic	O
acid	O
molecules	O
and	O
lipid	O
nanoparticle	O
(	O
LNP	O
)	O
formulations	O
of	O
such	O
small	O
nucleic	O
acid	O
molecules	O
.	O
Such	O
small	O
nucleic	O
acid	O
molecules	O
and	O
are	O
useful,	O
for	O
example,	O
in	O
providing	O
compositions	O
to	O
prevent,	O
inhibit,	O
or	O
reduce	O
metabolic	O
diseases	O
traits	O
and	O
conditions,	O
including	O
but	O
not	O
limited	O
to	O
hyperlipidemia,	O
hypercholesterolemia,	O
cardiovascular	O
disease,	O
atherosclerosis,	O
hypertension,	O
diabetis	O
(	O
e	O
.	O
g	O
.	O
,	O
type	O
I	O
and	O
/	O
or	O
type	O
II	O
diabetis	O
)	O
,	O
insulin	B-GENE
resistance,	O
obesity	O
and	O
/	O
or	O
other	O
disease	O
states,	O
conditions,	O
or	O
traits	O
associated	O
with	O
SREBP1	B-GENE
gene	O
expression	O
or	O
activity	O
in	O
a	O
subject	O
or	O
organism	O
.	O


The	O
invention	O
relates	O
to	O
a	O
cosmetic	O
composition	O
containing	O
at	O
least	O
one	O
15-hydroxy-prostaglandin	B-GENE
dehydrogenase	I-GENE
inhibitor	O
and	O
cosmetically	O
acceptable	O
excipients	O
.	O
It	O
also	O
relates	O
to	O
a	O
method	O
of	O
cosmetic	O
treatment	O
for	O
promoting	O
the	O
growth	O
and	O
/	O
or	O
preventing	O
or	O
delaying	O
the	O
loss	O
of	O
hair,	O
and	O
the	O
use	O
of	O
a	O
15-hydroxyprostaglandin	B-GENE
dehydrogenase	I-GENE
inhibitor	O
for	O
the	O
preparation	O
of	O
a	O
composition	O
intended	O
for	O
controlling	O
hair	O
loss	O
and	O
/	O
or	O
for	O
promoting	O
hair	O
regrowth	O
.	O


Adenoviral	O
serotypes	O
differ	O
in	O
their	O
natural	O
tropism	O
.	O
The	O
various	O
serotypes	O
of	O
adenovirus	O
have	O
been	O
found	O
to	O
differ	O
in	O
at	O
least	O
their	O
capsid	B-GENE
proteins	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
penton-base	O
and	O
hexon	B-GENE
proteins	I-GENE
)	O
,	O
proteins	O
responsible	O
for	O
cell	O
binding	O
(	O
e	O
.	O
g	O
.	O
,	O
fiber	O
proteins	O
)	O
,	O
and	O
proteins	O
involved	O
in	O
adenovirus	O
replication	O
.	O
This	O
difference	O
in	O
tropism	O
and	O
capsid	B-GENE
proteins	I-GENE
among	O
serotypes	O
has	O
led	O
to	O
many	O
research	O
efforts	O
aimed	O
at	O
redirecting	O
the	O
adenovirus	O
tropism	O
by	O
modification	O
of	O
the	O
capsid	B-GENE
proteins	I-GENE
.	O
The	O
present	O
invention	O
bypasses	O
such	O
requirement	O
for	O
capsid	O
protein	O
modification	O
as	O
it	O
presents	O
a	O
recombinant,	O
replication-defective	O
adenovirus	O
of	O
serotype	O
26,	O
a	O
rare	O
adenoviral	O
serotype,	O
and	O
methods	O
for	O
generating	O
the	O
alternative,	O
recombinant	O
adenovirus	O
.	O
Additionally,	O
means	O
of	O
employing	O
the	O
recombinant	O
adenovirus	O
for	O
delivery	O
and	O
expression	O
of	O
heterologous	O
genes	O
are	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
topical	O
method	O
of	O
treatment	O
for	O
dysfunction	O
of	O
certain	O
dermal	O
enzymes,	O
and	O
the	O
treatment	O
of	O
skin	O
condition	O
or	O
disorder	O
caused	O
by	O
said	O
dysfunction	O
.	O
The	O
said	O
method	O
of	O
treatment	O
consists	O
of	O
(	O
i	O
)	O
an	O
extra-cellular,	O
matrix	B-GENE
metalloprotease	I-GENE
regulating	O
agent,	O
and	O
(	O
ii	O
)	O
an	O
intra-cellular	O
ubiquitin—proteasome	O
regulating	O
agent,	O
and	O
(	O
iii	O
)	O
an	O
epidermal	O
melanocyte-regulating	O
agent	O
;	O
and,	O
wherein,	O
said	O
extra-cellular	O
agent,	O
said	O
intracellular	O
agent,	O
and	O
said	O
epidermal	O
agent	O
can,	O
surprisingly	O
and	O
unexpectedly,	O
be	O
a	O
single	O
multi-function	O
compound	O
having	O
chemical	O
formula	O
(	O
I	O
)	O
.	O
Additionally,	O
the	O
method	O
of	O
the	O
present	O
invention	O
provides	O
treatment	O
of	O
skin	O
condition	O
or	O
disorder	O
caused	O
by	O
dysfunction	O
of	O
said	O
dermal	O
enzymes	O
;	O
wherein	O
said	O
skin	O
disorder	O
is	O
skin	O
aging,	O
skin	O
wrinkles,	O
dark	O
skin,	O
age	O
spots,	O
acne,	O
skin	O
inflammation,	O
loss	O
of	O
cellular	O
antioxidants,	O
loss	O
of	O
collagen,	O
loss	O
of	O
skin	O
pliability,	O
loss	O
of	O
skin	O
suppleness,	O
oily	O
skin,	O
or	O
a	O
combination	O
thereof	O
:	O


This	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
a	O
subject	O
either	O
during	O
or	O
soon	O
after	O
a	O
seizure,	O
in	O
order	O
to	O
reduce	O
the	O
extent	O
of	O
neuronal	O
damage	O
in	O
the	O
subject	O
resulting	O
from	O
the	O
seizure	O
comprising	O
administering	O
to	O
the	O
subject,	O
either	O
during	O
or	O
soon	O
after	O
the	O
seizure,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
receptor	B-GENE
for	I-GENE
advanced	I-GENE
glycation	I-GENE
endproducts	I-GENE
(	O
RAGE	B-GENE
)	O
,	O
so	O
as	O
to	O
thereby	O
reduce	O
the	O
extent	O
of	O
neuronal	O
damage	O
in	O
the	O
subject	O
.	O
This	O
invention	O
further	O
provides	O
a	O
method	O
for	O
inhibiting	O
neuronal	O
damage	O
which	O
would	O
otherwise	O
result	O
from	O
a	O
seizure	O
in	O
a	O
subject	O
predisposed	O
to	O
having	O
a	O
seizure,	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
prophylactically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
receptor	B-GENE
for	I-GENE
advanced	I-GENE
glycation	I-GENE
endproducts	I-GENE
(	O
RAGE	B-GENE
)	O
,	O
so	O
as	O
to	O
inhibit	O
neuronal	O
damage	O
which	O
would	O
otherwise	O
result	O
from	O
a	O
seizure	O
in	O
the	O
event	O
the	O
subject	O
were	O
to	O
suffer	O
a	O
seizure	O
.	O


The	O
present	O
invention	O
relates	O
to	O
regulation	O
of	O
lymphocyte	O
activation	O
and	O
migration	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
nucleic	O
acids	O
encoding	O
EDG	B-GENE
family	I-GENE
GPCR	I-GENE
proteins,	O
e	O
.	O
g	O
.	O
,	O
EDG-1,	B-GENE
2,	I-GENE
3,	I-GENE
4,	I-GENE
5,	I-GENE
6,	I-GENE
7,	I-GENE
or	I-GENE
8,	O
which	O
are	O
involved	O
in	O
modulation	O
of	O
lymphocyte	O
activation	O
and	O
migration	O
.	O
The	O
invention	O
further	O
relates	O
to	O
methods	O
for	O
identifying	O
and	O
using	O
agents,	O
including	O
small	O
organic	O
molecules,	O
antibodies,	O
peptides,	O
cyclic	O
peptides,	O
nucleic	O
acids,	O
antisense	O
nucleic	O
acids,	O
sphingolipid	O
analogs,	O
and	O
ribozymes,	O
that	O
modulate	O
lymphocyte	O
activation	O
or	O
migration	O
via	O
modulation	O
of	O
EDG	B-GENE
GPCRs	I-GENE
and	O
EDG	O
related	O
signal	O
transduction	O
;	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
expression	O
profiles	O
and	O
compositions	O
in	O
diagnosis	O
and	O
therapy	O
related	O
to	O
lymphocyte	O
activation	O
and	O
suppression,	O
and	O
lymphocyte	O
migration	O
.	O


In	O
accordance	O
with	O
the	O
present	O
invention,	O
it	O
has	O
been	O
discovered	O
that	O
compounds	O
exhibiting	O
activity	O
as	O
a	O
potent	O
noradrenaline	O
reuptake	O
inhibitor	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
NA	O
:	O
5HT	O
ratio	O
of	O
greater	O
than	O
or	O
equal	O
to	O
about	O
1000	O
:	O
1	O
)	O
,	O
and	O
activity	O
at	O
the	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
sites	O
(	O
e	O
.	O
g	O
.	O
,	O
lofepramine	O
)	O
are	O
effective	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
diseases	O
and	O
disorders	O
associated	O
with	O
noradreanaline	O
reuptake,	O
such	O
as	O
ADHD,	O
CFS,	O
fibromyalgia,	O
and	O
depression	O
with	O
pain	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
inhibitors	O
of	O
TGF-β	B-GENE
of	O
Formula	O
I	O
:	O


There	O
is	O
provided	O
a	O
series	O
of	O
heterocyclic-containing	O
macrocyclic	O
acyl	O
guanidines	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
stereoisomer	O
;	O
or	O
a	O
nontoxic	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
n	O
and	O
X	O
as	O
defined	O
herein,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
.	O
These	O
novel	O
compounds	O
inhibit	O
the	O
processing	O
of	O
amyloid	B-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
by	O
β-secretase	B-GENE
and,	O
more	O
specifically,	O
inhibit	O
the	O
production	O
of	O
Aβ-peptide	B-GENE
.	O
The	O
present	O
disclosure	O
is	O
directed	O
to	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
neurological	O
disorders	O
related	O
to	O
β-amyloid	B-GENE
production,	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
and	O
other	O
conditions	O
affected	O
by	O
anti-amyloid	O
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
compositions	O
for	O
treating	O
or	O
preventing	O
obesity	O
and	O
obesity-related	O
disorders	O
in	O
a	O
subject	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
PGC-1	B-GENE
expression	O
levels	O
to	O
determine	O
the	O
safe	O
dosage	O
range	O
for	O
known	O
or	O
putative	O
respiration	O
uncoupling	O
agents	O
for	O
use	O
as	O
anti-obesity	O
therapeutics	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
for	O
identifying	O
new	O
compounds	O
that	O
have	O
respiration	O
uncoupling	O
activity	O
.	O


This	O
invention	O
is	O
directed	O
to	O
inhibitors	O
of	O
copper-containing	O
amine	O
oxidases	O
(	O
E	O
.	O
C	O
.	O
1	O
.	O
4	O
.	O
3	O
.	O
6	O
)	O
including	O
semicarbazide-sensitive	O
amine	O
oxidase	O
(	O
SSAO	B-GENE
;	O
also	O
known	O
as	O
vascular	B-GENE
adhesion	I-GENE
protein-1,	O
VAP-I	B-GENE
)	O
,	O
and	O
their	O
therapeutic	O
use	O
in	O
inflammatory	O
diseases,	O
diabetes	O
and	O
its	O
associated	O
complications,	O
atherosclerosis,	O
neurodegenerative	O
diseases,	O
obesity,	O
hypertension	O
and	O
cancer	O
.	O


The	O
present	O
invention	O
is	O
of	O
a	O
method	O
and	O
compounds	O
for	O
mediating	O
a	O
biological	O
activity	O
mediated	O
by	O
moesin,	O
and	O
in	O
particular,	O
for	O
such	O
a	O
method	O
and	O
compounds	O
for	O
mediating	O
a	O
biological	O
activity	O
that	O
is	O
capable	O
of	O
being	O
mediated	O
through	O
binding	O
of	O
a	O
disaccharide	O
to	O
moesin	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
comprising	O
an	O
oxazole	O
or	O
thiazole	O
moiety	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
and	O
their	O
uses	O
as	O
H3-receptor	B-GENE
ligands,	O
Formula	O
(	O
I	O
)	O
,	O
wherein,	O
A1	O
is	O
CH,	O
C	O
(	O
alkyl	O
)	O
,	O
C-halogen	O
or	O
N	O
;	O
R1	O
is	O
hydrogen,	O
halogen,	O
C1-6	O
alkyl	O
or	O
alkoxy	O
;	O
R2	O
is,	O
Formula	O
(	O
II′	O
)	O
,	O
A3	O
is	O
O	O
or	O
S	O
;	O
R3	O
is	O
hydrogen,	O
halogen,	O
C1-6	O
alkyl	O
or	O
alkoxy	O
;	O
R4	O
is	O
hydrogen,	O
halogen,	O
C1-6	O
alkyl,	O
alkoxy	O
or	O
—O-L	O
;	O
R5	O
is	O
hydrogen	O
or	O
—O-L,	O
wherein	O
L	O
is	O
an	O
aminoalkyl	O
group	O
and	O
at	O
least	O
one	O
of	O
R4	O
and	O
R5	O
should	O
be	O
—O-L	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
enantiomers,	O
diastereomers	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
I,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	B-GENE
kinase	I-GENE
.	O


A	O
method	O
is	O
provided	O
for	O
treating	O
a	O
degenerative	O
disease	O
in	O
a	O
vertebrate	O
eye	O
.	O
A	O
method	O
is	O
further	O
provided	O
for	O
preventing	O
photoreceptor	B-GENE
degeneration	O
in	O
a	O
vertebrate	O
eye	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
peptidic	O
sequence	O
which	O
comprises	O
or	O
is	O
constituted	O
of	O
a	O
peptidic	O
chain	O
of	O
at	O
least	O
contiguous	O
amino	O
acids	O
selected	O
from	O
the	O
amino	O
acid	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
4,	O
SEQ	O
ID	O
NO	O
:	O
4	O
being	O
delimited	O
by	O
the	O
amino	O
acid	O
in	O
position	O
76	O
and	O
by	O
the	O
amino	O
acid	O
in	O
position	O
160	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
(	O
human	B-GENE
Geminin	I-GENE
)	O
,	O
provided	O
that,	O
if	O
present,	O
the	O
flanking	O
regions	O
of	O
the	O
peptidic	O
chain	O
in	O
the	O
peptidic	O
sequence	O
are	O
different	O
from	O
the	O
flanking	O
regions	O
of	O
the	O
peptidic	O
chain	O
in	O
SEQ	O
ID	O
NO	O
:	O
2,	O
for	O
the	O
preparation	O
of	O
a	O
drug	O
intended	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
pathologies	O
implying	O
pathological	O
DNA	O
replication	O
and	O
/	O
or	O
differentiation	O
disorders,	O
or	O
disturbance	O
of	O
the	O
cellular	O
proliferation	O
/	O
differentiation	O
balance	O
.	O


Amino	O
terminus-blocked	O
peptide	O
boronate	O
compounds	O
of	O
Formulas	O
I	O
and	O
II	O
are	O
useful	O
for	O
inhibiting	O
Fibroblast	B-GENE
Activation	I-GENE
Protein	I-GENE
(	O
FAP	B-GENE
)	O
and	O
other	O
proteases,	O
and	O
for	O
treating	O
disorders	O
mediated	O
by	O
FAP	B-GENE
.	O
Methods	O
of	O
using	O
the	O
amino	O
terminus	O
blocked	O
peptide	O
boronate	O
compounds,	O
and	O
stereoisomers,	O
tautomers,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis,	O
prevention	O
or	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells,	O
or	O
associated	O
pathological	O
conditions	O
are	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
EP2	B-GENE
antagonist	O
azetidines	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Ar,	O
R1,	O
X,	O
and	O
Z	O
are	O
as	O
defined	O
herein,	O
to	O
their	O
use	O
in	O
medicine,	O
particularly	O
in	O
the	O
treatment	O
of	O
endometriosis	O
and	O
/	O
or	O
uterine	O
fibroids,	O
to	O
intermediates	O
useful	O
in	O
their	O
synthesis,	O
and	O
to	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
relates	O
to	O
CGRP-antagonists	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
are	O
defined	O
in	O
claim	O
1,	O
to	O
the	O
tautomers,	O
isomers,	O
diastereomers,	O
enantiomers,	O
hydrates,	O
mixtures	O
salts	O
and	O
salt	O
hydrates	O
thereof,	O
in	O
particular	O
to	O
10	O
salts	O
thereof,	O
which	O
are	O
physiologically	O
compatible	O
with	O
acids	O
or	O
inorganic	O
or	O
organic	O
bases	O
and	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
one	O
or	O
several	O
hydrogen	O
atoms	O
are	O
substituted	O
by	O
deuterium	O
.	O
Drugs	O
containing	O
said	O
compounds,	O
the	O
use	O
thereof	O
and	O
a	O
method	O
for	O
the	O
production	O
thereof	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
bitter-taste	B-GENE
receptors	I-GENE
and	O
their	O
role	O
in	O
bitter	O
taste	O
transduction	O
.	O
The	O
invention	O
also	O
relates	O
to	O
assays	O
for	O
screening	O
molecules	O
that	O
modulate,	O
e	O
.	O
g	O
.	O
suppress	O
or	O
block,	O
bitter	O
taste	O
transduction,	O
or	O
enhance	O
bitter	O
taste	O
response	O
.	O


The	O
invention	O
relates	O
generally	O
to	O
phosphoinositide	B-GENE
3-kinases	I-GENE
(	O
PI3Ks	B-GENE
)	O
,	O
and	O
more	O
particularly	O
to	O
methods	O
of	O
inhibiting	O
leukocyte	O
accumulation	O
comprising	O
selectively	O
inhibiting	O
phosphoinositide	B-GENE
3-kinase	I-GENE
delta	I-GENE
(	O
PI3Kδ	B-GENE
)	O
and	O
phosphoinositide	B-GENE
3-kinase	I-GENE
gamma	I-GENE
(	O
PI3Kγ	B-GENE
)	O
activities	O
in	O
endothelial	O
cells	O
.	O
The	O
disclosed	O
methods	O
may	O
be	O
used	O
to	O
treat	O
individuals	O
having	O
an	O
inflammatory	O
condition	O
where	O
leukocytes	O
are	O
found	O
to	O
be	O
accumulating	O
at	O
the	O
site	O
of	O
insult	O
or	O
inflamed	O
tissue	O
.	O
The	O
inflammatory	O
condition	O
may	O
be	O
attributed	O
to	O
or	O
associated	O
with	O
an	O
underlying	O
disorder	O
not	O
typically	O
associated	O
with	O
inflammation,	O
e	O
.	O
g	O
.	O
cancer,	O
coronary	O
vascular	O
disease,	O
etc	O
.	O


The	O
present	O
invention	O
relates	O
to	O
nociceptin	B-GENE
analogues	O
and	O
uses	O
thereof	O
to	O
modulate	O
biological	O
functions	O
.	O
In	O
one	O
aspect,	O
the	O
invention	O
provides	O
modified	O
triazo-spiro	O
compounds	O
that	O
include	O
at	O
least	O
one	O
specialized	O
chemical	O
group	O
that	O
is	O
bound	O
to	O
the	O
compounds	O
.	O
The	O
invention	O
has	O
a	O
wide	O
range	O
of	O
applications	O
including	O
providing	O
a	O
new	O
class	O
of	O
therapeutically	O
useful	O
aquatics	O
.	O


The	O
present	O
invention	O
provides	O
isolated	O
T	B-GENE
cell	I-GENE
receptors	I-GENE
(	O
TCRs	O
)	O
having	O
the	O
property	O
of	O
specifically	O
binding	O
to	O
the	O
VYGFVRACL-HLA-A24	O
peptide-MHC	O
.	O
Such	O
TCRs	O
are	O
useful,	O
either	O
alone	O
or	O
associated	O
with	O
a	O
therapeutic	O
agent,	O
for	O
targeting	O
cancerous	O
cells	O
presenting	O
the	O
complex	O
.	O


The	O
present	O
invention	O
describes	O
benzimidazole	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
which	O
constitute	O
potent	O
PARP	B-GENE
inhibitors	O
in	O
combination	O
with	O
temozolomide	O
(	O
TMZ	O
)	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
(	O
i	O
)	O
a	O
renin	B-GENE
inhibitor,	O
(	O
ii	O
)	O
a	O
calcium	B-GENE
channel	I-GENE
blocker	O
(	O
CCB	O
)	O
,	O
and	O
a	O
diuretic	O
and	O
to	O
a	O
method	O
of	O
using	O
such	O
composition	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
potent	O
cyclooxygenase-2	B-GENE
inhibitor	O
and	O
dosing	O
regimens	O
thereof	O
to	O
safely	O
treat	O
cyclooxygenase-2	B-GENE
mediated	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
chemical	O
compounds,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
of	O
the	O
formula	O
which	O
possess	O
CSF	B-GENE
1R	I-GENE
kinase	O
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
for	O
their	O
anti	O
cancer	O
activity	O
and	O
thus	O
in	O
methods	O
of	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
chemical	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
of	O
use	O
in	O
the	O
production	O
of	O
an	O
anti-cancer	O
effect	O
in	O
a	O
warm	O
blooded	O
animal	O
such	O
as	O
man	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
pyrazole	O
derivative	O
as	O
an	O
active	O
ingredient,	O
which	O
has	O
antagonistic	O
activity	O
against	O
serotonin	O
5-HT3A	B-GENE
and	O
is	O
effective	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
diseases,	O
including	O
emesis,	O
nausea,	O
alcoholism,	O
drug	O
abuse,	O
depression,	O
compulsive	O
neurosis,	O
anxiety,	O
seizure,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
chorea,	O
psychosis,	O
schizophrenia,	O
suicidal	O
tendency,	O
sleep	O
disorder,	O
appetite	O
disorder	O
and	O
migraine	O
.	O


Anthracyclines	O
induce	O
the	O
rapid,	O
pre-apoptotic	O
translocation	O
of	O
ERP57	B-GENE
to	O
the	O
cell	O
surface	O
.	O
Knock	O
down	O
of	O
ERP57	B-GENE
inhibit	O
the	O
translocation	O
of	O
CRT,	O
suppressed	O
the	O
phagocytosis	O
of	O
anthracyclines-treated	O
tumor	O
cells	O
by	O
dendritic	O
cells	O
and	O
abolished	O
their	O
immunogenicity	O
in	O
mammals,	O
such	O
as	O
mice	O
.	O
In	O
contrast,	O
the	O
blockade	O
of	O
ERP57	B-GENE
with	O
blocking	O
antibody	O
had	O
no	O
effect	O
on	O
phagocytosis	O
of	O
anthracyclines-treated	O
tumor	O
cells	O
by	O
dendritic	O
cells	O
and	O
their	O
immunogenicity	O
in	O
mammals,	O
such	O
as	O
mice	O
.	O
The	O
anthracyclines-induced	O
ERP57	B-GENE
translocation	O
was	O
mimicked	O
by	O
inhibition	O
of	O
the	O
protein	B-GENE
phosphatase1	I-GENE
/	O
GADD34	B-GENE
complex	O
.	O
Administration	O
of	O
recombinant	O
ERP57	B-GENE
did	O
not	O
restored	O
the	O
immunogenicity	O
of	O
cell	O
death	O
elicited	O
by	O
etoposide	O
and	O
mitomycin	O
C,	O
or	O
enhanced	O
their	O
antitumor	O
effects	O
in	O
vivo	O
in	O
contrast	O
to	O
the	O
administration	O
of	O
recombinant	O
CRT	B-GENE
.	O
These	O
data	O
identify	O
the	O
presence	O
of	O
ERP57	B-GENE
crucial	O
for	O
the	O
translocation	O
of	O
CRT	B-GENE
and	O
to	O
induce	O
immunogenic	O
cell	O
death	O
which	O
will	O
activate	O
a	O
anti-cancer	O
immune	O
responses	O
.	O


The	O
invention	O
provides	O
a	O
pharmaceutical	O
combination	O
comprising	O
:	O
	O
	O
	O
a	O
)	O
compounds	O
that	O
inhibit	O
the	O
binding	O
of	O
the	O
Smac	B-GENE
protein	O
to	O
IAPs	B-GENE
;	O
and	O
b	O
)	O
a	O
taxane,	O
and	O
a	O
method	O
for	O
treating	O
or	O
preventing	O
a	O
proliferative	O
disease	O
using	O
such	O
a	O
combination	O
.	O


Compositions	O
and	O
methods	O
for	O
treating,	O
preventing,	O
or	O
reducing	O
alcoholism,	O
in	O
particular	O
methods	O
for	O
increasing	O
patient	O
compliance	O
with	O
therapies	O
that	O
require	O
the	O
intake	O
of	O
an	O
ALDH	B-GENE
inhibitor	O
comprising	O
the	O
step	O
of	O
administering	O
a	O
monoamine	B-GENE
oxidase	I-GENE
B	I-GENE
inhibitor	O
.	O


A	O
method	O
for	O
selecting	O
a	O
female	O
breast	O
cancer	O
patient	O
for	O
AT1	B-GENE
receptor	O
antagonist	O
therapy	O
comprises	O
(	O
a	O
)	O
determining	O
whether	O
the	O
cancer	O
comprises	O
a	O
tumor	O
that	O
is	O
ER+	O
and	O
/	O
or	O
PR+	O
;	O
and	O
(	O
b	O
)	O
selecting	O
the	O
patient	O
for	O
AT1	B-GENE
receptor	O
antagonist	O
therapy	O
only	O
if	O
the	O
cancer	O
is	O
determined	O
to	O
comprise	O
an	O
ER+	O
and	O
/	O
or	O
PR+	O
tumor	O
.	O
A	O
method	O
for	O
treating	O
breast	O
cancer	O
in	O
a	O
female	O
patient	O
further	O
comprises	O
(	O
c	O
)	O
administering	O
to	O
the	O
patient,	O
if	O
so	O
selected,	O
an	O
AT1	B-GENE
receptor	O
antagonist	O
according	O
to	O
a	O
regimen	O
effective	O
to	O
reduce	O
growth,	O
invasiveness	O
and	O
/	O
or	O
metastasis	O
of	O
the	O
tumor	O
.	O


Provided	O
are	O
compounds	O
useful	O
for	O
treating	O
diseases	O
associated	O
with	O
a	O
cerebral	O
accumulation	O
of	O
Alzheimer	O
'	O
s	O
amyloid,	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treating	O
or	O
reducing	O
the	O
risk	O
of	O
developing	O
β-amyloid	B-GENE
production,	O
β-amyloid	B-GENE
deposition,	O
β-amyloid	B-GENE
neurotoxicity	O
(	O
including	O
abnormal	O
hyperphosphorylation	O
of	O
tau	B-GENE
)	O
and	O
microgliosis	O
associated	O
with	O
cerebral	O
accumulation	O
of	O
Alzheimer	O
'	O
s	O
amyloid	O
by	O
administering	O
therapeutically	O
effective	O
amounts	O
of	O
the	O
compounds	O
.	O
Further	O
provided	O
are	O
methods	O
for	O
diagnosing	O
diseases	O
associated	O
with	O
cerebral	O
accumulation	O
of	O
Alzheimer	O
'	O
s	O
amyloid	O
in	O
animals	O
or	O
humans	O
by	O
administering	O
diagnostically	O
effective	O
amounts	O
of	O
the	O
compounds	O
.	O


The	O
invention	O
discloses	O
aptamers	O
capable	O
of	O
binding	O
to	O
Immunoglobulin	B-GENE
E	I-GENE
(	O
“IgE”	O
)	O
useful	O
as	O
therapeutics	O
in	O
and	O
diagnostics	O
of	O
atopic	O
disease	O
and	O
/	O
or	O
other	O
diseases	O
or	O
disorders	O
in	O
which	O
IgE	B-GENE
has	O
been	O
implicated	O
.	O
The	O
invention	O
further	O
relates	O
to	O
materials	O
and	O
methods	O
for	O
the	O
administration	O
of	O
aptamers	O
capable	O
of	O
binding	O
to	O
IgE	B-GENE
.	O


Methods	O
for	O
treating	O
diseases	O
or	O
disorders	O
of	O
the	O
skin	O
which	O
are	O
characterized	O
by	O
angiogenesis	O
have	O
been	O
developed	O
using	O
curcumin	O
and	O
curcumin	O
analogs	O
.	O
Based	O
on	O
the	O
results	O
obtained	O
with	O
curcumin,	O
it	O
has	O
been	O
determined	O
that	O
other	O
angiogenesis	O
inhibitors	O
can	O
also	O
be	O
used	O
to	O
treat	O
these	O
skin	O
disorders	O
.	O
It	O
has	O
further	O
been	O
discovered	O
that	O
curcumin	O
acts	O
to	O
inhibit	O
angiogenesis	O
in	O
part	O
by	O
inhibition	O
of	O
basic	B-GENE
fibroblast	I-GENE
growth	I-GENE
factor	I-GENE
(	O
bFGF	B-GENE
)	O
,	O
and	O
thereby	O
provides	O
a	O
means	O
for	O
treating	O
other	O
disorders	O
characterized	O
by	O
elevated	O
levels	O
of	O
bFGF,	O
such	O
as	O
bladder	O
cancer,	O
using	O
curcumin	O
and	O
other	O
analogues	O
which	O
also	O
inhibit	O
bFGF	B-GENE
.	O
Representative	O
skin	O
disorders	O
to	O
be	O
treated	O
include	O
the	O
malignant	O
diseases	O
angiosarcoma,	O
hemangioendothelioma,	O
basal	O
cell	O
carcinoma,	O
squamous	O
cell	O
carcinoma,	O
malignant	O
melanoma	O
and	O
Karposi	O
'	O
s	O
sarcoma,	O
and	O
the	O
non-malignant	O
diseases	O
or	O
conditions	O
including	O
psoriasis,	O
lymphangiogenesis,	O
hemangioma	O
of	O
childhood,	O
Sturge-Weber	O
syndrome,	O
verruca	O
vulgaris,	O
neurofibromatosis,	O
tuberous	O
sclerosis,	O
pyogenic	O
granulomas,	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa,	O
venous	O
ulcers,	O
acne,	O
rosacea,	O
eczema,	O
molluscum	O
contagious,	O
seborrheic	O
keratosis,	O
and	O
actinic	O
keratosis	O
.	O


The	O
teachings	O
relates	O
to	O
the	O
three-dimensional	O
structure	O
of	O
a	O
crystal	O
of	O
a	O
cytochrome	O
protein	O
complexed	O
with	O
a	O
ligand	O
.	O
The	O
three-dimensional	O
structure	O
of	O
four	O
cytochrome	B-GENE
P450	I-GENE
2A6-ligand	O
complexes	O
are	O
disclosed	O
.	O
Cytochrome	B-GENE
P450	I-GENE
2A6-ligand	O
crystal	O
structures,	O
wherein	O
the	O
ligand	O
is	O
an	O
inhibitor	O
molecule,	O
are	O
useful	O
for	O
providing	O
structural	O
information	O
that	O
may	O
be	O
integrated	O
into	O
drug	O
screening	O
and	O
drug	O
design	O
processes	O
.	O
Thus,	O
the	O
teachings	O
also	O
relate	O
to	O
methods	O
for	O
utilizing	O
a	O
crystal	O
structure	O
of	O
a	O
cytochrome	B-GENE
P450	I-GENE
2A6-ligand	O
complex	O
for	O
identifying,	O
designing,	O
selecting,	O
or	O
testing	O
inhibitors	O
of	O
the	O
cytochrome	O
protein	O
.	O
Such	O
inhibitors	O
are	O
useful	O
as	O
therapeutics	O
for	O
the	O
treatment	O
or	O
modulation	O
of	O
i	O
)	O
diseases	O
;	O
ii	O
)	O
disease	O
symptoms	O
;	O
or	O
iii	O
)	O
the	O
effect	O
of	O
other	O
physiological	O
events	O
mediated	O
by	O
the	O
cytochrome	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
where	O
one	O
of	O
A1,	O
A2	O
or	O
A3	O
is	O
N,	O
and	O
the	O
others	O
are	O
independently	O
selected	O
from	O
CH	O
or	O
N	O
;	O
ring	O
B	O
is	O
a	O
fused	O
5	O
or	O
6-membered	O
carbocyclic	O
or	O
heterocyclic	O
which	O
is	O
optionally	O
substituted	O
as	O
defined	O
in	O
the	O
specification,	O
and	O
R1,	O
R2,	O
R3,	O
R4,	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
	O
	O
	O
	O
The	O
compounds	O
are	O
inhibitors	O
of	O
EphB4	B-GENE
or	O
EphA2	B-GENE
and	O
therefore	O
may	O
be	O
useful	O
in	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
cancer	O
.	O


Described	O
herein	O
are	O
compounds	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds,	O
which	O
inhibit	O
the	O
activity	O
of	O
histone	B-GENE
deacetylase	I-GENE
.	O
Also	O
described	O
herein	O
are	O
methods	O
of	O
using	O
such	O
HDAC	B-GENE
inhibitors,	O
alone	O
and	O
in	O
combination	O
with	O
other	O
compounds,	O
for	O
treating	O
diseases	O
or	O
conditions	O
that	O
would	O
benefit	O
from	O
inhibition	O
of	O
HDAC	B-GENE
activity	O
.	O


A	O
method	O
of	O
treating	O
a	O
patient	O
in	O
need	O
of	O
therapy	O
for	O
a	O
cytokine	B-GENE
dysregulation	O
comprising	O
administering	O
to	O
that	O
patient	O
a	O
therapeutically	O
effective	O
dose	O
of	O
a	O
monoglyceride	O
or	O
metabolic	O
precursor	O
thereof	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
the	O
fatty	O
acyl	O
group	O
of	O
an	O
essential	O
polyunsaturated	O
fatty	O
acid	O
selected	O
from	O
γ-linolenoyl,	O
γ-dihomolinolenoyl	O
and	O
arachidonoyl	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
translation	O
or	O
inflammatory	O
response	O
blockade	O
by	O
using	O
a	O
compound	O
that	O
binds	O
to	O
eIF4A,	O
which	O
is	O
the	O
264th	O
amino	O
acid	O
residue,	O
a	O
method	O
of	O
developing	O
an	O
anti-inflammation,	O
anti-cancer	O
or	O
anti-viral	O
agent	O
by	O
screening	O
a	O
compound	O
that	O
binds	O
to	O
eIF4A	B-GENE
.	O


New	O
substituted	O
benzazole	O
compounds,	O
compositions	O
and	O
methods	O
of	O
inhibition	O
of	O
Raf	B-GENE
kinase	O
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
provided	O
.	O
The	O
new	O
compounds	O
compositions	O
may	O
be	O
used	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
agent	O
for	O
the	O
treatment	O
of	O
a	O
Raf	B-GENE
kinase	O
mediated	O
disorder,	O
such	O
as	O
cancer	O
.	O


Compositions	O
and	O
methods	O
are	O
provided	O
for	O
decreasing	O
blood	O
glucose	O
levels	O
in	O
an	O
animal	O
or	O
for	O
preventing	O
or	O
de-laying	O
the	O
onset	O
of	O
a	O
rise	O
in	O
blood	O
glucose	O
levels	O
in	O
an	O
animal,	O
comprising	O
administering	O
to	O
said	O
animal	O
an	O
antisense	O
inhibitor	O
of	O
PTP1B	B-GENE
expression	O
in	O
combination	O
with	O
at	O
least	O
one	O
glucose-lowering	O
drug	O
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
compositions	O
and	O
methods	O
for	O
improving	O
insulin	B-GENE
sensitivity	O
in	O
an	O
animal	O
or	O
for	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
insulin	B-GENE
resistance	O
in	O
an	O
animal	O
.	O
Also	O
provided	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
a	O
metabolic	O
condition	O
in	O
an	O
animal	O
.	O
The	O
metabolic	O
condition	O
may	O
be,	O
e	O
.	O
g	O
.	O
,	O
diabetes	O
or	O
obesity	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
glaucoma,	O
methods	O
for	O
diagnosing	O
glaucoma,	O
and	O
methods	O
for	O
identifying	O
agents	O
which	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
glaucoma	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
describes	O
the	O
use	O
of	O
agents	O
that	O
modulate	O
the	O
expression	O
of	O
serum	B-GENE
amyloid	I-GENE
A	I-GENE
.	O


This	O
invention	O
relates	O
to	O
substituted	O
pyrido	O
(	O
3,2-d	O
)	O
pyrimidine	O
derivatives,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
N-oxides,	O
solvates,	O
pro-drugs	O
and	O
enantiomers,	O
possessing	O
unexpectedly	O
desirable	O
pharmaceutical	O
properties,	O
in	O
particular	O
which	O
are	O
highly	O
active	O
immunosuppressive	O
agents,	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
in	O
transplant	O
rejection	O
and	O
/	O
or	O
in	O
the	O
treatment	O
of	O
certain	O
inflammatory	O
diseases	O
.	O
These	O
derivatives	O
are	O
also	O
useful	O
in	O
preventing	O
or	O
treating	O
cardiovascular	O
disorders,	O
disorders	O
of	O
the	O
central	O
nervous	O
system,	O
TNF-α	B-GENE
related	O
disorders,	O
viral	O
diseases	O
(	O
including	O
hepatitis	O
C	O
)	O
,	O
erectile	O
dysfunction	O
and	O
cell	O
proliferative	O
disorders	O
.	O


Methods	O
for	O
treating	O
sepsis	O
or	O
septic	O
shock	O
in	O
a	O
patient	O
comprising	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
containing	O
an	O
adenosine	B-GENE
A2a	I-GENE
receptor	I-GENE
antagonist	O
.	O


A	O
method	O
of	O
treating	O
a	O
dermatological	O
disorder	O
in	O
a	O
subject	O
includes	O
the	O
step	O
of	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
PPARγ	B-GENE
agonist	O
or	O
derivative	O
thereof	O
to	O
the	O
subject	O
.	O


The	O
present	O
invention	O
encompasses	O
compounds	O
of	O
Formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
as	O
well	O
as	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
S1P1/Edg1	B-GENE
receptor	O
agonists	O
and	O
thus	O
have	O
immunosuppressive,	O
anti-inflammatory	O
and	O
hemostatic	O
activities	O
by	O
modulating	O
leukocyte	O
trafficking,	O
sequestering	O
lymphocytes	O
in	O
secondary	O
lymphoid	O
tissues,	O
and	O
enhancing	O
vascular	O
integrity	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
or	O
prevention	O
.	O


Compounds	O
according	O
to	O
formula,	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A,	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
herein,	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates	O
and	O
solvates	O
thereof	O
are	O
useful	O
for	O
the	O
modulation	O
of	O
CCR5	B-GENE
chemokine	B-GENE
receptor	I-GENE
activity	O
.	O


This	O
invention	O
is	O
directed	O
to	O
a	O
cannabinoid	O
modulator	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
form	O
thereof,	O
and	O
methods	O
for	O
use	O
in	O
treating,	O
ameliorating	O
or	O
preventing	O
a	O
cannabinoid	B-GENE
receptor	I-GENE
mediated	O
syndrome,	O
disorder	O
or	O
disease	O
.	O


The	O
present	O
invention	O
relate	O
to	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
	O
	O
	O
	O
	O
	O
	O
	O
ring	O
A	O
is	O
an	O
optionally	O
substituted	O
ring	O
(	O
the	O
ring	O
should	O
not	O
be	O
pyrrolidine,	O
piperidine	O
and	O
piperazine	O
)	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
ring	O
B	O
is	O
an	O
optionally	O
substituted	O
aromatic	O
ring,	O
	O
	O
	O
	O
	O
	O
	O
	O
ring	O
D	O
is	O
an	O
optionally	O
substituted	O
ring,	O
	O
	O
	O
	O
	O
	O
	O
	O
R1	O
and	O
R2	O
are	O
each	O
independently	O
a	O
hydrogen	O
atom	O
or	O
a	O
substituent,	O
	O
	O
	O
	O
	O
	O
	O
	O
R3	O
is	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-6	O
alkyl	O
group,	O
or	O
R3	O
is	O
bonded	O
to	O
	O
	O
	O
	O
	O
	O
	O
	O
ring	O
A	O
to	O
form	O
a	O
non-aromatic	O
ring,	O
	O
	O
	O
	O
	O
	O
	O
	O
ring	O
Aa	O
is	O
an	O
optionally	O
substituted	O
aromatic	O
hydrocarbon,	O
	O
	O
	O
	O
	O
	O
	O
	O
Y	O
is	O
CH	O
or	O
N,	O
	O
	O
	O
	O
	O
	O
	O
	O
Ra1	O
is	O
an	O
optionally	O
substituted	O
hydrocarbon	O
group,	O
and	O
	O
	O
	O
	O
	O
	O
	O
	O
Ra2	O
and	O
Ra3	O
are	O
each	O
independently	O
a	O
hydrogen	O
atom	O
or	O
a	O
substituent,	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
salt	O
thereof	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
having	O
a	O
DGAT	B-GENE
inhibitory	O
activity,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
or	O
amelioration	O
of	O
diseases	O
or	O
pathologies	O
caused	O
by	O
high	O
expression	O
or	O
high	O
activation	O
of	O
DGAT	B-GENE
.	O


Methods	O
of	O
utilizing	O
biomarkers	O
to	O
identify	O
patients	O
for	O
treatment	O
or	O
to	O
monitor	O
response	O
to	O
treatment	O
are	O
taught	O
herein	O
.	O
Alterations	O
in	O
levels	O
of	O
gene	O
expression	O
of	O
the	O
biomarkers,	O
particularly	O
in	O
response	O
to	O
FGFR3	B-GENE
inhibition,	O
are	O
measured	O
and	O
identifications	O
or	O
adjustments	O
may	O
be	O
made	O
accordingly	O
.	O


The	O
present	O
invention	O
provides	O
to	O
methods	O
of	O
preventing,	O
treating	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
associated	O
with	O
an	O
autoimmune	O
or	O
inflammatory	O
disorder	O
utilizing	O
combinatorial	O
therapy	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
preventing,	O
treating,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
associated	O
with	O
an	O
autoimmune	O
or	O
inflammatory	O
disorder	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
one	O
or	O
more	O
integrin	B-GENE
αVβ3	I-GENE
antagonists	O
and	O
at	O
least	O
one	O
other	O
prophylactic	O
or	O
therapeutic	O
agent	O
.	O
The	O
present	O
invention	O
also	O
provides	O
compositions	O
and	O
articles	O
of	O
manufacture	O
for	O
use	O
in	O
preventing,	O
treating	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
associated	O
with	O
an	O
autoimmune	O
or	O
inflammatory	O
disorder	O
.	O


The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
E6	B-GENE
and/or	I-GENE
E7	I-GENE
peptides	I-GENE
from	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
to	O
evaluate	O
a	O
cell-mediated	O
response	O
in	O
a	O
patient	O
infected	O
with	O
HPV	O
to	O
determine	O
the	O
prognosis	O
for	O
that	O
patient	O
with	O
respect	O
to	O
the	O
development	O
or	O
recurrence	O
of	O
pre-cancerous	O
or	O
cancerous	O
growths,	O
including	O
cervical	O
intraepithelial	O
neoplasia	O
(	O
CIN	O
)	O
.	O


Methods	O
for	O
increasing	O
urine	O
flow	O
are	O
disclosed,	O
comprising	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
GLP-1,	O
an	O
exendin,	O
or	O
an	O
exendin	B-GENE
or	O
GLP-1	B-GENE
agonist	O
.	O
Methods	O
for	O
increasing	O
urinary	O
sodium	O
excretion	O
and	O
decreasing	O
urinary	O
potassium	O
concentration	O
are	O
also	O
disclosed	O
.	O
The	O
methods	O
are	O
useful	O
for	O
treating	O
conditions	O
or	O
disorders	O
associated	O
with	O
toxic	O
hypervolemia,	O
such	O
as	O
renal	O
failure,	O
congestive	O
heart	O
failure,	O
nephrotic	O
syndrome,	O
cirrhosis,	O
pulmonary	O
edema,	O
and	O
hypertension	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
inducing	O
an	O
inotropic	O
response	O
comprising	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
GLP-1,	O
an	O
exendin,	O
or	O
an	O
exendin	B-GENE
or	O
GLP-1	B-GENE
agonist	O
.	O
These	O
methods	O
are	O
useful	O
for	O
treating	O
conditions	O
or	O
disorders	O
that	O
can	O
be	O
alleviated	O
by	O
an	O
increase	O
in	O
cardiac	O
contractility	O
such	O
as	O
congestive	O
heart	O
failure	O
.	O
Pharmaceutical	O
compositions	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
invention	O
are	O
also	O
disclosed	O
.	O


A	O
composition	O
for	O
treating	O
insulin-dependent	O
diabetes,	O
reducing	O
body	O
fat,	O
improving	O
insulin	B-GENE
sensitivity,	O
reducing	O
hyperglycemia,	O
and	O
reducing	O
hypercholesterolemia	O
with	O
at	O
least	O
one	O
chromium	O
complex	O
and	O
a	O
conjugated	O
fatty	O
acid	O
or	O
conjugated	O
fatty	O
alcohol	O
is	O
disclosed	O
.	O
A	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
insulin-dependent	O
diabetes	O
by	O
administering	O
a	O
composition	O
that	O
includes	O
at	O
least	O
one	O
chromium	O
complex	O
and	O
a	O
conjugated	O
fatty	O
acid	O
or	O
conjugated	O
fatty	O
alcohol	O
is	O
similarly	O
provided	O
.	O
The	O
administration	O
of	O
a	O
composition	O
containing	O
an	O
effective	O
dose	O
of	O
at	O
least	O
one	O
chromium	O
complex	O
and	O
a	O
conjugated	O
fatty	O
acid	O
or	O
conjugated	O
fatty	O
alcohol	O
for	O
the	O
treatment	O
of	O
obesity	O
is	O
likewise	O
provided	O
.	O


A	O
model	O
system	O
to	O
study	O
extracellular	O
enteric	O
bacterial	O
pathogen	O
(	O
e	O
.	O
g	O
.	O
,	O
Y	O
.	O
enterocolitica	O
)	O
infection	O
of	O
murine	O
neonates	O
through	O
the	O
natural	O
orogastric	O
(	O
o	O
.	O
g	O
.	O
)	O
route	O
of	O
transmission	O
has	O
been	O
developed	O
.	O
The	O
experiments	O
described	O
herein	O
led	O
to	O
the	O
discoveries	O
that	O
1	O
)	O
murine	O
neonates	O
are	O
resistant	O
to	O
intestinal	O
Yersinia	O
enterolcolitica	O
infection,	O
2	O
)	O
neonatal	O
mice	O
mount	O
robust	O
Th1,	O
Th2	O
and	O
Th17	O
responses	O
to	O
Yersinia	O
infection,	O
3	O
)	O
mice	O
infected	O
as	O
neonates	O
with	O
Yersinia	O
mount	O
robust	O
antibody	O
responses	O
when	O
re-exposed	O
as	O
adults,	O
4	O
)	O
mice	O
infected	O
as	O
neonates	O
with	O
Yersinia	O
develop	O
protective	O
immunity,	O
and	O
5	O
)	O
YopP	B-GENE
has	O
different	O
effects	O
in	O
neonates	O
and	O
adults,	O
i	O
.	O
e	O
.	O
,	O
while	O
adults	O
show	O
little	O
change	O
in	O
response	O
to	O
a	O
YopP	B-GENE
deletant,	O
neonates	O
are	O
more	O
susceptible	O
.	O
Compositions,	O
including	O
adjuvants	O
and	O
vaccines,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
and	O
preventing	O
gastroenteric	O
disease	O
in	O
neonates	O
and	O
children	O
(	O
e	O
.	O
g	O
.	O
,	O
humans	O
)	O
and	O
decreasing	O
or	O
preventing	O
inflammation	O
in	O
a	O
neonate	O
or	O
child	O
suffering	O
from	O
an	O
autoimmune	O
disease	O
are	O
described	O
herein	O
.	O


A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
is	O
selected	O
from	O
hydrogen	O
and	O
C1-4alkyl	O
;	O
R2	O
is	O
selected	O
from	O
:	O
R4—C	O
(	O
R5aR5b	O
)	O
—,	O
R4═C	O
(	O
R6	O
)	O
—	O
and	O
R7aC	O
(	O
R7b	O
)	O
═C	O
(	O
R6	O
)	O
—	O
;	O
R3X—	O
is	O
selected	O
from	O
methyl,	O
methoxymethyl	O
and	O
;	O
R4	O
is	O
selected	O
from	O
(	O
optionally	O
substituted	O
)	O
C1-4alkyl,	O
phenyl,	O
C3-6cycloalkyl	O
and	O
heteroaryl	O
;	O
R5a	O
and	O
R5b	O
are	O
independently	O
selected	O
from	O
hydrogen,	O
fluoro	O
and	O
C1-4alkyl	O
;	O
R6	O
is	O
selected	O
from	O
hydrogen	O
and	O
C1-4alkyl	O
;	O
R7a	O
and	O
R7b	O
are	O
optionally	O
substituted	O
C1-4alkyl	O
;	O
or	O
a	O
salt,	O
pro-drug	O
or	O
solvate	O
thereof,	O
are	O
described	O
.	O
Their	O
use	O
as	O
GLK	B-GENE
activators,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
processes	O
for	O
their	O
preparation	O
are	O
also	O
described	O
.	O


Described	O
are	O
specific	O
binding	O
members	O
e	O
.	O
g	O
.	O
antibodies	O
which	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
cathepsin	B-GENE
S	I-GENE
activity	O
.	O
The	O
specific	O
binding	O
members	O
binds	O
cathepsin	B-GENE
S	I-GENE
and	O
inhibits	O
its	O
proteolytic	O
activity	O
.	O
The	O
binding	O
members	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer,	O
inflammatory	O
diseases,	O
neurodegenerative	O
disorders,	O
autoimmune	O
disorders,	O
and	O
other	O
diseases	O
associated	O
with	O
excessive,	O
deregulated	O
or	O
inappropriate	O
angiogenesis	O
.	O


Dosage	O
forms	O
and	O
methods	O
of	O
use	O
are	O
disclosed	O
for	O
:	O
a	O
)	O
the	O
simultaneous	O
administration	O
of	O
tetrahydrobiopterin	O
(	O
BH4	O
)	O
or	O
a	O
derivative,	O
homolog	O
or	O
precursor	O
thereof	O
and	O
lipoic	O
acid	O
(	O
LA	O
)	O
,	O
or	O
dihydrolipoic	O
acid	O
(	O
DHLA	O
)	O
,	O
or	O
a	O
derivative,	O
homolog	O
or	O
salt	O
thereof	O
or,	O
b	O
)	O
the	O
administration	O
of	O
a	O
conjugate	O
consisting	O
of	O
tetrahydrobiopterin	O
bis-lipoate	O
(	O
TBL	O
)	O
.	O
The	O
invention	O
is	O
useful	O
for	O
the	O
amelioration	O
of	O
diabetes	O
mellitus	O
types	O
1	O
and	O
2	O
(	O
including	O
impaired	O
glucose	O
tolerance,	O
pre-diabetes,	O
insulin	B-GENE
resistance,	O
metabolic	O
syndrome	O
X	O
and	O
as	O
an	O
adjunct	O
to	O
oral	O
antidiabetic	O
agents	O
and	O
/	O
or	O
insulin	B-GENE
)	O
,	O
diabetic	O
and	O
non-diabetic	O
microvascular	O
diseases	O
(	O
including	O
nephropathy,	O
neuropathy	O
and	O
retinopathy	O
)	O
,	O
diabetic	O
and	O
non-diabetic	O
macrovascular	O
diseases	O
(	O
including	O
heart	O
attack,	O
stroke,	O
peripheral	O
vascular	O
disease	O
and	O
ischemia-reperfusion	O
injury	O
)	O
,	O
hypertension,	O
vasoconstriction,	O
obesity,	O
dyslipedemia,	O
and	O
neurodegenerative	O
disorders	O
(	O
including	O
Parkinson	O
'	O
s	O
disease,	O
mild	O
cognitive	O
impairment,	O
senile	O
dementia,	O
Alzheimer	O
'	O
s	O
disease,	O
hearing	O
loss	O
and	O
chronic	O
glaucomas	O
)	O
.	O
A	O
novel	O
method	O
for	O
the	O
preparation	O
of	O
TBL	O
is	O
also	O
disclosed	O
.	O


Certain	O
imidazoquinolines	O
with	O
a	O
hydroxymethyl	O
or	O
hydroxyethyl	O
substituent	O
at	O
the	O
2-position,	O
and	O
an	O
aryl	O
or	O
heteroaryl	O
substituent	O
at	O
the	O
7-position,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
intermediates,	O
methods	O
of	O
making	O
and	O
methods	O
of	O
use	O
of	O
these	O
compounds	O
as	O
immunomodulators,	O
for	O
preferentially	O
inducing	O
IFN-α	B-GENE
biosynthesis	O
in	O
animals	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
viral	O
and	O
neoplastic	O
diseases	O
are	O
disclosed	O
.	O


Compounds	O
that	O
bind	O
to	O
Bfl-1	B-GENE
as	O
well	O
as	O
conjugates	O
of	O
such	O
compounds	O
are	O
provided	O
.	O
Various	O
embodiments	O
additionally	O
provide	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
identify	O
additional	O
anti-apoptotic	O
Bfl-1	B-GENE
binding	O
compounds	O
.	O
Methods	O
of	O
using	O
such	O
compounds	O
to	O
increase	O
apoptosis	O
in	O
a	O
cell	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
hydroxamic	O
acid	O
derivatives	O
.	O
The	O
hydroxamic	O
acid	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
cancer	O
.	O
The	O
hydroxamic	O
acid	O
compounds	O
can	O
also	O
inhibit	O
histone	B-GENE
deacetylase	I-GENE
and	O
are	O
suitable	O
for	O
use	O
in	O
selectively	O
inducing	O
terminal	O
differentiation,	O
and	O
arresting	O
cell	O
growth	O
and	O
/	O
or	O
apoptosis	O
of	O
neoplastic	O
cells,	O
thereby	O
inhibiting	O
proliferation	O
of	O
such	O
cells	O
.	O
Thus,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
treating	O
a	O
patient	O
having	O
a	O
tumor	O
characterized	O
by	O
proliferation	O
of	O
neoplastic	O
cells	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
TRX-mediated	O
diseases,	O
such	O
as	O
autoimmune,	O
allergic	O
and	O
inflammatory	O
diseases,	O
and	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
such	O
as	O
neurodegenerative	O
diseases	O
.	O
The	O
present	O
invention	O
further	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
hydroxamic	O
acid	O
derivatives	O
and	O
safe	O
dosing	O
regimens	O
of	O
these	O
pharmaceutical	O
compositions,	O
which	O
are	O
easy	O
to	O
follow,	O
and	O
which	O
result	O
in	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
hydroxamic	O
acid	O
derivatives	O
in	O
vivo	O
.	O


A	O
therapeutic	O
composition	O
for	O
treating	O
a	O
proliferative	O
disorder	O
includes	O
a	O
VEGF	B-GENE
antagonist	O
and	O
β-glucan	O
.	O
VEGF	B-GENE
is	O
overexpressed	O
in	O
some	O
tumor	O
types	O
.	O
The	O
efficacy	O
of	O
treatment	O
with	O
VEGF	B-GENE
antagonists	O
capable	O
of	O
activating	O
complement	O
in	O
combination	O
with	O
β-glucan	O
is	O
significantly	O
increased	O
.	O


An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
agent	O
effective	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
motor	O
neuron	O
disease	O
such	O
as	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
.	O
The	O
present	O
invention	O
provides	O
a	O
therapeutic	O
and	O
/	O
or	O
preventive	O
agent	O
for	O
motor	O
neuron	O
disease	O
comprising	O
the	O
following	O
oligopeptide	O
shown	O
in	O
any	O
of	O
(	O
a	O
)	O
to	O
(	O
c	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
:	O
(	O
a	O
)	O
an	O
oligopeptide	O
consisting	O
of	O
the	O
amino	O
acid	O
sequence	O
represented	O
by	O
Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala	O
(	O
SEQ	O
ID	O
NO	O
:	O
1	O
)	O
;	O
(	O
b	O
)	O
an	O
oligopeptide	O
consisting	O
of	O
an	O
amino	O
acid	O
sequence	O
having	O
a	O
deletion,	O
substitution,	O
insertion,	O
or	O
addition	O
of	O
one	O
or	O
several	O
amino	O
acids	O
in	O
Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala	O
(	O
SEQ	O
ID	O
NO	O
:	O
1	O
)	O
,	O
and	O
having	O
an	O
activity	O
that	O
inhibits	O
neuronal	O
cell	O
death	O
caused	O
by	O
a	O
mutant	B-GENE
superoxide	I-GENE
dismutase-1	I-GENE
gene	I-GENE
;	O
and	O
(	O
c	O
)	O
a	O
modified	O
oligopeptide	O
from	O
the	O
oligopeptide	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
pteridine	O
derivatives	O
as	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
activators	O
.	O
In	O
particular,	O
the	O
derivatives	O
find	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
endothelial	O
dysfunction	O
such	O
as	O
cardiovascular	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
tumors	O
using	O
vectors	O
that	O
preferentially	O
target	O
tumor	O
cells	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
alphavirus-based,	O
preferably	O
Sindbis	O
virus-based,	O
vectors	O
and	O
to	O
non-alphavirus-based	O
vectors,	O
which	O
have	O
a	O
preferential	O
affinity	O
for	O
high	B-GENE
affinity	I-GENE
laminin	I-GENE
receptors	I-GENE
(	O
HALR	B-GENE
)	O
.	O
These	O
vectors	O
are	O
efficiently	O
targeted	O
to	O
tumors	O
and	O
have	O
the	O
ability	O
to	O
cause	O
tumor	O
necrosis	O
.	O


The	O
present	O
application	O
discloses	O
treatment	O
of	O
prostate	O
cancer	O
with	O
anti-ErbB2	O
antibodies	O
.	O


The	O
present	O
invention	O
provides	O
to	O
at	O
least	O
one	O
novel	O
human	B-GENE
GLP-1	B-GENE
receptor	I-GENE
agonist,	O
or	O
specified	O
portion	O
or	O
variant,	O
including	O
isolated	O
nucleic	O
acids	O
that	O
encode	O
at	O
least	O
one	O
GLP-1	B-GENE
receptor	I-GENE
agonist,	O
or	O
specified	O
portion	O
or	O
variant,	O
GLP-1	B-GENE
receptor	I-GENE
agonist,	O
or	O
specified	O
portion	O
or	O
variants,	O
vectors,	O
host	O
cells,	O
transgenic	O
animals	O
or	O
plants,	O
and	O
methods	O
of	O
making	O
and	O
using	O
thereof,	O
including	O
the	O
use	O
of	O
long	O
acting	O
GLP-1	B-GENE
receptor	I-GENE
agonists	O
to	O
improve	O
insulin	B-GENE
sensitivity	O
or	O
lipid	O
profiles	O
in	O
obesity	O
and	O
related	O
therapeutic	O
and	O
/	O
or	O
diagnostic	O
compositions,	O
methods	O
and	O
devices	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
p38	B-GENE
MAP	I-GENE
kinase,	O
and	O
are	O
therefore	O
of	O
utility	O
in	O
the	O
treatment	O
of,	O
inter	O
alia,	O
inflammatory	O
conditions	O
including	O
rheumatoid	O
arthritis	O
and	O
COPD	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
:	O
G	O
is	O
—N═	O
or	O
—CH═	O
;	O
D	O
is	O
an	O
optionally	O
substituted	O
divalent	O
mono-	O
or	O
bi-cyclic	O
aryl	O
or	O
heteroaryl	O
radical	O
having	O
5-13	O
ring	O
members	O
;	O
R6	O
is	O
hydrogen	O
or	O
optionally	O
substituted	O
C1-C3	O
alkyl	O
;	O
P	O
represents	O
hydrogen	O
and	O
U	O
represents	O
a	O
radical	O
of	O
formula	O
(	O
IA	O
)	O
;	O
or	O
U	O
represents	O
hydrogen	O
and	O
P	O
represents	O
a	O
radical	O
of	O
formula	O
-A-	O
(	O
CH2	O
)	O
,	O
—X1-L1-Y—NH—CHR1R2	O
wherein	O
A	O
represents	O
an	O
optionally	O
substituted	O
divalent	O
mono-	O
or	O
bicyclic	O
carbocyclic	O
or	O
heterocyclic	O
radical	O
having	O
5-13	O
ring	O
members	O
;	O
z,	O
Y,	O
L1,	O
and	O
X1	O
are	O
as	O
defined	O
in	O
the	O
specification	O
;	O
R1	O
is	O
a	O
carboxylic	O
acid	O
group	O
(	O
—COOH	O
)	O
,	O
or	O
an	O
ester	O
group	O
which	O
is	O
hydrolysable	O
by	O
one	O
or	O
more	O
intracellular	O
esterase	B-GENE
enzymes	O
to	O
a	O
carboxylic	O
acid	O
group	O
;	O
and	O
R2	O
is	O
the	O
side	O
chain	O
of	O
a	O
natural	O
or	O
non-natural	O
alpha	O
amino	O
acid	O
.	O


The	O
invention	O
provides	O
a	O
compound	O
for	O
use	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
disease	O
state	O
or	O
condition	O
mediated	O
by	O
protein	B-GENE
kinase	I-GENE
B,	O
the	O
compound	O
having	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
salts,	O
solvates,	O
tautomers	O
or	O
N-oxides	O
thereof,	O
wherein	O
T	O
is	O
N	O
or	O
CR5	O
;	O
J1-J2	O
is	O
N═C	O
(	O
R6	O
)	O
,	O
(	O
R7	O
)	O
C═N,	O
(	O
R8	O
)	O
N—C	O
(	O
O	O
)	O
,	O
(	O
R8	O
)	O
2C—C	O
(	O
O	O
)	O
,	O
N═N	O
or	O
(	O
R7	O
)	O
C═C	O
(	O
R6	O
)	O
;	O
A	O
is	O
an	O
optionally	O
substituted	O
saturated	O
C1-7	O
hydrocarbon	O
linker	O
group	O
having	O
a	O
maximum	O
chain	O
length	O
of	O
5	O
atoms	O
extending	O
between	O
R1	O
and	O
NR2R3	O
and	O
a	O
maximum	O
chain	O
length	O
of	O
4	O
atoms	O
extending	O
between	O
E	O
and	O
NR2R3,	O
one	O
of	O
the	O
carbon	O
atoms	O
in	O
the	O
linker	O
group	O
being	O
optionally	O
replaced	O
by	O
oxygen	O
or	O
nitrogen	O
;	O
E	O
is	O
a	O
monocyclic	O
or	O
bicyclic	O
carbocyclic	O
or	O
heterocyclic	O
group	O
or	O
an	O
acyclic	O
group	O
X-G	O
wherein	O
X	O
is	O
CH2,	O
O,	O
S	O
or	O
NH	O
and	O
G	O
is	O
a	O
C1-4	O
alkylene	O
chain	O
wherein	O
one	O
of	O
the	O
carbon	O
atoms	O
is	O
optionally	O
replaced	O
by	O
O,	O
S	O
or	O
NH	O
;	O
R1	O
is	O
hydrogen	O
or	O
an	O
aryl	O
or	O
heteroaryl	O
group	O
;	O
R2	O
and	O
R3	O
are	O
each	O
hydrogen,	O
optionally	O
substituted	O
C1-4	O
hydrocarbyl	O
or	O
optionally	O
substituted	O
C1-4	O
acyl	O
;	O
or	O
NR2R3	O
forms	O
an	O
imidazole	O
group	O
or	O
a	O
saturated	O
monocyclic	O
heterocyclic	O
group	O
having	O
4-7	O
ring	O
members	O
;	O
or	O
NR2R3	O
and	O
A	O
together	O
form	O
a	O
saturated	O
monocyclic	O
heterocyclic	O
group	O
having	O
4-7	O
ring	O
members	O
which	O
is	O
optionally	O
substituted	O
by	O
C1-4alkyl	O
;	O
or	O
NR2R3	O
and	O
the	O
adjacent	O
carbon	O
atom	O
of	O
linker	O
group	O
A	O
together	O
form	O
a	O
cyano	O
group	O
;	O
or	O
R1,	O
A	O
and	O
NR2R3	O
together	O
form	O
a	O
cyano	O
group	O
;	O
and	O
R4,	O
R5,	O
R6,	O
R7	O
and	O
R8	O
are	O
each	O
independently	O
selected	O
from	O
hydrogen	O
and	O
various	O
substituents	O
as	O
defined	O
in	O
the	O
claims	O
.	O


This	O
invention	O
relates	O
to	O
potent	O
selective	O
agonists	O
of	O
the	O
EP4	B-GENE
subtype	O
of	O
prostaglandin	O
E2	O
receptors,	O
their	O
use	O
or	O
a	O
formulation	O
thereof	O
in	O
the	O
treatment	O
of	O
glaucoma	O
and	O
other	O
conditions,	O
which	O
are	O
related	O
to	O
elevated	O
intraocular	O
pressure	O
in	O
the	O
eye	O
of	O
a	O
patient	O
.	O
This	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
the	O
compounds	O
of	O
this	O
invention	O
for	O
mediating	O
the	O
bone	O
modeling	O
and	O
remodeling	O
processes	O
of	O
the	O
osteoblasts	O
and	O
osteoclasts	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
having	O
the	O
general	O
Formula	O
(	O
I	O
)	O
with	O
the	O
definitions	O
of	O
R1,	O
R2,	O
R3,	O
and	O
R4	O
given	O
below,	O
and	O
/	O
or	O
a	O
salt	O
or	O
ester	O
thereof	O
.	O
	O
	O
	O
	O
Furthermore	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
said	O
compounds	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
their	O
use	O
for	O
the	O
modulation	O
of	O
γ-secretase	B-GENE
activity	O
.	O


Embodiments	O
include	O
compositions	O
and	O
methods	O
for	O
lower	O
the	O
surface	O
tension	O
of	O
a	O
liquid-air	O
interface	O
by	O
contacting	O
such	O
interface	O
with	O
all	O
or	O
part	O
of	O
a	O
PLUNC	B-GENE
polypeptide	O
.	O


are	O
useful	O
as	O
inhibitors	O
of	O
HIF	B-GENE
prolyl	I-GENE
hydroxylases	I-GENE
where	O
the	O
definitions	O
of	O
the	O
variables	O
are	O
provided	O
herein	O
.	O


Pharmacogenetics	O
was	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
polymorphisms	O
in	O
select	O
candidate	O
genes	O
on	O
the	O
response	O
of	O
patients	O
with	O
chronic	O
constipation	O
to	O
tegaserod	O
(	O
Zelmac®	O
/	O
Zelnorm®	O
)	O
.	O
The	O
analysis	O
identified	O
twelve	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
six	O
genes	O
(	O
HTR4,	O
HTR3B,	O
MLN,	O
AQP3,	O
SLC12A2,	O
SCNN1A	B-GENE
)	O
that	O
were	O
associated	O
with	O
at	O
least	O
a	O
60	O
%	O
response	O
rate	O
to	O
tegaserod	O
and	O
an	O
odds	O
ratios	O
of	O
5	O
or	O
greater	O
(	O
compared	O
to	O
placebo	O
)	O
after	O
4	O
weeks	O
of	O
treatment	O
.	O
The	O
identified	O
genes	O
display	O
a	O
wide	O
range	O
of	O
different	O
functions,	O
including	O
serotonin	O
signaling,	O
secretion	O
and	O
motility,	O
all	O
of	O
which	O
are	O
important	O
in	O
maintaining	O
the	O
normal	O
function	O
of	O
the	O
gastrointestinal	O
tract	O
.	O
Thus,	O
these	O
data	O
imply	O
that	O
chronic	O
constipation	O
may	O
result	O
from	O
a	O
variety	O
of	O
pathophysiological	O
mechanisms	O
related	O
to	O
variants	O
in	O
the	O
above	O
identified	O
genes,	O
all	O
of	O
which	O
respond	O
well	O
to	O
treatment	O
with	O
tegaserod	O
.	O
Patients	O
without	O
these	O
variants	O
do	O
not	O
respond	O
to	O
treatment	O
significantly	O
more	O
than	O
they	O
do	O
to	O
placebo,	O
which	O
could	O
indicate	O
that	O
their	O
chronic	O
constipation	O
is	O
not	O
due	O
to	O
pathophysiological	O
mechanisms	O
but	O
rather	O
to	O
environmental	O
or	O
possibly	O
psychological	O
factors	O
.	O
Patients	O
with	O
these	O
variants	O
are	O
also	O
less	O
likely	O
to	O
respond	O
to	O
placebo,	O
again	O
implying	O
that	O
these	O
variants	O
are	O
associated	O
with	O
a	O
true	O
pathophysiology	O
.	O


Various	O
compounds	O
comprising	O
a	O
thiazolidine	O
ring	O
are	O
described	O
as	O
well	O
as	O
the	O
use	O
of	O
such	O
compounds	O
to	O
inhibit	O
at	O
least	O
one	O
BCL-2	B-GENE
protein	O
family	O
member	O
.	O
One	O
of	O
the	O
compounds	O
described	O
has	O
the	O
structure	O
the	O
structure	O
A,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
each	O
of	O
R1,	O
and	O
R2	O
comprises	O
hydrogen,	O
a	O
substituted	O
or	O
unsubstituted	O
straight-chained	O
aliphatic	O
group,	O
a	O
halogen,	O
an	O
alkoxyl,	O
a	O
halogen-substituted	O
alkyl,	O
a	O
halogen-substituted	O
alkoxyl,	O
hydroxyl,	O
carboxyl,	O
cyano	O
group,	O
an	O
amido	O
group,	O
a	O
substituted	O
or	O
unsubstituted	O
cycloaliphatic	O
group,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
group,	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
heterocyclic	O
group	O
;	O
X	O
comprises	O
oxygen,	O
sulfur,	O
or	O
imino	O
group	O
;	O
and	O
Z	O
comprises	O
a	O
moiety	O
such	O
as	O
naphthaline	O
or	O
dehydronaphthaline,	O
among	O
others	O
.	O


The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
protecting	O
the	O
liver	O
and	O
/	O
or	O
promoting	O
liver	O
regeneration,	O
which	O
contains	O
a	O
heparin-binding	B-GENE
EGF-like	I-GENE
growth	I-GENE
factor-like	I-GENE
growth	I-GENE
factor	I-GENE
(	O
HB-EGF	B-GENE
)	O
or	O
a	O
partial	O
peptide	O
thereof,	O
or	O
a	O
nucleic	O
acid	O
that	O
encodes	O
same,	O
and	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
liver	O
diseases	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
for	O
producing	O
a	O
cell	O
for	O
liver	O
protection	O
and	O
/	O
or	O
promoting	O
liver	O
regeneration,	O
and	O
for	O
the	O
prophylaxis	O
/	O
treatment	O
of	O
a	O
liver	O
disease,	O
which	O
includes	O
introducing	O
a	O
nucleic	O
acid	O
that	O
encodes	O
HB-EGF	B-GENE
or	O
a	O
partial	O
peptide	O
thereof	O
into	O
a	O
cell	O
collected	O
from	O
an	O
animal	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
where	O
R1-R3	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description,	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
in	O
which	O
pi3	B-GENE
kinase	I-GENE
is	O
implicated	O
.	O


The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
a	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof,	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
various	O
ACC-related	O
disorders	O
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
provides	O
tetracyclic	O
compounds	O
of	O
formula	O
I	O
or	O
formula	O
II	O
(	O
wherein	O
the	O
various	O
moieties	O
are	O
as	O
defined	O
herein	O
)	O
useful	O
as	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
(	O
mGluR	B-GENE
)	O
antagonists,	O
particularly	O
as	O
selective	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
1	I-GENE
antagonists,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
and	O
compositions	O
to	O
treat	O
diseases	O
associated	O
with	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
mGluR1	B-GENE
)	O
such	O
as,	O
for	O
example,	O
pain,	O
migraine,	O
anxiety,	O
urinary	O
incontinence	O
and	O
neurodegenerative	O
diseases	O
such	O
Alzheimer	O
'	O
s	O
disease	O
.	O


This	O
invention	O
relates	O
to	O
methods	O
and	O
formulations	O
for	O
treating	O
metabolic	O
disorders	O
and	O
depression	O
.	O
In	O
some	O
embodiments,	O
the	O
methods	O
comprise	O
administering	O
a	O
dopamine	B-GENE
receptor	I-GENE
agonist	O
and	O
an	O
anti-depressant	O
.	O


A	O
method	O
of	O
treating	O
a	O
patient	O
in	O
need	O
of	O
therapy	O
for	O
a	O
cytokine	B-GENE
dysregulation	O
comprising	O
administering	O
to	O
that	O
patient	O
a	O
therapeutically	O
effective	O
dose	O
of	O
a	O
compound	O
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
together	O
form	O
a	O
group	O
—	O
(	O
CH2	O
)	O
n—CR4R5—	O
(	O
CH2	O
)	O
m—	O
wherein	O
n	O
and	O
m	O
are	O
independently	O
selected	O
integers	O
0,	O
1	O
or	O
2	O
and	O
R4	O
and	O
R5	O
are	O
independently	O
selected	O
from	O
H,	O
C1-18	O
alkyl,	O
C1-18	O
alkoxy,	O
C1-18n	O
hydroxyalkyl,	O
C2-18	O
alkenyl	O
and	O
C6-18	O
aryl	O
or	O
aralyalkyl	O
and	O
R3	O
is	O
the	O
fatty	O
acyl	O
group	O
of	O
an	O
essential	O
polyunsaturated	O
fatty	O
acid	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
compounds	O
that	O
are	O
3-benzazepine	O
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
More	O
specifically,	O
this	O
invention	O
relates	O
to	O
novel	O
3-benzazepine	O
derivatives	O
that	O
are	O
derivatives	O
of	O
lorcaserin	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
this	O
invention	O
and	O
a	O
carrier	O
and	O
the	O
use	O
of	O
the	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
5-HT2C	B-GENE
agonist,	O
such	O
as	O
lorcaserin	O
.	O


The	O
invention	O
provides	O
compounds	O
which	O
are	O
pyrimidines	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
—XR3	O
is	O
bonded	O
at	O
ring	O
position	O
2	O
and	O
—YR4	O
is	O
bonded	O
at	O
ring	O
position	O
5	O
or	O
6	O
;	O
R1	O
and	O
R2	O
form,	O
together	O
with	O
the	O
N	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
a	O
morphorine	O
ring	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
X	O
is	O
a	O
direct	O
bond	O
;	O
R3	O
is	O
selected	O
from	O
(	O
i	O
)	O
a	O
group	O
of	O
the	O
following	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
B	O
is	O
a	O
phenyl	O
ring	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
and	O
Z	O
is	O
selected	O
from	O
—OR,	O
CH2OR	O
and	O
—NRS	O
(	O
O	O
)	O
mR,	O
wherein	O
each	O
R	O
is	O
independently	O
selected	O
from	O
H,	O
C1-C6	O
alkyl,	O
C3-C10	O
cycloalkyl	O
and	O
a	O
5-	O
to	O
12-membered	O
aryl	O
or	O
heteroaryl	O
group,	O
the	O
group	O
being	O
unsubstituted	O
or	O
substituted,	O
and	O
m	O
is	O
2	O
;	O
and	O
(	O
ii	O
)	O
an	O
indazole	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
and	O
Y	O
is	O
selected	O
from	O
—O—	O
(	O
CH2	O
)	O
n—,	O
—NH—	O
(	O
CH2	O
)	O
n,	O
—NHC	O
(	O
O	O
)	O
—	O
(	O
CH2	O
)	O
n—	O
and	O
—C	O
(	O
O	O
)	O
NH—	O
(	O
CH2	O
)	O
n—	O
wherein	O
n	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
3,	O
and	O
R4	O
is	O
selected	O
from	O
an	O
unsaturated	O
5-	O
to	O
12-membered	O
carbocyclic	O
or	O
heterocyclic	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
and	O
a	O
group	O
—NR5R6	O
wherein	O
R5	O
and	O
R6,	O
which	O
are	O
the	O
same	O
or	O
different,	O
are	O
each	O
independently	O
selected	O
from	O
H,	O
C1-C6	O
alkyl	O
which	O
is	O
unsubstituted	O
or	O
substituted,	O
C3-C10	O
cycloalkyl	O
which	O
is	O
unsubstituted	O
or	O
substituted,	O
—C	O
(	O
O	O
)	O
R,	O
—C	O
(	O
O	O
)	O
N	O
(	O
R	O
)	O
2	O
and	O
—S	O
(	O
O	O
)	O
mR	O
wherein	O
R	O
and	O
m	O
are	O
as	O
defined	O
above,	O
or	O
R5	O
and	O
R6	O
together	O
form,	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached,	O
a	O
saturated	O
5-,	O
6-	O
or	O
7-membered	O
N-containing	O
heterocyclic	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
PI3K	B-GENE
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B-GENE
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


A	O
pigment	B-GENE
epithelium	I-GENE
derived	I-GENE
factor	I-GENE
(	O
“PEDF”	O
)	O
receptor	O
designated	O
PEDF-R	B-GENE
and	O
PEDF-R	B-GENE
encoding	O
nucleic	O
acid	O
and	O
amino	O
acid	O
sequences	O
.	O
Wild	O
type	O
PEDF-R,	O
PEDF-R	B-GENE
variants,	O
soluble	O
PEDF-R	B-GENE
variants,	O
chimeric	O
PEDF-R,	O
and	O
antibodies	O
which	O
bind	O
to	O
the	O
PEDF-R	B-GENE
(	O
including	O
agonist	O
and	O
neutralizing	O
antibodies	O
)	O
,	O
as	O
well	O
as	O
various	O
uses	O
for	O
these	O
molecules	O
are	O
described	O
.	O
Assay	O
systems	O
for	O
detecting	O
ligands	O
to	O
PEDF-R,	O
systems	O
for	O
studying	O
the	O
physiological	O
role	O
of	O
PEDF-R	B-GENE
and	O
its	O
ligands,	O
diagnostic	O
techniques	O
for	O
identifying	O
PEDF-related	O
conditions,	O
therapeutic	O
techniques	O
for	O
the	O
treatment	O
of	O
PEDF-related	O
and	O
PEDF-R	B-GENE
related	O
conditions,	O
and	O
methods	O
for	O
identifying	O
molecules	O
homologous	O
to	O
PEDF-R	B-GENE
.	O


The	O
present	O
application	O
relates	O
to	O
inhibitors	O
of	O
ribonucleotide	B-GENE
reductase	I-GENE
subunit	I-GENE
2	I-GENE
(	O
R2	B-GENE
)	O
,	O
and	O
methods	O
and	O
compositions	O
related	O
to	O
the	O
R2	B-GENE
inhibitors	O
.	O
In	O
certain	O
embodiments,	O
the	O
R2	B-GENE
inhibitors	O
include	O
nucleic	O
acids,	O
such	O
as	O
for	O
example	O
siRNAs	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
c-kit	B-GENE
inhibitor,	O
especially	O
a	O
c-kit	B-GENE
inhibitor	O
of	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
radicals	O
and	O
symbols	O
have	O
the	O
meanings	O
as	O
defined	O
in	O
the	O
specification,	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
myeloma,	O
in	O
particular	O
multiple	O
myeloma,	O
especially	O
myeloma	O
which	O
is	O
resistant	O
to	O
conventional	O
chemotherapy	O
;	O
to	O
a	O
combination	O
comprising	O
a	O
c-kit	B-GENE
inhibitor	O
and	O
a	O
compound	O
effecting	O
apoptosis	O
of	O
myeloma	O
cells,	O
preferably	O
dexamethasone,	O
for	O
simultaneous,	O
separate	O
or	O
sequential	O
use	O
;	O
to	O
methods	O
of	O
treating	O
myeloma	O
;	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
combination	O
.	O


The	O
present	O
invention	O
relates	O
to	O
polymorphic	O
forms	O
of	O
(	O
3R,4R,5S	O
)	O
-5-amino-4-acetylamino-3-	O
(	O
1-ethyl-propoxy	O
)	O
-cyclohex-1-ene-carboxylic	O
acid	O
ethyl	O
ester	O
phosphate,	O
which	O
is	O
a	O
potent	O
inhibitor	O
of	O
viral	B-GENE
neuraminidase	I-GENE
.	O


The	O
present	O
invention	O
features	O
compositions	O
(	O
e	O
.	O
g	O
.	O
,	O
nucleic	O
acids	O
encoding	O
fat-1,	O
optionally	O
and	O
operably	O
linked	O
to	O
a	O
constitutively	O
active	O
or	O
tissue-specific	O
promoter	O
or	O
other	O
regulatory	O
sequence	O
)	O
and	O
pharmaceutically	O
acceptable	O
formulations	O
including	O
nucleic	O
acids	O
encoding	O
fat-1	B-GENE
or	O
biologically	O
active	O
variants	O
thereof	O
and	O
methods	O
that	O
can	O
be	O
used	O
to	O
effectively	O
modify	O
the	O
content	O
of	O
PUFAs	O
in	O
animal	O
cells	O
(	O
i	O
.	O
e	O
.	O
,	O
cells	O
other	O
than	O
those	O
of	O
C	O
.	O
elegans,	O
for	O
example,	O
mammalian	O
cells	O
such	O
as	O
myocytes,	O
neurons	O
(	O
whether	O
of	O
the	O
peripheral	O
or	O
central	O
nervous	O
system	O
)	O
,	O
adipocytes,	O
endothelial	O
cells,	O
and	O
cancer	O
cells	O
)	O
.	O
The	O
modified	O
cells,	O
whether	O
in	O
vivo	O
or	O
ex	O
vivo	O
(	O
e	O
.	O
g	O
.	O
,	O
in	O
tissue	O
culture	O
)	O
,	O
transgenic	O
animals	O
containing	O
them,	O
and	O
food	O
products	O
obtained	O
from	O
those	O
animals	O
(	O
e	O
.	O
g	O
.	O
,	O
meat	O
or	O
other	O
edible	O
parts	O
of	O
the	O
animals	O
(	O
e	O
.	O
g	O
.	O
,	O
liver,	O
kidney,	O
or	O
sweetbreads	O
)	O
)	O
are	O
also	O
within	O
the	O
scope	O
of	O
the	O
present	O
invention	O
.	O


A	O
method	O
for	O
keratin	B-GENE
hyperproliferation	O
disorders	O
such	O
as	O
corns,	O
calluses,	O
or	O
keratosis	O
pilaris	O
(	O
KP	O
)	O
by	O
administering	O
to	O
a	O
subject	O
experiencing	O
the	O
disorder	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
RNA	O
sequence	O
which	O
inhibits	O
expression	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
keratin	B-GENE
selected	O
from	O
the	O
group	O
consisting	O
of	O
K6a,	O
K6b,	O
K16,	O
K17,	O
and	O
combinations	O
thereof	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
use	O
in	O
therapy,	O
particularly	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
mediated	O
by	O
CB1	B-GENE
receptors,	O
such	O
as	O
obesity,	O
wherein	O
:	O
R1	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
R2	O
is	O
alkyl,	O
aryl	O
or	O
heteroaryl	O
;	O
R3	O
is	O
alkyl,	O
aryl,	O
heteroaryl,	O
NR9R10,	O
OR15,	O
or	O
NR16C	O
(	O
O	O
)	O
R17	O
;	O
Y	O
is	O
C═O,	O
C═S,	O
SO2,	O
or	O
(	O
CR7R8	O
)	O
p	O
;	O
m	O
=	O
1	O
or	O
2	O
;	O
n	O
=	O
1	O
or	O
2	O
;	O
and	O
p	O
=	O
1,	O
2,	O
3	O
or	O
4,	O
R7	O
to	O
R17	O
being	O
as	O
defined	O
in	O
the	O
specification	O
;	O
wherein	O
if	O
—Y—R3	O
is	O
C	O
(	O
O	O
)	O
NH	O
(	O
alkyl	O
)	O
then	O
:	O
R1	O
and	O
/	O
or	O
R2	O
is	O
selected	O
from	O
heteroaryl	O
;	O
and	O
/	O
or	O
m	O
and	O
/	O
or	O
n	O
is	O
2	O
;	O
and	O
/	O
or	O
R11	O
and	O
/	O
or	O
R12	O
is	O
lower	O
alkyl,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O


The	O
present	O
invention	O
refers	O
to	O
isoxazole	O
derivatives,	O
in	O
particular	O
diarylisoxazole	O
derivatives	O
inhibitors	O
of	O
cyclooxygenase	B-GENE
(	O
COX	B-GENE
)	O
,	O
in	O
particular	O
cyclooxygenase-1	B-GENE
(	O
COX-1	B-GENE
)	O
,	O
to	O
their	O
pharmaceutical	O
compositions,	O
the	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
for	O
the	O
chemoprevention	O
and	O
treatment	O
of	O
inflammatory	O
syndromes	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
carcinomas,	O
in	O
particular	O
intestinal,	O
ovarian	O
and	O
cutaneous	O
carcinomas,	O
in	O
the	O
treatment	O
of	O
pain	O
syndromes,	O
in	O
particular	O
after	O
surgery,	O
and	O
in	O
the	O
cardiovascular	O
field	O
as	O
antithrombotics	O
/	O
vasoprotectives	O
/	O
cardioprotectives	O
.	O


Provided	O
herein	O
are	O
isolated	O
compounds	O
of	O
formula	O
1	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
processes	O
for	O
their	O
preparation	O
and	O
isolation,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
comprise	O
these	O
therapeutic	O
agents,	O
and	O
methods	O
of	O
use	O
therefore	O
the	O
treatment	O
and	O
/	O
or	O
control	O
of	O
conditions	O
associated	O
with	O
or	O
mediated	O
by	O
effects	O
of	O
histone	B-GENE
deacetylase	I-GENE
.	O


The	O
present	O
invention	O
provides	O
N-substituted-heterocycloalkyloxybenzamide	O
compounds,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
.	O
One	O
embodiment	O
of	O
the	O
invention	O
is	O
a	O
compound	O
having	O
the	O
structure	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R4,	O
T,	O
n,	O
w	O
and	O
x	O
are	O
as	O
described	O
herein	O
.	O
In	O
certain	O
embodiments	O
of	O
the	O
invention,	O
a	O
compound	O
of	O
the	O
present	O
invention	O
activates	O
the	O
AMPK	B-GENE
pathway,	O
and	O
can	O
be	O
used	O
to	O
treat	O
metabolism-related	O
disorders	O
and	O
conditions	O
.	O


The	O
invention	O
described	O
herein	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders,	O
for	O
example	O
cancers,	O
involving	O
cells	O
that	O
harbor	O
complex	O
karyotypes	O
.	O
The	O
present	O
invention	O
also	O
related	O
to	O
mutant	O
BCR-ABL	O
kinase	O
proteins,	O
and	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders,	O
for	O
example	O
cancers,	O
involving	O
cells	O
that	O
express	O
such	O
mutant	O
BCR-ABL	O
kinase	O
proteins	O
.	O


The	O
present	O
invention	O
discloses	O
(	O
1S,5S	O
)	O
-3-	O
(	O
5,6-dichloro-3-pyridinyl	O
)	O
-3,6-diazabicyclo	O
[	O
3	O
.	O
2	O
.	O
0	O
]	O
heptane,	O
salts	O
thereof,	O
and	O
its	O
use	O
to	O
treat	O
pain	O
and	O
other	O
disorders	O
associated	O
with	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
.	O


The	O
identification	O
of	O
novel	O
Syndecan-2	B-GENE
splice	O
variants	O
and	O
their	O
use	O
in	O
the	O
diagnosis	O
and	O
therapeutic	O
intervention	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
other	O
amyloid	O
diseases	O
.	O
In	O
addition	O
the	O
use	O
of	O
new	O
animal	O
models	O
expressing	O
or	O
devoid	O
of	O
syndecan-2	B-GENE
splice	O
variants	O
to	O
effectively	O
screen	O
and	O
identify	O
potential	O
therapeutic	O
compounds	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
invention	O
provides	O
preparations,	O
formulations,	O
kits	O
and	O
other	O
products	O
of	O
manufacture	O
(	O
e	O
.	O
g	O
.	O
,	O
blister	O
packs	O
)	O
comprising	O
combinations	O
of	O
beneficial	O
ingredients	O
that	O
are	O
serviceable	O
as	O
therapies	O
for	O
improving	O
states	O
and	O
disease	O
symptoms	O
such	O
as	O
involving	O
inflammation,	O
excessive	O
sympathoneural	O
drive,	O
cachexia,	O
anorexia,	O
and	O
anorexia-cachexia,	O
as	O
well	O
as	O
stress	O
or	O
anxiety	O
related	O
thereto,	O
and	O
methods	O
of	O
making	O
and	O
using	O
them	O
.	O
The	O
invention	O
provides	O
compositions	O
and	O
therapies	O
comprising	O
use	O
of	O
a	O
beta	O
adrenergic	O
antagonist	O
(	O
also	O
called	O
“beta	O
blockers”,	O
e	O
.	O
g	O
.	O
,	O
propranolol	O
)	O
in	O
combination	O
with	O
an	O
anti-inflammatory	O
agent,	O
e	O
.	O
g	O
.	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
,	O
an	O
angiotensin-converting	B-GENE
enzyme	I-GENE
(	O
ACE	B-GENE
)	O
inhibitor,	O
an	O
angiotensin	B-GENE
receptor	I-GENE
blocker	O
(	O
ARB	O
)	O
,	O
an	O
anabolic	O
steroid,	O
a	O
natural	O
oil	O
or	O
fatty	O
acid	O
or	O
any	O
combination	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
modulating	O
Toll-like	B-GENE
receptors	I-GENE
(	O
TLRs	B-GENE
)	O
for	O
enhancing	O
survival	O
of	O
activated	O
CD4+	O
T	O
cells	O
.	O
The	O
enhanced	O
survival	O
of	O
activated	O
CD4+	O
T	O
cells	O
provides	O
a	O
means	O
for	O
regulating	O
an	O
immune	O
response	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
for	O
treatment	O
of	O
cognitive	O
deficits	O
.	O
Such	O
compositions	O
can	O
have	O
a	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
ligand,	O
of	O
either	O
α4β2	B-GENE
subtype	I-GENE
or	O
α7	B-GENE
nicotinic	B-GENE
acetylcholine	I-GENE
subtype,	O
and	O
a	O
histamine-3	B-GENE
receptor	I-GENE
ligand,	O
a	O
method	O
of	O
using	O
the	O
same,	O
and	O
a	O
related	O
article	O
of	O
manufacture	O
.	O
Combinations	O
of	O
such	O
active	O
agents	O
with	O
psychostimulants	O
or	O
monoamine	O
reuptake	O
inhibitors	O
also	O
is	O
contemplated	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
disubstituted	O
aniline	O
compounds	O
.	O
These	O
compounds	O
can	O
inhibit	O
hi-stone	B-GENE
deacetylase	I-GENE
and	O
are	O
suitable	O
for	O
use	O
in	O
selectively	O
inducing	O
terminal	O
differentiation,	O
and	O
arresting	O
cell	O
growth	O
and	O
/	O
or	O
apoptosis	O
of	O
neoplastic	O
cells,	O
thereby	O
inhibiting	O
proliferation	O
of	O
such	O
cells	O
.	O
Thus,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
treating	O
a	O
patient	O
having	O
a	O
tumor	O
characterized	O
by	O
proliferation	O
of	O
neoplastic	O
cells	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
may	O
also	O
be	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
TRX-mediated	O
diseases,	O
such	O
as	O
autoimmune,	O
allergic	O
and	O
inflammatory	O
diseases,	O
and	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
such	O
as	O
neurodegenerative	O
diseases	O
.	O
The	O
present	O
invention	O
further	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
instant	O
invention	O
and	O
safe	O
dosing	O
regimens	O
of	O
these	O
pharmaceutical	O
compositions,	O
which	O
are	O
easy	O
to	O
follow,	O
and	O
which	O
result	O
in	O
a	O
therapeutically	O
effective	O
amount	O
of	O
these	O
compounds	O
in	O
vivo	O
.	O


Provided	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
prevention	O
and	O
treatment	O
of	O
drug	O
or	O
alcohol	O
addiction	O
or	O
bipolar	O
disorder,	O
comprising	O
sodium	O
phenylbutyrate	O
(	O
PBA	O
)	O
.	O
The	O
pharmaceutical	O
composition	O
for	O
prevention	O
and	O
treatment	O
of	O
drug	O
or	O
alcohol	O
addiction	O
or	O
bipolar	O
disorder	O
in	O
accordance	O
with	O
the	O
present	O
invention	O
provides	O
effects	O
capable	O
of	O
inhibiting	O
increases	O
in	O
locomotor	O
activity	O
which	O
is	O
a	O
behavioral	O
indicator	O
of	O
drug	O
or	O
alcohol	O
addiction	O
or	O
bipolar	O
disorder,	O
by	O
controlling	O
a	O
level	O
of	O
a	O
neurotransmitter	O
via	O
regulation	O
of	O
expression	O
of	O
a	O
neurotransmitter	B-GENE
transporter	I-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
having	O
antithrombotic	O
activity	O
which	O
especially	O
inhibits	O
blood	B-GENE
clotting	I-GENE
factor	I-GENE
IXa,	O
to	O
methods	O
for	O
producing	O
the	O
same	O
and	O
to	O
the	O
use	O
thereof	O
as	O
drugs	O
.	O


The	O
present	O
invention	O
provides	O
topical	O
formulations	O
containing	O
a	O
vitamin	O
K	O
analog,	O
e	O
.	O
g	O
.	O
,	O
menadione,	O
that	O
deliver	O
a	O
uniform,	O
therapeutically	O
effective	O
concentration	O
of	O
the	O
vitamin	O
K	O
analog	O
to	O
the	O
skin	O
in	O
a	O
vehicle	O
which	O
is	O
stable,	O
non-irritating,	O
non-drying	O
and	O
cosmetically	O
acceptable	O
.	O
These	O
topical	O
formulations	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
dermatological	O
conditions	O
associated	O
with	O
inflammation,	O
particularly,	O
dermatological	O
conditions	O
resulting	O
from	O
anti-EGFR	O
therapies	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
identifying	O
or	O
determining	O
a	O
compound	O
that	O
inhibits	O
or	O
reduces	O
internal	B-GENE
ribosome	I-GENE
entry	I-GENE
site	I-GENE
(	O
IRES	B-GENE
)	O
mediated	O
translation	O
.	O
For	O
example,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
determining	O
a	O
compound	O
that	O
inhibits	O
IRES-mediated	O
translation,	O
said	O
method	O
comprising	O
expressing	O
in	O
a	O
cell	O
a	O
counter	O
selectable	O
marker	O
operably	O
under	O
the	O
control	O
of	O
an	O
IRES	B-GENE
.	O
A	O
candidate	O
compound	O
is	O
then	O
introduced	O
into	O
the	O
cell	O
or	O
contacted	O
with	O
the	O
cell	O
and	O
the	O
cell	O
maintained	O
under	O
conditions	O
that	O
select	O
against	O
a	O
cell	O
expressing	O
the	O
counter-selectable	O
marker	O
gene	O
.	O
Accordingly,	O
a	O
cell	O
in	O
which	O
IRES-mediated	O
translation	O
of	O
the	O
counter-selectable	O
reporter	O
gene	O
is	O
selected,	O
thereby	O
identifying	O
a	O
compound	O
that	O
inhibits	O
IRES-mediated	O
translation	O
.	O
The	O
present	O
invention	O
also	O
provides	O
compounds	O
identified	O
by	O
the	O
method	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
corticotropin-releasing	B-GENE
hormone	I-GENE
(CRH)	I-GENE
receptor-1	I-GENE
(R1)	I-GENE
antagonists	O
and	O
/	O
or	O
CRH-R2	B-GENE
receptor	O
agonists	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
via	O
regulation	O
of	O
monocyte	O
/	O
macrophage	O
cell	O
activation,	O
proliferation,	O
differentiation,	O
apoptosis,	O
and	O
inflammatory	O
cytokine	O
production	O
.	O
As	O
CRH	B-GENE
system	O
we	O
define	O
natural	O
and	O
synthetic	O
CRH	B-GENE
and	O
urocortin	B-GENE
(	O
UCN	B-GENE
)	O
agonists	O
and	O
antagonists	O
for	O
the	O
CRH-R1	B-GENE
and	O
CRH-R2	B-GENE
receptors	O
and	O
their	O
subtypes	O
as	O
well	O
as	O
the	O
CRH-binding	B-GENE
protein	I-GENE
(	O
BP	B-GENE
)	O
,	O
a	O
CRH	B-GENE
pseudo-receptor	I-GENE
.	O
The	O
invention	O
is	O
directed	O
towards	O
pharmacological	O
intervention	O
for	O
the	O
amelioration	O
or	O
treatment	O
of	O
inflammatory	O
diseases	O
using	O
the	O
CRH	B-GENE
system-mediated	O
control	O
of	O
monocyte	O
/	O
macrophage	O
cells	O
which	O
play	O
a	O
key	O
role	O
in	O
initiating	O
and	O
maintaining	O
the	O
inflammatory	O
response	O
via	O
production	O
of	O
pro-inflammatory	O
cytokines	O
such	O
as	O
is	O
the	O
interleukin	O
(	O
IL	O
)	O
-1,	O
IL-6	B-GENE
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	O
)	O
-alpha	O
.	O
By	O
the	O
term	O
inflammation	O
we	O
define	O
the	O
response	O
of	O
an	O
organism	O
to	O
noxious	O
endogenous	O
or	O
exogenous	O
stimuli	O
causing	O
tissue	O
injury	O
.	O
Inflammation	O
is	O
a	O
host	O
defence	O
mechanism,	O
which	O
might	O
harm	O
the	O
defending	O
organism	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
natural	O
and	O
synthetic	O
CRH	B-GENE
system	O
modulators	O
for	O
the	O
control	O
of	O
the	O
monocyte	O
/	O
macrophage	O
system	O
.	O


A	O
subject	O
of	O
the	O
invention	O
is	O
a	O
product	O
comprising	O
at	O
least	O
one	O
Cdc25	B-GENE
phosphatase	I-GENE
inhibitor	O
in	O
combination	O
with	O
at	O
least	O
one	O
other	O
anti-cancer	O
agent	O
for	O
a	O
therapeutic	O
use	O
which	O
is	O
simultaneous,	O
separate	O
or	O
spread	O
over	O
time	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O
	O
	O
	O
	O
According	O
to	O
the	O
invention,	O
the	O
other	O
anti-cancer	O
agent	O
is	O
preferably	O
chosen	O
from	O
:	O
	O
	O
	O
analogues	O
of	O
DNA	O
bases	O
such	O
as	O
5-fluorouracil	O
;	O
Type	O
I	O
and	O
/	O
or	O
II	O
topoisomerase	O
inhibitors	O
such	O
as	O
for	O
example	O
camptothecin	O
and	O
its	O
analogues,	O
doxorubicin	O
or	O
armsacrine	O
;	O
compounds	O
interacting	O
with	O
the	O
cell	O
spindle	O
such	O
as	O
for	O
example	O
paclitaxel	O
(	O
Taxol	O
)	O
;	O
compounds	O
acting	O
on	O
the	O
cytoskeleton	O
such	O
as	O
vinblastine	O
;	O
inhibitors	O
of	O
the	O
transduction	O
of	O
the	O
signal	O
passing	O
through	O
the	O
heterotrimeric	O
G	O
proteins	O
;	O
prenyltransferase	B-GENE
inhibitors,	O
and	O
in	O
particular	O
farnesyltransferase	B-GENE
inhibitors	O
;	O
cyclin-dependent	B-GENE
kinase	I-GENE
(	O
CDKs	B-GENE
)	O
inhibitors	O
;	O
alkylating	O
agents	O
such	O
as	O
cisplatin	O
;	O
antagonists	O
of	O
folic	O
acid	O
such	O
as	O
methotrexate	O
;	O
and	O
inhibitors	O
of	O
the	O
synthesis	O
of	O
DNA	O
and	O
cell	O
division	O
cell	O
such	O
as	O
mitomycin	O
C	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
A	O
further	O
subject	O
of	O
the	O
invention	O
is	O
(	O
1R	O
)	O
-1-	O
[	O
(	O
{	O
(	O
2R	O
)	O
-2-amino-3-	O
[	O
(	O
8S	O
)	O
-8-	O
(	O
cyclohexylmethyl	O
)	O
-2-phenyl-5,6-dihydroimidazo	O
[	O
1,2-a	O
]	O
pyrazin-7	O
(	O
8H	O
)	O
-yl	O
]	O
-3-oxopropyl	O
}	O
dithio	O
)	O
methyl	O
]	O
-2-	O
[	O
(	O
8S	O
)	O
-8-	O
(	O
cyclohexylmethyl	O
)	O
-2-phenyl-5,6-dihydroimidazo	O
[	O
1,2-a	O
]	O
pyrazin-7	O
(	O
8H	O
)	O
-yl	O
]	O
-2-oxoethylamine,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
useful	O
as	O
an	O
anticancer	O
agent	O
.	O


A	O
compound	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
groups	O
R1-R4,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
useful	O
to	O
treat	O
TNF-Alpha	B-GENE
and	O
IL-1	B-GENE
mediated	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1,	O
R2,	O
A,	O
B,	O
X	O
and	O
Y	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims,	O
and	O
/	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and	O
/	O
or	O
a	O
prodrug	O
thereof	O
.	O
Because	O
of	O
their	O
properties	O
as	O
inhibitors	O
of	O
chemokine	O
receptors,	O
especially	O
as	O
CXCR2	B-GENE
inhibitors,	O
the	O
compounds	O
of	O
the	O
formula	O
I	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
and	O
prodrugs	O
thereof	O
are	O
suitable	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
chemokine	O
mediated	O
diseases	O
.	O


Lovastatin,	O
pravastatin,	O
simvastatin,	O
mevastatin,	O
atorvastatin,	O
and	O
derivatives	O
and	O
analogs	O
thereof	O
are	O
known	O
as	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitors	O
and	O
are	O
used	O
as	O
antihypercholesterolemic	O
agents	O
.	O
The	O
majority	O
of	O
them	O
are	O
produced	O
by	O
fermentation	O
using	O
microorganisms	O
of	O
different	O
species	O
identified	O
as	O
species	O
belonging	O
to	O
Aspergillus,	O
Monascus,	O
Nocardia,	O
Amycolatopsis,	O
Mucor	O
or	O
Penicillium	O
genus,	O
and	O
some	O
are	O
obtained	O
by	O
treating	O
the	O
fermentation	O
products	O
using	O
the	O
methods	O
of	O
chemical	O
synthesis	O
or	O
they	O
are	O
the	O
products	O
of	O
total	O
chemical	O
synthesis	O
.	O
	O
	O
	O
	O
The	O
aforementioned	O
active	O
substances	O
may	O
be	O
destabilized	O
by	O
the	O
environmental	O
factors,	O
their	O
degradation	O
may	O
also	O
be	O
accelerated	O
by	O
interactions	O
with	O
other	O
pharmaceutical	O
ingredients,	O
such	O
as	O
fillers,	O
binders,	O
lubricants,	O
glidants	O
and	O
disintegrating	O
agents,	O
therefore	O
the	O
pharmaceutical	O
ingredients	O
and	O
the	O
process	O
for	O
preparation	O
of	O
the	O
pharmaceutical	O
formulation	O
should	O
be	O
meticulously	O
chosen	O
to	O
avoid	O
the	O
aforementioned	O
undesired	O
interactions	O
and	O
reactions	O
.	O
	O
	O
	O
	O
The	O
present	O
invention	O
relates	O
to	O
a	O
stable	O
solid	O
pharmaceutical	O
formulation	O
for	O
the	O
treatment	O
of	O
hypercholesterolemia	O
and	O
hyperlipidemia	O
.	O
More	O
precisely,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
new	O
stable	O
solid	O
pharmaceutical	O
formulation	O
containing	O
as	O
an	O
active	O
ingredient	O
a	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor,	O
such	O
as	O
atorvastatin,	O
pravastatin,	O
fluvastatin	O
and	O
cerivastatin	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
novel	O
oral	O
compositions	O
comprising	O
an	O
irreversible	O
gastric	O
H+	O
/	O
K+-ATPase	O
proton	B-GENE
pump	I-GENE
inhibitor	O
(	O
PPI	O
)	O
as	O
a	O
gastric	O
acid	O
secretion	O
inhibitor	O
and	O
one	O
or	O
more	O
aliphatic	O
carboxylic	O
acid	O
derivative	O
molecules	O
which	O
activate	O
parietal	O
cells,	O
wherein	O
the	O
derivatives	O
possess	O
delayed	O
or	O
sustained	O
enhancement	O
effect	O
on	O
the	O
PPI	O
activity	O
compared	O
to	O
the	O
non-derivatized	O
acid	O
molecules	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
using	O
such	O
compositions	O
to	O
reduce	O
gastric	O
acid	O
secretion	O
in	O
a	O
mammal	O
.	O


New	O
bicyclic	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
meanings	O
for	O
the	O
various	O
substituents	O
are	O
as	O
disclosed	O
in	O
the	O
description	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
p38	B-GENE
kinase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
identifying	O
an	O
agent	O
which	O
modulates	O
hydroxylation	O
of	O
hypoxia	B-GENE
inducible	I-GENE
factor	I-GENE
(	O
HIF	B-GENE
)	O
,	O
comprising	O
contacting	O
a	O
HIF	B-GENE
asparagine	B-GENE
hydroxylase	I-GENE
and	O
a	O
test	O
substance	O
in	O
the	O
presence	O
of	O
a	O
substrate	O
of	O
the	O
hydroxylase	O
under	O
conditions	O
in	O
which	O
asparagine	O
in	O
the	O
substrate	O
is	O
hydroxylated	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
;	O
and	O
determining	O
hydroxylation	O
of	O
the	O
substrate	O
.	O


Certain	O
atypical	O
antipsychotic	O
medications	O
(	O
particularly	O
clozapine	O
)	O
or	O
combinations	O
of	O
medications	O
are	O
useful	O
to	O
treat	O
alcohol	O
or	O
other	O
substance	O
abuse,	O
particularly	O
in	O
the	O
general	O
(	O
non-schizophrenic	O
)	O
population	O
.	O
Generally	O
stated,	O
one	O
aspect	O
of	O
the	O
invention	O
features	O
a	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
alcohol	O
or	O
other	O
substance	O
abuse	O
by	O
administering	O
to	O
the	O
patient	O
medication	O
effective	O
to	O
rectify	O
an	O
abuse-associated	O
dysfunction	O
in	O
the	O
DA-mediated	O
brain	O
reward	O
circuit	O
.	O
A	O
second	O
aspect	O
of	O
the	O
invention	O
features	O
administering	O
medication	O
that	O
strongly	O
antagonizes	O
α2	B-GENE
andrenergic	I-GENE
receptors	I-GENE
and	O
weakly	O
antagonizes	O
dopamine	B-GENE
D2	I-GENE
receptors	I-GENE
.	O
Preferably,	O
the	O
ratio	O
of	O
α2	B-GENE
receptor	I-GENE
blockade	O
to	O
D2o	B-GENE
receptor	I-GENE
blockade	O
is	O
similar	O
to	O
that	O
of	O
clozapine	O
.	O
The	O
medication	O
may	O
be	O
a	O
single	O
compound	O
(	O
such	O
as	O
clozapine	O
or	O
risperidone	O
)	O
,	O
or	O
it	O
may	O
include	O
two	O
or	O
more	O
compounds	O
which	O
together	O
achieve	O
the	O
specified	O
function	O
.	O
For	O
example,	O
the	O
medication	O
may	O
include	O
a	O
first	O
component	O
which	O
weakly	O
blocks	O
the	O
D2	O
receptor	I-GENE
(	O
such	O
as	O
clozapine,	O
quetiapine	O
or	O
ziprasidone	O
or	O
a	O
low	O
dose	O
of	O
another	O
anti-psychotic	O
that	O
is	O
a	O
more	O
potent	O
D2	O
blocker	O
)	O
and	O
a5	O
second	O
component	O
(	O
such	O
as	O
clozapine,	O
risperidone	O
or	O
idazoxan	O
)	O
which	O
strongly	O
blocks	O
α2	O
receptors,	O
particularly	O
the	O
α2C	O
receptor	O
.	O
Cocktails	O
of	O
the	O
two	O
components	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
creatine	O
compounds	O
for	O
treating	O
or	O
preventing	O
a	O
metabolic	O
disorder	O
related	O
to	O
body	O
weight	O
control	O
such	O
as	O
obesity,	O
and	O
it	O
'	O
s	O
associated	O
diseases	O
in	O
a	O
patient	O
experiencing	O
said	O
disorder	O
.	O
The	O
creatine	O
compounds	O
which	O
can	O
be	O
used	O
in	O
the	O
present	O
method	O
include	O
(	O
1	O
)	O
analogues	O
of	O
creatine	O
which	O
can	O
act	O
as	O
substrates	O
or	O
substrate	O
analogues	O
for	O
the	O
enzyme	O
creatine	B-GENE
kinase	I-GENE
;	O
(	O
2	O
)	O
compounds	O
which	O
can	O
act	O
as	O
inhibitors	O
of	O
creatine	B-GENE
kinase	I-GENE
;	O
(	O
3	O
)	O
compounds	O
which	O
can	O
modulate	O
the	O
creatine	B-GENE
transporter	I-GENE
(	O
4	O
)	O
N-phosphocreatine	O
analogues	O
bearing	O
transferable	O
or	O
non-transferable	O
moieties	O
which	O
mimic	O
the	O
N-phosphoryl	O
group	O
.	O
(	O
5	O
)	O
compounds	O
which	O
modify	O
the	O
association	O
of	O
creatine	B-GENE
kinase	I-GENE
with	O
other	O
cellular	O
components	O
.	O


A	O
method	O
for	O
treating	O
a	O
patient	O
having	O
lower	O
urinary	O
tract	O
symptoms	O
is	O
provided	O
.	O
The	O
method	O
comprises	O
a	O
step	O
of	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
treating	O
compound	O
of	O
7-	O
[	O
2-	O
[	O
4-	O
(	O
2-Chlorobenzene	O
)	O
piperazinyl	O
]	O
ethyl	O
]	O
-1,3-dimethyl	O
xanthine,	O
a	O
salt	O
of	O
the	O
treating	O
compound,	O
a	O
solvate	O
of	O
the	O
treating	O
compound	O
and	O
a	O
combination	O
thereof,	O
wherein	O
the	O
compound	O
has	O
an	O
effect	O
on	O
treating	O
the	O
benign	O
prostate	O
hyperplasia	O
via	O
a	O
mechanism	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
an	O
activation	O
of	O
PKG	B-GENE
pathway,	O
a	O
blockage	O
of	O
an	O
adrenoceptor,	O
an	O
opening	O
of	O
a	O
potassium	B-GENE
channel	I-GENE
and	O
an	O
inhibition	O
of	O
PDE	B-GENE
activity	O
.	O


Disclosed	O
are	O
compounds	O
Formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
R1,	O
R2,	O
R4,	O
and	O
R5	O
are	O
defined	O
herein	O
.	O
These	O
compounds	O
are	O
useful	O
for	O
treating	O
diseases	O
and	O
conditions	O
caused	O
or	O
exacerbated	O
by	O
unregulated	O
p38	B-GENE
MAP	I-GENE
Kinase	I-GENE
and	O
/	O
or	O
TNF	B-GENE
activity	O
.	O
Pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
methods	O
of	O
preparing	O
the	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
are	O
also	O
disclosed	O
.	O


Chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
and	O
in	O
particular	O
imatinib	O
resistant	O
CML	O
is	O
treated	O
using	O
compositions	O
and	O
methods	O
in	O
which	O
a	O
Rad51-inhibitor	O
and	O
a	O
kinase	B-GENE
inhibitor	O
are	O
administered	O
.	O
Most	O
preferably,	O
the	O
Rad51	B-GENE
inhibitor	O
comprises	O
an	O
indolyl	O
isoquinoline	O
structure	O
and	O
the	O
kinase	B-GENE
inhibitor	O
is	O
a	O
BCR-ABL	O
inhibitor	O
.	O


The	O
use	O
of	O
inhibitors	O
of	O
GSK-3	B-GENE
useful	O
for	O
treating	O
glaucoma	O
is	O
disclosed	O
.	O


The	O
present	O
disclosure	O
provides	O
methods	O
of	O
reducing	O
pregnancy	O
loss	O
or	O
miscarriage	O
in	O
patients	O
by	O
administering	O
compounds	O
that	O
inhibit	O
tissue	B-GENE
factor	I-GENE
(	O
TF	B-GENE
)	O
expression	O
and	O
/	O
or	O
activity	O
on	O
neutrophils	O
and	O
/	O
or	O
monocytes,	O
such	O
as	O
for	O
example,	O
statins,	O
and	O
methods	O
of	O
diagnosing	O
patients	O
having	O
an	O
increased	O
risk	O
of	O
miscarrying	O
.	O


New	O
substituted	O
quinazoline,	O
quinoxaline,	O
quinoline	O
and	O
isoquinoline	O
compounds,	O
compositions	O
and	O
methods	O
of	O
inhibition	O
of	O
Raf	B-GENE
kinase	I-GENE
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
provided	O
.	O
The	O
new	O
compounds	O
compositions	O
may	O
be	O
used	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
agent	O
for	O
the	O
treatment	O
of	O
a	O
Raf	B-GENE
kinase	I-GENE
mediated	O
disorder,	O
such	O
as	O
cancer	O
.	O


An	O
anti-hemorrhage	O
medication	O
pack	O
for	O
administering	O
an	O
anti-hemorrhage	O
drug,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
hemorrhage	O
caused	O
by	O
trauma	O
in	O
emergency	O
situations	O
comprises	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
comprising	O
the	O
1-24	O
amino	O
acid	O
sequence	O
of	O
the	O
adrenocorticotropic	B-GENE
hormone	I-GENE
(	O
ACTH	B-GENE
1-24	I-GENE
)	O
and	O
all	O
its	O
fragments	O
and	O
analogues,	O
and	O
analogues	O
of	O
fragments,	O
with	O
agonist	O
activity	O
on	O
the	O
MC4	B-GENE
melanocortin	I-GENE
receptors,	O
and	O
all	O
the	O
synthesis	O
agonists,	O
including	O
those	O
with	O
a	O
nonpeptidic	O
structure,	O
of	O
the	O
MC4	B-GENE
melanocortin	I-GENE
receptors	I-GENE
.	O
An	O
auto-injector	O
(	O
1	O
;	O
11	O
)	O
includes	O
the	O
drug	O
for	O
automatically	O
injecting	O
a	O
patient	O
with	O
the	O
drug	O
.	O


Compounds	O
of	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
wherein	O
variables	O
A1,	O
A2,	O
A3,	O
A4,	O
A5,	O
A6,	O
A7,	O
B,	O
E1,	O
E2,	O
E3,	O
E4,	O
E5,	O
G1,	O
G2,	O
J	O
and	O
K	O
are	O
as	O
described	O
herein	O
)	O
which	O
are	O
antagonists	O
of	O
CGRP	B-GENE
receptors	I-GENE
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
CGRP	O
is	O
involved,	O
such	O
as	O
migraine	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	O
is	O
involved	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
(	O
in	O
particular,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
compounds	O
or	O
salts	O
as	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
type	I-GENE
IV	I-GENE
(	O
PDE4	B-GENE
)	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
or	O
allergic	O
diseases	O
such	O
as	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
asthma,	O
rhinitis,	O
atopic	O
dermatitis	O
or	O
psoriasis,	O
e	O
.	O
g	O
.	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
.	O


The	O
invention	O
relates	O
to	O
a	O
process	O
for	O
producing	O
a	O
compound	O
according	O
to	O
formula	O
(	O
i	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
salt	O
thereof,	O
	O
wherein	O
R1	O
and	O
R1′	O
are	O
independently	O
hydrogen	O
or	O
an	O
amine	O
protecting	O
group	O
and	O
R2	O
is	O
a	O
carboxyl	O
group	O
or	O
an	O
ester	O
group,	O
comprising	O
reacting	O
a	O
compound	O
according	O
to	O
formula	O
(	O
ii	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
salt	O
thereof,	O
	O
wherein	O
R1,	O
R1′	O
and	O
R2	O
are	O
defined	O
as	O
above,	O
with	O
hydrogen	O
in	O
the	O
presence	O
of	O
a	O
transition	O
metal	O
catalyst	O
and	O
a	O
chiral	O
ligand,	O
wherein	O
the	O
transition	O
metal	O
is	O
selected	O
from	O
group	O
7,	O
8	O
or	O
9	O
of	O
the	O
periodic	O
table	O
.	O
Furthermore,	O
the	O
invention	O
relates	O
to	O
products	O
obtainable	O
by	O
said	O
process	O
and	O
to	O
their	O
use	O
in	O
the	O
production	O
of	O
NEP	B-GENE
inhibitors	O
.	O
Moreover,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
transition	O
metal	O
catalyst	O
in	O
the	O
preparation	O
of	O
NEP	B-GENE
inhibitors	O
or	O
prodrugs	O
thereof	O
.	O


Vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
and	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
HGF	B-GENE
/	O
SF	B-GENE
)	O
are	O
potent	O
mitogens	O
with	O
proven	O
angiogenic	O
activities	O
in	O
human	O
and	O
animal	O
disease	O
models	O
.	O
These	O
growth	O
factors	I-GENE
display	O
little	O
overlap	O
in	O
angiogenesis	O
signaling	O
cascades	O
.	O
The	O
application	O
reports	O
angiogenesis	O
in	O
lung	O
adenocarcinomas	O
to	O
be	O
coordinated	O
by	O
hemostatic	O
events	O
.	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
identifying	O
therapeutical	O
targets	O
in	O
tumors,	O
in	O
particular	O
in	O
advanced	O
stage	O
tumor	O
malignancies,	O
the	O
use	O
of	O
novel	O
targets	O
for	O
identifying,	O
determining,	O
and	O
targeting	O
angiogenesis	O
and	O
hemostasis	O
related	O
to	O
adenocarcinomas	O
of	O
the	O
lung,	O
and	O
the	O
use	O
of	O
the	O
therapeutical	O
targets	O
identified	O
for	O
screening	O
and	O
determining	O
means	O
and	O
/	O
or	O
drugs	O
.	O
The	O
aim	O
of	O
the	O
present	O
invention	O
is	O
therefore	O
to	O
make	O
available	O
an	O
easy	O
and	O
efficient	O
method	O
for	O
identifying	O
therapeutical	O
targets	O
in	O
tumors,	O
in	O
particular	O
in	O
advanced	O
stage	O
tumor	O
malignancies	O
.	O
Furthermore	O
the	O
aim	O
is	O
the	O
use	O
of	O
novel	O
therapeutical	O
targets	O
identified	O
by	O
the	O
method	O
for	O
screening	O
and	O
determining	O
beneficial	O
means	O
and	O
/	O
or	O
drugs,	O
and	O
means	O
and	O
drugs	O
for	O
identifying,	O
determining	O
and	O
treating	O
angiogenesis	O
and	O
hemostasis	O
related	O
to	O
adenocarcinomas,	O
in	O
particular	O
of	O
advanced	O
stage	O
tumors	O
of	O
the	O
lung	O
.	O
The	O
method	O
for	O
identifying	O
therapeutical	O
targets	O
in	O
tumors,	O
in	O
particular	O
in	O
advanced	O
stage	O
tumor	O
malignancies,	O
comprising	O
the	O
steps	O
of—isolating	O
RNA	O
(	O
1	O
)	O
from	O
the	O
tissue	O
of	O
the	O
tumor	O
;	O
—determining	O
for	O
the	O
isolated	O
RNA	O
(	O
1	O
)	O
a	O
gene	O
expression	O
profile	O
(	O
2	O
)	O
of	O
at	O
least	O
two	O
genes,	O
wherein	O
at	O
least	O
one	O
gene	O
(	O
3	O
)	O
is	O
coding	O
for	O
a	O
VEGF	B-GENE
activity	O
modulator	O
and	O
at	O
least	O
one	O
gene	O
(	O
4	O
)	O
is	O
coding	O
for	O
a	O
hemostatic	O
factor	O
by	O
screening	O
the	O
presence	O
of	O
mRNA	O
coding	O
for	O
the	O
factors	O
to	O
be	O
screened	O
and	O
by	O
determining	O
the	O
levels	O
of	O
expression	O
of	O
thereof	O
;	O
—determining	O
the	O
changes	O
of	O
expression	O
of	O
the	O
at	O
least	O
two	O
genes	O
screened	O
by	O
the	O
gene	O
expression	O
profile	O
(	O
2	O
)	O
in	O
comparison	O
with	O
healthy	O
tissue	O
or	O
with	O
an	O
early	O
stage	O
tumor	O
;	O
and—identifying	O
the	O
therapeutical	O
target	O
as	O
a	O
hemostatic	O
factor,	O
being	O
upregulated	O
or	O
down-regulated	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
substituted	O
ethanolamine	O
adrenergic	B-GENE
receptor	I-GENE
modulators,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
disclosure	O
provides	O
compounds	O
having	O
affinity	O
for	O
the	O
5-HT6	B-GENE
receptor	O
which	O
are	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
A,	O
B,	O
D,	O
E,	O
G,	O
Ar,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
such	O
compounds,	O
compositions	O
containing	O
such	O
compounds,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
substituted-1,1-dioxo-benzo	O
[	O
1,2,4	O
]	O
thiadiazin-3-ones	O
acting	O
as	O
a	O
5HT6	B-GENE
receptor	O
antagonist,	O
a	O
preparation	O
method	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
for	O
treatment	O
of	O
the	O
central	O
nervous	O
system	O
disorders	O
.	O
The	O
compounds	O
of	O
substituted-1,1-dioxo-benzo	O
[	O
1,2,4	O
]	O
thiadiazin-3-ones	O
according	O
to	O
the	O
present	O
invention	O
have	O
excellent	O
binding	O
affinity	O
for	O
the	O
5HT6	B-GENE
receptor	O
and	O
excellent	O
selectivity	O
for	O
the	O
5HT6	B-GENE
receptor	O
over	O
other	O
receptors	O
.	O
Also,	O
the	O
compounds	O
reverse	O
a	O
disruption	O
of	O
PPI	O
by	O
apomorphine	O
and	O
don	O
'	O
t	O
show	O
rotatod	O
deficit	O
in	O
mice	O
.	O
Therefore	O
the	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
may	O
be	O
valuably	O
used	O
for	O
treatment	O
of	O
a	O
5HT6	B-GENE
receptor	O
relating	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
ameliorating	O
cue-induced	O
cravings	O
for	O
an	O
addictive	O
substance	O
in	O
abstinent	O
addicts	O
by	O
administering	O
a	O
compound	O
capable	O
of	O
blockade	O
of	O
GluR2-lacking	O
AMPA	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
is	O
directed	O
towards	O
new	O
18F-folate	O
radio-pharmaceuticals,	O
wherein	O
the	O
fluorine-18	O
is	O
covalently	O
linked	O
to	O
the	O
aminobenzoyl	O
moiety,	O
which	O
connects	O
the	O
condensed	O
pyrimidine	O
heterocycle	O
to	O
the	O
amino	O
acid	O
portion	O
within	O
folate	O
structures,	O
as	O
well	O
as	O
their	O
precursors	O
and	O
their	O
non-radioactive	O
references,	O
a	O
method	O
of	O
their	O
preparation,	O
as	O
well	O
as	O
their	O
use	O
in	O
diagnosis	O
of	O
a	O
cell	O
or	O
population	O
of	O
cells	O
expressing	O
a	O
folate-receptor	B-GENE
and	O
monitoring	O
of	O
cancer	O
and	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
therapy	O
thereof	O
.	O


The	O
present	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
treating	O
arthritic	O
joints	O
found	O
in	O
patients	O
with	O
autoinflammation,	O
e	O
.	O
g	O
.	O
,	O
systemic	O
onset	O
juvenile	O
idiopathic	O
arthritis,	O
by	O
administering	O
at	O
the	O
site	O
of	O
inflammation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
agent	O
that	O
reduces	O
or	O
blocks	O
the	O
bioavailability	O
of	O
interleukin-1β	B-GENE
.	O


Compounds	O
of	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
residues	O
have	O
various	O
meanings,	O
their	O
pharmaceutical	O
use,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
for	O
preparation	O
and	O
use	O
for	O
the	O
treatment	O
of	O
protein	B-GENE
kinase	I-GENE
modulation	O
responsive	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
arylpiperazine	O
modulators	O
of	O
D2	O
receptors,	O
5-HT1A	B-GENE
receptors,	O
and	O
/	O
or	O
5-HT2A	B-GENE
receptors,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
heterocyclyl-substituted	O
sulfonamides	O
with	O
5-HT6	B-GENE
receptor	O
affinity,	O
and	O
compositions	O
thereof,	O
and	O
the	O
use	O
of	O
said	O
compounds	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
various	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
that	O
mutations	O
in	O
SCN9A	B-GENE
are	O
causative	O
of	O
Congenital	O
Indifference	O
to	O
Pain	O
(	O
CIP	O
)	O
in	O
humans	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
utilizing	O
the	O
SCN9A	B-GENE
gene	O
and	O
expression	O
products	O
thereof	O
for	O
the	O
screening	O
and	O
identification	O
of	O
therapeutic	O
agents,	O
including	O
small	O
organic	O
compounds,	O
which	O
are	O
selective	O
for	O
SCN9A,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
disorders	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
these	O
compounds	O
to	O
treat	O
or	O
otherwise	O
ameliorate	O
such	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
treatment	O
of	O
depression,	O
including	O
treatment-resistant	O
depression,	O
and	O
other	O
mood	O
disorders	O
using	O
a	O
combination	O
of	O
an	O
NMDA	B-GENE
receptor	I-GENE
antagonist	O
and	O
a	O
SSRI	O
that	O
is	O
citalopram	O
or	O
escitalopram	O
.	O
It	O
has	O
unexpectedly	O
been	O
shown	O
that	O
the	O
combination	O
has	O
a	O
synergistic	O
and	O
potentiated	O
effect	O
of	O
either	O
compound	O
as	O
monotherapy,	O
resulting	O
in	O
an	O
enhanced	O
therapeutic	O
effect	O
at	O
lower	O
doses	O
.	O


Methods	O
for	O
slowing	O
disease	O
progression	O
in	O
an	O
individual	O
suffering	O
from	O
familial	O
ALS	O
are	O
provided	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
increasing	O
the	O
survival	O
time	O
of	O
an	O
individual	O
suffering	O
from	O
familial	O
ALS	O
.	O
These	O
methods	O
employ	O
antisense	O
oligonucleotides	O
targeted	O
to	O
SOD1,	O
for	O
use	O
in	O
inhibiting	O
the	O
expression	O
of	O
SOD1	B-GENE
in	O
the	O
central	O
nervous	O
system	O
of	O
an	O
individual	O
suffering	O
from	O
familial	O
ALS	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
semi-solid	O
formulations	O
of	O
inhibitors	O
of	O
phospholipase	B-GENE
enzymes,	O
such	O
as	O
cytosolic	O
PLA2,	O
compositions	O
containing	O
the	O
same	O
and	O
processes	O
for	O
manufacture	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
shikonin	O
compounds,	O
especially,	O
isobutyryl	O
shikonin,	O
β-β-dimethylacryl	O
shikonin,	O
isovaleryl	O
shikonin,	O
and	O
α-methyl-n-butyryl	O
shikonin	O
as	O
an	O
active	O
ingredient	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
diabetes	O
mellitus	O
and	O
the	O
use	O
thereof	O
.	O
The	O
composition	O
of	O
the	O
present	O
invention	O
showed	O
stimulating	O
effect	O
on	O
the	O
release	O
of	O
insulin	O
in	O
the	O
beta	O
cell	O
of	O
the	O
pancreas	O
due	O
to	O
inhibitory	O
effect	O
on	O
KATP	B-GENE
ion	I-GENE
channel	I-GENE
of	O
beta	O
cell	O
in	O
pancreas	O
together	O
with	O
promoting	O
effect	O
on	O
the	O
increase	O
of	O
calcium	O
concentration	O
.	O
Therefore,	O
it	O
can	O
be	O
used	O
as	O
the	O
therapeutics,	O
health	O
functional	O
food	O
or	O
food	O
additive	O
for	O
treating	O
and	O
preventing	O
diabetes	O
mellitus	O
.	O


The	O
invention	O
relates	O
2-	O
(	O
benzimidazol-1-yl	O
)	O
-N-	O
(	O
4-phenylthiazol-2-yl	O
)	O
acetamide	O
derivatives	O
having	O
the	O
general	O
Formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1	O
is	O
H,	O
(	O
C1-4	O
)	O
alkyl,	O
(	O
C1-4	O
)	O
alkyloxy	O
or	O
halogen	O
;	O
R2	O
represents	O
1-3	O
substituents	O
selected	O
from	O
H,	O
(	O
C1-4	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
with	O
1	O
or	O
more	O
halogens	O
)	O
,	O
(	O
C1-4	O
)	O
alkyl-oxy	O
(	O
optionally	O
substituted	O
with	O
1	O
or	O
more	O
halogens	O
)	O
,	O
halogen,	O
CF3	O
or	O
cyano	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
to	O
the	O
use	O
of	O
said	O
2-	O
(	O
benzimidazol-1-yl	O
)	O
-N-	O
(	O
4-phenylthiazol-2-yl	O
)	O
acetamide	O
derivatives	O
in	O
the	O
treatment	O
of	O
TRPV1	B-GENE
mediated	O
disorders	O
.	O


The	O
present	O
disclosure	O
provides	O
compositions	O
and	O
methods	O
for	O
enhancing	O
resistance	O
to	O
viral	O
infections	O
.	O
The	O
compositions	O
include	O
adenovirus	O
vectors	O
containing	O
nucleic	O
acid	O
molecules	O
encoding	O
CARD	O
domains	O
from	O
RIG-I	B-GENE
and	O
MDA5,	O
recombinant	O
adenoviruses	O
and	O
immunogenic	O
compositions	O
comprising	O
such	O
recombinant	O
adenovirus	O
vectors	O
and	O
adenoviruses	O
.	O
Methods	O
for	O
enhancing	O
resistance	O
to	O
viral	O
infections	O
involving	O
administering	O
such	O
adenovirus	O
vectors	O
or	O
recombinant	O
adenovirus	O
are	O
also	O
provided	O
.	O


Disclosed	O
are	O
compounds	O
having	O
the	O
ability	O
to	O
modulate,	O
namely	O
to	O
improve,	O
enhance	O
and	O
or	O
modify	O
fragrance	O
compositions	O
due	O
to	O
their	O
ability	O
to	O
inhibit	O
cytochrome	B-GENE
P450	I-GENE
enzymes,	O
e	O
.	O
g	O
.	O
CYP2A13	B-GENE
and	O
CYP2B6	B-GENE
.	O


The	O
present	O
invention	O
provides	O
novel	O
compositions	O
comprising	O
a	O
combination	O
of	O
a	O
5-HT3	B-GENE
receptor	I-GENE
antagonist	O
and	O
a	O
selective	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
antagonist	O
for	O
the	O
treatment	O
of	O
alcohol	O
dependence	O
and	O
other	O
dopamine	O
pathway-associated	O
disorders	O
or	O
conditions	O
.	O
Preferably,	O
the	O
pharmaceutical	O
compositions	O
of	O
the	O
present	O
invention	O
comprise	O
amounts	O
of	O
the	O
5-HT3	B-GENE
receptor	I-GENE
antagonist	O
ondansetron	O
and	O
the	O
selective	O
dopamine	B-GENE
D2	I-GENE
receptor	I-GENE
antagonist	O
olanzapine	O
that	O
are	O
sufficient	O
to	O
control	O
a	O
subject	O
'	O
s	O
craving	O
for	O
alcohol	O
or	O
other	O
addictive	O
substances	O
.	O
Kits	O
comprising	O
the	O
combination	O
of	O
antagonists	O
for	O
the	O
treatment	O
of	O
addictive	O
disorders	O
such	O
as	O
alcohol	O
dependence	O
are	O
also	O
provided	O
.	O


This	O
invention	O
concerns	O
compositions	O
for	O
the	O
treatment	O
of	O
Lower	O
Urinary	O
Tract	O
Symptoms	O
(	O
LUTS	O
)	O
,	O
and	O
especially	O
LUTS	O
which	O
results	O
from	O
benign	O
prostatic	O
hypertrophy	O
.	O
The	O
compositions	O
of	O
the	O
invention	O
comprise	O
a	O
Beta-3	O
agonist	O
described	O
below,	O
optionally	O
in	O
combination	O
with	O
a	O
5-alpha	B-GENE
reductase	I-GENE
inhibitor,	O
or	O
an	O
NK-1	B-GENE
antagonist	O
or	O
an	O
alpha-1	B-GENE
adrenergic	I-GENE
antagonist	O
or	O
an	O
anti-muscarinic	O
agent	O
.	O
The	O
invention	O
also	O
includes	O
compositions	O
comprising	O
a	O
beta-3	O
agonist	O
and	O
two	O
additional	O
active	O
agents	O
selected	O
from	O
a	O
5-alpha	B-GENE
reductase	I-GENE
inhibitor,	O
an	O
NK-1	B-GENE
antagonist,	O
an	O
alpha-1	B-GENE
adrenergic	I-GENE
antagonist	O
or	O
an	O
anti-muscarinic	O
agent	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
processes	O
for	O
the	O
preparation	O
of	O
tri-substituted	O
pyridine	O
and	O
tri-substituted	O
pyrimidine	O
derivatives,	O
useful	O
as	O
glucose	B-GENE
dependent	I-GENE
insulinotropic	I-GENE
receptor	I-GENE
agonist,	O
for	O
the	O
treatment	O
of	O
metabolic-related	O
disorders	O
and	O
complications	O
thereof,	O
such	O
as,	O
diabetes	O
and	O
obesity	O
.	O


A	O
method	O
of	O
treatment	O
using	O
pharmaceutical	O
compositions	O
containing	O
novel	O
antagonists	O
or	O
inverse	O
agonists	O
at	O
opioid	B-GENE
receptors	I-GENE
for	O
the	O
treatment	O
of	O
binge	O
eating	O
disorder,	O
anorexia	O
nervosa,	O
bulimia	O
nervosa,	O
excess	O
drug	O
or	O
alcohol	O
use,	O
or	O
eating	O
disorder	O
not	O
otherwise	O
specified	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
topical	O
application	O
of	O
the	O
malonamide	O
ACAT	B-GENE
inhibitors	O
described	O
by	O
Formula	O
I	O
.	O
Other	O
aspects	O
of	O
the	O
invention	O
are	O
directed	O
to	O
topical	O
formulations	O
of	O
these	O
diamides,	O
their	O
use	O
to	O
treat	O
sebaceous	O
gland	O
disorders	O
and	O
their	O
use	O
to	O
alleviate	O
oily	O
skin	O
.	O


Gold	O
nanoparticles	O
conjugated	O
to	O
polyethylene	O
glycol	O
and	O
active	O
binding	O
molecules	O
such	O
as	O
antibodies,	O
proteins,	O
lectins	B-GENE
and	O
DNA	O
are	O
suspended	O
in	O
a	O
water	O
vehicle	O
at	O
concentration	O
from	O
107	O
to	O
1015	O
and	O
then	O
placed	O
in	O
a	O
sealed	O
container	O
such	O
as	O
a	O
centrifuge	O
tube,	O
and	O
then	O
the	O
centrifuge	O
tube	O
is	O
sealed	O
in	O
a	O
film	O
package	O
that	O
is	O
non-air	O
permeable	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
	O
	O
	O
R1	O
is	O
C1-8alkylamino,	O
C1-8alkoxy,	O
C3-7cycloalkylC1-6alkylamino,	O
C3-7cycloalkylC1-6alkoxy,	O
C1-3alkoxyC2-3alkoxy,	O
or	O
Hetb-C1-3alkoxy	O
;	O
Hetb	O
is	O
a	O
5-	O
or	O
6-membered	O
saturated	O
aliphatic	O
heterocycle	O
containing	O
one	O
oxygen	O
atom	O
;	O
R2	O
is	O
—	O
(	O
CH2	O
)	O
n-Het	O
;	O
n	O
is	O
an	O
integer	O
having	O
a	O
value	O
of	O
1	O
to	O
4	O
;	O
Het	O
is	O
a	O
5-	O
or	O
6-membered	O
saturated	O
aliphatic	O
heterocycle	O
containing	O
one	O
oxygen	O
heteroatom,	O
which	O
heterocycle	O
may	O
be	O
substituted	O
by	O
one	O
or	O
two	O
C1-4alkyl	O
groups,	O
and	O
salts	O
and	O
solvates	O
thereof,	O
are	O
inducers	O
of	O
human	B-GENE
interferon	I-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
in	O
particular	O
infectious	O
diseases,	O
cancer,	O
and	O
allergic	O
diseases	O
and	O
other	O
inflammatory	O
conditions	O
for	O
example	O
allergic	O
rhinitis	O
and	O
asthma,	O
and	O
as	O
vaccine	O
adjuvants	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
treating,	O
preventing,	O
and	O
delaying	O
the	O
onset	O
of	O
dementia	O
and	O
mild	O
cognitive	O
impairments	O
by	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
at	O
least	O
one	O
cinnamide	O
compound	O
and	O
one	O
or	O
more	O
second-line	O
active	O
ingredients,	O
such	O
as	O
cholinesterase	B-GENE
inhibitors	O
;	O
AMPA	B-GENE
receptor	I-GENE
antagonists	O
;	O
NMDA	B-GENE
receptor	I-GENE
antagonists	O
;	O
and	O
the	O
like	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions,	O
combinations,	O
and	O
kits	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
renal	O
failure	O
.	O
Particularly,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
renal	O
failure	O
by	O
administering	O
to	O
a	O
subject	O
complexes	O
that	O
include	O
a	O
member	O
of	O
the	O
IL-6	B-GENE
family	I-GENE
linked	O
to	O
a	O
soluble	O
receptor	O
of	O
the	O
member	O
of	O
the	O
IL-6	O
family,	O
or	O
isolated	O
polynucleotides	O
encoding	O
same,	O
the	O
complexes	O
capable	O
of	O
activating	O
a	O
gp130	B-GENE
mediated	O
signaling	O
pathway,	O
thereby	O
treating	O
acute	O
or	O
chronic	O
renal	O
failure	O
.	O


A	O
method	O
of	O
detecting	O
proliferative	O
diseases	O
causing	O
sclerosis,	O
comprising	O
measuring	O
the	O
expression	O
of	O
at	O
least	O
one	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
STAT3,	O
phosphorylated	O
STAT3,	O
Smad1,	O
phosphorylated	O
Smad1,	O
activin	B-GENE
receptor-like	I-GENE
kinase	I-GENE
1,	O
activin	B-GENE
receptor-like	I-GENE
kinase	I-GENE
3	I-GENE
and	O
bone	B-GENE
morphogenetic	I-GENE
proteins	I-GENE
in	O
a	O
biological	O
sample	O
.	O
A	O
kit	O
therefor	O
.	O
A	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
proliferative	O
diseases	O
causing	O
sclerosis,	O
comprising	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
having	O
an	O
inhibitory	O
effect	O
on	O
the	O
expression	O
of	O
at	O
least	O
one	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
STAT3,	O
phosphorylated	O
STAT3,	O
Smad1	B-GENE
and	O
phosphorylated	B-GENE
Smad1	B-GENE
.	O
A	O
method	O
of	O
identifying	O
substances	O
effective	O
in	O
preventing	O
and	O
/	O
or	O
treating	O
proliferative	O
diseases	O
causing	O
sclerosis,	O
comprising	O
judging	O
whether	O
or	O
not	O
a	O
test	O
substance	O
inhibits	O
the	O
expression	O
of	O
at	O
least	O
one	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
STAT3,	O
phosphorylated	O
STAT3,	O
Smad1	B-GENE
and	O
phosphorylated	B-GENE
Smad1	B-GENE
.	O
A	O
kit	O
therefor	O
.	O


Modulation	O
of	O
iron	O
homeostasis	O
by	O
regulating	O
BMP-6	B-GENE
activity	O
is	O
provided	O
.	O
Methods	O
of	O
using	O
BMP-6	B-GENE
and	O
BMP-6	B-GENE
protein-specific	O
reagents,	O
such	O
as	O
antibodies,	O
for	O
altering	O
serum	O
iron	O
levels	O
in	O
humans	O
are	O
provided	O
.	O
Such	O
antibodies	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
hemochromatosis	O
and	O
anemia	O
of	O
inflammation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
TRPA1	B-GENE
activation	O
inhibitor,	O
more	O
precisely	O
a	O
TRPA1	B-GENE
activity	O
inhibitor	O
containing	O
isopentenyl	O
pyrophosphate	O
and	O
a	O
method	O
for	O
inhibiting	O
pain	O
containing	O
the	O
step	O
of	O
administering	O
isopentenyl	O
pyrophosphate	O
to	O
a	O
subject	O
.	O
Isopentenyl	O
pyrophosphate	O
of	O
the	O
present	O
invention	O
can	O
regulate	O
pain	O
caused	O
by	O
TRPA1,	O
so	O
that	O
it	O
can	O
be	O
effectively	O
used	O
for	O
the	O
development	O
of	O
a	O
pain	O
inhibitor	O
which	O
is	O
effective	O
but	O
has	O
less	O
side	O
effects	O
.	O


Compositions,	O
formulations,	O
methods,	O
and	O
systems	O
for	O
treating	O
regional	O
fat	O
deposits	O
and	O
fat-related	O
conditions,	O
dermal	O
conditions,	O
and	O
muscular	O
conditions	O
.	O
Methods	O
comprise	O
administering	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
compound	O
that	O
reduces	O
desensitization	O
of	O
beta	B-GENE
adrenergic	I-GENE
receptors,	O
for	O
example	O
a	O
glucocorticosteroid,	O
and	O
/	O
or	O
at	O
least	O
one	O
long-acting	O
beta-2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist,	O
for	O
example,	O
formoterol	O
.	O
Compositions	O
to	O
be	O
administered	O
include	O
sustained	O
release	O
formulations	O
comprising	O
at	O
least	O
one	O
long-acting	O
beta-2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist,	O
at	O
least	O
one	O
compound	O
that	O
reduces	O
desensitization	O
of	O
beta	B-GENE
adrenergic	I-GENE
receptors,	O
or	O
both	O
in	O
a	O
sustained	O
crystalline	O
microparticle	O
form	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
quinazoline	O
inhibitors	O
of	O
EGFR	B-GENE
tyrosine	O
kinase,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
substituted	O
benzodiazepinones,	O
benzoxazepinones	O
and	O
benzothiazepinones	O
compounds	O
that	O
are	O
sodium	B-GENE
channel	I-GENE
blockers	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
and	O
neuropathic	O
pain	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
other	O
conditions,	O
including	O
disorders	O
of	O
the	O
CNS	O
such	O
as	O
anxiety,	O
depression,	O
epilepsy,	O
manic	O
depression	O
and	O
bipolar	O
disorder	O
.	O
This	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
the	O
present	O
invention,	O
either	O
alone,	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
therapeutically	O
active	O
compounds,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
This	O
invention	O
further	O
comprises	O
methods	O
for	O
the	O
treatment	O
of	O
acute	O
pain,	O
chronic	O
pain,	O
visceral	O
pain,	O
inflammatory	O
pain,	O
neuropathic	O
pain	O
and	O
disorders	O
of	O
the	O
CNS	O
including,	O
but	O
not	O
limited	O
to,	O
epilepsy,	O
manic	O
depression,	O
depression,	O
anxiety	O
and	O
bipolar	O
disorder	O
comprising	O
administering	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
present	O
invention	O
.	O


Specific	O
quinoline	O
derivatives	O
are	O
CRTH2	B-GENE
antagonists,	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
having	O
an	O
inflammatory	O
component	O
.	O


Disclosed	O
herein	O
are	O
siRNA	O
compositions	O
and	O
methods	O
useful	O
for	O
inhibiting	O
expression	O
of	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
isoforms	O
.	O
Such	O
compositions	O
and	O
methods	O
further	O
involve	O
siRNA	O
capable	O
of	O
selectively	O
targeting	O
angiogenic	O
VEGF	B-GENE
isoforms	O
while	O
selectively	O
sparing	O
anti-angiogenic	O
isoforms	O
.	O
Diseases	O
which	O
involve	O
angiogenesis	O
stimulated	O
by	O
overexpression	O
of	O
VEGF,	O
such	O
as	O
diabetic	O
retinopathy,	O
age	O
related	O
macular	O
degeneration	O
and	O
many	O
types	O
of	O
cancer,	O
can	O
be	O
treated	O
by	O
administering	O
small	O
interfering	O
RNAs	O
as	O
disclosed	O
.	O


One	O
aspect	O
of	O
the	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
the	O
formation	O
of	O
advanced	O
glycation	O
end	O
products	O
.	O
Another	O
aspect	O
of	O
the	O
invention	O
relates	O
to	O
a	O
proteasome	O
activity-based	O
screening	O
assay	O
to	O
select	O
compounds	O
which	O
may	O
be	O
useful	O
for	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease,	O
and	O
the	O
materials	O
used	O
therein	O
.	O
Yet	O
another	O
aspect	O
of	O
the	O
invention	O
relates	O
to	O
molecules,	O
and	O
methods	O
of	O
use	O
thereof,	O
which	O
bind	O
at	O
or	O
adjacent	O
to	O
SOD-I	B-GENE
Trp32,	O
including	O
molecules	O
that	O
bind	O
in	O
a	O
site	O
adjacent	O
to	O
SOD-I	B-GENE
Trp32	O
whether	O
or	O
not	O
it	O
is	O
oxidized,	O
for	O
treating	O
or	O
preventing	O
neurodegenerative	O
disease	O
.	O


The	O
invention	O
includes	O
;	O
a	O
method	O
of	O
modulating	O
a	O
level	O
of	O
chaperone	O
protein,	O
a	O
method	O
of	O
modulating	O
a	O
level	O
of	O
ERP57,	O
a	O
method	O
of	O
alleviating	O
a	O
symptom	O
of	O
a	O
disease	O
associated	O
with	O
decreased	O
levels	O
of	O
chaperone	O
proteins,	O
and	O
a	O
method	O
of	O
alleviating	O
a	O
symptom	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O
The	O
methods	O
include	O
administering	O
to	O
a	O
patient	O
a	O
substituted	O
biphenylmethane	O
compound	O
.	O
Preferably	O
the	O
compound	O
is	O
an	O
analog	O
to	O
methoxychlor	O
.	O
More	O
preferably	O
the	O
compound	O
is	O
methoxychlor	O
.	O
The	O
invention	O
also	O
includes	O
pharmaceutical	O
compositions	O
.	O
The	O
pharmaceutical	O
compositions	O
include	O
substituted	O
biphenylmethanes	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
Preferably	O
the	O
pharmaceutical	O
compositions	O
include	O
methoxychlor	O
analogs	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
More	O
preferably	O
the	O
pharmaceutical	O
compositions	O
include	O
methoxychlor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


The	O
invention	O
concerns	O
a	O
method	O
for	O
inhibiting	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
(	O
VEGFR2	B-GENE
)	O
signalling	O
in	O
an	O
individual	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
agent	O
capable	O
of	O
activating	O
T	B-GENE
cell	I-GENE
protein	I-GENE
tyrosine	I-GENE
phosphatase	I-GENE
(	O
TCPTP	B-GENE
)	O
,	O
and	O
a	O
method	O
for	O
inhibiting	O
angiogenesis	O
and	O
treating	O
or	O
preventing	O
diseases	O
related	O
thereto	O
.	O
Furthermore,	O
this	O
invention	O
concerns	O
a	O
method	O
for	O
stimulating	O
angiogenesis	O
or	O
for	O
treatment	O
or	O
prevention	O
of	O
a	O
disease	O
benefiting	O
from	O
increasing	O
the	O
growth	O
of	O
blood	O
vessels	O
in	O
an	O
individual	O
by	O
inhibiting	O
TCPTP	B-GENE
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
salts	O
thereof,	O
which	O
inhibit	O
acetyl	B-GENE
CoA	I-GENE
(acetyl	I-GENE
coenzyme	I-GENE
A):diacylglycerol	I-GENE
acyltransferase	I-GENE
(	O
DGAT1	B-GENE
)	O
activity	O
are	O
provided,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein,	O
for	O
example,	O
R1	O
is	O
an	O
optionally	O
substituted	O
aryl	O
or	O
optionally	O
substituted	O
heteroaryl	O
group	O
;	O
T	O
is	O
N,	O
CH	O
or	O
CMe	O
;	O
Y	O
is	O
a	O
direct	O
bond,	O
or	O
a	O
defined	O
linking	O
group	O
and	O
R2	O
is	O
an	O
optionally	O
substituted	O
aryl,	O
an	O
optionally	O
substituted	O
cycloalkyl	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O


An	O
in	O
vitro	O
method	O
of	O
screening	O
for	O
candidate	O
compounds	O
for	O
the	O
preventive	O
or	O
curative	O
treatment	O
of	O
acne	O
entails	O
determination	O
of	O
the	O
ability	O
of	O
a	O
compound	O
to	O
inhibit	O
the	O
expression	O
or	O
the	O
activity	O
of	O
TACE,	O
and	O
also	O
to	O
the	O
administration	O
of	O
inhibitors	O
of	O
the	O
expression	O
or	O
of	O
the	O
activity	O
of	O
this	O
enzyme,	O
in	O
the	O
treatment	O
of	O
acne	O
.	O


The	O
invention	O
provides	O
a	O
non-human	O
mammal	O
or	O
a	O
cell	O
line	O
that	O
has	O
a	O
targeted	O
gene	O
disruption	O
in	O
an	O
endogenous	O
Iqgap2	B-GENE
gene	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
a	O
compound	O
as	O
a	O
therapeutic	O
agent	O
for	O
the	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
hepatocellular	O
carcinoma	O
.	O


Compounds	O
are	O
provided	O
that	O
act	O
as	O
potent	O
antagonists	O
of	O
the	O
CCR1	B-GENE
receptor,	O
and	O
have	O
in	O
vivo	O
anti-inflammatory	O
activity	O
.	O
The	O
compounds	O
are	O
3-imidazoyl-pyrazolo	O
[	O
3,4-b	O
]	O
pyridine	O
derivatives	O
and	O
are	O
useful	O
in	O
pharmaceutical	O
compositions,	O
methods	O
for	O
the	O
treatment	O
of	O
CCR1-mediated	O
disease,	O
and	O
as	O
controls	O
in	O
assays	O
for	O
the	O
identification	O
of	O
competitive	O
CCR1	B-GENE
antagonists	O
.	O


The	O
present	O
invention	O
features	O
a	O
method	O
for	O
determining	O
the	O
prognosis	O
for	O
survival	O
of	O
a	O
cancer	O
patient	O
.	O
Methods	O
for	O
measuring	O
the	O
level	O
of	O
NOL3	B-GENE
expression	O
in	O
a	O
cancer	O
cell-containing	O
sample	O
from	O
a	O
patient,	O
and	O
comparing	O
the	O
level	O
of	O
NOL3	B-GENE
expression	O
in	O
the	O
sample	O
to	O
a	O
reference	O
level	O
of	O
NOL3	B-GENE
expression	O
are	O
also	O
included	O
.	O
A	O
higher	O
level	O
of	O
NOL3	B-GENE
relative	O
to	O
the	O
reference	O
level	O
correlates	O
with	O
decreased	O
survival	O
of	O
the	O
patient,	O
and	O
an	O
equivalent	O
or	O
lower	O
level	O
of	O
NOL3	B-GENE
relative	O
to	O
the	O
reference	O
level	O
correlates	O
with	O
increased	O
survival	O
of	O
the	O
patient	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
enhancing	O
memory	O
in	O
animals,	O
including	O
humans	O
by	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
an	O
atypical	O
form	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
such	O
as	O
protein	B-GENE
kinase	I-GENE
M	I-GENE
zeta	I-GENE
(	O
PKMζ	B-GENE
)	O
or	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
iota	O
/	O
lambda	O
.	O


A	O
muscarinic	B-GENE
receptor	I-GENE
antagonist	O
is	O
useful	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
condition	O
associated	O
with	O
excess	O
sebum	O
production	O
or	O
excretion	O
.	O


The	O
present	O
invention	O
features	O
improved	O
methods	O
for	O
treating,	O
stabilizing,	O
or	O
preventing	O
a	O
bacterial	O
or	O
a	O
fungal	O
infection	O
in	O
a	O
plant	O
or	O
an	O
animal,	O
such	O
as	O
a	O
mammal	O
.	O
In	O
particular,	O
these	O
methods	O
involve	O
the	O
use	O
of	O
a	O
compound,	O
that	O
is	O
controlled	O
by	O
MvfR,	O
and	O
that	O
affects	O
the	O
expression	O
of	O
an	O
MvfR	B-GENE
protein	O
or	O
that	O
promotes	O
its	O
modification	O
or	O
inactivation,	O
or	O
a	O
compound	O
produced	O
by	O
P	O
.	O
aeruginosa	O
strain	O
PA14,	O
but	O
not	O
by	O
P	O
.	O
aeruginosa	O
containing	O
an	O
mvfR	B-GENE
mutation,	O
in	O
late	O
stationary	O
phase	O
cultures	O
.	O


The	O
present	O
invention	O
relates	O
to	O
(	O
3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl	O
)	O
-acetic	O
acid	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5	O
and	O
R6	O
are	O
as	O
described	O
in	O
the	O
description	O
and	O
their	O
use	O
as	O
prostaglandin	B-GENE
receptor	I-GENE
modulators,	O
most	O
particularly	O
as	O
prostaglandin	B-GENE
D2	I-GENE
receptor	I-GENE
modulators,	O
in	O
the	O
treatment	O
of	O
various	O
prostaglandin-mediated	O
diseases	O
and	O
disorders,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
to	O
processes	O
for	O
their	O
preparation	O
.	O


The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
PI3Kβ	B-GENE
protein	O
and	O
/	O
or	O
encoding	O
gene	O
for	O
the	O
screening	O
for	O
substances	O
useful	O
in	O
the	O
treatment	O
of	O
cancers,	O
preferably	O
breast	O
cancers	O
.	O
The	O
present	O
invention	O
also	O
concerns	O
a	O
method	O
for	O
the	O
diagnosis	O
of	O
malignant	O
cell	O
growth	O
comprising	O
the	O
measuring	O
the	O
expression	O
of	O
PI3Kβ	B-GENE
gene	O
.	O
The	O
invention	O
concerns	O
also	O
non-human	O
transgenic	O
animals	O
as	O
model	O
study	O
for	O
human	O
pathologies,	O
preferably	O
breast	O
cancer,	O
being	O
transgenic	O
for	O
having	O
altered	O
PI3Kβ	B-GENE
and	O
Neu-T	B-GENE
expression	O
.	O


Immunophilin	B-GENE
ligands	O
and	O
their	O
uses	O
as	O
modulators	O
of	O
calcium	B-GENE
channel	I-GENE
activity	O
are	O
disclosed	O
.	O
Screening,	O
therapeutic	O
and	O
prophylactic	O
methods	O
for	O
conditions	O
associated	O
with	O
calcium	B-GENE
channel	I-GENE
dysfunction,	O
e	O
.	O
g	O
.	O
,	O
neurodegenerative	O
and	O
cardiovascular	O
disorders,	O
are	O
also	O
disclosed	O
.	O


Purine	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
meanings	O
for	O
the	O
various	O
substituents	O
are	O
as	O
disclosed	O
in	O
the	O
description	O
.	O
These	O
compounds	O
are	O
useful	O
as	O
JAK3	B-GENE
kinase	O
inhibitors	O
.	O


A	O
method	O
for	O
preventing	O
or	O
treating	O
xerosis	O
by	O
applying	O
a	O
prostaglandin	B-GENE
D	I-GENE
receptor	I-GENE
selective	O
agonist	O
to	O
a	O
mammal	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
1,4-diaza-bicyclo	O
[	O
3	O
.	O
2	O
.	O
2	O
]	O
nonyl	O
heteroaryl	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
.	O
	O
	O
	O
	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-degeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O


Methods	O
of	O
preventing	O
the	O
development	O
and	O
reversing	O
or	O
partially	O
reversing	O
opioid	O
tolerance	O
in	O
a	O
subject	O
are	O
provided	O
herein	O
.	O
Such	O
methods	O
include	O
the	O
step	O
of	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
PDGFR	B-GENE
modulator	O
or	O
EGFR	B-GENE
modulator	O
alone	O
or	O
together	O
with	O
an	O
opiate	O
analgesic	O
.	O
The	O
methods	O
can	O
also	O
be	O
used	O
for	O
the	O
treatment	O
of	O
refractory	O
neuropathic	O
pain,	O
physical	O
dependence	O
or	O
addiction	O
.	O


This	O
invention	O
relates	O
to	O
methods	O
of	O
imaging	O
amyloid	O
deposits,	O
radiolabeled	O
compounds,	O
and	O
methods	O
of	O
making	O
radiolabeled	O
compounds	O
useful	O
in	O
imaging	O
amyloid	O
deposits	O
.	O
This	O
invention	O
also	O
relates	O
to	O
compounds	O
and	O
methods	O
of	O
making	O
compounds	O
for	O
inhibiting	O
the	O
aggregation	O
of	O
amyloid	B-GENE
proteins	I-GENE
to	O
form	O
amyloid	O
deposits	O
and	O
methods	O
of	O
delivering	O
therapeutic	O
agents	O
to	O
amyloid	O
deposits	O
.	O


Disclosed	O
are	O
compounds	O
that	O
are	O
agonists	O
or	O
antagonists	O
of	O
the	O
S1P5	O
receptor,	O
compositions	O
comprising	O
said	O
compounds,	O
and	O
methods	O
of	O
using	O
said	O
compounds	O
and	O
compositions	O
.	O
In	O
certain	O
embodiments,	O
said	O
compounds	O
are	O
1-benzylazetidine-3-carboxylic	O
acid	O
derivatives	O
.	O
In	O
certain	O
embodiments,	O
said	O
methods	O
relate	O
to	O
the	O
treatment	O
of	O
neuropatic	O
pain	O
and	O
/	O
or	O
a	O
neurodegenerative	O
disorder	O
.	O
In	O
certain	O
embodiments,	O
said	O
compounds	O
may	O
be	O
used	O
in	O
combination	O
with	O
a	O
second	O
therapeutic	O
agent	O
.	O


Exemplary	O
embodiments	O
disclosed	O
herein	O
demonstrate	O
that	O
the	O
Snail1	O
gene	O
contributes	O
to	O
FGFR3	B-GENE
receptor	O
signal	O
transduction,	O
which	O
contributes	O
to	O
chondrodysplasias	O
(	O
achondroplasia	O
(	O
ACH	O
)	O
,	O
thanatophoric	O
dysplasia	O
(	O
TD	O
)	O
and	O
hypochondroplasia	O
(	O
HCH	O
)	O
)	O
.	O
The	O
exemplary	O
embodiments	O
identify	O
Snail1	O
as	O
a	O
therapeutic	O
and	O
diagnostic	O
target	O
for	O
chondrodysplasia,	O
as	O
well	O
as	O
the	O
use	O
of	O
inhibitors	O
thereof	O
as	O
drugs	O
for	O
the	O
treatment	O
of	O
these	O
diseases	O
.	O


The	O
present	O
invention	O
pertains	O
to	O
a	O
combination	O
comprising	O
(	O
a	O
)	O
at	O
least	O
one	O
c-Jun	B-GENE
N-terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
inhibitor	O
and	O
(	O
b	O
)	O
4-	O
(	O
4-methylpiperazin-1-ylmethyl	O
)	O
-N-	O
[	O
4-methyl-3-	O
(	O
4-pyridin-3-yl	O
)	O
pyrimidin-2-ylamino	O
)	O
phenyl	O
]	O
-benzamide	O
or	O
a	O
pyrimidylaminobenzamide	O
of	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
radicals	O
and	O
symbols	O
are	O
as	O
defined	O
herein,	O
or,	O
respectively,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
its	O
use	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumors	O
.	O


The	O
present	O
patent	O
application	O
relates	O
to	O
novel	O
combinations	O
of	O
a	O
triazine	O
derivative	O
and	O
of	O
an	O
insulin	B-GENE
secretion	O
stimulator	O
.	O


The	O
present	O
invention	O
provides	O
methods,	O
compositions,	O
and	O
kits	O
for	O
detecting	O
TC	B-GENE
I	I-GENE
deficiency	O
in	O
individuals	O
with	O
low	O
serum	O
cobalamin	O
levels	O
.	O
Methods	O
for	O
detecting	O
TCN1	B-GENE
mutations	O
and	O
/	O
or	O
the	O
TC	B-GENE
I	I-GENE
isoforms	O
or	O
products	O
of	O
TCN1	B-GENE
mutations	O
are	O
useful	O
for	O
detecting	O
and	O
diagnosing	O
those	O
who	O
have	O
TC	B-GENE
I	I-GENE
deficiency	O
and	O
thereby	O
can	O
be	O
said	O
to	O
have	O
TC	B-GENE
I	I-GENE
deficiency	O
instead	O
of	O
cobalamin	O
deficiency	O
.	O


An	O
expression	O
inhibitor	O
of	O
a	O
nuclear	B-GENE
transcription	I-GENE
factor	I-GENE
AP-1	I-GENE
is	O
provided	O
that	O
is	O
excellent	O
in	O
safety	O
and	O
activity	O
of	O
inhibiting	O
the	O
expression	O
of	O
a	O
nuclear	B-GENE
transcription	I-GENE
factor	I-GENE
AP-1	I-GENE
.	O
The	O
AP-1	O
expression	O
inhibitor	O
of	O
the	O
present	O
invention	O
is	O
characterized	O
by	O
containing	O
chamaemeloside	O
.	O
In	O
the	O
present	O
invention,	O
chamaemeloside	O
may	O
be	O
contained	O
as	O
an	O
extract	O
of	O
Roman	O
chamomile	O
or	O
German	O
chamomile	O
.	O
The	O
chamaemeloside	O
is	O
contained	O
in	O
Roman	O
chamomile	O
or	O
German	O
chamomile	O
.	O
Conventionally,	O
Roman	O
chamomile	O
and	O
German	O
chamomile	O
have	O
been	O
used	O
as	O
cosmetic	O
materials	O
and	O
herb	O
teas	O
and	O
have	O
no	O
problems	O
in	O
safety	O
.	O
An	O
extract	O
of	O
Roman	O
chamomile	O
or	O
German	O
chamomile	O
and	O
chamaemeloside	O
inhibit	O
the	O
expression	O
of	O
the	O
AP-1	O
at	O
the	O
gene	O
level	O
(	O
see	O
FIG	O
.	O
2	O
)	O
and	O
therefore	O
are	O
excellent	O
in	O
an	O
inhibition	O
effect	O
as	O
compared	O
to	O
a	O
conventional	O
inhibitor	O
that	O
inhibits	O
binding	O
of	O
the	O
AP-1	O
to	O
DNA	O
.	O


The	O
method	O
for	O
qualitative	O
and	O
quantitative	O
detecting	O
of	O
the	O
extend	O
of	O
use	O
and	O
the	O
correct	O
process	O
flow	O
of	O
the	O
mammalian	O
aerobic	O
glucose	O
fermentation	O
metabolic	O
pathway	O
(	O
mam-aGF	O
)	O
in	O
a	O
mammalian	O
individual	O
is	O
characterized	O
in	O
that	O
the	O
enzyme	O
TKTL1	B-GENE
is	O
used	O
as	O
indicator	O
and	O
target	O
molecule	O
and	O
the	O
structural	O
and	O
/	O
or	O
functional	O
parameter	O
of	O
said	O
TKTL1	B-GENE
in	O
a	O
biological	O
sample	O
of	O
said	O
individual	O
(	O
patient	O
)	O
are	O
taken	O
as	O
indication	O
for	O
the	O
qualitative	O
and	O
quantitative	O
run	O
of	O
the	O
mam-aGF	O
in	O
the	O
cells	O
and	O
/	O
or	O
tissue	O
of	O
said	O
individual	O
(	O
patient	O
)	O
.	O
In	O
combination	O
with	O
the	O
use	O
of	O
inhibitors	O
and	O
activators	O
of	O
the	O
mam-aGF	O
the	O
method	O
is	O
further	O
suitable	O
for	O
checking	O
and	O
controlling	O
the	O
mam-aGF	O
in	O
an	O
individual	O
(	O
patient	O
)	O
.	O


Antisense	O
compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
kinesin-like	B-GENE
1	I-GENE
.	O
The	O
compositions	O
comprise	O
antisense	O
compounds,	O
particularly	O
antisense	O
oligonucleotides,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
kinesin-like	B-GENE
1	I-GENE
.	O
Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
kinesin-like	B-GENE
1	I-GENE
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
kinesin-like	B-GENE
1	I-GENE
are	O
provided	O
.	O


The	O
invention	O
provides	O
a	O
method	O
for	O
determining	O
whether	O
a	O
patient	O
suffering	O
from	O
a	O
condition	O
that	O
is	O
susceptible	O
to	O
treatment	O
with	O
a	O
compound	O
that	O
activates	O
the	O
brain	O
serotonin	O
system	O
is	O
resistant	O
to	O
treatment	O
with	O
the	O
compound	O
.	O
The	O
method	O
comprises	O
observing	O
whether	O
the	O
genome	O
of	O
the	O
patient	O
contains	O
at	O
least	O
one	O
copy	O
of	O
the	O
BDNF	B-GENE
allele	I-GENE
containing	O
a	O
genetic	O
alteration,	O
and	O
correlating	O
the	O
presence	O
of	O
the	O
allele	O
containing	O
the	O
genetic	O
alteration	O
with	O
patients	O
who	O
are	O
resistant	O
to	O
treatment	O
with	O
the	O
compound	O
.	O
In	O
another	O
embodiment,	O
the	O
method	O
comprises	O
observing	O
whether	O
the	O
patient	O
expresses	O
a	O
BDNF	O
protein	O
containing	O
an	O
amino	O
acid	O
alteration,	O
and	O
correlating	O
the	O
expression	O
of	O
the	O
BDNF	O
protein	O
containing	O
the	O
amino	O
acid	O
alteration	O
with	O
patients	O
who	O
are	O
resistant	O
to	O
treatment	O
with	O
the	O
compound	O
.	O


Novel	O
peptides	O
are	O
useful	O
as	O
antagonists	O
of	O
RAGE	B-GENE
and	O
may	O
be	O
used	O
to	O
treat	O
cancer,	O
inflammation,	O
diabetes	O
and	O
arthritis	O
through	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
peptide	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


A	O
method	O
for	O
treating	O
skin,	O
reducing	O
oxidative	O
damage	O
to	O
a	O
skin	O
cell,	O
reducing	O
lipoxygenase	B-GENE
(	O
LO	B-GENE
)	O
activity	O
in	O
a	O
skin	O
cell,	O
reducing	O
cyclooxygenase	B-GENE
(	O
COX	B-GENE
)	O
activity	O
in	O
a	O
skin	O
cell,	O
reducing	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TNF-α	B-GENE
)	O
in	O
a	O
skin	O
cell,	O
or	O
reduction	O
matrix	B-GENE
metalloproteinase	I-GENE
enzyme	O
activity	O
in	O
a	O
skin	O
cell	O
comprising	O
contacting	O
skin	O
or	O
a	O
skin	O
cell	O
with	O
an	O
aromatic	O
skin-active	O
ingredient	O
.	O


A	O
method	O
for	O
treating	O
hyperproliferative	O
tissue	O
in	O
a	O
mammal	O
which	O
tissue	O
expresses	O
ABCG2	B-GENE
including	O
the	O
steps	O
of	O
:	O
a	O
)	O
systemically	O
introducing	O
from	O
about	O
100	O
to	O
about	O
1000	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
of	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibiting	O
compound	O
into	O
the	O
mammal	O
;	O
b	O
)	O
within	O
from	O
about	O
0	O
.	O
5	O
to	O
about	O
24	O
hours	O
after	O
the	O
introducing	O
in	O
step	O
a	O
)	O
systemically	O
introducing	O
from	O
about	O
0	O
.	O
05	O
to	O
about	O
0	O
.	O
5	O
μmol	O
per	O
kilogram	O
of	O
body	O
weight	O
of	O
a	O
tumor	O
avid	O
photosensitizing	O
compound,	O
that	O
acts	O
as	O
a	O
substrate	O
for	O
ABC	B-GENE
family	I-GENE
transport	I-GENE
protein,	O
ABCG2	B-GENE
and	O
that	O
has	O
a	O
preferential	O
light	O
absorbance	O
frequency	O
;	O
and	O
c	O
)	O
exposing	O
the	O
hyperproliferative	O
tissue	O
to	O
light	O
at	O
a	O
fluence	O
of	O
from	O
about	O
50	O
to	O
about	O
150	O
J	O
/	O
cm2	O
delivered	O
at	O
a	O
rate	O
of	O
from	O
about	O
5	O
to	O
about	O
25	O
mW	O
/	O
cm2	O
at	O
the	O
light	O
absorbance	O
frequency	O
.	O
The	O
photosensitizing	O
compound	O
is	O
preferably	O
a	O
tetrapyrollic	O
photosensitizer	O
compound	O
where	O
the	O
tetrapyrollic	O
compound	O
is	O
a	O
chlorin,	O
bacteriochlorin,	O
porphyrin,	O
pheophorbide	O
including	O
pyropheophorbides,	O
purpurinimide,	O
or	O
bacteriopurpurinimide	O
and	O
derivatives	O
thereof	O
;	O
provided	O
that,	O
the	O
photosensizing	O
compound	O
is	O
not	O
a	O
meso-tetra	O
(	O
3-hydroxyphenyl	O
)	O
derivative,	O
is	O
not	O
a	O
saccharide	O
derivative	O
and	O
is	O
not	O
a	O
hematoporphyrin	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
fused	O
bicyclic	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
	O
the	O
symbols	O
are	O
defined	O
herein,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
processes	O
for	O
preparing	O
the	O
compounds,	O
and	O
to	O
methods	O
of	O
using	O
the	O
compounds,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
.	O
The	O
compounds	O
are	O
antagonists	O
of	O
the	O
platelet	O
glycoprotein	B-GENE
IIb/IIIa	I-GENE
fibrinogen	B-GENE
receptor	I-GENE
complex,	O
and	O
are	O
therefore	O
useful	O
for	O
the	O
inhibition	O
of	O
platelet	O
aggregation,	O
and	O
for	O
the	O
treatment	O
of	O
thrombotic	O
diseases	O
and	O
other	O
diseases	O
.	O


Methods	O
of	O
treating	O
disorders	O
related	O
to	O
Oxytocin	B-GENE
Receptor	I-GENE
activity	O
utilize	O
OXYTOCIN	B-GENE
RECEPTOR	I-GENE
antagonists,	O
such	O
as	O
antibodies,	O
including	O
specified	O
portions	O
or	O
variants,	O
polypeptides,	O
polynucleotides,	O
small	O
molecule	O
drugs,	O
siRNA,	O
shRNA,	O
and	O
DNAzymes	O
.	O
Disorders	O
related	O
to	O
Oxytocin	B-GENE
Receptor	I-GENE
activity	O
include	O
inflammatory	O
disorders,	O
such	O
as	O
pulmonary	O
disorders,	O
for	O
example,	O
asthma,	O
emphysema,	O
and	O
COPD	O
.	O


Compositions	O
comprising	O
the	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptor	I-GENE
alpha	I-GENE
(	O
PPARα	B-GENE
)	O
-ligand	O
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine	O
(	O
16	O
:	O
0	O
/	O
18	O
:	O
1-GPC	O
)	O
are	O
disclosed	O
.	O
These	O
compositions	O
may	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
PPARα-related	O
liver	O
disorders	O
including,	O
but	O
not	O
necessarily	O
limited	O
to,	O
fatty	O
liver	O
disease,	O
to	O
lower	O
lipid	O
and	O
triglyceride	O
levels,	O
and	O
to	O
increase	O
high	O
density	O
lipoprotein	O
levels	O
in	O
animals	O
.	O
Foods	O
modified	O
with	O
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine	O
(	O
16	O
:	O
0	O
/	O
18	O
:	O
1GPC	O
)	O
may	O
be	O
used	O
to	O
improve	O
the	O
metabolism	O
of	O
animals	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
with	O
a	O
variety	O
of	O
therapeutic	O
uses,	O
more	O
particularly	O
the	O
substituted	O
cyclic	O
alkylidene	O
compounds	O
are	O
useful	O
for	O
selective	O
estrogen	B-GENE
receptor	I-GENE
modulation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds,	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
disease	O
in	O
an	O
animal,	O
which	O
disease	O
is	O
responsive	O
to	O
inhibiting	O
of	O
functional	B-GENE
cystic	I-GENE
fibrosis	I-GENE
transmembrane	I-GENE
conductance	I-GENE
regulator	I-GENE
(	O
CFTR	B-GENE
)	O
polypeptide	O
by	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
defined	O
herein	O
(	O
including	O
those	O
compounds	O
set	O
forth	O
in	O
Tables	O
1	O
or	O
2	O
or	O
encompassed	O
by	O
formulas	O
I,	O
Ia,	O
II,	O
III,	O
and	O
IV	O
)	O
or	O
compositions	O
comprising	O
these	O
compounds,	O
thereby	O
treating	O
the	O
disease	O
.	O
The	O
present	O
invention	O
particularly,	O
relates	O
to	O
a	O
method	O
of	O
treating	O
diarrhea	O
and	O
polycystic	O
kidney	O
disease	O
.	O


Disclosed	O
are	O
quinazoline-based	O
modulators	O
of	O
Liver	B-GENE
X	I-GENE
receptors	I-GENE
(	O
LXRs	B-GENE
)	O
and	O
related	O
methods	O
.	O
The	O
modulators	O
include	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
in	O
which	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
R10,	O
R11,	O
R12,	O
R13,	O
R14,	O
R15,	O
W,	O
W1,	O
W2,	O
W3,	O
A,	O
Ra,	O
Ra′,	O
Rb,	O
Rb′,	O
Rc,	O
Rd,	O
Rd′,	O
Re,	O
Rf,	O
Rg,	O
Rh,	O
Ri	O
Rj,	O
Rk,	O
Rm,	O
Rn,	O
Ro,	O
Rp,	O
Rq,	O
and	O
n,	O
can	O
be,	O
independently,	O
as	O
defined	O
anywhere	O
herein	O
.	O
In	O
general,	O
these	O
compounds	O
can	O
be	O
used	O
for	O
treating	O
or	O
preventing	O
one	O
or	O
more	O
diseases,	O
disorders,	O
conditions	O
or	O
symptoms	O
mediated	O
by	O
LXRs	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
the	O
treatment	O
and	O
diagnosis	O
of	O
bone	O
mineral	O
density	O
related	O
disorders	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
diagnosing	O
or	O
predicting	O
a	O
bone	O
mineral	O
density	O
related	O
disease,	O
or	O
a	O
risk	O
of	O
a	O
bone	O
mineral	O
density	O
related	O
disease,	O
in	O
a	O
subject,	O
which	O
method	O
comprises	O
detecting	O
a	O
mutation	O
in	O
the	O
TBXAS1	B-GENE
gene,	O
wherein	O
the	O
presence	O
of	O
said	O
mutation	O
is	O
indicative	O
of	O
a	O
bone	O
mineral	O
density	O
related	O
disease	O
or	O
of	O
a	O
risk	O
of	O
a	O
bone	O
mineral	O
density	O
related	O
disease	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
compound	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
a	O
thromboxane	B-GENE
synthase	I-GENE
(	O
TXAS	B-GENE
)	O
encoding	O
polynucleotide,	O
a	O
TXAS,	O
thromboxane	O
A2	O
or	O
an	O
analog	O
thereof	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
associated	O
with	O
an	O
increased	O
bone	O
mineral	O
density	O
(	O
e	O
.	O
g	O
.	O
,	O
Ghosal	O
hematodiaphyseal	O
dysplasia	O
syndrome	O
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
inhibitor	O
of	O
TBXAS1	B-GENE
gene	O
expression	O
or	O
a	O
thromboxane	O
inhibitor	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
associated	O
with	O
a	O
decreased	O
bone	O
mineral	O
density	O
(	O
e	O
.	O
g	O
.	O
,	O
osteoporosis	O
)	O
.	O


The	O
present	O
invention	O
provides	O
therapeutic	O
compositions	O
and	O
methods	O
for	O
treating	O
and	O
preventing	O
fungal	O
disease	O
or	O
conditions	O
including	O
mucormycosis	O
.	O
The	O
therapeutic	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
include	O
vaccine	O
compositions	O
having	O
an	O
FTR	B-GENE
polypeptide	O
or	O
an	O
antigenic	O
fragment	O
of	O
the	O
polypeptide	O
;	O
a	O
vector	O
including	O
a	O
nucleotide	O
sequence	O
that	O
is	O
substantially	O
complimentary	O
to	O
at	O
least	O
18	O
contiguous	O
nucleotides	O
of	O
FTR	B-GENE
sequence	O
;	O
an	O
antisense	O
;	O
a	O
small	O
interfering	O
RNA	O
or	O
an	O
antibody	O
inhibitor	O
of	O
FTR	B-GENE
.	O
The	O
vaccine	O
compositions	O
of	O
the	O
invention	O
can	O
further	O
include	O
an	O
adjuvant	O
.	O


Disclosed	O
are	O
nontoxic	O
ricin	B-GENE
mutants	O
and	O
uses	O
in	O
connection	O
with	O
vaccines	O
and	O
cancer	O
therapy	O
.	O


A	O
compound	O
of	O
the	O
formula	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
is	O
disclosed	O
as	O
a	O
prodrug	O
of	O
an	O
HIV	B-GENE
protease	I-GENE
inhibitor	O
.	O
Methods	O
and	O
compositions	O
for	O
inhibiting	O
HIV	B-GENE
protease	I-GENE
activity	O
and	O
treating	O
HIV	O
infection	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
elevating	O
IKBKAP	B-GENE
gene	O
expression	O
and	O
the	O
level	O
of	O
functional	O
IKAP	B-GENE
protein	O
in	O
cells,	O
which	O
are	O
beneficial	O
to	O
human	O
individual,	O
such	O
as	O
an	O
individual	O
suffering	O
from	O
Familial	O
Dysautonomia,	O
by	O
providing	O
one	O
or	O
more	O
tocotrienols	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
tocopherols	O
to	O
the	O
cells	O
.	O
The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
Familial	O
Dysautonomia	O
by	O
providing	O
tocotrienols	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
tocopherols	O
to	O
a	O
patient	O
having	O
Familial	O
Dysautonomia	O
.	O
Related	O
therapeutic	O
kits	O
are	O
also	O
provided	O
.	O


This	O
invention	O
is	O
directed	O
to	O
a	O
3-	O
(	O
amido	O
or	O
sulphamido	O
)	O
-4-	O
(	O
4-substituted-azinyl	O
)	O
benzamide	O
or	O
benzsulphonamide	O
compound	O
as	O
defined	O
herein	O
.	O
The	O
3-	O
(	O
amido	O
or	O
sulphamido	O
)	O
-	O
(	O
4-substituted-azinyl	O
)	O
benzamide	O
or	O
benzsulphonamide	O
compound	O
is	O
useful	O
as	O
a	O
inhibitor	O
of	O
the	O
chemokine	B-GENE
receptor	I-GENE
CxCR3,	O
and	O
for	O
preventing	O
or	O
treating	O
a	O
CxCR3	O
chemokine	B-GENE
receptor	I-GENE
mediated	O
disease	O
or	O
condition	O
related	O
thereto	O
in	O
a	O
patient	O
in	O
need	O
of	O
such	O
.	O


This	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
which	O
is	O
a	O
glycogen	B-GENE
phosphorylase	I-GENE
inhibitor	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
diabetes	O
and	O
other	O
conditions	O
associated	O
therewith	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
and	O
to	O
processes	O
for	O
preparing	O
the	O
compound	O
and	O
pharmaceutical	O
composition	O
.	O


Embodiments	O
of	O
the	O
invention	O
relate	O
to	O
hyaluronidase	B-GENE
as	O
an	O
adjuvant	O
to	O
increase	O
the	O
injection	O
volume	O
and	O
dispersion	O
of	O
large	O
diameter	O
synthetic	O
membrane	O
vesicles	O
containing	O
one	O
or	O
more	O
therapeutic	O
agents	O
.	O
In	O
particular,	O
embodiments	O
of	O
the	O
invention	O
relate	O
to	O
compositions	O
comprising	O
hyaluronidase	B-GENE
and	O
large	O
diameter	O
synthetic	O
membrane	O
vesicles	O
containing	O
a	O
therapeutic	O
agent,	O
and	O
methods	O
of	O
administration	O
of	O
the	O
same	O
.	O
Methods	O
of	O
making	O
large	O
diameter	O
synthetic	O
membrane	O
vesicles	O
containing	O
an	O
active	O
pharmaceutical	O
ingredient	O
and	O
their	O
use	O
in	O
combination	O
with	O
hyaluronidase	B-GENE
as	O
medicaments	O
are	O
provided	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
diagnosing	O
inflammatory	O
diseases	O
based	O
on	O
the	O
marker	O
CALGRANULIN	O
C,	O
particularly	O
for	O
diagnosing	O
specific	O
stages	O
of	O
inflammatory	O
diseases	O
and	O
/	O
or	O
for	O
determining	O
the	O
risk	O
of	O
relapse	O
and	O
/	O
or	O
for	O
discriminating	O
between	O
diseases	O
with	O
similar	O
symptoms,	O
said	O
method	O
comprising	O
the	O
steps	O
of	O
(	O
a	O
)	O
obtaining	O
a	O
biological	O
sample	O
of	O
mammalian	O
body	O
fluid	O
or	O
tissue	O
to	O
be	O
diagnosed	O
;	O
(	O
b	O
)	O
determining	O
the	O
amount	O
and	O
/	O
or	O
concentration	O
of	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptide	O
and	O
/	O
or	O
nucleic	O
acids	O
encoding	O
the	O
polypeptide	O
present	O
in	O
said	O
biological	O
sample	O
;	O
and	O
(	O
c	O
)	O
comparing	O
the	O
amount	O
and	O
/	O
or	O
concentration	O
of	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptide	O
determine	O
in	O
said	O
biological	O
sample	O
with	O
the	O
amount	O
and	O
/	O
or	O
concentration	O
of	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptide	O
as	O
determined	O
in	O
a	O
control	O
sample	O
and	O
/	O
or	O
comparing	O
the	O
amount	O
and	O
/	O
or	O
concentration	O
of	O
nucleic	O
acids	O
encoding	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptide	O
determined	O
in	O
said	O
biological	O
sample	O
with	O
the	O
amount	O
and	O
/	O
or	O
concentration	O
of	O
nucleic	O
acids	O
encoding	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptides	O
measured	O
in	O
a	O
control	O
sample,	O
wherein	O
the	O
difference	O
in	O
the	O
amount	O
of	O
CALGRANULIN	B-GENE
C	I-GENE
polypeptide	O
and	O
/	O
or	O
nucleic	O
acids	O
encoding	O
the	O
polypeptide	O
is	O
indicative	O
for	O
the	O
stages	O
of	O
the	O
disease	O
to	O
be	O
diagnosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
tinnitus,	O
hearing	O
loss,	O
or	O
tinnitus	O
and	O
hearing	O
loss	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
an	O
NK1	B-GENE
receptor	I-GENE
antagonist	O
alone,	O
or	O
in	O
combination	O
with	O
an	O
effective	O
amount	O
of	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
.	O
Compositions	O
and	O
pharmaceutical	O
formulations	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
to	O
treat	O
glycerophosphodiester	B-GENE
phosphodiesterase	I-GENE
(	O
GDE	B-GENE
)	O
related	O
disorders	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
treating	O
GDE	B-GENE
related	O
disorders	O
.	O
The	O
invention	O
further	O
relates	O
to	O
kits	O
for	O
treating	O
GDE	B-GENE
related	O
disorders	O
in	O
a	O
subject	O
.	O
The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
identifying	O
novel	O
treatments	O
for	O
treating	O
GDE	B-GENE
related	O
disorders	O
in	O
a	O
subject	O
.	O


A	O
method	O
of	O
treating	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
in	O
a	O
subject	O
are	O
provided	O
.	O
The	O
method	O
comprise	O
altering	O
in	O
cells	O
of	O
the	O
subject	O
activity	O
and	O
/	O
or	O
expression	O
of	O
at	O
least	O
one	O
gene	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Mpo,	O
Ltf,	O
Lcn,	O
Camp,	O
Ngp,	O
Slfn,	O
Ctsg,	O
Thbs1,	O
S100a8,	O
1190003K14Rik,	O
Prtn3,	O
S100a9,	O
Tfpi,	O
Fzd6,	O
Nid1,	O
5830484A20Rik,	O
5830484A20	O
LOC	O
545340,	O
Tnfsf4,	O
IPstpip2,	O
Pigr,	O
270022B06Rik,	O
L5R-alpha,	O
A130040M12Rik,	O
Gpr132,	O
Cd8b1,	O
Dhx9,	O
Cyp11a1,	O
Lmo7,	O
Rnf184,	O
Pstpip2,	O
Hdgfrp3,	O
Ass1	B-GENE
and	O
Zbtb20,	O
thereby	O
treating	O
SLE	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
diagnosing	O
SLE	O
and	O
monitoring	O
treatment	O
of	O
SLE	O
.	O


Compounds	O
of	O
Formula	O
I	O
:	O
I	O
(	O
where	O
variables	O
R1A,	O
R1B,	O
R2,	O
R3,	O
R4,	O
A,	O
and	O
Z	O
are	O
as	O
defined	O
herein	O
)	O
useful	O
as	O
antagonists	O
of	O
CGRP	O
receptors,	O
and	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
CGRP	B-GENE
receptors	I-GENE
are	O
involved,	O
such	O
as	O
headache,	O
and	O
in	O
particular	O
migraine	O
and	O
cluster	O
headache	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	B-GENE
receptors	I-GENE
are	O
involved	O
.	O


A	O
skin-sensitizing	O
formulation	O
is	O
provided	O
in	O
an	O
edible,	O
softgel	O
pill	O
.	O
A	O
person	O
engaged	O
in	O
a	O
sexual	O
activity	O
bites	O
down	O
on	O
the	O
pill,	O
thereby	O
effectuating	O
the	O
oral	O
release	O
of	O
the	O
skin-sensitizing	O
formulation	O
.	O
This	O
allows	O
the	O
skin-sensitizing	O
formulation	O
to	O
be	O
spread	O
to	O
a	O
sexual	O
partner,	O
on	O
any	O
part	O
of	O
the	O
skin	O
or	O
sexual	O
region	O
of	O
the	O
body	O
preferably	O
through	O
oral	O
contact	O
with	O
the	O
partner	O
.	O
The	O
skin-sensitizing	O
substance	O
is	O
spread	O
to	O
the	O
partner	O
directly	O
on	O
the	O
skin	O
or	O
through	O
oral	O
contact	O
or	O
beneath	O
a	O
condom	O
worn	O
by	O
the	O
partner	O
.	O
The	O
skin-sensitizing	O
formulation	O
may	O
include	O
an	O
essential	O
mint	O
oil,	O
analog	O
or	O
derivative,	O
and	O
may	O
further	O
includes	O
an	O
enhancer,	O
rubefacient,	O
counterirritant,	O
anesthetic,	O
K-Opoid	B-GENE
Receptor	I-GENE
activator,	O
or	O
TRPM8	B-GENE
activator	O
.	O
Various	O
inactive	O
ingredients	O
are	O
also	O
disclosed	O
.	O


Methods	O
of	O
modulating	O
blood	O
glucose	O
levels	O
treating	O
hyperglycemia	O
and	O
related	O
complications	O
and	O
conditions	O
by	O
administration	O
of	O
a	O
VGF	B-GENE
biomolecule	O
to	O
a	O
patient	O
in	O
need	O
of	O
such	O
treatment	O
are	O
provided	O
.	O
Methods	O
of	O
enhancing	O
insulin	B-GENE
secretion	O
from	O
islet	O
beta	O
cells	O
in	O
a	O
mammal	O
exhibiting	O
reduced	O
insulin	B-GENE
secretion	O
by	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
VGF	B-GENE
biomolecule	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
where	O
R53,	O
R54,	O
p,	O
q,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
have	O
been	O
found	O
to	O
be	O
useful	O
as	O
17α-hydroxylase/C17,20-lyase	B-GENE
inhibitors	O
.	O


The	O
CA125	B-GENE
gene	O
has	O
been	O
cloned	O
and	O
multiple	O
repeat	O
sequences	O
as	O
well	O
as	O
the	O
carboxy	O
terminus	O
have	O
been	O
identified	O
.	O
The	O
CA125	B-GENE
molecule	O
comprises	O
three	O
major	O
domains	O
:	O
an	O
extracellular	O
amino	O
terminal	O
domain	O
(	O
Domain	O
1	O
)	O
;	O
a	O
large	O
multiple	O
repeat	O
domain	O
(	O
Domain	O
2	O
)	O
;	O
and	O
a	O
carboxy	O
terminal	O
domain	O
(	O
Domain	O
3	O
)	O
which	O
includes	O
a	O
transmembrane	O
anchor	O
with	O
a	O
short	O
cytoplasmic	O
domain	O
.	O
The	O
amino	O
terminal	O
domain	O
is	O
dominated	O
by	O
its	O
capacity	O
for	O
O-glycosylation	O
and	O
its	O
resultant	O
richness	O
in	O
serine	O
and	O
threonine	O
residues	O
.	O
An	O
amino	O
terminal	O
extension	O
is	O
presented,	O
which	O
comprises	O
four	O
genomic	O
exons	O
.	O
The	O
molecular	O
structure	O
is	O
dominated	O
by	O
a	O
repeat	O
domain	O
comprising	O
156	O
amino	O
acid	O
repeat	O
units,	O
which	O
encompass	O
the	O
epitope	O
binding	O
sites	O
.	O
More	O
than	O
60	O
repeat	O
units	O
have	O
been	O
identified,	O
sequenced,	O
and	O
contiguously	O
placed	O
in	O
the	O
CA125	B-GENE
domain	O
structure	O
.	O
More	O
specifically,	O
this	O
invention	O
is	O
directed	O
to	O
a	O
CA125	B-GENE
cDNA	O
sequence	O
which	O
can	O
be	O
introduced	O
into	O
animal	O
or	O
human	O
cells	O
to	O
achieve	O
transcription	O
or	O
expression	O
of	O
the	O
cDNA	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
formula	O
(	O
IV	O
)	O
(	O
M	O
)	O
-	O
(	O
L	O
)	O
-	O
(	O
M	O
)	O
(	O
I	O
)	O
[	O
(	O
M	O
)	O
-	O
(	O
L4	O
)	O
]	O
t-G	O
(	O
VI	O
)	O
wherein	O
M,	O
L,	O
L4,	O
G	O
and	O
t	O
are	O
as	O
defined	O
in	O
the	O
specification	O
and	O
optical	O
isomers,	O
racemates	O
and	O
tautomers	O
thereof,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
human	B-GENE
neutrophil	I-GENE
elastase	I-GENE
.	O


Antisense	O
oligonucleotides	O
directed	O
to	O
the	O
coding	O
region	O
of	O
a	O
mammalian	B-GENE
thymidylate	B-GENE
synthase	I-GENE
mRNA	I-GENE
that	O
are	O
capable	O
of	O
inhibiting	O
the	O
proliferation	O
of	O
cancer	O
cells	O
without	O
decreasing	O
the	O
level	O
of	O
thymidylate	B-GENE
synthase	I-GENE
mRNA	I-GENE
in	O
the	O
cells	O
are	O
provided	O
.	O
The	O
antisense	O
oligonucleotides	O
are	O
also	O
capable	O
of	O
inducing	O
apoptosis	O
in	O
the	O
cancer	O
cells	O
.	O
The	O
antisense	O
oligonucleotides	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
proliferation	O
of	O
cancer	O
cells	O
and	O
to	O
induce	O
apoptosis	O
in	O
cancer	O
cells	O
.	O
Methods	O
of	O
treating	O
cancer,	O
and	O
in	O
particular	O
breast	O
cancer,	O
with	O
the	O
antisense	O
oligonucleotides,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutics,	O
are	O
also	O
provided	O
.	O


The	O
invention	O
relates	O
to	O
a	O
double-stranded	O
ribonucleic	O
acid	O
(	O
dsRNA	O
)	O
for	O
inhibiting	O
the	O
expression	O
of	O
an	O
Aha	B-GENE
gene	O
(	O
Aha1	B-GENE
gene	O
)	O
,	O
comprising	O
an	O
antisense	O
strand	O
having	O
a	O
nucleotide	O
sequence	O
which	O
is	O
less	O
that	O
30	O
nucleotides	O
in	O
length,	O
generally	O
19-25	O
nucleotides	O
in	O
length,	O
and	O
which	O
is	O
substantially	O
complementary	O
to	O
at	O
least	O
a	O
part	O
of	O
an	O
Aha	B-GENE
gene	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
dsRNA	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
;	O
methods	O
for	O
treating	O
diseases	O
caused	O
by	O
Aha1	B-GENE
expression	O
and	O
the	O
expression	O
of	O
an	O
Aha	B-GENE
gene	O
using	O
the	O
pharmaceutical	O
composition	O
;	O
and	O
methods	O
for	O
inhibiting	O
the	O
expression	O
of	O
an	O
Aha	B-GENE
gene	O
in	O
a	O
cell	O
.	O


The	O
present	O
invention	O
relates	O
to	O
5,6-bisaryl-2-pyridinecarboxamides,	O
to	O
their	O
preparation	O
and	O
to	O
their	O
therapeutic	O
use	O
as	O
urotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonists	O
.	O


Crystals	O
of	O
isopropyl	O
ester	O
of	O
N-	O
(	O
2,6-dichlorobenzoyl	O
)	O
-4-	O
[	O
6-	O
(	O
methylamino	O
)	O
methyl-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3	O
(	O
2H	O
)	O
-yl	O
]	O
-L-phenylalanine	O
hydrochloride	O
are	O
useful	O
as	O
α4	B-GENE
integrin	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
targets	O
of	O
loss	O
of	O
imprinting	O
(	O
LOI	O
)	O
affected	O
IGF2	B-GENE
gene	O
products	O
in	O
pre-malignant	O
tissues,	O
where	O
methods	O
of	O
inhibiting	O
those	O
targets,	O
including	O
IGFR1,	O
are	O
disclosed	O
to	O
prevent	O
tumor	O
development	O
in	O
subjects	O
at	O
risk	O
for	O
developing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
identifying	O
increased	O
risk	O
in	O
developing	O
CRC	O
in	O
a	O
subject,	O
including	O
methods	O
of	O
assessing	O
the	O
efficacy	O
of	O
a	O
chemotherapeutic	O
regimen	O
.	O
Further,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
identifying	O
anti-neoplastic	O
agents	O
.	O


A	O
solid	O
pharmaceutical	O
dosage	O
form	O
providing	O
improved	O
oral	O
bioavailability	O
is	O
disclosed	O
for	O
inhibitors	O
of	O
HIV	B-GENE
protease	I-GENE
.	O
In	O
particular,	O
the	O
dosage	O
form	O
comprises	O
a	O
solid	O
dispersion	O
of	O
at	O
least	O
one	O
HIV	B-GENE
protease	I-GENE
inhibitor	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
water-soluble	O
polymer	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
surfactant,	O
said	O
pharmaceutically	O
acceptable	O
water-soluble	O
polymer	O
having	O
a	O
Tg	O
of	O
at	O
least	O
about	O
50°	O
C	O
.	O
Preferably,	O
the	O
pharmaceutically	O
acceptable	O
surfactant	O
has	O
an	O
HLB	O
value	O
of	O
from	O
about	O
4	O
to	O
about	O
10	O
.	O


The	O
present	O
invention	O
provides	O
methods,	O
compositions	O
and	O
kits	O
for	O
preventing,	O
inhibiting,	O
reducing	O
and	O
reversing	O
weight	O
gain	O
induced	O
by	O
antipsychotic	O
medications,	O
for	O
example	O
olanzapine	O
and	O
clozapine,	O
by	O
co-administration	O
of	O
an	O
M1R-selective	O
antagonist,	O
for	O
example,	O
telenzepine	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
modulating	O
bile	O
acid	O
and	O
lipid	O
transport	O
via	O
the	O
organic	B-GENE
solute	I-GENE
and	I-GENE
steroid	I-GENE
transporter	I-GENE
Ostα-Ostβ	O
.	O
The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
of	O
treating	O
a	O
patient	O
having	O
dyslipidemia	O
or	O
a	O
condition	O
associated	O
with	O
altered	O
bile	O
acid	O
homeostasis	O
.	O
Therapeutic	O
agents	O
and	O
pharmaceutical	O
compositions	O
that	O
modulate	O
Ostα-Ostβ	O
heteromeric	O
complex	O
formation	O
and	O
/	O
or	O
transport	O
activity	O
are	O
also	O
disclosed	O
.	O


A	O
composition	O
for	O
use	O
in	O
cardiovascular	O
therapy	O
includes	O
transfer	O
factor	I-GENE
.	O
The	O
transfer	O
factor	I-GENE
may	O
be	O
nonmammalian	B-GENE
transfer	I-GENE
factor,	O
such	O
as	O
that	O
derived	O
from	O
eggs,	O
or	O
mammalian	B-GENE
transfer	I-GENE
factor,	O
such	O
as	O
that	O
derived	O
from	O
colostrum	O
.	O
The	O
composition	O
may	O
also	O
include	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
an	O
LDL	O
receptor-binding	O
element	O
;	O
a	O
blood	O
flow-enhancing	O
element	O
;	O
a	O
cholesterol	O
reducing	O
element	O
;	O
a	O
fat	O
oxidation	O
prevention	O
element,	O
and	O
an	O
antioxidant	O
.	O
Treatment	O
methods	O
include	O
enlisting	O
the	O
immune	O
system	O
of	O
a	O
subject	O
receiving	O
therapy	O
to	O
attack	O
pathogens	O
that	O
cause	O
inflammation	O
of	O
blood	O
vessels	O
or	O
to	O
otherwise	O
reduce	O
inflammation	O
of	O
blood	O
vessels	O
.	O


Pharmaceutical	O
compositions	O
for	O
treating	O
male	O
sub-fertility	O
that	O
include	O
an	O
agent	O
that	O
causes	O
a	O
reduction	O
in	O
an	O
effect	O
of	O
extracellular	O
DNA	O
on	O
sperm	O
cells,	O
are	O
provided	O
.	O
The	O
agent	O
may	O
be,	O
for	O
example,	O
an	O
enzyme	O
that	O
degrades	O
DNA	O
such	O
as	O
DNase,	O
a	O
substance	O
that	O
blocks	O
the	O
interaction	O
between	O
cell	O
free	O
DNA	O
and	O
sperm	O
cell	O
surface	O
receptors,	O
a	O
substance	O
that	O
binds	O
to	O
DNA,	O
a	O
substance	O
that	O
inhibits	O
endogenous	O
sperm	O
cell	O
DNase,	O
a	O
substance	O
that	O
inhibits	O
a	O
member	O
of	O
a	O
signal	O
transduction	O
pathway	O
mediated	O
by	O
DNA	O
binding	O
to	O
sperm	O
cell	O
surface	O
receptors,	O
or	O
an	O
agent	O
that	O
stimulates	O
production	O
of	O
an	O
endogenous	O
substance	O
that	O
causes	O
a	O
reduction	O
in	O
an	O
antifertility	O
effect	O
of	O
cell	O
free	O
DNA	O
on	O
sperm	O
cells	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
treating	O
male	O
sub-fertility	O
by	O
administering	O
the	O
pharmaceutical	O
composition	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O
Further	O
provided	O
are	O
methods	O
for	O
determining	O
a	O
fertility	O
status	O
in	O
a	O
male	O
subject,	O
methods	O
for	O
assisted	O
reproduction,	O
methods	O
for	O
selecting	O
an	O
assisted	O
reproduction	O
technique	O
(	O
ART	O
)	O
,	O
and	O
methods	O
for	O
selecting	O
sperm	O
cells	O
in	O
a	O
sperm	O
cell	O
population	O
for	O
use	O
in	O
an	O
assisted	O
reproduction	O
technique	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
CGRP	B-GENE
antagonists	O
of	O
general	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
claim	O
1,	O
the	O
tautomers,	O
the	O
isomers,	O
the	O
diastereomers,	O
the	O
enantiomers,	O
the	O
hydrates	O
thereof,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
and	O
the	O
hydrates	O
of	O
the	O
salts	O
thereof,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases,	O
as	O
well	O
as	O
those	O
compounds	O
of	O
general	O
formula	O
I	O
wherein	O
one	O
or	O
more	O
hydrogen	O
atoms	O
are	O
replaced	O
by	O
deuterium,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
their	O
use	O
and	O
processes	O
for	O
preparing	O
them	O
.	O


MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
diverse	O
and	O
abundant	O
class	O
of	O
˜22-nucleotide	O
(	O
nt	O
)	O
endogenous	O
regulatory	O
RNAs	O
that	O
play	O
a	O
variety	O
of	O
roles	O
in	O
animal	O
cells	O
by	O
controlling	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
.	O
Increased	O
miR-181a	B-GENE
expression	O
in	O
mature	O
T	O
cells	O
is	O
shown	O
to	O
cause	O
a	O
marked	O
increase	O
in	O
T	B-GENE
cell	I-GENE
activation	O
and	O
augments	O
T	B-GENE
cell	I-GENE
sensitivity	O
to	O
peptide	O
antigens	O
.	O
Moreover,	O
T	B-GENE
cell	I-GENE
blasts	O
with	O
higher	O
miR-181a	B-GENE
expression	O
become	O
reactive	O
to	O
antagonists	O
.	O
The	O
effects	O
of	O
miR-181a	B-GENE
on	O
antigen	O
discrimination	O
are	O
in	O
part	O
achieved	O
by	O
dampening	O
the	O
expression	O
of	O
multiple	O
negative	O
regulators	O
in	O
the	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
(	O
TCR	B-GENE
)	O
signaling	O
pathway,	O
including	O
PTPN22	B-GENE
and	O
the	O
dual	B-GENE
specificity	I-GENE
phosphatases	I-GENE
DUSP5	B-GENE
and	O
DUSP6	B-GENE
.	O
This	O
results	O
in	O
a	O
reduction	O
in	O
the	O
TCR	B-GENE
signaling	O
threshold,	O
thus	O
quantitatively	O
and	O
qualitatively	O
enhancing	O
T	B-GENE
cell	I-GENE
sensitivity	O
to	O
antigens	O
.	O


A	O
method	O
to	O
determine	O
the	O
clinical	O
outcome	O
of	O
breast	O
tumour	O
affecting	O
a	O
patient	O
if	O
treated	O
with	O
an	O
antitumoural	O
agent	O
against	O
breast	O
tumour	O
.	O
The	O
method	O
includes	O
the	O
step	O
of	O
assaying	O
a	O
sample	O
of	O
a	O
breast	O
tumour	O
from	O
the	O
patient	O
for	O
an	O
expression	O
level	O
of	O
selected	O
genes,	O
by	O
contacting	O
mRNA	O
sequences	O
from	O
the	O
cells	O
of	O
this	O
breast	O
tumour	O
with	O
a	O
set	O
of	O
more	O
than	O
3	O
nucleotide	O
sequences	O
related	O
to	O
human	O
mutated	O
PIK3CA	B-GENE
.	O


The	O
present	O
invention	O
provides	O
compounds	O
which	O
have	O
an	O
inhibitory	O
effect	O
on	O
hormone-sensitive	B-GENE
lipase	I-GENE
or	O
endothelial	B-GENE
lipase	I-GENE
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
azolopyridin-2-one	O
derivatives	O
of	O
the	O
general	O
formula	O
I	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
substituents	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
wherein	O
R2	O
is	O
hydrogen	O
are	O
distinguished	O
by	O
favorable	O
effects	O
on	O
disorders	O
of	O
lipid	O
metabolism	O
.	O
They	O
beneficially	O
influence	O
the	O
HDL	O
to	O
LDL	O
ratio	O
and	O
increase	O
in	O
particular	O
the	O
HDL	O
level	O
and	O
are	O
suitable	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dyslipidemias	O
and	O
metabolic	O
syndrome	O
and	O
their	O
diverse	O
sequelae	O
such	O
as	O
atherosclerosis,	O
coronary	O
heart	O
disease,	O
heart	O
failure,	O
obesity	O
and	O
diabetes	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
wherein	O
R1	O
and	O
R2	O
together	O
form	O
a	O
ring	O
system	O
are	O
distinguished	O
by	O
favorable	O
effects	O
on	O
metabolic	O
disorders	O
.	O
They	O
beneficially	O
influence	O
lipid	O
and	O
sugar	O
metabolism	O
;	O
in	O
particular	O
they	O
lower	O
the	O
triglyceride	O
level	O
and	O
are	O
suitable	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
type	O
II	O
diabetes	O
and	O
arteriosclerosis	O
and	O
the	O
diverse	O
sequelae	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
Q	O
have	O
a	O
meaning	O
as	O
defined	O
herein	O
in	O
the	O
specification	O
.	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
allosteric	O
modulators	O
of	O
the	O
A1	B-GENE
adenosine	I-GENE
receptor	I-GENE
and,	O
thus,	O
may	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
the	O
Al	B-GENE
adenosine	I-GENE
receptor	I-GENE
.	O
Accordingly,	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
may	O
be	O
employed	O
for	O
treatment	O
of	O
pain,	O
in	O
particular,	O
chronic	O
pain	O
such	O
as	O
neuropathic	O
pain	O
;	O
cardiac	O
disease	O
or	O
disorder	O
such	O
as	O
cardiac	O
disarrhythmias,	O
e	O
.	O
g	O
.	O
,	O
peroxysmal	O
supraventricular	O
tachycardia,	O
angina,	O
myocardial	O
infarction	O
and	O
stroke	O
;	O
neurological	O
disease	O
or	O
injury	O
;	O
sleep	O
disorder	O
;	O
epilepsy	O
;	O
and	O
depression	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
aminopyrimidine	O
inhibitors	O
of	O
tyrosine	B-GENE
kinase	I-GENE
activity,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O


Disclosed	O
is	O
a	O
human	B-GENE
serum	I-GENE
albumin	I-GENE
(	O
HSA	B-GENE
)	O
linker	O
and	O
HSA	B-GENE
linker	O
with	O
binding,	O
diagnostic,	O
and	O
therapeutic	O
agents	O
conjugated	O
thereto	O
.	O
Also	O
disclosed	O
is	O
a	O
conjugate	O
in	O
which	O
the	O
HSA	B-GENE
linker	O
is	O
covalently	O
bonded	O
to	O
amino	O
and	O
carboxy	O
terminal	O
binding	O
moieties	O
that	O
are	O
first	O
and	O
second	O
single-chain	O
Fv	O
molecules	O
(	O
scFvs	O
)	O
.	O
Exemplified	O
conjugates	O
are	O
useful,	O
e	O
.	O
g	O
.	O
,	O
in	O
reducing	O
tumor	O
cell	O
proliferation,	O
e	O
.	O
g	O
.	O
,	O
for	O
therapeutic	O
therapeutic	O
applications	O
.	O
Also	O
disclosed	O
are	O
methods	O
and	O
kits	O
for	O
the	O
diagnostic	O
and	O
therapeutic	O
application	O
of	O
an	O
HSA	B-GENE
linker	O
conjugate	O
.	O


This	O
invention	O
concerns	O
N-	O
(	O
2-arylamino	O
)	O
aryl	O
sulfonamide	O
compounds	O
which	O
are	O
inhibitors	O
of	O
MEK	B-GENE
including	O
crystalline	O
polymorphic	O
forms	O
which	O
exhibit	O
a	O
specific	O
powder	O
x-ray	O
diffraction	O
profile	O
and	O
/	O
or	O
a	O
specific	O
differential	O
scanning	O
calorimetry	O
profile	O
.	O
This	O
invention	O
also	O
concerns	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
described	O
herein	O
and	O
methods	O
of	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
described	O
herein,	O
including	O
the	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
cancer,	O
hyperproliferative	O
diseases	O
and	O
inflammatory	O
conditions	O
.	O
The	O
invention	O
also	O
concerns	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
compositions	O
described	O
herein	O
.	O


The	O
invention	O
includes	O
a	O
compound	O
of	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
X,	O
Z,	O
n,	O
and	O
m	O
have	O
any	O
of	O
the	O
values	O
described	O
herein,	O
as	O
well	O
as	O
salts	O
of	O
such	O
compounds,	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
therapeutic	O
methods	O
that	O
comprise	O
the	O
administration	O
of	O
such	O
compounds	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PDE4	B-GENE
function	O
and	O
are	O
useful	O
for	O
improving	O
cognitive	O
function	O
in	O
animals	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
substituted	O
triazolo-pyridazines	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
an	O
α1-GABAA	B-GENE
receptor	I-GENE
antagonist	O
or	O
an	O
α2-	B-GENE
and/or	I-GENE
an	I-GENE
α3-GABAA	I-GENE
receptor	I-GENE
partial	O
agonist	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
amidines	O
and	O
quanidines,	O
the	O
production	O
and	O
use	O
thereof	O
and	O
the	O
use	O
thereof	O
as	O
trypsine-type	B-GENE
serine	I-GENE
protease	I-GENE
competitive	O
inhibitors,	O
especially	O
thrombine	B-GENE
and	O
compliment	B-GENE
proteases	I-GENE
CIs	I-GENE
and	O
C1r	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
which	O
contain	O
said	O
compounds	O
as	O
active	O
ingredients,	O
in	O
addition	O
to	O
the	O
use	O
of	O
the	O
compounds	O
as	O
thrombine	B-GENE
inhibitors,	O
anticoagulants,	O
compliment	O
inhibitors	O
and	O
anti-inflammatory	O
agents	O
.	O
The	O
novel	O
compositions	O
are	O
characterised	O
by	O
the	O
linkage	O
of	O
a	O
serine	O
protease	I-GENE
inhibitor	O
having	O
amidine	O
or	O
guanidine	O
functions	O
with	O
an	O
alkyl	O
radical	O
having	O
two	O
or	O
more	O
hydroxyl	O
functions,	O
whereby	O
said	O
alkyl	O
radical	O
is	O
derived	O
from	O
sugar	O
derivates	O
.	O
Several	O
sugar	O
structural	O
components	O
or	O
components	O
derived	O
from	O
sugar	O
can	O
therefore	O
be	O
linked	O
to	O
each	O
other	O
.	O
Said	O
principle	O
of	O
linking	O
sugar	O
derivates	O
enables	O
oral	O
active	O
compounds	O
to	O
be	O
obtained	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
amyloid	B-GENE
binding	O
compounds	O
and	O
methods	O
for	O
measuring	O
effects	O
of	O
the	O
compounds,	O
by	O
measuring	O
changes	O
of	O
amyloid	B-GENE
plaque	O
level	O
in	O
living	O
patients	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
compounds	O
of	O
this	O
invention	O
as	O
tracers	O
in	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
to	O
study	O
amyloid	B-GENE
deposits	O
in	O
brain	O
in	O
vivo	O
to	O
allow	O
diagnosis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Thus,	O
the	O
present	O
invention	O
relates	O
to	O
use	O
of	O
the	O
novel	O
amyloid	B-GENE
binding	O
compounds	O
as	O
a	O
diagnostic	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
measuring	O
clinical	O
efficacy	O
of	O
Alzheimer	O
'	O
s	O
disease	O
therapeutic	O
agents	O
.	O
Specifically,	O
the	O
present	O
invention	O
relates	O
to	O
novel	O
aryl	O
or	O
heteroaryl	O
substituted	O
indole	O
derivatives,	O
compositions,	O
and	O
therapeutic	O
uses	O
and	O
processes	O
for	O
making	O
such	O
compounds	O
.	O


Embodiments	O
of	O
the	O
present	O
invention	O
concern	O
methods,	O
compositions	O
and	O
uses	O
thereof,	O
relating	O
to	O
at	O
least	O
one	O
of	O
vitiligo,	O
or	O
vitiligo-associated	O
autoimmune	O
/	O
autoinflammatory	O
disease	O
(	O
VAAAD	O
)	O
.	O
In	O
particular	O
embodiments,	O
genetic	O
variations	O
in	O
the	O
NALP1	B-GENE
gene	O
are	O
of	O
use	O
to	O
detect,	O
diagnose,	O
predict	O
the	O
risk	O
of	O
or	O
treat	O
at	O
least	O
one	O
of	O
vitiligo	O
or	O
VAAAD	O
.	O
In	O
more	O
particular	O
embodiments,	O
the	O
presence	O
of	O
genetic	O
variations	O
such	O
as	O
single-nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
NALP1	B-GENE
genetic	O
region	O
are	O
of	O
use	O
to	O
detect,	O
diagnose	O
or	O
predict	O
the	O
risk	O
of	O
VAAAD	O
.	O
In	O
other	O
embodiments,	O
inhibitors	O
targeted	O
to	O
NALP1,	O
caspase-1	B-GENE
or	O
caspase-5,	O
ASC	B-GENE
(	O
PYCARD	B-GENE
)	O
,	O
interleukin-1β,	O
interleukin-1β	B-GENE
receptor,	O
or	O
interleukin	B-GENE
18	I-GENE
may	O
be	O
administered	O
to	O
a	O
subject	O
to	O
treat	O
VAAAD	O
.	O


Methods	O
of	O
increasing	O
the	O
permeability	O
of	O
corneal	O
epithelium	O
to	O
facilitate	O
the	O
diffusion	O
of	O
agents	O
into	O
the	O
collagen	B-GENE
fibrillar	O
network	O
of	O
the	O
stroma	O
are	O
provided	O
.	O
Used	O
in	O
combination,	O
these	O
methods	O
open	O
the	O
epithelium	O
to	O
facilitate	O
diffusion	O
of	O
stabilization	O
molecules	O
into	O
the	O
stroma	O
and	O
dissociate	O
bridging	O
molecules	O
from	O
stromal	O
collagen	B-GENE
fibers,	O
thereby	O
priming	O
the	O
collagen	B-GENE
fibrillar	O
network	O
for	O
restabilization	O
by	O
stabilization	O
molecules	O
.	O
These	O
methods	O
can	O
be	O
used	O
to	O
increase	O
the	O
effectiveness	O
and	O
longevity	O
of	O
non-invasive	O
corneal	O
reshaping,	O
such	O
as	O
orthokeratology,	O
for	O
correcting	O
myopia,	O
hyperopia	O
and	O
astigmatism	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
guanine	O
nucleotide	O
analogs	O
which	O
inhibit	O
RelA	B-GENE
and	O
Relseq	O
synthetic	O
activity	O
and	O
which	O
possess	O
anti-bacterial	O
activity	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
that	O
include	O
such	O
compounds,	O
and	O
to	O
methods	O
of	O
use	O
of	O
such	O
compounds	O
or	O
compositions	O
for	O
combating	O
bacteria	O
and	O
treating	O
bacterial	O
infections	O
.	O


Selected	O
compounds	O
are	O
effective	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
inflammation	O
and	O
inflammatory	O
disorders,	O
such	O
as	O
NIK-mediated	O
disorders	O
.	O
The	O
invention	O
encompasses	O
novel	O
compounds,	O
analogs,	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
and	O
other	O
maladies	O
or	O
conditions	O
involving,	O
inflammation	O
and	O
the	O
like	O
.	O


A2A	B-GENE
agonists	O
of	O
formula	O
(	O
I	O
)	O
is	O
provided,	O
wherein	O
R1,	O
R2,	O
R4,	O
R5,	O
X,	O
Y,	O
Z,	O
n,	O
p,	O
and	O
q	O
are	O
as	O
described	O
herein	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
Also	O
provided	O
are	O
compositions	O
comprising	O
and	O
methods	O
of	O
using	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
provides	O
compositions	O
containing	O
hydroxyethyl	O
starch	O
and	O
polypeptides,	O
including	O
therapeutic	O
polypeptides	O
such	O
as	O
interleukin-11,	O
that	O
provide	O
for	O
enhanced	O
stability	O
of	O
the	O
polypeptide	O
following	O
storage	O
at	O
room	O
temperature	O
or	O
elevated	O
temperatures	O
.	O


Diamino-pyridine,	O
pyrimidine	O
and	O
pyridazine	O
compounds	O
which	O
may	O
be	O
used	O
as	O
H4	B-GENE
receptor	I-GENE
modulators,	O
and	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disease	O
states,	O
disorders,	O
and	O
conditions	O
mediated	O
by	O
H4	B-GENE
receptor	I-GENE
activity,	O
such	O
as	O
allergy,	O
asthma,	O
autoimmune	O
diseases,	O
and	O
pruritis	O
.	O


Compounds,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
stabilizing	O
transthyretin	B-GENE
and	O
for	O
treating,	O
preventing,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
transthyretin	B-GENE
mediated	O
diseases	O
.	O
In	O
one	O
embodiment,	O
the	O
compounds	O
are	O
benzoxazoles	O
and	O
related	O
compounds	O
.	O


Aspects	O
featured	O
in	O
the	O
invention	O
relate	O
to	O
compositions	O
and	O
methods	O
for	O
inhibiting	O
alpha-synuclein	B-GENE
(	O
SNCA	B-GENE
)	O
gene	O
expression,	O
such	O
as	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O
An	O
anti-SNCA	O
agent	O
featured	O
herein	O
that	O
targets	O
the	O
SNCA	B-GENE
gene	O
can	O
have	O
been	O
modified	O
to	O
alter	O
distribution	O
in	O
favor	O
of	O
neural	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
diagnosis	O
and	O
therapy	O
of	O
hematological	O
malignancies	O
based	O
on	O
the	O
tumor	O
antigen	O
FMR1NB	B-GENE
(	O
also	O
called	O
NY-SAR-35,	O
Cancer/testis	B-GENE
antigen	I-GENE
37	I-GENE
or	O
Fragile	B-GENE
X	I-GENE
mental	I-GENE
retardation	I-GENE
1	I-GENE
neighbor	I-GENE
protein	I-GENE
)	O
and	O
agents	O
specifically	O
targeting	O
this	O
antigen	O
or	O
cells	O
expressing	O
the	O
same,	O
e	O
.	O
g	O
.	O
,	O
antibodies	O
.	O
The	O
inventors	O
were	O
able	O
to	O
prove	O
that	O
the	O
molecule	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
and	O
thus	O
represents	O
a	O
particularly	O
advantageous	O
target	O
in	O
cancer	O
therapy	O
and	O
vaccination	O
.	O
Surprisingly,	O
FMR1NB	B-GENE
was	O
found	O
to	O
be	O
associated	O
with	O
hematological	O
malignancies,	O
e	O
.	O
g	O
.	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
or	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
HLA-A	B-GENE
*	O
1101-restricted	O
WT1	O
peptide,	O
specifically,	O
a	O
peptide	O
comprising	O
an	O
amino	O
acid	O
sequence	O
consisting	O
of	O
9	O
contiguous	O
amino	O
acids	O
from	O
a	O
	O
	O
	O
	O
WT1	O
protein,	O
wherein	O
the	O
peptide	O
has	O
an	O
ability	O
to	O
bind	O
to	O
an	O
HLA-A	B-GENE
*	O
1101	O
molecule,	O
and	O
has	O
an	O
ability	O
to	O
induce	O
a	O
CTL	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
peptide	O
dimer	O
having	O
an	O
ability	O
to	O
bind	O
to	O
an	O
HLA-A	B-GENE
*	O
1101	O
molecule	O
and	O
having	O
an	O
ability	O
to	O
induce	O
a	O
CTL,	O
in	O
which	O
two	O
peptide	O
monomers	O
each	O
comprising	O
an	O
amino	O
acid	O
sequence	O
consisting	O
of	O
9	O
contiguous	O
amino	O
acids	O
from	O
a	O
WT1	B-GENE
protein	I-GENE
and	O
comprising	O
at	O
least	O
one	O
cysteine	O
residue	O
are	O
bound	O
to	O
each	O
other	O
through	O
a	O
disulfide	O
bond	O
.	O
Furthermore,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
polynucleotide	O
encoding	O
the	O
peptide,	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
a	O
cancer	O
comprising	O
the	O
same	O
and	O
the	O
like	O
.	O


Analogs	O
and	O
derivatives	O
of	O
rapamycin	O
are	O
provided,	O
wherein	O
the	O
analogs	O
and	O
derivatives	O
can	O
bind	O
to	O
FK-506	B-GENE
binding	I-GENE
protein	I-GENE
(	O
FKBP	B-GENE
)	O
,	O
or	O
inhibit	O
the	O
mTOR	B-GENE
function	O
of	O
an	O
FKBP,	O
or	O
both	O
.	O
The	O
analogs	O
and	O
derivatives	O
are	O
rapamycin	O
include	O
the	O
rapamycin	O
skeleton	O
substituted	O
at	O
the	O
42-hydroxyl	O
group	O
with	O
certain	O
specified	O
chemically	O
feasible	O
groups	O
.	O
Methods	O
of	O
using	O
the	O
rapamycin	O
analogs	O
and	O
derivatives	O
in	O
treatment	O
of	O
malconditions	O
such	O
as	O
cancer,	O
and	O
methods	O
of	O
synthesizing	O
the	O
rapamycin	O
analogs	O
and	O
derivatives,	O
are	O
provided	O
.	O


The	O
present	O
concerns	O
a	O
solidifiable	O
bone	O
precursor	O
composition	O
which	O
can	O
be	O
used	O
to	O
produce	O
a	O
mineralized	O
substitute	O
bone	O
tissue	O
material	O
and	O
the	O
method	O
of	O
making	O
the	O
substitute	O
bone	O
tissue	O
material	O
.	O
The	O
substitute	O
bone	O
tissue	O
material	O
includes	O
a	O
collagen	B-GENE
matrix	O
comprising	O
pores,	O
and	O
an	O
apatitic	O
mineral	O
within	O
the	O
pores	O
of	O
general	O
formula	O
:	O
	O
	O
	O
	O
	O
As	O
(	O
TOx	O
)	O
t	O
(	O
QOx	O
)	O
uZy	O
	O
	O
	O
	O
	O
	O
wherein	O
A	O
is	O
a	O
cation	O
selected	O
from	O
Na,	O
K,	O
Mg,	O
Ca,	O
Fe3+,	O
Al3+	O
or	O
combinations	O
thereof,	O
T	O
and	O
Q	O
are	O
an	O
anion	O
oxide	O
selected	O
from	O
P	O
or	O
C,	O
Z	O
is	O
a	O
H,	O
OH	O
or	O
a	O
halogen	O
group,	O
and	O
s	O
is	O
1	O
to	O
10,	O
x	O
is	O
2	O
to	O
4,	O
t	O
is	O
1	O
to	O
3,	O
is	O
0	O
to	O
3	O
and	O
y	O
is	O
0	O
to	O
3	O
.	O
The	O
solidifiable	O
bone	O
precursor	O
composition	O
includes	O
:	O
an	O
aqueous	O
dispersion	O
comprising	O
:	O
at	O
least	O
one	O
cation	O
;	O
and	O
a	O
polyphosphate	O
combined	O
to	O
produce	O
a	O
cation-polyphosphate	O
granule	O
;	O
and	O
a	O
collagen	B-GENE
.	O


This	O
application	O
discloses	O
5-phenyl-1H-pyridin-2-one	O
and	O
6-phenyl-2H-pyridazin-3-one	O
derivatives	O
according	O
to	O
generic	O
Formulae	O
I-IV	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein,	O
variables	O
R,	O
X,	O
Y1,	O
Y2,	O
Y2′,	O
Y3,	O
Y4,	O
n	O
and	O
m	O
are	O
defined	O
as	O
described	O
herein,	O
which	O
inhibit	O
Btk	B-GENE
.	O
The	O
compounds	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
Btk	B-GENE
and	O
treat	O
diseases	O
associated	O
with	O
excessive	O
Btk	B-GENE
activity	O
.	O
The	O
compounds	O
are	O
further	O
useful	O
to	O
treat	O
inflammatory	O
and	O
auto	O
immune	O
diseases	O
associated	O
with	O
aberrant	O
B-cell	O
proliferation	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O
Also	O
disclosed	O
are	O
compositions	O
comprising	O
compounds	O
of	O
Formulae	O
I-IV	O
and	O
at	O
least	O
one	O
carrier,	O
diluent	O
or	O
excipient	O
.	O


The	O
present	O
invention	O
provides	O
imidazole	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
RAGE-mediated	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
Disease	O
.	O
	O
	O
	O
	O
The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
the	O
use	O
the	O
such	O
compounds	O
and	O
/	O
or	O
pharmaceutical	O
compositions	O
in	O
treating	O
RAGE-mediated	O
diseases	O
.	O


Disclosed	O
herein	O
are	O
compounds,	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
a	O
Gemin	B-GENE
Gene	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
target	O
validation	O
.	O
Also	O
provided	O
are	O
uses	O
of	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders	O
.	O


A	O
method	O
of	O
utilizing	O
the	O
physiological	O
activity	O
of	O
a	O
rare	O
saccharide,	O
wherein	O
physiological-activity	O
sensitive	O
cells	O
are	O
treated	O
with	O
the	O
rare	O
saccharide	O
to	O
modify	O
the	O
function	O
of	O
the	O
cells	O
.	O
A	O
composition	O
containing,	O
as	O
an	O
active	O
ingredient,	O
a	O
rare	O
saccharide	O
which	O
is	O
introduced	O
into	O
physiological-activity	O
sensitive	O
cells	O
and	O
has	O
an	O
effect	O
of	O
modifying	O
the	O
function	O
of	O
the	O
cells	O
.	O
The	O
cells	O
are	O
human	O
cells	O
.	O
The	O
composition	O
is	O
a	O
functional	O
food,	O
a	O
drug,	O
or	O
a	O
cosmetic	O
.	O
The	O
rare	O
saccharide	O
is	O
a	O
rare	O
saccharide	O
belonging	O
to	O
aldose	O
and	O
/	O
or	O
ketose	O
.	O
The	O
aldose	O
is	O
D-allose,	O
and	O
the	O
cells	O
are	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
cancer-cell	O
proliferation	O
inhibitory	O
activity	O
sensitive	O
cells	O
and	O
active-oxygen	O
production	O
inhibitory	O
activity	O
sensitive	O
cells	O
.	O
The	O
ketose	O
is	O
D-psicose,	O
and	O
the	O
cells	O
are	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
chemokine	B-GENE
secretion	O
inhibitory	O
activity	O
sensitive	O
cells,	O
microglia	O
migration	O
inhibitory	O
activity	O
sensitive	O
cells,	O
and	O
hypoglycemic	O
activity	O
sensitive	O
cells	O
.	O


The	O
invention	O
relates	O
to	O
aryl-sulphonamido	O
compounds	O
endowed	O
with	O
affinity	O
against	O
metallo	B-GENE
proteases	I-GENE
MMP,	O
having	O
formula	O
(	O
I	O
)	O
below	O
wherein	O
R,	O
R1,	O
R2,	O
R3,	O
G	O
and	O
n	O
have	O
the	O
meanings	O
reported	O
in	O
the	O
specification,	O
properly	O
labelled	O
with	O
diagnostic	O
imaging	O
moieties	O
or	O
even	O
radiotherapeutic	O
moieties	O
.	O
The	O
invention	O
also	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
to	O
their	O
use	O
as	O
diagnostic	O
imaging	O
agents	O
or	O
radiotherapeutic	O
agents	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
1,4-diaza-bicyclo	O
[	O
3	O
.	O
2	O
.	O
1	O
]	O
octane	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
and	I-GENE
modulators	O
of	O
the	O
monoamine	B-GENE
receptors	I-GENE
and	I-GENE
transporters	O
.	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-degeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O
(	O
formula	O
)	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
kinase	B-GENE
inhibitors	O
and	O
modulator	O
compounds	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O
More	O
particularly,	O
the	O
invention	O
is	O
concerned	O
with	O
such	O
compounds,	O
kinase	B-GENE
/	O
compound	O
adducts,	O
methods	O
of	O
treating	O
diseases,	O
and	O
methods	O
of	O
synthesis	O
of	O
the	O
compounds	O
.	O
Preferrably,	O
the	O
compounds	O
are	O
useful	O
for	O
the	O
modulation	O
of	O
kinase	B-GENE
activity	O
of	O
Raf	B-GENE
kinases	I-GENE
and	O
disease	O
polymorphs	O
thereof	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
mammalian	O
cancers	O
and	O
especially	O
human	O
cancers	O
including	O
but	O
not	O
limited	O
to	O
malignant	O
melanoma,	O
colorectal	O
cancer,	O
ovarian	O
cancer,	O
papillary	O
thyroid	O
carcinoma,	O
non	O
small	O
cell	O
lung	O
cancer,	O
and	O
mesothelioma	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
also	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
and	O
retinopathies	O
including	O
diabetic	O
retinal	O
neuropathy	O
and	O
macular	O
degeneration	O
.	O


This	O
disclosure	O
relates	O
to	O
methods	O
of	O
predicting	O
and	O
diagnosing	O
preeclampsia	O
and	O
eclampsia	O
in	O
pregnant	O
subjects	O
.	O
These	O
methods	O
include	O
detecting	O
a	O
decrease	O
of	O
soluble	O
c-kit	B-GENE
in	O
a	O
sample	O
obtained	O
from	O
the	O
pregnant	O
subject	O
.	O
A	O
significantly	O
reduced	O
concentration	O
of	O
soluble	O
c-kit	B-GENE
in	O
the	O
sample	O
as	O
compared	O
to	O
a	O
gestational	O
age-adjusted	O
control	O
indicates	O
that	O
the	O
pregnant	O
subject	O
will	O
develop	O
or	O
has	O
preeclampsia	O
or	O
eclampsia	O
.	O


The	O
present	O
invention	O
deals	O
with	O
a	O
multiparticulate	O
tablet,	O
which	O
disintegrates	O
in	O
the	O
mouth	O
containing	O
:	O
i	O
)	O
a	O
proton	B-GENE
pomp	I-GENE
inhibiting	O
agent,	O
in	O
particular	O
of	O
the	O
benzimidazole	O
type,	O
in	O
the	O
form	O
of	O
enteric	O
coated	O
microgranules,	O
which	O
enteric	O
coated	O
granules	O
are	O
overcoated	O
with	O
at	O
least	O
one	O
barrier	O
coating,	O
such	O
as	O
for	O
instance	O
a	O
methacrylic	O
copolymer-based	O
protective	O
film	O
;	O
ii	O
)	O
at	O
least	O
one	O
antacid	O
in	O
the	O
form	O
of	O
granules,	O
for	O
instance	O
based	O
on	O
CaCO3	O
and	O
/	O
or	O
Mg	O
(	O
OH	O
)	O
2	O
and	O
/	O
or	O
Al	O
(	O
OH	O
)	O
3	O
;	O
and,	O
iii	O
)	O
a	O
mixture	O
of	O
excipients	O
comprising	O
at	O
least	O
one	O
disintegrating	O
agent,	O
one	O
diluent	O
agent,	O
a	O
lubricant,	O
and	O
optionally	O
a	O
swelling	O
agent,	O
a	O
permeabilising	O
agent,	O
sweeteners,	O
flavourings	O
and	O
colours	O
.	O
Furthermore,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
the	O
tablet	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O


This	O
invention	O
is	O
related	O
to	O
a	O
pharmaceutical	O
composition	O
in	O
the	O
patient-friendly	O
orally	O
disintegrating	O
tablet	O
form	O
comprising	O
a	O
weakly	O
basic,	O
selective	O
serotonin	O
5-HT3	B-GENE
blocking	O
agent	O
for	O
the	O
prevention	O
of	O
nausea	O
and	O
/	O
or	O
vomiting	O
for	O
up	O
to	O
24	O
hrs	O
postdosing	O
in	O
cancer	O
patients	O
prior	O
to	O
undergoing	O
moderately	O
emetogenic	O
chemotherapy	O
or	O
partial	O
or	O
whole	O
body	O
radiotherapy	O
or	O
in	O
subjects	O
at	O
moderate	O
to	O
high	O
risk	O
of	O
postoperative	O
or	O
postdischarge	O
nausea	O
and	O
/	O
or	O
vomiting	O
prior	O
to	O
inpatient	O
or	O
outpatient	O
ambulatory	O
surgery	O
.	O
The	O
unit	O
dosage	O
form	O
comprising	O
a	O
multitude	O
of	O
immediate-release	O
drug	O
particles	O
providing	O
dissolution	O
profiles	O
similar	O
to	O
that	O
of	O
reference	O
drug	O
product,	O
and	O
one	O
or	O
more	O
timed,	O
pulsatile-release	O
bead	O
populations,	O
comprising	O
at	O
least	O
one	O
organic	O
acid,	O
which	O
solubilizes	O
said	O
weakly	O
basic	O
selective	O
serotonin	O
5-HT3	B-GENE
blocking	O
agent	O
prior	O
to	O
releasing	O
it	O
into	O
the	O
hostile	O
intestinal	O
environment,	O
wherein	O
the	O
blocking	O
agent	O
is	O
practically	O
insoluble,	O
is	O
capable	O
of	O
delivering	O
said	O
antiemetic	O
agent	O
in	O
patients	O
in	O
need	O
thereof	O
in	O
a	O
sustained-released	O
fashion	O
to	O
be	O
suitable	O
for	O
a	O
once-daily	O
dosing	O
regimen	O
.	O


Cycling	O
of	O
ApoE4	B-GENE
isoform	O
is	O
promoted	O
in	O
a	O
person	O
in	O
need	O
thereof	O
by	O
contacting	O
the	O
person	O
with	O
an	O
effective	O
amount	O
of	O
a	O
pharmaceutically-acceptable	O
modulator	O
of	O
intracellular	O
ApoE4	B-GENE
transport	O
vesicle	O
pH	O
.	O


Compounds	O
which	O
are	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyridine	O
derivatives	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
their	O
preparation	O
process	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
disclosed	O
;	O
these	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
caused	O
by	O
and	O
/	O
or	O
associated	O
with	O
an	O
altered	O
protein	B-GENE
kinase	I-GENE
activity	O
such	O
as	O
cancer,	O
cell	O
proliferative	O
disorders,	O
Alzheimer	O
'	O
s	O
disease,	O
viral	O
infections,	O
auto-immune	O
diseases	O
and	O
neurodegenerative	O
disorders	O
;	O
also	O
disclosed	O
is	O
a	O
process	O
under	O
SPS	O
conditions	O
for	O
preparing	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
chemical	O
libraries	O
comprising	O
a	O
plurality	O
of	O
them	O
.	O


Provided	O
is	O
a	O
method	O
for	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
FIP	O
in	O
cats	O
.	O
The	O
method	O
is	O
performed	O
by	O
administering	O
to	O
a	O
cat	O
a	O
composition	O
comprising	O
a	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
amount	O
of	O
a	O
cysteine	B-GENE
protease	I-GENE
inhibitor	O
.	O
The	O
cysteine	B-GENE
protease	I-GENE
inhibitor	O
can	O
be	O
a	O
selective	O
cathepsin	B-GENE
B	I-GENE
inhibitor	O
.	O
Also	O
provided	O
is	O
a	O
method	O
for	O
inhibiting	O
FIPV	O
replication	O
.	O
The	O
method	O
comprises	O
contacting	O
a	O
cell	O
infected	O
with	O
FIPV	O
with	O
a	O
cysteine	B-GENE
protease	I-GENE
inhibitor	O
in	O
an	O
amount	O
effective	O
to	O
inhibit	O
replication	O
of	O
FIPV	O
.	O
It	O
is	O
expected	O
the	O
method	O
will	O
be	O
effective	O
for	O
therapy	O
or	O
prophylaxis	O
of	O
FIP	O
in	O
any	O
species	O
of	O
cat	O
and	O
will	O
be	O
effective	O
against	O
any	O
strain	O
of	O
feline	O
coronavirus	O
.	O


Compositions,	O
which	O
are	O
stable	O
in	O
storage,	O
and	O
a	O
method	O
of	O
production	O
of	O
pharmaceutical	O
based	O
nanoparticulate	O
formulations	O
for	O
photodynamic	O
therapy	O
comprising	O
a	O
hydrophobic	O
photosensitizer,	O
human	B-GENE
serum	I-GENE
albumin	I-GENE
(	O
HSA	B-GENE
)	O
and	O
stabilizing	O
agent	O
are	O
provided	O
.	O
These	O
nanoparticulate	O
formulations	O
provide	O
therapeutically	O
effective	O
amounts	O
of	O
photosensitizer	O
(	O
PS	O
)	O
for	O
parenteral	O
administration	O
.	O
In	O
particular,	O
tetrapyrrole	O
derivatives	O
can	O
be	O
used	O
as	O
photosensitizers	O
whose	O
efficacy	O
and	O
safety	O
are	O
enhanced	O
by	O
such	O
nanoparticulate	O
formulations	O
.	O
A	O
method	O
of	O
preparing	O
the	O
HSA-based	O
nanoparticles	O
under	O
sterile	O
conditions	O
is	O
also	O
provided	O
.	O
In	O
one	O
of	O
the	O
preferred	O
embodiments	O
of	O
the	O
present	O
invention	O
temoporfin,	O
a	O
hydrophobic	O
PS,	O
is	O
formulated	O
as	O
a	O
nanoparticle	O
for	O
parenteral	O
administration	O
.	O
The	O
formulations	O
are	O
useful	O
for	O
treating	O
hyperplasic	O
and	O
neoplasic	O
conditions,	O
inflammatory	O
problems,	O
and	O
more	O
specifically	O
to	O
target	O
tumor	O
cells	O
.	O


The	O
present	O
invention	O
provides	O
therapeutically	O
active	O
oxazolidine	O
derivatives	O
and	O
compositions	O
as	O
NMDA	O
antagonists,	O
which	O
are	O
useful	O
in	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
by	O
inhibiting	O
over-activation	O
of	O
NMDA	B-GENE
receptors	I-GENE
.	O
In	O
one	O
aspect,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
and	O
/	O
or	O
preventing	O
neurodegenerative	O
diseases	O
and	O
neuropathological	O
disorders,	O
methods	O
of	O
providing	O
neuroprotection	O
under	O
stress	O
conditions	O
such	O
as	O
a	O
stroke,	O
and	O
methods	O
of	O
enhancing	O
the	O
brain	O
'	O
s	O
cognitive	O
functions	O
in	O
mammals	O
and	O
humans	O
.	O
For	O
example,	O
the	O
compounds	O
can	O
prevent	O
glutamate-induced	O
neuro-toxicity	O
by	O
inhibiting	O
the	O
activities	O
of	O
the	O
NMDA	B-GENE
receptor	I-GENE
in	O
the	O
presence	O
of	O
toxic	O
doses	O
of	O
NMDA	O
.	O
In	O
addition,	O
the	O
compounds	O
can	O
potentiate	O
the	O
calcium	O
current	O
in	O
the	O
presence	O
of	O
low	O
dose	O
of	O
NMDA	O
.	O


Compositions	O
and	O
methods	O
are	O
disclosed	O
for	O
treating	O
vitiligo	O
and	O
promoting	O
the	O
formation	O
of	O
collagen	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
Shiga	B-GENE
toxin	I-GENE
B-subunit	O
moiety	O
as	O
carrier	O
for	O
therapeutic	O
agents,	O
for	O
example,	O
anti-cancer	O
agents	O
such	O
as	O
anti-cancer	O
agents	O
that	O
require	O
intracellular	O
uptake	O
to	O
exert	O
their	O
anti-cancer	O
effects	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
conjugates	O
comprising	O
a	O
Shiga	B-GENE
toxin	I-GENE
moiety	O
covalently	O
linked	O
to	O
an	O
anti-cancer	O
agent	O
through	O
a	O
self-immolative	O
spacer,	O
and	O
methods	O
of	O
using	O
such	O
conjugates	O
to	O
increase	O
cellular	O
uptake	O
and	O
/	O
or	O
specificity	O
for	O
cancer	O
cells	O
of	O
the	O
anti-cancer	O
drug	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treatment	O
involving	O
administration	O
of	O
such	O
conjugates,	O
and	O
pharmaceutical	O
compositions	O
and	O
kits	O
useful	O
for	O
carrying	O
out	O
such	O
methods	O
of	O
treatment	O
.	O


Disclosed	O
herein	O
is	O
method	O
of	O
treating	O
glaucoma	O
or	O
ocular	O
hypertension	O
comprising	O
administering	O
a	O
prostaglandin	O
agonist	O
and	O
a	O
second	O
therapeutically	O
active	O
agent	O
to	O
a	O
mammal	O
in	O
need	O
thereof,	O
wherein	O
said	O
second	O
therapeutically	O
active	O
agent	O
is	O
selected	O
from	O
:	O
β-Blockers,	O
Adrenergic	O
Agonists,	O
non-selective	O
adrenergic	O
agonists,	O
α2-selective	O
adrenergic	O
agonists,	O
Carbonic	B-GENE
Anhydrase	I-GENE
Inhibitors,	O
Cholinergic	O
Agonists,	O
direct	O
acting	O
cholinergic	O
agonists,	O
chlolinesterase	B-GENE
inhibitors,	O
Glutamate	O
Antagonists,	O
Ca2+	B-GENE
channel	I-GENE
blockers,	O
Prostamides,	O
Prostaglandins,	O
Cannabinoids,	O
and	O
combinations	O
thereof	O
.	O
Compositions	O
and	O
medicaments	O
containing	O
a	O
combination	O
of	O
these	O
two	O
active	O
agents	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
application	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
reducing	O
glucose	O
excursions	O
in	O
a	O
normal	O
subject	O
or	O
a	O
subject	O
having	O
an	O
insulin-related	O
disorder	O
or	O
dysglycemia	O
.	O
The	O
pharmaceutical	O
composition	O
contains	O
one	O
or	O
more	O
active	O
agent-containing	O
layers,	O
which	O
each	O
contain	O
a	O
dry	O
blended	O
mixture	O
including	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
polar	O
ionizable	O
insulin-sensitizing	O
oral	O
hypoglycemic	O
agent	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
an	O
amphipathic	O
compound	O
in	O
monomelic	O
form	O
consisting	O
of	O
an	O
amphipathic	O
ionic	O
compound	O
in	O
monomelic	O
form	O
.	O
Each	O
dry	O
blended	O
mixture	O
contains	O
a	O
sufficient	O
amount	O
of	O
the	O
amphipathic	O
ionic	O
compound	O
such	O
that	O
upon	O
contact	O
with	O
an	O
aqueous	O
fluid,	O
the	O
amphipathic	O
ionic	O
compound	O
forms	O
a	O
reverse	O
micelle	O
comprising	O
the	O
polar	O
ionizable	O
insulin-sensitizing	O
oral	O
hypoglycemic	O
agent	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
use	O
of	O
a	O
modified	O
release	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
insulin-sensitizing	O
oral	O
hypoglycemic	O
agent	O
for	O
sensitizing	O
pre-prandial	O
(	O
basal	O
)	O
insulin	B-GENE
levels	O
and	O
/	O
or	O
reducing	O
postprandial	O
glucose	O
excursions	O
in	O
a	O
normal	O
patient	O
or	O
a	O
patient	O
having	O
an	O
insulin-related	O
disorder	O
.	O


A	O
new	O
class	O
of	O
neuramidase	B-GENE
inhibitor	O
prodrugs	O
is	O
provided	O
characterized	O
by	O
a	O
prodrug	O
moiety	O
of	O
a	O
carboxyl	O
group	O
modified	O
to	O
form	O
a	O
carbonyl	O
ethoxy	O
amino	O
acid,	O
a	O
carbonyl	O
ethoxy	O
dipeptide	O
or	O
a	O
carbonyl	O
ethoxy	O
tripeptide,	O
a	O
guanidine	O
group	O
modified	O
to	O
form	O
a	O
carbonyl	O
ethoxy	O
amino	O
acid,	O
a	O
carbonyl	O
ethoxy	O
dipeptide,	O
a	O
carbonyl	O
ethoxy	O
tripeptide	O
;	O
a	O
primary	O
alcohol	O
modified	O
to	O
form	O
an	O
esterified	O
single	O
amino	O
acid,	O
dipeptide	O
or	O
tripeptide	O
of	O
zanavimir	O
of	O
the	O
unaltered	O
therapeutic	O
agent	O
.	O
Exemplary	O
therapeutic	O
agents	O
so	O
modified	O
to	O
form	O
prodrugs	O
include	O
zanavimir,	O
oseltamivir	O
and	O
peramivir	O
.	O
The	O
prodrug	O
has	O
increased	O
oral	O
bioavailability	O
relative	O
to	O
the	O
unaltered	O
neuraminidase	B-GENE
inhibitor	O
and	O
is	O
effective	O
in	O
the	O
inhibition	O
of	O
viral	O
infections	O
involving	O
neuraminidase	B-GENE
in	O
the	O
viral	O
reproductive	O
cycle	O
.	O


Described	O
herein	O
is	O
the	O
discovery	O
that	O
HGFs	B-GENE
activate	O
the	O
growth	O
and	O
migration	O
of	O
lymphatic	O
endothelial	O
cells	O
and	O
thereby	O
promote	O
lymphangiogenesis	O
.	O
The	O
present	O
invention	O
is	O
based	O
on	O
this	O
finding,	O
and	O
provides	O
lymphangiogenesis-promoting	O
agents	O
comprising	O
as	O
active	O
ingredients	O
HGFs,	O
or	O
proteins	O
or	O
compounds	O
functionally	O
equivalent	O
thereto	O
.	O
Based	O
on	O
the	O
finding	O
described	O
above,	O
the	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
promoting	O
lymphangiogenesis	O
which	O
comprise	O
the	O
step	O
of	O
locally	O
administering	O
HGFs	B-GENE
or	O
proteins	O
functionally	O
equivalent	O
thereto	O
to	O
affected	O
areas	O
in	O
patients	O
with	O
lymphedema	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
reducing	O
and	O
/	O
or	O
preventing	O
ototoxicity	O
caused	O
by	O
an	O
ototoxic	O
agent,	O
noise	O
or	O
head	O
and	O
/	O
or	O
neck	O
radiation	O
.	O
It	O
is	O
also	O
directed	O
to	O
a	O
method	O
for	O
preventing	O
or	O
reducing	O
generation	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
inner	O
ear	O
of	O
a	O
patient	O
.	O
The	O
methods	O
of	O
the	O
present	O
invention	O
include	O
administering	O
at	O
least	O
one	O
siRNA	O
directed	O
against	O
TRPV1	B-GENE
mRNA,	O
NOX3	B-GENE
mRNA	O
or	O
a	O
combination	O
thereof	O
.	O


Compositions	O
and	O
methods	O
for	O
treating	O
disorders	O
of	O
the	O
outer	O
retina	O
with	O
compounds	O
that	O
inhibit	O
monoamine	B-GENE
oxidase	I-GENE
are	O
disclosed	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
forumula	O
(	O
I	O
)	O
and	O
their	O
use	O
in	O
the	O
inhibition	O
of	O
c-Jun	B-GENE
N-terminal	I-GENE
kinases	I-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
the	O
use	O
of	O
these	O
compounds	O
in	O
medicine,	O
in	O
particular	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
neurodegenerative	O
disorders	O
related	O
to	O
apoptosis	O
and	O
/	O
or	O
inflammation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
at	O
least	O
one	O
nutritive,	O
at	O
least	O
one	O
disinfecting	O
or	O
decontaminating	O
and	O
/	O
or	O
at	O
least	O
one	O
protease-inhibiting	O
active	O
compound	O
and	O
/	O
or	O
active	O
compound	O
complex	O
for	O
the	O
external	O
care	O
and	O
/	O
or	O
treatment	O
of	O
wounds	O
of	O
the	O
human	O
or	O
animal	O
body	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
the	O
underlying	O
dysregulation	O
of	O
the	O
emotional	O
functionality	O
of	O
mental	O
disorders	O
(	O
i	O
.	O
e	O
.	O
affect	O
instability—hypersensitivity—hyperaesthesia—dissociative	O
phenomena—	O
.	O
.	O
.	O
)	O
using	O
compounds	O
and	O
compositions	O
of	O
compounds	O
having	O
D4	B-GENE
and	O
/	O
or	O
5-HT2A	B-GENE
antagonistic,	O
partial	O
agonistic	O
or	O
inverse	O
agonistic	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
comprising	O
administering	O
to	O
a	O
patient	O
diagnosed	O
as	O
having	O
a	O
neuropsychiatric	O
disorder	O
a	O
pharmaceutical	O
composition	O
containing	O
(	O
i	O
)	O
compounds	O
having	O
D4	B-GENE
antagonistic,	O
partial	O
agonistic	O
or	O
inverse	O
agonistic	O
activity	O
and	O
/	O
or	O
(	O
ii	O
)	O
compounds	O
having	O
5-HT2A	B-GENE
antagonistic,	O
partial	O
agonistic	O
or	O
inverse	O
agonistic,	O
and	O
/	O
or	O
(	O
iii	O
)	O
any	O
known	O
medicinal	O
compound	O
and	O
compositions	O
of	O
said	O
compounds	O
.	O
The	O
combined	O
D4	B-GENE
and	O
5-HT2A	B-GENE
antagonistic,	O
partial	O
agonistic	O
or	O
inverse	O
agonistic	O
effects	O
may	O
reside	O
within	O
the	O
same	O
chemical	O
or	O
biological	O
compound	O
or	O
in	O
two	O
different	O
chemical	O
and	O
/	O
or	O
biological	O
compounds	O
.	O


This	O
invention	O
concerns	O
fluorinated	O
3,4-diaryl-4,5-dihydro-1H-pyrazole-1-carboxamidine	O
derivatives	O
as	O
cannabinoid-CB1	O
receptor	O
antagonists,	O
methods	O
for	O
preparing	O
these	O
compounds,	O
novel	O
intermediates	O
useful	O
for	O
the	O
synthesis	O
of	O
said	O
compounds,	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
intermediates,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
these	O
dihydropyrazole	O
derivatives	O
as	O
active	O
ingredient,	O
as	O
well	O
as	O
the	O
use	O
of	O
these	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
obesity	O
and	O
obesity-related	O
cardiovascular	O
disorders,	O
drug	O
addiction,	O
cognition	O
deficits,	O
liver	O
fibrosis	O
and	O
inflammatory	O
disorders	O
.	O
The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O


Provided	O
are	O
compounds	O
capable	O
of	O
inhibiting	O
expression	O
of	O
TGF-beta	B-GENE
1	I-GENE
and	O
compositions	O
containing	O
same	O
as	O
well	O
as	O
methods	O
using	O
such	O
compounds	O
for	O
treating	O
fibrotic	O
diseases	O
including	O
the	O
reduction	O
of	O
scarring	O
resulting	O
from	O
wound	O
healing	O
.	O


Methods	O
are	O
provided	O
for	O
modulating	O
CREB	B-GENE
by	O
administering	O
a	O
CREB-specific	O
modulator	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
treating	O
cardiovascular	O
and	O
metabolic	O
disorders	O
in	O
a	O
subject	O
or	O
delaying	O
or	O
preventing	O
risk	O
factors	O
thereof	O
through	O
the	O
modulation	O
of	O
CREB	B-GENE
.	O
The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
methods	O
of	O
decreasing	O
lipid	O
levels	O
in	O
a	O
subject	O
or	O
for	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
a	O
rise	O
in	O
lipid	O
levels	O
in	O
a	O
subject,	O
comprising	O
administering	O
to	O
said	O
subject	O
a	O
CREB-specific	O
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
modulating	O
a	O
β-cell	O
population	O
using	O
a	O
TM4SF4	B-GENE
modulator	O
or	O
a	O
modulator	O
of	O
a	O
TM4SF4	B-GENE
homolog	O
.	O
More	O
particularly,	O
the	O
invention	O
relates,	O
inter	O
alia,	O
to	O
methods	O
and	O
compositions	O
for	O
generating,	O
expanding,	O
and	O
maintaining	O
a	O
β-cell	O
population	O
and	O
treatment	O
of	O
diseases	O
associated	O
with	O
the	O
loss	O
of	O
β-cells	O
using	O
a	O
TM4SF4	B-GENE
modulator	O
or	O
a	O
modulator	O
of	O
a	O
TM4SF4	B-GENE
homolog	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
treating	O
pain	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
α7	B-GENE
nAChR	I-GENE
ligand	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
to	O
a	O
mammal	O
in	O
need	O
of	O
treatment	O
thereof	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
a	O
compound	O
or	O
salt	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
fulvestrant	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
in	O
patients	O
who	O
have	O
previously	O
been	O
treated	O
with	O
a	O
Selective	O
Estrogen	B-GENE
Receptor	I-GENE
Modulator	O
(	O
SERM	O
)	O
and	O
an	O
aromatase	B-GENE
inhibitor	O
.	O


Potent	O
and	O
selective	O
ligands	O
for	O
the	O
dopamine	B-GENE
3	I-GENE
(D3)	I-GENE
receptor	I-GENE
are	O
disclosed	O
.	O
The	O
D3	B-GENE
receptor	I-GENE
ligands	O
have	O
a	O
structural	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
is	O
C═O	O
or	O
SO2,	O
R1	O
is	O
C1-6	O
alkyl,	O
R2	O
is	O
aryl,	O
heteroaryl,	O
aryl,	O
—	O
(	O
CH2	O
)	O
1-3aryl,	O
or	O
—	O
(	O
CH2	O
)	O
1-3heteroaryl,	O
and	O
n	O
is	O
0	O
or	O
1	O
.	O
Methods	O
of	O
using	O
the	O
D3	B-GENE
receptor	I-GENE
ligands	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
conditions	O
wherein	O
modulation	O
of	O
the	O
D3	B-GENE
receptor	I-GENE
provides	O
a	O
benefit	O
also	O
are	O
disclosed	O
.	O


Methods	O
of	O
modulating	O
a	O
kinase	B-GENE
activity	O
of	O
a	O
wild-type	O
kinase	B-GENE
species,	O
oncogenic	O
forms	O
thereof,	O
aberrant	O
fusion	O
proteins	O
thereof	O
and	O
polymorphs	O
of	O
any	O
of	O
the	O
foregoing,	O
are	O
provided	O
which	O
employ	O
compounds	O
of	O
the	O
formula	O
Ia	O
:	O


The	O
present	O
invention	O
provides	O
reliable	O
methods	O
to	O
identify	O
subsets	O
of	O
subjects	O
with	O
a	O
cancer	O
of	O
epithelial	O
origin	O
characterized	O
by	O
a	O
high	O
level	O
of	O
phosphorylated	O
c-erbB2	B-GENE
which	O
does	O
not	O
correlate	O
with	O
the	O
over-expression	O
of	O
total	O
c-erbB2	B-GENE
as	O
measured	O
by	O
IHC	O
or	O
FISH,	O
for	O
selection	O
and	O
inclusion	O
for	O
c-erbB2-direct	O
treatment	O
and	O
therapy	O
.	O
Furthermore,	O
the	O
present	O
invention	O
provides	O
a	O
reliable	O
method	O
to	O
determine	O
whether	O
a	O
subject	O
with	O
a	O
cancer	O
of	O
epithelial	O
origin	O
who	O
has	O
been	O
determined	O
to	O
be	O
c-erbB2	B-GENE
positive	O
by	O
IHC	O
and	O
by	O
FISH	O
should	O
be	O
excluded	O
from	O
c-erbB2-direct	O
treatment	O
because	O
of	O
a	O
non-significant	O
level	O
of	O
phosphorylated	O
c-erbB2	B-GENE
in	O
epithelial	O
tumor	O
tissue	O
.	O


The	O
invention	O
provides	O
for	O
a	O
method	O
for	O
screening	O
compounds	O
that	O
bind	O
to	O
and	O
modulate	O
the	O
hair-specific	O
G-protein	O
coupled	O
receptor,	O
P2RY5	B-GENE
.	O
The	O
invention	O
further	O
provides	O
for	O
methods	O
for	O
controlling	O
hair	O
growth	O
by	O
administering	O
a	O
P2RY5	B-GENE
modulating	O
compound	O
to	O
a	O
subject	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
selective	O
inhibition	O
of	O
protein	O
expression	O
of	O
CAG	O
repeat-related	O
disease	O
proteins	O
such	O
as	O
Huntingtin	B-GENE
using	O
nucleic	O
acid	O
analogs	O
.	O
Peptide	O
nucleic	O
acids	O
and	O
locked	O
nucleic	O
acids	O
are	O
particularly	O
useful	O
analogs	O
.	O


The	O
present	O
invention	O
relates	O
to	O
cyclohexyloxy-substituted	O
heterocycles	O
of	O
general	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
the	O
tautomers,	O
the	O
stereoisomers,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids,	O
which	O
have	O
valuable	O
pharmacological	O
properties,	O
particularly	O
an	O
inhibitory	O
effect	O
on	O
signal	O
transduction	O
mediated	O
by	O
tyrosine	O
kinases,	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
diseases,	O
particularly	O
tumoral	O
diseases	O
as	O
well	O
as	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
diseases	O
of	O
the	O
lungs	O
and	O
airways	O
and	O
the	O
preparation	O
thereof	O
.	O


Novel	O
compounds	O
comprising	O
a	O
guanidine-rich	O
head	O
covalently	O
coupled	O
to	O
one	O
or	O
more	O
oligonucleotide	O
antisense	O
sequences	O
which	O
are	O
useful	O
to	O
modulate	O
blood	O
coagulation	O
by	O
affecting	O
the	O
expression	O
of	O
integrin	B-GENE
αIIb	I-GENE
or	I-GENE
β3	I-GENE
are	O
described	O
herein	O
.	O
This	O
invention	O
also	O
includes	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
with	O
or	O
without	O
other	O
therapeutic	O
agents,	O
and	O
to	O
methods	O
of	O
using	O
these	O
compounds	O
as	O
inhibitor	O
of	O
platelet	O
aggregation,	O
as	O
thrombolytics,	O
and	O
/	O
or	O
for	O
the	O
treatment	O
of	O
other	O
thromboembolic	O
disorders	O
.	O
Vivo-MOs,	O
which	O
include	O
eight	O
guanidine	O
groups	O
dendrimerically	O
arranged	O
in	O
the	O
guanidine-rich	O
head	O
and	O
two	O
synthetic	O
antisense	O
morpholino	O
oligonucleotides,	O
are	O
representative	O
compounds	O
of	O
the	O
present	O
invention	O
.	O


The	O
invention	O
encompasses	O
pyrimidine	O
derivatives	O
as	O
gamma	O
secretase	O
modulators,	O
useful	O
for	O
treating	O
diseases	O
associated	O
with	O
the	O
deposition	O
of	O
beta-amyloid	B-GENE
peptide	O
in	O
the	O
brain,	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
or	O
of	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
dementia	O
associated	O
with	O
such	O
diseases	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
included	O
.	O


Provided	O
are	O
compounds	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
kinase-mediated	O
disorders	O
therewith	O
.	O


The	O
present	O
disclosure	O
is	O
generally	O
directed	O
to	O
compounds	O
that	O
can	O
inhibit	O
DAGLα	B-GENE
and/or	I-GENE
β	I-GENE
activity,	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
methods	O
for	O
inhibiting	O
DAGLα	B-GENE
and/or	I-GENE
β	I-GENE
activity	O
.	O


A	O
novel	O
class	O
of	O
transporter	O
protein,	O
referred	O
to	O
as	O
SWEET,	O
GLUE	B-GENE
or	O
Glü,	O
is	O
disclosed	O
.	O
These	O
transporters	O
provide	O
a	O
novel	O
system	O
for	O
the	O
transportation	O
of	O
sugars	O
across	O
membranes	O
within	O
a	O
cell	O
and	O
between	O
the	O
inside	O
and	O
outside	O
of	O
a	O
cell	O
.	O
Such	O
transporters	O
are	O
useful	O
for	O
understanding	O
and	O
altering	O
the	O
sugar	O
concentration	O
within	O
certain	O
organs	O
of	O
an	O
organism,	O
and	O
within	O
certain	O
organelles	O
within	O
the	O
cell	O
.	O
These	O
transporters	O
are	O
also	O
useful	O
in	O
protecting	O
plants	O
from	O
a	O
pathogen	O
attack	O
.	O


The	O
present	O
invention	O
resides	O
in	O
the	O
discovery	O
that	O
the	O
specific	O
interaction	O
between	O
neuregulin	B-GENE
1	I-GENE
(	O
NRG1	B-GENE
)	O
and	O
integrin	B-GENE
is	O
important	O
for	O
ErbB	B-GENE
signaling,	O
which	O
in	O
turn	O
plays	O
an	O
important	O
role	O
in	O
cellular	O
signaling	O
in	O
various	O
physiological	O
processes	O
such	O
as	O
cell	O
proliferation,	O
especially	O
in	O
cancer	O
cells	O
overexpressing	O
ErbB	B-GENE
family	O
members	O
.	O
Thus,	O
this	O
invention	O
provides	O
for	O
a	O
novel	O
method	O
for	O
inhibiting	O
ErbB	B-GENE
signaling	O
by	O
using	O
an	O
inhibitor	O
of	O
NRG1-integrin	B-GENE
binding	O
.	O
A	O
method	O
for	O
identifying	O
inhibitors	O
of	O
NRG1-integrin	B-GENE
binding	O
is	O
also	O
described	O
.	O
Further	O
disclosed	O
are	O
polypeptides,	O
nucleic	O
acids,	O
and	O
corresponding	O
compositions	O
for	O
inhibiting	O
ErbB	B-GENE
signaling	O
.	O


Provided	O
herein	O
are	O
novel	O
bridged	O
cyclic	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
analogs,	O
tautomeric	O
forms,	O
stereoisomers,	O
polymorphs,	O
solvates,	O
intermediates,	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutical	O
compositions,	O
metabolites	O
and	O
prodrugs	O
thereof	O
.	O
These	O
compounds	O
can	O
inhibit	O
HDACs	B-GENE
and	O
are	O
useful	O
as	O
therapeutic	O
or	O
ameliorating	O
agent	O
for	O
diseases	O
that	O
are	O
involved	O
in	O
cellular	O
growth	O
such	O
as	O
malignant	O
tumors,	O
autoimmune	O
diseases,	O
skin	O
diseases,	O
infections,	O
inflammation,	O
neurode-generative	O
disorders	O
etc	O
.	O


The	O
present	O
invention	O
features	O
inhibitors	O
of	O
nitric	O
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
,	O
particularly	O
those	O
that	O
selectively	O
inhibit	O
neuronal	B-GENE
nitric	I-GENE
oxide	I-GENE
synthase	I-GENE
(	O
nNOS	B-GENE
)	O
in	O
preference	O
to	O
other	O
NOS	B-GENE
isoforms	O
.	O
The	O
NOS	B-GENE
inhibitors	O
of	O
the	O
invention,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
pharmaceutically	O
active	O
agents,	O
can	O
be	O
used	O
for	O
treating	O
or	O
preventing	O
conditions	O
such	O
as,	O
for	O
example,	O
stroke,	O
reperfusion	O
injury,	O
neurodegeneration,	O
head	O
trauma,	O
CABG,	O
migraine	O
headache	O
with	O
and	O
without	O
aura,	O
migraine	O
with	O
allodynia,	O
central	O
post-stroke	O
pain	O
(	O
CPSP	O
)	O
,	O
neuropathic	O
pain,	O
morphine	O
/	O
opioid	O
induced	O
tolerance	O
and	O
hyperalgesia	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
and	O
reagents	O
for	O
the	O
detection	O
of	O
a	O
mutation	O
in	O
BRAF	B-GENE
and	O
methods	O
of	O
selecting,	O
patients	O
for	O
treatment	O
if	O
a	O
B-Raf	B-GENE
kinase	O
inhibitor,	O
such	O
as	O
a	O
selective	O
B-Raf	B-GENE
kinase	O
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
to	O
determine	O
whether	O
a	O
patient	O
with	O
a	O
lysosomal	O
storage	O
disorder	O
will	O
benefit	O
from	O
treatment	O
with	O
a	O
specific	O
pharmacological	O
chaperone	O
.	O
The	O
present	O
invention	O
exemplifies	O
an	O
in	O
vitro	O
method	O
for	O
determining	O
α-galactosidase	B-GENE
A	I-GENE
responsiveness	O
to	O
a	O
pharmacological	O
chaperone	O
such	O
as	O
1-deoxygalactonojirimycin	O
in	O
a	O
cell	O
line	O
expressing	O
a	O
mutant	O
from	O
of	O
α-galactosidase	B-GENE
A	I-GENE
.	O
The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
diagnosing	O
Fabry	O
disease	O
in	O
patients	O
suspected	O
of	O
having	O
Fabry	O
disease	O
.	O


Azido-diarylpyrimidine	O
(	O
azido-DAPY	O
)	O
compounds,	O
and	O
compositions	O
containing	O
such	O
compounds,	O
are	O
provided	O
.	O
In	O
addition,	O
methods	O
of	O
using	O
azido-diarylpyrimidines	O
to	O
inactivate	O
reverse	O
transcriptases,	O
prepare	O
inactivated	O
viruses,	O
and	O
treat	O
or	O
prevent	O
viral	O
infections	O
are	O
also	O
provided	O
.	O


Embodiments	O
of	O
the	O
present	O
invention	O
provide	O
adamantyl	O
benzamide	O
derivtives	O
and	O
pharmaceutical	O
compositions	O
comprising	O
adamantyl	O
benzamide	O
derivatives	O
.	O
Methods	O
of	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
to	O
modulate	O
the	O
activity	O
of	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11βHSD1	B-GENE
)	O
in	O
a	O
subject	O
are	O
also	O
provided	O
.	O


Modulators	O
of	O
specific	O
PACAP	B-GENE
receptors	O
are	O
useful	O
for	O
treating	O
inflammatory	O
skin	O
diseases	O
having	O
a	O
neurogenic	O
component,	O
and	O
more	O
particularly	O
rosacea	O
and	O
/	O
or	O
facial	O
erythema,	O
compositions	O
containing	O
these	O
and	O
screening	O
methods	O
are	O
described	O
for	O
identifying	O
PACAP	B-GENE
signaling	O
pathway	O
modulators	O
.	O


The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
retinopathy	O
or	O
AMD	O
containing	O
PRDX	B-GENE
5	I-GENE
or	O
PRDX	O
6,	O
as	O
well	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
retinopathy	O
or	O
AMD	O
containing	O
a	O
polynucleotide	O
encoding	O
PRDX	B-GENE
5	I-GENE
or	O
PRDX	B-GENE
6	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
retinopathy	O
or	O
AMD	O
in	O
a	O
patient	O
suffering	O
from	O
the	O
disease,	O
which	O
includes	O
administering	O
to	O
the	O
patient	O
an	O
effective	O
amount	O
of	O
PRDX	B-GENE
5	I-GENE
or	O
PRDX	O
6,	O
or	O
administering	O
to	O
the	O
patient	O
an	O
effective	O
amount	O
of	O
a	O
polynucleotide	O
encoding	O
PRDX	B-GENE
5	I-GENE
or	O
PRDX	B-GENE
6	I-GENE
.	O


The	O
subject	O
matter	O
of	O
the	O
present	O
disclosure	O
relates	O
to	O
an	O
in	O
vitro	O
method	O
for	O
the	O
screening	O
of	O
anti-cancer	O
compounds	O
based	O
on	O
the	O
capacity	O
for	O
these	O
compounds	O
to	O
interact	O
with	O
neurotrophin	B-GENE
3	I-GENE
(	O
NT-3	B-GENE
or	O
NT3	B-GENE
)	O
,	O
to	O
the	O
extracellular	O
domain,	O
or	O
TrkC	B-GENE
receptor	O
and	O
/	O
or	O
to	O
inhibit	O
the	O
dimerization	O
of	O
the	O
intracellular	O
domain	O
of	O
the	O
TrkC	B-GENE
receptor	O
expressed	O
in	O
tumor	O
cells,	O
particularly	O
in	O
neuroblastoma	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
a	O
method	O
for	O
predicting	O
the	O
presence	O
of	O
metastatic	O
cancer	O
or	O
a	O
bad	O
prognosis	O
cancer,	O
or	O
for	O
determining	O
the	O
efficiency	O
of	O
an	O
anti-cancer	O
treatment	O
based	O
on	O
the	O
measuring	O
of	O
the	O
expression	O
level	O
of	O
neurotrophin	B-GENE
3	I-GENE
.	O
The	O
disclosure	O
further	O
comprises	O
kits	O
and	O
compounds	O
as	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
neuroblastoma	O
or	O
cancer	O
overexpressing	O
neurotrophin	B-GENE
3	I-GENE
by	O
the	O
tumor	O
cells	O
.	O


Certain	O
heteroaryl-substituted	O
piperidinyl	O
and	O
piperazinyl	O
urea	O
compounds	O
are	O
described,	O
which	O
are	O
useful	O
as	O
FAAH	B-GENE
inhibitors	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
disease	O
states,	O
disorders,	O
and	O
conditions	O
mediated	O
by	O
fatty	B-GENE
acid	I-GENE
amide	I-GENE
hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
activity,	O
such	O
as	O
anxiety,	O
pain,	O
inflammation,	O
sleep	O
disorders,	O
eating	O
disorders,	O
insulin	B-GENE
resistance,	O
diabetes,	O
osteoporosis,	O
and	O
movement	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
multiple	O
sclerosis	O
)	O
.	O


The	O
invention	O
provides	O
novel	O
double	O
stranded	O
oligoribonucleotides	O
that	O
inhibit	O
the	O
Nrf2	B-GENE
gene	O
.	O
The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
one	O
or	O
more	O
such	O
oligoribonucleotides,	O
and	O
a	O
vector	O
capable	O
of	O
expressing	O
the	O
oligoribonucleotide	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
the	O
incidence	O
or	O
severity	O
of	O
a	O
cancerous	O
disease,	O
particularly	O
various	O
lung	O
cancers	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
such	O
as	O
heart	O
failure,	O
hyperlipidemia,	O
hypercholesterolemia,	O
gonadotropin	O
deficiency,	O
diabetes	O
mellitus,	O
metabolic	O
syndrome,	O
hyperglycemia,	O
insulin	B-GENE
resistance,	O
glucose	O
intolerance,	O
obesity,	O
psoriasis,	O
atopic	O
dermatitis,	O
and	O
cancer	O
.	O


CXCR3	B-GENE
agonists,	O
including	O
natural	O
CXCR3	B-GENE
ligands,	O
promote	O
bone	O
marrow	O
regeneration,	O
increase	O
peripheral	O
white	O
blood	O
cells,	O
and	O
increase	O
survival	O
if	O
administered	O
prior	O
to	O
treatment	O
of	O
a	O
subject	O
with	O
chemotherapy	O
or	O
radiotherapy	O
.	O
Similar	O
effects	O
are	O
obtained	O
by	O
administering	O
an	O
CXCR3	B-GENE
antagonists	O
following	O
chemotherapy	O
radiotherapy	O
.	O
Compositions	O
and	O
methods	O
are	O
presented	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
bone	O
marrow	O
diseases	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
neurological	O
diseases	O
that	O
cause	O
neurogenic	O
and	O
neuropathic	O
pain,	O
inflammatory	O
diseases,	O
renal	O
ischaemia,	O
cardiovascular	O
disease	O
and	O
other	O
pathologies	O
caused	O
by	O
the	O
presence	O
of	O
endogenous	O
cannabinoids	O
and	O
or	O
other	O
substrates	O
resulting	O
from	O
the	O
metabolic	O
activities	O
of	O
fatty	B-GENE
acid	I-GENE
amido	I-GENE
hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
.	O
These	O
compounds	O
are	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A,	O
n,	O
R1,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O


Methods	O
for	O
treatment	O
of	O
peripheral	O
nerve	O
sensory	O
loss	O
are	O
disclosed	O
.	O
The	O
methods	O
involve	O
treating	O
a	O
patient	O
with	O
a	O
compound	O
having	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
activity	O
.	O


The	O
invention	O
relates	O
to	O
new	O
compounds	O
for	O
cancer	O
therapy	O
or	O
diagnosis	O
and	O
more	O
specifically	O
to	O
the	O
use	O
of	O
a	O
non-toxic	O
B	O
subunit	I-GENE
of	O
Shiga	O
toxin	O
mutant	O
as	O
a	O
vector	O
for	O
diagnostic	O
products	O
or	O
drugs	O
in	O
over-expressing	O
Gb3	B-GENE
receptor	I-GENE
cells,	O
such	O
compounds	O
having	O
the	O
following	O
formula	O
:	O
STxB-Z	O
(	O
n	O
)	O
-Cys-Y	O
(	O
m	O
)	O
-T	O
wherein	O
	O
	O
	O
STxB	B-GENE
is	O
the	O
Shiga	B-GENE
Toxin	I-GENE
B	I-GENE
subunit	I-GENE
or	O
a	O
functional	O
equivalent	O
thereof,	O
Z	O
(	O
n	O
)	O
whrein	O
n	O
is	O
0	O
or	O
1	O
and	O
when	O
n	O
is	O
1,	O
Z	O
is	O
an	O
amino-acid	O
residue	O
devoidof	O
sulfydryl	O
group,	O
or	O
is	O
a	O
polypeptide,	O
Cys	O
is	O
the	O
amino-acid	O
residue	O
for	O
Cysteine,	O
T	O
is	O
a	O
molecule	O
linked	O
by	O
a	O
covalent	O
bound	O
to	O
the	O
S	O
part	O
of	O
Cys,	O
selected	O
in	O
a	O
group	O
comprising	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
agents	O
for	O
in	O
vivo	O
diagnosis,	O
cytotoxic	O
agents,	O
prodrugs,	O
or	O
enzymes	O
for	O
the	O
conversion	O
of	O
a	O
prodrug	O
to	O
a	O
drug,	O
	O
	O
Y	O
(	O
m	O
)	O
wherein	O
m	O
is	O
0	O
or	O
1	O
and	O
when	O
m	O
is	O
1,	O
Y	O
is	O
a	O
linker	O
between	O
T	O
and	O
Cys,	O
said	O
linker	O
being	O
either	O
cleavable	O
or	O
not	O
cleavable	O
for	O
the	O
release	O
of	O
T	O
after	O
the	O
internalization	O
of	O
the	O
hybrid	O
compound	O
into	O
said	O
cells	O
.	O


The	O
present	O
invention	O
relates	O
to	O
formula	O
I	O
compounds	O
having	O
antitumoural	O
activities	O
through,	O
as	O
one	O
possible	O
biological	O
target,	O
the	O
molecular	O
chaperone	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
(	O
Hsp90	B-GENE
)	O
inhibition	O
.	O
The	O
invention	O
includes	O
the	O
use	O
of	O
such	O
compounds	O
in	O
medicine,	O
in	O
relation	O
to	O
cancer	O
disease	O
as	O
well	O
as	O
other	O
diseases	O
where	O
an	O
inhibition	O
of	O
Hsp90	B-GENE
is	O
responsive,	O
and	O
the	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O


Preferred	O
embodiments	O
of	O
the	O
present	O
invention	O
are	O
related	O
to	O
novel	O
therapeutic	O
drug	O
combinations	O
and	O
methods	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
hypertension	O
and	O
complications	O
in	O
patients	O
with	O
diabetes	O
and	O
/	O
or	O
metabolic	O
syndrome	O
.	O
More	O
particularly,	O
aspects	O
of	O
the	O
present	O
invention	O
are	O
related	O
to	O
using	O
a	O
combination	O
of	O
cicletanine	O
and	O
a	O
second	O
antihypertensive	O
agent	O
(	O
preferably	O
a	O
calcium	O
antagonist,	O
an	O
ACE	B-GENE
inhibitor,	O
or	O
an	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
)	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
hypertension	O
and	O
complications	O
in	O
patients	O
with	O
diabetes	O
and	O
/	O
or	O
metabolic	O
syndrome	O
.	O


Provided	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
and	O
preventing	O
hyperproliferative	O
disorders	O
such	O
as	O
psoriasis	O
by	O
administration	O
of	O
a	O
cardiac	O
glycoside	O
alone	O
or	O
in	O
combination	O
locally	O
or	O
systemically	O
with	O
a	O
calciotropic	O
agents	O
and	O
/	O
or	O
a	O
diffusion-limiting	O
component,	O
such	O
a	O
vasoconstrictor	O
or	O
collagen	B-GENE
barrier	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
gamma	B-GENE
secretase	I-GENE
modulators	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
gamma	B-GENE
secretase	I-GENE
modulators	O
for	O
treating	O
renal	O
disorders,	O
cancer,	O
neurodegenerative	O
disorders	O
as	O
well	O
as	O
related	O
disorders	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
a	O
anticancer	O
composition	O
comprising	O
full	O
length	O
GRS	B-GENE
protein	I-GENE
or	O
a	O
fragment	O
thereof,	O
a	O
nucleic	O
acid	O
encoding	O
the	O
GRS	B-GENE
protein	I-GENE
or	O
a	O
fragment	O
thereof	O
.	O
Since	O
the	O
GRS	B-GENE
proteins	I-GENE
or	O
fragments	O
thereof	O
have	O
activity	O
to	O
induce	O
apoptosis	O
of	O
cancer	O
cell	O
specifically,	O
a	O
composition	O
comprising	O
the	O
GRS	B-GENE
proteins	I-GENE
or	O
fragments	O
thereof	O
or	O
a	O
nucleic	O
acid	O
encoding	O
thereof	O
may	O
be	O
useful	O
to	O
treatment	O
of	O
cancer	O
.	O


The	O
present	O
invention	O
allows	O
a	O
screening	O
method	O
for	O
identifying	O
novel	O
drugs	O
for	O
the	O
treatment	O
of	O
tuberculosis	O
as	O
well	O
as	O
a	O
diagnostic	O
method	O
for	O
identifying	O
clinical	O
strains	O
that	O
are	O
resistant	O
to	O
these	O
novel	O
drugs	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
screening	O
in	O
vitro	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
tuberculosis	O
by	O
interfering	O
with	O
the	O
arabinogalactan	O
biosynthesis,	O
the	O
said	O
method	O
comprising	O
a	O
step	O
of	O
putting	O
into	O
contact	O
a	O
Mycobacterium	O
tuberculosis	O
cell	O
culture	O
overexpressing	O
a	O
protein	O
that	O
performs	O
the	O
transformation	O
of	O
decaprenyl-P-ribose	O
to	O
decaprenyl-P-arabinose	O
and	O
that	O
can	O
be	O
encoded	O
by	O
rv3790	B-GENE
gene	O
or	O
homologues	O
thereof	O
or	O
any	O
open-reading	O
artificial	O
frame	O
whose	O
gene	O
product	O
is	O
identical	O
or	O
homologue	O
to	O
Rv3790	B-GENE
protein,	O
with	O
a	O
drug	O
candidate	O
and	O
then	O
evaluating	O
the	O
percentage	O
of	O
inhibition	O
caused	O
by	O
the	O
drug	O
candidate	O
against	O
a	O
control	O
in	O
an	O
assay	O
test,	O
such	O
as	O
an	O
antibacterial	O
test	O
or	O
an	O
enzymatic	O
test	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
method,	O
and	O
the	O
process	O
to	O
manufacture	O
a	O
medicament,	O
for	O
treating	O
gout	O
or	O
pseudogout,	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
inhibitors	O
blocking	O
IL-1	B-GENE
or	O
its	O
maturation	O
by	O
the	O
NALP3	B-GENE
inflammasome	O
.	O


7-Hydroxy-benzoimidazole-4-yl-methanone	O
Derivatives,	O
which	O
are	O
useful	O
for	O
PBK	B-GENE
inhibitors,	O
are	O
provided	O
.	O


The	O
invention	O
relates	O
in	O
part	O
to	O
molecules	O
having	O
certain	O
biological	O
activities	O
that	O
include,	O
but	O
are	O
not	O
limited	O
to,	O
inhibiting	O
cell	O
proliferation,	O
modulating	O
protein	B-GENE
kinase	I-GENE
activity	O
and	O
modulating	O
polymerase	B-GENE
activity	O
.	O
Molecules	O
of	O
the	O
invention	O
can	O
modulate	O
casein	B-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
activity	O
and	O
/	O
or	O
poly(ADP-ribose)polymerase	B-GENE
(	O
PARP	B-GENE
)	O
activity	O
.	O
The	O
invention	O
also	O
relates	O
in	O
part	O
to	O
methods	O
for	O
using	O
such	O
molecules	O
.	O


The	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
compounds,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
diseases	O
or	O
disorders	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
B	O
cell	O
activities,	O
particularly	O
diseases	O
or	O
disorders	O
that	O
involve	O
aberrant	O
activation	O
of	O
inositol	B-GENE
1,4,5-trisphosphate	I-GENE
3-kinase	I-GENE
B	I-GENE
(	O
ITPKb	B-GENE
)	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
2,3-disubstituted	O
piperidine	O
amide	O
compounds	O
which	O
are	O
antagonists	O
of	O
orexin	O
receptors,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
and	O
diseases	O
in	O
which	O
orexin	B-GENE
receptors	I-GENE
are	O
involved	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
orexin	B-GENE
receptors	I-GENE
are	O
involved	O
.	O


A	O
small	O
interfering	O
RNA	O
for	O
gene	O
knockdown	O
of	O
the	O
N-methyl-D-aspartate	B-GENE
receptor	I-GENE
NR1	I-GENE
subunit	I-GENE
comprises	O
21	O
to	O
25	O
ribonucleic	O
acids,	O
which	O
are	O
homologous	O
to	O
the	O
RNA	O
sequence	O
of	O
N-methyl-D-aspartate	B-GENE
receptor	I-GENE
NR1	I-GENE
subunit	I-GENE
.	O
A	O
method	O
of	O
using	O
the	O
small	O
interfering	O
RNA,	O
applying	O
the	O
small	O
interfering	O
RNA	O
on	O
subcutaneous	O
tissues	O
temporary	O
interfere	O
with	O
the	O
genetic	O
expression	O
of	O
the	O
NMDA	B-GENE
receptor	I-GENE
NR1	I-GENE
subunit	I-GENE
in	O
hypoderm	O
.	O
A	O
use	O
of	O
the	O
small	O
interfering	O
RNA	O
on	O
pharmaceutics,	O
applying	O
the	O
small	O
interfering	O
RNA	O
manufacture	O
into	O
new	O
analgesic	O
drugs	O
for	O
moderating	O
the	O
inflammatory	O
pain	O
or	O
intolerable	O
chronic	O
pain,	O
especially	O
on	O
clinical	O
chronic	O
pain	O
and	O
burn	O
pain	O
patients	O
.	O
An	O
analgesic	O
drug	O
for	O
skin	O
inflammatory	O
pain	O
comprising	O
:	O
the	O
small	O
interfering	O
RNA	O
and	O
a	O
siRNA	O
acceptable	O
vehicle	O
.	O


Compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
X	O
is	O
S,	O
Se	O
or	O
NH,	O
and	O
stereoisomers	O
thereof,	O
and	O
de-O-sulfonated	O
analogues	O
of	O
all	O
of	O
the	O
foregoing,	O
but	O
excluding	O
naturally	O
occurring	O
kotalanol	O
and	O
de-O-sulfonated	O
kotalanol,	O
and	O
methods	O
for	O
synthesizing	O
same	O
.	O
The	O
compounds	O
are	O
useful	O
as	O
glycosidase	B-GENE
inhibitors,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diabetes	O
.	O
The	O
synthetic	O
compounds	O
may	O
also	O
be	O
used	O
as	O
standards	O
in	O
the	O
calibration	O
or	O
grading	O
of	O
natural	O
or	O
herbal	O
remedies	O
produced	O
from	O
natural	O
sources	O
of	O
glycosidase	B-GENE
inhibitors	O
such	O
as	O
kotalanol	O
.	O


Described	O
herein	O
are	O
novel	O
enzyme	O
inhibitors	O
.	O
In	O
some	O
embodiments	O
the	O
enzyme	O
inhibitors	O
are	O
integrase	O
inhibitors,	O
particularly	O
HIV	B-GENE
integrase	I-GENE
inhibitors	O
.	O
Also	O
described	O
herein	O
are	O
compositions	O
containing	O
them	O
and	O
methods	O
of	O
using	O
them	O
.	O
Thus,	O
the	O
compounds	O
and	O
compositions	O
described	O
herein	O
are	O
useful	O
for	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
inhibition	O
of	O
HIV	B-GENE
integrase	I-GENE
as	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
HIV,	O
AIDS	O
or	O
related	O
disorders	O
.	O


Disclosed	O
herein	O
are	O
compounds	O
and	O
methods	O
for	O
decreasing	O
PrP	B-GENE
and	O
preventing,	O
ameliorating,	O
or	O
treating	O
a	O
prion	O
disease	O
or	O
conformational	O
neurodegenerative	O
disorder,	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
.	O
Examples	O
of	O
disease	O
conditions	O
that	O
can	O
be	O
ameliorated	O
with	O
the	O
administration	O
of	O
antisense	O
compounds	O
targeted	O
to	O
PrP	B-GENE
include	O
Creutzfeldt-Jakob	O
disease	O
(	O
CJD	O
)	O
;	O
variant	O
Creutzfeldt-Jakob	O
Disease	O
(	O
vCJD	O
)	O
;	O
Gerstmann-Straussler-Scheinker	O
syndrome	O
;	O
fatal	O
familial	O
insomnia	O
;	O
kuru	O
;	O
Bovine	O
Spongiform	O
Encephalopathy	O
(	O
BSE	O
)	O
,	O
e	O
.	O
g	O
.	O
“mad	O
cow	O
disease”	O
;	O
Chronic	O
Wasting	O
Disease	O
(	O
CWD	O
)	O
;	O
scrapie	O
;	O
transmissible	O
mink	O
encephalopathy	O
;	O
feline	O
spongiform	O
encephalopathy	O
;	O
ungulate	O
spongiform	O
encephalopathy	O
;	O
Alzheimer	O
'	O
s	O
disease	O
;	O
Parkinson	O
'	O
s	O
disease	O
;	O
Huntington	O
'	O
s	O
disease	O
;	O
and	O
Amyotrophic	O
Lateral	O
Sclerosis	O
(	O
ALS	O
)	O
.	O


Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
modulating	O
apoptosis	O
by	O
targeting	O
SKIP	B-GENE
(	O
Ski-interacting	B-GENE
protein	I-GENE
)	O
activity	O
.	O
Methods	O
of	O
increasing	O
DNA	O
damage-induced	O
cell	O
death	O
in	O
cancer	O
cells,	O
and	O
reducing	O
DNA	O
damage-induced	O
cell	O
death	O
in	O
normal	O
cells	O
are	O
provided	O
.	O


The	O
invention	O
is	O
directed	O
to	O
β-carboline	O
sulphonylurea	O
derivatives	O
as	O
EP4	B-GENE
receptor	I-GENE
antagonists	O
useful	O
for	O
the	O
treatment	O
of	O
EP4	B-GENE
mediated	O
diseases	O
or	O
conditions,	O
such	O
as	O
acute	O
and	O
chronic	O
pain,	O
inflammation,	O
osteoarthritis,	O
and	O
rheumatoid	O
arthritis	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
also	O
included	O
.	O


VEGF-D,	O
a	O
new	O
member	O
of	O
the	O
PDGF	B-GENE
family	O
of	O
growth	O
factors,	O
which	O
among	O
other	O
things	O
stimulates	O
endothelial	O
cell	O
proliferation	O
and	O
angiogenesis	O
and	O
increases	O
vascular	O
permeability,	O
as	O
well	O
as	O
nucleotide	O
sequences	O
encoding	O
it,	O
methods	O
for	O
producing	O
it,	O
antibodies	O
and	O
other	O
antagonists	O
to	O
it,	O
transfected	O
or	O
transformed	O
host	O
cells	O
for	O
expressing	O
it,	O
pharmaceutical	O
compositions	O
containing	O
it,	O
and	O
uses	O
thereof	O
in	O
medical	O
and	O
diagnostic	O
applications	O
.	O


The	O
present	O
invention	O
provides	O
new	O
methods	O
for	O
the	O
prevention	O
of	O
migration	O
of	O
leukocytes	O
into	O
the	O
CNS	O
.	O
These	O
methods,	O
which	O
rely	O
on	O
inhibition	O
of	O
EMMPRIN	B-GENE
activity	O
or	O
expression,	O
can	O
be	O
used	O
to	O
treat	O
or	O
slow	O
the	O
onset	O
of	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
and	O
EAE	O
.	O


Administration	O
of	O
low	O
molecular	O
weight	O
(	O
10,000-20,000	O
Daltons,	O
or	O
lower	O
)	O
pectins,	O
particularly	O
modified	O
citrus	O
pectins	O
(	O
MCP	O
)	O
,	O
like	O
PectaSol-C	O
reduces	O
galectins-3	B-GENE
levels	O
in	O
vivo	O
.	O
Reduction	O
of	O
galectin-3	B-GENE
levels	O
by	O
MCP	O
inhibits	O
inflammation,	O
inhibits	O
fibrosis	O
formation	O
in	O
organs	O
and	O
tissues,	O
and	O
inhibits	O
cancer	O
formation,	O
progression,	O
transformation	O
and	O
metastases	O
.	O
The	O
reduction	O
in	O
circulating,	O
serum	O
and	O
cellular	O
galectin-3,	O
inherently	O
resulting	O
from	O
the	O
administration	O
of	O
MCP,	O
provides	O
benefit	O
over	O
a	O
spectrum	O
of	O
biological	O
conditions,	O
as	O
evidenced	O
by	O
in	O
vivo	O
trials	O
.	O


The	O
present	O
invention	O
generally	O
relates	O
to	O
the	O
neuroprotective	O
activity	O
of	O
condensed	O
diazepinones,	O
e	O
.	O
g	O
.	O
condensed	O
benzodiazepinones	O
such	O
as	O
pirenzepine	O
or	O
compounds	O
which	O
are	O
metabolized	O
to	O
condensed	O
benzodiazepinones	O
such	O
as	O
olanzapine	O
.	O
These	O
compounds	O
are	O
suitable	O
as	O
co-medicaments	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
drug-induced	O
neurotoxic	O
effects	O
in	O
general	O
and	O
neurotoxic	O
side	O
effects	O
during	O
cancer	O
treatments	O
with	O
cytostatic	O
drugs	O
such	O
as	O
platinum-derivatives,	O
e	O
.	O
g	O
.	O
cis-,	O
carbo-	O
and	O
oxaliplatin,	O
taxanes,	O
bleomycin,	O
cyclophosphamide	O
and	O
vincristine	O
etc	O
.	O
Further,	O
these	O
compounds	O
have	O
an	O
intrinsic	O
anti-cancer	O
activity	O
on	O
their	O
own	O
due	O
to	O
PARP-1	B-GENE
inhibition,	O
which	O
prevents	O
NADH	O
depletion	O
in	O
oxidative	O
metabolism	O
of	O
healthy	O
cells	O
thus	O
preventing	O
the	O
shift	O
to	O
anoxygenic,	O
glycolytic	O
metabolism	O
present	O
in	O
many	O
types	O
of	O
tumour	O
cells	O
thus	O
eliminating	O
this	O
crucial	O
metabolic	O
advantage	O
favoring	O
tumour	O
growth	O
.	O
These	O
results	O
exploit	O
the	O
fact	O
of	O
differential	O
PARP-1	B-GENE
expression	O
between	O
many	O
cancer	O
cells	O
and	O
healthy	O
tissues	O
.	O


Immunostimulatory	O
sequence-specific	O
RNA	O
oligonucleotides	O
corresponding	O
to	O
3′	O
terminal	O
sequences	O
of	O
single-stranded	O
minus-sense	O
RNA	O
genomic	O
RNAs	O
are	O
provided	O
.	O
Also	O
provided	O
are	O
compositions	O
and	O
methods	O
relating	O
to	O
an	O
immunostimulatory	O
4-mer	O
RNA	O
motif	O
provided	O
as	O
5′-C	O
/	O
U-U-G	O
/	O
U-U-3′	O
.	O
Incorporation	O
of	O
this	O
short	O
RNA	O
motif	O
is	O
sufficient	O
to	O
confer	O
new	O
and	O
altered	O
immunostimulatory	O
properties	O
in	O
new	O
and	O
existing	O
oligonucleotides,	O
including	O
CpG	O
oligodeoxynucleotides	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
use	O
of	O
the	O
immunostimulatory	O
RNA	O
oligonucleotides	O
and	O
DNA	O
:	O
RNA	O
chimeric	O
oligonucleotides	O
of	O
the	O
invention	O
to	O
induce	O
an	O
immune	O
response	O
in	O
vitro	O
and	O
in	O
vivo,	O
as	O
well	O
as	O
to	O
treat	O
allergy,	O
asthma,	O
infection,	O
and	O
cancer	O
in	O
a	O
subject	O
.	O
Single-stranded	O
oligoribonucleotides	O
of	O
the	O
invention	O
are	O
believed	O
to	O
signal	O
through	O
a	O
Toll-like	B-GENE
receptor	I-GENE
(	O
TLR	B-GENE
)	O
chosen	O
from	O
TLR9,	O
TLR8,	O
TLR7,	O
and	O
TLR3	B-GENE
.	O
The	O
oligoribonucleotides	O
can	O
also	O
be	O
used	O
in	O
a	O
method	O
to	O
screen	O
for	O
TLR	B-GENE
antagonists	O
.	O


Compounds	O
of	O
the	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
	O
wherein	O
m,	O
n	O
.	O
X,	O
R1,	O
R2,	O
R3,	O
R5,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
using	O
the	O
compounds	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
LRRK2	B-GENE
receptor,	O
such	O
as	O
Parkinson	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds,	O
methods,	O
and	O
compositions	O
capable	O
of	O
decreasing	O
HIF	B-GENE
hydroxylase	I-GENE
enzyme	O
activity,	O
thereby	O
increasing	O
the	O
stability	O
and	O
/	O
or	O
activity	O
of	O
hypoxia	B-GENE
inducible	I-GENE
factor	I-GENE
(	O
HIF	B-GENE
)	O
.	O


Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
are	O
provided	O
.	O
Compositions	O
of	O
the	O
invention	O
may	O
comprise	O
proteins	O
with	O
a	O
zinc-finger	O
domain	O
fused	O
to	O
a	O
regulatory	O
domain	O
that	O
is	O
capable	O
of	O
either	O
activating	O
or	O
repressing	O
the	O
expression	O
of	O
a	O
target	O
gene	O
involved	O
in	O
neuropathic	O
pain	O
.	O
Alternatively,	O
compositions	O
of	O
the	O
invention	O
may	O
comprise	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
a	O
protein	O
of	O
the	O
invention,	O
which	O
nucleic	O
acid	O
sequence	O
may	O
optionally	O
be	O
provided	O
as	O
a	O
plasmid	O
or	O
within	O
a	O
virus	O
or	O
other	O
vector	O
for	O
delivery	O
to	O
a	O
target	O
cell	O
or	O
tissue	O
.	O
Methods	O
of	O
treating	O
neuropathic	O
pain	O
involving	O
treatment	O
of	O
subject	O
with	O
the	O
compositions	O
of	O
the	O
invention	O
are	O
also	O
provided	O
.	O
Exemplary	O
target	O
genes	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
include	O
VR1,	O
NaV1	O
.	O
8,	O
and	O
TrkA	B-GENE
.	O


Unsaturated	O
nitrogen	O
heterocyclic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
as	O
defined	O
in	O
the	O
specification,	O
compositions	O
containing	O
them,	O
and	O
processes	O
for	O
preparing	O
such	O
compounds	O
.	O
Provided	O
herein	O
also	O
are	O
methods	O
of	O
treating	O
disorders	O
or	O
diseases	O
treatable	O
by	O
inhibition	O
of	O
PDE10,	O
such	O
as	O
obesity,	O
Huntington	O
'	O
s	O
Disease,	O
non-insulin	O
dependent	O
diabetes,	O
schizophrenia,	O
bipolar	O
disorder,	O
obsessive-compulsive	O
disorder,	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
benzazepine	O
inhibitors	O
of	O
gamma-secretase	B-GENE
activity,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O


Disclosed	O
herein	O
are	O
cannabinoid	B-GENE
receptor	I-GENE
ligands	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
A1	O
and	O
Rx	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
presented	O
.	O


The	O
present	O
invention	O
relates	O
to	O
N-heterocyclic	O
sulphonamide	O
compounds,	O
in	O
particular	O
pyrazole	O
sulphonamide	O
compounds,	O
and	O
their	O
use	O
as	O
N-myristoyl	B-GENE
transferase	I-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
I	O
and	O
use	O
thereof	O
as	O
inhibitors	O
of	O
protein	O
kinases	O
AbI	B-GENE
and	O
Src	B-GENE
and	O
the	O
method	O
of	O
production	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
medici-nal	O
products	O
comprising	O
these	O
compounds	O
.	O


The	O
present	O
invention	O
concerns	O
two	O
human	O
nucleic	O
acids	O
comprising	O
sequences	O
which	O
code	O
two	O
novel	O
isoforms	O
of	O
human	B-GENE
somatostatin	I-GENE
receptor	I-GENE
type	I-GENE
5	I-GENE
produced	O
by	O
alternative	O
adjustment,	O
called	O
sst5B	B-GENE
and	O
sst5C	B-GENE
and	O
with	O
possible	O
uses	O
in	O
tumoral	O
processes	O
.	O
Additionally,	O
the	O
invention	O
concerns	O
oligonucleotide	O
pairs	O
used	O
for	O
the	O
differential	O
detection	O
of	O
said	O
isoforms	O
by	O
means	O
of	O
the	O
PCR	O
technique	O
in	O
different	O
tissues	O
.	O


Long	O
non-coding	O
RNAs	O
(	O
lincRNAs	B-GENE
)	O
,	O
a	O
relatively	O
recently	O
recognized	O
class	O
of	O
widely	O
transcribed	O
genes,	O
are	O
thought	O
to	O
affect	O
chromatin	O
state	O
and	O
epigenetic	O
regulation,	O
but	O
their	O
mechanisms	O
of	O
action	O
and	O
potential	O
roles	O
in	O
human	O
disease	O
are	O
poorly	O
understood	O
.	O
The	O
present	O
invention	O
shows	O
that	O
long	O
non-coding	O
RNAs	O
in	O
the	O
human	O
HOX	B-GENE
loci	I-GENE
are	O
systematically	O
dysregulated	O
during	O
breast	O
cancer	O
progression,	O
and	O
that	O
expression	O
levels	O
of	O
the	O
lincRNA	B-GENE
termed	O
HOTAIR	B-GENE
can	O
predict	O
cancer	O
metastasis	O
.	O
Elevated	O
levels	O
of	O
HOTAIR	B-GENE
can	O
lead	O
to	O
altered	O
patterns	O
of	O
Polycomb	O
binding	O
to	O
the	O
genome	O
.	O
These	O
findings	O
indicate	O
that	O
lincRNAs	B-GENE
have	O
active	O
roles	O
in	O
modulating	O
the	O
cancer	O
epigenome	O
and	O
may	O
be	O
important	O
targets	O
for	O
cancer	O
diagnosis	O
and	O
therapy	O
.	O


The	O
present	O
invention	O
relates	O
to	O
polymorphic	O
forms	O
of	O
a	O
compound	O
of	O
formula	O
A	O
:	O
This	O
compound	O
is	O
useful	O
as	O
a	O
glucagon	B-GENE
receptor	I-GENE
antagonist	O
and	O
serves	O
as	O
a	O
pharmaceutically	O
active	O
ingredient	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
and	O
related	O
conditions,	O
such	O
as	O
hyperglycemia,	O
obesity,	O
dyslipidemia,	O
and	O
the	O
metabolic	O
syndrome	O
.	O
Hydrates,	O
hemihydrates,	O
anhydrates	O
and	O
similar	O
polymorphic	O
forms	O
are	O
included	O
.	O


The	O
present	O
invention	O
relates	O
to	O
N,N-dimethyl	O
imidodicarbonimidic	O
diamide	O
acetate,	O
a	O
method	O
of	O
preparing	O
the	O
same	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same,	O
and	O
more	O
particularly,	O
to	O
N,N-dimethyl	O
imidodicarbonimidic	O
diamide	O
acetate	O
which	O
is	O
a	O
crystalline	O
acid	O
addition	O
salt	O
prepared	O
by	O
reacting	O
N,N-dimethyl	O
imidodicarbonimidic	O
diamide	O
with	O
acetic	O
acid,	O
and	O
which	O
is	O
very	O
effective	O
as	O
a	O
therapeutic	O
agent	O
for	O
treating	O
metabolic	O
syndromes	O
that	O
glycosuria	O
and	O
diabetes	O
mellitus,	O
obesity,	O
hyperlipidemia,	O
fatty	O
liver,	O
coronary	O
heart	O
disease,	O
osteoporosis,	O
polycystic	O
ovarian	O
syndrome,	O
a	O
cancer	O
depleted	O
of	O
gene	O
P53,	O
etc	O
.	O
are	O
complexly	O
occurred	O
;	O
treating	O
diabetes	O
mellitus	O
and	O
preventing	O
its	O
complication	O
;	O
and	O
treating	O
a	O
cancer	O
and	O
preventing	O
myalgia,	O
muscle	O
cell	O
cytotoxicity	O
and	O
rhabdomyolysis,	O
etc	O
.	O
since	O
the	O
acid	O
addition	O
salt	O
is	O
excellent	O
in	O
physicochemical	O
properties	O
such	O
as	O
solubility,	O
stability,	O
non-hygroscopicity,	O
anti-adhering	O
property,	O
etc	O
.	O
,	O
and	O
low	O
toxicity,	O
a	O
method	O
of	O
preparing	O
the	O
same	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
.	O


This	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
predicting	O
and	O
improving	O
a	O
chemotherapy	O
response	O
to	O
treat	O
an	O
ovarian	O
cancer	O
.	O
In	O
one	O
embodiment,	O
the	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
detecting	O
the	O
expression	O
level	O
of	O
Let-7i	B-GENE
microRNA	I-GENE
to	O
predict	O
a	O
chemotherapy	O
response	O
.	O
In	O
another	O
embodiment,	O
the	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
enhancing	O
the	O
expression	O
level	O
of	O
Let-7i	B-GENE
microRNA	I-GENE
to	O
improve	O
a	O
chemotherapy	O
response	O
.	O


The	O
invention	O
provides	O
purified	O
19-substituted	O
geldanamycin	O
derivatives,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
prodrugs	O
thereof	O
that	O
are	O
potent	O
Hsp90	B-GENE
binding	O
agents	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
the	O
amelioration	O
of	O
symptoms	O
of	O
cancer	O
and	O
other	O
proliferative	O
tissue	O
disorders	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
I,	O
wherein	O
ring	O
R1a	O
to	O
R1c,	O
R2a	O
to	O
R2e,	O
and	O
X	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
leukotriene	B-GENE
C4	I-GENE
synthase	I-GENE
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
a	O
respiratory	O
disorder	O
and	O
/	O
or	O
inflammation	O
.	O


Gamma-amino-butyric	O
acid	O
derivatives	O
that	O
are	O
GABAB	B-GENE
receptor	I-GENE
ligands,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
derivatives,	O
and	O
methods	O
of	O
using	O
such	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
thereof	O
for	O
treating	O
diseases	O
are	O
disclosed	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Y,	O
ring	O
A,	O
D1,	O
D2a,	O
D2b,	O
D3,	O
L1,	O
Y1,	O
L2	O
and	O
Y2	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
leukotriene	B-GENE
C4	I-GENE
synthase	I-GENE
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
a	O
respiratory	O
disorder	O
and	O
/	O
or	O
inflammation	O
.	O


Histone	O
deacetylase	O
is	O
a	O
metallo-enzyme	O
with	O
zinc	O
at	O
the	O
active	O
site	O
.	O
Compounds	O
having	O
a	O
zinc-binding	O
moiety,	O
such	O
as,	O
for	O
example,	O
a	O
hydroxamic	O
acid	O
group	O
or	O
a	O
carboxylic	O
acid	O
group,	O
can	O
inhibit	O
histone	B-GENE
deacetylase	I-GENE
.	O
Histone	O
deacetylase	O
can	O
repress	O
gene	O
expression,	O
including	O
expression	O
of	O
genes	O
related	O
to	O
tumor	O
suppression	O
.	O
Accordingly,	O
inhibition	O
of	O
histone	B-GENE
deacetylase	I-GENE
can	O
provide	O
an	O
alternate	O
route	O
for	O
treating	O
cancer,	O
hematological	O
disorders,	O
e	O
.	O
g	O
.	O
,	O
hemoglobinopathies,	O
and	O
genetic	O
related	O
metabolic	O
disorders,	O
e	O
.	O
g	O
.	O
,	O
cystic	O
fibrosis	O
and	O
adrenoleukodystrophy	O
.	O


The	O
invention	O
relates	O
to	O
the	O
treating	O
cancer	O
having	O
an	O
aberrant	O
EGFR	B-GENE
or	O
KRAS	B-GENE
genotype,	O
with	O
an	O
AMPK	B-GENE
activator,	O
as	O
well	O
as	O
related	O
methods,	O
compounds	O
and	O
compositions	O
.	O


A	O
compound	O
represented	O
by	O
the	O
formula	O
[	O
I	O
]	O
:	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
or	O
ester	O
thereof,	O
wherein	O
Ring	O
A	O
represents	O
a	O
five-membered	O
aromatic	O
heterocyclic	O
group	O
or	O
the	O
like	O
fused	O
with	O
a	O
non-aromatic	O
ring	O
group,	O
which	O
may	O
be	O
substituted,	O
Ring	O
B	O
represents	O
a	O
phenyl	O
group	O
or	O
the	O
like	O
which	O
may	O
be	O
substituted,	O
X1	O
represents	O
a	O
single	O
bond	O
or	O
the	O
like,	O
R1	O
and	O
R2	O
each	O
represent	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like,	O
m	O
represents	O
an	O
integer	O
of	O
0	O
to	O
3,	O
and	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
2,	O
is	O
effective	O
as	O
a	O
therapeutic	O
agent	O
for	O
a	O
disease	O
caused	O
by	O
Aβ	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
evaluating	O
the	O
prognosis	O
of	O
patients	O
with	O
estrogen	O
receptor-positive	O
breast	O
cancer	O
on	O
the	O
basis	O
of	O
Rab27B	B-GENE
expression	O
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
kit	O
comprising	O
an	O
assay	O
for	O
measuring	O
Rab27B	B-GENE
levels	O
in	O
said	O
patients	O
and	O
to	O
the	O
usage	O
of	O
Rab27B	B-GENE
as	O
a	O
target	O
to	O
screen	O
for	O
drugs	O
capable	O
of	O
inhibiting	O
or	O
diminishing	O
metastasis	O
of	O
said	O
cancer	O
.	O
Furthermore,	O
the	O
invention	O
discloses	O
compounds	O
which	O
can	O
be	O
used	O
to	O
treat	O
estrogen	O
receptor-positive	O
breast	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
PARP	B-GENE
inhibitors	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
R1,	O
L1,	O
L2,	O
X,	O
Y	O
and	O
Z	O
have	O
defined	O
meanings	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
present	O
specification,	O
which	O
has	O
a	O
superior	O
RBP4-lowering	O
action	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
an	O
increase	O
in	O
RBP4	B-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
which	O
possesses	O
an	O
excellent	O
inhibitory	O
effect	O
on	O
NHE3	B-GENE
(	O
Na+	O
/	O
H+	O
exchanger	O
type	I-GENE
3	I-GENE
)	O
and	O
effectively	O
improves	O
diseases	O
or	O
conditions	O
of	O
organs	O
in	O
which	O
NHE3	B-GENE
is	O
expressed	O
.	O


For	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
chymase-mediated	O
diseases	O
such	O
as	O
skin	O
diseases,	O
circulatory	O
diseases,	O
digestive	O
system	O
diseases,	O
respiratory	O
diseases,	O
liver	O
diseases,	O
ocular	O
diseases	O
or	O
the	O
like,	O
a	O
drug	O
is	O
provided	O
having	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
having	O
extremely	O
strong	O
chymase	B-GENE
inhibitory	O
activity,	O
high	O
safety,	O
and	O
high	O
metabolic	O
stability	O
.	O
The	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
all	O
symbols	O
have	O
the	O
same	O
meanings	O
as	O
in	O
the	O
description,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
a	O
salt	O
thereof,	O
an	O
N-oxide	O
thereof	O
or	O
a	O
solvate	O
thereof,	O
or	O
a	O
prodrug	O
thereof,	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
ingredient	O
having	O
chymase	B-GENE
inhibitory	O
activity	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
of	O
chymase-mediated	O
disease,	O
such	O
as	O
skin	O
diseases,	O
circulatory	O
diseases,	O
digestive	O
system	O
diseases,	O
respiratory	O
diseases,	O
liver	O
diseases,	O
ocular	O
diseases	O
or	O
the	O
like	O
.	O


The	O
present	O
invention	O
pertains	O
generally	O
to	O
the	O
field	O
of	O
therapeutic	O
compounds	O
.	O
More	O
specifically	O
the	O
present	O
invention	O
pertains	O
to	O
certain	O
amido-isothiazole	O
compounds	O
that,	O
inter	O
alia,	O
inhibit	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11β-HSD1	B-GENE
)	O
.	O
The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions,	O
both	O
in	O
vitro	O
and	O
in	O
vivo,	O
to	O
inhibit	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
;	O
to	O
treat	O
disorders	O
that	O
are	O
ameliorated	O
by	O
the	O
inhibition	O
of	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
;	O
to	O
treat	O
the	O
metabolic	O
syndrome,	O
which	O
includes	O
disorders	O
such	O
as	O
type	O
2	O
diabetes	O
and	O
obesity,	O
and	O
associated	O
disorders	O
including	O
insulin	B-GENE
resistance,	O
hypertension,	O
lipid	O
disorders	O
and	O
cardiovascular	O
disorders	O
such	O
as	O
ischaemic	O
(	O
coronary	O
)	O
heart	O
disease	O
;	O
to	O
treat	O
CNS	O
disorders	O
such	O
as	O
mild	O
cognitive	O
impairment	O
and	O
early	O
dementia,	O
including	O
Alzheimer	O
'	O
s	O
disease	O
;	O
etc	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
for	O
diagnosing	O
and	O
treating	O
an	O
immune-mediated	O
disease,	O
e	O
.	O
g	O
.	O
,	O
an	O
autoimmune	O
disease,	O
an	O
allergy	O
or	O
an	O
inflammatory	O
disease	O
.	O
Diagnosis	O
is	O
made	O
by	O
detecting	O
a	O
heterozygous	O
or	O
homozygous	O
genotype	O
of	O
haptoglobin	O
2	O
or	O
by	O
detecting	O
and	O
quantifying	O
pre-haptoglobin	B-GENE
2	I-GENE
mRNA	O
or	O
protein	O
.	O
After	O
diagnosis,	O
the	O
disease	O
may	O
be	O
treated	O
by	O
decreasing	O
cell	O
permeability	O
leading	O
to	O
increased	O
transepithelial	O
electrical	O
resistance,	O
for	O
example,	O
by	O
administering	O
an	O
antibody	O
directed	O
against	O
single	O
chain	O
zonulin	B-GENE
thereby	O
inhibiting	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
and	O
inhibiting	O
proteinase-activated	B-GENE
receptor	I-GENE
2	I-GENE
(	O
PAR2	B-GENE
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
synthesis	O
of	O
conjugates	O
of	O
glycosaminoglycanes	O
(	O
GAG	O
)	O
with	O
biologically	O
active	O
molecules	O
of	O
varying	O
nature,	O
comprising	O
small	O
molecules	O
and	O
macro-molecules	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
conjugation	O
of	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
and	O
its	O
derivatives	O
with	O
polypeptides	O
and	O
proteins	O
with	O
a	O
biological	O
action,	O
such	O
as,	O
for	O
example,	O
interferons,	O
erythropoietins,	O
growth	O
factors,	O
insulin,	O
cytokines,	O
antibodies	O
and	O
hormones	O
.	O
	O
	O
	O
	O
An	O
object	O
of	O
the	O
present	O
invention	O
also	O
relates	O
to	O
isolatable	O
intermediates	O
obtained	O
by	O
the	O
partial	O
or	O
total	O
reaction	O
of	O
GAG	O
with	O
protected	O
amino	O
aldehydes	O
in	O
the	O
conjugation	O
process	O
mentioned	O
above	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
use	O
of	O
selective	O
GABA	B-GENE
A	I-GENE
α5	I-GENE
negative	O
allosteric	O
modulators	O
for	O
the	O
treatment,	O
prevention	O
and	O
/	O
or	O
delay	O
of	O
progression	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
conditions	O
related	O
to	O
excessive	O
GABAergic	O
inhibition	O
in	O
the	O
brain	O
.	O


Substituted	O
heteroaromatic	O
carboxamide	O
and	O
urea	O
compounds	O
corresponding	O
to	O
formula	O
(	O
i	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
processes	O
for	O
the	O
preparation	O
thereof,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
also	O
a	O
method	O
of	O
using	O
these	O
compounds	O
in	O
pharmaceutical	O
compositions	O
for	O
treating	O
or	O
inhibiting	O
pain	O
and	O
other	O
conditions	O
mediated	O
at	O
least	O
in	O
part	O
via	O
the	O
vanilloid	B-GENE
receptor	I-GENE
1	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
renin	B-GENE
inhibitors	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
novel	O
intermediates	O
involved	O
in	O
their	O
synthesis,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
of	O
preparing	O
compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
their	O
tautomeric	O
forms,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
and	O
novel	O
intermediates	O
involved	O
in	O
their	O
synthesis	O
.	O


Methods	O
for	O
the	O
rapid	O
and	O
long-term	O
lowering	O
of	O
lipid	O
levels	O
in	O
human	O
subjects	O
and	O
for	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
elevated	O
LDL-cholesterol	O
and	O
elevated	O
apolipoprotein	B-GENE
B	I-GENE
are	O
provided	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
RNAi	O
agents	O
useful	O
in	O
methods	O
of	O
treating	O
Beta-ENaC-related	O
diseases	O
such	O
as	O
cystic	O
fibrosis,	O
pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
,	O
Liddle	O
'	O
s	O
syndrome,	O
hypertension,	O
alkalosis,	O
hypokalemia,	O
and	O
obesity-associated	O
hypertension,	O
using	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
RNAi	O
agent	O
to	O
Beta-ENaC	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
designed	O
for	O
the	O
treatment,	O
management,	O
prevention	O
and	O
/	O
or	O
amelioration	O
of	O
non-neoplastic	O
hyperproliferative	O
epithelial	O
and	O
/	O
or	O
endothelial	O
cell	O
disorders,	O
including	O
but	O
not	O
limited	O
to	O
disorders	O
associated	O
with	O
increased	O
deposition	O
of	O
extracellular	O
matrix	O
components	O
(	O
e	O
.	O
g	O
.	O
,	O
collagen,	O
proteoglycans,	O
tenascin	O
and	O
fibronectin	O
)	O
and	O
/	O
or	O
aberrant	O
angiogenesis	O
.	O
Non-limiting	O
examples	O
of	O
such	O
disorders	O
include	O
cirrhosis,	O
fibrosis	O
(	O
e	O
.	O
g	O
.	O
,	O
fibrosis	O
of	O
the	O
liver,	O
kidney,	O
lungs,	O
heart,	O
retina	O
and	O
other	O
viscera	O
)	O
,	O
asthma,	O
ischemia,	O
atherosclerosis,	O
diabetic	O
retinopathy,	O
retinopathy	O
of	O
prematurity,	O
vascular	O
restenosis,	O
macular	O
degeneration,	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
infantile	O
hemangioma,	O
verruca	O
vulgaris,	O
Kaposi	O
'	O
s	O
sarcoma,	O
neurofibromatosis,	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa,	O
ankylosing	O
spondylitis,	O
systemic	O
lupus,	O
Reiter	O
'	O
s	O
syndrome,	O
Sjogren	O
'	O
s	O
syndrome,	O
endometriosis,	O
preeclampsia,	O
atherosclerosis,	O
coronary	O
artery	O
disease,	O
psoriatic	O
arthropathy	O
and	O
psoriasis	O
.	O
The	O
methods	O
of	O
the	O
invention	O
comprise	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
agents	O
that	O
are	O
modulators	O
of	O
EphA2	B-GENE
and	O
/	O
or	O
its	O
endogenous	O
ligand,	O
EphrinA1	B-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
EphA2	B-GENE
/	O
EphrinA1	B-GENE
Modulators	O
of	O
the	O
invention	O
either	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
agents	O
useful	O
for	O
therapy	O
for	O
such	O
non-neoplastic	O
hyperproliferative	O
epithelial	O
and	O
/	O
or	O
endothelial	O
disorders	O
.	O
Diagnostic	O
methods	O
and	O
methods	O
for	O
screening	O
for	O
EphA2	B-GENE
/	O
EphrinA1	B-GENE
Modulators	O
are	O
also	O
provided	O
.	O


Disclosed	O
herein	O
are	O
methods	O
of	O
treating	O
cancer	O
by	O
administering	O
to	O
a	O
patient	O
a	O
small	O
molecule	O
inhibitor	O
of	O
Survivin	B-GENE
.	O
Also	O
disclosed	O
herein	O
are	O
methods	O
of	O
inhibiting	O
Survivin	B-GENE
dimerization	O
in	O
a	O
patient	O
by	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
or	O
(	O
IV	O
)	O
.	O
Methods	O
of	O
inducing	O
cell	O
cycle	O
arrest	O
in	O
cancer	O
cells,	O
comprising	O
G2	O
/	O
M	O
stage	O
arrest,	O
in	O
a	O
patient	O
by	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
or	O
(	O
IV	O
)	O
are	O
also	O
disclosed	O
.	O
Further	O
disclosed	O
herein	O
are	O
methods	O
of	O
inducing	O
apoptosis	O
in	O
cancer	O
cells	O
in	O
a	O
patient	O
by	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
or	O
(	O
IV	O
)	O
.	O


Chemical	O
agents,	O
such	O
as	O
disulfonamide	O
derivatives	O
of	O
fluorene,	O
anthracene,	O
xanthene,	O
dibenzosuberone	O
and	O
acridine,	O
and	O
similar	O
heterocyclic	O
ring	O
structures,	O
including	O
salts	O
thereof,	O
that	O
act	O
as	O
anti-cancer	O
and	O
anti-tumor	O
agents,	O
especially	O
where	O
such	O
agents	O
modulate	O
the	O
activity	O
of	O
the	O
Wnt/β-catenin	B-GENE
signaling	O
pathway,	O
and	O
serve	O
to	O
reduce	O
β-catenin	B-GENE
levels	O
present	O
in	O
cells,	O
such	O
as	O
cancer	O
cells,	O
or	O
where	O
the	O
agents	O
modulate	O
levels	O
of	O
gene	O
expression	O
in	O
cellular	O
systems,	O
including	O
cancer	O
cells,	O
are	O
disclosed,	O
along	O
with	O
methods	O
for	O
preparing	O
such	O
agents,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
agents	O
as	O
active	O
ingredients	O
and	O
methods	O
of	O
using	O
these	O
as	O
therapeutic	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
salt	O
forms	O
of	O
1-	O
[	O
(	O
4-methyl-quinazolin-2-yl	O
)	O
methyl	O
]	O
-3-methyl-7-	O
(	O
2-butyn-1-yl	O
)	O
-8-	O
(	O
3-	O
(	O
R	O
)	O
-amino-piperidin-1-yl	O
)	O
-xanthine,	O
a	O
DPP-4	B-GENE
inhibitor	O
and	O
their	O
use	O
in	O
pharmaceutical	O
compositions	O
useful	O
in	O
the	O
treatment	O
of	O
type	O
2,	O
diabetes,	O
as	O
well	O
as	O
their	O
production	O
.	O


A	O
microbial	O
ethyl	O
esther	O
sophorolipid	O
derivative	O
with	O
no	O
acetylated	O
groups	O
produced	O
by	O
Candida	O
species,	O
for	O
treating	O
and	O
preventing	O
sepsis	O
/	O
septic	O
shock	O
.	O
The	O
method	O
of	O
producing	O
sophorolipids	O
is	O
through	O
microbial	O
resting	O
cells	O
of	O
Candida	O
bombicola	O
.	O
The	O
sophorolipids	O
obtained	O
from	O
resting	O
state	O
cultures	O
are	O
isolated	O
as	O
a	O
complex	O
mixture	O
of	O
compounds	O
and	O
then	O
decanted	O
as	O
a	O
dense	O
oil	O
from	O
the	O
culture	O
broth,	O
subsequently	O
washed	O
to	O
remove	O
free	O
fatty	O
acids	O
.	O
Secondary	O
chemical	O
transformation	O
via	O
base	O
catalyzed	O
hydrolysis	O
is	O
used	O
to	O
reduce	O
the	O
8	O
possible	O
structural	O
sophorolipid	O
species	O
to	O
a	O
single	O
moiety,	O
the	O
17-L-	O
[	O
(	O
2′-O-b-D-glucopyranosyl-b-D-glucopyranosyl	O
)	O
-oxy	O
]	O
-cis-9-octadecenoate	O
de-acetylated	O
free	O
acid	O
.	O
The	O
compound	O
acts	O
primarily	O
through	O
decreasing	O
inflammatory	O
cytokines	O
and	O
eliciting	O
other	O
synergistic	O
anti-inflammatory	O
mechanisms	O
by	O
blocking	O
TLR4-CD14	O
upstream	O
of	O
the	O
inflammatory	O
signaling	O
cascade	O
.	O
The	O
compound	O
can	O
be	O
administered	O
either	O
intraperitoneally	O
or	O
intravenously	O
at	O
single	O
or	O
multiple	O
doses	O
of	O
5-30	O
mg	O
/	O
kg	O
of	O
weight	O
in	O
solvent	O
media	O
or	O
in	O
capped	O
nanoparticles,	O
preferably	O
within	O
48	O
hours	O
of	O
sepsis	O
inception	O
.	O


The	O
invention	O
discloses	O
a	O
human	O
cancer-related	O
gene,	O
LAPTM4B,	O
its	O
encoded	O
products	O
and	O
their	O
applications	O
thereof	O
.	O
This	O
human	O
cancer-related	O
gene	O
provided	O
by	O
this	O
invention	O
comprises	O
one	O
of	O
the	O
following	O
nucleotide	O
sequences	O
:	O
(	O
1	O
)	O
SEQ	O
ID	O
No	O
:	O
1,	O
SEQ	O
ID	O
No	O
:	O
2,	O
SEQ	O
ID	O
No	O
:	O
3,	O
SEQ	O
ID	O
No	O
:	O
6,	O
or	O
SEQ	O
ID	O
No	O
:	O
8	O
in	O
the	O
sequence	O
listings	O
;	O
(	O
2	O
)	O
SEQ	O
ID	O
No	O
:	O
4,	O
SEQ	O
ID	O
No	O
:	O
5,	O
or	O
SEQ	O
ID	O
No	O
:	O
7	O
in	O
the	O
sequence	O
listings	O
which	O
are	O
proteins	O
encoded	O
by	O
the	O
polynucleotides	O
in	O
sequences	O
of	O
SEQ	O
ID	O
No	O
:	O
1,	O
SEQ	O
ID	O
No	O
:	O
2,	O
SEQ	O
ID	O
No	O
:	O
3	O
and	O
SEQ	O
ID	O
No	O
:	O
6	O
.	O
(	O
3	O
)	O
Applications	O
of	O
the	O
polynucleotides	O
and	O
polypeptides	O
in	O
the	O
listings	O
in	O
diagnosis	O
and	O
treatments	O
of	O
cancer	O
.	O
This	O
invention	O
enables	O
the	O
developments	O
of	O
new	O
cancer	O
diagnostic	O
markers	O
and	O
new	O
anti-cancer	O
medicines	O
.	O
It	O
would	O
create	O
a	O
significant	O
impact	O
on	O
human	O
society	O
.	O


The	O
present	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
the	O
use	O
of	O
an	O
encapsulation	O
additive	O
having	O
between	O
about	O
0	O
.	O
1	O
to	O
about	O
30	O
percent	O
isolated	O
and	O
purified	O
vitelline	B-GENE
protein	I-GENE
B	I-GENE
to	O
provide	O
for	O
mixed	O
and	O
extended	O
release	O
formulations	O
.	O


Disclosed	O
are	O
compounds	O
of	O
Formula	O
I,	O
including	O
steroisomers,	O
geometric	O
isomers,	O
tautomers,	O
solvates,	O
metabolites	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
that	O
are	O
useful	O
in	O
modulating	O
PIKK	B-GENE
related	I-GENE
kinase	I-GENE
signaling,	O
e	O
.	O
g	O
.	O
,	O
mTOR,	O
and	O
for	O
the	O
treatment	O
of	O
diseases	O
(	O
e	O
.	O
g	O
.	O
,	O
cancer	O
)	O
that	O
are	O
mediated	O
at	O
least	O
in	O
part	O
by	O
the	O
dysregulation	O
of	O
the	O
PIKK	O
signaling	O
pathway	O
(	O
e	O
.	O
g	O
.	O
,	O
mTOR	B-GENE
)	O
.	O


The	O
invention	O
comprises	O
the	O
administration	O
of	O
an	O
amount	O
of	O
honokiol	O
(	O
HNK	O
)	O
and	O
Modified	O
Citrus	O
Pectin	O
(	O
MCP	O
)	O
or	O
similar	O
pectin	O
or	O
alginate	O
in	O
amounts	O
synergistic	O
to	O
inhibit	O
cancer	O
.	O
The	O
inhibition	O
can	O
be	O
of	O
the	O
formation	O
of	O
cancer,	O
the	O
progression	O
of	O
a	O
cancer	O
already	O
formed,	O
or	O
the	O
transformation	O
of	O
a	O
primary	O
cancer	O
to	O
a	O
metastatic	O
one	O
.	O
HNK	O
and	O
MCP	O
appear	O
to	O
be	O
synergistic	O
across	O
their	O
effective	O
ranges,	O
and	O
the	O
synergy	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
binding	O
of	O
galectin-3	B-GENE
on	O
the	O
surface	O
of	O
tumor	O
cells	O
by	O
MCP,	O
which	O
better	O
presents	O
the	O
cell	O
for	O
the	O
cytotoxic	O
effects	O
of	O
HNK	O
.	O
Compositions	O
of	O
matter	O
which	O
combine	O
the	O
two	O
agents,	O
HNK	O
and	O
MCP,	O
in	O
synergistic	O
amounts	O
intended	O
for	O
daily	O
administration	O
are	O
also	O
contemplated	O
.	O
The	O
administration	O
of	O
MCP	O
and	O
HNK	O
may	O
be	O
combined	O
with	O
the	O
administration	O
of	O
conventional	O
anti-cancer	O
therapeutics	O
.	O


Compositions	O
and	O
methods	O
are	O
disclosed	O
for	O
inhibiting	O
semicarbazide-sensitive	B-GENE
amine	I-GENE
oxidase	I-GENE
(	O
SSAO	B-GENE
)	O
,	O
also	O
known	O
as	O
vascular	B-GENE
adhesion	I-GENE
protein-1	I-GENE
(	O
VAP-1	B-GENE
)	O
.	O
The	O
compounds	O
disclosed	O
are	O
amine-containing	O
and	O
amide-containing	O
compounds	O
.	O
The	O
compounds	O
and	O
compositions	O
are	O
useful	O
for	O
treatment	O
of	O
diseases,	O
including	O
inflammation,	O
inflammatory	O
diseases	O
and	O
autoimmune	O
disorders	O
.	O


Methods	O
of	O
inhibiting	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
delta	I-GENE
isoform	I-GENE
(	O
PI3Kδ	B-GENE
)	O
activity,	O
and	O
methods	O
of	O
treating	O
diseases,	O
such	O
as	O
disorders	O
of	O
immunity	O
and	O
inflammation,	O
in	O
which	O
PI3Kδ	B-GENE
plays	O
a	O
role	O
in	O
leukocyte	O
function	O
are	O
disclosed	O
.	O
Preferably,	O
the	O
methods	O
employ	O
active	O
agents	O
that	O
selectively	O
inhibit	O
PI3Kδ,	O
while	O
not	O
significantly	O
inhibiting	O
activity	O
of	O
other	O
PI3K	B-GENE
isoforms	I-GENE
.	O
Compounds	O
are	O
provided	O
that	O
inhibit	O
PI3Kδ	B-GENE
activity,	O
including	O
compounds	O
that	O
selectively	O
inhibit	O
PI3Kδ	B-GENE
activity	O
.	O
Methods	O
of	O
using	O
PI3Kδ	B-GENE
inhibitory	O
compounds	O
to	O
inhibit	O
cancer	O
cell	O
growth	O
or	O
proliferation	O
are	O
also	O
provided	O
.	O
Accordingly,	O
the	O
invention	O
provides	O
methods	O
of	O
using	O
PI3Kδ	B-GENE
inhibitory	O
compounds	O
to	O
inhibit	O
PI3Kδ-mediated	O
processes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
polynucleotides	O
and	O
polypeptides	O
involved	O
in	O
insulin	B-GENE
and	O
adiponectin	O
signaling	O
and	O
regulation	O
of	O
glucose	O
production	O
.	O
The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
the	O
identified	O
polynucleotides	O
and	O
polypeptides,	O
and	O
inhibitors	O
of	O
the	O
polynucleotides	O
and	O
polypeptides,	O
in	O
the	O
regulation	O
of	O
glucose	O
production	O
and	O
the	O
monitoring	O
and	O
treatment	O
of	O
metabolic	O
disorders	O
such	O
as	O
diabetes	O
.	O


This	O
invention	O
features	O
methods	O
and	O
compositions	O
useful	O
for	O
treating	O
and	O
diagnosing	O
diseases	O
of	O
the	O
nervous	O
system,	O
retina,	O
skin,	O
muscle,	O
joint,	O
and	O
cartilage	O
using	O
a	O
Dragon	B-GENE
family	I-GENE
protein	I-GENE
.	O
Protein	O
and	O
nucleic	O
acid	O
sequences	O
of	O
human,	O
murine,	O
zebrafish,	O
and	O
C	O
.	O
elegans	O
Dragon	B-GENE
family	I-GENE
members	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
polymers	O
comprising	O
monomer	O
units	O
derived	O
from	O
captopril,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
collagen	O
deposition,	O
fibrosis,	O
scars,	O
burns,	O
or	O
unwanted	O
tissue	O
formation	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
said	O
polymers	O
and	O
to	O
pharmaceutical	O
compositions	O
and	O
medical	O
products	O
comprising	O
the	O
polymers	O
.	O
Also	O
encompassed	O
by	O
the	O
present	O
invention	O
are	O
polymers	O
comprising	O
monomer	O
units	O
derived	O
from	O
other	O
ACE	B-GENE
inhibitors	O
such	O
as	O
zofenopril,	O
alacepril,	O
rentiapril	O
or	O
pivalopril,	O
or	O
from	O
vasopeptidase	B-GENE
inhibitors	O
such	O
as	O
fasidotrilat,	O
omapatrilat	O
or	O
ilepatril	O
.	O


Disclosed	O
herein	O
are	O
diagnostic	O
and	O
prognostic	O
methods	O
for	O
determining	O
the	O
overall	O
survival,	O
and	O
therapeutic	O
regimes,	O
for	O
multiple	O
myeloma	O
patients	O
.	O
The	O
methods	O
involve	O
the	O
detection	O
of	O
PTHR1	B-GENE
gene	O
expression	O
alone	O
or	O
in	O
combination	O
with	O
other	O
clinical	O
factors	O
.	O
The	O
tests	O
are	O
suitable	O
for	O
diagnosing	O
and	O
monitoring	O
treatment	O
of	O
patients	O
having	O
or	O
suspected	O
of	O
having	O
multiple	O
myeloma	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
proteasome	O
inhibitors	O
and	O
other	O
activators	O
of	O
PTHR1,	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O


Disclosed	O
are	O
substituted	O
benzoimidazolesulfonamides	O
and	O
substituted	O
indolesulfonamides	O
as	O
mGluR4	B-GENE
potentiators	O
.	O


The	O
invention	O
relates	O
to	O
an	O
antigenic	O
polypeptide	O
referred	O
to	O
as	O
DivlB	B-GENE
and	O
variants	O
thereof,	O
vaccines	O
comprising	O
said	O
polypeptide	O
and	O
the	O
use	O
of	O
the	O
vaccine	O
in	O
protecting	O
subjects	O
from	O
microbial	O
infection	O
.	O


The	O
disclosure	O
relates	O
to	O
methods	O
of	O
treating	O
tuberous	O
sclerosis	O
in	O
a	O
subject,	O
comprising	O
administering	O
a	O
composition	O
comprising	O
an	O
mTOR	B-GENE
inhibitor	O
and	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
to	O
a	O
subject	O
that	O
is	O
diagnosed	O
with,	O
suspected	O
of,	O
or	O
exhibiting	O
symptoms	O
of	O
cancer	O
.	O
In	O
some	O
embodiments,	O
the	O
cancer	O
is	O
tuberous	O
sclerosis	O
.	O
In	O
some	O
embodiments,	O
the	O
mTOR	B-GENE
inhibitor	O
is	O
sirolimus	O
and	O
the	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
is	O
imatinib	O
.	O
In	O
some	O
embodiments,	O
the	O
disclosure	O
relates	O
to	O
a	O
composition	O
comprising	O
an	O
mTOR	B-GENE
inhibitor	O
and	O
a	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
.	O
In	O
some	O
embodiments,	O
the	O
disclosure	O
relates	O
to	O
a	O
composition	O
comprising	O
sirolimus	O
and	O
imatinib	O
.	O


A	O
novel	O
combination	O
comprising	O
the	O
MEK	B-GENE
inhibitor	O
N-	O
{	O
3-	O
[	O
3-cyclopropyl-5-	O
(	O
2-fluoro-4-iodo-phenylamino	O
)	O
6,8-dimethyl	O
;	O
-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido	O
[	O
4,3-d	O
]	O
pyrimidin-1-yl	O
]	O
phenyl	O
}	O
acetamide,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
with	O
a	O
B-Raf	B-GENE
inhibitor,	O
particularly	O
N-	O
{	O
3-	O
[	O
5-	O
(	O
2-Amino-4-pyrimidinyl	O
)	O
-2-	O
(	O
1,1-dimethylethyl	O
)	O
-1,3-thiazol-4-yl	O
]	O
-2-fluorophen-	O
}	O
-2,6-difluorobenzenesulfonamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
of	O
using	O
such	O
combinations	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
conditions	O
in	O
which	O
the	O
inhibition	O
of	O
MEK	B-GENE
and	O
/	O
or	O
B-Raf	B-GENE
is	O
beneficial,	O
eg	O
.	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
predicting	O
and	O
evaluating	O
metastasis	O
of	O
solid	O
cancers,	O
such	O
as	O
melanoma,	O
in	O
a	O
subject	O
by	O
measuring	O
serum	O
biomarkers	O
associated	O
with	O
a	O
metastatic	O
phenotype	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
a	O
serum	O
gene	O
expression	O
signature	O
that	O
is	O
different	O
between	O
highly	O
aggressive	O
and	O
more	O
metastatic	O
versus	O
less	O
aggressive	O
and	O
less	O
metastatic	O
melanomas	O
by	O
quantitatively	O
measuring	O
the	O
levels	O
of,	O
inter	O
alia,	O
lymphoid-specific	B-GENE
helicase	I-GENE
(	O
HELLS	B-GENE
)	O
and	O
condensing	B-GENE
complex	I-GENE
subunit	I-GENE
2	I-GENE
(	O
NCAPH	B-GENE
)	O
transcripts	O
in	O
a	O
subject	O
.	O


Novel	O
PI3K,	O
especially	O
PI3K	B-GENE
delta	I-GENE
isoform,	O
selective	O
inhibitors	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
useful	O
in	O
treating	O
disorders	O
related	O
to	O
abnormal	O
PI3K	B-GENE
or	O
PI3Kδ	B-GENE
activities	O
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
disorders	O
and	O
neurological	O
disorders	O
.	O


HDAC	B-GENE
inhibitors	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
as	O
described	O
herein,	O
are	O
useful	O
as	O
inhibitors	O
of	O
histone	B-GENE
deacetylases	I-GENE
or	O
other	O
deacetylases,	O
and	O
thus	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
and	O
disorders	O
associated	O
with	O
acetylase	O
/	O
deacetylase	O
activity	O
as	O
described	O
herein	O
(	O
e	O
.	O
g	O
.	O
,	O
cancer	O
)	O
.	O
In	O
certain	O
embodiments,	O
the	O
compounds	O
of	O
the	O
invention	O
selectively	O
target	O
either	O
a	O
class	O
or	O
isoform	O
of	O
the	O
HDAC	B-GENE
family	O
.	O
Another	O
aspect	O
of	O
the	O
invention	O
provides	O
an	O
assay	O
for	O
determining	O
the	O
inhibitory	O
effect	O
of	O
a	O
test	O
compound	O
on	O
an	O
HDAC	B-GENE
protein	O
comprising	O
:	O
incubating	O
the	O
HDAC	B-GENE
protein	O
with	O
a	O
substrate	O
of	O
general	O
formula	O
(	O
IIIc	O
)	O
in	O
the	O
presence	O
of	O
a	O
test	O
compound	O
;	O
and	O
determining	O
the	O
activity	O
of	O
the	O
HDAC	B-GENE
protein	O
.	O


Disclosed	O
are	O
isoform	O
selective	O
Phospholipase	B-GENE
D	I-GENE
inhibitors	O
.	O
In	O
one	O
aspect,	O
the	O
disclosed	O
compounds	O
can	O
have	O
a	O
structure	O
represented	O
by	O
a	O
formula	O
(	O
I	O
)	O
:	O
Also	O
disclosed	O
are	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
and	O
kits	O
comprising	O
the	O
compounds	O
.	O
This	O
abstract	O
is	O
intended	O
as	O
a	O
scanning	O
tool	O
for	O
purposes	O
of	O
searching	O
in	O
the	O
particular	O
art	O
and	O
is	O
not	O
intended	O
to	O
be	O
limiting	O
of	O
the	O
present	O
invention	O
.	O


Imidamide	O
(	O
amidine	O
)	O
analogs	O
that	O
can	O
inhibit	O
the	O
activity	O
of	O
sphingosine	B-GENE
kinase	I-GENE
1	I-GENE
and	O
sphingosine	B-GENE
kinase	I-GENE
2	I-GENE
(	O
SphK1	B-GENE
&	O
SphK2	B-GENE
)	O
are	O
provided	O
.	O
The	O
compounds	O
can	O
prevent	O
angiogenesis	O
in	O
tumors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
consensus	O
nucleotide	O
and	O
protein	O
sequences	O
for	O
HIV-1	O
Clade	O
A	O
antigens,	O
and	O
to	O
nucleotide	O
and	O
protein	O
sequences	O
for	O
Clade	O
A	O
antigens	O
from	O
circulating	O
HIV-1	O
field	O
isolates	O
wherein	O
the	O
antigen	O
sequences	O
are	O
closely	O
related	O
to	O
the	O
these	O
consensus	O
sequences	O
.	O
Advantageously,	O
the	O
present	O
invention	O
relates	O
to	O
HIV-1	O
Clade	O
A	O
transgenes	O
that	O
are	O
derived	O
from	O
such	O
sequences,	O
and	O
that	O
encode	O
either	O
HIV-1	O
Clade	O
A	O
Gag,	O
Pol	B-GENE
(	O
RT	B-GENE
and	O
Int	B-GENE
)	O
,	O
and	O
Nef	B-GENE
(	O
collectively	O
“GRIN”	O
)	O
,	O
HIV-1	O
Clade	O
A	O
Gag,	O
RT,	O
and	O
Nef	B-GENE
(	O
collectively	O
“GRN”	O
)	O
,	O
or	O
HIV-1	O
Clade	O
A	O
Env	B-GENE
.	O
The	O
invention	O
also	O
relates	O
to	O
vectors	O
containing	O
such	O
transgenes,	O
including	O
adenovirus	O
vectors	O
containing	O
such	O
transgenes	O
.	O
The	O
invention	O
also	O
relates	O
to	O
immunogenic	O
compositions	O
comprising	O
the	O
HIV-1	O
Clade	O
A	O
antigens,	O
nucleotide	O
sequences,	O
vectors,	O
or	O
transgenes	O
of	O
the	O
invention,	O
and	O
to	O
methods	O
of	O
generating	O
an	O
immune	O
response	O
against	O
HIV	O
in	O
a	O
subject	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
such	O
immunogenic	O
compositions	O
.	O


An	O
N-oxide	O
of	O
3-	O
(	O
2,6-Dichloro-3,5-dimethoxy-phenyl	O
)	O
-1-	O
{	O
6-	O
[	O
4-	O
(	O
4-ethyl-piperazin-1-yl	O
)	O
-phenylamino	O
]	O
-pyrimidin-4-yl	O
}	O
-1-methyl-urea,	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
compositions	O
including	O
the	O
compound	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts,	O
and	O
methods	O
of	O
preparing	O
the	O
compound	O
and	O
the	O
compositions	O
(	O
such	O
as,	O
for	O
example,	O
by	O
oxidizing	O
3-	O
(	O
2,6-Dichloro-3,5-dimethoxy-phenyl	O
)	O
-1-	O
{	O
6-	O
[	O
4-	O
(	O
4-ethyl-piperazin-1-yl	O
)	O
-phenylamino	O
]	O
-pyrimidin-4-yl	O
}	O
-1-methyl-urea	O
with	O
an	O
oxidizing	O
agent	O
)	O
are	O
described	O
.	O
Further	O
described	O
herein	O
are	O
methods	O
of	O
using	O
the	O
compound	O
and	O
compositions	O
of	O
the	O
present	O
technology,	O
alone	O
and	O
in	O
combination	O
with	O
other	O
suitable	O
agents,	O
to	O
treat	O
various	O
diseases,	O
including	O
but	O
not	O
limited	O
to,	O
those	O
that	O
can	O
be	O
prevented,	O
inhibited	O
or	O
ameliorated	O
by	O
inhibition	O
of	O
kinase	B-GENE
activity	O
selected	O
from	O
FGFR1,	O
FGFR2,	O
FGFR3	B-GENE
or	O
FGFR4	B-GENE
.	O


A	O
composition	O
comprising	O
chromium	O
and	O
insulin	B-GENE
and	O
/	O
or	O
a	O
chromium-insulin	O
complex,	O
its	O
method	O
of	O
preparation,	O
and	O
its	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
hypoglycemia	O
and	O
hypoglycemia-related	O
conditions	O
.	O
This	O
composition	O
can	O
be	O
administered	O
in	O
numerous	O
ways,	O
including	O
parenterally,	O
intranasally,	O
and	O
orally	O
.	O
The	O
composition	O
stabilizes	O
serum	O
glucose	O
levels	O
and	O
has	O
a	O
synergistic	O
effect	O
compared	O
to	O
chromium	O
and	O
insulin	B-GENE
administered	O
separately	O
.	O


Methods	O
and	O
agents	O
for	O
reducing	O
a	O
level	O
of	O
an	O
acetylated	O
Tau	B-GENE
polypeptide	O
in	O
a	O
cell	O
are	O
provided	O
.	O
Methods	O
for	O
treating	O
a	O
tauopathy	O
in	O
an	O
individual	O
are	O
also	O
provided	O
.	O
Also	O
provided	O
is	O
a	O
method	O
for	O
diagnosing	O
a	O
cognitive	O
impairment	O
disorder	O
in	O
an	O
individual	O
.	O
Methods	O
for	O
identifying	O
an	O
agent	O
suitable	O
for	O
treating	O
a	O
tauopathy	O
are	O
also	O
provided	O
.	O


The	O
present	O
application	O
relates	O
to	O
novel	O
substituted	O
aminopyridine	O
derivatives,	O
to	O
their	O
use	O
in	O
therapy,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
derivatives,	O
to	O
the	O
use	O
of	O
said	O
derivatives	O
in	O
the	O
manufacture	O
of	O
a	O
medicament,	O
and	O
to	O
therapeutic	O
methods	O
comprising	O
the	O
administration	O
of	O
the	O
derivatives	O
.	O
The	O
present	O
derivatives	O
are	O
useful	O
for	O
treating	O
a	O
disorder	O
responsive	O
to	O
activation	O
of	O
Kv7	B-GENE
channels	I-GENE
.	O
Due	O
to	O
the	O
distribution	O
of	O
Kv7	B-GENE
channels	I-GENE
within	O
the	O
organism,	O
Kv7	B-GENE
channel	I-GENE
modulators	O
are	O
considered	O
potentially	O
useful	O
for	O
the	O
treatment	O
or	O
alleviation	O
of	O
conditions	O
as	O
diverse	O
as	O
CNS	O
disorders,	O
psychiatric	O
disorders,	O
CNS	O
damage	O
caused	O
by	O
trauma,	O
stroke	O
or	O
neurodegenerative	O
illness	O
or	O
diseases,	O
a	O
variety	O
of	O
neuronal	O
hyperexcitability	O
disorders	O
and	O
conditions,	O
epilepsy,	O
pain,	O
neuropathic	O
pain,	O
migraine,	O
tension	O
type	O
headache,	O
learning	O
and	O
cognitive	O
disorders,	O
motion	O
and	O
motor	O
disorders,	O
multiple	O
sclerosis,	O
cardiac	O
disorders,	O
heart	O
failure,	O
cardio-myopathia,	O
inflammatory	O
diseases,	O
ophthalmic	O
conditions,	O
deafness,	O
progressive	O
hearing	O
loss,	O
tinnitus,	O
obstructive	O
or	O
inflammatory	O
airway	O
diseases,	O
for	O
inducing	O
or	O
maintaining	O
bladder	O
control	O
including	O
the	O
treatment	O
or	O
prevention	O
of	O
urinary	O
incontinence	O
.	O


A	O
method	O
for	O
predicting	O
a	O
subject	O
'	O
s	O
response	O
to	O
a	O
TUSC2	B-GENE
therapy	O
is	O
provided	O
.	O
In	O
particular,	O
a	O
subject	O
'	O
s	O
response	O
is	O
predicted	O
based	O
on	O
the	O
proportion	O
of	O
cancers	O
cells	O
that	O
are	O
apoptotic	O
.	O
Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
a	O
subject	O
previously	O
predicted	O
to	O
have	O
a	O
favorable	O
response	O
with	O
a	O
TUSC2	B-GENE
therapy	O
.	O
Methods	O
for	O
treating	O
cancer	O
by	O
administration	O
of	O
a	O
TUSC2	B-GENE
therapeutic	O
in	O
conjunction	O
with	O
an	O
EGFR	B-GENE
inhibitor	O
and	O
/	O
or	O
a	O
protein	B-GENE
kinase	I-GENE
inhibitor	O
are	O
also	O
disclosed	O
.	O
Kits	O
and	O
reagents	O
for	O
use	O
in	O
TUSC2	B-GENE
therapy	O
are	O
provided	O
.	O


The	O
present	O
invention	O
generally	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
protease	B-GENE
proenzyme	O
and	O
use	O
thereof	O
for	O
treating	O
cancer	O
.	O
The	O
pharmaceutical	O
compositions	O
are	O
directed	O
to	O
compositions	O
comprising	O
a	O
protease	B-GENE
proenzyme	O
and	O
an	O
active	O
agent,	O
the	O
composition	O
being	O
capable	O
of	O
providing	O
a	O
multi-functional	O
approach	O
for	O
treating	O
cancer	O
.	O
The	O
pharmaceutical	O
compositions	O
are	O
also	O
directed	O
to	O
compositions	O
comprising	O
a	O
first	O
and	O
a	O
second	O
protease	B-GENE
proenzyme	O
capable	O
of	O
activation	O
at	O
or	O
near	O
a	O
surface	O
of	O
a	O
tumour	O
cell	O
to	O
enhance	O
cell-to-cell	O
adhesion	O
of	O
tumour	O
cells,	O
effect	O
proteolysis	O
of	O
tumour	O
cells,	O
or	O
induce	O
tumour	O
cell	O
apoptosis,	O
differentiation	O
or	O
immunorecognition,	O
wherein	O
the	O
first	O
protease	B-GENE
proenzyme	O
is	O
chymotrypsinogen	O
and	O
the	O
second	O
protease	B-GENE
proenzyme	O
is	O
trypsinogen	O
.	O
The	O
pharmaceutical	O
compositions	O
are	O
also	O
directed	O
to	O
compositions	O
comprising	O
a	O
first	O
and	O
second	O
active	O
agent	O
each	O
capable	O
of	O
inducing	O
intracellular	O
activity	O
in	O
tumour	O
cells	O
.	O


Compounds	O
of	O
the	O
following	O
formula	O
are	O
provided	O
for	O
use	O
with	O
glucokinase	B-GENE
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
and	O
intermediates	O
useful	O
for	O
making	O
the	O
compounds	O
;	O
and	O
methods	O
of	O
using	O
said	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
apolipoprotein	O
B,	O
and	O
more	O
particularly	O
to	O
the	O
downregulation	O
of	O
apolipoprotein	B-GENE
B	I-GENE
by	O
chemically	O
modified	O
oligonucleotides	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
mutant	O
of	O
MITF	B-GENE
which	O
is	O
useful	O
as	O
a	O
marker	O
for	O
predisposition	O
to	O
the	O
development	O
of	O
cancer	O
and	O
to	O
uses	O
thereof	O
in	O
diagnosis	O
and	O
preventive	O
treatments,	O
sumoylation	O
being	O
reduced	O
or	O
absent	O
in	O
this	O
mutant	O
.	O


A	O
tissue	O
thickness	O
compensator	O
may	O
generally	O
comprise	O
a	O
first	O
layer	O
comprising	O
a	O
first	O
medicament,	O
a	O
second	O
layer	O
comprising	O
a	O
second	O
medicament,	O
and	O
a	O
third	O
layer	O
comprising	O
a	O
third	O
medicament	O
.	O
The	O
tissue	O
thickness	O
compensator	O
may	O
comprise	O
a	O
first	O
layer	O
comprising	O
a	O
first	O
medicament,	O
a	O
second	O
layer	O
comprising	O
a	O
second	O
medicament,	O
and	O
a	O
reservoir	O
comprising	O
a	O
third	O
medicament	O
disposed	O
within	O
the	O
reservoir	O
.	O
The	O
medicaments	O
may	O
be	O
independently	O
selected	O
from	O
a	O
haemostatic	O
agent,	O
an	O
anti-inflammatory	O
agent,	O
an	O
antibiotic	O
agent,	O
anti-microbial	O
agent,	O
an	O
anti-adhesion	O
agent,	O
an	O
anti-coagulant	O
agent,	O
a	O
pharmaceutically	O
active	O
agent,	O
a	O
matrix	B-GENE
metalloproteinase	I-GENE
inhibitor,	O
and	O
combinations	O
thereof	O
.	O
Articles	O
of	O
manufacture	O
comprising	O
the	O
tissue	O
thickness	O
compensator	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
tissue	O
thickness	O
compensator	O
are	O
also	O
described	O
.	O


The	O
present	O
invention	O
relates	O
to	O
inhibitors	O
of	O
protein	O
kinases	B-GENE
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O


A	O
pharmaceutical	O
composition	O
for	O
use	O
in	O
treating,	O
inhibiting,	O
and	O
/	O
or	O
preventing	O
breast	O
and	O
/	O
or	O
ovarian	O
cancer	O
can	O
include	O
:	O
a	O
molecule	O
having	O
a	O
structure	O
of	O
one	O
of	O
Compounds	O
1-38,	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
analog	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
containing	O
the	O
compound	O
.	O
The	O
pharmaceutically	O
acceptable	O
carrier	O
can	O
be	O
configured	O
for	O
oral,	O
systemic,	O
transdermal,	O
intranasal,	O
suppository,	O
parenteral,	O
intramuscular,	O
intravenous,	O
or	O
subcutaneous	O
administration	O
.	O
The	O
compound	O
can	O
be	O
present	O
in	O
the	O
composition	O
in	O
a	O
therapeutically	O
effective	O
amount	O
for	O
treating,	O
inhibiting,	O
and	O
/	O
or	O
preventing	O
breast	O
and	O
/	O
or	O
ovarian	O
cancer	O
.	O
Also,	O
the	O
compound	O
can	O
be	O
present	O
in	O
a	O
therapeutically	O
effective	O
amount	O
for	O
enhancing	O
production	O
of	O
BRCA1	B-GENE
.	O


For	O
enhancing	O
bioavailability,	O
a	O
composition	O
is	O
administered	O
comprising	O
a	O
Transient	B-GENE
Receptor	I-GENE
Potential	I-GENE
cation	I-GENE
channel	I-GENE
subfamily	I-GENE
V	I-GENE
member	I-GENE
1	I-GENE
(	O
TRPV1	B-GENE
)	O
agonist	O
with	O
a	O
combined	O
Scoville	O
Heat	O
Unit	O
(	O
SHU	O
)	O
milligram	O
(	O
mg	O
)	O
dose	O
in	O
the	O
range	O
of	O
280,000	O
to	O
400,000	O
SHU	O
mg	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
treating	O
a	O
myeloma	O
patient	O
by	O
administering	O
one	O
or	O
more	O
of	O
thalidomide,	O
a	O
Total	O
Therapy	O
2	O
regimen,	O
an	O
interleukin-6	B-GENE
signaling	O
suppressor,	O
an	O
interleukin-6R	B-GENE
signaling	O
suppressor,	O
an	O
IGF1	B-GENE
signaling	O
suppressor,	O
an	O
IGF1	B-GENE
R	I-GENE
signaling	O
suppressor,	O
shRNA	O
or	O
other	O
modulators	O
of	O
gene	O
expression	O
.	O
Also,	O
provided	O
are	O
methods	O
for	O
predicting	O
outcome	O
of	O
a	O
treatment	O
for	O
an	O
individual	O
having	O
a	O
cancer,	O
e	O
.	O
g	O
.	O
,	O
myeloma,	O
by	O
performing	O
one	O
or	O
more	O
of	O
karyotyping	O
or	O
expression	O
profiling	O
of	O
chromosomes	O
1	O
and	O
13	O
or	O
expression	O
level	O
measurement	O
of	O
IL-6R	B-GENE
.	O


The	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
for	O
modulating	O
one	O
or	O
more	O
components	O
of	O
a	O
kinase	B-GENE
cascade	O
.	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
methods	O
of	O
protecting	O
against	O
or	O
treating	O
hearing	O
loss,	O
osteoporosis,	O
cell	O
proliferative	O
disorders,	O
obesity,	O
diabetes,	O
eye	O
disease,	O
stroke,	O
atherosclerosis,	O
neuropathic	O
pain	O
or	O
hepatitis	O
B	O
.	O


The	O
present	O
invention	O
relates	O
to	O
selective	O
CB2	B-GENE
agonists	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
alcoholic	O
liver	O
disease	O
and	O
particularly	O
alcoholic	O
hepatic	O
steatosis	O
and	O
liver	O
inflammation,	O
and	O
pharmaceutical	O
composition	O
thereof	O
.	O


The	O
invention	O
relates	O
to	O
cytokine	B-GENE
receptor-like	I-GENE
factor	I-GENE
2	I-GENE
(	O
CRLF2	B-GENE
)	O
,	O
and	O
particularly	O
certain	O
mutant	O
forms	O
of	O
CRLF2,	O
as	O
prognostic	O
and	O
therapeutic	O
targets	O
in	O
precursor	O
B-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
B-ALL	O
)	O
.	O
Mutant	O
CRLF2	B-GENE
with	O
a	O
Phe232-Cys	B-GENE
(	O
F232C	B-GENE
)	O
mutation	O
is	O
overexpressed	O
and	O
constitutively	O
activates	O
STAT5	B-GENE
in	O
a	O
subset	O
of	O
B-ALL	O
patients	O
with	O
particularly	O
poor	O
prognosis	O
.	O
Methods	O
and	O
compositions	O
useful	O
for	O
identifying,	O
inhibiting	O
expression,	O
and	O
inhibiting	O
activity	O
of	O
the	O
mutant	O
CRLF2	B-GENE
are	O
provided	O
.	O
Also	O
provided	O
are	O
methods	O
and	O
compositions	O
useful	O
for	O
treating	O
B-ALL	O
.	O


Methods	O
for	O
treating	O
methylmalonic	O
acidemia	O
in	O
which	O
at	O
least	O
one	O
allele	O
of	O
a	O
gene	O
associated	O
with	O
MMA	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
MUT,	O
MMAA,	O
or	O
MMAB	B-GENE
gene	O
)	O
contains	O
a	O
mutation	O
(	O
e	O
.	O
g	O
.	O
,	O
nonsense	O
mutation	O
)	O
that	O
results	O
in	O
a	O
premature	O
stop	O
codon	O
in	O
RNA	O
encoded	O
by	O
an	O
allele	O
of	O
the	O
gene	O
associated	O
with	O
MMA	O
involving	O
the	O
administration	O
of	O
a	O
compound	O
that	O
promotes	O
readthrough	O
of	O
RNA	O
(	O
e	O
.	O
g	O
.	O
,	O
messenger	O
RNA	O
)	O
containing	O
a	O
premature	O
stop	O
codon	O
encoded	O
by	O
an	O
allele	O
of	O
the	O
gene	O
associated	O
with	O
MMA	O
are	O
described	O
.	O
The	O
compound	O
can	O
be	O
administered	O
as	O
a	O
single-agent	O
therapy	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapies	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatment	O
.	O


Long	O
non-coding	O
RNAs	O
(	O
lncRNAs	O
)	O
and	O
methods	O
of	O
using	O
them	O
diagnostically	O
and	O
therapeutically	O
for	O
treatment	O
of	O
cancer,	O
stem	O
cell	O
therapy,	O
or	O
regenerative	O
medicine	O
are	O
disclosed	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
lncRNAs	O
that	O
that	O
play	O
roles	O
in	O
regulation	O
of	O
genes	O
involved	O
in	O
cell	O
proliferation,	O
differentiation,	O
and	O
apoptosis	O
.	O
Such	O
lncRNAs	O
can	O
be	O
used	O
as	O
biomarkers	O
to	O
monitor	O
cell	O
proliferation	O
and	O
differentiation	O
during	O
cancer	O
progression	O
or	O
tissue	O
regeneration	O
.	O
One	O
of	O
the	O
identified	O
lncRNAs,	O
referred	O
to	O
as	O
PANDA	O
(	O
a	O
P21-Associated	O
NcRNA,	O
DNA	O
damage	O
Activated	O
)	O
,	O
inhibits	O
the	O
expression	O
of	O
apoptotic	O
genes	O
normally	O
activated	O
by	O
the	O
transcription	O
factor	O
NF-YA	B-GENE
Inhibitors	O
of	O
PANDA	O
sensitize	O
cancerous	O
cells	O
to	O
chemotherapy	O
and	O
can	O
be	O
used	O
in	O
combination	O
with	O
chemotherapeutic	O
agents	O
for	O
treatment	O
of	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
for	O
a	O
method	O
for	O
treating	O
a	O
disease	O
condition	O
associated	O
with	O
PI3-kinase	B-GENE
α	I-GENE
and	O
/	O
or	O
mTOR	B-GENE
in	O
a	O
subject	O
.	O
In	O
another	O
aspect,	O
the	O
invention	O
provides	O
for	O
a	O
method	O
for	O
treating	O
a	O
disease	O
condition	O
associated	O
with	O
PI3-kinase	B-GENE
α	I-GENE
and	O
/	O
or	O
mTOR	B-GENE
in	O
a	O
subject	O
.	O
In	O
yet	O
another	O
aspect,	O
a	O
method	O
of	O
inhibiting	O
phosphorylation	O
of	O
both	O
Akt	O
(	O
S473	O
)	O
and	O
Akt	O
(	O
T308	O
)	O
in	O
a	O
cell	O
is	O
set	O
forth	O
.	O


Provided	O
is	O
a	O
1,3,4-oxadiazole-2-carboxamide	O
compound	O
which	O
has	O
STAT3	B-GENE
inhibitory	O
activity	O
and	O
is	O
useful	O
as	O
an	O
anticancer	O
agent	O
.	O
Provided	O
is	O
a	O
1,3,4-oxadiazole-2-carboxamide	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
(	O
in	O
the	O
formula,	O
Ar	O
represents	O
a	O
furyl	O
group	O
or	O
the	O
like	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
and	O
—X—Y	O
represents	O
a	O
diaryl	O
group	O
such	O
as	O
a	O
biphenyl	O
group	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
inflammation,	O
an	O
inflammatory	O
disease,	O
an	O
immune	O
or	O
an	O
autoimmune	O
disorder,	O
which	O
comprises	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates,	O
geometrical	O
isomers,	O
tautomers,	O
optical	O
isomers	O
or	O
N-oxides,	O
which	O
are	O
inhibitors	O
of	O
SSAO	B-GENE
activity	O
.	O


The	O
invention	O
concerns	O
the	O
use	O
an	O
mGluR	B-GENE
modulator,	O
e	O
.	O
g	O
.	O
an	O
mGluR5	B-GENE
modulator,	O
for	O
the	O
treatment,	O
prevention	O
or	O
delay	O
of	O
progression	O
of	O
cognitive	O
dysfunction	O
.	O


A	O
modification	O
of	O
the	O
existing	O
INSM1	B-GENE
promoter	O
region	O
has	O
been	O
discovered	O
that	O
incorporated	O
DNA	O
elements	O
that	O
silence	O
expression	O
of	O
neuronal	O
genes	O
in	O
non-neuronal	O
cells	O
and	O
that	O
has	O
increased	O
the	O
effectiveness	O
and	O
safety	O
of	O
using	O
the	O
INSM1	B-GENE
promoter	O
for	O
tumor	O
treatment	O
.	O
One	O
modification	O
was	O
addition	O
of	O
one	O
or	O
two	O
tandem	O
copies	O
of	O
neuronal	B-GENE
restrictive	I-GENE
silencer	I-GENE
elements	I-GENE
(	O
NRSEs	B-GENE
)	O
derived	O
either	O
from	O
the	O
mouse	B-GENE
nicotinic	I-GENE
acetylcholine	I-GENE
receptor	I-GENE
(	O
nAChR	B-GENE
)	O
or	O
the	O
rat	O
superior	O
cervical	O
ganglion	O
10	O
(	O
SCG10	O
)	O
promoters	O
.	O
These	O
NRSEs	B-GENE
were	O
placed	O
in	O
the	O
expression	O
construct	O
either	O
directly	O
upstream	O
or	O
downstream	O
of	O
the	O
INSM1	B-GENE
promoter	O
sequence	O
.	O
The	O
most	O
effective	O
expression	O
construct	O
was	O
the	O
nAChR	B-GENE
NRSE	B-GENE
element	O
positioned	O
downstream	O
of	O
the	O
INSM1	B-GENE
promoter	O
.	O
This	O
expression	O
construct	O
increased	O
the	O
tissue	O
specificity	O
of	O
the	O
INSM1	B-GENE
promoter	O
without	O
a	O
significant	O
decrease	O
in	O
its	O
activity	O
.	O
In	O
addition,	O
the	O
modified	O
INSM1	B-GENE
promoter	O
was	O
placed	O
into	O
a	O
viral	O
vector,	O
adenovirus	O
5	O
.	O
Constructs	O
with	O
an	O
insulator	O
element,	O
the	O
chicken	O
HS4	O
β-globin	O
insulator	O
element,	O
with	O
the	O
INSM1	B-GENE
promoter	O
was	O
shown	O
to	O
decrease	O
the	O
interference	O
of	O
the	O
viral	O
genome	O
on	O
its	O
expression	O
.	O
Constructs	O
have	O
been	O
made	O
that	O
do	O
not	O
decrease	O
the	O
INSM1	B-GENE
promoter	O
activity	O
but	O
significantly	O
augment	O
the	O
tumor	O
specificity	O
of	O
the	O
promoter	O
.	O
Linking	O
the	O
construct	O
to	O
a	O
reporter	O
gene	O
allowed	O
for	O
detection	O
of	O
the	O
placement	O
of	O
the	O
viral	O
vector,	O
and	O
this	O
detection	O
can	O
be	O
used	O
for	O
diagnosing	O
or	O
locating	O
neuroendocrine	O
tumors	O
.	O


Provided	O
herein	O
are	O
novel	O
fluoroergoline	O
derivatives	O
and	O
compositions	O
thereof	O
.	O
In	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment,	O
prevention,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as,	O
for	O
example,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O
In	O
still	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as,	O
for	O
example,	O
the	O
5-HT1D	B-GENE
and	O
/	O
or	O
the	O
5-HT1B	B-GENE
receptor,	O
without	O
agonizing	O
the	O
5-HT2B	B-GENE
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O
In	O
still	O
other	O
embodiments,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as,	O
for	O
example,	O
the	O
adrenergic	O
alpha2A	B-GENE
and	O
/	O
or	O
the	O
alpha2B	B-GENE
receptors	I-GENE
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
brain	O
cancer	O
in	O
a	O
subject	O
by	O
administering	O
to	O
said	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
modulator	O
of	O
the	O
interaction	O
between	O
SPARC	B-GENE
related	I-GENE
modular	I-GENE
calcium	I-GENE
binding	I-GENE
1	I-GENE
(	O
SMOC1	B-GENE
)	O
and	O
tenascin-C,	O
for	O
example	O
a	O
specific	O
antibody	O
or	O
a	O
siRNA	O
.	O
The	O
present	O
invention	O
also	O
encompasses	O
methods	O
of	O
diagnosing	O
cancer	O
by	O
measuring	O
levels	O
of	O
SMOC1,	O
as	O
well	O
as	O
method	O
of	O
targeted	O
therapy	O
using	O
anti-SMOC1	O
or	O
tenascin-C	B-GENE
antibodies	O
conjugated	O
to	O
therapeutic	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
improving	O
the	O
therapeutic	O
effect	O
of	O
acupuncture	O
in	O
a	O
subject	O
.	O
The	O
method	O
involves	O
administering	O
adenosine,	O
an	O
adenosine	O
mimetric,	O
an	O
adenosine	O
modulator,	O
an	O
adenosine	O
transport	O
inhibitor,	O
enzymes	O
involved	O
in	O
adenosine	O
metabolism,	O
and	O
/	O
or	O
an	O
adenosine	B-GENE
receptor	I-GENE
agonist	O
to	O
the	O
subject	O
under	O
conditions	O
effective	O
to	O
improve	O
the	O
therapeutic	O
effect	O
of	O
the	O
acupuncture	O
.	O


The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
to	O
selectively	O
and	O
directly	O
deliver	O
nanoparticles	O
carrying	O
an	O
active	O
agent	O
to	O
tumor	O
cells	O
.	O
The	O
active	O
agent	O
is	O
internalized	O
by	O
the	O
tumor	O
cells,	O
producing	O
an	O
anti-tumor	O
effect	O
for	O
therapeutic	O
applications	O
and	O
/	O
or	O
depositing	O
a	O
detectable	O
marker	O
for	O
diagnostic	O
applications	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
p53	B-GENE
chimera	I-GENE
that	O
circumvents	O
the	O
dominant	O
negative	O
activity	O
of	O
mutant	O
p53	O
as	O
a	O
therapeutic	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
reduction	O
of	O
mor	O
size	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
having	O
the	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
are	O
soluble	B-GENE
guanylate	I-GENE
cyclase	I-GENE
activators	O
.	O
The	O
compounds	O
are	O
capable	O
of	O
modulating	O
the	O
body	O
'	O
s	O
production	O
of	O
cyclic	O
guanosine	O
monophosphate	O
(	O
“cGMP”	O
)	O
and	O
are	O
generally	O
suitable	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
a	O
disturbed	O
cGMP	O
balance	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
treatment	O
or	O
prevention	O
of	O
cardiovascular	O
diseases,	O
endothelial	O
dysfunction,	O
diastolic	O
dysfunction,	O
atherosclerosis,	O
hypertension,	O
pulmonary	O
hypertension,	O
angina	O
pectoris,	O
thromboses,	O
restenosis,	O
myocardial	O
infarction,	O
strokes,	O
cardiac	O
insufficiency,	O
pulmonary	O
hypertonia,	O
erectile	O
dysfunction,	O
asthma	O
bronchiale,	O
chronic	O
kidney	O
insufficiency,	O
diabetes,	O
or	O
cirrhosis	O
of	O
the	O
liver	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
preventing	O
and	O
treating	O
Staphylococcus	O
aureus	O
in	O
a	O
subject	O
.	O
Therapeutic	O
compositions	O
of	O
the	O
present	O
invention	O
comprise	O
leukocidin	B-GENE
E	I-GENE
and/or	I-GENE
D	I-GENE
proteins	O
or	O
polypeptides	O
and	O
anti-leukocidin	O
E	O
and/or	I-GENE
D	I-GENE
antibodies	O
.	O
The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
identifying	O
inhibitors	O
of	O
LukE/D	B-GENE
cytotoxicity	O
and	O
inhibitors	O
of	O
LukE	O
/	O
D-leukocyte	O
binding	O
.	O


Novel	O
peptides	O
that	O
inhibit	O
the	O
release	O
of	O
microparticles	O
from	O
cells	O
are	O
disclosed	O
.	O
The	O
peptide	O
contains	O
at	O
least	O
one	O
VGFPV	B-GENE
motif	I-GENE
at	O
the	O
N-terminal	O
and	O
has	O
a	O
length	O
of	O
10-100	O
amino	O
acids	O
.	O
Also	O
disclosed	O
is	O
polynucleotide	O
encoding	O
the	O
peptide,	O
expression	O
vectors	O
carrying	O
the	O
polynucleotide,	O
and	O
methods	O
for	O
treating	O
AIDS	O
and	O
tumors	O
using	O
the	O
novel	O
peptides	O
.	O


The	O
present	O
invention	O
provides	O
an	O
indole	O
derivative	O
having	O
a	O
melanin-concentrating	B-GENE
hormone	I-GENE
receptor	I-GENE
antagonistic	O
action,	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
obesity	O
and	O
the	O
like	O
.	O
	O
	O
	O
	O
The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification,	O
or	O
a	O
salt	O
thereof	O
.	O


Materials	O
and	O
Methods	O
are	O
provided	O
for	O
the	O
diagnosis,	O
monitoring,	O
and	O
personalized	O
treatments	O
of	O
gynecological	O
cancers	O
.	O
The	O
methods	O
comprise	O
determining	O
levels	O
of	O
PLA2	B-GENE
activity	O
in	O
sample	O
of	O
tissue	O
or	O
fluid	O
recovered	O
from	O
patient	O
;	O
elevated	O
levels	O
of	O
PLA2	B-GENE
activity	O
are	O
consistent	O
with	O
epithelial	O
ovarian	O
cancer	O
(	O
EOC	O
)	O
.	O
These	O
methods	O
include	O
assaying	O
for	O
PLA2	B-GENE
activity	O
within	O
tissue,	O
ascites,	O
blood,	O
and	O
other	O
tissue	O
forms	O
by	O
exposing	O
the	O
patient	O
sample	O
to	O
a	O
fluorogenic	O
compound	O
such	O
as	O
DBPC	O
.	O
The	O
methods	O
disclosed	O
herein	O
further	O
include	O
correlating	O
the	O
fluorogenic	O
detection	O
with	O
a	O
disease	O
state	O
in	O
the	O
patient,	O
including	O
diseases	O
such	O
as	O
gynecological	O
cancers,	O
such	O
as	O
EOC	O
.	O
The	O
methods	O
comprise	O
determining	O
levels	O
of	O
total	O
PLA2	B-GENE
activity,	O
and	O
of	O
specific	O
isoforms	O
of	O
PLA2	B-GENE
such	O
as	O
iPLA2,	O
iPLA2β,	O
cPLA2,	O
among	O
other	O
isoforms	O
.	O


Provided	O
are	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer,	O
tautomer,	O
salt,	O
hydrate	O
or	O
prodrug	O
thereof	O
that	O
modulate	O
tyrosine	B-GENE
kinase	I-GENE
activity,	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
their	O
use	O
.	O


The	O
invention	O
provides	O
crystalline	O
solid	O
forms	O
of	O
(	O
S	O
)	O
-4-	O
(	O
(	O
2S,3S	O
)	O
-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino	O
)	O
-2-cyclohexylmethyl-butyric	O
acid	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
such	O
crystalline	O
solid	O
forms,	O
methods	O
of	O
using	O
such	O
crystalline	O
solid	O
forms	O
to	O
treat	O
diseases	O
associated	O
with	O
mu	B-GENE
opioid	I-GENE
receptor	I-GENE
activity,	O
and	O
processes	O
useful	O
for	O
preparing	O
such	O
crystalline	O
solid	O
forms	O
.	O


The	O
present	O
invention	O
relates	O
to	O
N-	O
[	O
4-	O
(	O
1H-pyrazolo	O
[	O
3,4-b	O
]	O
pyrazin-6-yl	O
)	O
-phenyl	O
]	O
-sulfonamides	O
of	O
the	O
formula	O
I,	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
Ar,	O
R1,	O
R2	O
and	O
n	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
which	O
modulate	O
protein	B-GENE
kinase	I-GENE
activity,	O
specifically	O
the	O
activity	O
of	O
serum	B-GENE
and	I-GENE
glucocorticoid	I-GENE
regulated	I-GENE
kinase	I-GENE
(	O
SGK	B-GENE
)	O
,	O
in	O
particular	O
of	O
serum	B-GENE
and	I-GENE
glucocorticoid	I-GENE
regulated	I-GENE
kinase	I-GENE
isoform	I-GENE
1	I-GENE
(	O
SGK-1,	O
SGK1	B-GENE
)	O
,	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
SGK	B-GENE
activity	O
is	O
inappropriate,	O
for	O
example	O
degenerative	O
joint	O
disorders	O
or	O
inflammatory	O
processes	O
such	O
as	O
osteoarthritis	O
or	O
rheumatism	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I,	O
their	O
use	O
as	O
pharmaceuticals,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
piperazine	O
compounds	O
;	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
;	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
therapy	O
to	O
treat	O
diseases	O
for	O
which	O
blocking	O
the	O
Cav2.2	B-GENE
calcium	O
channels	O
is	O
beneficial	O
and	O
to	O
treat	O
diseases	O
for	O
which	O
blocking	O
the	O
Cav2.2	B-GENE
and	O
Cav3.2	B-GENE
calcium	O
channels	O
is	O
beneficial,	O
e	O
.	O
g	O
.	O
to	O
treat	O
pain	O
.	O


Behavioral	O
pharmacological	O
data	O
with	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
novel	O
and	O
selective	O
5HT2A/2C	B-GENE
receptor	I-GENE
inverse	O
agonist,	O
demonstrate	O
in	O
vivo	O
efficacy	O
in	O
models	O
of	O
psychosis	O
and	O
dyskinesias	O
.	O
This	O
includes	O
activity	O
in	O
reversing	O
MK-801	O
induced	O
locomotor	O
behaviors,	O
suggesting	O
that	O
this	O
compound	O
may	O
be	O
an	O
efficacious	O
anti-psychotic,	O
and	O
activity	O
in	O
an	O
MPTP	O
primate	O
model	O
of	O
dyskinesias,	O
suggesting	O
efficacy	O
as	O
an	O
anti-dyskinesia	O
agent	O
.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
5HT2A/2C	B-GENE
receptor	I-GENE
inverse	O
agonism	O
may	O
confer	O
antipsychotic	O
and	O
anti-dyskinetic	O
efficacy	O
in	O
humans,	O
and	O
indicate	O
a	O
use	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
related	O
agents	O
as	O
novel	O
therapeutics	O
for	O
Parkinson	O
'	O
s	O
Disease,	O
related	O
human	O
neurodegenerative	O
diseases,	O
and	O
psychosis	O
.	O


The	O
invention	O
provides	O
methods	O
of	O
preventing	O
or	O
treating	O
a	O
condition	O
associated	O
with	O
DNA	O
damage	O
in	O
an	O
animal	O
comprising	O
the	O
administration	O
of	O
a	O
substance	O
that	O
interferes	O
with	O
the	O
activity	O
of	O
the	O
CUL4A	B-GENE
ubiquitin	I-GENE
ligase	I-GENE
.	O
The	O
invention	O
also	O
provides	O
a	O
substance	O
that	O
interferes	O
with	O
the	O
activity	O
of	O
CUL4A,	O
as	O
well	O
as	O
compositions	O
comprising	O
the	O
interfering	O
substance	O
and	O
a	O
carrier	O
.	O
The	O
substance	O
of	O
the	O
invention	O
preferably	O
enhances	O
nucleotide	O
excision	O
repair	O
activity	O
in	O
an	O
animal	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
identifying	O
substances	O
that	O
negatively	O
or	O
positively	O
modulate	O
the	O
expression	O
and	O
/	O
or	O
activity	O
of	O
CUL4A	O
.	O


In	O
one	O
aspect,	O
the	O
invention	O
relates	O
to	O
imidazopyrimidin-5	O
(	O
6H	O
)	O
-one	O
analogs,	O
derivatives	O
thereof,	O
and	O
related	O
compounds,	O
which	O
are	O
useful	O
as	O
positive	O
allosteric	O
modulators	O
of	O
the	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
subtype	I-GENE
5	I-GENE
(	O
mGluR5	B-GENE
)	O
;	O
synthetic	O
methods	O
for	O
making	O
the	O
compounds	O
;	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
;	O
and	O
methods	O
of	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
associated	O
with	O
glutamate	O
dysfunction	O
using	O
the	O
compounds	O
and	O
compositions	O
.	O
This	O
abstract	O
is	O
intended	O
as	O
a	O
scanning	O
tool	O
for	O
purposes	O
of	O
searching	O
in	O
the	O
particular	O
art	O
and	O
is	O
not	O
intended	O
to	O
be	O
limiting	O
of	O
the	O
present	O
invention	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
bilayer	O
pharmaceutical	O
tablet	O
comprising	O
a	O
first	O
layer	O
formulated	O
for	O
immediate	O
release	O
of	O
the	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
telmisartan	O
from	O
a	O
dissolving	O
tablet	O
matrix	O
which	O
contains	O
telmisartan	O
in	O
substantially	O
amorphous	O
form,	O
and	O
a	O
second	O
layer	O
formulated	O
for	O
immediate	O
release	O
of	O
a	O
diuretic	O
like	O
hydrochlorothiazide	O
from	O
a	O
fast	O
disintegrating	O
tablet	O
matrix	O
.	O
A	O
method	O
of	O
producing	O
the	O
bilayer	O
tablet	O
is	O
also	O
disclosed	O
.	O


A	O
method	O
for	O
treating	O
a	O
mammal	O
having	O
an	O
infection	O
with	O
an	O
organism	O
that	O
persists	O
intracellularly	O
in	O
a	O
mammalian	O
cell	O
by	O
inducing	O
an	O
autophagy	O
defect	O
includes	O
administering	O
to	O
the	O
mammal	O
an	O
effective	O
dose	O
of	O
a	O
bioavailable	O
agent	O
that	O
restores	O
autophagy	O
function,	O
by	O
inhibition	O
of	O
the	O
mTOR	B-GENE
pathway	O
.	O


A	O
pharmaceutical	O
combination	O
comprising	O
an	O
accelerated	O
lymphocyte	O
homing	O
agent	O
in	O
free	O
form	O
or	O
in	O
pharmaceutically	O
acceptable	O
salt	O
form,	O
and	O
one	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
antibody	O
to	O
the	O
IL-2	O
receptor,	O
an	O
immunosuppressive	O
macrocyclic	O
lactone	O
and	O
a	O
soluble	B-GENE
human	I-GENE
complement	I-GENE
inhibitor	O
is	O
used	O
to	O
treat	O
or	O
prevent	O
insulin-producing	O
cell	O
graft	O
rejection	O
.	O


Skin	O
whitening	O
compositions	O
contain	O
at	O
least	O
one	O
α-hydroxytetronic	O
derivative	O
such	O
as	O
diphenyl	O
hydroxytetronic	O
acid	O
.	O
Some	O
embodiments	O
contain	O
adjunct	O
ingredients	O
that	O
enhance	O
the	O
efficacy	O
and	O
stability	O
of	O
skin	O
whitening	O
formulations	O
such	O
as	O
a	O
tetronic	O
acid	O
derivative	O
that	O
inhibits	O
tyrosinase	B-GENE
or	O
tyrosine	O
phosphatase,	O
hydroquinone,	O
an	O
α-hydroxy	O
acid	O
such	O
as	O
glycolic	O
acid,	O
and	O
a	O
fatty	O
acid	O
ester	O
of	O
ascorbic	O
acid	O
such	O
as	O
ascorbyl	O
palmitate	O
.	O


The	O
impact	O
of	O
lipoxin	O
A4	O
(	O
LXA4	O
)	O
and	O
aspirin-triggered-lipoxins	O
(	O
ATL	O
)	O
was	O
investigated	O
in	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNFα	B-GENE
)	O
-initiated	O
neutrophil	O
(	O
PMN	O
)	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
metabolically	O
stable	O
LX	O
analogs	O
.	O
At	O
concentrations	O
as	O
low	O
as	O
1–10	O
nM,	O
the	O
LXA4	O
and	O
ATL	O
analogs	O
each	O
inhibited	O
TNFα-stimulated	O
superoxide	O
anion	O
generation	O
and	O
IL-1β	B-GENE
release	O
by	O
human	O
PMN	O
.	O


A	O
method	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
conditions	O
of	O
aging	O
in	O
humans,	O
such	O
conditions	O
of	O
aging	O
associated	O
with	O
a	O
decreased	O
presence	O
of	O
one	O
or	O
more	O
cell-specific	O
carbonic	B-GENE
anhydrase	I-GENE
enzymes	O
.	O
Such	O
conditions	O
include	O
chronic	O
neurodegenerative	O
conditions	O
including	O
dementia	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
.	O
The	O
method	O
comprises	O
administering	O
to	O
the	O
patient	O
a	O
pharmaceutically	O
effective,	O
non-toxic	O
amount	O
of	O
a	O
compound	O
that	O
increases	O
the	O
presence	O
of	O
one	O
or	O
more	O
cell-specific	O
carbonic	B-GENE
anhydrase	I-GENE
enzymes	O
whose	O
levels	O
are	O
reduced	O
in	O
the	O
patient	O
.	O
Such	O
compound	O
may	O
be	O
the	O
cell-specific	O
carbonic	B-GENE
anhydrase	I-GENE
enzyme,	O
a	O
compound	O
that	O
when	O
absorbed	O
by	O
the	O
body	O
reacts	O
or	O
dissociates	O
to	O
form	O
the	O
cell-specific	O
carbonic	B-GENE
anhydrase	I-GENE
enzyme,	O
or	O
a	O
compound	O
that	O
promotes	O
the	O
natural	O
generation	O
of	O
the	O
cell-specific	O
carbonic	B-GENE
anhydrase	I-GENE
enzyme	O
within	O
the	O
body	O
.	O


The	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
fatty	O
substance	O
chemistry,	O
specifically	O
of	O
the	O
ceramide-type	O
compound	O
synthesis	O
.	O
The	O
invention	O
resides	O
substantially	O
in	O
the	O
synthesis	O
of	O
ceramide-type	O
compounds	O
.	O
Specifically,	O
the	O
aim	O
of	O
the	O
invention	O
is	O
a	O
new	O
enzymatic	O
synthesis	O
method,	O
comprising	O
at	O
least	O
one	O
amidification	O
step	O
and	O
one	O
esterification	O
step,	O
achieved	O
through	O
lipases,	O
among	O
fatty	O
acids	O
and	O
/	O
or	O
esters	O
thereof	O
and	O
amino	O
alcohols	O
.	O
The	O
resulting	O
ceramide-type	O
compounds	O
can	O
be	O
used	O
as	O
cosmetic	O
and	O
/	O
or	O
pharmaceutical	O
compositions,	O
in	O
particular	O
as	O
dermatological	O
compositions	O
in	O
conjunction	O
or	O
in	O
admixture	O
with	O
one	O
or	O
more	O
suitable	O
cosmetic	O
and	O
/	O
or	O
pharmaceutical	O
excipients	O
or	O
carriers	O
.	O
The	O
method	O
has	O
an	O
interest	O
particularly	O
in	O
the	O
synthesis	O
of	O
active	O
compounds	O
useful	O
in	O
the	O
fields	O
of	O
cosmetology	O
and	O
/	O
or	O
pharmacology	O
and	O
specifically	O
of	O
dermatology	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
wherein	O
the	O
groups	O
are	O
as	O
defined	O
in	O
the	O
description	O
are	O
disclosed	O
.	O
	O
	O
	O
	O
	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
endowed	O
with	O
reversible	O
inhibiting	O
activity	O
of	O
carnitine	B-GENE
palmitoyl-transferase	I-GENE
and	O
are	O
useful	O
in	O
the	O
preparation	O
of	O
medicaments	O
useful	O
in	O
the	O
pathologies	O
related	O
to	O
a	O
hyperactivity	O
of	O
carnitine	O
palmitoyl-transferase,	O
such	O
as	O
hyperglycemia,	O
diabetes	O
and	O
pathologies	O
related	O
thereto,	O
heart	O
failure,	O
ischemia	O
.	O


Methods	O
for	O
the	O
treatment,	O
prevention,	O
or	O
inhibition	O
of	O
pain,	O
inflammation,	O
or	O
inflammation-related	O
disorder,	O
and	O
for	O
the	O
treatment	O
or	O
inhibition	O
of	O
cardiovascular	O
disease	O
or	O
disorder,	O
and	O
for	O
the	O
treatment	O
or	O
inhibition	O
of	O
cancer,	O
and	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment,	O
prevention,	O
or	O
inhibition,	O
include	O
treating	O
the	O
subject	O
with	O
a	O
peroxisome	B-GENE
proliferator	I-GENE
activated	I-GENE
receptor-α	I-GENE
agonist	O
and	O
a	O
cyclooxygenase-2	B-GENE
selective	O
inhibitor	O
or	O
prodrug	O
thereof	O
.	O
Compositions,	O
pharmaceutical	O
compositions	O
and	O
kits	O
for	O
effecting	O
the	O
particular	O
methods	O
are	O
also	O
described	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
modulating	O
an	O
Edg-2,	O
Edg-3,	O
Ed-4	B-GENE
or	O
Edg7	B-GENE
receptor	I-GENE
mediated	O
biological	O
activity	O
in	O
a	O
cell	O
.	O
A	O
cell	O
expressing	O
the	O
Edg-2,	O
Edg-3,	O
Edg-4	B-GENE
or	O
Edg	B-GENE
7	I-GENE
receptor	I-GENE
is	O
contacted	O
with	O
a	O
modulator	O
of	O
the	O
Edg-2,	O
Edg-3,	O
Ed-4	B-GENE
or	O
Edg	B-GENE
7	I-GENE
receptor	I-GENE
sufficient	O
to	O
modulate	O
receptor	O
mediated	O
biological	O
activity	O
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
modulating	O
an	O
Edg-2,	O
Edg-3,	O
Ed-4	B-GENE
or	O
Edg-7	B-GENE
receptor	I-GENE
mediated	O
biological	O
in	O
a	O
subject	O
.	O
A	O
therapeutically	O
effective	O
amount	O
of	O
a	O
modulator	O
of	O
the	O
Edg-2,	O
Edg-3,	O
Ed-4	B-GENE
or	O
Edg7	B-GENE
receptor	I-GENE
is	O
administered	O
to	O
the	O
subject	O
.	O


Methods	O
of	O
making	O
cells	O
hypermutable	O
are	O
disclosed	O
using	O
PMS2	B-GENE
homologs	O
that	O
have	O
a	O
common	O
sequence	O
motif	O
.	O
The	O
PMS2	B-GENE
homologs	O
of	O
the	O
invention	O
have	O
ATPase-like	O
motifs	O
and	O
are	O
at	O
least	O
about	O
90	O
%	O
identical	O
to	O
PMS2-134	O
.	O
Methods	O
of	O
generating	O
mutant	O
libraries	O
and	O
using	O
the	O
PMS2	B-GENE
homologs	O
in	O
diagnostic	O
and	O
therapeutic	O
applications	O
for	O
cancer	O
are	O
also	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
4-amino-substituted	O
pyrimidine	O
derivatives,	O
which	O
stimulate	O
soluble	B-GENE
guanylate	I-GENE
cyclase,	O
method	O
for	O
production	O
and	O
use	O
thereof	O
for	O
the	O
production	O
of	O
medicaments,	O
in	O
particular	O
medicaments	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
the	O
preparation	O
and	O
pharmaceutical	O
use	O
of	O
novel	O
benzamide	O
derivatives	O
as	O
defined	O
in	O
the	O
specification	O
of	O
formula	O
(	O
I	O
)	O
as	O
histone	B-GENE
deacetylase	I-GENE
inhibitors	O
(	O
HDACI	O
)	O
,	O
their	O
preparations	O
and	O
the	O
methods	O
of	O
using	O
these	O
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salt	O
in	O
the	O
treatment	O
of	O
cell	O
proliferative	O
diseases,	O
e	O
.	O
g	O
.	O
cancer	O
and	O
psoriasis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
DPP-IV,	O
such	O
as	O
diabetes,	O
particularly	O
non-insulin	O
dependent	O
diabetes	O
mellitus,	O
and	O
impaired	O
glucose	O
tolerance	O
.	O


The	O
invention	O
is	O
directed	O
to	O
biaryl	O
compounds	O
with	O
two	O
six	O
membered	O
rings	O
fused	O
wherein	O
at	O
least	O
one	O
six	O
membered	O
ring	O
is	O
substituted	O
with	O
a	O
thiophenyl	O
or	O
furanyl	O
ring	O
.	O
Useful	O
in	O
the	O
inhibition	O
of	O
PKB	O
kinase,	O
the	O
treatment	O
of	O
cancer,	O
or	O
the	O
inhibition	O
of	O
tumor	O
growth	O
.	O


GnRH	B-GENE
receptor	I-GENE
antagonists	O
are	O
disclosed	O
that	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
sex-hormone	O
related	O
conditions	O
in	O
both	O
men	O
and	O
women	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
have	O
the	O
structure	O
:	O
wherein	O
R1a,	O
R1b,	O
R1c,	O
R2a,	O
R2b,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
X	O
are	O
as	O
defined	O
herein,	O
including	O
stereoisomers,	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
Also	O
disclosed	O
are	O
compositions	O
containing	O
a	O
compound	O
of	O
this	O
invention	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier,	O
as	O
well	O
as	O
methods	O
relating	O
to	O
the	O
use	O
thereof	O
for	O
antagonizing	O
gonadotropin-releasing	B-GENE
hormone	I-GENE
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O


This	O
invention	O
provides	O
methods	O
for	O
treating	O
neoplasias	O
in	O
a	O
mammal	O
.	O
In	O
particular,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
various	O
types	O
of	O
lymphomas,	O
including	O
relapsed	O
forms	O
of	O
non-Hodgkin’s	O
Lymphoma	O
.	O
These	O
methods	O
involve	O
the	O
co-administration	O
of	O
liposome-encapsulated	O
vinca	O
alkaloids,	O
e	O
.	O
g	O
.	O
,	O
vincristine,	O
with	O
a	O
topoisomerase	B-GENE
II	I-GENE
inhibitor,	O
e	O
.	O
g	O
.	O
,	O
etoposide	O
or	O
NK-611,	O
to	O
a	O
mammal	O
with	O
a	O
lymphoma	O
or	O
a	O
sarcoma	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
use	O
of	O
LXR	B-GENE
agonists	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
inhibitor	O
of	O
at	O
least	O
one	O
ABC-­transporter	B-GENE
capable	O
of	O
transporting	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
such	O
as	O
verapamil	O
or	O
valspodar,	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
which	O
is	O
associated	O
with	O
an	O
excess	O
transport	O
of	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
e	O
.	O
g	O
.	O
arthritis	O
.	O
Furthermore,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
screening	O
a	O
compound	O
which	O
is	O
suitable	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
which	O
is	O
associated	O
with	O
an	O
excess	O
transport	O
of	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
e	O
.	O
g	O
.	O
arthritis	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
screening	O
a	O
compound	O
which	O
reduces	O
the	O
transport	O
of	O
hyaluronan	O
mediated	O
by	O
(	O
an	O
)	O
ABC-transporter	O
(	O
s	O
)	O
.	O
Furthermore,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
identifying	O
a	O
subject	O
at	O
risk	O
for	O
a	O
disease	O
which	O
is	O
associated	O
with	O
an	O
excess	O
transport	O
of	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
e	O
.	O
g	O
.	O
arthritis	O
as	O
well	O
as	O
to	O
a	O
method	O
of	O
screening	O
for	O
a	O
compound	O
which	O
is	O
suitable	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
which	O
is	O
associated	O
with	O
an	O
excess	O
transport	O
of	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
e	O
.	O
g	O
.	O
arthritis	O
in	O
a	O
subject	O
.	O
In	O
addition,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
preventing,	O
ameliorating	O
and	O
/	O
or	O
treating	O
the	O
symptoms	O
of	O
a	O
disease	O
which	O
is	O
associated	O
with	O
an	O
excess	O
transport	O
of	O
hyaluronan	O
across	O
a	O
lipid	O
bilayer,	O
e	O
.	O
g	O
.	O
arthritis	O
in	O
a	O
subject	O
.	O


Compounds	O
of	O
Formula	O
(	O
I-a	O
)	O
and	O
all	O
pharmaceutically-acceptable	O
forms	O
thereof,	O
are	O
described	O
herein	O
.	O
The	O
variables	O
R1,	O
R2,	O
R3,	O
Z1,	O
Q,	O
and	O
A	O
shown	O
in	O
Formula	O
I-a	O
are	O
defined	O
herein	O
.	O
Pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
compounds	O
of	O
Formula	O
(	O
I-a	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
form	O
of	O
such	O
compounds,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
carriers,	O
excipients,	O
or	O
diluents	O
are	O
provided	O
herein	O
.	O
Methods	O
of	O
treating	O
patients	O
suffering	O
from	O
certain	O
diseases	O
responsive	O
to	O
inhibition	O
of	O
tyrosine	B-GENE
kinase	B-GENE
activity	O
are	O
also	O
given	O
.	O
In	O
certain	O
embodiments	O
the	O
diseases	O
are	O
responsive	O
to	O
inhibition	O
of	O
Btk	B-GENE
activity	O
and	O
/	O
or	O
B-cell	O
proliferation	O
.	O
Such	O
methods	O
comprise	O
administering	O
to	O
such	O
patients	O
an	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
(	O
I-a	O
)	O
effective	O
to	O
reduce	O
signs	O
or	O
symptoms	O
of	O
the	O
disease	O
.	O
These	O
diseases	O
include	O
cancer,	O
an	O
autoimmune	O
and	O
/	O
or	O
inflammatory	O
disease,	O
or	O
an	O
acute	O
inflammatory	O
reaction	O
.	O
Thus	O
methods	O
of	O
treatment	O
include	O
administering	O
a	O
sufficient	O
amount	O
of	O
a	O
compound	O
or	O
salt	O
as	O
provided	O
herein	O
to	O
decrease	O
the	O
symptoms	O
or	O
slow	O
the	O
progression	O
of	O
these	O
diseases	O
.	O
Other	O
embodiments	O
include	O
methods	O
of	O
treating	O
other	O
animals,	O
including	O
livestock	O
and	O
domesticated	O
companion	O
animals,	O
suffering	O
from	O
a	O
disease	O
responsive	O
to	O
inhibition	O
of	O
kinase	B-GENE
activity	O
.	O
Methods	O
of	O
treatment	O
include	O
administering	O
a	O
compound	O
of	O
Formula	O
(	O
I-a	O
)	O
as	O
a	O
single	O
active	O
agent	O
or	O
administering	O
a	O
compound	O
of	O
Formula	O
(	O
I-a	O
)	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
therapeutic	O
agent	O
.	O
A	O
method	O
for	O
determining	O
the	O
presence	O
of	O
Btk	B-GENE
in	O
a	O
sample,	O
comprising	O
contacting	O
the	O
sample	O
with	O
a	O
compound	O
or	O
form	O
thereof	O
of	O
Formula	O
(	O
I-a	O
)	O
under	O
conditions	O
that	O
permit	O
detection	O
of	O
Btk	B-GENE
activity,	O
detecting	O
a	O
level	O
of	O
Btk	B-GENE
activity	O
in	O
the	O
sample,	O
and	O
therefrom	O
determining	O
the	O
presence	O
or	O
absence	O
of	O
Btk	B-GENE
in	O
the	O
sample	O
.	O


A	O
compound	O
capable	O
of	O
binding	O
S1P	B-GENE
receptors	I-GENE
(	O
especially	O
EDG-6,	O
preferably	O
EDG-1	B-GENE
and	O
EDG-6	B-GENE
)	O
.	O
For	O
example,	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
its	O
salt	O
or	O
solvate,	O
or	O
a	O
prodrug	O
thereof	O
is	O
capable	O
of	O
binding	O
S1P	B-GENE
receptors	I-GENE
(	O
especially	O
EDG-6,	O
preferably	O
EDG-1	B-GENE
and	O
EDG-6	B-GENE
)	O
and	O
is	O
thus	O
useful	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
immunological	O
reaction	O
to	O
transplant,	O
graft	O
versus	O
host	O
disease,	O
autoimmune	O
disease,	O
allergosis,	O
etc	O
.	O
(	O
I	O
)	O
(	O
wherein	O
the	O
ring	O
A	O
is	O
a	O
cyclic	O
group	O
;	O
the	O
ring	O
B	O
is	O
an	O
optionally	O
substituted	O
cyclic	O
group	O
;	O
X	O
is	O
a	O
spacer	O
with	O
a	O
main	O
chain	O
of	O
1	O
to	O
8	O
atoms,	O
etc	O
.	O
;	O
Y	O
is	O
a	O
spacer	O
with	O
a	O
main	O
chain	O
of	O
1	O
to	O
10	O
atoms,	O
etc	O
.	O
;	O
and	O
n	O
is	O
0	O
or	O
1	O
provided	O
that	O
when	O
n	O
is	O
0,	O
m	O
is	O
1	O
and	O
R1	O
is	O
a	O
hydrogen	O
atom	O
or	O
a	O
substituent	O
and	O
that	O
when	O
n	O
is	O
1,	O
m	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
7	O
and	O
R1	O
is	O
a	O
substituent,	O
in	O
which	O
when	O
m	O
is	O
2	O
or	O
greater,	O
R1s	O
may	O
be	O
identical	O
with	O
or	O
different	O
from	O
each	O
other	O
)	O
.	O


Compositions	O
comprising	O
a	O
catechin	O
as	O
found	O
in	O
green	O
tea,	O
e	O
.	O
g	O
.	O
,	O
epigallocatechin	O
gallate,	O
and	O
ligand	O
which	O
activates	O
the	O
peroxisome	B-GENE
proliferator­activated	I-GENE
receptor	I-GENE
gamma	I-GENE
(	O
PPAR-gamma	B-GENE
are	O
useful	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
diabetes	O
mellitus	O
)	O
.	O


Among	O
compounds	O
represented	O
by	O
the	O
following	O
general	O
formula	O
:	O
[	O
Chemical	O
formula	O
1	O
]	O
(	O
I	O
)	O
compounds	O
having	O
antagonism	O
to	O
CXCR3	B-GENE
are	O
useful	O
in	O
preventing	O
and	O
/	O
or	O
treating	O
CXCR3-mediated	O
diseases	O
such	O
as	O
inflammatory	O
or	O
allergic	O
diseases,	O
metabolic	O
or	O
endocrine	O
diseases,	O
cancer,	O
infectious	O
diseases	O
or	O
diseases	O
accompanying	O
infection	O
;	O
and	O
compounds	O
having	O
11β-HSD1	B-GENE
inhibitory	O
effect	O
are	O
useful	O
in	O
preventing	O
and	O
/	O
or	O
treating	O
diseases	O
caused	O
by	O
the	O
production	O
of	O
cortisol	O
such	O
as	O
type	O
II	O
diabetes,	O
impaired	O
glucose	O
tolerance,	O
hyperglycemia,	O
insulin	B-GENE
resistance,	O
lipid	O
metabolic	O
error,	O
lipemia,	O
hyperlipidemia,	O
hypertriglyceridemia,	O
obesity,	O
athelomatous	O
arteriosclerosis,	O
syndrome	O
X,	O
Cushing’s	O
syndrome,	O
hypertension,	O
cognitive	O
impairment,	O
memory	O
impairment,	O
depression,	O
anxiety,	O
dementia,	O
Alzheimer’s	O
disease,	O
osteoporosis,	O
glaucoma	O
or	O
immune	O
diseases	O
.	O


It	O
is	O
an	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
an	O
agent	O
effective	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
heart	O
failure	O
and	O
/	O
or	O
cardiac	O
hypertrophy	O
.	O
A	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
heart	O
failure	O
and	O
/	O
or	O
cardiac	O
hypertrophy,	O
comprising	O
an	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonist	O
and	O
a	O
matrix	O
metalloproteinase	O
inhibitor	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
in	O
treating	O
Alzheimer	O
'	O
s	O
disease	O
and	O
other	O
similar	O
diseases	O
.	O
These	O
compounds	O
include	O
inhibitors	O
of	O
the	O
beta-­secretase	B-GENE
enzyme	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
other	O
diseases	O
characterized	O
by	O
deposition	O
of	O
A	O
beta	O
peptide	O
in	O
a	O
mammal	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
to	O
reduce	O
A	O
beta	O
peptide	O
formation	O
.	O


The	O
present	O
invention	O
provides	O
for	O
a	O
novel	O
muscle	B-GENE
growth	I-GENE
regulating	I-GENE
factor,	O
including	O
polynucleotide	O
and	O
polypeptide	O
sequences,	O
promoter	O
sequences,	O
constructs	O
comprising	O
the	O
sequences,	O
and	O
compositions	O
for	O
regulating	O
muscle	B-GENE
growth	I-GENE
and	O
treating	O
diseases	O
associated	O
with	O
muscle	B-GENE
growth	I-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
to	O
the	O
use	O
of	O
the	O
present	O
sequences	O
in	O
identifying	O
animals	O
with	O
altered	O
muscle	O
mass,	O
and	O
for	O
selective	O
breeding	O
programmes	O
to	O
produce	O
animals	O
with	O
altered	O
muscle	O
mass	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
novel	O
of	O
silymarin	O
for	O
the	O
preparation	O
of	O
pharmaceutical	O
composition	O
to	O
treat	O
and	O
prevent	O
sepsis	O
or	O
inflammation	O
mediated	O
diseases	O
in	O
a	O
mammal	O
including	O
human	O
in	O
need	O
thereof	O
.	O
Silymarin	O
showed	O
potent	O
inhibiting	O
effect	O
on	O
NO	O
(	O
Nitric	O
Oxide	O
)	O
,	O
TNF(Tumor	B-GENE
Necrosis	I-GENE
Factor)-	I-GENE
alpha	I-GENE
,	O
Interleukin-1	B-GENE
beta	I-GENE
(	O
IL-1	B-GENE
beta	I-GENE
)	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
NF-	B-GENE
kappa	I-GENE
B	I-GENE
and	O
the	O
activity	O
of	O
sepsis,	O
therefore	O
it	O
can	O
be	O
useful	O
in	O
treating	O
or	O
preventing	O
sepsis	O
or	O
inflammation	O
mediated	O
disease	O
such	O
as	O
bronchitis,	O
gastritis,	O
colitis,	O
arthritis,	O
nephritis,	O
hepatitis,	O
cancer	O
or	O
generative	O
diseases	O
as	O
a	O
medicament	O
or	O
functional	O
health	O
food	O
.	O


A	O
platelet	O
aggregation	O
inhibitor	O
not	O
inhibiting	O
COX-1	B-GENE
and	O
COX-2,	O
comprised	O
of	O
a	O
compound	O
of	O
the	O
general	O
formula	O
:	O
(	O
I	O
)	O
(	O
wherein	O
each	O
of	O
Ar1	O
and	O
Ar2	O
independently	O
represents	O
a	O
5-membered	O
or	O
6-membered	O
aromatic	O
heterocycle	O
optionally	O
having	O
one	O
to	O
three	O
substituents,	O
or	O
a	O
C6-C14	O
aryl	O
optionally	O
having	O
one	O
to	O
three	O
substituents	O
;	O
each	O
of	O
R1	O
and	O
R2	O
independently	O
represents	O
hydrogen	O
or	O
a	O
lower	O
alkyl	O
;	O
R3	O
is	O
hydrogen	O
or	O
an	O
optionally	O
substituted	O
lower	O
alkyl	O
;	O
R4	O
is	O
an	O
optionally	O
substituted	O
lower	O
alkyl,	O
an	O
optionally	O
substituted	O
amino,	O
an	O
optionally	O
substituted	O
lower	O
alkoxy,	O
an	O
optionally	O
substituted	O
carbamoyl	O
or	O
a	O
heterocycle	O
optionally	O
having	O
one	O
to	O
three	O
substituents	O
;	O
and	O
n	O
is	O
0	O
or	O
1	O
)	O
,	O
or	O
its	O
salt	O
or	O
a	O
solvate	O
thereof	O
.	O


A	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula,	O
a	O
salt	O
thereof,	O
or	O
a	O
hydrate	O
of	O
either	O
.	O
They	O
have	O
excellent	O
inhibitory	O
activity	O
against	O
a	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
HGFR	B-GENE
)	O
and	O
have	O
antitumor	O
activity,	O
angiogenesis	O
inhibitory	O
activity,	O
or	O
cancer	O
metastasis	O
inhibitory	O
activity	O
.	O
(	O
In	O
the	O
formula,	O
R1	O
means	O
C1-6	O
alkyl,	O
etc	O
.	O
;	O
R2	O
and	O
R3	O
each	O
means	O
hydrogen	O
;	O
R4,	O
R5,	O
R6,	O
and	O
R7	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
means	O
hydrogen,	O
halogeno,	O
C1-6	O
alkyl,	O
etc	O
.	O
;	O
R8	O
means	O
hydrogen,	O
etc	O
.	O
;	O
R9	O
means	O
C1-6	O
alkyl,	O
etc	O
.	O
;	O
V1	O
means	O
oxygen,	O
etc	O
.	O
;	O
V2	O
means	O
oxygen	O
or	O
sulfur	O
;	O
W	O
means	O
-NH-,	O
etc	O
.	O
;	O
X	O
means	O
-CH	O
=	O
,	O
nitrogen,	O
etc	O
.	O
;	O
and	O
Y	O
means	O
oxygen,	O
etc	O
.	O
)	O


A	O
pharmaceutical	O
composition	O
containing	O
a	O
substance	O
capable	O
of	O
suppressing	O
the	O
multiplication	O
of	O
synovial	O
tissue	O
or	O
synovial	O
cells	O
and	O
the	O
production	O
of	O
interleukin	B-GENE
6	I-GENE
.	O
There	O
is	O
provided	O
a	O
pharmaceutical	O
composition	O
capable	O
of	O
suppressing	O
the	O
multiplication	O
of	O
synovial	O
tissue	O
or	O
synovial	O
cells	O
and	O
the	O
production	O
of	O
interleukin	O
6,	O
which	O
pharmaceutical	O
composition	O
is	O
useful	O
for	O
diagnosing	O
or	O
treating	O
of	O
at	O
least	O
one	O
disease	O
selected	O
from	O
among	O
rheumatism,	O
fibrosis,	O
arthritis,	O
cancer	O
and	O
cranial	O
nerve	O
disorder	O
.	O
Further,	O
there	O
is	O
provided	O
a	O
method	O
of	O
suppressing	O
the	O
multiplication	O
of	O
synovial	O
cells	O
and	O
the	O
production	O
of	O
interleukin	O
6,	O
characterized	O
in	O
that	O
the	O
expression	O
of	O
hsHRD3	O
in	O
synovial	O
cells	O
is	O
suppressed	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
human	B-GENE
amyloid	I-GENE
β	I-GENE
peptide	I-GENE
(	O
hereinafter	O
referred	O
to	O
as	O
Aβ	B-GENE
)	O
antibody	O
which	O
binds	O
to	O
Aβ	B-GENE
and	O
inhibits	O
the	O
aggregation	O
of	O
Aβ	B-GENE
molecules,	O
and	O
its	O
antibody	O
fragment	O
.	O
The	O
above-described	O
antibody	O
or	O
its	O
antibody	O
fragment	O
has	O
the	O
variable	O
region	O
of	O
human	O
anti-Aβ	O
antibody	O
and	O
strongly	O
reacts	O
with	O
Aβ	B-GENE
to	O
thereby	O
exert	O
an	O
effect	O
of	O
inhibiting	O
the	O
aggregation	O
thereof	O
.	O
The	O
above	O
antibody	O
and	O
its	O
antibody	O
fragment	O
are	O
usable	O
as	O
Aβ	B-GENE
detection	O
reagents,	O
preventives	O
/	O
remedies	O
for	O
Alzheimer’s	O
disease	O
or	O
diagnostics	O
therefor	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
provided,	O
in	O
which	O
variables	O
are	O
as	O
described	O
herein	O
.	O
Such	O
compounds	O
may	O
be	O
used	O
to	O
modulate	O
MCH	O
binding	O
to	O
MCH	B-GENE
receptors	I-GENE
in	O
vivo	O
or	O
in	O
vitro,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
metabolic,	O
feeding	O
and	O
sexual	O
disorders	O
in	O
humans,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O
Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
such	O
disorders	O
are	O
provided,	O
as	O
are	O
methods	O
for	O
using	O
such	O
ligands	O
for	O
detecting	O
MCH	B-GENE
receptors	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
receptor	O
localization	O
studies	O
)	O
.	O


In	O
order	O
to	O
make	O
available	O
an	O
ophthalmic	O
percutaneously	O
absorbed	O
preparation	O
that	O
is	O
capable	O
of	O
maintaining	O
a	O
therapeutically	O
effective	O
concentration	O
of	O
muscarinic	B-GENE
receptor	I-GENE
agonist	O
for	O
facilitating	O
lacrimation	O
and	O
that	O
realizes	O
reduction	O
of	O
side	O
effects	O
such	O
as	O
pupillary	O
constriction,	O
and	O
in	O
order	O
to	O
make	O
available	O
a	O
method	O
of	O
facilitating	O
lacrimation	O
through	O
administration	O
of	O
an	O
ophthalmic	O
percutaneously	O
absorbed	O
preparation	O
containing	O
a	O
muscarinic	B-GENE
receptor	I-GENE
agonist	O
to	O
a	O
surface	O
of	O
eyelid	O
skin,	O
there	O
is	O
provided	O
an	O
ophthalmic	O
percutaneously	O
absorbed	O
preparation	O
comprising	O
a	O
muscarinic	B-GENE
receptor	I-GENE
agonist	O
that	O
is	O
capable	O
of	O
facilitating	O
lacrimation	O
through	O
administration	O
to	O
a	O
surface	O
of	O
eyelid	O
skin	O
and	O
that	O
realizes	O
reduction	O
of	O
side	O
effects	O
such	O
as	O
pupillary	O
constriction	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
niacinamide	O
or	O
a	O
derivatives	O
therefrom,	O
specifically,	O
agents	O
for	O
preventing	O
cancer	O
and	O
therapeutics	O
comprising	O
a	O
niacinamide	O
or	O
a	O
derivatives	O
therefrom	O
enhancing	O
the	O
expression	O
of	O
RUNX3	B-GENE
gene,	O
cancer-suppressing	O
gene	O
which	O
is	O
inactivated	O
by	O
methylation	O
.	O
agents	O
for	O
preventing	O
cancer	O
and	O
therapeutics	O
of	O
the	O
present	O
invention	O
is	O
used	O
to	O
cancer	O
which	O
relates	O
to	O
inactivation	O
of	O
RUNX3	B-GENE
such	O
as	O
gastric,	O
lung,	O
liver,	O
larynx,	O
colon,	O
bladdar,	O
prostate,	O
pancreas,	O
uterine	O
and	O
breast	O
cancer	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
pyrimidine	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
,	O
which	O
are	O
efficacious	O
inhibitors	O
of	O
protein	O
kinases,	O
in	O
particular	O
of	O
one	O
or	O
more	O
isoforms	O
of	O
the	O
protein	B-GENE
kinase	I-GENE
B	I-GENE
/	O
Akt	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
alpha	B-GENE
1a	I-GENE
and	O
/	O
or	O
alpha	B-GENE
1d	I-GENE
adrenergic	I-GENE
receptor	I-GENE
antagonists	O
.	O
Compounds	O
described	O
can	O
function	O
as	O
alpha	B-GENE
1a	I-GENE
and	O
/	O
or	O
alpha	B-GENE
1d	I-GENE
adrenergic	I-GENE
receptor	I-GENE
antagonists	O
and	O
can	O
be	O
used	O
to	O
treat	O
diseases	O
or	O
disorders	O
mediated	O
through	O
alpha	B-GENE
1a	I-GENE
and	O
/	O
or	O
alpha	B-GENE
1d	I-GENE
adrenergic	I-GENE
receptors	I-GENE
.	O
Compounds	O
described	O
can	O
also	O
be	O
used	O
to	O
treat	O
benign	O
prostatic	O
hyperplasia	O
or	O
related	O
symptoms	O
thereof	O
.	O
Compounds	O
described	O
can	O
also	O
be	O
used	O
to	O
treat	O
lower	O
urinary	O
tract	O
symptoms	O
associated	O
with	O
or	O
without	O
benign	O
prostatic	O
hyperplasia	O
.	O
Also	O
described	O
are	O
processes	O
to	O
prepare	O
the	O
described	O
compounds,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
of	O
treating	O
benign	O
prostatic	O
hyperplasia	O
or	O
related	O
symptoms	O
thereof	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
and	O
composition	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
infection,	O
said	O
method	O
comprising	O
orally	O
administering	O
a	O
composition	O
to	O
a	O
mammal,	O
said	O
composition	O
comprising	O
a	O
galactose	O
containing	O
indigestible	O
oligosaccharide	O
and	O
immunoglobulin	B-GENE
from	O
the	O
milk	O
or	O
colostrum	O
of	O
hyperimmunized	O
cows	O
.	O


The	O
present	O
invention	O
relates	O
to	O
metalloprotein	B-GENE
inhibitors	O
comprising	O
:	O
a	O
.	O
an	O
organic	O
substituent	O
and	O
at	O
least	O
one	O
zinc	O
binding	O
group	O
(	O
ZBG	O
)	O
covalently	O
attached	O
thereto	O
;	O
or	O
b	O
.	O
a	O
ZBG	O
substituted	O
by	O
a	O
side	O
chain	O
wherein	O
the	O
ZBG	O
is	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
X	O
is	O
O	O
or	O
S	O
and	O
each	O
R1,	O
R2,	O
R3,	O
and	O
R4	O
is	O
individually	O
hydrogen	O
or	O
an	O
organic	O
radical	O
.	O
The	O
metalloprotein	B-GENE
inhibitors	O
are	O
useful	O
for	O
preventing	O
or	O
treating	O
a	O
pathological	O
disease,	O
condition,	O
or	O
symptom	O
that	O
is	O
associated	O
with	O
pathological	O
metalloprotein	B-GENE
activity	O
and	O
/	O
or	O
that	O
is	O
alleviated	O
by	O
inhibition	O
of	O
said	O
activity	O
.	O


The	O
present	O
invention	O
provides	O
phenanthridine	O
carbonyl	O
compounds	O
and	O
compositions,	O
particularly	O
those	O
that	O
find	O
use	O
as	O
ligands	O
for	O
the	O
estrogen	B-GENE
receptor	I-GENE
.	O
Representative	O
compounds	O
of	O
the	O
invention	O
include	O
those	O
of	O
formula	O
1	O
.	O


The	O
invention	O
provides	O
novel	O
ß2	B-GENE
adrenergic	I-GENE
receptor	I-GENE
agonist	O
compounds	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
associated	O
with	O
ß2adrenergic	B-GENE
receptor	I-GENE
activity,	O
and	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
1,5-Naphthyridine	O
azolidinones	O
of	O
the	O
formula	O
(	O
I	O
)	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
compounds,	O
as	O
well	O
as	O
medicaments	O
containing	O
them	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
CDK1	B-GENE
and	O
show	O
anti	O
prol	O
if	O
erative	O
activity	O
.	O
They	O
are	O
therefore	O
useful	O
as	O
anti-cancer	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
modulators	O
of	O
PPAR-gamma	B-GENE
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
to	O
processes	O
for	O
the	O
preparation	O
and	O
use	O
of	O
the	O
same	O
.	O
Such	O
PPAR-gamma	B-GENE
modulators	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
and	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
anthranilamide	O
pyridinureas	O
as	O
VEGF	B-GENE
receptor	I-GENE
kinase	I-GENE
inhibitors,	O
their	O
production	O
and	O
use	O
as	O
pharmaceutical	O
agents	O
for	O
preventing	O
or	O
treating	O
diseases	O
that	O
are	O
triggered	O
by	O
persistent	O
angiogenesis	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
A,	O
Y,	O
Z1,	O
Z2,	O
R1	O
to	O
R3	O
and	O
X1	O
to	O
X4	O
have	O
the	O
meaning	O
as	O
cited	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O
For	O
example	O
A	O
is	O
4	O
'	O
-fluorobiphen-4-yl	O
;	O
Y	O
is	O
-S	O
(	O
O	O
)	O
2NH-	O
;	O
R1,	O
R2	O
are	O
H	O
;	O
X1,	O
X2,	O
X4	O
are	O
CH	O
;	O
X3	O
is	O
C-F	O
;	O
Z	O
'	O
is	O
=	O
0	O
;	O
and	O
Z2-R3	O
is	O
N	O
(	O
CH2CH3	O
)	O
2	O
.	O
Said	O
compounds	O
are	O
useful	O
as	O
11ß-HSD1	B-GENE
inhibitors	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
such	O
compounds	O
as	O
well	O
as	O
the	O
production	O
and	O
use	O
as	O
medicament	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
caspase	B-GENE
inhibitor	O
which	O
contains,	O
as	O
the	O
active	O
ingredient,	O
a	O
cobalt	O
porphyrin	O
complex	O
compound	O
or	O
a	O
cobalt	O
choline	O
complex	O
compound	O
.	O
By	O
this	O
caspase	B-GENE
inhibitor,	O
caspase	B-GENE
activity	O
can	O
be	O
strongly	O
and	O
specifically	O
inhibited	O
.	O
Moreover,	O
the	O
caspase	B-GENE
inhibitor	O
and	O
the	O
cobalt	O
porphyrin	O
complex	O
compound	O
or	O
the	O
cobalt	O
choline	O
complex	O
compound	O
as	O
described	O
above	O
are	O
useful	O
as	O
drugs	O
for	O
preventing	O
or	O
treating	O
various	O
apoptosis-associated	O
diseases	O
.	O


The	O
invention	O
disclosed	O
relates	O
to	O
spindle	B-GENE
checkpoint	I-GENE
kinase	I-GENE
modulators,	O
especially	O
modulators	O
of	O
Mps	B-GENE
1	I-GENE
kinase	I-GENE
which	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
and	O
diagnosis	O
of	O
disease,	O
such	O
as	O
cancer	O
.	O
Pharmaceutical	O
compositions	O
and	O
treatments	O
are	O
disclosed	O
comprising	O
a	O
modulator	O
of	O
Mps	B-GENE
l	I-GENE
kinase	I-GENE
activity	O
and	O
a	O
taxol	O
.	O


An	O
antisense	O
oligonucleotide	O
of	O
15	O
to	O
19	O
bases	O
targeting	O
a	O
nucleic	O
acid	O
molecule	O
coding	O
for	O
11β-hydroxylated	B-GENE
steroid	I-GENE
dehydrogenase	I-GENE
type	I-GENE
1,	O
wherein	O
at	O
least	O
one	O
of	O
the	O
sugars	O
as	O
constituents	O
of	O
the	O
antisense	O
oligonucleotide	O
is	O
2’-O,4’-C-alkylenated,	O
or	O
2’-O-alkylated,	O
or	O
2’-O-alkenylated,	O
or	O
2’-O-alkynylated	O
;	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
of	O
the	O
antisense	O
oligonucleotide	O
.	O
Further,	O
there	O
is	O
provided	O
an	O
inhibitor,	O
or	O
pharmaceutical	O
composition,	O
for	O
expression	O
of	O
11β-hydroxylated	B-GENE
steroid	I-GENE
dehydrogenase	I-GENE
type	I-GENE
1,	O
comprising	O
the	O
above	O
antisense	O
oligonucleotide	O
.	O


Potassium	O
salts	O
of	O
Compound	O
A	O
disclosed,	O
wherein	O
Compound	O
A	O
is	O
of	O
formula	O
(	O
I	O
)	O
.	O
Compound	O
A	O
is	O
an	O
HIV	B-GENE
integrase	I-GENE
inhibitor	O
useful	O
for	O
treating	O
or	O
prophylaxis	O
of	O
HIV	O
infection,	O
for	O
delaying	O
the	O
onset	O
of	O
AIDS,	O
and	O
for	O
treating	O
or	O
prophylaxis	O
of	O
AIDS	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrazole	O
derivatives	O
of	O
Formula	O
(	O
Ia	O
)	O
and	O
pharmaceutical	O
compositions	O
thereof	O
that	O
modulate	O
the	O
activity	O
of	O
the	O
5-HT2A	B-GENE
serotonin	I-GENE
receptor	I-GENE
.	O
Compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
directed	O
to	O
methods	O
useful	O
in	O
the	O
treatment	O
of	O
platelet	O
aggregation,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
transient	O
ischemic	O
attack,	O
angina,	O
stroke,	O
atrial	O
fibrillation,	O
reducing	O
the	O
risk	O
of	O
blood	O
clot	O
formation,	O
asthma	O
or	O
symptoms	O
thereof,	O
agitation	O
or	O
a	O
symptom,	O
behavioral	O
disorders,	O
drug	O
induced	O
psychosis,	O
excitative	O
psychosis,	O
Gilles	O
de	O
la	O
Tourette	O
'	O
s	O
syndrome,	O
manic	O
disorder,	O
organic	O
or	O
NOS	O
psychosis,	O
psychotic	O
disorder,	O
psychosis,	O
acute	O
schizophrenia,	O
chronic	O
schizophrenia,	O
NOS	O
schizophrenia	O
and	O
related	O
disorders,	O
sleep	O
disorders,	O
diabetic-related	O
disorders,	O
progressive	O
multifocal	O
leukoencephalopathy	O
and	O
the	O
like	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
methods	O
for	O
the	O
treatment	O
of	O
5-HT2A	B-GENE
serotonin	I-GENE
receptor	I-GENE
mediated	O
disorders	O
in	O
combination	O
with	O
other	O
pharmaceutical	O
agents	O
administered	O
separately	O
or	O
together	O
.	O


A	O
preventive	O
and	O
/	O
or	O
therapeutic	O
composition	O
for	O
liver	O
diseases,	O
comprising	O
as	O
an	O
active	O
ingredient	O
an	O
amino	O
acid	O
having	O
an	O
insulin	B-GENE
sensitivity	O
enhancing	O
activity	O
.	O
In	O
particular,	O
there	O
is	O
provided	O
a	O
preventive	O
and	O
/	O
or	O
therapeutic	O
composition	O
for	O
liver	O
diseases,	O
characterized	O
by	O
containing	O
at	O
least	O
one	O
amino	O
acid	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aspartic	O
acid,	O
alanine,	O
cystine,	O
glutamine,	O
glycine,	O
histidine	O
and	O
salts	O
thereof	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
an	O
adiponectin	B-GENE
preparation	O
having	O
an	O
effect	O
of	O
regulating	O
adiponectin	B-GENE
which	O
is	O
capable	O
of	O
regulating	O
adiponectin,	O
originates	O
in	O
a	O
natural	O
substance	O
and,	O
therefore,	O
has	O
a	O
high	O
safety	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
An	O
adiponectin	B-GENE
regulator	O
characterized	O
by	O
containing	O
a	O
hop	O
bract	O
extract	O
or	O
an	O
apple	O
extract	O
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1,	O
R2	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
for	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
pathologies	O
in	O
which	O
inhibition	O
of	O
the	O
interaction	O
between	O
HIF-1α	B-GENE
and	O
p300	B-GENE
is	O
beneficial,	O
in	O
particular	O
as	O
antiangiogenic	O
medicaments	O
for	O
the	O
therapy	O
of	O
solid	O
tumors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
pharmaceutical	O
dosage	O
form	O
of	O
PDE	B-GENE
inhibitors	O
for	O
the	O
intravenous	O
application	O
thereof	O
and	O
application	O
thereof	O
for	O
the	O
treatment	O
of	O
diseases	O
.	O


A	O
hypoxia	O
response	O
enhancing	O
agent	O
comprising	O
arginine	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
a	O
therapeutic	O
agent	O
for	O
diseases	O
accompanied	O
by	O
ischemia	O
or	O
hypoxia	O
condition,	O
comprising	O
the	O
hypoxia	O
response	O
enhancing	O
agent	O
.	O
This	O
hypoxia	O
response	O
enhancing	O
agent	O
can	O
enhance	O
the	O
activity	O
of	O
HIF-1	B-GENE
being	O
a	O
hypoxia	B-GENE
inducing	I-GENE
factor,	O
thereby	O
realizing	O
an	O
enhancement	O
of	O
hypoxia	O
response	O
.	O


Disclosed	O
herein	O
is	O
a	O
novel	O
class	O
of	O
aminophenyl	O
compounds	O
having	O
the	O
structure	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
cyano	O
or	O
nitro	O
and	O
ring	O
A	O
is	O
a	O
bi-	O
or	O
tricyclic	O
bridged	O
heterocycle	O
and	O
to	O
their	O
use	O
as	O
modulators	O
of	O
androgen	B-GENE
receptor	I-GENE
for	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
relating	O
thereto	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
Wherein	O
T,	O
Y,	O
X1	O
,	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
R5	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
the	O
activity	O
of	O
a	O
member	O
of	O
the	O
MAPEG	B-GENE
family	I-GENE
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
inflammation	O
.	O


The	O
invention	O
provides	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt,	O
tautomer,	O
solvate	O
or	O
N-oxides	O
thereof	O
;	O
wherein	O
:	O
R1	O
is	O
selected	O
from	O
(	O
a	O
)	O
2,6-dichlorophenyl	O
;	O
(	O
b	O
)	O
2,6-difluorophenyl	O
;	O
(	O
c	O
)	O
a	O
2,3,6-trisubstituted	O
phenyl	O
group	O
wherein	O
the	O
substituents	O
are	O
fluorine,	O
chlorine,	O
methyl	O
or	O
methoxy	O
;	O
and	O
(	O
d	O
)	O
a	O
group	O
R0	O
wherein	O
R0	O
is	O
a	O
3-12	O
membered	O
carbocyclic	O
or	O
heterocyclic	O
group	O
;	O
or	O
optionally	O
substituted	O
C1-8	O
hydrocarbyl	O
;	O
R2a	O
and	O
R2b	O
are	O
each	O
hydrogen	O
or	O
methyl	O
;	O
and	O
R3	O
is	O
as	O
defined	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
have	O
activity	O
as	O
inhibitors	O
of	O
Cyclin	B-GENE
Dependent	I-GENE
Kinases	I-GENE
(	O
CDK	B-GENE
)	O
and	O
Glycogen	B-GENE
Synthase	I-GENE
Kinases	I-GENE
(	O
GSK	B-GENE
)	O
kinases	B-GENE
and	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
disease	O
states	O
or	O
conditions	O
mediated	O
by	O
the	O
kinases	B-GENE
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
medicinal	O
composition	O
for	O
the	O
efficient	O
transdermal	O
absorption	O
of	O
an	O
opioid	B-GENE
receptor	I-GENE
antagonist	O
typified	O
by	O
pentazocine	O
having	O
an	O
analgesic	O
effect,	O
etc	O
.	O
Namely,	O
a	O
medicinal	O
composition	O
for	O
transdermal	O
absorption	O
which	O
contains	O
an	O
opioid	B-GENE
receptor	I-GENE
antagonist,	O
a	O
fatty	O
acid	O
ester	O
and	O
a	O
glycerol	O
fatty	O
acid	O
ester	O
or	O
a	O
sorbitan	O
fatty	O
acid	O
ester	O
.	O
More	O
specifically	O
speaking,	O
the	O
above-described	O
fatty	O
acid	O
ester	O
is	O
a	O
fatty	O
acid	O
ester	O
prepared	O
form	O
a	O
fatty	O
acid	O
having	O
from	O
6	O
to	O
22	O
carbon	O
atoms	O
with	O
an	O
alcohol	O
having	O
from	O
1	O
to	O
12	O
carbon	O
atoms,	O
more	O
preferably	O
isopropyl	O
myristate	O
.	O
The	O
above-described	O
glycerol	O
fatty	O
acid	O
ester	O
or	O
sorbitan	O
fatty	O
acid	O
ester	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
glycerol	O
caprylate,	O
glycerol	O
caprate,	O
sorbitan	O
caprate	O
and	O
glycerol	O
laurate	O
.	O
It	O
is	O
adequate	O
that	O
this	O
medicinal	O
composition	O
for	O
transdermal	O
absorption	O
is	O
in	O
a	O
dosage	O
form	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
patch,	O
a	O
tape,	O
a	O
cream,	O
a	O
lotion,	O
an	O
ointment	O
and	O
a	O
gel	O
.	O


This	O
invention	O
relates	O
to	O
a	O
group	O
of	O
trisubstituted	O
pyrido	O
(	O
2,3-d	O
)	O
pyrimidine	O
derivatives,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
N-oxides,	O
solvates	O
and	O
enantiomers,	O
possessing	O
unexpectedly	O
desirable	O
pharmaceutical	O
properties,	O
in	O
particular	O
which	O
are	O
highly	O
active	O
immunosuppressive	O
agents,	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
in	O
transplant	O
rejection	O
and	O
/	O
or	O
in	O
the	O
treatment	O
of	O
certain	O
inflammatory	O
diseases	O
.	O
These	O
derivatives	O
are	O
also	O
useful	O
in	O
preventing	O
or	O
treating	O
cardiovascular	O
disorders,	O
disorders	O
of	O
the	O
central	O
nervous	O
system,	O
TNF-α	B-GENE
related	O
disorders	O
and	O
cell	O
proliferative	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
sphingosine-1-phosphate	O
analogs	O
that	O
are	O
potent,	O
and	O
selective	O
agonists	O
at	O
one	O
or	O
more	O
S1P	O
receptors,	O
specifically	O
the	O
S1P1	B-GENE
receptor	O
type	O
.	O
The	O
compounds	O
invention	O
include	O
compounds	O
having	O
a	O
phosphate	O
moiety	O
as	O
well	O
as	O
compounds	O
with	O
hydrolysis-resistant	O
phosphate	O
surrogates	O
such	O
as	O
phosphonates,	O
alpha-substituted	O
phosphonates,	O
and	O
phosphothionates	O
.	O


Compounds	O
having	O
the	O
formula	O
(	O
I	O
)	O
are	O
hepatitis	B-GENE
C	I-GENE
(HCV)	I-GENE
polymerase	I-GENE
inhibitors	O
.	O
Also	O
disclosed	O
are	O
compositions	O
and	O
methods	O
for	O
inhibiting	O
hepatitis	B-GENE
C	I-GENE
(HCV)	I-GENE
polymerase,	O
processes	O
for	O
making	O
the	O
compounds,	O
and	O
synthetic	O
intermediates	O
employed	O
in	O
the	O
processes	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
selected	O
from	O
compounds	O
of	O
formula	O
I	O
as	O
ligand	O
binding	O
to	O
the	O
HDM2	B-GENE
protein,	O
inducing	O
apoptosis	O
and	O
inhibiting	O
proliferation,and	O
having	O
therapeutic	O
utility	O
in	O
cancer	O
therapy	O
.	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
as	O
therapeutics	O
for	O
treating	O
stroke,	O
myocardial	O
infarction,	O
ischemia,	O
multi-organ	O
failure,	O
spinal	O
cord	O
injury,	O
Alzheimer	O
'	O
s	O
Disease,	O
injury	O
from	O
ischemic	O
events,	O
heart	O
valvular	O
degenerative	O
disease	O
Moreover,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
to	O
decrease	O
the	O
side	O
effects	O
from	O
cytotoxic	O
cancer	O
agents	O
and	O
to	O
treat	O
viral	O
infections	O
.	O


An	O
apoptosis	O
inducing	O
agent	O
for	O
prostate	O
carcinoma	O
cells	O
comprising	O
REIC	B-GENE
/	O
Dkk-3	B-GENE
DNA	I-GENE
or	O
a	O
REIC	B-GENE
/	O
Dkk-3	B-GENE
protein,	O
a	O
therapeutic	O
agent	O
for	O
prostate	O
carcinoma	O
comprising	O
the	O
apoptosis	O
inducing	O
agent,	O
and	O
an	O
agent	O
for	O
inhibiting	O
the	O
metastasis	O
of	O
prostate	O
carcinoma	O
comprising	O
the	O
apoptosis	O
inducing	O
agent	O
.	O
The	O
apoptosis	O
inducing	O
agent	O
for	O
prostate	O
carcinoma	O
cells	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
a	O
REIC	B-GENE
/	O
Dkk-3	B-GENE
protein	O
of	O
the	O
following	O
item	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
or	O
REIC	B-GENE
/	O
Dkk-3	B-GENE
DNA	I-GENE
of	O
the	O
following	O
item	O
(	O
c	O
)	O
or	O
(	O
d	O
)	O
:	O
(	O
a	O
)	O
a	O
protein	O
comprising	O
an	O
amino	O
acid	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO	O
:	O
2	O
;	O
(	O
b	O
)	O
a	O
protein	O
having	O
substitution	O
or	O
deletion	O
of	O
one	O
or	O
several	O
amino	O
acid	O
residues	O
in	O
the	O
amino	O
acid	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO	O
:	O
2	O
;	O
(	O
c	O
)	O
DNA	O
comprising	O
a	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO	O
:	O
1	O
;	O
and	O
(	O
d	O
)	O
DNA	O
which	O
is	O
capable	O
of	O
hybridizing	O
with	O
DNA	O
comprising	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO	O
:	O
1	O
under	O
stringent	O
conditions	O
and	O
which	O
encodes	O
a	O
protein	O
having	O
an	O
apoptotic	O
activity	O
.	O


This	O
invention	O
is	O
related	O
to	O
novel	O
aminoalkyl-	O
and	O
amidoalkyl-	O
b	O
enzopyran	O
derivatives	O
of	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
the	O
group	O
(	O
a	O
)	O
is	O
a	O
substituent	O
in	O
position	O
6	O
or	O
7	O
wherein	O
:	O
R	O
is	O
amono-	O
or	O
bi-cyclic	O
(	O
C6-C10	O
)	O
aryl	O
or	O
a	O
mono-	O
or	O
bi-cyclic	O
(	O
5-10	O
)	O
membered	O
heteroaryl	O
radical,	O
said	O
radicals	O
rings	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
substituents	O
selected	O
from	O
(	O
C1-C5	O
)	O
straight	O
or	O
branched	O
alkyl,	O
(	O
C1-C5	O
)	O
straight	O
or	O
branched	O
alkoxy,	O
hydroxy,	O
halo	O
and	O
trifluoromethyl	O
;	O
m	O
is	O
zero	O
or	O
an	O
integer	O
from	O
1	O
to	O
3	O
;	O
n,	O
p,	O
R1	O
and	O
R2	O
are	O
as	O
herein	O
indicated	O
and	O
R3	O
and	O
R4	O
are	O
both	O
hydrogen	O
or	O
taken	O
together	O
represent	O
an	O
oxygen	O
atom,	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
that	O
are	O
active	O
as	O
selective	O
and	O
reversible	O
MAO-B	B-GENE
inhibitors	O
in	O
vitro	O
and	O
in	O
vivo,	O
are	O
useful	O
as	O
medicaments	O
for	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
CNS	O
degenerative	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
formula	O
(	O
I	O
)	O
compounds	O
inhibit	O
tyrosine	O
kinase	O
activity	O
of	O
growth	B-GENE
factor	I-GENE
receptors	I-GENE
such	O
as	O
HER1,	O
HER2	B-GENE
and	O
HER4	B-GENE
thereby	O
making	O
them	O
useful	O
as	O
antiproliferative	O
agents	O
.	O
The	O
formula	O
(	O
I	O
)	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
signal	O
transduction	O
pathways	O
operating	O
through	O
growth	B-GENE
factor	I-GENE
receptors	I-GENE
.	O


Certain	O
appropriately	O
substituted	O
fused	O
bicyclic	O
pyrimidine	O
compounds	O
having	O
an	O
amide-substituted	O
pyridylamine	O
group	O
at	O
C-4	O
of	O
the	O
pyrimidine	O
ring	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
excessive	O
TGFβ	B-GENE
activity	O
and	O
certain	O
viral	O
disorders	O
.	O


Pyrimidine	O
having	O
a	O
pyridylamine	O
group	O
at	O
C-	O
4	O
of	O
the	O
pyrimidine	O
and	O
an	O
amide	O
group	O
on	O
the	O
pyridine	O
ring	O
(	O
compounds	O
of	O
formula	O
I	O
)	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
excessive	O
TGFB	B-GENE
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
pyridyl-lactams,	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
a	O
group	O
of	O
the	O
formula	O
G1,	O
G2,	O
G3	O
or	O
G4	O
depicted	O
below,	O
and	O
R3,	O
Y,	O
R6,	O
R7,	O
R8,	O
R13,	O
a,	O
n	O
and	O
m	O
are	O
as	O
defined	O
herein,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
pharmaceutical	O
compositions,	O
their	O
preparation	O
and	O
intermediates	O
therefrom,	O
and	O
their	O
use	O
in	O
treating	O
or	O
preventing	O
depression,	O
anxiety,	O
obsessive	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
and	O
other	O
disorders	O
for	O
which	O
a	O
5-HT1B	B-GENE
antagonist	O
is	O
indicated	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
wherein	O
•	O
R1	O
is	O
hydrogen	O
or	O
C1-4alkyl	O
;	O
•	O
R2	O
is	O
C1-4alkyl	O
;	O
•	O
R3	O
is	O
hydrogen,	O
or	O
a	O
phenyl	O
group,	O
a	O
heterocyclyl	O
group,	O
a	O
5-	O
or	O
6-membered	O
heteroaromatic	O
group,	O
or	O
a	O
8-	O
to	O
11-membered	O
bicyclic	O
group,	O
any	O
of	O
which	O
groups	O
is	O
optionally	O
substituted	O
by	O
1,	O
2,	O
3	O
or	O
4	O
substituents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
halogen,	O
cyano,	O
C1-4alkyl,	O
haloC1-4alkyl,	O
C1-4alkoxy,	O
C1-4alkanoyl	O
and	O
SF5	O
;	O
•	O
p	O
is	O
0,	O
1	O
,	O
2,	O
3	O
or	O
4	O
;	O
and	O
•	O
R4	O
is	O
independently	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
:	O
halogen,	O
hydroxy,	O
cyano,	O
C1-4alkyl,	O
haloC1-4alkyl,	O
C1-4alkoxy,	O
haloC1-4alkoxy	O
and	O
C1-4alkanoyl	O
;	O
•	O
n	O
is	O
0	O
or	O
1	O
;	O
wherein	O
when	O
R4	O
is	O
chlorine	O
and	O
p	O
is	O
1	O
,	O
such	O
R4	O
is	O
not	O
present	O
in	O
the	O
ortho	O
position	O
with	O
respect	O
to	O
the	O
linking	O
bond	O
to	O
the	O
rest	O
of	O
the	O
molecule	O
;	O
and	O
wherein,	O
if	O
n	O
is	O
0,	O
R3	O
comprises	O
at	O
least	O
one	O
SF5	O
group	O
as	O
a	O
substituent	O
;	O
processes	O
for	O
their	O
preparation,	O
intermediates	O
used	O
in	O
these	O
processes,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy,	O
as	O
modulators	O
of	O
dopamine	B-GENE
D3	I-GENE
receptors,	O
e	O
.	O
g	O
.	O
to	O
treat	O
drug	O
dependency,	O
as	O
antipsychotic	O
agents,	O
to	O
treat	O
obsessive	O
compulsive	O
spectrum	O
disorders,	O
premature	O
ejaculation	O
or	O
cognition	O
impairment	O
.	O


The	O
present	O
invention	O
provides	O
at	O
least	O
one	O
chemical	O
entity	O
chosen	O
from	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
represents	O
a	O
group	O
selected	O
from	O
formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
,	O
(	O
V	O
)	O
,	O
(	O
VI	O
)	O
,	O
(	O
VII	O
)	O
,	O
each	O
ring	O
of	O
which	O
optionally	O
contains	O
a	O
further	O
heteroatom	O
N,	O
Z	O
represents	O
an	O
optional	O
substituent	O
halogen,	O
-C1-3alkyl	O
or	O
-NRaRb,	O
alk	O
represents	O
alkylene	O
or	O
alkenylene,	O
T	O
represents	O
S,	O
O	O
or	O
NH	O
;	O
Ra	O
and	O
Rb	O
independently	O
represent	O
hydrogen	O
or	O
-C1-3alkyl	O
;	O
R2	O
represents	O
a	O
group	O
selected	O
from	O
formula	O
(	O
VIII	O
)	O
,	O
(	O
IX	O
)	O
,	O
W,	O
X	O
and	O
Y	O
independently	O
represent	O
CH,	O
C-R5	O
or	O
N	O
;	O
R5	O
represents	O
halogen	O
or	O
C1-3alkyl	O
;	O
V	O
represents	O
NR3,	O
S	O
or	O
O	O
;	O
R3	O
represents	O
hydrogen	O
or	O
C1-3alkyl	O
;	O
one	O
of	O
A1	O
and	O
A2	O
represents	O
N	O
and	O
the	O
other	O
represents	O
CH	O
;	O
Each	O
R4,	O
R6,	O
R7,	O
R8,	O
R9	O
independently	O
represents	O
hydrogen	O
or	O
C1-3alkyl	O
;	O
R10	O
represents	O
hydrogen,	O
-C1-6alkyl,	O
-C1-3alkylCONRaRb,	O
-C1-3alkylCO2C1-4alkyl,	O
-CO2C1-4alkyl	O
or	O
-C1-3alkylCO2H	O
;	O
and	O
pharmaceutically	O
acceptable	O
derivative	O
(	O
s	O
)	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compound	O
(	O
s	O
)	O
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
containing	O
compound	O
(	O
s	O
)	O
of	O
formula	O
(	O
I	O
)	O
and	O
to	O
the	O
use	O
of	O
compound	O
(	O
s	O
)	O
of	O
formula	O
(	O
I	O
)	O
in	O
medicine,	O
particularly	O
in	O
the	O
amelioration	O
of	O
a	O
clinical	O
condition	O
for	O
which	O
a	O
Factor	B-GENE
Xa	I-GENE
inhibitor	O
is	O
indicated	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
HDAC	B-GENE
inhibitors	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
amelioration,	O
treatment	O
or	O
prevention	O
of	O
malignancies	O
related	O
to	O
ischemic	O
events	O
or	O
brain	O
damage,	O
whereby	O
said	O
HDAC	B-GENE
inhibitor	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
SAHA,	O
M344,	O
MS-275,	O
CBHA	O
and	O
SBHA	O
and	O
whereby	O
said	O
HDAC	B-GENE
inhibitor	O
is	O
most	O
preferably	O
SAHA	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
;	O
R2	O
;	O
R3	O
;	O
V	O
;	O
G1	O
and	O
G2	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
.	O
They	O
exhibit	O
a	O
strong	O
antithrombotic	O
effect	O
and	O
are	O
suitable,	O
for	O
example,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
cardiovascular	O
disorders	O
like	O
thromboembolic	O
diseases	O
or	O
restenoses	O
.	O
They	O
are	O
reversible	O
inhibitors	O
of	O
the	O
blood	O
clotting	O
enzymes	O
factor	O
Xa,	O
and	O
can	O
in	O
general	O
be	O
applied	O
in	O
conditions	O
in	O
which	O
an	O
undesired	O
activity	O
of	O
factor	B-GENE
Xa	I-GENE
is	O
present	O
or	O
for	O
the	O
cure	O
or	O
prevention	O
of	O
which	O
an	O
inhibition	O
of	O
factor	B-GENE
Xa	I-GENE
is	O
intended	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
their	O
use,	O
in	O
particular	O
as	O
active	O
ingredients	O
in	O
pharmaceuticals,	O
and	O
pharmaceutical	O
preparations	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
c-Abl-,	O
PDGF-R-,	O
c-kit-,	O
or	O
ARG-tyrosine	O
kinase	O
inhibitors,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
for	O
the	O
treatment,	O
amelioration,	O
and	O
diagnosis	O
of	O
disorders	O
associated	O
with	O
aberrant	O
expression	O
of	O
adipocyte-specific	O
peptide	O
hormone	O
in	O
a	O
patient,	O
e	O
.	O
g	O
.	O
,	O
metabolic	O
disorders,	O
e	O
.	O
g	O
.	O
,	O
type	O
I	O
diabetes	O
or	O
type	O
II	O
diabetes,	O
and	O
for	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment,	O
amelioration,	O
and	O
diagnosis	O
of	O
disorders	O
associated	O
with	O
aberrant	O
expression	O
of	O
adipocyte-specific	O
peptide	O
hormone	O
in	O
a	O
patient	O
.	O
Examples	O
of	O
c-Abl-,	O
PDGF-R-,	O
c-kit-,	O
or	O
ARG-tyrosine	O
kinase	O
inhibitors	O
include	O
Compound	O
I	O
and	O
Compound	O
II,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
ability	O
of	O
the	O
c-Abl-,	O
PDGF-R-,	O
c-kit-,	O
or	O
ARG-tyrosine	O
kinase	O
inhibitors,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
to	O
treat	O
metabolic	O
disorders	O
is	O
based	O
at	O
least	O
in	O
part	O
on	O
their	O
ability	O
to	O
bind	O
adipocyte-specific	O
peptide	O
hormones	O
such	O
as	O
adiponectin	O
.	O


ABSTRACT	O
This	O
invention	O
relates	O
to	O
certain	O
bicyclic	O
6-alkylidene	O
penems	O
which	O
act	O
as	O
a	O
inhibitor	O
of	O
class-D	B-GENE
enzymes	I-GENE
.	O
β-Lactamases	B-GENE
hydrolyze	O
β-lactam	O
antibiotics,	O
and	O
as	O
such	O
serve	O
as	O
the	O
primary	O
cause	O
of	O
bacterial	O
resistance	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
when	O
combined	O
with	O
β-lactam	O
antibiotics	O
will	O
provide	O
an	O
effective	O
treatment	O
against	O
life	O
threatening	O
bacterial	O
infections	O
.	O
In	O
accordance	O
with	O
the	O
present	O
invention	O
there	O
are	O
provided	O
compounds	O
of	O
general	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
in	O
vivo	O
hydrolyzable	O
ester	O
R5	O
thereof	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
:	O
One	O
of	O
A	O
and	O
B	O
denotes	O
hydrogen	O
and	O
the	O
other	O
an	O
optionally	O
substituted	O
fused	O
bicyclic	O
heteroaryl	O
group	O
;	O
and	O
X	O
=	O
O	O
or	O
S	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O
These	O
compounds	O
are	O
a	O
novel	O
type	O
of	O
peptide	B-GENE
deformylase	I-GENE
(	O
PDF	O
)	O
inhibitors,	O
and	O
are	O
therefore	O
of	O
great	O
interest	O
especially	O
as	O
new	O
antibiotics	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
in	O
treating	O
conditions	O
or	O
disorders	O
prevented	O
by	O
or	O
ameliorated	O
by	O
histamine-3	B-GENE
receptor	I-GENE
ligands	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
histamine-3	B-GENE
receptor	I-GENE
ligands,	O
methods	O
for	O
using	O
such	O
compounds	O
and	O
compositions,	O
and	O
a	O
process	O
for	O
preparing	O
compounds	O
within	O
the	O
scope	O
of	O
formula	O
(	O
I	O
)	O
.	O


The	O
invention	O
provides	O
novel	O
benzoimidazolone-carboxamide	O
5-HT4	B-GENE
receptor	O
agonist	O
compounds	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
associated	O
with	O
5-HT4	B-GENE
receptor	O
activity,	O
and	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O


An	O
improved	O
blood	O
substitute	O
composition	O
comprising	O
a	O
blood	O
substitute	O
and	O
a	O
renin-angiotensin-aldosterone	O
system	O
inhibitor	O
.	O
A	O
method	O
of	O
treating	O
a	O
patient	O
having	O
a	O
disorder	O
requiring	O
a	O
blood	O
transfusion	O
comprising	O
administering	O
a	O
free	O
hemoglobin	B-GENE
based	O
blood	O
substitute	O
and	O
a	O
renin-angiotensin-aldosterone	O
system	O
inhibitor	O
.	O
A	O
renin-angiotensin-aldosterone	O
system	O
activator	O
comprising	O
hemoglobin	B-GENE
or	O
hemoglobin	B-GENE
and	O
a	O
peroxide	O
.	O
A	O
method	O
of	O
increasing	O
the	O
activity	O
of	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
comprising	O
incubation	O
with	O
hemoglobin	B-GENE
or	O
hemoglobin	B-GENE
and	O
peroxide	O
.	O
A	O
method	O
according	O
of	O
activating	O
the	O
renin-angiotensin-aldosterone	O
system	O
comprising	O
contacting	O
in	O
vivo	O
a	O
free	O
hemoglobin	B-GENE
based	O
blood	O
substitute	O
with	O
a	O
peroxide	O
wherein	O
the	O
product	O
induces	O
the	O
production	O
of	O
angiotensin	B-GENE
I	I-GENE
metabolites	O
which	O
comprise	O
metabolites	O
capable	O
of	O
affecting	O
the	O
vascular	O
tone	O
and	O
/	O
or	O
stimulating	O
aldosterone	O
production	O
.	O


An	O
agent	O
for	O
topical	O
administration	O
comprising	O
a	O
compound	O
having	O
a	O
P38MAPK	B-GENE
(	O
Mitogen-Activated	B-GENE
Protein	I-GENE
Kinase	I-GENE
)	O
inhibitory	O
effect	O
or	O
a	O
pharmacologically	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient,	O
wherein,	O
when	O
the	O
agent	O
is	O
administered	O
topically,	O
the	O
concentration	O
of	O
the	O
compound	O
or	O
salt	O
at	O
the	O
topically	O
administered	O
site	O
is	O
350	O
times	O
or	O
more	O
higher	O
than	O
that	O
in	O
the	O
blood	O
plasma	O
.	O
In	O
the	O
agent	O
for	O
topical	O
administration,	O
the	O
compound	O
having	O
the	O
P38MAPK	B-GENE
inhibitory	O
effect	O
may	O
be,	O
for	O
example,	O
a	O
phenol	O
derivative	O
or	O
a	O
fused	O
heterocyclic	O
compound	O
having	O
a	O
phenol	O
structure	O
in	O
the	O
fused	O
ring	O
system	O
.	O


A	O
amino	O
acid	O
other	O
than	O
glutamic	O
acid	O
is	O
used	O
as	O
a	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
activator	O
.	O
More	O
preferably,	O
aspartic	O
acid,	O
valine	O
or	O
cysteine	O
is	O
used	O
as	O
a	O
group	O
I	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
activator	O
;	O
alanine,	O
arginine,	O
asparagine,	O
aspartic	O
acid,	O
cysteine,	O
glutamine,	O
glycine,	O
histidine,	O
isoleucine,	O
leucine,	O
lysine,	O
methionine,	O
phenylalanine,	O
proline,	O
serine,	O
threonine,	O
tryptophan,	O
tyrosine,	O
valine,	O
ornithine,	O
taurine	O
or	O
hydroxyproline	O
is	O
used	O
as	O
a	O
group	B-GENE
II	I-GENE
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
activator	O
;	O
and	O
cysteine	O
is	O
used	O
as	O
a	O
group	B-GENE
III	I-GENE
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
activator	O
.	O


It	O
is	O
now	O
found	O
that	O
p53	B-GENE
tumor	O
suppressor	O
protein	O
can	O
be	O
activated	O
by	O
the	O
inhibition	O
of	O
the	O
function	O
of	O
synoviolin	O
.	O
A	O
substance	O
capable	O
of	O
inhibiting	O
the	O
function	O
of	O
synoviolin	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
cancer	O
.	O
It	O
is	O
also	O
found	O
that	O
the	O
inhibition	O
of	O
the	O
function	O
of	O
synoviolin	O
leads	O
to	O
the	O
inhibition	O
of	O
the	O
ubiquitination	O
of	O
p53,	O
the	O
increase	O
in	O
the	O
activity	O
of	O
phosphorylated	B-GENE
p53	B-GENE
protein	O
and	O
the	O
like	O
.	O
Based	O
on	O
these	O
findings,	O
a	O
method	O
is	O
provided	O
which	O
can	O
screen	O
a	O
therapeutic	O
agent	O
for	O
cancer	O
with	O
good	O
efficiency	O
.	O
Further,	O
it	O
is	O
also	O
found	O
that	O
the	O
proliferation	O
of	O
a	O
rheumatoid	O
synovial	O
cell	O
can	O
be	O
suppressed	O
by	O
controlling	O
the	O
autoubiquitination	O
of	O
synoviolin	O
protein	O
.	O
A	O
substance	O
capable	O
of	O
controlling	O
the	O
autoubiquitination	O
of	O
synoviolin	O
protein	O
is	O
useful	O
as	O
an	O
anti-rheumatic	O
agent	O
.	O
Also	O
provided	O
is	O
a	O
method	O
for	O
screening	O
an	O
anti-rheumatic	O
agent	O
with	O
good	O
efficiency	O
.	O


The	O
invention	O
provides	O
novel	O
compositions	O
and	O
compounds	O
that	O
inhibit	O
CatSper	B-GENE
channel	O
activity,	O
that	O
preferentially	O
inhibits	O
sperm	O
hyperactivity	O
over	O
sperm	O
motility,	O
or	O
both	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
as	O
contraceptive	O
agents	O
that	O
may	O
be	O
adminstered	O
to	O
males,	O
females,	O
or	O
concurrently	O
to	O
both	O
sexual	O
partners	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
conducting	O
drug	O
discovery	O
business	O
and	O
of	O
conducting	O
a	O
reproductive	O
medicine	O
business	O
.	O
The	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
compounds	O
that	O
modulate	O
sperm	O
hypermotility	O
.	O


Compounds	O
that	O
regulate	O
the	O
zinc	B-GENE
metalloprotease	I-GENE
meprin	I-GENE
can	O
play	O
a	O
role	O
in	O
preventing,	O
ameliorating,	O
or	O
correcting	O
dysfunctions	O
or	O
diseases	O
including	O
cardiovascular	O
and	O
renal	O
disorders	O
.	O
The	O
invention	O
provides	O
assays	O
for	O
the	O
identification	O
of	O
such	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
medical	O
use	O
of	O
compounds	O
acting	O
as	O
inhibitors	O
of	O
enzymes	O
having	O
histone	B-GENE
deacetylase	I-GENE
activity	O
in	O
conditions	O
where	O
their	O
combination	O
with	O
compounds	O
known	O
as	O
NSAID´s,	O
Non	O
Steroidal	O
Anti	O
Inflammatory	O
Drugs,	O
causes	O
an	O
enhanced	O
beneficial	O
therapeutic	O
effect	O
.	O
These	O
conditions	O
comprise	O
cancer,	O
cancer	O
predisposing	O
conditions,	O
inflammatory	O
and	O
metabolic	O
diseases	O
.	O
Furthermore,	O
the	O
invention	O
includes	O
the	O
manufacture	O
of	O
clinically	O
used	O
medicaments	O
for	O
the	O
therapy	O
of	O
the	O
diseases	O
mentioned	O
herein,	O
administering	O
the	O
compounds	O
separately	O
in	O
the	O
form	O
of	O
two	O
individual	O
drugs	O
or	O
in	O
an	O
administrative	O
form	O
which	O
contains	O
both	O
drugs	O
in	O
a	O
single	O
application	O
unit	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof,	O
process	O
for	O
their	O
preparation,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
tachykinins	B-GENE
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O


The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders,	O
comprising	O
an	O
effective	O
quantity	O
of	O
a	O
tungsten	O
compound	O
(	O
VI	O
)	O
,	O
preferably	O
a	O
tungstate	O
salt	O
and	O
more	O
preferably	O
sodium	O
tungstate	O
(	O
Na2WO4	O
)	O
.	O
	O
The	O
inventive	O
pharmaceutical	O
compositions	O
can	O
be	O
used	O
for	O
the	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
treatment	O
of	O
neurodegenerative	O
disorders	O
in	O
mammals,	O
including	O
humans,	O
and,	O
in	O
particular,	O
for	O
the	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
schizophrenia	O
.	O
	O
The	O
effect	O
of	O
sodium	O
tungstate	O
dihydrate	O
in	O
tau	B-GENE
phosphorylation	O
was	O
assessed	O
using	O
a	O
model	O
of	O
insulin-resistant	O
mice	O
and	O
a	O
Type	O
1	O
diabetes	O
model	O
.	O
	O
The	O
therapeutic	O
treatment	O
of	O
tauopathies	O
that	O
derive	O
from	O
said	O
invention	O
affords	O
numerous	O
advantages	O
:	O
GSK3	B-GENE
inhibition,	O
specificity	O
owing	O
to	O
a	O
reduction	O
in	O
abnormal	O
tau	B-GENE
hyperphosphorylation	O
caused	O
by	O
a	O
specific	O
neural	O
protein,	O
efficacy,	O
absence	O
of	O
toxicity,	O
and	O
low	O
price	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
regulating	O
splicings	O
in	O
mammalian	O
cells	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
PP1	B-GENE
inhibitors	O
to	O
prevent	O
abnormal	O
splicings	O
in	O
various	O
pathological	O
situations	O
.	O
The	O
invention	O
may	O
be	O
used	O
to	O
prevent	O
or	O
treat	O
various	O
diseases,	O
including	O
degenerative	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
the	O
hetaryl-substituted	O
guanidine	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
enantiomeres,	O
diastereomeres	O
and	O
/	O
or	O
tautomeres	O
thereof,	O
in	O
addition	O
to	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
the	O
prodrugs	O
of	O
the	O
known	O
compounds	O
.	O
	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
hetaryl-substituted	O
guanidine	O
compounds	O
as	O
binding	O
partners	O
for	O
5-HT5-receptors	O
for	O
treating	O
and	O
/	O
or	O
for	O
the	O
prophylaxis	O
of	O
illnesses	O
which	O
are	O
modulated	O
by	O
a	O
5-HT5-receptor	O
activity,	O
in	O
particular,	O
for	O
treating	O
and	O
/	O
or	O
for	O
the	O
prophylaxis	O
of	O
neurodegenerative	O
and	O
neuropsychiatric	O
disorders,	O
and	O
signs,	O
symptoms	O
and	O
dysfunctions	O
associated	O
with	O
said	O
disorders	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
providing	O
neural	O
protection	O
in	O
human	O
patients	O
suffering	O
from	O
amyotrophic	O
lateral	O
sclerosis	O
comprising	O
administering	O
to	O
said	O
patients	O
suffering	O
from	O
said	O
amyotrophic	O
lateral	O
sclerosis	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
ryanodine	B-GENE
receptor	I-GENE
antagonist	O
in	O
pharmaceutically	O
acceptable	O
vehicle	O
to	O
inhibit	O
or	O
prevent	O
neuronal	O
injury	O
or	O
death	O
.	O


The	O
present	O
invention	O
relates	O
to	O
amide	O
and	O
urea	O
derivatives	O
of	O
heteroaryl-	O
substituted	O
diazatricycloalkanes,	O
of	O
the	O
Formula	O
(	O
I	O
)	O
with	O
the	O
definition	O
as	O
set	O
out	O
in	O
the	O
description	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds,	O
methods	O
of	O
preparing	O
the	O
compounds,	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
.	O
More	O
specifically,	O
the	O
methods	O
of	O
treatment	O
involve	O
modulating	O
the	O
activity	O
of	O
the	O
α7	B-GENE
nAChR	I-GENE
subtype	O
by	O
administering	O
one	O
or	O
more	O
of	O
the	O
compounds	O
to	O
treat	O
or	O
prevent	O
disorders	O
mediated	O
by	O
the	O
α7	B-GENE
nAChR	I-GENE
subtype	O
.	O
The	O
diazatricycloalkanes	O
typically	O
consist	O
of	O
a	O
1-azabicyclooctane	O
fused	O
to	O
pyrrolidine	O
ring	O
.	O
The	O
substituent	O
heteroaryl	O
groups	O
are	O
5-	O
or	O
6-membered	O
ring	O
heteroaromatics,	O
such	O
as	O
3-pyridinyl	O
and	O
5-pyrimidinyl	O
moieties,	O
which	O
are	O
attached	O
directly	O
to	O
the	O
diazatricycloalkane	O
.	O
The	O
secondary	O
nitrogen	O
of	O
the	O
pyrrolidine	O
moiety	O
is	O
substituted	O
with	O
an	O
arylcarbonyl	O
(	O
amide	O
type	O
derivative	O
)	O
or	O
an	O
arylaminocarbonyl	O
(	O
N-	O
arylcarbamoyl	O
)	O
(	O
urea	O
type	O
derivative	O
)	O
group	O
.	O
The	O
compounds	O
are	O
beneficial	O
in	O
therapeutic	O
applications	O
requiring	O
a	O
selective	O
interaction	O
at	O
certain	O
nAChR	O
subtypes	O
.	O
That	O
is,	O
the	O
compounds	O
modulate	O
the	O
activity	O
of	O
certain	O
nAChR	O
subtypes,	O
particularly	O
the	O
α7	B-GENE
nAChR	I-GENE
subtype,	O
and	O
do	O
not	O
have	O
appreciable	O
activity	O
toward	O
muscarinic	O
receptors	O
.	O
Radiolabeled	O
versions	O
of	O
the	O
compounds	O
can	O
be	O
used	O
in	O
diagnostic	O
methods	O
.	O


Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
A,	O
D,	O
E,	O
G,	O
J,	O
X,	O
Y,	O
Z	O
R6,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
diseases	O
mediated	O
by	O
a	O
P2X3	B-GENE
and	O
/	O
or	O
a	O
P2X2/3	B-GENE
receptor	I-GENE
antagonist	O
and	O
methods	O
of	O
making	O
the	O
compounds	O
.	O


The	O
invention	O
relates	O
to	O
fused	O
and	O
spirocycle	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
prodrug,	O
or	O
solvate	O
thereof,	O
wherein	O
R1,	O
R2,	O
Q1-Q3,	O
and	O
Z	O
are	O
defined	O
as	O
set	O
forth	O
in	O
the	O
specification	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
to	O
treat,	O
prevent	O
or	O
ameliorate	O
a	O
disorder	O
responsive	O
to	O
the	O
blockade	O
of	O
calcium	O
channels,	O
and	O
particularly	O
N-type	B-GENE
calcium	B-GENE
channels	I-GENE
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
especially	O
useful	O
for	O
treating	O
pain	O
.	O


The	O
invention	O
relates	O
to	O
aminopurine	O
derivatives	O
useful	O
in	O
treating	O
disorders	O
that	O
are	O
mediated	O
by	O
adenosine	B-GENE
receptor	I-GENE
function,	O
including	O
neurodegenerative	O
diseases	O
and	O
inflammation	O
.	O
The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
features	O
methods	O
of	O
inhibiting	O
ribonucleotide	B-GENE
reductase	I-GENE
and	O
DNA	O
synthesis	O
after	O
administration	O
of	O
a	O
dose	O
of	O
ionizing	O
radiation	O
to	O
cells	O
.	O
The	O
present	O
invention	O
further	O
features	O
methods	O
of	O
treating	O
patients	O
suffering	O
from	O
cancer	O
comprising	O
contemporaneous	O
or	O
sequential	O
administration	O
of	O
a	O
radiosensitizing	O
dose	O
of	O
a	O
2-carboxyaldehyde	O
pyridine	O
thiosemicarbazone	O
compound	O
and	O
ionizing	O
radiation	O
.	O


Disclosed	O
is	O
an	O
aryl-substituted	O
nitrogen-containing	O
heterocyclic	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
This	O
compound	O
serves	O
as	O
a	O
nociceptin	B-GENE
receptor	I-GENE
antagonist	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
for	O
treating	O
diseases	O
associated	O
with	O
a	O
nociceptin	B-GENE
receptor	I-GENE
.	O
(	O
I	O
)	O
[	O
In	O
the	O
formula,	O
A1,	O
A2	O
and	O
A3	O
independently	O
represent	O
a	O
carbon	O
atom	O
or	O
a	O
nitrogen	O
atom,	O
and	O
one	O
or	O
two	O
of	O
A1,	O
A2	O
and	O
A3	O
represent	O
a	O
carbon	O
atom	O
;	O
R1	O
represents	O
a	O
lower	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
phenyl	O
group	O
which	O
may	O
be	O
substituted	O
by	O
a	O
halogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
lower	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
and	O
R4	O
represents	O
a	O
lower	O
alkyl	O
group	O
or	O
the	O
like	O
.	O
]	O


This	O
invention	O
is	O
directed	O
to	O
a	O
substituted	O
3-amido-tetrahydro-indazolyl	O
cannabinoid	O
modulator	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
a	O
method	O
for	O
use	O
in	O
treating,	O
ameliorating	O
or	O
preventing	O
a	O
cannabinoid	B-GENE
receptor	I-GENE
mediated	O
syndrome,	O
disorder	O
or	O
disease	O
.	O


Pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
compound	O
of	O
the	O
formulas	O
(	O
Ia	O
)	O
or	O
(	O
Ib	O
)	O
or	O
(	O
IIa	O
)	O
or	O
(	O
IIb	O
)	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
symbols	O
and	O
substituents	O
have	O
the	O
following	O
meaning	O
-X-	O
is	O
e	O
.	O
g	O
.	O
and	O
Y	O
being	O
e	O
.	O
g	O
.	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
can	O
be	O
applied	O
to	O
modulate	O
the	O
in-	O
vitro	O
and	O
in-	O
vivo	O
binding	O
processes	O
mediated	O
by	O
E-,	B-GENE
P-	I-GENE
or	I-GENE
L-selectin	I-GENE
binding	O
.	O


The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
fused	O
pyrrole	O
carboxylic	O
acids	O
of	O
formula	O
(	O
I	O
)	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
to	O
inhibit	O
D-amino	B-GENE
acid	I-GENE
oxidase,	O
particularly	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
and	O
psychiatric	O
disorders	O
or	O
diseases	O
;	O
certain	O
compounds	O
of	O
formula	O
I	O
being	O
novel,	O
pharmaceutical	O
compositions	O
containing	O
them,	O
their	O
use	O
in	O
medicine	O
and	O
methods	O
of	O
treatment	O
using	O
them	O
are	O
also	O
disclosed	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
(	O
M	O
)	O
-	O
(	O
L	O
)	O
-	O
(	O
M	O
)	O
or	O
formula	O
(	O
IV	O
)	O
[	O
(	O
M	O
)	O
-	O
(	O
L	O
)	O
t	O
]	O
-G	O
:	O
wherein	O
each	O
M	O
is	O
independently	O
an	O
inhibitor	O
of	O
HNE	B-GENE
;	O
each	O
L	O
is	O
independently	O
a	O
linker	O
group	O
;	O
t	O
is	O
2	O
to	O
20	O
;	O
G	O
is	O
aryl,	O
heteroaryl,	O
alkyl,	O
cycloalkyl,	O
nitrogen,	O
a	O
dendrimer	O
or	O
a	O
group	O
of	O
any	O
of	O
formulae	O
(	O
V	O
)	O
to	O
(	O
VII	O
)	O
:	O
wherein	O
Ar	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
and	O
u	O
is	O
2	O
to	O
20	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
N-oxide	O
or	O
prodrug	O
thereof	O
.	O


Various	O
calcilytic	O
compounds	O
and	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
are	O
disclosed	O
.	O
Calcilytic	O
compounds	O
are	O
compounds	O
capable	O
of	O
inhibiting	O
calcium	B-GENE
receptor	I-GENE
activity	O
.	O
Methods	O
for	O
preparing	O
calcilytic	O
compounds,	O
oral	O
bioavailability	O
of	O
calcilytic	O
compounds,	O
and	O
their	O
use	O
as	O
calcium	B-GENE
receptor	I-GENE
antagonists	O
are	O
also	O
disclosed	O
.	O


Provided	O
herein	O
are	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
muscarinic	B-GENE
receptor	I-GENE
antagonists	O
(	O
'	O
MRA	O
'	O
)	O
,	O
and	O
at	O
least	O
one	O
additional	O
active	O
ingredients	O
selected	O
from	O
one	O
or	O
more	O
ß2-agonists,	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
inhibitors,	O
PDE-IV	B-GENE
inhibitors,	O
corticosteroids	O
or	O
a	O
mixture	O
thereof	O
and	O
optionally	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
carriers,	O
excipients	O
or	O
diluents	O
.	O
In	O
addition,	O
methods	O
of	O
treating	O
autoimmune,	O
inflammatory	O
or	O
allergic	O
diseases	O
or	O
disorders	O
are	O
provided	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
ATR	B-GENE
inhibitor	O
containing,	O
as	O
the	O
active	O
ingredient,	O
a	O
tricyclic	O
compound	O
selected	O
from	O
among	O
various	O
schizandrins,	O
gomisins	O
and	O
so	O
on	O
which	O
are	O
useful	O
as	O
ATR	B-GENE
protein	O
kinase	O
inhibitors	O
.	O


The	O
present	O
invention	O
relates	O
to	O
(	O
hetero	O
)	O
aryl	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
and	O
radicals	O
A,	O
B,	O
Q,	O
W,	O
X,	O
Y,	O
Z,	O
R1,	O
R2,	O
R4a,	O
R4b,	O
R5a,	O
R5b,	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1	O
.	O
Moreover	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
compound	O
according	O
to	O
the	O
invention	O
.	O
By	O
virtue	O
of	O
their	O
MCH-receptor	B-GENE
antagonistic	O
activity	O
the	O
pharmaceutical	O
compositions	O
according	O
to	O
10	O
the	O
invention	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
and	O
/	O
or	O
eating	O
disorders,	O
particularly	O
obesity,	O
bulimia,	O
anorexia,	O
hyperphagia	O
and	O
diabetes	O
.	O


The	O
object	O
is	O
to	O
analyze	O
a	O
TRPV1-binding	O
protein	O
for	O
the	O
purpose	O
of	O
controlling	O
a	O
pain	O
or	O
the	O
protection	O
activity	O
of	O
a	O
gastric	O
mucosa	O
induced	O
by	O
TRPV1	B-GENE
and	O
to	O
achieve	O
the	O
regulation	O
of	O
the	O
action	O
of	O
TRPV1	B-GENE
.	O
Disclosed	O
are	O
:	O
a	O
mutant	O
EHD4	B-GENE
which	O
has	O
a	O
mutation	O
in	O
at	O
least	O
one	O
amino	O
acid	O
residue	O
selected	O
from	O
amino	O
acid	O
residues	O
corresponding	O
to	O
position-66,	O
position-184	O
and	O
position-225	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
a	O
normal	O
murine	B-GENE
EHD4	B-GENE
;	O
and	O
a	O
gene	O
encoding	O
the	O
mutant	O
protein	O
;	O
a	O
regulator	O
of	O
the	O
activity	O
of	O
TRPV1,	O
which	O
comprises	O
the	O
mutant	O
protein	O
;	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
EHD4,	O
a	O
substance	O
capable	O
of	O
increasing	O
the	O
activity	O
of	O
EHD4	B-GENE
or	O
a	O
substance	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
EHD4	B-GENE
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O


Disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
unstable	O
cerebrospinal	O
pressure	O
syndrome	O
.	O
It	O
is	O
found	O
that	O
there	O
exists	O
a	O
disease	O
induced	O
by	O
a	O
large	O
fluctuation	O
and	O
instability	O
in	O
a	O
cerebrospinal	O
pressure	O
compared	O
to	O
that	O
in	O
normal	O
persons,	O
and	O
the	O
disease	O
is	O
named	O
“unstable	O
cerebrospinal	O
pressure	O
syndrome”	O
.	O
The	O
therapeutic	O
agent	O
comprises	O
a	O
carbonic	B-GENE
anhydrase	I-GENE
inhibitor	O
as	O
an	O
active	O
ingredient	O
and	O
is	O
effective	O
on	O
unstable	O
cerebrospinal	O
pressure	O
syndrome	O
.	O
Since	O
a	O
carbonic	B-GENE
anhydrase	I-GENE
inhibitor	O
can	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
carbonic	B-GENE
anhydrase	I-GENE
and	O
therefore	O
is	O
effective	O
for	O
stabilization	O
of	O
a	O
cerebrospinal	O
pressure,	O
the	O
inhibitor	O
can	O
be	O
used	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
unstable	O
cerebrospinal	O
pressure	O
syndrome	O
.	O


It	O
has	O
been	O
found	O
that	O
compounds	O
of	O
formula	O
(	O
I-B	O
)	O
wherein,	O
in	O
preferred	O
embodiments,	O
X1	O
and	O
X2	O
are	O
N-H	O
or	O
N-	O
R3	O
or	O
N-R4,	O
RN	O
and	O
RC	O
are	O
both	O
H,	O
R1	O
and	O
R3	O
are	O
independently	O
from	O
each	O
other	O
optionally	O
substituted	O
phenyl,	O
or	O
R1	O
and	O
R2	O
and	O
/	O
or	O
R3	O
and	O
R4	O
form	O
together	O
with	O
the	O
N	O
to	O
which	O
R2	O
and	O
/	O
or	O
R4,	O
respectively,	O
are	O
bound	O
a	O
5	O
or	O
6	O
membered	O
heterocycle	O
comprising	O
1	O
or	O
2	O
heteroatoms,	O
and	O
A	O
is	O
preferably	O
halogen	O
substituted	O
phenyl	O
or	O
a	O
preferably	O
phenyl	O
substituted	O
furanyl	O
are	O
good	O
β-secretase	B-GENE
inhibitors	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O


Disclosed	O
are	O
:	O
a	O
pharmaceutical	O
composition	O
having	O
an	O
excellent	O
anti-tumor	O
effect	O
;	O
and	O
a	O
therapeutic	O
method	O
for	O
cancer	O
.	O
4-	O
(	O
3-Chloro-4-	O
(	O
cyclopropylaminocarbonyl	O
)	O
aminophenoxy	O
)	O
-7	O
-methoxy-6-quinolinecarboxamide	O
or	O
an	O
analogue	O
thereof	O
can	O
be	O
used	O
in	O
combination	O
with	O
a	O
substance	O
having	O
a	O
c-kit	B-GENE
kinase-inhibiting	O
activity	O
to	O
produce	O
an	O
excellent	O
anti-tumor	O
effect	O
.	O


The	O
present	O
invention	O
describes	O
a	O
method	O
or	O
uses	O
of	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
cancer	O
or	O
a	O
tumor,	O
and	O
in	O
particular	O
to	O
a	O
combination	O
therapy,	O
methods,	O
compositions	O
and	O
pharmaceutical	O
packages	O
comprising	O
an	O
inhibitor	O
of	O
receptors	O
of	O
the	O
EGFR	B-GENE
family	I-GENE
or	O
a	O
chemotherapeutically	O
active	O
pyrimidine	O
analogue	O
and	O
certain	O
platinum-based	O
chemotherapeutic	O
agents	O
.	O


The	O
present	O
invention	O
provides	O
a	O
oxazole	O
compound	O
represented	O
by	O
Formula	O
(	O
1	O
)	O
,	O
or	O
a	O
salt	O
thereof	O
:	O
wherein	O
R1	O
is	O
an	O
aryl	O
group	O
which	O
may	O
have	O
one	O
or	O
more	O
substituents	O
;	O
R2	O
is	O
an	O
aryl	O
group	O
or	O
a	O
nitrogen	O
atom-containing	O
heterocyclic	O
group	O
each	O
of	O
which	O
may	O
have	O
one	O
or	O
more	O
substituents	O
;	O
and	O
W	O
is	O
a	O
divalent	O
group	O
represented	O
by	O
-Y1-A1-	O
or	O
-Y2-C	O
(	O
=	O
O	O
)	O
-	O
wherein	O
Y1	O
is	O
a	O
group	O
such	O
as	O
-C	O
(	O
=	O
O	O
)	O
-,	O
A1	O
is	O
a	O
group	O
such	O
as	O
a	O
lower	O
alkylene	O
group,	O
and	O
Y2	O
is	O
a	O
group	O
such	O
as	O
a	O
piperazinediyl	O
group	O
.	O
The	O
oxazole	O
compound	O
has	O
a	O
specific	O
inhibitory	O
action	O
against	O
phosphodiesterase	B-GENE
4	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
individual	O
enantiomers	O
and	O
diastereomers	O
thereof,	O
as	O
GIyTl	B-GENE
inhibitors	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
combinations	O
with	O
improved	O
sodium	B-GENE
channel	I-GENE
blocking	O
effect	O
.	O
Further,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
said	O
pharmaceutical	O
combinations	O
in	O
neurodegenerative	O
disorders,	O
chronic	O
pain,	O
in	O
disturbances	O
of	O
the	O
motor	O
system,	O
in	O
epilepsy,	O
as	O
well	O
as	O
in	O
other	O
therapeutic	O
fields	O
where	O
the	O
use	O
of	O
sodium	B-GENE
channel	I-GENE
blockers	O
is	O
acceptable	O
.	O


4-Bromo-2-	O
[	O
1-	O
(	O
3,5-dichloropyridin-2-yl	O
)	O
-1H-pyrazole-4-carbonyl	O
]	O
-phenoxyacetic	O
acid,	O
4-bromo­2-	O
[	O
1-	O
(	O
3,5-dichloro-1-oxypyridin-4-yl	O
)	O
-1	O
H-pyrazole-4-carbonyl	O
]	O
-phenoxyacetic	O
acid,	O
4-bromo-2­	O
[	O
1	O
-	O
(	O
3,5-dichloro-2-hydroxypyridin-4-yl	O
)	O
-1	O
H-pyrazole-4-carbonyl	O
]	O
-phenoxyacetic	O
acid,	O
and	O
{	O
4­cyclopropyl-2-	O
[	O
1-	O
(	O
2,6-dichloro-phenyl	O
)	O
-1	O
H-pyrazole-4-carbonyl	O
]	O
-phenoxy	O
}	O
-acetic	O
acid	O
and	O
salts,	O
hydrates	O
and	O
solvates	O
thereof	O
are	O
ligands	O
of	O
the	O
CRTH2	B-GENE
receptor,	O
and	O
of	O
value	O
for	O
the	O
treatment	O
of,	O
inter	O
alia,	O
asthma,	O
rhinitis,	O
allergic	O
airway	O
syndrome,	O
or	O
allergic	O
rhinobronchitis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R4	O
and	O
G	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	B-GENE
receptors	I-GENE
.	O


The	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
wherein	O
:	O
m	O
is	O
0,	O
1	O
or	O
2	O
;	O
X	O
is	O
O,	O
S	O
or	O
N-CN	O
;	O
R	O
is	O
F,	O
Cl	O
or	O
CN	O
;	O
A	O
is	O
a	O
C3-6	O
cycloalkylene	O
group	O
optionally	O
substituted	O
with	O
a	O
C1-4	O
alkyl	O
group	O
;	O
and	O
B	O
is	O
a	O
single	O
bond	O
or	O
a	O
C1-2	O
alkylene	O
group	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
polymorph	O
or	O
prodrug	O
thereof	O
.	O
The	O
compounds	O
are	O
PDE7	B-GENE
inhibitors	O
and	O
have	O
a	O
number	O
of	O
therapeutic	O
applications,	O
particularly	O
in	O
the	O
treatment	O
of	O
pain,	O
especially	O
neuropathic	O
pain	O
.	O


The	O
present	O
invention	O
addresses	O
the	O
treatment	O
of	O
ocular	O
conditions	O
by	O
the	O
enhancement	O
of	O
lens	O
regeneration	O
.	O
This	O
is	O
accomplished	O
by	O
the	O
administration	O
of	O
a	O
high	O
viscosity	O
composition	O
including	O
a	O
hyaluronic	O
acid	O
compound	O
.	O
Excess	O
high	O
viscosity	O
composition	O
may	O
be	O
removed	O
by	O
focal	O
laser	O
photophacoablation	O
.	O
Additionally,	O
a	O
collagen	B-GENE
product	O
may	O
be	O
injected	O
within	O
the	O
lens	O
capsule	O
to	O
improve	O
lens	O
cell	O
proliferation	O
and	O
differentiation,	O
and	O
to	O
improve	O
the	O
configuration,	O
shape	O
and	O
structure	O
of	O
regenerated	O
lenses	O
.	O
Various	O
embodiments	O
involving	O
the	O
enhancement	O
of	O
lens	O
regeneration	O
are	O
described	O
.	O
For	O
example,	O
lens	O
regeneration	O
may	O
be	O
enhanced	O
by	O
filling	O
the	O
lens	O
capsule	O
bag	O
with	O
the	O
inventive	O
hyaluronic	O
acid	O
compound	O
;	O
by	O
inserting	O
at	O
least	O
one	O
collagen	B-GENE
patch	O
in	O
the	O
lens	O
capsule	O
;	O
and	O
/	O
or	O
by	O
injecting	O
a	O
collagen-based	O
product	O
into	O
the	O
lens	O
capsule	O
.	O


In	O
part,	O
the	O
present	O
invention	O
is	O
directed	O
towards	O
compounds	O
with	O
FabI	B-GENE
inhibiting	O
properties	O
.	O
Such	O
compounds	O
may	O
also	O
inhibit	O
other	O
enzymes,	O
including	O
those	O
similar	O
to	O
FabI	B-GENE
either	O
structurally	O
or	O
functionally,	O
for	O
example,	O
Fab	B-GENE
K	I-GENE
.	O
Kits	O
and	O
compositions	O
that	O
include	O
the	O
disclosed	O
compounds	O
are	O
also	O
provided	O
.	O
Methods	O
of	O
treating	O
a	O
subject	O
with	O
a	O
bacterial	O
illness	O
is	O
also	O
disclosed	O
.	O


A	O
method	O
of	O
treating	O
chronic	O
pain	O
in	O
a	O
mammal	O
is	O
provided	O
comprising	O
the	O
steps	O
of	O
inhibiting	O
CaMKIV	B-GENE
in	O
the	O
mammal	O
and	O
administering	O
to	O
the	O
mammal	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
opioid	O
.	O


This	O
invention	O
relates	O
to	O
the	O
combined	O
use	O
of	O
a	O
PDE5	B-GENE
inhibitor	O
and	O
a	O
5-alpha	B-GENE
reductase	I-GENE
antagonist	O
in	O
the	O
treatment	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
,	O
such	O
as	O
urgency,	O
frequency,	O
nocturia	O
and	O
urge	O
incontinence	O
.	O


This	O
invention	O
relates	O
to	O
the	O
combined	O
use	O
of	O
a	O
PDE5	B-GENE
inhibitor	O
and	O
a	O
muscarinic	B-GENE
antagonist	O
in	O
the	O
treatment	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
,	O
such	O
as	O
urgency,	O
frequency,	O
nocturia	O
and	O
urge	O
incontinence	O
.	O


A	O
pellet	O
composition	O
for	O
oral	O
administration	O
comprising	O
simultaneously	O
a	O
proton	B-GENE
pump	I-GENE
inhibitor,	O
a	O
clarithromycin	O
compound	O
and	O
an	O
amoxicillin	O
compound	O
.	O
Said	O
compositions	O
are	O
suitable	O
to	O
be	O
filled	O
in	O
sachets	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
Helicobacter	O
bacteria	O
.	O


This	O
invention	O
relates	O
to	O
substituted	O
bis-amide	O
pyrimidine	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metalloprotease	O
mediated	O
diseases,	O
in	O
particular	O
MMP-13	B-GENE
related	O
diseases	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
treatment	O
of	O
a	O
cognitive	O
disorder	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
which	O
comprises	O
providing	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
combination	O
of	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
a	O
5-hydroxytryptamine-6	B-GENE
antagonist	O
.	O


Compounds	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
are	O
inhibitors	O
of	O
mTOR	B-GENE
and	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
18-30	O
base-pair	O
double-stranded	O
RNA	O
which	O
induces	O
cell	O
death	O
of	O
a	O
human	O
cell	O
by	O
destroying	O
the	O
transcript	O
mRNA	O
of	O
Argonaute2	B-GENE
gene	O
in	O
the	O
cell	O
.	O
The	O
double-stranded	O
RNA	O
can	O
be	O
an	O
effective	O
material	O
for,	O
for	O
example,	O
cancer	O
therapy	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
diaza-bicyclo-alkane	O
derivatives,	O
which	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
and	I-GENE
modulators	O
of	O
the	O
monoamine	B-GENE
receptors	I-GENE
and	I-GENE
transporters	I-GENE
.	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-degeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O


The	O
present	O
invention	O
provided	O
a	O
kind	O
of	O
triazolyl-containing	O
oxazolidinone	O
derivatives	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts,	O
preparation	O
method	O
and	O
the	O
uses	O
for	O
the	O
manufacture	O
of	O
medicament	O
for	O
the	O
treatment	O
of	O
infectious	O
diseases,	O
especially	O
the	O
infectious	O
diseases	O
caused	O
by	O
Multi-drug	O
resistant	O
bacteria	O
.	O
The	O
triazolyl-containing	O
oxazolidinone	O
derivatives	O
of	O
the	O
present	O
application,	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
have	O
excellent	O
antibiotic	O
activity	O
and	O
metabolic	O
activity	O
in	O
vitro	O
or	O
in	O
vivo,	O
they	O
can	O
decrease	O
the	O
inhibitory	O
activity	O
of	O
C-5	O
acetamido	O
oxazolidinone	O
derivatives	O
to	O
MAO-A,	O
so	O
that	O
the	O
clinical	O
negative	O
reactions	O
of	O
these	O
medicaments	O
are	O
decreased	O
.	O


This	O
invention	O
discloses	O
the	O
substituted	O
[	O
1,3,5	O
]	O
triazine	O
compounds	O
of	O
following	O
formula,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
or	O
hydrates,	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
and	O
the	O
uses	O
thereof	O
.	O
The	O
compositions	O
of	O
the	O
present	O
invention	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
inflammation	O
diseases,	O
which	O
have	O
good	O
effect	O
.	O
The	O
substituted	O
[	O
1,3,5	O
]	O
triazine	O
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
show	O
remarkable	O
EGFR	B-GENE
enzyme	O
inhibitory	O
activity	O
and	O
antitumor	O
activity	O
in	O
a	O
serious	O
of	O
selective	O
tests	O
of	O
EGFR	B-GENE
enzyme	O
level	O
and	O
tumor	O
cell	O
level	O
(	O
human	O
HT-29	O
and	O
HCT-116	O
)	O
.	O
So	O
The	O
compositions	O
of	O
the	O
present	O
invention	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
and	O
/	O
or	O
aid	O
treatment	O
of	O
tumor	O
diseases	O
.	O


The	O
present	O
inventors	O
found	O
that	O
a	O
polypeptide	O
comprising	O
an	O
amino	O
acid	O
sequence	O
shown	O
in	O
any	O
one	O
of	O
SEQ	O
ID	O
NOS	O
:	O
1	O
to	O
6	O
binds	O
to	O
PILRα	B-GENE
and	O
that	O
the	O
polypeptide	O
activates	O
an	O
immune	O
cell	O
or	O
suppresses	O
the	O
activation	O
of	O
the	O
immune	O
cell	O
.	O
The	O
polypeptide	O
can	O
be	O
preferably	O
applied	O
to	O
a	O
pharmaceutical	O
or	O
the	O
like	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
or	O
its	O
salt	O
:	O
(	O
1	O
)	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O
The	O
above-described	O
compound	O
or	O
its	O
salt	O
can	O
preferentially	O
induce	O
the	O
production	O
of	O
IL-4	B-GENE
that	O
is	O
one	O
of	O
cytokines	O
controlling	O
the	O
functions	O
of	O
immunocytes,	O
which	O
makes	O
them	O
useful	O
in	O
preventing	O
and	O
treating	O
autoimmune	O
diseases,	O
infections	O
and	O
so	O
on	O
and	O
preventing	O
and	O
treating	O
diseases	O
caused	O
by	O
the	O
hyperfunction	O
of	O
Th1	O
cells	O
.	O
.	O


Compositions	O
for	O
cosmetic,	O
pharmaceutical,	O
food	O
or	O
veterinary	O
use,	O
intended	O
to	O
delay	O
ageing	O
in	O
mammals	O
through	O
their	O
activating	O
action	O
on	O
genes	O
of	O
Sirtuin	B-GENE
type,	O
which	O
genes	O
are	O
naturally	O
activated	O
during	O
calorie	O
restriction	O
.	O
These	O
compositions	O
are	O
characterized	O
in	O
that	O
they	O
contain	O
one	O
or	O
more	O
oligomers	O
of	O
resveratrol,	O
and	O
more	O
particularly	O
ε-viniferin,	O
and	O
/	O
or	O
glucosides	O
and	O
/	O
or	O
the	O
corresponding	O
esters	O
of	O
these	O
oligomers	O
and	O
/	O
or	O
the	O
natural	O
extracts	O
containing	O
them	O
.	O
It	O
has	O
been	O
shown,	O
on	O
several	O
living	O
species,	O
that	O
calorie	O
restriction	O
extends	O
the	O
lifespan	O
and	O
reduces	O
the	O
deleterious	O
effects	O
of	O
ageing	O
.	O
Studies	O
on	O
primates	O
and	O
on	O
human	O
populations	O
have	O
corroborated	O
these	O
results	O
.	O
It	O
has	O
also	O
been	O
shown	O
that	O
calorie	O
restriction	O
activates	O
certain	O
genes	O
called	O
Sirtuins	B-GENE
(	O
silent	O
information	O
regulator	O
)	O
.	O
Consequently,	O
natural	O
or	O
synthetic	O
ingredients	O
or	O
molecules	O
which	O
activate	O
genes	O
and	O
make	O
it	O
possible	O
to	O
do	O
without	O
a	O
difficult	O
long-term	O
calorie	O
restriction	O
have	O
been	O
sought	O
.	O
Resveratrol	O
or	O
3,4	O
'	O
,5-trihydroxystilbene	O
is	O
known	O
to	O
activate	O
certain	O
genes	O
of	O
the	O
Sirtuin	B-GENE
family	O
.	O
The	O
present	O
invention	O
describes,	O
for	O
the	O
first	O
time,	O
the	O
activation	O
of	O
these	O
genes	O
by	O
oligomers	O
of	O
resveratrol,	O
in	O
particular	O
Pε-viniferin	O
.	O
A	O
specific	O
test	O
has	O
been	O
carried	O
out	O
and	O
shows	O
that	O
Pε-viniferin	O
and	O
an	O
extract	O
of	O
vine	O
shoot	O
containing	O
it,	O
and	O
also	O
other	O
oligomers	O
of	O
resveratrol,	O
completely	O
activate	O
the	O
SIRTl	B-GENE
enzyme	O
.	O
Cosmetic,	O
pharmaceutical,	O
food	O
and	O
veterinary	O
compositions	O
are	O
described	O
by	O
way	O
of	O
examples	O
.	O
The	O
cosmetic	O
composition	O
described,	O
and	O
which	O
contains	O
an	O
extract	O
of	O
vine	O
shoot,	O
was	O
subjected	O
to	O
tests	O
which	O
showed	O
that	O
it	O
is	O
completely	O
innocuous	O
on	O
human	O
skin	O
.	O
It	O
was	O
also	O
subjected	O
to	O
a	O
test	O
on	O
humans	O
showing	O
its	O
effectiveness	O
in	O
decreasing	O
the	O
effects	O
of	O
ageing	O
.	O
The	O
invention	O
claims	O
cosmetic,	O
pharmaceutical,	O
food	O
and	O
veterinary	O
compositions	O
whose	O
activating	O
action	O
on	O
Sirtuin	B-GENE
genes	O
makes	O
it	O
possible	O
to	O
delay	O
ageing	O
in	O
mammals	O
and	O
combat	O
the	O
harmful	O
effects	O
thereof	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
means	O
which	O
is	O
efficacious	O
in	O
digesting	O
a	O
protein	O
forming	O
aggregates	O
in	O
a	O
eukaryotic	O
cell	O
such	O
as	O
mutant	B-GENE
superoxide	I-GENE
dismutase	I-GENE
1	I-GENE
or	O
an	O
androgen	B-GENE
receptor	I-GENE
having	O
an	O
abnormally	O
extended	O
polyglutamine	O
chain	O
.	O
Namely,	O
an	O
expression	O
construct	O
for	O
digesting	O
an	O
aggregating	O
protein	O
which	O
has	O
a	O
nucleic	O
acid	O
encoding	O
an	O
archaeal	O
proteasome	O
and	O
being	O
connected	O
in	O
an	O
operable	O
manner	O
to	O
a	O
promoter	O
for	O
eukaryotic	O
cells	O
.	O
By	O
transferring	O
this	O
expression	O
construct	O
into	O
a	O
eukaryotic	O
cell,	O
the	O
aggregating	O
protein	O
is	O
digested	O
owing	O
to	O
the	O
action	O
of	O
the	O
archaeal	O
proteasome	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
method	O
for	O
inhibiting	O
activation	O
of	O
signal	O
transduction	O
pathway	O
through	O
erbB1	B-GENE
or	O
erbB2	B-GENE
in	O
human	O
cells	O
and	O
a	O
signal	O
transduction	O
inhibitor	O
to	O
be	O
used	O
in	O
the	O
method	O
.	O
The	O
activation	O
of	O
signal	O
transduction	O
pathway	O
can	O
be	O
inhibited	O
by	O
a	O
polypeptide	O
containing	O
at	O
least	O
either	O
one	O
of	O
PTB	B-GENE
domain	I-GENE
of	O
human	B-GENE
FRS2β	I-GENE
or	O
ERK2-binding	B-GENE
domain	I-GENE
.	O
The	O
polypeptide	O
may	O
be	O
introduced	O
to	O
a	O
cell	O
as	O
such	O
or	O
a	O
nucleic	O
acid	O
encoding	O
the	O
polypeptide	O
may	O
be	O
introduced	O
to	O
a	O
cell	O
to	O
express	O
the	O
polypeptide	O
therein	O
.	O
Such	O
a	O
polypeptide	O
or	O
nucleic	O
acid	O
can	O
be	O
used	O
as,	O
for	O
example,	O
a	O
signal	O
transduction	O
inhibitor	O
.	O
Further,	O
erbB1	B-GENE
and	O
erbB2	B-GENE
are	O
involved	O
in	O
occurrence	O
of	O
cancer,	O
therefore,	O
the	O
signal	O
transduction	O
inhibitor	O
is	O
also	O
useful	O
as,	O
for	O
example,	O
an	O
anticancer	O
agent	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
straight	O
chain,	O
branched	O
or	O
cyclic	O
aliphatic,	O
aromatic	O
or	O
heterocyclyl	O
group	O
comprising	O
at	O
least	O
8	O
carbon	O
atoms,	O
e	O
.	O
g	O
.	O
8	O
to	O
22,	O
R2	O
is	O
a	O
straight	O
chain,	O
branched	O
or	O
cyclic	O
aliphatic,	O
aromatic	O
or	O
heterocyclic	O
group	O
comprising	O
from	O
1	O
to	O
12	O
carbon	O
atoms,	O
and	O
ring	O
A	O
is	O
heterocycyl,	O
fused	O
with	O
the	O
phenyl	O
ring	O
to	O
which	O
ring	O
A	O
is	O
attached	O
comprising	O
5	O
or	O
6	O
ring	O
members,	O
and	O
1	O
to	O
4	O
heteroatoms	O
selected	O
from	O
N,S,O	O
;	O
wherein	O
certain	O
compounds	O
are	O
excluded	O
by	O
proviso	O
and	O
the	O
use	O
of	O
such	O
compounds	O
without	O
proviso	O
as	O
pharmaceuticals	O
in	O
disorders	O
which	O
are	O
mediated	O
by	O
ceramide	B-GENE
kinase	I-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
polymorphic	O
forms	O
and	O
amorphous	O
form	O
of	O
(	O
2R,Z	O
)	O
-2-amino-2-cyclohexyl-N-	O
(	O
5-	O
(	O
1-methyl-1H-pyrazol-4-yl	O
)	O
-1-oxo-2,6-dihydro-1H-	O
[	O
1,2	O
]	O
diazepino	O
[	O
4,5,6-cd	O
]	O
indol-8-yl	O
)	O
acetamide,	O
and	O
to	O
processes	O
for	O
their	O
preparation	O
.	O
Such	O
polymorphic	O
forms	O
and	O
amorphous	O
form	O
may	O
be	O
a	O
component	O
of	O
a	O
pharmaceutical	O
composition	O
and	O
may	O
be	O
used	O
to	O
treat	O
a	O
cancer	O
or	O
a	O
mammalian	O
disease	O
condition	O
mediated	O
by	O
protein	B-GENE
kinase	I-GENE
activity	O
.	O
Formula	O
(	O
I	O
)	O
.	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
below,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
salt,	O
which	O
is	O
useful	O
as	O
an	O
inhibitor	O
of	O
11β-hydroxysteroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
I	I-GENE
.	O
wherein	O
R1	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
-C	O
(	O
=	O
O	O
)	O
NR4R5	O
(	O
wherein	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen,	O
an	O
alkyl	O
which	O
may	O
be	O
substituted,	O
or	O
the	O
like	O
)	O
or	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
-NR6C	O
(	O
=	O
O	O
)	O
R7	O
(	O
wherein	O
R6	O
and	O
R7	O
independently	O
represent	O
a	O
hydrogen,	O
an	O
alkyl	O
which	O
may	O
be	O
substituted,	O
or	O
the	O
like	O
)	O
;	O
X	O
and	O
Y	O
independently	O
represent	O
-O-	O
or	O
the	O
like	O
;	O
Z	O
represents	O
a	O
single	O
bond	O
or	O
the	O
like	O
;	O
R2	O
represents	O
an	O
alkyl	O
which	O
may	O
be	O
substituted,	O
an	O
alkenyl	O
which	O
may	O
be	O
substituted,	O
or	O
the	O
like	O
;	O
and	O
R3	O
represents	O
an	O
alkyl	O
which	O
may	O
be	O
substituted,	O
an	O
alkenyl	O
which	O
may	O
be	O
substituted,	O
or	O
the	O
like	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
3,4-diamino-3-cyclobutene-1,2-dione	O
derivatives,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
related	O
to	O
potassium	B-GENE
channel	I-GENE
.	O


A	O
novel	O
class	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
in	O
therapy,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
.	O
The	O
present	O
compounds	O
modulate	O
the	O
activity	O
of	O
11β-hydroxy-steroid	B-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11βHSD1	B-GENE
)	O
and	O
are	O
accordingly	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
such	O
a	O
modulation	O
is	O
beneficial,	O
e	O
.	O
g	O
.	O
the	O
metabolic	O
syndrome	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
are	O
agonists	O
of	O
GPR119	B-GENE
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
as	O
peripheral	O
regulators	O
of	O
satiety,	O
e	O
.	O
g	O
.	O
for	O
the	O
treatment	O
of	O
obesity	O
and	O
metabolic	O
syndrome	O
.	O


The	O
present	O
invention	O
relates	O
to	O
aryloxyethylamine	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
the	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
thereof	O
.	O
The	O
variables	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
the	O
description	O
.	O
The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
a	O
medical	O
disorder	O
susceptible	O
to	O
treatment	O
with	O
a	O
dopamine	B-GENE
D3	I-GENE
receptor	I-GENE
ligand	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
a	O
central	O
nervous	O
system	O
disorder	O
related	O
to	O
or	O
affected	O
by	O
the	O
5-HT6	B-GENE
receptor	O
.	O


The	O
invention	O
encompasses	O
compounds	O
of	O
Formula	O
I,	O
including	O
pharmaceutically	O
acceptable	O
salts,	O
their	O
pharmaceutical	O
compositions,	O
and	O
their	O
use	O
in	O
treating	O
disorders	O
associated	O
with	O
an	O
excess	O
or	O
imbalance	O
of	O
tachykinins	B-GENE
or	O
serotonin	O
or	O
both	O
.	O


The	O
invention	O
relates	O
to	O
chemical	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
possess	O
Edg-1	B-GENE
antagonistic	O
activity	O
and	O
are	O
accordingly	O
useful	O
for	O
their	O
anti	O
cancer	O
activity	O
and	O
thus	O
in	O
methods	O
of	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
chemical	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
of	O
use	O
in	O
the	O
production	O
of	O
an	O
anti-cancer	O
effect	O
in	O
a	O
warm	O
blooded	O
animal	O
such	O
as	O
man	O
.	O


Provide	O
is	O
a	O
method	O
for	O
preparing	O
low	O
molecular	O
weight	O
proteoglycan	O
and	O
collagen	B-GENE
compostions,	O
which	O
comprises	O
the	O
steps	O
of	O
choosing	O
material	O
and	O
cleaning,	O
smash	O
and	O
homogenization,	O
proteolysis,	O
catalysis,	O
sterilization	O
and	O
disinfection,	O
filtration	O
or	O
ultrafiltration,	O
concentration,	O
drying	O
and	O
packaging	O
.	O
The	O
obtained	O
products	O
can	O
be	O
used	O
for	O
manufacturing	O
medical	O
and	O
health	O
products,	O
cosmetics,	O
preventing	O
and	O
treating	O
arthrosis	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
1,4-diaza-bicyclo	O
[	O
3	O
.	O
2	O
.	O
2	O
]	O
nonane	O
derivatives,	O
which	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
and	O
modulators	O
of	O
the	O
monoamine	B-GENE
receptors	I-GENE
and	O
transporters	B-GENE
.	O
Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction,	O
endocrine	O
diseases	O
or	O
disorders,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-degeneration,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation,	O
pain,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
Het	O
has	O
the	O
meaning	O
given	O
in	O
the	O
description,	O
as	O
well	O
as	O
salts	O
and	O
enantiomers	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds,	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
in	O
therapy,	O
e	O
.	O
g	O
.	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O
The	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
.	O
The	O
compounds	O
are	O
neurokinin	B-GENE
(NK)	I-GENE
receptor	I-GENE
antagonists	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
sterol	O
absorption	O
inhibitor,	O
a	O
CETP	B-GENE
inhibitor,	O
which	O
may	O
further	O
comprise	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor	O
as	O
well	O
as	O
methods	O
for	O
treating	O
sitosterolemia,	O
hypercholesterolemia,	O
hyperlipidemia,	O
atherosclerosis,	O
mixed	O
dyslopidemia,	O
vascular	O
events	O
prevention	O
and	O
related	O
disorders	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
by	O
administering	O
said	O
pharmaceutical	O
compositions	O
to	O
the	O
mammal	O
.	O


The	O
invention	O
relates	O
to	O
substituted	O
pyrazolopyridines	O
according	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
A,	O
B,	O
D,	O
E,	O
Ra,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5	O
and	O
q	O
are	O
as	O
defined	O
in	O
the	O
claims,	O
and	O
salts	O
thereof,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
substituted	O
pyrazolopyridine	O
compounds,	O
to	O
methods	O
of	O
preparing	O
said	O
substituted	O
pyrazolopyridines,	O
as	O
well	O
as	O
to	O
uses	O
thereof	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
dysregulated	O
vascular	O
growth	O
or	O
of	O
diseases	O
which	O
are	O
accompanied	O
with	O
dysregulated	O
vascular	O
growth,	O
wherein	O
the	O
compounds	O
effectively	O
interfere	O
with	O
Tie2	B-GENE
signalling	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
R3,	O
Ra	O
and	O
E	O
are	O
are	O
defined	O
within,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates	O
and	O
N-oxides	O
thereof	O
having	O
utility	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
cathepsin	B-GENE
S	I-GENE
.	O


Disclosed	O
is	O
a	O
method	O
for	O
screening	O
for	O
a	O
therapeutic	O
agent	O
for	O
cancer,	O
comprising	O
the	O
steps	O
of	O
adding	O
a	O
candidate	O
substance	O
to	O
a	O
test	O
system	O
in	O
the	O
presence	O
of	O
a	O
cancer	O
gene	O
product	O
Rda9	O
and	O
a	O
cancer	O
suppressor	O
gene	O
product	O
p53	B-GENE
and	O
selecting	O
a	O
biologically	O
active	O
substance	O
capable	O
of	O
controlling	O
the	O
binding	O
between	O
Rda9	O
and	O
p53	B-GENE
.	O
	O
Also	O
disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
cancer,	O
which	O
an	O
control	O
the	O
binding	O
between	O
Rda9	O
and	O
p53	B-GENE
.	O


The	O
invention	O
relates	O
to	O
novel	O
kinase	B-GENE
inhibitors	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Q	O
and	O
R1	O
are	O
defined	O
as	O
in	O
the	O
claims	O
.	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
producing	O
said	O
inhibitors,	O
to	O
intermediates	O
for	O
producing	O
the	O
same	O
and	O
to	O
uses	O
thereof	O
.	O


A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof,	O
which	O
is	O
useful	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
pharmaceutical	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
disease	O
induced	O
by	O
the	O
activation	O
of	O
STAT6	B-GENE
and	O
/	O
or	O
NF-κB	B-GENE
.	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3	O
and	O
R4	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
nitro	O
group,	O
a	O
C1-4	O
alkyl	O
group,	O
a	O
halogenated	O
C1-4	O
alkyl	O
group,	O
or	O
a	O
C1-4	O
alkoxy	O
group	O
;	O
R5	O
represents	O
a	O
halogen	O
atom,	O
a	O
cyano	O
group,	O
a	O
C1-4	O
alkyl	O
group,	O
a	O
halogenated	O
C1-4	O
alkyl	O
group,	O
or	O
a	O
C1-4	O
alkoxy	O
group	O
;	O
R6represents	O
a	O
C5-7	O
cycloalkyl	O
group,	O
a	O
substituted	O
C5-7	O
cycloalkyl	O
group,	O
a	O
completely	O
saturated	O
5-	O
to	O
7-membered	O
heterocyclic	O
group	O
or	O
a	O
substituted,	O
completely	O
saturated	O
5-	O
to	O
7-membered	O
heterocyclic	O
group	O
;	O
X	O
represents	O
a	O
single	O
bond,	O
an	O
oxygen	O
atom,	O
a	O
sulfur	O
atom,	O
NR7,	O
-O-CH2	O
or	O
–N	O
(	O
R8	O
)	O
-CH2-	O
;	O
R7	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-4	O
alkyl	O
group,	O
or	O
together	O
with	O
a	O
substituent	O
in	O
R6	O
forms	O
a	O
single	O
bond,	O
a	O
methylene	O
group	O
or	O
an	O
ethylene	O
group	O
;	O
and	O
R8	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-4	O
alkyl	O
group,	O
or	O
a	O
C7-12	O
aralkyl	O
group	O
.	O


The	O
present	O
application	O
has	O
disclosed	O
2,4,5-trisubstituted	O
thiazole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
all	O
possible	O
isomers,	O
pharmaceutically	O
acceptable	O
salts,	O
produgs,	O
solvates	O
or	O
hydrates	O
thereof,in	O
which	O
the	O
definitions	O
of	O
substituents	O
are	O
illuminated	O
as	O
description	O
.	O
The	O
compounds	O
have	O
the	O
activity	O
of	O
inhibiting	O
PLTP	B-GENE
and	O
/	O
or	O
CETP	B-GENE
of	O
blood	O
plasma	O
.	O
The	O
present	O
application	O
has	O
also	O
disclosed	O
preparation	O
methods	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same,	O
as	O
well	O
as	O
their	O
medical	O
uses	O
in	O
preparation	O
of	O
medicament	O
which	O
are	O
used	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
mammal	O
diseases	O
related	O
to	O
raising	O
PLTP	B-GENE
and	O
/	O
or	O
CETP	B-GENE
activity	O
of	O
blood	O
plasma,	O
such	O
as	O
atherosclerosis,	O
cardiovascular	O
diseases	O
and	O
peripheral	O
vascular	O
diseases	O
et	O
al	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
gastrointestinal	O
motility	O
disorder	O
in	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
comprising	O
coadministering	O
an	O
effective	O
amount	O
of	O
a	O
5-HT3	B-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof	O
and	O
an	O
effective	O
amount	O
of	O
a	O
GABA	B-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate	O
or	O
solvate	O
thereof	O
.	O
Preferably,	O
the	O
subject	O
is	O
a	O
human	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
of	O
increasing	O
esophageal	O
motility	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
comprising	O
coadministering	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
5-HT3	B-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof	O
and	O
an	O
effective	O
amount	O
of	O
a	O
GABA	B-GENE
receptor	I-GENE
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
hydrate,	O
or	O
solvate	O
thereof	O
.	O


Compounds	O
of	O
the	O
formulae	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
CCRl	B-GENE
antagonists	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O
Other	O
embodiments	O
are	O
also	O
disclosed	O
.	O


Antagonists	O
of	O
S1P3	B-GENE
(	O
Edg-3	B-GENE
)	O
receptors	O
are	O
provided	O
for	O
attenuation	O
of	O
Smad	O
signaling	O
in	O
a	O
method	O
of	O
down-regulation	O
of	O
receptor	O
signaling	O
and	O
downstream	O
decreased	O
production	O
of	O
connective	B-GENE
tissue	I-GENE
growth	I-GENE
factor	I-GENE
in	O
ocular	O
disorders	O
involving	O
CTGF	B-GENE
accumulation	O
.	O
Ocular	O
disorders	O
involving	O
inappropriate	O
CTGF	B-GENE
accumulation	O
include	O
ocular	O
hypertension,	O
glaucoma,	O
glaucomatous	O
retinopathy,	O
optic	O
neuropathy,	O
macular	O
degeneration,	O
diabetic	O
retinopathy,	O
choroidal	O
neovascularization,	O
proliferative	O
vitreoretinopathy	O
and	O
ocular	O
wound	O
healing,	O
for	O
example	O
.	O
Such	O
disorders	O
are	O
treated	O
by	O
administering	O
antagonists	O
of	O
the	O
present	O
invention	O
.	O


A	O
method	O
of	O
treating	O
a	O
FLT3-mediated	O
condition	O
in	O
a	O
patient	O
in	O
need	O
thereof,	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
(	O
I	O
)	O
,	O
The	O
conditions	O
that	O
can	O
be	O
treated	O
by	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
and	O
the	O
definitions	O
for	O
the	O
variables	O
in	O
formula	O
(	O
I	O
)	O
are	O
provided	O
herein	O
.	O


Disclosed	O
is	O
a	O
novel	O
compound	O
which	O
has	O
an	O
excellent	O
inhibitory	O
activity	O
on	O
IκB	B-GENE
kinase	I-GENE
and	O
is	O
intended	O
to	O
be	O
use	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
a	O
disease	O
associated	O
with	O
NF-κB	B-GENE
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
Also	O
disclosed	O
is	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
or	O
the	O
salt	O
.	O
(	O
1	O
)	O
wherein	O
R1	O
represents	O
a	O
phenyl,	O
heterocyclic,	O
C1-C6	O
alkyl,	O
C1-C6	O
alkoxy,	O
phenoxy	O
or	O
C1-C6	O
alkylamino	O
group	O
which	O
may	O
be	O
substituted	O
;	O
and	O
R2	O
represents	O
an	O
amino	O
or	O
mercapto	O
group	O
which	O
may	O
be	O
substituted	O
.	O


Disclosed	O
are	O
compounds	O
of	O
formula	O
(	O
IA	O
)	O
,	O
formula	O
(	O
IV	O
)	O
or	O
formula	O
(	O
V	O
)	O
,	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
which	O
are	O
useful	O
for	O
treating	O
a	O
subject	O
with	O
a	O
proliferative	O
disorder,	O
such	O
as	O
cancer	O
.	O
The	O
disclosed	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
also	O
useful	O
for	O
treating	O
disorders	O
responsive	O
to	O
Hsp70	B-GENE
induction	O
and	O
/	O
or	O
natural	O
killer	O
induction	O
.	O


The	O
antibiotics	O
composition	O
comprising	O
at	O
least	O
one	O
of	O
beta-lactam	O
antibiotics	O
and	O
buffers,	O
further	O
comprising	O
at	O
least	O
one	O
of	O
beta-lactamase	B-GENE
inhibitors	O
.	O
The	O
composition	O
can	O
be	O
formulated	O
with	O
at	O
least	O
one	O
of	O
aminoglycoside	O
antibiotics	O
into	O
solution	O
for	O
controlling	O
microbial	O
infection	O
in	O
a	O
container	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
have	O
HSP90	B-GENE
inhibitory	O
activity	O
:	O
ring	O
A	O
is	O
an	O
aryl	O
or	O
heteroaryl	O
ring	O
or	O
ring	O
system	O
;	O
R1	O
is	O
hydrogen,	O
fluoro,	O
chloro,	O
bromo,	O
or	O
a	O
radical	O
of	O
formula	O
(	O
1A	O
)	O
:	O
-X-Alk1-	O
(	O
Z	O
)	O
m-	O
(	O
Alk2	O
)	O
n-Q	O
(	O
IA	O
)	O
wherein	O
X	O
is	O
a	O
bond,	O
-O-,	O
-S-,	O
-S	O
(	O
O	O
)	O
-,	O
-SO2-,	O
or	O
-NH-,	O
Z	O
is	O
-O-,	O
-S-,	O
-	O
(	O
C	O
=	O
O	O
)	O
-,	O
-	O
(	O
C	O
=	O
S	O
)	O
-,	O
-S	O
(	O
O	O
)	O
-,	O
-SO2-,	O
-NRA-,	O
or,	O
in	O
either	O
orientation	O
-C	O
(	O
=	O
O	O
)	O
O-,	O
-C	O
(	O
=	O
O	O
)	O
NRA-,	O
-C	O
(	O
=	O
S	O
)	O
NRA-,	O
-SO2NRA-,	O
-NRAC	O
(	O
=	O
O	O
)	O
-,	O
or	O
-NRASO2-	O
wherein	O
RA	O
is	O
hydrogen	O
or	O
C1-C6	O
alkyl	O
in	O
which	O
one	O
or	O
more	O
hydrogens	O
is	O
optionally	O
substituted	O
by	O
fluorine	O
;	O
Alk1	O
and	O
AIk2	O
are	O
optionally	O
substituted	O
divalent	O
C1-C3	O
alkylene	O
:	O
or	O
C2-C3	O
alkenylene	O
radicals,	O
m	O
and	O
n	O
are	O
independently	O
0	O
or	O
1,	O
and	O
Q	O
is	O
hydrogen	O
or	O
an	O
optionally	O
substituted	O
carbocyclic	O
or	O
heterocyclic	O
radical	O
;	O
R2	O
is	O
cyano	O
(	O
-CN	O
)	O
,	O
fluoro,	O
chloro,	O
bromo,	O
methyl,	O
ethyl,	O
-OH,	O
-CH2OH,	O
-C	O
(	O
=	O
O	O
)	O
NH2,-C	O
(	O
=	O
O	O
)	O
H,	O
-C	O
(	O
=	O
O	O
)	O
CH3,	O
or	O
-NH2	O
;	O
R3	O
and	O
R4	O
are	O
independently	O
selected	O
from	O
hydrogen,	O
fluoro,	O
chloro,	O
bromo,	O
cyano	O
(	O
-CN	O
)	O
,	O
C1-C3alkyl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
fluorine	O
substituents,	O
C1-C3alkoxy	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
fluorine	O
substituents,	O
-CH	O
=	O
CH2,	O
-C≡CH,	O
cyclopropyl	O
and	O
-NH2,	O
or	O
R3	O
and	O
R4	O
together	O
represent	O
methylenedioxy	O
(	O
-OCH2O-	O
)	O
or	O
ethylenedioxy	O
(	O
-OCH2CH2O-	O
)	O
in	O
either	O
of	O
which	O
one	O
or	O
more	O
hydrogens	O
are	O
optionally	O
replaced	O
by	O
fluorine	O
;	O
S1	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O


The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
an	O
estrogen	O
responsive	O
condition	O
using	O
an	O
agonist	O
of	O
an	O
orphan	B-GENE
nuclear	I-GENE
receptor,	O
wherein	O
the	O
orphan	B-GENE
nuclear	I-GENE
receptor	I-GENE
is	O
an	O
inhibitor	O
of	O
estrogen	O
activity	O
.	O
The	O
invention	O
further	O
provides	O
methods	O
for	O
reducing	O
the	O
size	O
of	O
tumors	O
associated	O
with	O
estrogen	O
responsive	O
conditions	O
.	O


Methods	O
of	O
inhibiting	O
BTK	B-GENE
activity	O
by	O
inhibiting	O
phosphorylation	O
of	O
Y551	B-GENE
of	O
BTK,	O
methods	O
of	O
treating	O
patients	O
by	O
inhibiting	O
BTK	B-GENE
activity	O
by	O
inhibiting	O
phosphorylation	O
of	O
Y551	B-GENE
of	O
BTK,	O
chemical	O
entities	O
that	O
bind	O
to	O
BTK	B-GENE
and	O
inhibited	O
complexes	O
are	O
provided	O
.	O


A	O
therapeutic	O
formulation	O
comprising	O
of	O
Alphaglucosidase	B-GENE
Inhibitors	O
as	O
active	O
agents	O
namely,	O
Acarbose	O
and	O
Miglitol,	O
characterized	O
in	O
that	O
said	O
Alphaglucosidase	B-GENE
Inhibitors	O
are	O
combined	O
or	O
complexated	O
with	O
NO	O
Scavenger	O
to	O
prevent	O
Diabetic	O
Complications	O
arising	O
out	O
of	O
Nitrosative	O
stress	O
.	O


A	O
nucleic	O
acid	O
molecule	O
comprising	O
a	O
nucleotide	O
sequence	O
configured	O
for	O
controllable	O
expression	O
of	O
a	O
mammalian	B-GENE
cysteine	I-GENE
protease	I-GENE
suitable	O
for	O
enhancing	O
an	O
immune	O
response	O
directed	O
against	O
Mycobacterium	O
A	O
recombinant	O
Mycobacterium	O
Bacille	O
Calmette-Guerm	O
(	O
BCG	O
)	O
provided	O
with	O
the	O
nucleic	O
acid	O
molecule	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
recombinant	O
BCG	O
are	O
suitable	O
for	O
use	O
in	O
immunotherapy	O
and	O
in	O
vaccinations	O
against	O
tuberculosis	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof,	O
or	O
a	O
hydrate	O
or	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
salt,	O
which	O
has	O
an	O
inhibitory	O
activity	O
on	O
plasminogen	B-GENE
activator	I-GENE
inhibitor-1	I-GENE
(	O
PAI-1	B-GENE
)	O
.	O
(	O
I	O
)	O
wherein	O
R1	O
represents	O
a	O
C6-10	O
aryl	O
group	O
or	O
a	O
substituted	O
C6-10	O
aryl	O
group	O
;	O
R2	O
represents	O
a	O
C6-10	O
aryl	O
group	O
or	O
a	O
C6-10	O
aryl	O
group	O
substituted	O
by	O
a	O
group	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
halogen	O
atom,	O
a	O
nitro	O
group,	O
a	O
C1-6	O
alkyl	O
group,	O
a	O
halogenated	O
C1-6	O
alkyl	O
group,	O
a	O
C1-6	O
alkoxy	O
group,	O
a	O
halogenated	O
C1-6	O
alkoxy	O
group,	O
a	O
phenyl	O
groupand	O
a	O
carboxy	O
group	O
;	O
X	O
represents	O
-CH2-,	O
-CH2CH2-,	O
-CH	O
=	O
CH-	O
or	O
-N	O
(	O
R3	O
)	O
-C	O
(	O
=	O
O	O
)	O
-	O
;	O
Y	O
represents	O
a	O
carboxy	O
group	O
or	O
a	O
biological	O
equivalent	O
of	O
a	O
carboxy	O
group	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-4	O
alkyl	O
group	O
or	O
a	O
C7-12	O
aralkyl	O
group	O
;	O
and	O
m	O
represents	O
a	O
number	O
of	O
0	O
or	O
1	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
G1,	O
G2,	O
Y,	O
n,	O
and	O
Ar1	O
are	O
as	O
defined	O
in	O
the	O
specification,	O
pharmaceutical	O
compositions	O
containing	O
said	O
compounds	O
useful	O
as	O
calcium	B-GENE
channel	I-GENE
antagonists,	O
and	O
to	O
methods	O
of	O
causing	O
vasodilation	O
of	O
treating	O
a	O
disease	O
selected	O
from	O
hypertension,	O
congestive	O
heart	O
failure,	O
stroke,	O
ischaemic	O
heart	O
disease,	O
and	O
angina	O
pectoris	O
and	O
of	O
reducing	O
myocardial	O
tissue	O
damage	O
(	O
e	O
.	O
g	O
.	O
,	O
substantially	O
preventing	O
tissue	O
damage,	O
inducing	O
tissue	O
protection	O
)	O
during	O
surgery	O
(	O
e	O
.	O
g	O
.	O
,	O
coronary	O
artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
surgeries,	O
vascular	O
surgeries,	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
or	O
any	O
percutaneous	O
transluminal	O
coronary	O
intervention	O
(	O
PTCI	O
)	O
,	O
organ	O
transplantation,	O
or	O
other	O
non-cardiac	O
surgeries	O
)	O
,	O
chronic	O
pain,	O
inflammatory	O
pain,	O
neuropathic	O
pain,	O
visceral	O
pain,	O
nociceptive	O
pain,	O
multiple	O
sclerosis,	O
neurodegenerative	O
disorder,	O
irritable	O
bowel	O
syndrome,	O
osteoarthritis,	O
rheumatoid	O
arthritis,	O
neuropathological	O
disorders,	O
functional	O
bowel	O
disorders,	O
inflammatory	O
bowel	O
diseases,	O
pain	O
associated	O
with	O
dysmenorrhea,	O
pelvic	O
pain,	O
cystitis,	O
pancreatitis,	O
migraine,	O
cluster	O
and	O
tension	O
headaches,	O
diabetic	O
neuropathy,	O
sciatica,	O
fibromyalgia	O
and	O
causalgia	O
.	O


Disclosed	O
herein	O
are	O
benzoimidazole	O
compounds	O
;	O
pharmaceutical	O
compositions	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
same	O
;	O
methods	O
of	O
modulating	O
the	O
activity	O
of	O
an	O
MrgX1	B-GENE
or	O
an	O
MrgX2	B-GENE
receptor	O
using	O
the	O
same	O
;	O
and	O
methods	O
of	O
alleviating	O
acute,	O
chronic	O
and	O
neuropathic	O
pain	O
in	O
a	O
subject	O
using	O
the	O
same	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
identifying	O
a	O
benzoimidazole	O
compound	O
that	O
modulates	O
the	O
activity	O
of	O
an	O
MrgX1	B-GENE
or	O
an	O
MrgX2	B-GENE
receptor	O
;	O
methods	O
of	O
identifying	O
a	O
benzoimidazole	O
compound	O
effective	O
for	O
the	O
treatment	O
of	O
pain	O
.	O


The	O
invention	O
provides	O
a	O
pharmaceutical	O
product,	O
kit	O
or	O
composition	O
comprising	O
a	O
first	O
active	O
ingredient	O
which	O
is	O
a	O
hNE	B-GENE
inhibitor	O
or	O
a	O
MMP	B-GENE
inhibitor	O
and	O
a	O
second	O
active	O
ingredient,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
such	O
as	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
asthma	O
.	O


Compounds,	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds,	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O
are	O
disclosed	O
.	O
The	O
compounds	O
are	O
amide	O
compounds	O
which	O
can	O
be	O
prepared	O
from	O
certain	O
heteoraryl	O
carboxylic	O
acids	O
and	O
certain	O
diazabicycloalkanes	O
.	O
The	O
compounds	O
exhibit	O
selectivity	O
for,	O
and	O
bind	O
with	O
high	O
affinity	O
to,	O
neuronal	B-GENE
nicotinic	I-GENE
receptors	I-GENE
of	O
the	O
a4ß2	B-GENE
subtype	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
The	O
compounds	O
and	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
and	O
/	O
or	O
prevent	O
a	O
wide	O
variety	O
of	O
conditions	O
or	O
disorders,	O
particuarly	O
CNS	O
disorders	O
.	O
The	O
compounds	O
can	O
:	O
(	O
i	O
)	O
alter	O
the	O
number	O
of	O
nicotinic	O
cholinergic	I-GENE
receptors	I-GENE
of	O
the	O
brain	O
of	O
the	O
patient,	O
(	O
ii	O
)	O
exhibit	O
neuroprotective	O
effects,	O
and	O
(	O
iii	O
)	O
when	O
employed	O
in	O
effective	O
amounts,	O
not	O
result	O
in	O
appreciable	O
adverse	O
side	O
effects	O
(	O
e	O
.	O
g	O
.	O
side	O
effects	O
such	O
as	O
significant	O
increases	O
in	O
blood	O
pressure	O
and	O
heart	O
rate,	O
significant	O
negative	O
effects	O
upon	O
the	O
gastrointestinal	O
tract,	O
and	O
significant	O
effects	O
upon	O
skeletal	O
muscle	O
)	O
.	O


A	O
V-ATPase	B-GENE
or	O
gastric	B-GENE
proton	I-GENE
pump	I-GENE
inhibiting	O
lignan	O
such	O
as	O
diphyllin	O
and	O
related	O
glycosides	O
and	O
derivatives,	O
for	O
use	O
as	O
a	O
medicament	O
in	O
the	O
treatment	O
of	O
excessive	O
osteoclast	O
action	O
or	O
in	O
the	O
treatment	O
of	O
excessive	O
gastric	O
acidification,	O
suitably	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
Rb	O
	O
and	O
Rc	O
may	O
together	O
form	O
an	O
alkylene	O
bridge	O
;	O
Rd	O
and	O
Re	O
also	O
may	O
together	O
form	O
an	O
alkylene	O
bridge	O
;	O
and	O
each	O
dotted	O
bond	O
independently	O
is	O
present	O
or	O
absent	O
;	O
and	O
wherein	O
the	O
lactone	O
ring	O
is	O
optionally	O
opened	O
and	O
is	O
optionally	O
esterified	O
.	O


The	O
invention	O
aims	O
at	O
providing	O
compounds	O
which	O
have	O
sufficiently	O
high	O
affinity	O
for	O
NMDA	B-GENE
receptor	I-GENE
and	O
can	O
inhibit	O
the	O
inflow	O
of	O
calcium	O
ions	O
efficiently	O
and	O
which	O
have	O
low	O
cytotoxicity	O
and	O
low	O
molecular	O
weights	O
and	O
can	O
be	O
expected	O
to	O
exhibit	O
excellent	O
transmigration	O
to	O
the	O
brain	O
.	O
The	O
invention	O
provides	O
compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
:	O
[	O
Chemical	O
formula	O
1	O
]	O
X-NH-Y-NH-R1	O
(	O
I	O
)	O
wherein	O
X	O
is	O
R2-SO2-	O
(	O
wherein	O
R2	O
is	O
optionally	O
substituted	O
lower	O
alkyl	O
or	O
phenyl	O
)	O
;	O
Y	O
is	O
a	O
group	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-R3-NH-R4-,	O
-R5-NH-R6-NH-R7-,	O
-R8-NH-R9-NH-R10-NH-R11-	O
and	O
-R12-NH-R13-NH-R14-NH-R15-	O
(	O
wherein	O
R3	O
to	O
R15	O
are	O
each	O
independently	O
C3-C5	O
alkylene	O
)	O
;	O
and	O
R1	O
is	O
hydrogen	O
or	O
optionally	O
substituted	O
lower	O
alkyl,	O
with	O
the	O
proviso	O
that	O
the	O
case	O
wherein	O
X	O
is	O
tosyl	O
;	O
Y	O
is	O
-	O
(	O
CH2	O
)	O
3-NH-	O
(	O
CH2	O
)	O
4-NH-	O
(	O
CH2	O
)	O
3-	O
;	O
and	O
R1	O
is	O
hydrogen	O
is	O
excepted	O
.	O


Formula	O
(	O
I	O
)	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	O
possessing	O
inhibiting	O
fatty	O
acid	O
synthase	O
FabH	B-GENE
effect,	O
its	O
preparation,	O
pharmaceutical	O
composition	O
and	O
use	O
of	O
such	O
compound	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
bacterial	O
infections	O
.	O


Benzocycloheptyl	O
analogs	O
that	O
have	O
agonist	O
activity	O
at	O
one	O
or	O
more	O
of	O
the	O
S	B-GENE
IP	I-GENE
receptors	I-GENE
are	O
provided	O
.	O
The	O
compounds	O
are	O
sphingosine	O
analogs,	O
which,	O
after	O
phosphorylation,	O
can	O
behave	O
as	O
agonists	O
at	O
SlP	B-GENE
receptors	I-GENE
.	O


The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
protein	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
inhibitors	O
for	O
the	O
treatment	O
of	O
musculoskeletal	O
diseases,	O
particularly	O
for	O
the	O
treatment	O
of	O
muscle	O
atrophy	O
.	O


This	O
invention	O
relates	O
to	O
a	O
nictonamide	O
derivative	O
and	O
its	O
use	O
as	O
a	O
pharmaceutical,	O
particularly	O
as	O
a	O
p38	B-GENE
kinase	I-GENE
inhibitor,	O
for	O
the	O
treatment	O
of	O
conditions	O
or	O
disease	O
states	O
mediated	O
by	O
p38	B-GENE
kinase	I-GENE
activity	O
or	O
mediated	O
by	O
cytokines	O
produced	O
by	O
the	O
activity	O
of	O
p38	B-GENE
kinase	I-GENE
.	O


Substituted	O
triazoles	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
are	O
disclosed	O
as	O
being	O
useful	O
in	O
inhibiting	O
the	O
activity	O
of	O
the	O
receptor	B-GENE
protein	I-GENE
tyrosine	I-GENE
kinase	I-GENE
Axl	I-GENE
.	O
Methods	O
of	O
using	O
the	O
compounds	O
in	O
treating	O
diseases	O
or	O
conditions	O
associated	O
with	O
Axl	O
activity	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
application	O
relates	O
to	O
a	O
method	O
of	O
determining	O
a	O
treatment	O
regime	O
for	O
ADHD	O
for	O
a	O
single	O
patient	O
comprising	O
providing	O
a	O
series	O
of	O
tests	O
to	O
an	O
ADHD	O
group	O
and	O
a	O
normative	O
group	O
to	O
determine	O
a	O
series	O
of	O
brain	O
markers	O
determining	O
the	O
expected	O
effect	O
of	O
a	O
series	O
of	O
candidate	O
drugs	O
on	O
the	O
markers,	O
providing	O
the	O
series	O
of	O
tests	O
to	O
the	O
single	O
patient,	O
determining	O
the	O
likely	O
effect	O
of	O
a	O
combination	O
of	O
candidate	O
drugs	O
on	O
the	O
single	O
patient,	O
and	O
selecting	O
and	O
administering	O
a	O
combination	O
of	O
candidate	O
drugs	O
to	O
the	O
single	O
patient	O
.	O
The	O
present	O
application	O
also	O
relates	O
to	O
methods	O
o	O
treating	O
ADHD	O
comprising	O
administering	O
at	O
least	O
one	O
dopaminergic	O
agent	O
and	O
at	O
least	O
one	O
cholinesterase	B-GENE
agent,	O
and	O
optionally	O
one	O
or	O
more	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
NMDA	B-GENE
receptor	I-GENE
antagonists,	O
mGluR	B-GENE
agonists,	O
antagonists,	O
and	O
positive	O
modulators	O
of	O
AMPA	O
receptors,	O
and	O
more	O
preferably	O
administering	O
a	O
Dl	B-GENE
receptor	I-GENE
agonist	O
an	O
a	O
nicotinic	O
agonist	O
and	O
/	O
or	O
an	O
anti-cholinesterase	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
stereoisomers	O
or	O
tautomers	O
thereof	O
which	O
are	O
inhibitors	O
of	O
poly	B-GENE
(ADP-ribose)	I-GENE
polymerase	I-GENE
(	O
PARP	B-GENE
)	O
and	O
thus	O
useful	O
for	O
the	O
treatment	O
of	O
cancer,	O
inflammatory	O
diseases,	O
reperfusion	O
injuries,	O
ischemic	O
conditions,	O
stroke,	O
renal	O
failure,	O
cardiovascular	O
diseases,	O
vascular	O
diseases	O
other	O
than	O
cardiovascular	O
diseases,	O
diabetes,	O
neurodegenerat	O
ive	O
diseases,	O
retroviral	O
infection,	O
retinal	O
damage	O
or	O
skin	O
senescence	O
and	O
UV-	O
induced	O
skin	O
damage,	O
and	O
as	O
chemo-	O
and	O
/	O
or	O
radiosensitizers	O
for	O
cancer	O
treatment	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
diets,	O
compounds,	O
e	O
.	O
g	O
.	O
,	O
GCN2	B-GENE
agonists	O
and	O
methods	O
that	O
selectively	O
reduce	O
adipose	O
tissue	O
mass	O
relative	O
to	O
the	O
mass	O
of	O
other	O
tissue	O
types	O
and	O
increase	O
insulin	B-GENE
sensitivity	O
.	O
Another	O
aspect	O
of	O
the	O
disclosure	O
relates	O
to	O
methods	O
for	O
identifying	O
GCN2	B-GENE
agonists	O
that	O
will	O
decrease	O
the	O
activity	O
and	O
/	O
or	O
expression	O
of	O
one	O
or	O
more	O
of	O
adipogenic	O
genes	O
thereby	O
selectively	O
inhibiting	O
the	O
cellular	O
mechanisms	O
that	O
lead	O
to	O
fat	O
production	O
.	O
Such	O
agonists	O
have	O
the	O
effect	O
of	O
reducing	O
adipose	O
tissue	O
mass	O
in	O
an	O
individual	O
.	O


Disclosed	O
are	O
novel	O
aminoindazole	O
urea	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
L,	O
X,	O
Y,	O
R3,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
indicated	O
in	O
claim	O
1	O
.	O
Said	O
aminoindazole	O
urea	O
derivatives	O
are	O
SGK	B-GENE
inhibitors	O
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
SGK-induced	O
diseases	O
and	O
ailments	O
such	O
as	O
diabetes,	O
obesity,	O
metabolic	O
syndrome	O
(	O
dyslipidemia	O
)	O
,	O
systemic	O
and	O
pulmonary	O
hypertension,	O
cardiovascular	O
diseases,	O
and	O
kidney	O
diseases,	O
more	O
generally	O
for	O
any	O
kind	O
of	O
fibroses	O
and	O
inflammatory	O
processes	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
inhibit	O
HSP90	B-GENE
function,	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
them	O
as	O
the	O
active	O
ingredient,	O
to	O
their	O
use	O
as	O
medicaments	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
treatment	O
in	O
warm	O
blooded	O
animals	O
such	O
as	O
humans	O
of	O
diseases	O
such	O
as	O
for	O
the	O
treatment	O
of	O
solid	O
tumours	O
.	O


PPARγ	B-GENE
activators	O
/	O
modulators	O
which	O
contain	O
as	O
the	O
active	O
ingredient	O
cercosporamide	O
derivatives	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmacologically	O
acceptable	O
salts	O
or	O
esters	O
thereof	O
;	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
PPARγ	B-GENE
participates	O
:	O
(	O
I	O
)	O
wherein	O
X	O
is	O
oxygen	O
or	O
the	O
like	O
;	O
R1	O
is	O
hydrogen	O
or	O
C1-6	O
alkyl	O
;	O
R2	O
is	O
hydrogen,	O
C1-6	O
alkyl,	O
or	O
the	O
like	O
;	O
R3	O
is	O
hydrogen	O
or	O
C1-6	O
alkyl	O
;	O
R4	O
is	O
C6-10	O
aryl	O
which	O
may	O
be	O
substituted	O
with	O
one	O
to	O
five	O
groups	O
independently	O
selected	O
from	O
group	O
(	O
a	O
)	O
of	O
substituents,	O
or	O
the	O
like	O
;	O
n	O
is	O
1,	O
2	O
or	O
3	O
;	O
and	O
group	O
(	O
a	O
)	O
of	O
substituents	O
includes	O
halogeno,	O
C1-6	O
alkyl,	O
C1-6	O
haloalkyl,	O
and	O
so	O
on	O
.	O


Pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
provided	O
:	O
wherein	O
the	O
constituent	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
plasminogen	B-GENE
activator	I-GENE
inhibitor-1	I-GENE
(	O
PAI-1	B-GENE
)	O
and	O
the	O
compositions	O
are	O
useful	O
for	O
treating	O
conditions	O
resulting	O
from	O
fibrinolytic	O
disorders,	O
such	O
as	O
deep	O
vein	O
thrombosis	O
and	O
coronary	O
heart	O
disease,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
pulmonary	O
fibrosis	O
.	O


The	O
invention	O
relates	O
to	O
the	O
products	O
of	O
formula	O
(	O
I	O
)	O
:	O
with	O
R	O
represents	O
H	O
or	O
Hal	O
;	O
R2,	O
R3	O
and	O
R4	O
are	O
chosen	O
from	O
H,	O
Hal,	O
CN,	O
CONH2,	O
CONHalk,	O
CON	O
(	O
alk	O
)	O
2,	O
and	O
alkyl	O
and	O
alkoxy	O
optionally	O
substituted	O
with	O
Hal,	O
CN,	O
CONH2,	O
CONHalk,	O
CON	O
(	O
alk	O
)	O
2,	O
OH	O
or	O
OCH3,	O
it	O
being	O
understood	O
that	O
one	O
or	O
two	O
of	O
R2,	O
R3	O
and	O
R4	O
represent	O
(	O
s	O
)	O
H,	O
or	O
all	O
three	O
of	O
R2,	O
R3	O
and	O
R4	O
represent	O
methoxy	O
;	O
z	O
represents	O
SO2	O
or	O
CO	O
;	O
and	O
N	O
(	O
D	O
)	O
(	O
W	O
)	O
such	O
that	O
:	O
either	O
W	O
represents	O
-ring	O
(	O
Y	O
)	O
and	O
D	O
represents	O
H	O
or	O
cycloalkyl,	O
alkyl,	O
alkenyl	O
or	O
alkynyl	O
which	O
may	O
be	O
optionally	O
substituted	O
;	O
ring	O
(	O
Y	O
)	O
with	O
Y	O
represents	O
O,	O
S,	O
SO,	O
SO2,	O
NRlO,	O
C	O
=	O
O,	O
CF2,	O
CH-OR8	O
or	O
CH-NR8R9	O
;	O
or	O
W	O
and	O
D	O
form,	O
with	O
N,	O
a	O
ring	O
(	O
N	O
)	O
substituted	O
with	O
R1	O
and	O
R6	O
such	O
that,	O
for	O
example,	O
R1	O
represents	O
-X1-R7	O
with	O
X1	O
representing	O
-	O
(	O
CH2	O
)	O
m-	O
and	O
R6	O
representing	O
H,	O
OH,	O
-CH2OH,	O
-CO-	O
N-,	O
-CO2H	O
or	O
-CO2alk	O
;	O
and	O
R7	O
represents	O
optionally	O
substituted	O
heterocycloalkyl,	O
aryl	O
or	O
heteroaryl	O
;	O
with	O
m	O
=	O
1-3	O
;	O
wherein	O
these	O
products	O
are	O
in	O
any	O
of	O
the	O
isomer	O
forms	O
and	O
the	O
salts,	O
as	O
medicaments,	O
in	O
particular	O
as	O
IKK	B-GENE
inhibitors	O
.	O


Disclosed	O
is	O
a	O
5HT4	B-GENE
receptor	O
antagonist	O
capable	O
of	O
binding	O
to	O
a	O
serotonin	O
5HT4	B-GENE
receptor,	O
which	O
comprises	O
creosote	O
.	O


Selective	O
estrogen	B-GENE
receptor	I-GENE
modulators,	O
as	O
well	O
their	O
related	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use,	O
are	O
provided	O
herein	O
.	O
These	O
estrogen	B-GENE
receptor	I-GENE
modulators	O
include	O
compounds	O
that	O
primarily	O
exhibit	O
estrogen	B-GENE
receptor	I-GENE
antagonist	O
activity	O
or	O
primarily	O
exhibit	O
selective	O
estrogen	B-GENE
receptor	I-GENE
antagonist	O
and	O
agonist	O
activity,	O
i	O
.	O
e	O
.	O
,	O
SERM	O
activity,	O
in	O
specific	O
tissue	O
types	O
.	O
Particular	O
embodiments	O
provide	O
compounds	O
that	O
behave	O
as	O
NeuroSERMs	O
promoting	O
neurotrophism	O
and	O
neuroprotection	O
in	O
brain	O
tissue	O
.	O
These	O
NeuroSERMs	O
represent	O
a	O
subset	O
of	O
the	O
modulators	O
compounds	O
provided	O
herein	O
that	O
can	O
cross	O
the	O
blood-brain-barrier	O
and	O
exert	O
estrogen	B-GENE
receptor	I-GENE
agonist-like	O
effects	O
in	O
the	O
brain	O
.	O
The	O
compounds	O
should	O
be	O
useful	O
for	O
treating	O
a	O
variety	O
of	O
diseases,	O
particularly	O
estrogen	O
receptor-mediated	O
diseases	O
and	O
disorders,	O
such	O
as	O
osteoporosis,	O
breast	O
and	O
endometrial	O
cancers,	O
atherosclerosis	O
and	O
Alzheimer	O
'	O
s	O
disease	O
.	O


The	O
present	O
invention	O
includes	O
methods	O
of	O
enhancing	O
immune	O
responses	O
by	O
administering	O
an	O
inhibitor	O
of	O
indoleamine-2,3-dioxygenase	B-GENE
(	O
IDO	B-GENE
)	O
along	O
with	O
one	O
or	O
more	O
inhibitors	O
of	O
the	O
PD-1	B-GENE
/	O
PD-L	B-GENE
pathway	O
and	O
/	O
or	O
one	O
or	O
more	O
inhibitors	O
of	O
the	O
CTLA4	B-GENE
pathway	O
.	O


Squamous	O
cell	O
carcinomas,	O
such	O
as	O
squamous	O
head	O
and	O
neck	O
cancer,	O
are	O
treated	O
with	O
a	O
combination	O
of	O
radio-therapy	O
and	O
a	O
therapeutic	O
agent	O
that	O
reduces	O
the	O
amount	O
of	O
hsp27	B-GENE
in	O
the	O
squamous	O
cancer	O
cells	O
.	O
In	O
specific	O
embodiments,	O
the	O
therapeutic	O
agent	O
that	O
reduces	O
the	O
amount	O
of	O
hsp27	B-GENE
is	O
an	O
antisense	O
oligonucleotide	O
therapeutic	O
agent	O
.	O


The	O
use	O
of	O
substituted	O
amides	O
of	O
structure	O
(	O
I	O
)	O
for	O
modulating	O
the	O
activity	O
of	O
11	B-GENE
β-hydroxysteroid	I-GENE
dehydrogenase	I-GENE
type	I-GENE
1	I-GENE
(	O
11	B-GENE
βHSD1	I-GENE
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutical	O
compositions,	O
are	O
described	O
.	O
Also	O
a	O
novel	O
class	O
of	O
substituted	O
amides,	O
their	O
use	O
in	O
therapy,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
.	O
The	O
present	O
compounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11	B-GENE
βHSD1	I-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
/	O
or	O
prophylaxis	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	O
is	O
desirable	O
.	O


Provided	O
herein	O
are	O
methods	O
of	O
treatment	O
of	O
an	O
interstitial	O
lung	O
disease	O
(	O
ILD	O
)	O
by	O
administering	O
an	O
endothelin	B-GENE
antagonist,	O
such	O
as	O
sitaxsentan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


This	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
m,	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
herein,	O
as	O
a	O
stereoisomer,	O
enantiomer,	O
tautomer	O
thereof	O
or	O
mixtures	O
thereof	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate	O
or	O
prodrug	O
thereof,	O
and	O
their	O
use	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
sodium	O
channel-mediated	O
diseases	O
or	O
conditions,	O
such	O
as	O
pain	O
.	O


Disclosed	O
is	O
an	O
Eg5	B-GENE
inhibitor	O
containing	O
a	O
cysteine	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O
	O
Also	O
disclosed	O
is	O
an	O
agent	O
for	O
treatment	O
of	O
cell	O
proliferative	O
diseases	O
.	O
	O
[	O
chemical	O
formula	O
1	O
]	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
(	O
I	O
)	O
	O
(	O
In	O
the	O
formula,	O
Ar	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	O
group	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
heterocyclic	O
group	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
protecting	O
group	O
of	O
an	O
amino	O
group	O
;	O
and	O
R2	O
represents	O
a	O
hydroxy	O
group,	O
an	O
alkoxy	O
group,	O
an	O
amino	O
group,	O
a	O
-NH	O
(	O
CH2	O
)	O
2O	O
(	O
CH2	O
)	O
2NH2	O
group	O
or	O
the	O
like	O
.	O
	O
In	O
this	O
connection,	O
when	O
Ar	O
is	O
a	O
phenyl	O
group,	O
R2	O
is	O
a	O
group	O
other	O
than	O
a	O
hydroxy	O
group	O
.	O
)	O


A	O
means	O
for	O
decreasing	O
bacterial	O
virulence	O
in	O
a	O
mammal	O
including	O
man	O
or	O
in	O
a	O
plant	O
by	O
inhibition	O
of	O
the	O
Type	B-GENE
III	I-GENE
secretion	I-GENE
system	I-GENE
at	O
concentrations	O
that	O
do	O
not	O
prevent	O
or	O
substantially	O
reduce	O
bacterial	O
growth	O
comprises	O
an	O
N-substituted	O
7-quinolylmethyl	O
amine,	O
in	O
particular	O
one	O
that	O
is	O
further	O
substituted	O
in	O
5-	O
and	O
8-position	O
on	O
the	O
quinoline	O
ring	O
.	O
A	O
corresponding	O
therapeutic	O
method	O
and	O
a	O
pharmaceutical	O
composition	O
are	O
also	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
combination	O
therapies	O
involving	O
BLyS	B-GENE
or	O
BLyS	B-GENE
/	O
APRIL	B-GENE
inhibition	O
and	O
immunosuppressants	O
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
.	O
One	O
preferred	O
method	O
is	O
where	O
the	O
BLyS	B-GENE
and	O
/	O
or	O
APRIL	B-GENE
antagonist	O
is	O
a	O
Fc-fusion	B-GENE
protein	I-GENE
which	O
can	O
be	O
a	O
TACI-Fc-fusion	O
protein	O
comprising	O
the	O
extracellular	O
domain	O
of	O
TACI	B-GENE
or	O
a	O
functional	O
fragment	O
thereof,	O
a	O
BAFF-R-Fc-fusion	O
protein	O
comprising	O
the	O
extracellular	O
domain	O
of	O
BAFF-R	B-GENE
or	O
a	O
functional	O
fragment	O
thereof,	O
or	O
a	O
BCMA-Fc-fusion	O
protein	O
comprising	O
the	O
extracellular	O
domain	O
of	O
BCMA	B-GENE
or	O
a	O
functional	O
fragment	O
thereof	O
.	O
In	O
the	O
methods	O
of	O
the	O
present	O
invention	O
some	O
of	O
the	O
immunosuppressive	O
drugs	O
contemplated	O
include	O
cyclophosphamide	O
(	O
CYC	O
)	O
,	O
azathioprine	O
(	O
AZA	O
)	O
,	O
cyclosporine	O
A	O
(	O
CSA	O
)	O
,	O
or	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
,	O
although	O
any	O
drug	O
that	O
suppresses	O
the	O
immune	O
system	O
may	O
be	O
suitable	O
.	O
The	O
methods	O
of	O
the	O
present	O
invention	O
reduce	O
the	O
levels	O
of	O
various	O
immunoglobulins	O
in	O
patients	O
in	O
need	O
of	O
such	O
reduction,	O
such	O
as	O
those	O
suffering	O
from	O
autoimmune	O
diseases	O
.	O


Compositions	O
and	O
methods	O
are	O
provided	O
for	O
using	O
leukocyte	O
sequestration	O
agents	O
to	O
treat	O
infection	O
.	O
In	O
particular,	O
the	O
methods	O
and	O
compositions	O
comprise	O
leukocyte	O
sequestration	O
agents	O
that	O
are	O
lymphocyte	O
sequestration	O
agents	O
such	O
as	O
sphingosine	B-GENE
1	I-GENE
-phosphate	I-GENE
(SlP)	I-GENE
receptor	I-GENE
agonists	O
(	O
particularly	O
FTY720	O
)	O
,	O
sphingosine	B-GENE
kinase	I-GENE
inhibitors,	O
and	O
SlP	B-GENE
lyase	I-GENE
inhibitors	O
.	O
Infections	O
to	O
be	O
treated	O
or	O
prevented	O
according	O
to	O
the	O
present	O
invention	O
include	O
bacterial,	O
viral,	O
fungal,	O
or	O
parasitic	O
infection,	O
particularly	O
bacterial	O
or	O
viral	O
infection	O
.	O


Compounds	O
of	O
Formula	O
I	O
:	O
in	O
which	O
A,	O
B,	O
R1,	O
R1a,	O
R2,	O
R3,	O
R4,	O
R5	O
R6,	O
R7	O
and	O
R8	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification,	O
are	O
receptor	O
tyrosine	I-GENE
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
class	B-GENE
3	I-GENE
and	I-GENE
class	B-GENE
5	I-GENE
receptor	I-GENE
tyrosine	I-GENE
kinases	I-GENE
.	O
Particular	O
compounds	O
of	O
this	O
invention	O
have	O
also	O
been	O
found	O
to	O
be	O
inhibitors	O
of	O
Pim-1	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
drug	O
discovery	O
methods,	O
particularly	O
methods	O
for	O
assaying	O
compounds	O
for	O
activity	O
as	O
Aurora	B-GENE
kinase	I-GENE
inhibitors	O
.	O
This	O
invention	O
also	O
relates	O
to	O
a	O
pharmacophore	O
describing	O
compounds	O
that	O
are	O
able	O
to	O
promote	O
a	O
conformational	O
change	O
in	O
the	O
protein	O
AuroraB	B-GENE
and	O
whose	O
binding	O
constant	O
for	O
the	O
two-step	O
process	O
is	O
given	O
as	O
Ki	O
*	O
.	O
Finally,	O
this	O
invention	O
also	O
relates	O
to	O
compounds	O
having	O
the	O
features	O
of	O
the	O
pharmacophore	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
includes	O
a	O
radiolabeled	O
atom	O
is	O
used	O
to	O
probe	O
Hsp90	B-GENE
in	O
vivo	O
using	O
molecular	O
imaging	O
modalities	O
.	O
A	O
method	O
of	O
making	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
uses	O
in	O
monitoring	O
disorders	O
associated	O
with	O
disfunction	O
of	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
90	I-GENE
are	O
also	O
included	O
within	O
the	O
invention	O
.	O


Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
salt	O
thereof	O
.	O
The	O
compound	O
is	O
useful	O
as	O
a	O
p38	B-GENE
MAPK	I-GENE
inhibitor	O
and	O
/	O
or	O
a	O
TNF-α	B-GENE
production	O
inhibitor	O
.	O
(	O
In	O
the	O
formula,	O
Xa,	O
Xb	O
and	O
Xc	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
an	O
optionally	O
substituted	O
CH	O
or	O
a	O
nitrogen	O
atom,	O
and	O
either	O
one	O
of	O
them	O
represents	O
a	O
nitrogen	O
atom	O
;	O
Xd	O
represents	O
an	O
optionally	O
substituted	O
CH	O
;	O
Ra	O
represents	O
an	O
optionally	O
substituted	O
phenyl	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
;	O
Rb	O
represents	O
a	O
hydrogen	O
atom	O
;	O
Rc	O
represents	O
an	O
optionally	O
substituted	O
nitrogen-containing	O
heterocyclic	O
N-oxide,	O
an	O
N-	O
(	O
optionally	O
substituted	O
nitrogen-containing	O
heterocyclic	O
N-oxide-C1-6-alkyl	O
)	O
amino	O
or	O
an	O
optionally	O
substituted	O
nitrogen-containing	O
heterocyclic	O
N-oxide-carbonylamino-C1-6-	O
alkyl	O
.	O
)	O


The	O
present	O
invention	O
relates	O
to	O
substituted	O
anthranilamides	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
D,	O
M,	O
A4,	O
A5,	O
R2,	O
R3,	O
R4	O
and	O
R6	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O
The	O
compounds	O
have	O
an	O
antithrombotic	O
and	O
a	O
factor	B-GENE
Xa	I-GENE
inhibiting	O
activity	O
.	O


Compounds	O
of	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
are	O
effective	O
modulators	O
of	O
JNK	B-GENE
:	O
(	O
formula	O
)	O
wherein	O
X,	O
Y,	O
Z,	O
R4,	O
R5,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
herein	O
.	O


Disclosed	O
are	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
ester,	O
amide,	O
or	O
prodrug	O
thereof	O
;	O
and	O
methods	O
of	O
modulating	O
the	O
activity	O
of	O
a	O
cannabinoid	B-GENE
CB2	I-GENE
receptor	I-GENE
comprising	O
contacting	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
with	O
the	O
cannabinoid	B-GENE
CB2	I-GENE
receptor	I-GENE
.	O
Said	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
condition	O
and	O
disorders	O
such	O
as	O
pain,	O
and	O
neurodegenerative	O
disorders	O
.	O


Disclosed	O
are	O
small	O
molecule	O
inhibitors	O
which	O
are	O
useful	O
in	O
treating	O
various	O
diseases	O
and	O
conditions	O
involving	O
chymase	B-GENE
.	O


The	O
present	O
invention	O
provides	O
derivatives	O
of	O
pyrido	O
[	O
2,	O
3-d	O
]	O
pyrimidin-7-one	O
.	O
These	O
compounds	O
are	O
kinase	B-GENE
inhibitors,	O
including	O
compounds	O
that	O
show	O
anti-proliferative	O
activity,	O
including	O
against	O
tumor	O
cells,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
cancer	O
.	O


The	O
present	O
invention	O
is	O
drawn	O
to	O
combinations	O
of	O
pharmaceutical	O
agents	O
having	O
similar	O
chemical	O
and	O
/	O
or	O
pharmacological	O
properties,	O
wherein	O
the	O
combinations	O
maximize	O
the	O
therapeutic	O
effect	O
of	O
the	O
drug	O
while	O
minimizing	O
their	O
adverse	O
effects	O
.	O
The	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
obesity	O
and	O
related	O
conditions	O
which	O
involves	O
treating	O
a	O
subject	O
with	O
a	O
sympathomimetic	O
agent	O
(	O
e	O
.	O
g	O
.	O
,	O
phentermine	O
or	O
a	O
phentermine-like	O
drug	O
)	O
or	O
bupropion	O
in	O
combination	O
with	O
an	O
anti-epileptic	O
agent	O
(	O
e	O
.	O
g	O
.	O
,	O
topiramate,	O
zonisamide	O
)	O
,	O
CBl	B-GENE
antagonists	O
(	O
e	O
.	O
g	O
.	O
,	O
rimonabant	O
)	O
,	O
or	O
a	O
5HT2c-selective	B-GENE
serotonin	I-GENE
receptor	I-GENE
agonist,	O
(	O
e	O
.	O
g	O
.	O
,	O
lorcaserin	O
)	O
for	O
the	O
treatment	O
of	O
obesity	O
and	O
related	O
conditions	O
.	O
The	O
invention	O
also	O
features	O
kits	O
for	O
use	O
in	O
the	O
practice	O
of	O
these	O
novel	O
therapies	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
salts	O
of	O
(	O
R	O
)	O
-1-	O
{	O
2-	O
[	O
4	O
'	O
-	O
(	O
3-methoxy-propane-1-sulfonyl	O
)	O
-biphenyl-4-yl	O
]	O
-ethyl	O
}	O
-2-methyl-pyrrolidine,	O
and	O
crystalline	O
forms,	O
and	O
compositions	O
thereof	O
that	O
modulate	O
the	O
activity	O
of	O
the	O
histamine	B-GENE
H3-receptor	I-GENE
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
histamine	B-GENE
H3-receptor	I-GENE
associated	O
disorders,	O
such	O
as,	O
cognitive	O
disorders,	O
epilepsy,	O
brain	O
trauma,	O
depression,	O
obesity,	O
disorders	O
of	O
sleep	O
and	O
wakefulness	O
such	O
as	O
narcolepsy,	O
shift-work	O
syndrome,	O
drowsiness	O
as	O
a	O
side	O
effect	O
from	O
a	O
medication,	O
maintenance	O
of	O
vigilance	O
to	O
aid	O
in	O
completion	O
of	O
tasks	O
and	O
the	O
like,	O
cataplexy,	O
hypersomnia,	O
somnolence	O
syndrome,	O
jet	O
lag,	O
sleep	O
apnea	O
and	O
the	O
like,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
schizophrenia,	O
allergies,	O
allergic	O
responses	O
in	O
the	O
upper	O
airway,	O
allergic	O
rhinitis,	O
nasal	O
congestion,	O
pain,	O
dementia,	O
Alzheimer	O
'	O
s	O
disease	O
and	O
the	O
like	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
treating	O
or	O
preventing	O
bone	O
and	O
cartilage	O
disorders	O
comprising	O
administering	O
to	O
a	O
mammal	O
an	O
inhibitor	O
of	O
Axl	B-GENE
gene	O
expression	O
or	O
an	O
inhibitor	O
of	O
Axl	B-GENE
protein	O
activity	O
.	O


It	O
is	O
intended	O
to	O
provide	O
an	O
agent	O
and	O
a	O
method	O
for	O
maintaining	O
and	O
promoting	O
stabilization	O
of	O
a	O
membrane	O
protein,	O
particularly	O
a	O
transporter	O
(	O
for	O
example,	O
ABC	B-GENE
transporter	I-GENE
)	O
on	O
a	O
cell	O
membrane	O
.	O
	O
The	O
invention	O
provides	O
a	O
method	O
for	O
maintaining	O
and	O
promoting	O
the	O
stability	O
of	O
a	O
protein	O
present	O
on	O
a	O
cell	O
membrane	O
by	O
treating	O
a	O
cell	O
with	O
a	O
carboxylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
including	O
4-phenylbutyric	O
acid	O
thereby	O
suppressing	O
degradation	O
of	O
the	O
protein	O
on	O
the	O
membrane,	O
and	O
an	O
agent	O
for	O
stabilizing	O
a	O
membrane	O
protein	O
containing	O
a	O
carboxylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
including	O
4-phenylbutyric	O
acid	O
.	O


The	O
present	O
invention	O
features	O
imidazolidinone	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
imidazolidinone	O
compounds	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
utilized	O
in	O
methods	O
of	O
treating	O
a	O
a	O
deubiquitination-related	O
disorder	O
in	O
a	O
subject	O
and	O
inhibiting	O
p97-associated	O
deubiquitination	O
.	O


This	O
application	O
describes	O
compositions,	O
methods	O
of	O
treatment,	O
and	O
methods	O
of	O
manufacturing	O
a	O
medicament	O
for	O
reducing	O
injury	O
or	O
damage	O
to	O
cells,	O
tissues	O
or	O
organs	O
during	O
ischemia,	O
reperfusion,	O
or	O
following	O
ischemia	O
or	O
trauma	O
.	O
The	O
methods	O
for	O
reducing	O
damage	O
to	O
a	O
cell,	O
tissue	O
or	O
organ	O
comprise	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
including	O
(	O
i	O
)	O
a	O
potassium	B-GENE
channel	I-GENE
opener	O
or	O
agonist	O
and	O
/	O
or	O
adenosine	B-GENE
receptor	I-GENE
agonist	O
;	O
and	O
(	O
ii	O
)	O
an	O
antiarrhythmic	O
agent	O
.	O
The	O
methods	O
may	O
further	O
include	O
postconditioning	O
the	O
cell,	O
tissue	O
or	O
organ	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt,	O
suitably	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
or	O
solvate	O
thereof,	O
wherein	O
the	O
groups	O
R1,	O
R2,	O
Ar	O
'	O
,	O
A	O
and	O
B	O
are	O
defined	O
in	O
the	O
description,	O
to	O
compositions	O
and	O
use	O
of	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
diseases	O
ameloriated	O
by	O
inhibition	O
of	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
hair	O
loss-preventing	O
agent	O
and	O
a	O
hair	O
depigmentation-preventing	O
agent	O
.	O
Hair	O
loss	O
or	O
hair	O
depigmentation	O
can	O
be	O
prevented	O
by	O
type	O
XVII	B-GENE
collagen	I-GENE
.	O


The	O
present	O
invention	O
provides	O
compounds	O
and	O
methods	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
ischemia	O
reperfusion	O
injury	O
.	O
In	O
particular	O
the	O
invention	O
provides	O
compounds	O
which	O
function	O
to	O
suppress	O
Toll-like	B-GENE
Receptor	I-GENE
2	I-GENE
biological	O
function	O
or	O
expression	O
.	O


A	O
method	O
for	O
the	O
prophylaxis	O
and	O
/	O
or	O
therapy	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
which	O
method	O
comprises	O
administering	O
to	O
a	O
mammalian	O
subject	O
in	O
need	O
of	O
such	O
prophylaxis	O
and	O
/	O
or	O
therapy	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
glucokinase	B-GENE
(	O
GLK	B-GENE
)	O
activator	O
.	O


The	O
present	O
invention	O
relates	O
to	O
naphthylpyrimidine	O
analogs,	O
methods	O
of	O
making	O
naphthylpyrimidine	O
analogs,	O
compositions	O
comprising	O
a	O
naphthylpyrimidine	O
analog,	O
and	O
methods	O
for	O
treating	O
canonical	O
Wnt-[beta-symbol]-catenin	B-GENE
cellular	O
messaging	O
system-related	O
disorders	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
naphthylpyrimidine,	O
naphthylpyrazine	O
and	O
naphthylpyridazine	O
analog	O
.	O


Disclosed	O
are	O
methods	O
relating	O
to	O
the	O
use	O
of	O
kinamycin	O
F	O
as	O
an	O
anti-cancer	O
agent	O
.	O
Cytotoxic	O
methods	O
induced	O
by	O
kinamycin	O
F	O
include	O
DNA	O
and	O
protein	O
damage	O
and	O
topoisomerase	B-GENE
inhibition	O
.	O
As	O
set	O
forth	O
herein,	O
the	O
anti-cancer	O
effects	O
of	O
kinamycin	O
F	O
may	O
be	O
attributed	O
to,	O
for	O
example,	O
DNA	O
binding,	O
DNA	O
intercalation,	O
topoisomerase	B-GENE
Ilα	I-GENE
decatenation	O
activity	O
inhibition	O
and	O
/	O
or	O
production	O
of	O
radical	O
species	O
by	O
kinamycin	O
F	O
.	O


Provided	O
herein	O
are	O
compositions,	O
combinations,	O
and	O
methods	O
comprising	O
NMDA	O
antagonists	O
including,	O
but	O
not	O
limited	O
to,	O
NMDA	B-GENE
glutamate	I-GENE
receptor	I-GENE
antagonists	O
such	O
as	O
[	O
2-	O
(	O
8,9-dioxo-2,6-diazabicyclo	O
[	O
5	O
.	O
2	O
.	O
0	O
]	O
non-1-	O
(	O
7	O
)	O
-en-2-yl	O
)	O
alkyl	O
]	O
phosphonic	O
acid	O
and	O
derivatives	O
thereof,	O
which	O
are	O
effective	O
in	O
reducing	O
the	O
amount	O
of	O
anesthetic	O
required	O
to	O
maintain	O
anesthesia	O
(	O
i	O
.	O
e	O
.	O
to	O
achieve	O
an	O
anesthetic-sparing	O
effect	O
)	O
.	O


Disclosed	O
are	O
:	O
a	O
para-terphenyl	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
;	O
a	O
method	O
for	O
producing	O
the	O
para-terphenyl	O
compound	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
use	O
of	O
the	O
para-terphenyl	O
compound	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O
(	O
1	O
)	O
[	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
an	O
alkyl,	O
cyclic	O
alkyl,	O
alkoxyalkyl,	O
siloxyalkyl	O
or	O
phenyl	O
group	O
having	O
1	O
to	O
6	O
carbon	O
atoms	O
or	O
an	O
alkylene	O
group	O
having	O
3	O
or	O
4	O
carbon	O
atoms	O
;	O
and	O
R3	O
and	O
R4	O
independently	O
represent	O
a	O
hydrogen	O
or	O
a	O
protective	O
group	O
for	O
a	O
hydroxyl	O
group	O
.	O
]	O
Thus,	O
a	O
compound	O
having	O
an	O
inhibitory	O
activity	O
on	O
the	O
production	O
of	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(TNF)-α	I-GENE
can	O
be	O
produced	O
by	O
a	O
chemical	O
synthesis	O
.	O
The	O
compound	O
has	O
no	O
toxic	O
activity,	O
and	O
is	O
therefore	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
an	O
autoimmune	O
disease,	O
an	O
allergic	O
disease	O
or	O
the	O
like	O
.	O


Disclosed	O
are	O
:	O
a	O
type-3	B-GENE
17β-hydroxysteroid	I-GENE
dehydrogenase-inhibiting	O
composition	O
which	O
is	O
characterized	O
by	O
comprising	O
a	O
coumarin	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
A	O
)	O
or	O
the	O
like	O
and	O
an	O
inert	O
carrier	O
;	O
and	O
others	O
.	O


Methods	O
and	O
compositions	O
for	O
treating	O
immunological	O
and	O
inflammatory	O
diseases	O
and	O
disorders	O
are	O
disclosed	O
.	O
Particular	O
methods	O
and	O
compositions	O
comprise	O
the	O
administration	O
of	O
an	O
agent	O
that	O
inhibits	O
S1P	B-GENE
lyase	I-GENE
activity	O
and	O
at	O
least	O
one	O
additional	O
immunosuppressive	O
and	O
/	O
or	O
anti-inflammatory	O
agent	O
.	O


The	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
mammalian	O
disease	O
manifested	O
by	O
abnormal	O
cell	O
growth	O
and/or	O
abnormal	O
cell	O
proliferation	O
.	O
More	O
particularly,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
combination	O
therapies	O
to	O
control	O
abnormal	O
cell	O
growth	O
and/or	O
abnormal	O
cell	O
proliferation	O
.	O
In	O
particular,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
isotype-selective	O
inhibitors	O
of	O
histone	B-GENE
deacetylases	I-GENE
1,	I-GENE
2	I-GENE
and/or	I-GENE
3	I-GENE
(	O
HDACs	B-GENE
1-3	I-GENE
)	O
,	O
as	O
well	O
as	O
isotype-selective	O
inhibitors	O
of	O
HDAC1	B-GENE
and/or	I-GENE
HDAC2,	O
to	O
potentiate	O
therapeutic	O
activity	O
of	O
microtubule-stabilization	O
agents	O
.	O


The	O
present	O
invention	O
relates	O
to	O
3-azabicyclo	O
[	O
3	O
.	O
1	O
.	O
0	O
]	O
hexane	O
derivatives,	O
which	O
can	O
be	O
used	O
as	O
vanilloid	B-GENE
receptor	I-GENE
ligands,	O
methods	O
of	O
treating	O
diseases,	O
conditions	O
and	O
/	O
or	O
disorders	O
modulated	O
by	O
vanilloid	O
receptors	O
with	O
them,	O
and	O
processes	O
for	O
preparing	O
them	O
.	O


The	O
present	O
invention	O
consists	O
of	O
a	O
method	O
of	O
treating	O
a	O
subject	O
with	O
an	O
ischemic	O
eye	O
disease	O
associated	O
with	O
the	O
down-regulation	O
of	O
HIF	B-GENE
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
induces	O
HIF	B-GENE
activity	O
and	O
/	O
or	O
induces	O
EPO	B-GENE
activity	O
to	O
induce	O
and	O
maintain	O
growth	O
or	O
normal	O
retinal	O
blood	O
vessels	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
a	O
microbial	O
infection	O
.	O
In	O
the	O
present	O
invention,	O
RNase-L	B-GENE
activity	O
has	O
been	O
shown	O
to	O
play	O
an	O
integral	O
role	O
in	O
innate	O
immunity	O
and	O
for	O
defense	O
against	O
invading	O
microbes	O
.	O
The	O
present	O
invention	O
is	O
drawn	O
to	O
exploiting	O
the	O
role	O
of	O
RNase-L	B-GENE
in	O
innate	O
immunity	O
for	O
methods	O
of	O
treating	O
a	O
microbial	O
infection	O
.	O
The	O
present	O
invention	O
is	O
also	O
drawn	O
to	O
exploiting	O
the	O
role	O
of	O
RNase-L	B-GENE
in	O
innate	O
immunity	O
for	O
methods	O
of	O
treating	O
an	O
immune	O
related	O
disease	O
or	O
disorder	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
Ihb	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
with	O
an	O
acid	O
or	O
a	O
base	O
or	O
a	O
stereoisomer	O
thereof	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
disease	O
associated	O
with	O
increased	O
cytokine	B-GENE
release,	O
wherein	O
Y	O
'	O
is	O
O	O
or	O
NR2	O
'	O
;	O
Z	O
is	O
N	O
or	O
CR2	O
'	O
;	O
X	O
is	O
NR2	O
'	O
,	O
O	O
or	O
S	O
;	O
R2	O
'	O
is	O
H,	O
alkyl,	O
-C	O
(	O
O	O
)	O
NR7,	O
-C	O
(	O
O	O
)	O
Re,	O
cycloalkyl,	O
haloalkyl,	O
hydroxyalkyl,	O
hydroxyalkylamino,	O
alkylamino,	O
heteroaryl,	O
or	O
aryl	O
;	O
R3	O
is	O
H,	O
methyl,	O
ethyl,	O
methoxy,	O
amine,	O
alkylamine,	O
morpholino,	O
N-methylpiperazine,	O
CF3,	O
or	O
OCF3	O
;	O
R2a	O
is	O
substituted	O
or	O
unsubstituted	O
aryl,	O
benzyl	O
or	O
heteroaryl	O
.	O


Disclosed	O
is	O
a	O
compound	O
which	O
is	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
a	O
sex	O
hormone-dependent	O
disease	O
or	O
the	O
like	O
.	O
Specifically	O
disclosed	O
are	O
:	O
a	O
nitrogenated	O
fused-ring	O
derivative	O
which	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
which	O
has	O
a	O
GnRH	B-GENE
antagonistic	O
activity,	O
or	O
a	O
prodrug	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative,	O
the	O
prodrug	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
;	O
use	O
of	O
the	O
derivative,	O
the	O
prodrug	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
for	O
medical	O
purposes	O
;	O
and	O
others	O
.	O
In	O
the	O
formula	O
(	O
I	O
)	O
,	O
the	O
rings	O
A	O
and	O
B	O
independently	O
represent	O
an	O
aryl	O
or	O
a	O
heteroaryl	O
;	O
RA	O
and	O
RB	O
independently	O
represent	O
a	O
halogen,	O
a	O
nitro,	O
an	O
alkyl,	O
-OW1,	O
-COW2,	O
-NW3W4	O
or	O
the	O
like	O
;	O
E	O
represents	O
an	O
oxygen	O
atom	O
or	O
the	O
like	O
;	O
U	O
represents	O
a	O
single	O
bond	O
or	O
the	O
like	O
;	O
and	O
X	O
represents	O
-SO2-Y,	O
-O-	O
(	O
alkylene	O
)	O
-Y	O
or	O
the	O
like	O
[	O
wherein	O
Y	O
represents	O
Z,	O
an	O
amino	O
or	O
the	O
like	O
;	O
Z	O
represents	O
a	O
heterocycloalkyl,	O
an	O
aryl	O
or	O
the	O
like	O
]	O
.	O


Disclosed	O
is	O
a	O
compound	O
useful	O
as	O
a	O
type-I	B-GENE
11β-hydroxysteroid	I-GENE
dehydrogenase	I-GENE
inhibitor	O
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
shown	O
below,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt,	O
wherein	O
X	O
represents	O
O	O
or	O
S	O
;	O
and	O
the	O
broken	O
line	O
and	O
the	O
wavy	O
lines	O
independently	O
represent	O
the	O
presence	O
or	O
absence	O
of	O
a	O
bond,	O
provided	O
that	O
:	O
(	O
i	O
)	O
when	O
the	O
broken	O
line	O
represents	O
the	O
presence	O
of	O
a	O
bond,	O
then	O
the	O
wavy	O
lines	O
independently	O
represent	O
the	O
absence	O
of	O
a	O
bond	O
and	O
R2	O
and	O
R3	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
halogen	O
or	O
the	O
like	O
;	O
and	O
(	O
ii	O
)	O
when	O
the	O
broken	O
line	O
represents	O
the	O
absence	O
of	O
a	O
bond,	O
then	O
the	O
wavy	O
lines	O
independently	O
represent	O
the	O
presence	O
of	O
a	O
bond,	O
R1	O
and	O
R4	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
halogen	O
or	O
the	O
like,	O
R2	O
and	O
R3	O
independently	O
represent	O
a	O
hydrogen,	O
a	O
halogen	O
or	O
the	O
like,	O
and	O
R5	O
and	O
R6	O
independently	O
represent	O
a	O
hydrogen,	O
an	O
alkyl	O
which	O
may	O
be	O
substituted	O
or	O
the	O
like	O
.	O


It	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
long-chain	O
fatty	O
acid	O
derivative	O
compound	O
having	O
an	O
agonistic	O
activity	O
to	O
GPR120	B-GENE
and	O
GPR40	B-GENE
.	O
The	O
long-chain	O
fatty	O
acid	O
derivative	O
compound	O
of	O
the	O
invention	O
is	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
.	O
In	O
the	O
formula,	O
m+n	O
means	O
an	O
integer	O
of	O
20	O
or	O
less,	O
R	O
means	O
a	O
hydrogen	O
atom	O
or	O
an	O
ester	O
residue,	O
Y1	O
and	O
Y2	O
mean	O
a	O
halogen	O
atom,	O
the	O
ring	O
Q	O
means	O
a	O
carbocyclic	O
group	O
or	O
a	O
heterocyclic	O
group	O
which	O
may	O
be	O
condensed,	O
X1,	O
X2,	O
and	O
X3	O
mean	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
or	O
the	O
like,	O
W	O
means	O
-C	O
(	O
=	O
N-OR1	O
)	O
-,	O
-CH	O
(	O
NR2R3	O
)	O
-	O
or	O
-CH	O
(	O
N3	O
)	O
-	O
.	O
A	O
medicament	O
containing	O
the	O
long-chain	O
fatty	O
acid	O
derivative	O
compound	O
as	O
an	O
active	O
ingredient	O
is	O
effective	O
as	O
an	O
appetite	O
regulating	O
agent,	O
an	O
antiobesity	O
agent,	O
a	O
therapeutic	O
agent	O
for	O
diabetes,	O
a	O
pancreatic	O
beta	O
cell	O
proliferation	O
and	O
differentiation	O
accelerator,	O
a	O
therapeutic	O
agent	O
for	O
metabolic	O
syndrome,	O
a	O
therapeutic	O
agent	O
for	O
gastrointestinal	O
diseases,	O
a	O
therapeutic	O
agent	O
for	O
neuropathy,	O
a	O
therapeutic	O
agent	O
for	O
psychiatric	O
disorder,	O
a	O
therapeutic	O
agent	O
for	O
lung	O
diseases,	O
a	O
therapeutic	O
agent	O
for	O
pituitary	O
hormone	O
deficiency,	O
and	O
a	O
fat	O
flavor	O
seasoning	O
.	O


The	O
present	O
invention	O
relates	O
to	O
improved	O
methods	O
of	O
resolution	O
and	O
recrystallization	O
for	O
synthesizing	O
compounds	O
of	O
formulae	O
(	O
I-1	O
)	O
or	O
(	O
A	O
)	O
useful	O
as	O
5HT2	B-GENE
agonists	O
or	O
partial	O
agonists,	O
including	O
intermediates	O
thereto	O
.	O


[	O
PROBLEMS	O
]	O
To	O
provide	O
an	O
antagonist	O
of	O
a	O
melanin-concentrating	B-GENE
hormone	I-GENE
receptor,	O
which	O
is	O
useful	O
as	O
a	O
medicine	O
for	O
a	O
central	O
nervous	O
system	O
disease,	O
a	O
cardiovascular	O
disease	O
or	O
a	O
metabolic	O
disease	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
The	O
antagonist	O
comprises,	O
as	O
an	O
active	O
ingredient,	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
.	O
(	O
I	O
)	O
wherein	O
R1a	O
and	O
R1b	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-6	O
alkyl	O
group	O
;	O
R2a,	O
R2b,	O
R3a	O
and	O
R3b	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group,	O
or	O
the	O
like	O
;	O
Y	O
represents	O
H	O
or	O
-OH	O
;	O
Z	O
represents	O
-OR8,	O
or	O
the	O
like	O
;	O
R8	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
;	O
R9a	O
and	O
R9b	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group,	O
or	O
the	O
like	O
;	O
Ar1	O
represents	O
an	O
aromatic	O
carbon	O
ring	O
group,	O
or	O
an	O
aromatic	O
heteroring	O
group	O
;	O
Ar2	O
represents	O
a	O
group	O
produced	O
by	O
removing	O
two	O
hydrogen	O
atoms	O
from	O
an	O
aromatic	O
carbon	O
ring,	O
or	O
the	O
like	O
;	O
and	O
the	O
ring	O
group	O
A	O
represents	O
an	O
unsaturated	O
heteroring	O
group	O
.	O


A	O
method	O
of	O
inhibiting	O
tumour	O
angiogenesis	O
in	O
an	O
individual,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
individual	O
an	O
inhibitor	O
of	O
ECSM2	B-GENE
.	O
A	O
method	O
of	O
combating	O
a	O
solid	O
tumour	O
in	O
an	O
individual,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
individual	O
an	O
inhibitor	O
of	O
ECSM2	B-GENE
.	O
The	O
inhibitor	O
may	O
be	O
an	O
antibody,	O
an	O
siRNA	O
molecule,	O
an	O
antisense	O
molecule,	O
or	O
a	O
ribozyme	O
.	O


Compositions	O
of	O
matter	O
and	O
methods	O
of	O
treating	O
cancer	O
patients	O
may	O
prevent	O
or	O
limit	O
cardiotoxicity	O
during	O
or	O
after	O
chemotherapy,	O
and	O
/	O
or	O
may	O
prevent	O
or	O
lower	O
resistance	O
to	O
anthracycline	O
drugs,	O
both	O
of	O
which	O
are	O
believed	O
to	O
be	O
caused	O
by	O
the	O
human	B-GENE
enzyme	I-GENE
carbonyl	I-GENE
reductase	I-GENE
.	O
Thus,	O
the	O
compositions	O
and	O
methods	O
may	O
be	O
used	O
to	O
reduce	O
the	O
dosages	O
of	O
anthracycline	O
anti-cancer	O
drugs	O
necessary	O
to	O
produce	O
a	O
desired	O
cancer-cell-killing	O
performance	O
.	O
Preferred	O
embodiments	O
comprise	O
treating	O
cancer	O
patients	O
with	O
a	O
pharmaceutical	O
composition	O
comprising	O
biphenyl	O
compounds	O
having	O
at	O
least	O
one	O
alkylated,	O
halogenated	O
(	O
or	O
pseudo-halogenaled	O
)	O
and	O
/	O
or	O
hydroxylated,	O
aryl	O
group	O
which	O
is	O
linked	O
by	O
a	O
bridging	O
atom	O
or	O
compound	O
to	O
another	O
aiyl	O
group	O
.	O
The	O
preferred	O
composition	O
of	O
biphenyl	O
compound	O
(	O
s	O
)	O
may	O
be	O
administered	O
in	O
a	O
pharmaceutical	O
composition	O
also	O
comprising	O
at	O
least	O
one	O
anthracycline	O
compound,	O
or	O
may	O
be	O
administered	O
separately	O
than	O
the	O
at	O
least	O
one	O
anthracycline	O
compound	O
.	O
Especially-preferred	O
biphenyl	O
compounds	O
include	O
triclosan,	O
hexachlorophene,	O
dichlorophene,	O
and	O
resveratrol	O
.	O


The	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
pyrazole	O
derivatives	O
of	O
fatty	O
acid	O
amides	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
hydrates	O
thereof,	O
which	O
demonstrate	O
selective	O
affinity	O
for	O
the	O
alpha	O
subtype	O
of	O
the	O
peroxisome	B-GENE
proliferator-activated	I-GENE
receptors	I-GENE
(	O
PPAR	B-GENE
)	O
and	O
which	O
consequently	O
modulate	O
the	O
actions	O
regulated	O
by	O
said	O
receptors,	O
specifically	O
satiety	O
induction	O
and	O
food	O
intake	O
control,	O
reduction	O
in	O
body	O
mass	O
gain	O
and	O
regulation	O
of	O
fat	O
metabolism	O
.	O


The	O
present	O
invention	O
provides	O
inhalation	O
compositions	O
comprising	O
montelukast	O
acid	O
and	O
a	O
second	O
active	O
agent	O
selected	O
from	O
a	O
PDE4	B-GENE
inhibitor	O
and	O
an	O
inhaled	O
corticosteroid	O
.	O
Also	O
provided	O
is	O
a	O
method	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
such	O
as	O
asthma	O
using	O
such	O
compositions	O
.	O


Thienopyrimidines	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
W	O
and	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims,	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
inhibitors	O
of	O
PI3K	B-GENE
and	I-GENE
are	O
selective	O
for	O
the	O
p110δ	O
isoform,	O
which	O
is	O
a	O
class	B-GENE
Ia	I-GENE
PI3	I-GENE
kinase,	O
over	O
both	O
other	O
class	B-GENE
Ia	I-GENE
and	I-GENE
class	B-GENE
Ib	I-GENE
kinases	I-GENE
.	O
The	O
compounds	O
may	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	O
kinase	I-GENE
such	O
as	O
cancer,	O
immune	O
disorders,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


[	O
PROBLEMS	O
]	O
	O
To	O
provide	O
a	O
compound	O
which	O
is	O
useful	O
as	O
a	O
medicinal	O
agent	O
having	O
an	O
agonistic	O
activity	O
on	O
a	O
GPR40	B-GENE
receptor,	O
particularly	O
an	O
insulin	B-GENE
secretion	O
promoter	O
or	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
diabetes	O
.	O
[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
	O
A	O
study	O
was	O
made	O
on	O
the	O
compounds	O
having	O
an	O
agonistic	O
activity	O
on	O
a	O
GPR40	B-GENE
receptor	O
.	O
	O
As	O
a	O
result,	O
it	O
is	O
now	O
found	O
that	O
an	O
oxadiazolidinedione	O
compound	O
which	O
has,	O
at	O
position-2	O
in	O
an	O
oxadiazolidinedione	O
ring,	O
a	O
substituent	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
benzyl	O
group	O
)	O
that	O
is	O
bound	O
to	O
a	O
substituent	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
phenyl	O
group	O
)	O
through	O
a	O
linker	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
has	O
an	O
excellent	O
GPR40	B-GENE
agonistic	O
activity	O
.	O
	O
The	O
oxadiazolidinedione	O
compound	O
has	O
an	O
excellent	O
activity	O
of	O
promoting	O
the	O
insulin	B-GENE
secretion	O
and	O
an	O
excellent	O
activity	O
of	O
inhibiting	O
the	O
increase	O
in	O
blood	O
glucose	O
level,	O
and	O
therefore	O
can	O
be	O
used	O
as	O
an	O
insulin	B-GENE
secretion	O
promoter	O
or	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
diabetes	O
.	O


A	O
composition	O
for	O
modulating	O
generation	O
of	O
pro-inflammatory	O
cytokines	B-GENE
comprises	O
levocabastine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
.	O
Such	O
composition	O
is	O
useful	O
for	O
treating	O
or	O
controlling	O
diseases	O
having	O
an	O
inflammatory	O
component,	O
such	O
as	O
ocular	O
diseases	O
that	O
are	O
caused	O
by	O
inflammation	O
or	O
have	O
inflammatory	O
sequelae	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
a	O
psychotic	O
disorder	O
or	O
condition,	O
associated	O
with	O
cognitive	O
impairment	O
.	O
The	O
pharmaceutical	O
composition	O
comprises	O
:	O
(	O
a	O
)	O
an	O
amount	O
of	O
an	O
antipsychotic	O
agent	O
and	O
(	O
b	O
)	O
an	O
amount	O
of	O
a	O
PDE4	B-GENE
inhibitor	O
compound,	O
wherein	O
the	O
amounts	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
are	O
together	O
effective	O
in	O
treating	O
the	O
cognitive	O
impairment	O
or	O
psychotic	O
disorder	O
such	O
as	O
schizophrenia	O
.	O
The	O
method	O
of	O
treatment	O
comprises	O
administering	O
to	O
a	O
patient	O
(	O
a	O
)	O
an	O
amount	O
of	O
a	O
antipsychotic	O
agent	O
and	O
(	O
b	O
)	O
an	O
amount	O
of	O
a	O
PDE4	B-GENE
inhibitor	O
compound,	O
wherein	O
the	O
amounts	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
are	O
together	O
effective	O
in	O
treating	O
the	O
psychotic	O
disorder	O
such	O
as	O
schizophrenia	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
The	O
instant	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formulae	O
(	O
I	O
A	O
)	O
,	O
(	O
I	O
B	O
)	O
,	O
(	O
X	O
A	O
)	O
,	O
(	O
X	O
B	O
)	O
,	O
(	O
Y	O
A	O
)	O
or	O
(	O
Y	O
B	O
)	O
,	O
wherein	O
R	O
'	O
represents	O
(	O
formula	O
)	O
and	O
R	O
'	O
represents	O
hydrogen,	O
hydroxy,	O
C1-C7alkoxy,	O
C1-C8-alkanoyloxy,	O
or	O
R5R4N-CO-O-,	O
where	O
R4	O
and	O
R5	O
independently	O
are	O
C1-C7alkyl	O
or	O
phenyl	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
by	O
a	O
substitutent	O
selected	O
from	O
C1-C7alkyl,	O
C1-C7alkoxy,	O
halogen	O
and	O
trifluoromethyl	O
and	O
where	O
R4	O
additionally	O
is	O
hydrogen	O
;	O
or	O
R4	O
and	O
R5	O
together	O
represent	O
C3-C6alkylene	O
;	O
in	O
free	O
form	O
or	O
in	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
.	O
Compounds	O
of	O
formulae	O
(	O
I	O
A	O
)	O
,	O
(	O
I	O
B	O
)	O
,	O
(	O
X	O
A	O
)	O
,	O
(	O
X	O
B	O
)	O
,	O
(	O
Y	O
A	O
)	O
or	O
(	O
Y	O
B	O
)	O
inhibit	O
DPP-IV	B-GENE
(	O
dipeptidyl-	B-GENE
peptidase-IV	I-GENE
)	O
activity	O
.	O
They	O
are	O
therefore	O
indicated	O
for	O
use	O
as	O
pharmaceuticals	O
in	O
inhibiting	O
DPP-IV	B-GENE
and	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
DPP-IV,	O
such	O
as	O
non-insulin-	O
dependent	O
diabetes	O
mellitus,	O
arthritis,	O
obesity,	O
osteoporosis	O
and	O
further	O
conditions	O
of	O
impaired	O
glucose	O
tolerance	O
.	O


The	O
present	O
invention	O
involves	O
the	O
use	O
of	O
a	O
steroid	O
linked	O
to	O
nitric	O
oxide	O
(	O
preferred	O
steroid	O
is	O
budesonide	O
)	O
for	O
treating	O
respirator	O
}	O
'	O
diseases	O
by	O
decreasing	O
neutrophil	O
sputum	O
levels	O
and	O
decreasing	O
plasma	O
CRP	B-GENE
levels	O
Respiratory	O
diseases	O
treated	O
include	O
asthma,	O
COPD	O
(	O
chronic	O
obstructive	O
pulmonary	O
disorder	O
)	O
,	O
eosinophilic	O
cough,	O
bronchitis,	O
sarcoidosis,	O
pulmonary	O
fibrosis,	O
rhinitis,	O
pulmonary	O
hypertension,	O
cystic	O
fibrosis,	O
bronchiectasis	O
and	O
sinusitis	O


This	O
invention	O
discloses	O
the	O
use	O
of	O
an	O
E-selectin	B-GENE
antagonist	O
and	O
a	O
mobilizer	O
of	O
hematopoietic	O
stem	O
cells	O
or	O
progenitor	O
cells	O
in	O
methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
immunocompromised	O
conditions	O
resulting	O
from	O
medical	O
treatment	O
.	O
The	O
present	O
invention	O
is	O
particular	O
relevant	O
for	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
hematopoeitic	O
disorders	O
including	O
neutropenia,	O
agranulocytosis,	O
anemia	O
and	O
thrombocytopenia	O
in	O
individuals	O
receiving	O
or	O
proposed	O
to	O
receive	O
treatments	O
that	O
target	O
rapidly	O
dividing	O
cells	O
or	O
that	O
disrupt	O
the	O
cell	O
cycle	O
or	O
cell	O
division	O
.	O


O-	O
(	O
3-Piperidino-2-hydroxy-1-propyl	O
)	O
-nicotinic	O
amidoxime	O
or	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
is	O
administered	O
to	O
patients	O
suffering	O
from	O
overweight	O
or	O
obesity	O
and	O
treated	O
with	O
a	O
cannabinoid	B-GENE
CB1	I-GENE
receptor	I-GENE
antagonist	O
such	O
as	O
rimonabant	O
to	O
reduce	O
the	O
unfavourable	O
psychiatric	O
side	O
effect	O
of	O
the	O
latter	O
.	O


The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
preventing	O
EthR	B-GENE
from	O
binding	O
to	O
the	O
ethA	O
promoter,	O
for	O
example	O
a	O
compound	O
of	O
formula	O
1	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
phenyl	O
or	O
optionally	O
substituted	O
pyridyl	O
;	O
R2	O
is	O
(	O
CH2	O
)	O
n	O
wherein	O
n	O
is	O
1,	O
2,	O
3	O
or	O
4	O
;	O
R3	O
is	O
CH3	O
(	O
CH2	O
)	O
m	O
wherein	O
m	O
is	O
0,	O
1,	O
2	O
or	O
3	O
;	O
X1	O
is	O
O,	O
S,	O
NH,	O
N	O
(	O
CH3	O
)	O
or	O
CH2	O
;	O
and	O
X2	O
is	O
O,	O
S	O
or	O
NH	O
;	O
in	O
particular	O
2-phenylethyl	O
butyrate,	O
and	O
a	O
thioamide	O
or	O
thiourea	O
of	O
formula	O
2	O
wherein	O
R4	O
is	O
optionally	O
substituted	O
phenyl,	O
optionally	O
substituted	O
pyridyl,	O
optionally	O
substituted	O
indolyl,	O
-NR7R8	O
;	O
or	O
-NH-N	O
=	O
CH-R9	O
;	O
and	O
substituents	O
R5	O
to	O
R9	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description,	O
in	O
particular	O
ethionamide	O
.	O
The	O
pharmaceutical	O
composition	O
is	O
useful,	O
e	O
.	O
g	O
.	O
,	O
in	O
the	O
treatment	O
of	O
multidrug-resistant	O
tuberculosis	O
.	O


This	O
invention	O
relates	O
to	O
novel	O
carboxyl-	O
or	O
hydroxylsubstituted	O
benzimidazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R6	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O
These	O
compounds	O
bind	O
to	O
FXR	B-GENE
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O


The	O
invention	O
concerns	O
bicyclic	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
integers	O
X1,	O
X2,	O
X3,	O
Ring	O
A,	O
R4,	O
R5	O
and	O
m	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
androgen-receptor	B-GENE
associated	O
conditions	O
.	O


This	O
invention	O
relates	O
generally	O
to	O
imidazo	O
[	O
1,2-b	O
]	O
pyridazine-based	O
modulators	O
of	O
Liver	B-GENE
X	I-GENE
receptors	I-GENE
(	O
LXRs	B-GENE
)	O
having	O
formula	O
(	O
I	O
)	O
and	O
related	O
methods	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
R2	O
is	O
C6-C10	O
aryl	O
or	O
heteroaryl	O
including	O
5-10	O
atoms,	O
each	O
of	O
which	O
is	O
:	O
(	O
i	O
)	O
substituted	O
with	O
1	O
R6,	O
and	O
(	O
ii	O
)	O
optionally	O
substituted	O
with	O
from	O
1-5	O
Re	O
;	O
and	O
R1,	O
R3,	O
R4,	O
R5,	O
R6	O
and	O
Re	O
are	O
defined	O
herein	O
.	O


The	O
invention	O
enables	O
smokers	O
to	O
stop	O
consuming	O
tobacco	O
without	O
indefinitely	O
and	O
without	O
suffering	O
from	O
significant	O
undesired	O
effects,	O
and	O
also	O
enables	O
consumers	O
of	O
generally	O
addictive	O
drugs	O
(	O
opiacea,	O
psychostimulants,	O
alcohol	O
)	O
to	O
stop	O
consuming	O
said	O
drugs	O
.	O
CONTEXT	O
OF	O
THE	O
INVENTION	O
.	O
The	O
products	O
available	O
on	O
the	O
market	O
for	O
controlling	O
smoking	O
include	O
three	O
types	O
:	O
a	O
.	O
nicotine	O
additives	O
(	O
patch,	O
chewing	O
gum,	O
etc	O
.	O
)	O
:	O
nicotine	O
has	O
no	O
toxic	O
effect,	O
but	O
additives	O
solely	O
containing	O
nicotine	O
have	O
a	O
significant	O
effect	O
on	O
tobacco	O
consumption	O
only	O
during	O
the	O
first	O
weeks	O
of	O
the	O
treatment	O
.	O
Relapses	O
are	O
very	O
frequent	O
(	O
higher	O
than	O
75	O
%	O
)	O
.	O
b	O
.	O
Zyban	O
(	O
Bupropion	O
)	O
:	O
Zyban,	O
whether	O
consumed	O
with	O
or	O
without	O
nicotine,	O
does	O
not	O
act	O
as	O
an	O
addictive	O
substitute	O
.	O
From	O
a	O
clinical	O
point	O
of	O
view,	O
relapse	O
up	O
to	O
80	O
%	O
is	O
observed	O
after	O
a	O
month	O
treatment	O
.	O
It	O
further	O
has	O
undesired	O
cardiovascular	O
effects	O
.	O
c	O
.	O
Champix	O
(	O
Varenicline	O
)	O
:	O
Champix	O
has	O
been	O
released	O
recently	O
on	O
the	O
market	O
.	O
Its	O
function	O
is	O
to	O
partially	O
inhibit	O
the	O
effect	O
of	O
nicotine	O
.	O
It	O
does	O
not	O
operate	O
as	O
an	O
addictive	O
substitute	O
.	O
From	O
a	O
clinical	O
point	O
of	O
view,	O
the	O
quitting	O
figures	O
published	O
until	O
today	O
are	O
approximately	O
44	O
%	O
after	O
one	O
month,	O
with	O
very	O
high	O
levels	O
of	O
relapse	O
in	O
the	O
following	O
months	O
.	O
Significant	O
side	O
effects,	O
such	O
as	O
sleep	O
disorders,	O
have	O
been	O
reported	O
since	O
it	O
has	O
been	O
made	O
available	O
on	O
the	O
market	O
.	O
The	O
main	O
current	O
research	O
has	O
not	O
been	O
able	O
to	O
compensate	O
for	O
the	O
deficiencies	O
of	O
these	O
products	O
:	O
a	O
.	O
Rimonabant,	O
a	O
cannabinoid	O
receptor	O
antagonist	O
product,	O
was	O
not	O
released	O
on	O
the	O
market	O
because	O
clinical	O
tests	O
revealed	O
a	O
strong	O
depression-promoting	O
effect	O
.	O
b	O
.	O
Other	O
research	O
focuses	O
on	O
the	O
action	O
of	O
compounds	O
associated	O
with	O
nicotine	O
for	O
explaining	O
the	O
strong	O
addictive	O
potential	O
of	O
tobacco	O
;	O
however,	O
the	O
selected	O
compounds	O
did	O
not	O
appear	O
as	O
effective	O
solutions	O
.	O
Indeed,	O
several	O
works	O
suggest	O
that	O
the	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
(	O
IMAOs	O
)	O
contained	O
in	O
tobacco	O
and	O
in	O
the	O
smoke	O
thereof	O
are	O
the	O
compounds	O
that,	O
in	O
association	O
with	O
nicotine,	O
impart	O
an	O
addictive	O
effect	O
to	O
tobacco	O
(	O
4,	O
10,	O
11	O
)	O
.	O
The	O
research	O
focuses	O
on	O
the	O
addition	O
of	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
(	O
IMAOs	O
)	O
to	O
nicotine	O
.	O
This	O
solution	O
is	O
not	O
effective	O
enough	O
in	O
that	O
the	O
blocking	O
of	O
monoamine	B-GENE
oxidases	I-GENE
may	O
have	O
dangerous	O
physiological	O
consequences	O
(	O
serotoninergic	O
syndrome	O
)	O
.	O
Consequently,	O
we	O
do	O
not	O
currently	O
know	O
of	O
any	O
tobacco	O
substitution	O
product,	O
either	O
on	O
the	O
market	O
or	O
in	O
development,	O
which	O
is	O
sufficiently	O
effective	O
in	O
smoking	O
control	O
.	O
There	O
is	O
no	O
substitution	O
product	O
for	O
psychostimulants	O
(	O
cocaine,	O
amphetamine	O
)	O
,	O
and	O
two	O
products	O
are	O
available	O
on	O
the	O
market	O
as	O
a	O
substitute	O
for	O
opiacea,	O
i	O
.	O
e	O
.	O
subutex	O
(	O
buprenorphine	O
)	O
and	O
methadone	O
.	O
Although	O
they	O
are	O
effective	O
as	O
substitution	O
products,	O
the	O
latter	O
are	O
not	O
advantageous	O
in	O
that	O
they	O
maintain	O
the	O
consumer	O
in	O
a	O
strong	O
physical	O
addiction	O
state	O
(	O
10	O
days	O
and	O
more	O
)	O
,	O
which	O
makes	O
weaning	O
difficult	O
or	O
even	O
impossible	O
.	O
Furthermore,	O
there	O
is	O
no	O
substitution	O
product	O
for	O
alcohol,	O
and	O
the	O
products	O
used	O
today	O
are	O
intended	O
for	O
repelling	O
a	O
drinker	O
and	O
are	O
not	O
sufficient	O
for	O
weaning	O
.	O


Disclosed	O
is	O
a	O
compound	O
having	O
a	O
novel	O
structure,	O
few	O
adverse	O
side	O
effects	O
and	O
an	O
excellent	O
inhibitory	O
activity	O
on	O
human	B-GENE
SGLT1	I-GENE
and	O
/	O
or	O
SGLT2,	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
.	O
Also	O
disclosed	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
type-1	O
diabetes,	O
type-2	O
diabetes,	O
gestational	O
diabetes,	O
hyperglycemia	O
induced	O
by	O
other	O
factor,	O
impaired	O
glucose	O
tolerance	O
(	O
IGT	O
)	O
,	O
diabetes-related	O
diseases	O
or	O
diabetic	O
complications,	O
which	O
comprises	O
the	O
compound	O
or	O
the	O
hydrate	O
as	O
an	O
active	O
ingredient	O
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
shown	O
below	O
or	O
a	O
hydrate	O
thereof	O
.	O


Orally	O
administered	O
physiologically	O
acceptable	O
anti-biofilm	O
compositions	O
comprising	O
enzymes	O
and	O
if	O
desired	O
additional	O
components	O
such	O
as	O
antimicrobials,	O
antibiotics,	O
antifungals,	O
herbals,	O
chelating	O
agents,	O
lactoferrin	B-GENE
and	O
related	O
compounds,	O
minerals,	O
surfactants,	O
binders,	O
and	O
fillers	O
useful	O
for	O
the	O
inhibition	O
and	O
treatment	O
of	O
gastrointestinal	O
biofilms	O
in	O
humans	O
.	O
Physiologically	O
acceptable	O
anti-biofilm	O
compositions	O
containing	O
these	O
enzymes	O
are	O
useful	O
in	O
the	O
inhibition,	O
reduction	O
and	O
/	O
or	O
treatment	O
of	O
gastrointestinal	O
biofilm	O
infections,	O
and	O
associated	O
systemic	O
symptoms	O
caused	O
by	O
biofilms	O
associated	O
microorganisms	O
within	O
the	O
gastrointestinal	O
tract	O
.	O
Methods	O
of	O
identification,	O
preparation	O
and	O
use	O
of	O
such	O
physiologically	O
acceptable	O
anti-biofilm	O
compositions	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
piperidine	O
sulphonamide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
Ar1,	O
Ar2,	O
R1,	O
R2,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims,	O
or	O
pharmaceutically	O
suitable	O
acid	O
addition	O
salts	O
thereof	O
.	O
The	O
compounds	O
of	O
formula	O
I	O
are	O
orexin	B-GENE
receptor	I-GENE
antagonists	O
and	O
the	O
related	O
compounds	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
sleep	O
apnea,	O
narcolepsy,	O
insomnia,	O
parasomnia,	O
jet	O
lag	O
syndrome,	O
circadian	O
rhythms	O
disorder	O
or	O
sleep	O
disorders	O
associated	O
with	O
neurological	O
diseases	O
.	O


A	O
composition	O
for	O
the	O
treatment	O
of	O
acne	O
vulgaris,	O
rosacea	O
and	O
/	O
or	O
rhinophym	O
comprising	O
at	O
least	O
one	O
inhibitor	O
of	O
the	O
FGFR2	B-GENE
signal	O
pathway	O
and	O
/	O
or	O
IGFR1	B-GENE
signal	O
pathway	O
.	O


Aspects	O
of	O
this	O
invention	O
relate	O
to	O
the	O
fields	O
of	O
molecular	O
biology	O
and	O
medicine	O
.	O
More	O
specifically,	O
disclosed	O
herein	O
are	O
several	O
approaches	O
to	O
provide	O
subjects	O
suffering	O
from	O
cancer	O
with	O
an	O
inhibitor	O
of	O
S100A6	B-GENE
and	O
/	O
or	O
S	B-GENE
100A4	I-GENE
alone	O
or	O
in	O
combination	O
with	O
other	O
cancer	O
therapies	O
so	O
as	O
to	O
improve	O
the	O
cancer	O
therapy	O
and	O
/	O
or	O
more	O
efficiently	O
treat	O
cancer,	O
in	O
particular	O
forms	O
of	O
cancer	O
that	O
are	O
resistant	O
to	O
other	O
therapies	O
.	O
Also	O
disclosed	O
herein	O
are	O
approaches	O
for	O
using	O
S	B-GENE
100A6	I-GENE
and	O
/	O
or	O
S	B-GENE
100A4	I-GENE
as	O
a	O
biomarker	O
for	O
metastases	O
.	O
Further,	O
disclosed	O
herein	O
are	O
approaches	O
for	O
using	O
S	B-GENE
100A6	I-GENE
and	O
/	O
or	O
S	B-GENE
100A4	I-GENE
as	O
a	O
biomarker	O
for	O
cancer	O
therapies,	O
in	O
particular,	O
as	O
a	O
biomarker	O
to	O
determine	O
individual	O
responses	O
to	O
cancer	O
therapies	O
.	O
In	O
addition,	O
disclosed	O
herein	O
are	O
approaches	O
to	O
identifying	O
S	B-GENE
100A6	I-GENE
and	O
/	O
or	O
S	B-GENE
100A4	I-GENE
inhibitors,	O
for	O
example,	O
that	O
act	O
synergistically	O
with	O
a	O
cancer	O
therapy	O
.	O


Disclosed	O
is	O
a	O
promoter	O
for	O
the	O
secretion	O
of	O
insulin-like	B-GENE
growth	I-GENE
factor-1,	O
which	O
is	O
safe,	O
can	O
be	O
ingested	O
on	O
a	O
daily	O
basis,	O
and	O
comprises	O
a	O
polyphenol	O
as	O
an	O
active	O
ingredient	O
.	O
Also	O
disclosed	O
is	O
a	O
food	O
or	O
beverage	O
containing	O
the	O
promoter	O
.	O
Further	O
disclosed	O
is	O
a	O
method	O
for	O
promoting	O
the	O
secretion	O
of	O
insulin-like	B-GENE
growth	I-GENE
factor-1	I-GENE
in	O
the	O
blood	O
or	O
an	O
organ	O
in	O
a	O
mammal,	O
which	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
polyphenol	O
to	O
the	O
mammal	O
.	O


The	O
present	O
invention	O
relates	O
to	O
l-aryl-3-aniline-5-alkyl-l,	O
2,4-triazole	O
derivatives	O
and	O
analogues	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy,	O
according	O
to	O
Formula	O
(	O
I	O
)	O
.	O
The	O
invention	O
particularly	O
relates	O
to	O
potent	O
positive	O
allosteric	O
modulators	O
of	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors,	O
such	O
positive	O
allosteric	O
modulator	O
having	O
the	O
capability	O
to	O
increase	O
the	O
efficacy	O
of	O
nicotinic	B-GENE
receptor	I-GENE
agonists	O
.	O


The	O
disclosure	O
generally	O
relates	O
to	O
the	O
novel	O
compounds	O
of	O
formula	O
I,	O
including	O
their	O
salts,	O
which	O
inhibit	O
HIV	B-GENE
integrase	I-GENE
and	O
prevent	O
viral	O
integration	O
into	O
human	O
DNA	O
.	O
This	O
action	O
makes	O
the	O
compounds	O
useful	O
for	O
treating	O
HIV	O
infection	O
and	O
AIDS	O
.	O
The	O
invention	O
also	O
encompasses	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
those	O
infected	O
with	O
HIV	O
.	O
Formule	O
(	O
I	O
)	O
.	O


Disclosed	O
herein,	O
in	O
certain	O
embodiments,	O
is	O
a	O
method	O
for	O
treating	O
an	O
MIF-mediated	O
disorder	O
.	O
In	O
some	O
embodiments,	O
the	O
method	O
comprises	O
administering	O
an	O
active	O
agent	O
that	O
inhibits	O
(	O
i	O
)	O
MIF	B-GENE
binding	O
to	O
CXCR2	B-GENE
and	O
CXCR4	B-GENE
and	O
/	O
or	O
(	O
ii	O
)	O
MIF-activation	O
of	O
CXCR2	B-GENE
and	O
CXCR4	B-GENE
;	O
(	O
iii	O
)	O
the	O
ability	O
of	O
MIF	B-GENE
to	O
form	O
a	O
homomultimer	O
;	O
or	O
a	O
combination	O
thereof	O


A	O
series	O
of	O
fused	O
bicyclic	O
thiophene	O
and	O
thiazole	O
derivatives	O
(	O
I	O
)	O
which	O
are	O
substituted	O
in	O
the	O
2-position	O
by	O
an	O
optionally	O
substituted	O
morpholin-4-yl	O
moiety,	O
and	O
wherein	O
the	O
thiophene	O
or	O
thiazole	O
ring	O
is	O
fused	O
to	O
a	O
six-membered	O
carbocyclic	O
ring	O
containing	O
an	O
alpha-hydroxyketone	O
functionality,	O
being	O
selective	O
inhibitors	O
of	O
PI3	B-GENE
kinase	I-GENE
enzymes,	O
are	O
accordingly	O
of	O
benefit	O
in	O
medicine,	O
for	O
example	O
in	O
the	O
treatment	O
of	O
inflammatory,	O
autoimmune,	O
cardiovascular,	O
neurodegenerative,	O
metabolic,	O
oncological,	O
nociceptive	O
or	O
ophthalmic	O
conditions	O
.	O


Provided	O
is	O
an	O
excellent	O
medicinal	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
vascular	O
diseases	O
.	O
A	O
medicinal	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
vascular	O
diseases	O
which	O
comprises	O
:	O
1	O
)	O
a	O
COX-1	B-GENE
selective	O
inhibitor	O
;	O
and	O
2	O
)	O
clopidogrel	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
	O
The	O
medicinal	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
vascular	O
diseases	O
thus	O
provided	O
is	O
particularly	O
useful	O
as	O
a	O
medicinal	O
composition	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
arterial	O
thrombosis,	O
ischemic	O
heart	O
disease,	O
ischemic	O
brain	O
disease,	O
pulmonary	O
embolism,	O
peripheral	O
circulation	O
disorder,	O
restenosis	O
and	O
reocclusion,	O
essential	O
thrombocytosis	O
and	O
so	O
on	O
.	O


Described	O
herein	O
are	O
tricyclic	O
macrolactones	O
.	O
The	O
macrolactones	O
have	O
a	O
high	O
binding	O
affinity	O
for	O
PKC	B-GENE
.	O
The	O
compounds	O
described	O
herein	O
can	O
be	O
used	O
in	O
a	O
number	O
of	O
therapeutic	O
applications	O
including	O
cancer	O
and	O
Alzheimer	O
'	O
s	O
prevention	O
and	O
treatment	O
.	O
The	O
compounds	O
described	O
herein	O
can	O
also	O
treat	O
memory	O
loss	O
.	O
Also	O
described	O
herein	O
are	O
methods	O
for	O
producing	O
macrolactones	O
.	O
The	O
methods	O
permit	O
the	O
high-yield	O
synthesis	O
of	O
macrolactones	O
in	O
fewer	O
steps	O
and	O
with	O
a	O
higher	O
degree	O
of	O
substitution	O
and	O
specificity	O
.	O


Cellobio-oligosaccharides	O
(	O
CBO	O
)	O
produced	O
by	O
the	O
dextransucrase-catalyzed	O
transglycosylation	O
reaction	O
of	O
sucrose	O
and	O
cellobiose	O
were	O
discovered	O
to	O
be	O
effective	O
as	O
antifungal	O
agents	O
against	O
dental	O
caries	O
and	O
against	O
fungi	O
who	O
rely	O
on	O
glucan	O
as	O
an	O
integral	O
part	O
of	O
the	O
cell	O
wall,	O
e	O
.	O
g	O
.	O
,	O
A	O
.	O
terreus	O
.	O
The	O
cellobio-oligosaccharides	O
were	O
found	O
to	O
be	O
inhibitors	O
of	O
β-(l,3)-glucan	O
synthase,	O
an	O
important	O
enzyme	O
involving	O
in	O
fungal	O
cell	O
wall	O
component	O
synthesis	O
.	O
The	O
CBO	O
caused	O
structural	O
changes	O
in	O
the	O
growing	O
fungal	O
cells	O
.	O
In	O
addition,	O
the	O
CBO	O
were	O
shown	O
to	O
be	O
effective	O
as	O
anti-cariogenic	O
agents	O
in	O
preventing	O
bacterial	O
adherence	O
to	O
teeth	O
by	O
inhibiting	O
the	O
formation	O
of	O
the	O
bacterial	O
plaque	O
(	O
glucans	O
)	O
,	O
e	O
.	O
g	O
.	O
,	O
that	O
formed	O
by	O
Streptococcus	O
mutans	O
.	O
Cellobio-oligosaccharides	O
produced	O
by	O
dextransucrase	B-GENE
were	O
analyzed	O
and	O
shown	O
to	O
have	O
a	O
degree	O
of	O
polymerization	O
(	O
DP	O
)	O
ranging	O
from	O
3	O
to	O
6	O
glucosyl	O
groups	O
.	O
Examples	O
of	O
these	O
cellobio-oligosaccharides	O
produced	O
by	O
this	O
method	O
include,	O
but	O
are	O
not	O
limited	O
to,	O
trisaccharides	O
such	O
as	O
α-D-glucopyranosyl-	O
(	O
l→2	O
)	O
-β-D-glucopyranosyl-	O
(	O
1→4	O
)	O
-D-glucopyranose	O
and	O
α-D-glucopyranosyl-	O
(	O
1→6	O
)	O
-β-D-glucopyranosyl-	O
(	O
1	O
→4	O
)	O
-D-glucopyranose	O
.	O


Compounds	O
useful	O
for	O
promoting	O
lysosomal	O
processes	O
and	O
thereby	O
ameliorating	O
the	O
disruption	O
of	O
cellular	O
and	O
functional	O
integrity	O
induced	O
by	O
Aβ	B-GENE
and	O
other	O
protein	O
and	O
glycoconjugate	O
species	O
are	O
provided	O
.	O
Methods	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
that	O
involve	O
protein	O
accumulation	O
and	O
aggregation	O
in	O
the	O
brain,	O
such	O
as	O
Alzheimer	O
'	O
s,	O
Parkinson	O
'	O
s	O
and	O
Huntington	O
'	O
s	O
Disease,	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
disease	O
in	O
an	O
animal,	O
which	O
disease	O
is	O
responsive	O
to	O
inhibiting	O
of	O
functional	O
cystic	B-GENE
fibrosis	I-GENE
transmembrane	I-GENE
conductance	I-GENE
regulator	I-GENE
(	O
CFTR	B-GENE
)	O
polypeptide	O
by	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
defined	O
herein	O
(	O
including	O
those	O
compounds	O
set	O
forth	O
in	O
Table	O
1	O
or	O
encompassed	O
by	O
formula	O
I	O
)	O
or	O
compositions	O
thereof,	O
thereby	O
treating	O
the	O
disease	O
.	O
	O
The	O
present	O
invention	O
particularly,	O
relates	O
to	O
a	O
method	O
of	O
treating	O
diarrhea	O
and	O
polycystic	O
kidney	O
disease	O
.	O


The	O
present	O
invention	O
concerns	O
a	O
compound,	O
which	O
modulates	O
protein	B-GENE
kinase	I-GENE
activity,	O
having	O
the	O
following	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
ester	O
or	O
prodrug	O
thereof,	O
wherein	O
R1,	O
R2	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
are	O
each	O
independently	O
chosen	O
from	O
hydrogen,	O
branched	O
or	O
linear	O
alkyl,	O
branched	O
or	O
linear	O
hydroxyalkylene,	O
nitro,	O
amino,	O
-C	O
(	O
=	O
O	O
)	O
OR4,	O
-C	O
(	O
=	O
O	O
)	O
NR5R6,	O
and	O
-NHC	O
(	O
=	O
O	O
)	O
R7,	O
as	O
well	O
as	O
compositions	O
comprising	O
the	O
compound	O
as	O
an	O
active	O
agent	O
and	O
use	O
of	O
the	O
compounds	O
and	O
the	O
compositions	O
in	O
manufacturing	O
medicaments	O
for	O
regulating	O
protein	B-GENE
kinase	I-GENE
activity	O
in	O
a	O
subject	O
by	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
comprising	O
a	O
compound	O
of	O
the	O
invention	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
ester	O
or	O
prodrug	O
thereof,	O
in	O
an	O
amount	O
effective	O
to	O
regulate	O
the	O
protein	B-GENE
kinase	I-GENE
activity	O
.	O


This	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
screening	O
of	O
microRNA	O
capable	O
of	O
modulating	O
gene	O
expression	O
in	O
the	O
apoptotic	O
pathway	O
in	O
the	O
presence	O
of	O
HSP90	B-GENE
inhibitor	O
.	O
The	O
use	O
of	O
miRNA	O
for	O
enhancing	O
the	O
activity	O
of	O
therapeutic	O
agents	O
not	O
limited	O
to	O
HSP90	B-GENE
inhibitor	O
is	O
also	O
disclosed	O
.	O
The	O
diagnostic	O
use	O
of	O
miRNA	O
for	O
predicting	O
response	O
to	O
therapy	O
not	O
limited	O
to	O
therapeutic	O
agents	O
is	O
also	O
disclosed	O
.	O
A	O
method	O
for	O
the	O
identification	O
and	O
therapeutic	O
application	O
of	O
small	O
molecules	O
which	O
are	O
modulators	O
of	O
these	O
nucleic	O
acids	O
are	O
also	O
included	O
in	O
this	O
application	O
.	O


Dihydroindolinone	O
compounds	O
which	O
may	O
modulate	O
the	O
activity	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinases,	O
their	O
preparation	O
methods,	O
compositions	O
comprising	O
the	O
compounds	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
described	O
herein	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinases	I-GENE
related	O
diseases	O
in	O
organism,	O
particularly	O
cancer	O
and	O
the	O
proliferation	O
of	O
fibroblast	O
related	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
in	O
part	O
to	O
stabilized	O
rice	O
bran	O
extracts	O
enriched	O
in	O
compounds	O
that	O
have	O
inhibitory	O
activity	O
against	O
certain	O
anti-	O
inflammatory	O
therapeutic	O
endpoints,	O
such	O
as	O
the	O
COX-1,	O
COX-2	B-GENE
and	O
5-LOX	B-GENE
enzymes	O
.	O
Another	O
aspect	O
of	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
extracts	O
and	O
to	O
methods	O
of	O
treating	O
inflammatory	O
diseases	O
comprising	O
administering	O
the	O
aforementioned	O
extracts	O
.	O


This	O
disclosure	O
relates	O
to	O
deuterated	O
Tizanidine,	O
to	O
compositions	O
comprising	O
the	O
compound	O
of	O
this	O
disclosure	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by-	O
administering	O
an	O
alpha2-adrenoreceptor	B-GENE
agonist	O
.	O


Provided	O
is	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
which	O
can	O
be	O
used	O
in	O
pharmaceutical	O
applications,	O
and	O
an	O
agent	O
for	O
blocking	O
GIP	B-GENE
receptor	I-GENE
binding	O
for	O
preventing	O
or	O
ameliorating	O
obesity,	O
insulin	B-GENE
resistance	O
or	O
the	O
accumulation	O
of	O
lipid	O
in	O
the	O
liver,	O
based	O
on	O
blocking	O
GIP	O
function	O
and	O
more	O
precisely	O
based	O
on	O
blocking	O
GIP	B-GENE
receptor	I-GENE
binding,	O
wherein	O
said	O
compound	O
forms	O
the	O
effective	O
component	O
.	O
[	O
In	O
this	O
formula,	O
for	O
example,	O
W	O
represents	O
CR1	O
(	O
where	O
R1	O
is	O
a	O
halogen	O
atom	O
or	O
a	O
cyano	O
group	O
)	O
etc	O
.	O
,	O
and	O
Z	O
is	O
a	O
group	O
represented	O
by	O
general	O
formula	O
(	O
VI	O
)	O
,	O
(	O
V2	O
)	O
or	O
(	O
Y1	O
)	O
.	O
]	O
[	O
In	O
these	O
formulae,	O
for	O
example,	O
A	O
represents	O
an	O
optionally	O
substituted	O
aryl	O
group	O
etc	O
.	O
,	O
R2	O
represents	O
an	O
optionally	O
substituted	O
aryl	O
group	O
etc	O
.	O
,	O
R3	O
represents	O
an	O
optionally	O
substituted	O
phenylsulfonyl	O
group	O
etc	O
.	O
and	O
R4	O
and	O
R5	O
represent	O
hydrogen	O
or	O
an	O
optionally	O
substituted	O
alkyl	O
group	O
etc	O
.	O
having	O
1	O
to	O
3	O
carbon	O
atoms	O
]	O


The	O
application	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates,	O
geometrical	O
isomers,	O
tautomers,	O
optical	O
isomersor	O
N-oxides	O
thereof	O
.	O
The	O
application	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
medical	O
conditions	O
relating	O
to	O
disorders	O
of	O
the	O
G-protein-	B-GENE
coupled	I-GENE
receptor	I-GENE
GPR119,	O
such	O
as	O
diabetes,	O
obesity	O
and	O
osteoporosis	O
.	O


Disclosed	O
is	O
a	O
human	B-GENE
β3	I-GENE
adrenergic	I-GENE
receptor	I-GENE
ligand	O
containing	O
the	O
three	O
components	O
listed	O
below	O
.	O
	O
Also	O
disclosed	O
are	O
food	O
and	O
pharmaceutical	O
products	O
each	O
containing	O
the	O
human	B-GENE
β3	I-GENE
adrenergic	I-GENE
receptor	I-GENE
ligand,	O
particularly	O
a	O
preventive	O
and	O
/	O
or	O
ameliorating	O
agent	O
for	O
obesity,	O
adiposis,	O
diabetes,	O
hyperlipemia,	O
hypertension,	O
gout	O
and	O
the	O
like	O
.	O
(	O
A	O
)	O
an	O
unsaturated	O
fatty	O
acid	O
having	O
three	O
or	O
more	O
double	O
bonds	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
(	O
B	O
)	O
an	O
unsaturated	O
fatty	O
acid	O
having	O
one	O
or	O
two	O
double	O
bonds	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
(	O
C	O
)	O
a	O
saturated	O
fatty	O
acid	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
substituted	O
(	O
1,2,4-oxadiazol-3-yl	O
)	O
indolin-2-yl	O
carboxylic	O
acid	O
derivatives	O
of	O
Formula	O
(	O
Ia	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
exhibit	O
useful	O
pharmacological	O
properties,	O
for	O
example,	O
as	O
agonists	O
of	O
the	O
SlPl	B-GENE
receptor	O
.	O
Also	O
provided	O
by	O
the	O
present	O
invention	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
the	O
invention,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
in	O
the	O
treatment	O
of	O
SlPl	B-GENE
receptor-associated	O
disorders,	O
for	O
example,	O
psoriasis,	O
rheumatoid	O
arthritis,	O
Crohn	O
'	O
s	O
disease,	O
transplant	O
rejection,	O
multiple	O
sclerosis,	O
systemic	O
lupus	O
erythematosus,	O
ulcerative	O
colitis,	O
type	O
I	O
diabetes,	O
acne,	O
microbial	O
infections	O
or	O
diseases	O
and	O
viral	O
infections	O
or	O
diseases	O
.	O


Compounds	O
and	O
salts	O
thereof,	O
formulations	O
thereof,	O
conjugates	O
thereof,	O
derivatives	O
thereof,	O
forms	O
thereof	O
and	O
uses	O
thereof	O
are	O
described	O
.	O
In	O
certain	O
aspects	O
and	O
embodiments,	O
the	O
described	O
compounds	O
or	O
salts	O
thereof,	O
formulations	O
thereof,	O
conjugates	O
thereof,	O
derivatives	O
thereof,	O
forms	O
thereof	O
are	O
active	O
on	O
at	O
least	O
one	O
Raf	B-GENE
protein	O
kinase	O
.	O
Also	O
described	O
are	O
methods	O
of	O
use	O
thereof	O
to	O
treat	O
diseases	O
and	O
conditions,	O
including	O
diseases	O
and	O
conditions	O
associated	O
with	O
activity	O
of	O
Raf	B-GENE
protein	O
kinases,	O
including	O
melanoma,	O
colorectal	O
cancer,	O
thyroid	O
cancer,	O
ovarian	O
cancer,	O
cholangiocarcinoma,	O
pain	O
or	O
polycystic	O
kidney	O
disease	O
.	O


Disclosed	O
are	O
aspartic	B-GENE
protease	I-GENE
inhibitors	O
represented	O
by	O
the	O
following	O
Formula	O
:	O
wherein	O
R1	O
,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7a,	O
R7b	O
and	O
n	O
are	O
as	O
defined	O
herein,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
for	O
treating	O
an	O
aspartic	B-GENE
protease	I-GENE
mediated	O
disorder	O
using	O
the	O
same	O
.	O


Compounds	O
for	O
modulating	O
RecA	B-GENE
protein	O
activity	O
are	O
provided	O
.	O
In	O
some	O
embodiments,	O
the	O
compounds	O
modulate	O
RecA	B-GENE
activity	O
by	O
interfering	O
with	O
assembly	O
of	O
monomeric	O
RecA	B-GENE
protein	O
subunits	O
into	O
a	O
nucleoprotein	O
filament	O
.	O
In	O
some	O
embodiments,	O
the	O
compounds	O
modulate	O
RecA	B-GENE
activity	O
by	O
interfering	O
with	O
adenosine	O
triphosphate	O
hydrolysis	O
by	O
the	O
RecA	B-GENE
protein	O
.	O
In	O
some	O
embodiments,	O
the	O
compound	O
is	O
a	O
N6	O
-modified	O
adenosine	O
compound	O
.	O
Methods	O
of	O
screening	O
for	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
purine	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
are	O
useful	O
as	O
kinase	B-GENE
inhibitors	O
.	O
More	O
particularly,	O
the	O
present	O
invention	O
relates	O
to	O
purine	O
compounds,	O
methods	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
proliferative	O
conditions	O
or	O
disorders	O
.	O
These	O
compounds	O
may	O
be	O
useful	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
a	O
number	O
of	O
proliferative	O
conditions	O
or	O
disorders	O
including	O
tumours	O
and	O
cancers	O
as	O
well	O
as	O
other	O
disorders	O
or	O
conditions	O
related	O
to	O
or	O
associated	O
with	O
PI3K	B-GENE
and	O
/	O
or	O
mTOR	B-GENE
kinases	B-GENE
.	O


This	O
invention	O
is	O
directed	O
to	O
combination	O
therapies	O
to	O
treat	O
iron	O
overload	O
disorders	O
utilizing	O
inhibitors	O
of	O
divalent	B-GENE
metal	I-GENE
transporter-1	I-GENE
(	O
DMT1	B-GENE
)	O
,	O
proton	B-GENE
pump	I-GENE
inhibitors	O
(	O
PPIs	O
)	O
,	O
calcium	B-GENE
channel	I-GENE
blockers	O
and	O
iron	O
chelators	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
general	O
Formula	O
(	O
I	O
)	O
having	O
histone	B-GENE
deacetylase	I-GENE
(	O
HDAC	B-GENE
)	O
and	O
/	O
or	O
Cyclin-dependent	B-GENE
kinase	I-GENE
(	O
CDK	B-GENE
)	O
inhibitory	O
activity,	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound,	O
and	O
a	O
method	O
useful	O
to	O
treat	O
diseases	O
using	O
the	O
compound	O
.	O
Formula	O
(	O
I	O
)	O


The	O
use	O
of	O
an	O
S1P	B-GENE
receptor	I-GENE
modulator	O
of	O
the	O
formula	O
(	O
Ia	O
)	O
or	O
(	O
Ib	O
)	O
wherein	O
the	O
meaning	O
of	O
the	O
different	O
residues	O
is	O
that	O
indicated	O
in	O
claim	O
1,	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
preventing,	O
inhibiting	O
or	O
treating	O
an	O
inflammatory	O
condition	O
selected	O
from	O
polymyositis,	O
dermatomyositis	O
and	O
nerve-muscle	O
diseases	O
e	O
.	O
g	O
.	O
muscular	O
dystrophies	O
and	O
inclusion	O
body	O
myositis	O
.	O


Disclosed	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
accompanied	O
by	O
the	O
increase	O
in	O
an	O
activity	O
of	O
at	O
least	O
one	O
member	O
selected	O
from	O
DYRK1A,	O
DYRK1B	B-GENE
and	O
DYRK2	B-GENE
.	O
	O
Specifically	O
disclosed	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
accompanied	O
by	O
the	O
increase	O
in	O
an	O
activity	O
of	O
at	O
least	O
one	O
member	O
selected	O
from	O
DYRK1A,	O
DYRK1B	B-GENE
and	O
DYRK2,	O
which	O
comprises	O
a	O
compound	O
capable	O
of	O
inhibiting	O
the	O
protein	O
phosphorylation	O
activity	O
of	O
at	O
least	O
one	O
member	O
selected	O
from	O
DYRK1A,	O
DYRK1B	B-GENE
and	O
DYRK2	B-GENE
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
a	O
use	O
of	O
a	O
steroid	B-GENE
sulfatase	I-GENE
inhibitor	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
preventing	O
or	O
inhibiting	O
premature	O
uterine	O
contractions	O
.	O
Specifically,	O
the	O
present	O
invention	O
is	O
related	O
to	O
steroid	B-GENE
sulfatase	I-GENE
inhibitors	O
useful	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
formulation	O
for	O
the	O
modulation,	O
notably	O
the	O
inhibition	O
of	O
pre-term	O
labor	O
.	O


Provided	O
is	O
a	O
novel	O
compound	O
useful	O
as	O
a	O
pharmaceutical	O
that	O
exhibits	O
strong	O
antibacterial	O
activity	O
for	O
gram	O
negative	O
bacteria,	O
such	O
as	O
Pseudomonas	O
aeruginosa,	O
and	O
for	O
drug-resistant	O
bacterial	O
strains	O
thereof,	O
based	O
on	O
LpxC	B-GENE
inhibitory	O
activity	O
.	O
Provided	O
is	O
a	O
hydroxamic	O
acid	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmacologically	O
permitted	O
salt	O
thereof	O
.	O
(	O
1	O
)	O


The	O
present	O
invention	O
pertains	O
generally	O
to	O
the	O
field	O
of	O
therapeutic	O
compounds,	O
and	O
more	O
specifically	O
to	O
compounds	O
related	O
to	O
rhodanine,	O
which	O
compounds	O
are	O
inter	O
alia	O
inhibitors	O
and	O
/	O
or	O
binders	O
of	O
antiapoptotic	O
/	O
pro-survival	O
Bcl-2	B-GENE
proteins	O
such	O
as	O
Bcl-XL	B-GENE
and	O
/	O
or	O
Mcl-1	B-GENE
.	O
More	O
specifically,	O
the	O
present	O
invention	O
is	O
concerned	O
with	O
Rhodanine-	O
based	O
Pan-Bcl-2	O
inhibitors	O
and	O
Mcl-1	B-GENE
-specific	O
inhibitors	O
as	O
anti-cancer	O
compounds	O
.	O
The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions,	O
both	O
in	O
vitro	O
and	O
in	O
vivo,	O
to	O
inhibit	O
and	O
/	O
or	O
bind	O
Bcl-2	B-GENE
proteins	O
such	O
as	O
Bcl-XL	B-GENE
and	O
/	O
or	O
Mcl-1,	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
conditions	O
that	O
are	O
mediated	O
by	O
Bcl-2	B-GENE
proteins,	O
that	O
are	O
ameliorated	O
by	O
the	O
inhibition	O
of	O
Bcl-2	B-GENE
protein	O
function	O
(	O
such	O
as	O
Bcl-XL	B-GENE
and	O
/	O
or	O
Mcl-1	B-GENE
)	O
including	O
proliferative	O
conditions	O
such	O
as	O
cancer,	O
optionally	O
in	O
combination	O
with	O
another	O
agent	O
.	O


The	O
present	O
invention	O
provides	O
PLK	B-GENE
inhibitors	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
and	O
intermediates	O
useful	O
for	O
making	O
the	O
compounds	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
are	O
provided	O
as	O
modulators	O
of	O
Rb	B-GENE
:	O
Raf-1	B-GENE
interactions	O
which	O
are	O
potent,	O
selective	O
disruptors	O
of	O
Rb	B-GENE
:	O
Raf-1	B-GENE
binding	O
.	O
Therapeutic	O
methods	O
of	O
using	O
the	O
compounds,	O
for	O
example	O
for	O
treating	O
or	O
ameliorating	O
a	O
cell	O
proliferation	O
disorder	O
such	O
as	O
cancer,	O
are	O
provided	O
.	O


The	O
present	O
invention	O
is	O
concerned	O
with	O
6-substituted	O
benzoxazine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X,	O
Y,	O
R1	O
and	O
R2	O
are	O
as	O
described	O
herein,	O
as	O
well	O
as	O
their	O
manufacture,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
5-HT5A	B-GENE
receptor	O
antagonists,	O
useful	O
in	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
depression,	O
anxiety	O
disorders,	O
schizophrenia,	O
panic	O
disorders,	O
agoraphobia,	O
social	O
phobia,	O
obsessive	O
compulsive	O
disorders,	O
post-traumatic	O
stress	O
disorders,	O
pain,	O
memory	O
disorders,	O
dementia,	O
disorders	O
of	O
eating	O
behaviors,	O
sexual	O
dysfunction,	O
sleep	O
disorders,	O
abuse	O
of	O
drugs,	O
motor	O
disorders,	O
Parkinson	O
'	O
s	O
disease,	O
psychiatric	O
disorders	O
or	O
gastrointestinal	O
disorders	O
.	O


Disclosed	O
are	O
iPS	O
cells	O
derived	O
from	O
somatic	O
cells,	O
such	O
as	O
NKT	O
cells,	O
in	O
which	O
the	O
α-chain	O
region	O
of	O
the	O
T-cell	B-GENE
antigen	I-GENE
receptor	I-GENE
gene	O
has	O
been	O
rearranged	O
to	O
a	O
uniform	O
Vα-Jα	O
arrangement	O
in	O
the	O
mode	O
specific	O
to	O
NKT-cell	O
receptors,	O
NKT	O
cells	O
that	O
have	O
been	O
differentiated	O
from	O
said	O
iPS	O
cells,	O
and	O
methods	O
for	O
producing	O
the	O
same,	O
as	O
well	O
as	O
immuno-cell	O
therapeutic	O
agents	O
using	O
cells	O
differentiated	O
from	O
said	O
iPS	O
cells	O
.	O
Disclosed	O
are	O
iPS	O
cells	O
(	O
NKT-iPS	O
cells	O
)	O
,	O
such	O
as	O
NKT	O
cells,	O
in	O
which	O
TCRα	B-GENE
has	O
been	O
rearranged	O
to	O
an	O
NKT-TCR	O
arrangement	O
and	O
that	O
are	O
obtained	O
by	O
bringing	O
a	O
nuclear	O
reprogramming	O
factor	O
in	O
contact	O
with	O
somatic	O
cells	O
in	O
which	O
the	O
a-chain	O
region	O
of	O
the	O
T-cell	B-GENE
antigen	I-GENE
receptor	I-GENE
gene	O
has	O
been	O
rearranged	O
to	O
a	O
uniform	O
Vα-Jα	O
arrangement	O
in	O
the	O
mode	O
specific	O
to	O
NKT-cell	O
receptors,	O
and	O
NKT	O
cells	O
(	O
iPS-NKT	O
cells	O
)	O
obtained	O
and	O
isolated	O
by	O
in	O
vitro	O
differentiation	O
of	O
said	O
cells	O
.	O
Also	O
disclosed	O
are	O
a	O
method	O
for	O
preparing	O
CD4	B-GENE
/	O
CD8	B-GENE
double-positive	O
NKT	O
cells	O
(	O
DP-NKT	O
cells	O
)	O
and	O
mature	O
NKT	O
cells	O
from	O
NKT-iPS	O
cells	O
by	O
changing	O
the	O
combination	O
of	O
feeder	O
cells	O
and	O
/	O
or	O
cytokines,	O
and	O
a	O
method	O
for	O
proliferating	O
these	O
iPS-NKT	O
cells	O
.	O
Further	O
disclosed	O
is	O
an	O
NKT	O
cell	O
therapeutic	O
agent	O
that	O
contains	O
NKT	O
cells	O
that	O
have	O
been	O
activated	O
by	O
α-galactosylceramide	O
(	O
α-GalCer	O
)	O
,	O
or	O
is	O
composed	O
of	O
iPS-NKT	O
cells	O
and	O
α-GalCer	O
.	O


An	O
embodiment	O
of	O
the	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
prodrug,	O
hydrate,	O
or	O
solvate	O
thereof	O
.	O
Another	O
embodiment	O
of	O
the	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
condition	O
associated	O
with	O
increased	O
expression	O
and	O
/	O
or	O
activity	O
of	O
an	O
NFκB	B-GENE
pathway	O
using	O
same	O
compounds	O
.	O
A	O
further	O
embodiment	O
of	O
the	O
invention	O
provides	O
a	O
method	O
of	O
diagnosing	O
a	O
condition	O
in	O
an	O
individual	O
using	O
same	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
having	O
affinity	O
and	O
selectivity	O
for	O
the	O
dopamine	B-GENE
D3	I-GENE
receptors,	O
their	O
manufacture,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O
The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
the	O
therapeutic	O
and	O
/	O
or	O
prophylactic	O
treatment	O
of	O
cognitive	O
disorders	O
.	O


Disclosed	O
are	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof,	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
salt,	O
and	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
the	O
compound,	O
salt	O
or	O
solvate	O
as	O
an	O
active	O
ingredient	O
and	O
serves	O
as	O
a	O
TRPV1	B-GENE
receptor	O
function	O
regulating	O
agent	O
.	O
(	O
In	O
the	O
formula,	O
n	O
represents	O
an	O
integer	O
of	O
0-2	O
;	O
R1	O
represents	O
a	O
halogen	O
atom,	O
an	O
optionally	O
substituted	O
hydrocarbon	O
group,	O
a	O
heterocyclic	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
optionally	O
substituted	O
C1-4	O
alkyl	O
group	O
or	O
a	O
C1-4	O
alkoxyl	O
group	O
;	O
R3	O
represents	O
a	O
-A1-A2	O
group	O
(	O
wherein	O
A1	O
represents	O
a	O
single	O
bond,	O
a	O
methylene	O
group,	O
a	O
C2-6	O
alkylene	O
group,	O
a	O
carbonyl	O
group	O
or	O
a	O
sulfonyl	O
group,	O
and	O
A2	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
optionally	O
substituted	O
C1-6	O
alkyl	O
group,	O
a	O
C3-6	O
cycloalkyl	O
group,	O
an	O
aryl	O
group	O
or	O
a	O
heterocyclic	O
group	O
)	O
;	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
C1-4	O
alkyl	O
group	O
or	O
a	O
phenyl	O
group	O
;	O
Q	O
represents	O
an	O
optionally	O
substituted	O
aryl	O
group	O
or	O
a	O
heterocyclic	O
group	O
;	O
and	O
Z	O
represents	O
=	O
CR6-	O
or	O
=	O
N-	O
.	O
)	O


Methods	O
for	O
reducing	O
or	O
preventing	O
the	O
effects	O
of	O
cytotoxic	O
compounds	O
in	O
healthy	O
cells	O
are	O
provided	O
.	O
The	O
methods	O
relate	O
to	O
the	O
use	O
of	O
selective	O
cyclin-	B-GENE
dependent	I-GENE
kinase	I-GENE
(CDK)	I-GENE
4/6	I-GENE
inhibitors	O
to	O
induce	O
transient	O
quiescence	O
in	O
CDK4/6	B-GENE
dependent	I-GENE
cells,	O
such	O
as	O
hematopoietic	O
stem	O
cells	O
and	O
/	O
or	O
hematopoietic	O
progenitor	O
cells	O
.	O
Also	O
described	O
is	O
a	O
method	O
of	O
selecting	O
compounds	O
for	O
reducing	O
or	O
preventing	O
the	O
effects	O
of	O
cytotoxic	O
agents	O
compounds	O
in	O
healthy	O
cells	O
.	O


In	O
its	O
many	O
embodiments,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
benzodioxan	O
analogues	O
as	O
modulators	O
of	O
the	O
α2C	B-GENE
adrenergic	I-GENE
receptor,	O
methods	O
of	O
preparing	O
such	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
such	O
compounds,	O
methods	O
of	O
preparing	O
pharmaceutical	O
formulations	O
comprising	O
one	O
or	O
more	O
such	O
compounds,	O
and	O
methods	O
of	O
treatment,	O
prevention,	O
inhibition,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
conditions	O
associated	O
with	O
the	O
α2C	B-GENE
adrenergic	I-GENE
receptors	I-GENE
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O


Disclosed	O
is	O
a	O
compound	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
abnormal	O
plasma	O
uric	O
acid	O
level	O
and	O
the	O
like	O
.	O
Specifically	O
disclosed	O
is	O
a	O
5-membered	O
heteroaryl	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
prodrug	O
or	O
salt	O
thereof,	O
or	O
the	O
like,	O
which	O
has	O
a	O
xanthine	B-GENE
oxidase	I-GENE
inhibiting	O
activity	O
and	O
is	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
abnormal	O
plasma	O
uric	O
acid	O
level	O
.	O
	O
In	O
formula	O
(	O
I	O
)	O
,	O
the	O
ring	O
A	O
represents	O
a	O
thiophene	O
or	O
a	O
pyrrole	O
;	O
R1	O
represents	O
an	O
aryl,	O
an	O
aryl-	O
(	O
C1-6-alkyl	O
)	O
,	O
a	O
hydroxy-	O
(	O
C1-6-alkyl	O
)	O
,	O
a	O
(	O
C1-6-alkoxy	O
)	O
-	O
(	O
C1-6-alkyl	O
)	O
,	O
an	O
amino-	O
(	O
C1-6-alkyl	O
)	O
,	O
or	O
the	O
like	O
;	O
and	O
the	O
ring	O
B	O
represents	O
a	O
benzene,	O
a	O
pyridine	O
or	O
the	O
like	O
which	O
may	O
be	O
substituted	O
.	O


A	O
novel	O
compound	O
having	O
an	O
excellent	O
NFκB	B-GENE
inhibitory	O
effect	O
.	O
	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
.	O
(	O
In	O
the	O
formula,	O
R1	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
lower	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
lower	O
alkyl	O
group,	O
a	O
halogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
lower	O
alkyl	O
group,	O
a	O
hydroxy	O
group	O
or	O
a	O
halogen	O
atom	O
;	O
R4	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
lower	O
alkyloxy	O
group	O
;	O
R5	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
lower	O
alkyloxy	O
group,	O
a	O
halogen	O
atom	O
or	O
a	O
hydroxy	O
group,	O
or	O
alternatively	O
forms	O
a	O
methylenedioxy	O
group	O
or	O
an	O
isopropylidenedioxy	O
group	O
together	O
with	O
R6	O
;	O
R6	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
lower	O
alkyloxy	O
group,	O
or	O
alternatively	O
forms	O
a	O
methylenedioxy	O
group	O
or	O
an	O
isopropylidenedioxy	O
group	O
together	O
with	O
R5	O
;	O
R7	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
lower	O
alkyl	O
group	O
;	O
and	O
R8	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
hydroxy	O
group,	O
an	O
amino	O
group,	O
a	O
lower	O
alkylcarbonyloxy	O
group	O
or	O
a	O
halogen	O
atom	O
.	O
)	O


Autoimmune	O
disorders,	O
transplant	O
rejection,	O
and	O
inflammatory	O
disorders	O
share	O
a	O
common	O
origin	O
in	O
that	O
the	O
host	O
'	O
s	O
immune	O
system	O
is	O
activated	O
such	O
that	O
it	O
attacks	O
otherwise	O
healthy	O
tissue	O
.	O
Aminoacyl	B-GENE
t-RNA	I-GENE
synthetase	I-GENE
inhibitors,	O
such	O
as	O
borrelidin,	O
have	O
now	O
been	O
shown	O
to	O
act	O
as	O
broad	O
spectrum	O
immunosuppressants	O
.	O
Said	O
compounds,	O
and	O
compositions	O
comprising	O
said	O
compounds,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
the	O
aforementioned	O
diseases	O
.	O


Provided	O
herein	O
are	O
7-azaspiro	O
[	O
3	O
.	O
5	O
]	O
nonane-7-carboxamide	O
compounds	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds	O
useful	O
in	O
treating	O
diseases	O
or	O
conditions	O
associated	O
with	O
fatty	B-GENE
acid	I-GENE
amide	I-GENE
hydrolase	I-GENE
(	O
FAAH	B-GENE
)	O
activity,	O
conditions	O
including	O
including	O
acute	O
pain,	O
chronic	O
pain,	O
neuropathic	O
pain,	O
nociceptive	O
pain,	O
inflammatory	O
pain,	O
cancer	O
and	O
cancer	O
pain,	O
fibromyalgia,	O
rheumatoid	O
arthritis,	O
inflammatory	O
bowel	O
disease,	O
lupus,	O
diabetes,	O
allergic	O
asthma,	O
vascular	O
inflammation,	O
urinary	O
incontinence,	O
overactive	O
bladder,	O
emesis,	O
cognitive	O
disorders,	O
anxiety,	O
depression,	O
sleeping	O
disorders,	O
eating	O
disorders,	O
movement	O
disorders,	O
glaucoma,	O
psoriasis,	O
multiple	O
sclerosis,	O
cerebrovascular	O
disorders,	O
brain	O
injury,	O
gastrointestinal	O
disorders,	O
hypertension,	O
or	O
cardiovascular	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
coadministration	O
of	O
an	O
estrogen	B-GENE
receptor	I-GENE
antagonist	O
and	O
a	O
progestin	O
to	O
treat	O
gynecological	O
diseases	O
resulting	O
from	O
abnormal	O
growth	O
of	O
uterine	O
tissue,	O
such	O
as	O
endometriosis	O
or	O
uterine	O
fibroids	O
.	O


Methods	O
of	O
treating	O
tumor	O
cells	O
in	O
an	O
individual	O
comprise	O
administering	O
to	O
the	O
individual	O
a	O
drug	O
having	O
anti-tumor	O
effect,	O
wherein	O
the	O
drug	O
is	O
delivered	O
into	O
the	O
tumor	O
cells	O
via	O
Right-	B-GENE
Handed	I-GENE
Coiled-Coil	I-GENE
(RHCC)	I-GENE
protein	I-GENE
or	O
a	O
fragment	O
or	O
variant	O
thereof	O
.	O
The	O
drug	O
may,	O
for	O
example,	O
be	O
a	O
metal-containing	O
compound,	O
a	O
protein	O
or	O
peptide	O
drug,	O
and	O
/	O
or	O
an	O
organic	O
hydrophobic	O
compound	O
.	O


A	O
hydrogel	O
system	O
comprising	O
polymer-conjugated	O
albumin	B-GENE
molecules	O
is	O
provided	O
for	O
controlled	O
release	O
delivery	O
of	O
therapeutic	O
agents	O
.	O
The	O
polymer	O
is	O
a	O
functionalized	O
synthetic	O
polymer,	O
preferably	O
PEG-diacrylate	O
.	O
The	O
polymer-conjugated	O
albumin	B-GENE
is	O
preferably	O
mono-PEGylated	O
albumin	B-GENE
.	O
The	O
hydrogel	O
system	O
may	O
comprise	O
a	O
matrix	O
to	O
which	O
the	O
polymer-conjugated	O
albumin	B-GENE
molecules	O
are	O
linked	O
via	O
a	O
functional	O
group	O
of	O
the	O
polymer	O
.	O
The	O
matrix	O
may	O
be	O
formed	O
from	O
the	O
same	O
polymer	O
of	O
the	O
polymer-albumin	O
conjugate	O
.	O


This	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
and	O
R6	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PLK	B-GENE
and	O
are	O
thus	O
useful	O
for	O
treating	O
proliferative,	O
inflammatory,	O
or	O
cardiovascular	O
disorders	O
.	O


A	O
compound	O
of	O
the	O
formula	O
where	O
R1,	O
R2a,	O
R2D,	O
R3,	O
L1,	O
L2,	O
Q,	O
J,	O
X,	O
m	O
and	O
n	O
are	O
as	O
defined,	O
or	O
an	O
enantiomer,	O
stereoisomer	O
or	O
diastereoisomer	O
thereof,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
the	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
diseases,	O
syndromes	O
and	O
conditions	O
modulated	O
by	O
melanocortin	B-GENE
receptors	I-GENE
.	O
;	O


The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
wherein	O
A,	O
B,	O
R1,	O
R2	O
and	O
R3	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description,	O
the	O
stereoisomers,	O
as	O
well	O
as	O
the	O
salts	O
of	O
the	O
stereoisomers	O
thereof	O
are	O
effective	O
CCR3	B-GENE
modulators	O
.	O


The	O
invention	O
related	O
to	O
alkanoic	O
acid	O
derivatives	O
of	O
Formula	O
(	O
IIa	O
)	O
and	O
(	O
IIb	O
)	O
.	O
These	O
compounds	O
of	O
the	O
invention	O
were	O
found	O
to	O
have	O
activity	O
as	O
HDAC	B-GENE
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
derivatives	O
of	O
6-cycloamino-3-	O
(	O
1	O
H-pyrrolo	O
[	O
2,3-b	O
]	O
pyridin-4-yl	O
)	O
imidazo	O
[	O
1,2b	O
]	O
pyridazine	O
with	O
general	O
formula	O
(	O
I	O
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
preparation	O
and	O
therapeutic	O
application	O
thereof,	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
illnesses	O
involving	O
casein	B-GENE
kinase	I-GENE
1	I-GENE
epsilon	I-GENE
and	O
/	O
or	O
casein	B-GENE
kinase	I-GENE
1	I-GENE
delta	I-GENE
.	O


Administration	O
of	O
a	O
salt	O
of	O
bi-cyclo	O
[	O
2	O
.	O
2	O
.	O
2	O
]	O
octane-2-carbonic	O
acid	O
reduces	O
dysphoria	O
in	O
dysphoric	O
subjects,	O
ameliorates	O
ethanol	O
craving	O
in	O
alcoholics,	O
reduces	O
the	O
erythrocyte	O
sedimentation	O
rate	O
and	O
the	O
level	O
of	O
liver	O
function	O
markers	O
(	O
AST,	O
ALT,	O
and	O
bilirubin	O
)	O
in	O
human	O
subjects,	O
and	O
reduces	O
the	O
number	O
or	O
strength	O
of	O
seizures	O
in	O
epileptics	O
.	O


The	O
invention	O
provides	O
a	O
new	O
kind	O
of	O
dihydroindene	O
amide	O
compounds	O
of	O
general	O
formula	O
I	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
or	O
prodrug	O
thereof	O
which	O
can	O
be	O
used	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitor	O
.	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
kind	O
of	O
compounds,	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds,	O
the	O
method	O
for	O
preventing	O
or	O
curing	O
the	O
diseases	O
related	O
to	O
the	O
abnormity	O
of	O
activities	O
of	O
protein	O
kinases,	O
especially	O
Abl,	O
Bcr-Abl,	O
c-Kit	B-GENE
and	O
PDGFR,	O
using	O
them	O
as	O
protein	B-GENE
kinase	I-GENE
inhibitor,	O
and	O
their	O
preparation	O
use	O
of	O
drug	O
used	O
for	O
preventing	O
or	O
curing	O
the	O
diseases	O
related	O
to	O
the	O
abnormity	O
of	O
activities	O
of	O
protein	O
kinases,	O
especially	O
Abl,	O
Bcr-Abl,	O
c-Kit	B-GENE
and	O
PDGFR	B-GENE
.	O


Inhibition	O
of	O
eIF-2α	B-GENE
phosphorylation	O
can	O
be	O
used	O
to	O
improve	O
cognitive	O
function	O
and	O
/	O
or	O
to	O
treat	O
dementia,	O
including	O
Alzheimer	O
'	O
s	O
Disease	O
.	O
In	O
particular,	O
this	O
can	O
be	O
achieved	O
by	O
inhibiting	O
the	O
kinase	O
activity	O
of	O
PKR	B-GENE
in	O
a	O
non-toxic	O
manner	O
.	O


Provided	O
are	O
novel	O
low-molecular	O
compounds	O
which	O
exhibit	O
calcium	B-GENE
receptor	I-GENE
antagonist	O
activity,	O
and	O
which	O
are	O
highly	O
safe	O
and	O
orally	O
administrable,	O
namely,	O
compounds	O
having	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
.	O
	O
In	O
the	O
general	O
formula,	O
R1,	O
R2a,	O
and	O
R2b	O
are	O
each	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
is	O
methyl,	O
ethyl,	O
or	O
the	O
like	O
;	O
Z	O
is	O
carboxyl	O
or	O
the	O
like	O
;	O
Ar	O
is	O
phenyl	O
or	O
the	O
like	O
;	O
A	O
is	O
a	O
single	O
bond	O
or	O
the	O
like	O
;	O
B	O
is	O
a	O
single	O
bond	O
or	O
the	O
like	O
;	O
n	O
is	O
0	O
or	O
1	O
;	O
and	O
m	O
is	O
an	O
integer	O
of	O
0	O
to	O
6	O
.	O


Use	O
of	O
an	O
inverse	O
antagonist	O
and	O
/	O
or	O
agonist	O
of	O
CB1	O
receptors,	O
preferably	O
rimonabant,	O
for	O
preparing	O
drugs	O
that	O
are	O
useful	O
for	O
increasing	O
motor	O
neurone	O
excitability	O
at	O
the	O
level	O
of	O
the	O
cerebral	O
cortex	O
and	O
/	O
or	O
the	O
brainstem	O
and	O
/	O
or	O
at	O
the	O
spinal	O
level,	O
and	O
also	O
a	O
method	O
for	O
increasing	O
motor	O
neurone	O
excitability	O
by	O
means	O
of	O
the	O
administration	O
of	O
an	O
inverse	O
antagonist	O
/	O
agonist	O
of	O
CB1	O
receptors,	O
and	O
to	O
the	O
use	O
of	O
a	O
pharmaceutical	O
composition	O
that	O
comprises	O
an	O
inverse	O
antagonist	O
and	O
/	O
or	O
agonist	O
of	O
CB1	O
receptors,	O
preferably	O
rimonabant,	O
for	O
increasing	O
motor	O
neurone	O
excitability	O
at	O
the	O
level	O
of	O
the	O
cerebral	O
cortex	O
and	O
/	O
or	O
the	O
brainstem	O
and	O
/	O
or	O
at	O
the	O
spinal	O
level	O
.	O


This	O
invention	O
relates	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
Helicobacter	O
pylori	O
induced	O
gastric	O
cancer	O
comprising	O
administering	O
a	O
blocker	O
of	O
Poly	B-GENE
(ADP-ribose)	I-GENE
Polymerase	I-GENE
(	O
PARP	B-GENE
)	O
,	O
and	O
the	O
use	O
of	O
such	O
blockers	O
in	O
said	O
prevention	O
and	O
treatment	O
and	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Helicobacter	O
pylori	O
induced	O
gastric	O
cancer	O
.	O


The	O
present	O
application	O
is	O
related	O
to	O
compounds	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
,	O
which	O
are	O
novel	O
allosteric	O
modulators	O
of	O
α7nAChR	B-GENE
.	O
The	O
application	O
also	O
discloses	O
the	O
treatment	O
of	O
disorders	O
that	O
are	O
responsive	O
to	O
modulation	O
of	O
acetylcholine	O
action	O
on	O
α7nAChR	B-GENE
in	O
a	O
mammal	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
.	O


Disclosed	O
is	O
a	O
medicinal	O
agent	O
that	O
enables	O
the	O
repair	O
and	O
regeneration	O
of	O
joint	O
cartilages	O
which	O
have	O
not	O
been	O
achieved	O
by	O
the	O
conventional	O
pharmaceutical	O
preparations,	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
joint	O
diseases	O
such	O
as	O
osteoarthritis,	O
and	O
is	O
safe	O
and	O
inexpensive	O
.	O
Specifically	O
disclosed	O
is	O
a	O
combined	O
preparation	O
for	O
administering	O
hyaluronic	O
acid	O
and	O
an	O
animal-derived	O
mucin-type	B-GENE
glycoprotein	I-GENE
simultaneously,	O
separately	O
or	O
sequentially	O
in	O
the	O
treatment	O
of	O
a	O
joint	O
disease	O
.	O


Nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
(	O
NOS	B-GENE
)	O
inhibitor	O
compounds	O
comprising	O
bi-terminal	O
aromatic	O
ring	O
moieties,	O
and	O
related	O
methods	O
of	O
NOS	B-GENE
inhibition	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
I,	O
wherein	O
Y,	O
ring	O
A,	O
Da,	O
Db,	O
D2,	O
D3,	O
L1,	O
Y1,	O
L2,	O
Y2,	O
L3	O
and	O
Y3	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
leukotriene	B-GENE
C4	I-GENE
synthase	I-GENE
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
a	O
respiratory	O
disorder	O
and	O
/	O
or	O
inflammation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
new	O
triazolyl	O
purine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
for	O
the	O
treatment	O
of	O
neurological	O
disorders	O
or	O
cerebral	O
ischaemia	O
for	O
which	O
inhibition	O
of	O
adenosine	B-GENE
A2A	I-GENE
receptor	I-GENE
will	O
result	O
at	O
improving	O
the	O
health	O
state	O
of	O
a	O
patient	O
.	O


We	O
describe	O
for	O
the	O
first	O
time	O
that	O
andrographolide	O
dirivatives	O
such	O
as	O
DDAG	O
effectively	O
reduced	O
OVA-induced	O
inflammatory	O
cell	O
recruitment	O
into	O
BAL	O
fluid,	O
IL-4,	O
IL-5,	O
IL-13	B-GENE
and	O
eotaxin	O
production,	O
serum	O
IgE	B-GENE
synthesis,	O
pulmonary	O
eosinophilia,	O
mucus	O
hypersecretion	O
and	O
AHR	O
in	O
a	O
mouse	O
asthma	O
model	O
potentially	O
via	O
inhibition	O
of	O
NF-?B	B-GENE
activity	O
.	O
Moreover,	O
low	O
dose	O
of	O
DDAG	O
and	O
glucocorticoid	O
combination	O
treatment	O
synergistically	O
attenuate	O
inflammation	O
in	O
mouse	O
asthma	O
model	O
.	O
These	O
findings	O
support	O
a	O
therapeutic	O
value	O
for	O
DDAG	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O


The	O
invention	O
relates	O
to	O
acrylamide	O
compounds	O
of	O
Formula	O
I	O
mentioned	O
below	O
.	O
The	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
compounds	O
of	O
Formula	O
I	O
to	O
treat	O
or	O
prevent	O
a	O
disorder	O
responsive	O
to	O
the	O
blockade	O
of	O
calcium	O
channels,	O
and	O
particularly	O
N-type	B-GENE
calcium	B-GENE
channels	I-GENE
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
especially	O
useful	O
for	O
treating	O
pain	O
.	O


The	O
present	O
invention	O
relates	O
to	O
phthalimide	O
derivatives	O
of	O
non-steroidal	O
anti-inflammatory	O
compounds	O
and	O
/	O
or	O
TNF-α	B-GENE
modulators,	O
to	O
a	O
method	O
for	O
producing	O
these	O
derivatives,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
derivatives,	O
and	O
to	O
uses	O
thereof,	O
including	O
the	O
use	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases,	O
in	O
particular	O
those	O
associated	O
with	O
chronic	O
inflammatory	O
conditions,	O
such	O
as	O
rheumatoid	O
arthritis,	O
and	O
inflammatory	O
intestinal	O
diseases	O
(	O
such	O
as	O
Crohn	O
'	O
s	O
disease	O
)	O
,	O
and	O
to	O
the	O
use	O
of	O
these	O
compositions	O
as	O
antipyretics,	O
analgesics	O
and	O
platelet	O
aggregation	O
inhibitors	O
.	O


Methods	O
and	O
compositions	O
of	O
PI-3	B-GENE
kinase	I-GENE
inhibitors	O
and	O
their	O
use	O
in	O
inhibiting	O
PI-3	B-GENE
kinase	I-GENE
activity	O
in	O
mammals	O
and	O
the	O
treatment	O
of	O
fibrosing	O
syndromes	O
in	O
a	O
subject	O
are	O
described	O
herein	O


Compounds	O
which	O
inhibit	O
the	O
activity	O
of	O
signal	B-GENE
transducer	I-GENE
and	I-GENE
activator	I-GENE
of	I-GENE
transcription	I-GENE
3	I-GENE
(	O
STAT3	B-GENE
)	O
are	O
provided	O
together	O
with	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O
.	O
The	O
compounds	O
are	O
designed	O
to	O
bind	O
to	O
the	O
SH2	O
domain	O
of	O
STAT3,	O
preventing	O
STAT3	B-GENE
from	O
binding	O
to	O
receptors	O
for	O
interleukin-6	B-GENE
family	O
cytokines,	O
growth	B-GENE
factors	I-GENE
such	O
as	O
the	O
platelet-derived	B-GENE
growth	O
factor,	O
the	O
epidermal	B-GENE
growth	O
factor,	O
vascular	B-GENE
endothelial	I-GENE
growth	O
factor,	O
and	O
other	O
signaling	O
molecules	O
such	O
as	O
leptin	O
.	O
Blocking	O
these	O
interactions	O
prevents	O
STAT3	B-GENE
from	O
being	O
phosphorylated	O
on	O
Tyr705,	O
which	O
is	O
required	O
for	O
the	O
dimerization	O
of	O
STAT3,	O
translocation	O
to	O
the	O
nucleus,	O
binding	O
to	O
STAT3	B-GENE
response	O
elements	O
on	O
promotors,	O
and	O
transcription	I-GENE
of	I-GENE
genes	O
.	O
In	O
addition	O
to	O
these	O
activities,	O
binding	O
to	O
the	O
SH2	O
domain	O
of	O
STAT3	B-GENE
breaks	O
up	O
pre-formed	O
dimmers,	O
thereby	O
preventing	O
the	O
transcriptional	O
activity	O
of	O
the	O
inhibitor	O
.	O


Methods	O
and	O
apparatus	O
are	O
disclosed	O
for	O
diagnosing	O
and	O
treating	O
oxidative	O
skin	O
damage	O
in	O
a	O
subject	O
.	O
The	O
therapeutic	O
method	O
can	O
comprise	O
:	O
(	O
i	O
)	O
diagnosing	O
a	O
level	O
of	O
oxidative	O
skin	O
damage	O
in	O
a	O
sample	O
comprising	O
stratum	O
corneum	O
of	O
the	O
subject	O
;	O
and	O
(	O
ii	O
)	O
recommending	O
a	O
therapeutic	O
regime	O
for	O
treatment	O
of	O
oxidative	O
skin	O
damage	O
in	O
the	O
subject,	O
wherein	O
said	O
recommendation	O
comprises	O
a	O
recommendation	O
to	O
administer	O
a	O
pharmaceutical	O
formulation	O
comprising	O
an	O
amount	O
of	O
one	O
or	O
more	O
specific	O
synthetic	O
SOD	B-GENE
/	O
catalase	B-GENE
mimetics	O
sufficient	O
to	O
treat	O
the	O
level	O
of	O
oxidative	O
skin	O
damage	O
of	O
the	O
subject	O
as	O
diagnosed	O
.	O
The	O
diagnostic	O
method	O
can	O
further	O
include	O
obtaining	O
a	O
sample	O
from	O
the	O
stratum	O
corneum	O
of	O
a	O
subject	O
;	O
measuring	O
the	O
level	O
of	O
at	O
least	O
one	O
oxidized	O
substance	O
in	O
the	O
sample	O
;	O
and	O
comparing	O
a	O
detected	O
level	O
of	O
the	O
oxidized	O
substance	O
with	O
a	O
standard,	O
whereby	O
an	O
elevated	O
level	O
of	O
the	O
oxidized	O
substance	O
is	O
indicative	O
of	O
skin	O
damage	O
.	O


Disclosed	O
is	O
a	O
diazaspiroalkane	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
II	O
)	O
[	O
wherein	O
R11,	O
R12	O
and	O
R13	O
independently	O
represent	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
a	O
C1-8	O
alkyl	O
group,	O
a	O
C1-8	O
alkoxy	O
group,	O
a	O
C1-8	O
alkyl	O
group	O
which	O
is	O
substituted	O
by	O
1	O
to	O
3	O
halogen	O
atoms,	O
a	O
C1-8	O
alkylsulfonyl	O
group,	O
or	O
the	O
like	O
;	O
T1,	O
U1,	O
V1	O
and	O
W1	O
independently	O
represent	O
a	O
bond	O
or	O
a	O
C1-5	O
alkylene	O
group	O
which	O
may	O
have	O
a	O
substituent	O
;	O
B1	O
represents	O
C	O
(	O
=	O
O	O
)	O
,	O
a	O
C1-5	O
alkylene	O
group	O
which	O
may	O
have	O
a	O
substituent,	O
or	O
the	O
like	O
;	O
Y1	O
and	O
Z1	O
independently	O
represent	O
a	O
C1-3	O
alkylene	O
group	O
which	O
may	O
have	O
a	O
substituent	O
;	O
and	O
R	O
represents	O
a	O
C1-8	O
alkyl	O
group,	O
or	O
the	O
like	O
]	O
,	O
which	O
is	O
a	O
GPR119	B-GENE
agonist,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O
The	O
diazaspiroalkane	O
derivative	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
can	O
be	O
used	O
as	O
a	O
therapeutic	O
agent	O
for	O
diabetes	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
combinations	O
of	O
a	O
microtubule	O
stabilising	O
agent	O
and	O
a	O
sigma	B-GENE
receptor	I-GENE
ligand	O
for	O
use	O
in	O
treating	O
cancer	O
.	O


An	O
acrylamide	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
are	O
provided	O
.	O
A	O
drug	O
containing	O
the	O
said	O
acrylamide	O
derivative	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
as	O
the	O
active	O
ingredient	O
is	O
also	O
provided,	O
which	O
can	O
be	O
used	O
to	O
treat	O
disorders	O
associated	O
with	O
tyrosine	B-GENE
kinase	I-GENE
especially	O
Bcr-Abl,	O
including	O
proliferative	O
disorders	O
such	O
as	O
cancers,	O
and	O
inflammations,	O
etc	O
.	O


Compounds	O
with	O
two	O
fused	O
bicyclic	O
heteroaryl	O
moieties	O
of	O
formula	O
I	O
and	O
their	O
pharmaceutical	O
compositions,	O
and	O
methods	O
of	O
using	O
them	O
as	O
leukotriene	B-GENE
A4	I-GENE
hydrolase	I-GENE
(	O
LTA4H	B-GENE
)	O
modulators	O
and	O
for	O
the	O
treatment	O
of	O
diseases,	O
disorders	O
and	O
conditions	O
mediated	O
by	O
LTA4H	B-GENE
.	O


There	O
is	O
provided	O
a	O
method	O
for	O
promoting	O
dynamin	B-GENE
ring	O
formation	O
and	O
/	O
or	O
maintenance	O
of	O
dynamin	B-GENE
rings	O
in	O
a	O
cell,	O
comprising	O
treating	O
the	O
cell	O
with	O
an	O
effective	O
amount	O
of	O
a	O
dynamin	B-GENE
ring	O
stabilizer,	O
or	O
a	O
prodrug	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
dynamin	B-GENE
ring	O
stabilizer	O
.	O
The	O
maintenance	O
or	O
accumulation	O
of	O
dynamin	B-GENE
ring	O
formation	O
has	O
particular	O
application	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
kidney	O
disease	O
or	O
condition	O
characterized	O
by	O
proteinuria	O
.	O
A	O
dynamin	B-GENE
ring	O
stabilizer	O
can	O
be	O
any	O
agent	O
that	O
interacts	O
with	O
dynamin	B-GENE
to	O
promote	O
dynamin	B-GENE
ring	O
assembly	O
and	O
/	O
or	O
inhibit	O
dynamin	B-GENE
ring	O
disassembly	O
.	O
There	O
are	O
also	O
provided	O
methods	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
podocyte	O
dysfunction	O
and	O
/	O
or	O
maintaining	O
or	O
inducing	O
actin	B-GENE
cytoskeleton	O
formation	O
in	O
a	O
cell	O
utilizing	O
dynamin	B-GENE
ring	O
stabilizers,	O
and	O
for	O
screening	O
a	O
test	O
agent	O
for	O
use	O
as	O
a	O
dynamin	B-GENE
ring	O
stabilizer	O
.	O


Disclosed	O
are	O
compositions	O
and	O
methods	O
useful	O
for	O
modulating	O
adipocyte	O
differentiation	O
and	O
/	O
or	O
development	O
.	O
Also	O
disclosed	O
are	O
compounds,	O
compositions,	O
and	O
methods	O
useful	O
for	O
altering	O
the	O
expression	O
and	O
/	O
or	O
activity	O
of	O
one	O
or	O
more	O
genes	O
involved	O
in	O
pathways	O
relating	O
to	O
adipogenesis	O
and	O
/	O
or	O
adipocyte	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
particular,	O
the	O
present	O
invention	O
provides	O
small	O
interfering	O
nucleic	O
acid	O
molecules,	O
and	O
in	O
particular,	O
micro-	O
RNA	O
and	O
miR-155-derived	O
molecules,	O
and	O
methods	O
for	O
their	O
use	O
in	O
altering	O
the	O
expression,	O
regulation,	O
or	O
accumulation	O
of	O
one	O
or	O
more	O
adipogenic	O
or	O
anti-adipogenic	O
genes	O
or	O
a	O
gene	O
products	O
in	O
a	O
mammal,	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
uses	O
of	O
Hydroxyproline	O
in	O
a	O
pharmaceutical	O
or	O
dietary	O
food	O
supplement	O
composition	O
for	O
treating,	O
ameliorating,	O
or	O
curing	O
certain	O
diseases	O
and	O
disorders	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
such	O
as	O
a	O
human	O
being,	O
in	O
particular	O
diseases	O
and	O
disorders	O
in	O
tissues	O
and	O
organs	O
having	O
high	O
levels	O
of	O
collagen	B-GENE
and	O
/	O
or	O
elastin,	O
such	O
as	O
muscle	O
and	O
/	O
or	O
connective	O
tissue,	O
said	O
tissues	O
having	O
high	O
levels	O
of	O
collagen	B-GENE
and	O
/	O
or	O
elastin	B-GENE
.	O
The	O
invention	O
further	O
relates	O
to	O
a	O
food	O
composition	O
comprising	O
hydroxyproline	O
for	O
feeding	O
animals,	O
such	O
as	O
fish,	O
resulting	O
in	O
increased	O
muscle	O
strength,	O
texture	O
and	O
firmness	O
.	O


Disclosed	O
is	O
use	O
of	O
a	O
compound	O
having	O
an	O
acid	B-GENE
pump	I-GENE
antagonistic	O
activity,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
the	O
production	O
of	O
a	O
medicinal	O
agent	O
for	O
preventing	O
or	O
treating	O
diseases	O
associated	O
with	O
abnormal	O
gastrointestinal	O
movement	O
.	O
Also	O
disclosed	O
is	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
the	O
diseases,	O
which	O
comprises	O
administering	O
the	O
compound	O
or	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
to	O
a	O
human	O
or	O
animal	O
.	O
The	O
compound,	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
the	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
may	O
be	O
used	O
in	O
combination	O
with	O
at	O
least	O
one	O
second	O
active	O
substance	O
.	O
Further	O
disclosed	O
are	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
kit	O
both	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
the	O
diseases,	O
each	O
of	O
which	O
contains	O
a	O
compound	O
having	O
an	O
acid	B-GENE
pump	I-GENE
antagonistic	O
activity	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
certain	O
compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
and	O
hydrates	O
thereof,	O
which	O
exhibit	O
useful	O
pharmacological	O
properties,	O
for	O
example,	O
as	O
agonists	O
of	O
the	O
S1P1	B-GENE
receptor	O
.	O
Also	O
provided	O
by	O
the	O
present	O
invention	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
the	O
invention,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
in	O
the	O
treatment	O
of	O
S1P1	B-GENE
receptor-associated	O
disorders,	O
for	O
example,	O
psoriasis,	O
rheumatoid	O
arthritis,	O
Crohn	O
'	O
s	O
disease,	O
transplant	O
rejection,	O
multiple	O
sclerosis,	O
systemic	O
lupus	O
erythematosus,	O
ulcerative	O
colitis,	O
type	O
I	O
diabetes,	O
acne,	O
myocardial	O
ischemia-reperfusion	O
injury,	O
hypertensive	O
nephropathy,	O
glomerulosclerosis,	O
gastritis,	O
polymyositis,	O
thyroiditis,	O
vitiligo,	O
hepatitis,	O
biliary	O
cirrhosis,	O
microbial	O
infections	O
and	O
associated	O
diseases,	O
viral	O
infections	O
and	O
associated	O
diseases,	O
diseases	O
and	O
disorders	O
mediated	O
by	O
lymphocytes,	O
auto	O
immune	O
diseases,	O
inflammatory	O
diseases,	O
and	O
cancer	O
.	O


The	O
present	O
invention	O
relates	O
to	O
benzoxazinone	O
derivatives,	O
processes	O
for	O
their	O
preparation,	O
pharmaceutical	O
compositions	O
and	O
medicaments	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
treating	O
disorders	O
mediated	O
by	O
GlyT1,	O
including	O
neurological	O
and	O
neuropsychiatric	O
disorders,	O
in	O
particular	O
psychoses,	O
dementia	O
or	O
attention	O
deficit	O
disorder	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
3-phenoxy-4-pyrone,	O
3-phenoxy-4-pyridone,	O
or	O
4-pyridone	O
derivatives,	O
or	O
to	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
to	O
a	O
method	O
for	O
preparing	O
same,	O
and	O
to	O
an	O
antibacterial	O
composition	O
containing	O
same	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
composition	O
containing	O
the	O
novel	O
3-phenoxy-4-pyrone,	O
3-phenoxy-4-pyridone,	O
or	O
4-pyridone	O
derivatives	O
according	O
to	O
the	O
present	O
invention	O
effectively	O
inhibits	O
enoyl-ACP	B-GENE
reductase	I-GENE
(	O
RabI	B-GENE
)	O
,	O
which	O
serves	O
as	O
a	O
bacterial	O
fatty	O
acid	O
biosynthesis	O
enzyme,	O
and	O
thus	O
can	O
be	O
effectively	O
used	O
as	O
an	O
antibacterial	O
agent	O
.	O


A	O
method	O
of	O
treating	O
or	O
preventing	O
Huntington	O
'	O
s	O
disease	O
in	O
a	O
human	O
patient	O
in	O
need	O
thereof	O
comprising	O
co-administering	O
D-cycloserine	O
and	O
an	O
NMDA	B-GENE
receptor	I-GENE
antagonist	O
or	O
sigma	B-GENE
receptor	I-GENE
agonist	O
to	O
said	O
patient	O
.	O


Provided	O
are	O
novel	O
benzyl	O
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
exhibit	O
excellent	O
bronchodilating	O
effect	O
that	O
relies	O
on	O
potent	O
EP2	B-GENE
agonist	O
activity	O
;	O
or	O
salts	O
thereof	O
.	O


Provided	O
is	O
an	O
external	O
preparation	O
for	O
the	O
skin	O
which	O
is	O
excellent	O
in	O
terms	O
of	O
promoting	O
production	O
of	O
the	O
extracellular	O
matrix,	O
specifically	O
collagen	B-GENE
and	O
hyaluronic	O
acid,	O
and	O
is	O
effective	O
in	O
the	O
prevention	O
and	O
improvement	O
of	O
age-associated	O
wrinkling	O
and	O
sagging	O
.	O
The	O
external	O
preparation	O
for	O
the	O
skin	O
comprises	O
a	O
C5-24	O
α-ketol	O
or	O
γ-ketol	O
fatty	O
acid	O
as	O
the	O
active	O
ingredient,	O
wherein	O
the	O
number	O
of	O
double	O
bonds	O
between	O
carbon	O
atoms	O
is	O
from	O
1	O
to	O
6,	O
or	O
a	O
derivative	O
thereof	O
.	O


The	O
present	O
invention	O
concerns	O
novel	O
aminoacids	O
derivatives,	O
in	O
particular	O
some	O
aminoacid	O
amides	O
derivatives,	O
their	O
process	O
of	O
preparation	O
and	O
their	O
use	O
for	O
inhibiting	O
Met-triggered	O
disorders,	O
in	O
particular	O
cancer	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A1,	O
A2,	O
A3,	O
A4,	O
n,	O
the	O
dotted	O
lines,	O
B1,	O
B1a,	O
B2,	O
B2a,	O
B3,	O
B3a,	O
B4,	O
B4a,	O
R2	O
and	O
R3	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
esters,	O
amides,	O
solvates	O
or	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	B-GENE
kinase	I-GENE
(	O
e	O
.	O
g	O
.	O
a	O
PI3-K	B-GENE
and	O
/	O
or	O
mTOR	B-GENE
)	O
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O


Disclosed	O
are	O
a	O
therapeutic	O
agent	O
for	O
tumor,	O
in	O
particular,	O
drug-resistant	O
cancer,	O
an	O
agent	O
for	O
inhibiting	O
or	O
preventing	O
tumor	O
metastasis,	O
and	O
an	O
agent	O
for	O
inhibiting	O
or	O
preventing	O
cancer	O
recurrence,	O
each	O
comprising	O
a	O
nucleic	O
acid	O
containing	O
miR27b	B-GENE
or	O
a	O
nucleotide	O
which	O
comprises	O
a	O
nucleotide	O
sequence	O
having	O
a	O
70	O
%	O
or	O
more	O
identity	O
with	O
the	O
nucleotide	O
sequence	O
represented	O
by	O
SEQ	O
ID	O
NO	O
:	O
1	O
and	O
has	O
the	O
same	O
function	O
as	O
that	O
of	O
miR27b	B-GENE
.	O


Provided	O
is	O
a	O
novel	O
and	O
non-natural	O
sialic	O
acid-containing	O
sugar	O
chain	O
compound,	O
which	O
has	O
a	O
binding	O
activity	O
to	O
a	O
viral	O
particle	O
and	O
remains	O
stable	O
even	O
in	O
the	O
presence	O
of	O
sialidase,	O
obtained	O
by	O
using	O
a	O
reaction	O
with	O
the	O
use	O
of	O
a	O
glycosyltransferase	O
having	O
high	O
substrate	O
specificity	O
and	O
high	O
reaction	O
selectivity	O
.	O
A	O
compound	O
having	O
a	O
sugar	O
chain	O
structure	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
:	O
Siaα2-3	O
(	O
Siaα2-6	O
)	O
Galβ1-4	O
(	O
Fucα1-3	O
)	O
GlcNAc	O
(	O
1	O
)	O
,	O
or	O
a	O
salt	O
thereof	O
.	O


Disclosed	O
are	O
fused	O
heterocyclic	O
compounds	O
that	O
are	O
useful	O
for	O
prophylaxis,	O
therapy	O
or	O
amelioration	O
of	O
diseases	O
on	O
which	O
a	O
thrombopoietin	B-GENE
receptor	I-GENE
activation	O
effect	O
is	O
effective	O
.	O
Specifically	O
disclosed	O
are	O
a	O
fused	O
heterocyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
R1	O
represents	O
an	O
aryl	O
group	O
that	O
is	O
fused	O
to	O
a	O
saturated	O
ring,	O
or	O
the	O
like	O
;	O
and	O
A,	O
B,	O
L1,	O
R2,	O
L2,	O
L3,	O
Y,	O
L4,	O
R3	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
)	O
,	O
a	O
tautomer,	O
prodrug	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound,	O
and	O
a	O
solvate	O
of	O
the	O
compound,	O
tautomer,	O
prodrug	O
or	O
pharmaceutically	O
acceptable	O
salt	O
.	O


The	O
present	O
invention	O
provides	O
methods,	O
and	O
compositions	O
for	O
prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
a	O
mammal	O
(	O
e	O
.	O
g	O
.	O
a	O
human	O
)	O
suffering	O
from	O
an	O
osteoarticular	O
disease,	O
such	O
as	O
osteoarthritis	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
MAPK	B-GENE
signalling	O
pathway	O
modulators,	O
such	O
as	O
ERK	B-GENE
1/2	I-GENE
inhibitors,	O
CFBA1	O
inhibitors	O
and	O
p38	B-GENE
activators,	O
to	O
modulate	O
the	O
pathological	O
interactions	O
that	O
occur	O
between	O
subchondral	O
bone	O
cells	O
and	O
cartilage	O
cells	O
during	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
osteoarticular	O
diseases	O
.	O
Suitably,	O
modulation	O
of	O
these	O
interactions	O
at	O
least	O
partly	O
alleviates	O
major	O
symptoms	O
associated	O
with	O
osteoarticular	O
diseases	O
and	O
slows	O
disease	O
progression,	O
thereby	O
reducing	O
the	O
need	O
for	O
surgical	O
intervention	O
and	O
anti-inflammatory	O
medication	O
.	O


The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
CYR61	B-GENE
protein	O
and	O
inhibitors	O
thereof	O
for	O
preparing	O
medicine	O
for	O
treating	O
rheumatic	O
disease,	O
wherein	O
the	O
inhibitors	O
are	O
selected	O
from	O
anti-CYR61	O
antibody	O
or	O
interfering	O
RNA	O
of	O
CYR61	B-GENE
gene	O
.	O


A	O
method	O
and	O
pharmaceutical	O
composition	O
for	O
treating	O
a	O
disease	O
or	O
condition	O
associated	O
with	O
elevated	O
hypothalamic	O
T	B-GENE
cell	I-GENE
protein	I-GENE
tyrosine	I-GENE
phosphatase	I-GENE
(	O
TCPTP	B-GENE
)	O
such	O
as	O
obesity,	O
weight	O
gain,	O
type	O
2	O
diabetes	O
mellitus,	O
insulin	B-GENE
sensitivity,	O
impaired	O
glucose	O
tolerance,	O
and	O
inflammation	O
is	O
disclosed	O
.	O
The	O
method	O
involves	O
administering	O
a	O
subject	O
with	O
an	O
agent	O
which	O
inhibits	O
the	O
activity	O
or	O
expression	O
of	O
TCPTP,	O
wherein	O
the	O
agent	O
is	O
administered,	O
adapted	O
and	O
/	O
or	O
formulated	O
in	O
a	O
manner	O
ensuring	O
that	O
an	O
effective	O
amount	O
of	O
said	O
agent	O
is	O
delivered	O
to	O
the	O
hypothalamus	O
and	O
inhibits	O
the	O
activity	O
and	O
/	O
or	O
expression	O
of	O
hypothalamic	O
TCPTP	B-GENE
.	O
Also	O
disclosed	O
is	O
a	O
method	O
for	O
alleviating	O
or	O
preventing	O
leptin	B-GENE
resistance	O
in	O
an	O
obese	O
or	O
overweight	O
subject,	O
a	O
method	O
for	O
sensitising	O
a	O
subject	O
to	O
weight	O
loss	O
through	O
dieting,	O
and	O
a	O
dieting	O
kit	O
.	O


The	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
endometriosis	O
using	O
cMet	B-GENE
inhibitors,	O
and	O
medication	O
comprising	O
cMet	B-GENE
inhibitors	O
for	O
treating	O
endometriosis	O
.	O


A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
wherein	O
R1	O
to	O
R4	O
have	O
the	O
significance	O
given	O
in	O
claim	O
1,	O
can	O
be	O
used	O
as	O
a	O
modulator	O
of	O
AMPK	B-GENE
.	O


The	O
present	O
application	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen,	O
halogen,	O
cyano,	O
lower	O
alkyl	O
or	O
lower	O
alkyl	O
substituted	O
by	O
halogen	O
;	O
n	O
is	O
1,	O
2	O
or	O
3,	O
if	O
n	O
is	O
2	O
or	O
3,	O
R1	O
can	O
be	O
different	O
;	O
R2	O
is	O
C2-7-alkyl	O
or	O
C3-6-cycloalkyl	O
;	O
R3	O
is	O
the	O
group	O
(	O
II	O
)	O
wherein	O
X	O
is	O
CH	O
or	O
N	O
;	O
R5	O
is	O
hydrogen,	O
-C	O
(	O
O	O
)	O
-lower	O
alkyl,	O
-C	O
(	O
O	O
)	O
O-lower	O
alkyl,	O
S	O
(	O
O	O
)	O
2-lower	O
alkyl,	O
-C	O
(	O
O	O
)	O
CH2O-lower	O
alkyl,	O
-C	O
(	O
O	O
)	O
-CH2-CN,	O
or	O
is	O
-	O
or	O
-C	O
(	O
O	O
)	O
-cycloalkyl,	O
cycloalkyl,	O
or	O
-CH2-cycloalkyl,	O
wherein	O
the	O
cycloalkyl	O
groups	O
are	O
optionally	O
substituted	O
by	O
lower	O
alkyl,	O
-CH2-O-Iower	O
alkyl,	O
lower	O
alkoxy,	O
CF3,	O
halogen	O
or	O
cyano,	O
or	O
is	O
-C	O
(	O
O	O
)	O
-heterocycloalkyl	O
or	O
heterocycloalkyl,	O
or	O
is	O
-C	O
(	O
O	O
)	O
-heteroaryl	O
or	O
is	O
heteroaryl	O
or	O
is	O
-C	O
(	O
O	O
)	O
-aryl	O
or	O
aryl,	O
which	O
heterocycloalkyl,	O
heteroaryl	O
or	O
aryl	O
groups	O
are	O
optionally	O
substituted	O
by	O
halogen,	O
lower	O
alkyl,	O
=	O
O,	O
lower	O
alkoxy,	O
lower	O
alkyl	O
substituted	O
by	O
halogen,	O
lower	O
alkyl	O
substituted	O
by	O
hydroxy,	O
-C	O
(	O
O	O
)	O
-CH2-N	O
(	O
di-lower	O
alkyl	O
)	O
,	O
C	O
(	O
O	O
)	O
NH-lower	O
alkyl,	O
C	O
(	O
O	O
)	O
NH2,	O
-O-C	O
(	O
O	O
)	O
-	O
lower	O
alkyl,	O
C	O
(	O
O	O
)	O
-lower	O
alkyl,	O
S	O
(	O
O	O
)	O
2-lower	O
alkyl	O
or	O
cyano	O
;	O
R4	O
is	O
aryl,	O
which	O
is	O
optionally	O
substituted	O
by	O
halogen,	O
hydroxy,	O
lower	O
alkyl,	O
lower	O
alkyl	O
substituted	O
by	O
halogen,	O
S	O
(	O
O	O
)	O
2-lower	O
alkyl,	O
cyano	O
or	O
by	O
lower	O
alkoxy	O
;	O
or	O
to	O
a	O
pharmaceutically	O
active	O
salt	O
thereof	O
.	O
It	O
has	O
been	O
found	O
that	O
the	O
present	O
compounds	O
are	O
high	O
potential	O
NK-3	B-GENE
receptor	I-GENE
antagonists	O
for	O
the	O
treatment	O
of	O
depression,	O
pain,	O
psychosis,	O
Parkinson	O
'	O
s	O
disease,	O
schizophrenia,	O
anxiety	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O


Disclosed	O
is	O
a	O
novel	O
compound	O
which	O
has	O
histamine	B-GENE
H4	I-GENE
receptor	I-GENE
modulating	O
activity	O
.	O
Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
salt	O
.	O
(	O
In	O
the	O
formula,	O
ring	O
A	O
represents	O
an	O
aromatic	O
heterocyclic	O
ring	O
;	O
-B1	O
represents	O
a	O
group	O
represented	O
by	O
-X-	O
(	O
CR8aR8b	O
)	O
m-Y	O
;	O
X	O
represents	O
a	O
group	O
represented	O
by	O
N	O
(	O
R7c	O
)	O
or	O
the	O
like	O
;	O
R7c	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R8a	O
and	O
R8b	O
each	O
independently	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom	O
or	O
the	O
like	O
;	O
m	O
represents	O
an	O
integer	O
of	O
0-5	O
;	O
Y	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
cycloalkylthio	O
group	O
or	O
the	O
like	O
;	O
and	O
-B2	O
represents	O
a	O
group	O
represented	O
by	O
formula	O
(	O
II	O
)	O
(	O
wherein	O
R10s	O
each	O
independently	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R11	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
and	O
p	O
represents	O
an	O
integer	O
of	O
0-4	O
)	O
or	O
the	O
like	O
.	O
)	O


Disclosed	O
are	O
compositions	O
and	O
methods	O
related	O
to	O
identification	O
of	O
modulators	O
of	O
EGFR	B-GENE
and	O
VEGFR	B-GENE
.	O


This	O
invention	O
provides	O
bisphenol	O
derivatives	O
having	O
a	O
structure	O
of	O
formula	O
I	O
.	O
Said	O
compounds	O
are	O
modulators	O
of	O
the	O
androgen	B-GENE
receptor	I-GENE
activity	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
diseases,	O
including	O
prostate	O
cancer,	O
breast	O
cancer,	O
ovarian	O
cancer,	O
endometrial	O
cancer,	O
acne,	O
ovarian	O
cysts,	O
polycystic	O
ovarian	O
disease,	O
age-related	O
macular	O
degeneration,	O
precocious	O
puberty,	O
hirsutism	O
and	O
air	O
loss	O
.	O


There	O
are	O
described	O
cydohexyl	O
amide	O
derivatives	O
useful	O
as	O
corticotropin	B-GENE
releasing	I-GENE
factor	I-GENE
(CRF)	I-GENE
receptor	I-GENE
antagonists	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
and	O
preventing	O
renal	O
impairment	O
by	O
administering	O
to	O
a	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
A1	B-GENE
adenosine	I-GENE
receptor	I-GENE
antagonist	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent	O
.	O
The	O
invention	O
further	O
encompasses	O
pharmaceutical	O
compositions	O
comprising	O
an	O
A1	B-GENE
adenosine	I-GENE
receptor	I-GENE
antagonist	O
alone	O
or	O
with,	O
at	O
least,	O
one	O
additional	O
therapeutic	O
agent	O
in	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O
The	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
find	O
use	O
in	O
methods	O
for	O
treating	O
and	O
preventing	O
renal	O
impairment	O
.	O


This	O
invention	O
is	O
based	O
on	O
strong	O
antioxidants	O
which	O
are	O
useful	O
for	O
all	O
age	O
group	O
.	O
The	O
basic	O
composition	O
of	O
ingredients	O
are-EPA	O
150	O
mg,	O
DHA	O
100	O
mg,	O
Folic	O
Acid	O
5	O
mg	O
and	O
Lycopene	O
50	O
mg	O
.	O
DHA	O
is	O
a	O
major	O
fatty	O
acid	O
in	O
sperm	O
and	O
brain	O
phospholipids,	O
particularly	O
in	O
the	O
retina	O
.	O
Dietary	O
DHA	O
may	O
reduce	O
the	O
risk	O
of	O
heart	O
disease	O
by	O
reducing	O
the	O
level	O
of	O
blood	O
triglycerides	O
in	O
humans	O
.	O
Low	O
levels	O
of	O
DHA	O
have	O
been	O
associated	O
with	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Vitamin	O
B9	O
(	O
folic	O
acid	O
and	O
folate	O
inclusive	O
)	O
is	O
essential	O
to	O
numerous	O
bodily	O
functions	O
ranging	O
from	O
nucleotide	O
biosynthesis	O
to	O
the	O
remethylation	O
of	O
homocysteine	O
.	O
The	O
human	O
body	O
needs	O
folate	O
to	O
synthesize	O
DNA,	O
repair	O
DNA,	O
and	O
methylate	O
DNA	O
as	O
well	O
as	O
to	O
act	O
as	O
a	O
cofactor	O
in	O
biological	O
reactions	O
involving	O
folate	O
.	O
It	O
is	O
especially	O
important	O
during	O
periods	O
of	O
rapid	O
cell	O
division	O
and	O
growth	O
.	O
Both	O
children	O
and	O
adults	O
require	O
folic	O
acid	O
to	O
produce	O
healthy	O
red	O
blood	O
cells	O
and	O
prevent	O
anemia	O
.	O
Folate	O
and	O
folic	O
acid	O
derive	O
their	O
names	O
from	O
the	O
Latin	O
word	O
folium	O
(	O
which	O
means	O
"leaf"	O
)	O
.	O
Leafy	O
vegetables	O
are	O
a	O
principal	O
source,	O
although	O
in	O
Western	O
diets	O
fortified	O
cereals	O
and	O
bread	O
may	O
be	O
a	O
larger	O
dietary	O
source	O
.	O
EPA	O
has	O
inhibitory	O
effect	O
on	O
CYP2C9	B-GENE
and	O
CYP2C19	B-GENE
hepatic	O
enzymes	O
.	O
At	O
high	O
dose,	O
it	O
may	O
also	O
inhibit	O
the	O
activity	O
of	O
CYP2D6	B-GENE
and	O
CYP3A4,	O
important	O
enzymes	O
involved	O
in	O
drug	O
metabolism	O
.	O
EPA	O
improves	O
the	O
response	O
of	O
patients	O
to	O
chemotherapy,	O
possibly	O
by	O
modulating	O
the	O
production	O
of	O
eicosanoid	O
.	O
It	O
might	O
also	O
reduce	O
the	O
risk	O
of	O
developing	O
certain	O
types	O
of	O
cancer	O
;	O
including	O
multiple	O
myeloma	O
.	O
Lycopene	O
helps	O
neutralize	O
harmful	O
free	O
radicals,	O
which	O
are	O
implicated	O
in	O
cancer,	O
heart	O
disease,	O
macular	O
degeneration	O
and	O
other	O
age-	O
related	O
illnesses	O
.	O
The	O
evidence	O
for	O
a	O
benefit	O
was	O
strongest	O
for	O
cancers	O
of	O
the	O
prostate,	O
lung,	O
and	O
stomach	O
.	O
Data	O
were	O
also	O
suggestive	O
of	O
a	O
benefit	O
for	O
cancers	O
of	O
the	O
pancreas,	O
colon	O
and	O
rectum,	O
esophagus,	O
oral	O
cavity,	O
breast,	O
and	O
cervix	O
.	O


The	O
present	O
invention	O
provides	O
a	O
novel	O
pyrimidine	O
derivative	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
same,	O
which	O
can	O
effectively	O
inhibit	O
the	O
growth	O
of	O
cancer	O
cells	O
induced	O
by	O
the	O
overexpression	O
of	O
EGFR	B-GENE
including	O
subtypes	O
and	O
also	O
prevents	O
the	O
development	O
of	O
drug	O
resistance	O
caused	O
by	O
the	O
mutation	O
of	O
EGFR	B-GENE
tyrosine	O
kinase	O
including	O
subtypes	O
.	O


Disclosed	O
are	O
compounds,	O
pharmaceutical	O
compositions	O
containing	O
those	O
compounds,	O
and	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
as	O
modulators	O
of	O
casein	B-GENE
kinase	I-GENE
1	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CK1γ	B-GENE
)	O
,	O
the	O
TGFβ	B-GENE
pathway	O
and	O
/	O
or	O
the	O
Wnt	B-GENE
pathway	O
.	O
Uses	O
are	O
also	O
disclosed	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
range	O
of	O
therapeutic	O
indications	O
due	O
at	O
least	O
in	O
part	O
to	O
aberrant	O
physiological	O
activity	O
of	O
casein	B-GENE
kinase	I-GENE
1	I-GENE
(	O
e	O
.	O
g	O
.	O
,	O
CK1γ	B-GENE
)	O
,	O
the	O
TGFβ	B-GENE
pathway	O
and	O
/	O
or	O
the	O
Wnt	B-GENE
pathway	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
microRNA-185	B-GENE
(	O
miR-185	B-GENE
)	O
as	O
a	O
tumor	O
suppressor	O
.	O
Embodiments	O
of	O
the	O
invention	O
are	O
directed	O
to	O
the	O
use	O
of	O
miR-185	B-GENE
to	O
modulate	O
the	O
expression	O
of	O
tumor-	O
causing	O
genes	O
and	O
to	O
treat	O
subjects	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
minimizing	O
the	O
risk	O
of	O
skin	O
cancer	O
developing	O
in	O
an	O
individual,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
for	O
treating	O
existing	O
skin	O
cancers	O
to	O
manage	O
the	O
symptoms	O
and	O
/	O
or	O
minimize	O
the	O
risk	O
of	O
the	O
skin	O
cancer	O
metastasising	O
.	O
To	O
this	O
effect,	O
the	O
inventors	O
have	O
identified	O
a	O
protein,	O
TRIM16,	O
whose	O
pattern	O
of	O
expression	O
is	O
linked	O
to	O
a	O
skin	O
cancer	O
or	O
pre-cancer	O
phenotype	O


The	O
disclosed	O
composition	O
containing	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
(	O
refer	O
to	O
the	O
Description	O
for	O
the	O
definitions	O
of	O
the	O
symbols	O
used	O
in	O
the	O
formula	O
)	O
,	O
or	O
a	O
salt	O
thereof,	O
has	O
excellent	O
CaSR	B-GENE
agonist	O
effects	O
and	O
provides	O
pharmaceutical	O
products,	O
CaSR	B-GENE
agonist	O
agents,	O
therapeutic	O
agents	O
against	O
e	O
.	O
g	O
.	O
diseases	O
that	O
are	O
remedied	O
by	O
CaSR	B-GENE
activation,	O
seasonings,	O
and	O
body-taste	O
imparting	O
agents	O
.	O


The	O
invention	O
provides	O
compounds,	O
compositions,	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
diseases,	O
disorders,	O
or	O
conditions	O
that	O
are	O
modulated	O
by	O
matrix	B-GENE
metalloproteinases	I-GENE
(	O
MMPs	B-GENE
)	O
.	O
The	O
disease,	O
disorder,	O
or	O
condition	O
can	O
include,	O
for	O
example,	O
stroke,	O
neurological	O
disorders,	O
or	O
ophthalmological	O
disorders	O
.	O
The	O
treatment	O
can	O
include	O
administering	O
a	O
compound	O
or	O
composition	O
described	O
herein,	O
thereby	O
providing	O
a	O
prodrug	O
compound	O
that	O
metabolizes	O
to	O
an	O
active	O
MMP	B-GENE
inhibitor	O
in	O
vivo	O
.	O
The	O
MMP	B-GENE
inhibition	O
can	O
be	O
selective	O
inhibition,	O
for	O
example,	O
selective	O
inhibition	O
of	O
MMP-2,	O
MMP-9,	O
and	O
/	O
or	O
MMP-14	B-GENE
.	O
Thus,	O
the	O
invention	O
provides	O
non-mutagenic	O
prodrug	O
compounds	O
of	O
the	O
formulas	O
described	O
herein	O
that	O
result	O
in	O
the	O
inhibition	O
of	O
MMPs	B-GENE
upon	O
in	O
vivo	O
administration	O
.	O


Disclosed	O
is	O
a	O
transdermal	O
pharmaceutical	O
which	O
uses	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonists	O
such	O
as	O
ropinirole	O
hydrochlorides	O
or	O
pramipexole	O
hydrochlorides	O
.	O
The	O
disclosed	O
pharmaceutical	O
takes	O
into	O
account	O
skin	O
safety	O
and	O
drug	O
stability,	O
exhibits	O
excellent	O
skin	O
permeability,	O
and	O
uses	O
the	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonists	O
such	O
as	O
ropinirole	O
that	O
are	O
currently	O
used	O
as	O
oral	O
preparations	O
in	O
a	O
new	O
manner	O
as	O
transdermal	O
agents	O
.	O
The	O
disclosed	O
transdermal	O
pharmaceutical	O
is	O
formed	O
by	O
combining	O
a	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonist	O
with	O
a	O
hydrophobic	O
solvent	O
and	O
surfactant	O
to	O
form	O
a	O
minute	O
micelle	O
in	O
a	O
water-polyhydric	O
alcohol	O
solvent,	O
and	O
then	O
preparing	O
a	O
colloidal	O
solution	O
containing	O
the	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonist	O
.	O
By	O
selecting	O
and	O
adjusting	O
the	O
pH	O
of	O
the	O
colloidal	O
solution,	O
the	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonists	O
project	O
from	O
the	O
exterior	O
of	O
the	O
micelle,	O
increasing	O
the	O
transdermal	O
absorbability	O
and	O
the	O
initial	O
permeability	O
of	O
the	O
non-ergot	O
antidopaminergic	O
D2	O
receptor	I-GENE
agonists	O
.	O


The	O
invention	O
provides	O
methods	O
for	O
the	O
identification	O
of	O
small	O
molecules	O
that	O
inhibit	O
MUC1	B-GENE
oligomerization,	O
and	O
the	O
functions	O
flowing	O
therefrom	O
.	O
In	O
addition,	O
small	O
molecules	O
that	O
prevent	O
MUC1	B-GENE
oligomerization,	O
such	O
as	O
some	O
flavonoids,	O
are	O
disclosed	O
.	O
Identified	O
molecules	O
will	O
find	O
use	O
in	O
treating	O
a	O
variety	O
of	O
MUC1	B-GENE
-related	O
inflammatory	O
conditions,	O
including	O
MUC1	B-GENE
-related	O
cancers	O
.	O
The	O
screening	O
methods	O
involve	O
two	O
MUC1	B-GENE
-derived	O
peptides	O
comprising	O
at	O
least	O
four	O
consecutive	O
residues	O
of	O
the	O
MUC1	B-GENE
sequence	O
and	O
the	O
motive	O
CQC,	O
e	O
.	O
g	O
.	O
CQCR,	O
CQCRR,	O
CQCRRR,	O
CQCRRRR,	O
CQCRRK	O
and	O
CQCRRKN	O
.	O


The	O
present	O
invention	O
generally	O
relates	O
to	O
compositions	O
and	O
kits	O
comprising	O
a	O
β2-AR	B-GENE
agonist	O
and	O
a	O
modulator	O
of	O
a	O
β2-AR	B-GENE
regulator	O
gene,	O
where	O
the	O
modulator	O
of	O
the	O
β2-AR	B-GENE
regulator	O
gene	O
inhibits	O
the	O
internalization	O
and	O
/	O
or	O
degradation	O
of	O
the	O
β2-adrenergic	B-GENE
receptor	I-GENE
(	O
β2-ΑR	B-GENE
)	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
an	O
agonist	O
of	O
β2-adrenergic	B-GENE
receptor	I-GENE
(	O
β2-ΑR	B-GENE
)	O
and	O
an	O
agent	O
which	O
inhibits	O
agonist	O
induced	O
β2-adrenergic	B-GENE
receptor	I-GENE
(	O
β2-ΑR	B-GENE
)	O
internalization	O
and	O
/	O
or	O
degradation	O
in	O
method	O
for	O
the	O
treatment	O
of	O
a	O
respiratory	O
disorder	O
in	O
a	O
subject	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
R1	O
is	O
methyl,	O
n-hexyl,	O
aminoethyl,	O
methylaminoethyl,	O
ethylaminoethyl,	O
dimethylaminoethyl,	O
acryloylaminoethyl,	O
methacryloylaminoethyl,	O
methoxyethyl,	O
ethoxyethyl,	O
d-C4-alkyl-	O
sulfonyl,	O
acryloyl,	O
or	O
methacryloyl	O
;	O
or	O
R1	O
is	O
aminoethyl,	O
acryloyl	O
or	O
acryloylaminoethyl	O
carrying	O
a	O
linker	O
and	O
a	O
tag,	O
and	O
R2	O
and	O
R3,	O
independently	O
of	O
each	O
other,	O
are	O
hydrogen	O
or	O
CrC4-alkyl,	O
or	O
R2	O
and	O
R3	O
together	O
form	O
a	O
methylene	O
or	O
an	O
ethylene	O
bridge	O
;	O
and	O
tautomers,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
These	O
compounds	O
are	O
effective	O
in	O
preventing	O
or	O
treating	O
a	O
disease	O
or	O
disorder	O
modulated	O
by	O
PI3	B-GENE
kinases	I-GENE
and	O
/	O
or	O
mTOR,	O
in	O
particular	O
treating	O
a	O
hyperproliferative	O
disorder	O
.	O


A	O
medicinal	O
agent	O
for	O
preventing	O
and	O
/	O
or	O
treating	O
hepatitis	O
C,	O
which	O
comprises	O
a	O
combination	O
of	O
an	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitor,	O
a	O
salt	O
thereof	O
or	O
a	O
solvate	O
of	O
the	O
inhibitor	O
or	O
the	O
salt	O
and	O
a	O
non-cyclic	O
retinoid,	O
a	O
salt	O
thereof	O
or	O
a	O
solvate	O
of	O
the	O
retinoid	O
or	O
the	O
salt	O
.	O


Disclosed	O
are	O
imidazopyridazinyl	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
salts	O
and	O
prodrugs	O
thereof,	O
wherein	O
R3	O
is	O
C2-4alkenyl	O
or	O
a	O
cyclic	O
group,	O
and	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
.	O
Also	O
disclosed	O
are	O
methods	O
of	O
using	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
at	O
least	O
one	O
CYP17	B-GENE
associated	O
condition,	O
such	O
as,	O
for	O
example,	O
cancer,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O


The	O
present	O
invention	O
provides	O
aryl	O
substituted	O
olefinic	O
compounds	O
as	O
Phosphodiesterase	B-GENE
1	I-GENE
0A	I-GENE
(	O
PDE	B-GENE
1	I-GENE
0A	I-GENE
)	O
inhibitors	O
.	O
In	O
particular,	O
compounds	O
described	O
herein	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
diseases,	O
conditions	O
and	O
/	O
or	O
disorders	O
by	O
inhibiting	O
Phosphodiesterase	B-GENE
1	I-GENE
0A	I-GENE
enzyme	O
.	O
Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein,	O
intermediates	O
used	O
in	O
their	O
synthesis,	O
pharmaceutical	O
compositions	O
thereof	O
.	O


The	O
invention	O
provides	O
uses	O
for	O
phospholipid	O
conjugates	O
of	O
TLR	B-GENE
agonists,	O
for	O
instance	O
in	O
vaccines,	O
and	O
to	O
prevent,	O
inhibit	O
or	O
treat	O
a	O
variety	O
of	O
disorders	O
including	O
inflammation,	O
cancer	O
and	O
pathogen,	O
e	O
.	O
g	O
.	O
,	O
microbe,	O
infection	O
.	O


Disclosed	O
are	O
high	O
throughput	O
and	O
virtual	O
screening	O
methods	O
that	O
can	O
identify	O
potential	O
anti-viral	O
agents	O
.	O
The	O
said	O
methods	O
identify	O
compounds	O
that	O
inhibit	O
viral	O
infection	O
by	O
binding	O
to	O
viral	B-GENE
nucleoprotein	I-GENE
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
formulations	O
useful	O
for	O
treating	O
or	O
preventing	O
viral	O
infections,	O
especially	O
influenza	O
A	O
.	O


Disclosed	O
herein	O
are	O
surgical	O
adjuvant	O
compositions	O
comprising	O
isotonic	O
phosphate	O
buffered	O
saline,	O
high	O
molecular	O
weight	O
dextran,	O
ascorbate,	O
transferrin	B-GENE
and	O
poloxamer	O
surfactant	O
P188	O
.	O
Also	O
described	O
are	O
surgical	O
methods	O
which	O
include	O
the	O
use	O
of	O
the	O
adjuvant	O
composition	O
to	O
reduce	O
tissure	O
and	O
cellular	O
damage	O
such	O
as	O
necrosis	O
and	O
/	O
or	O
apoptosis	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
and	O
their	O
use	O
as	O
pharmaceutical	O
ingredients,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
CNS	O
related	O
diseases	O
(	O
PDE	B-GENE
10A	I-GENE
inhibitors	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
dosage	O
comprising	O
a	O
B7-H3	B-GENE
antagonist	O
and	O
a	O
taxane	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
preventing	O
the	O
progression	O
of	O
cancer	O
in	O
a	O
human	O
.	O
An	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
a	O
B7-H3	B-GENE
antagonist	O
for	O
sensitizing	O
a	O
cancer	O
cell	O
to	O
a	O
taxane	O
.	O
Another	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
the	O
progression	O
of	O
cancer	O
comprising	O
providing	O
an	O
individual	O
in	O
need	O
thereof,	O
and	O
administration	O
to	O
said	O
individual	O
a	O
combination	O
dosage	O
comprising	O
a	O
B7-H3	B-GENE
antagonist	O
and	O
a	O
taxane	O
.	O


The	O
invention	O
provides	O
compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
and	O
stereoisomers,	O
tautomers,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4	O
and	O
n	O
are	O
defined	O
herein,	O
compositions	O
including	O
the	O
compounds	O
and	O
method	O
of	O
using	O
the	O
compounds	O
to	O
treat	O
a	O
disease	O
or	O
disorder	O
mediated	O
by	O
the	O
p110	B-GENE
delta	I-GENE
isoform	O
of	O
ΡI3	B-GENE
kinase	I-GENE
selected	O
from	O
immune	O
disorders,	O
cancer,	O
cardiovascular	O
disease,	O
viral	O
infection,	O
inflammation,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
novel	O
use	O
of	O
EDG2	B-GENE
inhibitors	O
for	O
treating	O
rheumatoid	O
arthritis,	O
particularly	O
in	O
those	O
patients	O
exhibiting	O
elevated	O
levels	O
of	O
pro-inflammatory	O
molecules	O
despite	O
having	O
been	O
treated	O
with	O
anti-inflammatories,	O
i	O
.	O
e	O
.	O
patients	O
not	O
responding	O
to	O
said	O
treatments	O
.	O


The	O
present	O
invention	O
relates	O
to	O
erlotinib	O
dichloroacetate	O
and	O
an	O
anti-cancer	O
agent	O
comprising	O
the	O
same	O
.	O
The	O
erlotinib	O
dichloroacetate	O
of	O
the	O
present	O
invention	O
can	O
inhibit	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
as	O
well	O
as	O
induce	O
cancer	O
cells	O
to	O
kill	O
themselves	O
via	O
apoptosis,	O
thereby	O
inhibit	O
growth	O
of	O
cancer	O
cells	O
and	O
lead	O
to	O
their	O
destruction,	O
and	O
show	O
significantly	O
enhanced	O
anti-cancer	O
effects	O
by	O
synergy	O
between	O
erlotinib	O
and	O
dichloroacetic	O
acid	O
.	O


Disclosed	O
herein	O
are	O
methods	O
of	O
treating	O
fragile	O
X	O
syndrome,	O
fragile	O
X-associated	O
tremor	O
/	O
ataxia	O
syndrome,	O
Down	O
'	O
s	O
syndrome	O
and	O
other	O
forms	O
of	O
mental	O
retardation,	O
and	O
/	O
or	O
autism	O
comprising	O
administering	O
a	O
GABAB	B-GENE
agonist	O
prodrug	O
to	O
a	O
subject	O
suffering	O
therefrom	O
.	O
The	O
GABAB	B-GENE
agonist	O
prodrugs	O
can	O
be	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
or	O
(	O
III	O
)	O
as	O
disclosed	O
herein	O
.	O


Bivalent	O
multifunctional	O
Αβ	B-GENE
oligomerization	O
inhibitors	O
(	O
BMAOIs	O
)	O
that	O
target	O
multiple	O
risk	O
factors	O
involved	O
in	O
Alzheimer	O
'	O
s	O
disease	O
are	O
provided	O
.	O
The	O
BMAOIs	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
Alzheimer	O
'	O
s	O
disease,	O
as	O
well	O
as	O
for	O
diagnostic	O
imaging	O
of	O
Αβ	B-GENE
plaques	O
in	O
brain	O
tissue	O
.	O
The	O
BMAOIs	O
comprise	O
i	O
)	O
an	O
Αβ	B-GENE
oligomer	O
(	O
ApO	O
)	O
-inhibitor	O
moiety	O
which	O
may	O
have	O
antioxidant	O
activity	O
(	O
e	O
.	O
g	O
.	O
curcumin,	O
curcumin	O
derivatives,	O
curcumin	O
hybrids,	O
resveratrol,	O
etc	O
.	O
)	O
;	O
ii	O
)	O
a	O
cell	O
membrane	O
/	O
lipid	O
raft	O
(	O
CM	O
/	O
LR	O
)	O
anchoring	O
moiety	O
(	O
e	O
.	O
g	O
.	O
cholesterol,	O
cholesterylamine,	O
a	O
steroid,	O
etc	O
.	O
)	O
;	O
and	O
iii	O
)	O
a	O
spacer	O
or	O
linker	O
moiety	O
that	O
stably	O
links	O
i	O
)	O
and	O
ii	O
)	O
together	O
.	O


The	O
present	O
application	O
relates	O
to	O
the	O
field	O
of	O
cancer,	O
particularly	O
cancers	O
wherein	O
p53	B-GENE
tumour	O
suppression	O
function	O
is	O
lost	O
or	O
impaired	O
.	O
It	O
is	O
shown	O
herein	O
that	O
Dicer	O
is	O
a	O
synthetic	O
lethal	O
partner	O
of	O
p53,	O
allowing	O
the	O
selective	O
targeting	O
and	O
killing	O
of	O
cancer	O
cells	O
.	O
The	O
effects	O
of	O
Dicer	O
on	O
survival	O
on	O
cancer	O
cells	O
are	O
mediated	O
through	O
the	O
miR17-92	B-GENE
cluster	O
and	O
inhibition	O
of	O
members	O
of	O
this	O
miRNA	O
cluster	O
is	O
an	O
attractive	O
treatment	O
strategy	O
in	O
cancer	O
.	O
Most	O
particularly,	O
these	O
findings	O
are	O
of	O
importance	O
in	O
the	O
field	O
of	O
retinoblastoma	O
.	O


[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
which	O
can	O
act	O
relying	O
on	O
an	O
agonistic	O
activity	O
on	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
and	O
is	O
therefore	O
useful	O
as	O
a	O
novel	O
and	O
excellent	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
.	O
[	O
Solution	O
]	O
Examination	O
was	O
made	O
on	O
compounds	O
having	O
an	O
agonistic	O
activity	O
on	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2,	O
and	O
it	O
is	O
confirmed	O
that	O
a	O
condensed	O
ring	O
pyridine	O
compound	O
of	O
the	O
invention	O
has	O
an	O
excellent	O
agonistic	O
activity	O
on	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
.	O
This	O
condensed	O
ring	O
pyridine	O
compound	O
has	O
an	O
agonistic	O
activity	O
on	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2,	O
and	O
can	O
be	O
used	O
as	O
a	O
prophylactic	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
cannabinoid	B-GENE
receptor	I-GENE
type	I-GENE
2,	O
such	O
as	O
inflammatory	O
diseases	O
and	O
pain	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
c-Met	B-GENE
inhibitor	O
(	O
disclosed	O
herein	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
useful	O
in	O
treating	O
cancer	O
mediated	O
by	O
activity	O
of	O
c-Met	B-GENE
receptors	O
.	O


The	O
present	O
invention	O
regards	O
a	O
composition	O
comprising	O
Glutathione	B-GENE
Reductase	I-GENE
(	O
GSSG-r	B-GENE
)	O
and	O
Oxidized	O
Glutathione	O
(	O
GSSG	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
pharmaceutical	O
use	O
as	O
antiviral	O
and	O
antibacterial	O
agents	O
and	O
for	O
the	O
protection	O
against	O
the	O
toxicity	O
of	O
the	O
free	O
radicals	O
and	O
in	O
particular	O
the	O
radicals	O
produced	O
by	O
the	O
radiolysis	O
of	O
cellular	O
water	O
.	O


Provided	O
herein	O
are	O
methods	O
for	O
treating	O
androgen-mediated	O
carcinomas	O
.	O
The	O
methods	O
include	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
pharmaceutical	O
product	O
that	O
includes	O
at	O
least	O
one	O
selective	O
and	O
reversible	O
monoamine	B-GENE
oxidase	I-GENE
A	I-GENE
inhibitor	O
.	O


Disclosed	O
herein	O
are	O
modulators	O
of	O
TRPV3	B-GENE
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
G1,	O
X1,	O
X2,	O
X3,	O
X4,	O
X5,	O
G2,	O
Z1,	O
Ra,	O
Rb,	O
u,	O
and	O
p	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
Compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
presented	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
phthalazinone	O
derivative,	O
and	O
a	O
preparation	O
method	O
and	O
a	O
pharmaceutical	O
use	O
thereof,	O
and	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
a	O
new	O
phthalazinone	O
derivative	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method	O
thereof,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
derivative,	O
and	O
a	O
use	O
thereof	O
as	O
a	O
therapeutic	O
agent	O
and	O
especially	O
as	O
a	O
poly	B-GENE
(ADP-ribose)	I-GENE
polymerase	I-GENE
(	O
PARP	B-GENE
)	O
inhibitor	O
.	O


The	O
invention	O
provides	O
:	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester,	O
amide,	O
or	O
salt	O
thereof,	O
including	O
a	O
salt	O
of	O
such	O
an	O
ester	O
or	O
amide,	O
wherein	O
A,	O
B,	O
R1,	O
R2,	O
R4,	O
R5,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
indention	O
also	O
provides	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
condition	O
associated	O
with	O
a	O
disease	O
or	O
disorder	O
associated	O
with	O
estrogen	B-GENE
receptor	I-GENE
activity	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
roles	O
played	O
by	O
the	O
LHX4	B-GENE
gene	O
in	O
lung	O
cancer	O
carcinogenesis	O
and	O
features	O
a	O
method	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
lung	O
cancer	O
by	O
administering	O
a	O
double-stranded	O
molecule	O
against	O
the	O
LHX4	B-GENE
gene,	O
Ku70	B-GENE
gene	O
or	O
Ku86	B-GENE
gene,	O
or	O
vector	O
encoding	O
the	O
double-stranded	O
molecule	O
.	O
The	O
present	O
invention	O
also	O
features	O
methods	O
for	O
diagnosing	O
lung	O
cancer,	O
using	O
LHX4	B-GENE
gene	O
.	O
To	O
that	O
end,	O
LHX4	B-GENE
may	O
serve	O
as	O
a	O
novel	O
serological	O
biomarker	O
for	O
lung	O
cancer	O
.	O
Also,	O
disclosed	O
are	O
methods	O
of	O
identifying	O
substances	O
for	O
treating	O
or	O
/	O
and	O
preventing	O
lung	O
cancer,	O
using	O
as	O
an	O
index	O
their	O
effect	O
on	O
an	O
expression	O
of	O
LHX4	B-GENE
gene	O
or	O
a	O
biological	O
activity	O
of	O
LHX4	B-GENE
polypeptide	O
.	O


Provided	O
herein	O
are	O
thienopyridine	O
and	O
thienopyrimidine	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
for	O
treatment	O
of	O
JAK	B-GENE
kinase	I-GENE
mediated	O
diseases,	O
including	O
JAK2	B-GENE
kinase-,	O
JAK3	B-GENE
kinase-	O
or	O
TYK2	B-GENE
kinase-mediated	O
diseases	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
.	O


Pyridazinone	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
including	O
stereoisomers,	O
tautomers,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
useful	O
for	O
inhibiting	O
Btk	B-GENE
kinase,	O
and	O
for	O
treating	O
immune	O
disorders	O
such	O
as	O
inflammation	O
mediated	O
by	O
Btk	B-GENE
kinase	O
.	O
Methods	O
of	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis,	O
and	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells,	O
or	O
associated	O
pathological	O
conditions,	O
are	O
disclosed	O
.	O


The	O
invention	O
relates	O
to	O
2-	O
(	O
R2-thio	O
)	O
-10-	O
[	O
3-	O
(	O
4-R1-piperazin-1-yl	O
)	O
propyl	O
]	O
-10H-phenothiazine	O
according	O
to	O
general	O
formula	O
I,	O
for	O
treating	O
a	O
β-amyloidopathy	O
or	O
an	O
α-synucleinopathy	O
accompanied	O
by	O
a	O
cerebral	O
protein	O
deposit	O
and	O
a	O
reduced	O
activity	O
of	O
the	O
cerebral	O
ABCC1-transporter	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
diagnosis	O
or	O
prediagnosis	O
of	O
a	O
β-amyloidopathy	O
or	O
an	O
α-synucleopathy	O
accompanied	O
by	O
a	O
cerebral	O
protein	O
deposit	O
and	O
a	O
reduced	O
activity	O
of	O
the	O
cerebral	O
ABCC1-transporter,	O
or	O
for	O
determining	O
the	O
risk	O
of	O
a	O
proband	O
suffering	O
from	O
such	O
an	O
illness,	O
the	O
proband	O
already	O
having	O
accumulated	O
substances	O
transported	O
by	O
the	O
cerebral	O
ABCC1	B-GENE
transporter	O
.	O


The	O
present	O
invention	O
provides	O
imidazotriazinone	O
compounds	O
which	O
are	O
inhibitors	O
of	O
phosphodiesterase	B-GENE
9	I-GENE
.	O
The	O
present	O
invention	O
further	O
provides	O
processes,	O
pharmaceutical	O
compositions,	O
pharmaceutical	O
preparations	O
and	O
pharmaceutical	O
use	O
of	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
PDE9	O
associated	O
diseases	O
or	O
disorders	O
in	O
mammals,	O
including	O
CNS	O
or	O
neurodegeneration	O
disorder	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
producing	O
a	O
composition	O
containing	O
2-acyl-lysophosphatidylserine,	O
the	O
method	O
comprising	O
:	O
(	O
a	O
)	O
a	O
step	O
for	O
obtaining	O
a	O
composition	O
containing	O
phosphatidylserine	O
by	O
causing	O
phospholipase	B-GENE
D	I-GENE
to	O
act	O
on	O
a	O
starting	O
material	O
containing	O
phosphatidylcholine	O
while	O
in	O
the	O
presence	O
of	O
serine	O
;	O
and	O
(	O
b	O
)	O
a	O
step	O
for	O
obtaining	O
a	O
composition	O
containing	O
2-acyl-lysophosphatidylserine	O
by	O
causing	O
phospholipase	B-GENE
A1	I-GENE
to	O
act	O
on	O
the	O
composition	O
containing	O
phosphatidylserine	O
while	O
in	O
the	O
presence	O
of	O
at	O
least	O
one	O
type	O
of	O
additive	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
and	O
(	O
III	O
)	O
.	O
(	O
I	O
)	O
represents	O
at	O
least	O
one	O
monovalent	O
cationic	O
salt	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
sulfates,	O
phosphates,	O
nitrates,	O
citrates	O
and	O
tartrates,	O
(	O
II	O
)	O
represents	O
a	O
gum,	O
and	O
(	O
III	O
)	O
represents	O
an	O
emulsifier	O
.	O


Disclosed	O
are	O
compounds	O
which	O
inhibit	O
the	O
activity	O
of	O
focal	B-GENE
adhesion	I-GENE
kinase	I-GENE
(	O
FAK	B-GENE
)	O
and	O
anaplastic	O
lymphoma	O
kinase	O
(	O
ALK	B-GENE
)	O
,	O
compositions	O
containing	O
the	O
compounds,	O
and	O
methods	O
of	O
treating	O
diseases	O
during	O
which	O
FAK	B-GENE
and	O
ALK	B-GENE
are	O
expressed	O
.	O
The	O
diseases	O
are,	O
for	O
example,	O
cancers	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
along	O
with	O
processes	O
for	O
their	O
preparation	O
that	O
are	O
useful	O
for	O
treating,	O
preventing	O
and	O
/	O
or	O
managing	O
the	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
modulated	O
by	O
VGSCs	B-GENE
.	O
The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
treating,	O
preventing	O
managing	O
and	O
/	O
or	O
lessening	O
the	O
diseases,	O
disorders,	O
syndromes	O
or	O
conditions	O
by	O
modulators	O
of	O
VGSC	B-GENE
of	O
Formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
rheumatoid	O
arthritis	O
containing	O
a	O
gamma	B-GENE
secretase	I-GENE
inhibitor	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
gamma	B-GENE
secretase	I-GENE
inhibitor	O
according	O
to	O
the	O
present	O
invention	O
reduces	O
the	O
extent	O
of	O
arthritis	O
induction	O
and	O
reduces	O
the	O
inflow	O
of	O
inflammatory	O
cells	O
into	O
the	O
knee	O
joint,	O
in	O
a	O
dose-dependent	O
fashion,	O
and	O
also	O
reduces	O
the	O
amount	O
of	O
cytokines	B-GENE
and	O
chemokines,	O
and	O
reduces	O
the	O
amount	O
of	O
expression	O
of	O
NICD	B-GENE
(	O
notch	B-GENE
intracellular	I-GENE
domain	I-GENE
)	O
.	O
Consequently,	O
the	O
gamma	B-GENE
secretase	I-GENE
inhibitor	O
according	O
to	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
a	O
medicinal	O
product	O
and	O
a	O
functional	O
health	O
food	O
which	O
is	O
useful	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
rheumatoid	O
arthritis,	O
since	O
it	O
regulates	O
the	O
activation,	O
differentiation	O
and	O
growth	O
of	O
immune	O
cells	O
and	O
hence	O
has	O
an	O
outstanding	O
effect	O
in	O
suppressing	O
the	O
production	O
of	O
NICD	B-GENE
which	O
plays	O
a	O
highly	O
important	O
role	O
in	O
notch	O
signal	O
transmission	O
whereby	O
inflammatory	O
reactions	O
occur	O
.	O


A	O
pharmaceutical	O
composition	O
for	O
inhibiting	O
at	O
least	O
protein	B-GENE
kinase	I-GENE
in	O
a	O
cell	O
of	O
a	O
subject	O
includes	O
a	O
purine	O
based	O
triazole	O
.	O


Seizure	O
disorders	O
are	O
treated	O
by	O
Ras	B-GENE
inhibitors	O
.	O
In	O
an	O
embodiment,	O
the	O
Ras	B-GENE
inhibitor	O
includes	O
a	O
farnesyl	B-GENE
transferase	I-GENE
inhibitor	O
.	O
In	O
another	O
embodiment,	O
the	O
farnesyl	B-GENE
transferase	I-GENE
inhibitor	O
includes	O
a	O
3-hydroxy-3-methylglutaryl-Coenzyme	B-GENE
A	I-GENE
reductase	I-GENE
inhibitor	O
.	O
In	O
another	O
embodiment,	O
the	O
3-hydroxy-3-methylglutaryl-	B-GENE
Coenzyme	I-GENE
A	I-GENE
reductase	I-GENE
inhibitor	O
is	O
not	O
a	O
Ras	B-GENE
inhibitor	O
.	O
Subjects	O
having	O
fragile	O
X	O
syndrome,	O
autism,	O
Angelman	O
syndrome,	O
Costello	O
syndrome,	O
cardio	O
facio	O
cutaneous	O
syndrome,	O
neurofibromatosis	O
type	O
I,	O
Noonan	O
syndrome	O
and	O
Coffm-Lowry	O
syndrome	O
that	O
have	O
seizure	O
disorders	O
can	O
be	O
treated	O
.	O


The	O
use	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
inhibitors	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
the	O
treatment	O
of	O
ocular	O
vascular	O
disease	O
is	O
provided	O
.	O
Dosing	O
regimes,	O
including	O
once	O
weekly	O
administration,	O
of	O
certain	O
VEGF-R2	B-GENE
inhibitors	O
are	O
provided	O
which	O
deliver	O
therapeutically	O
effective	O
concentrations	O
of	O
the	O
VEGF-R2	B-GENE
compounds	O
in	O
ocular	O
tissues	O
for	O
at	O
least	O
one	O
week	O
for	O
the	O
treatment	O
of	O
ocular	O
vascular	O
disease	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
A	O
for	O
the	O
treatment	O
of	O
neoplasia	O
with	O
inducibly	O
expressed	O
STAT3	B-GENE
.	O
Further,	O
the	O
present	O
invention	O
relates	O
to	O
determining	O
treatment	O
regimens	O
and	O
therapeutic	O
efficacy	O
with	O
respect	O
to	O
treatment	O
of	O
neoplasia	O
with	O
inducibly	O
expressed	O
STAT3	B-GENE
.	O


The	O
present	O
invention	O
concerns	O
new	O
methods	O
for	O
treating	O
HIV	O
infection	O
by	O
using	O
kinesin	B-GENE
inhibitors	O
and	O
methods	O
for	O
identifying	O
new	O
molecules	O
of	O
interest	O
for	O
treating	O
AIDS	O
.	O


Compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
Q,	O
R1,	O
R2,	O
R3	O
and	O
R4	O
are	O
each	O
as	O
defined	O
in	O
claim	O
1	O
are	O
PDK1	B-GENE
inhibitors	O
and	O
can	O
be	O
used	O
for	O
treatment	O
of	O
tumors	O
.	O


Disclosed	O
is	O
a	O
genistein	O
derivative,	O
4	O
'	O
,5-dihydroxy-7-	O
[	O
4-	O
(	O
N,	O
N-diethylamino	O
)	O
butoxy	O
]	O
isoflavones,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O
The	O
4	O
'	O
,5-dihydroxy-7-	O
[	O
4-	O
(	O
N,	O
N-diethylamino	O
)	O
butoxy	O
]	O
isoflavones	O
is	O
acquired	O
via	O
chemical	O
modification	O
of	O
genistein,	O
has	O
acetylcholinesterase	B-GENE
inhibiting	O
activity,	O
and	O
estrogenic	O
activity,	O
and	O
offers	O
protection	O
for	O
nerve	O
cells	O
.	O
As	O
a	O
compound	O
having	O
multiple	O
active	O
target	O
sites,	O
the	O
compound	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
an	O
anti-Alzheimer	O
disease	O
medicament	O
.	O


Compounds	O
according	O
to	O
Formula	O
(	O
I	O
)	O
,	O
are	O
potent	O
inhibitors	O
of	O
protein	B-GENE
kinase	I-GENE
D	I-GENE
(	O
pan-PKD	O
)	O
activity	O
.	O
PKD	B-GENE
controls	O
key	O
signaling	O
cascades	O
in	O
cells,	O
affecting	O
cell	O
proliferation,	O
gene	O
transcription,	O
and	O
protein	O
trafficking	O
.	O
Accordingly,	O
pharmaceutically	O
acceptable	O
compositions	O
of	O
the	O
inventive	O
compounds	O
are	O
candidate	O
therapeutics	O
for	O
pathological	O
conditions	O
conditioned	O
by	O
changes	O
in	O
PKD	B-GENE
activity	O
.	O


Tricyclic	O
PI3k	B-GENE
inhibitor	O
compounds	O
of	O
Formula	O
I	O
with	O
anti-cancer	O
activity,	O
anti-	O
inflammatory	O
activity,	O
or	O
immunoregulatory	O
properties,	O
and	O
more	O
specifically	O
with	O
PI3	B-GENE
kinase	I-GENE
modulating	O
or	O
inhibitory	O
activity	O
are	O
described	O
.	O
Methods	O
are	O
described	O
for	O
using	O
the	O
tricyclic	O
PI3K	B-GENE
inhibitor	O
compounds	O
of	O
Formula	O
I	O
for	O
in	O
vitro,	O
in	O
situ,	O
and	O
in	O
vivo	O
diagnosis	O
or	O
treatment	O
of	O
mammalian	O
cells,	O
organisms,	O
or	O
associated	O
pathological	O
conditions	O
.	O
Formula	O
I	O
compounds	O
include	O
stereoisomers,	O
geometric	O
isomers,	O
tautomers,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O
The	O
dashed	O
lines	O
indicate	O
an	O
optional	O
double	O
bond,	O
and	O
at	O
least	O
one	O
dashed	O
line	O
is	O
a	O
double	O
bond	O
.	O
The	O
substituents	O
are	O
as	O
described	O
.	O


The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
(	O
C1-C7	O
)	O
alkyl,	O
(	O
C2-C7	O
)	O
alkenyl	O
or	O
(	O
C2-C7	O
)	O
alkynyl	O
;	O
wherein	O
R	O
is	O
substituted	O
with	O
R1	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
hydrates,	O
or	O
solvates	O
thereof,	O
for	O
use	O
-alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds-	O
in	O
therapy,	O
for	O
preventing,	O
treating	O
or	O
ameliorating	O
diseases	O
or	O
conditions	O
responsive	O
to	O
stimulation	O
of	O
neutrophil	O
oxidative	O
burst,	O
responsive	O
to	O
stimulation	O
of	O
keratinocyte	O
IL-8	B-GENE
release	O
or	O
responsive	O
to	O
induction	O
of	O
necrosis	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
compound	O
which	O
has	O
a	O
MGAT	B-GENE
inhibitory	O
effect	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product,	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
of	O
the	O
compound	O
;	O
and	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
the	O
compound	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O
A	O
bicyclic	O
pyrimidine	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
thereof	O
.	O
(	O
In	O
the	O
formula,	O
R1	O
represents	O
an	O
optionally	O
substituted	O
lower	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
each	O
independently	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
X	O
represents	O
an	O
oxygen	O
atom	O
or	O
the	O
like	O
;	O
Y	O
represents	O
-N	O
(	O
R9	O
)	O
C	O
(	O
=	O
Z	O
)	O
-	O
(	O
wherein	O
R9	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
and	O
Z	O
represents	O
an	O
oxygen	O
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
m	O
represents	O
1	O
;	O
and	O
n	O
represents	O
2	O
.	O
)	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
which	O
may	O
be	O
useful	O
as	O
inhibitors	O
of	O
glycolysis,	O
inhibitors	O
of	O
protein	O
glycosylation,	O
anti-virals,	O
and	O
down-regulators	O
of	O
insulin	B-GENE
receptor	I-GENE
and	O
IGF-	B-GENE
1	I-GENE
receptor	I-GENE
for	O
the	O
treatment	O
or	O
prevention	O
of	O
inflammatory	O
dermatological	O
diseases	O
or	O
proliferative	O
dermatological	O
diseases	O
.	O


There	O
is	O
provided	O
compounds	O
of	O
formula	O
I,	O
wherein	O
R1,	O
R2,	O
R3	O
and	O
R4	O
(	O
and	O
the	O
-CH2-CH2	O
moiety	O
)	O
have	O
meanings	O
given	O
in	O
the	O
description,	O
and	O
pharmaceutically-acceptable	O
esters,	O
amides,	O
solvates	O
or	O
salts	O
thereof,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	B-GENE
or	I-GENE
lipid	I-GENE
kinase	I-GENE
(	O
e	O
.	O
g	O
.	O
a	O
PIM	B-GENE
family	I-GENE
kinase,	O
such	O
as	O
PIM-1,	O
PIM-2	B-GENE
and	O
/	O
or	O
PIM-3	B-GENE
)	O
is	O
desired	O
and	O
/	O
or	O
required,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
a	O
pyrimidine	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
one	O
of	O
X	O
and	O
Y	O
but	O
not	O
both	O
is	O
N,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
enantiomers,	O
stereoisomers,	O
rotamers,	O
tautomers,	O
diastereomers,	O
deuterated	O
versions,	O
or	O
racemates	O
thereof	O
.	O
These	O
compounds	O
inhibit	O
the	O
activity	O
of	O
CDK9	B-GENE
and	O
are	O
thus	O
useful	O
as	O
pharmaceuticals	O
.	O
Also	O
provided	O
are	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
CDK9	B-GENE
using	O
the	O
compounds	O
of	O
Formula	O
I	O
and	O
isomers	O
thereof,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O


The	O
prevent	O
invention	O
provides	O
a	O
composition	O
containing	O
a	O
methylhonokiol	O
derivative	O
as	O
an	O
active	O
ingredient	O
for	O
the	O
treatment,	O
prevention	O
or	O
improvement	O
of	O
dementia	O
.	O
The	O
methylhonokiol	O
derivative	O
of	O
the	O
invention	O
exhibits	O
a	O
β-amyloid	B-GENE
aggregation	O
inhibitory	O
effect,	O
β-secretase	B-GENE
activity	O
inhibitory	O
effect,	O
neuronal	O
apoptosis	O
inhibitory	O
effect	O
by	O
β-amyloid	B-GENE
.	O
Therefore,	O
the	O
methylhonokiol	O
derivative	O
of	O
the	O
invention	O
can	O
be	O
developed	O
as	O
a	O
therapeutic	O
agent	O
for	O
dementia	O
caused	O
by	O
β-amyloid	B-GENE
and	O
as	O
an	O
active	O
component	O
of	O
functional	O
health	O
foods	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
class	O
of	O
bicyclic	O
heteroaryl	O
compounds	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds,	O
and	O
their	O
use	O
for	O
modulating	O
the	O
activity	O
of	O
GPR119	B-GENE
in	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
and	O
complications	O
thereof,	O
as	O
well	O
as	O
methods	O
for	O
the	O
treatment	O
of	O
the	O
metabolic	O
disorders	O
and	O
complications	O
thereof	O
.	O


Provided	O
is	O
a	O
method	O
for	O
screening	O
a	O
more	O
effective	O
inhibitor	O
of	O
Ras	B-GENE
function	O
.	O
Further	O
provided	O
are	O
amino	O
acid	O
residues	O
at	O
an	O
important	O
site	O
for	O
interaction	O
with	O
an	O
inhibitor	O
of	O
Ras	B-GENE
function	O
in	O
a	O
Ras	B-GENE
polypeptide	O
.	O
By	O
confirming	O
a	O
difference	O
between	O
the	O
conformational	O
information	O
of	O
the	O
Ras	B-GENE
polypeptide	O
by	O
NMR	O
and	O
the	O
conformational	O
information	O
of	O
a	O
complex	O
of	O
the	O
Ras	B-GENE
polypeptide	O
with	O
a	O
seed	O
compound	O
by	O
NMR,	O
a	O
lead	O
compound	O
which	O
is	O
more	O
effective	O
than	O
the	O
seed	O
compound	O
can	O
be	O
selected	O
.	O
As	O
a	O
result	O
of	O
an	O
analysis	O
on	O
the	O
basis	O
of	O
the	O
conformational	O
information	O
of	O
the	O
Ras	B-GENE
polypeptide	O
by	O
NMR,	O
the	O
amino	O
acid	O
residues	O
which	O
can	O
interact	O
with	O
a	O
candidate	O
inhibitor	O
(	O
a	O
)	O
of	O
Ras	B-GENE
function	O
of	O
the	O
invention	O
are	O
K5,	O
E37,	O
D38,	O
S39,	O
L56,	O
E63,	O
Y64,	O
A66,	O
M67,	O
Q70,	O
Y71,	O
R73,	O
and	O
T74	O
when	O
the	O
amino	O
acid	O
sequence	O
represented	O
by	O
SEQ	O
ID	O
NO	O
:	O
1	O
is	O
used	O
as	O
a	O
reference	O
.	O


The	O
present	O
invention	O
relates	O
to	O
tricyclic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
mPGES-1	B-GENE
inhibitors	O
.	O
These	O
compounds	O
are	O
inhibitors	O
of	O
the	O
microsomal	B-GENE
prostaglandin	I-GENE
E	I-GENE
synthase-	I-GENE
1	I-GENE
(	O
mPGES-1	B-GENE
)	O
enzyme	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
/	O
or	O
inflammation	O
from	O
a	O
variety	O
of	O
diseases	O
or	O
conditions,	O
such	O
as	O
asthama,	O
osteoarthritis,	O
rheumatoid	O
arthritis,	O
acute	O
or	O
chronic	O
pain	O
and	O
neurodegenerative	O
diseases	O
.	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
oxime	O
derivatives,	O
a	O
method	O
for	O
preparing	O
the	O
same,	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
and	O
use	O
thereof	O
.	O
The	O
oxime	O
derivatives	O
according	O
to	O
the	O
present	O
invention	O
act	O
as	O
GPR119	B-GENE
agonists	O
to	O
stimulate	O
the	O
secretion	O
of	O
insulin	O
and	O
promote	O
GLP-1	B-GENE
formation	O
for	O
preventing	O
or	O
treating	O
type	O
2	O
diabetes,	O
complications	O
of	O
diabetes,	O
obesity,	O
dyslipidemia	O
or	O
osteoporosis	O
.	O


Disclosed	O
is	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z,	O
m	O
and	O
R1	O
-R6	O
are	O
as	O
described	O
herein,	O
as	O
a	O
modulator	O
of	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptors	I-GENE
particularly	O
the	O
α7	B-GENE
subtype,	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
as	O
well	O
as	O
analogues,	O
prodrugs,	O
isotopically	O
substituted	O
analogs,	O
metabolites,	O
pharmaceutically	O
acceptable	O
salts,	O
polymorphs,	O
solvates,	O
isomers,	O
clathrates,	O
and	O
co-crystal	O
thereofs,	O
for	O
use	O
either	O
alone	O
or	O
in	O
combinations	O
with	O
suitable	O
other	O
medicaments,	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
analogues	O
.	O
Also	O
disclosed	O
are	O
a	O
process	O
of	O
preparation	O
of	O
the	O
compounds	O
and	O
the	O
intended	O
uses	O
thereof	O
in	O
therapy,	O
particularly	O
in	O
the	O
prophylaxis	O
and	O
therapy	O
of	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease,	O
mild	O
cognitive	O
impairment,	O
senile	O
dementia,	O
and	O
the	O
like	O
.	O


An	O
inhibitor	O
cited	O
in	O
(	O
a	O
)	O
below,	O
or	O
a	O
tumor	O
therapeutic	O
agent	O
containing	O
a	O
nucleic	O
acid	O
cited	O
in	O
(	O
b	O
)	O
below	O
:	O
(	O
a	O
)	O
an	O
miR-151-3p	B-GENE
inhibitor,	O
an	O
miR-886-3p	B-GENE
inhibitor,	O
or	O
an	O
SMPD3	B-GENE
inhibitor	O
;	O
and	O
(	O
b	O
)	O
(	O
1	O
)	O
a	O
nucleic	O
acid	O
comprising	O
a	O
nucleotide	O
sequence	O
having	O
at	O
least	O
70	O
%	O
identity	O
with	O
a	O
nucleotide	O
sequence	O
represented	O
by	O
any	O
of	O
SEQ	O
ID	O
NO	O
:	O
1	O
to	O
6,	O
or	O
miR-29b-1	O
*	O
,	O
has-miR-221	O
*	O
,	O
miR-138,	O
miR-584,	O
miR-30a,	O
or	O
miR-146a,	O
the	O
nucleic	O
acid	O
containing	O
a	O
nucleotide	O
having	O
inhibitory	O
activity	O
on	O
the	O
expression	O
of	O
a	O
target	O
gene	O
;	O
or	O
(	O
2	O
)	O
a	O
nucleic	O
acid	O
that	O
is	O
an	O
expression	O
vector	O
capable	O
of	O
expressing	O
the	O
nucleic	O
acid	O
of	O
(	O
1	O
)	O
.	O


The	O
present	O
invention	O
provides	O
:	O
a	O
compound,	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
below,	O
that	O
has	O
both	O
angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonism	O
and	O
a	O
PPARγ	B-GENE
activation	O
effect	O
and	O
that	O
is	O
useful	O
as	O
a	O
preventative	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
high	O
blood	O
pressure,	O
cardiac	O
disease,	O
arteriosclerosis,	O
type-2	O
diabetes,	O
and	O
the	O
like	O
;	O
and	O
a	O
drug	O
composition	O
containing	O
the	O
compound	O
.	O
General	O
formula	O
(	O
I	O
)	O
(	O
in	O
the	O
formula	O
:	O
ring	O
A	O
represents	O
a	O
pyridine	O
ring	O
;	O
ring	O
B	O
represents	O
a	O
tetrazole	O
ring	O
or	O
an	O
oxadiazole-5	O
(	O
4H	O
)	O
-one	O
ring	O
;	O
X	O
represents	O
C-R5	O
or	O
a	O
nitrogen	O
atom	O
;	O
R1	O
represents	O
an	O
alkyl	O
group	O
;	O
R2	O
represents	O
an	O
alkyl	O
group	O
or	O
a	O
cycloalkyl	O
group	O
;	O
and	O
R3,	O
R4,	O
and	O
R5	O
each	O
independently	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
halogen	O
atom,	O
an	O
alkyl	O
group,	O
an	O
alkoxy	O
group	O
or	O
similar	O
.	O


Provided	O
is	O
a	O
novel	O
bleomycin	B-GENE
hydrolase	I-GENE
production	O
promoting	O
agent	O
.	O
Provided	O
are	O
a	O
bleomycin	B-GENE
hydrolase	I-GENE
production	O
promoting	O
agent,	O
a	O
natural	O
moisturizing	O
factor	O
production	O
promoting	O
agent,	O
and	O
an	O
agent	O
for	O
improving	O
dry	O
skin	O
containing	O
as	O
an	O
active	O
component	O
one	O
or	O
multiple	O
items	O
out	O
of	O
the	O
group	O
consisting	O
of	O
Rosa	O
roxburghii	O
extract,	O
Ligusticum	O
acutilobum	O
extract,	O
Phellodendron	O
amurense	O
extract,	O
Lamium	O
album	O
extract,	O
rosemary	O
extract,	O
benzenesulfonyl	O
GABA,	O
and	O
erythritol	O
.	O


Novel	O
compounds	O
for	O
the	O
treatment	O
of	O
estrogen	O
receptor-mediated	O
disorders,	O
including	O
breast	O
cancer,	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
novel	O
compounds	O
.	O
The	O
novel	O
compounds,	O
when	O
administered	O
in	O
a	O
safe	O
and	O
effective	O
amount,	O
present	O
extended	O
binding	O
to	O
estrogen	B-GENE
receptors	I-GENE
in	O
breast	O
tissue	O
without	O
activating	O
the	O
estrogen	B-GENE
receptors	I-GENE
.	O
Estrogen	O
is	O
blocked	O
from	O
binding	O
to	O
the	O
estrogen	B-GENE
receptors	I-GENE
for	O
an	O
extended	O
period	O
of	O
time,	O
effectively	O
hindering	O
growth	O
of	O
breast	O
cancer	O
cells	O
.	O


The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
improving	O
a	O
therapeutic	O
response	O
to	O
a	O
cancer	O
treatment,	O
in	O
a	O
subject,	O
the	O
method	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
enhances	O
the	O
expression	O
of	O
microRNA-140-5p	B-GENE
or	O
an	O
agent	O
that	O
mimics	O
the	O
effects	O
of	O
microRNA-140-5p	B-GENE
.	O
Further	O
provided	O
is	O
a	O
method	O
of	O
treating	O
a	O
cancer	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
comprising	O
the	O
step	O
of	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
microRNA-140-5p	B-GENE
or	O
an	O
agent	O
that	O
enhances	O
the	O
expression	O
of	O
microRNA-140-5p	B-GENE
.	O


This	O
invention	O
relates	O
to	O
a	O
salt	O
of	O
3-	O
[	O
6-	O
(	O
2-methoxyethyl	O
)	O
-3-pyridinyl	O
]	O
-2-methyl-8-	O
(	O
4-	O
morpholinyl	O
)	O
-imidazo	O
[	O
1,2-b	O
]	O
pyridazine,	O
a	O
phosphodiesterase	B-GENE
10	I-GENE
enzyme	O
(	O
PDE10	B-GENE
)	O
inhibitor,	O
as	O
well	O
as	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same,	O
the	O
salt	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
central	O
nervous	O
system	O
disorder,	O
or	O
a	O
metabolic	O
disorderand	O
methods	O
of	O
treatment	O
using	O
the	O
same	O
.	O


Pterostilbene,	O
a	O
natural	O
analog	O
of	O
resveratrol,	O
shows	O
anxiolytic-like	O
action	O
by	O
downregulating	O
phosphorylated	O
levels	O
of	O
ERKs	B-GENE
in	O
the	O
hippocampus	O
of	O
mice	O
.	O
Mice	O
administered	O
pterostilbene	O
(	O
1-10	O
mg	O
/	O
kg	O
BW	O
)	O
by	O
oral	O
gavage	O
were	O
subjected	O
to	O
the	O
Elevated-plus	O
maze	O
(	O
EPM	O
)	O
test	O
.	O
Pterostilbene	O
manifested	O
anxiolytic	O
activity	O
at	O
1	O
and	O
2	O
mg	O
/	O
kg	O
doses,	O
demonstrated	O
by	O
increased	O
percent	O
permanence-time	O
and	O
number	O
of	O
entries	O
in	O
open-arms,	O
critical	O
determinants	O
for	O
anxiety	O
.	O
This	O
anxiolytic	O
activity	O
was	O
comparable	O
to	O
diazepam	O
at	O
1	O
and	O
2	O
mg	O
/	O
kg	O
in	O
the	O
EPM	O
.	O
The	O
percent	O
traveled-distance	O
and	O
permanence-time	O
in	O
the	O
enclosed-arms	O
decreased	O
with	O
1	O
and	O
2	O
mg	O
/	O
kg	O
doses	O
.	O
5	O
and	O
10	O
mg	O
/	O
kg	O
doses	O
did	O
not	O
show	O
any	O
anxiolytic	O
effect	O
.	O
Locomotor	O
activity	O
was	O
unaffected	O
in	O
all	O
doses	O
.	O
Western	O
blot	O
analysis	O
corroborated	O
the	O
EPM	O
observations	O
.	O
Pterostilbene	O
was	O
detected	O
in	O
serum	O
and	O
brain	O
tissue	O
following	O
a	O
single	O
oral	O
administration,	O
demonstrating	O
the	O
compound	O
crosses	O
the	O
blood-brain	O
barrier	O
and	O
thereby	O
exert	O
its	O
anxiolytic	O
effect	O
.	O
Resveratrol	O
did	O
not	O
have	O
any	O
anxiolytic	O
effect	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
insulin	O
resistance	O
syndrome	O
in	O
an	O
animal	O
body	O
by	O
administering	O
an	O
inhibitor	O
of	O
protein	B-GENE
kinase	I-GENE
RNA-like	B-GENE
endoplasmic	I-GENE
reticulum	I-GENE
kinase	I-GENE
(	O
PERK	B-GENE
)	O
gene,	O
or	O
a	O
functional	O
variant	O
thereof,	O
or	O
an	O
inhibitor	O
of	O
PERK	B-GENE
protein	O
or	O
a	O
functional	O
variant	O
thereof	O
or	O
a	O
method	O
of	O
reducing	O
activity	O
of	O
transcription	O
factors	O
of	O
the	O
FOXO	B-GENE
family	I-GENE
(	O
Foxo	O
1,	O
3a,	O
4	O
and	O
6	O
)	O
by	O
administering	O
an	O
inhibitor	O
of	O
protein	B-GENE
kinase	I-GENE
RNA-like	B-GENE
endoplasmic	I-GENE
reticulum	I-GENE
kinase	I-GENE
(	O
PERK	B-GENE
)	O
gene,	O
or	O
a	O
functional	O
variant	O
thereof,	O
or	O
an	O
inhibitor	O
of	O
PERK	B-GENE
protein	O
or	O
a	O
functional	O
variant	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
different	O
compounds	O
and	O
methods	O
for	O
using	O
PERK	B-GENE
gene	O
or	O
PERK	B-GENE
protein	O
.	O


The	O
invention	O
relates	O
to	O
morpholino-derivatives	O
according	O
to	O
Formula	O
(	O
I	O
)	O
or	O
stereoisomers	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvate	O
thereof,	O
wherein	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
R9,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
compounds	O
are	O
antagonists,	O
reverse	O
agonists	O
or	O
agonists	O
of	O
G-protein	O
coupled	O
receptors,	O
such	O
as	O
dopamine	B-GENE
D4	I-GENE
and	O
5HT1a	B-GENE
.	O
The	O
inventions	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
involving	O
the	O
compounds	O
and	O
compositions	O
.	O
The	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
may	O
in	O
particular	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
disorders,	O
such	O
as	O
neurological	O
and	O
neurodegenerative	O
diseases	O
;	O
or	O
as	O
lead	O
compounds	O
for	O
the	O
design	O
and	O
selection	O
of	O
further	O
therapeutic	O
compounds	O
.	O


A	O
pharmaceutical	O
composition	O
comprising	O
a	O
CHK	B-GENE
inhibitor,	O
and	O
an	O
Hsp90	B-GENE
inhibitor	O
according	O
to	O
the	O
following	O
formulae	O
or	O
tautomers,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
wherein	O
the	O
variables	O
in	O
the	O
structural	O
formulae	O
are	O
defined	O
herein	O
.	O
Also	O
provided	O
are	O
methods	O
for	O
treating	O
a	O
proliferative	O
disorder	O
in	O
a	O
subject	O
in	O
need	O
thereof,	O
using	O
pharmaceutical	O
compositions	O
described	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
with	O
a	O
diphenylmethane	O
moiety	O
having	O
an	O
inhibitory	O
activity	O
against	O
sodium-dependent	B-GENE
glucose	I-GENE
cotransporter	I-GENE
2	I-GENE
(	O
SGLT2	B-GENE
)	O
being	O
present	O
in	O
the	O
intestine	O
and	O
kidney,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient,	O
which	O
is	O
useful	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders,	O
particularly	O
diabetes	O
.	O
The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
compound,	O
and	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders,	O
particularly	O
diabetes,	O
by	O
using	O
the	O
compound	O
.	O


[	O
Problem	O
]	O
To	O
provide	O
a	O
novel	O
N-	O
(	O
pyridin-2-yl	O
)	O
alkanamide	O
derivative	O
and	O
a	O
novel	O
insulin	O
sensitizer	O
containing	O
this	O
derivative	O
as	O
an	O
active	O
ingredient	O
.	O
[	O
Solution	O
]	O
A	O
novel	O
N-	O
(	O
pyridin-2-yl	O
)	O
alkanamide	O
derivative	O
or	O
salt	O
thereof,	O
wherein	O
R1	O
and	O
R2a	O
in	O
the	O
above	O
general	O
formula	O
[	O
1a	O
]	O
represent	O
a	O
hydrogen	O
atom	O
or	O
a	O
halogen	O
atom,	O
and	O
A	O
represents	O
an	O
alkylene	O
group	O
or	O
a	O
bond,	O
has	O
an	O
inhibitory	O
effect	O
on	O
SHIP2,	O
and	O
is	O
useful	O
as	O
an	O
insulin	O
sensitizer	O
by	O
causing	O
an	O
increase	O
in	O
insulin	O
sensitivity	O
.	O


Highly	O
selective	O
COX1	B-GENE
inhibitors	O
can	O
be	O
used	O
to	O
treat	O
a	O
neuroinflammatory	O
disease	O
.	O


The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
in	O
which	O
R1,	O
R7,	O
R8,	O
R9,	O
R10,	O
R17,	O
R18,	O
R19,	O
R20	O
and	O
m	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description,	O
are	O
novel	O
effective	O
inhibitors	O
of	O
type	B-GENE
4	I-GENE
and	I-GENE
5	I-GENE
phosphodiesterase	I-GENE
.	O


Inhibitors	O
are	O
provided	O
for	O
inhibiting	O
the	O
activity	O
of	O
clathrin	O
.	O
In	O
particular,	O
binding	O
site	O
(	O
s	O
)	O
on	O
the	O
clathrin	B-GENE
terminal	I-GENE
doman	I-GENE
(TD)	I-GENE
for	O
binding	O
inhibitors	O
have	O
been	O
identified	O
.	O
The	O
binding	O
sites	O
are	O
defined	O
by	O
amino	O
acid	O
(	O
s	O
)	O
in	O
the	O
group	O
Ile	O
52,	O
Ile	O
62,	O
Ile	O
80,	O
Phe	O
91,	O
and	O
Ile	O
93	O
of	O
the	O
clathrin	O
TD	O
(	O
SEQ	O
ID	O
No	O
.	O
1	O
)	O
.	O
In	O
at	O
least	O
some	O
forms,	O
the	O
binding	O
site	O
may	O
be	O
further	O
defined	O
by	O
amino	O
acid	O
(	O
s	O
)	O
in	O
the	O
group	O
Ile	O
66,	O
Arg	O
64,	O
Leu	O
82	O
andf	O
Lys	O
96	O
of	O
SEQ	O
ID	O
No	O
.	O
1,	O
or	O
by	O
Val	O
50	O
of	O
SEQ	O
ID	O
No	O
.	O
1	O
.	O
There	O
are	O
also	O
provided	O
methods	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
disease	O
and	O
conditions	O
responsive	O
to	O
the	O
inhibition	O
of	O
clathrin	O
.	O


The	O
disclosure	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
inflammatory	O
conditions	O
and	O
cancers	O
that	O
have	O
misregulated	O
NF-κB	B-GENE
.	O
In	O
some	O
embodiments,	O
the	O
disclosure	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
inflammatory	O
conditions,	O
inflammatory	O
states	O
associated	O
with	O
treating	O
HIV	O
and	O
AIDS	O
infections,	O
and	O
cancers	O
that	O
include	O
administering	O
strontium	O
ranelate	O
to	O
a	O
subject	O
diagnosed	O
with	O
or	O
at	O
risk	O
of	O
inflammatory	O
conditions,	O
inflammatory	O
states,	O
and	O
cancers,	O
respectively	O
.	O


The	O
invention	O
relates	O
to	O
necroptosis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
of	O
the	O
gastrointestinal	O
tract	O
.	O
Particularly,	O
the	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	O
receptor-interacting	B-GENE
protein-1	I-GENE
/	O
receptor-interacting	B-GENE
protein-3	I-GENE
(	O
RIP1	B-GENE
/	O
RIP3	B-GENE
)	O
complex,	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
or	O
conditions	O
of	O
the	O
gastrointestinal	O
tract,	O
in	O
particular	O
inflammatory	O
bowel	O
disease	O
.	O


The	O
present	O
invention	O
provides	O
a	O
composition	O
for	O
regulating	O
a	O
URAT1	B-GENE
activity,	O
characterized	O
by	O
containing	O
taurine,	O
which	O
is	O
a	O
substance	O
that	O
is	O
safe	O
even	O
when	O
ingested	O
on	O
daily	O
basis,	O
as	O
an	O
active	O
ingredient	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
nucleic	O
acid	O
molecule	O
of	O
up	O
to	O
150	O
nucleotides	O
comprising	O
consecutively	O
from	O
5	O
'	O
to	O
3	O
'	O
(	O
a	O
)	O
a	O
first	O
part	O
whose	O
sequence	O
is	O
between	O
50	O
%	O
and	O
100	O
%	O
complementary	O
to	O
the	O
sequence	O
AAAAGCUGGGUUGAGAGGGCGA	B-GENE
;	O
(	O
b	O
)	O
a	O
second	O
part	O
capable	O
of	O
forming	O
a	O
loop	O
between	O
the	O
first	O
and	O
the	O
third	O
part	O
;	O
and	O
(	O
c	O
)	O
a	O
third	O
part	O
comprising	O
or	O
consisting	O
of	O
the	O
sequence	O
AAAAGCUGGGUUGAGAGGGCGA	B-GENE
;	O
for	O
use	O
as	O
a	O
medicament	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
nucleic	O
acid	O
molecule	O
of	O
up	O
to	O
25	O
nucleotides	O
comprising	O
the	O
sequence	O
AAAAGCUGGGUUGAGAGGGCGA,	O
for	O
use	O
as	O
a	O
medicament	O
.	O
In	O
another	O
aspect,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
mature	O
miRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hsa-miR-320a,	O
ptr-miR-320a,	O
ppy-miR-320a,	O
bta-miR-320,	O
cfa-miR-320,	O
mmu-miR-320,	O
rno-miR-320,	O
and	O
mml-miR-320,	O
and	O
/	O
or	O
one	O
or	O
more	O
mir-RNA	O
precursor	O
(	O
s	O
)	O
thereof,	O
for	O
use	O
as	O
a	O
medicament	O
.	O


Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
cancer	O
disclosed	O
herein	O
.	O
The	O
method	O
of	O
the	O
present	O
invention	O
comprises	O
administration	O
of	O
compositions	O
comprising	O
β-glucan,	O
a	O
natural	O
ligand	O
for	O
dectin-1,	O
to	O
block	O
OX40L	B-GENE
expression	O
on	O
tumor	O
associated	O
mDCs	O
by	O
blocking	O
STAT6	B-GENE
phosphorylation	O
.	O
The	O
β-glucan-treated	O
mDCs	O
secrete	O
higher	O
levels	O
of	O
IL-12p70	B-GENE
and	O
do	O
not	O
expand	O
TNFα	B-GENE
and	O
IL-	B-GENE
13	I-GENE
-producing	O
CD4+	O
T	O
cells,	O
further	O
resulting	O
in	O
inhibition	O
of	O
Th2	O
responses	O
.	O
Thus,	O
compositions	O
disclosed	O
herein	O
reprogram	O
the	O
function	O
of	O
mDCs	O
in	O
breast	O
tumor	O
microenvironment	O
and	O
turn	O
tumor	O
promoting	O
Th2-type	O
chronic	O
inflammation	O
into	O
Thl-type	O
acute	O
inflammation	O
that	O
are	O
able	O
to	O
reject	O
tumors	O
.	O
The	O
present	O
invention	O
finds	O
particular	O
uses	O
for	O
the	O
intratumoral	O
administration	O
of	O
the	O
composition	O
thereby	O
directly	O
binding	O
to	O
and	O
directing	O
a	O
Thl-	O
type	O
acute	O
inflammation	O
.	O


The	O
present	O
invention	O
relates	O
to	O
cannabinnoid-2-receptor	B-GENE
(	O
CB2R	B-GENE
)	O
agonist	O
compounds	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
compounds,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
to	O
their	O
use	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
or	O
conditions	O
in	O
which	O
CB2R	B-GENE
stimulation	O
is	O
beneficial	O
(	O
especially	O
inflammatory	O
conditions	O
)	O
.	O


Disclosed	O
in	O
the	O
present	O
invention	O
are	O
a	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
used	O
for	O
inhibiting	O
the	O
activity	O
of	O
a	O
kidney-type	O
glutaminase,	O
and	O
the	O
use	O
of	O
the	O
compound	O
in	O
treatment,	O
especially	O
in	O
treating	O
or	O
preventing	O
diseases,	O
in	O
particular	O
cancer,	O
related	O
to	O
the	O
increase	O
in	O
activity	O
of	O
glutaminase	O
.	O


The	O
invention	O
provides	O
novel	O
substituted	O
benzyl	O
piperidine	O
compounds	O
according	O
to	O
Formula	O
(	O
I	O
)	O
as	O
lysophosphatidic	B-GENE
acid	I-GENE
(LPA)	I-GENE
receptor	I-GENE
antagonists,	O
their	O
manufacture	O
and	O
use	O
for	O
the	O
treatment	O
of	O
proliferative	O
or	O
inflammatory	O
diseases,	O
such	O
as	O
cancer,	O
fibrosis	O
or	O
arthritis	O
.	O


S1P	B-GENE
receptor	I-GENE
modulators	O
or	O
agonists	O
are	O
administered	O
following	O
a	O
dosage	O
regimen	O
whereby	O
during	O
the	O
initial	O
days	O
of	O
treatment	O
the	O
daily	O
dosage	O
is	O
lower	O
than	O
the	O
standard	O
daily	O
dosage	O
.	O


The	O
inventive	O
compounds	O
are	O
small	O
molecule	O
therapeutics	O
that	O
are	O
potent	O
inhibitors	O
of	O
Arginase	B-GENE
I	I-GENE
and	I-GENE
II	I-GENE
activity	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
of	O
the	O
inventive	O
compounds	O
and	O
methods	O
for	O
using	O
the	O
inventive	O
compounds	O
for	O
treating	O
or	O
preventing	O
a	O
disease	O
or	O
a	O
condition	O
associated	O
with	O
arginase	B-GENE
activity	O
.	O


This	O
document	O
relates	O
to	O
inhibitors	O
of	O
G	B-GENE
protein	I-GENE
coupled	I-GENE
receptor	I-GENE
6	I-GENE
kinase	I-GENE
(	O
GRK6	B-GENE
)	O
polypeptides	O
as	O
well	O
as	O
methods	O
and	O
materials	O
for	O
using	O
such	O
inhibitors	O
to	O
treat	O
hematological	O
malignancies,	O
inflammation	O
diseases,	O
and	O
autoimmune	O
disorders	O
.	O


The	O
invention	O
relates	O
to	O
a	O
cosmetic	O
composition,	O
in	O
particular	O
a	O
composition	O
for	O
making	O
up	O
and	O
/	O
or	O
caring	O
for	O
keratin	B-GENE
materials,	O
preferably	O
a	O
nail	O
makeup,	O
comprising	O
the	O
compound	O
of	O
chemical	O
formula	O
(	O
I	O
)	O
below	O
:	O
(	O
I	O
)	O
in	O
which	O
:	O
m	O
represents	O
an	O
integer	O
equal	O
to	O
0	O
or	O
1	O
;	O
n	O
represents	O
an	O
integer	O
between	O
2	O
and	O
8	O
;	O
R1	O
represents	O
a	O
group	O
(	O
C1-C20	O
)	O
alkyl	O
or	O
an	O
aryl	O
group,	O
or	O
alternatively,	O
when	O
m	O
is	O
equal	O
to	O
0,	O
R1	O
may	O
also	O
represent	O
a	O
carbonyl	O
;	O
R2	O
and	O
R3	O
represent	O
an	O
ethoxy	O
group	O
or	O
a	O
group	O
(	O
C1-C20	O
)	O
alkyl,	O
optionally	O
substituted	O
with	O
an	O
amino	O
group	O
;	O
Y	O
represents	O
a	O
polyurea	O
or	O
a	O
polyurethane	O
or	O
alternatively	O
a	O
hydrocarbon-based	O
group	O
comprising	O
from	O
2	O
to	O
100	O
carbon	O
atoms	O
.	O
The	O
invention	O
also	O
relates	O
to	O
a	O
cosmetic	O
process,	O
in	O
particular	O
a	O
makeup	O
or	O
hair	O
shaping	O
process,	O
preferably	O
a	O
process	O
for	O
making	O
up	O
keratin	B-GENE
materials,	O
in	O
particular	O
the	O
nails	O
and	O
/	O
or	O
the	O
hair,	O
characterized	O
in	O
that	O
it	O
comprises	O
at	O
least	O
one	O
step	O
which	O
consists	O
in	O
applying	O
a	O
cosmetic	O
composition	O
as	O
above	O
defined	O
to	O
keratin	B-GENE
materials	O
.	O


The	O
present	O
invention	O
provides	O
a	O
small	O
molecule	O
treatment	O
of	O
diseases	O
/	O
conditions	O
caused	O
by	O
a	O
virus	O
carrying	O
a	O
viral	O
oncoprotein	O
.	O
In	O
one	O
embodiment,	O
the	O
virus	O
which	O
carries	O
the	O
viral	O
oncoprotein	O
is	O
HPV	O
.	O
The	O
small	O
molecule	O
useful	O
herein	O
includes	O
thiadiazolin-3,5-dione	O
compounds	O
having	O
an	O
optionally	O
substituted	O
aryl	O
group	O
bound	O
to	O
one	O
nitrogen	O
atom	O
of	O
said	O
thiadiazolin-3,5-	O
dione	O
compound	O
.	O
The	O
small	O
molecules	O
may	O
also	O
be	O
administered	O
with	O
a	O
compound	O
which	O
inhibits	O
binding	O
of	O
HPV	B-GENE
E6	I-GENE
to	O
p53	B-GENE
.	O
In	O
one	O
embodiment,	O
the	O
thiadiazolin-3,5-	O
dione	O
compound	O
has	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt,	O
prodrug,	O
solvate,	O
or	O
metabolite	O
thereof,	O
wherein	O
R	O
1	O
and	O
R	O
2	O
are	O
defined	O
herein	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
2,5-dioxoimidazolidin-l-yl-3-	O
phenylurea	O
derivatives	O
of	O
formula	O
I,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
the	O
N-formyl	B-GENE
peptide	I-GENE
receptor	I-GENE
like-1	I-GENE
(	O
FPRL-1	B-GENE
)	O
receptor	O
.	O


Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1,	O
R2,	O
X	O
and	O
Y	O
have	O
the	O
meanings	O
specified	O
in	O
claim	O
1,	O
are	O
inhibitors	O
of	O
TBK1	B-GENE
and	O
ΙΚΚε,	O
and	O
can	O
be	O
used,	O
among	O
other	O
things,	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
diseases	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
an	O
immunomodulator	O
which	O
can	O
be	O
used	O
as	O
an	O
immunostimulator	O
useful	O
for	O
maintaining,	O
improving	O
or	O
suppressing	O
an	O
immune	O
function	O
in	O
association	O
with	O
CD300a	B-GENE
activity	O
signaling,	O
or	O
as	O
an	O
immunosuppressor	O
useful	O
for	O
suppressing	O
the	O
immune	O
function	O
;	O
use	O
of	O
a	O
CD300a	B-GENE
gene-deficient	O
mouse	O
for	O
the	O
analysis	O
of	O
clinical	O
conditions	O
or	O
the	O
like	O
;	O
an	O
anti-CD300a	O
antibody	O
;	O
and	O
others	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
preventing,	O
treating	O
or	O
alleviating	O
atopic	O
dermatitis	O
comprising	O
an	O
immunosuppressant	O
and	O
a	O
transglutaminase	B-GENE
2	I-GENE
inhibitor	O
as	O
active	O
ingredients	O
.	O
Conjoint	O
administration	O
of	O
an	O
immunosuppressant	O
and	O
a	O
transglutaminase	B-GENE
2	I-GENE
inhibitor	O
according	O
to	O
the	O
present	O
invention	O
makes	O
it	O
possible	O
to	O
achieve	O
far	O
better	O
therapeutic	O
effects	O
than	O
with	O
administration	O
of	O
either	O
an	O
immunosuppressant	O
or	O
a	O
transglutaminase	B-GENE
2	I-GENE
inhibitor	O
alone,	O
since	O
there	O
is	O
a	O
reduction	O
in	O
the	O
dose	O
of	O
an	O
immunosuppressant	O
which	O
is	O
difficult	O
to	O
administer	O
for	O
a	O
long	O
time	O
because	O
of	O
side	O
effects	O
and	O
with	O
which,	O
when	O
discontinued,	O
lesions	O
are	O
liable	O
to	O
become	O
exacerbated	O
to	O
the	O
original	O
state,	O
and	O
since	O
an	O
immunosuppressant	O
is	O
mixed	O
with	O
a	O
transglutaminase	B-GENE
2	I-GENE
inhibitor	O
which	O
in	O
some	O
patients	O
has	O
a	O
lacklustre	O
effect	O
in	O
treating	O
atopic	O
dermatitis	O
.	O


The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
useful	O
for	O
treating	O
and	O
preventing	O
neovascular	O
AMD	O
by	O
inhibition	O
of	O
CCR3	B-GENE
.	O
The	O
compositions	O
and	O
methods	O
are	O
useful	O
for	O
treating	O
and	O
preventing	O
diseases	O
and	O
disorders	O
such	O
as	O
but	O
not	O
limited	O
to,	O
neovascular	O
AMD	O
.	O


Provided	O
are	O
imidazolidinedione	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
preparation,	O
uses	O
and	O
pharmaceutically	O
compositions	O
thereof	O
.	O
Said	O
imidazolidinedione	O
compounds	O
possess	O
androgen	B-GENE
receptor	I-GENE
antagonist	O
activity	O
and	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
diseases	O
and	O
disorders	O
related	O
to	O
androgen	O
receptor,	O
such	O
as	O
prostate	O
cancer,	O
alopecia,	O
hair	O
regeneration,	O
acne	O
and	O
adolescent	O
acne	O
.	O


The	O
invention	O
relates	O
to	O
dihydro-benzo-oxazine	O
and	O
dihydro-pyrido-oxazine	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
/	O
or	O
pharmaceutically	O
acceptable	O
salts	O
and	O
/	O
or	O
solvates	O
thereof,	O
wherein	O
Y,	O
V,	O
W,	O
U,	O
Q,	O
R1,	O
R5,	O
R7	O
and	O
R30	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O
Such	O
compounds	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
or	O
disease	O
which	O
is	O
mediated	O
by	O
the	O
activity	O
of	O
the	O
PI3K	B-GENE
enzymes	O
.	O


A	O
transdermal	O
pharmaceutical	O
composition	O
comprising	O
a	O
phosphodiesterase	B-GENE
type-5	I-GENE
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutically	O
excipient,	O
wherein	O
the	O
transdermal	O
pharmaceutical	O
composition	O
comprises	O
an	O
enhancer	O
selected	O
from	O
the	O
group	O
of	O
cocamidopropyl	O
betaine,	O
sodium	O
lauroamphoacetate,	O
quaternium-60,	O
isostearamidopropyl	O
morpholine	O
lactate,	O
dipropylene	O
glycol	O
and	O
a	O
combination	O
thereof	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
reducing	O
the	O
body	O
weight	O
of	O
a	O
subject	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
estrogen	B-GENE
receptor	I-GENE
modulator	O
(	O
ERM	O
)	O
,	O
optionally,	O
in	O
combination	O
with	O
an	O
anti-obesity	O
or	O
weight	O
loss	O
agent	O
.	O


The	O
present	O
application	O
relates	O
to	O
combinations	O
of	O
inhibitors	O
directed	O
at	O
down-regulation	O
of	O
genes	O
associated	O
with	O
hearing	O
loss	O
including	O
HES1,	O
HES5,	O
HEY2,	O
CDKN1B	B-GENE
and	O
NOTCH1,	O
exhibiting	O
a	O
beneficial	O
effect	O
and	O
useful	O
in	O
treating	O
or	O
attenuating	O
hearing	O
loss,	O
treating	O
balance	O
impairment,	O
promoting	O
the	O
replacement,	O
regeneration,	O
or	O
protection	O
of	O
otic	O
(	O
sensory	O
)	O
hair	O
cells	O
of	O
the	O
inner	O
ear,	O
and	O
or	O
effecting	O
hearing	O
restoration	O
/	O
regeneration	O
.	O


Peptide	O
targeting	O
agents	O
are	O
provided	O
that	O
may	O
be	O
used	O
as	O
imaging	O
and	O
/	O
or	O
therapeutic	O
agents	O
for	O
tumor	O
cells	O
overexpressing	O
Ephrin	B-GENE
receptors	I-GENE
.	O
In	O
particular,	O
the	O
agents	O
can	O
be	O
used	O
for	O
targeting	O
cells	O
expressing	O
EphB4	B-GENE
and	O
/	O
or	O
EphA2	B-GENE
receptors	I-GENE
.	O
Methods	O
for	O
non-invasive	O
imaging	O
and	O
anticancer	O
therapy	O
using	O
the	O
targeting	O
agents	O
are	O
likewise	O
provided	O
.	O


Novel	O
genes	O
and	O
pathways	O
associated	O
with	O
the	O
regulation	O
of	O
innate	O
immunity,	O
more	O
particularly	O
of	O
Type	B-GENE
I	I-GENE
and	I-GENE
Type	B-GENE
III	I-GENE
interferon	I-GENE
(	O
IFN	B-GENE
)	O
production	O
in	O
response	O
to	O
viral	O
infection	O
.	O
Methods	O
for	O
modulating	O
innate	O
immunity	O
and	O
Type	B-GENE
I/Type	I-GENE
III	I-GENE
IFN	B-GENE
production,	O
and	O
for	O
the	O
identification	O
of	O
modulators	O
of	O
innate	O
immunity	O
and	O
Type	B-GENE
I/Type	I-GENE
III	I-GENE
IFN	B-GENE
production,	O
are	O
described	O
.	O


The	O
invention	O
provides	O
the	O
use	O
of	O
phosphorylation	O
pathway-related	O
factor,	O
an	O
agonist	O
or	O
antagonist	O
thereof	O
in	O
preparing	O
a	O
composition	O
for	O
regulating	O
the	O
immune	O
function	O
of	O
regulatory	O
T	O
cell	O
.	O
The	O
phosphorylation	O
pathway-related	O
factor	O
is	O
selected	O
from	O
the	O
proto-oncogene	O
expression	O
protein	O
PIM1	B-GENE
and	O
/	O
or	O
the	O
coding	O
sequence	O
thereof	O
.	O
Activity	O
of	O
the	O
regulatory	O
factor	O
of	O
regulatory	O
T	O
cell	O
is	O
regulated	O
and	O
the	O
regulatory	O
factor	O
is	O
selected	O
from	O
FOXP3,	O
IL-2,	O
GITR,	O
CTLA4	B-GENE
or	O
combination	O
thereof	O
.	O
The	O
invention	O
also	O
provides	O
the	O
corresponding	O
composition	O
and	O
the	O
method	O
for	O
regulating	O
regulatory	O
T	O
cell	O
.	O


The	O
present	O
invention	O
relates	O
to	O
heterocyclic	O
compounds	O
useful	O
for	O
antagonising	B-GENE
angiotensin	I-GENE
II	I-GENE
Type	I-GENE
2	I-GENE
(AT2)	I-GENE
receptor	I-GENE
.	O
More	O
particularly	O
the	O
invention	O
relates	O
to	O
piperidine	O
compounds,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
methods	O
of	O
treating	O
or	O
preventing	O
disorders	O
or	O
diseases	O
associated	O
with	O
AT2	B-GENE
receptor	I-GENE
function	O
including	O
neuropathic	O
pain,	O
inflammatory	O
pain,	O
conditions	O
associated	O
with	O
neuronal	O
hypersensitivity,	O
impaired	O
nerve	O
conduction	O
velocity,	O
cell	O
proliferation	O
disorders,	O
disorders	O
associated	O
with	O
an	O
imbalance	O
between	O
bone	O
resorption	O
and	O
bone	O
formation	O
and	O
disorders	O
associated	O
with	O
aberrant	O
nerve	O
regeneration	O
.	O


The	O
present	O
invention	O
relates	O
to	O
marinopyrrole	O
A	O
derivatives	O
and	O
pyoluteorin	O
derivatives	O
and	O
methods	O
of	O
treatment	O
of	O
disorders	O
associated	O
with	O
misregulation	O
of	O
Mcl-l,	O
e	O
.	O
g	O
.	O
,	O
leukemia,	O
lymphoma,	O
multiple	O
myeloma,	O
melanoma,	O
or	O
pancreatic	O
cancer	O
.	O
We	O
describe	O
exemplary	O
compounds,	O
which	O
may	O
be	O
contained	O
in	O
pharmaceutical	O
compositions,	O
and	O
their	O
use	O
as	O
therapeutic	O
agents	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
anti-cancer	O
treatments,	O
e	O
.	O
g	O
.	O
,	O
anti-Bcl-	O
2	O
agents	O
.	O


An	O
isolated	O
si	O
RNA	O
comprising	O
a	O
sense	O
sequence	O
and	O
an	O
antisense	O
sequence,	O
wherein	O
the	O
sense	O
and	O
the	O
antisense	O
sequence	O
are	O
substantially	O
complementary	O
to	O
each	O
other	O
to	O
form	O
a	O
double-stranded	O
structure	O
that	O
is	O
17-25	O
base	O
pairs	O
in	O
length,	O
and	O
wherein	O
the	O
antisense	O
sequence	O
comprises	O
a	O
nucleotide	O
sequence	O
sufficiently	O
complementary	O
to	O
a	O
target	O
human	B-GENE
ICAM-1	I-GENE
nucleotide	O
sequence	O
selected	O
from	O
the	O
group	O
of	O
sequences	O
shown	O
in	O
Table	O
1	O
.	O


Compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
R1,	O
R2	O
and	O
R4	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1,	O
are	O
inhibitors	O
of	O
Syk,	O
and	O
can	O
be	O
employed,	O
inter	O
alia,	O
for	O
the	O
treatment	O
of	O
cancer,	O
rheumatoid	O
arthritis	O
and	O
/	O
or	O
systemic	O
lupus	O


The	O
present	O
invention	O
relates	O
to	O
conformationally	O
constrained	O
homo-	O
and	O
heterodimeric	O
mimetics	O
of	O
Smac	O
with	O
function	O
as	O
inhibitors	O
of	O
Inhibitor	B-GENE
of	I-GENE
Apoptosis	I-GENE
Proteins	I-GENE
(	O
IAPs	B-GENE
)	O
,	O
the	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
therapy,	O
wherein	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
is	O
beneficial,	O
especially	O
in	O
the	O
treatment	O
of	O
cancer,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
active	O
ingredients	O
.	O


Provided	O
herein	O
are	O
methods	O
for	O
reducing	O
corneal	O
inflammation,	O
reducing	O
inflammatory	O
cell	O
(	O
e	O
.	O
g	O
.	O
,	O
dendritic	O
cell	O
)	O
recruitment	O
to	O
the	O
cornea,	O
and	O
treating	O
an	O
corneal	O
inflammatory	O
disorder	O
in	O
a	O
subject	O
that	O
include	O
administering	O
to	O
the	O
subject	O
one	O
or	O
more	O
of	O
a	O
MadC	B-GENE
AM-	I-GENE
1	I-GENE
antagonist,	O
an	O
α4β7	B-GENE
integrin	O
antagonist,	O
a	O
L-selectin	B-GENE
antagonist,	O
and	O
an	O
E-	B-GENE
selectin	I-GENE
antagonist	O
.	O
Also	O
provided	O
are	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
a	O
MadC	B-GENE
AM-	I-GENE
1	I-GENE
antagonist,	O
an	O
α4β7	B-GENE
integrin	O
antagonist,	O
a	O
L-selectin	B-GENE
antagonist,	O
and	O
an	O
E-selectin	B-GENE
antagonist,	O
and	O
kits	O
containing	O
these	O
compositions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
groups	O
R1,	O
R2,	O
and	O
A	O
are	O
as	O
defined	O
in	O
the	O
application,	O
which	O
have	O
valuable	O
pharmacological	O
properties,	O
and	O
in	O
particular	O
bind	O
to	O
the	O
GPR1	B-GENE
19	I-GENE
receptor	O
and	O
modulate	O
its	O
activity	O
.	O


The	O
present	O
invention	O
provides	O
gonadotropin	B-GENE
releasing	I-GENE
hormone	I-GENE
receptor	I-GENE
antagonists	O
and	O
the	O
pharmaceutical	O
composition	O
comprising	O
the	O
same,	O
which	O
can	O
be	O
useful	O
in	O
preventing	O
or	O
treating	O
a	O
sex	O
hormone-related	O
disease	O
such	O
as	O
endometriosis,	O
amenorrhea,	O
irregular	O
menstruation,	O
uterine	O
myoma,	O
uterine	O
fibroids,	O
polycystic	O
ovarian	O
disease,	O
lupus	O
erythematous,	O
hypertrichosis,	O
precocious	O
puberty,	O
short	O
stature,	O
acne,	O
alopecia,	O
gonadal	O
steroid-dependent	O
neoplasms,	O
gonadotropin-producing	O
pituitary	O
adenoma,	O
sleep	O
apnea,	O
irritable	O
bowel	O
syndrome,	O
premenstrual	O
syndrome,	O
benign	O
prostatic	O
hyperplasia,	O
contraception,	O
and	O
infertility,	O
as	O
well	O
as	O
Alzheimer	O
disease	O
.	O


The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
produce	O
a	O
therapeutic	O
agent	O
for	O
cancer	O
and	O
a	O
substance	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
SLC6A6	B-GENE
using	O
a	O
novel	O
monoclonal	O
antibody	O
capable	O
of	O
binding	O
to	O
SLC6A6	B-GENE
or	O
an	O
extracellular	O
domain	O
thereof	O
.	O
The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
monoclonal	O
antibody	O
capable	O
of	O
recognizing	O
native	O
SLC6A6	B-GENE
or	O
a	O
polypeptide	O
for	O
an	O
extracellular	O
domain	O
of	O
SLC6A6	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
aminoquinazoline	O
derivative	O
and	O
a	O
use	O
thereof	O
in	O
preparing	O
an	O
anti-malignant	O
tumor	O
medicament	O
for	O
prevention	O
and	O
/	O
or	O
treatment	O
thereof	O
.	O
The	O
aminoquinazoline	O
compound	O
of	O
the	O
present	O
invention	O
is	O
an	O
ideal,	O
highly-efficient,	O
and	O
irreversible	O
double	O
kinase	B-GENE
inhibitor	O
for	O
EGFR	B-GENE
and	O
HER2,	O
applicable	O
in	O
treatment	O
or	O
prevention	O
of	O
various	O
malignant	O
tumor	O
diseases	O
such	O
as	O
breast	O
cancer,	O
ovarian	O
cancer,	O
gastrointestinal	O
cancer,	O
esophageal	O
cancer,	O
lung	O
cancer,	O
head	O
and	O
neck	O
squamous-cell	O
carcinoma,	O
pancreatic	O
cancer,	O
squamous-cell	O
skin	O
cancer,	O
prostate	O
cancer,	O
glioma,	O
and	O
nasopharyngeal	O
cancer	O
.	O


The	O
present	O
invention	O
provides	O
analog	O
compounds	O
of	O
DPA-713	O
which	O
specifically	O
bind	O
the	O
translocator	B-GENE
protein	I-GENE
(	O
TSPO	B-GENE
)	O
,	O
which	O
is	O
upregulated	O
in	O
activated	O
leukocytes,	O
some	O
malignant	O
tumors	O
and	O
tissues	O
involved	O
in	O
steroid	O
biogenesis	O
.	O
These	O
compounds	O
are	O
linked	O
via	O
a	O
linking	O
moiety	O
to	O
a	O
variety	O
of	O
imaging	O
agents,	O
including,	O
for	O
example,	O
near	O
infra-red	O
dyes	O
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
both	O
pre-clinical	O
near-IR	O
fluorescence	O
imaging	O
(	O
NIRF	O
)	O
and	O
use	O
in	O
optically-guided	O
interventions	O
including	O
NIRF	O
endoscopy	O
.	O
Methods	O
of	O
use	O
in	O
diagnosis	O
and	O
treatment	O
of	O
TSPO	B-GENE
related	O
disease	O
are	O
also	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
substituted	O
and	O
aurora	O
kinase-inhibiting	O
pyrimidine	O
derivative	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
(	O
Ia	O
)	O
,	O
tautomer,	O
hydrate,	O
solvate,	O
ester	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
pharmaceutical	O
composition	O
comprising	O
the	O
compounds	O
as	O
active	O
ingredients,	O
as	O
well	O
as	O
uses	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
composition	O
thereof	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
protecting	O
against,	O
treating,	O
curing	O
or	O
alleviating	O
proliferative	O
diseases	O
of	O
a	O
patient	O
.	O


Provided	O
is	O
a	O
therapeutic	O
or	O
prophylactic	O
agent	O
for	O
mood	O
disorders,	O
anxiety,	O
schizophrenia,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
chorea,	O
eating	O
disorders,	O
hypertension,	O
digestive	O
diseases,	O
drug	O
dependence,	O
epilepsy,	O
cerebral	O
infarction,	O
cerebral	O
ischemia,	O
cerebral	O
edema,	O
head	O
injury,	O
inflammation,	O
immune	O
related	O
diseases,	O
depilation,	O
and	O
so	O
on	O
.	O
More	O
specifically,	O
provided	O
is	O
a	O
fused	O
azole	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
has	O
arginine	O
vasopressin	B-GENE
1b	I-GENE
receptor	I-GENE
antagonism,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
disclosed	O
.	O
The	O
variables	O
.	O
R1-R13,	O
m,	O
n,	O
o,	O
and	O
p	O
are	O
disclosed	O
herein	O
.	O
The	O
compounds	O
are	O
useful	O
for	O
treating	O
Gaucher	O
disease	O
and	O
inhibiting	O
the	O
onset	O
of	O
Gaucher	O
disease	O
symptoms	O
in	O
a	O
patient	O
having	O
a	O
GBA	B-GENE
gene	O
mutation	O
and	O
for	O
treating	O
Parkinson	O
'	O
s	O
disease	O
.	O
Pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treatment	O
comprising	O
administering	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
also	O
disclosed	O
.	O


The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
wherein	O
R1	O
is	O
H,	O
C1-6-alkyl,	O
C0-4-alkyl-C3-6-cycloalkyl,	O
C1-6-haloalkyl	O
;	O
R2	O
is	O
H,	O
C1-6-alkyl	O
;	O
X	O
is	O
an	O
anion	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
chloride	O
or	O
½	O
dibenzoyltartrate	O
j	O
is	O
1	O
or	O
2	O
.	O
processes	O
for	O
the	O
preparation	O
thereof,	O
and	O
their	O
use	O
to	O
treat	O
diseases	O
connected	O
with	O
the	O
CCR3	B-GENE
receptor	O


The	O
present	O
invention	O
comprises	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O
Formula	O
(	O
I	O
)	O
wherein	O
:	O
R0,	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
and	O
A	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O
The	O
invention	O
also	O
comprises	O
a	O
method	O
of	O
preventing,	O
treating	O
or	O
ameliorating	O
a	O
syndrome,	O
disorder	O
or	O
disease,	O
wherein	O
said	O
syndrome,	O
disorder	O
or	O
disease	O
is	O
type	O
II	O
diabetes,	O
obesity	O
and	O
asthma	O
.	O
The	O
invention	O
also	O
comprises	O
a	O
method	O
of	O
inhibiting	O
CCR2	B-GENE
activity	O
in	O
a	O
mammal	O
by	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
ATR	B-GENE
protein	O
kinase	B-GENE
and	O
combination	O
therapies	O
thereof	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
methods	O
of	O
treating	O
of	O
various	O
diseases,	O
disorders,	O
and	O
conditions	O
using	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
intermediates	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
in	O
vitro	O
applications,	O
such	O
as	O
the	O
study	O
of	O
kinases	B-GENE
in	O
biological	O
and	O
pathological	O
phenomena	O
;	O
the	O
study	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
mediated	O
by	O
such	O
kinases	B-GENE
;	O
and	O
the	O
comparative	O
evaluation	O
of	O
new	O
kinase	B-GENE
inhibitors	O
.	O
The	O
compounds	O
of	O
this	O
invention	O
have	O
formula	O
I	O
:	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O


This	O
invention	O
is	O
directed	O
to	O
asymmetric	O
syntheses	O
of	O
certain	O
spiro-oxindole	O
derivatives,	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
sodium	O
channel-mediated	O
diseases	O
or	O
conditions,	O
such	O
as	O
pain	O
.	O


The	O
present	O
disclosure	O
relates	O
to	O
a	O
class	O
of	O
substituted	O
bicyclic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
tautomers,	O
polymorphs,	O
stereoisomers,	O
prodrugs,	O
solvates,	O
hydrates,	O
N-oxides,	O
co-crystals,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O
The	O
disclosure	O
also	O
relates	O
to	O
the	O
process	O
of	O
preparation	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O
These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment,	O
prevention,	O
prophylaxis,	O
management,	O
or	O
adjunct	O
treatment	O
of	O
all	O
medical	O
conditions	O
related	O
to	O
inhibition	O
of	O
Bruton's	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
Btk	B-GENE
)	O
,	O
such	O
as	O
inflammatory	O
and	O
/	O
or	O
autoimmune	O
disorder,	O
cell	O
proliferation,	O
rheumatoid	O
arthritis,	O
psoriasis,	O
psoriatic	O
arthritis,	O
transplant	O
rejection,	O
graft-versus-host	O
disease,	O
multiple	O
sclerosis,	O
inflammatory	O
bowel	O
disease,	O
allergic	O
diseases,	O
asthma,	O
type	O
1	O
diabetes,	O
myasthenia	O
gravis,	O
hematopoetic	O
disfunction,	O
B-cell	O
malignancies,	O
systemic	O
lupus,	O
erythematosus	O
or	O
other	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
modified	O
dextran	O
to	O
prevent	O
or	O
treat	O
anemia	O
in	O
mammals	O
by	O
increasing	O
the	O
number	O
of	O
red	O
blood	O
cells	O
and	O
/	O
or	O
hemoglobin	B-GENE
and	O
/	O
or	O
the	O
hematocrit	O
levels	O
in	O
blood	O
.	O
Dextran	O
is	O
modified	O
by	O
substitution	O
of	O
the	O
cationic	O
compound	O
containing	O
amino	O
and	O
/	O
or	O
ammonium	O
groups	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
composition	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
cerebral	O
malaria	O
that	O
comprises	O
an	O
angiotensin	B-GENE
receptor	I-GENE
type-2	I-GENE
agonist	O
and	O
an	O
antimalaria	O
drug	O
.	O
The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
for	O
treating	O
and	O
preventing	O
cerebral	O
malaria	O
that	O
involve	O
administering	O
an	O
angiotensin	B-GENE
receptor	I-GENE
type-2	I-GENE
agonist	O
and	O
/	O
or	O
an	O
angiotensin	B-GENE
receptor	I-GENE
type-	I-GENE
1	I-GENE
antagonist	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
quinazolines,	O
their	O
derivatives,	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
and	O
hydrates	O
thereof	O
.	O
The	O
compounds	O
and	O
compositions	O
of	O
the	O
present	O
invention	O
have	O
protein	B-GENE
kinases	I-GENE
inhibitory	O
activities	O
and	O
are	O
expected	O
to	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
protein	B-GENE
kinases	I-GENE
mediated	O
diseases	O
and	O
conditions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
SIRS	O
and	O
/	O
or	O
sepsis	O
comprising	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
a	O
certain	O
DPP-4	B-GENE
inhibitor,	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
a	O
certain	O
DPP-4	B-GENE
inhibitor	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
metabolic	O
disease	O
in	O
a	O
patient	O
with	O
or	O
at	O
risk	O
of	O
SIRS	O
and	O
/	O
or	O
sepsis	O
.	O


The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
residues	O
R1	O
to	O
R6,	O
V,	O
G	O
and	O
M	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
diverse	O
disorders,	O
for	O
example	O
cardiovascular	O
disorders	O
like	O
thromboembolic	O
diseases	O
or	O
restenoses	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
effective	O
antagonists	O
of	O
the	O
platelet	O
LPA	B-GENE
receptor	I-GENE
LPAR5	I-GENE
(	O
GPR92	B-GENE
)	O
and	O
can	O
in	O
general	O
be	O
applied	O
in	O
conditions	O
in	O
which	O
an	O
undesired	O
activation	O
of	O
the	O
platelet	O
LPA	B-GENE
receptor	I-GENE
LPAR5,	O
the	O
mast	O
cell	O
LPA	B-GENE
receptor	I-GENE
LPAR5	I-GENE
or	O
the	O
microglia	O
cell	O
LPA	B-GENE
receptor	I-GENE
LPAR5	I-GENE
is	O
present,	O
or	O
for	O
the	O
cure	O
or	O
prevention	O
of	O
which	O
an	O
inhibition	O
of	O
the	O
platelet,	O
mast	O
cell	O
or	O
microglia	O
cell	O
LPA	B-GENE
receptor	I-GENE
LPAR5	I-GENE
is	O
intended	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
I,	O
their	O
use,	O
in	O
particular	O
as	O
active	O
ingredients	O
in	O
medicaments,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
provides	O
the	O
following	O
:	O
a	O
cardiovascular	O
disease	O
primary	O
prevention	O
agent,	O
which	O
comprises	O
as	O
the	O
active	O
ingredient	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
EPA,	O
salts	O
thereof,	O
and	O
esters	O
thereof	O
and	O
is	O
for	O
lowering	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
by	O
administration	O
to	O
subjects	O
having	O
a	O
blood	O
(	O
serum	O
or	O
plasma	O
)	O
hs-CRP	B-GENE
level	O
of	O
1	O
.	O
0	O
mg	O
/	O
L	O
or	O
higher	O
in	O
spite	O
of	O
no	O
history	O
of	O
cardiovascular	O
disease	O
;	O
a	O
combination	O
marker	O
comprising	O
the	O
hs-CRP	B-GENE
value	O
in	O
blood	O
and	O
serum	O
EPA	O
/	O
AA	O
ratio	O
for	O
evaluating	O
the	O
primary	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
subjects	O
having	O
no	O
history	O
of	O
cardiovascular	O
disease	O
;	O
and	O
a	O
method	O
for	O
sampling	O
subjects	O
at	O
high	O
risk	O
of	O
cardiovascular	O
disease	O
and	O
/	O
or	O
a	O
method	O
for	O
preventing	O
cardiovascular	O
disease	O
.	O


Aspects	O
of	O
the	O
invention	O
provide	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
MECP2	B-GENE
.	O
Further	O
aspects	O
provide	O
compositions	O
and	O
kits	O
comprising	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
MECP2	B-GENE
.	O
Methods	O
for	O
modulating	O
expression	O
of	O
MECP2	B-GENE
using	O
the	O
single	O
stranded	O
oligonucleotides	O
are	O
also	O
provided	O
.	O
Further	O
aspects	O
of	O
the	O
invention	O
provide	O
methods	O
for	O
selecting	O
a	O
candidate	O
oligonucleotide	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
MECP2	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	I-GENE
activity	O
of	O
Complex	B-GENE
(III)	I-GENE
of	I-GENE
the	I-GENE
mitochondrial	I-GENE
electron	I-GENE
transport	I-GENE
chain	I-GENE
and	O
use	O
thereof	O
in	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
cancers	O
presenting	O
tumour-initiating	O
cells	O
.	O
The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
said	O
inhibitors	O
alone	O
or	O
in	O
combination	O
with	O
other	O
pharmaceutically	O
active	O
agents,	O
and	O
their	O
use	O
as	O
medicaments	O
or	O
as	O
agrochemicals	O
where	O
their	O
properties	O
as	O
inhibitors	O
of	O
the	I-GENE
mitochondrial	I-GENE
respiration	O
is	O
of	O
benefit	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
neurodegenerative	O
disease	O
therapeutic	O
agent,	O
and,	O
more	O
specifically,	O
provides	O
a	O
composition	O
containing,	O
as	O
an	O
active	O
ingredient,	O
an	O
ALK	B-GENE
(	O
anaplastic	B-GENE
lymphoma	I-GENE
kinase	I-GENE
)	O
activity	O
or	O
expression	O
inhibiting	O
substance	O
in	O
order	O
to	O
treat	O
a	O
degenerative	O
brain	O
disease	O
caused	O
by	O
the	O
phosphorylation	O
or	O
coagulation	O
of	O
tau	B-GENE
proteins	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
series	O
of	O
chemical	O
compounds	O
with	O
a	O
novel	O
norneolignan	O
skeleton	O
(	O
chemical	O
formula	O
I	O
)	O
possessing	O
a	O
biological	O
activity	O
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
especially	O
memory-enhancing	O
and	O
acetylcholinesterase	B-GENE
inhibitory	O
activity,	O
individually,	O
or	O
in	O
combination	O
thereof	O
.	O
The	O
novel	O
compounds	O
of	O
a	O
new	O
series	O
have	O
been	O
named	O
as	O
Clitorienolactones	O
.	O
(	O
The	O
chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O
)	O
wherein	O
R1,	O
R2	O
is	O
H,	O
OH	O
or	O
OCH3	O
;	O
Ring	O
A	O
and	O
B	O
may	O
be	O
mono-	O
to	O
polysubstituted	O


A	O
method	O
of	O
treating	O
triple	O
negative	O
breast	O
cancer	O
in	O
a	O
subject	O
is	O
provided	O
.	O
The	O
method	O
involves	O
administering	O
an	O
effective	O
dose	O
of	O
an	O
inhibitor	O
against	O
the	O
p90	B-GENE
ribosomal	I-GENE
S6	I-GENE
kinase	I-GENE
(	O
RSK	B-GENE
)	O
family	O
of	O
kinases	O
to	O
the	O
subject	O
.	O
The	O
method	O
may	O
involve	O
selective	O
inhibition	O
of	O
RSK1	B-GENE
or	O
RSK2	B-GENE
.	O
The	O
inhibitor	O
may	O
be	O
a	O
siRNA,	O
BI-D1870	O
or	O
SL0101	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
diseases	O
and	O
disorders	O
wherein	O
a	O
modulator	O
of	O
Kv3.3	B-GENE
channels	O
is	O
required,	O
including	O
spinocerebellar	O
ataxia,	O
by	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
N-	O
[	O
2,4-bis	O
(	O
1,1-dimethylethyl	O
)	O
-5-hydroxyphenyl	O
]	O
-1,4-dihydro-4-oxoquinoline-3-carboxamide	O
(	O
Compound	O
1	O
)	O
,	O
solids	O
forms,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
for	O
the	O
treatment	O
of	O
CFTR-mediated	O
diseases,	O
particularly	O
cystic	O
fibrosis,	O
in	O
patients	O
possessing	O
specific	O
genetic	O
mutations	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
Compound	O
ί	O
in	O
combination	O
with	O
3-	O
(	O
6-	O
(	O
1-	O
(	O
2,2-difluorobenzo	O
[	O
d	O
]	O
[	O
1,3	O
]	O
dioxoI-	O
5-yl	O
)	O
cyclopropanecarboxamide	O
)	O
-3-methylpyridin-2-yl	O
)	O
benzoic	O
acid	O
(	O
Compound	O
2	O
)	O
,	O
and	O
Compound	O
1	O
in	O
combination	O
with	O
(	O
S	O
)	O
-1-	O
(	O
2,2-difluorobenzo	O
[	O
d	O
]	O
[	O
1,3	O
]	O
dioxol-5-yl	O
)	O
-N-	O
(	O
1-	O
(	O
2,3-	O
dihydroxypropyl	O
)	O
-6-fluoro-2-	O
(	O
1-hydroxy-2-methylpropan-2-yl	O
)	O
-	O
1H-indol-5-yl	O
)	O
cyclopropanecarboxamide	O
(	O
Compound	O
3	O
)	O
,	O
for	O
the	O
treatment	O
of	O
CFTR-mediated	O
diseases,	O
particularly	O
cystic	O
fibrosis,	O
in	O
patients	O
possessing	O
specific	O
genetic	O
mutations	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
solid	O
forms	O
and	O
formulations	O
of	O
Compound	O
2	O
or	O
Compound	O
3	O
in	O
combination	O
with	O
Compound	O
1,	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
for	O
the	O
treatment	O
of	O
CFTR-mediated	O
diseases,	O
particularly	O
cystic	O
fibrosis,	O
in	O
patients	O
possessing	O
specific	O
genetic	O
mutations	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
having	O
the	O
structure	O
of	O
Formula	O
I	O
as	O
inhibitor	O
of	O
WNT	B-GENE
signal	O
transduction	O
pathways,	O
as	O
well	O
as	O
a	O
composition	O
comprising	O
the	O
compound	O
.	O
Further,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
compound	O
and	O
the	O
method	O
of	O
inhibiting	O
the	O
WNT	B-GENE
signal	O
transduction	O
pathways	O
.	O


Insulin	B-GENE
preparations	O
comprising	O
an	O
insulin	B-GENE
compound	O
or	O
a	O
mixture	O
of	O
two	O
or	O
more	O
insulin	B-GENE
compounds,	O
a	O
nicotinic	O
compound	O
and	O
arginine	O
.	O


The	O
present	O
invention	O
relates	O
to	O
novel	O
piperidine	O
derivatives,	O
stereoisomers	O
thereof	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
methods	O
for	O
preparing	O
the	O
compound	O
;	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compound	O
.	O
The	O
novel	O
piperidine	O
derivatives,	O
according	O
to	O
the	O
present	O
invention,	O
having	O
an	O
effect	O
as	O
GPR119	B-GENE
agonist	O
can	O
be	O
used	O
for	O
treatment	O
of	O
metabolic	O
disorders,	O
including	O
diabetes	O
mellitus	O
(	O
especially	O
type	O
II	O
)	O
and	O
related	O
disorders	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
wounds	O
or	O
reproducing	O
skin	O
comprising	O
Euphorbia	O
kansui	O
extracts,	O
fractions	O
thereof	O
or	O
diterpene	O
compounds	O
separated	O
from	O
the	O
fractions	O
as	O
an	O
active	O
ingredient	O
.	O
The	O
Euphorbia	O
kansui	O
extracts	O
may	O
act	O
on	O
epithelial	O
cells	O
to	O
induce	O
PKD1	B-GENE
activity	O
required	O
for	O
improving	O
the	O
reproduction	O
capability	O
of	O
differentiated	O
epithelial	O
cells,	O
and	O
thus	O
may	O
induce	O
a	O
phosphorylation	O
of	O
lower	O
ERK1	B-GENE
and	O
the	O
generation	O
of	O
Cyclin	O
D,	O
thus	O
exhibiting	O
an	O
excellent	O
ability	O
to	O
activate	O
the	O
reproduction	O
of	O
damaged	O
skin	O
.	O
Therefore,	O
the	O
Euphorbia	O
kansui	O
extracts	O
may	O
be	O
used	O
effectively	O
as	O
an	O
active	O
ingredient	O
in	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
wounds	O
or	O
reproducing	O
skin,	O
a	O
health	O
food	O
for	O
recovering	O
skin	O
damage	O
or	O
reproducing	O
skin,	O
or	O
a	O
functional	O
cosmetic	O
for	O
inducing	O
skin	O
cell	O
activity	O
.	O


﻿The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmacology	O
and	O
clinical	O
medicine	O
.	O
A	O
pharmaceutical	O
composition	O
in	O
the	O
form	O
of	O
tablets,	O
said	O
composition	O
comprising	O
an	O
S1P	B-GENE
receptor	I-GENE
modulator,	O
which	O
constitutes	O
2-amino-2-	O
[	O
2-	O
(	O
4-octylphenyl	O
)	O
ethyl	O
]	O
propane-1,3-diol	O
and	O
/	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
auxiliary	O
substances	O
:	O
microcrystalline	O
cellulose,	O
sodium	O
carboxymethyl	O
starch,	O
potassium	O
stearate	O
or	O
magnesium	O
stearate,	O
with	O
a	O
defined	O
content	O
of	O
the	O
components	O
.	O
The	O
composition	O
is	O
more	O
stable	O
and	O
has	O
fewer	O
side	O
effects	O
.	O


The	O
present	O
invention	O
encompasses	O
compounds	O
of	O
the	O
formulas	O
(	O
I	O
)	O
&	O
(	O
II	O
)	O
,	O
wherein	O
the	O
groups	O
A,	O
L	O
and	O
Ar	O
are	O
defined	O
as	O
in	O
claim	O
1,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
KCa3	O
.	O
1,	O
process	O
of	O
making,	O
pharmaceutical	O
preparations	O
which	O
contain	O
compounds	O
and	O
their	O
methods	O
of	O
use	O
.	O


The	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
and	O
diagnosis	O
of	O
subjects	O
with	O
cancer	O
.	O
In	O
some	O
aspects,	O
the	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
and	O
diagnosis	O
of	O
subjects	O
with	O
cancer,	O
wherein	O
the	O
cancer	O
is	O
characterized	O
by	O
a	O
Notch	B-GENE
pathway	O
activation	O
mutation	O
or	O
by	O
resistance	O
to	O
a	O
Notch	B-GENE
pathway	O
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
a	O
method	O
for	O
manufacturing	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
its	O
therapeutic	O
uses	O
as	O
complement	B-GENE
pathway	I-GENE
modulators	O
for	O
the	O
treatment	O
of	O
ocular	O
diseases	O
.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
combination	O
of	O
pharmacologically	O
active	O
agents	O
and	O
a	O
pharmaceutical	O
composition	O
.	O


The	O
present	O
invention	O
relates	O
generally	O
to	O
methods	O
for	O
inhibiting	O
neuron	O
apoptosis	O
and	O
necrosis	O
associated	O
with	O
excess	O
glutamate	O
release	O
by	O
administering	O
a	O
TRPC3	B-GENE
inhibitor	O
to	O
a	O
subject	O
.	O


The	O
present	O
invention	O
relates	O
to	O
an	O
inhibitor	O
of	O
the	O
expression	O
of	O
IRS-1	B-GENE
for	O
treating	O
an	O
angiogenic	O
and	O
/	O
or	O
inflammatory	O
skin	O
disease	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
transdermal	O
composition,	O
preferably	O
an	O
ointment,	O
comprising	O
an	O
inhibitor	O
of	O
the	O
expression	O
of	O
IRS-1,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
treating	O
an	O
angiogenic	O
and	O
/	O
or	O
inflammatory	O
skin	O
disease	O
.	O


It	O
was	O
discovered	O
that,	O
by	O
an	O
experiment	O
using	O
colitis	O
model	O
mice,	O
an	O
siRNA	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
CHST15	B-GENE
gene	O
exerts	O
a	O
therapeutic	O
effect	O
on	O
Crohn	O
'	O
s	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
Therefore,	O
the	O
present	O
invention	O
has	O
been	O
completed	O
based	O
on	O
the	O
finding	O
that	O
the	O
siRNA	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
CHST15	B-GENE
gene	O
is	O
usable	O
as	O
a	O
mucosal	O
healing	O
promoter,	O
in	O
particular,	O
as	O
a	O
remedy	O
for	O
Crohn	O
'	O
s	O
disease	O
or	O
ulcerative	O
colitis	O
.	O


Disclosed	O
are	O
a	O
broussonetine	O
compound,	O
a	O
preparation	O
method	O
therefor,	O
and	O
an	O
application	O
thereof	O
.	O
A	O
structural	O
formula	O
of	O
the	O
compound	O
is	O
shown	O
in	O
formula	O
I,	O
n	O
being	O
0	O
to	O
20	O
;	O
R1	O
and	O
R2	O
each	O
being	O
a	O
hydrogen	O
or	O
an	O
acetyl	O
;	O
and	O
R3	O
to	O
R7	O
each	O
being	O
at	O
least	O
one	O
selected	O
from	O
hydrogen,a	O
benzyl,	O
a	O
benzoyl,	O
a	O
phenyl,	O
a	O
phenyl	O
comprising	O
a	O
substituent,	O
a	O
benzyl	O
comprising	O
a	O
substituent,	O
an	O
acetyl,	O
a	O
methoxymethyl,	O
an	O
ethoxymethyl,	O
an	O
isopropylidene,	O
and	O
an	O
oxocyclohexyl	O
.	O
The	O
glycosidase	B-GENE
inhibitory	O
effect	O
test	O
proves	O
that	O
the	O
compound	O
shown	O
in	O
formula	O
I	O
has	O
selective	O
inhibitory	O
activity	O
against	O
different	O
glycosidases	B-GENE
.	O


A	O
pharmaceutical	O
product	O
for	O
lowering	O
blood	O
LDL,	O
which	O
is	O
a	O
pharmaceutical	O
product	O
that	O
contains	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
as	O
an	O
active	O
ingredient,	O
said	O
compound	O
having	O
actions	O
of	O
inhibiting	O
the	O
expression	O
of	O
PCSK9mRNA,	O
lowering	O
the	O
amount	O
of	O
PCSK9	B-GENE
protein,	O
and	O
increasing	O
the	O
amount	O
of	O
an	O
LDL	B-GENE
receptor	I-GENE
.	O
(	O
In	O
formula	O
(	O
I	O
)	O
,	O
R1	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
hydroxyl	O
group,	O
a	O
C1-6	O
alkoxy	O
group	O
or	O
the	O
like	O
;	O
R	O
represents	O
a	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like	O
;	O
the	O
ring	O
structure	O
Q	O
represents	O
a	O
phenyl	O
group	O
or	O
a	O
monocyclic	O
or	O
bicyclic	O
heterocyclic	O
ring	O
;	O
and	O
each	O
of	O
R2	O
and	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
a	O
C1-6	O
alkyl	O
group,	O
a	O
C2-6	O
alkenyl	O
group,	O
a	O
C3-8	O
cycloalkyl	O
C1-6	O
alkyl	O
group	O
or	O
the	O
like	O
.	O
)	O


The	O
present	O
invention	O
provides	O
a	O
fused	O
ring	O
compound	O
containing	O
furan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
a	O
method	O
for	O
preparing	O
same,	O
a	O
pharmaceutical	O
composition	O
comprising	O
same,	O
and	O
a	O
use	O
thereof	O
.	O
The	O
fused	O
ring	O
compound	O
containing	O
furan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
inhibits	O
the	O
activity	O
of	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
(	O
PI3K	B-GENE
)	O
and	O
can	O
therefore	O
be	O
used	O
in	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
and	O
preventing	O
respiratory	O
diseases,	O
inflammatory	O
diseases,	O
proliferative	O
diseases,	O
cardiovascular	O
diseases,	O
or	O
central	O
nervous	O
system	O
diseases	O
which	O
occur	O
due	O
to	O
the	O
over-activation	O
of	O
PI3K	B-GENE
.	O


Disclosed	O
are	O
methods	O
of	O
treating,	O
inhibiting,	O
or	O
preventing	O
a	O
viral	O
infection	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
by	O
administering	O
a	O
therapeutically	O
or	O
prophylactically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
FAP,	O
an	O
inhibitor	O
of	O
DPPIV,	O
an	O
inhibitor	O
of	O
DPP8,	O
or	O
an	O
inhibitor	O
of	O
DPP9	B-GENE
.	O
The	O
inhibitor	O
may	O
act	O
as	O
both	O
an	O
inhibitor	O
of	O
DPPIV	B-GENE
and	O
an	O
inhibitor	O
of	O
DPP8	B-GENE
/	O
9	O
.	O
The	O
viral	O
infection	O
includes,	O
but	O
is	O
not	O
limited	O
to,	O
hepatitis	O
B	O
virus,	O
hepatitis	O
C	O
virus,	O
human	O
immunodeficiency	O
virus,	O
Polio	O
virus,	O
Coxsackie	O
A	O
virus,	O
Coxsackie	O
B	O
virus,	O
Rhino	O
virus,	O
respiratory	O
syncytial	O
virus,	O
dengue	O
virus,	O
equine	O
infectious	O
anemia	O
virus,	O
Echo	O
virus,	O
small	O
pox	O
virus,	O
Ebola	O
virus,	O
and	O
West	O
Nile	O
virus	O
.	O


The	O
present	O
invention	O
is	O
related	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
may	O
inhibit	O
the	O
activity	O
of	O
the	O
FabI	B-GENE
enzyme,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
.	O
It	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds,	O
and	O
chemical	O
processes	O
for	O
preparing	O
these	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
N2,N4-bis	O
(	O
4-	O
(	O
piperazine-1-yl	O
)	O
phenyl	O
)	O
pirimidine-2,4-diamine	O
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
and	O
to	O
a	O
composition	O
containing	O
same	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
or	O
treating	O
cancer	O
.	O
Since	O
the	O
compound	O
according	O
to	O
the	O
present	O
invention	O
has	O
good	O
effects	O
in	O
inhibiting	O
the	O
activities	O
of	O
anaplastic	B-GENE
lymphoma	I-GENE
kinase	I-GENE
(	O
ALK	B-GENE
)	O
and	O
activated	B-GENE
Cdc42-associated	I-GENE
kinase	I-GENE
(	O
ACK1	B-GENE
)	O
,	O
the	O
compound	O
can	O
have	O
improved	O
therapeutic	O
effects	O
against	O
cancer	O
cells	O
having	O
ALK	B-GENE
fusion	O
proteins	O
such	O
as	O
EML4-ALK	O
and	O
NPM-ALK	O
and	O
is	O
expected	O
to	O
be	O
effective	O
in	O
preventing	O
the	O
recurrence	O
of	O
cancer	O
.	O
Therefore,	O
the	O
compound	O
can	O
be	O
effectively	O
used	O
as	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
cancer	O
.	O


Disclosed	O
are	O
compounds	O
of	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
.	O
Such	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
RORgammaT-mediated	O
diseases	O
or	O
conditions	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
that	O
are	O
GPR6	B-GENE
modulators	O
and	O
are	O
therefore	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
treatable	O
by	O
modulation	O
of	O
GPR6,	O
in	O
particular	O
treating	O
Parkinson	O
disease,	O
levodopa	O
induced	O
dyskinesias,	O
Huntington	O
'	O
s	O
disease,	O
other	O
dyskinesias,	O
akinesias,	O
and	O
motor	O
disorders	O
involving	O
dysfunction	O
of	O
the	O
striatum,	O
schizophrenia	O
and	O
drug	O
addiction	O
.	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
processes	O
for	O
preparing	O
such	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
substituted	O
oxazolidinone	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
and	O
a	O
use	O
thereof	O
.	O
Particularly,	O
disclosed	O
are	O
a	O
compound	O
shown	O
in	O
formula	O
(	O
I	O
)	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O
The	O
compound	O
has	O
an	O
excellent	O
activity	O
of	O
suppressing	O
a	O
factor	B-GENE
Xa	I-GENE
and	O
an	O
anticoagulating	O
effect,	O
and	O
can	O
be	O
used	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
thromboembolic	O
diseases	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
novel	O
pyrrolo	O
[	O
2,3-	O
b	O
]	O
]	O
pyrazines	O
wherein	O
all	O
variable	O
substituents	O
are	O
defined	O
as	O
described	O
herein,	O
which	O
are	O
SYK	B-GENE
inhibitors	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto-immune	O
and	O
inflammatory	O
diseases	O
.	O


Novel	O
compounds	O
of	O
the	O
structural	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
AMP-protein	B-GENE
kinase	I-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
AMPKactivated	B-GENE
protein	I-GENE
kinase	I-GENE
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Type	O
2	O
diabetes,	O
hyperglycemia,	O
metabolic	O
syndrome,	O
obesity,	O
hypercholesterolemia,	O
and	O
hypertension	O
.	O


[	O
Problem	O
]	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
method	O
for	O
detection	O
of	O
cancer	O
in	O
which	O
samples	O
are	O
easily	O
acquired	O
and	O
measured	O
.	O
[	O
Solution	O
]	O
This	O
method	O
for	O
detection	O
of	O
cancer	O
comprises	O
the	O
detection	O
of	O
ERO1-Lα	B-GENE
proteins	O
in	O
a	O
specimen	O
obtained	O
from	O
a	O
subject,	O
wherein	O
the	O
presence	O
of	O
ERO1-Lα	B-GENE
proteins	O
in	O
the	O
specimen	O
indicates	O
the	O
presence	O
of	O
cancer	O
in	O
the	O
subject	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
thienopyrrole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
Tec	O
kinase	O
inhibitors,	O
in	O
particular	O
ITK	B-GENE
(	O
interleukin-2	B-GENE
inducible	I-GENE
tyrosine	I-GENE
kinase	I-GENE
)	O
inhibitors	O
.	O
Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein,	O
intermediates	O
used	O
in	O
their	O
synthesis,	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases,	O
conditions	O
and	O
/	O
or	O
disorders	O
mediated	O
by	O
ITK	B-GENE
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
DYRK1A	B-GENE
inhibitor	O
or	O
an	O
inhibitor	O
of	O
DYRK1A	B-GENE
gene	O
expression	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
hypothyroidism	O
in	O
a	O
Down	O
Syndrome	O
patient	O
.	O


The	O
present	O
invention	O
provides	O
novel	O
compounds	O
(	O
e	O
.	O
g	O
.	O
,	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts,	O
solvates,	O
hydrates,	O
polymorphs,	O
co-crystals,	O
tautomers,	O
stereoisomers,	O
isotopically	O
labeled	O
derivatives,	O
prodrugs,	O
and	O
compositions	O
thereof	O
.	O
Also	O
provided	O
are	O
methods	O
and	O
kits	O
comprising	O
the	O
inventive	O
compounds,	O
or	O
compositions	O
thereof,	O
for	O
treating	O
and	O
/	O
or	O
preventing	O
a	O
fungal	O
or	O
protozoan	O
infection,	O
inhibiting	O
the	O
activity	O
of	O
a	O
fungal	O
or	O
protozoan	O
enzyme,	O
killing	O
a	O
fungus	O
or	O
protozoon,	O
or	O
inhibiting	O
the	O
growth	O
of	O
a	O
fungus	O
or	O
protozoon	O
.	O
The	O
fungus	O
may	O
be	O
a	O
Candida	O
species,	O
Aspergillus	O
species,	O
or	O
other	O
pathogenic	O
fungal	O
species	O
.	O
The	O
compounds	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
activity	O
of	O
fungal	O
or	O
protozoan	O
cytochrome	O
b	O
and	O
/	O
or	O
fungal	O
or	O
protozoan	O
Hsp90	B-GENE
.	O
The	O
present	O
invention	O
also	O
provides	O
synthetic	O
methods	O
of	O
the	O
inventive	O
compounds	O
.	O


The	O
present	O
invention	O
relates	O
to	O
BET	B-GENE
protein-inhibiting	O
5-aryl	O
triazole	O
azepines,	O
particularly	O
BRD4-inhibiting	O
5-aryl	O
triazole	O
azepines	O
of	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R1,	O
R2,	O
R3	O
and	O
R4	O
have	O
the	O
meanings	O
indicated	O
in	O
general	O
formula	O
(	O
I	O
)	O
.	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
agents	O
containing	O
the	O
compounds	O
according	O
to	O
the	O
invention	O
and	O
the	O
prophylactic	O
and	O
therapeutic	O
use	O
thereof	O
in	O
hyperproliferative	O
disorders,	O
particularly	O
in	O
tumorous	O
diseases	O
.	O
Furthermore,	O
this	O
invention	O
relates	O
to	O
the	O
use	O
of	O
BET	B-GENE
protein	O
inhibitors	O
in	O
viral	O
infections,	O
in	O
neurodegenerative	O
diseases,	O
in	O
inflammatory	O
diseases,	O
in	O
atherosclerotic	O
diseases	O
and	O
in	O
monitoring	O
male	O
fertility	O
.	O


The	O
present	O
invention	O
provides	O
oligonucleotides	O
that	O
inhibit	O
the	O
binding	O
of	O
miR-27a	B-GENE
to	O
VE-cadherin	B-GENE
mRNA,	O
particularly	O
in	O
the	O
form	O
of	O
blockmirs	O
.	O
The	O
invention	O
also	O
provides	O
compositions	O
comprising	O
such	O
oligonucleotides	O
and	O
methods	O
of	O
use	O
of	O
such	O
oligonucleotides	O
to	O
modulate	O
the	O
activity	O
of	O
VE-cadherin,	O
inhibit	O
or	O
reduce	O
vascular	O
permeability,	O
treat	O
or	O
prevent	O
a	O
vascular	O
permeability-associated	O
disease	O
or	O
condition,	O
inhibit	O
tumour	O
growth,	O
treat	O
ischaemic	O
injury,	O
enhance	O
recovery	O
from	O
ischaemic	O
injury,	O
treat	O
surgical	O
wounds	O
and	O
/	O
or	O
promotes	O
post-operative	O
recovery,	O
and	O
promote	O
or	O
induce	O
angiogenesis	O
.	O


A	O
drug	O
composition	O
for	O
inhibiting	O
or	O
preventing	O
the	O
metastasis	O
of	O
malignant	O
tumors	O
which	O
includes	O
at	O
least	O
one	O
vasoprotector	O
selected	O
from	O
among	O
(	O
i	O
)	O
-	O
(	O
iv	O
)	O
,	O
below,	O
or	O
a	O
pharmacologically-acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O
(	O
i	O
)	O
Angiotensin	B-GENE
II	I-GENE
receptor	I-GENE
antagonists	O
(	O
ii	O
)	O
HMG-CoA	B-GENE
reductase	I-GENE
inhibitors	O
(	O
iii	O
)	O
Ghrelin	B-GENE
and	O
derivatives	O
thereof	O
(	O
iv	O
)	O
Adrenomedullin	B-GENE
and	O
derivatives	O
thereof	O


Novel	O
chemical	O
entities	O
that	O
inhibit	O
the	O
activity	O
of	O
human	B-GENE
5-lipoxygenase	I-GENE
(	O
5-LOX	B-GENE
)	O
.	O


The	O
plasma	O
concentration	O
of	O
at	O
least	O
one	O
branched	O
chain	O
amino	O
acid	O
in	O
a	O
mammal	O
in	O
need	O
of	O
such	O
reduction	O
is	O
reduced	O
by	O
administering	O
an	O
agent	O
that	O
increases	O
the	O
plasma	O
concentration	O
of	O
large	O
neutral	O
amino	O
acids	O
.	O
The	O
invention	O
also	O
includes	O
related	O
compositions	O
and	O
methods	O
.	O
These	O
methods	O
and	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
insulin	B-GENE
resistance,	O
type	O
2	O
diabetes	O
and	O
metabolic	O
syndrome	O
.	O


The	O
invention	O
relates	O
to	O
certain	O
compounds	O
for	O
the	O
use	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
diseases	O
and	O
/	O
or	O
disorders	O
that	O
are,	O
at	O
least	O
partially,	O
mediated	O
by	O
TSPO	B-GENE
activity	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
strategies	O
for	O
the	O
treatment	O
of	O
cancer	O
patients	O
based	O
on	O
a	O
combination	O
of	O
an	O
opioid	B-GENE
receptor	I-GENE
agonist	O
and	O
an	O
anticancer	O
compound	O
.	O


The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I,	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O
Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
inhibiting	O
kinase	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
GSK3	B-GENE
(	O
e	O
.	O
g	O
.	O
,	O
GSK3a	B-GENE
or	O
GSK3P	B-GENE
)	O
or	O
CK1	B-GENE
)	O
activity	O
.	O
The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
using	O
the	O
compounds	O
described	O
herein	O
for	O
treating	O
kinase-mediated	O
disorders,	O
such	O
as	O
neurological	O
diseases,	O
psychriatic	O
disorders,	O
metabolic	O
disorders,	O
and	O
cancer	O
.	O
I	O


The	O
present	O
disclosure	O
relates	O
generally	O
to	O
alpha-helix	O
mimetic	O
structures	O
and	O
specifically	O
to	O
alpha-helix	O
mimetic	O
structures	O
that	O
are	O
inhibitors	O
of	O
β-catenin	B-GENE
.	O
The	O
disclosure	O
also	O
relates	O
to	O
applications	O
in	O
the	O
treatment	O
of	O
pulmonary	O
fibrosis,	O
including	O
usual	O
interstitial	O
pneumonia	O
and	O
idiopathic	O
pulmonary	O
fibrosis,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
alpha	O
helix	O
mimetic	O
β-catenin	B-GENE
inhibitors	O
.	O


The	O
present	O
invention	O
comprises	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R1,	O
R2,	O
R3,	O
R4,	O
R5,	O
R6,	O
R7,	O
R8,	O
and	O
R9	O
are	O
defined	O
in	O
the	O
specification	O
.	O
The	O
invention	O
also	O
comprises	O
a	O
method	O
of	O
treating	O
or	O
ameliorating	O
a	O
syndrome,	O
disorder	O
or	O
disease,	O
wherein	O
said	O
syndrome,	O
disorder	O
or	O
disease	O
is	O
rheumatoid	O
arthritis	O
or	O
psoriasis	O
.	O
The	O
invention	O
also	O
comprises	O
a	O
method	O
of	O
modulating	O
RORγt	B-GENE
activity	O
in	O
a	O
mammal	O
by	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
of	O
claim	O
1	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
all	O
variable	O
substituents	O
are	O
defined	O
as	O
described	O
herein,	O
which	O
are	O
SYK	B-GENE
inhibitors	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto-immune	O
and	O
inflammatory	O
diseases	O
.	O


The	O
invention	O
relates	O
to	O
novel	O
(	O
3-arylsulfonyl-quinoline-8-yl	O
)	O
-dialkyl-amines	O
of	O
general	O
formula	O
1,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof,	O
which	O
are	O
selective	O
serotonin	B-GENE
5-HT6	I-GENE
receptor	I-GENE
antagonists	O
.	O
The	O
compounds	O
can	O
be	O
used	O
as	O
a	O
medicinal	O
principle	O
in	O
pharmaceutical	O
compositions	O
and	O
drugs	O
for	O
treating	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
pathogenesis	O
of	O
which	O
is	O
associated	O
with	O
5-HT6	O
receptors	O
.	O
In	O
particular,	O
the	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
disease,	O
and	O
cognitive	O
or	O
anxiety	O
disorders,	O
and	O
to	O
improve	O
intellectual	O
abilities	O
.	O
In	O
general	O
formula	O
1,	O
Ar	O
is	O
a	O
phenyl,	O
optionally	O
substituted	O
with	O
a	O
halogen	O
atom	O
in	O
position	O
3,	O
or	O
a	O
naphthyl	O
;	O
R	O
1	O
and	O
R2	O
are	O
an	O
unsubstituted	O
methyl	O
or	O
an	O
ethyl	O
.	O


The	O
present	O
invention	O
provides	O
a	O
compound	O
that	O
is	O
useful	O
as	O
an	O
AMPK	B-GENE
activating	O
agent	O
.	O
A	O
compound	O
expressed	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
permissible	O
salt	O
thereof	O
(	O
X	O
represents	O
-CR5	O
=	O
or	O
-N,	O
Y	O
represents	O
(	O
II	O
)	O
,	O
Z	O
represents	O
(	O
III	O
)	O
,	O
R	O
1	O
represents	O
a	O
hydrogen,	O
etc	O
.	O
,	O
R	O
2	O
represents	O
a	O
halogen,	O
etc	O
.	O
,	O
R	O
3-R	O
7	O
represents	O
hydrogen,	O
a	O
halogen,	O
etc	O
.	O
,	O
m	O
is	O
an	O
integer	O
of	O
0-4,	O
R	O
8-R	O
15	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl,	O
R	O
16-R	O
21	O
represents	O
a	O
halogen,	O
etc	O
.	O
,	O
n	O
is	O
an	O
integer	O
of	O
0-4,	O
R	O
22-R	O
27	O
represents	O
hydrogen,	O
a	O
halogen,	O
etc	O
.	O
,	O
R	O
28	O
and	O
R	O
36	O
represent	O
hydrogen,	O
etc	O
.	O
,	O
R	O
29-R	O
35	O
and	O
R	O
37	O
represents	O
a	O
halogen,	O
etc	O
.	O
,	O
and	O
p	O
is	O
an	O
integer	O
of	O
0-4	O
)	O
.	O


A	O
drug	O
combination	O
comprising	O
at	O
least	O
one	O
inhibitor	O
of	O
tyrosine	B-GENE
kinase	I-GENE
and	O
at	O
least	O
one	O
inhibitor	O
of	O
glycolysis	O
.	O
The	O
drug	O
combination	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders,	O
such	O
as	O
liver	O
or	O
colon	O
cancer	O
.	O
The	O
inhibitor	O
of	O
tyrosine	B-GENE
kinase	I-GENE
may	O
be	O
an	O
inhibitor	O
of	O
at	O
least	O
one	O
of	O
the	O
tyrosine	B-GENE
kinases	I-GENE
Fer	B-GENE
and	O
FerT.	B-GENE


The	O
invention	O
provides	O
white	O
keratin	B-GENE
protein	O
compositions	O
and	O
methods	O
of	O
making	O
and	O
using	O
white	O
keratin	B-GENE
protein	O
compositions	O
.	O


Disclosed	O
herein	O
are	O
embodiments	O
of	O
a	O
compound	O
capable	O
of	O
treating	O
HIV	O
.	O
In	O
particular	O
disclosed	O
embodiments,	O
the	O
compound	O
is	O
capable	O
of	O
inhibiting	O
Nef,	O
such	O
as	O
by	O
acting	O
as	O
antagonists	O
of	O
HIV	O
Nef	B-GENE
function	O
.	O
Also	O
disclosed	O
are	O
embodiments	O
of	O
a	O
method	O
of	O
making	O
the	O
compound,	O
embodiments	O
of	O
a	O
method	O
of	O
using	O
the	O
compound,	O
and	O
embodiments	O
of	O
a	O
method	O
of	O
identifying	O
HIV	O
Nef	B-GENE
antagonists	O
.	O
The	O
disclosed	O
compound	O
may	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
other	O
pharmacologically	O
active	O
agents	O
in	O
order	O
to	O
promote	O
reducing	O
drug	O
resistance	O
and	O
/	O
or	O
cumulative	O
toxicity	O
.	O


Provided	O
in	O
the	O
present	O
invention	O
are	O
the	O
use	O
of	O
compounds	O
having	O
the	O
structure	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
medicinal	O
salts,	O
hydrates	O
or	O
solvates	O
thereof	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
nervous	O
system	O
diseases	O
associated	O
with	O
dopamine	O
receptors,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
compounds	O
having	O
the	O
structure	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
medicinal	O
salts,	O
hydrates	O
or	O
solvates	O
thereof	O
.	O
The	O
compounds	O
have	O
multiple	O
pharmacological	O
functions	O
such	O
as	O
the	O
functions	O
of	O
activating	O
μ	B-GENE
opioid	I-GENE
receptors	I-GENE
and	O
blocking	O
dopamine	B-GENE
D2	I-GENE
receptors,	O
and	O
have	O
good	O
physicochemical	O
properties	O
and	O
oral	O
bioavailability	O
.	O
Animal	O
experiments	O
as	O
a	O
whole	O
show	O
that	O
such	O
compounds	O
have	O
significant	O
and	O
long-acting	O
analgesic	O
and	O
calming	O
effects	O
and	O
can	O
be	O
used	O
to	O
treat	O
pain	O
and	O
other	O
mental	O
illnesses	O
.	O


This	O
application	O
discloses	O
compounds	O
according	O
to	O
generic	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
all	O
variables	O
are	O
defined	O
as	O
described	O
herein,	O
which	O
inhibit	O
Btk	B-GENE
.	O
The	O
compounds	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
Btk	B-GENE
and	O
treat	O
diseases	O
associated	O
with	O
excessive	O
Btk	B-GENE
activity	O
.	O
The	O
compounds	O
are	O
further	O
useful	O
to	O
treat	O
inflammatory	O
and	O
auto	O
immune	O
diseases	O
associated	O
with	O
aberrant	O
B-cell	O
proliferation	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O
Also	O
disclosed	O
are	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
I	O
and	O
at	O
least	O
one	O
carrier,	O
diluent	O
or	O
excipient	O
.	O


Provided	O
is	O
a	O
highly	O
effective	O
radiation	O
exposure	O
treatment	O
agent	O
.	O
This	O
radiation	O
exposure	O
treatment	O
agent	O
contains	O
a	O
thrombopoietin	B-GENE
receptor	I-GENE
agonist	O
for	O
removing	O
antibodies,	O
and	O
regenerates	O
organs	O
damaged	O
by	O
radiation	O
exposure	O
.	O
Romiplostim	O
is	O
used	O
as	O
the	O
thrombopoietin	B-GENE
receptor	I-GENE
agonist	O
.	O
The	O
romiplostim	O
is	O
administered	O
at	O
an	O
amount,	O
at	O
each	O
administration,	O
5-50	O
times	O
greater	O
than	O
that	O
for	O
treatment	O
of	O
chronic	O
immune	O
thrombocytopenic	O
purpura	O
.	O
Specifically,	O
romiplostim	O
is	O
administered	O
after	O
exposure	O
at	O
an	O
amount	O
of	O
10-100	O
μg	O
/	O
kg	O
per	O
administration,	O
once	O
a	O
day	O
for	O
three	O
or	O
more	O
days	O
.	O


Compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
stereoisomers,	O
tautomers,	O
or	O
pharmaceutically	O
acceptable	O
salts,	O
solvates	O
or	O
prodrugs	O
thereof,	O
wherein	O
Ring	O
A,	O
Ring	O
C	O
and	O
X	O
are	O
as	O
defined	O
herein,	O
are	O
inhibitors	O
of	O
TrkA	B-GENE
kinase	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
which	O
can	O
be	O
treated	O
with	O
a	O
TrkA	B-GENE
kinase	O
inhibitor	O
such	O
as	O
pain,	O
cancer,	O
inflammation	O
/	O
inflammatory	O
diseases,	O
neurodegenerative	O
diseases,	O
certain	O
infectious	O
diseases,	O
Sjogren	O
'	O
s	O
syndrome,	O
endometriosis,	O
diabetic	O
peripheral	O
neuropathy,	O
prostatitis	O
or	O
pelvic	O
pain	O
syndrome	O
.	O


Disclosed	O
herein	O
are	O
compounds	O
that	O
form	O
covalent	O
bonds	O
with	O
Bruton's	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
Btk	B-GENE
)	O
.	O
Also	O
described	O
are	O
irreversible	O
inhibitors	O
of	O
Btk	B-GENE
.	O
In	O
addition,	O
reversible	O
inhibitors	O
of	O
Btk	B-GENE
are	O
also	O
described	O
.	O
Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
that	O
include	O
the	O
compounds	O
.	O
Methods	O
of	O
using	O
the	O
Btk	B-GENE
inhibitors	O
are	O
disclosed,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents,	O
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
or	O
conditions,	O
heteroimmune	O
diseases	O
or	O
conditions,	O
cancer,	O
including	O
lymphoma,	O
and	O
inflammatory	O
diseases	O
or	O
conditions	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
pyrrolotriazine	O
derivative,	O
a	O
preparation	O
method	O
thereof	O
and	O
an	O
application	O
thereof	O
in	O
medicine	O
.	O
Specifically,	O
disclosed	O
is	O
a	O
pyrrolotriazine	O
derivative	O
that	O
has	O
remarkable	O
inhibition	O
activity	O
to	O
tyrosine	B-GENE
kinase	I-GENE
and	O
is	O
an	O
effective	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
.	O
The	O
pyrrolotriazine	O
derivative	O
provides	O
a	O
new	O
research	O
direction	O
and	O
path	O
for	O
developing	O
new	O
tyrosine	B-GENE
kinase	I-GENE
inhibiting	O
medicine	O
that	O
has	O
low	O
drug	O
resistance	O
or	O
can	O
relieve	O
early	O
inhibitor	O
drug	O
resistance,	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
and	O
a	O
high	O
medicinal	O
value	O
.	O


Provided	O
are	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
Ia,	O
or	O
pharmaceutically	O
acceptable	O
salt,	O
solvate,	O
polymorph,	O
enantiomer	O
or	O
racemic	O
mixture	O
thereof	O
.	O
As	O
a	O
neuraminidase	B-GENE
inhibitor	O
prodrug,	O
the	O
compound	O
can	O
improve	O
the	O
half-life	O
in	O
vivo	O
of	O
the	O
neuraminidase	B-GENE
inhibitor	O
.	O
Also	O
provided	O
are	O
a	O
preparation	O
method	O
of	O
the	O
compound,	O
pharmaceutical	O
composition	O
containing	O
the	O
compound,	O
and	O
uses	O
of	O
the	O
compound	O
and	O
the	O
pharmaceutical	O
composition	O
in	O
the	O
preparation	O
of	O
neuraminidase	B-GENE
inhibitor	O
drugs	O
for	O
treating	O
related	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
diseases	O
mediated	O
by	O
the	O
cathepsin	B-GENE
C	I-GENE
enzyme	O
such	O
as	O
cystic	O
fibrosis,	O
non-cystic	O
fibrosis	O
bronchiectasis,	O
and	O
anti-neutrophil	O
cytoplasmic	O
auto	O
antibody	O
-	O
related	O
diseases	O
.	O


The	O
fluorine-substituted	O
piperidine	O
compound	O
represented	O
in	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
that	O
are	O
on	O
the	O
basis	O
of	O
orexin	B-GENE
(OX)	I-GENE
receptor	I-GENE
antagonism	O
including	O
sleep	O
disorders,	O
depression,	O
anxiety	O
disorders,	O
panic	O
disorders,	O
schizophrenia,	O
drug	O
dependence,	O
Alzheimer	O
'	O
s	O
disease,	O
Parkinson	O
'	O
s	O
disease,	O
Huntington	O
'	O
s	O
disease,	O
eating	O
disorders,	O
headaches,	O
migraines,	O
pain,	O
gastrointestinal	O
diseases,	O
epilepsy,	O
inflammation,	O
immunological	O
disorders,	O
endocrine	O
disorders,	O
and	O
high	O
blood	O
pressure	O
.	O


[	O
Problem	O
]	O
To	O
provide	O
a	O
novel	O
compound	O
that	O
exhibits	O
an	O
agonistic	O
effect	O
on	O
dopamine	B-GENE
D2	I-GENE
receptors	I-GENE
.	O
[	O
Solution	O
]	O
A	O
compound	O
that	O
can	O
be	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
(	O
in	O
which	O
R1	O
represents	O
a	O
C1-6	O
alkyl	O
or	O
the	O
like	O
;	O
R2	O
represents	O
hydrogen	O
or	O
the	O
like	O
;	O
R3	O
and	O
R4	O
each	O
represent	O
either	O
hydrogen,	O
a	O
C1-6	O
alkyl,	O
a	O
R10R11N-C1-6	O
alkyl,	O
an	O
aralkyl,	O
or	O
the	O
like	O
;	O
R5	O
and	O
R6	O
each	O
represent	O
hydrogen	O
or	O
the	O
like	O
;	O
and	O
R7	O
represents	O
hydrogen	O
or	O
the	O
like	O
)	O
or	O
a	O
pharmacologically	O
permitted	O
salt	O
thereof	O
is	O
provided,	O
as	O
are	O
a	O
pharmaceutical	O
composition	O
containing	O
same	O
and	O
uses	O
for	O
said	O
compound	O
/	O
salt	O
and	O
composition	O
.	O
This	O
compound	O
exhibits	O
a	O
superb	O
stimulatory	O
effect	O
on	O
dopamine	B-GENE
D2	I-GENE
receptors	I-GENE
and	O
thus	O
is	O
useful	O
as	O
a	O
therapeutic	O
or	O
prophylactic	O
agent	O
for	O
Parkinson	O
'	O
s	O
disease	O
and	O
the	O
like	O
.	O


The	O
present	O
invention	O
provides	O
a	O
highly	O
safe	O
tyrosinase	B-GENE
activity	O
inhibitor	O
having	O
good	O
activity	O
.	O
The	O
present	O
invention	O
relates	O
to	O
:	O
a	O
tyrosinase	B-GENE
activity	O
inhibitor	O
containing	O
one	O
or	O
more	O
4-alkylresorcinol	O
derivatives	O
or	O
salts	O
thereof	O
having	O
a	O
hydrophilic	O
ester	O
or	O
ether	O
substituent	O
in	O
the	O
4-alkyl	O
chain	O
;	O
a	O
skin	O
external	O
preparation	O
containing	O
same	O
;	O
a	O
whitening	O
agent	O
;	O
and	O
a	O
cosmetic	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
and	O
associated	O
methods	O
for	O
treatment,	O
prevention,	O
amelioration,	O
and	O
/	O
or	O
delaying	O
the	O
onset	O
of	O
hepatic	O
fibrosis	O
and	O
/	O
or	O
associated	O
diseases	O
.	O
The	O
methods	O
preferably	O
involve	O
regulating	O
at	O
least	O
one	O
of	O
Rev-erbα	B-GENE
expression,	O
activity,	O
and	O
subcellular	O
localization	O
.	O
In	O
particular,	O
certain	O
embodiments	O
of	O
the	O
present	O
invention	O
relate	O
to	O
compositions	O
and	O
methods	O
of	O
using	O
a	O
Rev-erb-modulating	O
agent	O
(	O
REMA	O
)	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hepatic	O
fibrosis	O
and	O
/	O
or	O
associated	O
diseases	O
.	O
Preferably,	O
the	O
amount	O
of	O
a	O
REMA	O
administered	O
comprises	O
a	O
quantity	O
sufficient	O
to	O
modulate	O
at	O
least	O
one	O
of	O
Rev-erbα	B-GENE
expression,	O
activity,	O
and	O
subcellular	O
localization	O
and	O
reduce	O
the	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
.	O


Disclosed	O
herein	O
are	O
anti-EGFR	O
antibodies	O
conjugated	O
with	O
maytansinoid	O
drugs	O
for	O
targeted	O
delivery	O
to	O
disease	O
tissues	O
.	O
Methods	O
related	O
to	O
the	O
preparation	O
and	O
uses	O
of	O
such	O
antibody	O
drug	O
conjugates	O
to	O
treat	O
EGFR	B-GENE
positive	O
cells	O
in	O
cancers	O
are	O
provided	O
.	O


The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
fucosterol	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases,	O
and	O
more	O
particularly,	O
to	O
a	O
pharmaceutical	O
composition	O
and	O
functional	O
health	O
food	O
comprising	O
fucosterol,	O
as	O
an	O
active	O
ingredient,	O
for	O
preventing	O
or	O
treating	O
neurodegenerative	O
diseases	O
.	O
The	O
fucosterol	O
of	O
the	O
present	O
invention	O
may	O
effectively	O
increase	O
the	O
expression	O
of	O
ADAM10	B-GENE
which	O
is	O
α-secretase	B-GENE
.	O
Therefore,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
comprising	O
the	O
fucosterol,	O
as	O
an	O
active	O
ingredient,	O
has	O
excellent	O
effects	O
of	O
inhibiting	O
an	O
amyloid	B-GENE
beta	I-GENE
(Aβ)	I-GENE
peptide	I-GENE
production,	O
and	O
thus	O
can	O
be	O
effectively	O
used	O
in	O
pharmaceutical	O
drugs,	O
functional	O
food,	O
and	O
the	O
like	O
for	O
preventing	O
or	O
treating	O
(	O
alleviating	O
)	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
.	O
Particularly,	O
the	O
fucosterol	O
of	O
the	O
present	O
invention	O
is	O
derived	O
from	O
a	O
natural	O
substance,	O
is	O
free	O
of	O
cytotoxicity,	O
and	O
has	O
stability	O
.	O
Therefore,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
comprising	O
the	O
fucosterol,	O
as	O
an	O
active	O
ingredient,	O
has	O
advantages	O
of	O
being	O
safe	O
for	O
long-term	O
use	O
without	O
causing	O
side	O
effects	O
to	O
the	O
human	O
body	O
.	O


The	O
application	O
relates	O
to	O
the	O
macrolide	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
*	O
indicates	O
a	O
stereocentre	O
which	O
is	O
in	O
(	O
R	O
)	O
or	O
(	O
S	O
)	O
configuration,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
and	O
their	O
use	O
as	O
PDE4	B-GENE
inhibitors	O
.	O


The	O
invention	O
relates	O
to	O
a	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
one	O
of	O
the	O
salts	O
thereof,	O
wherein	O
:	O
R	O
represents	O
a	O
linear	O
or	O
branched	O
aliphatic	O
chain	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
C1-C16	O
saturated	O
hydrocarbonated	O
chain	O
and	O
a	O
C2-C16	O
unsaturated	O
hydrocarbonated	O
chain,	O
in	O
the	O
production	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
mutant	O
lysosomal	B-GENE
ß-galactosidase	I-GENE
enzymes	I-GENE
in	O
humans	O
.	O


Provided	O
is	O
a	O
novel	O
α-halogen	O
substituted	O
thiophene	O
compound	O
which	O
has	O
strong	O
LPA	B-GENE
receptor	O
antagonist	O
activity	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O
A	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
.	O
(	O
In	O
the	O
formula,	O
A	O
represents	O
a	O
phenyl	O
ring,	O
a	O
thiophene	O
ring	O
or	O
an	O
isothiazole	O
ring	O
;	O
R1	O
moieties	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
a	O
halogen	O
atom	O
or	O
a	O
C1-C3	O
alkyl	O
group	O
;	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-C6	O
alkyl	O
group	O
;	O
p	O
represents	O
an	O
integer	O
of	O
0-5	O
;	O
V	O
represents	O
a	O
CR3	O
group	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom,	O
an	O
amino	O
group,	O
a	O
nitro	O
group	O
or	O
a	O
C1-C3	O
alkoxy	O
group	O
)	O
or	O
a	O
nitrogen	O
atom	O
;	O
and	O
X	O
represents	O
a	O
halogen	O
atom	O
.	O
)	O


The	O
present	O
invention	O
is	O
directed	O
to	O
aminopyridine	O
derived	O
compounds	O
of	O
formula	O
(	O
A	O
)	O
.	O
The	O
compounds	O
are	O
considered	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
LRRK2	B-GENE
such	O
a	O
Lewy	O
body	O
dementia,	O
Parkinson	O
'	O
s	O
disease	O
or	O
cancer	O
.	O


Substituted	O
indazole	O
or	O
imidazole	O
derivatives	O
of	O
formula	O
I	O
as	O
in	O
vitro	O
selective	O
and	O
reversible	O
MAO-B	B-GENE
inhibitors	O
and	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
meurodegenerative	O
disorders	O
such	O
as	O
Parkinson	O
'	O
s	O
disease,	O
Alzheimer	O
'	O
s	O
disase	O
and	O
dementia	O


The	O
present	O
invention	O
relates	O
to	O
solid	O
state	O
forms	O
of	O
JAK	B-GENE
inhibitor	O
(	O
R	O
)	O
-2-	O
(	O
2-	O
(	O
lH-pyrrolo	O
[	O
2,3-b	O
]	O
pyridin-3-yl	O
)	O
pyrimidin-4-ylamino	O
)	O
-2-methyl-N-	O
(	O
2,2,2-trifluoroethyl	O
)	O
butanamide	O
(	O
Compound	O
1	O
)	O
including	O
solvates,	O
salts,	O
co-crystals,	O
and	O
an	O
amorphous	O
form	O
thereof	O
.	O
The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
these	O
solid	O
forms	O
of	O
Compound	O
1	O
and	O
methods	O
of	O
treating	O
a	O
JAK	B-GENE
mediated	O
disease	O
therewith	O
.	O


The	O
present	O
disclosure	O
describes	O
bicyclic	O
aromatic	O
carboxamide	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
their	O
compositions	O
and	O
methods	O
of	O
use	O
.	O
The	O
compounds	O
inhibit	O
the	O
activity	O
of	O
the	O
Pim	O
kinases,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
the	O
activity	O
of	O
Pim	B-GENE
kinases	I-GENE
including,	O
e	O
.	O
g	O
.	O
,	O
cancer	O
and	O
other	O
diseases	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
drug	O
abuse	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
drug	O
abuse	O
by	O
preventing	O
GAPDH	B-GENE
nitrosylation	O
.	O
In	O
one	O
specific	O
embodiment,	O
a	O
method	O
for	O
preventing	O
the	O
stimulant	O
and	O
neurotoxic	O
effects	O
of	O
cocaine	O
comprises	O
the	O
step	O
of	O
administering	O
a	O
compound	O
that	O
prevents	O
the	O
nitrosylation	O
of	O
glyceraldehyde-3-phosphate	B-GENE
dehydrogenase	I-GENE
(	O
GAPDH	B-GENE
)	O
by	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O
In	O
another	O
embodiment,	O
a	O
method	O
for	O
preventing	O
the	O
stimulant	O
and	O
neurotoxic	O
effects	O
of	O
cocaine	O
comprises	O
the	O
step	O
of	O
administering	O
a	O
compound	O
that	O
prevents	O
the	O
binding	O
of	O
GAPDH	B-GENE
to	O
Siah	O
.	O


The	O
present	O
invention	O
relates	O
to	O
alkene	O
derivatives,	O
processes	O
for	O
preparing	O
them,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-phosphate	B-GENE
receptors	I-GENE
.	O


The	O
present	O
invention	O
provides	O
a	O
MDM2	B-GENE
inhibitor	O
compound,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof,	O
which	O
compound	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent,	O
particularly	O
for	O
the	O
treatment	O
of	O
cancers	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
that	O
contains	O
the	O
MDM2	B-GENE
inhibitor	O
.	O


The	O
present	O
invention	O
provides	O
a	O
new	O
class	O
of	O
compounds	O
useful	O
for	O
the	O
modulation	O
of	O
beta-secretase	B-GENE
enzyme	I-GENE
(	O
BACE	B-GENE
)	O
activity	O
.	O
The	O
compounds	O
have	O
a	O
general	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
variables	O
A4,	O
A5,	O
A6,	O
A8,	O
each	O
of	O
R1	O
and	O
R2,	O
R3	O
and	O
R7	O
of	O
Formula	O
I,	O
independently,	O
are	O
defined	O
herein	O
.	O
The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds,	O
and	O
corresponding	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
disorders	O
and	O
/	O
or	O
conditions	O
related	O
to	O
A-beta	O
plaque	O
formation	O
and	O
deposition,	O
resulting	O
from	O
the	O
biological	O
activity	O
of	O
BACE	B-GENE
.	O
Such	O
BACE	B-GENE
mediated	O
disorders	O
include,	O
for	O
example,	O
Alzheimer	O
'	O
s	O
Disease,	O
cognitive	O
deficits,	O
cognitive	O
impairments,	O
schizophrenia	O
and	O
other	O
central	O
nervous	O
system	O
conditions	O
.	O
The	O
invention	O
further	O
provides	O
compounds	O
of	O
Formulas	O
II	O
and	O
III,	O
and	O
sub-formula	O
embodiments	O
thereof,	O
intermediates	O
and	O
processes	O
and	O
methods	O
useful	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
Formulas	O
I-III	O
.	O


One	O
embodiment	O
of	O
the	O
present	O
invention	O
is	O
to	O
improve	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
administration	O
of	O
GHB	O
or	O
a	O
salt	O
thereof	O
to	O
a	O
patient	O
.	O
It	O
has	O
been	O
discovered	O
that	O
the	O
concomitant	O
administration	O
of	O
an	O
MCT	B-GENE
inhibitor,	O
such	O
as	O
diclofenac,	O
valproate,	O
or	O
ibuprofen,	O
will	O
affect	O
GHB	O
administration	O
.	O
For	O
example,	O
it	O
has	O
been	O
discovered	O
that	O
diclofenac	O
lowers	O
the	O
effect	O
of	O
GHB	O
in	O
the	O
body,	O
thereby	O
potentially	O
causing	O
an	O
unsafe	O
condition	O
.	O
Furthermore,	O
it	O
has	O
been	O
discovered	O
that	O
valproate	O
increases	O
the	O
effect	O
of	O
GHB	O
on	O
the	O
body,	O
thereby	O
potentially	O
causing	O
an	O
unsafe	O
condition	O
.	O


The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
cancer	O
.	O
More	O
specifically,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
useful	O
for	O
diagnosing	O
and	O
treating	O
MYC-driven	O
tumors	O
.	O
In	O
one	O
embodiment,	O
a	O
method	O
for	O
treating	O
a	O
cancer	O
associated	O
with	O
MYC	B-GENE
in	O
a	O
patient	O
comprises	O
the	O
step	O
of	O
administering	O
a	O
glutamine	O
metabolism	O
inhibitor	O
to	O
the	O
patient	O
.	O
In	O
specific	O
embodiments,	O
the	O
cancer	O
associated	O
with	O
MYC	B-GENE
is	O
medulloblastoma,	O
glioblastoma	O
or	O
a	O
primitive	O
neuroectodermal	O
tumor	O
.	O


The	O
present	O
invention	O
is	O
directed	O
to	O
substituted	O
pyridizinone	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders	O
associated	O
with	O
phosphodiesterase	B-GENE
10	I-GENE
(	O
PDE10	B-GENE
)	O
.	O
The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders,	O
such	O
as	O
schizophrenia,	O
psychosis	O
or	O
Huntington	O
'	O
s	O
disease,	O
and	O
those	O
associated	O
with	O
striatal	O
hypofunction	O
or	O
basal	O
ganglia	O
dysfunction	O
.	O


Novel	O
compounds	O
of	O
the	O
structural	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
AMP-protein	B-GENE
kinase	I-GENE
and	O
may	O
be	O
useful	O
in	O
the	O
treatment,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
AMPK-activated	B-GENE
protein	I-GENE
kinase	I-GENE
.	O
The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Type	O
2	O
diabetes,	O
hyperglycemia,	O
metabolic	O
syndrome,	O
obesity,	O
hypercholesterolemia,	O
and	O
hypertension	O
.	O


N-	O
(	O
4-	O
(	O
Azaindazol-6-yl	O
)	O
-phenyl	O
)	O
-sulfonamides	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
The	O
present	O
invention	O
relates	O
to	O
N-	O
(	O
4-	O
(	O
azaindazol-6-yl	O
)	O
-phenyl	O
)	O
-sulfonamides	O
of	O
the	O
formula	O
I,	O
wherein	O
Ar,	O
n,	O
X,	O
Z,	O
R1,	O
R2	O
and	O
R3	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
.	O
The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
which	O
modulate	O
protein	B-GENE
kinase	I-GENE
activity,	O
specifically	O
the	O
activity	O
of	O
serum	B-GENE
and	I-GENE
glucocorticoid	I-GENE
regulated	I-GENE
kinase	I-GENE
(	O
SGK	B-GENE
)	O
,	O
in	O
particular	O
of	O
serum	B-GENE
and	I-GENE
glucocorticoid	I-GENE
regulated	I-GENE
kinase	I-GENE
isoform	I-GENE
1	I-GENE
(	O
SGK-1,	O
SGK1	B-GENE
)	O
,	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
SGK	B-GENE
activity	O
is	O
inappropriate,	O
for	O
example	O
degenerative	O
joint	O
disorders	O
or	O
inflammatory	O
processes	O
such	O
as	O
osteoarthritis	O
or	O
rheumatism	O
.	O
The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I,	O
their	O
use	O
as	O
pharmaceuticals,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O


The	O
present	O
invention	O
relates	O
to	O
macrocyclic	O
compounds	O
and	O
compositions	O
containing	O
said	O
compounds	O
acting	O
as	O
kinase	B-GENE
inhibitors,	O
in	O
particular	O
as	O
inhibitors	O
of	O
SIK	O
kinase,	O
more	O
in	O
particular	O
SIK1,	O
SIK2	B-GENE
and	O
/	O
or	O
SIK3	B-GENE
and	O
/	O
or	O
mutants	O
thereof,	O
for	O
use	O
in	O
the	O
diagnosis,	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
SIK-kinase	B-GENE
associated	O
diseases	O
.	O
Moreover,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
said	O
compounds,	O
for	O
instance	O
as	O
a	O
medicine	O
or	O
diagnostic	O
agent	O
.	O


Preparations	O
containing	O
hepatocyte	B-GENE
growth	I-GENE
factor	I-GENE
(	O
HGF	B-GENE
)	O
and	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O
.	O
The	O
HGF	B-GENE
and	O
HA	O
preparations	O
can	O
be	O
prepared	O
together	O
in	O
solution	O
as	O
an	O
injectable	O
fluid	O
without	O
gelatinization,	O
or	O
impregnated	O
within	O
a	O
porous	O
hydrophilic	O
matrix	O
material	O
with,	O
or	O
without,	O
cross-linking	O
of	O
the	O
HA	O
with	O
the	O
matrix	O
material	O
.	O
The	O
preparations	O
can	O
be	O
used	O
as	O
a	O
dermal	O
filler	O
or	O
to	O
generate	O
and	O
promote	O
healing	O
of	O
cartilage,	O
vertebral	O
discs,	O
connective	O
tissues	O
such	O
as	O
tendons	O
and	O
ligaments	O
and	O
bone	O
in	O
vivo	O
.	O


The	O
instant	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
which	O
are	O
JAK	B-GENE
inhibitors,	O
and	O
as	O
such	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
JAK-mediated	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis,	O
asthma,	O
COPD	O
and	O
cancer	O
.	O


Provided	O
is	O
a	O
fused	O
ring	O
compound	O
having	O
GPR40	B-GENE
receptor	O
function	O
regulating	O
action,	O
and	O
preparation	O
method	O
and	O
pharmaceutical	O
compositions	O
thereof,	O
and	O
the	O
use	O
thereof	O
in	O
drugs	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
diseases	O
associated	O
with	O
GPR40,	O
especially	O
diabetes	O
.	O


The	O
present	O
invention	O
features	O
interferon-	O
and	O
ribavirin-free	O
therapies	O
for	O
the	O
treatment	O
of	O
HCV	O
.	O
Preferably,	O
the	O
treatment	O
is	O
over	O
a	O
shorter	O
duration	O
of	O
treatment,	O
such	O
as	O
no	O
more	O
than	O
12	O
weeks	O
.	O
In	O
one	O
aspect,	O
the	O
treatment	O
comprises	O
administering	O
at	O
least	O
two	O
direct	O
acting	O
antiviral	O
agents	O
without	O
interferon	B-GENE
and	O
ribavirin	O
to	O
a	O
subject	O
with	O
HCV	O
infection,	O
wherein	O
the	O
treatment	O
lasts	O
for	O
12	O
weeks,	O
and	O
said	O
at	O
least	O
two	O
direct	O
acting	O
antiviral	O
agents	O
comprise	O
(	O
a	O
)	O
Compound	O
1	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
b	O
)	O
Compound	O
2	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O


Pharmaceiiticai	O
compositions	O
of	O
the	O
invention	O
comprise	O
functionalized	O
lactone	O
derivatives	O
having	O
a	O
disease-modifying	O
action	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
dysregulation	O
of	O
5-hydroxytryptamine	B-GENE
receptor	I-GENE
7	I-GENE
activity	O
.	O


